
-DOCSTART- (6794356)

Tricuspid	NN	O	B-Disease
valve	NN	O	I-Disease
regurgitation	NN	O	I-Disease
and	NN	O	O
lithium	NN	O	B-Chemical
carbonate	NN	O	I-Chemical
toxicity	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
newborn	NN	O	O
infant	NN	O	O
.	NN	O	O

A	NN	O	O
newborn	NN	O	O
with	NN	O	O
massive	NN	O	O
tricuspid	NN	O	B-Disease
regurgitation	NN	O	I-Disease
,	NN	O	O
atrial	NN	O	B-Disease
flutter	NN	O	I-Disease
,	NN	O	O
congestive	NN	O	B-Disease
heart	NN	O	I-Disease
failure	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
a	NN	O	O
high	NN	O	O
serum	NN	O	O
lithium	NN	O	B-Chemical
level	NN	O	O
is	NN	O	O
described	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
patient	NN	O	O
to	NN	O	O
initially	NN	O	O
manifest	NN	O	O
tricuspid	NN	O	B-Disease
regurgitation	NN	O	I-Disease
and	NN	O	O
atrial	NN	O	B-Disease
flutter	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
the	NN	O	O
11th	NN	O	O
described	NN	O	O
patient	NN	O	O
with	NN	O	O
cardiac	NN	O	B-Disease
disease	NN	O	I-Disease
among	NN	O	O
infants	NN	O	O
exposed	NN	O	O
to	NN	O	O
lithium	NN	O	B-Chemical
compounds	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
trimester	NN	O	O
of	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

Sixty	NN	O	O
-	NN	O	O
three	NN	O	O
percent	NN	O	O
of	NN	O	O
these	NN	O	O
infants	NN	O	O
had	NN	O	O
tricuspid	NN	O	O
valve	NN	O	O
involvement	NN	O	O
.	NN	O	O

Lithium	NN	O	B-Chemical
carbonate	NN	O	I-Chemical
may	NN	O	O
be	NN	O	O
a	NN	O	O
factor	NN	O	O
in	NN	O	O
the	NN	O	O
increasing	NN	O	O
incidence	NN	O	O
of	NN	O	O
congenital	NN	O	B-Disease
heart	NN	O	I-Disease
disease	NN	O	I-Disease
when	NN	O	O
taken	NN	O	O
during	NN	O	O
early	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

It	NN	O	O
also	NN	O	O
causes	NN	O	O
neurologic	NN	O	B-Disease
depression	NN	O	I-Disease
,	NN	O	O
cyanosis	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
cardiac	NN	O	B-Disease
arrhythmia	NN	O	I-Disease
when	NN	O	O
consumed	NN	O	O
prior	NN	O	O
to	NN	O	O
delivery	NN	O	O
.	NN	O	O


-DOCSTART- (6504332)

Phenobarbital	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesia	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
neurologically	NN	O	B-Disease
-	NN	O	I-Disease
impaired	NN	O	I-Disease
child	NN	O	O
.	NN	O	O

A	NN	O	O
2	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
child	NN	O	O
with	NN	O	O
known	NN	O	O
neurologic	NN	O	B-Disease
impairment	NN	O	I-Disease
developed	NN	O	O
a	NN	O	O
dyskinesia	NN	O	B-Disease
soon	NN	O	O
after	NN	O	O
starting	NN	O	O
phenobarbital	NN	O	B-Chemical
therapy	NN	O	O
for	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

Known	NN	O	O
causes	NN	O	O
of	NN	O	O
movement	NN	O	B-Disease
disorders	NN	O	I-Disease
were	NN	O	O
eliminated	NN	O	O
after	NN	O	O
evaluation	NN	O	O
.	NN	O	O

On	NN	O	O
repeat	NN	O	O
challenge	NN	O	O
with	NN	O	O
phenobarbital	NN	O	B-Chemical
,	NN	O	O
the	NN	O	O
dyskinesia	NN	O	B-Disease
recurred	NN	O	O
.	NN	O	O

Phenobarbital	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
added	NN	O	O
to	NN	O	O
the	NN	O	O
list	NN	O	O
of	NN	O	O
anticonvulsant	NN	O	O
drugs	NN	O	O
that	NN	O	O
can	NN	O	O
cause	NN	O	O
movement	NN	O	B-Disease
disorders	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (6436733)

Acute	NN	O	O
changes	NN	O	O
of	NN	O	O
blood	NN	O	O
ammonia	NN	O	B-Chemical
may	NN	O	O
predict	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
valproic	NN	O	B-Chemical
acid	NN	O	I-Chemical
.	NN	O	O

Valproic	NN	O	B-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
VPA	NN	O	B-Chemical
)	NN	O	O
was	NN	O	O
given	NN	O	O
to	NN	O	O
24	NN	O	O
epileptic	NN	O	B-Disease
patients	NN	O	O
who	NN	O	O
were	NN	O	O
already	NN	O	O
being	NN	O	O
treated	NN	O	O
with	NN	O	O
other	NN	O	O
antiepileptic	NN	O	O
drugs	NN	O	O
.	NN	O	O

A	NN	O	O
standardized	NN	O	O
loading	NN	O	O
dose	NN	O	O
of	NN	O	O
VPA	NN	O	B-Chemical
was	NN	O	O
administered	NN	O	O
,	NN	O	O
and	NN	O	O
venous	NN	O	O
blood	NN	O	O
was	NN	O	O
sampled	NN	O	O
at	NN	O	O
0	NN	O	O
,	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
and	NN	O	O
4	NN	O	O
hours	NN	O	O
.	NN	O	O

Ammonia	NN	O	B-Chemical
(	NN	O	O
NH3	NN	O	B-Chemical
)	NN	O	O
was	NN	O	O
higher	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
,	NN	O	O
during	NN	O	O
continuous	NN	O	O
therapy	NN	O	O
,	NN	O	O
complained	NN	O	O
of	NN	O	O
drowsiness	NN	O	B-Disease
(	NN	O	O
7	NN	O	O
patients	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
those	NN	O	O
who	NN	O	O
were	NN	O	O
symptom	NN	O	O
-	NN	O	O
free	NN	O	O
(	NN	O	O
17	NN	O	O
patients	NN	O	O
)	NN	O	O
,	NN	O	O
although	NN	O	O
VPA	NN	O	B-Chemical
plasma	NN	O	O
levels	NN	O	O
were	NN	O	O
similar	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

By	NN	O	O
measuring	NN	O	O
VPA	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
changes	NN	O	O
of	NN	O	O
blood	NN	O	O
NH3	NN	O	B-Chemical
content	NN	O	O
,	NN	O	O
it	NN	O	O
may	NN	O	O
be	NN	O	O
possible	NN	O	O
to	NN	O	O
identify	NN	O	O
patients	NN	O	O
at	NN	O	O
higher	NN	O	O
risk	NN	O	O
of	NN	O	O
obtundation	NN	O	O
when	NN	O	O
VPA	NN	O	B-Chemical
is	NN	O	O
given	NN	O	O
chronically	NN	O	O
.	NN	O	O


-DOCSTART- (6293644)

Effects	NN	O	O
of	NN	O	O
calcitonin	NN	O	O
on	NN	O	O
rat	NN	O	O
extrapyramidal	NN	O	O
motor	NN	O	O
system	NN	O	O
:	NN	O	O
behavioral	NN	O	O
and	NN	O	O
biochemical	NN	O	O
data	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
i.v.c	NN	O	O
.	NN	O	O

injection	NN	O	O
of	NN	O	O
human	NN	O	O
and	NN	O	O
salmon	NN	O	O
calcitonin	NN	O	O
on	NN	O	O
biochemical	NN	O	O
and	NN	O	O
behavioral	NN	O	O
parameters	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
extrapyramidal	NN	O	O
motor	NN	O	O
system	NN	O	O
,	NN	O	O
were	NN	O	O
investigated	NN	O	O
in	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

Calcitonin	NN	O	O
injection	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
potentiation	NN	O	O
of	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
and	NN	O	O
a	NN	O	O
partial	NN	O	O
prevention	NN	O	O
of	NN	O	O
apomorphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B-Disease
.	NN	O	O

Moreover	NN	O	O
calcitonin	NN	O	O
induced	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
nigral	NN	O	O
GAD	NN	O	O
activity	NN	O	O
but	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
striatal	NN	O	O
DA	NN	O	B-Chemical
and	NN	O	O
DOPAC	NN	O	B-Chemical
concentration	NN	O	O
or	NN	O	O
GAD	NN	O	O
activity	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
are	NN	O	O
discussed	NN	O	O
in	NN	O	O
view	NN	O	O
of	NN	O	O
a	NN	O	O
primary	NN	O	O
action	NN	O	O
of	NN	O	O
calcitonin	NN	O	O
on	NN	O	O
the	NN	O	O
striatonigral	NN	O	O
GABAergic	NN	O	O
pathway	NN	O	O
mediating	NN	O	O
the	NN	O	O
DA	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
behavioral	NN	O	O
messages	NN	O	O
of	NN	O	O
striatal	NN	O	O
origin	NN	O	O
.	NN	O	O


-DOCSTART- (6203632)

Development	NN	O	O
of	NN	O	O
isoproterenol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B-Disease
hypertrophy	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
development	NN	O	O
of	NN	O	O
cardiac	NN	O	B-Disease
hypertrophy	NN	O	I-Disease
was	NN	O	O
studied	NN	O	O
in	NN	O	O
adult	NN	O	O
female	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
following	NN	O	O
daily	NN	O	O
subcutaneous	NN	O	O
injections	NN	O	O
of	NN	O	O
isoproterenol	NN	O	B-Chemical
(	NN	O	O
ISO	NN	O	B-Chemical
)	NN	O	O
(	NN	O	O
0.3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
time	NN	O	O
course	NN	O	O
was	NN	O	O
established	NN	O	O
for	NN	O	O
the	NN	O	O
change	NN	O	O
in	NN	O	O
tissue	NN	O	O
mass	NN	O	O
,	NN	O	O
RNA	NN	O	O
and	NN	O	O
DNA	NN	O	O
content	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
hydroxyproline	NN	O	B-Chemical
content	NN	O	O
.	NN	O	O

Heart	NN	O	O
weight	NN	O	O
increased	NN	O	O
44%	NN	O	O
after	NN	O	O
8	NN	O	O
days	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
a	NN	O	O
half	NN	O	O
time	NN	O	O
of	NN	O	O
3.4	NN	O	O
days	NN	O	O
.	NN	O	O

Ventricular	NN	O	O
RNA	NN	O	O
content	NN	O	O
was	NN	O	O
elevated	NN	O	O
26%	NN	O	O
after	NN	O	O
24	NN	O	O
h	NN	O	O
of	NN	O	O
a	NN	O	O
single	NN	O	O
injection	NN	O	O
and	NN	O	O
reached	NN	O	O
a	NN	O	O
maximal	NN	O	O
level	NN	O	O
following	NN	O	O
8	NN	O	O
days	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
half	NN	O	O
time	NN	O	O
for	NN	O	O
RNA	NN	O	O
accumulation	NN	O	O
was	NN	O	O
2.0	NN	O	O
days	NN	O	O
.	NN	O	O

The	NN	O	O
total	NN	O	O
content	NN	O	O
of	NN	O	O
hydroxyproline	NN	O	B-Chemical
remained	NN	O	O
stable	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
2	NN	O	O
days	NN	O	O
of	NN	O	O
treatment	NN	O	O
but	NN	O	O
increased	NN	O	O
46%	NN	O	O
after	NN	O	O
4	NN	O	O
days	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

Ventricular	NN	O	O
DNA	NN	O	O
content	NN	O	O
was	NN	O	O
unchanged	NN	O	O
during	NN	O	O
the	NN	O	O
early	NN	O	O
stage	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
4	NN	O	O
days	NN	O	O
)	NN	O	O
of	NN	O	O
hypertrophic	NN	O	B-Disease
growth	NN	O	O
but	NN	O	O
increased	NN	O	O
to	NN	O	O
a	NN	O	O
new	NN	O	O
steady	NN	O	O
-	NN	O	O
state	NN	O	O
level	NN	O	O
19%	NN	O	O
above	NN	O	O
the	NN	O	O
controls	NN	O	O
after	NN	O	O
8	NN	O	O
days	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Intraventricular	NN	O	O
pressures	NN	O	O
and	NN	O	O
coronary	NN	O	O
flow	NN	O	O
measures	NN	O	O
were	NN	O	O
similar	NN	O	O
for	NN	O	O
control	NN	O	O
and	NN	O	O
experimental	NN	O	O
animals	NN	O	O
following	NN	O	O
4	NN	O	O
days	NN	O	O
of	NN	O	O
developed	NN	O	O
hypertrophy	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
dP	NN	O	O
/	NN	O	O
dt	NN	O	O
in	NN	O	O
the	NN	O	O
ISO	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
hearts	NN	O	O
was	NN	O	O
slightly	NN	O	O
but	NN	O	O
significantly	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
elevated	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
adaptive	NN	O	O
response	NN	O	O
to	NN	O	O
ISO	NN	O	B-Chemical
shows	NN	O	O
an	NN	O	O
early	NN	O	O
hypertrophic	NN	O	B-Disease
phase	NN	O	O
(	NN	O	O
1	NN	O	O
-	NN	O	O
4	NN	O	O
days	NN	O	O
)	NN	O	O
characterized	NN	O	O
by	NN	O	O
a	NN	O	O
substantial	NN	O	O
increase	NN	O	O
in	NN	O	O
RNA	NN	O	O
content	NN	O	O
and	NN	O	O
cardiac	NN	O	O
mass	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
changes	NN	O	O
in	NN	O	O
DNA	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
prolonged	NN	O	O
stimulation	NN	O	O
(	NN	O	O
8	NN	O	O
-	NN	O	O
12	NN	O	O
days	NN	O	O
)	NN	O	O
appears	NN	O	O
to	NN	O	O
represent	NN	O	O
a	NN	O	O
complex	NN	O	O
integration	NN	O	O
of	NN	O	O
both	NN	O	O
cellular	NN	O	O
hypertrophy	NN	O	B-Disease
and	NN	O	O
hyperplasia	NN	O	B-Disease
within	NN	O	O
the	NN	O	O
heart	NN	O	O
.	NN	O	O


-DOCSTART- (3131282)

Co	NN	O	O
-	NN	O	O
carcinogenic	NN	O	B-Disease
effect	NN	O	O
of	NN	O	O
retinyl	NN	O	B-Chemical
acetate	NN	O	I-Chemical
on	NN	O	O
forestomach	NN	O	B-Disease
carcinogenesis	NN	O	I-Disease
of	NN	O	O
male	NN	O	O
F344	NN	O	O
rats	NN	O	O
induced	NN	O	O
with	NN	O	O
butylated	NN	O	B-Chemical
hydroxyanisole	NN	O	I-Chemical
.	NN	O	O

The	NN	O	O
potential	NN	O	O
modifying	NN	O	O
effect	NN	O	O
of	NN	O	O
retinyl	NN	O	B-Chemical
acetate	NN	O	I-Chemical
(	NN	O	O
RA	NN	O	B-Chemical
)	NN	O	O
on	NN	O	O
butylated	NN	O	B-Chemical
hydroxyanisole	NN	O	I-Chemical
(	NN	O	O
BHA	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
rat	NN	O	O
forestomach	NN	O	B-Disease
tumorigenesis	NN	O	I-Disease
was	NN	O	O
examined	NN	O	O
.	NN	O	O

Male	NN	O	O
F344	NN	O	O
rats	NN	O	O
,	NN	O	O
5	NN	O	O
weeks	NN	O	O
of	NN	O	O
age	NN	O	O
,	NN	O	O
were	NN	O	O
maintained	NN	O	O
on	NN	O	O
diet	NN	O	O
containing	NN	O	O
1%	NN	O	O
or	NN	O	O
2%	NN	O	O
BHA	NN	O	B-Chemical
by	NN	O	O
weight	NN	O	O
and	NN	O	O
simultaneously	NN	O	O
on	NN	O	O
drinking	NN	O	O
water	NN	O	O
supplemented	NN	O	O
with	NN	O	O
RA	NN	O	B-Chemical
at	NN	O	O
various	NN	O	O
concentrations	NN	O	O
(	NN	O	O
w	NN	O	O
/	NN	O	O
v	NN	O	O
)	NN	O	O
for	NN	O	O
52	NN	O	O
weeks	NN	O	O
.	NN	O	O

In	NN	O	O
groups	NN	O	O
given	NN	O	O
2%	NN	O	O
BHA	NN	O	B-Chemical
,	NN	O	O
although	NN	O	O
marked	NN	O	O
hyperplastic	NN	O	O
changes	NN	O	O
of	NN	O	O
the	NN	O	O
forestomach	NN	O	O
epithelium	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
all	NN	O	O
animals	NN	O	O
,	NN	O	O
co	NN	O	O
-	NN	O	O
administration	NN	O	O
of	NN	O	O
0.25%	NN	O	O
RA	NN	O	B-Chemical
significantly	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
increased	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
forestomach	NN	O	B-Disease
tumors	NN	O	I-Disease
(	NN	O	O
squamous	NN	O	B-Disease
cell	NN	O	I-Disease
papilloma	NN	O	I-Disease
and	NN	O	O
carcinoma	NN	O	B-Disease
)	NN	O	O
to	NN	O	O
60%	NN	O	O
(	NN	O	O
9	NN	O	O
/	NN	O	O
15	NN	O	O
,	NN	O	O
2	NN	O	O
rats	NN	O	O
with	NN	O	O
carcinoma	NN	O	B-Disease
)	NN	O	O
from	NN	O	O
15%	NN	O	O
(	NN	O	O
3	NN	O	O
/	NN	O	O
20	NN	O	O
,	NN	O	O
one	NN	O	O
rat	NN	O	O
with	NN	O	O
carcinoma	NN	O	B-Disease
)	NN	O	O
in	NN	O	O
the	NN	O	O
group	NN	O	O
given	NN	O	O
RA	NN	O	B-Chemical
-	NN	O	O
free	NN	O	O
water	NN	O	O
.	NN	O	O

In	NN	O	O
rats	NN	O	O
given	NN	O	O
1%	NN	O	O
BHA	NN	O	B-Chemical
,	NN	O	O
RA	NN	O	B-Chemical
co	NN	O	O
-	NN	O	O
administered	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
0.05	NN	O	O
,	NN	O	O
0.1	NN	O	O
,	NN	O	O
0.2	NN	O	O
or	NN	O	O
0.25%	NN	O	O
showed	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
enhancing	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
the	NN	O	O
BHA	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
epithelial	NN	O	B-Disease
hyperplasia	NN	O	I-Disease
.	NN	O	O

Tumors	NN	O	B-Disease
,	NN	O	O
all	NN	O	O
papillomas	NN	O	B-Disease
,	NN	O	O
were	NN	O	O
induced	NN	O	O
in	NN	O	O
3	NN	O	O
rats	NN	O	O
(	NN	O	O
17%	NN	O	O
)	NN	O	O
with	NN	O	O
0.25%	NN	O	O
RA	NN	O	B-Chemical
and	NN	O	O
in	NN	O	O
one	NN	O	O
rat	NN	O	O
(	NN	O	O
10%	NN	O	O
)	NN	O	O
with	NN	O	O
0.05%	NN	O	O
RA	NN	O	B-Chemical
co	NN	O	O
-	NN	O	O
administration	NN	O	O
.	NN	O	O

RA	NN	O	B-Chemical
alone	NN	O	O
did	NN	O	O
not	NN	O	O
induce	NN	O	O
hyperplastic	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
forestomach	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
RA	NN	O	B-Chemical
acted	NN	O	O
as	NN	O	O
a	NN	O	O
co	NN	O	O
-	NN	O	O
carcinogen	NN	O	O
in	NN	O	O
the	NN	O	O
BHA	NN	O	B-Chemical
forestomach	NN	O	B-Disease
carcinogenesis	NN	O	I-Disease
of	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O


-DOCSTART- (3115150)

Ketanserin	NN	O	B-Chemical
pretreatment	NN	O	O
reverses	NN	O	O
alfentanil	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
.	NN	O	O

Systemic	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
ketanserin	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
relatively	NN	O	O
specific	NN	O	O
type	NN	O	O
-	NN	O	O
2	NN	O	O
serotonin	NN	O	B-Chemical
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
the	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
produced	NN	O	O
in	NN	O	O
rats	NN	O	O
by	NN	O	O
the	NN	O	O
potent	NN	O	O
short	NN	O	O
-	NN	O	O
acting	NN	O	O
opiate	NN	O	O
agonist	NN	O	O
alfentanil	NN	O	B-Chemical
.	NN	O	O

Following	NN	O	O
placement	NN	O	O
of	NN	O	O
subcutaneous	NN	O	O
electrodes	NN	O	O
in	NN	O	O
each	NN	O	O
animal	NN	O	O
'	NN	O	O
s	NN	O	O
left	NN	O	O
gastrocnemius	NN	O	O
muscle	NN	O	O
,	NN	O	O
rigidity	NN	O	B-Disease
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
analyzing	NN	O	O
root	NN	O	O
-	NN	O	O
mean	NN	O	O
-	NN	O	O
square	NN	O	O
electromyographic	NN	O	O
activity	NN	O	O
.	NN	O	O

Intraperitoneal	NN	O	O
ketanserin	NN	O	B-Chemical
administration	NN	O	O
at	NN	O	O
doses	NN	O	O
of	NN	O	O
0.63	NN	O	O
and	NN	O	O
2.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
prevented	NN	O	O
the	NN	O	O
alfentanil	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
increase	NN	O	O
in	NN	O	O
electromyographic	NN	O	O
activity	NN	O	O
compared	NN	O	O
with	NN	O	O
animals	NN	O	O
pretreated	NN	O	O
with	NN	O	O
saline	NN	O	O
.	NN	O	O

Chlordiazepoxide	NN	O	B-Chemical
at	NN	O	O
doses	NN	O	O
up	NN	O	O
to	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
failed	NN	O	O
to	NN	O	O
significantly	NN	O	O
influence	NN	O	O
the	NN	O	O
rigidity	NN	O	B-Disease
produced	NN	O	O
by	NN	O	O
alfentanil	NN	O	B-Chemical
.	NN	O	O

Despite	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
rigidity	NN	O	B-Disease
,	NN	O	O
animals	NN	O	O
that	NN	O	O
received	NN	O	O
ketanserin	NN	O	B-Chemical
(	NN	O	O
greater	NN	O	O
than	NN	O	O
0.31	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.p.	NN	O	O
)	NN	O	O
followed	NN	O	O
by	NN	O	O
alfentanil	NN	O	B-Chemical
were	NN	O	O
motionless	NN	O	O
,	NN	O	O
flaccid	NN	O	O
,	NN	O	O
and	NN	O	O
less	NN	O	O
responsive	NN	O	O
to	NN	O	O
external	NN	O	O
stimuli	NN	O	O
than	NN	O	O
were	NN	O	O
animals	NN	O	O
receiving	NN	O	O
alfentanil	NN	O	B-Chemical
alone	NN	O	O
.	NN	O	O

Rats	NN	O	O
that	NN	O	O
received	NN	O	O
ketanserin	NN	O	B-Chemical
and	NN	O	O
alfentanil	NN	O	B-Chemical
exhibited	NN	O	O
less	NN	O	O
rearing	NN	O	O
and	NN	O	O
exploratory	NN	O	O
behavior	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
60	NN	O	O
-	NN	O	O
min	NN	O	O
recording	NN	O	O
period	NN	O	O
than	NN	O	O
did	NN	O	O
animals	NN	O	O
that	NN	O	O
received	NN	O	O
ketanserin	NN	O	B-Chemical
alone	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
,	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
previous	NN	O	O
work	NN	O	O
,	NN	O	O
suggest	NN	O	O
that	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
,	NN	O	O
a	NN	O	O
clinically	NN	O	O
relevant	NN	O	O
side	NN	O	O
-	NN	O	O
effect	NN	O	O
of	NN	O	O
parenteral	NN	O	O
narcotic	NN	O	O
administration	NN	O	O
,	NN	O	O
may	NN	O	O
be	NN	O	O
partly	NN	O	O
mediated	NN	O	O
via	NN	O	O
serotonergic	NN	O	O
pathways	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
type	NN	O	O
-	NN	O	O
2	NN	O	O
serotonin	NN	O	B-Chemical
antagonists	NN	O	O
may	NN	O	O
be	NN	O	O
clinically	NN	O	O
useful	NN	O	O
in	NN	O	O
attenuating	NN	O	O
opiate	NN	O	O
-	NN	O	O
induced	NN	O	O
rigidity	NN	O	B-Disease
,	NN	O	O
although	NN	O	O
further	NN	O	O
studies	NN	O	O
will	NN	O	O
be	NN	O	O
necessary	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
interaction	NN	O	O
of	NN	O	O
possibly	NN	O	O
enhanced	NN	O	O
CNS	NN	O	O
,	NN	O	O
cardiovascular	NN	O	B-Disease
,	NN	O	I-Disease
and	NN	O	I-Disease
respiratory	NN	O	I-Disease
depression	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (2917114)

Glycopyrronium	NN	O	B-Chemical
requirements	NN	O	O
for	NN	O	O
antagonism	NN	O	O
of	NN	O	O
the	NN	O	O
muscarinic	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
edrophonium	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
have	NN	O	O
compared	NN	O	O
,	NN	O	O
in	NN	O	O
60	NN	O	O
adult	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
effects	NN	O	O
of	NN	O	O
glycopyrronium	NN	O	B-Chemical
5	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
and	NN	O	O
10	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
given	NN	O	O
either	NN	O	O
simultaneously	NN	O	O
or	NN	O	O
1	NN	O	O
min	NN	O	O
before	NN	O	O
edrophonium	NN	O	B-Chemical
1	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
.	NN	O	O

Significant	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
four	NN	O	O
groups	NN	O	O
were	NN	O	O
detected	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

Both	NN	O	O
groups	NN	O	O
receiving	NN	O	O
10	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
showed	NN	O	O
increases	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
of	NN	O	O
up	NN	O	O
to	NN	O	O
30	NN	O	O
beat	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
95%	NN	O	O
confidence	NN	O	O
limits	NN	O	O
28	NN	O	O
-	NN	O	O
32	NN	O	O
beat	NN	O	O
min	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

Use	NN	O	O
of	NN	O	O
glycopyrronium	NN	O	B-Chemical
5	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
provided	NN	O	O
greater	NN	O	O
cardiovascular	NN	O	O
stability	NN	O	O
and	NN	O	O
,	NN	O	O
given	NN	O	O
1	NN	O	O
min	NN	O	O
before	NN	O	O
the	NN	O	O
edrophonium	NN	O	B-Chemical
,	NN	O	O
was	NN	O	O
sufficient	NN	O	O
to	NN	O	O
minimize	NN	O	O
early	NN	O	O
,	NN	O	O
edrophonium	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
bradycardias	NN	O	B-Disease
.	NN	O	O

This	NN	O	O
low	NN	O	O
dose	NN	O	O
of	NN	O	O
glycopyrronium	NN	O	B-Chemical
provided	NN	O	O
good	NN	O	O
control	NN	O	O
of	NN	O	O
oropharyngeal	NN	O	O
secretions	NN	O	O
.	NN	O	O


-DOCSTART- (2564649)

Involvement	NN	O	O
of	NN	O	O
locus	NN	O	O
coeruleus	NN	O	O
and	NN	O	O
noradrenergic	NN	O	O
neurotransmission	NN	O	O
in	NN	O	O
fentanyl	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
muscular	NN	O	B-Disease
rigidity	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Whereas	NN	O	O
muscular	NN	O	B-Disease
rigidity	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
well	NN	O	O
-	NN	O	O
known	NN	O	O
side	NN	O	O
effect	NN	O	O
that	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
fentanyl	NN	O	B-Chemical
anesthesia	NN	O	O
,	NN	O	O
a	NN	O	O
paucity	NN	O	O
of	NN	O	O
information	NN	O	O
exists	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
its	NN	O	O
underlying	NN	O	O
mechanism	NN	O	O
(	NN	O	O
s	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
the	NN	O	O
possible	NN	O	O
engagement	NN	O	O
of	NN	O	O
locus	NN	O	O
coeruleus	NN	O	O
of	NN	O	O
the	NN	O	O
pons	NN	O	O
in	NN	O	O
this	NN	O	O
phenomenon	NN	O	O
,	NN	O	O
using	NN	O	O
male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
anesthetized	NN	O	O
with	NN	O	O
ketamine	NN	O	B-Chemical
.	NN	O	O

Under	NN	O	O
proper	NN	O	O
control	NN	O	O
of	NN	O	O
respiration	NN	O	O
,	NN	O	O
body	NN	O	O
temperature	NN	O	O
and	NN	O	O
end	NN	O	O
-	NN	O	O
tidal	NN	O	O
CO2	NN	O	B-Chemical
,	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
fentanyl	NN	O	B-Chemical
(	NN	O	O
50	NN	O	O
or	NN	O	O
100	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
consistently	NN	O	O
promoted	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
electromyographic	NN	O	O
activity	NN	O	O
recorded	NN	O	O
from	NN	O	O
the	NN	O	O
gastrocnemius	NN	O	O
and	NN	O	O
abdominal	NN	O	O
rectus	NN	O	O
muscles	NN	O	O
.	NN	O	O

Such	NN	O	O
an	NN	O	O
induced	NN	O	O
muscular	NN	O	B-Disease
rigidity	NN	O	I-Disease
by	NN	O	O
the	NN	O	O
narcotic	NN	O	O
agent	NN	O	O
was	NN	O	O
significantly	NN	O	O
antagonized	NN	O	O
or	NN	O	O
even	NN	O	O
reduced	NN	O	O
by	NN	O	O
prior	NN	O	O
electrolytic	NN	O	O
lesions	NN	O	O
of	NN	O	O
the	NN	O	O
locus	NN	O	O
coeruleus	NN	O	O
or	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
the	NN	O	O
alpha	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
blocker	NN	O	O
,	NN	O	O
prazosin	NN	O	B-Chemical
.	NN	O	O

Microinjection	NN	O	O
of	NN	O	O
fentanyl	NN	O	B-Chemical
(	NN	O	O
2.5	NN	O	O
micrograms	NN	O	O
/	NN	O	O
50	NN	O	O
nl	NN	O	O
)	NN	O	O
directly	NN	O	O
into	NN	O	O
this	NN	O	O
pontine	NN	O	O
nucleus	NN	O	O
,	NN	O	O
on	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
elicited	NN	O	O
discernible	NN	O	O
electromyographic	NN	O	O
excitation	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
speculated	NN	O	O
that	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
muscular	NN	O	B-Disease
rigidity	NN	O	I-Disease
by	NN	O	O
fentanyl	NN	O	B-Chemical
may	NN	O	O
involve	NN	O	O
the	NN	O	O
coerulospinal	NN	O	O
noradrenergic	NN	O	O
fibers	NN	O	O
to	NN	O	O
the	NN	O	O
spinal	NN	O	O
motoneurons	NN	O	O
.	NN	O	O


-DOCSTART- (2339463)

Cerebral	NN	O	B-Disease
sinus	NN	O	I-Disease
thrombosis	NN	O	I-Disease
as	NN	O	O
a	NN	O	O
potential	NN	O	O
hazard	NN	O	O
of	NN	O	O
antifibrinolytic	NN	O	O
treatment	NN	O	O
in	NN	O	O
menorrhagia	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
42	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
who	NN	O	O
developed	NN	O	O
superior	NN	O	O
sagittal	NN	O	B-Disease
and	NN	O	I-Disease
left	NN	O	I-Disease
transverse	NN	O	I-Disease
sinus	NN	O	I-Disease
thrombosis	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
prolonged	NN	O	O
epsilon	NN	O	B-Chemical
-	NN	O	I-Chemical
aminocaproic	NN	O	I-Chemical
acid	NN	O	I-Chemical
therapy	NN	O	O
for	NN	O	O
menorrhagia	NN	O	B-Disease
.	NN	O	O

This	NN	O	O
antifibrinolytic	NN	O	O
agent	NN	O	O
has	NN	O	O
been	NN	O	O
used	NN	O	O
in	NN	O	O
women	NN	O	O
with	NN	O	O
menorrhagia	NN	O	B-Disease
to	NN	O	O
promote	NN	O	O
clotting	NN	O	O
and	NN	O	O
reduce	NN	O	O
blood	NN	O	B-Disease
loss	NN	O	I-Disease
.	NN	O	O

Although	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
thromboembolic	NN	O	B-Disease
disease	NN	O	I-Disease
has	NN	O	O
been	NN	O	O
reported	NN	O	O
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
epsilon	NN	O	B-Chemical
-	NN	O	I-Chemical
aminocaproic	NN	O	I-Chemical
acid	NN	O	I-Chemical
,	NN	O	O
cerebral	NN	O	B-Disease
sinus	NN	O	I-Disease
thrombosis	NN	O	I-Disease
has	NN	O	O
not	NN	O	O
been	NN	O	O
previously	NN	O	O
described	NN	O	O
.	NN	O	O

Careful	NN	O	O
use	NN	O	O
of	NN	O	O
epsilon	NN	O	B-Chemical
-	NN	O	I-Chemical
aminocaproic	NN	O	I-Chemical
acid	NN	O	I-Chemical
therapy	NN	O	O
is	NN	O	O
recommended	NN	O	O
.	NN	O	O


-DOCSTART- (1545575)

Hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
complicating	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
.	NN	O	O

Hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
potentially	NN	O	O
serious	NN	O	O
complication	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
cyclophosphamide	NN	O	B-Chemical
therapy	NN	O	O
administered	NN	O	O
before	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
.	NN	O	O

As	NN	O	O
standard	NN	O	O
practice	NN	O	O
at	NN	O	O
our	NN	O	O
institution	NN	O	O
,	NN	O	O
patients	NN	O	O
who	NN	O	O
are	NN	O	O
scheduled	NN	O	O
to	NN	O	O
receive	NN	O	O
a	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplant	NN	O	O
are	NN	O	O
treated	NN	O	O
prophylactically	NN	O	O
with	NN	O	O
forced	NN	O	O
hydration	NN	O	O
and	NN	O	O
bladder	NN	O	O
irrigation	NN	O	O
.	NN	O	O

In	NN	O	O
an	NN	O	O
attempt	NN	O	O
to	NN	O	O
obviate	NN	O	O
the	NN	O	O
inconvenience	NN	O	O
of	NN	O	O
bladder	NN	O	O
irrigation	NN	O	O
,	NN	O	O
we	NN	O	O
conducted	NN	O	O
a	NN	O	O
feasibility	NN	O	O
trial	NN	O	O
of	NN	O	O
uroprophylaxis	NN	O	O
with	NN	O	O
mesna	NN	O	B-Chemical
,	NN	O	O
which	NN	O	O
neutralizes	NN	O	O
the	NN	O	O
hepatic	NN	O	O
metabolite	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	B-Chemical
that	NN	O	O
causes	NN	O	O
hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
.	NN	O	O

Of	NN	O	O
97	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
standard	NN	O	O
prophylaxis	NN	O	O
,	NN	O	O
4	NN	O	O
had	NN	O	O
symptomatic	NN	O	O
hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
two	NN	O	O
of	NN	O	O
four	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
mesna	NN	O	B-Chemical
uroprophylaxis	NN	O	O
before	NN	O	O
allogeneic	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
had	NN	O	O
severe	NN	O	O
hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
for	NN	O	O
at	NN	O	O
least	NN	O	O
2	NN	O	O
weeks	NN	O	O
.	NN	O	O

Because	NN	O	O
of	NN	O	O
this	NN	O	O
suboptimal	NN	O	O
result	NN	O	O
,	NN	O	O
we	NN	O	O
resumed	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
bladder	NN	O	O
irrigation	NN	O	O
and	NN	O	O
forced	NN	O	O
hydration	NN	O	O
to	NN	O	O
minimize	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (1286498)

Reversal	NN	O	O
of	NN	O	O
central	NN	O	O
benzodiazepine	NN	O	B-Chemical
effects	NN	O	O
by	NN	O	O
flumazenil	NN	O	B-Chemical
after	NN	O	O
intravenous	NN	O	O
conscious	NN	O	O
sedation	NN	O	O
with	NN	O	O
diazepam	NN	O	B-Chemical
and	NN	O	O
opioids	NN	O	O
:	NN	O	O
report	NN	O	O
of	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
multicenter	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
Flumazenil	NN	O	B-Chemical
in	NN	O	O
Intravenous	NN	O	O
Conscious	NN	O	O
Sedation	NN	O	O
with	NN	O	O
Diazepam	NN	O	B-Chemical
Multicenter	NN	O	O
Study	NN	O	O
Group	NN	O	O
II	NN	O	O
.	NN	O	O

The	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
benzodiazepine	NN	O	B-Chemical
antagonist	NN	O	O
,	NN	O	O
flumazenil	NN	O	B-Chemical
,	NN	O	O
were	NN	O	O
assessed	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
multicenter	NN	O	O
study	NN	O	O
.	NN	O	O

Flumazenil	NN	O	B-Chemical
(	NN	O	O
mean	NN	O	O
dose	NN	O	O
,	NN	O	O
0.76	NN	O	O
mg	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	O
(	NN	O	O
mean	NN	O	O
dose	NN	O	O
,	NN	O	O
8.9	NN	O	O
ml	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
intravenously	NN	O	O
to	NN	O	O
130	NN	O	O
and	NN	O	O
67	NN	O	O
patients	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
who	NN	O	O
had	NN	O	O
been	NN	O	O
given	NN	O	O
diazepam	NN	O	B-Chemical
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
an	NN	O	O
opioid	NN	O	O
(	NN	O	O
fentanyl	NN	O	B-Chemical
,	NN	O	O
meperidine	NN	O	B-Chemical
,	NN	O	O
or	NN	O	O
morphine	NN	O	B-Chemical
)	NN	O	O
for	NN	O	O
the	NN	O	O
induction	NN	O	O
and	NN	O	O
maintenance	NN	O	O
of	NN	O	O
intravenous	NN	O	O
conscious	NN	O	O
sedation	NN	O	O
for	NN	O	O
diagnostic	NN	O	O
or	NN	O	O
therapeutic	NN	O	O
surgical	NN	O	O
procedures	NN	O	O
.	NN	O	O

The	NN	O	O
group	NN	O	O
assessable	NN	O	O
for	NN	O	O
efficacy	NN	O	O
comprised	NN	O	O
122	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
flumazenil	NN	O	B-Chemical
and	NN	O	O
64	NN	O	O
patients	NN	O	O
given	NN	O	O
placebo	NN	O	O
.	NN	O	O

After	NN	O	O
5	NN	O	O
minutes	NN	O	O
,	NN	O	O
80	NN	O	O
/	NN	O	O
115	NN	O	O
(	NN	O	O
70%	NN	O	O
)	NN	O	O
flumazenil	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
21	NN	O	O
/	NN	O	O
63	NN	O	O
(	NN	O	O
33%	NN	O	O
)	NN	O	O
placebo	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
,	NN	O	O
were	NN	O	O
completely	NN	O	O
awake	NN	O	O
and	NN	O	O
alert	NN	O	O
,	NN	O	O
as	NN	O	O
indicated	NN	O	O
by	NN	O	O
a	NN	O	O
score	NN	O	O
of	NN	O	O
5	NN	O	O
on	NN	O	O
the	NN	O	O
Observer	NN	O	O
'	NN	O	O
s	NN	O	O
Assessment	NN	O	O
of	NN	O	O
Alertness	NN	O	O
/	NN	O	O
Sedation	NN	O	O
Scale	NN	O	O
.	NN	O	O

Ninety	NN	O	O
-	NN	O	O
five	NN	O	O
percent	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
who	NN	O	O
attained	NN	O	O
a	NN	O	O
score	NN	O	O
of	NN	O	O
5	NN	O	O
at	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
minute	NN	O	O
assessment	NN	O	O
showed	NN	O	O
no	NN	O	O
loss	NN	O	O
of	NN	O	O
alertness	NN	O	O
throughout	NN	O	O
the	NN	O	O
180	NN	O	O
-	NN	O	O
minute	NN	O	O
assessment	NN	O	O
period	NN	O	O
.	NN	O	O

Flumazenil	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
also	NN	O	O
performed	NN	O	O
significantly	NN	O	O
better	NN	O	O
on	NN	O	O
the	NN	O	O
Finger	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
Nose	NN	O	O
Test	NN	O	O
and	NN	O	O
the	NN	O	O
recall	NN	O	O
of	NN	O	O
pictures	NN	O	O
shown	NN	O	O
at	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
minute	NN	O	O
assessment	NN	O	O
.	NN	O	O

Flumazenil	NN	O	B-Chemical
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
serious	NN	O	O
adverse	NN	O	O
effects	NN	O	O
reported	NN	O	O
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
nine	NN	O	O
(	NN	O	O
30%	NN	O	O
)	NN	O	O
of	NN	O	O
flumazenil	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
17	NN	O	O
(	NN	O	O
25%	NN	O	O
)	NN	O	O
of	NN	O	O
placebo	NN	O	O
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
had	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
drug	NN	O	O
-	NN	O	O
related	NN	O	O
adverse	NN	O	O
experiences	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
adverse	NN	O	O
effects	NN	O	O
were	NN	O	O
nausea	NN	O	B-Disease
and	NN	O	O
vomiting	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
flumazenil	NN	O	B-Chemical
group	NN	O	O
and	NN	O	O
nausea	NN	O	B-Disease
and	NN	O	O
injection	NN	O	O
-	NN	O	O
site	NN	O	O
pain	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
.	NN	O	O

Flumazenil	NN	O	B-Chemical
was	NN	O	O
found	NN	O	O
to	NN	O	O
promptly	NN	O	O
reverse	NN	O	O
sedation	NN	O	O
induced	NN	O	O
by	NN	O	O
diazepam	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
opioids	NN	O	O
.	NN	O	O


-DOCSTART- (839274)

Hepatic	NN	O	O
adenomas	NN	O	B-Disease
and	NN	O	O
focal	NN	O	B-Disease
nodular	NN	O	I-Disease
hyperplasia	NN	O	I-Disease
of	NN	O	O
the	NN	O	O
liver	NN	O	O
in	NN	O	O
young	NN	O	O
women	NN	O	O
on	NN	O	O
oral	NN	O	B-Chemical
contraceptives	NN	O	I-Chemical
:	NN	O	O
case	NN	O	O
reports	NN	O	O
.	NN	O	O

Two	NN	O	O
cases	NN	O	O
of	NN	O	O
hepatic	NN	O	O
adenoma	NN	O	B-Disease
and	NN	O	O
one	NN	O	O
of	NN	O	O
focal	NN	O	B-Disease
nodular	NN	O	I-Disease
hyperplasia	NN	O	I-Disease
presumably	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
oral	NN	O	B-Chemical
contraceptives	NN	O	I-Chemical
,	NN	O	O
are	NN	O	O
reported	NN	O	O
.	NN	O	O

Special	NN	O	O
reference	NN	O	O
is	NN	O	O
made	NN	O	O
to	NN	O	O
their	NN	O	O
clinical	NN	O	O
presentation	NN	O	O
,	NN	O	O
which	NN	O	O
may	NN	O	O
be	NN	O	O
totally	NN	O	O
asymptomatic	NN	O	O
.	NN	O	O

Liver	NN	O	O
-	NN	O	O
function	NN	O	O
tests	NN	O	O
are	NN	O	O
of	NN	O	O
little	NN	O	O
diagnostic	NN	O	O
value	NN	O	O
,	NN	O	O
but	NN	O	O
valuable	NN	O	O
information	NN	O	O
may	NN	O	O
be	NN	O	O
obtained	NN	O	O
from	NN	O	O
both	NN	O	O
liver	NN	O	O
scanning	NN	O	O
and	NN	O	O
hepatic	NN	O	O
angiography	NN	O	O
.	NN	O	O

Histologic	NN	O	O
differences	NN	O	O
and	NN	O	O
clinical	NN	O	O
similarities	NN	O	O
between	NN	O	O
hepatic	NN	O	O
adenoma	NN	O	B-Disease
and	NN	O	O
focal	NN	O	B-Disease
nodular	NN	O	I-Disease
hyperplasia	NN	O	I-Disease
of	NN	O	O
the	NN	O	O
liver	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O


-DOCSTART- (591536)

Arterial	NN	O	O
thromboembolism	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
systemic	NN	O	O
heparin	NN	O	B-Chemical
therapy	NN	O	O
:	NN	O	O
a	NN	O	O
complication	NN	O	O
associated	NN	O	O
with	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
.	NN	O	O

Arterial	NN	O	O
thromboembolism	NN	O	B-Disease
is	NN	O	O
a	NN	O	O
recognized	NN	O	O
complication	NN	O	O
of	NN	O	O
systemic	NN	O	O
heparin	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Characteristic	NN	O	O
of	NN	O	O
the	NN	O	O
entity	NN	O	O
is	NN	O	O
arterial	NN	O	B-Disease
occlusion	NN	O	I-Disease
by	NN	O	O
platelet	NN	O	O
-	NN	O	O
fibrin	NN	O	O
thrombi	NN	O	B-Disease
with	NN	O	O
distal	NN	O	O
ischemia	NN	O	B-Disease
occurring	NN	O	O
four	NN	O	O
to	NN	O	O
twenty	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
heparin	NN	O	B-Chemical
therapy	NN	O	O
,	NN	O	O
preceded	NN	O	O
by	NN	O	O
profound	NN	O	O
thrombocytopenia	NN	O	B-Disease
with	NN	O	O
platelet	NN	O	O
counts	NN	O	O
in	NN	O	O
the	NN	O	O
range	NN	O	O
of	NN	O	O
30	NN	O	O
,	NN	O	O
000	NN	O	O
to	NN	O	O
40	NN	O	O
,	NN	O	O
000	NN	O	O
per	NN	O	O
cubic	NN	O	O
millimeter	NN	O	O
.	NN	O	O

The	NN	O	O
clinically	NN	O	O
apparent	NN	O	O
occlusion	NN	O	O
may	NN	O	O
be	NN	O	O
preceded	NN	O	O
by	NN	O	O
gastrointestinal	NN	O	B-Disease
and	NN	O	I-Disease
musculoskeletal	NN	O	I-Disease
symptoms	NN	O	I-Disease
that	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
ischemic	NN	O	B-Disease
in	NN	O	O
origin	NN	O	O
,	NN	O	O
and	NN	O	O
might	NN	O	O
serve	NN	O	O
to	NN	O	O
warn	NN	O	O
the	NN	O	O
clinician	NN	O	O
of	NN	O	O
these	NN	O	O
complications	NN	O	O
.	NN	O	O

Previous	NN	O	O
reports	NN	O	O
of	NN	O	O
these	NN	O	O
phenomena	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
recent	NN	O	O
studies	NN	O	O
of	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
heparin	NN	O	B-Chemical
are	NN	O	O
reviewed	NN	O	O
.	NN	O	O

The	NN	O	O
common	NN	O	O
factor	NN	O	O
relating	NN	O	O
thromboembolism	NN	O	B-Disease
and	NN	O	O
thrombocytopenia	NN	O	B-Disease
is	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
platelet	NN	O	B-Disease
aggregation	NN	O	I-Disease
.	NN	O	O

Appropriate	NN	O	O
treatment	NN	O	O
consists	NN	O	O
of	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
heparin	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
anticoagulation	NN	O	O
with	NN	O	O
sodium	NN	O	B-Chemical
warfarin	NN	O	I-Chemical
if	NN	O	O
necessary	NN	O	O
.	NN	O	O

Vascular	NN	O	O
procedures	NN	O	O
are	NN	O	O
performed	NN	O	O
as	NN	O	O
indicated	NN	O	O
.	NN	O	O


-DOCSTART- (20735774)

Long	NN	O	O
-	NN	O	O
term	NN	O	O
prognosis	NN	O	O
for	NN	O	O
transplant	NN	O	O
-	NN	O	O
free	NN	O	O
survivors	NN	O	O
of	NN	O	O
paracetamol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
prognosis	NN	O	O
for	NN	O	O
transplant	NN	O	O
-	NN	O	O
free	NN	O	O
survivors	NN	O	O
of	NN	O	O
paracetamol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
remains	NN	O	O
unknown	NN	O	O
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
To	NN	O	O
examine	NN	O	O
whether	NN	O	O
paracetamol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
increases	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
mortality	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
followed	NN	O	O
up	NN	O	O
all	NN	O	O
transplant	NN	O	O
-	NN	O	O
free	NN	O	O
survivors	NN	O	O
of	NN	O	O
paracetamol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
injury	NN	O	I-Disease
,	NN	O	O
hospitalized	NN	O	O
in	NN	O	O
a	NN	O	O
Danish	NN	O	O
national	NN	O	O
referral	NN	O	O
centre	NN	O	O
during	NN	O	O
1984	NN	O	O
-	NN	O	O
2004	NN	O	O
.	NN	O	O

We	NN	O	O
compared	NN	O	O
age	NN	O	O
-	NN	O	O
specific	NN	O	O
mortality	NN	O	O
rates	NN	O	O
from	NN	O	O
1	NN	O	O
year	NN	O	O
post	NN	O	O
-	NN	O	O
discharge	NN	O	O
through	NN	O	O
2008	NN	O	O
between	NN	O	O
those	NN	O	O
in	NN	O	O
whom	NN	O	O
the	NN	O	O
liver	NN	O	B-Disease
injury	NN	O	I-Disease
led	NN	O	O
to	NN	O	O
an	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
and	NN	O	O
those	NN	O	O
in	NN	O	O
whom	NN	O	O
it	NN	O	O
did	NN	O	O
not	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
We	NN	O	O
included	NN	O	O
641	NN	O	O
patients	NN	O	O
.	NN	O	O

On	NN	O	O
average	NN	O	O
,	NN	O	O
age	NN	O	O
-	NN	O	O
specific	NN	O	O
mortality	NN	O	O
rates	NN	O	O
were	NN	O	O
slightly	NN	O	O
higher	NN	O	O
for	NN	O	O
the	NN	O	O
101	NN	O	O
patients	NN	O	O
whose	NN	O	O
paracetamol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
liver	NN	O	B-Disease
injury	NN	O	I-Disease
had	NN	O	O
caused	NN	O	O
an	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
(	NN	O	O
adjusted	NN	O	O
mortality	NN	O	O
rate	NN	O	O
ratio	NN	O	O
=	NN	O	O
1.70	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
1.02	NN	O	O
-	NN	O	O
2.85	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
association	NN	O	O
was	NN	O	O
age	NN	O	O
-	NN	O	O
dependent	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
survivors	NN	O	O
of	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
died	NN	O	O
of	NN	O	O
liver	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
whereas	NN	O	O
suicides	NN	O	O
were	NN	O	O
frequent	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

These	NN	O	O
observations	NN	O	O
speak	NN	O	O
against	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
effects	NN	O	O
of	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
.	NN	O	O

More	NN	O	O
likely	NN	O	O
,	NN	O	O
the	NN	O	O
elevated	NN	O	O
mortality	NN	O	O
rate	NN	O	O
ratio	NN	O	O
resulted	NN	O	O
from	NN	O	O
incomplete	NN	O	O
adjustment	NN	O	O
for	NN	O	O
the	NN	O	O
greater	NN	O	O
prevalence	NN	O	O
of	NN	O	O
substance	NN	O	B-Disease
abuse	NN	O	I-Disease
among	NN	O	O
survivors	NN	O	O
of	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Paracetamol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
did	NN	O	O
not	NN	O	O
affect	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
mortality	NN	O	O
.	NN	O	O

Clinical	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
may	NN	O	O
be	NN	O	O
justified	NN	O	O
by	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
the	NN	O	O
liver	NN	O	B-Disease
failure	NN	O	I-Disease
,	NN	O	O
but	NN	O	O
not	NN	O	O
by	NN	O	O
the	NN	O	O
liver	NN	O	B-Disease
failure	NN	O	I-Disease
itself	NN	O	O
.	NN	O	O


-DOCSTART- (20705401)

Serotonin	NN	O	B-Chemical
6	NN	O	O
receptor	NN	O	O
gene	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
methamphetamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
Japanese	NN	O	O
population	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Altered	NN	O	O
serotonergic	NN	O	O
neural	NN	O	O
transmission	NN	O	O
is	NN	O	O
hypothesized	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
susceptibility	NN	O	O
factor	NN	O	O
for	NN	O	O
psychotic	NN	O	B-Disease
disorders	NN	O	I-Disease
such	NN	O	O
as	NN	O	O
schizophrenia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
serotonin	NN	O	B-Chemical
6	NN	O	O
(	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
6	NN	O	O
)	NN	O	O
receptor	NN	O	O
is	NN	O	O
therapeutically	NN	O	O
targeted	NN	O	O
by	NN	O	O
several	NN	O	O
second	NN	O	O
generation	NN	O	O
antipsychotics	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
clozapine	NN	O	B-Chemical
and	NN	O	O
olanzapine	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
d	NN	O	B-Chemical
-	NN	O	I-Chemical
amphetamine	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
is	NN	O	O
corrected	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
a	NN	O	O
selective	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
6	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
the	NN	O	O
disrupted	NN	O	O
prepulse	NN	O	O
inhibition	NN	O	O
induced	NN	O	O
by	NN	O	O
d	NN	O	B-Chemical
-	NN	O	I-Chemical
amphetamine	NN	O	I-Chemical
or	NN	O	O
phencyclidine	NN	O	B-Chemical
was	NN	O	O
restored	NN	O	O
by	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
6	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
in	NN	O	O
an	NN	O	O
animal	NN	O	O
study	NN	O	O
using	NN	O	O
rats	NN	O	O
.	NN	O	O

These	NN	O	O
animal	NN	O	O
models	NN	O	O
were	NN	O	O
considered	NN	O	O
to	NN	O	O
reflect	NN	O	O
the	NN	O	O
positive	NN	O	O
symptoms	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
the	NN	O	O
above	NN	O	O
evidence	NN	O	O
suggests	NN	O	O
that	NN	O	O
altered	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
6	NN	O	O
receptors	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
psychotic	NN	O	B-Disease
disorders	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
symptoms	NN	O	O
of	NN	O	O
methamphetamine	NN	O	B-Chemical
(	NN	O	O
METH	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B-Disease
are	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
of	NN	O	O
paranoid	NN	O	B-Disease
type	NN	O	I-Disease
schizophrenia	NN	O	I-Disease
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
we	NN	O	O
conducted	NN	O	O
an	NN	O	O
analysis	NN	O	O
of	NN	O	O
the	NN	O	O
association	NN	O	O
of	NN	O	O
the	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
6	NN	O	O
gene	NN	O	O
(	NN	O	O
HTR6	NN	O	O
)	NN	O	O
with	NN	O	O
METH	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B-Disease
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
Using	NN	O	O
five	NN	O	O
tagging	NN	O	O
SNPs	NN	O	O
(	NN	O	O
rs6693503	NN	O	O
,	NN	O	O
rs1805054	NN	O	O
,	NN	O	O
rs4912138	NN	O	O
,	NN	O	O
rs3790757	NN	O	O
and	NN	O	O
rs9659997	NN	O	O
)	NN	O	O
,	NN	O	O
we	NN	O	O
conducted	NN	O	O
a	NN	O	O
genetic	NN	O	O
association	NN	O	O
analysis	NN	O	O
of	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
samples	NN	O	O
(	NN	O	O
197	NN	O	O
METH	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B-Disease
patients	NN	O	O
and	NN	O	O
337	NN	O	O
controls	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
Japanese	NN	O	O
population	NN	O	O
.	NN	O	O

The	NN	O	O
age	NN	O	O
and	NN	O	O
sex	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
subjects	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
from	NN	O	O
those	NN	O	O
of	NN	O	O
the	NN	O	O
methamphetamine	NN	O	B-Chemical
dependence	NN	O	O
patients	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
rs6693503	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
METH	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B-Disease
patients	NN	O	O
in	NN	O	O
the	NN	O	O
allele	NN	O	O
/	NN	O	O
genotype	NN	O	O
-	NN	O	O
wise	NN	O	O
analysis	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
this	NN	O	O
association	NN	O	O
remained	NN	O	O
significant	NN	O	O
after	NN	O	O
Bonferroni	NN	O	O
correction	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
haplotype	NN	O	O
-	NN	O	O
wise	NN	O	O
analysis	NN	O	O
,	NN	O	O
we	NN	O	O
detected	NN	O	O
an	NN	O	O
association	NN	O	O
between	NN	O	O
two	NN	O	O
markers	NN	O	O
(	NN	O	O
rs6693503	NN	O	O
and	NN	O	O
rs1805054	NN	O	O
)	NN	O	O
and	NN	O	O
three	NN	O	O
markers	NN	O	O
(	NN	O	O
rs6693503	NN	O	O
,	NN	O	O
rs1805054	NN	O	O
and	NN	O	O
rs4912138	NN	O	O
)	NN	O	O
in	NN	O	O
HTR6	NN	O	O
and	NN	O	O
METH	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B-Disease
patients	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
HTR6	NN	O	O
may	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
METH	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
Japanese	NN	O	O
population	NN	O	O
.	NN	O	O


-DOCSTART- (19105845)

Effect	NN	O	O
of	NN	O	O
increasing	NN	O	O
intraperitoneal	NN	O	O
infusion	NN	O	O
rates	NN	O	O
on	NN	O	O
bupropion	NN	O	B-Chemical
hydrochloride	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
in	NN	O	O
mice	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
It	NN	O	O
is	NN	O	O
not	NN	O	O
known	NN	O	O
if	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
relationship	NN	O	O
between	NN	O	O
input	NN	O	O
rate	NN	O	O
and	NN	O	O
incidence	NN	O	O
of	NN	O	O
bupropion	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

This	NN	O	O
is	NN	O	O
important	NN	O	O
,	NN	O	O
since	NN	O	O
different	NN	O	O
controlled	NN	O	O
release	NN	O	O
formulations	NN	O	O
of	NN	O	O
bupropion	NN	O	B-Chemical
release	NN	O	O
the	NN	O	O
active	NN	O	O
drug	NN	O	O
at	NN	O	O
different	NN	O	O
rates	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
investigated	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
varying	NN	O	O
the	NN	O	O
intraperitoneal	NN	O	O
infusion	NN	O	O
rates	NN	O	O
of	NN	O	O
bupropion	NN	O	B-Chemical
HCl	NN	O	I-Chemical
120	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
a	NN	O	O
known	NN	O	O
convulsive	NN	O	B-Disease
dose	NN	O	O
50	NN	O	O
(	NN	O	O
CD50	NN	O	O
)	NN	O	O
,	NN	O	O
on	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
bupropion	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
Swiss	NN	O	O
albino	NN	O	O
mice	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
69	NN	O	O
mice	NN	O	O
,	NN	O	O
approximately	NN	O	O
7	NN	O	O
weeks	NN	O	O
of	NN	O	O
age	NN	O	O
,	NN	O	O
and	NN	O	O
weighing	NN	O	O
21.0	NN	O	O
to	NN	O	O
29.1	NN	O	O
g	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
bupropion	NN	O	B-Chemical
HCl	NN	O	I-Chemical
120	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
treatment	NN	O	O
by	NN	O	O
intraperitoneal	NN	O	O
(	NN	O	O
IP	NN	O	O
)	NN	O	O
administration	NN	O	O
in	NN	O	O
7	NN	O	O
groups	NN	O	O
(	NN	O	O
9	NN	O	O
to	NN	O	O
10	NN	O	O
animals	NN	O	O
per	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

Bupropion	NN	O	B-Chemical
HCl	NN	O	I-Chemical
was	NN	O	O
infused	NN	O	O
through	NN	O	O
a	NN	O	O
surgically	NN	O	O
implanted	NN	O	O
IP	NN	O	O
dosing	NN	O	O
catheter	NN	O	O
with	NN	O	O
infusions	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
of	NN	O	O
0	NN	O	O
min	NN	O	O
,	NN	O	O
15	NN	O	O
min	NN	O	O
,	NN	O	O
30	NN	O	O
min	NN	O	O
,	NN	O	O
60	NN	O	O
min	NN	O	O
,	NN	O	O
90	NN	O	O
min	NN	O	O
,	NN	O	O
120	NN	O	O
min	NN	O	O
,	NN	O	O
and	NN	O	O
240	NN	O	O
min	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
,	NN	O	O
time	NN	O	O
of	NN	O	O
onset	NN	O	O
,	NN	O	O
duration	NN	O	O
and	NN	O	O
the	NN	O	O
intensity	NN	O	O
of	NN	O	O
the	NN	O	O
convulsions	NN	O	B-Disease
or	NN	O	O
absence	NN	O	O
of	NN	O	O
convulsions	NN	O	B-Disease
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
IP	NN	O	O
administration	NN	O	O
of	NN	O	O
bupropion	NN	O	B-Chemical
HCl	NN	O	I-Chemical
120	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
by	NN	O	O
bolus	NN	O	O
injection	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
in	NN	O	O
6	NN	O	O
out	NN	O	O
of	NN	O	O
10	NN	O	O
mice	NN	O	O
(	NN	O	O
60%	NN	O	O
of	NN	O	O
convulsing	NN	O	O
mice	NN	O	O
)	NN	O	O
in	NN	O	O
group	NN	O	O
1	NN	O	O
.	NN	O	O

Logistic	NN	O	O
regression	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
that	NN	O	O
infusion	NN	O	O
time	NN	O	O
was	NN	O	O
significant	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.0004	NN	O	O
;	NN	O	O
odds	NN	O	O
ratio	NN	O	O
=	NN	O	O
0.974	NN	O	O
)	NN	O	O
and	NN	O	O
increasing	NN	O	O
the	NN	O	O
IP	NN	O	O
infusion	NN	O	O
time	NN	O	O
of	NN	O	O
bupropion	NN	O	B-Chemical
HCl	NN	O	I-Chemical
120	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
91%	NN	O	O
reduced	NN	O	O
odds	NN	O	O
of	NN	O	O
convulsions	NN	O	B-Disease
at	NN	O	O
infusion	NN	O	O
times	NN	O	O
of	NN	O	O
15	NN	O	O
to	NN	O	O
90	NN	O	O
min	NN	O	O
compared	NN	O	O
to	NN	O	O
bolus	NN	O	O
injection	NN	O	O
.	NN	O	O

Further	NN	O	O
increase	NN	O	O
in	NN	O	O
infusion	NN	O	O
time	NN	O	O
resulted	NN	O	O
in	NN	O	O
further	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
odds	NN	O	O
of	NN	O	O
convulsions	NN	O	B-Disease
to	NN	O	O
99.8%	NN	O	O
reduction	NN	O	O
at	NN	O	O
240	NN	O	O
min	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
the	NN	O	O
demonstration	NN	O	O
of	NN	O	O
an	NN	O	O
inverse	NN	O	O
relationship	NN	O	O
between	NN	O	O
infusion	NN	O	O
time	NN	O	O
of	NN	O	O
a	NN	O	O
fixed	NN	O	O
and	NN	O	O
convulsive	NN	O	B-Disease
dose	NN	O	O
of	NN	O	O
bupropion	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
convulsions	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
prospective	NN	O	O
study	NN	O	O
is	NN	O	O
novel	NN	O	O
.	NN	O	O


-DOCSTART- (18657397)

Detailed	NN	O	O
spectral	NN	O	O
profile	NN	O	O
analysis	NN	O	O
of	NN	O	O
penicillin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
epileptiform	NN	O	B-Disease
activity	NN	O	I-Disease
in	NN	O	O
anesthetized	NN	O	O
rats	NN	O	O
.	NN	O	O

Penicillin	NN	O	B-Chemical
model	NN	O	O
is	NN	O	O
a	NN	O	O
widely	NN	O	O
used	NN	O	O
experimental	NN	O	O
model	NN	O	O
for	NN	O	O
epilepsy	NN	O	B-Disease
research	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
we	NN	O	O
aimed	NN	O	O
to	NN	O	O
portray	NN	O	O
a	NN	O	O
detailed	NN	O	O
spectral	NN	O	O
analysis	NN	O	O
of	NN	O	O
penicillin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
epileptiform	NN	O	B-Disease
activity	NN	O	I-Disease
in	NN	O	O
comparison	NN	O	O
with	NN	O	O
basal	NN	O	O
brain	NN	O	O
activity	NN	O	O
in	NN	O	O
anesthetized	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

Male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
were	NN	O	O
anesthetized	NN	O	O
with	NN	O	O
i.p.	NN	O	O
urethane	NN	O	B-Chemical
and	NN	O	O
connected	NN	O	O
to	NN	O	O
an	NN	O	O
electrocorticogram	NN	O	O
setup	NN	O	O
.	NN	O	O

After	NN	O	O
a	NN	O	O
short	NN	O	O
period	NN	O	O
of	NN	O	O
basal	NN	O	O
activity	NN	O	O
recording	NN	O	O
,	NN	O	O
epileptic	NN	O	B-Disease
focus	NN	O	O
was	NN	O	O
induced	NN	O	O
by	NN	O	O
injecting	NN	O	O
400IU	NN	O	O
/	NN	O	O
2	NN	O	O
microl	NN	O	O
penicillin	NN	O	B-Chemical
-	NN	O	I-Chemical
G	NN	O	I-Chemical
potassium	NN	O	I-Chemical
into	NN	O	O
the	NN	O	O
left	NN	O	O
lateral	NN	O	O
ventricle	NN	O	O
while	NN	O	O
the	NN	O	O
cortical	NN	O	O
activity	NN	O	O
was	NN	O	O
continuously	NN	O	O
recorded	NN	O	O
.	NN	O	O

Basal	NN	O	O
activity	NN	O	O
,	NN	O	O
latent	NN	O	O
period	NN	O	O
and	NN	O	O
the	NN	O	O
penicillin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
epileptiform	NN	O	B-Disease
activity	NN	O	I-Disease
periods	NN	O	O
were	NN	O	O
then	NN	O	O
analyzed	NN	O	O
using	NN	O	O
both	NN	O	O
conventional	NN	O	O
methods	NN	O	O
and	NN	O	O
spectral	NN	O	O
analysis	NN	O	O
.	NN	O	O

Spectral	NN	O	O
analyses	NN	O	O
were	NN	O	O
conducted	NN	O	O
by	NN	O	O
dividing	NN	O	O
the	NN	O	O
whole	NN	O	O
spectrum	NN	O	O
into	NN	O	O
different	NN	O	O
frequency	NN	O	O
bands	NN	O	O
including	NN	O	O
delta	NN	O	O
,	NN	O	O
theta	NN	O	O
(	NN	O	O
slow	NN	O	O
and	NN	O	O
fast	NN	O	O
)	NN	O	O
,	NN	O	O
alpha	NN	O	O
-	NN	O	O
sigma	NN	O	O
,	NN	O	O
beta	NN	O	O
(	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
)	NN	O	O
and	NN	O	O
gamma	NN	O	O
(	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
)	NN	O	O
bands	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
most	NN	O	O
affected	NN	O	O
frequency	NN	O	O
bands	NN	O	O
were	NN	O	O
delta	NN	O	O
,	NN	O	O
theta	NN	O	O
,	NN	O	O
beta	NN	O	O
-	NN	O	O
2	NN	O	O
and	NN	O	O
gamma	NN	O	O
-	NN	O	O
2	NN	O	O
bands	NN	O	O
during	NN	O	O
the	NN	O	O
epileptiform	NN	O	B-Disease
activity	NN	O	I-Disease
and	NN	O	O
there	NN	O	O
were	NN	O	O
marked	NN	O	O
differences	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
spectral	NN	O	O
densities	NN	O	O
between	NN	O	O
three	NN	O	O
investigated	NN	O	O
episodes	NN	O	O
(	NN	O	O
basal	NN	O	O
activity	NN	O	O
,	NN	O	O
latent	NN	O	O
period	NN	O	O
and	NN	O	O
epileptiform	NN	O	B-Disease
activity	NN	O	I-Disease
)	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
may	NN	O	O
help	NN	O	O
to	NN	O	O
analyze	NN	O	O
novel	NN	O	O
data	NN	O	O
obtained	NN	O	O
using	NN	O	O
similar	NN	O	O
experimental	NN	O	O
models	NN	O	O
and	NN	O	O
the	NN	O	O
simple	NN	O	O
analysis	NN	O	O
method	NN	O	O
described	NN	O	O
here	NN	O	O
can	NN	O	O
be	NN	O	O
used	NN	O	O
in	NN	O	O
similar	NN	O	O
studies	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
basic	NN	O	O
neuronal	NN	O	O
mechanism	NN	O	O
of	NN	O	O
this	NN	O	O
or	NN	O	O
other	NN	O	O
types	NN	O	O
of	NN	O	O
experimental	NN	O	O
epilepsies	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (18363626)

High	NN	O	O
dose	NN	O	O
dexmedetomidine	NN	O	B-Chemical
as	NN	O	O
the	NN	O	O
sole	NN	O	O
sedative	NN	O	O
for	NN	O	O
pediatric	NN	O	O
MRI	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
This	NN	O	O
large	NN	O	O
-	NN	O	O
scale	NN	O	O
retrospective	NN	O	O
review	NN	O	O
evaluates	NN	O	O
the	NN	O	O
sedation	NN	O	O
profile	NN	O	O
of	NN	O	O
dexmedetomidine	NN	O	B-Chemical
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
the	NN	O	O
hemodynamic	NN	O	O
responses	NN	O	O
,	NN	O	O
efficacy	NN	O	O
and	NN	O	O
adverse	NN	O	O
events	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
high	NN	O	O
dose	NN	O	O
dexmedetomidine	NN	O	B-Chemical
as	NN	O	O
the	NN	O	O
sole	NN	O	O
sedative	NN	O	O
for	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
(	NN	O	O
MRI	NN	O	O
)	NN	O	O
studies	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Dexmedetomidine	NN	O	B-Chemical
has	NN	O	O
been	NN	O	O
used	NN	O	O
at	NN	O	O
our	NN	O	O
institution	NN	O	O
since	NN	O	O
2005	NN	O	O
to	NN	O	O
provide	NN	O	O
sedation	NN	O	O
for	NN	O	O
pediatric	NN	O	O
radiological	NN	O	O
imaging	NN	O	O
studies	NN	O	O
.	NN	O	O

Over	NN	O	O
time	NN	O	O
,	NN	O	O
an	NN	O	O
effective	NN	O	O
protocol	NN	O	O
utilizing	NN	O	O
high	NN	O	O
dose	NN	O	O
dexmedetomidine	NN	O	B-Chemical
as	NN	O	O
the	NN	O	O
sole	NN	O	O
sedative	NN	O	O
agent	NN	O	O
has	NN	O	O
evolved	NN	O	O
.	NN	O	O

METHODS	NN	O	O
/	NN	O	O
MATERIALS	NN	O	O
:	NN	O	O
As	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
ongoing	NN	O	O
Quality	NN	O	O
Assurance	NN	O	O
process	NN	O	O
,	NN	O	O
data	NN	O	O
on	NN	O	O
all	NN	O	O
sedations	NN	O	O
are	NN	O	O
reviewed	NN	O	O
monthly	NN	O	O
and	NN	O	O
protocols	NN	O	O
modified	NN	O	O
as	NN	O	O
needed	NN	O	O
.	NN	O	O

Data	NN	O	O
were	NN	O	O
analyzed	NN	O	O
from	NN	O	O
all	NN	O	O
747	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
dexmedetomidine	NN	O	B-Chemical
for	NN	O	O
MRI	NN	O	O
sedation	NN	O	O
from	NN	O	O
April	NN	O	O
2005	NN	O	O
to	NN	O	O
April	NN	O	O
2007	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Since	NN	O	O
2005	NN	O	O
,	NN	O	O
the	NN	O	O
10	NN	O	O
-	NN	O	O
min	NN	O	O
loading	NN	O	O
dose	NN	O	O
of	NN	O	O
our	NN	O	O
dexmedetomidine	NN	O	B-Chemical
protocol	NN	O	O
increased	NN	O	O
from	NN	O	O
2	NN	O	O
to	NN	O	O
3	NN	O	O
microg.kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
infusion	NN	O	O
rate	NN	O	O
increased	NN	O	O
from	NN	O	O
1	NN	O	O
to	NN	O	O
1.5	NN	O	O
to	NN	O	O
2	NN	O	O
microg.kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.h	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
current	NN	O	O
sedation	NN	O	O
protocol	NN	O	O
progressively	NN	O	O
increased	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
successful	NN	O	O
sedation	NN	O	O
(	NN	O	O
able	NN	O	O
to	NN	O	O
complete	NN	O	O
the	NN	O	O
imaging	NN	O	O
study	NN	O	O
)	NN	O	O
when	NN	O	O
using	NN	O	O
dexmedetomidine	NN	O	B-Chemical
alone	NN	O	O
from	NN	O	O
91.8%	NN	O	O
to	NN	O	O
97.6%	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.009	NN	O	O
)	NN	O	O
,	NN	O	O
reducing	NN	O	O
the	NN	O	O
requirement	NN	O	O
for	NN	O	O
adjuvant	NN	O	O
pentobarbital	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
event	NN	O	O
of	NN	O	O
sedation	NN	O	O
failure	NN	O	O
with	NN	O	O
dexmedetomidine	NN	O	B-Chemical
alone	NN	O	O
and	NN	O	O
decreased	NN	O	O
the	NN	O	O
mean	NN	O	O
recovery	NN	O	O
time	NN	O	O
by	NN	O	O
10	NN	O	O
min	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

Although	NN	O	O
dexmedetomidine	NN	O	B-Chemical
sedation	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
16%	NN	O	O
incidence	NN	O	O
of	NN	O	O
bradycardia	NN	O	B-Disease
,	NN	O	O
all	NN	O	O
concomitant	NN	O	O
mean	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressures	NN	O	O
were	NN	O	O
within	NN	O	O
20%	NN	O	O
of	NN	O	O
age	NN	O	O
-	NN	O	O
adjusted	NN	O	O
normal	NN	O	O
range	NN	O	O
and	NN	O	O
oxygen	NN	O	B-Chemical
saturations	NN	O	O
were	NN	O	O
95%	NN	O	O
or	NN	O	O
higher	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Dexmedetomidine	NN	O	B-Chemical
in	NN	O	O
high	NN	O	O
doses	NN	O	O
provides	NN	O	O
adequate	NN	O	O
sedation	NN	O	O
for	NN	O	O
pediatric	NN	O	O
MRI	NN	O	O
studies	NN	O	O
.	NN	O	O

While	NN	O	O
use	NN	O	O
of	NN	O	O
high	NN	O	O
dose	NN	O	O
dexmedetomidine	NN	O	B-Chemical
is	NN	O	O
associated	NN	O	O
with	NN	O	O
decreases	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
blood	NN	O	O
pressure	NN	O	O
outside	NN	O	O
the	NN	O	O
established	NN	O	O
'	NN	O	O
awake	NN	O	O
'	NN	O	O
norms	NN	O	O
,	NN	O	O
this	NN	O	O
deviation	NN	O	O
is	NN	O	O
generally	NN	O	O
within	NN	O	O
20%	NN	O	O
of	NN	O	O
norms	NN	O	O
,	NN	O	O
and	NN	O	O
is	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
adverse	NN	O	O
sequelae	NN	O	O
.	NN	O	O

Dexmedetomidine	NN	O	B-Chemical
is	NN	O	O
useful	NN	O	O
as	NN	O	O
the	NN	O	O
sole	NN	O	O
sedative	NN	O	O
for	NN	O	O
pediatric	NN	O	O
MRI	NN	O	O
.	NN	O	O


-DOCSTART- (16192988)

Methamphetamine	NN	O	B-Chemical
causes	NN	O	O
alterations	NN	O	O
in	NN	O	O
the	NN	O	O
MAP	NN	O	O
kinase	NN	O	O
-	NN	O	O
related	NN	O	O
pathways	NN	O	O
in	NN	O	O
the	NN	O	O
brains	NN	O	O
of	NN	O	O
mice	NN	O	O
that	NN	O	O
display	NN	O	O
increased	NN	O	O
aggressiveness	NN	O	B-Disease
.	NN	O	O

Aggressive	NN	O	B-Disease
behaviors	NN	O	I-Disease
have	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
suffer	NN	O	O
from	NN	O	O
some	NN	O	O
psychiatric	NN	O	B-Disease
disorders	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
are	NN	O	O
common	NN	O	O
in	NN	O	O
methamphetamine	NN	O	B-Chemical
(	NN	O	O
METH	NN	O	B-Chemical
)	NN	O	O
abusers	NN	O	O
.	NN	O	O

Herein	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
that	NN	O	O
multiple	NN	O	O
(	NN	O	O
but	NN	O	O
not	NN	O	O
single	NN	O	O
)	NN	O	O
injections	NN	O	O
of	NN	O	O
METH	NN	O	B-Chemical
significantly	NN	O	O
increased	NN	O	O
aggressiveness	NN	O	B-Disease
in	NN	O	O
male	NN	O	O
CD	NN	O	O
-	NN	O	O
1	NN	O	O
mice	NN	O	O
.	NN	O	O

This	NN	O	O
increase	NN	O	O
in	NN	O	O
aggressiveness	NN	O	B-Disease
was	NN	O	O
not	NN	O	O
secondary	NN	O	O
to	NN	O	O
METH	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B-Disease
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
protein	NN	O	O
expression	NN	O	O
using	NN	O	O
antibody	NN	O	O
microarrays	NN	O	O
and	NN	O	O
Western	NN	O	O
blotting	NN	O	O
revealed	NN	O	O
differential	NN	O	O
changes	NN	O	O
in	NN	O	O
MAP	NN	O	O
kinase	NN	O	O
-	NN	O	O
related	NN	O	O
pathways	NN	O	O
after	NN	O	O
multiple	NN	O	O
and	NN	O	O
single	NN	O	O
METH	NN	O	B-Chemical
injections	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
statistically	NN	O	O
significant	NN	O	O
(	NN	O	O
p<0.05	NN	O	O
)	NN	O	O
decreases	NN	O	O
in	NN	O	O
MEK1	NN	O	O
,	NN	O	O
Erk2p	NN	O	O
,	NN	O	O
GSK3alpha	NN	O	O
,	NN	O	O
14	NN	O	O
-	NN	O	O
3	NN	O	O
-	NN	O	O
3e	NN	O	O
,	NN	O	O
and	NN	O	O
MEK7	NN	O	O
in	NN	O	O
the	NN	O	O
striata	NN	O	O
of	NN	O	O
mice	NN	O	O
after	NN	O	O
multiple	NN	O	O
injections	NN	O	O
of	NN	O	O
METH	NN	O	B-Chemical
.	NN	O	O

MEK1	NN	O	O
was	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
also	NN	O	O
after	NN	O	O
a	NN	O	O
single	NN	O	O
injection	NN	O	O
of	NN	O	O
METH	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
to	NN	O	O
a	NN	O	O
much	NN	O	O
lesser	NN	O	O
degree	NN	O	O
than	NN	O	O
after	NN	O	O
multiple	NN	O	O
injections	NN	O	O
of	NN	O	O
METH	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
the	NN	O	O
frontal	NN	O	O
cortex	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
GSK3alpha	NN	O	O
after	NN	O	O
multiple	NN	O	O
(	NN	O	O
but	NN	O	O
not	NN	O	O
single	NN	O	O
)	NN	O	O
injections	NN	O	O
of	NN	O	O
METH	NN	O	B-Chemical
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
alterations	NN	O	O
in	NN	O	O
MAP	NN	O	O
kinase	NN	O	O
-	NN	O	O
related	NN	O	O
pathways	NN	O	O
in	NN	O	O
the	NN	O	O
prefronto	NN	O	O
-	NN	O	O
striatal	NN	O	O
circuitries	NN	O	O
might	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
manifestation	NN	O	O
of	NN	O	O
aggressive	NN	O	B-Disease
behaviors	NN	O	I-Disease
in	NN	O	O
mice	NN	O	O
.	NN	O	O


-DOCSTART- (16157917)

Lamotrigine	NN	O	B-Chemical
associated	NN	O	O
with	NN	O	O
exacerbation	NN	O	O
or	NN	O	O
de	NN	O	O
novo	NN	O	O
myoclonus	NN	O	B-Disease
in	NN	O	O
idiopathic	NN	O	B-Disease
generalized	NN	O	I-Disease
epilepsies	NN	O	I-Disease
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
with	NN	O	O
idiopathic	NN	O	B-Disease
generalized	NN	O	I-Disease
epilepsies	NN	O	I-Disease
(	NN	O	O
IGE	NN	O	B-Disease
)	NN	O	O
treated	NN	O	O
with	NN	O	O
lamotrigine	NN	O	B-Chemical
(	NN	O	O
LTG	NN	O	B-Chemical
)	NN	O	O
experienced	NN	O	O
exacerbation	NN	O	O
or	NN	O	O
de	NN	O	O
novo	NN	O	O
appearance	NN	O	O
of	NN	O	O
myoclonic	NN	O	B-Disease
jerks	NN	O	I-Disease
(	NN	O	O
MJ	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

In	NN	O	O
three	NN	O	O
patients	NN	O	O
,	NN	O	O
LTG	NN	O	B-Chemical
exacerbated	NN	O	O
MJ	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
with	NN	O	O
early	NN	O	O
aggravation	NN	O	O
during	NN	O	O
titration	NN	O	O
.	NN	O	O

MJ	NN	O	B-Disease
disappeared	NN	O	O
when	NN	O	O
LTG	NN	O	B-Chemical
dose	NN	O	O
was	NN	O	O
decreased	NN	O	O
by	NN	O	O
25	NN	O	O
to	NN	O	O
50%	NN	O	O
.	NN	O	O

In	NN	O	O
two	NN	O	O
patients	NN	O	O
,	NN	O	O
LTG	NN	O	B-Chemical
exacerbated	NN	O	O
MJ	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
delayed	NN	O	O
but	NN	O	O
more	NN	O	O
severe	NN	O	O
manner	NN	O	O
,	NN	O	O
with	NN	O	O
myoclonic	NN	O	B-Disease
status	NN	O	I-Disease
that	NN	O	O
only	NN	O	O
ceased	NN	O	O
after	NN	O	O
LTG	NN	O	B-Chemical
withdrawal	NN	O	O
.	NN	O	O


-DOCSTART- (16116131)

rTMS	NN	O	O
of	NN	O	O
supplementary	NN	O	O
motor	NN	O	O
area	NN	O	O
modulates	NN	O	O
therapy	NN	O	O
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
in	NN	O	O
Parkinson	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
neural	NN	O	O
mechanisms	NN	O	O
and	NN	O	O
circuitry	NN	O	O
involved	NN	O	O
in	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesia	NN	O	B-Disease
are	NN	O	O
unclear	NN	O	O
.	NN	O	O

Using	NN	O	O
repetitive	NN	O	O
transcranial	NN	O	O
magnetic	NN	O	O
stimulation	NN	O	O
(	NN	O	O
rTMS	NN	O	O
)	NN	O	O
over	NN	O	O
the	NN	O	O
supplementary	NN	O	O
motor	NN	O	O
area	NN	O	O
(	NN	O	O
SMA	NN	O	O
)	NN	O	O
in	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
Parkinson	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
the	NN	O	O
authors	NN	O	O
investigated	NN	O	O
whether	NN	O	O
modulation	NN	O	O
of	NN	O	O
SMA	NN	O	O
excitability	NN	O	O
may	NN	O	O
result	NN	O	O
in	NN	O	O
a	NN	O	O
modification	NN	O	O
of	NN	O	O
a	NN	O	O
dyskinetic	NN	O	B-Disease
state	NN	O	O
induced	NN	O	O
by	NN	O	O
continuous	NN	O	O
apomorphine	NN	O	B-Chemical
infusion	NN	O	O
.	NN	O	O

rTMS	NN	O	O
at	NN	O	O
1	NN	O	O
Hz	NN	O	O
was	NN	O	O
observed	NN	O	O
to	NN	O	O
markedly	NN	O	O
reduce	NN	O	O
drug	NN	O	B-Disease
-	NN	O	I-Disease
induced	NN	O	I-Disease
dyskinesias	NN	O	I-Disease
,	NN	O	O
whereas	NN	O	O
5	NN	O	O
-	NN	O	O
Hz	NN	O	O
rTMS	NN	O	O
induced	NN	O	O
a	NN	O	O
slight	NN	O	O
but	NN	O	O
not	NN	O	O
significant	NN	O	O
increase	NN	O	O
.	NN	O	O


-DOCSTART- (15930398)

Assessment	NN	O	O
of	NN	O	O
the	NN	O	O
onset	NN	O	O
and	NN	O	O
persistence	NN	O	O
of	NN	O	O
amnesia	NN	O	B-Disease
during	NN	O	O
procedural	NN	O	O
sedation	NN	O	O
with	NN	O	O
propofol	NN	O	B-Chemical
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
patients	NN	O	O
'	NN	O	O
ability	NN	O	O
to	NN	O	O
repeat	NN	O	O
and	NN	O	O
recall	NN	O	O
words	NN	O	O
presented	NN	O	O
to	NN	O	O
them	NN	O	O
while	NN	O	O
undergoing	NN	O	O
procedural	NN	O	O
sedation	NN	O	O
with	NN	O	O
propofol	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
correlate	NN	O	O
their	NN	O	O
recall	NN	O	O
with	NN	O	O
their	NN	O	O
level	NN	O	O
of	NN	O	O
awareness	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
bispectral	NN	O	O
index	NN	O	O
(	NN	O	O
BIS	NN	O	O
)	NN	O	O
monitoring	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
was	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
single	NN	O	O
-	NN	O	O
intervention	NN	O	O
study	NN	O	O
of	NN	O	O
consenting	NN	O	O
adult	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
procedural	NN	O	O
sedation	NN	O	O
with	NN	O	O
propofol	NN	O	B-Chemical
between	NN	O	O
December	NN	O	O
28	NN	O	O
,	NN	O	O
2002	NN	O	O
,	NN	O	O
and	NN	O	O
October	NN	O	O
31	NN	O	O
,	NN	O	O
2003	NN	O	O
.	NN	O	O

BIS	NN	O	O
monitoring	NN	O	O
was	NN	O	O
initiated	NN	O	O
starting	NN	O	O
3	NN	O	O
minutes	NN	O	O
before	NN	O	O
the	NN	O	O
procedure	NN	O	O
and	NN	O	O
continuing	NN	O	O
until	NN	O	O
the	NN	O	O
patient	NN	O	O
had	NN	O	O
regained	NN	O	O
baseline	NN	O	O
mental	NN	O	O
status	NN	O	O
.	NN	O	O

At	NN	O	O
1	NN	O	O
-	NN	O	O
minute	NN	O	O
intervals	NN	O	O
during	NN	O	O
the	NN	O	O
procedural	NN	O	O
sedation	NN	O	O
,	NN	O	O
until	NN	O	O
the	NN	O	O
patient	NN	O	O
regained	NN	O	O
baseline	NN	O	O
mental	NN	O	O
status	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
procedure	NN	O	O
,	NN	O	O
a	NN	O	O
word	NN	O	O
from	NN	O	O
a	NN	O	O
standardized	NN	O	O
list	NN	O	O
was	NN	O	O
read	NN	O	O
aloud	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
asked	NN	O	O
to	NN	O	O
immediately	NN	O	O
repeat	NN	O	O
the	NN	O	O
word	NN	O	O
to	NN	O	O
the	NN	O	O
investigator	NN	O	O
.	NN	O	O

The	NN	O	O
BIS	NN	O	O
score	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
the	NN	O	O
word	NN	O	O
was	NN	O	O
read	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
ability	NN	O	O
to	NN	O	O
repeat	NN	O	O
the	NN	O	O
word	NN	O	O
were	NN	O	O
recorded	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
procedure	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
asked	NN	O	O
to	NN	O	O
state	NN	O	O
all	NN	O	O
of	NN	O	O
the	NN	O	O
words	NN	O	O
from	NN	O	O
the	NN	O	O
list	NN	O	O
that	NN	O	O
he	NN	O	O
or	NN	O	O
she	NN	O	O
could	NN	O	O
recall	NN	O	O
,	NN	O	O
and	NN	O	O
to	NN	O	O
identify	NN	O	O
the	NN	O	O
last	NN	O	O
word	NN	O	O
recalled	NN	O	O
from	NN	O	O
prior	NN	O	O
to	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
the	NN	O	O
procedure	NN	O	O
and	NN	O	O
the	NN	O	O
first	NN	O	O
word	NN	O	O
recalled	NN	O	O
from	NN	O	O
after	NN	O	O
the	NN	O	O
procedure	NN	O	O
was	NN	O	O
completed	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Seventy	NN	O	O
-	NN	O	O
five	NN	O	O
consenting	NN	O	O
patients	NN	O	O
were	NN	O	O
enrolled	NN	O	O
;	NN	O	O
one	NN	O	O
patient	NN	O	O
was	NN	O	O
excluded	NN	O	O
from	NN	O	O
data	NN	O	O
analysis	NN	O	O
for	NN	O	O
a	NN	O	O
protocol	NN	O	O
violation	NN	O	O
.	NN	O	O

No	NN	O	O
serious	NN	O	O
adverse	NN	O	O
events	NN	O	O
were	NN	O	O
noted	NN	O	O
during	NN	O	O
the	NN	O	O
procedural	NN	O	O
sedations	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
standard	NN	O	O
deviation	NN	O	O
)	NN	O	O
time	NN	O	O
of	NN	O	O
data	NN	O	O
collection	NN	O	O
was	NN	O	O
16.4	NN	O	O
minutes	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7.1	NN	O	O
;	NN	O	O
range	NN	O	O
5	NN	O	O
to	NN	O	O
34	NN	O	O
minutes	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
initial	NN	O	O
(	NN	O	O
preprocedure	NN	O	O
)	NN	O	O
BIS	NN	O	O
score	NN	O	O
was	NN	O	O
97.1	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.3	NN	O	O
;	NN	O	O
range	NN	O	O
92	NN	O	O
to	NN	O	O
99	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
lowest	NN	O	O
BIS	NN	O	O
score	NN	O	O
occurring	NN	O	O
during	NN	O	O
these	NN	O	O
procedural	NN	O	O
sedations	NN	O	O
was	NN	O	O
66.9	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
14.4	NN	O	O
;	NN	O	O
range	NN	O	O
33	NN	O	O
to	NN	O	O
91	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
lowest	NN	O	O
BIS	NN	O	O
score	NN	O	O
corresponding	NN	O	O
to	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
the	NN	O	O
patient	NN	O	O
to	NN	O	O
immediately	NN	O	O
repeat	NN	O	O
words	NN	O	O
read	NN	O	O
from	NN	O	O
the	NN	O	O
list	NN	O	O
was	NN	O	O
77.1	NN	O	O
(	NN	O	O
95%	NN	O	O
CI	NN	O	O
=	NN	O	O
74.3	NN	O	O
to	NN	O	O
80.0	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
highest	NN	O	O
BIS	NN	O	O
score	NN	O	O
corresponding	NN	O	O
to	NN	O	O
the	NN	O	O
inability	NN	O	B-Disease
to	NN	O	I-Disease
repeat	NN	O	I-Disease
words	NN	O	I-Disease
was	NN	O	O
81.5	NN	O	O
(	NN	O	O
95%	NN	O	O
CI	NN	O	O
=	NN	O	O
78.1	NN	O	O
to	NN	O	O
84.8	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
BIS	NN	O	O
score	NN	O	O
corresponding	NN	O	O
to	NN	O	O
the	NN	O	O
last	NN	O	O
word	NN	O	O
recalled	NN	O	O
from	NN	O	O
prior	NN	O	O
to	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
the	NN	O	O
sedation	NN	O	O
was	NN	O	O
96.7	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.4	NN	O	O
;	NN	O	O
range	NN	O	O
84	NN	O	O
to	NN	O	O
98	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
BIS	NN	O	O
score	NN	O	O
corresponding	NN	O	O
to	NN	O	O
the	NN	O	O
first	NN	O	O
word	NN	O	O
recalled	NN	O	O
after	NN	O	O
the	NN	O	O
procedure	NN	O	O
was	NN	O	O
completed	NN	O	O
was	NN	O	O
91.2	NN	O	O
(	NN	O	O
95%	NN	O	O
CI	NN	O	O
=	NN	O	O
88.1	NN	O	O
to	NN	O	O
94.3	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
recalled	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
word	NN	O	O
that	NN	O	O
had	NN	O	O
been	NN	O	O
read	NN	O	O
to	NN	O	O
them	NN	O	O
during	NN	O	O
the	NN	O	O
protocol	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
lowest	NN	O	O
BIS	NN	O	O
score	NN	O	O
for	NN	O	O
any	NN	O	O
recalled	NN	O	O
word	NN	O	O
was	NN	O	O
91.5	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
11.1	NN	O	O
;	NN	O	O
range	NN	O	O
79	NN	O	O
to	NN	O	O
98	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
words	NN	O	O
were	NN	O	O
recalled	NN	O	O
when	NN	O	O
the	NN	O	O
corresponding	NN	O	O
BIS	NN	O	O
score	NN	O	O
was	NN	O	O
less	NN	O	O
than	NN	O	O
90	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
There	NN	O	O
is	NN	O	O
a	NN	O	O
range	NN	O	O
of	NN	O	O
BIS	NN	O	O
scores	NN	O	O
during	NN	O	O
which	NN	O	O
sedated	NN	O	O
patients	NN	O	O
are	NN	O	O
able	NN	O	O
to	NN	O	O
repeat	NN	O	O
words	NN	O	O
read	NN	O	O
to	NN	O	O
them	NN	O	O
but	NN	O	O
are	NN	O	O
not	NN	O	O
able	NN	O	O
to	NN	O	O
subsequently	NN	O	O
recall	NN	O	O
these	NN	O	O
words	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
patients	NN	O	O
had	NN	O	O
no	NN	O	O
recall	NN	O	O
of	NN	O	O
words	NN	O	O
repeated	NN	O	O
prior	NN	O	O
to	NN	O	O
procedural	NN	O	O
sedation	NN	O	O
in	NN	O	O
BIS	NN	O	O
ranges	NN	O	O
associated	NN	O	O
with	NN	O	O
recall	NN	O	O
after	NN	O	O
procedural	NN	O	O
sedation	NN	O	O
,	NN	O	O
suggestive	NN	O	O
of	NN	O	O
retrograde	NN	O	B-Disease
amnesia	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (15867025)

Assessment	NN	O	O
of	NN	O	O
perinatal	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
and	NN	O	O
rubella	NN	O	B-Disease
prevention	NN	O	O
in	NN	O	O
New	NN	O	O
Hampshire	NN	O	O
delivery	NN	O	O
hospitals	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
current	NN	O	O
performance	NN	O	O
on	NN	O	O
recommended	NN	O	O
perinatal	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
and	NN	O	O
rubella	NN	O	B-Disease
prevention	NN	O	O
practices	NN	O	O
in	NN	O	O
New	NN	O	O
Hampshire	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Data	NN	O	O
were	NN	O	O
extracted	NN	O	O
from	NN	O	O
2021	NN	O	O
paired	NN	O	O
mother	NN	O	O
-	NN	O	O
infant	NN	O	O
records	NN	O	O
for	NN	O	O
the	NN	O	O
year	NN	O	O
2000	NN	O	O
birth	NN	O	O
cohort	NN	O	O
in	NN	O	O
New	NN	O	O
Hampshire	NN	O	O
'	NN	O	O
s	NN	O	O
25	NN	O	O
delivery	NN	O	O
hospitals	NN	O	O
.	NN	O	O

Assessment	NN	O	O
was	NN	O	O
done	NN	O	O
on	NN	O	O
the	NN	O	O
following	NN	O	O
:	NN	O	O
prenatal	NN	O	O
screening	NN	O	O
for	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
and	NN	O	O
rubella	NN	O	B-Disease
,	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
vaccine	NN	O	O
birth	NN	O	O
dose	NN	O	O
to	NN	O	O
all	NN	O	O
infants	NN	O	O
,	NN	O	O
administration	NN	O	O
of	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
immune	NN	O	O
globulin	NN	O	O
to	NN	O	O
infants	NN	O	O
who	NN	O	O
were	NN	O	O
born	NN	O	O
to	NN	O	O
hepatitis	NN	O	B-Chemical
B	NN	O	I-Chemical
surface	NN	O	I-Chemical
antigen	NN	O	I-Chemical
-	NN	O	O
positive	NN	O	O
mothers	NN	O	O
,	NN	O	O
rubella	NN	O	B-Disease
immunity	NN	O	O
,	NN	O	O
and	NN	O	O
administration	NN	O	O
of	NN	O	O
in	NN	O	O
-	NN	O	O
hospital	NN	O	O
postpartum	NN	O	O
rubella	NN	O	B-Disease
vaccine	NN	O	O
to	NN	O	O
rubella	NN	O	B-Disease
nonimmune	NN	O	O
women	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Prenatal	NN	O	O
screening	NN	O	O
rates	NN	O	O
for	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
(	NN	O	O
98.8%	NN	O	O
)	NN	O	O
and	NN	O	O
rubella	NN	O	B-Disease
(	NN	O	O
99.4%	NN	O	O
)	NN	O	O
were	NN	O	O
high	NN	O	O
.	NN	O	O

Hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
vaccine	NN	O	O
birth	NN	O	O
dose	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
76.2%	NN	O	O
of	NN	O	O
all	NN	O	O
infants	NN	O	O
.	NN	O	O

All	NN	O	O
infants	NN	O	O
who	NN	O	O
were	NN	O	O
born	NN	O	O
to	NN	O	O
hepatitis	NN	O	B-Chemical
B	NN	O	I-Chemical
surface	NN	O	I-Chemical
antigen	NN	O	I-Chemical
-	NN	O	O
positive	NN	O	O
mothers	NN	O	O
also	NN	O	O
received	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
immune	NN	O	O
globulin	NN	O	O
.	NN	O	O

Multivariate	NN	O	O
logistic	NN	O	O
regression	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
month	NN	O	O
of	NN	O	O
delivery	NN	O	O
and	NN	O	O
infant	NN	O	O
birth	NN	O	O
weight	NN	O	O
were	NN	O	O
independent	NN	O	O
predictors	NN	O	O
of	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
vaccination	NN	O	O
.	NN	O	O

The	NN	O	O
proportion	NN	O	O
of	NN	O	O
infants	NN	O	O
who	NN	O	O
were	NN	O	O
vaccinated	NN	O	O
in	NN	O	O
January	NN	O	O
and	NN	O	O
February	NN	O	O
2000	NN	O	O
(	NN	O	O
48.5%	NN	O	O
and	NN	O	O
67.5%	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
was	NN	O	O
less	NN	O	O
than	NN	O	O
any	NN	O	O
other	NN	O	O
months	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
proportion	NN	O	O
who	NN	O	O
were	NN	O	O
vaccinated	NN	O	O
in	NN	O	O
December	NN	O	O
2000	NN	O	O
(	NN	O	O
88.2%	NN	O	O
)	NN	O	O
was	NN	O	O
the	NN	O	O
highest	NN	O	O
.	NN	O	O

Women	NN	O	O
who	NN	O	O
were	NN	O	O
born	NN	O	O
between	NN	O	O
1971	NN	O	O
and	NN	O	O
1975	NN	O	O
had	NN	O	O
the	NN	O	O
highest	NN	O	O
rate	NN	O	O
of	NN	O	O
rubella	NN	O	B-Disease
nonimmunity	NN	O	O
(	NN	O	O
9.5%	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
-	NN	O	O
hospital	NN	O	O
postpartum	NN	O	O
rubella	NN	O	B-Disease
vaccine	NN	O	O
administration	NN	O	O
was	NN	O	O
documented	NN	O	O
for	NN	O	O
75.6%	NN	O	O
of	NN	O	O
nonimmune	NN	O	O
women	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
documents	NN	O	O
good	NN	O	O
compliance	NN	O	O
in	NN	O	O
New	NN	O	O
Hampshire	NN	O	O
'	NN	O	O
s	NN	O	O
birthing	NN	O	O
hospitals	NN	O	O
with	NN	O	O
national	NN	O	O
guidelines	NN	O	O
for	NN	O	O
perinatal	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
and	NN	O	O
rubella	NN	O	B-Disease
prevention	NN	O	O
and	NN	O	O
highlights	NN	O	O
potential	NN	O	O
areas	NN	O	O
for	NN	O	O
improvement	NN	O	O
.	NN	O	O


-DOCSTART- (14975762)

Expression	NN	O	O
of	NN	O	O
p300	NN	O	O
protects	NN	O	O
cardiac	NN	O	O
myocytes	NN	O	O
from	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

Doxorubicin	NN	O	B-Chemical
is	NN	O	O
an	NN	O	O
anti	NN	O	O
-	NN	O	O
tumor	NN	O	B-Disease
agent	NN	O	O
that	NN	O	O
represses	NN	O	O
cardiac	NN	O	O
-	NN	O	O
specific	NN	O	O
gene	NN	O	O
expression	NN	O	O
and	NN	O	O
induces	NN	O	O
myocardial	NN	O	O
cell	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

Doxorubicin	NN	O	B-Chemical
depletes	NN	O	O
cardiac	NN	O	O
p300	NN	O	O
,	NN	O	O
a	NN	O	O
transcriptional	NN	O	O
coactivator	NN	O	O
that	NN	O	O
is	NN	O	O
required	NN	O	O
for	NN	O	O
the	NN	O	O
maintenance	NN	O	O
of	NN	O	O
the	NN	O	O
differentiated	NN	O	O
phenotype	NN	O	O
of	NN	O	O
cardiac	NN	O	O
myocytes	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
p300	NN	O	O
in	NN	O	O
protection	NN	O	O
against	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
apoptosis	NN	O	O
is	NN	O	O
unknown	NN	O	O
.	NN	O	O

Transgenic	NN	O	O
mice	NN	O	O
overexpressing	NN	O	O
p300	NN	O	O
in	NN	O	O
the	NN	O	O
heart	NN	O	O
and	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
mice	NN	O	O
were	NN	O	O
subjected	NN	O	O
to	NN	O	O
doxorubicin	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
mice	NN	O	O
,	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
exhibited	NN	O	O
higher	NN	O	O
survival	NN	O	O
rate	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
more	NN	O	O
preserved	NN	O	O
left	NN	O	O
ventricular	NN	O	O
function	NN	O	O
and	NN	O	O
cardiac	NN	O	O
expression	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
sarcomeric	NN	O	O
actin	NN	O	O
.	NN	O	O

Doxorubicin	NN	O	B-Chemical
induced	NN	O	O
myocardial	NN	O	O
cell	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
mice	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
transgenic	NN	O	O
mice	NN	O	O
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
p300	NN	O	O
increased	NN	O	O
the	NN	O	O
cardiac	NN	O	O
level	NN	O	O
of	NN	O	O
bcl	NN	O	O
-	NN	O	O
2	NN	O	O
and	NN	O	O
mdm	NN	O	O
-	NN	O	O
2	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
that	NN	O	O
of	NN	O	O
p53	NN	O	O
or	NN	O	O
other	NN	O	O
members	NN	O	O
of	NN	O	O
the	NN	O	O
bcl	NN	O	O
-	NN	O	O
2	NN	O	O
family	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
overexpression	NN	O	O
of	NN	O	O
p300	NN	O	O
protects	NN	O	O
cardiac	NN	O	O
myocytes	NN	O	O
from	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
apoptosis	NN	O	O
and	NN	O	O
reduces	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
acute	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
in	NN	O	O
adult	NN	O	O
mice	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O


-DOCSTART- (14736955)

Mitochondrial	NN	O	O
DNA	NN	O	O
and	NN	O	O
its	NN	O	O
respiratory	NN	O	O
chain	NN	O	O
products	NN	O	O
are	NN	O	O
defective	NN	O	O
in	NN	O	O
doxorubicin	NN	O	B-Chemical
nephrosis	NN	O	B-Disease
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Doxorubicin	NN	O	B-Chemical
induces	NN	O	O
a	NN	O	O
self	NN	O	O
-	NN	O	O
perpetuating	NN	O	O
nephropathy	NN	O	B-Disease
characterized	NN	O	O
by	NN	O	O
early	NN	O	O
glomerular	NN	O	B-Disease
and	NN	O	I-Disease
late	NN	O	I-Disease
-	NN	O	I-Disease
onset	NN	O	I-Disease
tubular	NN	O	I-Disease
lesions	NN	O	I-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
potential	NN	O	O
role	NN	O	O
of	NN	O	O
mitochondrial	NN	O	B-Disease
injury	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
these	NN	O	O
lesions	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
intravenous	NN	O	O
doxorubicin	NN	O	B-Chemical
(	NN	O	O
1	NN	O	O
mg	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
week	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
)	NN	O	O
for	NN	O	O
7	NN	O	O
weeks	NN	O	O
and	NN	O	O
were	NN	O	O
sacrificed	NN	O	O
either	NN	O	O
1	NN	O	O
week	NN	O	O
(	NN	O	O
'	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
'	NN	O	O
)	NN	O	O
or	NN	O	O
30	NN	O	O
weeks	NN	O	O
(	NN	O	O
'	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
'	NN	O	O
)	NN	O	O
following	NN	O	O
the	NN	O	O
last	NN	O	O
dose	NN	O	O
.	NN	O	O

Additional	NN	O	O
rats	NN	O	O
received	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
either	NN	O	O
6	NN	O	O
days	NN	O	O
or	NN	O	O
2	NN	O	O
h	NN	O	O
prior	NN	O	O
to	NN	O	O
euthanasia	NN	O	O
.	NN	O	O

All	NN	O	O
rats	NN	O	O
were	NN	O	O
killed	NN	O	O
at	NN	O	O
48	NN	O	O
weeks	NN	O	O
of	NN	O	O
age	NN	O	O
.	NN	O	O

Glomerular	NN	O	B-Disease
and	NN	O	I-Disease
tubular	NN	O	I-Disease
injury	NN	O	I-Disease
was	NN	O	O
monitored	NN	O	O
and	NN	O	O
correlated	NN	O	O
to	NN	O	O
the	NN	O	O
activity	NN	O	O
or	NN	O	O
expression	NN	O	O
of	NN	O	O
respiratory	NN	O	O
chain	NN	O	O
components	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
we	NN	O	O
quantified	NN	O	O
both	NN	O	O
nuclear	NN	O	O
and	NN	O	O
mitochondrial	NN	O	O
DNA	NN	O	O
(	NN	O	O
mtDNA	NN	O	O
)	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
superoxide	NN	O	B-Chemical
production	NN	O	O
and	NN	O	O
the	NN	O	O
4834	NN	O	O
base	NN	O	O
pair	NN	O	O
'	NN	O	O
common	NN	O	O
'	NN	O	O
mtDNA	NN	O	O
deletion	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
'	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
'	NN	O	O
group	NN	O	O
had	NN	O	O
significant	NN	O	O
glomerular	NN	O	B-Disease
and	NN	O	I-Disease
tubular	NN	O	I-Disease
lesions	NN	O	I-Disease
,	NN	O	O
depressed	NN	O	O
activities	NN	O	O
of	NN	O	O
mtDNA	NN	O	O
-	NN	O	O
encoded	NN	O	O
NADH	NN	O	O
dehydrogenase	NN	O	O
and	NN	O	O
cytochrome	NN	O	O
-	NN	O	O
c	NN	O	O
oxidase	NN	O	O
(	NN	O	O
COX	NN	O	O
)	NN	O	O
and	NN	O	O
increased	NN	O	O
citrate	NN	O	B-Chemical
synthase	NN	O	O
activity	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
mtDNA	NN	O	O
-	NN	O	O
encoded	NN	O	O
COX	NN	O	O
subunit	NN	O	O
I	NN	O	O
was	NN	O	O
reduced	NN	O	O
and	NN	O	O
mtDNA	NN	O	O
levels	NN	O	O
were	NN	O	O
decreased	NN	O	O
.	NN	O	O

In	NN	O	O
'	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
'	NN	O	O
rats	NN	O	O
,	NN	O	O
there	NN	O	O
were	NN	O	O
fewer	NN	O	O
tubular	NN	O	B-Disease
lesions	NN	O	I-Disease
,	NN	O	O
but	NN	O	O
similar	NN	O	O
numbers	NN	O	O
of	NN	O	O
glomerular	NN	O	B-Disease
lesions	NN	O	I-Disease
activity	NN	O	O
.	NN	O	O

Among	NN	O	O
all	NN	O	O
animals	NN	O	O
,	NN	O	O
glomerular	NN	O	B-Disease
and	NN	O	I-Disease
tubular	NN	O	I-Disease
injury	NN	O	I-Disease
were	NN	O	O
inversely	NN	O	O
correlated	NN	O	O
with	NN	O	O
mtDNA	NN	O	O
levels	NN	O	O
,	NN	O	O
mtDNA	NN	O	O
-	NN	O	O
encoded	NN	O	O
respiratory	NN	O	O
chain	NN	O	O
activities	NN	O	O
and	NN	O	O
with	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
the	NN	O	O
mtDNA	NN	O	O
-	NN	O	O
encoded	NN	O	O
respiratory	NN	O	O
chain	NN	O	O
subunit	NN	O	O
COX	NN	O	O
-	NN	O	O
I	NN	O	O
.	NN	O	O

Injury	NN	O	O
was	NN	O	O
positively	NN	O	O
correlated	NN	O	O
with	NN	O	O
superoxide	NN	O	B-Chemical
production	NN	O	O
and	NN	O	O
the	NN	O	O
activities	NN	O	O
of	NN	O	O
nucleus	NN	O	O
-	NN	O	O
encoded	NN	O	O
mitochondrial	NN	O	O
or	NN	O	O
cytoplasmic	NN	O	O
enzymes	NN	O	O
.	NN	O	O

Kidneys	NN	O	O
from	NN	O	O
the	NN	O	O
'	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
'	NN	O	O
group	NN	O	O
showed	NN	O	O
more	NN	O	O
mtDNA	NN	O	O
deletions	NN	O	O
than	NN	O	O
in	NN	O	O
'	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
'	NN	O	O
animals	NN	O	O
and	NN	O	O
these	NN	O	O
were	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
These	NN	O	O
results	NN	O	O
suggest	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
for	NN	O	O
quantitative	NN	O	O
and	NN	O	O
qualitative	NN	O	O
mtDNA	NN	O	O
alterations	NN	O	O
through	NN	O	O
the	NN	O	O
reduction	NN	O	O
of	NN	O	O
mtDNA	NN	O	O
-	NN	O	O
encoded	NN	O	O
respiratory	NN	O	O
chain	NN	O	O
function	NN	O	O
and	NN	O	O
induction	NN	O	O
of	NN	O	O
superoxide	NN	O	B-Chemical
in	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
renal	NN	O	B-Disease
lesions	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (11573852)

Amphotericin	NN	O	B-Chemical
B	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
AIDS	NN	O	B-Disease
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
multiple	NN	O	O
episodes	NN	O	O
of	NN	O	O
seizure	NN	O	B-Disease
activity	NN	O	O
in	NN	O	O
an	NN	O	O
AIDS	NN	O	B-Disease
patent	NN	O	O
following	NN	O	O
amphotericin	NN	O	B-Chemical
B	NN	O	I-Chemical
infusion	NN	O	O
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
46	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
African	NN	O	O
-	NN	O	O
American	NN	O	O
man	NN	O	O
experienced	NN	O	O
recurrent	NN	O	O
grand	NN	O	B-Disease
mal	NN	O	I-Disease
seizures	NN	O	I-Disease
during	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
of	NN	O	O
amphotericin	NN	O	B-Chemical
B	NN	O	I-Chemical
,	NN	O	O
then	NN	O	O
petit	NN	O	O
mal	NN	O	O
seizures	NN	O	B-Disease
as	NN	O	O
the	NN	O	O
infusion	NN	O	O
was	NN	O	O
stopped	NN	O	O
and	NN	O	O
the	NN	O	O
drug	NN	O	O
concentrations	NN	O	O
decreased	NN	O	O
with	NN	O	O
time	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
concurrent	NN	O	O
medications	NN	O	O
included	NN	O	O
didanosine	NN	O	B-Chemical
,	NN	O	O
hydroxyzine	NN	O	B-Chemical
,	NN	O	O
promethazine	NN	O	B-Chemical
,	NN	O	O
hydrocortisone	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
prochlorperazine	NN	O	B-Chemical
.	NN	O	O

Despite	NN	O	O
administration	NN	O	O
of	NN	O	O
phenytoin	NN	O	B-Chemical
and	NN	O	O
lorazepam	NN	O	B-Chemical
,	NN	O	O
the	NN	O	O
seizures	NN	O	B-Disease
persisted	NN	O	O
and	NN	O	O
occurred	NN	O	O
only	NN	O	O
during	NN	O	O
amphotercin	NN	O	B-Chemical
B	NN	O	I-Chemical
administration	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
AIDS	NN	O	B-Disease
and	NN	O	O
cryptococcal	NN	O	B-Disease
meningitis	NN	O	I-Disease
,	NN	O	O
both	NN	O	O
of	NN	O	O
which	NN	O	O
the	NN	O	O
patient	NN	O	O
had	NN	O	O
,	NN	O	O
can	NN	O	O
potentially	NN	O	O
cause	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
patient	NN	O	O
had	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
alcohol	NN	O	B-Disease
abuse	NN	O	I-Disease
;	NN	O	O
alcohol	NN	O	B-Chemical
intake	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
withdrawal	NN	O	O
can	NN	O	O
also	NN	O	O
cause	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

Didanosine	NN	O	B-Chemical
also	NN	O	O
has	NN	O	O
a	NN	O	O
potential	NN	O	O
for	NN	O	O
inducing	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
these	NN	O	O
other	NN	O	O
potential	NN	O	O
causes	NN	O	O
of	NN	O	O
seizure	NN	O	B-Disease
were	NN	O	O
ruled	NN	O	O
out	NN	O	O
.	NN	O	O

The	NN	O	O
time	NN	O	O
course	NN	O	O
of	NN	O	O
events	NN	O	O
suggested	NN	O	O
that	NN	O	O
amphotericin	NN	O	B-Chemical
B	NN	O	I-Chemical
was	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
the	NN	O	O
seizures	NN	O	B-Disease
in	NN	O	O
this	NN	O	O
AIDS	NN	O	B-Disease
patient	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Amphotericin	NN	O	B-Chemical
B	NN	O	I-Chemical
seems	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
probable	NN	O	O
cause	NN	O	O
of	NN	O	O
the	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

To	NN	O	O
date	NN	O	O
,	NN	O	O
only	NN	O	O
three	NN	O	O
cases	NN	O	O
of	NN	O	O
seizures	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
amphotericin	NN	O	B-Chemical
B	NN	O	I-Chemical
have	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
,	NN	O	O
but	NN	O	O
healthcare	NN	O	O
providers	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
potential	NN	O	O
for	NN	O	O
this	NN	O	O
rare	NN	O	O
adverse	NN	O	O
effect	NN	O	O
.	NN	O	O


-DOCSTART- (9875685)

Therapeutic	NN	O	O
drug	NN	O	O
monitoring	NN	O	O
of	NN	O	O
tobramycin	NN	O	B-Chemical
:	NN	O	O
once	NN	O	O
-	NN	O	O
daily	NN	O	O
versus	NN	O	O
twice	NN	O	O
-	NN	O	O
daily	NN	O	O
dosage	NN	O	O
schedules	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
dosage	NN	O	O
regimen	NN	O	O
(	NN	O	O
once	NN	O	O
-	NN	O	O
daily	NN	O	O
vs	NN	O	O
.	NN	O	O

twice	NN	O	O
-	NN	O	O
daily	NN	O	O
)	NN	O	O
of	NN	O	O
tobramicyn	NN	O	B-Chemical
on	NN	O	O
steady	NN	O	O
-	NN	O	O
state	NN	O	O
serum	NN	O	O
concentrations	NN	O	O
and	NN	O	O
toxicity	NN	O	B-Disease
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Patients	NN	O	O
undergoing	NN	O	O
treatment	NN	O	O
with	NN	O	O
i.v.	NN	O	O
tobramycin	NN	O	B-Chemical
(	NN	O	O
4	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
were	NN	O	O
randomised	NN	O	O
to	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

Group	NN	O	O
OD	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
22	NN	O	O
)	NN	O	O
received	NN	O	O
a	NN	O	O
once	NN	O	O
-	NN	O	O
daily	NN	O	O
dose	NN	O	O
of	NN	O	O
tobramycin	NN	O	B-Chemical
and	NN	O	O
group	NN	O	O
TD	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
21	NN	O	O
)	NN	O	O
received	NN	O	O
the	NN	O	O
same	NN	O	O
dose	NN	O	O
divided	NN	O	O
into	NN	O	O
two	NN	O	O
doses	NN	O	O
daily	NN	O	O
.	NN	O	O

Tobramycin	NN	O	B-Chemical
serum	NN	O	O
concentrations	NN	O	O
(	NN	O	O
peak	NN	O	O
and	NN	O	O
trough	NN	O	O
)	NN	O	O
were	NN	O	O
measured	NN	O	O
by	NN	O	O
enzyme	NN	O	O
multiplied	NN	O	O
immunoassay	NN	O	O
.	NN	O	O

The	NN	O	O
renal	NN	O	O
and	NN	O	O
auditory	NN	O	O
functions	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
monitored	NN	O	O
before	NN	O	O
,	NN	O	O
during	NN	O	O
and	NN	O	O
immediately	NN	O	O
after	NN	O	O
treatment	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
two	NN	O	O
groups	NN	O	O
were	NN	O	O
comparable	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
sex	NN	O	O
,	NN	O	O
age	NN	O	O
,	NN	O	O
body	NN	O	O
weight	NN	O	O
and	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

No	NN	O	O
statistically	NN	O	O
significant	NN	O	O
differences	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
mean	NN	O	O
daily	NN	O	O
dose	NN	O	O
,	NN	O	O
duration	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
or	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
.	NN	O	O

Trough	NN	O	O
concentrations	NN	O	O
were	NN	O	O
<	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
ml	NN	O	O
in	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
(	NN	O	O
100%	NN	O	O
)	NN	O	O
.	NN	O	O

Peak	NN	O	O
concentrations	NN	O	O
were	NN	O	O
>	NN	O	O
6	NN	O	O
microg	NN	O	O
/	NN	O	O
ml	NN	O	O
in	NN	O	O
100%	NN	O	O
of	NN	O	O
the	NN	O	O
OD	NN	O	O
group	NN	O	O
and	NN	O	O
in	NN	O	O
67%	NN	O	O
of	NN	O	O
the	NN	O	O
TD	NN	O	O
group	NN	O	O
(	NN	O	O
P<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

Mean	NN	O	O
peak	NN	O	O
concentrations	NN	O	O
were	NN	O	O
markedly	NN	O	O
different	NN	O	O
:	NN	O	O
11.00+	NN	O	O
/	NN	O	O
-	NN	O	O
2.89	NN	O	O
microg	NN	O	O
/	NN	O	O
ml	NN	O	O
in	NN	O	O
OD	NN	O	O
vs	NN	O	O
.	NN	O	O

6.53+	NN	O	O
/	NN	O	O
-	NN	O	O
1.45	NN	O	O
microg	NN	O	O
/	NN	O	O
ml	NN	O	O
in	NN	O	O
TD	NN	O	O
(	NN	O	O
P<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
pharmacokinetics	NN	O	O
parameters	NN	O	O
were	NN	O	O
:	NN	O	O
Ke	NN	O	O
,	NN	O	O
(	NN	O	O
0.15+	NN	O	O
/	NN	O	O
-	NN	O	O
0.03	NN	O	O
/	NN	O	O
h	NN	O	O
in	NN	O	O
OD	NN	O	O
vs	NN	O	O
.	NN	O	O

0.24+	NN	O	O
/	NN	O	O
-	NN	O	O
0.06	NN	O	O
/	NN	O	O
h	NN	O	O
in	NN	O	O
TD	NN	O	O
)	NN	O	O
,	NN	O	O
t1	NN	O	O
/	NN	O	O
2	NN	O	O
,	NN	O	O
(	NN	O	O
4.95+	NN	O	O
/	NN	O	O
-	NN	O	O
1.41	NN	O	O
h	NN	O	O
in	NN	O	O
OD	NN	O	O
vs	NN	O	O
.	NN	O	O

3.07+	NN	O	O
/	NN	O	O
-	NN	O	O
0.71	NN	O	O
h	NN	O	O
in	NN	O	O
TD	NN	O	O
)	NN	O	O
,	NN	O	O
Vd	NN	O	O
(	NN	O	O
0.35+	NN	O	O
/	NN	O	O
-	NN	O	O
0.11	NN	O	O
l	NN	O	O
/	NN	O	O
kg	NN	O	O
in	NN	O	O
OD	NN	O	O
vs	NN	O	O
.	NN	O	O

0.33+	NN	O	O
/	NN	O	O
-	NN	O	O
0.09	NN	O	O
l	NN	O	O
/	NN	O	O
kg	NN	O	O
in	NN	O	O
TD	NN	O	O
)	NN	O	O
,	NN	O	O
Cl	NN	O	O
(	NN	O	O
0.86+	NN	O	O
/	NN	O	O
-	NN	O	O
0.29	NN	O	O
ml	NN	O	O
/	NN	O	O
min	NN	O	O
/	NN	O	O
kg	NN	O	O
in	NN	O	O
OD	NN	O	O
vs	NN	O	O
.	NN	O	O

1.28+	NN	O	O
/	NN	O	O
-	NN	O	O
0.33	NN	O	O
ml	NN	O	O
/	NN	O	O
min	NN	O	O
/	NN	O	O
kg	NN	O	O
in	NN	O	O
TD	NN	O	O
)	NN	O	O
.	NN	O	O

Increased	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
was	NN	O	O
observed	NN	O	O
in	NN	O	O
73%	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
OD	NN	O	O
versus	NN	O	O
57%	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
TD	NN	O	O
,	NN	O	O
without	NN	O	O
evidence	NN	O	O
of	NN	O	O
nephrotoxicity	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
TD	NN	O	O
group	NN	O	O
,	NN	O	O
three	NN	O	O
patients	NN	O	O
developed	NN	O	O
decreased	NN	O	B-Disease
auditory	NN	O	I-Disease
function	NN	O	I-Disease
,	NN	O	O
of	NN	O	O
which	NN	O	O
one	NN	O	O
presented	NN	O	O
with	NN	O	O
an	NN	O	O
auditory	NN	O	B-Disease
loss	NN	O	I-Disease
of	NN	O	O
-	NN	O	O
30	NN	O	O
dB	NN	O	O
,	NN	O	O
whereas	NN	O	O
in	NN	O	O
the	NN	O	O
OD	NN	O	O
group	NN	O	O
only	NN	O	O
one	NN	O	O
patient	NN	O	O
presented	NN	O	O
decreased	NN	O	B-Disease
auditory	NN	O	I-Disease
function	NN	O	I-Disease
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
small	NN	O	O
study	NN	O	O
suggests	NN	O	O
that	NN	O	O
a	NN	O	O
once	NN	O	O
-	NN	O	O
daily	NN	O	O
dosing	NN	O	O
regimen	NN	O	O
of	NN	O	O
tobramycin	NN	O	B-Chemical
is	NN	O	O
at	NN	O	O
least	NN	O	O
as	NN	O	O
effective	NN	O	O
as	NN	O	O
and	NN	O	O
is	NN	O	O
no	NN	O	O
more	NN	O	O
and	NN	O	O
possibly	NN	O	O
less	NN	O	O
toxic	NN	O	O
than	NN	O	O
the	NN	O	O
twice	NN	O	O
-	NN	O	O
daily	NN	O	O
regimen	NN	O	O
.	NN	O	O

Using	NN	O	O
a	NN	O	O
single	NN	O	O
-	NN	O	O
dose	NN	O	O
therapy	NN	O	O
,	NN	O	O
peak	NN	O	O
concentration	NN	O	O
determination	NN	O	O
is	NN	O	O
not	NN	O	O
necessary	NN	O	O
,	NN	O	O
only	NN	O	O
trough	NN	O	O
samples	NN	O	O
should	NN	O	O
be	NN	O	O
monitored	NN	O	O
to	NN	O	O
ensure	NN	O	O
levels	NN	O	O
below	NN	O	O
2	NN	O	O
microg	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O


-DOCSTART- (9848575)

Chronic	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
novel	NN	O	O
synthetic	NN	O	O
anthracycline	NN	O	B-Chemical
derivative	NN	O	O
(	NN	O	O
SM	NN	O	B-Chemical
-	NN	O	I-Chemical
5887	NN	O	I-Chemical
)	NN	O	O
on	NN	O	O
normal	NN	O	O
heart	NN	O	O
and	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B-Disease
in	NN	O	O
beagle	NN	O	O
dogs	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
chronic	NN	O	O
cardiotoxic	NN	O	B-Disease
potential	NN	O	O
of	NN	O	O
SM	NN	O	B-Chemical
-	NN	O	I-Chemical
5887	NN	O	I-Chemical
and	NN	O	O
a	NN	O	O
possible	NN	O	O
deteriorating	NN	O	O
effect	NN	O	O
of	NN	O	O
SM	NN	O	B-Chemical
-	NN	O	I-Chemical
5887	NN	O	I-Chemical
on	NN	O	O
low	NN	O	O
-	NN	O	O
grade	NN	O	O
cardiotoxicity	NN	O	B-Disease
pre	NN	O	O
-	NN	O	O
induced	NN	O	O
by	NN	O	O
doxorubicin	NN	O	B-Chemical
in	NN	O	O
beagle	NN	O	O
dogs	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
chronic	NN	O	O
treatment	NN	O	O
,	NN	O	O
beagle	NN	O	O
dogs	NN	O	O
of	NN	O	O
each	NN	O	O
sex	NN	O	O
were	NN	O	O
given	NN	O	O
intravenously	NN	O	O
once	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
,	NN	O	O
either	NN	O	O
a	NN	O	O
sublethal	NN	O	O
dose	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
(	NN	O	O
1.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
or	NN	O	O
SM	NN	O	B-Chemical
-	NN	O	I-Chemical
5887	NN	O	I-Chemical
(	NN	O	O
2.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
experiment	NN	O	O
was	NN	O	O
terminated	NN	O	O
3	NN	O	O
weeks	NN	O	O
after	NN	O	O
the	NN	O	O
ninth	NN	O	O
dosing	NN	O	O
.	NN	O	O

Animals	NN	O	O
which	NN	O	O
received	NN	O	O
over	NN	O	O
six	NN	O	O
courses	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
demonstrated	NN	O	O
the	NN	O	O
electrocardiogram	NN	O	O
(	NN	O	O
ECG	NN	O	O
)	NN	O	O
changes	NN	O	O
,	NN	O	O
decrease	NN	O	O
of	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
high	NN	O	O
-	NN	O	O
grade	NN	O	O
histopathological	NN	O	O
cardiomyopathy	NN	O	B-Disease
,	NN	O	O
while	NN	O	O
animals	NN	O	O
which	NN	O	O
were	NN	O	O
terminally	NN	O	O
sacrificed	NN	O	O
after	NN	O	O
the	NN	O	O
SM	NN	O	B-Chemical
-	NN	O	I-Chemical
5887	NN	O	I-Chemical
administration	NN	O	O
did	NN	O	O
not	NN	O	O
show	NN	O	O
any	NN	O	O
changes	NN	O	O
in	NN	O	O
ECG	NN	O	O
,	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
histopathological	NN	O	O
examinations	NN	O	O
.	NN	O	O

To	NN	O	O
examine	NN	O	O
a	NN	O	O
possibly	NN	O	O
deteriorating	NN	O	O
cardiotoxic	NN	O	B-Disease
effect	NN	O	O
of	NN	O	O
SM	NN	O	B-Chemical
-	NN	O	I-Chemical
5887	NN	O	I-Chemical
,	NN	O	O
low	NN	O	O
-	NN	O	O
grade	NN	O	O
cardiomyopathy	NN	O	B-Disease
was	NN	O	O
induced	NN	O	O
in	NN	O	O
dogs	NN	O	O
by	NN	O	O
four	NN	O	O
courses	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
(	NN	O	O
1.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

Nine	NN	O	O
weeks	NN	O	O
after	NN	O	O
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
,	NN	O	O
dogs	NN	O	O
were	NN	O	O
given	NN	O	O
four	NN	O	O
courses	NN	O	O
of	NN	O	O
either	NN	O	O
doxorubicin	NN	O	B-Chemical
(	NN	O	O
1.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
or	NN	O	O
SM	NN	O	B-Chemical
-	NN	O	I-Chemical
5887	NN	O	I-Chemical
(	NN	O	O
2.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
once	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
low	NN	O	O
-	NN	O	O
grade	NN	O	O
cardiotoxic	NN	O	B-Disease
changes	NN	O	O
were	NN	O	O
enhanced	NN	O	O
by	NN	O	O
the	NN	O	O
additional	NN	O	O
doxorubicin	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
contrary	NN	O	O
,	NN	O	O
the	NN	O	O
SM	NN	O	B-Chemical
-	NN	O	I-Chemical
5887	NN	O	I-Chemical
treatment	NN	O	O
did	NN	O	O
not	NN	O	O
progress	NN	O	O
the	NN	O	O
grade	NN	O	O
of	NN	O	O
cardiomyopathy	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
SM	NN	O	B-Chemical
-	NN	O	I-Chemical
5887	NN	O	I-Chemical
does	NN	O	O
not	NN	O	O
have	NN	O	O
any	NN	O	O
potential	NN	O	O
of	NN	O	O
chronic	NN	O	O
cardiotoxicity	NN	O	B-Disease
and	NN	O	O
deteriorating	NN	O	O
effect	NN	O	O
on	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B-Disease
in	NN	O	O
dogs	NN	O	O
.	NN	O	O


-DOCSTART- (9321531)

Posteroventral	NN	O	O
medial	NN	O	O
pallidotomy	NN	O	O
in	NN	O	O
advanced	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Posteroventral	NN	O	O
medial	NN	O	O
pallidotomy	NN	O	O
sometimes	NN	O	O
produces	NN	O	O
striking	NN	O	O
improvement	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
but	NN	O	O
the	NN	O	O
studies	NN	O	O
to	NN	O	O
date	NN	O	O
have	NN	O	O
involved	NN	O	O
small	NN	O	O
numbers	NN	O	O
of	NN	O	O
patients	NN	O	O
and	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Forty	NN	O	O
patients	NN	O	O
with	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
underwent	NN	O	O
serial	NN	O	O
,	NN	O	O
detailed	NN	O	O
assessments	NN	O	O
both	NN	O	O
after	NN	O	O
drug	NN	O	O
withdrawal	NN	O	O
(	NN	O	O
"	NN	O	O
off	NN	O	O
"	NN	O	O
period	NN	O	O
)	NN	O	O
and	NN	O	O
while	NN	O	O
taking	NN	O	O
their	NN	O	O
optimal	NN	O	O
medical	NN	O	O
regimens	NN	O	O
(	NN	O	O
"	NN	O	O
on	NN	O	O
"	NN	O	O
period	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
were	NN	O	O
examined	NN	O	O
preoperatively	NN	O	O
and	NN	O	O
39	NN	O	O
were	NN	O	O
examined	NN	O	O
at	NN	O	O
six	NN	O	O
months	NN	O	O
;	NN	O	O
27	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
also	NN	O	O
examined	NN	O	O
at	NN	O	O
one	NN	O	O
year	NN	O	O
,	NN	O	O
and	NN	O	O
11	NN	O	O
at	NN	O	O
two	NN	O	O
years	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
percent	NN	O	O
improvements	NN	O	O
at	NN	O	O
six	NN	O	O
months	NN	O	O
were	NN	O	O
as	NN	O	O
follows	NN	O	O
:	NN	O	O
off	NN	O	O
-	NN	O	O
period	NN	O	O
score	NN	O	O
for	NN	O	O
overall	NN	O	O
motor	NN	O	O
function	NN	O	O
,	NN	O	O
28	NN	O	O
percent	NN	O	O
(	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
19	NN	O	O
to	NN	O	O
38	NN	O	O
percent	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
most	NN	O	O
of	NN	O	O
the	NN	O	O
improvement	NN	O	O
in	NN	O	O
the	NN	O	O
contralateral	NN	O	O
limbs	NN	O	O
;	NN	O	O
off	NN	O	O
-	NN	O	O
period	NN	O	O
score	NN	O	O
for	NN	O	O
activities	NN	O	O
of	NN	O	O
daily	NN	O	O
living	NN	O	O
,	NN	O	O
29	NN	O	O
percent	NN	O	O
(	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
19	NN	O	O
to	NN	O	O
39	NN	O	O
percent	NN	O	O
)	NN	O	O
;	NN	O	O
on	NN	O	O
-	NN	O	O
period	NN	O	O
score	NN	O	O
for	NN	O	O
contralateral	NN	O	O
dyskinesias	NN	O	B-Disease
,	NN	O	O
82	NN	O	O
percent	NN	O	O
(	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
72	NN	O	O
to	NN	O	O
91	NN	O	O
percent	NN	O	O
)	NN	O	O
;	NN	O	O
and	NN	O	O
on	NN	O	O
-	NN	O	O
period	NN	O	O
score	NN	O	O
for	NN	O	O
ipsilateral	NN	O	O
dyskinesias	NN	O	B-Disease
,	NN	O	O
44	NN	O	O
percent	NN	O	O
(	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
29	NN	O	O
to	NN	O	O
59	NN	O	O
percent	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
improvements	NN	O	O
in	NN	O	O
dyskinesias	NN	O	B-Disease
and	NN	O	O
the	NN	O	O
total	NN	O	O
scores	NN	O	O
for	NN	O	O
off	NN	O	O
-	NN	O	O
period	NN	O	O
parkinsonism	NN	O	B-Disease
,	NN	O	O
contralateral	NN	O	O
bradykinesia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
rigidity	NN	O	B-Disease
were	NN	O	O
sustained	NN	O	O
in	NN	O	O
the	NN	O	O
11	NN	O	O
patients	NN	O	O
examined	NN	O	O
at	NN	O	O
two	NN	O	O
years	NN	O	O
.	NN	O	O

The	NN	O	O
improvement	NN	O	O
in	NN	O	O
ipsilateral	NN	O	O
dyskinesias	NN	O	B-Disease
was	NN	O	O
lost	NN	O	O
after	NN	O	O
one	NN	O	O
year	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
improvements	NN	O	O
in	NN	O	O
postural	NN	O	O
stability	NN	O	O
and	NN	O	O
gait	NN	O	O
lasted	NN	O	O
only	NN	O	O
three	NN	O	O
to	NN	O	O
six	NN	O	O
months	NN	O	O
.	NN	O	O

Approximately	NN	O	O
half	NN	O	O
the	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
been	NN	O	O
dependent	NN	O	O
on	NN	O	O
assistance	NN	O	O
in	NN	O	O
activities	NN	O	O
of	NN	O	O
daily	NN	O	O
living	NN	O	O
in	NN	O	O
the	NN	O	O
off	NN	O	O
period	NN	O	O
before	NN	O	O
surgery	NN	O	O
became	NN	O	O
independent	NN	O	O
after	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
complications	NN	O	O
of	NN	O	O
surgery	NN	O	O
were	NN	O	O
generally	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
and	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
significant	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
medication	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
late	NN	O	O
-	NN	O	O
stage	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
pallidotomy	NN	O	O
significantly	NN	O	O
reduces	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
and	NN	O	O
off	NN	O	O
-	NN	O	O
period	NN	O	O
disability	NN	O	O
.	NN	O	O

Much	NN	O	O
of	NN	O	O
the	NN	O	O
benefit	NN	O	O
is	NN	O	O
sustained	NN	O	O
at	NN	O	O
two	NN	O	O
years	NN	O	O
,	NN	O	O
although	NN	O	O
some	NN	O	O
improvements	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
those	NN	O	O
on	NN	O	O
the	NN	O	O
ipsilateral	NN	O	O
side	NN	O	O
and	NN	O	O
in	NN	O	O
axial	NN	O	O
symptoms	NN	O	O
,	NN	O	O
wane	NN	O	O
within	NN	O	O
the	NN	O	O
first	NN	O	O
year	NN	O	O
.	NN	O	O

The	NN	O	O
on	NN	O	O
-	NN	O	O
period	NN	O	O
symptoms	NN	O	O
that	NN	O	O
are	NN	O	O
resistant	NN	O	O
to	NN	O	O
dopaminergic	NN	O	O
therapy	NN	O	O
do	NN	O	O
not	NN	O	O
respond	NN	O	O
to	NN	O	O
pallidotomy	NN	O	O
.	NN	O	O


-DOCSTART- (9305828)

Neuropeptide	NN	O	O
-	NN	O	O
Y	NN	O	O
immunoreactivity	NN	O	O
in	NN	O	O
the	NN	O	O
pilocarpine	NN	O	B-Chemical
model	NN	O	O
of	NN	O	O
temporal	NN	O	B-Disease
lobe	NN	O	I-Disease
epilepsy	NN	O	I-Disease
.	NN	O	O

Neuropeptide	NN	O	O
-	NN	O	O
Y	NN	O	O
(	NN	O	O
NPY	NN	O	O
)	NN	O	O
is	NN	O	O
expressed	NN	O	O
by	NN	O	O
granule	NN	O	O
cells	NN	O	O
and	NN	O	O
mossy	NN	O	O
fibres	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampal	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
during	NN	O	O
experimental	NN	O	O
temporal	NN	O	B-Disease
lobe	NN	O	I-Disease
epilepsy	NN	O	I-Disease
(	NN	O	O
TLE	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

This	NN	O	O
expression	NN	O	O
may	NN	O	O
represent	NN	O	O
an	NN	O	O
endogenous	NN	O	O
damping	NN	O	O
mechanism	NN	O	O
since	NN	O	O
NPY	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
block	NN	O	O
seizure	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
events	NN	O	O
following	NN	O	O
high	NN	O	O
-	NN	O	O
frequency	NN	O	O
stimulation	NN	O	O
in	NN	O	O
hippocampal	NN	O	O
slices	NN	O	O
.	NN	O	O

The	NN	O	O
pilocarpine	NN	O	B-Chemical
(	NN	O	O
PILO	NN	O	B-Chemical
)	NN	O	O
model	NN	O	O
of	NN	O	O
epilepsy	NN	O	B-Disease
is	NN	O	O
characterized	NN	O	O
by	NN	O	O
an	NN	O	O
acute	NN	O	O
period	NN	O	O
of	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
followed	NN	O	O
by	NN	O	O
spontaneous	NN	O	O
recurrent	NN	O	O
seizures	NN	O	B-Disease
and	NN	O	O
related	NN	O	O
brain	NN	O	B-Disease
damage	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
report	NN	O	O
peroxidase	NN	O	O
-	NN	O	O
antiperoxidase	NN	O	O
immunostaining	NN	O	O
for	NN	O	O
NPY	NN	O	O
in	NN	O	O
several	NN	O	O
brain	NN	O	O
regions	NN	O	O
in	NN	O	O
this	NN	O	O
model	NN	O	O
.	NN	O	O

PILO	NN	O	B-Chemical
-	NN	O	O
injected	NN	O	O
animals	NN	O	O
exhibited	NN	O	O
NPY	NN	O	O
immunoreactivity	NN	O	O
in	NN	O	O
the	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
mossy	NN	O	O
fibre	NN	O	O
terminals	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
inner	NN	O	O
molecular	NN	O	O
layer	NN	O	O
and	NN	O	O
,	NN	O	O
in	NN	O	O
a	NN	O	O
few	NN	O	O
cases	NN	O	O
,	NN	O	O
within	NN	O	O
presumed	NN	O	O
granule	NN	O	O
cells	NN	O	O
.	NN	O	O

NPY	NN	O	O
immunoreactivity	NN	O	O
was	NN	O	O
also	NN	O	O
dramatically	NN	O	O
changed	NN	O	O
in	NN	O	O
the	NN	O	O
entorhinal	NN	O	O
cortex	NN	O	O
,	NN	O	O
amygdala	NN	O	O
and	NN	O	O
sensorimotor	NN	O	O
areas	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
PILO	NN	O	B-Chemical
injected	NN	O	O
animals	NN	O	O
exhibited	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
NPY	NN	O	O
-	NN	O	O
immunoreactive	NN	O	O
interneurons	NN	O	O
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
changes	NN	O	O
in	NN	O	O
NPY	NN	O	O
expression	NN	O	O
,	NN	O	O
including	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
granule	NN	O	O
cells	NN	O	O
and	NN	O	O
mossy	NN	O	O
fibres	NN	O	O
and	NN	O	O
the	NN	O	O
loss	NN	O	O
of	NN	O	O
vulnerable	NN	O	O
NPY	NN	O	O
neurons	NN	O	O
,	NN	O	O
are	NN	O	O
present	NN	O	O
in	NN	O	O
the	NN	O	O
PILO	NN	O	B-Chemical
model	NN	O	O
of	NN	O	O
TLE	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
significance	NN	O	O
of	NN	O	O
this	NN	O	O
changed	NN	O	O
synthesis	NN	O	O
of	NN	O	O
NPY	NN	O	O
remains	NN	O	O
to	NN	O	O
be	NN	O	O
determined	NN	O	O
.	NN	O	O


-DOCSTART- (9041081)

Effect	NN	O	O
of	NN	O	O
myopic	NN	O	O
excimer	NN	O	O
laser	NN	O	O
photorefractive	NN	O	O
keratectomy	NN	O	O
on	NN	O	O
the	NN	O	O
electrophysiologic	NN	O	O
function	NN	O	O
of	NN	O	O
the	NN	O	O
retina	NN	O	O
and	NN	O	O
optic	NN	O	O
nerve	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
by	NN	O	O
electrophysiologic	NN	O	O
testing	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
photorefractive	NN	O	O
keratectomy	NN	O	O
(	NN	O	O
PRK	NN	O	O
)	NN	O	O
on	NN	O	O
the	NN	O	O
retina	NN	O	O
and	NN	O	O
optic	NN	O	O
nerve	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
Eye	NN	O	O
Clinic	NN	O	O
,	NN	O	O
S	NN	O	O
.	NN	O	O

Salvatore	NN	O	O
Hospital	NN	O	O
,	NN	O	O
L	NN	O	O
'	NN	O	O
Aquila	NN	O	O
University	NN	O	O
,	NN	O	O
Italy	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Standard	NN	O	O
pattern	NN	O	O
electroretinograms	NN	O	O
(	NN	O	O
P	NN	O	O
-	NN	O	O
ERGs	NN	O	O
)	NN	O	O
and	NN	O	O
standard	NN	O	O
pattern	NN	O	O
visual	NN	O	O
evoked	NN	O	O
potentials	NN	O	O
(	NN	O	O
P	NN	O	O
-	NN	O	O
VEPs	NN	O	O
)	NN	O	O
were	NN	O	O
done	NN	O	O
in	NN	O	O
25	NN	O	O
eyes	NN	O	O
of	NN	O	O
25	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
myopic	NN	O	O
PRK	NN	O	O
for	NN	O	O
an	NN	O	O
attempted	NN	O	O
correction	NN	O	O
between	NN	O	O
5.00	NN	O	O
and	NN	O	O
15.00	NN	O	O
diopters	NN	O	O
(	NN	O	O
D	NN	O	O
)	NN	O	O
(	NN	O	O
mean	NN	O	O
8.00	NN	O	O
D	NN	O	O
)	NN	O	O
.	NN	O	O

Testing	NN	O	O
was	NN	O	O
done	NN	O	O
preoperatively	NN	O	O
and	NN	O	O
3	NN	O	O
,	NN	O	O
6	NN	O	O
,	NN	O	O
12	NN	O	O
,	NN	O	O
and	NN	O	O
18	NN	O	O
months	NN	O	O
postoperatively	NN	O	O
.	NN	O	O

The	NN	O	O
contralateral	NN	O	O
eyes	NN	O	O
served	NN	O	O
as	NN	O	O
controls	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
,	NN	O	O
3	NN	O	O
patients	NN	O	O
(	NN	O	O
12%	NN	O	O
)	NN	O	O
developed	NN	O	O
steroid	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
elevated	NN	O	B-Disease
intraocular	NN	O	I-Disease
pressure	NN	O	I-Disease
(	NN	O	O
IOP	NN	O	O
)	NN	O	O
that	NN	O	O
resolved	NN	O	O
after	NN	O	O
corticosteroid	NN	O	B-Chemical
therapy	NN	O	O
was	NN	O	O
discontinued	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
No	NN	O	O
statistically	NN	O	O
significant	NN	O	O
differences	NN	O	O
were	NN	O	O
seen	NN	O	O
between	NN	O	O
treated	NN	O	O
and	NN	O	O
control	NN	O	O
eyes	NN	O	O
nor	NN	O	O
between	NN	O	O
treated	NN	O	O
eyes	NN	O	O
preoperatively	NN	O	O
and	NN	O	O
postoperatively	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Myopic	NN	O	O
excimer	NN	O	O
laser	NN	O	O
PRK	NN	O	O
did	NN	O	O
not	NN	O	O
seem	NN	O	O
to	NN	O	O
affect	NN	O	O
the	NN	O	O
posterior	NN	O	O
segment	NN	O	O
.	NN	O	O

The	NN	O	O
transient	NN	O	O
steroid	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
IOP	NN	O	B-Disease
rise	NN	O	I-Disease
did	NN	O	O
not	NN	O	O
seem	NN	O	O
to	NN	O	O
cause	NN	O	O
functional	NN	O	O
impairment	NN	O	O
.	NN	O	O


-DOCSTART- (8305357)

Liposomal	NN	O	O
daunorubicin	NN	O	B-Chemical
in	NN	O	O
advanced	NN	O	O
Kaposi	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
sarcoma	NN	O	I-Disease
:	NN	O	O
a	NN	O	O
phase	NN	O	O
II	NN	O	O
study	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
randomized	NN	O	O
Phase	NN	O	O
II	NN	O	O
clinical	NN	O	O
trial	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
liposomal	NN	O	O
daunorubicin	NN	O	B-Chemical
(	NN	O	O
DaunoXome	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
AIDS	NN	O	B-Disease
related	NN	O	O
Kaposi	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
sarcoma	NN	O	I-Disease
.	NN	O	O

Eleven	NN	O	O
homosexual	NN	O	O
men	NN	O	O
with	NN	O	O
advanced	NN	O	O
Kaposi	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
sarcoma	NN	O	I-Disease
were	NN	O	O
entered	NN	O	O
in	NN	O	O
the	NN	O	O
trial	NN	O	O
.	NN	O	O

Changes	NN	O	O
in	NN	O	O
size	NN	O	O
,	NN	O	O
colour	NN	O	O
and	NN	O	O
associated	NN	O	O
oedema	NN	O	B-Disease
of	NN	O	O
selected	NN	O	O
'	NN	O	O
target	NN	O	O
'	NN	O	O
lesions	NN	O	O
were	NN	O	O
measured	NN	O	O
.	NN	O	O

Clinical	NN	O	O
,	NN	O	O
biochemical	NN	O	O
and	NN	O	O
haematological	NN	O	O
toxicities	NN	O	B-Disease
were	NN	O	O
assessed	NN	O	O
.	NN	O	O

Ten	NN	O	O
subjects	NN	O	O
were	NN	O	O
evaluated	NN	O	O
.	NN	O	O

A	NN	O	O
partial	NN	O	O
response	NN	O	O
was	NN	O	O
achieved	NN	O	O
in	NN	O	O
four	NN	O	O
,	NN	O	O
of	NN	O	O
whom	NN	O	O
two	NN	O	O
subsequently	NN	O	O
relapsed	NN	O	O
.	NN	O	O

Stabilization	NN	O	O
of	NN	O	O
Kaposi	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
sarcoma	NN	O	I-Disease
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
remaining	NN	O	O
six	NN	O	O
,	NN	O	O
maintained	NN	O	O
until	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
trial	NN	O	O
period	NN	O	O
in	NN	O	O
four	NN	O	O
.	NN	O	O

The	NN	O	O
drug	NN	O	O
was	NN	O	O
generally	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
with	NN	O	O
few	NN	O	O
mild	NN	O	O
symptoms	NN	O	O
of	NN	O	O
toxicity	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
main	NN	O	O
problem	NN	O	O
encountered	NN	O	O
was	NN	O	O
haematological	NN	O	O
toxicity	NN	O	B-Disease
,	NN	O	O
with	NN	O	O
three	NN	O	O
subjects	NN	O	O
experiencing	NN	O	O
severe	NN	O	O
neutropenia	NN	O	B-Disease
(	NN	O	O
neutrophil	NN	O	O
count	NN	O	O
<	NN	O	O
0.5	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
/	NN	O	O
l	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
cardiotoxicity	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
this	NN	O	O
small	NN	O	O
patient	NN	O	O
sample	NN	O	O
,	NN	O	O
liposomal	NN	O	O
daunorubicin	NN	O	B-Chemical
was	NN	O	O
an	NN	O	O
effective	NN	O	O
and	NN	O	O
well	NN	O	O
tolerated	NN	O	O
agent	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
Kaposi	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
sarcoma	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (8012887)

Failure	NN	O	O
of	NN	O	O
ancrod	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
arterial	NN	O	O
thrombosis	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
morbidity	NN	O	O
and	NN	O	O
mortality	NN	O	O
associated	NN	O	O
with	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombosis	NN	O	B-Disease
remain	NN	O	O
high	NN	O	O
despite	NN	O	O
numerous	NN	O	O
empirical	NN	O	O
therapies	NN	O	O
.	NN	O	O

Ancrod	NN	O	O
has	NN	O	O
been	NN	O	O
used	NN	O	O
successfully	NN	O	O
for	NN	O	O
prophylaxis	NN	O	O
against	NN	O	O
development	NN	O	O
of	NN	O	O
thrombosis	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
with	NN	O	O
heparin	NN	O	B-Chemical
induced	NN	O	O
platelet	NN	O	B-Disease
aggregation	NN	O	I-Disease
who	NN	O	O
require	NN	O	O
brief	NN	O	O
reexposure	NN	O	O
to	NN	O	O
heparin	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
its	NN	O	O
success	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
developed	NN	O	O
the	NN	O	O
thrombosis	NN	O	B-Disease
syndrome	NN	O	O
is	NN	O	O
not	NN	O	O
well	NN	O	O
defined	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
failure	NN	O	O
of	NN	O	O
ancrod	NN	O	O
treatment	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombosis	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (7651879)

Seizure	NN	O	B-Disease
after	NN	O	O
flumazenil	NN	O	B-Chemical
administration	NN	O	O
in	NN	O	O
a	NN	O	O
pediatric	NN	O	O
patient	NN	O	O
.	NN	O	O

Flumazenil	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
benzodiazepine	NN	O	B-Chemical
receptor	NN	O	O
antagonist	NN	O	O
used	NN	O	O
to	NN	O	O
reverse	NN	O	O
sedation	NN	O	O
and	NN	O	O
respiratory	NN	O	B-Disease
depression	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
benzodiazepines	NN	O	B-Chemical
.	NN	O	O

Seizures	NN	O	B-Disease
and	NN	O	O
cardiac	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
have	NN	O	O
complicated	NN	O	O
its	NN	O	O
use	NN	O	O
in	NN	O	O
adult	NN	O	O
patients	NN	O	O
.	NN	O	O

Overdose	NN	O	B-Disease
patients	NN	O	O
who	NN	O	O
have	NN	O	O
coingested	NN	O	O
tricyclic	NN	O	O
antidepressants	NN	O	O
have	NN	O	O
a	NN	O	O
higher	NN	O	O
risk	NN	O	O
of	NN	O	O
these	NN	O	O
complications	NN	O	O
.	NN	O	O

Little	NN	O	O
information	NN	O	O
exists	NN	O	O
concerning	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
flumazenil	NN	O	B-Chemical
in	NN	O	O
children	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
a	NN	O	O
generalized	NN	O	O
tonic	NN	O	B-Disease
-	NN	O	I-Disease
clonic	NN	O	I-Disease
seizure	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
pediatric	NN	O	O
patient	NN	O	O
following	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
flumazenil	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (3015327)

Remodelling	NN	O	O
of	NN	O	O
nerve	NN	O	O
structure	NN	O	O
in	NN	O	O
experimental	NN	O	O
isoniazid	NN	O	B-Chemical
neuropathy	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

The	NN	O	O
neuropathy	NN	O	B-Disease
caused	NN	O	O
by	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
isoniazid	NN	O	B-Chemical
in	NN	O	O
rats	NN	O	O
was	NN	O	O
studied	NN	O	O
with	NN	O	O
a	NN	O	O
computer	NN	O	O
-	NN	O	O
assisted	NN	O	O
morphometric	NN	O	O
method	NN	O	O
.	NN	O	O

Scatter	NN	O	O
diagrams	NN	O	O
of	NN	O	O
the	NN	O	O
g	NN	O	O
ratio	NN	O	O
(	NN	O	O
quotient	NN	O	O
fibre	NN	O	O
diameter	NN	O	O
/	NN	O	O
axon	NN	O	O
diameter	NN	O	O
)	NN	O	O
define	NN	O	O
regenerating	NN	O	O
fibres	NN	O	O
as	NN	O	O
a	NN	O	O
distinct	NN	O	O
population	NN	O	O
,	NN	O	O
distinguishable	NN	O	O
from	NN	O	O
the	NN	O	O
surviving	NN	O	O
fibres	NN	O	O
by	NN	O	O
reduced	NN	O	O
sheath	NN	O	O
thickness	NN	O	O
and	NN	O	O
reduced	NN	O	O
axon	NN	O	O
calibre	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
also	NN	O	O
evidence	NN	O	O
of	NN	O	O
a	NN	O	O
subtle	NN	O	O
direct	NN	O	O
toxic	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
entire	NN	O	O
fibre	NN	O	O
population	NN	O	O
,	NN	O	O
causing	NN	O	O
axon	NN	O	O
shrinkage	NN	O	O
masked	NN	O	O
by	NN	O	O
readjustment	NN	O	O
of	NN	O	O
the	NN	O	O
myelin	NN	O	O
sheath	NN	O	O
.	NN	O	O


-DOCSTART- (2980315)

Selective	NN	O	O
injection	NN	O	O
of	NN	O	O
iopentol	NN	O	B-Chemical
,	NN	O	O
iohexol	NN	O	B-Chemical
and	NN	O	O
metrizoate	NN	O	B-Chemical
into	NN	O	O
the	NN	O	O
left	NN	O	O
coronary	NN	O	O
artery	NN	O	O
of	NN	O	O
the	NN	O	O
dog	NN	O	O
.	NN	O	O

Induction	NN	O	O
of	NN	O	O
ventricular	NN	O	B-Disease
fibrillation	NN	O	I-Disease
and	NN	O	O
decrease	NN	O	O
of	NN	O	O
aortic	NN	O	O
pressure	NN	O	O
.	NN	O	O

In	NN	O	O
twenty	NN	O	O
beagle	NN	O	O
dogs	NN	O	O
selective	NN	O	O
injections	NN	O	O
were	NN	O	O
made	NN	O	O
into	NN	O	O
the	NN	O	O
left	NN	O	O
coronary	NN	O	O
artery	NN	O	O
with	NN	O	O
iopentol	NN	O	B-Chemical
,	NN	O	O
iohexol	NN	O	B-Chemical
and	NN	O	O
metrizoate	NN	O	B-Chemical
in	NN	O	O
doses	NN	O	O
of	NN	O	O
4	NN	O	O
ml	NN	O	O
,	NN	O	O
8	NN	O	O
ml	NN	O	O
and	NN	O	O
16	NN	O	O
ml	NN	O	O
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
six	NN	O	O
iopentol	NN	O	B-Chemical
injections	NN	O	O
,	NN	O	O
35	NN	O	O
iohexol	NN	O	B-Chemical
injections	NN	O	O
and	NN	O	O
37	NN	O	O
metrizoate	NN	O	B-Chemical
injections	NN	O	O
were	NN	O	O
made	NN	O	O
.	NN	O	O

Frequencies	NN	O	O
of	NN	O	O
ventricular	NN	O	B-Disease
fibrillation	NN	O	I-Disease
were	NN	O	O
significantly	NN	O	O
lower	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
after	NN	O	O
iopentol	NN	O	B-Chemical
(	NN	O	O
0%	NN	O	O
)	NN	O	O
and	NN	O	O
iohexol	NN	O	B-Chemical
(	NN	O	O
3%	NN	O	O
)	NN	O	O
than	NN	O	O
after	NN	O	O
metrizoate	NN	O	B-Chemical
(	NN	O	O
22%	NN	O	O
)	NN	O	O
.	NN	O	O

Iopentol	NN	O	B-Chemical
and	NN	O	O
iohexol	NN	O	B-Chemical
also	NN	O	O
produced	NN	O	O
significantly	NN	O	O
less	NN	O	O
decrease	NN	O	O
in	NN	O	O
aortic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
than	NN	O	O
metrizoate	NN	O	B-Chemical
at	NN	O	O
the	NN	O	O
different	NN	O	O
doses	NN	O	O
.	NN	O	O


-DOCSTART- (2819587)

Magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
of	NN	O	O
cerebral	NN	O	O
venous	NN	O	B-Disease
thrombosis	NN	O	I-Disease
secondary	NN	O	O
to	NN	O	O
"	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
"	NN	O	O
birth	NN	O	O
control	NN	O	O
pills	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
and	NN	O	O
radiographic	NN	O	O
features	NN	O	O
of	NN	O	O
cerebral	NN	O	O
deep	NN	O	B-Disease
venous	NN	O	I-Disease
thrombosis	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
21	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
white	NN	O	O
woman	NN	O	O
are	NN	O	O
presented	NN	O	O
.	NN	O	O

This	NN	O	O
nulliparous	NN	O	O
patient	NN	O	O
presented	NN	O	O
with	NN	O	O
relatively	NN	O	O
mild	NN	O	O
clinical	NN	O	O
symptoms	NN	O	O
and	NN	O	O
progressing	NN	O	O
mental	NN	O	O
status	NN	O	O
changes	NN	O	O
.	NN	O	O

The	NN	O	O
only	NN	O	O
known	NN	O	O
risk	NN	O	O
factor	NN	O	O
was	NN	O	O
"	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
"	NN	O	O
oral	NN	O	B-Chemical
contraceptive	NN	O	I-Chemical
pills	NN	O	O
.	NN	O	O

The	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
image	NN	O	O
(	NN	O	O
MRI	NN	O	O
)	NN	O	O
showed	NN	O	O
increased	NN	O	O
signal	NN	O	O
intensity	NN	O	O
from	NN	O	O
the	NN	O	O
internal	NN	O	O
cerebral	NN	O	O
veins	NN	O	O
,	NN	O	O
vein	NN	O	O
of	NN	O	O
Galen	NN	O	O
,	NN	O	O
and	NN	O	O
straight	NN	O	O
sinus	NN	O	O
.	NN	O	O

The	NN	O	O
diagnosis	NN	O	O
was	NN	O	O
confirmed	NN	O	O
by	NN	O	O
arterial	NN	O	O
angiography	NN	O	O
.	NN	O	O


-DOCSTART- (1564236)

Relation	NN	O	O
of	NN	O	O
perfusion	NN	O	O
defects	NN	O	O
observed	NN	O	O
with	NN	O	O
myocardial	NN	O	O
contrast	NN	O	O
echocardiography	NN	O	O
to	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
coronary	NN	O	B-Disease
stenosis	NN	O	I-Disease
:	NN	O	O
correlation	NN	O	O
with	NN	O	O
thallium	NN	O	B-Chemical
-	NN	O	O
201	NN	O	O
single	NN	O	O
-	NN	O	O
photon	NN	O	O
emission	NN	O	O
tomography	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
been	NN	O	O
previously	NN	O	O
shown	NN	O	O
that	NN	O	O
myocardial	NN	O	O
contrast	NN	O	O
echocardiography	NN	O	O
is	NN	O	O
a	NN	O	O
valuable	NN	O	O
technique	NN	O	O
for	NN	O	O
delineating	NN	O	O
regions	NN	O	O
of	NN	O	O
myocardial	NN	O	O
underperfusion	NN	O	O
secondary	NN	O	O
to	NN	O	O
coronary	NN	O	B-Disease
occlusion	NN	O	I-Disease
and	NN	O	O
to	NN	O	O
critical	NN	O	O
coronary	NN	O	B-Disease
stenoses	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
hyperemic	NN	O	B-Disease
stimulation	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
myocardial	NN	O	O
contrast	NN	O	O
echocardiography	NN	O	O
performed	NN	O	O
with	NN	O	O
a	NN	O	O
stable	NN	O	O
solution	NN	O	O
of	NN	O	O
sonicated	NN	O	O
albumin	NN	O	O
could	NN	O	O
detect	NN	O	O
regions	NN	O	O
of	NN	O	O
myocardial	NN	O	O
underperfusion	NN	O	O
resulting	NN	O	O
from	NN	O	O
various	NN	O	O
degrees	NN	O	O
of	NN	O	O
coronary	NN	O	B-Disease
stenosis	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
perfusion	NN	O	O
defect	NN	O	O
produced	NN	O	O
in	NN	O	O
16	NN	O	O
open	NN	O	O
chest	NN	O	O
dogs	NN	O	O
was	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
anatomic	NN	O	O
area	NN	O	O
at	NN	O	O
risk	NN	O	O
measured	NN	O	O
by	NN	O	O
the	NN	O	O
postmortem	NN	O	O
dual	NN	O	O
-	NN	O	O
perfusion	NN	O	O
technique	NN	O	O
and	NN	O	O
with	NN	O	O
thallium	NN	O	B-Chemical
-	NN	O	O
201	NN	O	O
single	NN	O	O
-	NN	O	O
photon	NN	O	O
emission	NN	O	O
tomography	NN	O	O
(	NN	O	O
SPECT	NN	O	O
)	NN	O	O
.	NN	O	O

During	NN	O	O
a	NN	O	O
transient	NN	O	O
(	NN	O	O
20	NN	O	O
-	NN	O	O
s	NN	O	O
)	NN	O	O
coronary	NN	O	B-Disease
occlusion	NN	O	I-Disease
,	NN	O	O
a	NN	O	O
perfusion	NN	O	O
defect	NN	O	O
was	NN	O	O
observed	NN	O	O
with	NN	O	O
contrast	NN	O	O
echocardiography	NN	O	O
in	NN	O	O
14	NN	O	O
of	NN	O	O
the	NN	O	O
15	NN	O	O
dogs	NN	O	O
in	NN	O	O
which	NN	O	O
the	NN	O	O
occlusion	NN	O	O
was	NN	O	O
produced	NN	O	O
.	NN	O	O

The	NN	O	O
perfusion	NN	O	O
defect	NN	O	O
correlated	NN	O	O
significantly	NN	O	O
with	NN	O	O
the	NN	O	O
anatomic	NN	O	O
area	NN	O	O
at	NN	O	O
risk	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.74	NN	O	O
;	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.002	NN	O	O
)	NN	O	O
.	NN	O	O

During	NN	O	O
dipyridamole	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperemia	NN	O	B-Disease
,	NN	O	O
12	NN	O	O
of	NN	O	O
the	NN	O	O
16	NN	O	O
dogs	NN	O	O
with	NN	O	O
a	NN	O	O
partial	NN	O	O
coronary	NN	O	B-Disease
stenosis	NN	O	I-Disease
had	NN	O	O
a	NN	O	O
visible	NN	O	O
area	NN	O	O
of	NN	O	O
hypoperfusion	NN	O	O
by	NN	O	O
contrast	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

The	NN	O	O
four	NN	O	O
dogs	NN	O	O
without	NN	O	O
a	NN	O	O
perfusion	NN	O	O
defect	NN	O	O
had	NN	O	O
a	NN	O	O
stenosis	NN	O	O
that	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
mild	NN	O	O
(	NN	O	O
0%	NN	O	O
to	NN	O	O
50%	NN	O	O
)	NN	O	O
reduction	NN	O	O
in	NN	O	O
dipyridamole	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperemia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
size	NN	O	O
of	NN	O	O
the	NN	O	O
perfusion	NN	O	O
defect	NN	O	O
during	NN	O	O
stenosis	NN	O	O
correlated	NN	O	O
significantly	NN	O	O
with	NN	O	O
the	NN	O	O
anatomic	NN	O	O
area	NN	O	O
at	NN	O	O
risk	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.61	NN	O	O
;	NN	O	O
p	NN	O	O
=	NN	O	O
0.02	NN	O	O
)	NN	O	O
.	NN	O	O

Thallium	NN	O	B-Chemical
-	NN	O	O
201	NN	O	O
SPECT	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
perfusion	NN	O	O
defect	NN	O	O
in	NN	O	O
all	NN	O	O
14	NN	O	O
dogs	NN	O	O
analyzed	NN	O	O
during	NN	O	O
dipyridamole	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperemia	NN	O	B-Disease
;	NN	O	O
the	NN	O	O
size	NN	O	O
of	NN	O	O
the	NN	O	O
perfusion	NN	O	O
defect	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
anatomic	NN	O	O
area	NN	O	O
at	NN	O	O
risk	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.58	NN	O	O
;	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.03	NN	O	O
)	NN	O	O
and	NN	O	O
with	NN	O	O
the	NN	O	O
perfusion	NN	O	O
defect	NN	O	O
by	NN	O	O
contrast	NN	O	O
echocardiography	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.58	NN	O	O
;	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.03	NN	O	O
)	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
myocardial	NN	O	O
contrast	NN	O	O
echocardiography	NN	O	O
can	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
visualize	NN	O	O
and	NN	O	O
quantitate	NN	O	O
the	NN	O	O
amount	NN	O	O
of	NN	O	O
jeopardized	NN	O	O
myocardium	NN	O	O
during	NN	O	O
moderate	NN	O	O
to	NN	O	O
severe	NN	O	O
degrees	NN	O	O
of	NN	O	O
coronary	NN	O	B-Disease
stenosis	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
results	NN	O	O
obtained	NN	O	O
show	NN	O	O
a	NN	O	O
correlation	NN	O	O
with	NN	O	O
the	NN	O	O
anatomic	NN	O	O
area	NN	O	O
at	NN	O	O
risk	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
obtained	NN	O	O
with	NN	O	O
thallium	NN	O	B-Chemical
-	NN	O	O
201	NN	O	O
SPECT	NN	O	O
.	NN	O	O


-DOCSTART- (1300436)

Potential	NN	O	O
deleterious	NN	O	O
effect	NN	O	O
of	NN	O	O
furosemide	NN	O	B-Chemical
in	NN	O	O
radiocontrast	NN	O	O
nephropathy	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
furosemide	NN	O	B-Chemical
in	NN	O	O
addition	NN	O	O
to	NN	O	O
intravenous	NN	O	O
fluids	NN	O	O
in	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
radiocontrast	NN	O	O
nephropathy	NN	O	B-Disease
.	NN	O	O

18	NN	O	O
patients	NN	O	O
,	NN	O	O
referred	NN	O	O
to	NN	O	O
a	NN	O	O
radiocontrast	NN	O	O
study	NN	O	O
,	NN	O	O
considered	NN	O	O
at	NN	O	O
risk	NN	O	O
because	NN	O	O
of	NN	O	O
preexisting	NN	O	O
renal	NN	O	B-Disease
insufficiency	NN	O	I-Disease
,	NN	O	O
were	NN	O	O
enrolled	NN	O	O
in	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
trial	NN	O	O
,	NN	O	O
performed	NN	O	O
at	NN	O	O
the	NN	O	O
secondary	NN	O	O
care	NN	O	O
center	NN	O	O
of	NN	O	O
a	NN	O	O
1	NN	O	O
,	NN	O	O
100	NN	O	O
-	NN	O	O
bed	NN	O	O
private	NN	O	O
university	NN	O	O
hospital	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
fluids	NN	O	O
,	NN	O	O
the	NN	O	O
treatment	NN	O	O
group	NN	O	O
received	NN	O	O
furosemide	NN	O	B-Chemical
(	NN	O	O
mean	NN	O	O
dose	NN	O	O
110	NN	O	O
mg	NN	O	O
)	NN	O	O
intravenously	NN	O	O
30	NN	O	O
min	NN	O	O
prior	NN	O	O
to	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
contrast	NN	O	O
material	NN	O	O
.	NN	O	O

The	NN	O	O
control	NN	O	O
group	NN	O	O
received	NN	O	O
fluids	NN	O	O
(	NN	O	O
mean	NN	O	O
3	NN	O	O
liters	NN	O	O
)	NN	O	O
.	NN	O	O

Radiological	NN	O	O
studies	NN	O	O
were	NN	O	O
mostly	NN	O	O
angiographies	NN	O	O
performed	NN	O	O
with	NN	O	O
both	NN	O	O
ionic	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
ionic	NN	O	O
contrast	NN	O	O
material	NN	O	O
,	NN	O	O
at	NN	O	O
an	NN	O	O
average	NN	O	O
dose	NN	O	O
of	NN	O	O
245	NN	O	O
ml	NN	O	O
.	NN	O	O

Renal	NN	O	B-Disease
function	NN	O	I-Disease
significantly	NN	O	I-Disease
deteriorated	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
group	NN	O	O
pretreated	NN	O	O
with	NN	O	O
furosemide	NN	O	B-Chemical
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.005	NN	O	O
by	NN	O	O
ANOVA	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
rise	NN	O	O
in	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
from	NN	O	O
145	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
13	NN	O	O
to	NN	O	O
182	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
16	NN	O	O
mumol	NN	O	O
/	NN	O	O
l	NN	O	O
at	NN	O	O
24	NN	O	O
h	NN	O	O
,	NN	O	O
while	NN	O	O
no	NN	O	O
change	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
from	NN	O	O
141	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6	NN	O	O
to	NN	O	O
142	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
mumol	NN	O	O
/	NN	O	O
l	NN	O	O
)	NN	O	O
.	NN	O	O

Renal	NN	O	B-Disease
failure	NN	O	I-Disease
was	NN	O	O
associated	NN	O	O
with	NN	O	O
weight	NN	O	B-Disease
loss	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
furosemide	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
group	NN	O	O
.	NN	O	O

Furosemide	NN	O	B-Chemical
may	NN	O	O
be	NN	O	O
deleterious	NN	O	O
in	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
radiocontrast	NN	O	O
nephropathy	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (1141447)

The	NN	O	O
renal	NN	O	O
pathology	NN	O	O
in	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
diabetes	NN	O	B-Disease
insipidus	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
diabetes	NN	O	B-Disease
insipidus	NN	O	I-Disease
is	NN	O	O
reported	NN	O	O
.	NN	O	O

At	NN	O	O
necropsy	NN	O	O
microscopy	NN	O	O
shoed	NN	O	O
unique	NN	O	O
and	NN	O	O
extensive	NN	O	O
damage	NN	O	O
to	NN	O	O
cells	NN	O	O
lining	NN	O	O
the	NN	O	O
distal	NN	O	O
nephron	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
these	NN	O	O
changes	NN	O	O
represent	NN	O	O
a	NN	O	O
specific	NN	O	O
toxic	NN	O	O
effect	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
,	NN	O	O
reported	NN	O	O
here	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O


-DOCSTART- (188339)

Etiologic	NN	O	O
factors	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
liver	NN	O	B-Disease
tumors	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
oral	NN	O	B-Chemical
contraceptives	NN	O	I-Chemical
.	NN	O	O

Within	NN	O	O
the	NN	O	O
last	NN	O	O
several	NN	O	O
years	NN	O	O
,	NN	O	O
previously	NN	O	O
rare	NN	O	O
liver	NN	O	B-Disease
tumors	NN	O	I-Disease
have	NN	O	O
been	NN	O	O
seen	NN	O	O
in	NN	O	O
young	NN	O	O
women	NN	O	O
using	NN	O	O
oral	NN	O	B-Chemical
contraceptive	NN	O	I-Chemical
steroids	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
Registry	NN	O	O
for	NN	O	O
Liver	NN	O	B-Disease
Tumors	NN	O	I-Disease
Associated	NN	O	O
with	NN	O	O
Oral	NN	O	B-Chemical
Contraceptives	NN	O	I-Chemical
at	NN	O	O
the	NN	O	O
University	NN	O	O
of	NN	O	O
California	NN	O	O
,	NN	O	O
Irvine	NN	O	O
,	NN	O	O
has	NN	O	O
clearly	NN	O	O
identified	NN	O	O
27	NN	O	O
cases	NN	O	O
.	NN	O	O

The	NN	O	O
recent	NN	O	O
literature	NN	O	O
contains	NN	O	O
44	NN	O	O
case	NN	O	O
reports	NN	O	O
.	NN	O	O

Common	NN	O	O
to	NN	O	O
these	NN	O	O
71	NN	O	O
cases	NN	O	O
has	NN	O	O
been	NN	O	O
a	NN	O	O
histopathologic	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
focal	NN	O	B-Disease
nodular	NN	O	I-Disease
hyperplasia	NN	O	I-Disease
,	NN	O	O
adenoma	NN	O	B-Disease
,	NN	O	O
hamartoma	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
hepatoma	NN	O	B-Disease
.	NN	O	O

Significant	NN	O	O
statistical	NN	O	O
etiologic	NN	O	O
factors	NN	O	O
include	NN	O	O
prolonged	NN	O	O
uninterrupted	NN	O	O
usage	NN	O	O
of	NN	O	O
oral	NN	O	B-Chemical
contraceptive	NN	O	I-Chemical
steroids	NN	O	B-Chemical
.	NN	O	O

Eight	NN	O	O
deaths	NN	O	O
and	NN	O	O
liver	NN	O	O
rupture	NN	O	B-Disease
in	NN	O	O
18	NN	O	O
patients	NN	O	O
attest	NN	O	O
to	NN	O	O
the	NN	O	O
seriousness	NN	O	O
of	NN	O	O
this	NN	O	O
new	NN	O	O
potentially	NN	O	O
lethal	NN	O	O
adverse	NN	O	O
phenomenon	NN	O	O
.	NN	O	O


-DOCSTART- (19135948)

Graft	NN	O	B-Disease
-	NN	O	I-Disease
versus	NN	O	I-Disease
-	NN	O	I-Disease
host	NN	O	I-Disease
disease	NN	O	I-Disease
prophylaxis	NN	O	O
with	NN	O	O
everolimus	NN	O	B-Chemical
and	NN	O	O
tacrolimus	NN	O	B-Chemical
is	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
sinusoidal	NN	O	B-Disease
obstruction	NN	O	I-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
microangiopathy	NN	O	B-Disease
:	NN	O	O
results	NN	O	O
of	NN	O	O
the	NN	O	O
EVTAC	NN	O	O
trial	NN	O	O
.	NN	O	O

A	NN	O	O
calcineurin	NN	O	O
inhibitor	NN	O	O
combined	NN	O	O
with	NN	O	O
methotrexate	NN	O	B-Chemical
is	NN	O	O
the	NN	O	O
standard	NN	O	O
prophylaxis	NN	O	O
for	NN	O	O
graft	NN	O	B-Disease
-	NN	O	I-Disease
versus	NN	O	I-Disease
-	NN	O	I-Disease
host	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
GVHD	NN	O	B-Disease
)	NN	O	O
after	NN	O	O
allogeneic	NN	O	O
hematopoietic	NN	O	O
stem	NN	O	O
cell	NN	O	O
transplantation	NN	O	O
(	NN	O	O
HSCT	NN	O	O
)	NN	O	O
.	NN	O	O

Everolimus	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
derivative	NN	O	O
of	NN	O	O
sirolimus	NN	O	B-Chemical
,	NN	O	O
seems	NN	O	O
to	NN	O	O
mediate	NN	O	O
antileukemia	NN	O	O
effects	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
on	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
everolimus	NN	O	B-Chemical
and	NN	O	O
tacrolimus	NN	O	B-Chemical
in	NN	O	O
24	NN	O	O
patients	NN	O	O
(	NN	O	O
median	NN	O	O
age	NN	O	O
,	NN	O	O
62	NN	O	O
years	NN	O	O
)	NN	O	O
with	NN	O	O
either	NN	O	O
myelodysplastic	NN	O	B-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
MDS	NN	O	B-Disease
;	NN	O	O
n	NN	O	O
=	NN	O	O
17	NN	O	O
)	NN	O	O
or	NN	O	O
acute	NN	O	B-Disease
myeloid	NN	O	I-Disease
leukemia	NN	O	I-Disease
(	NN	O	O
AML	NN	O	B-Disease
;	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
undergoing	NN	O	O
intensive	NN	O	O
conditioning	NN	O	O
followed	NN	O	O
by	NN	O	O
HSCT	NN	O	O
from	NN	O	O
related	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
)	NN	O	O
or	NN	O	O
unrelated	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
20	NN	O	O
)	NN	O	O
donors	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
engrafted	NN	O	O
,	NN	O	O
and	NN	O	O
only	NN	O	O
1	NN	O	O
patient	NN	O	O
experienced	NN	O	O
grade	NN	O	O
IV	NN	O	O
mucositis	NN	O	B-Disease
.	NN	O	O

Nine	NN	O	O
patients	NN	O	O
(	NN	O	O
37%	NN	O	O
)	NN	O	O
developed	NN	O	O
acute	NN	O	O
grade	NN	O	O
II	NN	O	O
-	NN	O	O
IV	NN	O	O
GVHD	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
11	NN	O	O
of	NN	O	O
17	NN	O	O
evaluable	NN	O	O
patients	NN	O	O
(	NN	O	O
64%	NN	O	O
)	NN	O	O
developed	NN	O	O
chronic	NN	O	O
extensive	NN	O	O
GVHD	NN	O	B-Disease
.	NN	O	O

Transplantation	NN	O	B-Disease
-	NN	O	I-Disease
associated	NN	O	I-Disease
microangiopathy	NN	O	I-Disease
(	NN	O	O
TMA	NN	O	B-Disease
)	NN	O	O
occurred	NN	O	O
in	NN	O	O
7	NN	O	O
patients	NN	O	O
(	NN	O	O
29%	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
2	NN	O	O
cases	NN	O	O
of	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
study	NN	O	O
was	NN	O	O
terminated	NN	O	O
prematurely	NN	O	O
because	NN	O	O
an	NN	O	O
additional	NN	O	O
6	NN	O	O
patients	NN	O	O
(	NN	O	O
25%	NN	O	O
)	NN	O	O
developed	NN	O	O
sinusoidal	NN	O	B-Disease
obstruction	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
SOS	NN	O	B-Disease
)	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
fatal	NN	O	O
in	NN	O	O
2	NN	O	O
cases	NN	O	O
.	NN	O	O

With	NN	O	O
a	NN	O	O
median	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
26	NN	O	O
months	NN	O	O
,	NN	O	O
the	NN	O	O
2	NN	O	O
-	NN	O	O
year	NN	O	O
overall	NN	O	O
survival	NN	O	O
rate	NN	O	O
was	NN	O	O
47%	NN	O	O
.	NN	O	O

Although	NN	O	O
this	NN	O	O
new	NN	O	O
combination	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
effective	NN	O	O
as	NN	O	O
a	NN	O	O
prophylactic	NN	O	O
regimen	NN	O	O
for	NN	O	O
acute	NN	O	O
GVHD	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
TMA	NN	O	B-Disease
and	NN	O	O
SOS	NN	O	B-Disease
is	NN	O	O
considerably	NN	O	O
higher	NN	O	O
than	NN	O	O
seen	NN	O	O
with	NN	O	O
other	NN	O	O
regimens	NN	O	O
.	NN	O	O


-DOCSTART- (14704468)

Effect	NN	O	O
of	NN	O	O
some	NN	O	O
convulsants	NN	O	O
on	NN	O	O
the	NN	O	O
protective	NN	O	O
activity	NN	O	O
of	NN	O	O
loreclezole	NN	O	B-Chemical
and	NN	O	O
its	NN	O	O
combinations	NN	O	O
with	NN	O	O
valproate	NN	O	B-Chemical
or	NN	O	O
clonazepam	NN	O	B-Chemical
in	NN	O	O
amygdala	NN	O	O
-	NN	O	O
kindled	NN	O	O
rats	NN	O	O
.	NN	O	O

Loreclezole	NN	O	B-Chemical
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
exerted	NN	O	O
a	NN	O	O
significant	NN	O	O
protective	NN	O	O
action	NN	O	O
in	NN	O	O
amygdala	NN	O	O
-	NN	O	O
kindled	NN	O	O
rats	NN	O	O
,	NN	O	O
reducing	NN	O	O
both	NN	O	O
seizure	NN	O	B-Disease
and	NN	O	O
afterdischarge	NN	O	O
durations	NN	O	O
.	NN	O	O

The	NN	O	O
combinations	NN	O	O
of	NN	O	O
loreclezole	NN	O	B-Chemical
(	NN	O	O
2.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
with	NN	O	O
valproate	NN	O	B-Chemical
,	NN	O	O
clonazepam	NN	O	B-Chemical
,	NN	O	O
or	NN	O	O
carbamazepine	NN	O	B-Chemical
(	NN	O	O
applied	NN	O	O
at	NN	O	O
their	NN	O	O
subprotective	NN	O	O
doses	NN	O	O
)	NN	O	O
also	NN	O	O
exhibited	NN	O	O
antiseizure	NN	O	O
effect	NN	O	O
in	NN	O	O
this	NN	O	O
test	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
only	NN	O	O
two	NN	O	O
first	NN	O	O
combinations	NN	O	O
occurred	NN	O	O
to	NN	O	O
be	NN	O	O
of	NN	O	O
pharmacodynamic	NN	O	O
nature	NN	O	O
.	NN	O	O

Among	NN	O	O
several	NN	O	O
chemoconvulsants	NN	O	O
,	NN	O	O
bicuculline	NN	O	B-Chemical
,	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
-	NN	O	I-Chemical
D	NN	O	I-Chemical
-	NN	O	I-Chemical
aspartic	NN	O	I-Chemical
acid	NN	O	I-Chemical
and	NN	O	O
BAY	NN	O	B-Chemical
k	NN	O	I-Chemical
-	NN	O	I-Chemical
8644	NN	O	I-Chemical
(	NN	O	O
the	NN	O	O
opener	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
type	NN	O	O
calcium	NN	O	B-Chemical
channels	NN	O	O
)	NN	O	O
reversed	NN	O	O
the	NN	O	O
protective	NN	O	O
activity	NN	O	O
of	NN	O	O
loreclezole	NN	O	B-Chemical
alone	NN	O	O
and	NN	O	O
its	NN	O	O
combination	NN	O	O
with	NN	O	O
valproate	NN	O	B-Chemical
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
bicuculline	NN	O	B-Chemical
,	NN	O	O
aminophylline	NN	O	B-Chemical
and	NN	O	O
BAY	NN	O	B-Chemical
k	NN	O	I-Chemical
-	NN	O	I-Chemical
8644	NN	O	I-Chemical
inhibited	NN	O	O
the	NN	O	O
anticonvulsive	NN	O	O
action	NN	O	O
of	NN	O	O
loreclezole	NN	O	B-Chemical
combined	NN	O	O
with	NN	O	O
clonazepam	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
results	NN	O	O
support	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
the	NN	O	O
protective	NN	O	O
activity	NN	O	O
of	NN	O	O
loreclezole	NN	O	B-Chemical
and	NN	O	O
its	NN	O	O
combinations	NN	O	O
with	NN	O	O
other	NN	O	O
antiepileptics	NN	O	O
may	NN	O	O
involve	NN	O	O
potentiation	NN	O	O
of	NN	O	O
GABAergic	NN	O	O
neurotransmission	NN	O	O
and	NN	O	O
blockade	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
type	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
channels	NN	O	O
.	NN	O	O


-DOCSTART- (12549952)

Acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
with	NN	O	O
concurrent	NN	O	O
bupropion	NN	O	B-Chemical
and	NN	O	O
carbimazole	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
fatal	NN	O	O
liver	NN	O	B-Disease
failure	NN	O	I-Disease
possibly	NN	O	O
associated	NN	O	O
with	NN	O	O
concurrent	NN	O	O
use	NN	O	O
of	NN	O	O
bupropion	NN	O	B-Chemical
and	NN	O	O
carbimazole	NN	O	B-Chemical
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
41	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Chinese	NN	O	O
man	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
hyperthyroidism	NN	O	B-Disease
had	NN	O	O
been	NN	O	O
treated	NN	O	O
with	NN	O	O
carbimazole	NN	O	B-Chemical
and	NN	O	O
propranolol	NN	O	B-Chemical
for	NN	O	O
the	NN	O	O
past	NN	O	O
5	NN	O	O
years	NN	O	O
.	NN	O	O

He	NN	O	O
received	NN	O	O
a	NN	O	O
10	NN	O	O
-	NN	O	O
day	NN	O	O
course	NN	O	O
of	NN	O	O
bupropion	NN	O	B-Chemical
as	NN	O	O
an	NN	O	O
aid	NN	O	O
for	NN	O	O
smoking	NN	O	O
cessation	NN	O	O
10	NN	O	O
weeks	NN	O	O
prior	NN	O	O
to	NN	O	O
presentation	NN	O	O
.	NN	O	O

He	NN	O	O
developed	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
with	NN	O	O
rapid	NN	O	O
deterioration	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

Liver	NN	O	O
biopsy	NN	O	O
showed	NN	O	O
evidence	NN	O	O
of	NN	O	O
nonspecific	NN	O	O
drug	NN	O	B-Disease
-	NN	O	I-Disease
induced	NN	O	I-Disease
acute	NN	O	I-Disease
liver	NN	O	I-Disease
injury	NN	O	I-Disease
.	NN	O	O

His	NN	O	O
condition	NN	O	O
was	NN	O	O
further	NN	O	O
complicated	NN	O	O
by	NN	O	O
sepsis	NN	O	B-Disease
and	NN	O	O
coagulopathy	NN	O	B-Disease
.	NN	O	O

Death	NN	O	O
resulted	NN	O	O
19	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
symptoms	NN	O	O
.	NN	O	O

The	NN	O	O
likelihood	NN	O	O
that	NN	O	O
bupropion	NN	O	B-Chemical
induced	NN	O	O
hepatotoxicity	NN	O	B-Disease
in	NN	O	O
our	NN	O	O
patient	NN	O	O
was	NN	O	O
possible	NN	O	O
,	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
Naranjo	NN	O	O
probability	NN	O	O
scale	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
Although	NN	O	O
there	NN	O	O
is	NN	O	O
increasing	NN	O	O
evidence	NN	O	O
of	NN	O	O
hepatotoxicity	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
bupropion	NN	O	B-Chemical
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
of	NN	O	O
fatality	NN	O	O
that	NN	O	O
could	NN	O	O
have	NN	O	O
resulted	NN	O	O
from	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
patient	NN	O	O
receiving	NN	O	O
bupropion	NN	O	B-Chemical
while	NN	O	O
on	NN	O	O
concomitant	NN	O	O
treatment	NN	O	O
with	NN	O	O
carbimazole	NN	O	B-Chemical
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Clinicians	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
insult	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
bupropion	NN	O	B-Chemical
given	NN	O	O
concurrently	NN	O	O
with	NN	O	O
other	NN	O	O
hepatotoxic	NN	O	B-Disease
drugs	NN	O	O
.	NN	O	O


-DOCSTART- (19370593)

Long	NN	O	O
term	NN	O	O
hormone	NN	O	O
therapy	NN	O	O
for	NN	O	O
perimenopausal	NN	O	O
and	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Hormone	NN	O	O
therapy	NN	O	O
(	NN	O	O
HT	NN	O	O
)	NN	O	O
is	NN	O	O
widely	NN	O	O
used	NN	O	O
for	NN	O	O
controlling	NN	O	O
menopausal	NN	O	O
symptoms	NN	O	O
and	NN	O	O
has	NN	O	O
also	NN	O	O
been	NN	O	O
used	NN	O	O
for	NN	O	O
the	NN	O	O
management	NN	O	O
and	NN	O	O
prevention	NN	O	O
of	NN	O	O
cardiovascular	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
osteoporosis	NN	O	B-Disease
and	NN	O	O
dementia	NN	O	B-Disease
in	NN	O	O
older	NN	O	O
women	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
an	NN	O	O
updated	NN	O	O
version	NN	O	O
of	NN	O	O
the	NN	O	O
original	NN	O	O
Cochrane	NN	O	O
review	NN	O	O
first	NN	O	O
published	NN	O	O
in	NN	O	O
2005	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
HT	NN	O	O
on	NN	O	O
mortality	NN	O	O
,	NN	O	O
cardiovascular	NN	O	O
outcomes	NN	O	O
,	NN	O	O
cancer	NN	O	B-Disease
,	NN	O	O
gallbladder	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
cognition	NN	O	O
,	NN	O	O
fractures	NN	O	B-Disease
and	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
.	NN	O	O

SEARCH	NN	O	O
STRATEGY	NN	O	O
:	NN	O	O
We	NN	O	O
searched	NN	O	O
the	NN	O	O
following	NN	O	O
databases	NN	O	O
to	NN	O	O
November	NN	O	O
2007	NN	O	O
:	NN	O	O
Trials	NN	O	O
Register	NN	O	O
of	NN	O	O
the	NN	O	O
Cochrane	NN	O	O
Menstrual	NN	O	B-Disease
Disorders	NN	O	I-Disease
and	NN	O	O
Subfertility	NN	O	O
Group	NN	O	O
,	NN	O	O
Cochrane	NN	O	O
Central	NN	O	O
Register	NN	O	O
of	NN	O	O
Controlled	NN	O	O
Trials	NN	O	O
,	NN	O	O
MEDLINE	NN	O	O
,	NN	O	O
EMBASE	NN	O	O
,	NN	O	O
Biological	NN	O	O
Abstracts	NN	O	O
.	NN	O	O

Also	NN	O	O
relevant	NN	O	O
non	NN	O	O
-	NN	O	O
indexed	NN	O	O
journals	NN	O	O
and	NN	O	O
conference	NN	O	O
abstracts	NN	O	O
.	NN	O	O

SELECTION	NN	O	O
CRITERIA	NN	O	O
:	NN	O	O
Randomised	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
trials	NN	O	O
of	NN	O	O
HT	NN	O	O
versus	NN	O	O
placebo	NN	O	O
,	NN	O	O
taken	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
year	NN	O	O
by	NN	O	O
perimenopausal	NN	O	O
or	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
.	NN	O	O

HT	NN	O	O
included	NN	O	O
oestrogens	NN	O	B-Chemical
,	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
progestogens	NN	O	B-Chemical
,	NN	O	O
via	NN	O	O
oral	NN	O	O
,	NN	O	O
transdermal	NN	O	O
,	NN	O	O
subcutaneous	NN	O	O
or	NN	O	O
transnasal	NN	O	O
routes	NN	O	O
.	NN	O	O

DATA	NN	O	O
COLLECTION	NN	O	O
AND	NN	O	O
ANALYSIS	NN	O	O
:	NN	O	O
Two	NN	O	O
authors	NN	O	O
independently	NN	O	O
assessed	NN	O	O
trial	NN	O	O
quality	NN	O	O
and	NN	O	O
extracted	NN	O	O
data	NN	O	O
.	NN	O	O

MAIN	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
Nineteen	NN	O	O
trials	NN	O	O
involving	NN	O	O
41	NN	O	O
,	NN	O	O
904	NN	O	O
women	NN	O	O
were	NN	O	O
included	NN	O	O
.	NN	O	O

In	NN	O	O
relatively	NN	O	O
healthy	NN	O	O
women	NN	O	O
,	NN	O	O
combined	NN	O	O
continuous	NN	O	O
HT	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B-Disease
thrombo	NN	O	I-Disease
-	NN	O	I-Disease
embolism	NN	O	I-Disease
or	NN	O	O
coronary	NN	O	O
event	NN	O	O
(	NN	O	O
after	NN	O	O
one	NN	O	O
year	NN	O	O
'	NN	O	O
s	NN	O	O
use	NN	O	O
)	NN	O	O
,	NN	O	O
stroke	NN	O	B-Disease
(	NN	O	O
after	NN	O	O
three	NN	O	O
years	NN	O	O
)	NN	O	O
,	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
and	NN	O	O
gallbladder	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
oestrogen	NN	O	B-Chemical
-	NN	O	O
only	NN	O	O
HT	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B-Disease
thrombo	NN	O	I-Disease
-	NN	O	I-Disease
embolism	NN	O	I-Disease
,	NN	O	O
stroke	NN	O	B-Disease
and	NN	O	O
gallbladder	NN	O	B-Disease
disease	NN	O	I-Disease
(	NN	O	O
after	NN	O	O
one	NN	O	O
to	NN	O	O
two	NN	O	O
years	NN	O	O
,	NN	O	O
three	NN	O	O
years	NN	O	O
and	NN	O	O
seven	NN	O	O
years	NN	O	O
'	NN	O	O
use	NN	O	O
respectively	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
significantly	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
only	NN	O	O
statistically	NN	O	O
significant	NN	O	O
benefits	NN	O	O
of	NN	O	O
HT	NN	O	O
were	NN	O	O
a	NN	O	O
decreased	NN	O	O
incidence	NN	O	O
of	NN	O	O
fractures	NN	O	B-Disease
and	NN	O	O
(	NN	O	O
for	NN	O	O
combined	NN	O	O
HT	NN	O	O
)	NN	O	O
colon	NN	O	B-Disease
cancer	NN	O	I-Disease
,	NN	O	O
with	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
.	NN	O	O

Among	NN	O	O
women	NN	O	O
aged	NN	O	O
over	NN	O	O
65	NN	O	O
who	NN	O	O
were	NN	O	O
relatively	NN	O	O
healthy	NN	O	O
(	NN	O	O
i.e.	NN	O	O
generally	NN	O	O
fit	NN	O	O
,	NN	O	O
without	NN	O	O
overt	NN	O	O
disease	NN	O	O
)	NN	O	O
and	NN	O	O
taking	NN	O	O
continuous	NN	O	O
combined	NN	O	O
HT	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
dementia	NN	O	B-Disease
.	NN	O	O

Among	NN	O	O
women	NN	O	O
with	NN	O	O
cardiovascular	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
combined	NN	O	O
continuous	NN	O	O
HT	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B-Disease
thrombo	NN	O	I-Disease
-	NN	O	I-Disease
embolism	NN	O	I-Disease
.One	NN	O	O
trial	NN	O	O
analysed	NN	O	O
subgroups	NN	O	O
of	NN	O	O
2839	NN	O	O
relatively	NN	O	O
healthy	NN	O	O
50	NN	O	O
to	NN	O	O
59	NN	O	O
year	NN	O	O
old	NN	O	O
women	NN	O	O
taking	NN	O	O
combined	NN	O	O
continuous	NN	O	O
HT	NN	O	O
and	NN	O	O
1637	NN	O	O
taking	NN	O	O
oestrogen	NN	O	B-Chemical
-	NN	O	O
only	NN	O	O
HT	NN	O	O
,	NN	O	O
versus	NN	O	O
similar	NN	O	O
-	NN	O	O
sized	NN	O	O
placebo	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
only	NN	O	O
significantly	NN	O	O
increased	NN	O	O
risk	NN	O	O
reported	NN	O	O
was	NN	O	O
for	NN	O	O
venous	NN	O	B-Disease
thrombo	NN	O	I-Disease
-	NN	O	I-Disease
embolism	NN	O	I-Disease
in	NN	O	O
women	NN	O	O
taking	NN	O	O
combined	NN	O	O
continuous	NN	O	O
HT	NN	O	O
:	NN	O	O
their	NN	O	O
absolute	NN	O	O
risk	NN	O	O
remained	NN	O	O
low	NN	O	O
,	NN	O	O
at	NN	O	O
less	NN	O	O
than	NN	O	O
1	NN	O	O
/	NN	O	O
500	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
not	NN	O	O
powered	NN	O	O
to	NN	O	O
detect	NN	O	O
differences	NN	O	O
between	NN	O	O
groups	NN	O	O
of	NN	O	O
younger	NN	O	O
women	NN	O	O
.	NN	O	O

AUTHORS	NN	O	O
'	NN	O	O
CONCLUSIONS	NN	O	O
:	NN	O	O
HT	NN	O	O
is	NN	O	O
not	NN	O	O
indicated	NN	O	O
for	NN	O	O
the	NN	O	O
routine	NN	O	O
management	NN	O	O
of	NN	O	O
chronic	NN	O	O
disease	NN	O	O
.	NN	O	O

We	NN	O	O
need	NN	O	O
more	NN	O	O
evidence	NN	O	O
on	NN	O	O
the	NN	O	O
safety	NN	O	O
of	NN	O	O
HT	NN	O	O
for	NN	O	O
menopausal	NN	O	O
symptom	NN	O	O
control	NN	O	O
,	NN	O	O
though	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
relatively	NN	O	O
safe	NN	O	O
for	NN	O	O
healthy	NN	O	O
younger	NN	O	O
women	NN	O	O
.	NN	O	O


-DOCSTART- (17019386)

Passage	NN	O	O
of	NN	O	O
mannitol	NN	O	B-Chemical
into	NN	O	O
the	NN	O	O
brain	NN	O	O
around	NN	O	O
gliomas	NN	O	B-Disease
:	NN	O	O
a	NN	O	O
potential	NN	O	O
cause	NN	O	O
of	NN	O	O
rebound	NN	O	O
phenomenon	NN	O	O
.	NN	O	O

A	NN	O	O
study	NN	O	O
on	NN	O	O
21	NN	O	O
patients	NN	O	O
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
Widespread	NN	O	O
use	NN	O	O
of	NN	O	O
mannitol	NN	O	B-Chemical
to	NN	O	O
reduce	NN	O	O
brain	NN	O	B-Disease
edema	NN	O	I-Disease
and	NN	O	O
lower	NN	O	O
elevated	NN	O	B-Disease
ICP	NN	O	I-Disease
in	NN	O	O
brain	NN	O	B-Disease
tumor	NN	O	I-Disease
patients	NN	O	O
continues	NN	O	O
to	NN	O	O
be	NN	O	O
afflicted	NN	O	O
by	NN	O	O
the	NN	O	O
so	NN	O	O
-	NN	O	O
called	NN	O	O
rebound	NN	O	O
phenomenon	NN	O	O
.	NN	O	O

Leakage	NN	O	O
of	NN	O	O
mannitol	NN	O	B-Chemical
into	NN	O	O
the	NN	O	O
brain	NN	O	O
parenchyma	NN	O	O
through	NN	O	O
an	NN	O	O
altered	NN	O	O
BBB	NN	O	O
and	NN	O	O
secondary	NN	O	O
reversal	NN	O	O
of	NN	O	O
osmotic	NN	O	O
gradient	NN	O	O
is	NN	O	O
considered	NN	O	O
the	NN	O	O
major	NN	O	O
cause	NN	O	O
of	NN	O	O
rebound	NN	O	O
.	NN	O	O

This	NN	O	O
has	NN	O	O
only	NN	O	O
been	NN	O	O
demonstrated	NN	O	O
experimentally	NN	O	O
in	NN	O	O
animals	NN	O	O
.	NN	O	O

As	NN	O	O
a	NN	O	O
contribution	NN	O	O
to	NN	O	O
this	NN	O	O
issue	NN	O	O
we	NN	O	O
decided	NN	O	O
to	NN	O	O
research	NN	O	O
the	NN	O	O
possible	NN	O	O
passage	NN	O	O
of	NN	O	O
mannitol	NN	O	B-Chemical
into	NN	O	O
the	NN	O	O
brain	NN	O	O
after	NN	O	O
administration	NN	O	O
to	NN	O	O
21	NN	O	O
brain	NN	O	B-Disease
tumor	NN	O	I-Disease
patients	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Mannitol	NN	O	B-Chemical
(	NN	O	O
18%	NN	O	O
solution	NN	O	O
;	NN	O	O
1	NN	O	O
g	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
as	NN	O	O
a	NN	O	O
bolus	NN	O	O
to	NN	O	O
patients	NN	O	O
(	NN	O	O
ten	NN	O	O
had	NN	O	O
malignant	NN	O	B-Disease
glioma	NN	O	I-Disease
,	NN	O	O
seven	NN	O	O
brain	NN	O	O
metastases	NN	O	B-Disease
and	NN	O	O
four	NN	O	O
meningioma	NN	O	B-Disease
)	NN	O	O
about	NN	O	O
30	NN	O	O
minutes	NN	O	O
before	NN	O	O
craniotomy	NN	O	O
.	NN	O	O

During	NN	O	O
resection	NN	O	O
,	NN	O	O
a	NN	O	O
sample	NN	O	O
of	NN	O	O
the	NN	O	O
surrounding	NN	O	O
edematous	NN	O	B-Disease
white	NN	O	O
matter	NN	O	O
was	NN	O	O
taken	NN	O	O
at	NN	O	O
the	NN	O	O
same	NN	O	O
time	NN	O	O
as	NN	O	O
a	NN	O	O
10	NN	O	O
ml	NN	O	O
venous	NN	O	O
blood	NN	O	O
sample	NN	O	O
.	NN	O	O

Mannitol	NN	O	B-Chemical
concentrations	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
plasma	NN	O	O
and	NN	O	O
white	NN	O	O
matter	NN	O	O
by	NN	O	O
a	NN	O	O
modified	NN	O	O
version	NN	O	O
of	NN	O	O
the	NN	O	O
enzyme	NN	O	O
assay	NN	O	O
of	NN	O	O
Blonquist	NN	O	O
et	NN	O	O
al	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
In	NN	O	O
most	NN	O	O
glioma	NN	O	B-Disease
patients	NN	O	O
,	NN	O	O
mannitol	NN	O	B-Chemical
concentrations	NN	O	O
in	NN	O	O
white	NN	O	O
matter	NN	O	O
were	NN	O	O
2	NN	O	O
to	NN	O	O
6	NN	O	O
times	NN	O	O
higher	NN	O	O
than	NN	O	O
in	NN	O	O
plasma	NN	O	O
(	NN	O	O
mean	NN	O	O
3.5	NN	O	O
times	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
meningioma	NN	O	B-Disease
and	NN	O	O
metastases	NN	O	B-Disease
patients	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
of	NN	O	O
mannitol	NN	O	B-Chemical
were	NN	O	O
higher	NN	O	O
than	NN	O	O
white	NN	O	O
matter	NN	O	O
concentrations	NN	O	O
except	NN	O	O
in	NN	O	O
three	NN	O	O
cases	NN	O	O
with	NN	O	O
infiltration	NN	O	O
by	NN	O	O
neoplastic	NN	O	O
cells	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
of	NN	O	O
our	NN	O	O
study	NN	O	O
show	NN	O	O
that	NN	O	O
even	NN	O	O
after	NN	O	O
a	NN	O	O
single	NN	O	O
bolus	NN	O	O
,	NN	O	O
mannitol	NN	O	B-Chemical
may	NN	O	O
leak	NN	O	O
through	NN	O	O
the	NN	O	O
altered	NN	O	O
BBB	NN	O	O
near	NN	O	O
gliomas	NN	O	B-Disease
,	NN	O	O
reversing	NN	O	O
the	NN	O	O
initial	NN	O	O
plasma	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
blood	NN	O	O
osmotic	NN	O	O
gradient	NN	O	O
,	NN	O	O
aggravating	NN	O	O
peritumoral	NN	O	O
edema	NN	O	B-Disease
and	NN	O	O
promoting	NN	O	O
rebound	NN	O	O
of	NN	O	O
ICP	NN	O	O
.	NN	O	O


-DOCSTART- (12452237)

Can	NN	O	O
lidocaine	NN	O	B-Chemical
reduce	NN	O	O
succinylcholine	NN	O	B-Chemical
induced	NN	O	O
postoperative	NN	O	B-Disease
myalgia	NN	O	I-Disease
?	NN	O	O
This	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
pretreatment	NN	O	O
on	NN	O	O
reduction	NN	O	O
of	NN	O	O
succinylcholine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
myalgia	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
general	NN	O	O
anesthesia	NN	O	O
for	NN	O	O
gynecological	NN	O	O
surgery	NN	O	O
.	NN	O	O

One	NN	O	O
hundred	NN	O	O
and	NN	O	O
thirty	NN	O	O
-	NN	O	O
five	NN	O	O
patients	NN	O	O
were	NN	O	O
assigned	NN	O	O
to	NN	O	O
one	NN	O	O
of	NN	O	O
three	NN	O	O
groups	NN	O	O
in	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
double	NN	O	O
blind	NN	O	O
,	NN	O	O
randomized	NN	O	O
manner	NN	O	O
.	NN	O	O

Group	NN	O	O
PS	NN	O	O
,	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
received	NN	O	O
normal	NN	O	O
saline	NN	O	O
and	NN	O	O
succinylcholine	NN	O	B-Chemical
1.5	NN	O	O
mg	NN	O	O
x	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
;	NN	O	O
Group	NN	O	O
LS	NN	O	O
,	NN	O	O
lidocaine	NN	O	B-Chemical
1.5	NN	O	O
mg	NN	O	O
x	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
and	NN	O	O
succinylcholine	NN	O	B-Chemical
1.5	NN	O	O
mg	NN	O	O
x	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
;	NN	O	O
Group	NN	O	O
PR	NN	O	O
,	NN	O	O
normal	NN	O	O
saline	NN	O	O
and	NN	O	O
rocuronium	NN	O	B-Chemical
0.6	NN	O	O
mg	NN	O	O
x	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

Morphine	NN	O	B-Chemical
0.1	NN	O	O
mg	NN	O	O
x	NN	O	O
kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
iv	NN	O	O
was	NN	O	O
given	NN	O	O
for	NN	O	O
premedication	NN	O	O
and	NN	O	O
all	NN	O	O
patients	NN	O	O
were	NN	O	O
monitored	NN	O	O
with	NN	O	O
a	NN	O	O
noninvasive	NN	O	O
blood	NN	O	O
pressure	NN	O	O
monitor	NN	O	O
,	NN	O	O
ECG	NN	O	O
and	NN	O	O
pulse	NN	O	O
oximetry	NN	O	O
.	NN	O	O

Anesthesia	NN	O	O
was	NN	O	O
induced	NN	O	O
with	NN	O	O
5	NN	O	O
mg.kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
thiopental	NN	O	B-Chemical
iv	NN	O	O
.	NN	O	O

followed	NN	O	O
by	NN	O	O
succinylcholine	NN	O	B-Chemical
(	NN	O	O
Group	NN	O	O
PS	NN	O	O
,	NN	O	O
LS	NN	O	O
)	NN	O	O
or	NN	O	O
rocuronium	NN	O	B-Chemical
(	NN	O	O
Group	NN	O	O
PR	NN	O	O
)	NN	O	O
for	NN	O	O
tracheal	NN	O	O
intubation	NN	O	O
.	NN	O	O

Following	NN	O	O
administration	NN	O	O
of	NN	O	O
these	NN	O	O
agents	NN	O	O
,	NN	O	O
the	NN	O	O
presence	NN	O	O
,	NN	O	O
and	NN	O	O
degree	NN	O	O
of	NN	O	O
fasciculation	NN	O	B-Disease
were	NN	O	O
assessed	NN	O	O
visually	NN	O	O
on	NN	O	O
a	NN	O	O
four	NN	O	O
point	NN	O	O
scale	NN	O	O
by	NN	O	O
one	NN	O	O
investigator	NN	O	O
who	NN	O	O
was	NN	O	O
blinded	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
administered	NN	O	O
.	NN	O	O

The	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
of	NN	O	O
each	NN	O	O
patient	NN	O	O
were	NN	O	O
monitored	NN	O	O
on	NN	O	O
nine	NN	O	O
occasions	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
four	NN	O	O
hours	NN	O	O
later	NN	O	O
,	NN	O	O
any	NN	O	O
myalgia	NN	O	B-Disease
experienced	NN	O	O
was	NN	O	O
assessed	NN	O	O
according	NN	O	O
to	NN	O	O
a	NN	O	O
structured	NN	O	O
questionaire	NN	O	O
and	NN	O	O
graded	NN	O	O
by	NN	O	O
a	NN	O	O
four	NN	O	O
point	NN	O	O
scale	NN	O	O
by	NN	O	O
one	NN	O	O
investigator	NN	O	O
blinded	NN	O	O
to	NN	O	O
the	NN	O	O
intraoperative	NN	O	O
management	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
muscle	NN	O	B-Disease
fasciculation	NN	O	I-Disease
was	NN	O	O
not	NN	O	O
found	NN	O	O
in	NN	O	O
Group	NN	O	O
PR	NN	O	O
while	NN	O	O
the	NN	O	O
patients	NN	O	O
in	NN	O	O
Group	NN	O	O
LS	NN	O	O
had	NN	O	O
a	NN	O	O
lower	NN	O	O
incidence	NN	O	O
of	NN	O	O
muscle	NN	O	B-Disease
fasciculation	NN	O	I-Disease
than	NN	O	O
those	NN	O	O
in	NN	O	O
Group	NN	O	O
PS	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

At	NN	O	O
24	NN	O	O
h	NN	O	O
,	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
myalgia	NN	O	B-Disease
was	NN	O	O
higher	NN	O	O
in	NN	O	O
Group	NN	O	O
PS	NN	O	O
than	NN	O	O
in	NN	O	O
Group	NN	O	O
LS	NN	O	O
and	NN	O	O
PR	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
correlation	NN	O	O
was	NN	O	O
not	NN	O	O
found	NN	O	O
between	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
myalgia	NN	O	B-Disease
and	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
muscle	NN	O	B-Disease
fasciculation	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
changes	NN	O	O
in	NN	O	O
systolic	NN	O	O
and	NN	O	O
diastolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
were	NN	O	O
not	NN	O	O
significant	NN	O	O
among	NN	O	O
the	NN	O	O
three	NN	O	O
groups	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
where	NN	O	O
succinylcholine	NN	O	B-Chemical
is	NN	O	O
used	NN	O	O
,	NN	O	O
lidocaine	NN	O	B-Chemical
is	NN	O	O
proven	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
useful	NN	O	O
pretreatment	NN	O	O
agent	NN	O	O
for	NN	O	O
the	NN	O	O
reduction	NN	O	O
of	NN	O	O
postoperative	NN	O	B-Disease
myalgia	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (9564988)

Open	NN	O	O
-	NN	O	O
label	NN	O	O
assessment	NN	O	O
of	NN	O	O
levofloxacin	NN	O	B-Chemical
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	O
bacterial	NN	O	O
sinusitis	NN	O	B-Disease
in	NN	O	O
adults	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
levofloxacin	NN	O	B-Chemical
(	NN	O	O
500	NN	O	O
mg	NN	O	O
orally	NN	O	O
once	NN	O	O
daily	NN	O	O
for	NN	O	O
10	NN	O	O
to	NN	O	O
14	NN	O	O
days	NN	O	O
)	NN	O	O
in	NN	O	O
treating	NN	O	O
adult	NN	O	O
outpatients	NN	O	O
with	NN	O	O
acute	NN	O	O
bacterial	NN	O	O
sinusitis	NN	O	B-Disease
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
329	NN	O	O
patients	NN	O	O
enrolled	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
at	NN	O	O
24	NN	O	O
centers	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
pre	NN	O	O
-	NN	O	O
therapy	NN	O	O
Gram	NN	O	O
'	NN	O	O
s	NN	O	O
stain	NN	O	O
and	NN	O	O
culture	NN	O	O
of	NN	O	O
sinus	NN	O	O
exudate	NN	O	O
obtained	NN	O	O
by	NN	O	O
antral	NN	O	O
puncture	NN	O	O
or	NN	O	O
nasal	NN	O	O
endoscopy	NN	O	O
.	NN	O	O

Clinical	NN	O	O
response	NN	O	O
was	NN	O	O
assessed	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
signs	NN	O	O
and	NN	O	O
symptoms	NN	O	O
and	NN	O	O
sinus	NN	O	O
radiograph	NN	O	O
or	NN	O	O
computed	NN	O	O
tomography	NN	O	O
results	NN	O	O
.	NN	O	O

Microbiologic	NN	O	O
cure	NN	O	O
rates	NN	O	O
were	NN	O	O
determined	NN	O	O
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
presumed	NN	O	O
plus	NN	O	O
documented	NN	O	O
eradication	NN	O	O
of	NN	O	O
the	NN	O	O
pre	NN	O	O
-	NN	O	O
therapy	NN	O	O
pathogen	NN	O	O
(	NN	O	O
s	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
most	NN	O	O
common	NN	O	O
pathogens	NN	O	O
were	NN	O	O
Haemophilus	NN	O	O
influenzae	NN	O	O
,	NN	O	O
Streptococcus	NN	O	O
pneumoniae	NN	O	O
,	NN	O	O
Staphylococcus	NN	O	O
aureus	NN	O	O
,	NN	O	O
and	NN	O	O
Moraxella	NN	O	O
catarrhalis	NN	O	O
.	NN	O	O

Of	NN	O	O
300	NN	O	O
clinically	NN	O	O
evaluable	NN	O	O
patients	NN	O	O
,	NN	O	O
175	NN	O	O
(	NN	O	O
58%	NN	O	O
)	NN	O	O
were	NN	O	O
cured	NN	O	O
and	NN	O	O
90	NN	O	O
(	NN	O	O
30%	NN	O	O
)	NN	O	O
were	NN	O	O
improved	NN	O	O
at	NN	O	O
the	NN	O	O
post	NN	O	O
-	NN	O	O
therapy	NN	O	O
evaluation	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
a	NN	O	O
clinical	NN	O	O
success	NN	O	O
rate	NN	O	O
of	NN	O	O
88%	NN	O	O
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
five	NN	O	O
patients	NN	O	O
(	NN	O	O
12%	NN	O	O
)	NN	O	O
clinically	NN	O	O
failed	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
microbiologic	NN	O	O
eradication	NN	O	O
rate	NN	O	O
(	NN	O	O
presumed	NN	O	O
plus	NN	O	O
documented	NN	O	O
)	NN	O	O
among	NN	O	O
138	NN	O	O
microbiologically	NN	O	O
evaluable	NN	O	O
patients	NN	O	O
was	NN	O	O
92%	NN	O	O
.	NN	O	O

Microbiologic	NN	O	O
eradication	NN	O	O
rates	NN	O	O
(	NN	O	O
presumed	NN	O	O
plus	NN	O	O
documented	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
pathogens	NN	O	O
ranged	NN	O	O
from	NN	O	O
93%	NN	O	O
(	NN	O	O
M	NN	O	O
.	NN	O	O

catarrhalis	NN	O	O
)	NN	O	O
to	NN	O	O
100%	NN	O	O
(	NN	O	O
S	NN	O	O
.	NN	O	O

pneumoniae	NN	O	O
)	NN	O	O
at	NN	O	O
the	NN	O	O
post	NN	O	O
-	NN	O	O
therapy	NN	O	O
visit	NN	O	O
.	NN	O	O

All	NN	O	O
but	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
265	NN	O	O
patients	NN	O	O
who	NN	O	O
were	NN	O	O
cured	NN	O	O
or	NN	O	O
improved	NN	O	O
at	NN	O	O
post	NN	O	O
-	NN	O	O
therapy	NN	O	O
returned	NN	O	O
for	NN	O	O
a	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
visit	NN	O	O
;	NN	O	O
243	NN	O	O
(	NN	O	O
92%	NN	O	O
)	NN	O	O
remained	NN	O	O
well	NN	O	O
4	NN	O	O
to	NN	O	O
6	NN	O	O
weeks	NN	O	O
after	NN	O	O
therapy	NN	O	O
;	NN	O	O
and	NN	O	O
21	NN	O	O
(	NN	O	O
8%	NN	O	O
)	NN	O	O
had	NN	O	O
a	NN	O	O
relapse	NN	O	O
of	NN	O	O
symptoms	NN	O	O
.	NN	O	O

Adverse	NN	O	O
events	NN	O	O
considered	NN	O	O
to	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
levofloxacin	NN	O	B-Chemical
administration	NN	O	O
were	NN	O	O
reported	NN	O	O
by	NN	O	O
29	NN	O	O
patients	NN	O	O
(	NN	O	O
9%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
drug	NN	O	O
-	NN	O	O
related	NN	O	O
adverse	NN	O	O
events	NN	O	O
were	NN	O	O
diarrhea	NN	O	B-Disease
,	NN	O	O
flatulence	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
nausea	NN	O	B-Disease
;	NN	O	O
most	NN	O	O
adverse	NN	O	O
events	NN	O	O
were	NN	O	O
mild	NN	O	O
to	NN	O	O
moderate	NN	O	O
in	NN	O	O
severity	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
indicate	NN	O	O
that	NN	O	O
levofloxacin	NN	O	B-Chemical
500	NN	O	O
mg	NN	O	O
once	NN	O	O
daily	NN	O	O
is	NN	O	O
an	NN	O	O
effective	NN	O	O
and	NN	O	O
safe	NN	O	O
treatment	NN	O	O
for	NN	O	O
acute	NN	O	O
bacterial	NN	O	O
sinusitis	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (7596955)

Clinical	NN	O	O
evaluation	NN	O	O
on	NN	O	O
combined	NN	O	O
administration	NN	O	O
of	NN	O	O
oral	NN	O	O
prostacyclin	NN	O	B-Chemical
analogue	NN	O	O
beraprost	NN	O	B-Chemical
and	NN	O	O
phosphodiesterase	NN	O	O
inhibitor	NN	O	O
cilostazol	NN	O	B-Chemical
.	NN	O	O

Among	NN	O	O
various	NN	O	O
oral	NN	O	O
antiplatelets	NN	O	O
,	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
a	NN	O	O
novel	NN	O	O
prostacyclin	NN	O	B-Chemical
analogue	NN	O	O
beraprost	NN	O	B-Chemical
(	NN	O	O
BPT	NN	O	B-Chemical
)	NN	O	O
and	NN	O	O
a	NN	O	O
potent	NN	O	O
phosphodiesterase	NN	O	O
inhibitor	NN	O	O
cilostazol	NN	O	B-Chemical
(	NN	O	O
CLZ	NN	O	B-Chemical
)	NN	O	O
may	NN	O	O
result	NN	O	O
in	NN	O	O
untoward	NN	O	O
clinical	NN	O	O
effects	NN	O	O
due	NN	O	O
to	NN	O	O
possible	NN	O	O
synergistic	NN	O	O
elevation	NN	O	O
of	NN	O	O
intracellular	NN	O	O
cAMP	NN	O	B-Chemical
(	NN	O	O
cyclic	NN	O	B-Chemical
adenosine	NN	O	I-Chemical
3	NN	O	I-Chemical
'	NN	O	I-Chemical
,	NN	O	I-Chemical
5	NN	O	I-Chemical
'	NN	O	I-Chemical
-	NN	O	I-Chemical
monophosphate	NN	O	I-Chemical
)	NN	O	O
.	NN	O	O

Thereby	NN	O	O
,	NN	O	O
a	NN	O	O
clinical	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
combined	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
agents	NN	O	O
was	NN	O	O
attempted	NN	O	O
.	NN	O	O

Twelve	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
were	NN	O	O
assigned	NN	O	O
to	NN	O	O
take	NN	O	O
BPT	NN	O	B-Chemical
/	NN	O	O
CLZ	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
following	NN	O	O
schedule	NN	O	O
;	NN	O	O
BPT	NN	O	B-Chemical
:	NN	O	O
40	NN	O	O
micrograms	NN	O	O
at	NN	O	O
day	NN	O	O
1	NN	O	O
and	NN	O	O
120	NN	O	O
micrograms	NN	O	O
t.i.d	NN	O	O
.	NN	O	O

from	NN	O	O
day	NN	O	O
7	NN	O	O
to	NN	O	O
14	NN	O	O
,	NN	O	O
CLZ	NN	O	B-Chemical
:	NN	O	O
200	NN	O	O
mg	NN	O	O
t.i.d	NN	O	O
.	NN	O	O

from	NN	O	O
day	NN	O	O
3	NN	O	O
to	NN	O	O
14	NN	O	O
.	NN	O	O

At	NN	O	O
various	NN	O	O
time	NN	O	O
intervals	NN	O	O
,	NN	O	O
physical	NN	O	O
examination	NN	O	O
and	NN	O	O
blood	NN	O	O
collection	NN	O	O
for	NN	O	O
ex	NN	O	O
vivo	NN	O	O
platelet	NN	O	B-Disease
aggregation	NN	O	I-Disease
and	NN	O	O
determination	NN	O	O
of	NN	O	O
intraplatelet	NN	O	O
cAMP	NN	O	B-Chemical
were	NN	O	O
performed	NN	O	O
.	NN	O	O

Throughout	NN	O	O
the	NN	O	O
observation	NN	O	O
period	NN	O	O
,	NN	O	O
no	NN	O	O
significant	NN	O	O
alteration	NN	O	O
in	NN	O	O
vital	NN	O	O
signs	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

Seven	NN	O	O
out	NN	O	O
of	NN	O	O
12	NN	O	O
subjects	NN	O	O
experienced	NN	O	O
headache	NN	O	B-Disease
of	NN	O	O
a	NN	O	O
short	NN	O	O
duration	NN	O	O
accompanying	NN	O	O
facial	NN	O	B-Disease
flush	NN	O	I-Disease
in	NN	O	O
one	NN	O	O
and	NN	O	O
nausea	NN	O	B-Disease
in	NN	O	O
one	NN	O	O
,	NN	O	O
especially	NN	O	O
after	NN	O	O
ingestion	NN	O	O
of	NN	O	O
CLZ	NN	O	B-Chemical
.	NN	O	O

All	NN	O	O
of	NN	O	O
these	NN	O	O
symptoms	NN	O	O
,	NN	O	O
probably	NN	O	O
caused	NN	O	O
by	NN	O	O
the	NN	O	O
vasodilating	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
agents	NN	O	O
,	NN	O	O
were	NN	O	O
of	NN	O	O
mild	NN	O	O
degree	NN	O	O
and	NN	O	O
no	NN	O	O
special	NN	O	O
treatment	NN	O	O
was	NN	O	O
required	NN	O	O
.	NN	O	O

Intraplatelet	NN	O	O
cAMP	NN	O	B-Chemical
content	NN	O	O
was	NN	O	O
gradually	NN	O	O
but	NN	O	O
significantly	NN	O	O
increased	NN	O	O
to	NN	O	O
9.84	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4.59	NN	O	O
pmol	NN	O	O
per	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
platelets	NN	O	O
at	NN	O	O
day	NN	O	O
14	NN	O	O
in	NN	O	O
comparison	NN	O	O
with	NN	O	O
the	NN	O	O
initial	NN	O	O
value	NN	O	O
(	NN	O	O
6.87	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.25	NN	O	O
pmol	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
platelet	NN	O	O
aggregability	NN	O	O
was	NN	O	O
significantly	NN	O	O
suppressed	NN	O	O
at	NN	O	O
various	NN	O	O
time	NN	O	O
intervals	NN	O	O
but	NN	O	O
no	NN	O	O
additive	NN	O	O
or	NN	O	O
synergistic	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
by	NN	O	O
the	NN	O	O
combined	NN	O	O
administration	NN	O	O
was	NN	O	O
noted	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
the	NN	O	O
combined	NN	O	O
administration	NN	O	O
of	NN	O	O
BPT	NN	O	B-Chemical
/	NN	O	O
CLZ	NN	O	B-Chemical
is	NN	O	O
safe	NN	O	O
at	NN	O	O
doses	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
,	NN	O	O
though	NN	O	O
the	NN	O	O
beneficial	NN	O	O
clinical	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
combined	NN	O	O
administration	NN	O	O
has	NN	O	O
yet	NN	O	O
to	NN	O	O
be	NN	O	O
elucidated	NN	O	O
.	NN	O	O


-DOCSTART- (17965424)

Gastrointestinal	NN	O	O
tolerability	NN	O	O
of	NN	O	O
etoricoxib	NN	O	B-Chemical
in	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
patients	NN	O	O
:	NN	O	O
results	NN	O	O
of	NN	O	O
the	NN	O	O
etoricoxib	NN	O	B-Chemical
vs	NN	O	O
diclofenac	NN	O	B-Chemical
sodium	NN	O	I-Chemical
gastrointestinal	NN	O	O
tolerability	NN	O	O
and	NN	O	O
effectiveness	NN	O	O
trial	NN	O	O
(	NN	O	O
EDGE	NN	O	O
-	NN	O	O
II	NN	O	O
)	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
A	NN	O	O
randomised	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
study	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
gastrointestinal	NN	O	O
(	NN	O	O
GI	NN	O	O
)	NN	O	O
tolerability	NN	O	O
,	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
etoricoxib	NN	O	B-Chemical
and	NN	O	O
diclofenac	NN	O	B-Chemical
in	NN	O	O
patients	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
(	NN	O	O
RA	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
4086	NN	O	O
patients	NN	O	O
(	NN	O	O
mean	NN	O	O
age	NN	O	O
60.8	NN	O	O
years	NN	O	O
)	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
RA	NN	O	B-Disease
were	NN	O	O
enrolled	NN	O	O
and	NN	O	O
received	NN	O	O
etoricoxib	NN	O	B-Chemical
90	NN	O	O
mg	NN	O	O
daily	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
2032	NN	O	O
)	NN	O	O
or	NN	O	O
diclofenac	NN	O	B-Chemical
75	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
2054	NN	O	O
)	NN	O	O
.	NN	O	O

Use	NN	O	O
of	NN	O	O
gastroprotective	NN	O	O
agents	NN	O	O
and	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
aspirin	NN	O	B-Chemical
was	NN	O	O
allowed	NN	O	O
.	NN	O	O

The	NN	O	O
prespecified	NN	O	O
primary	NN	O	O
end	NN	O	O
point	NN	O	O
consisted	NN	O	O
of	NN	O	O
the	NN	O	O
cumulative	NN	O	O
rate	NN	O	O
of	NN	O	O
patient	NN	O	O
discontinuations	NN	O	O
due	NN	O	O
to	NN	O	O
clinical	NN	O	O
and	NN	O	O
laboratory	NN	O	O
GI	NN	O	O
adverse	NN	O	O
experiences	NN	O	O
(	NN	O	O
AEs	NN	O	O
)	NN	O	O
.	NN	O	O

General	NN	O	O
safety	NN	O	O
was	NN	O	O
also	NN	O	O
assessed	NN	O	O
,	NN	O	O
including	NN	O	O
adjudicated	NN	O	O
thrombotic	NN	O	B-Disease
cardiovascular	NN	O	I-Disease
event	NN	O	O
data	NN	O	O
.	NN	O	O

Efficacy	NN	O	O
was	NN	O	O
evaluated	NN	O	O
using	NN	O	O
the	NN	O	O
Patient	NN	O	O
Global	NN	O	O
Assessment	NN	O	O
of	NN	O	O
Disease	NN	O	O
Status	NN	O	O
(	NN	O	O
PGADS	NN	O	O
;	NN	O	O
0	NN	O	O
-	NN	O	O
4	NN	O	O
point	NN	O	O
scale	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Mean	NN	O	O
(	NN	O	O
SD	NN	O	O
;	NN	O	O
maximum	NN	O	O
)	NN	O	O
duration	NN	O	O
of	NN	O	O
treatment	NN	O	O
was	NN	O	O
19.3	NN	O	O
(	NN	O	O
10.3	NN	O	O
;	NN	O	O
32.9	NN	O	O
)	NN	O	O
and	NN	O	O
19.1	NN	O	O
(	NN	O	O
10.4	NN	O	O
;	NN	O	O
33.1	NN	O	O
)	NN	O	O
months	NN	O	O
in	NN	O	O
the	NN	O	O
etoricoxib	NN	O	B-Chemical
and	NN	O	O
diclofenac	NN	O	B-Chemical
groups	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
cumulative	NN	O	O
discontinuation	NN	O	O
rate	NN	O	O
due	NN	O	O
to	NN	O	O
GI	NN	O	B-Disease
AEs	NN	O	I-Disease
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
with	NN	O	O
etoricoxib	NN	O	B-Chemical
than	NN	O	O
diclofenac	NN	O	B-Chemical
(	NN	O	O
5.2	NN	O	O
vs	NN	O	O
8.5	NN	O	O
events	NN	O	O
per	NN	O	O
100	NN	O	O
patient	NN	O	O
-	NN	O	O
years	NN	O	O
,	NN	O	O
respectively	NN	O	O
;	NN	O	O
hazard	NN	O	O
ratio	NN	O	O
0.62	NN	O	O
(	NN	O	O
95%	NN	O	O
CI	NN	O	O
:	NN	O	O
0.47	NN	O	O
,	NN	O	O
0.81	NN	O	O
;	NN	O	O
p<or=0.001	NN	O	O
)	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
discontinuations	NN	O	O
for	NN	O	O
hypertension	NN	O	B-Disease
-	NN	O	O
related	NN	O	O
and	NN	O	O
oedema	NN	O	B-Disease
-	NN	O	O
related	NN	O	O
AEs	NN	O	O
were	NN	O	O
significantly	NN	O	O
higher	NN	O	O
with	NN	O	O
etoricoxib	NN	O	B-Chemical
(	NN	O	O
2.5%	NN	O	O
and	NN	O	O
1.1%	NN	O	O
respectively	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
diclofenac	NN	O	B-Chemical
(	NN	O	O
1.5%	NN	O	O
and	NN	O	O
0.4%	NN	O	O
respectively	NN	O	O
;	NN	O	O
p<0.001	NN	O	O
for	NN	O	O
hypertension	NN	O	B-Disease
and	NN	O	O
p<0.01	NN	O	O
for	NN	O	O
oedema	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Etoricoxib	NN	O	B-Chemical
and	NN	O	O
diclofenac	NN	O	B-Chemical
treatment	NN	O	O
resulted	NN	O	O
in	NN	O	O
similar	NN	O	O
efficacy	NN	O	O
(	NN	O	O
PGADS	NN	O	O
mean	NN	O	O
changes	NN	O	O
from	NN	O	O
baseline	NN	O	O
-	NN	O	O
0.62	NN	O	O
vs	NN	O	O
-	NN	O	O
0.58	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Etoricoxib	NN	O	B-Chemical
90	NN	O	O
mg	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
significantly	NN	O	O
lower	NN	O	O
risk	NN	O	O
for	NN	O	O
discontinuing	NN	O	O
treatment	NN	O	O
due	NN	O	O
to	NN	O	O
GI	NN	O	B-Disease
AEs	NN	O	I-Disease
compared	NN	O	O
with	NN	O	O
diclofenac	NN	O	B-Chemical
150	NN	O	O
mg	NN	O	O
.	NN	O	O

Discontinuations	NN	O	O
from	NN	O	O
renovascular	NN	O	O
AEs	NN	O	O
,	NN	O	O
although	NN	O	O
less	NN	O	O
common	NN	O	O
than	NN	O	O
discontinuations	NN	O	O
from	NN	O	O
GI	NN	O	B-Disease
AEs	NN	O	I-Disease
,	NN	O	O
were	NN	O	O
significantly	NN	O	O
higher	NN	O	O
with	NN	O	O
etoricoxib	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (17042884)

Placebo	NN	O	O
-	NN	O	O
level	NN	O	O
incidence	NN	O	O
of	NN	O	O
extrapyramidal	NN	O	B-Disease
symptoms	NN	O	I-Disease
(	NN	O	O
EPS	NN	O	B-Disease
)	NN	O	O
with	NN	O	O
quetiapine	NN	O	B-Chemical
in	NN	O	O
controlled	NN	O	O
studies	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
bipolar	NN	O	B-Disease
mania	NN	O	I-Disease
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
extrapyramidal	NN	O	B-Disease
symptoms	NN	O	I-Disease
(	NN	O	O
EPS	NN	O	B-Disease
)	NN	O	O
,	NN	O	O
including	NN	O	O
akathisia	NN	O	B-Disease
,	NN	O	O
with	NN	O	O
quetiapine	NN	O	B-Chemical
in	NN	O	O
patients	NN	O	O
with	NN	O	O
bipolar	NN	O	B-Disease
mania	NN	O	I-Disease
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Data	NN	O	O
were	NN	O	O
analyzed	NN	O	O
from	NN	O	O
four	NN	O	O
similarly	NN	O	O
designed	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
3	NN	O	O
-	NN	O	O
to	NN	O	O
12	NN	O	O
-	NN	O	O
week	NN	O	O
studies	NN	O	O
.	NN	O	O

Two	NN	O	O
studies	NN	O	O
evaluated	NN	O	O
quetiapine	NN	O	B-Chemical
monotherapy	NN	O	O
(	NN	O	O
up	NN	O	O
to	NN	O	O
800	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
209	NN	O	O
)	NN	O	O
versus	NN	O	O
placebo	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
198	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
lithium	NN	O	B-Chemical
or	NN	O	O
haloperidol	NN	O	B-Chemical
monotherapy	NN	O	O
as	NN	O	O
respective	NN	O	O
active	NN	O	O
controls	NN	O	O
.	NN	O	O

Two	NN	O	O
studies	NN	O	O
evaluated	NN	O	O
quetiapine	NN	O	B-Chemical
(	NN	O	O
up	NN	O	O
to	NN	O	O
800	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
a	NN	O	O
mood	NN	O	O
stabilizer	NN	O	O
(	NN	O	O
lithium	NN	O	B-Chemical
or	NN	O	O
divalproex	NN	O	B-Chemical
,	NN	O	O
QTP	NN	O	B-Chemical
+	NN	O	O
Li	NN	O	B-Chemical
/	NN	O	O
DVP	NN	O	B-Chemical
)	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
196	NN	O	O
)	NN	O	O
compared	NN	O	O
to	NN	O	O
placebo	NN	O	O
and	NN	O	O
mood	NN	O	O
stabilizer	NN	O	O
(	NN	O	O
PBO	NN	O	O
+	NN	O	O
Li	NN	O	B-Chemical
/	NN	O	O
DVP	NN	O	B-Chemical
)	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
203	NN	O	O
)	NN	O	O
.	NN	O	O

Extrapyramidal	NN	O	B-Disease
symptoms	NN	O	I-Disease
were	NN	O	O
evaluated	NN	O	O
using	NN	O	O
the	NN	O	O
Simpson	NN	O	O
-	NN	O	O
Angus	NN	O	O
Scale	NN	O	O
(	NN	O	O
SAS	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
Barnes	NN	O	O
Akathisia	NN	O	O
Rating	NN	O	O
Scale	NN	O	O
(	NN	O	O
BARS	NN	O	O
)	NN	O	O
,	NN	O	O
adverse	NN	O	O
event	NN	O	O
reports	NN	O	O
and	NN	O	O
anticholinergic	NN	O	O
drug	NN	O	O
usage	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
incidence	NN	O	O
of	NN	O	O
EPS	NN	O	B-Disease
-	NN	O	O
related	NN	O	O
adverse	NN	O	O
events	NN	O	O
,	NN	O	O
including	NN	O	O
akathisia	NN	O	B-Disease
,	NN	O	O
was	NN	O	O
no	NN	O	O
different	NN	O	O
with	NN	O	O
quetiapine	NN	O	B-Chemical
monotherapy	NN	O	O
(	NN	O	O
12.9%	NN	O	O
)	NN	O	O
than	NN	O	O
with	NN	O	O
placebo	NN	O	O
(	NN	O	O
13.1%	NN	O	O
)	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
EPS	NN	O	B-Disease
-	NN	O	O
related	NN	O	O
adverse	NN	O	O
events	NN	O	O
with	NN	O	O
QTP	NN	O	B-Chemical
+	NN	O	O
Li	NN	O	B-Chemical
/	NN	O	O
DVP	NN	O	B-Chemical
(	NN	O	O
21.4%	NN	O	O
)	NN	O	O
were	NN	O	O
no	NN	O	O
different	NN	O	O
than	NN	O	O
with	NN	O	O
PBO	NN	O	O
+	NN	O	O
Li	NN	O	B-Chemical
/	NN	O	O
DVP	NN	O	B-Chemical
(	NN	O	O
19.2%	NN	O	O
)	NN	O	O
.	NN	O	O

Adverse	NN	O	O
events	NN	O	O
related	NN	O	O
to	NN	O	O
EPS	NN	O	B-Disease
occurred	NN	O	O
in	NN	O	O
59.6%	NN	O	O
of	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
haloperidol	NN	O	B-Chemical
(	NN	O	O
n	NN	O	O
=	NN	O	O
99	NN	O	O
)	NN	O	O
monotherapy	NN	O	O
,	NN	O	O
whereas	NN	O	O
26.5%	NN	O	O
of	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
lithium	NN	O	B-Chemical
(	NN	O	O
n	NN	O	O
=	NN	O	O
98	NN	O	O
)	NN	O	O
monotherapy	NN	O	O
experienced	NN	O	O
adverse	NN	O	O
events	NN	O	O
related	NN	O	O
to	NN	O	O
EPS	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
akathisia	NN	O	B-Disease
was	NN	O	O
low	NN	O	O
and	NN	O	O
similar	NN	O	O
with	NN	O	O
quetiapine	NN	O	B-Chemical
monotherapy	NN	O	O
(	NN	O	O
3.3%	NN	O	O
)	NN	O	O
and	NN	O	O
placebo	NN	O	O
(	NN	O	O
6.1%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
with	NN	O	O
QTP	NN	O	B-Chemical
+	NN	O	O
Li	NN	O	B-Chemical
/	NN	O	O
DVP	NN	O	B-Chemical
(	NN	O	O
3.6%	NN	O	O
)	NN	O	O
and	NN	O	O
PBO	NN	O	O
+	NN	O	O
Li	NN	O	B-Chemical
/	NN	O	O
DVP	NN	O	B-Chemical
(	NN	O	O
4.9%	NN	O	O
)	NN	O	O
.	NN	O	O

Lithium	NN	O	B-Chemical
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
significantly	NN	O	O
higher	NN	O	O
incidence	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
of	NN	O	O
tremor	NN	O	B-Disease
(	NN	O	O
18.4%	NN	O	O
)	NN	O	O
than	NN	O	O
quetiapine	NN	O	B-Chemical
(	NN	O	O
5.6%	NN	O	O
)	NN	O	O
;	NN	O	O
cerebellar	NN	O	O
tremor	NN	O	B-Disease
,	NN	O	O
which	NN	O	O
is	NN	O	O
a	NN	O	O
known	NN	O	O
adverse	NN	O	O
effect	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
,	NN	O	O
may	NN	O	O
have	NN	O	O
contributed	NN	O	O
to	NN	O	O
the	NN	O	O
elevated	NN	O	O
rate	NN	O	O
of	NN	O	O
tremor	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
lithium	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Haloperidol	NN	O	B-Chemical
induced	NN	O	O
a	NN	O	O
significantly	NN	O	O
higher	NN	O	O
incidence	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
of	NN	O	O
akathisia	NN	O	B-Disease
(	NN	O	O
33.3%	NN	O	O
versus	NN	O	O
5.9%	NN	O	O
)	NN	O	O
,	NN	O	O
tremor	NN	O	B-Disease
(	NN	O	O
30.3%	NN	O	O
versus	NN	O	O
7.8%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
extrapyramidal	NN	O	B-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
35.4%	NN	O	O
versus	NN	O	O
5.9%	NN	O	O
)	NN	O	O
than	NN	O	O
quetiapine	NN	O	B-Chemical
.	NN	O	O

No	NN	O	O
significant	NN	O	O
differences	NN	O	O
were	NN	O	O
observed	NN	O	O
between	NN	O	O
quetiapine	NN	O	B-Chemical
and	NN	O	O
placebo	NN	O	O
on	NN	O	O
SAS	NN	O	O
and	NN	O	O
BARS	NN	O	O
scores	NN	O	O
.	NN	O	O

Anticholinergic	NN	O	O
use	NN	O	O
was	NN	O	O
low	NN	O	O
and	NN	O	O
similar	NN	O	O
with	NN	O	O
quetiapine	NN	O	B-Chemical
or	NN	O	O
placebo	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
bipolar	NN	O	B-Disease
mania	NN	O	I-Disease
,	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
EPS	NN	O	B-Disease
,	NN	O	O
including	NN	O	O
akathisia	NN	O	B-Disease
,	NN	O	O
with	NN	O	O
quetiapine	NN	O	B-Chemical
therapy	NN	O	O
is	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
with	NN	O	O
placebo	NN	O	O
.	NN	O	O


-DOCSTART- (8586822)

Contribution	NN	O	O
of	NN	O	O
the	NN	O	O
sympathetic	NN	O	O
nervous	NN	O	O
system	NN	O	O
to	NN	O	O
salt	NN	O	O
-	NN	O	O
sensitivity	NN	O	O
in	NN	O	O
lifetime	NN	O	O
captopril	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B-Disease
rats	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
test	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
,	NN	O	O
in	NN	O	O
lifetime	NN	O	O
captopril	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B-Disease
rats	NN	O	O
(	NN	O	O
SHR	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
sympathetic	NN	O	O
nervous	NN	O	O
system	NN	O	O
contributes	NN	O	O
importantly	NN	O	O
to	NN	O	O
the	NN	O	O
hypertensive	NN	O	B-Disease
effect	NN	O	O
of	NN	O	O
dietary	NN	O	B-Chemical
sodium	NN	O	I-Chemical
chloride	NN	O	I-Chemical
supplementation	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Male	NN	O	O
SHR	NN	O	O
(	NN	O	O
aged	NN	O	O
6	NN	O	O
weeks	NN	O	O
)	NN	O	O
that	NN	O	O
had	NN	O	O
been	NN	O	O
treated	NN	O	O
from	NN	O	O
conception	NN	O	O
onward	NN	O	O
with	NN	O	O
either	NN	O	O
captopril	NN	O	B-Chemical
or	NN	O	O
vehicle	NN	O	O
remained	NN	O	O
on	NN	O	O
a	NN	O	O
basal	NN	O	O
sodium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
diet	NN	O	O
or	NN	O	O
were	NN	O	O
fed	NN	O	O
a	NN	O	O
high	NN	O	O
sodium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
diet	NN	O	O
.	NN	O	O

After	NN	O	O
2	NN	O	O
weeks	NN	O	O
,	NN	O	O
the	NN	O	O
rats	NN	O	O
were	NN	O	O
subjected	NN	O	O
to	NN	O	O
ganglionic	NN	O	O
blockade	NN	O	O
and	NN	O	O
2	NN	O	O
days	NN	O	O
later	NN	O	O
,	NN	O	O
an	NN	O	O
infusion	NN	O	O
of	NN	O	O
clonidine	NN	O	B-Chemical
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Lifetime	NN	O	O
captopril	NN	O	B-Chemical
treatment	NN	O	O
significantly	NN	O	O
lowered	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
infusion	NN	O	O
of	NN	O	O
the	NN	O	O
ganglionic	NN	O	O
blocker	NN	O	O
hexamethonium	NN	O	B-Chemical
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
rapid	NN	O	O
decline	NN	O	O
in	NN	O	O
MAP	NN	O	O
that	NN	O	O
eliminated	NN	O	O
the	NN	O	O
dietary	NN	O	B-Chemical
sodium	NN	O	I-Chemical
chloride	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
increase	NN	O	B-Disease
in	NN	O	I-Disease
MAP	NN	O	I-Disease
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

Infusion	NN	O	O
of	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
alpha2	NN	O	B-Chemical
-	NN	O	I-Chemical
adrenergic	NN	O	I-Chemical
receptor	NN	O	I-Chemical
agonist	NN	O	I-Chemical
clonidine	NN	O	B-Chemical
also	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
greater	NN	O	O
reduction	NN	O	O
in	NN	O	O
MAP	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
of	NN	O	O
SHR	NN	O	O
that	NN	O	O
were	NN	O	O
fed	NN	O	O
the	NN	O	O
high	NN	O	O
(	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
basal	NN	O	O
)	NN	O	O
sodium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
diet	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
both	NN	O	O
lifetime	NN	O	O
captopril	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
and	NN	O	O
control	NN	O	O
SHR	NN	O	O
,	NN	O	O
the	NN	O	O
sympathetic	NN	O	O
nervous	NN	O	O
system	NN	O	O
contributes	NN	O	O
to	NN	O	O
the	NN	O	O
pressor	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
high	NN	O	O
sodium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
diet	NN	O	O
.	NN	O	O


-DOCSTART- (3961813)

Dose	NN	O	O
-	NN	O	O
related	NN	O	O
beneficial	NN	O	O
and	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
dietary	NN	O	O
corticosterone	NN	O	B-Chemical
on	NN	O	O
organophosphorus	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
delayed	NN	O	O
neuropathy	NN	O	B-Disease
in	NN	O	O
chickens	NN	O	O
.	NN	O	O

Tri	NN	O	B-Chemical
-	NN	O	I-Chemical
ortho	NN	O	I-Chemical
-	NN	O	I-Chemical
tolyl	NN	O	I-Chemical
phosphate	NN	O	I-Chemical
(	NN	O	O
TOTP	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
360	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
po	NN	O	O
,	NN	O	O
and	NN	O	O
0	NN	O	B-Chemical
,	NN	O	I-Chemical
0	NN	O	I-Chemical
'	NN	O	I-Chemical
-	NN	O	I-Chemical
diisopropyl	NN	O	I-Chemical
phosphorofluoridate	NN	O	I-Chemical
(	NN	O	O
DFP	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
sc	NN	O	O
,	NN	O	O
were	NN	O	O
administered	NN	O	O
to	NN	O	O
adult	NN	O	O
White	NN	O	O
Leghorn	NN	O	O
chickens	NN	O	O
24	NN	O	O
hr	NN	O	O
after	NN	O	O
they	NN	O	O
were	NN	O	O
placed	NN	O	O
on	NN	O	O
diets	NN	O	O
containing	NN	O	O
0	NN	O	O
to	NN	O	O
300	NN	O	O
ppm	NN	O	O
corticosterone	NN	O	B-Chemical
.	NN	O	O

Supplemented	NN	O	O
diets	NN	O	O
were	NN	O	O
continued	NN	O	O
until	NN	O	O
clinical	NN	O	O
signs	NN	O	O
and	NN	O	O
lesions	NN	O	O
of	NN	O	O
delayed	NN	O	O
neuropathy	NN	O	B-Disease
appeared	NN	O	O
.	NN	O	O

Although	NN	O	O
low	NN	O	O
concentrations	NN	O	O
(	NN	O	O
less	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
50	NN	O	O
ppm	NN	O	O
)	NN	O	O
of	NN	O	O
corticosterone	NN	O	B-Chemical
had	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
on	NN	O	O
TOTP	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
neuropathy	NN	O	B-Disease
,	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
200	NN	O	O
ppm	NN	O	O
exacerbated	NN	O	O
clinical	NN	O	O
signs	NN	O	O
in	NN	O	O
chickens	NN	O	O
given	NN	O	O
either	NN	O	O
TOTP	NN	O	B-Chemical
or	NN	O	O
DFP	NN	O	B-Chemical
.	NN	O	O

Neurotoxic	NN	O	B-Disease
esterase	NN	O	O
activities	NN	O	O
24	NN	O	O
hr	NN	O	O
after	NN	O	O
TOTP	NN	O	B-Chemical
or	NN	O	O
DFP	NN	O	B-Chemical
were	NN	O	O
less	NN	O	O
than	NN	O	O
20%	NN	O	O
of	NN	O	O
values	NN	O	O
measured	NN	O	O
in	NN	O	O
chickens	NN	O	O
not	NN	O	O
given	NN	O	O
organophosphorous	NN	O	B-Chemical
compounds	NN	O	O
.	NN	O	O

Chickens	NN	O	O
given	NN	O	O
200	NN	O	O
ppm	NN	O	O
corticosterone	NN	O	B-Chemical
without	NN	O	O
TOTP	NN	O	B-Chemical
or	NN	O	O
DFP	NN	O	B-Chemical
had	NN	O	O
significantly	NN	O	O
elevated	NN	O	O
activity	NN	O	O
of	NN	O	O
plasma	NN	O	O
cholinesterase	NN	O	O
and	NN	O	O
significantly	NN	O	O
inhibited	NN	O	O
activity	NN	O	O
of	NN	O	O
liver	NN	O	O
carboxylesterase	NN	O	O
.	NN	O	O

Degenerating	NN	O	B-Disease
myelinated	NN	O	I-Disease
fibers	NN	O	I-Disease
were	NN	O	O
also	NN	O	O
evident	NN	O	O
in	NN	O	O
distal	NN	O	O
levels	NN	O	O
of	NN	O	O
the	NN	O	O
peripheral	NN	O	O
nerves	NN	O	O
of	NN	O	O
chickens	NN	O	O
given	NN	O	O
TOTP	NN	O	B-Chemical
or	NN	O	O
DFP	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (20973483)

In	NN	O	O
vivo	NN	O	O
characterization	NN	O	O
of	NN	O	O
a	NN	O	O
dual	NN	O	O
adenosine	NN	O	B-Chemical
A2A	NN	O	I-Chemical
/	NN	O	I-Chemical
A1	NN	O	I-Chemical
receptor	NN	O	I-Chemical
antagonist	NN	O	I-Chemical
in	NN	O	O
animal	NN	O	O
models	NN	O	O
of	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
in	NN	O	O
vivo	NN	O	O
characterization	NN	O	O
of	NN	O	O
a	NN	O	O
dual	NN	O	O
adenosine	NN	O	B-Chemical
A	NN	O	I-Chemical
(	NN	O	I-Chemical
2A	NN	O	I-Chemical
)	NN	O	I-Chemical
/	NN	O	I-Chemical
A	NN	O	I-Chemical
(	NN	O	I-Chemical
1	NN	O	I-Chemical
)	NN	O	I-Chemical
receptor	NN	O	I-Chemical
antagonist	NN	O	I-Chemical
in	NN	O	O
several	NN	O	O
animal	NN	O	O
models	NN	O	O
of	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
is	NN	O	O
described	NN	O	O
.	NN	O	O

Discovery	NN	O	O
and	NN	O	O
scale	NN	O	O
-	NN	O	O
up	NN	O	O
syntheses	NN	O	O
of	NN	O	O
compound	NN	O	O
1	NN	O	O
are	NN	O	O
described	NN	O	O
in	NN	O	O
detail	NN	O	O
,	NN	O	O
highlighting	NN	O	O
optimization	NN	O	O
steps	NN	O	O
that	NN	O	O
increased	NN	O	O
the	NN	O	O
overall	NN	O	O
yield	NN	O	O
of	NN	O	O
1	NN	O	O
from	NN	O	O
10.0%	NN	O	O
to	NN	O	O
30.5%	NN	O	O
.	NN	O	O

Compound	NN	O	O
1	NN	O	O
is	NN	O	O
a	NN	O	O
potent	NN	O	O
A	NN	O	O
(	NN	O	O
2A	NN	O	O
)	NN	O	O
/	NN	O	O
A	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
in	NN	O	O
vitro	NN	O	O
(	NN	O	O
A	NN	O	O
(	NN	O	O
2A	NN	O	O
)	NN	O	O
K	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
=	NN	O	O
4.1	NN	O	O
nM	NN	O	O
;	NN	O	O
A	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
K	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
=	NN	O	O
17.0	NN	O	O
nM	NN	O	O
)	NN	O	O
that	NN	O	O
has	NN	O	O
excellent	NN	O	O
activity	NN	O	O
,	NN	O	O
after	NN	O	O
oral	NN	O	O
administration	NN	O	O
,	NN	O	O
across	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
animal	NN	O	O
models	NN	O	O
of	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
including	NN	O	O
mouse	NN	O	O
and	NN	O	O
rat	NN	O	O
models	NN	O	O
of	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
,	NN	O	O
mouse	NN	O	O
model	NN	O	O
of	NN	O	O
reserpine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
akinesia	NN	O	B-Disease
,	NN	O	O
rat	NN	O	O
6	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxydopamine	NN	O	I-Chemical
(	NN	O	O
6	NN	O	B-Chemical
-	NN	O	I-Chemical
OHDA	NN	O	I-Chemical
)	NN	O	O
lesion	NN	O	O
model	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
rotation	NN	O	O
,	NN	O	O
and	NN	O	O
MPTP	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
non	NN	O	O
-	NN	O	O
human	NN	O	O
primate	NN	O	O
model	NN	O	O
.	NN	O	O


-DOCSTART- (17511042)

An	NN	O	O
extremely	NN	O	O
rare	NN	O	O
case	NN	O	O
of	NN	O	O
delusional	NN	O	B-Disease
parasitosis	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
chronic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
C	NN	O	I-Disease
patient	NN	O	O
during	NN	O	O
pegylated	NN	O	B-Chemical
interferon	NN	O	I-Chemical
alpha	NN	O	I-Chemical
-	NN	O	I-Chemical
2b	NN	O	I-Chemical
and	NN	O	O
ribavirin	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

During	NN	O	O
treatment	NN	O	O
of	NN	O	O
chronic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
C	NN	O	I-Disease
patients	NN	O	O
with	NN	O	O
interferon	NN	O	O
and	NN	O	O
ribavirin	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
lot	NN	O	O
of	NN	O	O
side	NN	O	O
effects	NN	O	O
are	NN	O	O
described	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
three	NN	O	O
percent	NN	O	O
to	NN	O	O
44%	NN	O	O
of	NN	O	O
patients	NN	O	O
develop	NN	O	O
depression	NN	O	B-Disease
.	NN	O	O

A	NN	O	O
minority	NN	O	O
of	NN	O	O
patients	NN	O	O
evolve	NN	O	O
to	NN	O	O
psychosis	NN	O	B-Disease
.	NN	O	O

To	NN	O	O
the	NN	O	O
best	NN	O	O
of	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
no	NN	O	O
cases	NN	O	O
of	NN	O	O
psychogenic	NN	O	B-Disease
parasitosis	NN	O	I-Disease
occurring	NN	O	O
during	NN	O	O
interferon	NN	O	O
therapy	NN	O	O
have	NN	O	O
been	NN	O	O
described	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
a	NN	O	O
49	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
who	NN	O	O
developed	NN	O	O
a	NN	O	O
delusional	NN	O	B-Disease
parasitosis	NN	O	I-Disease
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
pegylated	NN	O	B-Chemical
interferon	NN	O	I-Chemical
alpha	NN	O	I-Chemical
-	NN	O	I-Chemical
2b	NN	O	I-Chemical
weekly	NN	O	O
and	NN	O	O
ribavirin	NN	O	B-Chemical
.	NN	O	O

She	NN	O	O
complained	NN	O	O
of	NN	O	O
seeing	NN	O	O
parasites	NN	O	O
and	NN	O	O
the	NN	O	O
larvae	NN	O	O
of	NN	O	O
fleas	NN	O	O
in	NN	O	O
her	NN	O	O
stools	NN	O	O
.	NN	O	O

This	NN	O	O
could	NN	O	O
not	NN	O	O
be	NN	O	O
confirmed	NN	O	O
by	NN	O	O
any	NN	O	O
technical	NN	O	O
examination	NN	O	O
.	NN	O	O

All	NN	O	O
the	NN	O	O
complaints	NN	O	O
disappeared	NN	O	O
after	NN	O	O
stopping	NN	O	O
pegylated	NN	O	B-Chemical
interferon	NN	O	I-Chemical
alpha	NN	O	I-Chemical
-	NN	O	I-Chemical
2b	NN	O	I-Chemical
and	NN	O	O
reappeared	NN	O	O
after	NN	O	O
restarting	NN	O	O
it	NN	O	O
.	NN	O	O

She	NN	O	O
had	NN	O	O
a	NN	O	O
complete	NN	O	O
sustained	NN	O	O
viral	NN	O	O
response	NN	O	O
.	NN	O	O


-DOCSTART- (16720068)

Possible	NN	O	O
neuroleptic	NN	O	B-Disease
malignant	NN	O	I-Disease
syndrome	NN	O	I-Disease
related	NN	O	O
to	NN	O	O
concomitant	NN	O	O
treatment	NN	O	O
with	NN	O	O
paroxetine	NN	O	B-Chemical
and	NN	O	O
alprazolam	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
74	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
depressive	NN	O	B-Disease
symptoms	NN	O	I-Disease
was	NN	O	O
admitted	NN	O	O
to	NN	O	O
a	NN	O	O
psychiatric	NN	O	B-Disease
hospital	NN	O	O
due	NN	O	O
to	NN	O	O
insomnia	NN	O	B-Disease
,	NN	O	O
loss	NN	O	B-Disease
of	NN	O	I-Disease
appetite	NN	O	I-Disease
,	NN	O	O
exhaustion	NN	O	O
,	NN	O	O
and	NN	O	O
agitation	NN	O	B-Disease
.	NN	O	O

Medical	NN	O	O
treatment	NN	O	O
was	NN	O	O
initiated	NN	O	O
at	NN	O	O
a	NN	O	O
daily	NN	O	O
dose	NN	O	O
of	NN	O	O
20	NN	O	O
mg	NN	O	O
paroxetine	NN	O	B-Chemical
and	NN	O	O
1.2	NN	O	O
mg	NN	O	O
alprazolam	NN	O	B-Chemical
.	NN	O	O

On	NN	O	O
the	NN	O	O
10th	NN	O	O
day	NN	O	O
of	NN	O	O
paroxetine	NN	O	B-Chemical
and	NN	O	O
alprazolam	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
exhibited	NN	O	O
marked	NN	O	O
psychomotor	NN	O	B-Disease
retardation	NN	O	I-Disease
,	NN	O	O
disorientation	NN	O	O
,	NN	O	O
and	NN	O	O
severe	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
with	NN	O	O
tremors	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
patient	NN	O	O
had	NN	O	O
a	NN	O	O
fever	NN	O	B-Disease
(	NN	O	O
38.2	NN	O	O
degrees	NN	O	O
C	NN	O	O
)	NN	O	O
,	NN	O	O
fluctuating	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
between	NN	O	O
165	NN	O	O
/	NN	O	O
90	NN	O	O
and	NN	O	O
130	NN	O	O
/	NN	O	O
70	NN	O	O
mg	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
severe	NN	O	O
extrapyramidal	NN	O	B-Disease
symptoms	NN	O	I-Disease
.	NN	O	O

Laboratory	NN	O	O
tests	NN	O	O
showed	NN	O	O
an	NN	O	O
elevation	NN	O	O
of	NN	O	O
creatine	NN	O	B-Chemical
phosphokinase	NN	O	O
(	NN	O	O
2218	NN	O	O
IU	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
,	NN	O	O
aspartate	NN	O	B-Chemical
aminotransferase	NN	O	O
(	NN	O	O
134	NN	O	O
IU	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
,	NN	O	O
alanine	NN	O	B-Chemical
aminotransferase	NN	O	O
(	NN	O	O
78	NN	O	O
IU	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
BUN	NN	O	O
(	NN	O	O
27.9	NN	O	O
mg	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
levels	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
received	NN	O	O
bromocriptine	NN	O	B-Chemical
and	NN	O	O
diazepam	NN	O	B-Chemical
to	NN	O	O
treat	NN	O	O
his	NN	O	O
symptoms	NN	O	O
.	NN	O	O

7	NN	O	O
days	NN	O	O
later	NN	O	O
,	NN	O	O
the	NN	O	O
fever	NN	O	B-Disease
disappeared	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
serum	NN	O	O
CPK	NN	O	O
levels	NN	O	O
were	NN	O	O
normalized	NN	O	O
(	NN	O	O
175	NN	O	O
IU	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
patient	NN	O	O
presented	NN	O	O
with	NN	O	O
symptoms	NN	O	O
of	NN	O	O
neuroleptic	NN	O	B-Disease
malignant	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
NMS	NN	O	B-Disease
)	NN	O	O
,	NN	O	O
thus	NN	O	O
demonstrating	NN	O	O
that	NN	O	O
NMS	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
symptoms	NN	O	O
can	NN	O	O
occur	NN	O	O
after	NN	O	O
combined	NN	O	O
paroxetine	NN	O	B-Chemical
and	NN	O	O
alprazolam	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reaction	NN	O	O
score	NN	O	O
obtained	NN	O	O
by	NN	O	O
the	NN	O	O
Naranjo	NN	O	O
algorithm	NN	O	O
was	NN	O	O
6	NN	O	O
in	NN	O	O
our	NN	O	O
case	NN	O	O
,	NN	O	O
indicating	NN	O	O
a	NN	O	O
probable	NN	O	O
relationship	NN	O	O
between	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
NMS	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
adverse	NN	O	O
symptoms	NN	O	O
and	NN	O	O
the	NN	O	O
combined	NN	O	O
treatment	NN	O	O
used	NN	O	O
in	NN	O	O
this	NN	O	O
case	NN	O	O
.	NN	O	O

The	NN	O	O
involvement	NN	O	O
of	NN	O	O
physiologic	NN	O	O
and	NN	O	O
environmental	NN	O	O
aspects	NN	O	O
specific	NN	O	O
to	NN	O	O
this	NN	O	O
patient	NN	O	O
was	NN	O	O
suspected	NN	O	O
.	NN	O	O

Several	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
NMS	NN	O	B-Disease
should	NN	O	O
be	NN	O	O
noted	NN	O	O
in	NN	O	O
elderly	NN	O	O
depressive	NN	O	B-Disease
patients	NN	O	O
whose	NN	O	O
symptoms	NN	O	O
often	NN	O	O
include	NN	O	O
dehydration	NN	O	B-Disease
,	NN	O	O
agitation	NN	O	B-Disease
,	NN	O	O
malnutrition	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
exhaustion	NN	O	O
.	NN	O	O

Careful	NN	O	O
therapeutic	NN	O	O
intervention	NN	O	O
is	NN	O	O
necessary	NN	O	O
in	NN	O	O
cases	NN	O	O
involving	NN	O	O
elderly	NN	O	O
patients	NN	O	O
who	NN	O	O
suffer	NN	O	O
from	NN	O	O
depression	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (16596970)

Pilocarpine	NN	O	B-Chemical
seizures	NN	O	B-Disease
cause	NN	O	O
age	NN	O	O
-	NN	O	O
dependent	NN	O	O
impairment	NN	O	B-Disease
in	NN	O	I-Disease
auditory	NN	O	I-Disease
location	NN	O	I-Disease
discrimination	NN	O	I-Disease
.	NN	O	O

Children	NN	O	O
who	NN	O	O
have	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
have	NN	O	O
continuous	NN	O	O
or	NN	O	O
rapidly	NN	O	O
repeating	NN	O	O
seizures	NN	O	B-Disease
that	NN	O	O
may	NN	O	O
be	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
and	NN	O	O
may	NN	O	O
cause	NN	O	O
life	NN	O	O
-	NN	O	O
long	NN	O	O
changes	NN	O	O
in	NN	O	O
brain	NN	O	O
and	NN	O	O
behavior	NN	O	O
.	NN	O	O

The	NN	O	O
extent	NN	O	O
to	NN	O	O
which	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
causes	NN	O	O
deficits	NN	O	B-Disease
in	NN	O	I-Disease
auditory	NN	O	I-Disease
discrimination	NN	O	I-Disease
is	NN	O	O
unknown	NN	O	O
.	NN	O	O

A	NN	O	O
naturalistic	NN	O	O
auditory	NN	O	O
location	NN	O	O
discrimination	NN	O	O
method	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
evaluate	NN	O	O
this	NN	O	O
question	NN	O	O
using	NN	O	O
an	NN	O	O
animal	NN	O	O
model	NN	O	O
of	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
.	NN	O	O

Male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
were	NN	O	O
injected	NN	O	O
with	NN	O	O
saline	NN	O	O
on	NN	O	O
postnatal	NN	O	O
day	NN	O	O
(	NN	O	O
P	NN	O	O
)	NN	O	O
20	NN	O	O
,	NN	O	O
or	NN	O	O
a	NN	O	O
convulsant	NN	O	O
dose	NN	O	O
of	NN	O	O
pilocarpine	NN	O	B-Chemical
on	NN	O	O
P20	NN	O	O
or	NN	O	O
P45	NN	O	O
.	NN	O	O

Pilocarpine	NN	O	B-Chemical
on	NN	O	O
either	NN	O	O
day	NN	O	O
induced	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
;	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
at	NN	O	O
P45	NN	O	O
resulted	NN	O	O
in	NN	O	O
CA3	NN	O	O
cell	NN	O	O
loss	NN	O	O
and	NN	O	O
spontaneous	NN	O	O
seizures	NN	O	B-Disease
,	NN	O	O
whereas	NN	O	O
P20	NN	O	O
rats	NN	O	O
had	NN	O	O
no	NN	O	O
cell	NN	O	O
loss	NN	O	O
or	NN	O	O
spontaneous	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

Mature	NN	O	O
rats	NN	O	O
were	NN	O	O
trained	NN	O	O
with	NN	O	O
sound	NN	O	O
-	NN	O	O
source	NN	O	O
location	NN	O	O
and	NN	O	O
sound	NN	O	O
-	NN	O	O
silence	NN	O	O
discriminations	NN	O	O
.	NN	O	O

Control	NN	O	O
(	NN	O	O
saline	NN	O	O
P20	NN	O	O
)	NN	O	O
rats	NN	O	O
acquired	NN	O	O
both	NN	O	O
discriminations	NN	O	O
immediately	NN	O	O
.	NN	O	O

In	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
(	NN	O	O
P20	NN	O	O
)	NN	O	O
rats	NN	O	O
,	NN	O	O
acquisition	NN	O	O
of	NN	O	O
the	NN	O	O
sound	NN	O	O
-	NN	O	O
source	NN	O	O
location	NN	O	O
discrimination	NN	O	O
was	NN	O	O
moderately	NN	O	O
impaired	NN	O	O
.	NN	O	O

Status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
(	NN	O	O
P45	NN	O	O
)	NN	O	O
rats	NN	O	O
failed	NN	O	O
to	NN	O	O
acquire	NN	O	O
either	NN	O	O
sound	NN	O	O
-	NN	O	O
source	NN	O	O
location	NN	O	O
or	NN	O	O
sound	NN	O	O
-	NN	O	O
silence	NN	O	O
discriminations	NN	O	O
.	NN	O	O

Status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
in	NN	O	O
rat	NN	O	O
causes	NN	O	O
an	NN	O	O
age	NN	O	O
-	NN	O	O
dependent	NN	O	O
,	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
impairment	NN	O	B-Disease
in	NN	O	I-Disease
auditory	NN	O	I-Disease
discrimination	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
impairment	NN	O	O
may	NN	O	O
explain	NN	O	O
one	NN	O	O
cause	NN	O	O
of	NN	O	O
impaired	NN	O	B-Disease
auditory	NN	O	I-Disease
location	NN	O	I-Disease
discrimination	NN	O	I-Disease
in	NN	O	O
humans	NN	O	O
.	NN	O	O


-DOCSTART- (16586083)

Cardiovascular	NN	O	O
risk	NN	O	O
with	NN	O	O
cyclooxygenase	NN	O	B-Chemical
inhibitors	NN	O	I-Chemical
:	NN	O	O
general	NN	O	O
problem	NN	O	O
with	NN	O	O
substance	NN	O	O
specific	NN	O	O
differences?	NN	O	O
Randomised	NN	O	O
clinical	NN	O	O
trials	NN	O	O
and	NN	O	O
observational	NN	O	O
studies	NN	O	O
have	NN	O	O
shown	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
,	NN	O	O
stroke	NN	O	B-Disease
,	NN	O	O
hypertension	NN	O	B-Disease
and	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
cyclooxygenase	NN	O	B-Chemical
inhibitors	NN	O	I-Chemical
.	NN	O	O

Adverse	NN	O	O
cardiovascular	NN	O	O
effects	NN	O	O
occurred	NN	O	O
mainly	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
exclusively	NN	O	O
,	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
concomitant	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

Cyclooxygenase	NN	O	B-Chemical
inhibitors	NN	O	I-Chemical
cause	NN	O	O
complex	NN	O	O
changes	NN	O	O
in	NN	O	O
renal	NN	O	O
,	NN	O	O
vascular	NN	O	O
and	NN	O	O
cardiac	NN	O	O
prostanoid	NN	O	O
profiles	NN	O	O
thereby	NN	O	O
increasing	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
and	NN	O	O
fluid	NN	O	O
retention	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
cardiovascular	NN	O	O
adverse	NN	O	O
events	NN	O	O
tends	NN	O	O
to	NN	O	O
increase	NN	O	O
with	NN	O	O
the	NN	O	O
daily	NN	O	O
dose	NN	O	O
and	NN	O	O
total	NN	O	O
exposure	NN	O	O
time	NN	O	O
.	NN	O	O

A	NN	O	O
comparison	NN	O	O
of	NN	O	O
individual	NN	O	O
selective	NN	O	O
and	NN	O	O
unselective	NN	O	O
cyclooxygenase	NN	O	B-Chemical
inhibitors	NN	O	I-Chemical
suggests	NN	O	O
substance	NN	O	O
-	NN	O	O
specific	NN	O	O
differences	NN	O	O
,	NN	O	O
which	NN	O	O
may	NN	O	O
depend	NN	O	O
on	NN	O	O
differences	NN	O	O
in	NN	O	O
pharmacokinetic	NN	O	O
parameters	NN	O	O
or	NN	O	O
inhibitory	NN	O	O
potency	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
contributed	NN	O	O
by	NN	O	O
prostaglandin	NN	O	B-Chemical
-	NN	O	O
independent	NN	O	O
effects	NN	O	O
.	NN	O	O

Diagnostic	NN	O	O
markers	NN	O	O
such	NN	O	O
as	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
terminal	NN	O	I-Chemical
pro	NN	O	I-Chemical
brain	NN	O	I-Chemical
natriuretic	NN	O	I-Chemical
peptide	NN	O	I-Chemical
(	NN	O	O
NT	NN	O	B-Chemical
-	NN	O	I-Chemical
proBNP	NN	O	I-Chemical
)	NN	O	O
or	NN	O	O
high	NN	O	O
-	NN	O	O
sensitive	NN	O	O
C	NN	O	O
-	NN	O	O
reactive	NN	O	O
protein	NN	O	O
might	NN	O	O
help	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
identification	NN	O	O
of	NN	O	O
patients	NN	O	O
at	NN	O	O
risk	NN	O	O
,	NN	O	O
thus	NN	O	O
avoiding	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
serious	NN	O	O
cardiovascular	NN	O	B-Disease
toxicity	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (10539815)

Predictors	NN	O	O
of	NN	O	O
decreased	NN	O	B-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
with	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
during	NN	O	O
angiotensin	NN	O	B-Chemical
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
therapy	NN	O	O
:	NN	O	O
results	NN	O	O
from	NN	O	O
the	NN	O	O
studies	NN	O	O
of	NN	O	O
left	NN	O	B-Disease
ventricular	NN	O	I-Disease
dysfunction	NN	O	I-Disease
(	NN	O	O
SOLVD	NN	O	O
)	NN	O	O
BACKGROUND	NN	O	O
:	NN	O	O
Although	NN	O	O
angiotensin	NN	O	B-Chemical
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
therapy	NN	O	O
reduces	NN	O	O
mortality	NN	O	O
rates	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
congestive	NN	O	B-Disease
heart	NN	O	I-Disease
failure	NN	O	I-Disease
(	NN	O	O
CHF	NN	O	B-Disease
)	NN	O	O
,	NN	O	O
it	NN	O	O
may	NN	O	O
also	NN	O	O
cause	NN	O	O
decreased	NN	O	B-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
.	NN	O	O

Little	NN	O	O
information	NN	O	O
is	NN	O	O
available	NN	O	O
to	NN	O	O
predict	NN	O	O
which	NN	O	O
patients	NN	O	O
are	NN	O	O
at	NN	O	O
highest	NN	O	O
risk	NN	O	O
for	NN	O	O
this	NN	O	O
complication	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
quantify	NN	O	O
specific	NN	O	O
clinical	NN	O	O
predictors	NN	O	O
of	NN	O	O
reduction	NN	O	B-Disease
in	NN	O	I-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
with	NN	O	O
CHF	NN	O	B-Disease
who	NN	O	O
are	NN	O	O
prescribed	NN	O	O
angiotensin	NN	O	B-Chemical
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
therapy	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
We	NN	O	O
analyzed	NN	O	O
data	NN	O	O
from	NN	O	O
the	NN	O	O
Studies	NN	O	O
of	NN	O	O
Left	NN	O	B-Disease
Ventricular	NN	O	I-Disease
Dysfunction	NN	O	I-Disease
(	NN	O	O
SOLVD	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
trial	NN	O	O
of	NN	O	O
enalapril	NN	O	B-Chemical
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
CHF	NN	O	B-Disease
.	NN	O	O

There	NN	O	O
were	NN	O	O
3379	NN	O	O
patients	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
enalapril	NN	O	B-Chemical
with	NN	O	O
a	NN	O	O
median	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
974	NN	O	O
days	NN	O	O
and	NN	O	O
3379	NN	O	O
patients	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
placebo	NN	O	O
with	NN	O	O
a	NN	O	O
mean	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
967	NN	O	O
days	NN	O	O
.	NN	O	O

Decreased	NN	O	B-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
was	NN	O	O
defined	NN	O	O
as	NN	O	O
a	NN	O	O
rise	NN	O	O
in	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
>	NN	O	O
/	NN	O	O
=0.5	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
(	NN	O	O
44	NN	O	O
micromol	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
from	NN	O	O
baseline	NN	O	O
.	NN	O	O

We	NN	O	O
used	NN	O	O
time	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
event	NN	O	O
analysis	NN	O	O
to	NN	O	O
identify	NN	O	O
potential	NN	O	O
predictors	NN	O	O
of	NN	O	O
decrease	NN	O	O
in	NN	O	O
renal	NN	O	O
function	NN	O	O
including	NN	O	O
age	NN	O	O
,	NN	O	O
baseline	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
,	NN	O	O
baseline	NN	O	O
creatinine	NN	O	B-Chemical
,	NN	O	O
low	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
<100	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
,	NN	O	O
history	NN	O	O
of	NN	O	O
hypertension	NN	O	B-Disease
,	NN	O	O
diabetes	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
use	NN	O	O
of	NN	O	O
antiplatelet	NN	O	O
,	NN	O	O
diuretic	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
beta	NN	O	O
-	NN	O	O
blocker	NN	O	O
therapy	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Patients	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
enalapril	NN	O	B-Chemical
had	NN	O	O
a	NN	O	O
33%	NN	O	O
greater	NN	O	O
likelihood	NN	O	O
of	NN	O	O
decreased	NN	O	B-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
than	NN	O	O
controls	NN	O	O
(	NN	O	O
P	NN	O	O
=.003	NN	O	O
)	NN	O	O
.	NN	O	O

By	NN	O	O
multivariate	NN	O	O
analysis	NN	O	O
,	NN	O	O
in	NN	O	O
both	NN	O	O
the	NN	O	O
placebo	NN	O	O
and	NN	O	O
enalapril	NN	O	B-Chemical
groups	NN	O	O
older	NN	O	O
age	NN	O	O
,	NN	O	O
diuretic	NN	O	B-Chemical
therapy	NN	O	O
,	NN	O	O
and	NN	O	O
diabetes	NN	O	B-Disease
were	NN	O	O
associated	NN	O	O
with	NN	O	O
decreased	NN	O	B-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
,	NN	O	O
whereas	NN	O	O
beta	NN	O	O
-	NN	O	O
blocker	NN	O	O
therapy	NN	O	O
and	NN	O	O
higher	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
were	NN	O	O
renoprotective	NN	O	O
.	NN	O	O

Older	NN	O	O
age	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
greater	NN	O	O
risk	NN	O	O
of	NN	O	O
developing	NN	O	O
decreased	NN	O	B-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
in	NN	O	O
both	NN	O	O
groups	NN	O	O
,	NN	O	O
but	NN	O	O
significantly	NN	O	O
more	NN	O	O
so	NN	O	O
in	NN	O	O
the	NN	O	O
enalapril	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
enalapril	NN	O	B-Chemical
:	NN	O	O
risk	NN	O	O
ratio	NN	O	O
[	NN	O	O
RR	NN	O	O
]	NN	O	O
1.42	NN	O	O
per	NN	O	O
10	NN	O	O
years	NN	O	O
,	NN	O	O
95%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
[	NN	O	O
CI	NN	O	O
]	NN	O	O
1.32	NN	O	O
-	NN	O	O
1.52	NN	O	O
with	NN	O	O
enalapril	NN	O	B-Chemical
;	NN	O	O
placebo	NN	O	O
:	NN	O	O
RR	NN	O	O
1.18	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
1.12	NN	O	O
-	NN	O	O
1.25	NN	O	O
)	NN	O	O
.	NN	O	O

Diuretic	NN	O	B-Chemical
therapy	NN	O	O
was	NN	O	O
likewise	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
greater	NN	O	O
risk	NN	O	O
of	NN	O	O
decreased	NN	O	B-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
enalapril	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
RR	NN	O	O
1.89	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
1.70	NN	O	O
-	NN	O	O
2.08	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
(	NN	O	O
RR	NN	O	O
1.35	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
1.09	NN	O	O
-	NN	O	O
1.66	NN	O	O
)	NN	O	O
.	NN	O	O

Conversely	NN	O	O
,	NN	O	O
enalapril	NN	O	B-Chemical
had	NN	O	O
a	NN	O	O
relative	NN	O	O
renoprotective	NN	O	O
effect	NN	O	O
(	NN	O	O
RR	NN	O	O
1.33	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
1.13	NN	O	O
-	NN	O	O
1.53	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
placebo	NN	O	O
(	NN	O	O
RR	NN	O	O
1.96	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
1.57	NN	O	O
-	NN	O	O
2.44	NN	O	O
)	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
diabetes	NN	O	B-Disease
.	NN	O	O

A	NN	O	O
lower	NN	O	O
risk	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
impairment	NN	O	I-Disease
was	NN	O	O
seen	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
with	NN	O	O
beta	NN	O	O
-	NN	O	O
blocker	NN	O	O
therapy	NN	O	O
(	NN	O	O
RR	NN	O	O
0.70	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
0.57	NN	O	O
-	NN	O	O
0.85	NN	O	O
)	NN	O	O
and	NN	O	O
higher	NN	O	O
baseline	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
(	NN	O	O
RR	NN	O	O
0.93	NN	O	O
per	NN	O	O
5%	NN	O	O
increment	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
0.91	NN	O	O
-	NN	O	O
0	NN	O	O
.	NN	O	O

96	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Enalapril	NN	O	B-Chemical
use	NN	O	O
caused	NN	O	O
a	NN	O	O
33%	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
decreased	NN	O	B-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
with	NN	O	O
CHF	NN	O	B-Disease
.	NN	O	O

Diuretic	NN	O	B-Chemical
use	NN	O	O
and	NN	O	O
advanced	NN	O	O
age	NN	O	O
increased	NN	O	O
this	NN	O	O
risk	NN	O	O
.	NN	O	O

Diabetes	NN	O	B-Disease
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
impairment	NN	O	I-Disease
in	NN	O	O
all	NN	O	O
patients	NN	O	O
with	NN	O	O
CHF	NN	O	B-Disease
,	NN	O	O
but	NN	O	O
this	NN	O	O
risk	NN	O	O
was	NN	O	O
reduced	NN	O	O
in	NN	O	O
the	NN	O	O
enalapril	NN	O	B-Chemical
group	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
.	NN	O	O

beta	NN	O	O
-	NN	O	O
Blocker	NN	O	O
therapy	NN	O	O
and	NN	O	O
higher	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
were	NN	O	O
renoprotective	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
regardless	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O


-DOCSTART- (9022662)

Pemoline	NN	O	B-Chemical
induced	NN	O	O
acute	NN	O	O
choreoathetosis	NN	O	B-Disease
:	NN	O	O
case	NN	O	O
report	NN	O	O
and	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Pemoline	NN	O	B-Chemical
is	NN	O	O
an	NN	O	O
oxazolidine	NN	O	B-Chemical
derivative	NN	O	O
that	NN	O	O
is	NN	O	O
structurally	NN	O	O
different	NN	O	O
from	NN	O	O
amphetamines	NN	O	B-Chemical
and	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
attention	NN	O	B-Disease
deficit	NN	O	I-Disease
disorder	NN	O	I-Disease
.	NN	O	O

Pemoline	NN	O	B-Chemical
has	NN	O	O
not	NN	O	O
been	NN	O	O
commonly	NN	O	O
associated	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
as	NN	O	O
a	NN	O	O
cause	NN	O	O
of	NN	O	O
acute	NN	O	O
movement	NN	O	B-Disease
disorders	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
following	NN	O	O
case	NN	O	O
describes	NN	O	O
two	NN	O	O
children	NN	O	O
acutely	NN	O	O
poisoned	NN	O	O
with	NN	O	O
pemoline	NN	O	B-Chemical
who	NN	O	O
experienced	NN	O	O
profound	NN	O	O
choreoathetosis	NN	O	B-Disease
.	NN	O	O

CASE	NN	O	O
REPORT	NN	O	O
:	NN	O	O
Two	NN	O	O
,	NN	O	O
3	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
,	NN	O	O
identical	NN	O	O
twin	NN	O	O
siblings	NN	O	O
presented	NN	O	O
to	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
after	NN	O	O
found	NN	O	O
playing	NN	O	O
with	NN	O	O
a	NN	O	O
an	NN	O	O
empty	NN	O	O
bottle	NN	O	O
of	NN	O	O
pemoline	NN	O	B-Chemical
originally	NN	O	O
containing	NN	O	O
59	NN	O	O
tablets	NN	O	O
.	NN	O	O

The	NN	O	O
children	NN	O	O
had	NN	O	O
a	NN	O	O
medical	NN	O	O
history	NN	O	O
significant	NN	O	O
for	NN	O	O
attention	NN	O	B-Disease
deficit	NN	O	I-Disease
disorder	NN	O	I-Disease
previously	NN	O	O
treated	NN	O	O
with	NN	O	O
methylphenidate	NN	O	B-Chemical
without	NN	O	O
success	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
their	NN	O	O
first	NN	O	O
day	NN	O	O
of	NN	O	O
pemoline	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
choreoathetoid	NN	O	B-Disease
movements	NN	O	O
began	NN	O	O
45	NN	O	O
min	NN	O	O
to	NN	O	O
1	NN	O	O
h	NN	O	O
after	NN	O	O
ingestion	NN	O	O
.	NN	O	O

The	NN	O	O
children	NN	O	O
gave	NN	O	O
no	NN	O	O
history	NN	O	O
of	NN	O	O
prior	NN	O	O
movement	NN	O	B-Disease
disorders	NN	O	I-Disease
and	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
family	NN	O	O
history	NN	O	O
of	NN	O	O
movement	NN	O	B-Disease
disorders	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
children	NN	O	O
received	NN	O	O
gastrointestinal	NN	O	O
decontamination	NN	O	O
and	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
intravenous	NN	O	O
benzodiazepines	NN	O	B-Chemical
in	NN	O	O
an	NN	O	O
attempt	NN	O	O
to	NN	O	O
control	NN	O	O
the	NN	O	O
choreoathetoid	NN	O	B-Disease
movements	NN	O	O
.	NN	O	O

Despite	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
children	NN	O	O
continued	NN	O	O
to	NN	O	O
have	NN	O	O
choreoathetosis	NN	O	B-Disease
for	NN	O	O
approximately	NN	O	O
24	NN	O	O
hours	NN	O	O
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
eight	NN	O	O
hours	NN	O	O
after	NN	O	O
admission	NN	O	O
,	NN	O	O
the	NN	O	O
children	NN	O	O
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
at	NN	O	O
their	NN	O	O
baseline	NN	O	O
and	NN	O	O
were	NN	O	O
discharged	NN	O	O
home	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Pemoline	NN	O	B-Chemical
associated	NN	O	O
movement	NN	O	B-Disease
disorder	NN	O	I-Disease
has	NN	O	O
been	NN	O	O
rarely	NN	O	O
reported	NN	O	O
in	NN	O	O
the	NN	O	O
acute	NN	O	O
toxicology	NN	O	O
literature	NN	O	O
.	NN	O	O

The	NN	O	O
possibility	NN	O	O
of	NN	O	O
choreoathetoid	NN	O	B-Disease
movements	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
in	NN	O	O
patients	NN	O	O
presenting	NN	O	O
after	NN	O	O
pemoline	NN	O	B-Chemical
overdose	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (8677458)

Continuous	NN	O	O
subcutaneous	NN	O	O
administration	NN	O	O
of	NN	O	O
mesna	NN	O	B-Chemical
to	NN	O	O
prevent	NN	O	O
ifosfamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
.	NN	O	O

Hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
major	NN	O	O
potential	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
ifosfamide	NN	O	B-Chemical
that	NN	O	O
can	NN	O	O
be	NN	O	O
prevented	NN	O	O
by	NN	O	O
administering	NN	O	O
mesna	NN	O	B-Chemical
along	NN	O	O
with	NN	O	O
the	NN	O	O
cytotoxic	NN	O	O
agent	NN	O	O
.	NN	O	O

Mesna	NN	O	B-Chemical
is	NN	O	O
generally	NN	O	O
administered	NN	O	O
by	NN	O	O
the	NN	O	O
intravenous	NN	O	O
route	NN	O	O
,	NN	O	O
although	NN	O	O
experience	NN	O	O
with	NN	O	O
oral	NN	O	O
delivery	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
has	NN	O	O
increased	NN	O	O
.	NN	O	O

The	NN	O	O
continuous	NN	O	O
subcutaneous	NN	O	O
administration	NN	O	O
of	NN	O	O
mesna	NN	O	B-Chemical
has	NN	O	O
the	NN	O	O
advantage	NN	O	O
of	NN	O	O
not	NN	O	O
requiring	NN	O	O
intravenous	NN	O	O
access	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
subcutaneous	NN	O	O
delivery	NN	O	O
of	NN	O	O
the	NN	O	O
neutralizing	NN	O	O
agent	NN	O	O
will	NN	O	O
not	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
inadequate	NN	O	O
urinary	NN	O	O
mesna	NN	O	B-Chemical
concentrations	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
taking	NN	O	O
oral	NN	O	O
mesna	NN	O	B-Chemical
who	NN	O	O
experiences	NN	O	O
severe	NN	O	O
ifosfamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
emesis	NN	O	B-Disease
and	NN	O	O
is	NN	O	O
unable	NN	O	O
to	NN	O	O
absorb	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

Limited	NN	O	O
clinical	NN	O	O
experience	NN	O	O
with	NN	O	O
continuous	NN	O	O
subcutaneous	NN	O	O
mesna	NN	O	B-Chemical
administration	NN	O	O
suggests	NN	O	O
it	NN	O	O
is	NN	O	O
a	NN	O	O
safe	NN	O	O
,	NN	O	O
practical	NN	O	O
,	NN	O	O
and	NN	O	O
economic	NN	O	O
method	NN	O	O
of	NN	O	O
drug	NN	O	O
delivery	NN	O	O
that	NN	O	O
permits	NN	O	O
ifosfamide	NN	O	B-Chemical
to	NN	O	O
be	NN	O	O
administered	NN	O	O
successfully	NN	O	O
in	NN	O	O
the	NN	O	O
outpatient	NN	O	O
setting	NN	O	O
.	NN	O	O


-DOCSTART- (6323692)

Modification	NN	O	O
of	NN	O	O
drug	NN	O	O
action	NN	O	O
by	NN	O	O
hyperammonemia	NN	O	B-Disease
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
ammonium	NN	O	B-Chemical
acetate	NN	O	I-Chemical
(	NN	O	O
NH4Ac	NN	O	B-Chemical
)	NN	O	O
(	NN	O	O
6	NN	O	O
mmol	NN	O	O
/	NN	O	O
kg	NN	O	O
s.c.	NN	O	O
)	NN	O	O
approximately	NN	O	O
doubled	NN	O	O
the	NN	O	O
time	NN	O	O
morphine	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
mice	NN	O	O
remained	NN	O	O
on	NN	O	O
a	NN	O	O
hot	NN	O	O
surface	NN	O	O
and	NN	O	O
similarly	NN	O	O
increased	NN	O	O
muscular	NN	O	O
incoordination	NN	O	B-Disease
by	NN	O	O
diazepam	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
NH4Ac	NN	O	B-Chemical
treatment	NN	O	O
alone	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
hyperammonemia	NN	O	B-Disease
is	NN	O	O
capable	NN	O	O
of	NN	O	O
altering	NN	O	O
drug	NN	O	O
action	NN	O	O
and	NN	O	O
must	NN	O	O
be	NN	O	O
considered	NN	O	O
along	NN	O	O
with	NN	O	O
impaired	NN	O	O
drug	NN	O	O
metabolism	NN	O	O
in	NN	O	O
enhanced	NN	O	O
drug	NN	O	O
responses	NN	O	O
associated	NN	O	O
with	NN	O	O
liver	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

Experiments	NN	O	O
in	NN	O	O
vitro	NN	O	O
showed	NN	O	O
that	NN	O	O
acetylcholine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catecholamine	NN	O	B-Chemical
release	NN	O	O
from	NN	O	O
bovine	NN	O	O
adrenal	NN	O	O
medulla	NN	O	O
is	NN	O	O
depressed	NN	O	O
as	NN	O	O
much	NN	O	O
as	NN	O	O
50%	NN	O	O
by	NN	O	O
0.3	NN	O	O
mM	NN	O	O
NH4Ac	NN	O	B-Chemical
and	NN	O	O
KCl	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
contractions	NN	O	O
of	NN	O	O
guinea	NN	O	O
-	NN	O	O
pig	NN	O	O
ileum	NN	O	O
were	NN	O	O
inhibited	NN	O	O
20%	NN	O	O
by	NN	O	O
5	NN	O	O
mM	NN	O	O
NH4Ac	NN	O	B-Chemical
.	NN	O	O

Addition	NN	O	O
of	NN	O	O
excess	NN	O	O
calcium	NN	O	B-Chemical
reversed	NN	O	O
the	NN	O	O
depression	NN	O	B-Disease
in	NN	O	O
both	NN	O	O
tissues	NN	O	O
,	NN	O	O
but	NN	O	O
calcium	NN	O	B-Chemical
-	NN	O	O
independent	NN	O	O
catecholamine	NN	O	B-Chemical
release	NN	O	O
by	NN	O	O
acetaldehyde	NN	O	B-Chemical
was	NN	O	O
not	NN	O	O
blocked	NN	O	O
by	NN	O	O
NH4Ac	NN	O	B-Chemical
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggested	NN	O	O
that	NN	O	O
ammonia	NN	O	B-Chemical
blocks	NN	O	O
calcium	NN	O	B-Chemical
channels	NN	O	O
.	NN	O	O

Parallels	NN	O	O
in	NN	O	O
the	NN	O	O
actions	NN	O	O
of	NN	O	O
NH4Ac	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
calcium	NN	O	B-Chemical
channel	NN	O	O
blocker	NN	O	O
verapamil	NN	O	B-Chemical
support	NN	O	O
this	NN	O	O
concept	NN	O	O
.	NN	O	O

Both	NN	O	O
verapamil	NN	O	B-Chemical
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.p.	NN	O	O
)	NN	O	O
and	NN	O	O
NH4Ac	NN	O	B-Chemical
pretreatment	NN	O	O
enhanced	NN	O	O
morphine	NN	O	B-Chemical
analgesia	NN	O	B-Disease
-	NN	O	O
and	NN	O	O
diazepam	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
muscular	NN	O	O
incoordination	NN	O	B-Disease
and	NN	O	O
antagonized	NN	O	O
amphetamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
motor	NN	O	O
activity	NN	O	O
,	NN	O	O
and	NN	O	O
neither	NN	O	O
verapamil	NN	O	B-Chemical
nor	NN	O	O
NH4Ac	NN	O	B-Chemical
affected	NN	O	O
the	NN	O	O
convulsant	NN	O	O
action	NN	O	O
of	NN	O	O
metrazol	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
hyperammonemia	NN	O	B-Disease
exerts	NN	O	O
a	NN	O	O
calcium	NN	O	B-Chemical
channel	NN	O	O
blocking	NN	O	O
action	NN	O	O
which	NN	O	O
enhances	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
depressants	NN	O	O
and	NN	O	O
certain	NN	O	O
opioid	NN	O	O
analgesics	NN	O	O
.	NN	O	O


-DOCSTART- (20195852)

Risk	NN	O	O
of	NN	O	O
nephropathy	NN	O	B-Disease
after	NN	O	O
consumption	NN	O	O
of	NN	O	O
nonionic	NN	O	O
contrast	NN	O	B-Chemical
media	NN	O	I-Chemical
by	NN	O	O
children	NN	O	O
undergoing	NN	O	O
cardiac	NN	O	O
angiography	NN	O	O
:	NN	O	O
a	NN	O	O
prospective	NN	O	O
study	NN	O	O
.	NN	O	O

Despite	NN	O	O
increasing	NN	O	O
reports	NN	O	O
on	NN	O	O
nonionic	NN	O	O
contrast	NN	O	B-Chemical
media	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B-Disease
(	NN	O	O
CIN	NN	O	B-Disease
)	NN	O	O
in	NN	O	O
hospitalized	NN	O	O
adult	NN	O	O
patients	NN	O	O
during	NN	O	O
cardiac	NN	O	O
procedures	NN	O	O
,	NN	O	O
the	NN	O	O
studies	NN	O	O
in	NN	O	O
pediatrics	NN	O	O
are	NN	O	O
limited	NN	O	O
,	NN	O	O
with	NN	O	O
even	NN	O	O
less	NN	O	O
focus	NN	O	O
on	NN	O	O
possible	NN	O	O
predisposing	NN	O	O
factors	NN	O	O
and	NN	O	O
preventive	NN	O	O
measures	NN	O	O
for	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
cardiac	NN	O	O
angiography	NN	O	O
.	NN	O	O

This	NN	O	O
prospective	NN	O	O
study	NN	O	O
determined	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
CIN	NN	O	B-Disease
for	NN	O	O
two	NN	O	O
nonionic	NN	O	O
contrast	NN	O	B-Chemical
media	NN	O	I-Chemical
(	NN	O	O
CM	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
iopromide	NN	O	B-Chemical
and	NN	O	O
iohexol	NN	O	B-Chemical
,	NN	O	O
among	NN	O	O
80	NN	O	O
patients	NN	O	O
younger	NN	O	O
than	NN	O	O
18	NN	O	O
years	NN	O	O
and	NN	O	O
compared	NN	O	O
the	NN	O	O
rates	NN	O	O
for	NN	O	O
this	NN	O	O
complication	NN	O	O
in	NN	O	O
relation	NN	O	O
to	NN	O	O
the	NN	O	O
type	NN	O	O
and	NN	O	O
dosage	NN	O	O
of	NN	O	O
CM	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
cyanosis	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
80	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
consecutively	NN	O	O
received	NN	O	O
either	NN	O	O
iopromide	NN	O	B-Chemical
(	NN	O	O
group	NN	O	O
A	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
40	NN	O	O
)	NN	O	O
or	NN	O	O
iohexol	NN	O	B-Chemical
(	NN	O	O
group	NN	O	O
B	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
40	NN	O	O
)	NN	O	O
.	NN	O	O

Serum	NN	O	O
sodium	NN	O	B-Chemical
(	NN	O	O
Na	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
potassium	NN	O	B-Chemical
(	NN	O	O
K	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
and	NN	O	O
creatinine	NN	O	B-Chemical
(	NN	O	O
Cr	NN	O	B-Chemical
)	NN	O	O
were	NN	O	O
measured	NN	O	O
24	NN	O	O
h	NN	O	O
before	NN	O	O
angiography	NN	O	O
as	NN	O	O
baseline	NN	O	O
values	NN	O	O
,	NN	O	O
then	NN	O	O
measured	NN	O	O
again	NN	O	O
at	NN	O	O
12	NN	O	O
-	NN	O	O
,	NN	O	O
24	NN	O	O
-	NN	O	O
,	NN	O	O
and	NN	O	O
48	NN	O	O
-	NN	O	O
h	NN	O	O
intervals	NN	O	O
after	NN	O	O
CM	NN	O	B-Chemical
use	NN	O	O
.	NN	O	O

Urine	NN	O	O
samples	NN	O	O
for	NN	O	O
Na	NN	O	B-Chemical
and	NN	O	O
Cr	NN	O	B-Chemical
also	NN	O	O
were	NN	O	O
checked	NN	O	O
at	NN	O	O
the	NN	O	O
same	NN	O	O
intervals	NN	O	O
.	NN	O	O

Risk	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
,	NN	O	O
Injury	NN	O	B-Disease
to	NN	O	I-Disease
the	NN	O	I-Disease
kidney	NN	O	I-Disease
,	NN	O	O
Failure	NN	O	B-Disease
of	NN	O	I-Disease
kidney	NN	O	I-Disease
function	NN	O	I-Disease
,	NN	O	O
Loss	NN	O	B-Disease
of	NN	O	I-Disease
kidney	NN	O	I-Disease
function	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
End	NN	O	O
-	NN	O	O
stage	NN	O	O
renal	NN	O	B-Disease
damage	NN	O	I-Disease
(	NN	O	O
RIFLE	NN	O	O
criteria	NN	O	O
)	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
define	NN	O	O
CIN	NN	O	B-Disease
and	NN	O	O
its	NN	O	O
incidence	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
population	NN	O	O
.	NN	O	O

Accordingly	NN	O	O
,	NN	O	O
among	NN	O	O
the	NN	O	O
15	NN	O	O
CIN	NN	O	B-Disease
patients	NN	O	O
(	NN	O	O
18.75%	NN	O	O
)	NN	O	O
,	NN	O	O
7.5%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
in	NN	O	O
group	NN	O	O
A	NN	O	O
had	NN	O	O
increased	NN	O	O
risk	NN	O	O
and	NN	O	O
3.75%	NN	O	O
had	NN	O	O
renal	NN	O	B-Disease
injury	NN	O	I-Disease
,	NN	O	O
whereas	NN	O	O
5%	NN	O	O
of	NN	O	O
group	NN	O	O
B	NN	O	O
had	NN	O	O
increased	NN	O	O
risk	NN	O	O
and	NN	O	O
2.5%	NN	O	O
had	NN	O	O
renal	NN	O	B-Disease
injury	NN	O	I-Disease
.	NN	O	O

Whereas	NN	O	O
33.3%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
with	NN	O	O
CIN	NN	O	B-Disease
were	NN	O	O
among	NN	O	O
those	NN	O	O
who	NN	O	O
received	NN	O	O
the	NN	O	O
proper	NN	O	O
dosage	NN	O	O
of	NN	O	O
CM	NN	O	B-Chemical
,	NN	O	O
the	NN	O	O
percentage	NN	O	O
increased	NN	O	O
to	NN	O	O
66.6%	NN	O	O
among	NN	O	O
those	NN	O	O
who	NN	O	O
received	NN	O	O
larger	NN	O	O
doses	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
CIN	NN	O	B-Disease
related	NN	O	O
to	NN	O	O
the	NN	O	O
different	NN	O	O
dosages	NN	O	O
of	NN	O	O
CM	NN	O	B-Chemical
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.014	NN	O	O
)	NN	O	O
.	NN	O	O

Among	NN	O	O
the	NN	O	O
15	NN	O	O
patients	NN	O	O
with	NN	O	O
CIN	NN	O	B-Disease
,	NN	O	O
6	NN	O	O
had	NN	O	O
cyanotic	NN	O	O
congenital	NN	O	B-Disease
heart	NN	O	I-Disease
diseases	NN	O	I-Disease
,	NN	O	O
but	NN	O	O
the	NN	O	O
incidence	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
significantly	NN	O	O
from	NN	O	O
that	NN	O	O
for	NN	O	O
the	NN	O	O
noncyanotic	NN	O	O
patients	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.243	NN	O	O
)	NN	O	O
.	NN	O	O

Although	NN	O	O
clinically	NN	O	O
silent	NN	O	O
,	NN	O	O
CIN	NN	O	B-Disease
is	NN	O	O
not	NN	O	O
rare	NN	O	O
in	NN	O	O
pediatrics	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
depends	NN	O	O
on	NN	O	O
dosage	NN	O	O
but	NN	O	O
not	NN	O	O
on	NN	O	O
the	NN	O	O
type	NN	O	O
of	NN	O	O
consumed	NN	O	O
nonionic	NN	O	O
CM	NN	O	B-Chemical
,	NN	O	O
nor	NN	O	O
on	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
cyanosis	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
although	NN	O	O
CIN	NN	O	B-Disease
usually	NN	O	O
is	NN	O	O
reversible	NN	O	O
,	NN	O	O
more	NN	O	O
concern	NN	O	O
is	NN	O	O
needed	NN	O	O
for	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
such	NN	O	O
a	NN	O	O
complication	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O


-DOCSTART- (18997632)

A	NN	O	O
case	NN	O	O
of	NN	O	O
ventricular	NN	O	B-Disease
tachycardia	NN	O	I-Disease
related	NN	O	O
to	NN	O	O
caffeine	NN	O	B-Chemical
pretreatment	NN	O	O
.	NN	O	O

Suboptimal	NN	O	O
seizure	NN	O	B-Disease
duration	NN	O	O
is	NN	O	O
commonly	NN	O	O
encountered	NN	O	O
in	NN	O	O
electroconvulsive	NN	O	O
therapy	NN	O	O
practice	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
older	NN	O	O
patients	NN	O	O
with	NN	O	O
higher	NN	O	O
seizure	NN	O	B-Disease
thresholds	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
caffeine	NN	O	B-Chemical
is	NN	O	O
commonly	NN	O	O
used	NN	O	O
to	NN	O	O
improve	NN	O	O
seizure	NN	O	B-Disease
duration	NN	O	O
and	NN	O	O
quality	NN	O	O
in	NN	O	O
such	NN	O	O
patients	NN	O	O
and	NN	O	O
is	NN	O	O
generally	NN	O	O
well	NN	O	O
tolerated	NN	O	O
aside	NN	O	O
from	NN	O	O
occasional	NN	O	O
reports	NN	O	O
of	NN	O	O
relatively	NN	O	O
benign	NN	O	O
ventricular	NN	O	B-Disease
ectopy	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
no	NN	O	O
previous	NN	O	O
history	NN	O	O
of	NN	O	O
cardiac	NN	O	B-Disease
disease	NN	O	I-Disease
or	NN	O	O
arrhythmia	NN	O	B-Disease
who	NN	O	O
developed	NN	O	O
sustained	NN	O	O
bigeminy	NN	O	O
and	NN	O	O
2	NN	O	O
brief	NN	O	O
runs	NN	O	O
of	NN	O	O
ventricular	NN	O	B-Disease
tachycardia	NN	O	I-Disease
after	NN	O	O
caffeine	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

Although	NN	O	O
intravenous	NN	O	O
caffeine	NN	O	B-Chemical
is	NN	O	O
generally	NN	O	O
well	NN	O	O
tolerated	NN	O	O
,	NN	O	O
the	NN	O	O
clinician	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
potential	NN	O	O
for	NN	O	O
unpredictable	NN	O	O
and	NN	O	O
serious	NN	O	O
ventricular	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (15565293)

Optical	NN	O	O
coherence	NN	O	O
tomography	NN	O	O
can	NN	O	O
measure	NN	O	O
axonal	NN	O	O
loss	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
ethambutol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
map	NN	O	O
and	NN	O	O
identify	NN	O	O
the	NN	O	O
pattern	NN	O	O
,	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
of	NN	O	O
axonal	NN	O	B-Disease
degeneration	NN	O	I-Disease
in	NN	O	O
ethambutol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
using	NN	O	O
optical	NN	O	O
coherence	NN	O	O
tomography	NN	O	O
(	NN	O	O
OCT	NN	O	O
)	NN	O	O
.	NN	O	O

Ethambutol	NN	O	B-Chemical
is	NN	O	O
an	NN	O	O
antimycobacterial	NN	O	O
agent	NN	O	O
often	NN	O	O
used	NN	O	O
to	NN	O	O
treat	NN	O	O
tuberculosis	NN	O	B-Disease
.	NN	O	O

A	NN	O	O
serious	NN	O	O
complication	NN	O	O
of	NN	O	O
ethambutol	NN	O	B-Chemical
is	NN	O	O
an	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
that	NN	O	O
impairs	NN	O	O
visual	NN	O	O
acuity	NN	O	O
,	NN	O	O
contrast	NN	O	O
sensitivity	NN	O	O
,	NN	O	O
and	NN	O	O
color	NN	O	O
vision	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
early	NN	O	O
on	NN	O	O
,	NN	O	O
when	NN	O	O
the	NN	O	O
toxic	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
is	NN	O	O
mild	NN	O	O
and	NN	O	O
partly	NN	O	O
reversible	NN	O	O
,	NN	O	O
the	NN	O	O
funduscopic	NN	O	O
findings	NN	O	O
are	NN	O	O
often	NN	O	O
subtle	NN	O	O
and	NN	O	O
easy	NN	O	O
to	NN	O	O
miss	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Three	NN	O	O
subjects	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
ethambutol	NN	O	B-Chemical
(	NN	O	O
EMB	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
of	NN	O	O
short	NN	O	O
-	NN	O	O
,	NN	O	O
intermediate	NN	O	O
-	NN	O	O
,	NN	O	O
and	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
visual	NN	O	B-Disease
deficits	NN	O	I-Disease
were	NN	O	O
administered	NN	O	O
a	NN	O	O
full	NN	O	O
neuro	NN	O	O
-	NN	O	O
ophthalmologic	NN	O	O
examination	NN	O	O
including	NN	O	O
visual	NN	O	O
acuity	NN	O	O
,	NN	O	O
color	NN	O	O
vision	NN	O	O
,	NN	O	O
contrast	NN	O	O
sensitivity	NN	O	O
,	NN	O	O
and	NN	O	O
fundus	NN	O	O
examination	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
OCT	NN	O	O
(	NN	O	O
OCT	NN	O	O
3000	NN	O	O
,	NN	O	O
Humphrey	NN	O	O
-	NN	O	O
Zeiss	NN	O	O
,	NN	O	O
Dublin	NN	O	O
,	NN	O	O
CA	NN	O	O
)	NN	O	O
was	NN	O	O
performed	NN	O	O
on	NN	O	O
both	NN	O	O
eyes	NN	O	O
of	NN	O	O
each	NN	O	O
subject	NN	O	O
using	NN	O	O
the	NN	O	O
retinal	NN	O	O
nerve	NN	O	O
fiber	NN	O	O
layer	NN	O	O
(	NN	O	O
RNFL	NN	O	O
)	NN	O	O
analysis	NN	O	O
protocol	NN	O	O
.	NN	O	O

OCT	NN	O	O
interpolates	NN	O	O
data	NN	O	O
from	NN	O	O
100	NN	O	O
points	NN	O	O
around	NN	O	O
the	NN	O	O
optic	NN	O	O
nerve	NN	O	O
to	NN	O	O
effectively	NN	O	O
map	NN	O	O
out	NN	O	O
the	NN	O	O
RNFL	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
were	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
calculated	NN	O	O
average	NN	O	O
RNFL	NN	O	O
of	NN	O	O
normal	NN	O	O
eyes	NN	O	O
accumulated	NN	O	O
from	NN	O	O
four	NN	O	O
prior	NN	O	O
studies	NN	O	O
using	NN	O	O
OCT	NN	O	O
,	NN	O	O
n=661	NN	O	O
.	NN	O	O

In	NN	O	O
all	NN	O	O
subjects	NN	O	O
with	NN	O	O
history	NN	O	O
of	NN	O	O
EMB	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
mean	NN	O	O
loss	NN	O	O
of	NN	O	O
72%	NN	O	O
nerve	NN	O	O
fiber	NN	O	O
layer	NN	O	O
thickness	NN	O	O
in	NN	O	O
the	NN	O	O
temporal	NN	O	O
quadrant	NN	O	O
(	NN	O	O
patient	NN	O	O
A	NN	O	O
,	NN	O	O
with	NN	O	O
eventual	NN	O	O
recovery	NN	O	O
of	NN	O	O
visual	NN	O	O
acuity	NN	O	O
and	NN	O	O
fields	NN	O	O
,	NN	O	O
58%	NN	O	O
loss	NN	O	O
;	NN	O	O
patient	NN	O	O
B	NN	O	O
,	NN	O	O
with	NN	O	O
intermediate	NN	O	O
visual	NN	O	B-Disease
deficits	NN	O	I-Disease
,	NN	O	O
68%	NN	O	O
loss	NN	O	O
;	NN	O	O
patient	NN	O	O
C	NN	O	O
,	NN	O	O
with	NN	O	O
chronic	NN	O	O
visual	NN	O	B-Disease
deficits	NN	O	I-Disease
,	NN	O	O
90%	NN	O	O
loss	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
an	NN	O	O
average	NN	O	O
mean	NN	O	O
optic	NN	O	O
nerve	NN	O	O
thickness	NN	O	O
of	NN	O	O
26+	NN	O	O
/	NN	O	O
-	NN	O	O
16	NN	O	O
microm	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
combined	NN	O	O
mean	NN	O	O
loss	NN	O	O
of	NN	O	O
46%	NN	O	O
of	NN	O	O
fibers	NN	O	O
from	NN	O	O
the	NN	O	O
superior	NN	O	O
,	NN	O	O
inferior	NN	O	O
,	NN	O	O
and	NN	O	O
nasal	NN	O	O
quadrants	NN	O	O
in	NN	O	O
the	NN	O	O
(	NN	O	O
six	NN	O	O
)	NN	O	O
eyes	NN	O	O
of	NN	O	O
all	NN	O	O
three	NN	O	O
subjects	NN	O	O
(	NN	O	O
mean	NN	O	O
average	NN	O	O
thickness	NN	O	O
of	NN	O	O
55+	NN	O	O
/	NN	O	O
-	NN	O	O
29	NN	O	O
microm	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
both	NN	O	O
sets	NN	O	O
(	NN	O	O
four	NN	O	O
)	NN	O	O
of	NN	O	O
eyes	NN	O	O
of	NN	O	O
the	NN	O	O
subjects	NN	O	O
with	NN	O	O
persistent	NN	O	O
visual	NN	O	B-Disease
deficits	NN	O	I-Disease
(	NN	O	O
patients	NN	O	O
B	NN	O	O
and	NN	O	O
C	NN	O	O
)	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
an	NN	O	O
average	NN	O	O
loss	NN	O	O
of	NN	O	O
79%	NN	O	O
of	NN	O	O
nerve	NN	O	O
fiber	NN	O	O
thickness	NN	O	O
in	NN	O	O
the	NN	O	O
temporal	NN	O	O
quadrant	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
OCT	NN	O	O
results	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
with	NN	O	O
EMB	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
show	NN	O	O
considerable	NN	O	O
loss	NN	O	O
especially	NN	O	O
of	NN	O	O
the	NN	O	O
temporal	NN	O	O
fibers	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
consistent	NN	O	O
with	NN	O	O
prior	NN	O	O
histopathological	NN	O	O
studies	NN	O	O
that	NN	O	O
show	NN	O	O
predominant	NN	O	O
loss	NN	O	O
of	NN	O	O
parvo	NN	O	O
-	NN	O	O
cellular	NN	O	O
axons	NN	O	O
(	NN	O	O
or	NN	O	O
small	NN	O	O
-	NN	O	O
caliber	NN	O	O
axons	NN	O	O
)	NN	O	O
within	NN	O	O
the	NN	O	O
papillo	NN	O	O
-	NN	O	O
macular	NN	O	O
bundle	NN	O	O
in	NN	O	O
toxic	NN	O	O
or	NN	O	O
hereditary	NN	O	O
optic	NN	O	B-Disease
neuropathies	NN	O	I-Disease
.	NN	O	O

OCT	NN	O	O
can	NN	O	O
be	NN	O	O
a	NN	O	O
valuable	NN	O	O
tool	NN	O	O
in	NN	O	O
the	NN	O	O
quantitative	NN	O	O
analysis	NN	O	O
of	NN	O	O
optic	NN	O	B-Disease
neuropathies	NN	O	I-Disease
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
management	NN	O	O
of	NN	O	O
EMB	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
,	NN	O	O
it	NN	O	O
is	NN	O	O
important	NN	O	O
to	NN	O	O
properly	NN	O	O
manage	NN	O	O
ethambutol	NN	O	B-Chemical
dosing	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
renal	NN	O	B-Disease
impairment	NN	O	I-Disease
and	NN	O	O
to	NN	O	O
achieve	NN	O	O
proper	NN	O	O
transition	NN	O	O
to	NN	O	O
a	NN	O	O
maintenance	NN	O	O
dose	NN	O	O
once	NN	O	O
an	NN	O	O
appropriate	NN	O	O
loading	NN	O	O
dose	NN	O	O
has	NN	O	O
been	NN	O	O
reached	NN	O	O
.	NN	O	O


-DOCSTART- (15266215)

Effects	NN	O	O
of	NN	O	O
the	NN	O	O
cyclooxygenase	NN	O	O
-	NN	O	O
2	NN	O	O
specific	NN	O	O
inhibitor	NN	O	O
valdecoxib	NN	O	B-Chemical
versus	NN	O	O
nonsteroidal	NN	O	O
antiinflammatory	NN	O	O
agents	NN	O	O
and	NN	O	O
placebo	NN	O	O
on	NN	O	O
cardiovascular	NN	O	O
thrombotic	NN	O	B-Disease
events	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
arthritis	NN	O	B-Disease
.	NN	O	O

There	NN	O	O
have	NN	O	O
been	NN	O	O
concerns	NN	O	O
that	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
cardiovascular	NN	O	O
thrombotic	NN	O	B-Disease
events	NN	O	O
may	NN	O	O
be	NN	O	O
higher	NN	O	O
with	NN	O	O
cyclooxygenase	NN	O	O
(	NN	O	O
COX	NN	O	O
)	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
specific	NN	O	O
inhibitors	NN	O	O
than	NN	O	O
nonselective	NN	O	O
nonsteroidal	NN	O	O
antiinflammatory	NN	O	O
drugs	NN	O	O
(	NN	O	O
NSAIDs	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
evaluated	NN	O	O
cardiovascular	NN	O	O
event	NN	O	O
data	NN	O	O
for	NN	O	O
valdecoxib	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
new	NN	O	O
COX	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
specific	NN	O	O
inhibitor	NN	O	O
in	NN	O	O
approximately	NN	O	O
8000	NN	O	O
patients	NN	O	O
with	NN	O	O
osteoarthritis	NN	O	B-Disease
and	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
treated	NN	O	O
with	NN	O	O
this	NN	O	O
agent	NN	O	O
in	NN	O	O
randomized	NN	O	O
clinical	NN	O	O
trials	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
cardiovascular	NN	O	O
thrombotic	NN	O	B-Disease
events	NN	O	O
(	NN	O	O
cardiac	NN	O	O
,	NN	O	O
cerebrovascular	NN	O	O
and	NN	O	O
peripheral	NN	O	O
vascular	NN	O	O
,	NN	O	O
or	NN	O	O
arterial	NN	O	O
thrombotic	NN	O	B-Disease
)	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
analyzing	NN	O	O
pooled	NN	O	O
valdecoxib	NN	O	B-Chemical
(	NN	O	O
10	NN	O	O
-	NN	O	O
80	NN	O	O
mg	NN	O	O
daily	NN	O	O
)	NN	O	O
,	NN	O	O
nonselective	NN	O	O
NSAID	NN	O	O
(	NN	O	O
diclofenac	NN	O	B-Chemical
75	NN	O	O
mg	NN	O	O
bid	NN	O	O
,	NN	O	O
ibuprofen	NN	O	B-Chemical
800	NN	O	O
mg	NN	O	O
tid	NN	O	O
,	NN	O	O
or	NN	O	O
naproxen	NN	O	B-Chemical
500	NN	O	O
mg	NN	O	O
bid	NN	O	O
)	NN	O	O
and	NN	O	O
placebo	NN	O	O
data	NN	O	O
from	NN	O	O
10	NN	O	O
randomized	NN	O	O
osteoarthritis	NN	O	B-Disease
and	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
trials	NN	O	O
that	NN	O	O
were	NN	O	O
6	NN	O	O
-	NN	O	O
52	NN	O	O
weeks	NN	O	O
in	NN	O	O
duration	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
rates	NN	O	O
of	NN	O	O
events	NN	O	O
were	NN	O	O
determined	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
7934	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
users	NN	O	O
of	NN	O	O
low	NN	O	O
-	NN	O	O
dose	NN	O	O
(	NN	O	O
<	NN	O	O
or	NN	O	O
=325	NN	O	O
mg	NN	O	O
daily	NN	O	O
)	NN	O	O
aspirin	NN	O	B-Chemical
(	NN	O	O
n	NN	O	O
=	NN	O	O
1051	NN	O	O
)	NN	O	O
and	NN	O	O
nonusers	NN	O	O
of	NN	O	O
aspirin	NN	O	B-Chemical
(	NN	O	O
n	NN	O	O
=	NN	O	O
6883	NN	O	O
)	NN	O	O
.	NN	O	O

Crude	NN	O	O
and	NN	O	O
exposure	NN	O	O
-	NN	O	O
adjusted	NN	O	O
incidences	NN	O	O
of	NN	O	O
thrombotic	NN	O	B-Disease
events	NN	O	O
were	NN	O	O
similar	NN	O	O
for	NN	O	O
valdecoxib	NN	O	B-Chemical
,	NN	O	O
NSAIDs	NN	O	O
,	NN	O	O
and	NN	O	O
placebo	NN	O	O
.	NN	O	O

The	NN	O	O
risk	NN	O	O
of	NN	O	O
serious	NN	O	O
thrombotic	NN	O	B-Disease
events	NN	O	O
was	NN	O	O
also	NN	O	O
similar	NN	O	O
for	NN	O	O
each	NN	O	O
valdecoxib	NN	O	B-Chemical
dose	NN	O	O
.	NN	O	O

Thrombotic	NN	O	B-Disease
risk	NN	O	O
was	NN	O	O
consistently	NN	O	O
higher	NN	O	O
for	NN	O	O
users	NN	O	O
of	NN	O	O
aspirin	NN	O	B-Chemical
users	NN	O	O
than	NN	O	O
nonusers	NN	O	O
of	NN	O	O
aspirin	NN	O	B-Chemical
(	NN	O	O
placebo	NN	O	O
,	NN	O	O
1.4%	NN	O	O
vs	NN	O	O
.	NN	O	O

0%	NN	O	O
;	NN	O	O
valdecoxib	NN	O	B-Chemical
,	NN	O	O
1.7%	NN	O	O
vs	NN	O	O
.	NN	O	O

0.2%	NN	O	O
;	NN	O	O
NSAIDs	NN	O	O
,	NN	O	O
1.9%	NN	O	O
vs	NN	O	O
.	NN	O	O

0.5%	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
rates	NN	O	O
of	NN	O	O
events	NN	O	O
in	NN	O	O
users	NN	O	O
of	NN	O	O
aspirin	NN	O	B-Chemical
were	NN	O	O
similar	NN	O	O
for	NN	O	O
all	NN	O	O
3	NN	O	O
treatment	NN	O	O
groups	NN	O	O
and	NN	O	O
across	NN	O	O
valdecoxib	NN	O	B-Chemical
doses	NN	O	O
.	NN	O	O

Short	NN	O	O
-	NN	O	O
and	NN	O	O
intermediate	NN	O	O
-	NN	O	O
term	NN	O	O
treatment	NN	O	O
with	NN	O	O
therapeutic	NN	O	O
(	NN	O	O
10	NN	O	O
or	NN	O	O
20	NN	O	O
mg	NN	O	O
daily	NN	O	O
)	NN	O	O
and	NN	O	O
supratherapeutic	NN	O	O
(	NN	O	O
40	NN	O	O
or	NN	O	O
80	NN	O	O
mg	NN	O	O
daily	NN	O	O
)	NN	O	O
valdecoxib	NN	O	B-Chemical
doses	NN	O	O
was	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
thrombotic	NN	O	B-Disease
events	NN	O	O
relative	NN	O	O
to	NN	O	O
nonselective	NN	O	O
NSAIDs	NN	O	O
or	NN	O	O
placebo	NN	O	O
in	NN	O	O
osteoarthritis	NN	O	B-Disease
and	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
patients	NN	O	O
in	NN	O	O
controlled	NN	O	O
clinical	NN	O	O
trials	NN	O	O
.	NN	O	O


-DOCSTART- (14742097)

A	NN	O	O
randomized	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
crossover	NN	O	O
study	NN	O	O
of	NN	O	O
ephedrine	NN	O	B-Chemical
for	NN	O	O
SSRI	NN	O	O
-	NN	O	O
induced	NN	O	O
female	NN	O	O
sexual	NN	O	B-Disease
dysfunction	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
ephedrine	NN	O	B-Chemical
,	NN	O	O
an	NN	O	O
alpha	NN	O	O
-	NN	O	O
and	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
agonist	NN	O	O
previously	NN	O	O
shown	NN	O	O
to	NN	O	O
enhance	NN	O	O
genital	NN	O	O
blood	NN	O	O
flow	NN	O	O
in	NN	O	O
women	NN	O	O
,	NN	O	O
has	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
in	NN	O	O
reversing	NN	O	O
antidepressant	NN	O	O
-	NN	O	O
induced	NN	O	O
sexual	NN	O	B-Disease
dysfunction	NN	O	I-Disease
.	NN	O	O

Nineteen	NN	O	O
sexually	NN	O	B-Disease
dysfunctional	NN	O	I-Disease
women	NN	O	O
receiving	NN	O	O
either	NN	O	O
fluoxetine	NN	O	B-Chemical
,	NN	O	O
sertraline	NN	O	B-Chemical
,	NN	O	O
or	NN	O	O
paroxetine	NN	O	B-Chemical
participated	NN	O	O
in	NN	O	O
an	NN	O	O
eight	NN	O	O
-	NN	O	O
week	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
cross	NN	O	O
-	NN	O	O
over	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
ephedrine	NN	O	B-Chemical
(	NN	O	O
50	NN	O	O
mg	NN	O	O
)	NN	O	O
on	NN	O	O
self	NN	O	O
-	NN	O	O
report	NN	O	O
measures	NN	O	O
of	NN	O	O
sexual	NN	O	O
desire	NN	O	O
,	NN	O	O
arousal	NN	O	O
,	NN	O	O
orgasm	NN	O	O
,	NN	O	O
and	NN	O	O
sexual	NN	O	O
satisfaction	NN	O	O
.	NN	O	O

Although	NN	O	O
there	NN	O	O
were	NN	O	O
significant	NN	O	O
improvements	NN	O	O
relative	NN	O	O
to	NN	O	O
baseline	NN	O	O
in	NN	O	O
sexual	NN	O	O
desire	NN	O	O
and	NN	O	O
orgasm	NN	O	O
intensity	NN	O	O
/	NN	O	O
pleasure	NN	O	O
on	NN	O	O
50	NN	O	O
mg	NN	O	O
ephedrine	NN	O	B-Chemical
1	NN	O	O
-	NN	O	O
hr	NN	O	O
prior	NN	O	O
to	NN	O	O
sexual	NN	O	O
activity	NN	O	O
,	NN	O	O
significant	NN	O	O
improvements	NN	O	O
in	NN	O	O
these	NN	O	O
measures	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
in	NN	O	O
sexual	NN	O	O
arousal	NN	O	O
and	NN	O	O
orgasmic	NN	O	O
ability	NN	O	O
also	NN	O	O
were	NN	O	O
noted	NN	O	O
with	NN	O	O
placebo	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
highlight	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
conducting	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
trials	NN	O	O
for	NN	O	O
this	NN	O	O
condition	NN	O	O
.	NN	O	O


-DOCSTART- (11890511)

Erectile	NN	O	B-Disease
dysfunction	NN	O	I-Disease
occurs	NN	O	O
following	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
lesions	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Erectile	NN	O	O
function	NN	O	O
was	NN	O	O
assessed	NN	O	O
6	NN	O	O
weeks	NN	O	O
following	NN	O	O
uni	NN	O	O
-	NN	O	O
and	NN	O	O
bilateral	NN	O	O
injections	NN	O	O
of	NN	O	O
6	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxydopamine	NN	O	I-Chemical
in	NN	O	O
the	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
nucleus	NN	O	O
of	NN	O	O
the	NN	O	O
brain	NN	O	O
.	NN	O	O

Behavioral	NN	O	O
apomorphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
penile	NN	O	O
erections	NN	O	O
were	NN	O	O
reduced	NN	O	O
(	NN	O	O
5	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
and	NN	O	O
increased	NN	O	O
(	NN	O	O
3	NN	O	O
/	NN	O	O
8	NN	O	O
)	NN	O	O
in	NN	O	O
uni	NN	O	O
-	NN	O	O
and	NN	O	O
bilateral	NN	O	O
lesioned	NN	O	O
animals	NN	O	O
.	NN	O	O

Intracavernous	NN	O	O
pressures	NN	O	O
,	NN	O	O
following	NN	O	O
electrical	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
cavernous	NN	O	O
nerve	NN	O	O
,	NN	O	O
decreased	NN	O	O
in	NN	O	O
lesioned	NN	O	O
animals	NN	O	O
.	NN	O	O

Lesions	NN	O	O
of	NN	O	O
the	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
were	NN	O	O
confirmed	NN	O	O
by	NN	O	O
histology	NN	O	O
.	NN	O	O

Concentration	NN	O	O
of	NN	O	O
dopamine	NN	O	B-Chemical
and	NN	O	O
its	NN	O	O
metabolites	NN	O	O
were	NN	O	O
decreased	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
of	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
lesioned	NN	O	O
rats	NN	O	O
.	NN	O	O

Lesions	NN	O	O
of	NN	O	O
the	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
are	NN	O	O
therefore	NN	O	O
associated	NN	O	O
with	NN	O	O
erectile	NN	O	B-Disease
dysfunction	NN	O	I-Disease
in	NN	O	O
rats	NN	O	O
and	NN	O	O
may	NN	O	O
serve	NN	O	O
as	NN	O	O
a	NN	O	O
model	NN	O	O
to	NN	O	O
study	NN	O	O
erectile	NN	O	B-Disease
dysfunction	NN	O	I-Disease
in	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (9270571)

Potential	NN	O	O
therapeutic	NN	O	O
use	NN	O	O
of	NN	O	O
the	NN	O	O
selective	NN	O	O
dopamine	NN	O	B-Chemical
D1	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
,	NN	O	O
A	NN	O	B-Chemical
-	NN	O	I-Chemical
86929	NN	O	I-Chemical
:	NN	O	O
an	NN	O	O
acute	NN	O	O
study	NN	O	O
in	NN	O	O
parkinsonian	NN	O	B-Disease
levodopa	NN	O	B-Chemical
-	NN	O	O
primed	NN	O	O
monkeys	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
utility	NN	O	O
of	NN	O	O
dopamine	NN	O	B-Chemical
(	NN	O	O
DA	NN	O	B-Chemical
)	NN	O	O
D1	NN	O	O
receptor	NN	O	O
agonists	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
PD	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
still	NN	O	O
unclear	NN	O	O
.	NN	O	O

The	NN	O	O
therapeutic	NN	O	O
use	NN	O	O
of	NN	O	O
selective	NN	O	O
DA	NN	O	B-Chemical
D1	NN	O	O
receptor	NN	O	O
agonists	NN	O	O
such	NN	O	O
as	NN	O	O
SKF	NN	O	B-Chemical
-	NN	O	I-Chemical
82958	NN	O	I-Chemical
(	NN	O	O
6	NN	O	B-Chemical
-	NN	O	I-Chemical
chloro	NN	O	I-Chemical
-	NN	O	I-Chemical
7	NN	O	I-Chemical
,	NN	O	I-Chemical
8	NN	O	I-Chemical
-	NN	O	I-Chemical
dihydroxy	NN	O	I-Chemical
-	NN	O	I-Chemical
3	NN	O	I-Chemical
-	NN	O	I-Chemical
allyl	NN	O	I-Chemical
-	NN	O	I-Chemical
1	NN	O	I-Chemical
-	NN	O	I-Chemical
phenyl	NN	O	I-Chemical
-	NN	O	I-Chemical
2	NN	O	I-Chemical
,	NN	O	I-Chemical
3	NN	O	I-Chemical
,	NN	O	I-Chemical
4	NN	O	I-Chemical
,	NN	O	I-Chemical
5	NN	O	I-Chemical
-	NN	O	I-Chemical
tetrahydro	NN	O	I-Chemical
-	NN	O	I-Chemical
1H	NN	O	I-Chemical
-	NN	O	I-Chemical
3	NN	O	I-Chemical
-	NN	O	I-Chemical
benzaze	NN	O	I-Chemical
pine	NN	O	I-Chemical
hydrobromide	NN	O	I-Chemical
)	NN	O	O
and	NN	O	O
A	NN	O	B-Chemical
-	NN	O	I-Chemical
77636	NN	O	I-Chemical
(	NN	O	O
[	NN	O	B-Chemical
1R	NN	O	I-Chemical
,	NN	O	I-Chemical
3S	NN	O	I-Chemical
]	NN	O	I-Chemical
3	NN	O	I-Chemical
-	NN	O	I-Chemical
[	NN	O	I-Chemical
1	NN	O	I-Chemical
'	NN	O	I-Chemical
-	NN	O	I-Chemical
admantyl	NN	O	I-Chemical
]	NN	O	I-Chemical
-	NN	O	I-Chemical
1	NN	O	I-Chemical
-	NN	O	I-Chemical
aminomethyl	NN	O	I-Chemical
-	NN	O	I-Chemical
3	NN	O	I-Chemical
,	NN	O	I-Chemical
4	NN	O	I-Chemical
-	NN	O	I-Chemical
dihydro	NN	O	I-Chemical
-	NN	O	I-Chemical
5	NN	O	I-Chemical
,	NN	O	I-Chemical
6	NN	O	I-Chemical
-	NN	O	I-Chemical
dihydroxy	NN	O	I-Chemical
-	NN	O	I-Chemical
1H	NN	O	I-Chemical
-	NN	O	I-Chemical
2	NN	O	I-Chemical
-	NN	O	I-Chemical
benzo	NN	O	I-Chemical
pyran	NN	O	I-Chemical
hydrochloride	NN	O	I-Chemical
)	NN	O	O
seems	NN	O	O
limited	NN	O	O
because	NN	O	O
of	NN	O	O
their	NN	O	O
duration	NN	O	O
of	NN	O	O
action	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
too	NN	O	O
short	NN	O	O
for	NN	O	O
SKF	NN	O	B-Chemical
-	NN	O	I-Chemical
82958	NN	O	I-Chemical
(	NN	O	O
<	NN	O	O
1	NN	O	O
hr	NN	O	O
)	NN	O	O
and	NN	O	O
too	NN	O	O
long	NN	O	O
for	NN	O	O
A	NN	O	B-Chemical
-	NN	O	I-Chemical
77636	NN	O	I-Chemical
(	NN	O	O
>	NN	O	O
20	NN	O	O
hr	NN	O	O
,	NN	O	O
leading	NN	O	O
to	NN	O	O
behavioral	NN	O	O
tolerance	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
therefore	NN	O	O
conducted	NN	O	O
the	NN	O	O
present	NN	O	O
acute	NN	O	O
dose	NN	O	O
-	NN	O	O
response	NN	O	O
study	NN	O	O
in	NN	O	O
four	NN	O	O
1	NN	O	B-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
-	NN	O	I-Chemical
4	NN	O	I-Chemical
-	NN	O	I-Chemical
phenyl	NN	O	I-Chemical
-	NN	O	I-Chemical
1	NN	O	I-Chemical
,	NN	O	I-Chemical
2	NN	O	I-Chemical
,	NN	O	I-Chemical
3	NN	O	I-Chemical
,	NN	O	I-Chemical
6	NN	O	I-Chemical
-	NN	O	I-Chemical
tetrahydropyridine	NN	O	I-Chemical
(	NN	O	O
MPTP	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
exposed	NN	O	O
cynomolgus	NN	O	O
monkeys	NN	O	O
primed	NN	O	O
to	NN	O	O
exhibit	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
locomotor	NN	O	O
and	NN	O	O
dyskinetic	NN	O	B-Disease
effects	NN	O	O
on	NN	O	O
challenge	NN	O	O
with	NN	O	O
four	NN	O	O
doses	NN	O	O
(	NN	O	O
from	NN	O	O
0.03	NN	O	O
to	NN	O	O
1.0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
of	NN	O	O
A	NN	O	B-Chemical
-	NN	O	I-Chemical
86929	NN	O	I-Chemical
(	NN	O	O
[	NN	O	B-Chemical
-	NN	O	I-Chemical
]	NN	O	I-Chemical
-	NN	O	I-Chemical
[	NN	O	I-Chemical
5aR	NN	O	I-Chemical
,	NN	O	I-Chemical
11bS	NN	O	I-Chemical
]	NN	O	I-Chemical
-	NN	O	I-Chemical
4	NN	O	I-Chemical
,	NN	O	I-Chemical
5	NN	O	I-Chemical
,	NN	O	I-Chemical
5a	NN	O	I-Chemical
,	NN	O	I-Chemical
6	NN	O	I-Chemical
,	NN	O	I-Chemical
7	NN	O	I-Chemical
,	NN	O	I-Chemical
11b	NN	O	I-Chemical
-	NN	O	I-Chemical
hexahydro	NN	O	I-Chemical
-	NN	O	I-Chemical
2	NN	O	I-Chemical
-	NN	O	I-Chemical
propyl	NN	O	I-Chemical
-	NN	O	I-Chemical
3	NN	O	I-Chemical
-	NN	O	I-Chemical
thia	NN	O	I-Chemical
-	NN	O	I-Chemical
5	NN	O	I-Chemical
-	NN	O	I-Chemical
+	NN	O	I-Chemical
++azacyclopent	NN	O	I-Chemical
-	NN	O	I-Chemical
1	NN	O	I-Chemical
-	NN	O	I-Chemical
ena	NN	O	I-Chemical
[	NN	O	I-Chemical
c	NN	O	I-Chemical
]	NN	O	I-Chemical
phenathrene	NN	O	I-Chemical
-	NN	O	I-Chemical
9	NN	O	I-Chemical
-	NN	O	I-Chemical
10	NN	O	I-Chemical
-	NN	O	I-Chemical
diol	NN	O	I-Chemical
)	NN	O	O
,	NN	O	O
a	NN	O	O
selective	NN	O	O
and	NN	O	O
full	NN	O	O
DA	NN	O	B-Chemical
D1	NN	O	O
-	NN	O	O
like	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
with	NN	O	O
an	NN	O	O
intermediate	NN	O	O
duration	NN	O	O
of	NN	O	O
action	NN	O	O
.	NN	O	O

Levodopa	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
DA	NN	O	B-Chemical
D2	NN	O	O
-	NN	O	O
like	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
,	NN	O	O
LY	NN	O	B-Chemical
-	NN	O	I-Chemical
171555	NN	O	I-Chemical
(	NN	O	O
[	NN	O	B-Chemical
4aR	NN	O	I-Chemical
-	NN	O	I-Chemical
trans	NN	O	I-Chemical
]	NN	O	I-Chemical
-	NN	O	I-Chemical
4	NN	O	I-Chemical
,	NN	O	I-Chemical
4a	NN	O	I-Chemical
,	NN	O	I-Chemical
5	NN	O	I-Chemical
,	NN	O	I-Chemical
6	NN	O	I-Chemical
,	NN	O	I-Chemical
7	NN	O	I-Chemical
,	NN	O	I-Chemical
8	NN	O	I-Chemical
,	NN	O	I-Chemical
8a	NN	O	I-Chemical
,	NN	O	I-Chemical
9	NN	O	I-Chemical
-	NN	O	I-Chemical
o	NN	O	I-Chemical
-	NN	O	I-Chemical
dihydro	NN	O	I-Chemical
-	NN	O	I-Chemical
5n	NN	O	I-Chemical
-	NN	O	I-Chemical
propyl	NN	O	I-Chemical
-	NN	O	I-Chemical
2H	NN	O	I-Chemical
-	NN	O	I-Chemical
pyrazo	NN	O	I-Chemical
lo	NN	O	I-Chemical
-	NN	O	I-Chemical
3	NN	O	I-Chemical
-	NN	O	I-Chemical
4	NN	O	I-Chemical
-	NN	O	I-Chemical
quinoline	NN	O	I-Chemical
hydrochloride	NN	O	I-Chemical
)	NN	O	O
were	NN	O	O
also	NN	O	O
used	NN	O	O
for	NN	O	O
comparison	NN	O	O
.	NN	O	O

Acute	NN	O	O
administration	NN	O	O
of	NN	O	O
A	NN	O	B-Chemical
-	NN	O	I-Chemical
86929	NN	O	I-Chemical
was	NN	O	O
as	NN	O	O
efficacious	NN	O	O
in	NN	O	O
alleviating	NN	O	O
MPTP	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
parkinsonism	NN	O	B-Disease
as	NN	O	O
levodopa	NN	O	B-Chemical
and	NN	O	O
LY	NN	O	B-Chemical
-	NN	O	I-Chemical
171555	NN	O	I-Chemical
,	NN	O	O
but	NN	O	O
was	NN	O	O
less	NN	O	O
likely	NN	O	O
to	NN	O	O
reproduce	NN	O	O
the	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
in	NN	O	O
these	NN	O	O
animals	NN	O	O
than	NN	O	O
with	NN	O	O
either	NN	O	O
LY	NN	O	B-Chemical
-	NN	O	I-Chemical
171555	NN	O	I-Chemical
or	NN	O	O
subsequent	NN	O	O
challenge	NN	O	O
of	NN	O	O
levodopa	NN	O	B-Chemical
.	NN	O	O

Selective	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
DA	NN	O	B-Chemical
D1	NN	O	O
receptor	NN	O	O
may	NN	O	O
provide	NN	O	O
better	NN	O	O
integration	NN	O	O
of	NN	O	O
neural	NN	O	O
inputs	NN	O	O
transmitted	NN	O	O
to	NN	O	O
the	NN	O	O
internal	NN	O	O
segment	NN	O	O
of	NN	O	O
the	NN	O	O
globus	NN	O	O
pallidus	NN	O	O
(	NN	O	O
referred	NN	O	O
to	NN	O	O
as	NN	O	O
the	NN	O	O
basal	NN	O	O
ganglia	NN	O	O
output	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
levodopa	NN	O	B-Chemical
and	NN	O	O
selective	NN	O	O
DA	NN	O	B-Chemical
D2	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
.	NN	O	O

Potent	NN	O	O
DA	NN	O	B-Chemical
D1	NN	O	O
receptor	NN	O	O
agents	NN	O	O
with	NN	O	O
an	NN	O	O
intermediate	NN	O	O
duration	NN	O	O
of	NN	O	O
efficacy	NN	O	O
such	NN	O	O
as	NN	O	O
A	NN	O	B-Chemical
-	NN	O	I-Chemical
86929	NN	O	I-Chemical
(	NN	O	O
approximately	NN	O	O
4	NN	O	O
hr	NN	O	O
at	NN	O	O
higher	NN	O	O
doses	NN	O	O
tested	NN	O	O
)	NN	O	O
are	NN	O	O
potential	NN	O	O
therapeutic	NN	O	O
tools	NN	O	O
in	NN	O	O
PD	NN	O	B-Disease
and	NN	O	O
merit	NN	O	O
further	NN	O	O
attention	NN	O	O
.	NN	O	O


-DOCSTART- (7189975)

Deaths	NN	O	O
from	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Median	NN	O	O
convulsant	NN	O	O
(	NN	O	O
CD50	NN	O	O
)	NN	O	O
and	NN	O	O
median	NN	O	O
lethal	NN	O	O
(	NN	O	O
LD50	NN	O	O
)	NN	O	O
doses	NN	O	O
of	NN	O	O
three	NN	O	O
representative	NN	O	O
local	NN	O	O
anesthetics	NN	O	O
were	NN	O	O
determined	NN	O	O
in	NN	O	O
adult	NN	O	O
mice	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
threat	NN	O	O
to	NN	O	O
life	NN	O	O
of	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
CD50	NN	O	O
and	NN	O	O
LD50	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
were	NN	O	O
57.7	NN	O	O
and	NN	O	O
58.7	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
for	NN	O	O
bupivacaine	NN	O	B-Chemical
,	NN	O	O
111.0	NN	O	O
and	NN	O	O
133.1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
for	NN	O	O
lidocaine	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
243.4	NN	O	O
and	NN	O	O
266.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
for	NN	O	O
chloroprocaine	NN	O	B-Chemical
.	NN	O	O

When	NN	O	O
given	NN	O	O
intraperitoneally	NN	O	O
,	NN	O	O
bupivacaine	NN	O	B-Chemical
thus	NN	O	O
was	NN	O	O
only	NN	O	O
about	NN	O	O
twice	NN	O	O
as	NN	O	O
toxic	NN	O	O
as	NN	O	O
lidocaine	NN	O	B-Chemical
and	NN	O	O
four	NN	O	O
times	NN	O	O
as	NN	O	O
toxic	NN	O	O
as	NN	O	O
chloroprocaine	NN	O	B-Chemical
.	NN	O	O

Convulsions	NN	O	B-Disease
always	NN	O	O
preceded	NN	O	O
death	NN	O	O
,	NN	O	O
except	NN	O	O
after	NN	O	O
precipitous	NN	O	O
cardiopulmonary	NN	O	B-Disease
arrest	NN	O	I-Disease
from	NN	O	O
extreme	NN	O	O
doses	NN	O	O
.	NN	O	O

A	NN	O	O
CD50	NN	O	O
dose	NN	O	O
of	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
(	NN	O	O
causing	NN	O	O
convulsions	NN	O	B-Disease
in	NN	O	O
50%	NN	O	O
of	NN	O	O
mice	NN	O	O
)	NN	O	O
was	NN	O	O
fatal	NN	O	O
in	NN	O	O
90%	NN	O	O
of	NN	O	O
bupivacaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
,	NN	O	O
in	NN	O	O
57%	NN	O	O
of	NN	O	O
the	NN	O	O
chloroprocaine	NN	O	B-Chemical
group	NN	O	O
,	NN	O	O
and	NN	O	O
in	NN	O	O
6%	NN	O	O
of	NN	O	O
the	NN	O	O
lidocaine	NN	O	B-Chemical
group	NN	O	O
.	NN	O	O

The	NN	O	O
narrow	NN	O	O
gap	NN	O	O
between	NN	O	O
convulsant	NN	O	O
and	NN	O	O
lethal	NN	O	O
doses	NN	O	O
of	NN	O	O
local	NN	O	O
anesthetics	NN	O	O
indicates	NN	O	O
that	NN	O	O
untreated	NN	O	O
convulsions	NN	O	B-Disease
present	NN	O	O
much	NN	O	O
more	NN	O	O
of	NN	O	O
a	NN	O	O
threat	NN	O	O
to	NN	O	O
life	NN	O	O
than	NN	O	O
heretofore	NN	O	O
appreciated	NN	O	O
.	NN	O	O


-DOCSTART- (6415512)

Myoclonic	NN	O	B-Disease
,	NN	O	I-Disease
atonic	NN	O	I-Disease
,	NN	O	I-Disease
and	NN	O	I-Disease
absence	NN	O	I-Disease
seizures	NN	O	I-Disease
following	NN	O	O
institution	NN	O	O
of	NN	O	O
carbamazepine	NN	O	B-Chemical
therapy	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O

Five	NN	O	O
children	NN	O	O
,	NN	O	O
aged	NN	O	O
3	NN	O	O
to	NN	O	O
11	NN	O	O
years	NN	O	O
,	NN	O	O
treated	NN	O	O
with	NN	O	O
carbamazepine	NN	O	B-Chemical
for	NN	O	O
epilepsy	NN	O	B-Disease
,	NN	O	O
had	NN	O	O
an	NN	O	O
acute	NN	O	O
aberrant	NN	O	O
reaction	NN	O	O
characterized	NN	O	O
by	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
myoclonic	NN	O	B-Disease
,	NN	O	I-Disease
atypical	NN	O	I-Disease
absence	NN	O	I-Disease
and	NN	O	I-Disease
/	NN	O	I-Disease
or	NN	O	I-Disease
atonic	NN	O	I-Disease
(	NN	O	I-Disease
minor	NN	O	I-Disease
motor	NN	O	I-Disease
)	NN	O	I-Disease
seizures	NN	O	I-Disease
within	NN	O	O
a	NN	O	O
few	NN	O	O
days	NN	O	O
.	NN	O	O

When	NN	O	O
the	NN	O	O
carbamazepine	NN	O	B-Chemical
was	NN	O	O
discontinued	NN	O	O
,	NN	O	O
two	NN	O	O
of	NN	O	O
the	NN	O	O
children	NN	O	O
returned	NN	O	O
to	NN	O	O
their	NN	O	O
former	NN	O	O
state	NN	O	O
very	NN	O	O
quickly	NN	O	O
,	NN	O	O
two	NN	O	O
had	NN	O	O
the	NN	O	O
minor	NN	O	O
motor	NN	O	O
seizures	NN	O	B-Disease
resolve	NN	O	O
in	NN	O	O
3	NN	O	O
and	NN	O	O
6	NN	O	O
months	NN	O	O
,	NN	O	O
and	NN	O	O
one	NN	O	O
had	NN	O	O
the	NN	O	O
seizures	NN	O	B-Disease
persist	NN	O	O
.	NN	O	O

The	NN	O	O
child	NN	O	O
in	NN	O	O
whom	NN	O	O
the	NN	O	O
seizures	NN	O	B-Disease
persisted	NN	O	O
was	NN	O	O
later	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
ceroid	NN	O	B-Disease
lipofuscinosis	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
other	NN	O	O
children	NN	O	O
are	NN	O	O
doing	NN	O	O
well	NN	O	O
on	NN	O	O
other	NN	O	O
anticonvulsants	NN	O	O
.	NN	O	O


-DOCSTART- (1928887)

Naloxone	NN	O	B-Chemical
reversal	NN	O	O
of	NN	O	O
hypotension	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
captopril	NN	O	B-Chemical
overdose	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
hemodynamic	NN	O	O
effects	NN	O	O
of	NN	O	O
captopril	NN	O	B-Chemical
and	NN	O	O
other	NN	O	O
angiotensin	NN	O	B-Chemical
-	NN	O	I-Chemical
converting	NN	O	I-Chemical
enzyme	NN	O	I-Chemical
inhibitors	NN	O	I-Chemical
may	NN	O	O
be	NN	O	O
mediated	NN	O	O
by	NN	O	O
the	NN	O	O
endogenous	NN	O	O
opioid	NN	O	O
system	NN	O	O
.	NN	O	O

The	NN	O	O
opioid	NN	O	O
antagonist	NN	O	O
naloxone	NN	O	B-Chemical
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
block	NN	O	O
or	NN	O	O
reverse	NN	O	O
the	NN	O	O
hypotensive	NN	O	B-Disease
actions	NN	O	O
of	NN	O	O
captopril	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
an	NN	O	O
intentional	NN	O	O
captopril	NN	O	B-Chemical
overdose	NN	O	B-Disease
,	NN	O	O
manifested	NN	O	O
by	NN	O	O
marked	NN	O	O
hypotension	NN	O	B-Disease
,	NN	O	O
that	NN	O	O
resolved	NN	O	O
promptly	NN	O	O
with	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
naloxone	NN	O	B-Chemical
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
reported	NN	O	O
case	NN	O	O
of	NN	O	O
captopril	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
treated	NN	O	O
with	NN	O	O
naloxone	NN	O	B-Chemical
.	NN	O	O

Our	NN	O	O
experience	NN	O	O
demonstrates	NN	O	O
a	NN	O	O
possible	NN	O	O
role	NN	O	O
of	NN	O	O
naloxone	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
reversal	NN	O	O
of	NN	O	O
hypotension	NN	O	B-Disease
resulting	NN	O	O
from	NN	O	O
captopril	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (1728915)

Carbamazepine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B-Disease
dysfunction	NN	O	I-Disease
.	NN	O	O

Characterization	NN	O	O
of	NN	O	O
two	NN	O	O
distinct	NN	O	O
clinical	NN	O	O
syndromes	NN	O	O
.	NN	O	O

A	NN	O	O
patient	NN	O	O
with	NN	O	O
sinus	NN	O	O
bradycardia	NN	O	B-Disease
and	NN	O	O
atrioventricular	NN	O	B-Disease
block	NN	O	I-Disease
,	NN	O	O
induced	NN	O	O
by	NN	O	O
carbamazepine	NN	O	B-Chemical
,	NN	O	O
prompted	NN	O	O
an	NN	O	O
extensive	NN	O	O
literature	NN	O	O
review	NN	O	O
of	NN	O	O
all	NN	O	O
previously	NN	O	O
reported	NN	O	O
cases	NN	O	O
.	NN	O	O

From	NN	O	O
the	NN	O	O
analysis	NN	O	O
of	NN	O	O
these	NN	O	O
cases	NN	O	O
,	NN	O	O
two	NN	O	O
distinct	NN	O	O
forms	NN	O	O
of	NN	O	O
carbamazepine	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
cardiac	NN	O	B-Disease
dysfunction	NN	O	I-Disease
emerged	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
group	NN	O	O
developed	NN	O	O
sinus	NN	O	B-Disease
tachycardias	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
setting	NN	O	O
of	NN	O	O
a	NN	O	O
massive	NN	O	O
carbamazepine	NN	O	B-Chemical
overdose	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
second	NN	O	O
group	NN	O	O
consisted	NN	O	O
almost	NN	O	O
exclusively	NN	O	O
of	NN	O	O
elderly	NN	O	O
women	NN	O	O
who	NN	O	O
developed	NN	O	O
potentially	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
bradyarrhythmias	NN	O	B-Disease
or	NN	O	O
atrioventricular	NN	O	B-Disease
conduction	NN	O	I-Disease
delay	NN	O	I-Disease
,	NN	O	O
associated	NN	O	O
with	NN	O	O
either	NN	O	O
therapeutic	NN	O	O
or	NN	O	O
modestly	NN	O	O
elevated	NN	O	O
carbamazepine	NN	O	B-Chemical
serum	NN	O	O
levels	NN	O	O
.	NN	O	O

Because	NN	O	O
carbamazepine	NN	O	B-Chemical
is	NN	O	O
widely	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
many	NN	O	O
neurologic	NN	O	O
and	NN	O	O
psychiatric	NN	O	B-Disease
conditions	NN	O	O
,	NN	O	O
the	NN	O	O
recognition	NN	O	O
of	NN	O	O
the	NN	O	O
latter	NN	O	O
syndrome	NN	O	O
has	NN	O	O
important	NN	O	O
implications	NN	O	O
for	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
.	NN	O	O


-DOCSTART- (20558148)

Glutamatergic	NN	O	O
neurotransmission	NN	O	O
mediated	NN	O	O
by	NN	O	O
NMDA	NN	O	B-Chemical
receptors	NN	O	O
in	NN	O	O
the	NN	O	O
inferior	NN	O	O
colliculus	NN	O	O
can	NN	O	O
modulate	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
inferior	NN	O	O
colliculus	NN	O	O
(	NN	O	O
IC	NN	O	O
)	NN	O	O
is	NN	O	O
primarily	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
processing	NN	O	O
of	NN	O	O
auditory	NN	O	O
information	NN	O	O
,	NN	O	O
but	NN	O	O
it	NN	O	O
is	NN	O	O
distinguished	NN	O	O
from	NN	O	O
other	NN	O	O
auditory	NN	O	O
nuclei	NN	O	O
in	NN	O	O
the	NN	O	O
brainstem	NN	O	O
by	NN	O	O
its	NN	O	O
connections	NN	O	O
with	NN	O	O
structures	NN	O	O
of	NN	O	O
the	NN	O	O
motor	NN	O	O
system	NN	O	O
.	NN	O	O

Functional	NN	O	O
evidence	NN	O	O
relating	NN	O	O
the	NN	O	O
IC	NN	O	O
to	NN	O	O
motor	NN	O	O
behavior	NN	O	O
derives	NN	O	O
from	NN	O	O
experiments	NN	O	O
showing	NN	O	O
that	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
IC	NN	O	O
by	NN	O	O
electrical	NN	O	O
stimulation	NN	O	O
or	NN	O	O
excitatory	NN	O	O
amino	NN	O	B-Chemical
acid	NN	O	I-Chemical
microinjection	NN	O	O
causes	NN	O	O
freezing	NN	O	O
,	NN	O	O
escape	NN	O	O
-	NN	O	O
like	NN	O	O
behavior	NN	O	O
,	NN	O	O
and	NN	O	O
immobility	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
nature	NN	O	O
of	NN	O	O
this	NN	O	O
immobility	NN	O	O
is	NN	O	O
still	NN	O	O
unclear	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
examined	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
excitatory	NN	O	O
amino	NN	O	B-Chemical
acid	NN	O	I-Chemical
-	NN	O	O
mediated	NN	O	O
mechanisms	NN	O	O
in	NN	O	O
the	NN	O	O
IC	NN	O	O
on	NN	O	O
the	NN	O	O
catalepsy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
the	NN	O	O
dopamine	NN	O	B-Chemical
receptor	NN	O	O
blocker	NN	O	O
haloperidol	NN	O	B-Chemical
administered	NN	O	O
systemically	NN	O	O
(	NN	O	O
1	NN	O	O
or	NN	O	O
0.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
was	NN	O	O
challenged	NN	O	O
with	NN	O	O
prior	NN	O	O
intracollicular	NN	O	O
microinjections	NN	O	O
of	NN	O	O
glutamate	NN	O	B-Chemical
NMDA	NN	O	B-Chemical
receptor	NN	O	O
antagonists	NN	O	O
,	NN	O	O
MK	NN	O	B-Chemical
-	NN	O	I-Chemical
801	NN	O	I-Chemical
(	NN	O	O
15	NN	O	O
or	NN	O	O
30	NN	O	O
mmol	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
)	NN	O	O
and	NN	O	O
AP7	NN	O	B-Chemical
(	NN	O	O
10	NN	O	O
or	NN	O	O
20	NN	O	O
nmol	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
of	NN	O	O
the	NN	O	O
NMDA	NN	O	B-Chemical
receptor	NN	O	O
agonist	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
-	NN	O	I-Chemical
d	NN	O	I-Chemical
-	NN	O	I-Chemical
aspartate	NN	O	I-Chemical
(	NN	O	O
NMDA	NN	O	B-Chemical
,	NN	O	O
20	NN	O	O
or	NN	O	O
30	NN	O	O
nmol	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
that	NN	O	O
intracollicular	NN	O	O
microinjection	NN	O	O
of	NN	O	O
MK	NN	O	B-Chemical
-	NN	O	I-Chemical
801	NN	O	I-Chemical
and	NN	O	O
AP7	NN	O	B-Chemical
previous	NN	O	O
to	NN	O	O
systemic	NN	O	O
injections	NN	O	O
of	NN	O	O
haloperidol	NN	O	B-Chemical
significantly	NN	O	O
attenuated	NN	O	O
the	NN	O	O
catalepsy	NN	O	B-Disease
,	NN	O	O
as	NN	O	O
indicated	NN	O	O
by	NN	O	O
a	NN	O	O
reduced	NN	O	O
latency	NN	O	O
to	NN	O	O
step	NN	O	O
down	NN	O	O
from	NN	O	O
a	NN	O	O
horizontal	NN	O	O
bar	NN	O	O
.	NN	O	O

Accordingly	NN	O	O
,	NN	O	O
intracollicular	NN	O	O
microinjection	NN	O	O
of	NN	O	O
NMDA	NN	O	B-Chemical
increased	NN	O	O
the	NN	O	O
latency	NN	O	O
to	NN	O	O
step	NN	O	O
down	NN	O	O
the	NN	O	O
bar	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
glutamate	NN	O	B-Chemical
-	NN	O	O
mediated	NN	O	O
mechanisms	NN	O	O
in	NN	O	O
the	NN	O	O
neural	NN	O	O
circuits	NN	O	O
at	NN	O	O
the	NN	O	O
IC	NN	O	O
level	NN	O	O
influence	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
and	NN	O	O
participate	NN	O	O
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
motor	NN	O	O
activity	NN	O	O
.	NN	O	O


-DOCSTART- (19940105)

Metabotropic	NN	O	O
glutamate	NN	O	B-Chemical
7	NN	O	O
receptor	NN	O	O
subtype	NN	O	O
modulates	NN	O	O
motor	NN	O	O
symptoms	NN	O	O
in	NN	O	O
rodent	NN	O	O
models	NN	O	O
of	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

Metabotropic	NN	O	O
glutamate	NN	O	B-Chemical
(	NN	O	O
mGlu	NN	O	O
)	NN	O	O
receptors	NN	O	O
modulate	NN	O	O
synaptic	NN	O	O
transmission	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
and	NN	O	O
represent	NN	O	O
promising	NN	O	O
therapeutic	NN	O	O
targets	NN	O	O
for	NN	O	O
symptomatic	NN	O	O
treatment	NN	O	O
of	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
PD	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Among	NN	O	O
the	NN	O	O
eight	NN	O	O
mGlu	NN	O	O
receptor	NN	O	O
subtypes	NN	O	O
,	NN	O	O
mGlu7	NN	O	O
receptor	NN	O	O
is	NN	O	O
prominently	NN	O	O
expressed	NN	O	O
in	NN	O	O
the	NN	O	O
basal	NN	O	O
ganglia	NN	O	O
,	NN	O	O
but	NN	O	O
its	NN	O	O
role	NN	O	O
in	NN	O	O
restoring	NN	O	O
motor	NN	O	O
function	NN	O	O
in	NN	O	O
animal	NN	O	O
models	NN	O	O
of	NN	O	O
PD	NN	O	B-Disease
is	NN	O	O
not	NN	O	O
known	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
N	NN	O	B-Chemical
,	NN	O	I-Chemical
N	NN	O	I-Chemical
'	NN	O	I-Chemical
-	NN	O	I-Chemical
dibenzhydrylethane	NN	O	I-Chemical
-	NN	O	I-Chemical
1	NN	O	I-Chemical
,	NN	O	I-Chemical
2	NN	O	I-Chemical
-	NN	O	I-Chemical
diamine	NN	O	I-Chemical
dihydrochloride	NN	O	I-Chemical
(	NN	O	O
AMN082	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
the	NN	O	O
first	NN	O	O
selective	NN	O	O
allosteric	NN	O	O
activator	NN	O	O
of	NN	O	O
mGlu7	NN	O	O
receptors	NN	O	O
,	NN	O	O
were	NN	O	O
thus	NN	O	O
tested	NN	O	O
in	NN	O	O
different	NN	O	O
rodent	NN	O	O
models	NN	O	O
of	NN	O	O
PD	NN	O	B-Disease
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
oral	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
or	NN	O	O
intrastriatal	NN	O	O
administration	NN	O	O
(	NN	O	O
0.1	NN	O	O
and	NN	O	O
0.5	NN	O	O
nmol	NN	O	O
)	NN	O	O
of	NN	O	O
AMN082	NN	O	B-Chemical
reverses	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

AMN082	NN	O	B-Chemical
(	NN	O	O
2.5	NN	O	O
and	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
reduces	NN	O	O
apomorphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
rotations	NN	O	O
in	NN	O	O
unilateral	NN	O	O
6	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxydopamine	NN	O	I-Chemical
(	NN	O	O
6	NN	O	B-Chemical
-	NN	O	I-Chemical
OHDA	NN	O	I-Chemical
)	NN	O	O
-	NN	O	O
lesioned	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
more	NN	O	O
complex	NN	O	O
task	NN	O	O
commonly	NN	O	O
used	NN	O	O
to	NN	O	O
evaluate	NN	O	O
major	NN	O	O
akinetic	NN	O	B-Disease
symptoms	NN	O	O
of	NN	O	O
PD	NN	O	B-Disease
patients	NN	O	O
,	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
AMN082	NN	O	B-Chemical
reverses	NN	O	O
the	NN	O	O
increased	NN	O	O
reaction	NN	O	O
time	NN	O	O
to	NN	O	O
respond	NN	O	O
to	NN	O	O
a	NN	O	O
cue	NN	O	O
of	NN	O	O
bilateral	NN	O	O
6	NN	O	B-Chemical
-	NN	O	I-Chemical
OHDA	NN	O	I-Chemical
-	NN	O	O
lesioned	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
AMN082	NN	O	B-Chemical
reduces	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
mGlu7	NN	O	O
receptor	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
in	NN	O	O
wild	NN	O	O
-	NN	O	O
type	NN	O	O
but	NN	O	O
not	NN	O	O
mGlu7	NN	O	O
receptor	NN	O	O
knockout	NN	O	O
mice	NN	O	O
.	NN	O	O

Higher	NN	O	O
doses	NN	O	O
of	NN	O	O
AMN082	NN	O	B-Chemical
(	NN	O	O
10	NN	O	O
and	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
p.o.	NN	O	O
)	NN	O	O
have	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
same	NN	O	O
models	NN	O	O
of	NN	O	O
PD	NN	O	B-Disease
.	NN	O	O

Overall	NN	O	O
these	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
mGlu7	NN	O	O
receptor	NN	O	O
activation	NN	O	O
can	NN	O	O
reverse	NN	O	O
motor	NN	O	O
dysfunction	NN	O	O
associated	NN	O	O
with	NN	O	O
reduced	NN	O	O
dopamine	NN	O	B-Chemical
activity	NN	O	O
.	NN	O	O

Selective	NN	O	O
ligands	NN	O	O
of	NN	O	O
mGlu7	NN	O	O
receptor	NN	O	O
subtypes	NN	O	O
may	NN	O	O
thus	NN	O	O
be	NN	O	O
considered	NN	O	O
as	NN	O	O
promising	NN	O	O
compounds	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
antiparkinsonian	NN	O	O
therapeutic	NN	O	O
strategies	NN	O	O
.	NN	O	O


-DOCSTART- (19923525)

Nimodipine	NN	O	B-Chemical
prevents	NN	O	O
memory	NN	O	B-Disease
impairment	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
nitroglycerin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
in	NN	O	O
adult	NN	O	O
mice	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Hypotension	NN	O	B-Disease
and	NN	O	O
a	NN	O	O
resultant	NN	O	O
decrease	NN	O	O
in	NN	O	O
cerebral	NN	O	O
blood	NN	O	O
flow	NN	O	O
have	NN	O	O
been	NN	O	O
implicated	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
cognitive	NN	O	B-Disease
dysfunction	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
tested	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
nimodipine	NN	O	B-Chemical
(	NN	O	O
NIMO	NN	O	B-Chemical
)	NN	O	O
administered	NN	O	O
at	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
nitroglycerin	NN	O	B-Chemical
(	NN	O	O
NTG	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
would	NN	O	O
preserve	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
associative	NN	O	O
memory	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
(	NN	O	O
PA	NN	O	O
)	NN	O	O
paradigm	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
assess	NN	O	O
memory	NN	O	O
retention	NN	O	O
.	NN	O	O

For	NN	O	O
PA	NN	O	O
training	NN	O	O
,	NN	O	O
latencies	NN	O	O
(	NN	O	O
seconds	NN	O	O
)	NN	O	O
were	NN	O	O
recorded	NN	O	O
for	NN	O	O
entry	NN	O	O
from	NN	O	O
a	NN	O	O
suspended	NN	O	O
platform	NN	O	O
into	NN	O	O
a	NN	O	O
Plexiglas	NN	O	O
tube	NN	O	O
where	NN	O	O
a	NN	O	O
shock	NN	O	O
was	NN	O	O
automatically	NN	O	O
delivered	NN	O	O
.	NN	O	O

Latencies	NN	O	O
were	NN	O	O
recorded	NN	O	O
48	NN	O	O
h	NN	O	O
later	NN	O	O
for	NN	O	O
a	NN	O	O
testing	NN	O	O
trial	NN	O	O
.	NN	O	O

Ninety	NN	O	O
-	NN	O	O
six	NN	O	O
Swiss	NN	O	O
-	NN	O	O
Webster	NN	O	O
mice	NN	O	O
(	NN	O	O
30	NN	O	O
-	NN	O	O
35	NN	O	O
g	NN	O	O
,	NN	O	O
6	NN	O	O
-	NN	O	O
8	NN	O	O
wk	NN	O	O
)	NN	O	O
,	NN	O	O
were	NN	O	O
randomized	NN	O	O
into	NN	O	O
6	NN	O	O
groups	NN	O	O
1	NN	O	O
)	NN	O	O
saline	NN	O	O
(	NN	O	O
control	NN	O	O
)	NN	O	O
,	NN	O	O
2	NN	O	O
)	NN	O	O
NTG	NN	O	B-Chemical
immediately	NN	O	O
after	NN	O	O
learning	NN	O	O
,	NN	O	O
3	NN	O	O
)	NN	O	O
NTG	NN	O	B-Chemical
3	NN	O	O
h	NN	O	O
after	NN	O	O
learning	NN	O	O
,	NN	O	O
4	NN	O	O
)	NN	O	O
NTG	NN	O	B-Chemical
and	NN	O	O
NIMO	NN	O	B-Chemical
,	NN	O	O
5	NN	O	O
)	NN	O	O
vehicle	NN	O	O
,	NN	O	O
and	NN	O	O
6	NN	O	O
)	NN	O	O
NIMO	NN	O	B-Chemical
alone	NN	O	O
.	NN	O	O

The	NN	O	O
extent	NN	O	O
of	NN	O	O
hypotension	NN	O	B-Disease
and	NN	O	O
changes	NN	O	O
in	NN	O	O
brain	NN	O	O
tissue	NN	O	O
oxygenation	NN	O	O
(	NN	O	O
PbtO	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
cerebral	NN	O	O
blood	NN	O	O
flow	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
a	NN	O	O
separate	NN	O	O
group	NN	O	O
of	NN	O	O
animals	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
All	NN	O	O
groups	NN	O	O
exhibited	NN	O	O
similar	NN	O	O
training	NN	O	O
latencies	NN	O	O
(	NN	O	O
17.0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4.6	NN	O	O
s	NN	O	O
)	NN	O	O
.	NN	O	O

Mice	NN	O	O
subjected	NN	O	O
to	NN	O	O
hypotensive	NN	O	B-Disease
episodes	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
latency	NN	O	O
time	NN	O	O
(	NN	O	O
178	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
156	NN	O	O
s	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
injected	NN	O	O
with	NN	O	O
saline	NN	O	O
,	NN	O	O
NTG	NN	O	B-Chemical
+	NN	O	O
NIMO	NN	O	B-Chemical
,	NN	O	O
or	NN	O	O
delayed	NN	O	O
NTG	NN	O	B-Chemical
(	NN	O	O
580	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
81	NN	O	O
s	NN	O	O
,	NN	O	O
557	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
67	NN	O	O
s	NN	O	O
,	NN	O	O
and	NN	O	O
493	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
146	NN	O	O
s	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
Kruskal	NN	O	O
-	NN	O	O
Wallis	NN	O	O
1	NN	O	O
-	NN	O	O
way	NN	O	O
analysis	NN	O	O
of	NN	O	O
variance	NN	O	O
indicated	NN	O	O
a	NN	O	O
significant	NN	O	O
difference	NN	O	O
among	NN	O	O
the	NN	O	O
4	NN	O	O
treatment	NN	O	O
groups	NN	O	O
(	NN	O	O
H	NN	O	O
=	NN	O	O
15.34	NN	O	O
;	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
separate	NN	O	O
group	NN	O	O
of	NN	O	O
mice	NN	O	O
not	NN	O	O
subjected	NN	O	O
to	NN	O	O
behavioral	NN	O	O
studies	NN	O	O
,	NN	O	O
the	NN	O	O
same	NN	O	O
dose	NN	O	O
of	NN	O	O
NTG	NN	O	B-Chemical
(	NN	O	O
n	NN	O	O
=	NN	O	O
3	NN	O	O
)	NN	O	O
and	NN	O	O
NTG	NN	O	B-Chemical
+	NN	O	O
NIMO	NN	O	B-Chemical
(	NN	O	O
n	NN	O	O
=	NN	O	O
3	NN	O	O
)	NN	O	O
caused	NN	O	O
mean	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
to	NN	O	O
decrease	NN	O	O
from	NN	O	O
85.9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3.8	NN	O	O
mm	NN	O	O
Hg	NN	O	O
sem	NN	O	O
to	NN	O	O
31.6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.8	NN	O	O
mm	NN	O	O
Hg	NN	O	O
sem	NN	O	O
and	NN	O	O
from	NN	O	O
86.2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3.7	NN	O	O
mm	NN	O	O
Hg	NN	O	O
sem	NN	O	O
to	NN	O	O
32.6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.2	NN	O	O
mm	NN	O	O
Hg	NN	O	O
sem	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Mean	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
in	NN	O	O
mice	NN	O	O
treated	NN	O	O
with	NN	O	O
NIMO	NN	O	B-Chemical
alone	NN	O	O
decreased	NN	O	O
from	NN	O	O
88.1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3.8	NN	O	O
mm	NN	O	O
Hg	NN	O	O
to	NN	O	O
80.0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.9	NN	O	O
mm	NN	O	O
Hg	NN	O	O
.	NN	O	O

The	NN	O	O
intergroup	NN	O	O
difference	NN	O	O
was	NN	O	O
statistically	NN	O	O
significant	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

PbtO	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
decreased	NN	O	O
from	NN	O	O
51.7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4.5	NN	O	O
mm	NN	O	O
Hg	NN	O	O
sem	NN	O	O
to	NN	O	O
33.8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5.2	NN	O	O
mm	NN	O	O
Hg	NN	O	O
sem	NN	O	O
in	NN	O	O
the	NN	O	O
NTG	NN	O	B-Chemical
group	NN	O	O
and	NN	O	O
from	NN	O	O
38.6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6.1	NN	O	O
mm	NN	O	O
Hg	NN	O	O
sem	NN	O	O
to	NN	O	O
25.4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.0	NN	O	O
mm	NN	O	O
Hg	NN	O	O
sem	NN	O	O
in	NN	O	O
the	NN	O	O
NTG	NN	O	B-Chemical
+	NN	O	O
NIMO	NN	O	B-Chemical
groups	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
significant	NN	O	O
differences	NN	O	O
among	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
In	NN	O	O
a	NN	O	O
PA	NN	O	O
retention	NN	O	O
paradigm	NN	O	O
,	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
NTG	NN	O	B-Chemical
immediately	NN	O	O
after	NN	O	O
learning	NN	O	O
produced	NN	O	O
a	NN	O	O
significant	NN	O	O
impairment	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
associative	NN	O	O
memory	NN	O	O
in	NN	O	O
mice	NN	O	O
,	NN	O	O
whereas	NN	O	O
delayed	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
had	NN	O	O
no	NN	O	O
effect	NN	O	O
.	NN	O	O

NIMO	NN	O	B-Chemical
attenuated	NN	O	O
the	NN	O	O
disruption	NN	O	O
in	NN	O	O
consolidation	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
memory	NN	O	O
caused	NN	O	O
by	NN	O	O
NTG	NN	O	B-Chemical
but	NN	O	O
did	NN	O	O
not	NN	O	O
improve	NN	O	O
latency	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
hypotension	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
observed	NN	O	O
effect	NN	O	O
of	NN	O	O
NIMO	NN	O	B-Chemical
may	NN	O	O
have	NN	O	O
been	NN	O	O
attributable	NN	O	O
to	NN	O	O
the	NN	O	O
preservation	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
homeostasis	NN	O	O
during	NN	O	O
hypotension	NN	O	B-Disease
,	NN	O	O
because	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
PbtO	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
indices	NN	O	O
among	NN	O	O
groups	NN	O	O
.	NN	O	O


-DOCSTART- (19058474)

Fatal	NN	O	O
haemopericardium	NN	O	B-Disease
and	NN	O	O
gastrointestinal	NN	O	B-Disease
haemorrhage	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
possible	NN	O	O
interaction	NN	O	O
of	NN	O	O
cranberry	NN	O	O
juice	NN	O	O
with	NN	O	O
warfarin	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
fatal	NN	O	O
internal	NN	O	O
haemorrhage	NN	O	B-Disease
in	NN	O	O
an	NN	O	O
elderly	NN	O	O
man	NN	O	O
who	NN	O	O
consumed	NN	O	O
only	NN	O	O
cranberry	NN	O	O
juice	NN	O	O
for	NN	O	O
two	NN	O	O
weeks	NN	O	O
while	NN	O	O
maintaining	NN	O	O
his	NN	O	O
usual	NN	O	O
dosage	NN	O	O
of	NN	O	O
warfarin	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
propose	NN	O	O
that	NN	O	O
naturally	NN	O	O
occurring	NN	O	O
compounds	NN	O	O
such	NN	O	O
as	NN	O	O
flavonoids	NN	O	B-Chemical
,	NN	O	O
which	NN	O	O
are	NN	O	O
present	NN	O	O
in	NN	O	O
fruit	NN	O	O
juices	NN	O	O
,	NN	O	O
may	NN	O	O
increase	NN	O	O
the	NN	O	O
potency	NN	O	O
of	NN	O	O
warfarin	NN	O	B-Chemical
by	NN	O	O
competing	NN	O	O
for	NN	O	O
the	NN	O	O
enzymes	NN	O	O
that	NN	O	O
normally	NN	O	O
inactivate	NN	O	O
warfarin	NN	O	B-Chemical
.	NN	O	O

While	NN	O	O
traditionally	NN	O	O
regarded	NN	O	O
as	NN	O	O
foodstuffs	NN	O	O
,	NN	O	O
consumption	NN	O	O
of	NN	O	O
fruit	NN	O	O
juices	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
when	NN	O	O
patients	NN	O	O
develop	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reactions	NN	O	O
.	NN	O	O


-DOCSTART- (18808529)

Isoproterenol	NN	O	B-Chemical
induces	NN	O	O
primary	NN	O	O
loss	NN	O	O
of	NN	O	O
dystrophin	NN	O	O
in	NN	O	O
rat	NN	O	O
hearts	NN	O	O
:	NN	O	O
correlation	NN	O	O
with	NN	O	O
myocardial	NN	O	B-Disease
injury	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
of	NN	O	O
isoproterenol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B-Disease
damage	NN	O	I-Disease
is	NN	O	O
unknown	NN	O	O
,	NN	O	O
but	NN	O	O
a	NN	O	O
mismatch	NN	O	O
of	NN	O	O
oxygen	NN	O	B-Chemical
supply	NN	O	O
vs	NN	O	O
.	NN	O	O

demand	NN	O	O
following	NN	O	O
coronary	NN	O	O
hypotension	NN	O	B-Disease
and	NN	O	O
myocardial	NN	O	B-Disease
hyperactivity	NN	O	I-Disease
is	NN	O	O
the	NN	O	O
best	NN	O	O
explanation	NN	O	O
for	NN	O	O
the	NN	O	O
complex	NN	O	O
morphological	NN	O	O
alterations	NN	O	O
observed	NN	O	O
.	NN	O	O

Severe	NN	O	O
alterations	NN	O	O
in	NN	O	O
the	NN	O	O
structural	NN	O	O
integrity	NN	O	O
of	NN	O	O
the	NN	O	O
sarcolemma	NN	O	O
of	NN	O	O
cardiomyocytes	NN	O	O
have	NN	O	O
been	NN	O	O
demonstrated	NN	O	O
to	NN	O	O
be	NN	O	O
caused	NN	O	O
by	NN	O	O
isoproterenol	NN	O	B-Chemical
.	NN	O	O

Taking	NN	O	O
into	NN	O	O
account	NN	O	O
that	NN	O	O
the	NN	O	O
sarcolemmal	NN	O	O
integrity	NN	O	O
is	NN	O	O
stabilized	NN	O	O
by	NN	O	O
the	NN	O	O
dystrophin	NN	O	O
-	NN	O	O
glycoprotein	NN	O	O
complex	NN	O	O
(	NN	O	O
DGC	NN	O	O
)	NN	O	O
that	NN	O	O
connects	NN	O	O
actin	NN	O	O
and	NN	O	O
laminin	NN	O	O
in	NN	O	O
contractile	NN	O	O
machinery	NN	O	O
and	NN	O	O
extracellular	NN	O	O
matrix	NN	O	O
and	NN	O	O
by	NN	O	O
integrins	NN	O	O
,	NN	O	O
this	NN	O	O
study	NN	O	O
tests	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
isoproterenol	NN	O	B-Chemical
affects	NN	O	O
sarcolemmal	NN	O	O
stability	NN	O	O
through	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
DGC	NN	O	O
and	NN	O	O
integrins	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
different	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
the	NN	O	O
DGC	NN	O	O
and	NN	O	O
integrin	NN	O	O
to	NN	O	O
isoproterenol	NN	O	B-Chemical
subcutaneous	NN	O	O
administration	NN	O	O
.	NN	O	O

Immunofluorescent	NN	O	O
staining	NN	O	O
revealed	NN	O	O
that	NN	O	O
dystrophin	NN	O	O
is	NN	O	O
the	NN	O	O
most	NN	O	O
sensitive	NN	O	O
among	NN	O	O
the	NN	O	O
structures	NN	O	O
connecting	NN	O	O
the	NN	O	O
actin	NN	O	O
in	NN	O	O
the	NN	O	O
cardiomyocyte	NN	O	O
cytoskeleton	NN	O	O
and	NN	O	O
the	NN	O	O
extracellular	NN	O	O
matrix	NN	O	O
.	NN	O	O

The	NN	O	O
sarcomeric	NN	O	O
actin	NN	O	O
dissolution	NN	O	O
occurred	NN	O	O
after	NN	O	O
the	NN	O	O
reduction	NN	O	O
or	NN	O	O
loss	NN	O	O
of	NN	O	O
dystrophin	NN	O	O
.	NN	O	O

Subsequently	NN	O	O
,	NN	O	O
after	NN	O	O
lysis	NN	O	O
of	NN	O	O
myofilaments	NN	O	O
,	NN	O	O
gamma	NN	O	O
-	NN	O	O
sarcoglycan	NN	O	O
,	NN	O	O
beta	NN	O	O
-	NN	O	O
dystroglycan	NN	O	O
,	NN	O	O
beta1	NN	O	O
-	NN	O	O
integrin	NN	O	O
,	NN	O	O
and	NN	O	O
laminin	NN	O	O
alpha	NN	O	O
-	NN	O	O
2	NN	O	O
expressions	NN	O	O
were	NN	O	O
reduced	NN	O	O
followed	NN	O	O
by	NN	O	O
their	NN	O	O
breakdown	NN	O	O
,	NN	O	O
as	NN	O	O
epiphenomena	NN	O	O
of	NN	O	O
the	NN	O	O
myocytolytic	NN	O	O
process	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
administration	NN	O	O
of	NN	O	O
isoproterenol	NN	O	B-Chemical
to	NN	O	O
rats	NN	O	O
results	NN	O	O
in	NN	O	O
primary	NN	O	O
loss	NN	O	O
of	NN	O	O
dystrophin	NN	O	O
,	NN	O	O
the	NN	O	O
most	NN	O	O
sensitive	NN	O	O
among	NN	O	O
the	NN	O	O
structural	NN	O	O
proteins	NN	O	O
that	NN	O	O
form	NN	O	O
the	NN	O	O
DGC	NN	O	O
that	NN	O	O
connects	NN	O	O
the	NN	O	O
extracellular	NN	O	O
matrix	NN	O	O
and	NN	O	O
the	NN	O	O
cytoskeleton	NN	O	O
in	NN	O	O
cardiomyocyte	NN	O	O
.	NN	O	O

These	NN	O	O
changes	NN	O	O
,	NN	O	O
related	NN	O	O
to	NN	O	O
ischaemic	NN	O	B-Disease
injury	NN	O	I-Disease
,	NN	O	O
explain	NN	O	O
the	NN	O	O
severe	NN	O	O
alterations	NN	O	O
in	NN	O	O
the	NN	O	O
structural	NN	O	O
integrity	NN	O	O
of	NN	O	O
the	NN	O	O
sarcolemma	NN	O	O
of	NN	O	O
cardiomyocytes	NN	O	O
and	NN	O	O
hence	NN	O	O
severe	NN	O	O
and	NN	O	O
irreversible	NN	O	O
injury	NN	O	O
induced	NN	O	O
by	NN	O	O
isoproterenol	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (18674790)

High	NN	O	O
fat	NN	O	B-Chemical
diet	NN	O	O
-	NN	O	O
fed	NN	O	O
obese	NN	O	B-Disease
rats	NN	O	O
are	NN	O	O
highly	NN	O	O
sensitive	NN	O	O
to	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B-Disease
.	NN	O	O

Often	NN	O	O
,	NN	O	O
chemotherapy	NN	O	O
by	NN	O	O
doxorubicin	NN	O	B-Chemical
(	NN	O	O
Adriamycin	NN	O	B-Chemical
)	NN	O	O
is	NN	O	O
limited	NN	O	O
due	NN	O	O
to	NN	O	O
life	NN	O	O
threatening	NN	O	O
cardiotoxicity	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
during	NN	O	O
and	NN	O	O
posttherapy	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
moderate	NN	O	O
diet	NN	O	O
restriction	NN	O	O
remarkably	NN	O	O
protects	NN	O	O
against	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B-Disease
.	NN	O	O

This	NN	O	O
cardioprotection	NN	O	O
is	NN	O	O
accompanied	NN	O	O
by	NN	O	O
decreased	NN	O	O
cardiac	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
and	NN	O	O
triglycerides	NN	O	B-Chemical
and	NN	O	O
increased	NN	O	O
cardiac	NN	O	O
fatty	NN	O	O
-	NN	O	O
acid	NN	O	O
oxidation	NN	O	O
,	NN	O	O
ATP	NN	O	B-Chemical
synthesis	NN	O	O
,	NN	O	O
and	NN	O	O
upregulated	NN	O	O
JAK	NN	O	O
/	NN	O	O
STAT3	NN	O	O
pathway	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
current	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
whether	NN	O	O
a	NN	O	O
physiological	NN	O	O
intervention	NN	O	O
by	NN	O	O
feeding	NN	O	O
40%	NN	O	O
high	NN	O	O
fat	NN	O	B-Chemical
diet	NN	O	O
(	NN	O	O
HFD	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
induces	NN	O	O
obesity	NN	O	B-Disease
in	NN	O	O
male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
(	NN	O	O
250	NN	O	O
-	NN	O	O
275	NN	O	O
g	NN	O	O
)	NN	O	O
,	NN	O	O
sensitizes	NN	O	O
to	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B-Disease
.	NN	O	O

A	NN	O	O
LD	NN	O	O
(	NN	O	O
10	NN	O	O
)	NN	O	O
dose	NN	O	O
(	NN	O	O
8	NN	O	O
mg	NN	O	O
doxorubicin	NN	O	B-Chemical
/	NN	O	O
kg	NN	O	O
,	NN	O	O
ip	NN	O	O
)	NN	O	O
administered	NN	O	O
on	NN	O	O
day	NN	O	O
43	NN	O	O
of	NN	O	O
the	NN	O	O
HFD	NN	O	O
feeding	NN	O	O
regimen	NN	O	O
led	NN	O	O
to	NN	O	O
higher	NN	O	O
cardiotoxicity	NN	O	B-Disease
,	NN	O	O
cardiac	NN	O	B-Disease
dysfunction	NN	O	I-Disease
,	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
,	NN	O	O
and	NN	O	O
80%	NN	O	O
mortality	NN	O	O
in	NN	O	O
the	NN	O	O
obese	NN	O	B-Disease
(	NN	O	O
OB	NN	O	B-Disease
)	NN	O	O
rats	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
any	NN	O	O
significant	NN	O	O
renal	NN	O	B-Disease
or	NN	O	I-Disease
hepatic	NN	O	I-Disease
toxicity	NN	O	I-Disease
.	NN	O	O

Doxorubicin	NN	O	B-Chemical
toxicokinetics	NN	O	O
studies	NN	O	O
revealed	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
accumulation	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
and	NN	O	O
doxorubicinol	NN	O	B-Chemical
(	NN	O	O
toxic	NN	O	O
metabolite	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
normal	NN	O	O
diet	NN	O	O
-	NN	O	O
fed	NN	O	O
(	NN	O	O
ND	NN	O	O
)	NN	O	O
and	NN	O	O
OB	NN	O	B-Disease
hearts	NN	O	O
.	NN	O	O

Mechanistic	NN	O	O
studies	NN	O	O
revealed	NN	O	O
that	NN	O	O
OB	NN	O	B-Disease
rats	NN	O	O
are	NN	O	O
sensitized	NN	O	O
due	NN	O	O
to	NN	O	O
:	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
higher	NN	O	O
oxyradical	NN	O	O
stress	NN	O	O
leading	NN	O	O
to	NN	O	O
upregulation	NN	O	O
of	NN	O	O
uncoupling	NN	O	O
proteins	NN	O	O
2	NN	O	O
and	NN	O	O
3	NN	O	O
,	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
downregulation	NN	O	O
of	NN	O	O
cardiac	NN	O	O
peroxisome	NN	O	O
proliferators	NN	O	O
activated	NN	O	O
receptor	NN	O	O
-	NN	O	O
alpha	NN	O	O
,	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
decreased	NN	O	O
plasma	NN	O	O
adiponectin	NN	O	O
levels	NN	O	O
,	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
decreased	NN	O	O
cardiac	NN	O	O
fatty	NN	O	O
-	NN	O	O
acid	NN	O	O
oxidation	NN	O	O
(	NN	O	O
666.9+	NN	O	O
/	NN	O	O
-	NN	O	O
14.0	NN	O	O
nmol	NN	O	O
/	NN	O	O
min	NN	O	O
/	NN	O	O
g	NN	O	O
heart	NN	O	O
in	NN	O	O
ND	NN	O	O
versus	NN	O	O
400.2+	NN	O	O
/	NN	O	O
-	NN	O	O
11.8	NN	O	O
nmol	NN	O	O
/	NN	O	O
min	NN	O	O
/	NN	O	O
g	NN	O	O
heart	NN	O	O
in	NN	O	O
OB	NN	O	B-Disease
)	NN	O	O
,	NN	O	O
(	NN	O	O
5	NN	O	O
)	NN	O	O
decreased	NN	O	O
mitochondrial	NN	O	O
AMP	NN	O	B-Chemical
-	NN	O	O
alpha2	NN	O	O
protein	NN	O	O
kinase	NN	O	O
,	NN	O	O
and	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
86%	NN	O	O
drop	NN	O	O
in	NN	O	O
cardiac	NN	O	O
ATP	NN	O	B-Chemical
levels	NN	O	O
accompanied	NN	O	O
by	NN	O	O
decreased	NN	O	O
ATP	NN	O	B-Chemical
/	NN	O	O
ADP	NN	O	B-Chemical
ratio	NN	O	O
after	NN	O	O
doxorubicin	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

Decreased	NN	O	O
cardiac	NN	O	O
erythropoietin	NN	O	O
and	NN	O	O
increased	NN	O	O
SOCS3	NN	O	O
further	NN	O	O
downregulated	NN	O	O
the	NN	O	O
cardioprotective	NN	O	O
JAK	NN	O	O
/	NN	O	O
STAT3	NN	O	O
pathway	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
HFD	NN	O	O
-	NN	O	O
induced	NN	O	O
obese	NN	O	B-Disease
rats	NN	O	O
are	NN	O	O
highly	NN	O	O
sensitized	NN	O	O
to	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B-Disease
by	NN	O	O
substantially	NN	O	O
downregulating	NN	O	O
cardiac	NN	O	O
mitochondrial	NN	O	O
ATP	NN	O	B-Chemical
generation	NN	O	O
,	NN	O	O
increasing	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
and	NN	O	O
downregulating	NN	O	O
the	NN	O	O
JAK	NN	O	O
/	NN	O	O
STAT3	NN	O	O
pathway	NN	O	O
.	NN	O	O


-DOCSTART- (18441470)

Complete	NN	O	O
atrioventricular	NN	O	B-Disease
block	NN	O	I-Disease
secondary	NN	O	O
to	NN	O	O
lithium	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Sinus	NN	O	B-Disease
node	NN	O	I-Disease
dysfunction	NN	O	I-Disease
has	NN	O	O
been	NN	O	O
reported	NN	O	O
most	NN	O	O
frequently	NN	O	O
among	NN	O	O
the	NN	O	O
adverse	NN	O	O
cardiovascular	NN	O	O
effects	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
case	NN	O	O
,	NN	O	O
complete	NN	O	O
atrioventricular	NN	O	B-Disease
(	NN	O	I-Disease
AV	NN	O	I-Disease
)	NN	O	I-Disease
block	NN	O	I-Disease
with	NN	O	O
syncopal	NN	O	B-Disease
attacks	NN	O	I-Disease
developed	NN	O	O
secondary	NN	O	O
to	NN	O	O
lithium	NN	O	B-Chemical
therapy	NN	O	O
,	NN	O	O
necessitating	NN	O	O
permanent	NN	O	O
pacemaker	NN	O	O
implantation	NN	O	O
.	NN	O	O

Serum	NN	O	O
lithium	NN	O	B-Chemical
levels	NN	O	O
remained	NN	O	O
under	NN	O	O
or	NN	O	O
within	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
range	NN	O	O
during	NN	O	O
the	NN	O	O
syncopal	NN	O	B-Disease
attacks	NN	O	I-Disease
.	NN	O	O

Lithium	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
used	NN	O	O
with	NN	O	O
extreme	NN	O	O
caution	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
mild	NN	O	O
disturbance	NN	O	O
of	NN	O	O
AV	NN	O	O
conduction	NN	O	O
.	NN	O	O


-DOCSTART- (17366349)

Neuroleptic	NN	O	B-Disease
malignant	NN	O	I-Disease
syndrome	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
ziprasidone	NN	O	B-Chemical
on	NN	O	O
the	NN	O	O
second	NN	O	O
day	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Neuroleptic	NN	O	B-Disease
malignant	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
NMS	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
the	NN	O	O
rarest	NN	O	O
and	NN	O	O
most	NN	O	O
serious	NN	O	O
of	NN	O	O
the	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
movement	NN	O	B-Disease
disorders	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
neuroleptic	NN	O	B-Disease
malignant	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
NMS	NN	O	B-Disease
)	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
ziprasidone	NN	O	B-Chemical
.	NN	O	O

Although	NN	O	O
conventional	NN	O	O
neuroleptics	NN	O	O
are	NN	O	O
more	NN	O	O
frequently	NN	O	O
associated	NN	O	O
with	NN	O	O
NMS	NN	O	B-Disease
,	NN	O	O
atypical	NN	O	O
antipsychotic	NN	O	O
drugs	NN	O	O
like	NN	O	O
ziprasidone	NN	O	B-Chemical
may	NN	O	O
also	NN	O	O
be	NN	O	O
a	NN	O	O
cause	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
is	NN	O	O
a	NN	O	O
24	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B-Disease
who	NN	O	O
developed	NN	O	O
signs	NN	O	O
and	NN	O	O
symptoms	NN	O	O
of	NN	O	O
NMS	NN	O	B-Disease
after	NN	O	O
2	NN	O	O
days	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
an	NN	O	O
80	NN	O	O
-	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
dose	NN	O	O
of	NN	O	O
orally	NN	O	O
administrated	NN	O	O
ziprasidone	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
case	NN	O	O
is	NN	O	O
the	NN	O	O
earliest	NN	O	O
(	NN	O	O
second	NN	O	O
day	NN	O	O
of	NN	O	O
treatment	NN	O	O
)	NN	O	O
NMS	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
ziprasidone	NN	O	B-Chemical
reported	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O


-DOCSTART- (16584858)

Role	NN	O	O
of	NN	O	O
mangiferin	NN	O	B-Chemical
on	NN	O	O
biochemical	NN	O	O
alterations	NN	O	O
and	NN	O	O
antioxidant	NN	O	O
status	NN	O	O
in	NN	O	O
isoproterenol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
current	NN	O	O
study	NN	O	O
dealt	NN	O	O
with	NN	O	O
the	NN	O	O
protective	NN	O	O
role	NN	O	O
of	NN	O	O
mangiferin	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
polyphenol	NN	O	B-Chemical
from	NN	O	O
Mangifera	NN	O	O
indica	NN	O	O
Linn	NN	O	O
.	NN	O	O

(	NN	O	O
Anacardiaceae	NN	O	O
)	NN	O	O
,	NN	O	O
on	NN	O	O
isoproterenol	NN	O	B-Chemical
(	NN	O	O
ISPH	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
(	NN	O	O
MI	NN	O	B-Disease
)	NN	O	O
in	NN	O	O
rats	NN	O	O
through	NN	O	O
its	NN	O	O
antioxidative	NN	O	O
mechanism	NN	O	O
.	NN	O	O

Subcutaneous	NN	O	O
injection	NN	O	O
of	NN	O	O
ISPH	NN	O	B-Chemical
(	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
in	NN	O	O
1	NN	O	O
ml	NN	O	O
saline	NN	O	O
)	NN	O	O
to	NN	O	O
rats	NN	O	O
for	NN	O	O
2	NN	O	O
consecutive	NN	O	O
days	NN	O	O
caused	NN	O	O
myocardial	NN	O	B-Disease
damage	NN	O	I-Disease
in	NN	O	O
rat	NN	O	O
heart	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
determined	NN	O	O
by	NN	O	O
the	NN	O	O
increased	NN	O	O
activity	NN	O	O
of	NN	O	O
serum	NN	O	O
lactate	NN	O	B-Chemical
dehydrogenase	NN	O	O
(	NN	O	O
LDH	NN	O	O
)	NN	O	O
and	NN	O	O
creatine	NN	O	B-Chemical
phosphokinase	NN	O	O
isoenzymes	NN	O	O
(	NN	O	O
CK	NN	O	O
-	NN	O	O
MB	NN	O	O
)	NN	O	O
,	NN	O	O
increased	NN	O	O
uric	NN	O	B-Chemical
acid	NN	O	I-Chemical
level	NN	O	O
and	NN	O	O
reduced	NN	O	O
plasma	NN	O	O
iron	NN	O	B-Chemical
binding	NN	O	O
capacity	NN	O	O
.	NN	O	O

The	NN	O	O
protective	NN	O	O
role	NN	O	O
of	NN	O	O
mangiferin	NN	O	B-Chemical
was	NN	O	O
analyzed	NN	O	O
by	NN	O	O
triphenyl	NN	O	B-Chemical
tetrazolium	NN	O	I-Chemical
chloride	NN	O	I-Chemical
(	NN	O	O
TTC	NN	O	B-Chemical
)	NN	O	O
test	NN	O	O
used	NN	O	O
for	NN	O	O
macroscopic	NN	O	O
enzyme	NN	O	O
mapping	NN	O	O
assay	NN	O	O
of	NN	O	O
the	NN	O	O
ischemic	NN	O	B-Disease
myocardium	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
heart	NN	O	O
tissue	NN	O	O
antioxidant	NN	O	O
enzymes	NN	O	O
such	NN	O	O
as	NN	O	O
superoxide	NN	O	B-Chemical
dismutase	NN	O	O
,	NN	O	O
catalase	NN	O	O
,	NN	O	O
glutathione	NN	O	B-Chemical
peroxidase	NN	O	O
,	NN	O	O
glutathione	NN	O	B-Chemical
transferase	NN	O	O
and	NN	O	O
glutathione	NN	O	B-Chemical
reductase	NN	O	O
activities	NN	O	O
,	NN	O	O
non	NN	O	O
-	NN	O	O
enzymic	NN	O	O
antioxidants	NN	O	O
such	NN	O	O
as	NN	O	O
cerruloplasmin	NN	O	O
,	NN	O	O
Vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
,	NN	O	O
Vitamin	NN	O	B-Chemical
E	NN	O	I-Chemical
and	NN	O	O
glutathione	NN	O	B-Chemical
levels	NN	O	O
were	NN	O	O
altered	NN	O	O
in	NN	O	O
MI	NN	O	B-Disease
rats	NN	O	O
.	NN	O	O

Upon	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
mangiferin	NN	O	B-Chemical
(	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
suspended	NN	O	O
in	NN	O	O
2	NN	O	O
ml	NN	O	O
of	NN	O	O
dimethyl	NN	O	B-Chemical
sulphoxide	NN	O	I-Chemical
)	NN	O	O
given	NN	O	O
intraperitoneally	NN	O	O
for	NN	O	O
28	NN	O	O
days	NN	O	O
to	NN	O	O
MI	NN	O	B-Disease
rats	NN	O	O
protected	NN	O	O
the	NN	O	O
above	NN	O	O
-	NN	O	O
mentioned	NN	O	O
parameters	NN	O	O
to	NN	O	O
fall	NN	O	O
from	NN	O	O
the	NN	O	O
normal	NN	O	O
levels	NN	O	O
.	NN	O	O

Activities	NN	O	O
of	NN	O	O
heart	NN	O	O
tissue	NN	O	O
enzymic	NN	O	O
antioxidants	NN	O	O
and	NN	O	O
serum	NN	O	O
non	NN	O	O
-	NN	O	O
enzymic	NN	O	O
antioxidants	NN	O	O
levels	NN	O	O
rose	NN	O	O
significantly	NN	O	O
upon	NN	O	O
mangiferin	NN	O	B-Chemical
administration	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
ISPH	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
MI	NN	O	B-Disease
rats	NN	O	O
.	NN	O	O

From	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
it	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
mangiferin	NN	O	B-Chemical
exerts	NN	O	O
a	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
against	NN	O	O
ISPH	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
MI	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
its	NN	O	O
antioxidant	NN	O	O
potential	NN	O	O
,	NN	O	O
which	NN	O	O
regulated	NN	O	O
the	NN	O	O
tissues	NN	O	O
defense	NN	O	O
system	NN	O	O
against	NN	O	O
cardiac	NN	O	B-Disease
damage	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (16563323)

Remifentanil	NN	O	B-Chemical
pretreatment	NN	O	O
reduces	NN	O	O
myoclonus	NN	O	B-Disease
after	NN	O	O
etomidate	NN	O	B-Chemical
.	NN	O	O

STUDY	NN	O	O
OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
remifentanil	NN	O	B-Chemical
1	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
and	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
gender	NN	O	O
on	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
myoclonus	NN	O	B-Disease
after	NN	O	O
anesthesia	NN	O	O
induction	NN	O	O
with	NN	O	O
etomidate	NN	O	B-Chemical
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
This	NN	O	O
was	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
study	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
The	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
at	NN	O	O
a	NN	O	O
university	NN	O	O
hospital	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
:	NN	O	O
Sixty	NN	O	O
patients	NN	O	O
were	NN	O	O
pretreated	NN	O	O
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
double	NN	O	O
-	NN	O	O
blinded	NN	O	O
fashion	NN	O	O
with	NN	O	O
remifentanil	NN	O	B-Chemical
1	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
or	NN	O	O
placebo	NN	O	O
.	NN	O	O

Two	NN	O	O
minutes	NN	O	O
after	NN	O	O
remifentanil	NN	O	B-Chemical
or	NN	O	O
placebo	NN	O	O
injection	NN	O	O
,	NN	O	O
etomidate	NN	O	B-Chemical
0.3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
was	NN	O	O
given	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
:	NN	O	O
Myoclonus	NN	O	B-Disease
was	NN	O	O
recorded	NN	O	O
with	NN	O	O
a	NN	O	O
scale	NN	O	O
of	NN	O	O
0	NN	O	O
to	NN	O	O
3	NN	O	O
.	NN	O	O

The	NN	O	O
grade	NN	O	O
of	NN	O	O
sedation	NN	O	O
(	NN	O	O
none	NN	O	O
,	NN	O	O
mild	NN	O	O
,	NN	O	O
moderate	NN	O	O
,	NN	O	O
severe	NN	O	O
)	NN	O	O
,	NN	O	O
nausea	NN	O	B-Disease
,	NN	O	O
pruritus	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
apnea	NN	O	B-Disease
were	NN	O	O
recorded	NN	O	O
after	NN	O	O
injection	NN	O	O
of	NN	O	O
both	NN	O	O
drugs	NN	O	O
.	NN	O	O

MAIN	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
incidence	NN	O	O
of	NN	O	O
myoclonus	NN	O	B-Disease
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
remifentanil	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
6.7%	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
(	NN	O	O
70%	NN	O	O
)	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
experienced	NN	O	O
sedation	NN	O	O
,	NN	O	O
apnea	NN	O	B-Disease
,	NN	O	O
nausea	NN	O	B-Disease
,	NN	O	O
or	NN	O	O
pruritus	NN	O	B-Disease
after	NN	O	O
injection	NN	O	O
of	NN	O	O
both	NN	O	O
drugs	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
,	NN	O	O
male	NN	O	O
patients	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
significantly	NN	O	O
increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
myoclonus	NN	O	B-Disease
after	NN	O	O
etomidate	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Pretreatment	NN	O	O
with	NN	O	O
remifentanil	NN	O	B-Chemical
1	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
reduced	NN	O	O
myoclonus	NN	O	B-Disease
after	NN	O	O
etomidate	NN	O	B-Chemical
induction	NN	O	O
without	NN	O	O
side	NN	O	O
effects	NN	O	O
such	NN	O	O
as	NN	O	O
sedation	NN	O	O
,	NN	O	O
apnea	NN	O	B-Disease
,	NN	O	O
nausea	NN	O	B-Disease
,	NN	O	O
or	NN	O	O
pruritus	NN	O	B-Disease
.	NN	O	O

Men	NN	O	O
experience	NN	O	O
increased	NN	O	O
incidence	NN	O	O
of	NN	O	O
myoclonus	NN	O	B-Disease
than	NN	O	O
women	NN	O	O
after	NN	O	O
etomidate	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O


-DOCSTART- (16428827)

Daidzein	NN	O	B-Chemical
activates	NN	O	O
choline	NN	O	B-Chemical
acetyltransferase	NN	O	O
from	NN	O	O
MC	NN	O	O
-	NN	O	O
IXC	NN	O	O
cells	NN	O	O
and	NN	O	O
improves	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
choline	NN	O	B-Chemical
acetyltransferase	NN	O	O
(	NN	O	O
ChAT	NN	O	O
)	NN	O	O
activator	NN	O	O
,	NN	O	O
which	NN	O	O
enhances	NN	O	O
cholinergic	NN	O	O
transmission	NN	O	O
via	NN	O	O
an	NN	O	O
augmentation	NN	O	O
of	NN	O	O
the	NN	O	O
enzymatic	NN	O	O
production	NN	O	O
of	NN	O	O
acetylcholine	NN	O	B-Chemical
(	NN	O	O
ACh	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
is	NN	O	O
an	NN	O	O
important	NN	O	O
factor	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
Alzheimer	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
AD	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Methanolic	NN	O	O
extracts	NN	O	O
from	NN	O	O
Pueraria	NN	O	O
thunbergiana	NN	O	O
exhibited	NN	O	O
an	NN	O	O
activation	NN	O	O
effect	NN	O	O
(	NN	O	O
46%	NN	O	O
)	NN	O	O
on	NN	O	O
ChAT	NN	O	O
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

Via	NN	O	O
the	NN	O	O
sequential	NN	O	O
isolation	NN	O	O
of	NN	O	O
Pueraria	NN	O	O
thunbergiana	NN	O	O
,	NN	O	O
the	NN	O	O
active	NN	O	O
component	NN	O	O
was	NN	O	O
ultimately	NN	O	O
identified	NN	O	O
as	NN	O	O
daidzein	NN	O	B-Chemical
(	NN	O	O
4	NN	O	B-Chemical
'	NN	O	I-Chemical
,	NN	O	I-Chemical
7	NN	O	I-Chemical
-	NN	O	I-Chemical
dihydroxy	NN	O	I-Chemical
-	NN	O	I-Chemical
isoflavone	NN	O	I-Chemical
)	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
daidzein	NN	O	B-Chemical
from	NN	O	O
Pueraria	NN	O	O
thunbergiana	NN	O	O
on	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
impairments	NN	O	B-Disease
of	NN	O	I-Disease
learning	NN	O	I-Disease
and	NN	O	I-Disease
memory	NN	O	I-Disease
,	NN	O	O
we	NN	O	O
conducted	NN	O	O
a	NN	O	O
series	NN	O	O
of	NN	O	O
in	NN	O	O
vivo	NN	O	O
tests	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
daidzein	NN	O	B-Chemical
(	NN	O	O
4.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
to	NN	O	O
mice	NN	O	O
was	NN	O	O
shown	NN	O	O
significantly	NN	O	O
to	NN	O	O
reverse	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B-Disease
,	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
a	NN	O	O
Y	NN	O	O
-	NN	O	O
maze	NN	O	O
test	NN	O	O
.	NN	O	O

Injections	NN	O	O
of	NN	O	O
scopolamine	NN	O	B-Chemical
into	NN	O	O
mice	NN	O	O
resulted	NN	O	O
in	NN	O	O
impaired	NN	O	O
performance	NN	O	O
on	NN	O	O
Y	NN	O	O
-	NN	O	O
maze	NN	O	O
tests	NN	O	O
(	NN	O	O
a	NN	O	O
37%	NN	O	O
decreases	NN	O	O
in	NN	O	O
alternation	NN	O	O
behavior	NN	O	O
)	NN	O	O
.	NN	O	O

By	NN	O	O
way	NN	O	O
of	NN	O	O
contrast	NN	O	O
,	NN	O	O
mice	NN	O	O
treated	NN	O	O
with	NN	O	O
daidzein	NN	O	B-Chemical
prior	NN	O	O
to	NN	O	O
the	NN	O	O
scopolamine	NN	O	B-Chemical
injections	NN	O	O
were	NN	O	O
noticeably	NN	O	O
protected	NN	O	O
from	NN	O	O
this	NN	O	O
performance	NN	O	O
impairment	NN	O	O
(	NN	O	O
an	NN	O	O
approximately	NN	O	O
12%	NN	O	O
-	NN	O	O
21%	NN	O	O
decrease	NN	O	O
in	NN	O	O
alternation	NN	O	O
behavior	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
daidzein	NN	O	B-Chemical
might	NN	O	O
play	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
acetylcholine	NN	O	B-Chemical
biosynthesis	NN	O	O
as	NN	O	O
a	NN	O	O
ChAT	NN	O	O
activator	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
it	NN	O	O
also	NN	O	O
ameliorates	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (15985056)

Possible	NN	O	O
azithromycin	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
hiccups	NN	O	B-Disease
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
persistent	NN	O	O
hiccups	NN	O	B-Disease
associated	NN	O	O
by	NN	O	O
azithromycin	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
76	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
presented	NN	O	O
with	NN	O	O
persistent	NN	O	O
hiccups	NN	O	B-Disease
after	NN	O	O
beginning	NN	O	O
azithromycin	NN	O	B-Chemical
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
pharyngitis	NN	O	B-Disease
.	NN	O	O

Hiccups	NN	O	B-Disease
were	NN	O	O
persistent	NN	O	O
and	NN	O	O
exhausting	NN	O	O
.	NN	O	O

Discontinuation	NN	O	O
of	NN	O	O
azithromycin	NN	O	B-Chemical
and	NN	O	O
therapy	NN	O	O
with	NN	O	O
baclofen	NN	O	B-Chemical
finally	NN	O	O
resolved	NN	O	O
hiccups	NN	O	B-Disease
.	NN	O	O

No	NN	O	O
organic	NN	O	O
cause	NN	O	O
of	NN	O	O
hiccups	NN	O	B-Disease
was	NN	O	O
identified	NN	O	O
despite	NN	O	O
extensive	NN	O	O
investigation	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
Pharmacotherapeutic	NN	O	O
agents	NN	O	O
have	NN	O	O
been	NN	O	O
uncommonly	NN	O	O
associated	NN	O	O
with	NN	O	O
hiccups	NN	O	B-Disease
.	NN	O	O

Corticosteroids	NN	O	O
(	NN	O	O
dexamethasone	NN	O	B-Chemical
and	NN	O	O
methylprednisolone	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
benzodiazepines	NN	O	B-Chemical
(	NN	O	O
midazolam	NN	O	B-Chemical
)	NN	O	O
and	NN	O	O
general	NN	O	O
anaesthesia	NN	O	O
have	NN	O	O
been	NN	O	O
the	NN	O	O
specific	NN	O	O
agents	NN	O	O
mentioned	NN	O	O
most	NN	O	O
frequently	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
as	NN	O	O
being	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
hiccups	NN	O	B-Disease
.	NN	O	O

Few	NN	O	O
cases	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hiccups	NN	O	B-Disease
have	NN	O	O
been	NN	O	O
reported	NN	O	O
related	NN	O	O
to	NN	O	O
macrolide	NN	O	B-Chemical
antimicrobials	NN	O	O
.	NN	O	O

Using	NN	O	O
the	NN	O	O
Naranjo	NN	O	O
adverse	NN	O	O
effect	NN	O	O
reaction	NN	O	O
probability	NN	O	O
scale	NN	O	O
this	NN	O	O
event	NN	O	O
could	NN	O	O
be	NN	O	O
classified	NN	O	O
as	NN	O	O
possible	NN	O	O
(	NN	O	O
score	NN	O	O
5	NN	O	O
points	NN	O	O
)	NN	O	O
,	NN	O	O
mostly	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
close	NN	O	O
temporal	NN	O	O
sequence	NN	O	O
,	NN	O	O
previous	NN	O	O
reports	NN	O	O
on	NN	O	O
this	NN	O	O
reaction	NN	O	O
with	NN	O	O
other	NN	O	O
macrolides	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
any	NN	O	O
alternative	NN	O	O
explanation	NN	O	O
for	NN	O	O
hiccups	NN	O	B-Disease
.	NN	O	O

Our	NN	O	O
hypothesis	NN	O	O
is	NN	O	O
that	NN	O	O
a	NN	O	O
vagal	NN	O	O
mechanism	NN	O	O
mediated	NN	O	O
by	NN	O	O
azithromycin	NN	O	B-Chemical
could	NN	O	O
be	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
hiccups	NN	O	B-Disease
in	NN	O	O
our	NN	O	O
patient	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Diagnosis	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hiccups	NN	O	B-Disease
is	NN	O	O
difficult	NN	O	O
and	NN	O	O
often	NN	O	O
achieved	NN	O	O
only	NN	O	O
by	NN	O	O
a	NN	O	O
process	NN	O	O
of	NN	O	O
elimination	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
macrolide	NN	O	B-Chemical
antimicrobials	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
hiccups	NN	O	B-Disease
and	NN	O	O
vagal	NN	O	O
mechanism	NN	O	O
could	NN	O	O
explain	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
this	NN	O	O
side	NN	O	O
-	NN	O	O
effect	NN	O	O
.	NN	O	O


-DOCSTART- (15276120)

Time	NN	O	O
trends	NN	O	O
in	NN	O	O
warfarin	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
hemorrhage	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
annual	NN	O	O
incidence	NN	O	O
of	NN	O	O
warfarin	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
bleeding	NN	O	B-Disease
at	NN	O	O
Brigham	NN	O	O
and	NN	O	O
Women	NN	O	O
'	NN	O	O
s	NN	O	O
Hospital	NN	O	O
increased	NN	O	O
from	NN	O	O
0.97	NN	O	O
/	NN	O	O
1	NN	O	O
,	NN	O	O
000	NN	O	O
patient	NN	O	O
admissions	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
period	NN	O	O
(	NN	O	O
January	NN	O	O
1995	NN	O	O
to	NN	O	O
October	NN	O	O
1998	NN	O	O
)	NN	O	O
to	NN	O	O
1.19	NN	O	O
/	NN	O	O
1	NN	O	O
,	NN	O	O
000	NN	O	O
patient	NN	O	O
admissions	NN	O	O
in	NN	O	O
the	NN	O	O
second	NN	O	O
time	NN	O	O
period	NN	O	O
(	NN	O	O
November	NN	O	O
1998	NN	O	O
to	NN	O	O
August	NN	O	O
2002	NN	O	O
)	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
proportion	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
major	NN	O	O
and	NN	O	O
intracranial	NN	O	B-Disease
bleeding	NN	O	I-Disease
increased	NN	O	O
from	NN	O	O
20.2%	NN	O	O
and	NN	O	O
1.9%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
period	NN	O	O
,	NN	O	O
to	NN	O	O
33.3%	NN	O	O
and	NN	O	O
7.8%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
second	NN	O	O
.	NN	O	O


-DOCSTART- (11271907)

Fatal	NN	O	O
haemorrhagic	NN	O	B-Disease
myocarditis	NN	O	I-Disease
secondary	NN	O	O
to	NN	O	O
cyclophosphamide	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Haemorrhagic	NN	O	B-Disease
myocarditis	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
rare	NN	O	O
but	NN	O	O
important	NN	O	O
complication	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Echocardiographic	NN	O	O
identification	NN	O	O
of	NN	O	O
the	NN	O	O
disorder	NN	O	O
can	NN	O	O
be	NN	O	O
made	NN	O	O
.	NN	O	O

We	NN	O	O
believe	NN	O	O
that	NN	O	O
the	NN	O	O
ultrasound	NN	O	O
features	NN	O	O
of	NN	O	O
this	NN	O	O
disorder	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
previously	NN	O	O
reported	NN	O	O
.	NN	O	O


-DOCSTART- (10524660)

Glyceryl	NN	O	B-Chemical
trinitrate	NN	O	I-Chemical
induces	NN	O	O
attacks	NN	O	O
of	NN	O	O
migraine	NN	O	B-Disease
without	NN	O	I-Disease
aura	NN	O	I-Disease
in	NN	O	O
sufferers	NN	O	O
of	NN	O	O
migraine	NN	O	B-Disease
with	NN	O	I-Disease
aura	NN	O	I-Disease
.	NN	O	O

Migraine	NN	O	B-Disease
with	NN	O	I-Disease
aura	NN	O	I-Disease
and	NN	O	O
migraine	NN	O	B-Disease
without	NN	O	I-Disease
aura	NN	O	I-Disease
have	NN	O	O
the	NN	O	O
same	NN	O	O
pain	NN	O	B-Disease
phase	NN	O	O
,	NN	O	O
thus	NN	O	O
indicating	NN	O	O
that	NN	O	O
migraine	NN	O	B-Disease
with	NN	O	I-Disease
aura	NN	O	I-Disease
and	NN	O	O
migraine	NN	O	B-Disease
without	NN	O	I-Disease
aura	NN	O	I-Disease
share	NN	O	O
a	NN	O	O
common	NN	O	O
pathway	NN	O	O
of	NN	O	O
nociception	NN	O	O
.	NN	O	O

In	NN	O	O
recent	NN	O	O
years	NN	O	O
,	NN	O	O
increasing	NN	O	O
evidence	NN	O	O
has	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
messenger	NN	O	O
molecule	NN	O	O
nitric	NN	O	B-Chemical
oxide	NN	O	I-Chemical
(	NN	O	O
NO	NN	O	B-Chemical
)	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
pain	NN	O	B-Disease
mechanisms	NN	O	O
of	NN	O	O
migraine	NN	O	B-Disease
without	NN	O	I-Disease
aura	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
clarify	NN	O	O
whether	NN	O	O
the	NN	O	O
same	NN	O	O
is	NN	O	O
true	NN	O	O
for	NN	O	O
migraine	NN	O	B-Disease
with	NN	O	I-Disease
aura	NN	O	I-Disease
,	NN	O	O
in	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
we	NN	O	O
examined	NN	O	O
the	NN	O	O
headache	NN	O	B-Disease
response	NN	O	O
to	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
of	NN	O	O
glyceryl	NN	O	B-Chemical
trinitrate	NN	O	I-Chemical
(	NN	O	O
GTN	NN	O	B-Chemical
)	NN	O	O
(	NN	O	O
0.5	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
for	NN	O	O
20	NN	O	O
min	NN	O	O
)	NN	O	O
in	NN	O	O
12	NN	O	O
sufferers	NN	O	O
of	NN	O	O
migraine	NN	O	B-Disease
with	NN	O	I-Disease
aura	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
specific	NN	O	O
aim	NN	O	O
was	NN	O	O
to	NN	O	O
elucidate	NN	O	O
whether	NN	O	O
an	NN	O	O
aura	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
an	NN	O	O
attack	NN	O	O
of	NN	O	O
migraine	NN	O	B-Disease
without	NN	O	I-Disease
aura	NN	O	I-Disease
could	NN	O	O
be	NN	O	O
induced	NN	O	O
.	NN	O	O

Fourteen	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
served	NN	O	O
as	NN	O	O
controls	NN	O	O
.	NN	O	O

Aura	NN	O	O
symptoms	NN	O	O
were	NN	O	O
not	NN	O	O
elicited	NN	O	O
in	NN	O	O
any	NN	O	O
subject	NN	O	O
.	NN	O	O

Headache	NN	O	B-Disease
was	NN	O	O
more	NN	O	O
severe	NN	O	O
in	NN	O	O
migraineurs	NN	O	B-Disease
than	NN	O	O
in	NN	O	O
the	NN	O	O
controls	NN	O	O
during	NN	O	O
and	NN	O	O
immediately	NN	O	O
after	NN	O	O
GTN	NN	O	B-Chemical
infusion	NN	O	O
(	NN	O	O
p=0.037	NN	O	O
)	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
during	NN	O	O
the	NN	O	O
following	NN	O	O
11	NN	O	O
h	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.008	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
controls	NN	O	O
,	NN	O	O
the	NN	O	O
GTN	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
headache	NN	O	B-Disease
gradually	NN	O	O
disappeared	NN	O	O
,	NN	O	O
whereas	NN	O	O
in	NN	O	O
migraineurs	NN	O	B-Disease
peak	NN	O	O
headache	NN	O	B-Disease
intensity	NN	O	O
occurred	NN	O	O
at	NN	O	O
a	NN	O	O
mean	NN	O	O
time	NN	O	O
of	NN	O	O
240	NN	O	O
min	NN	O	O
post	NN	O	O
-	NN	O	O
infusion	NN	O	O
.	NN	O	O

At	NN	O	O
this	NN	O	O
time	NN	O	O
the	NN	O	O
induced	NN	O	O
headache	NN	O	B-Disease
in	NN	O	O
6	NN	O	O
of	NN	O	O
12	NN	O	O
migraineurs	NN	O	B-Disease
fulfilled	NN	O	O
the	NN	O	O
diagnostic	NN	O	O
criteria	NN	O	O
for	NN	O	O
migraine	NN	O	B-Disease
without	NN	O	I-Disease
aura	NN	O	I-Disease
of	NN	O	O
the	NN	O	O
International	NN	O	O
Headache	NN	O	B-Disease
Society	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
therefore	NN	O	O
suggest	NN	O	O
that	NN	O	O
NO	NN	O	B-Chemical
is	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
pain	NN	O	B-Disease
mechanisms	NN	O	O
of	NN	O	O
migraine	NN	O	B-Disease
with	NN	O	I-Disease
aura	NN	O	I-Disease
.	NN	O	O

Since	NN	O	O
cortical	NN	O	O
spreading	NN	O	O
depression	NN	O	B-Disease
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
liberate	NN	O	O
NO	NN	O	B-Chemical
in	NN	O	O
animals	NN	O	O
,	NN	O	O
this	NN	O	O
finding	NN	O	O
may	NN	O	O
help	NN	O	O
our	NN	O	O
understanding	NN	O	O
of	NN	O	O
the	NN	O	O
coupling	NN	O	O
between	NN	O	O
cortical	NN	O	O
spreading	NN	O	O
depression	NN	O	B-Disease
and	NN	O	O
headache	NN	O	B-Disease
in	NN	O	O
migraine	NN	O	B-Disease
with	NN	O	I-Disease
aura	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (9799166)

Stroke	NN	O	B-Disease
and	NN	O	O
cocaine	NN	O	B-Chemical
or	NN	O	O
amphetamine	NN	O	B-Chemical
use	NN	O	O
.	NN	O	O

The	NN	O	O
association	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
and	NN	O	O
amphetamine	NN	O	B-Chemical
use	NN	O	O
with	NN	O	O
hemorrhagic	NN	O	O
and	NN	O	O
ischemic	NN	O	B-Disease
stroke	NN	O	B-Disease
is	NN	O	O
based	NN	O	O
almost	NN	O	O
solely	NN	O	O
on	NN	O	O
data	NN	O	O
from	NN	O	O
case	NN	O	O
series	NN	O	O
.	NN	O	O

The	NN	O	O
limited	NN	O	O
number	NN	O	O
of	NN	O	O
epidemiologic	NN	O	O
studies	NN	O	O
of	NN	O	O
stroke	NN	O	B-Disease
and	NN	O	O
use	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
and	NN	O	O
/	NN	O	O
or	NN	O	O
amphetamine	NN	O	B-Chemical
have	NN	O	O
been	NN	O	O
done	NN	O	O
in	NN	O	O
settings	NN	O	O
that	NN	O	O
serve	NN	O	O
mostly	NN	O	O
the	NN	O	O
poor	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
minorities	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
the	NN	O	O
defined	NN	O	O
population	NN	O	O
comprising	NN	O	O
members	NN	O	O
of	NN	O	O
Kaiser	NN	O	O
Permanente	NN	O	O
of	NN	O	O
Northern	NN	O	O
and	NN	O	O
Southern	NN	O	O
California	NN	O	O
.	NN	O	O

We	NN	O	O
attempted	NN	O	O
to	NN	O	O
identify	NN	O	O
all	NN	O	O
incident	NN	O	O
strokes	NN	O	B-Disease
in	NN	O	O
women	NN	O	O
ages	NN	O	O
15	NN	O	O
-	NN	O	O
44	NN	O	O
years	NN	O	O
during	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
year	NN	O	O
period	NN	O	O
using	NN	O	O
hospital	NN	O	O
admission	NN	O	O
and	NN	O	O
discharge	NN	O	O
records	NN	O	O
,	NN	O	O
emergency	NN	O	O
department	NN	O	O
logs	NN	O	O
,	NN	O	O
and	NN	O	O
payment	NN	O	O
requests	NN	O	O
for	NN	O	O
out	NN	O	O
-	NN	O	O
of	NN	O	O
-	NN	O	O
plan	NN	O	O
hospitalizations	NN	O	O
.	NN	O	O

We	NN	O	O
selected	NN	O	O
controls	NN	O	O
,	NN	O	O
matched	NN	O	O
on	NN	O	O
age	NN	O	O
and	NN	O	O
facility	NN	O	O
of	NN	O	O
usual	NN	O	O
care	NN	O	O
,	NN	O	O
at	NN	O	O
random	NN	O	O
from	NN	O	O
healthy	NN	O	O
members	NN	O	O
of	NN	O	O
the	NN	O	O
health	NN	O	O
plan	NN	O	O
.	NN	O	O

We	NN	O	O
obtained	NN	O	O
information	NN	O	O
in	NN	O	O
face	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
face	NN	O	O
interviews	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
347	NN	O	O
confirmed	NN	O	O
stroke	NN	O	B-Disease
cases	NN	O	O
and	NN	O	O
1	NN	O	O
,	NN	O	O
021	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
univariate	NN	O	O
matched	NN	O	O
odds	NN	O	O
ratio	NN	O	O
for	NN	O	O
stroke	NN	O	B-Disease
in	NN	O	O
women	NN	O	O
who	NN	O	O
admitted	NN	O	O
to	NN	O	O
using	NN	O	O
cocaine	NN	O	B-Chemical
and	NN	O	O
/	NN	O	O
or	NN	O	O
amphetamine	NN	O	B-Chemical
was	NN	O	O
8.5	NN	O	O
(	NN	O	O
95%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
=	NN	O	O
3.6	NN	O	O
-	NN	O	O
20.0	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
further	NN	O	O
adjustment	NN	O	O
for	NN	O	O
potential	NN	O	O
confounders	NN	O	O
,	NN	O	O
the	NN	O	O
odds	NN	O	O
ratio	NN	O	O
in	NN	O	O
women	NN	O	O
who	NN	O	O
reported	NN	O	O
using	NN	O	O
cocaine	NN	O	B-Chemical
and	NN	O	O
/	NN	O	O
or	NN	O	O
amphetamine	NN	O	B-Chemical
was	NN	O	O
7.0	NN	O	O
(	NN	O	O
95%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
=	NN	O	O
2.8	NN	O	O
-	NN	O	O
17.9	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
use	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
and	NN	O	O
/	NN	O	O
or	NN	O	O
amphetamine	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
strong	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	NN	O	O
stroke	NN	O	B-Disease
in	NN	O	O
this	NN	O	O
socioeconomically	NN	O	O
heterogeneous	NN	O	O
,	NN	O	O
insured	NN	O	O
urban	NN	O	O
population	NN	O	O
.	NN	O	O


-DOCSTART- (9672273)

Prevention	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
with	NN	O	O
tamoxifen	NN	O	B-Chemical
:	NN	O	O
preliminary	NN	O	O
findings	NN	O	O
from	NN	O	O
the	NN	O	O
Italian	NN	O	O
randomised	NN	O	O
trial	NN	O	O
among	NN	O	O
hysterectomised	NN	O	O
women	NN	O	O
.	NN	O	O

Italian	NN	O	O
Tamoxifen	NN	O	B-Chemical
Prevention	NN	O	O
Study	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Tamoxifen	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
candidate	NN	O	O
chemopreventive	NN	O	O
agent	NN	O	O
in	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
,	NN	O	O
although	NN	O	O
the	NN	O	O
drug	NN	O	O
may	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
endometrial	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

Therefore	NN	O	O
we	NN	O	O
did	NN	O	O
a	NN	O	O
trial	NN	O	O
in	NN	O	O
hysterectomised	NN	O	O
women	NN	O	O
of	NN	O	O
tamoxifen	NN	O	B-Chemical
as	NN	O	O
a	NN	O	O
chemopreventive	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
In	NN	O	O
October	NN	O	O
,	NN	O	O
1992	NN	O	O
,	NN	O	O
we	NN	O	O
started	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
randomised	NN	O	O
trial	NN	O	O
of	NN	O	O
tamoxifen	NN	O	B-Chemical
in	NN	O	O
women	NN	O	O
(	NN	O	O
mainly	NN	O	O
in	NN	O	O
Italy	NN	O	O
)	NN	O	O
who	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
and	NN	O	O
who	NN	O	O
had	NN	O	O
had	NN	O	O
a	NN	O	O
hysterectomy	NN	O	O
.	NN	O	O

Women	NN	O	O
were	NN	O	O
randomised	NN	O	O
to	NN	O	O
receive	NN	O	O
tamoxifen	NN	O	B-Chemical
20	NN	O	O
mg	NN	O	O
per	NN	O	O
day	NN	O	O
or	NN	O	O
placebo	NN	O	O
,	NN	O	O
both	NN	O	O
orally	NN	O	O
for	NN	O	O
5	NN	O	O
years	NN	O	O
.	NN	O	O

The	NN	O	O
original	NN	O	O
plan	NN	O	O
was	NN	O	O
to	NN	O	O
follow	NN	O	O
the	NN	O	O
intervention	NN	O	O
phase	NN	O	O
by	NN	O	O
5	NN	O	O
years	NN	O	O
'	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

In	NN	O	O
June	NN	O	O
,	NN	O	O
1997	NN	O	O
,	NN	O	O
the	NN	O	O
trialists	NN	O	O
and	NN	O	O
the	NN	O	O
data	NN	O	O
-	NN	O	O
monitoring	NN	O	O
committee	NN	O	O
decided	NN	O	O
to	NN	O	O
end	NN	O	O
recruitment	NN	O	O
primarily	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
women	NN	O	O
dropping	NN	O	O
out	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Recruitment	NN	O	O
ended	NN	O	O
on	NN	O	O
July	NN	O	O
11	NN	O	O
,	NN	O	O
1997	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
study	NN	O	O
will	NN	O	O
continue	NN	O	O
as	NN	O	O
planned	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
endpoints	NN	O	O
are	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
and	NN	O	O
deaths	NN	O	O
from	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
preliminary	NN	O	O
interim	NN	O	O
analysis	NN	O	O
is	NN	O	O
based	NN	O	O
on	NN	O	O
intention	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
treat	NN	O	O
.	NN	O	O

FINDINGS	NN	O	O
:	NN	O	O
5408	NN	O	O
women	NN	O	O
were	NN	O	O
randomised	NN	O	O
;	NN	O	O
participating	NN	O	O
women	NN	O	O
have	NN	O	O
a	NN	O	O
median	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
46	NN	O	O
months	NN	O	O
for	NN	O	O
major	NN	O	O
endpoints	NN	O	O
.	NN	O	O

41	NN	O	O
cases	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
occurred	NN	O	O
so	NN	O	O
far	NN	O	O
;	NN	O	O
there	NN	O	O
have	NN	O	O
been	NN	O	O
no	NN	O	O
deaths	NN	O	O
from	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

There	NN	O	O
is	NN	O	O
no	NN	O	O
difference	NN	O	O
in	NN	O	O
breast	NN	O	B-Disease
-	NN	O	I-Disease
cancer	NN	O	I-Disease
frequency	NN	O	O
between	NN	O	O
the	NN	O	O
placebo	NN	O	O
(	NN	O	O
22	NN	O	O
cases	NN	O	O
)	NN	O	O
and	NN	O	O
tamoxifen	NN	O	B-Chemical
(	NN	O	O
19	NN	O	O
)	NN	O	O
arms	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
reduction	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
among	NN	O	O
women	NN	O	O
receiving	NN	O	O
tamoxifen	NN	O	B-Chemical
who	NN	O	O
also	NN	O	O
used	NN	O	O
hormone	NN	O	O
-	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
during	NN	O	O
the	NN	O	O
trial	NN	O	O
:	NN	O	O
among	NN	O	O
390	NN	O	O
women	NN	O	O
on	NN	O	O
such	NN	O	O
therapy	NN	O	O
and	NN	O	O
allocated	NN	O	O
to	NN	O	O
placebo	NN	O	O
,	NN	O	O
we	NN	O	O
found	NN	O	O
eight	NN	O	O
cases	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
compared	NN	O	O
with	NN	O	O
one	NN	O	O
case	NN	O	O
among	NN	O	O
362	NN	O	O
women	NN	O	O
allocated	NN	O	O
to	NN	O	O
tamoxifen	NN	O	B-Chemical
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significantly	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
vascular	NN	O	B-Disease
events	NN	O	I-Disease
and	NN	O	O
hypertriglyceridaemia	NN	O	B-Disease
among	NN	O	O
women	NN	O	O
on	NN	O	O
tamoxifen	NN	O	B-Chemical
.	NN	O	O

INTERPRETATION	NN	O	O
:	NN	O	O
Although	NN	O	O
this	NN	O	O
preliminary	NN	O	O
analysis	NN	O	O
has	NN	O	O
low	NN	O	O
power	NN	O	O
,	NN	O	O
in	NN	O	O
this	NN	O	O
cohort	NN	O	O
of	NN	O	O
women	NN	O	O
at	NN	O	O
low	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
normal	NN	O	O
risk	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
,	NN	O	O
the	NN	O	O
postulated	NN	O	O
protective	NN	O	O
effects	NN	O	O
of	NN	O	O
tamoxifen	NN	O	B-Chemical
are	NN	O	O
not	NN	O	O
yet	NN	O	O
apparent	NN	O	O
.	NN	O	O

Women	NN	O	O
using	NN	O	O
hormone	NN	O	O
-	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
appear	NN	O	O
to	NN	O	O
have	NN	O	O
benefited	NN	O	O
from	NN	O	O
use	NN	O	O
of	NN	O	O
tamoxifen	NN	O	B-Chemical
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
deaths	NN	O	O
from	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
recorded	NN	O	O
in	NN	O	O
women	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
essential	NN	O	O
to	NN	O	O
continue	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
to	NN	O	O
quantify	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
risks	NN	O	O
and	NN	O	O
benefits	NN	O	O
of	NN	O	O
tamoxifen	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O


-DOCSTART- (8854309)

A	NN	O	O
measure	NN	O	O
of	NN	O	O
pupillary	NN	O	B-Disease
oscillation	NN	O	I-Disease
as	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
paranoia	NN	O	B-Disease
.	NN	O	O

Cocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
paranoia	NN	O	B-Disease
(	NN	O	O
CIP	NN	O	B-Disease
)	NN	O	O
remains	NN	O	O
an	NN	O	O
important	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
model	NN	O	O
of	NN	O	O
idiopathic	NN	O	O
paranoia	NN	O	B-Disease
for	NN	O	O
which	NN	O	O
no	NN	O	O
psychophysiologic	NN	O	O
marker	NN	O	O
has	NN	O	O
yet	NN	O	O
emerged	NN	O	O
.	NN	O	O

Measures	NN	O	O
of	NN	O	O
pupillary	NN	O	B-Disease
oscillation	NN	O	I-Disease
were	NN	O	O
able	NN	O	O
to	NN	O	O
significantly	NN	O	O
distinguish	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
abstinent	NN	O	O
crack	NN	O	B-Chemical
cocaine	NN	O	I-Chemical
abusers	NN	O	O
endorsing	NN	O	O
past	NN	O	O
CIP	NN	O	B-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
32	NN	O	O
)	NN	O	O
from	NN	O	O
another	NN	O	O
group	NN	O	O
of	NN	O	O
crack	NN	O	B-Chemical
addicts	NN	O	O
who	NN	O	O
denied	NN	O	O
past	NN	O	O
CIP	NN	O	B-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
29	NN	O	O
)	NN	O	O
.	NN	O	O


-DOCSTART- (8473723)

Seizures	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
combined	NN	O	O
levomepromazine	NN	O	B-Chemical
-	NN	O	O
fluvoxamine	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
combined	NN	O	O
levomepromazine	NN	O	B-Chemical
-	NN	O	O
fluvoxamine	NN	O	B-Chemical
treatment	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

It	NN	O	O
seems	NN	O	O
that	NN	O	O
combined	NN	O	O
treatment	NN	O	O
of	NN	O	O
fluvoxamine	NN	O	B-Chemical
with	NN	O	O
phenothiazines	NN	O	B-Chemical
may	NN	O	O
possess	NN	O	O
proconvulsive	NN	O	O
activity	NN	O	O
.	NN	O	O


-DOCSTART- (6674249)

Why	NN	O	O
may	NN	O	O
epsilon	NN	O	B-Chemical
-	NN	O	I-Chemical
aminocaproic	NN	O	I-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
EACA	NN	O	B-Chemical
)	NN	O	O
induce	NN	O	O
myopathy	NN	O	B-Disease
in	NN	O	O
man?	NN	O	O
Report	NN	O	O
of	NN	O	O
a	NN	O	O
case	NN	O	O
and	NN	O	O
literature	NN	O	O
review	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
necrotizing	NN	O	B-Disease
myopathy	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
a	NN	O	O
short	NN	O	O
epsilon	NN	O	B-Chemical
-	NN	O	I-Chemical
aminocaproic	NN	O	I-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
EACA	NN	O	B-Chemical
)	NN	O	O
treatment	NN	O	O
in	NN	O	O
a	NN	O	O
72	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
patient	NN	O	O
with	NN	O	O
subarachnoid	NN	O	B-Disease
haemorrhage	NN	O	I-Disease
(	NN	O	O
SAH	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
described	NN	O	O
.	NN	O	O

Pathogenetic	NN	O	O
hypotheses	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O


-DOCSTART- (6150641)

Comparison	NN	O	O
of	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
ranitidine	NN	O	B-Chemical
and	NN	O	O
cimetidine	NN	O	B-Chemical
in	NN	O	O
inhibiting	NN	O	O
acid	NN	O	O
secretion	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
gastric	NN	O	O
hypersecretory	NN	O	O
states	NN	O	O
.	NN	O	O

The	NN	O	O
H2	NN	O	O
-	NN	O	O
histamine	NN	O	B-Chemical
receptor	NN	O	O
antagonists	NN	O	O
ranitidine	NN	O	B-Chemical
and	NN	O	O
cimetidine	NN	O	B-Chemical
were	NN	O	O
compared	NN	O	O
for	NN	O	O
their	NN	O	O
abilities	NN	O	O
to	NN	O	O
control	NN	O	O
gastric	NN	O	O
acid	NN	O	O
hypersecretion	NN	O	O
on	NN	O	O
a	NN	O	O
short	NN	O	O
-	NN	O	O
and	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
basis	NN	O	O
in	NN	O	O
22	NN	O	O
patients	NN	O	O
with	NN	O	O
gastric	NN	O	O
acid	NN	O	O
hypersecretory	NN	O	O
states	NN	O	O
.	NN	O	O

Nineteen	NN	O	O
patients	NN	O	O
had	NN	O	O
Zollinger	NN	O	B-Disease
-	NN	O	I-Disease
Ellison	NN	O	I-Disease
syndrome	NN	O	I-Disease
,	NN	O	O
one	NN	O	O
patient	NN	O	O
had	NN	O	O
systemic	NN	O	B-Disease
mastocytosis	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
two	NN	O	O
patients	NN	O	O
had	NN	O	O
idiopathic	NN	O	O
hypersecretion	NN	O	O
.	NN	O	O

The	NN	O	O
rates	NN	O	O
of	NN	O	O
onset	NN	O	O
of	NN	O	O
the	NN	O	O
action	NN	O	O
of	NN	O	O
cimetidine	NN	O	B-Chemical
and	NN	O	O
ranitidine	NN	O	B-Chemical
were	NN	O	O
the	NN	O	O
same	NN	O	O
.	NN	O	O

The	NN	O	O
actions	NN	O	O
of	NN	O	O
both	NN	O	O
drugs	NN	O	O
were	NN	O	O
increased	NN	O	O
by	NN	O	O
anticholinergic	NN	O	O
agents	NN	O	O
,	NN	O	O
and	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
close	NN	O	O
correlation	NN	O	O
between	NN	O	O
the	NN	O	O
daily	NN	O	O
maintenance	NN	O	O
dose	NN	O	O
of	NN	O	O
each	NN	O	O
drug	NN	O	O
needed	NN	O	O
to	NN	O	O
control	NN	O	O
acid	NN	O	O
secretion	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
ranitidine	NN	O	B-Chemical
was	NN	O	O
threefold	NN	O	O
more	NN	O	O
potent	NN	O	O
than	NN	O	O
cimetidine	NN	O	B-Chemical
both	NN	O	O
in	NN	O	O
acute	NN	O	O
inhibition	NN	O	O
studies	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
median	NN	O	O
maintenance	NN	O	O
dose	NN	O	O
needed	NN	O	O
(	NN	O	O
1.2	NN	O	O
g	NN	O	O
per	NN	O	O
day	NN	O	O
for	NN	O	O
ranitidine	NN	O	B-Chemical
and	NN	O	O
3.6	NN	O	O
g	NN	O	O
per	NN	O	O
day	NN	O	O
for	NN	O	O
cimetidine	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

Sixty	NN	O	O
percent	NN	O	O
of	NN	O	O
the	NN	O	O
males	NN	O	O
developed	NN	O	O
breast	NN	O	O
changes	NN	O	O
or	NN	O	O
impotence	NN	O	B-Disease
while	NN	O	O
taking	NN	O	O
cimetidine	NN	O	B-Chemical
and	NN	O	O
in	NN	O	O
all	NN	O	O
cases	NN	O	O
these	NN	O	O
changes	NN	O	O
disappeared	NN	O	O
when	NN	O	O
cimetidine	NN	O	B-Chemical
was	NN	O	O
replaced	NN	O	O
by	NN	O	O
ranitidine	NN	O	B-Chemical
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
cimetidine	NN	O	B-Chemical
(	NN	O	O
one	NN	O	O
to	NN	O	O
60	NN	O	O
months	NN	O	O
;	NN	O	O
median	NN	O	O
,	NN	O	O
11	NN	O	O
months	NN	O	O
)	NN	O	O
or	NN	O	O
ranitidine	NN	O	B-Chemical
(	NN	O	O
two	NN	O	O
to	NN	O	O
31	NN	O	O
months	NN	O	O
;	NN	O	O
median	NN	O	O
,	NN	O	O
14	NN	O	O
months	NN	O	O
)	NN	O	O
was	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
hepatic	NN	O	B-Disease
or	NN	O	I-Disease
hematologic	NN	O	I-Disease
toxicity	NN	O	I-Disease
or	NN	O	O
alterations	NN	O	O
of	NN	O	O
serum	NN	O	O
gastrin	NN	O	O
concentrations	NN	O	O
,	NN	O	O
but	NN	O	O
ranitidine	NN	O	B-Chemical
therapy	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
significantly	NN	O	O
lower	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
level	NN	O	O
than	NN	O	O
seen	NN	O	O
with	NN	O	O
cimetidine	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
both	NN	O	O
drugs	NN	O	O
can	NN	O	O
adequately	NN	O	O
inhibit	NN	O	O
acid	NN	O	O
secretion	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
gastric	NN	O	O
hypersecretory	NN	O	O
states	NN	O	O
.	NN	O	O

Both	NN	O	O
are	NN	O	O
safe	NN	O	O
at	NN	O	O
high	NN	O	O
doses	NN	O	O
,	NN	O	O
but	NN	O	O
ranitidine	NN	O	B-Chemical
is	NN	O	O
threefold	NN	O	O
more	NN	O	O
potent	NN	O	O
and	NN	O	O
does	NN	O	O
not	NN	O	O
cause	NN	O	O
the	NN	O	O
antiandrogen	NN	O	O
side	NN	O	O
effects	NN	O	O
frequently	NN	O	O
seen	NN	O	O
with	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
cimetidine	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (3670965)

A	NN	O	O
catch	NN	O	O
in	NN	O	O
the	NN	O	O
Reye	NN	O	B-Disease
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
six	NN	O	O
cases	NN	O	O
of	NN	O	O
Reye	NN	O	B-Disease
syndrome	NN	O	I-Disease
from	NN	O	O
The	NN	O	O
Children	NN	O	O
'	NN	O	O
s	NN	O	O
Hospital	NN	O	O
,	NN	O	O
Camperdown	NN	O	O
,	NN	O	O
Australia	NN	O	O
,	NN	O	O
occurring	NN	O	O
between	NN	O	O
1973	NN	O	O
and	NN	O	O
1982	NN	O	O
were	NN	O	O
reviewed	NN	O	O
.	NN	O	O

Of	NN	O	O
these	NN	O	O
,	NN	O	O
20	NN	O	O
cases	NN	O	O
met	NN	O	O
the	NN	O	O
US	NN	O	O
Public	NN	O	O
Health	NN	O	O
Service	NN	O	O
Centers	NN	O	O
for	NN	O	O
Disease	NN	O	O
Control	NN	O	O
criteria	NN	O	O
for	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
Reye	NN	O	B-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Aspirin	NN	O	B-Chemical
or	NN	O	O
salicylate	NN	O	B-Chemical
ingestion	NN	O	O
had	NN	O	O
occurred	NN	O	O
in	NN	O	O
only	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
20	NN	O	O
cases	NN	O	O
(	NN	O	O
5%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
paracetamol	NN	O	B-Chemical
(	NN	O	O
acetaminophen	NN	O	B-Chemical
)	NN	O	O
had	NN	O	O
been	NN	O	O
administered	NN	O	O
in	NN	O	O
only	NN	O	O
six	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
(	NN	O	O
30%	NN	O	O
)	NN	O	O
.	NN	O	O

Pathologic	NN	O	O
confirmation	NN	O	O
of	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
Reye	NN	O	B-Disease
syndrome	NN	O	I-Disease
was	NN	O	O
accomplished	NN	O	O
in	NN	O	O
90%	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
Reye	NN	O	B-Disease
syndrome	NN	O	I-Disease
in	NN	O	O
New	NN	O	O
South	NN	O	O
Wales	NN	O	O
,	NN	O	O
Australia	NN	O	O
,	NN	O	O
is	NN	O	O
estimated	NN	O	O
from	NN	O	O
this	NN	O	O
study	NN	O	O
to	NN	O	O
be	NN	O	O
approximately	NN	O	O
nine	NN	O	O
cases	NN	O	O
per	NN	O	O
1	NN	O	O
million	NN	O	O
children	NN	O	O
compared	NN	O	O
with	NN	O	O
recent	NN	O	O
US	NN	O	O
data	NN	O	O
of	NN	O	O
ten	NN	O	O
to	NN	O	O
20	NN	O	O
cases	NN	O	O
per	NN	O	O
1	NN	O	O
million	NN	O	O
children	NN	O	O
and	NN	O	O
three	NN	O	O
to	NN	O	O
seven	NN	O	O
cases	NN	O	O
per	NN	O	O
1	NN	O	O
million	NN	O	O
children	NN	O	O
in	NN	O	O
Great	NN	O	O
Britain	NN	O	O
.	NN	O	O

The	NN	O	O
mortality	NN	O	O
for	NN	O	O
these	NN	O	O
Reye	NN	O	B-Disease
syndrome	NN	O	I-Disease
cases	NN	O	O
in	NN	O	O
Australia	NN	O	O
was	NN	O	O
45%	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
a	NN	O	O
32%	NN	O	O
case	NN	O	O
-	NN	O	O
fatality	NN	O	O
rate	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
.	NN	O	O

In	NN	O	O
Australia	NN	O	O
,	NN	O	O
the	NN	O	O
pediatric	NN	O	O
usage	NN	O	O
of	NN	O	O
aspirin	NN	O	B-Chemical
has	NN	O	O
been	NN	O	O
extremely	NN	O	O
low	NN	O	O
for	NN	O	O
the	NN	O	O
past	NN	O	O
25	NN	O	O
years	NN	O	O
(	NN	O	O
less	NN	O	O
than	NN	O	O
1%	NN	O	O
of	NN	O	O
total	NN	O	O
dosage	NN	O	O
units	NN	O	O
sold	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
paracetamol	NN	O	B-Chemical
(	NN	O	O
acetaminophen	NN	O	B-Chemical
)	NN	O	O
dominating	NN	O	O
the	NN	O	O
pediatric	NN	O	O
analgesic	NN	O	O
and	NN	O	O
antipyretic	NN	O	O
market	NN	O	O
.	NN	O	O

Reye	NN	O	B-Disease
syndrome	NN	O	I-Disease
may	NN	O	O
be	NN	O	O
disappearing	NN	O	O
from	NN	O	O
Australia	NN	O	O
despite	NN	O	O
a	NN	O	O
total	NN	O	O
lack	NN	O	O
of	NN	O	O
association	NN	O	O
with	NN	O	O
salicylates	NN	O	B-Chemical
or	NN	O	O
aspirin	NN	O	B-Chemical
ingestion	NN	O	O
,	NN	O	O
since	NN	O	O
there	NN	O	O
were	NN	O	O
no	NN	O	O
cases	NN	O	O
found	NN	O	O
at	NN	O	O
The	NN	O	O
Children	NN	O	O
'	NN	O	O
s	NN	O	O
Hospital	NN	O	O
in	NN	O	O
1983	NN	O	O
,	NN	O	O
1984	NN	O	O
,	NN	O	O
or	NN	O	O
1985	NN	O	O
.	NN	O	O


-DOCSTART- (3300918)

St	NN	O	B-Disease
.	NN	O	I-Disease
Anthony	NN	O	I-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
fire	NN	O	I-Disease
,	NN	O	O
then	NN	O	O
and	NN	O	O
now	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
and	NN	O	O
historical	NN	O	O
review	NN	O	O
.	NN	O	O

A	NN	O	O
rare	NN	O	O
case	NN	O	O
of	NN	O	O
morbid	NN	O	O
vasospasm	NN	O	B-Disease
,	NN	O	O
together	NN	O	O
with	NN	O	O
striking	NN	O	O
angiographic	NN	O	O
findings	NN	O	O
,	NN	O	O
is	NN	O	O
described	NN	O	O
secondary	NN	O	O
to	NN	O	O
the	NN	O	O
ingestion	NN	O	O
of	NN	O	O
methysergide	NN	O	B-Chemical
by	NN	O	O
a	NN	O	O
48	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
.	NN	O	O

A	NN	O	O
brief	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
on	NN	O	O
similar	NN	O	O
cases	NN	O	O
is	NN	O	O
presented	NN	O	O
.	NN	O	O

A	NN	O	O
discussion	NN	O	O
of	NN	O	O
the	NN	O	O
history	NN	O	O
of	NN	O	O
ergot	NN	O	B-Chemical
includes	NN	O	O
its	NN	O	O
original	NN	O	O
discovery	NN	O	O
,	NN	O	O
the	NN	O	O
epidemics	NN	O	O
of	NN	O	O
gangrene	NN	O	B-Disease
that	NN	O	O
it	NN	O	O
has	NN	O	O
caused	NN	O	O
through	NN	O	O
the	NN	O	O
ages	NN	O	O
and	NN	O	O
its	NN	O	O
past	NN	O	O
and	NN	O	O
present	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
migraine	NN	O	B-Disease
headache	NN	O	I-Disease
.	NN	O	O

Despite	NN	O	O
the	NN	O	O
advent	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
channel	NN	O	O
blockers	NN	O	O
and	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
antagonists	NN	O	O
,	NN	O	O
ergot	NN	O	B-Chemical
preparations	NN	O	O
continue	NN	O	O
to	NN	O	O
play	NN	O	O
a	NN	O	O
major	NN	O	O
role	NN	O	O
in	NN	O	O
migraine	NN	O	B-Disease
therapy	NN	O	O
,	NN	O	O
so	NN	O	O
that	NN	O	O
the	NN	O	O
danger	NN	O	O
of	NN	O	O
St	NN	O	B-Disease
.	NN	O	I-Disease
Anthony	NN	O	I-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
fire	NN	O	I-Disease
persists	NN	O	O
.	NN	O	O


-DOCSTART- (2826064)

Beta	NN	O	O
-	NN	O	O
2	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
-	NN	O	O
mediated	NN	O	O
hypokalemia	NN	O	B-Disease
and	NN	O	O
its	NN	O	O
abolishment	NN	O	O
by	NN	O	O
oxprenolol	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
time	NN	O	O
course	NN	O	O
and	NN	O	O
concentration	NN	O	O
-	NN	O	O
effect	NN	O	O
relationship	NN	O	O
of	NN	O	O
terbutaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypokalemia	NN	O	B-Disease
was	NN	O	O
studied	NN	O	O
,	NN	O	O
using	NN	O	O
computer	NN	O	O
-	NN	O	O
aided	NN	O	O
pharmacokinetic	NN	O	O
-	NN	O	O
dynamic	NN	O	O
modeling	NN	O	O
.	NN	O	O

Subsequently	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
oxprenolol	NN	O	B-Chemical
in	NN	O	O
antagonizing	NN	O	O
such	NN	O	O
hypokalemia	NN	O	B-Disease
,	NN	O	O
together	NN	O	O
with	NN	O	O
the	NN	O	O
pharmacokinetic	NN	O	O
interaction	NN	O	O
between	NN	O	O
both	NN	O	O
drugs	NN	O	O
.	NN	O	O

Six	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
were	NN	O	O
given	NN	O	O
a	NN	O	O
0.5	NN	O	O
mg	NN	O	O
subcutaneous	NN	O	O
dose	NN	O	O
of	NN	O	O
terbutaline	NN	O	B-Chemical
on	NN	O	O
two	NN	O	O
occasions	NN	O	O
:	NN	O	O
1	NN	O	O
hour	NN	O	O
after	NN	O	O
oral	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
placebo	NN	O	O
and	NN	O	O
1	NN	O	O
hour	NN	O	O
after	NN	O	O
80	NN	O	O
mg	NN	O	O
oxprenolol	NN	O	B-Chemical
orally	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
7	NN	O	O
-	NN	O	O
hour	NN	O	O
period	NN	O	O
after	NN	O	O
terbutaline	NN	O	B-Chemical
administration	NN	O	O
,	NN	O	O
plasma	NN	O	O
samples	NN	O	O
were	NN	O	O
taken	NN	O	O
for	NN	O	O
determination	NN	O	O
of	NN	O	O
plasma	NN	O	O
potassium	NN	O	B-Chemical
levels	NN	O	O
and	NN	O	O
drug	NN	O	O
concentrations	NN	O	O
.	NN	O	O

The	NN	O	O
sigmoid	NN	O	O
Emax	NN	O	O
model	NN	O	O
offered	NN	O	O
a	NN	O	O
good	NN	O	O
description	NN	O	O
of	NN	O	O
the	NN	O	O
relation	NN	O	O
between	NN	O	O
terbutaline	NN	O	B-Chemical
concentrations	NN	O	O
and	NN	O	O
potassium	NN	O	B-Chemical
effects	NN	O	O
.	NN	O	O

Oxprenolol	NN	O	B-Chemical
caused	NN	O	O
decreases	NN	O	O
of	NN	O	O
65%	NN	O	O
and	NN	O	O
56%	NN	O	O
of	NN	O	O
terbutaline	NN	O	B-Chemical
volume	NN	O	O
of	NN	O	O
distribution	NN	O	O
and	NN	O	O
clearance	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
and	NN	O	O
an	NN	O	O
increase	NN	O	O
of	NN	O	O
130%	NN	O	O
of	NN	O	O
its	NN	O	O
AUC	NN	O	O
.	NN	O	O

In	NN	O	O
spite	NN	O	O
of	NN	O	O
higher	NN	O	O
terbutaline	NN	O	B-Chemical
concentrations	NN	O	O
after	NN	O	O
oxprenolol	NN	O	B-Chemical
pretreatment	NN	O	O
,	NN	O	O
the	NN	O	O
hypokalemia	NN	O	B-Disease
was	NN	O	O
almost	NN	O	O
completely	NN	O	O
antagonized	NN	O	O
by	NN	O	O
the	NN	O	O
beta	NN	O	O
2	NN	O	O
-	NN	O	O
blocking	NN	O	O
action	NN	O	O
.	NN	O	O


-DOCSTART- (2422478)

Midline	NN	O	O
B3	NN	O	O
serotonin	NN	O	B-Chemical
nerves	NN	O	O
in	NN	O	O
rat	NN	O	O
medulla	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
hypotensive	NN	O	B-Disease
effect	NN	O	O
of	NN	O	O
methyldopa	NN	O	B-Chemical
.	NN	O	O

Previous	NN	O	O
experiments	NN	O	O
in	NN	O	O
this	NN	O	O
laboratory	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
microinjection	NN	O	O
of	NN	O	O
methyldopa	NN	O	B-Chemical
onto	NN	O	O
the	NN	O	O
ventrolateral	NN	O	O
cells	NN	O	O
of	NN	O	O
the	NN	O	O
B3	NN	O	O
serotonin	NN	O	B-Chemical
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
medulla	NN	O	O
elicits	NN	O	O
a	NN	O	O
hypotensive	NN	O	B-Disease
response	NN	O	O
mediated	NN	O	O
by	NN	O	O
a	NN	O	O
projection	NN	O	O
descending	NN	O	O
into	NN	O	O
the	NN	O	O
spinal	NN	O	O
cord	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
experiments	NN	O	O
were	NN	O	O
designed	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
midline	NN	O	O
cells	NN	O	O
of	NN	O	O
the	NN	O	O
B3	NN	O	O
serotonin	NN	O	B-Chemical
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
medulla	NN	O	O
,	NN	O	O
coinciding	NN	O	O
with	NN	O	O
the	NN	O	O
raphe	NN	O	O
magnus	NN	O	O
.	NN	O	O

In	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B-Disease
,	NN	O	O
stroke	NN	O	B-Disease
-	NN	O	O
prone	NN	O	O
rats	NN	O	O
,	NN	O	O
microinjection	NN	O	O
of	NN	O	O
methyldopa	NN	O	B-Chemical
into	NN	O	O
the	NN	O	O
area	NN	O	O
of	NN	O	O
the	NN	O	O
midline	NN	O	O
B3	NN	O	O
serotonin	NN	O	B-Chemical
cell	NN	O	O
group	NN	O	O
in	NN	O	O
the	NN	O	O
ventral	NN	O	O
medulla	NN	O	O
caused	NN	O	O
a	NN	O	O
potent	NN	O	O
hypotension	NN	O	B-Disease
of	NN	O	O
30	NN	O	O
-	NN	O	O
40	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
maximal	NN	O	O
2	NN	O	O
-	NN	O	O
3	NN	O	O
h	NN	O	O
after	NN	O	O
administration	NN	O	O
and	NN	O	O
was	NN	O	O
abolished	NN	O	O
by	NN	O	O
the	NN	O	O
serotonin	NN	O	B-Chemical
neurotoxin	NN	O	O
5	NN	O	B-Chemical
,	NN	O	I-Chemical
7	NN	O	I-Chemical
-	NN	O	I-Chemical
dihydroxytryptamine	NN	O	I-Chemical
(	NN	O	O
5	NN	O	B-Chemical
,	NN	O	I-Chemical
7	NN	O	I-Chemical
-	NN	O	I-Chemical
DHT	NN	O	I-Chemical
)	NN	O	O
injected	NN	O	O
intracerebroventricularly	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
intraspinal	NN	O	O
injection	NN	O	O
of	NN	O	O
5	NN	O	B-Chemical
,	NN	O	I-Chemical
7	NN	O	I-Chemical
-	NN	O	I-Chemical
DHT	NN	O	I-Chemical
to	NN	O	O
produce	NN	O	O
a	NN	O	O
more	NN	O	O
selective	NN	O	O
lesion	NN	O	O
of	NN	O	O
only	NN	O	O
descending	NN	O	O
serotonin	NN	O	B-Chemical
projections	NN	O	O
in	NN	O	O
the	NN	O	O
spinal	NN	O	O
cord	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
this	NN	O	O
hypotension	NN	O	B-Disease
.	NN	O	O

Further	NN	O	O
,	NN	O	O
5	NN	O	B-Chemical
,	NN	O	I-Chemical
7	NN	O	I-Chemical
-	NN	O	I-Chemical
DHT	NN	O	I-Chemical
lesion	NN	O	O
of	NN	O	O
serotonin	NN	O	B-Chemical
nerves	NN	O	O
travelling	NN	O	O
in	NN	O	O
the	NN	O	O
median	NN	O	O
forebrain	NN	O	O
bundle	NN	O	O
,	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
main	NN	O	O
ascending	NN	O	O
pathways	NN	O	O
from	NN	O	O
the	NN	O	O
B3	NN	O	O
serotonin	NN	O	B-Chemical
cells	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
affect	NN	O	O
the	NN	O	O
fall	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
midline	NN	O	O
B3	NN	O	O
serotonin	NN	O	B-Chemical
methyldopa	NN	O	B-Chemical
injection	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
therefore	NN	O	O
that	NN	O	O
,	NN	O	O
unlike	NN	O	O
the	NN	O	O
ventrolateral	NN	O	O
B3	NN	O	O
cells	NN	O	O
which	NN	O	O
mediate	NN	O	O
a	NN	O	O
methyldopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
via	NN	O	O
descending	NN	O	O
projections	NN	O	O
,	NN	O	O
the	NN	O	O
midline	NN	O	O
serotonin	NN	O	B-Chemical
B3	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
medulla	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
hypotensive	NN	O	B-Disease
action	NN	O	O
of	NN	O	O
methyldopa	NN	O	B-Chemical
,	NN	O	O
either	NN	O	O
by	NN	O	O
way	NN	O	O
of	NN	O	O
an	NN	O	O
ascending	NN	O	O
projection	NN	O	O
which	NN	O	O
does	NN	O	O
not	NN	O	O
pass	NN	O	O
through	NN	O	O
the	NN	O	O
median	NN	O	O
forebrain	NN	O	O
bundle	NN	O	O
,	NN	O	O
or	NN	O	O
through	NN	O	O
a	NN	O	O
projection	NN	O	O
restricted	NN	O	O
to	NN	O	O
the	NN	O	O
caudal	NN	O	O
brainstem	NN	O	O
.	NN	O	O


-DOCSTART- (1535072)

Yohimbine	NN	O	B-Chemical
treatment	NN	O	O
of	NN	O	O
sexual	NN	O	B-Disease
side	NN	O	I-Disease
effects	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
serotonin	NN	O	B-Chemical
reuptake	NN	O	O
blockers	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Preclinical	NN	O	O
and	NN	O	O
clinical	NN	O	O
studies	NN	O	O
suggest	NN	O	O
that	NN	O	O
yohimbine	NN	O	B-Chemical
facilitates	NN	O	O
sexual	NN	O	O
behavior	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
helpful	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
male	NN	O	B-Disease
impotence	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
single	NN	O	O
case	NN	O	O
report	NN	O	O
suggests	NN	O	O
that	NN	O	O
yohimbine	NN	O	B-Chemical
may	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
treat	NN	O	O
the	NN	O	O
sexual	NN	O	B-Disease
side	NN	O	I-Disease
effects	NN	O	I-Disease
of	NN	O	O
clomipramine	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
study	NN	O	O
evaluated	NN	O	O
yohimbine	NN	O	B-Chemical
as	NN	O	O
a	NN	O	O
treatment	NN	O	O
for	NN	O	O
the	NN	O	O
sexual	NN	O	B-Disease
side	NN	O	I-Disease
effects	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
serotonin	NN	O	B-Chemical
reuptake	NN	O	O
blockers	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
Six	NN	O	O
patients	NN	O	O
with	NN	O	O
either	NN	O	O
obsessive	NN	O	B-Disease
compulsive	NN	O	I-Disease
disorder	NN	O	I-Disease
,	NN	O	O
trichotillomania	NN	O	B-Disease
,	NN	O	O
anxiety	NN	O	B-Disease
,	NN	O	O
or	NN	O	O
affective	NN	O	B-Disease
disorders	NN	O	I-Disease
who	NN	O	O
suffered	NN	O	O
sexual	NN	O	B-Disease
side	NN	O	I-Disease
effects	NN	O	I-Disease
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
serotonin	NN	O	B-Chemical
reuptake	NN	O	O
blockers	NN	O	O
were	NN	O	O
given	NN	O	O
yohimbine	NN	O	B-Chemical
on	NN	O	O
a	NN	O	O
p.r.n	NN	O	O
.	NN	O	O

basis	NN	O	O
in	NN	O	O
an	NN	O	O
open	NN	O	O
clinical	NN	O	O
trial	NN	O	O
.	NN	O	O

Various	NN	O	O
doses	NN	O	O
of	NN	O	O
yohimbine	NN	O	B-Chemical
were	NN	O	O
used	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
ideal	NN	O	O
dose	NN	O	O
for	NN	O	O
each	NN	O	O
patient	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Five	NN	O	O
of	NN	O	O
the	NN	O	O
six	NN	O	O
patients	NN	O	O
experienced	NN	O	O
improved	NN	O	O
sexual	NN	O	O
functioning	NN	O	O
after	NN	O	O
taking	NN	O	O
yohimbine	NN	O	B-Chemical
.	NN	O	O

One	NN	O	O
patient	NN	O	O
who	NN	O	O
failed	NN	O	O
to	NN	O	O
comply	NN	O	O
with	NN	O	O
yohimbine	NN	O	B-Chemical
treatment	NN	O	O
had	NN	O	O
no	NN	O	O
therapeutic	NN	O	O
effects	NN	O	O
.	NN	O	O

Side	NN	O	O
effects	NN	O	O
of	NN	O	O
yohimbine	NN	O	B-Chemical
included	NN	O	O
excessive	NN	O	O
sweating	NN	O	O
,	NN	O	O
increased	NN	O	O
anxiety	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
a	NN	O	O
wound	NN	O	O
-	NN	O	O
up	NN	O	O
feeling	NN	O	O
in	NN	O	O
some	NN	O	O
patients	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
indicate	NN	O	O
that	NN	O	O
yohimbine	NN	O	B-Chemical
may	NN	O	O
be	NN	O	O
an	NN	O	O
effective	NN	O	O
treatment	NN	O	O
for	NN	O	O
the	NN	O	O
sexual	NN	O	B-Disease
side	NN	O	I-Disease
effects	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
serotonin	NN	O	B-Chemical
reuptake	NN	O	O
blockers	NN	O	O
.	NN	O	O

Future	NN	O	O
controlled	NN	O	O
studies	NN	O	O
are	NN	O	O
needed	NN	O	O
to	NN	O	O
further	NN	O	O
investigate	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
yohimbine	NN	O	B-Chemical
for	NN	O	O
this	NN	O	O
indication	NN	O	O
.	NN	O	O


-DOCSTART- (1504402)

Hypersensitivity	NN	O	B-Disease
immune	NN	O	O
reaction	NN	O	O
as	NN	O	O
a	NN	O	O
mechanism	NN	O	O
for	NN	O	O
dilevalol	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
hepatitis	NN	O	B-Disease
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
lymphocyte	NN	O	O
reactivity	NN	O	O
to	NN	O	O
dilevalol	NN	O	B-Chemical
and	NN	O	O
to	NN	O	O
serum	NN	O	O
containing	NN	O	O
putative	NN	O	O
ex	NN	O	O
vivo	NN	O	O
dilevalol	NN	O	B-Chemical
antigens	NN	O	O
or	NN	O	O
metabolites	NN	O	O
in	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
dilevalol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
liver	NN	O	B-Disease
injury	NN	O	I-Disease
.	NN	O	O

PATIENT	NN	O	O
:	NN	O	O
A	NN	O	O
58	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
a	NN	O	O
clinical	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
dilevalol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
liver	NN	O	B-Disease
injury	NN	O	I-Disease
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Peripheral	NN	O	O
blood	NN	O	O
mononuclear	NN	O	O
cells	NN	O	O
collected	NN	O	O
from	NN	O	O
the	NN	O	O
patient	NN	O	O
were	NN	O	O
cultured	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
a	NN	O	O
solution	NN	O	O
of	NN	O	O
dilevalol	NN	O	B-Chemical
and	NN	O	O
also	NN	O	O
with	NN	O	O
sera	NN	O	O
collected	NN	O	O
from	NN	O	O
a	NN	O	O
volunteer	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
dilevalol	NN	O	B-Chemical
intake	NN	O	O
.	NN	O	O

A	NN	O	O
similar	NN	O	O
protocol	NN	O	O
was	NN	O	O
performed	NN	O	O
with	NN	O	O
lymphocytes	NN	O	O
from	NN	O	O
a	NN	O	O
healthy	NN	O	O
subject	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
No	NN	O	O
lymphocyte	NN	O	O
proliferation	NN	O	O
was	NN	O	O
observed	NN	O	O
either	NN	O	O
in	NN	O	O
the	NN	O	O
patient	NN	O	O
or	NN	O	O
in	NN	O	O
the	NN	O	O
healthy	NN	O	O
volunteer	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
dilevalol	NN	O	B-Chemical
solutions	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
proliferative	NN	O	O
response	NN	O	O
to	NN	O	O
serum	NN	O	O
collected	NN	O	O
after	NN	O	O
dilevalol	NN	O	B-Chemical
intake	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
the	NN	O	O
patient	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
proliferative	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
serum	NN	O	O
collected	NN	O	O
before	NN	O	O
the	NN	O	O
drug	NN	O	O
intake	NN	O	O
.	NN	O	O

No	NN	O	O
reactivity	NN	O	O
was	NN	O	O
found	NN	O	O
when	NN	O	O
lymphocytes	NN	O	O
from	NN	O	O
the	NN	O	O
healthy	NN	O	O
subject	NN	O	O
were	NN	O	O
tested	NN	O	O
under	NN	O	O
similar	NN	O	O
conditions	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
methodology	NN	O	O
used	NN	O	O
allowed	NN	O	O
the	NN	O	O
detection	NN	O	O
of	NN	O	O
lymphocyte	NN	O	O
sensitization	NN	O	O
to	NN	O	O
sera	NN	O	O
containing	NN	O	O
ex	NN	O	O
vivo	NN	O	O
-	NN	O	O
prepared	NN	O	O
dilevalol	NN	O	B-Chemical
antigens	NN	O	O
,	NN	O	O
suggesting	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
an	NN	O	O
immunologic	NN	O	O
mechanism	NN	O	O
in	NN	O	O
dilevalol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
liver	NN	O	B-Disease
injury	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (19917396)

Reversible	NN	O	O
myocardial	NN	O	B-Disease
hypertrophy	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
tacrolimus	NN	O	B-Chemical
in	NN	O	O
a	NN	O	O
pediatric	NN	O	O
heart	NN	O	O
transplant	NN	O	O
recipient	NN	O	O
:	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

Tacrolimus	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
potent	NN	O	O
immunosuppressant	NN	O	O
that	NN	O	O
is	NN	O	O
frequently	NN	O	O
used	NN	O	O
in	NN	O	O
organ	NN	O	O
transplantation	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
adverse	NN	O	O
effects	NN	O	O
include	NN	O	O
cardiac	NN	O	B-Disease
toxicity	NN	O	I-Disease
.	NN	O	O

Herein	NN	O	O
we	NN	O	O
describe	NN	O	O
transient	NN	O	O
myocardial	NN	O	B-Disease
hypertrophy	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
tacrolimus	NN	O	B-Chemical
after	NN	O	O
heart	NN	O	O
transplantation	NN	O	O
.	NN	O	O

The	NN	O	O
hypertrophy	NN	O	B-Disease
caused	NN	O	O
no	NN	O	O
clinical	NN	O	O
symptoms	NN	O	O
but	NN	O	O
was	NN	O	O
noted	NN	O	O
because	NN	O	O
of	NN	O	O
elevation	NN	O	O
of	NN	O	O
plasma	NN	O	O
brain	NN	O	O
natriuretic	NN	O	O
peptide	NN	O	O
concentration	NN	O	O
and	NN	O	O
confirmed	NN	O	O
at	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

Initially	NN	O	O
,	NN	O	O
allograft	NN	O	O
rejection	NN	O	O
was	NN	O	O
feared	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
myocardial	NN	O	O
biopsy	NN	O	O
samples	NN	O	O
revealed	NN	O	O
only	NN	O	O
interstitial	NN	O	O
edema	NN	O	B-Disease
and	NN	O	O
mild	NN	O	O
myocardial	NN	O	B-Disease
hypertrophy	NN	O	I-Disease
;	NN	O	O
neither	NN	O	O
cellular	NN	O	O
nor	NN	O	O
humoral	NN	O	O
rejection	NN	O	O
was	NN	O	O
detected	NN	O	O
.	NN	O	O

The	NN	O	O
blood	NN	O	O
tacrolimus	NN	O	B-Chemical
concentration	NN	O	O
was	NN	O	O
higher	NN	O	O
than	NN	O	O
usual	NN	O	O
at	NN	O	O
that	NN	O	O
time	NN	O	O
;	NN	O	O
thus	NN	O	O
,	NN	O	O
tacrolimus	NN	O	B-Chemical
dosage	NN	O	O
was	NN	O	O
reduced	NN	O	O
.	NN	O	O

Myocardial	NN	O	B-Disease
hypertrophy	NN	O	I-Disease
completely	NN	O	O
resolved	NN	O	O
upon	NN	O	O
reducing	NN	O	O
the	NN	O	O
target	NN	O	O
concentration	NN	O	O
of	NN	O	O
tacrolimus	NN	O	B-Chemical
and	NN	O	O
did	NN	O	O
not	NN	O	O
recur	NN	O	O
,	NN	O	O
as	NN	O	O
confirmed	NN	O	O
at	NN	O	O
echocardiography	NN	O	O
and	NN	O	O
myocardial	NN	O	O
biopsy	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
we	NN	O	O
conclude	NN	O	O
that	NN	O	O
tacrolimus	NN	O	B-Chemical
induces	NN	O	O
reversible	NN	O	O
myocardial	NN	O	B-Disease
hypertrophy	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
patients	NN	O	O
receiving	NN	O	O
tacrolimus	NN	O	B-Chemical
therapy	NN	O	O
,	NN	O	O
blood	NN	O	O
concentration	NN	O	O
should	NN	O	O
be	NN	O	O
carefully	NN	O	O
controlled	NN	O	O
and	NN	O	O
extreme	NN	O	O
attention	NN	O	O
paid	NN	O	O
to	NN	O	O
cardiac	NN	O	O
involvement	NN	O	O
.	NN	O	O


-DOCSTART- (19234905)

Comparison	NN	O	O
of	NN	O	O
unilateral	NN	O	O
pallidotomy	NN	O	O
and	NN	O	O
subthalamotomy	NN	O	O
findings	NN	O	O
in	NN	O	O
advanced	NN	O	O
idiopathic	NN	O	B-Disease
Parkinson	NN	O	I-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
pilot	NN	O	O
study	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
stereotactic	NN	O	O
unilateral	NN	O	O
pallidotomy	NN	O	O
and	NN	O	O
subthalamotomy	NN	O	O
in	NN	O	O
advanced	NN	O	O
idiopathic	NN	O	B-Disease
Parkinson	NN	O	I-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
PD	NN	O	B-Disease
)	NN	O	O
refractory	NN	O	O
to	NN	O	O
medical	NN	O	O
treatment	NN	O	O
was	NN	O	O
designed	NN	O	O
.	NN	O	O

Ten	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
(	NN	O	O
mean	NN	O	O
age	NN	O	O
,	NN	O	O
58.4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6.8	NN	O	O
years	NN	O	O
;	NN	O	O
7	NN	O	O
men	NN	O	O
,	NN	O	O
3	NN	O	O
women	NN	O	O
)	NN	O	O
with	NN	O	O
similar	NN	O	O
characteristics	NN	O	O
at	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
disease	NN	O	O
(	NN	O	O
mean	NN	O	O
disease	NN	O	O
time	NN	O	O
,	NN	O	O
8.4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3.5	NN	O	O
years	NN	O	O
)	NN	O	O
,	NN	O	O
disabling	NN	O	O
motor	NN	O	O
fluctuations	NN	O	O
(	NN	O	O
Hoehn	NN	O	O
_	NN	O	O
Yahr	NN	O	O
stage	NN	O	O
3	NN	O	O
-	NN	O	O
5	NN	O	O
in	NN	O	O
off	NN	O	O
-	NN	O	O
drug	NN	O	O
phases	NN	O	O
)	NN	O	O
and	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
were	NN	O	O
selected	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
had	NN	O	O
bilateral	NN	O	O
symptoms	NN	O	O
and	NN	O	O
their	NN	O	O
levodopa	NN	O	B-Chemical
equivalent	NN	O	O
dosing	NN	O	O
were	NN	O	O
analysed	NN	O	O
.	NN	O	O

Six	NN	O	O
patients	NN	O	O
were	NN	O	O
operated	NN	O	O
on	NN	O	O
in	NN	O	O
the	NN	O	O
globus	NN	O	O
pallidus	NN	O	O
interna	NN	O	O
(	NN	O	O
GPi	NN	O	O
)	NN	O	O
and	NN	O	O
four	NN	O	O
in	NN	O	O
the	NN	O	O
subthalamic	NN	O	O
nucleus	NN	O	O
(	NN	O	O
STN	NN	O	O
)	NN	O	O
.	NN	O	O

Clinical	NN	O	O
evaluation	NN	O	O
included	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
the	NN	O	O
Unified	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
Disease	NN	O	I-Disease
Rating	NN	O	O
Scale	NN	O	O
(	NN	O	O
UPDRS	NN	O	O
)	NN	O	O
,	NN	O	O
Hoehn_Yahr	NN	O	O
score	NN	O	O
and	NN	O	O
Schwab	NN	O	O
England	NN	O	O
activities	NN	O	O
of	NN	O	O
daily	NN	O	O
living	NN	O	O
(	NN	O	O
ADL	NN	O	O
)	NN	O	O
score	NN	O	O
in	NN	O	O
'	NN	O	O
on	NN	O	O
'	NN	O	O
-	NN	O	O
and	NN	O	O
'	NN	O	O
off	NN	O	O
'	NN	O	O
-	NN	O	O
drug	NN	O	O
conditions	NN	O	O
before	NN	O	O
surgery	NN	O	O
and	NN	O	O
6	NN	O	O
months	NN	O	O
after	NN	O	O
surgery	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
statistically	NN	O	O
significant	NN	O	O
improvement	NN	O	O
in	NN	O	O
all	NN	O	O
contralateral	NN	O	O
major	NN	O	O
parkinsonian	NN	O	B-Disease
motor	NN	O	O
signs	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
followed	NN	O	O
for	NN	O	O
6	NN	O	O
months	NN	O	O
.	NN	O	O

Levodopa	NN	O	B-Chemical
equivalent	NN	O	O
daily	NN	O	O
intake	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
in	NN	O	O
the	NN	O	O
STN	NN	O	O
group	NN	O	O
.	NN	O	O

Changes	NN	O	O
in	NN	O	O
UPDRS	NN	O	O
,	NN	O	O
Hoehn	NN	O	O
_	NN	O	O
Yahr	NN	O	O
and	NN	O	O
Schwab	NN	O	O
England	NN	O	O
ADL	NN	O	O
scores	NN	O	O
were	NN	O	O
similar	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

Cognitive	NN	O	O
functions	NN	O	O
were	NN	O	O
unchanged	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

Complications	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
:	NN	O	O
one	NN	O	O
had	NN	O	O
a	NN	O	O
left	NN	O	O
homonymous	NN	O	B-Disease
hemianopsia	NN	O	I-Disease
after	NN	O	O
pallidotomy	NN	O	O
and	NN	O	O
another	NN	O	O
one	NN	O	O
developed	NN	O	O
left	NN	O	O
hemiballistic	NN	O	O
movements	NN	O	O
3	NN	O	O
days	NN	O	O
after	NN	O	O
subthalamotomy	NN	O	O
which	NN	O	O
partly	NN	O	O
improved	NN	O	O
within	NN	O	O
1	NN	O	O
month	NN	O	O
with	NN	O	O
Valproate	NN	O	B-Chemical
1000	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
.	NN	O	O

The	NN	O	O
findings	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
suggest	NN	O	O
that	NN	O	O
lesions	NN	O	O
of	NN	O	O
the	NN	O	O
unilateral	NN	O	O
STN	NN	O	O
and	NN	O	O
GPi	NN	O	O
are	NN	O	O
equally	NN	O	O
effective	NN	O	O
treatment	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
PD	NN	O	B-Disease
refractory	NN	O	O
to	NN	O	O
medical	NN	O	O
treatment	NN	O	O
.	NN	O	O


-DOCSTART- (18541230)

Protective	NN	O	O
effects	NN	O	O
of	NN	O	O
antithrombin	NN	O	O
on	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
nephrosis	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
antithrombin	NN	O	O
,	NN	O	O
a	NN	O	O
plasma	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
coagulation	NN	O	O
factors	NN	O	O
,	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
nephrosis	NN	O	B-Disease
,	NN	O	O
which	NN	O	O
is	NN	O	O
an	NN	O	O
experimental	NN	O	O
model	NN	O	O
of	NN	O	O
human	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Antithrombin	NN	O	O
(	NN	O	O
50	NN	O	O
or	NN	O	O
500	NN	O	O
IU	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
i.v.	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
rats	NN	O	O
once	NN	O	O
a	NN	O	O
day	NN	O	O
for	NN	O	O
10	NN	O	O
days	NN	O	O
immediately	NN	O	O
after	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
i.v.	NN	O	O
)	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
antithrombin	NN	O	O
attenuated	NN	O	O
the	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
hematological	NN	O	B-Disease
abnormalities	NN	O	I-Disease
.	NN	O	O

Puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
renal	NN	O	B-Disease
dysfunction	NN	O	I-Disease
and	NN	O	O
hyperlipidemia	NN	O	B-Disease
were	NN	O	O
also	NN	O	O
suppressed	NN	O	O
.	NN	O	O

Histopathological	NN	O	O
examination	NN	O	O
revealed	NN	O	O
severe	NN	O	O
renal	NN	O	B-Disease
damage	NN	O	I-Disease
such	NN	O	O
as	NN	O	O
proteinaceous	NN	O	O
casts	NN	O	O
in	NN	O	O
tubuli	NN	O	O
and	NN	O	O
tubular	NN	O	O
expansion	NN	O	O
in	NN	O	O
the	NN	O	O
kidney	NN	O	O
of	NN	O	O
control	NN	O	O
rats	NN	O	O
,	NN	O	O
while	NN	O	O
an	NN	O	O
improvement	NN	O	O
of	NN	O	O
the	NN	O	O
damage	NN	O	O
was	NN	O	O
seen	NN	O	O
in	NN	O	O
antithrombin	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
antithrombin	NN	O	O
treatment	NN	O	O
markedly	NN	O	O
suppressed	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
apoptosis	NN	O	O
of	NN	O	O
renal	NN	O	O
tubular	NN	O	O
epithelial	NN	O	O
cells	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
increases	NN	O	O
in	NN	O	O
renal	NN	O	O
cytokine	NN	O	O
content	NN	O	O
were	NN	O	O
also	NN	O	O
decreased	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
thrombin	NN	O	O
plays	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
antithrombin	NN	O	O
may	NN	O	O
be	NN	O	O
clinically	NN	O	O
effective	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (18177388)

Reverse	NN	O	O
or	NN	O	O
inverted	NN	O	O
left	NN	O	B-Disease
ventricular	NN	O	I-Disease
apical	NN	O	I-Disease
ballooning	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
reverse	NN	O	O
Takotsubo	NN	O	B-Disease
cardiomyopathy	NN	O	I-Disease
)	NN	O	O
in	NN	O	O
a	NN	O	O
young	NN	O	O
woman	NN	O	O
in	NN	O	O
the	NN	O	O
setting	NN	O	O
of	NN	O	O
amphetamine	NN	O	B-Chemical
use	NN	O	O
.	NN	O	O

Transient	NN	O	O
left	NN	O	B-Disease
ventricular	NN	O	I-Disease
apical	NN	O	I-Disease
ballooning	NN	O	I-Disease
syndrome	NN	O	I-Disease
was	NN	O	O
first	NN	O	O
described	NN	O	O
in	NN	O	O
Japan	NN	O	O
as	NN	O	O
"	NN	O	O
Takotsubo	NN	O	B-Disease
cardiomyopathy	NN	O	I-Disease
.	NN	O	O
"	NN	O	O
This	NN	O	O
syndrome	NN	O	O
has	NN	O	O
been	NN	O	O
identified	NN	O	O
in	NN	O	O
many	NN	O	O
other	NN	O	O
countries	NN	O	O
.	NN	O	O

Many	NN	O	O
variations	NN	O	O
of	NN	O	O
this	NN	O	O
syndrome	NN	O	O
have	NN	O	O
been	NN	O	O
recently	NN	O	O
described	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

One	NN	O	O
of	NN	O	O
the	NN	O	O
rarest	NN	O	O
is	NN	O	O
the	NN	O	O
reverse	NN	O	O
type	NN	O	O
of	NN	O	O
this	NN	O	O
syndrome	NN	O	O
,	NN	O	O
with	NN	O	O
hyperdynamic	NN	O	O
apex	NN	O	O
and	NN	O	O
complete	NN	O	O
akinesia	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
base	NN	O	O
(	NN	O	O
as	NN	O	O
opposed	NN	O	O
to	NN	O	O
the	NN	O	O
classic	NN	O	O
apical	NN	O	B-Disease
ballooning	NN	O	I-Disease
)	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
article	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
an	NN	O	O
interesting	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
young	NN	O	O
woman	NN	O	O
who	NN	O	O
presented	NN	O	O
with	NN	O	O
this	NN	O	O
rare	NN	O	O
type	NN	O	O
of	NN	O	O
reverse	NN	O	O
apical	NN	O	B-Disease
ballooning	NN	O	I-Disease
syndrome	NN	O	I-Disease
occurring	NN	O	O
after	NN	O	O
amphetamine	NN	O	B-Chemical
use	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
is	NN	O	O
followed	NN	O	O
by	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O


-DOCSTART- (17490864)

Attenuated	NN	O	O
disruption	NN	O	O
of	NN	O	O
prepulse	NN	O	O
inhibition	NN	O	O
by	NN	O	O
dopaminergic	NN	O	O
stimulation	NN	O	O
after	NN	O	O
maternal	NN	O	O
deprivation	NN	O	O
and	NN	O	O
adolescent	NN	O	O
corticosterone	NN	O	B-Chemical
treatment	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
development	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B-Disease
may	NN	O	O
include	NN	O	O
an	NN	O	O
early	NN	O	O
neurodevelopmental	NN	O	O
stress	NN	O	O
component	NN	O	O
which	NN	O	O
increases	NN	O	O
vulnerability	NN	O	O
to	NN	O	O
later	NN	O	O
stressful	NN	O	O
life	NN	O	O
events	NN	O	O
,	NN	O	O
in	NN	O	O
combination	NN	O	O
leading	NN	O	O
to	NN	O	O
overt	NN	O	O
disease	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
an	NN	O	O
early	NN	O	O
stress	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
form	NN	O	O
of	NN	O	O
maternal	NN	O	O
deprivation	NN	O	O
,	NN	O	O
combined	NN	O	O
with	NN	O	O
a	NN	O	O
later	NN	O	O
stress	NN	O	O
,	NN	O	O
simulated	NN	O	O
by	NN	O	O
chronic	NN	O	O
periadolescent	NN	O	O
corticosterone	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
on	NN	O	O
behaviour	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Acute	NN	O	O
treatment	NN	O	O
with	NN	O	O
apomorphine	NN	O	B-Chemical
caused	NN	O	O
disruption	NN	O	O
of	NN	O	O
prepulse	NN	O	O
inhibition	NN	O	O
(	NN	O	O
PPI	NN	O	O
)	NN	O	O
in	NN	O	O
controls	NN	O	O
and	NN	O	O
in	NN	O	O
rats	NN	O	O
that	NN	O	O
had	NN	O	O
undergone	NN	O	O
either	NN	O	O
maternal	NN	O	O
deprivation	NN	O	O
or	NN	O	O
corticosterone	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
but	NN	O	O
was	NN	O	O
surprisingly	NN	O	O
absent	NN	O	O
in	NN	O	O
rats	NN	O	O
that	NN	O	O
had	NN	O	O
undergone	NN	O	O
the	NN	O	O
combined	NN	O	O
early	NN	O	O
and	NN	O	O
late	NN	O	O
stress	NN	O	O
.	NN	O	O

Amphetamine	NN	O	B-Chemical
treatment	NN	O	O
significantly	NN	O	O
disrupted	NN	O	O
PPI	NN	O	O
in	NN	O	O
both	NN	O	O
non	NN	O	O
-	NN	O	O
deprived	NN	O	O
groups	NN	O	O
,	NN	O	O
but	NN	O	O
was	NN	O	O
absent	NN	O	O
in	NN	O	O
both	NN	O	O
maternally	NN	O	O
deprived	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
serotonin	NN	O	B-Chemical
-	NN	O	O
1A	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
,	NN	O	O
8	NN	O	B-Chemical
-	NN	O	I-Chemical
OH	NN	O	I-Chemical
-	NN	O	I-Chemical
DPAT	NN	O	I-Chemical
,	NN	O	O
induced	NN	O	O
a	NN	O	O
significant	NN	O	O
disruption	NN	O	O
of	NN	O	O
PPI	NN	O	O
in	NN	O	O
all	NN	O	O
groups	NN	O	O
.	NN	O	O

Amphetamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	B-Disease
hyperactivity	NN	O	I-Disease
was	NN	O	O
similar	NN	O	O
in	NN	O	O
all	NN	O	O
groups	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
show	NN	O	O
an	NN	O	O
inhibitory	NN	O	O
interaction	NN	O	O
of	NN	O	O
early	NN	O	O
stress	NN	O	O
,	NN	O	O
caused	NN	O	O
by	NN	O	O
maternal	NN	O	O
deprivation	NN	O	O
,	NN	O	O
combined	NN	O	O
with	NN	O	O
'	NN	O	O
adolescent	NN	O	O
'	NN	O	O
stress	NN	O	O
,	NN	O	O
simulated	NN	O	O
by	NN	O	O
corticosterone	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
on	NN	O	O
dopaminergic	NN	O	O
regulation	NN	O	O
of	NN	O	O
PPI	NN	O	O
.	NN	O	O

The	NN	O	O
altered	NN	O	O
effects	NN	O	O
of	NN	O	O
apomorphine	NN	O	B-Chemical
and	NN	O	O
amphetamine	NN	O	B-Chemical
could	NN	O	O
indicate	NN	O	O
differential	NN	O	O
changes	NN	O	O
in	NN	O	O
dopamine	NN	O	B-Chemical
receptor	NN	O	O
signalling	NN	O	O
leading	NN	O	O
to	NN	O	O
functional	NN	O	O
desensitisation	NN	O	O
,	NN	O	O
or	NN	O	O
altered	NN	O	O
modulation	NN	O	O
of	NN	O	O
sensory	NN	O	O
gating	NN	O	O
in	NN	O	O
the	NN	O	O
nucleus	NN	O	O
accumbens	NN	O	O
by	NN	O	O
limbic	NN	O	O
structures	NN	O	O
such	NN	O	O
as	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
.	NN	O	O


-DOCSTART- (17490790)

Peripheral	NN	O	O
iron	NN	O	B-Chemical
dextran	NN	O	I-Chemical
induced	NN	O	O
degeneration	NN	O	B-Disease
of	NN	O	I-Disease
dopaminergic	NN	O	I-Disease
neurons	NN	O	I-Disease
in	NN	O	O
rat	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
.	NN	O	O

Iron	NN	O	B-Chemical
accumulation	NN	O	O
is	NN	O	O
considered	NN	O	O
to	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

To	NN	O	O
demonstrate	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
peripheral	NN	O	O
iron	NN	O	B-Chemical
overload	NN	O	O
and	NN	O	O
dopaminergic	NN	O	O
neuron	NN	O	O
loss	NN	O	O
in	NN	O	O
rat	NN	O	O
substantia	NN	O	O
nigra	NN	O	O
(	NN	O	O
SN	NN	O	O
)	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
we	NN	O	O
used	NN	O	O
fast	NN	O	O
cyclic	NN	O	O
voltammetry	NN	O	O
,	NN	O	O
tyrosine	NN	O	B-Chemical
hydroxylase	NN	O	O
(	NN	O	O
TH	NN	O	O
)	NN	O	O
immunohistochemistry	NN	O	O
,	NN	O	O
Perls	NN	O	O
'	NN	O	O
iron	NN	O	B-Chemical
staining	NN	O	O
,	NN	O	O
and	NN	O	O
high	NN	O	O
performance	NN	O	O
liquid	NN	O	O
chromatography	NN	O	O
-	NN	O	O
electrochemical	NN	O	O
detection	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
degeneration	NN	O	B-Disease
of	NN	O	I-Disease
dopaminergic	NN	O	I-Disease
neurons	NN	O	I-Disease
and	NN	O	O
increased	NN	O	O
iron	NN	O	B-Chemical
content	NN	O	O
in	NN	O	O
the	NN	O	O
SN	NN	O	O
of	NN	O	O
iron	NN	O	B-Chemical
dextran	NN	O	I-Chemical
overloaded	NN	O	O
animals	NN	O	O
.	NN	O	O

The	NN	O	O
findings	NN	O	O
showed	NN	O	O
that	NN	O	O
peripheral	NN	O	O
iron	NN	O	B-Chemical
dextran	NN	O	I-Chemical
overload	NN	O	O
increased	NN	O	O
the	NN	O	O
iron	NN	O	B-Chemical
staining	NN	O	O
positive	NN	O	O
cells	NN	O	O
and	NN	O	O
reduced	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
TH	NN	O	O
-	NN	O	O
immunoreactive	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
SN	NN	O	O
.	NN	O	O

As	NN	O	O
a	NN	O	O
result	NN	O	O
,	NN	O	O
dopamine	NN	O	B-Chemical
release	NN	O	O
and	NN	O	O
content	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
its	NN	O	O
metabolites	NN	O	O
contents	NN	O	O
were	NN	O	O
decreased	NN	O	O
in	NN	O	O
caudate	NN	O	O
putamen	NN	O	O
.	NN	O	O

Even	NN	O	O
more	NN	O	O
dramatic	NN	O	O
changes	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
chronic	NN	O	O
overload	NN	O	O
group	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
peripheral	NN	O	O
iron	NN	O	B-Chemical
dextran	NN	O	I-Chemical
can	NN	O	O
increase	NN	O	O
the	NN	O	O
iron	NN	O	B-Chemical
level	NN	O	O
in	NN	O	O
the	NN	O	O
SN	NN	O	O
,	NN	O	O
where	NN	O	O
excessive	NN	O	O
iron	NN	O	B-Chemical
causes	NN	O	O
the	NN	O	O
degeneration	NN	O	B-Disease
of	NN	O	I-Disease
dopaminergic	NN	O	I-Disease
neurons	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
chronic	NN	O	O
iron	NN	O	B-Chemical
overload	NN	O	O
may	NN	O	O
be	NN	O	O
more	NN	O	O
destructive	NN	O	O
to	NN	O	O
dopaminergic	NN	O	O
neurons	NN	O	O
than	NN	O	O
the	NN	O	O
acute	NN	O	O
iron	NN	O	B-Chemical
overload	NN	O	O
.	NN	O	O


-DOCSTART- (16047871)

Warfarin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
leukocytoclastic	NN	O	B-Disease
vasculitis	NN	O	I-Disease
.	NN	O	O

Skin	NN	O	O
reactions	NN	O	O
associated	NN	O	O
with	NN	O	O
oral	NN	O	O
coumarin	NN	O	B-Chemical
-	NN	O	O
derived	NN	O	O
anticoagulants	NN	O	O
are	NN	O	O
an	NN	O	O
uncommon	NN	O	O
occurrence	NN	O	O
.	NN	O	O

Leukocytoclastic	NN	O	B-Disease
vasculitis	NN	O	I-Disease
(	NN	O	O
LV	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
primarily	NN	O	O
a	NN	O	O
cutaneous	NN	O	B-Disease
small	NN	O	I-Disease
vessel	NN	O	I-Disease
vasculitis	NN	O	I-Disease
,	NN	O	O
though	NN	O	O
systemic	NN	O	O
involvement	NN	O	O
may	NN	O	O
be	NN	O	O
encountered	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
4	NN	O	O
patients	NN	O	O
with	NN	O	O
late	NN	O	O
-	NN	O	O
onset	NN	O	O
LV	NN	O	B-Disease
probably	NN	O	O
due	NN	O	O
to	NN	O	O
warfarin	NN	O	B-Chemical
.	NN	O	O

All	NN	O	O
4	NN	O	O
patients	NN	O	O
presented	NN	O	O
with	NN	O	O
skin	NN	O	B-Disease
eruptions	NN	O	I-Disease
that	NN	O	O
developed	NN	O	O
after	NN	O	O
receiving	NN	O	O
warfarin	NN	O	B-Chemical
for	NN	O	O
several	NN	O	O
years	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
skin	NN	O	B-Disease
lesion	NN	O	I-Disease
biopsies	NN	O	O
were	NN	O	O
available	NN	O	O
in	NN	O	O
3	NN	O	O
patients	NN	O	O
,	NN	O	O
confirming	NN	O	O
LV	NN	O	B-Disease
Cutaneous	NN	O	I-Disease
lesions	NN	O	I-Disease
resolved	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
after	NN	O	O
warfarin	NN	O	B-Chemical
was	NN	O	O
discontinued	NN	O	O
.	NN	O	O

In	NN	O	O
2	NN	O	O
of	NN	O	O
the	NN	O	O
4	NN	O	O
patients	NN	O	O
,	NN	O	O
rechallenge	NN	O	O
with	NN	O	O
warfarin	NN	O	B-Chemical
led	NN	O	O
to	NN	O	O
recurrence	NN	O	O
of	NN	O	O
the	NN	O	O
lesions	NN	O	O
.	NN	O	O

LV	NN	O	B-Disease
may	NN	O	O
be	NN	O	O
a	NN	O	O
late	NN	O	O
-	NN	O	O
onset	NN	O	O
adverse	NN	O	O
reaction	NN	O	O
associated	NN	O	O
with	NN	O	O
warfarin	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O


-DOCSTART- (15673851)

The	NN	O	O
activation	NN	O	O
of	NN	O	O
spinal	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
-	NN	O	I-Chemical
D	NN	O	I-Chemical
-	NN	O	I-Chemical
aspartate	NN	O	I-Chemical
receptors	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
degeneration	NN	O	O
of	NN	O	O
spinal	NN	O	O
motor	NN	O	O
neurons	NN	O	O
induced	NN	O	O
by	NN	O	O
neuraxial	NN	O	O
morphine	NN	O	B-Chemical
after	NN	O	O
a	NN	O	O
noninjurious	NN	O	O
interval	NN	O	O
of	NN	O	O
spinal	NN	O	B-Disease
cord	NN	O	I-Disease
ischemia	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
the	NN	O	O
degeneration	NN	O	O
of	NN	O	O
spinal	NN	O	O
motor	NN	O	O
neurons	NN	O	O
and	NN	O	O
activation	NN	O	O
of	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
-	NN	O	I-Chemical
d	NN	O	I-Chemical
-	NN	O	I-Chemical
aspartate	NN	O	I-Chemical
(	NN	O	O
NMDA	NN	O	B-Chemical
)	NN	O	O
receptors	NN	O	O
after	NN	O	O
neuraxial	NN	O	O
morphine	NN	O	B-Chemical
following	NN	O	O
a	NN	O	O
noninjurious	NN	O	O
interval	NN	O	O
of	NN	O	O
aortic	NN	O	B-Disease
occlusion	NN	O	I-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Spinal	NN	O	B-Disease
cord	NN	O	I-Disease
ischemia	NN	O	I-Disease
was	NN	O	O
induced	NN	O	O
by	NN	O	O
aortic	NN	O	B-Disease
occlusion	NN	O	I-Disease
for	NN	O	O
6	NN	O	O
min	NN	O	O
with	NN	O	O
a	NN	O	O
balloon	NN	O	O
catheter	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
microdialysis	NN	O	O
study	NN	O	O
,	NN	O	O
10	NN	O	O
muL	NN	O	O
of	NN	O	O
saline	NN	O	O
(	NN	O	O
group	NN	O	O
C	NN	O	O
;	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
or	NN	O	O
30	NN	O	O
mug	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
(	NN	O	O
group	NN	O	O
M	NN	O	O
;	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
was	NN	O	O
injected	NN	O	O
intrathecally	NN	O	O
(	NN	O	O
IT	NN	O	O
)	NN	O	O
0.5	NN	O	O
h	NN	O	O
after	NN	O	O
reflow	NN	O	O
,	NN	O	O
and	NN	O	O
30	NN	O	O
mug	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
(	NN	O	O
group	NN	O	O
SM	NN	O	O
;	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
or	NN	O	O
10	NN	O	O
muL	NN	O	O
of	NN	O	O
saline	NN	O	O
(	NN	O	O
group	NN	O	O
SC	NN	O	O
;	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
was	NN	O	O
injected	NN	O	O
IT	NN	O	O
0.5	NN	O	O
h	NN	O	O
after	NN	O	O
sham	NN	O	O
operation	NN	O	O
.	NN	O	O

Microdialysis	NN	O	O
samples	NN	O	O
were	NN	O	O
collected	NN	O	O
preischemia	NN	O	O
,	NN	O	O
before	NN	O	O
IT	NN	O	O
injection	NN	O	O
,	NN	O	O
and	NN	O	O
at	NN	O	O
2	NN	O	O
,	NN	O	O
4	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
24	NN	O	O
,	NN	O	O
and	NN	O	O
48	NN	O	O
h	NN	O	O
of	NN	O	O
reperfusion	NN	O	O
(	NN	O	O
after	NN	O	O
IT	NN	O	O
injection	NN	O	O
)	NN	O	O
.	NN	O	O

Second	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
IT	NN	O	O
MK	NN	O	B-Chemical
-	NN	O	I-Chemical
801	NN	O	I-Chemical
(	NN	O	O
30	NN	O	O
mug	NN	O	O
)	NN	O	O
on	NN	O	O
the	NN	O	O
histopathologic	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
spinal	NN	O	O
cord	NN	O	O
after	NN	O	O
morphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
spastic	NN	O	B-Disease
paraparesis	NN	O	I-Disease
.	NN	O	O

After	NN	O	O
IT	NN	O	O
morphine	NN	O	B-Chemical
,	NN	O	O
the	NN	O	O
cerebrospinal	NN	O	O
fluid	NN	O	O
(	NN	O	O
CSF	NN	O	O
)	NN	O	O
glutamate	NN	O	B-Chemical
concentration	NN	O	O
was	NN	O	O
increased	NN	O	O
in	NN	O	O
group	NN	O	O
M	NN	O	O
relative	NN	O	O
to	NN	O	O
both	NN	O	O
baseline	NN	O	O
and	NN	O	O
group	NN	O	O
C	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
increase	NN	O	O
persisted	NN	O	O
for	NN	O	O
8	NN	O	O
hrs	NN	O	O
.	NN	O	O

IT	NN	O	O
MK	NN	O	B-Chemical
-	NN	O	I-Chemical
801	NN	O	I-Chemical
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
dark	NN	O	O
-	NN	O	O
stained	NN	O	O
alpha	NN	O	O
-	NN	O	O
motoneurons	NN	O	O
after	NN	O	O
morphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
spastic	NN	O	B-Disease
paraparesis	NN	O	I-Disease
compared	NN	O	O
with	NN	O	O
the	NN	O	O
saline	NN	O	O
group	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
IT	NN	O	O
morphine	NN	O	B-Chemical
induces	NN	O	O
spastic	NN	O	B-Disease
paraparesis	NN	O	I-Disease
with	NN	O	O
a	NN	O	O
concomitant	NN	O	O
increase	NN	O	O
in	NN	O	O
CSF	NN	O	O
glutamate	NN	O	B-Chemical
,	NN	O	O
which	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
NMDA	NN	O	B-Chemical
receptor	NN	O	O
activation	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
opioids	NN	O	O
may	NN	O	O
be	NN	O	O
neurotoxic	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
setting	NN	O	O
of	NN	O	O
spinal	NN	O	B-Disease
cord	NN	O	I-Disease
ischemia	NN	O	I-Disease
via	NN	O	O
NMDA	NN	O	B-Chemical
receptor	NN	O	O
activation	NN	O	O
.	NN	O	O


-DOCSTART- (12481039)

Reduced	NN	O	O
sodium	NN	O	B-Chemical
channel	NN	O	O
density	NN	O	O
,	NN	O	O
altered	NN	O	O
voltage	NN	O	O
dependence	NN	O	O
of	NN	O	O
inactivation	NN	O	O
,	NN	O	O
and	NN	O	O
increased	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
seizures	NN	O	B-Disease
in	NN	O	O
mice	NN	O	O
lacking	NN	O	O
sodium	NN	O	B-Chemical
channel	NN	O	O
beta	NN	O	O
2	NN	O	O
-	NN	O	O
subunits	NN	O	O
.	NN	O	O

Sodium	NN	O	B-Chemical
channel	NN	O	O
beta	NN	O	O
-	NN	O	O
subunits	NN	O	O
modulate	NN	O	O
channel	NN	O	O
gating	NN	O	O
,	NN	O	O
assembly	NN	O	O
,	NN	O	O
and	NN	O	O
cell	NN	O	O
surface	NN	O	O
expression	NN	O	O
in	NN	O	O
heterologous	NN	O	O
cell	NN	O	O
systems	NN	O	O
.	NN	O	O

We	NN	O	O
generated	NN	O	O
beta2	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
beta2	NN	O	O
in	NN	O	O
control	NN	O	O
of	NN	O	O
sodium	NN	O	B-Chemical
channel	NN	O	O
density	NN	O	O
,	NN	O	O
localization	NN	O	O
,	NN	O	O
and	NN	O	O
function	NN	O	O
in	NN	O	O
neurons	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

Measurements	NN	O	O
of	NN	O	O
[	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
H	NN	O	O
]	NN	O	O
saxitoxin	NN	O	B-Chemical
(	NN	O	O
STX	NN	O	B-Chemical
)	NN	O	O
binding	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
plasma	NN	O	O
membrane	NN	O	O
sodium	NN	O	B-Chemical
channels	NN	O	O
in	NN	O	O
beta2	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
neurons	NN	O	O
.	NN	O	O

The	NN	O	O
loss	NN	O	O
of	NN	O	O
beta2	NN	O	O
resulted	NN	O	O
in	NN	O	O
negative	NN	O	O
shifts	NN	O	O
in	NN	O	O
the	NN	O	O
voltage	NN	O	O
dependence	NN	O	O
of	NN	O	O
inactivation	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
significant	NN	O	O
decreases	NN	O	O
in	NN	O	O
sodium	NN	O	B-Chemical
current	NN	O	O
density	NN	O	O
in	NN	O	O
acutely	NN	O	O
dissociated	NN	O	O
hippocampal	NN	O	O
neurons	NN	O	O
.	NN	O	O

The	NN	O	O
integral	NN	O	O
of	NN	O	O
the	NN	O	O
compound	NN	O	O
action	NN	O	O
potential	NN	O	O
in	NN	O	O
optic	NN	O	O
nerve	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
threshold	NN	O	O
for	NN	O	O
action	NN	O	O
potential	NN	O	O
generation	NN	O	O
was	NN	O	O
increased	NN	O	O
,	NN	O	O
indicating	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
functional	NN	O	O
plasma	NN	O	O
membrane	NN	O	O
sodium	NN	O	B-Chemical
channels	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
conduction	NN	O	O
velocity	NN	O	O
,	NN	O	O
the	NN	O	O
number	NN	O	O
and	NN	O	O
size	NN	O	O
of	NN	O	O
axons	NN	O	O
in	NN	O	O
the	NN	O	O
optic	NN	O	O
nerve	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
specific	NN	O	O
localization	NN	O	O
of	NN	O	O
Na	NN	O	B-Chemical
(	NN	O	O
v	NN	O	O
)	NN	O	O
1.6	NN	O	O
channels	NN	O	O
in	NN	O	O
the	NN	O	O
nodes	NN	O	O
of	NN	O	O
Ranvier	NN	O	O
were	NN	O	O
unchanged	NN	O	O
.	NN	O	O

beta2	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
displayed	NN	O	O
increased	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
seizures	NN	O	B-Disease
,	NN	O	O
as	NN	O	O
indicated	NN	O	O
by	NN	O	O
reduced	NN	O	O
latency	NN	O	O
and	NN	O	O
threshold	NN	O	O
for	NN	O	O
pilocarpine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
,	NN	O	O
but	NN	O	O
seemed	NN	O	O
normal	NN	O	O
in	NN	O	O
other	NN	O	O
neurological	NN	O	O
tests	NN	O	O
.	NN	O	O

Our	NN	O	O
observations	NN	O	O
show	NN	O	O
that	NN	O	O
beta2	NN	O	O
-	NN	O	O
subunits	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
sodium	NN	O	B-Chemical
channel	NN	O	O
density	NN	O	O
and	NN	O	O
function	NN	O	O
in	NN	O	O
neurons	NN	O	O
in	NN	O	O
vivo	NN	O	O
and	NN	O	O
are	NN	O	O
required	NN	O	O
for	NN	O	O
normal	NN	O	O
action	NN	O	O
potential	NN	O	O
generation	NN	O	O
and	NN	O	O
control	NN	O	O
of	NN	O	O
excitability	NN	O	O
.	NN	O	O


-DOCSTART- (11185967)

Screening	NN	O	O
for	NN	O	O
stimulant	NN	O	O
use	NN	O	O
in	NN	O	O
adult	NN	O	O
emergency	NN	O	O
department	NN	O	O
seizure	NN	O	B-Disease
patients	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
positive	NN	O	O
plasma	NN	O	O
drug	NN	O	O
screening	NN	O	O
for	NN	O	O
cocaine	NN	O	B-Chemical
or	NN	O	O
amphetamine	NN	O	B-Chemical
in	NN	O	O
adult	NN	O	O
emergency	NN	O	O
department	NN	O	O
seizure	NN	O	B-Disease
patients	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
prospective	NN	O	O
study	NN	O	O
evaluated	NN	O	O
consecutive	NN	O	O
eligible	NN	O	O
seizure	NN	O	B-Disease
patients	NN	O	O
who	NN	O	O
had	NN	O	O
a	NN	O	O
plasma	NN	O	O
sample	NN	O	O
collected	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
their	NN	O	O
clinical	NN	O	O
evaluation	NN	O	O
.	NN	O	O

Plasma	NN	O	O
was	NN	O	O
tested	NN	O	O
for	NN	O	O
amphetamine	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
cocaine	NN	O	B-Chemical
metabolite	NN	O	O
benzoylecgonine	NN	O	B-Chemical
using	NN	O	O
enzyme	NN	O	O
-	NN	O	O
mediated	NN	O	O
immunoassay	NN	O	O
methodology	NN	O	O
.	NN	O	O

Plasma	NN	O	O
samples	NN	O	O
with	NN	O	O
benzoylecgonine	NN	O	B-Chemical
greater	NN	O	O
than	NN	O	O
150	NN	O	O
ng	NN	O	O
/	NN	O	O
mL	NN	O	O
or	NN	O	O
an	NN	O	O
amphetamine	NN	O	B-Chemical
greater	NN	O	O
than	NN	O	O
500	NN	O	O
ng	NN	O	O
/	NN	O	O
mL	NN	O	O
were	NN	O	O
defined	NN	O	O
as	NN	O	O
positive	NN	O	O
.	NN	O	O

Patient	NN	O	O
demographics	NN	O	O
,	NN	O	O
history	NN	O	O
of	NN	O	O
underlying	NN	O	O
drug	NN	O	O
or	NN	O	O
alcohol	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
seizure	NN	O	B-Disease
disorder	NN	O	O
,	NN	O	O
estimated	NN	O	O
time	NN	O	O
from	NN	O	O
seizure	NN	O	B-Disease
to	NN	O	O
sample	NN	O	O
collection	NN	O	O
,	NN	O	O
history	NN	O	O
or	NN	O	O
suspicion	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Disease
or	NN	O	I-Disease
amphetamine	NN	O	I-Disease
abuse	NN	O	I-Disease
,	NN	O	O
results	NN	O	O
of	NN	O	O
clinical	NN	O	O
urine	NN	O	O
testing	NN	O	O
for	NN	O	O
drugs	NN	O	O
of	NN	O	O
abuse	NN	O	O
,	NN	O	O
and	NN	O	O
assay	NN	O	O
results	NN	O	O
were	NN	O	O
recorded	NN	O	O
without	NN	O	O
patient	NN	O	O
identifiers	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Fourteen	NN	O	O
of	NN	O	O
248	NN	O	O
(	NN	O	O
5.6%	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
2.7%	NN	O	O
-	NN	O	O
8.5%	NN	O	O
)	NN	O	O
plasma	NN	O	O
samples	NN	O	O
were	NN	O	O
positive	NN	O	O
by	NN	O	O
immunoassay	NN	O	O
testing	NN	O	O
for	NN	O	O
benzoylecgonine	NN	O	B-Chemical
and	NN	O	O
no	NN	O	O
samples	NN	O	O
(	NN	O	O
0%	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
0	NN	O	O
-	NN	O	O
1.2%	NN	O	O
)	NN	O	O
were	NN	O	O
positive	NN	O	O
for	NN	O	O
amphetamine	NN	O	B-Chemical
.	NN	O	O

Positive	NN	O	O
test	NN	O	O
results	NN	O	O
were	NN	O	O
more	NN	O	O
common	NN	O	O
in	NN	O	O
patient	NN	O	O
visits	NN	O	O
where	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
history	NN	O	O
or	NN	O	O
suspicion	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Disease
or	NN	O	I-Disease
amphetamine	NN	O	I-Disease
abuse	NN	O	I-Disease
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.0005	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
During	NN	O	O
this	NN	O	O
study	NN	O	O
period	NN	O	O
,	NN	O	O
routine	NN	O	O
plasma	NN	O	O
screening	NN	O	O
for	NN	O	O
cocaine	NN	O	B-Chemical
and	NN	O	O
amphetamines	NN	O	B-Chemical
in	NN	O	O
adult	NN	O	O
seizure	NN	O	B-Disease
patients	NN	O	O
had	NN	O	O
a	NN	O	O
low	NN	O	O
yield	NN	O	O
.	NN	O	O

As	NN	O	O
a	NN	O	O
result	NN	O	O
,	NN	O	O
routine	NN	O	O
plasma	NN	O	O
screening	NN	O	O
would	NN	O	O
yield	NN	O	O
few	NN	O	O
cases	NN	O	O
of	NN	O	O
stimulant	NN	O	O
drug	NN	O	O
in	NN	O	O
which	NN	O	O
there	NN	O	O
was	NN	O	O
neither	NN	O	O
a	NN	O	O
history	NN	O	O
nor	NN	O	O
suspicion	NN	O	O
of	NN	O	O
drug	NN	O	B-Disease
abuse	NN	O	I-Disease
in	NN	O	O
this	NN	O	O
population	NN	O	O
.	NN	O	O


-DOCSTART- (11099450)

Evidence	NN	O	O
of	NN	O	O
functional	NN	O	O
somatotopy	NN	O	O
in	NN	O	O
GPi	NN	O	O
from	NN	O	O
results	NN	O	O
of	NN	O	O
pallidotomy	NN	O	O
.	NN	O	O

The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
explore	NN	O	O
the	NN	O	O
functional	NN	O	O
anatomy	NN	O	O
of	NN	O	O
the	NN	O	O
globus	NN	O	O
pallidus	NN	O	O
internus	NN	O	O
(	NN	O	O
GPi	NN	O	O
)	NN	O	O
by	NN	O	O
studying	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
unilateral	NN	O	O
pallidotomy	NN	O	O
on	NN	O	O
parkinsonian	NN	O	B-Disease
'	NN	O	O
off	NN	O	O
'	NN	O	O
signs	NN	O	O
and	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
(	NN	O	O
LID	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
significant	NN	O	O
positive	NN	O	O
correlations	NN	O	O
between	NN	O	O
the	NN	O	O
preoperative	NN	O	O
levodopa	NN	O	B-Chemical
responsiveness	NN	O	O
of	NN	O	O
motor	NN	O	O
signs	NN	O	O
and	NN	O	O
the	NN	O	O
levodopa	NN	O	B-Chemical
responsiveness	NN	O	O
of	NN	O	O
scores	NN	O	O
in	NN	O	O
timed	NN	O	O
tests	NN	O	O
(	NN	O	O
Core	NN	O	O
Assessment	NN	O	O
Program	NN	O	O
for	NN	O	O
Intracerebral	NN	O	O
Transplantations	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
contralateral	NN	O	O
limbs	NN	O	O
and	NN	O	O
the	NN	O	O
improvement	NN	O	O
in	NN	O	O
these	NN	O	O
scores	NN	O	O
after	NN	O	O
surgery	NN	O	O
,	NN	O	O
whereas	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
correlation	NN	O	O
with	NN	O	O
the	NN	O	O
improvement	NN	O	O
in	NN	O	O
LID	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
also	NN	O	O
found	NN	O	O
a	NN	O	O
highly	NN	O	O
significant	NN	O	O
correlation	NN	O	O
(	NN	O	O
P	NN	O	O
:	NN	O	O
<	NN	O	O
0.0001	NN	O	O
,	NN	O	O
r	NN	O	O
=	NN	O	O
0.8	NN	O	O
)	NN	O	O
between	NN	O	O
the	NN	O	O
volume	NN	O	O
of	NN	O	O
the	NN	O	O
ventral	NN	O	O
lesion	NN	O	O
in	NN	O	O
the	NN	O	O
GPi	NN	O	O
and	NN	O	O
the	NN	O	O
improvement	NN	O	O
in	NN	O	O
LID	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
contralateral	NN	O	O
limbs	NN	O	O
,	NN	O	O
whereas	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
correlation	NN	O	O
between	NN	O	O
the	NN	O	O
ventral	NN	O	O
volume	NN	O	O
and	NN	O	O
the	NN	O	O
improvement	NN	O	O
in	NN	O	O
parkinsonian	NN	O	B-Disease
'	NN	O	O
off	NN	O	O
'	NN	O	O
signs	NN	O	O
.	NN	O	O

The	NN	O	O
volumes	NN	O	O
of	NN	O	O
the	NN	O	O
total	NN	O	O
lesion	NN	O	O
cylinder	NN	O	O
and	NN	O	O
the	NN	O	O
dorsal	NN	O	O
lesion	NN	O	O
did	NN	O	O
not	NN	O	O
correlate	NN	O	O
with	NN	O	O
the	NN	O	O
outcome	NN	O	O
of	NN	O	O
either	NN	O	O
dyskinesias	NN	O	B-Disease
or	NN	O	O
parkinsonian	NN	O	B-Disease
'	NN	O	O
off	NN	O	O
'	NN	O	O
signs	NN	O	O
.	NN	O	O

The	NN	O	O
differential	NN	O	O
predictive	NN	O	O
value	NN	O	O
of	NN	O	O
levodopa	NN	O	B-Chemical
responsiveness	NN	O	O
for	NN	O	O
the	NN	O	O
outcome	NN	O	O
of	NN	O	O
parkinsonian	NN	O	B-Disease
'	NN	O	O
off	NN	O	O
'	NN	O	O
signs	NN	O	O
and	NN	O	O
LID	NN	O	B-Disease
and	NN	O	O
the	NN	O	O
different	NN	O	O
correlations	NN	O	O
of	NN	O	O
ventral	NN	O	O
lesion	NN	O	O
volume	NN	O	O
with	NN	O	O
dyskinesias	NN	O	B-Disease
and	NN	O	O
parkinsonian	NN	O	B-Disease
'	NN	O	O
off	NN	O	O
'	NN	O	O
signs	NN	O	O
indicate	NN	O	O
that	NN	O	O
different	NN	O	O
anatomical	NN	O	O
or	NN	O	O
pathophysiological	NN	O	O
substrates	NN	O	O
may	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
generation	NN	O	O
of	NN	O	O
parkinsonian	NN	O	B-Disease
'	NN	O	O
off	NN	O	O
'	NN	O	O
signs	NN	O	O
and	NN	O	O
dyskinesias	NN	O	B-Disease
.	NN	O	O

Whereas	NN	O	O
cells	NN	O	O
in	NN	O	O
a	NN	O	O
wider	NN	O	O
area	NN	O	O
of	NN	O	O
the	NN	O	O
GPi	NN	O	O
may	NN	O	O
be	NN	O	O
implicated	NN	O	O
in	NN	O	O
parkinsonism	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
ventral	NN	O	O
GPi	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
crucial	NN	O	O
for	NN	O	O
the	NN	O	O
manifestation	NN	O	O
of	NN	O	O
LID	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
our	NN	O	O
observations	NN	O	O
are	NN	O	O
additional	NN	O	O
proof	NN	O	O
of	NN	O	O
the	NN	O	O
functional	NN	O	O
somatotopy	NN	O	O
of	NN	O	O
the	NN	O	O
systems	NN	O	O
within	NN	O	O
the	NN	O	O
GPi	NN	O	O
that	NN	O	O
mediate	NN	O	O
parkinsonism	NN	O	B-Disease
and	NN	O	O
dyskinesias	NN	O	B-Disease
,	NN	O	O
especially	NN	O	O
along	NN	O	O
the	NN	O	O
dorsoventral	NN	O	O
trajectory	NN	O	O
used	NN	O	O
in	NN	O	O
pallidotomy	NN	O	O
.	NN	O	O

The	NN	O	O
outcome	NN	O	O
of	NN	O	O
pallidotomy	NN	O	O
in	NN	O	O
which	NN	O	O
the	NN	O	O
lesion	NN	O	O
involves	NN	O	O
the	NN	O	O
ventral	NN	O	O
and	NN	O	O
dorsal	NN	O	O
GPi	NN	O	O
could	NN	O	O
be	NN	O	O
the	NN	O	O
net	NN	O	O
effect	NN	O	O
of	NN	O	O
alteration	NN	O	O
in	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
pathways	NN	O	O
which	NN	O	O
mediate	NN	O	O
different	NN	O	O
symptoms	NN	O	O
,	NN	O	O
and	NN	O	O
hence	NN	O	O
could	NN	O	O
be	NN	O	O
variable	NN	O	O
.	NN	O	O


-DOCSTART- (11027904)

Pain	NN	O	B-Disease
responses	NN	O	O
in	NN	O	O
methadone	NN	O	B-Chemical
-	NN	O	O
maintained	NN	O	O
opioid	NN	O	O
abusers	NN	O	O
.	NN	O	O

Providing	NN	O	O
pain	NN	O	B-Disease
management	NN	O	O
for	NN	O	O
known	NN	O	O
opioid	NN	O	O
abusers	NN	O	O
is	NN	O	O
a	NN	O	O
challenging	NN	O	O
clinical	NN	O	O
task	NN	O	O
,	NN	O	O
in	NN	O	O
part	NN	O	O
because	NN	O	O
little	NN	O	O
is	NN	O	O
known	NN	O	O
about	NN	O	O
their	NN	O	O
pain	NN	O	B-Disease
experience	NN	O	O
and	NN	O	O
analgesic	NN	O	O
requirements	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
describe	NN	O	O
pain	NN	O	B-Disease
tolerance	NN	O	O
and	NN	O	O
analgesic	NN	O	O
response	NN	O	O
in	NN	O	O
a	NN	O	O
sample	NN	O	O
of	NN	O	O
opioid	NN	O	B-Disease
addicts	NN	O	I-Disease
stabilized	NN	O	O
in	NN	O	O
methadone	NN	O	B-Chemical
-	NN	O	O
maintenance	NN	O	O
(	NN	O	O
MM	NN	O	O
)	NN	O	O
treatment	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
60	NN	O	O
)	NN	O	O
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
matched	NN	O	O
nondependent	NN	O	O
control	NN	O	O
subjects	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
60	NN	O	O
)	NN	O	O
.	NN	O	O

By	NN	O	O
using	NN	O	O
a	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
two	NN	O	O
-	NN	O	O
way	NN	O	O
factorial	NN	O	O
design	NN	O	O
,	NN	O	O
tolerance	NN	O	O
to	NN	O	O
cold	NN	O	O
-	NN	O	O
pressor	NN	O	O
(	NN	O	O
CP	NN	O	O
)	NN	O	O
pain	NN	O	B-Disease
was	NN	O	O
examined	NN	O	O
,	NN	O	O
both	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
oral	NN	O	O
administration	NN	O	O
of	NN	O	O
therapeutic	NN	O	O
doses	NN	O	O
of	NN	O	O
common	NN	O	O
opioid	NN	O	O
(	NN	O	O
hydromorphone	NN	O	B-Chemical
2	NN	O	O
mg	NN	O	O
)	NN	O	O
and	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
(	NN	O	O
ketorolac	NN	O	B-Chemical
10	NN	O	O
mg	NN	O	O
)	NN	O	O
analgesic	NN	O	O
agents	NN	O	O
.	NN	O	O

Results	NN	O	O
showed	NN	O	O
that	NN	O	O
MM	NN	O	O
individuals	NN	O	O
were	NN	O	O
significantly	NN	O	O
less	NN	O	O
tolerant	NN	O	O
of	NN	O	O
CP	NN	O	O
pain	NN	O	B-Disease
than	NN	O	O
control	NN	O	O
subjects	NN	O	O
,	NN	O	O
replicating	NN	O	O
previous	NN	O	O
work	NN	O	O
.	NN	O	O

Analgesic	NN	O	O
effects	NN	O	O
were	NN	O	O
significant	NN	O	O
neither	NN	O	O
for	NN	O	O
medication	NN	O	O
nor	NN	O	O
group	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
MM	NN	O	O
opioid	NN	O	O
abusers	NN	O	O
represent	NN	O	O
a	NN	O	O
pain	NN	O	B-Disease
-	NN	O	I-Disease
intolerant	NN	O	I-Disease
subset	NN	O	O
of	NN	O	O
clinical	NN	O	O
patients	NN	O	O
.	NN	O	O

Their	NN	O	O
complaints	NN	O	O
of	NN	O	O
pain	NN	O	B-Disease
should	NN	O	O
be	NN	O	O
evaluated	NN	O	O
seriously	NN	O	O
and	NN	O	O
managed	NN	O	O
aggressively	NN	O	O
.	NN	O	O


-DOCSTART- (10193809)

Urine	NN	O	O
N	NN	O	O
-	NN	O	O
acetyl	NN	O	O
-	NN	O	O
beta	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
glucosaminidase	NN	O	O
-	NN	O	O
-	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
tubular	NN	O	O
damage?	NN	O	O
BACKGROUND	NN	O	O
:	NN	O	O
Although	NN	O	O
an	NN	O	O
indicator	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
tubular	NN	O	I-Disease
dysfunction	NN	O	I-Disease
,	NN	O	O
an	NN	O	O
increased	NN	O	O
urinary	NN	O	O
N	NN	O	O
-	NN	O	O
acetyl	NN	O	O
-	NN	O	O
beta	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
glucosaminidase	NN	O	O
(	NN	O	O
NAG	NN	O	O
)	NN	O	O
activity	NN	O	O
might	NN	O	O
reflect	NN	O	O
increased	NN	O	O
lysosomal	NN	O	O
activity	NN	O	O
in	NN	O	O
renal	NN	O	O
tubular	NN	O	O
cells	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
(	NN	O	O
PAN	NN	O	B-Chemical
)	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
Sprague	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
to	NN	O	O
induce	NN	O	O
proteinuria	NN	O	B-Disease
.	NN	O	O

Total	NN	O	O
protein	NN	O	O
,	NN	O	O
albumin	NN	O	O
,	NN	O	O
NAG	NN	O	O
activity	NN	O	O
and	NN	O	O
protein	NN	O	O
electrophoretic	NN	O	O
pattern	NN	O	O
were	NN	O	O
assessed	NN	O	O
in	NN	O	O
daily	NN	O	O
urine	NN	O	O
samples	NN	O	O
for	NN	O	O
33	NN	O	O
days	NN	O	O
.	NN	O	O

The	NN	O	O
morphological	NN	O	O
appearance	NN	O	O
of	NN	O	O
the	NN	O	O
kidneys	NN	O	O
was	NN	O	O
examined	NN	O	O
on	NN	O	O
days	NN	O	O
three	NN	O	O
,	NN	O	O
four	NN	O	O
,	NN	O	O
six	NN	O	O
,	NN	O	O
eight	NN	O	O
and	NN	O	O
thirty	NN	O	O
three	NN	O	O
and	NN	O	O
the	NN	O	O
NAG	NN	O	O
isoenzyme	NN	O	O
patterns	NN	O	O
on	NN	O	O
days	NN	O	O
zero	NN	O	O
,	NN	O	O
four	NN	O	O
,	NN	O	O
eight	NN	O	O
and	NN	O	O
thirty	NN	O	O
three	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Following	NN	O	O
intravenous	NN	O	O
PAN	NN	O	B-Chemical
urine	NN	O	O
volume	NN	O	O
and	NN	O	O
urine	NN	O	O
NAG	NN	O	O
activity	NN	O	O
increased	NN	O	O
significantly	NN	O	O
by	NN	O	O
day	NN	O	O
two	NN	O	O
,	NN	O	O
but	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
by	NN	O	O
day	NN	O	O
four	NN	O	O
.	NN	O	O

After	NN	O	O
day	NN	O	O
four	NN	O	O
all	NN	O	O
treated	NN	O	O
animals	NN	O	O
exhibited	NN	O	O
a	NN	O	O
marked	NN	O	O
rise	NN	O	O
in	NN	O	O
urine	NN	O	O
albumin	NN	O	O
,	NN	O	O
total	NN	O	O
protein	NN	O	O
excretion	NN	O	O
and	NN	O	O
NAG	NN	O	O
activity	NN	O	O
.	NN	O	O

Electrophoresis	NN	O	O
showed	NN	O	O
a	NN	O	O
generalised	NN	O	O
increase	NN	O	O
in	NN	O	O
middle	NN	O	O
and	NN	O	O
high	NN	O	O
molecular	NN	O	O
weight	NN	O	O
urine	NN	O	O
proteins	NN	O	O
from	NN	O	O
day	NN	O	O
four	NN	O	O
onwards	NN	O	O
.	NN	O	O

Protein	NN	O	O
droplets	NN	O	O
first	NN	O	O
appeared	NN	O	O
prominent	NN	O	O
in	NN	O	O
tubular	NN	O	O
cells	NN	O	O
on	NN	O	O
day	NN	O	O
four	NN	O	O
.	NN	O	O

Peak	NN	O	O
urine	NN	O	O
NAG	NN	O	O
activity	NN	O	O
and	NN	O	O
a	NN	O	O
change	NN	O	O
in	NN	O	O
NAG	NN	O	O
isoenzyme	NN	O	O
pattern	NN	O	O
coincided	NN	O	O
with	NN	O	O
both	NN	O	O
the	NN	O	O
peak	NN	O	O
proteinuria	NN	O	B-Disease
and	NN	O	O
the	NN	O	O
reduction	NN	O	O
in	NN	O	O
intracellular	NN	O	O
protein	NN	O	O
and	NN	O	O
NAG	NN	O	O
droplets	NN	O	O
(	NN	O	O
day	NN	O	O
six	NN	O	O
onwards	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
This	NN	O	O
animal	NN	O	O
model	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
lysosomal	NN	O	O
turnover	NN	O	O
and	NN	O	O
hence	NN	O	O
urine	NN	O	O
NAG	NN	O	O
activity	NN	O	O
,	NN	O	O
occurs	NN	O	O
when	NN	O	O
increased	NN	O	O
protein	NN	O	O
is	NN	O	O
presented	NN	O	O
to	NN	O	O
the	NN	O	O
tubular	NN	O	O
cells	NN	O	O
.	NN	O	O

Urine	NN	O	O
NAG	NN	O	O
activity	NN	O	O
is	NN	O	O
thus	NN	O	O
a	NN	O	O
measure	NN	O	O
of	NN	O	O
altered	NN	O	O
function	NN	O	O
in	NN	O	O
the	NN	O	O
renal	NN	O	O
tubules	NN	O	O
and	NN	O	O
not	NN	O	O
simply	NN	O	O
an	NN	O	O
indicator	NN	O	O
of	NN	O	O
damage	NN	O	O
.	NN	O	O


-DOCSTART- (9214597)

Over	NN	O	O
expression	NN	O	O
of	NN	O	O
vascular	NN	O	O
endothelial	NN	O	O
growth	NN	O	O
factor	NN	O	O
and	NN	O	O
its	NN	O	O
receptor	NN	O	O
during	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
estrogen	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
rat	NN	O	O
pituitary	NN	O	B-Disease
tumors	NN	O	I-Disease
may	NN	O	O
mediate	NN	O	O
estrogen	NN	O	B-Chemical
-	NN	O	O
initiated	NN	O	O
tumor	NN	O	B-Disease
angiogenesis	NN	O	O
.	NN	O	O

Estrogens	NN	O	B-Chemical
,	NN	O	O
which	NN	O	O
have	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
several	NN	O	O
types	NN	O	O
of	NN	O	O
human	NN	O	O
and	NN	O	O
animal	NN	O	O
cancers	NN	O	B-Disease
,	NN	O	O
can	NN	O	O
induce	NN	O	O
tumor	NN	O	B-Disease
angiogenesis	NN	O	O
in	NN	O	O
the	NN	O	O
pituitary	NN	O	O
of	NN	O	O
Fischer	NN	O	O
344	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
mechanistic	NN	O	O
details	NN	O	O
of	NN	O	O
tumor	NN	O	B-Disease
angiogenesis	NN	O	O
induction	NN	O	O
,	NN	O	O
during	NN	O	O
estrogen	NN	O	B-Chemical
carcinogenesis	NN	O	B-Disease
,	NN	O	O
are	NN	O	O
still	NN	O	O
unknown	NN	O	O
.	NN	O	O

To	NN	O	O
elucidate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
estrogen	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
tumor	NN	O	B-Disease
angiogenesis	NN	O	O
in	NN	O	O
the	NN	O	O
pituitary	NN	O	O
of	NN	O	O
female	NN	O	O
rats	NN	O	O
,	NN	O	O
the	NN	O	O
density	NN	O	O
of	NN	O	O
blood	NN	O	O
vessels	NN	O	O
was	NN	O	O
analysed	NN	O	O
using	NN	O	O
factor	NN	O	O
VIII	NN	O	O
related	NN	O	O
antigen	NN	O	O
(	NN	O	O
FVIIIRAg	NN	O	O
)	NN	O	O
immunohistochemistry	NN	O	O
and	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
vascular	NN	O	O
endothelial	NN	O	O
growth	NN	O	O
factor	NN	O	O
/	NN	O	O
vascular	NN	O	O
permeability	NN	O	O
factor	NN	O	O
(	NN	O	O
VEGF	NN	O	O
/	NN	O	O
VPF	NN	O	O
)	NN	O	O
was	NN	O	O
examined	NN	O	O
by	NN	O	O
Western	NN	O	O
blot	NN	O	O
and	NN	O	O
immunohistochemical	NN	O	O
analysis	NN	O	O
.	NN	O	O

The	NN	O	O
expression	NN	O	O
of	NN	O	O
VEGF	NN	O	O
receptor	NN	O	O
(	NN	O	O
VEGFR	NN	O	O
-	NN	O	O
2	NN	O	O
/	NN	O	O
Flk	NN	O	O
-	NN	O	O
1	NN	O	O
/	NN	O	O
KDR	NN	O	O
)	NN	O	O
was	NN	O	O
also	NN	O	O
examined	NN	O	O
by	NN	O	O
immunohistochemistry	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
17beta	NN	O	B-Chemical
-	NN	O	I-Chemical
estradiol	NN	O	I-Chemical
(	NN	O	O
E2	NN	O	B-Chemical
)	NN	O	O
induces	NN	O	O
neovascularization	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
growth	NN	O	O
and	NN	O	O
enlargement	NN	O	O
of	NN	O	O
blood	NN	O	O
vessels	NN	O	O
after	NN	O	O
7	NN	O	O
days	NN	O	O
of	NN	O	O
exposure	NN	O	O
.	NN	O	O

The	NN	O	O
high	NN	O	O
tumor	NN	O	B-Disease
angiogenic	NN	O	O
potential	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
elevated	NN	O	O
VEGF	NN	O	O
/	NN	O	O
VPF	NN	O	O
protein	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
E2	NN	O	B-Chemical
exposed	NN	O	O
pituitary	NN	O	O
of	NN	O	O
ovariectomized	NN	O	O
(	NN	O	O
OVEX	NN	O	O
)	NN	O	O
rats	NN	O	O
.	NN	O	O

VEGF	NN	O	O
/	NN	O	O
VPF	NN	O	O
and	NN	O	O
FVIIIRAg	NN	O	O
immunohistochemistry	NN	O	O
and	NN	O	O
endothelial	NN	O	O
specific	NN	O	O
lectin	NN	O	O
(	NN	O	O
UEA1	NN	O	O
)	NN	O	O
binding	NN	O	O
studies	NN	O	O
,	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
elevation	NN	O	O
of	NN	O	O
VEGF	NN	O	O
protein	NN	O	O
expression	NN	O	O
initially	NN	O	O
occurred	NN	O	O
in	NN	O	O
both	NN	O	O
blood	NN	O	O
vessels	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
.	NN	O	O

After	NN	O	O
15	NN	O	O
days	NN	O	O
of	NN	O	O
E2	NN	O	B-Chemical
exposure	NN	O	O
,	NN	O	O
VEGF	NN	O	O
/	NN	O	O
VPF	NN	O	O
protein	NN	O	O
expression	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
endothelial	NN	O	O
cell	NN	O	O
population	NN	O	O
,	NN	O	O
sharply	NN	O	O
declined	NN	O	O
and	NN	O	O
was	NN	O	O
restricted	NN	O	O
to	NN	O	O
the	NN	O	O
blood	NN	O	O
vessels	NN	O	O
.	NN	O	O

The	NN	O	O
function	NN	O	O
of	NN	O	O
non	NN	O	O
-	NN	O	O
endothelial	NN	O	O
-	NN	O	O
derived	NN	O	O
VEGF	NN	O	O
is	NN	O	O
not	NN	O	O
clear	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
immunohistochemical	NN	O	O
studies	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
VEGFR	NN	O	O
-	NN	O	O
2	NN	O	O
(	NN	O	O
flk	NN	O	O
-	NN	O	O
1	NN	O	O
/	NN	O	O
KDR	NN	O	O
)	NN	O	O
,	NN	O	O
expression	NN	O	O
was	NN	O	O
elevated	NN	O	O
significantly	NN	O	O
in	NN	O	O
the	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
of	NN	O	O
microblood	NN	O	O
vessels	NN	O	O
after	NN	O	O
7	NN	O	O
days	NN	O	O
of	NN	O	O
E2	NN	O	B-Chemical
exposure	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
over	NN	O	O
expression	NN	O	O
of	NN	O	O
VEGF	NN	O	O
and	NN	O	O
its	NN	O	O
receptor	NN	O	O
(	NN	O	O
VEGFR	NN	O	O
-	NN	O	O
2	NN	O	O
)	NN	O	O
may	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
initial	NN	O	O
step	NN	O	O
of	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
estrogen	NN	O	B-Chemical
induced	NN	O	O
tumor	NN	O	B-Disease
angiogenesis	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
pituitary	NN	O	O
.	NN	O	O


-DOCSTART- (7604176)

Pravastatin	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
myopathy	NN	O	B-Disease
.	NN	O	O

Report	NN	O	O
of	NN	O	O
a	NN	O	O
case	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	O
inflammatory	NN	O	B-Disease
myopathy	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
pravastatin	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
new	NN	O	O
hydrophilic	NN	O	O
3	NN	O	O
-	NN	O	O
hydroxy	NN	O	O
-	NN	O	O
3	NN	O	O
methylglutaril	NN	O	O
coenzyme	NN	O	O
A	NN	O	O
reductase	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
is	NN	O	O
reported	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
,	NN	O	O
a	NN	O	O
69	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
was	NN	O	O
affected	NN	O	O
by	NN	O	O
non	NN	O	B-Disease
-	NN	O	I-Disease
insulin	NN	O	I-Disease
-	NN	O	I-Disease
dependent	NN	O	I-Disease
diabetes	NN	O	I-Disease
mellitus	NN	O	I-Disease
and	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O

He	NN	O	O
assumed	NN	O	O
pravastatin	NN	O	B-Chemical
(	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
because	NN	O	O
of	NN	O	O
hypercholesterolemia	NN	O	B-Disease
.	NN	O	O

He	NN	O	O
was	NN	O	O
admitted	NN	O	O
with	NN	O	O
acute	NN	O	O
myopathy	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
lower	NN	O	O
limbs	NN	O	O
which	NN	O	O
resolved	NN	O	O
in	NN	O	O
a	NN	O	O
few	NN	O	O
days	NN	O	O
after	NN	O	O
pravastatin	NN	O	B-Chemical
discontinuation	NN	O	O
.	NN	O	O

A	NN	O	O
previously	NN	O	O
unknown	NN	O	O
hypothyroidism	NN	O	B-Disease
,	NN	O	O
probably	NN	O	O
due	NN	O	O
to	NN	O	O
chronic	NN	O	O
autoimmune	NN	O	B-Disease
thyroiditis	NN	O	I-Disease
,	NN	O	O
was	NN	O	O
evidenced	NN	O	O
.	NN	O	O

Muscle	NN	O	O
biopsy	NN	O	O
(	NN	O	O
left	NN	O	O
gastrocnemius	NN	O	O
)	NN	O	O
revealed	NN	O	O
a	NN	O	O
perimysial	NN	O	O
and	NN	O	O
endomysial	NN	O	O
inflammatory	NN	O	O
infiltrate	NN	O	O
with	NN	O	O
a	NN	O	O
prevalence	NN	O	O
of	NN	O	O
CD4+	NN	O	O
lymphocytes	NN	O	O
.	NN	O	O

While	NN	O	O
lovastatin	NN	O	B-Chemical
and	NN	O	O
simvastatin	NN	O	B-Chemical
have	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
toxic	NN	O	O
myopathy	NN	O	B-Disease
,	NN	O	O
pravastatin	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
myopathy	NN	O	B-Disease
could	NN	O	O
represent	NN	O	O
a	NN	O	O
distinct	NN	O	O
,	NN	O	O
inflammatory	NN	O	O
entity	NN	O	O
.	NN	O	O


-DOCSTART- (7282516)

Dose	NN	O	O
-	NN	O	O
effect	NN	O	O
and	NN	O	O
structure	NN	O	O
-	NN	O	O
function	NN	O	O
relationships	NN	O	O
in	NN	O	O
doxorubicin	NN	O	B-Chemical
cardiomyopathy	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
cardiomyopathy	NN	O	B-Disease
(	NN	O	O
CM	NN	O	B-Disease
)	NN	O	O
produced	NN	O	O
by	NN	O	O
the	NN	O	O
anticancer	NN	O	O
drug	NN	O	O
doxorubicin	NN	O	B-Chemical
(	NN	O	O
DXR	NN	O	B-Chemical
)	NN	O	O
(	NN	O	O
Adriamycin	NN	O	B-Chemical
)	NN	O	O
provides	NN	O	O
a	NN	O	O
unique	NN	O	O
opportunity	NN	O	O
to	NN	O	O
analyze	NN	O	O
dose	NN	O	O
-	NN	O	O
effect	NN	O	O
and	NN	O	O
structure	NN	O	O
-	NN	O	O
function	NN	O	O
relationships	NN	O	O
during	NN	O	O
development	NN	O	O
of	NN	O	O
myocardial	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
measured	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
morphologic	NN	O	O
damage	NN	O	O
by	NN	O	O
ultrastructural	NN	O	O
examination	NN	O	O
of	NN	O	O
endomyocardial	NN	O	O
biopsy	NN	O	O
and	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
performance	NN	O	O
abnormally	NN	O	O
by	NN	O	O
right	NN	O	O
heart	NN	O	O
catheterization	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
DXR	NN	O	B-Chemical
.	NN	O	O

Morphologic	NN	O	O
damage	NN	O	O
was	NN	O	O
variable	NN	O	O
but	NN	O	O
was	NN	O	O
proportional	NN	O	O
to	NN	O	O
the	NN	O	O
total	NN	O	O
cumulative	NN	O	O
DXR	NN	O	B-Chemical
dose	NN	O	O
between	NN	O	O
100	NN	O	O
and	NN	O	O
600	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
.	NN	O	O

Performance	NN	O	O
abnormalities	NN	O	O
correlated	NN	O	O
weakly	NN	O	O
with	NN	O	O
dose	NN	O	O
,	NN	O	O
exhibited	NN	O	O
a	NN	O	O
curvilinear	NN	O	O
relationship	NN	O	O
,	NN	O	O
and	NN	O	O
had	NN	O	O
a	NN	O	O
"	NN	O	O
threshold	NN	O	O
"	NN	O	O
for	NN	O	O
expression	NN	O	O
.	NN	O	O

Catheterization	NN	O	O
abnormalities	NN	O	O
correlated	NN	O	O
well	NN	O	O
with	NN	O	O
morphologic	NN	O	O
damage	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.57	NN	O	O
to	NN	O	O
0.78	NN	O	O
)	NN	O	O
in	NN	O	O
a	NN	O	O
subgroup	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
whom	NN	O	O
exercise	NN	O	O
hemodynamics	NN	O	O
were	NN	O	O
measured	NN	O	O
,	NN	O	O
and	NN	O	O
this	NN	O	O
relationship	NN	O	O
also	NN	O	O
exhibited	NN	O	O
a	NN	O	O
curvilinear	NN	O	O
,	NN	O	O
threshold	NN	O	O
configuration	NN	O	O
.	NN	O	O

In	NN	O	O
DXR	NN	O	B-Chemical
-	NN	O	O
CM	NN	O	B-Disease
myocardial	NN	O	B-Disease
damage	NN	O	I-Disease
is	NN	O	O
proportional	NN	O	O
to	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
cytotoxic	NN	O	O
insult	NN	O	O
(	NN	O	O
DXR	NN	O	B-Chemical
dose	NN	O	O
)	NN	O	O
while	NN	O	O
myocardial	NN	O	O
function	NN	O	O
is	NN	O	O
preserved	NN	O	O
until	NN	O	O
a	NN	O	O
critical	NN	O	O
dose	NN	O	O
or	NN	O	O
degree	NN	O	O
of	NN	O	O
damage	NN	O	O
is	NN	O	O
reached	NN	O	O
,	NN	O	O
after	NN	O	O
which	NN	O	O
myocardial	NN	O	O
performance	NN	O	O
deteriorates	NN	O	O
rapidly	NN	O	O
.	NN	O	O


-DOCSTART- (7072798)

Fatal	NN	O	O
aplastic	NN	O	B-Disease
anemia	NN	O	I-Disease
following	NN	O	O
topical	NN	O	O
administration	NN	O	O
of	NN	O	O
ophthalmic	NN	O	O
chloramphenicol	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
73	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
died	NN	O	O
of	NN	O	O
aplastic	NN	O	B-Disease
anemia	NN	O	I-Disease
less	NN	O	O
than	NN	O	O
two	NN	O	O
months	NN	O	O
after	NN	O	O
undergoing	NN	O	O
cataract	NN	O	B-Disease
extraction	NN	O	O
and	NN	O	O
beginning	NN	O	O
topical	NN	O	O
therapy	NN	O	O
with	NN	O	O
chloramphenicol	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
first	NN	O	O
signs	NN	O	O
of	NN	O	O
pancytopenia	NN	O	B-Disease
began	NN	O	O
within	NN	O	O
one	NN	O	O
month	NN	O	O
of	NN	O	O
the	NN	O	O
surgery	NN	O	O
.	NN	O	O

The	NN	O	O
pattern	NN	O	O
of	NN	O	O
the	NN	O	O
aplastic	NN	O	B-Disease
anemia	NN	O	I-Disease
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
idiosyncratic	NN	O	O
response	NN	O	O
to	NN	O	O
chloramphenicol	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
was	NN	O	O
the	NN	O	O
second	NN	O	O
report	NN	O	O
of	NN	O	O
fatal	NN	O	O
aplastic	NN	O	B-Disease
anemia	NN	O	I-Disease
after	NN	O	O
topical	NN	O	O
treatment	NN	O	O
with	NN	O	O
chloramphenicol	NN	O	B-Chemical
for	NN	O	O
ocular	NN	O	O
conditions	NN	O	O
,	NN	O	O
although	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
reversible	NN	O	O
bone	NN	O	B-Disease
marrow	NN	O	I-Disease
hypoplasia	NN	O	I-Disease
have	NN	O	O
also	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

Any	NN	O	O
other	NN	O	O
suspected	NN	O	O
cases	NN	O	O
of	NN	O	O
ocular	NN	O	B-Disease
toxicity	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
topically	NN	O	O
applied	NN	O	O
chloramphenicol	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
reported	NN	O	O
to	NN	O	O
the	NN	O	O
National	NN	O	O
Registry	NN	O	O
of	NN	O	O
Drug	NN	O	O
-	NN	O	O
Induced	NN	O	O
Ocular	NN	O	O
Side	NN	O	O
Effects	NN	O	O
,	NN	O	O
Oregon	NN	O	O
Health	NN	O	O
Sciences	NN	O	O
University	NN	O	O
,	NN	O	O
Portland	NN	O	O
,	NN	O	O
OR	NN	O	O
97201	NN	O	O
.	NN	O	O


-DOCSTART- (3769769)

Bradycardia	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
trihexyphenidyl	NN	O	B-Chemical
hydrochloride	NN	O	I-Chemical
.	NN	O	O

A	NN	O	O
chronic	NN	O	O
schizophrenic	NN	O	B-Disease
patient	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
an	NN	O	O
anticholinergic	NN	O	O
drug	NN	O	O
,	NN	O	O
trihexyphenidyl	NN	O	B-Chemical
hydrochloride	NN	O	I-Chemical
.	NN	O	O

The	NN	O	O
patient	NN	O	O
developed	NN	O	O
,	NN	O	O
paradoxically	NN	O	O
,	NN	O	O
sinus	NN	O	O
bradycardia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
reaction	NN	O	O
was	NN	O	O
specific	NN	O	O
to	NN	O	O
trihexyphenidyl	NN	O	B-Chemical
and	NN	O	O
not	NN	O	O
to	NN	O	O
other	NN	O	O
anticholinergic	NN	O	O
drugs	NN	O	O
.	NN	O	O

This	NN	O	O
antidyskinetic	NN	O	O
drug	NN	O	O
is	NN	O	O
widely	NN	O	O
used	NN	O	O
in	NN	O	O
clinical	NN	O	O
psychiatric	NN	O	B-Disease
practice	NN	O	O
and	NN	O	O
physicians	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
side	NN	O	O
effect	NN	O	O
.	NN	O	O


-DOCSTART- (3708922)

Experimental	NN	O	O
cyclosporine	NN	O	B-Chemical
nephrotoxicity	NN	O	B-Disease
:	NN	O	O
risk	NN	O	O
of	NN	O	O
concomitant	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

The	NN	O	O
role	NN	O	O
of	NN	O	O
cyclosporine	NN	O	B-Chemical
(	NN	O	O
CSA	NN	O	B-Chemical
)	NN	O	O
alone	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
various	NN	O	O
chemotherapeutics	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
toxicity	NN	O	I-Disease
was	NN	O	O
evaluated	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
CSA	NN	O	B-Chemical
for	NN	O	O
4	NN	O	O
weeks	NN	O	O
caused	NN	O	O
renal	NN	O	O
functional	NN	O	O
and	NN	O	O
structural	NN	O	O
changes	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
reported	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O

The	NN	O	O
combined	NN	O	O
administration	NN	O	O
of	NN	O	O
CSA	NN	O	B-Chemical
and	NN	O	O
various	NN	O	O
chemotherapeutic	NN	O	O
drugs	NN	O	O
with	NN	O	O
a	NN	O	O
nephrotoxic	NN	O	B-Disease
potential	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
gentamicin	NN	O	B-Chemical
(	NN	O	O
at	NN	O	O
therapeutic	NN	O	O
doses	NN	O	O
)	NN	O	O
,	NN	O	O
amphothericin	NN	O	B-Chemical
B	NN	O	I-Chemical
and	NN	O	O
ketoconazole	NN	O	B-Chemical
,	NN	O	O
which	NN	O	O
are	NN	O	O
frequently	NN	O	O
used	NN	O	O
in	NN	O	O
immunosuppressed	NN	O	O
patients	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
aggravate	NN	O	O
the	NN	O	O
CSA	NN	O	B-Chemical
induced	NN	O	O
toxicity	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
rat	NN	O	O
model	NN	O	O
.	NN	O	O

Gentamicin	NN	O	B-Chemical
at	NN	O	O
toxic	NN	O	O
doses	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
increased	NN	O	O
CSA	NN	O	B-Chemical
nephrotoxicity	NN	O	B-Disease
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
the	NN	O	O
nephrotoxicity	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
CSA	NN	O	B-Chemical
has	NN	O	O
a	NN	O	O
different	NN	O	O
pathogenetic	NN	O	O
mechanism	NN	O	O
.	NN	O	O


-DOCSTART- (3220106)

Receptor	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
nicotine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	B-Disease
hyperactivity	NN	O	I-Disease
in	NN	O	O
chronic	NN	O	O
nicotine	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
pretreated	NN	O	O
with	NN	O	O
saline	NN	O	O
or	NN	O	O
nicotine	NN	O	B-Chemical
(	NN	O	O
1.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
)	NN	O	O
by	NN	O	O
subcutaneously	NN	O	O
implanting	NN	O	O
each	NN	O	O
animal	NN	O	O
with	NN	O	O
an	NN	O	O
Alzet	NN	O	O
osmotic	NN	O	O
mini	NN	O	O
-	NN	O	O
pump	NN	O	O
which	NN	O	O
continuously	NN	O	O
released	NN	O	O
saline	NN	O	O
or	NN	O	O
nicotine	NN	O	B-Chemical
for	NN	O	O
1	NN	O	O
,	NN	O	O
5	NN	O	O
and	NN	O	O
14	NN	O	O
days	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
each	NN	O	O
pretreatment	NN	O	O
period	NN	O	O
,	NN	O	O
animals	NN	O	O
were	NN	O	O
used	NN	O	O
for	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
determining	NN	O	O
their	NN	O	O
locomotor	NN	O	O
response	NN	O	O
to	NN	O	O
acutely	NN	O	O
injected	NN	O	O
nicotine	NN	O	B-Chemical
(	NN	O	O
0.2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
s.c.	NN	O	O
)	NN	O	O
and	NN	O	O
(	NN	O	O
ii	NN	O	O
)	NN	O	O
measuring	NN	O	O
the	NN	O	O
density	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
nicotine	NN	O	B-Chemical
and	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
spiperone	NN	O	B-Chemical
binding	NN	O	O
sites	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
.	NN	O	O

We	NN	O	O
observed	NN	O	O
no	NN	O	O
changes	NN	O	O
in	NN	O	O
nicotine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	O
response	NN	O	O
,	NN	O	O
striatal	NN	O	O
L	NN	O	O
-	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
nicotine	NN	O	B-Chemical
and	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
spiperone	NN	O	B-Chemical
binding	NN	O	O
in	NN	O	O
the	NN	O	O
animals	NN	O	O
pretreated	NN	O	O
with	NN	O	O
nicotine	NN	O	B-Chemical
for	NN	O	O
1	NN	O	O
day	NN	O	O
.	NN	O	O

In	NN	O	O
rats	NN	O	O
which	NN	O	O
were	NN	O	O
pretreated	NN	O	O
with	NN	O	O
nicotine	NN	O	B-Chemical
for	NN	O	O
5	NN	O	O
days	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
nicotine	NN	O	B-Chemical
-	NN	O	O
stimulated	NN	O	O
locomotor	NN	O	O
response	NN	O	O
which	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
L	NN	O	O
-	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
nicotine	NN	O	B-Chemical
binding	NN	O	O
sites	NN	O	O
and	NN	O	O
also	NN	O	O
with	NN	O	O
an	NN	O	O
elevated	NN	O	O
dopamine	NN	O	B-Chemical
(	NN	O	O
DA	NN	O	B-Chemical
)	NN	O	O
level	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
striatal	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
spiperone	NN	O	B-Chemical
binding	NN	O	O
sites	NN	O	O
was	NN	O	O
not	NN	O	O
affected	NN	O	O
.	NN	O	O

In	NN	O	O
animals	NN	O	O
pretreated	NN	O	O
with	NN	O	O
nicotine	NN	O	B-Chemical
for	NN	O	O
14	NN	O	O
days	NN	O	O
,	NN	O	O
the	NN	O	O
nicotine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
locomotor	NN	O	O
response	NN	O	O
remained	NN	O	O
to	NN	O	O
be	NN	O	O
potentiated	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
this	NN	O	O
response	NN	O	O
was	NN	O	O
correlated	NN	O	O
with	NN	O	O
an	NN	O	O
elevated	NN	O	O
number	NN	O	O
of	NN	O	O
striatal	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
spiperone	NN	O	B-Chemical
binding	NN	O	O
sites	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
striatal	NN	O	O
L	NN	O	O
-	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
nicotine	NN	O	B-Chemical
binding	NN	O	O
sites	NN	O	O
and	NN	O	O
the	NN	O	O
striatal	NN	O	O
DA	NN	O	B-Chemical
level	NN	O	O
were	NN	O	O
normal	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
chronic	NN	O	O
nicotine	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
develop	NN	O	O
locomotor	NN	O	B-Disease
hyperactivity	NN	O	I-Disease
in	NN	O	O
response	NN	O	O
to	NN	O	O
nicotine	NN	O	B-Chemical
initially	NN	O	O
due	NN	O	O
to	NN	O	O
increases	NN	O	O
of	NN	O	O
both	NN	O	O
the	NN	O	O
density	NN	O	O
of	NN	O	O
nicotinic	NN	O	O
receptors	NN	O	O
and	NN	O	O
DA	NN	O	B-Chemical
concentration	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
inducing	NN	O	O
DA	NN	O	B-Chemical
receptor	NN	O	O
supersensitivity	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
.	NN	O	O


-DOCSTART- (2722224)

Hydrocortisone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B-Disease
in	NN	O	O
humans	NN	O	O
:	NN	O	O
pressor	NN	O	O
responsiveness	NN	O	O
and	NN	O	O
sympathetic	NN	O	O
function	NN	O	O
.	NN	O	O

Oral	NN	O	O
hydrocortisone	NN	O	B-Chemical
increases	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
enhances	NN	O	O
pressor	NN	O	O
responsiveness	NN	O	O
in	NN	O	O
normal	NN	O	O
human	NN	O	O
subjects	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
1	NN	O	O
week	NN	O	O
of	NN	O	O
oral	NN	O	O
hydrocortisone	NN	O	B-Chemical
(	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
on	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
cardiac	NN	O	O
output	NN	O	O
,	NN	O	O
total	NN	O	O
peripheral	NN	O	O
resistance	NN	O	O
,	NN	O	O
forearm	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
,	NN	O	O
and	NN	O	O
norepinephrine	NN	O	B-Chemical
spillover	NN	O	O
to	NN	O	O
plasma	NN	O	O
in	NN	O	O
eight	NN	O	O
healthy	NN	O	O
male	NN	O	O
volunteers	NN	O	O
.	NN	O	O

Although	NN	O	O
diastolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
,	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
increased	NN	O	O
from	NN	O	O
119	NN	O	O
to	NN	O	O
135	NN	O	O
mm	NN	O	O
Hg	NN	O	O
(	NN	O	O
SED	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3.4	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.01	NN	O	O
)	NN	O	O
,	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	B-Disease
cardiac	NN	O	I-Disease
output	NN	O	I-Disease
(	NN	O	O
5.85	NN	O	O
-	NN	O	O
7.73	NN	O	O
l	NN	O	O
/	NN	O	O
min	NN	O	O
,	NN	O	O
SED	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.46	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

Total	NN	O	O
peripheral	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
fell	NN	O	O
from	NN	O	O
15.1	NN	O	O
to	NN	O	O
12.2	NN	O	O
mm	NN	O	O
Hg	NN	O	O
/	NN	O	O
l	NN	O	O
/	NN	O	O
min	NN	O	O
(	NN	O	O
SED	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.03	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Resting	NN	O	O
forearm	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
reflex	NN	O	O
response	NN	O	O
to	NN	O	O
the	NN	O	O
cold	NN	O	O
pressor	NN	O	O
test	NN	O	O
was	NN	O	O
accentuated	NN	O	O
,	NN	O	O
the	NN	O	O
rise	NN	O	O
in	NN	O	O
resistance	NN	O	O
increasing	NN	O	O
from	NN	O	O
10.5	NN	O	O
mm	NN	O	O
Hg	NN	O	O
/	NN	O	O
ml	NN	O	O
/	NN	O	O
100	NN	O	O
ml	NN	O	O
/	NN	O	O
min	NN	O	O
(	NN	O	O
R	NN	O	O
units	NN	O	O
)	NN	O	O
before	NN	O	O
treatment	NN	O	O
to	NN	O	O
32.6	NN	O	O
R	NN	O	O
units	NN	O	O
after	NN	O	O
treatment	NN	O	O
(	NN	O	O
SED	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6.4	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.025	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
rise	NN	O	O
in	NN	O	O
forearm	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
accompanying	NN	O	O
intra	NN	O	O
-	NN	O	O
arterial	NN	O	O
norepinephrine	NN	O	B-Chemical
(	NN	O	O
25	NN	O	O
,	NN	O	O
50	NN	O	O
,	NN	O	O
and	NN	O	O
100	NN	O	O
ng	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
was	NN	O	O
also	NN	O	O
significantly	NN	O	O
greater	NN	O	O
after	NN	O	O
hydrocortisone	NN	O	B-Chemical
,	NN	O	O
increasing	NN	O	O
from	NN	O	O
an	NN	O	O
average	NN	O	O
of	NN	O	O
14.9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.4	NN	O	O
R	NN	O	O
units	NN	O	O
before	NN	O	O
treatment	NN	O	O
to	NN	O	O
35.1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5.5	NN	O	O
R	NN	O	O
units	NN	O	O
after	NN	O	O
hydrocortisone	NN	O	B-Chemical
(	NN	O	O
SED	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6.0	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
shift	NN	O	O
to	NN	O	O
the	NN	O	O
left	NN	O	O
in	NN	O	O
the	NN	O	O
dose	NN	O	O
-	NN	O	O
response	NN	O	O
relation	NN	O	O
and	NN	O	O
fall	NN	O	O
in	NN	O	O
threshold	NN	O	O
suggested	NN	O	O
increased	NN	O	O
sensitivity	NN	O	O
to	NN	O	O
norepinephrine	NN	O	B-Chemical
after	NN	O	O
treatment	NN	O	O
.	NN	O	O

Measurement	NN	O	O
of	NN	O	O
resting	NN	O	O
norepinephrine	NN	O	B-Chemical
spillover	NN	O	O
rate	NN	O	O
to	NN	O	O
plasma	NN	O	O
and	NN	O	O
norepinephrine	NN	O	B-Chemical
uptake	NN	O	O
indicated	NN	O	O
that	NN	O	O
overall	NN	O	O
resting	NN	O	O
sympathetic	NN	O	O
nervous	NN	O	O
system	NN	O	O
activity	NN	O	O
was	NN	O	O
not	NN	O	O
increased	NN	O	O
.	NN	O	O

The	NN	O	O
rise	NN	O	B-Disease
in	NN	O	I-Disease
resting	NN	O	I-Disease
blood	NN	O	I-Disease
pressure	NN	O	I-Disease
with	NN	O	O
hydrocortisone	NN	O	B-Chemical
is	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	B-Disease
cardiac	NN	O	I-Disease
output	NN	O	I-Disease
(	NN	O	O
presumably	NN	O	O
due	NN	O	O
to	NN	O	O
increased	NN	O	O
blood	NN	O	O
volume	NN	O	O
)	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

-DOCSTART- (1636026)

Effects	NN	O	O
of	NN	O	O
suprofen	NN	O	B-Chemical
on	NN	O	O
the	NN	O	O
isolated	NN	O	O
perfused	NN	O	O
rat	NN	O	O
kidney	NN	O	O
.	NN	O	O

Although	NN	O	O
suprofen	NN	O	B-Chemical
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
in	NN	O	O
greater	NN	O	O
than	NN	O	O
100	NN	O	O
subjects	NN	O	O
,	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
damage	NN	O	O
remains	NN	O	O
unclear	NN	O	O
.	NN	O	O

The	NN	O	O
direct	NN	O	O
nephrotoxic	NN	O	B-Disease
effects	NN	O	O
of	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
15	NN	O	O
mg	NN	O	O
of	NN	O	O
suprofen	NN	O	B-Chemical
were	NN	O	O
compared	NN	O	O
in	NN	O	O
the	NN	O	O
recirculating	NN	O	O
isolated	NN	O	O
rat	NN	O	O
kidney	NN	O	O
perfused	NN	O	O
with	NN	O	O
cell	NN	O	O
-	NN	O	O
free	NN	O	O
buffer	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
of	NN	O	O
uric	NN	O	B-Chemical
acid	NN	O	I-Chemical
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
renal	NN	O	O
sodium	NN	O	B-Chemical
excretion	NN	O	O
,	NN	O	O
oxygen	NN	O	B-Chemical
consumption	NN	O	O
,	NN	O	O
or	NN	O	O
urinary	NN	O	O
flow	NN	O	O
rates	NN	O	O
in	NN	O	O
kidneys	NN	O	O
perfused	NN	O	O
with	NN	O	O
suprofen	NN	O	B-Chemical
compared	NN	O	O
with	NN	O	O
the	NN	O	O
drug	NN	O	O
-	NN	O	O
free	NN	O	O
control	NN	O	O
groups	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
a	NN	O	O
significant	NN	O	O
decline	NN	O	O
in	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
was	NN	O	O
found	NN	O	O
after	NN	O	O
the	NN	O	O
introduction	NN	O	O
of	NN	O	O
suprofen	NN	O	B-Chemical
to	NN	O	O
the	NN	O	O
kidney	NN	O	O
perfused	NN	O	O
with	NN	O	O
uric	NN	O	B-Chemical
acid	NN	O	I-Chemical
;	NN	O	O
no	NN	O	O
changes	NN	O	O
were	NN	O	O
found	NN	O	O
with	NN	O	O
suprofen	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
uric	NN	O	B-Chemical
acid	NN	O	I-Chemical
.	NN	O	O

A	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
baseline	NN	O	O
excretion	NN	O	O
rate	NN	O	O
of	NN	O	O
uric	NN	O	B-Chemical
acid	NN	O	I-Chemical
was	NN	O	O
found	NN	O	O
in	NN	O	O
rats	NN	O	O
given	NN	O	O
suprofen	NN	O	B-Chemical
,	NN	O	O
compared	NN	O	O
with	NN	O	O
drug	NN	O	O
-	NN	O	O
free	NN	O	O
controls	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
fractional	NN	O	O
excretion	NN	O	O
of	NN	O	O
uric	NN	O	B-Chemical
acid	NN	O	I-Chemical
was	NN	O	O
unchanged	NN	O	O
between	NN	O	O
the	NN	O	O
groups	NN	O	O
over	NN	O	O
the	NN	O	O
experimental	NN	O	O
period	NN	O	O
.	NN	O	O

In	NN	O	O
summary	NN	O	O
,	NN	O	O
suprofen	NN	O	B-Chemical
causes	NN	O	O
acute	NN	O	B-Disease
declines	NN	O	I-Disease
in	NN	O	I-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
,	NN	O	O
most	NN	O	O
likely	NN	O	O
by	NN	O	O
directly	NN	O	O
altering	NN	O	O
the	NN	O	O
intrarenal	NN	O	O
distribution	NN	O	O
of	NN	O	O
uric	NN	O	B-Chemical
acid	NN	O	I-Chemical
.	NN	O	O


-DOCSTART- (1610717)

Cocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
brainstem	NN	O	O
seizures	NN	O	B-Disease
and	NN	O	O
behavior	NN	O	O
.	NN	O	O

A	NN	O	O
variety	NN	O	O
of	NN	O	O
abnormal	NN	O	O
sensory	NN	O	O
/	NN	O	O
motor	NN	O	O
behaviors	NN	O	O
associated	NN	O	O
with	NN	O	O
electrical	NN	O	O
discharges	NN	O	O
recorded	NN	O	O
from	NN	O	O
the	NN	O	O
bilateral	NN	O	O
brainstem	NN	O	O
were	NN	O	O
induced	NN	O	O
in	NN	O	O
adult	NN	O	O
WKY	NN	O	O
rats	NN	O	O
by	NN	O	O
mechanical	NN	O	O
(	NN	O	O
electrode	NN	O	O
implants	NN	O	O
)	NN	O	O
and	NN	O	O
DC	NN	O	O
electrical	NN	O	O
current	NN	O	O
stimulations	NN	O	O
and	NN	O	O
by	NN	O	O
acute	NN	O	O
and	NN	O	O
chronic	NN	O	O
administration	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
electrode	NN	O	O
implant	NN	O	O
implicated	NN	O	O
one	NN	O	O
side	NN	O	O
or	NN	O	O
the	NN	O	O
other	NN	O	O
of	NN	O	O
the	NN	O	O
reticular	NN	O	O
system	NN	O	O
of	NN	O	O
the	NN	O	O
brainstem	NN	O	O
but	NN	O	O
subjects	NN	O	O
were	NN	O	O
not	NN	O	O
incapacitated	NN	O	O
by	NN	O	O
the	NN	O	O
stimulations	NN	O	O
.	NN	O	O

Cocaine	NN	O	B-Chemical
(	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
injected	NN	O	O
subcutaneously	NN	O	O
for	NN	O	O
an	NN	O	O
acute	NN	O	O
experiment	NN	O	O
and	NN	O	O
subsequent	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
doses	NN	O	O
twice	NN	O	O
daily	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
in	NN	O	O
a	NN	O	O
chronic	NN	O	O
study	NN	O	O
.	NN	O	O

Cocaine	NN	O	B-Chemical
generated	NN	O	O
more	NN	O	O
abnormal	NN	O	O
behaviors	NN	O	O
in	NN	O	O
the	NN	O	O
brainstem	NN	O	O
perturbation	NN	O	O
group	NN	O	O
,	NN	O	O
especially	NN	O	O
the	NN	O	O
electrically	NN	O	O
perturbated	NN	O	O
subjects	NN	O	O
.	NN	O	O

The	NN	O	O
abnormal	NN	O	O
behaviors	NN	O	O
were	NN	O	O
yawning	NN	O	O
,	NN	O	O
retrocollis	NN	O	O
,	NN	O	O
hyperactivity	NN	O	B-Disease
,	NN	O	O
hypersensitivity	NN	O	B-Disease
,	NN	O	O
"	NN	O	O
beating	NN	O	O
drum	NN	O	O
"	NN	O	O
behavior	NN	O	O
,	NN	O	O
squealing	NN	O	O
,	NN	O	O
head	NN	O	O
bobbing	NN	O	O
,	NN	O	O
circling	NN	O	O
,	NN	O	O
sniffing	NN	O	O
,	NN	O	O
abnormal	NN	O	O
posturing	NN	O	O
,	NN	O	O
and	NN	O	O
facial	NN	O	O
twitching	NN	O	O
.	NN	O	O

Shifts	NN	O	O
in	NN	O	O
the	NN	O	O
power	NN	O	O
frequency	NN	O	O
spectra	NN	O	O
of	NN	O	O
the	NN	O	O
discharge	NN	O	O
patterns	NN	O	O
were	NN	O	O
noted	NN	O	O
between	NN	O	O
quiet	NN	O	O
and	NN	O	O
pacing	NN	O	O
behavioral	NN	O	O
states	NN	O	O
.	NN	O	O

Hypersensitivity	NN	O	B-Disease
to	NN	O	O
various	NN	O	O
auditory	NN	O	O
,	NN	O	O
tactile	NN	O	O
,	NN	O	O
and	NN	O	O
visual	NN	O	O
stimulation	NN	O	O
was	NN	O	O
present	NN	O	O
and	NN	O	O
shifts	NN	O	O
in	NN	O	O
the	NN	O	O
brainstem	NN	O	O
ambient	NN	O	O
power	NN	O	O
spectral	NN	O	O
frequency	NN	O	O
occurred	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
tactile	NN	O	O
stimulation	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
brainstem	NN	O	O
generates	NN	O	O
and	NN	O	O
propagates	NN	O	O
pathological	NN	O	O
discharges	NN	O	O
that	NN	O	O
can	NN	O	O
be	NN	O	O
elicited	NN	O	O
by	NN	O	O
mechanical	NN	O	O
and	NN	O	O
DC	NN	O	O
electrical	NN	O	O
perturbation	NN	O	O
.	NN	O	O

Cocaine	NN	O	B-Chemical
was	NN	O	O
found	NN	O	O
to	NN	O	O
activate	NN	O	O
the	NN	O	O
discharge	NN	O	O
system	NN	O	O
and	NN	O	O
thus	NN	O	O
induce	NN	O	O
abnormal	NN	O	O
behaviors	NN	O	O
that	NN	O	O
are	NN	O	O
generated	NN	O	O
at	NN	O	O
the	NN	O	O
discharge	NN	O	O
site	NN	O	O
and	NN	O	O
at	NN	O	O
distant	NN	O	O
sites	NN	O	O
to	NN	O	O
which	NN	O	O
the	NN	O	O
discharge	NN	O	O
propagates	NN	O	O
.	NN	O	O

Cognitive	NN	O	O
functions	NN	O	O
may	NN	O	O
also	NN	O	O
be	NN	O	O
involved	NN	O	O
since	NN	O	O
dopaminergic	NN	O	O
and	NN	O	O
serotonergic	NN	O	O
cellular	NN	O	O
elements	NN	O	O
at	NN	O	O
the	NN	O	O
brainstem	NN	O	O
level	NN	O	O
are	NN	O	O
also	NN	O	O
implicated	NN	O	O
.	NN	O	O


-DOCSTART- (873132)

Increased	NN	O	O
sulfation	NN	O	O
and	NN	O	O
decreased	NN	O	O
7alpha	NN	O	O
-	NN	O	O
hydroxylation	NN	O	O
of	NN	O	O
deoxycholic	NN	O	B-Chemical
acid	NN	O	I-Chemical
in	NN	O	O
ethinyl	NN	O	B-Chemical
estradiol	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
cholestasis	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Deoxycholic	NN	O	B-Chemical
acid	NN	O	I-Chemical
conjugation	NN	O	O
,	NN	O	O
transport	NN	O	O
capacity	NN	O	O
,	NN	O	O
and	NN	O	O
metabolism	NN	O	O
were	NN	O	O
compared	NN	O	O
in	NN	O	O
control	NN	O	O
and	NN	O	O
ethinyl	NN	O	B-Chemical
estradiol	NN	O	I-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Control	NN	O	O
rats	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
lower	NN	O	O
capacity	NN	O	O
to	NN	O	O
transport	NN	O	O
deoxycholic	NN	O	B-Chemical
acid	NN	O	I-Chemical
than	NN	O	O
taurodeoxycholic	NN	O	B-Chemical
acid	NN	O	I-Chemical
,	NN	O	O
and	NN	O	O
both	NN	O	O
were	NN	O	O
decreased	NN	O	O
by	NN	O	O
ethinyl	NN	O	B-Chemical
estradiol	NN	O	I-Chemical
treatment	NN	O	O
.	NN	O	O

During	NN	O	O
[	NN	O	O
24	NN	O	O
-	NN	O	O
14C	NN	O	O
]	NN	O	O
sodium	NN	O	B-Chemical
deoxycholate	NN	O	I-Chemical
infusion	NN	O	O
,	NN	O	O
[	NN	O	O
14C	NN	O	O
]	NN	O	O
biliary	NN	O	O
bile	NN	O	B-Chemical
acid	NN	O	I-Chemical
secretion	NN	O	O
increased	NN	O	O
,	NN	O	O
but	NN	O	O
bile	NN	O	O
flow	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
significantly	NN	O	O
in	NN	O	O
either	NN	O	O
control	NN	O	O
or	NN	O	O
ethinyl	NN	O	B-Chemical
estradiol	NN	O	I-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Ethinyl	NN	O	B-Chemical
estradiol	NN	O	I-Chemical
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
excreted	NN	O	O
significantly	NN	O	O
less	NN	O	O
14C	NN	O	O
as	NN	O	O
taurocholic	NN	O	B-Chemical
acid	NN	O	I-Chemical
than	NN	O	O
did	NN	O	O
control	NN	O	O
animals	NN	O	O
,	NN	O	O
consistent	NN	O	O
with	NN	O	O
an	NN	O	O
impairment	NN	O	O
of	NN	O	O
7alpha	NN	O	O
-	NN	O	O
hydroxylation	NN	O	O
of	NN	O	O
taurodeoxycholic	NN	O	B-Chemical
acid	NN	O	I-Chemical
.	NN	O	O

Ethinyl	NN	O	B-Chemical
estradiol	NN	O	I-Chemical
treatment	NN	O	O
did	NN	O	O
not	NN	O	O
impair	NN	O	O
conjugation	NN	O	O
of	NN	O	O
deoxycholic	NN	O	B-Chemical
acid	NN	O	I-Chemical
,	NN	O	O
but	NN	O	O
did	NN	O	O
result	NN	O	O
in	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
sulfation	NN	O	O
of	NN	O	O
taurodeoxycholic	NN	O	B-Chemical
acid	NN	O	I-Chemical
from	NN	O	O
1.5%	NN	O	O
in	NN	O	O
controls	NN	O	O
to	NN	O	O
nearly	NN	O	O
4.0%	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
the	NN	O	O
rat	NN	O	O
has	NN	O	O
a	NN	O	O
poorer	NN	O	O
tolerance	NN	O	O
for	NN	O	O
deoxycholic	NN	O	B-Chemical
acid	NN	O	I-Chemical
than	NN	O	O
do	NN	O	O
certain	NN	O	O
other	NN	O	O
species	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
rat	NN	O	O
converts	NN	O	O
deoxycholic	NN	O	B-Chemical
acid	NN	O	I-Chemical
,	NN	O	O
a	NN	O	O
poor	NN	O	O
choleretic	NN	O	O
,	NN	O	O
to	NN	O	O
taurocholic	NN	O	B-Chemical
acid	NN	O	I-Chemical
,	NN	O	O
a	NN	O	O
good	NN	O	O
choleretic	NN	O	O
.	NN	O	O

When	NN	O	O
this	NN	O	O
conversion	NN	O	O
is	NN	O	O
impaired	NN	O	O
with	NN	O	O
ethinyl	NN	O	B-Chemical
estradiol	NN	O	I-Chemical
treatment	NN	O	O
,	NN	O	O
sulfation	NN	O	O
may	NN	O	O
be	NN	O	O
an	NN	O	O
important	NN	O	O
alternate	NN	O	O
pathway	NN	O	O
for	NN	O	O
excretion	NN	O	O
of	NN	O	O
this	NN	O	O
potentially	NN	O	O
harmful	NN	O	O
bile	NN	O	B-Chemical
acid	NN	O	I-Chemical
.	NN	O	O


-DOCSTART- (783197)

Effects	NN	O	O
of	NN	O	O
ouabain	NN	O	B-Chemical
on	NN	O	O
myocardial	NN	O	O
oxygen	NN	O	B-Chemical
supply	NN	O	O
and	NN	O	O
demand	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
hemodynamic	NN	O	O
,	NN	O	O
volumetric	NN	O	O
,	NN	O	O
and	NN	O	O
metabolic	NN	O	O
study	NN	O	O
in	NN	O	O
patients	NN	O	O
without	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
digitalis	NN	O	B-Chemical
glycosides	NN	O	I-Chemical
on	NN	O	O
myocardial	NN	O	O
oxygen	NN	O	B-Chemical
supply	NN	O	O
and	NN	O	O
demand	NN	O	O
are	NN	O	O
of	NN	O	O
particular	NN	O	O
interest	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
obstructive	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
but	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
measured	NN	O	O
previously	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O

We	NN	O	O
assessed	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
ouabain	NN	O	B-Chemical
(	NN	O	O
0.015	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
on	NN	O	O
hemodynamic	NN	O	O
,	NN	O	O
volumetric	NN	O	O
,	NN	O	O
and	NN	O	O
metabolic	NN	O	O
parameters	NN	O	O
in	NN	O	O
11	NN	O	O
patients	NN	O	O
with	NN	O	O
severe	NN	O	O
chronic	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
without	NN	O	O
clinical	NN	O	O
congestive	NN	O	B-Disease
heart	NN	O	I-Disease
failure	NN	O	I-Disease
.	NN	O	O

Because	NN	O	O
the	NN	O	O
protocol	NN	O	O
was	NN	O	O
long	NN	O	O
and	NN	O	O
involved	NN	O	O
interventions	NN	O	O
which	NN	O	O
might	NN	O	O
affect	NN	O	O
the	NN	O	O
determinations	NN	O	O
,	NN	O	O
we	NN	O	O
also	NN	O	O
studied	NN	O	O
in	NN	O	O
nine	NN	O	O
patients	NN	O	O
using	NN	O	O
an	NN	O	O
identical	NN	O	O
protocol	NN	O	O
except	NN	O	O
that	NN	O	O
ouabain	NN	O	B-Chemical
administration	NN	O	O
was	NN	O	O
omitted	NN	O	O
.	NN	O	O

Left	NN	O	O
ventricular	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
pressure	NN	O	O
and	NN	O	O
left	NN	O	O
ventricular	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
volume	NN	O	O
fell	NN	O	O
in	NN	O	O
each	NN	O	O
patient	NN	O	O
given	NN	O	O
ouabain	NN	O	B-Chemical
,	NN	O	O
even	NN	O	O
though	NN	O	O
they	NN	O	O
were	NN	O	O
initially	NN	O	O
elevated	NN	O	O
in	NN	O	O
only	NN	O	O
two	NN	O	O
patients	NN	O	O
.	NN	O	O

Left	NN	O	O
ventricular	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
pressure	NN	O	O
fell	NN	O	O
from	NN	O	O
11.5+	NN	O	O
/	NN	O	O
-	NN	O	O
1.4	NN	O	O
(	NN	O	O
mean+	NN	O	O
/	NN	O	O
-	NN	O	O
SE	NN	O	O
)	NN	O	O
to	NN	O	O
5.6+	NN	O	O
/	NN	O	O
-	NN	O	O
0.9	NN	O	O
mm	NN	O	O
Hg	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
and	NN	O	O
left	NN	O	O
ventricular	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
volume	NN	O	O
fell	NN	O	O
from	NN	O	O
100+	NN	O	O
/	NN	O	O
-	NN	O	O
17	NN	O	O
to	NN	O	O
82+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
ml	NN	O	O
/	NN	O	O
m2	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.01	NN	O	O
)	NN	O	O
1	NN	O	O
h	NN	O	O
after	NN	O	O
ouabain	NN	O	B-Chemical
infusion	NN	O	O
was	NN	O	O
completed	NN	O	O
.	NN	O	O

The	NN	O	O
maximum	NN	O	O
velocity	NN	O	O
of	NN	O	O
contractile	NN	O	O
element	NN	O	O
shortening	NN	O	O
increased	NN	O	O
from	NN	O	O
1.68+	NN	O	O
/	NN	O	O
-	NN	O	O
0.11	NN	O	O
ml	NN	O	O
/	NN	O	O
s	NN	O	O
to	NN	O	O
2.18+	NN	O	O
/	NN	O	O
-	NN	O	O
0.21	NN	O	O
muscle	NN	O	O
-	NN	O	O
lengths	NN	O	O
/	NN	O	O
s	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
and	NN	O	O
is	NN	O	O
consistent	NN	O	O
with	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
contractility	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
change	NN	O	O
in	NN	O	O
these	NN	O	O
parameters	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
patients	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
change	NN	O	O
in	NN	O	O
myocardial	NN	O	O
oxygen	NN	O	B-Chemical
consumption	NN	O	O
occurred	NN	O	O
after	NN	O	O
ouabain	NN	O	B-Chemical
administration	NN	O	O
but	NN	O	O
this	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
a	NN	O	O
greater	NN	O	O
decrease	NN	O	O
in	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
in	NN	O	O
the	NN	O	O
ouabain	NN	O	B-Chemical
patients	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
patients	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
who	NN	O	O
are	NN	O	O
not	NN	O	O
in	NN	O	O
clinical	NN	O	O
congestive	NN	O	B-Disease
heart	NN	O	I-Disease
failure	NN	O	I-Disease
left	NN	O	B-Disease
ventricular	NN	O	I-Disease
end	NN	O	I-Disease
-	NN	O	I-Disease
diastolic	NN	O	I-Disease
volume	NN	O	I-Disease
falls	NN	O	I-Disease
after	NN	O	O
ouabain	NN	O	B-Chemical
administration	NN	O	O
even	NN	O	O
when	NN	O	O
it	NN	O	O
is	NN	O	O
initially	NN	O	O
normal	NN	O	O
.	NN	O	O

Though	NN	O	O
this	NN	O	O
fall	NN	O	O
would	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
wall	NN	O	O
tension	NN	O	O
,	NN	O	O
and	NN	O	O
,	NN	O	O
therefore	NN	O	O
,	NN	O	O
of	NN	O	O
myocardial	NN	O	O
oxygen	NN	O	B-Chemical
consumption	NN	O	O
,	NN	O	O
it	NN	O	O
may	NN	O	O
not	NN	O	O
be	NN	O	O
of	NN	O	O
sufficient	NN	O	O
magnitude	NN	O	O
to	NN	O	O
prevent	NN	O	O
a	NN	O	O
net	NN	O	O
increase	NN	O	O
in	NN	O	O
myocardial	NN	O	O
oxygen	NN	O	B-Chemical
consumption	NN	O	O
.	NN	O	O

Nevertheless	NN	O	O
,	NN	O	O
compensatory	NN	O	O
mechanisms	NN	O	O
prevent	NN	O	O
a	NN	O	O
deterioration	NN	O	O
of	NN	O	O
resting	NN	O	O
myocardial	NN	O	O
metabolism	NN	O	O
.	NN	O	O


-DOCSTART- (9545159)

Prolongation	NN	O	B-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
QT	NN	O	I-Disease
interval	NN	O	I-Disease
related	NN	O	O
to	NN	O	O
cisapride	NN	O	B-Chemical
-	NN	O	O
diltiazem	NN	O	B-Chemical
interaction	NN	O	O
.	NN	O	O

Cisapride	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
cytochrome	NN	O	O
P450	NN	O	O
3A4	NN	O	O
(	NN	O	O
CYP3A4	NN	O	O
)	NN	O	O
substrate	NN	O	O
,	NN	O	O
is	NN	O	O
widely	NN	O	O
prescribed	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
gastrointestinal	NN	O	B-Disease
motility	NN	O	I-Disease
disorders	NN	O	I-Disease
.	NN	O	O

Prolongation	NN	O	B-Disease
of	NN	O	I-Disease
QT	NN	O	I-Disease
interval	NN	O	I-Disease
,	NN	O	O
torsades	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
sudden	NN	O	B-Disease
cardiac	NN	O	I-Disease
death	NN	O	I-Disease
have	NN	O	O
been	NN	O	O
reported	NN	O	O
after	NN	O	O
concomitant	NN	O	O
administration	NN	O	O
with	NN	O	O
erythromycin	NN	O	B-Chemical
or	NN	O	O
azole	NN	O	B-Chemical
antifungal	NN	O	O
agents	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
with	NN	O	O
other	NN	O	O
CYP3A4	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

A	NN	O	O
possible	NN	O	O
drug	NN	O	O
interaction	NN	O	O
occurred	NN	O	O
in	NN	O	O
a	NN	O	O
45	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
who	NN	O	O
was	NN	O	O
taking	NN	O	O
cisapride	NN	O	B-Chemical
for	NN	O	O
gastroesophageal	NN	O	B-Disease
reflux	NN	O	I-Disease
disorder	NN	O	I-Disease
and	NN	O	O
diltiazem	NN	O	B-Chemical
,	NN	O	O
an	NN	O	O
agent	NN	O	O
that	NN	O	O
has	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
on	NN	O	O
CYP3A4	NN	O	O
,	NN	O	O
for	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
in	NN	O	O
near	NN	O	O
syncope	NN	O	B-Disease
and	NN	O	O
had	NN	O	O
QT	NN	O	B-Disease
-	NN	O	I-Disease
interval	NN	O	I-Disease
prolongation	NN	O	I-Disease
.	NN	O	O

After	NN	O	O
discontinuing	NN	O	O
cisapride	NN	O	B-Chemical
,	NN	O	O
the	NN	O	O
QT	NN	O	O
interval	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
and	NN	O	O
symptoms	NN	O	O
did	NN	O	O
not	NN	O	O
recur	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
caution	NN	O	O
be	NN	O	O
taken	NN	O	O
when	NN	O	O
cisapride	NN	O	B-Chemical
is	NN	O	O
prescribed	NN	O	O
with	NN	O	O
any	NN	O	O
potent	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
CYP3A4	NN	O	O
,	NN	O	O
including	NN	O	O
diltiazem	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (8643973)

Paclitaxel	NN	O	B-Chemical
combined	NN	O	O
with	NN	O	O
carboplatin	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
first	NN	O	O
-	NN	O	O
line	NN	O	O
treatment	NN	O	O
of	NN	O	O
advanced	NN	O	O
ovarian	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
a	NN	O	O
phase	NN	O	O
I	NN	O	O
study	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
maximum	NN	O	O
tolerated	NN	O	O
dose	NN	O	O
of	NN	O	O
paclitaxel	NN	O	B-Chemical
(	NN	O	O
Taxol	NN	O	B-Chemical
;	NN	O	O
Bristol	NN	O	O
-	NN	O	O
Myers	NN	O	O
Squibb	NN	O	O
Company	NN	O	O
,	NN	O	O
Princeton	NN	O	O
,	NN	O	O
NJ	NN	O	O
)	NN	O	O
given	NN	O	O
as	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
hour	NN	O	O
infusion	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
carboplatin	NN	O	B-Chemical
administered	NN	O	O
every	NN	O	O
21	NN	O	O
days	NN	O	O
to	NN	O	O
women	NN	O	O
with	NN	O	O
advanced	NN	O	O
ovarian	NN	O	B-Disease
cancer	NN	O	I-Disease
,	NN	O	O
paclitaxel	NN	O	B-Chemical
doses	NN	O	O
were	NN	O	O
escalated	NN	O	O
as	NN	O	O
follows	NN	O	O
:	NN	O	O
level	NN	O	O
1	NN	O	O
,	NN	O	O
135	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
;	NN	O	O
level	NN	O	O
2	NN	O	O
,	NN	O	O
160	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
;	NN	O	O
level	NN	O	O
3	NN	O	O
,	NN	O	O
185	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
;	NN	O	O
and	NN	O	O
level	NN	O	O
4	NN	O	O
,	NN	O	O
210	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
.	NN	O	O

The	NN	O	O
fixed	NN	O	O
dose	NN	O	O
of	NN	O	O
carboplatin	NN	O	B-Chemical
at	NN	O	O
levels	NN	O	O
1	NN	O	O
through	NN	O	O
4	NN	O	O
was	NN	O	O
given	NN	O	O
to	NN	O	O
achieve	NN	O	O
an	NN	O	O
area	NN	O	O
under	NN	O	O
the	NN	O	O
concentration	NN	O	O
-	NN	O	O
time	NN	O	O
curve	NN	O	O
(	NN	O	O
AUC	NN	O	O
)	NN	O	O
of	NN	O	O
5	NN	O	O
using	NN	O	O
the	NN	O	O
Calvert	NN	O	O
formula	NN	O	O
.	NN	O	O

In	NN	O	O
levels	NN	O	O
5	NN	O	O
and	NN	O	O
6	NN	O	O
the	NN	O	O
carboplatin	NN	O	B-Chemical
dose	NN	O	O
was	NN	O	O
targeted	NN	O	O
at	NN	O	O
AUCs	NN	O	O
of	NN	O	O
6	NN	O	O
and	NN	O	O
7.5	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
combined	NN	O	O
with	NN	O	O
a	NN	O	O
fixed	NN	O	O
paclitaxel	NN	O	B-Chemical
dose	NN	O	O
of	NN	O	O
185	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
.	NN	O	O

To	NN	O	O
date	NN	O	O
,	NN	O	O
30	NN	O	O
previously	NN	O	O
untreated	NN	O	O
patients	NN	O	O
,	NN	O	O
all	NN	O	O
with	NN	O	O
a	NN	O	O
good	NN	O	O
performance	NN	O	O
status	NN	O	O
(	NN	O	O
Eastern	NN	O	O
Cooperative	NN	O	O
Oncology	NN	O	O
Group	NN	O	O
0	NN	O	O
to	NN	O	O
2	NN	O	O
)	NN	O	O
have	NN	O	O
been	NN	O	O
entered	NN	O	O
into	NN	O	O
this	NN	O	O
ongoing	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
combination	NN	O	O
was	NN	O	O
myelosuppression	NN	O	B-Disease
(	NN	O	O
leukopenia	NN	O	B-Disease
,	NN	O	O
granulocytopenia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
thrombocytopenia	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Neurotoxicity	NN	O	B-Disease
was	NN	O	O
largely	NN	O	O
moderate	NN	O	O
.	NN	O	O

So	NN	O	O
far	NN	O	O
,	NN	O	O
14	NN	O	O
patients	NN	O	O
are	NN	O	O
evaluable	NN	O	O
for	NN	O	O
response	NN	O	O
;	NN	O	O
of	NN	O	O
these	NN	O	O
,	NN	O	O
eight	NN	O	O
(	NN	O	O
57%	NN	O	O
)	NN	O	O
showed	NN	O	O
objective	NN	O	O
(	NN	O	O
complete	NN	O	O
or	NN	O	O
partial	NN	O	O
)	NN	O	O
response	NN	O	O
and	NN	O	O
disease	NN	O	O
stabilized	NN	O	O
in	NN	O	O
six	NN	O	O
patients	NN	O	O
.	NN	O	O

No	NN	O	O
patient	NN	O	O
had	NN	O	O
disease	NN	O	O
progression	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
combination	NN	O	O
of	NN	O	O
paclitaxel	NN	O	B-Chemical
185	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
administered	NN	O	O
as	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
hour	NN	O	O
infusion	NN	O	O
followed	NN	O	O
immediately	NN	O	O
by	NN	O	O
a	NN	O	O
1	NN	O	O
-	NN	O	O
hour	NN	O	O
infusion	NN	O	O
of	NN	O	O
carboplatin	NN	O	B-Chemical
at	NN	O	O
an	NN	O	O
AUC	NN	O	O
of	NN	O	O
6	NN	O	O
can	NN	O	O
be	NN	O	O
administered	NN	O	O
safely	NN	O	O
in	NN	O	O
a	NN	O	O
21	NN	O	O
-	NN	O	O
day	NN	O	O
schedule	NN	O	O
in	NN	O	O
the	NN	O	O
outpatient	NN	O	O
setting	NN	O	O
.	NN	O	O

The	NN	O	O
recommended	NN	O	O
dose	NN	O	O
for	NN	O	O
phase	NN	O	O
III	NN	O	O
studies	NN	O	O
is	NN	O	O
paclitaxel	NN	O	B-Chemical
185	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
and	NN	O	O
carboplatin	NN	O	B-Chemical
AUC	NN	O	O
6	NN	O	O
.	NN	O	O


-DOCSTART- (10743694)

Treatment	NN	O	O
of	NN	O	O
tacrolimus	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
adverse	NN	O	O
effects	NN	O	O
by	NN	O	O
conversion	NN	O	O
to	NN	O	O
cyclosporine	NN	O	B-Chemical
in	NN	O	O
liver	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
.	NN	O	O

When	NN	O	O
tacrolimus	NN	O	B-Chemical
side	NN	O	O
effects	NN	O	O
persist	NN	O	O
despite	NN	O	O
dose	NN	O	O
reduction	NN	O	O
,	NN	O	O
conversion	NN	O	O
to	NN	O	O
cyclosporine	NN	O	B-Chemical
-	NN	O	O
based	NN	O	O
immunosuppression	NN	O	O
(	NN	O	O
CyA	NN	O	O
)	NN	O	O
is	NN	O	O
necessary	NN	O	O
.	NN	O	O

We	NN	O	O
characterized	NN	O	O
tacrolimus	NN	O	B-Chemical
side	NN	O	O
effects	NN	O	O
that	NN	O	O
warranted	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
,	NN	O	O
and	NN	O	O
outcomes	NN	O	O
after	NN	O	O
conversion	NN	O	O
.	NN	O	O

Of	NN	O	O
388	NN	O	O
liver	NN	O	O
recipients	NN	O	O
who	NN	O	O
received	NN	O	O
tacrolimus	NN	O	B-Chemical
as	NN	O	O
primary	NN	O	O
immunosuppression	NN	O	O
,	NN	O	O
70	NN	O	O
required	NN	O	O
conversion	NN	O	O
to	NN	O	O
CyA	NN	O	O
.	NN	O	O

We	NN	O	O
recorded	NN	O	O
indication	NN	O	O
for	NN	O	O
conversion	NN	O	O
,	NN	O	O
whether	NN	O	O
conversion	NN	O	O
was	NN	O	O
early	NN	O	O
or	NN	O	O
late	NN	O	O
after	NN	O	O
transplantation	NN	O	O
,	NN	O	O
tacrolimus	NN	O	B-Chemical
dose	NN	O	O
and	NN	O	O
trough	NN	O	O
blood	NN	O	O
level	NN	O	O
at	NN	O	O
conversion	NN	O	O
,	NN	O	O
and	NN	O	O
incidence	NN	O	O
of	NN	O	O
rejection	NN	O	O
after	NN	O	O
conversion	NN	O	O
.	NN	O	O

Conversion	NN	O	O
was	NN	O	O
early	NN	O	O
in	NN	O	O
29	NN	O	O
patients	NN	O	O
(	NN	O	O
41.4%	NN	O	O
)	NN	O	O
and	NN	O	O
late	NN	O	O
in	NN	O	O
41	NN	O	O
(	NN	O	O
58.6%	NN	O	O
)	NN	O	O
.	NN	O	O

Indications	NN	O	O
for	NN	O	O
early	NN	O	O
conversion	NN	O	O
were	NN	O	O
neurotoxicity	NN	O	B-Disease
(	NN	O	O
20	NN	O	O
)	NN	O	O
,	NN	O	O
(	NN	O	B-Disease
insulin	NN	O	I-Disease
-	NN	O	I-Disease
dependent	NN	O	I-Disease
)	NN	O	I-Disease
diabetes	NN	O	I-Disease
mellitus	NN	O	I-Disease
(	NN	O	O
IDDM	NN	O	B-Disease
)	NN	O	O
(	NN	O	O
5	NN	O	O
)	NN	O	O
,	NN	O	O
nephrotoxicity	NN	O	B-Disease
(	NN	O	O
3	NN	O	O
)	NN	O	O
,	NN	O	O
gastrointestinal	NN	O	B-Disease
(	NN	O	I-Disease
GI	NN	O	I-Disease
)	NN	O	I-Disease
toxicity	NN	O	I-Disease
(	NN	O	O
6	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
cardiomyopathy	NN	O	B-Disease
(	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
for	NN	O	O
late	NN	O	O
conversion	NN	O	O
were	NN	O	O
neurotoxicity	NN	O	B-Disease
(	NN	O	O
15	NN	O	O
)	NN	O	O
,	NN	O	O
IDDM	NN	O	B-Disease
(	NN	O	O
12	NN	O	O
)	NN	O	O
,	NN	O	O
nephrotoxicity	NN	O	B-Disease
(	NN	O	O
3	NN	O	O
)	NN	O	O
,	NN	O	O
GI	NN	O	B-Disease
toxicity	NN	O	I-Disease
(	NN	O	O
5	NN	O	O
)	NN	O	O
,	NN	O	O
hepatotoxicity	NN	O	B-Disease
(	NN	O	O
6	NN	O	O
)	NN	O	O
,	NN	O	O
post	NN	O	B-Disease
-	NN	O	I-Disease
transplant	NN	O	I-Disease
lmphoproliferate	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
PTLD	NN	O	B-Disease
)	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
cardiomyopathy	NN	O	B-Disease
(	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
(	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
pruritus	NN	O	B-Disease
(	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
early	NN	O	O
-	NN	O	O
conversion	NN	O	O
patients	NN	O	O
showed	NN	O	O
improvement	NN	O	O
/	NN	O	O
resolution	NN	O	O
of	NN	O	O
symptoms	NN	O	O
.	NN	O	O

Among	NN	O	O
late	NN	O	O
-	NN	O	O
conversion	NN	O	O
patients	NN	O	O
,	NN	O	O
37	NN	O	O
(	NN	O	O
90.2%	NN	O	O
)	NN	O	O
had	NN	O	O
improvement	NN	O	O
/	NN	O	O
resolution	NN	O	O
;	NN	O	O
in	NN	O	O
4	NN	O	O
(	NN	O	O
9.8%	NN	O	O
)	NN	O	O
,	NN	O	O
adverse	NN	O	O
effects	NN	O	O
persisted	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	O
rejection	NN	O	O
rate	NN	O	O
was	NN	O	O
30%	NN	O	O
.	NN	O	O

Sixty	NN	O	O
-	NN	O	O
two	NN	O	O
patients	NN	O	O
(	NN	O	O
88.6%	NN	O	O
)	NN	O	O
are	NN	O	O
alive	NN	O	O
with	NN	O	O
functioning	NN	O	O
grafts	NN	O	O
686	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
362	NN	O	O
days	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
154	NN	O	O
-	NN	O	O
1433	NN	O	O
days	NN	O	O
)	NN	O	O
after	NN	O	O
conversion	NN	O	O
.	NN	O	O

When	NN	O	O
tacrolimus	NN	O	B-Chemical
side	NN	O	O
effects	NN	O	O
are	NN	O	O
unresponsive	NN	O	O
to	NN	O	O
dose	NN	O	O
reduction	NN	O	O
,	NN	O	O
conversion	NN	O	O
to	NN	O	O
CyA	NN	O	O
can	NN	O	O
be	NN	O	O
accomplished	NN	O	O
safely	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
rejection	NN	O	O
and	NN	O	O
excellent	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
outcome	NN	O	O
.	NN	O	O


-DOCSTART- (3535719)

Relative	NN	O	O
efficacy	NN	O	O
and	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
netilmicin	NN	O	B-Chemical
and	NN	O	O
tobramycin	NN	O	B-Chemical
in	NN	O	O
oncology	NN	O	O
patients	NN	O	O
.	NN	O	O

We	NN	O	O
prospectively	NN	O	O
compared	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
netilmicin	NN	O	B-Chemical
sulfate	NN	O	I-Chemical
or	NN	O	O
tobramycin	NN	O	B-Chemical
sulfate	NN	O	I-Chemical
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
piperacillin	NN	O	B-Chemical
sodium	NN	O	I-Chemical
in	NN	O	O
118	NN	O	O
immunocompromised	NN	O	O
patients	NN	O	O
with	NN	O	O
presumed	NN	O	O
severe	NN	O	O
infections	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
two	NN	O	O
treatment	NN	O	O
regimens	NN	O	O
were	NN	O	O
equally	NN	O	O
efficacious	NN	O	O
.	NN	O	O

Nephrotoxicity	NN	O	B-Disease
occurred	NN	O	O
in	NN	O	O
a	NN	O	O
similar	NN	O	O
proportion	NN	O	O
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
netilmicin	NN	O	B-Chemical
and	NN	O	O
tobramycin	NN	O	B-Chemical
(	NN	O	O
17%	NN	O	O
vs	NN	O	O
11%	NN	O	O
)	NN	O	O
.	NN	O	O

Ototoxicity	NN	O	B-Disease
occurred	NN	O	O
in	NN	O	O
four	NN	O	O
(	NN	O	O
9.5%	NN	O	O
)	NN	O	O
of	NN	O	O
42	NN	O	O
netilmicin	NN	O	B-Chemical
and	NN	O	O
piperacillin	NN	O	B-Chemical
and	NN	O	O
in	NN	O	O
12	NN	O	O
(	NN	O	O
22%	NN	O	O
)	NN	O	O
of	NN	O	O
54	NN	O	O
tobramycin	NN	O	B-Chemical
and	NN	O	O
piperacillin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
.	NN	O	O

Of	NN	O	O
those	NN	O	O
evaluated	NN	O	O
with	NN	O	O
posttherapy	NN	O	O
audiograms	NN	O	O
,	NN	O	O
three	NN	O	O
of	NN	O	O
four	NN	O	O
netilmicin	NN	O	B-Chemical
and	NN	O	O
piperacillin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
had	NN	O	O
auditory	NN	O	O
thresholds	NN	O	O
return	NN	O	O
to	NN	O	O
baseline	NN	O	O
compared	NN	O	O
with	NN	O	O
one	NN	O	O
of	NN	O	O
nine	NN	O	O
tobramycin	NN	O	B-Chemical
and	NN	O	O
piperacillin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
15	NN	O	O
-	NN	O	O
dB	NN	O	O
increases	NN	O	O
in	NN	O	O
auditory	NN	O	O
threshold	NN	O	O
as	NN	O	O
a	NN	O	O
proportion	NN	O	O
of	NN	O	O
total	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
15	NN	O	O
-	NN	O	O
dB	NN	O	O
changes	NN	O	O
(	NN	O	O
increases	NN	O	O
and	NN	O	O
decreases	NN	O	O
)	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
netilmicin	NN	O	B-Chemical
and	NN	O	O
piperacillin	NN	O	B-Chemical
-	NN	O	O
vs	NN	O	O
tobramycin	NN	O	B-Chemical
and	NN	O	O
piperacillin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
(	NN	O	O
18	NN	O	O
of	NN	O	O
78	NN	O	O
vs	NN	O	O
67	NN	O	O
of	NN	O	O
115	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
aminoglycoside	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
ototoxicity	NN	O	B-Disease
was	NN	O	O
less	NN	O	O
severe	NN	O	O
and	NN	O	O
more	NN	O	O
often	NN	O	O
reversible	NN	O	O
with	NN	O	O
netilmicin	NN	O	B-Chemical
than	NN	O	O
with	NN	O	O
tobramycin	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (6433367)

Effect	NN	O	O
of	NN	O	O
prostaglandin	NN	O	B-Chemical
synthetase	NN	O	O
inhibitors	NN	O	O
on	NN	O	O
experimentally	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

To	NN	O	O
investigate	NN	O	O
the	NN	O	O
relationship	NN	O	O
of	NN	O	O
prostaglandins	NN	O	B-Chemical
(	NN	O	O
PGs	NN	O	B-Chemical
)	NN	O	O
to	NN	O	O
seizure	NN	O	B-Disease
induction	NN	O	O
,	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
six	NN	O	O
PG	NN	O	O
synthetase	NN	O	O
inhibitors	NN	O	O
on	NN	O	O
convulsions	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
flurothyl	NN	O	B-Chemical
,	NN	O	O
picrotoxin	NN	O	B-Chemical
,	NN	O	O
pentetrazol	NN	O	B-Chemical
(	NN	O	O
PTZ	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
electroshock	NN	O	O
or	NN	O	O
bicuculline	NN	O	B-Chemical
were	NN	O	O
evaluated	NN	O	O
.	NN	O	O

Ibuprofen	NN	O	B-Chemical
,	NN	O	O
sulindac	NN	O	B-Chemical
,	NN	O	O
mefenamic	NN	O	B-Chemical
acid	NN	O	I-Chemical
,	NN	O	O
and	NN	O	O
low	NN	O	O
dose	NN	O	O
meclofenamic	NN	O	B-Chemical
acid	NN	O	I-Chemical
increased	NN	O	O
the	NN	O	O
latency	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
onset	NN	O	O
in	NN	O	O
the	NN	O	O
flurothyl	NN	O	B-Chemical
and	NN	O	O
/	NN	O	O
or	NN	O	O
PTZ	NN	O	B-Chemical
models	NN	O	O
;	NN	O	O
the	NN	O	O
electroshock	NN	O	O
,	NN	O	O
picrotoxin	NN	O	B-Chemical
and	NN	O	O
bicuculline	NN	O	B-Chemical
models	NN	O	O
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
affected	NN	O	O
by	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
pretreatment	NN	O	O
agents	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
PGs	NN	O	B-Chemical
are	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
mechanism	NN	O	O
(	NN	O	O
s	NN	O	O
)	NN	O	O
underlying	NN	O	O
fluorthyl	NN	O	B-Chemical
-	NN	O	O
and	NN	O	O
PTZ	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
,	NN	O	O
but	NN	O	O
not	NN	O	O
picrotoxin	NN	O	B-Chemical
-	NN	O	O
,	NN	O	O
electroshock	NN	O	O
-	NN	O	O
,	NN	O	O
or	NN	O	O
bicuculline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (17285209)

Angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
(	NN	O	O
ACE	NN	O	O
)	NN	O	O
inhibitor	NN	O	O
-	NN	O	O
associated	NN	O	O
angioedema	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
stomach	NN	O	O
and	NN	O	O
small	NN	O	O
intestine	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
on	NN	O	O
a	NN	O	O
45	NN	O	O
-	NN	O	O
year	NN	O	O
old	NN	O	O
African	NN	O	O
-	NN	O	O
American	NN	O	O
female	NN	O	O
with	NN	O	O
newly	NN	O	O
diagnosed	NN	O	O
hypertension	NN	O	B-Disease
,	NN	O	O
who	NN	O	O
was	NN	O	O
started	NN	O	O
on	NN	O	O
a	NN	O	O
combination	NN	O	O
pill	NN	O	O
of	NN	O	O
amlodipine	NN	O	B-Chemical
/	NN	O	O
benazapril	NN	O	B-Chemical
10	NN	O	O
/	NN	O	O
5	NN	O	O
mg	NN	O	O
.	NN	O	O

The	NN	O	O
very	NN	O	O
next	NN	O	O
day	NN	O	O
,	NN	O	O
she	NN	O	O
presented	NN	O	O
at	NN	O	O
the	NN	O	O
emergency	NN	O	O
room	NN	O	O
(	NN	O	O
ER	NN	O	O
)	NN	O	O
with	NN	O	O
abdominal	NN	O	B-Disease
pain	NN	O	I-Disease
,	NN	O	O
nausea	NN	O	B-Disease
and	NN	O	O
vomiting	NN	O	B-Disease
.	NN	O	O

Physical	NN	O	O
exam	NN	O	O
,	NN	O	O
complete	NN	O	O
metabolic	NN	O	O
panel	NN	O	O
,	NN	O	O
and	NN	O	O
hemogram	NN	O	O
were	NN	O	O
in	NN	O	O
the	NN	O	O
normal	NN	O	O
range	NN	O	O
.	NN	O	O

She	NN	O	O
was	NN	O	O
discharged	NN	O	O
from	NN	O	O
the	NN	O	O
ER	NN	O	O
after	NN	O	O
a	NN	O	O
few	NN	O	O
hours	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
fluid	NN	O	O
and	NN	O	O
analgesics	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
she	NN	O	O
returned	NN	O	O
to	NN	O	O
the	NN	O	O
ER	NN	O	O
the	NN	O	O
next	NN	O	O
day	NN	O	O
with	NN	O	O
the	NN	O	O
same	NN	O	O
complaints	NN	O	O
.	NN	O	O

This	NN	O	O
time	NN	O	O
the	NN	O	O
physical	NN	O	O
exam	NN	O	O
was	NN	O	O
significant	NN	O	O
for	NN	O	O
a	NN	O	O
distended	NN	O	O
abdomen	NN	O	O
with	NN	O	O
dullness	NN	O	O
to	NN	O	O
percussion	NN	O	O
.	NN	O	O

CT	NN	O	O
scan	NN	O	O
of	NN	O	O
the	NN	O	O
abdomen	NN	O	O
revealed	NN	O	O
markedly	NN	O	O
thickened	NN	O	O
antrum	NN	O	O
of	NN	O	O
the	NN	O	O
stomach	NN	O	O
,	NN	O	O
duodenum	NN	O	O
and	NN	O	O
jejunum	NN	O	O
,	NN	O	O
along	NN	O	O
with	NN	O	O
fluid	NN	O	O
in	NN	O	O
the	NN	O	O
abdominal	NN	O	O
and	NN	O	O
pelvic	NN	O	O
cavity	NN	O	O
.	NN	O	O

Angiotensin	NN	O	O
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
inhibitor	NN	O	O
(	NN	O	O
ACEI	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
angioedema	NN	O	B-Disease
was	NN	O	O
suspected	NN	O	O
,	NN	O	O
and	NN	O	O
anti	NN	O	O
-	NN	O	O
hypertensive	NN	O	B-Disease
medications	NN	O	O
were	NN	O	O
discontinued	NN	O	O
.	NN	O	O

Her	NN	O	O
symptoms	NN	O	O
improved	NN	O	O
within	NN	O	O
the	NN	O	O
next	NN	O	O
24	NN	O	O
hours	NN	O	O
,	NN	O	O
and	NN	O	O
repeat	NN	O	O
CT	NN	O	O
after	NN	O	O
72	NN	O	O
hours	NN	O	O
revealed	NN	O	O
marked	NN	O	O
improvement	NN	O	O
in	NN	O	O
stomach	NN	O	O
and	NN	O	O
small	NN	O	O
bowel	NN	O	O
thickening	NN	O	O
and	NN	O	O
resolution	NN	O	O
of	NN	O	O
ascites	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
recognition	NN	O	O
of	NN	O	O
angiotensin	NN	O	B-Chemical
-	NN	O	O
converting	NN	O	O
enzyme	NN	O	O
(	NN	O	O
ACE	NN	O	O
)	NN	O	O
and	NN	O	O
angiotensin	NN	O	B-Chemical
receptor	NN	O	O
blocker	NN	O	O
(	NN	O	O
ARB	NN	O	O
)	NN	O	O
intestinal	NN	O	B-Disease
angioedema	NN	O	I-Disease
constitutes	NN	O	O
a	NN	O	O
challenge	NN	O	O
to	NN	O	O
primary	NN	O	O
care	NN	O	O
physicians	NN	O	O
,	NN	O	O
internists	NN	O	O
,	NN	O	O
emergency	NN	O	O
room	NN	O	O
personal	NN	O	O
and	NN	O	O
surgeons	NN	O	O
.	NN	O	O


-DOCSTART- (15858223)

Valproic	NN	O	B-Chemical
acid	NN	O	I-Chemical
I	NN	O	O
:	NN	O	O
time	NN	O	O
course	NN	O	O
of	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
biomarkers	NN	O	O
,	NN	O	O
liver	NN	O	B-Disease
toxicity	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
valproic	NN	O	B-Chemical
acid	NN	O	I-Chemical
metabolite	NN	O	O
levels	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

A	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
valproic	NN	O	B-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
VPA	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
a	NN	O	O
widely	NN	O	O
used	NN	O	O
antiepileptic	NN	O	O
drug	NN	O	O
,	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
in	NN	O	O
rats	NN	O	O
,	NN	O	O
as	NN	O	O
recently	NN	O	O
demonstrated	NN	O	O
by	NN	O	O
elevated	NN	O	O
levels	NN	O	O
of	NN	O	O
15	NN	O	B-Chemical
-	NN	O	I-Chemical
F	NN	O	I-Chemical
(	NN	O	I-Chemical
2t	NN	O	I-Chemical
)	NN	O	I-Chemical
-	NN	O	I-Chemical
isoprostane	NN	O	I-Chemical
(	NN	O	O
15	NN	O	B-Chemical
-	NN	O	I-Chemical
F	NN	O	I-Chemical
(	NN	O	I-Chemical
2t	NN	O	I-Chemical
)	NN	O	I-Chemical
-	NN	O	I-Chemical
IsoP	NN	O	I-Chemical
)	NN	O	O
.	NN	O	O

To	NN	O	O
determine	NN	O	O
whether	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
temporal	NN	O	O
relationship	NN	O	O
between	NN	O	O
VPA	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
and	NN	O	O
hepatotoxicity	NN	O	B-Disease
,	NN	O	O
adult	NN	O	O
male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
were	NN	O	O
treated	NN	O	O
ip	NN	O	O
with	NN	O	O
VPA	NN	O	B-Chemical
(	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
or	NN	O	O
0.9%	NN	O	O
saline	NN	O	O
(	NN	O	O
vehicle	NN	O	O
)	NN	O	O
once	NN	O	O
daily	NN	O	O
for	NN	O	O
2	NN	O	O
,	NN	O	O
4	NN	O	O
,	NN	O	O
7	NN	O	O
,	NN	O	O
10	NN	O	O
,	NN	O	O
or	NN	O	O
14	NN	O	O
days	NN	O	O
.	NN	O	O

Oxidative	NN	O	O
stress	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
determining	NN	O	O
plasma	NN	O	O
and	NN	O	O
liver	NN	O	O
levels	NN	O	O
of	NN	O	O
15	NN	O	B-Chemical
-	NN	O	I-Chemical
F	NN	O	I-Chemical
(	NN	O	I-Chemical
2t	NN	O	I-Chemical
)	NN	O	I-Chemical
-	NN	O	I-Chemical
IsoP	NN	O	I-Chemical
,	NN	O	O
lipid	NN	O	B-Chemical
hydroperoxides	NN	O	I-Chemical
(	NN	O	O
LPO	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
and	NN	O	O
thiobarbituric	NN	O	B-Chemical
acid	NN	O	I-Chemical
reactive	NN	O	I-Chemical
substances	NN	O	I-Chemical
(	NN	O	O
TBARs	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

Plasma	NN	O	O
and	NN	O	O
liver	NN	O	O
15	NN	O	B-Chemical
-	NN	O	I-Chemical
F	NN	O	I-Chemical
(	NN	O	I-Chemical
2t	NN	O	I-Chemical
)	NN	O	I-Chemical
-	NN	O	I-Chemical
IsoP	NN	O	I-Chemical
were	NN	O	O
elevated	NN	O	O
and	NN	O	O
reached	NN	O	O
a	NN	O	O
plateau	NN	O	O
after	NN	O	O
day	NN	O	O
2	NN	O	O
of	NN	O	O
VPA	NN	O	B-Chemical
treatment	NN	O	O
compared	NN	O	O
to	NN	O	O
control	NN	O	O
.	NN	O	O

Liver	NN	O	O
LPO	NN	O	B-Chemical
levels	NN	O	O
were	NN	O	O
not	NN	O	O
elevated	NN	O	O
until	NN	O	O
day	NN	O	O
7	NN	O	O
of	NN	O	O
treatment	NN	O	O
(	NN	O	O
1.8	NN	O	O
-	NN	O	O
fold	NN	O	O
versus	NN	O	O
control	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Liver	NN	O	O
and	NN	O	O
plasma	NN	O	O
TBARs	NN	O	B-Chemical
were	NN	O	O
not	NN	O	O
increased	NN	O	O
until	NN	O	O
14	NN	O	O
days	NN	O	O
(	NN	O	O
2	NN	O	O
-	NN	O	O
fold	NN	O	O
vs	NN	O	O
.	NN	O	O

control	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Liver	NN	O	B-Disease
toxicity	NN	O	I-Disease
was	NN	O	O
evaluated	NN	O	O
based	NN	O	O
on	NN	O	O
serum	NN	O	O
levels	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
glutathione	NN	O	B-Chemical
S	NN	O	O
-	NN	O	O
transferase	NN	O	O
(	NN	O	O
alpha	NN	O	O
-	NN	O	O
GST	NN	O	O
)	NN	O	O
and	NN	O	O
by	NN	O	O
histology	NN	O	O
.	NN	O	O

Serum	NN	O	O
alpha	NN	O	O
-	NN	O	O
GST	NN	O	O
levels	NN	O	O
were	NN	O	O
significantly	NN	O	O
elevated	NN	O	O
by	NN	O	O
day	NN	O	O
4	NN	O	O
,	NN	O	O
which	NN	O	O
corresponded	NN	O	O
to	NN	O	O
hepatotoxicity	NN	O	B-Disease
as	NN	O	O
shown	NN	O	O
by	NN	O	O
the	NN	O	O
increasing	NN	O	O
incidence	NN	O	O
of	NN	O	O
inflammation	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
liver	NN	O	O
capsule	NN	O	O
,	NN	O	O
necrosis	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
steatosis	NN	O	B-Disease
throughout	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
liver	NN	O	O
levels	NN	O	O
of	NN	O	O
beta	NN	O	O
-	NN	O	O
oxidation	NN	O	O
metabolites	NN	O	O
of	NN	O	O
VPA	NN	O	B-Chemical
were	NN	O	O
decreased	NN	O	O
by	NN	O	O
day	NN	O	O
14	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
4	NN	O	B-Chemical
-	NN	O	I-Chemical
ene	NN	O	I-Chemical
-	NN	O	I-Chemical
VPA	NN	O	I-Chemical
and	NN	O	O
(	NN	O	O
E	NN	O	O
)	NN	O	O
-	NN	O	O
2	NN	O	B-Chemical
,	NN	O	I-Chemical
4	NN	O	I-Chemical
-	NN	O	I-Chemical
diene	NN	O	I-Chemical
-	NN	O	I-Chemical
VPA	NN	O	I-Chemical
were	NN	O	O
not	NN	O	O
elevated	NN	O	O
throughout	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Overall	NN	O	O
,	NN	O	O
these	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
VPA	NN	O	B-Chemical
treatment	NN	O	O
results	NN	O	O
in	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
,	NN	O	O
as	NN	O	O
measured	NN	O	O
by	NN	O	O
levels	NN	O	O
of	NN	O	O
15	NN	O	B-Chemical
-	NN	O	I-Chemical
F	NN	O	I-Chemical
(	NN	O	I-Chemical
2t	NN	O	I-Chemical
)	NN	O	I-Chemical
-	NN	O	I-Chemical
IsoP	NN	O	I-Chemical
,	NN	O	O
which	NN	O	O
precedes	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
necrosis	NN	O	B-Disease
,	NN	O	O
steatosis	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
elevated	NN	O	O
levels	NN	O	O
of	NN	O	O
serum	NN	O	O
alpha	NN	O	O
-	NN	O	O
GST	NN	O	O
.	NN	O	O


-DOCSTART- (15811908)

Pheochromocytoma	NN	O	B-Disease
unmasked	NN	O	O
by	NN	O	O
amisulpride	NN	O	B-Chemical
and	NN	O	O
tiapride	NN	O	B-Chemical
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
describe	NN	O	O
the	NN	O	O
unmasking	NN	O	O
of	NN	O	O
pheochromocytoma	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
patient	NN	O	O
treated	NN	O	O
with	NN	O	O
amisulpride	NN	O	B-Chemical
and	NN	O	O
tiapride	NN	O	B-Chemical
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
42	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
white	NN	O	O
man	NN	O	O
developed	NN	O	O
acute	NN	O	O
hypertension	NN	O	B-Disease
with	NN	O	O
severe	NN	O	O
headache	NN	O	B-Disease
and	NN	O	O
vomiting	NN	O	B-Disease
2	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
first	NN	O	O
doses	NN	O	O
of	NN	O	O
amisulpride	NN	O	B-Chemical
100	NN	O	O
mg	NN	O	O
and	NN	O	O
tiapride	NN	O	B-Chemical
100	NN	O	O
mg	NN	O	O
.	NN	O	O

Both	NN	O	O
drugs	NN	O	O
were	NN	O	O
immediately	NN	O	O
discontinued	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
recovered	NN	O	O
after	NN	O	O
subsequent	NN	O	O
nicardipine	NN	O	B-Chemical
and	NN	O	O
verapamil	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

Abdominal	NN	O	O
ultrasound	NN	O	O
showed	NN	O	O
an	NN	O	O
adrenal	NN	O	O
mass	NN	O	O
,	NN	O	O
and	NN	O	O
postoperative	NN	O	O
histologic	NN	O	O
examination	NN	O	O
confirmed	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
pheochromocytoma	NN	O	B-Disease
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
Drug	NN	O	O
-	NN	O	O
induced	NN	O	O
symptoms	NN	O	O
of	NN	O	O
pheochromocytoma	NN	O	B-Disease
are	NN	O	O
often	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
substituted	NN	O	O
benzamide	NN	O	B-Chemical
drugs	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
underlying	NN	O	O
mechanism	NN	O	O
is	NN	O	O
unknown	NN	O	O
.	NN	O	O

In	NN	O	O
our	NN	O	O
case	NN	O	O
,	NN	O	O
use	NN	O	O
of	NN	O	O
the	NN	O	O
Naranjo	NN	O	O
probability	NN	O	O
scale	NN	O	O
indicated	NN	O	O
a	NN	O	O
possible	NN	O	O
relationship	NN	O	O
between	NN	O	O
the	NN	O	O
hypertensive	NN	O	B-Disease
crisis	NN	O	O
and	NN	O	O
amisulpride	NN	O	B-Chemical
and	NN	O	O
tiapride	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
As	NN	O	O
of	NN	O	O
March	NN	O	O
24	NN	O	O
,	NN	O	O
2005	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
reported	NN	O	O
case	NN	O	O
of	NN	O	O
amisulpride	NN	O	B-Chemical
-	NN	O	O
and	NN	O	O
tiapride	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypertensive	NN	O	B-Disease
crisis	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
pheochromocytoma	NN	O	B-Disease
.	NN	O	O

Physicians	NN	O	O
and	NN	O	O
other	NN	O	O
healthcare	NN	O	O
professionals	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
potential	NN	O	O
adverse	NN	O	O
effect	NN	O	O
of	NN	O	O
tiapride	NN	O	B-Chemical
and	NN	O	O
amisulpride	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (15764424)

Quantitative	NN	O	O
drug	NN	O	O
levels	NN	O	O
in	NN	O	O
stimulant	NN	O	O
psychosis	NN	O	B-Disease
:	NN	O	O
relationship	NN	O	O
to	NN	O	O
symptom	NN	O	O
severity	NN	O	O
,	NN	O	O
catecholamines	NN	O	B-Chemical
and	NN	O	O
hyperkinesia	NN	O	B-Disease
.	NN	O	O

To	NN	O	O
examine	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
quantitative	NN	O	O
stimulant	NN	O	O
drug	NN	O	O
levels	NN	O	O
,	NN	O	O
catecholamines	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
psychotic	NN	O	B-Disease
symptoms	NN	O	I-Disease
,	NN	O	O
nineteen	NN	O	O
patients	NN	O	O
in	NN	O	O
a	NN	O	O
psychiatric	NN	O	B-Disease
emergency	NN	O	O
service	NN	O	O
with	NN	O	O
a	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
amphetamine	NN	O	B-Chemical
-	NN	O	O
or	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
psychosis	NN	O	B-Disease
were	NN	O	O
interviewed	NN	O	O
,	NN	O	O
and	NN	O	O
plasma	NN	O	O
and	NN	O	O
urine	NN	O	O
were	NN	O	O
collected	NN	O	O
for	NN	O	O
quantitative	NN	O	O
assays	NN	O	O
of	NN	O	O
stimulant	NN	O	O
drug	NN	O	O
and	NN	O	O
catecholamine	NN	O	B-Chemical
metabolite	NN	O	O
levels	NN	O	O
.	NN	O	O

Methamphetamine	NN	O	B-Chemical
or	NN	O	O
amphetamine	NN	O	B-Chemical
levels	NN	O	O
were	NN	O	O
related	NN	O	O
to	NN	O	O
several	NN	O	O
psychopathology	NN	O	O
scores	NN	O	O
and	NN	O	O
the	NN	O	O
global	NN	O	O
hyperkinesia	NN	O	B-Disease
rating	NN	O	O
.	NN	O	O

HVA	NN	O	O
levels	NN	O	O
were	NN	O	O
related	NN	O	O
to	NN	O	O
global	NN	O	O
hyperkinesia	NN	O	B-Disease
but	NN	O	O
not	NN	O	O
to	NN	O	O
psychopathology	NN	O	O
ratings	NN	O	O
.	NN	O	O

Although	NN	O	O
many	NN	O	O
other	NN	O	O
factors	NN	O	O
such	NN	O	O
as	NN	O	O
sensitization	NN	O	O
may	NN	O	O
play	NN	O	O
a	NN	O	O
role	NN	O	O
,	NN	O	O
intensity	NN	O	O
of	NN	O	O
stimulant	NN	O	O
-	NN	O	O
induced	NN	O	O
psychotic	NN	O	B-Disease
symptoms	NN	O	I-Disease
and	NN	O	O
stereotypies	NN	O	B-Disease
appears	NN	O	O
to	NN	O	O
be	NN	O	O
at	NN	O	O
least	NN	O	O
in	NN	O	O
part	NN	O	O
dose	NN	O	O
-	NN	O	O
related	NN	O	O
.	NN	O	O


-DOCSTART- (12101159)

Delayed	NN	O	O
asystolic	NN	O	B-Disease
cardiac	NN	O	B-Disease
arrest	NN	O	I-Disease
after	NN	O	O
diltiazem	NN	O	B-Chemical
overdose	NN	O	B-Disease
;	NN	O	O
resuscitation	NN	O	O
with	NN	O	O
high	NN	O	O
dose	NN	O	O
intravenous	NN	O	O
calcium	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
51	NN	O	O
year	NN	O	O
old	NN	O	O
man	NN	O	O
took	NN	O	O
a	NN	O	O
mixed	NN	O	O
overdose	NN	O	B-Disease
including	NN	O	O
1.8	NN	O	O
-	NN	O	O
3.6	NN	O	O
g	NN	O	O
of	NN	O	O
diltiazem	NN	O	B-Chemical
,	NN	O	O
paracetamol	NN	O	B-Chemical
,	NN	O	O
aspirin	NN	O	B-Chemical
,	NN	O	O
isosorbide	NN	O	B-Chemical
nitrate	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
alcohol	NN	O	B-Chemical
.	NN	O	O

He	NN	O	O
initially	NN	O	O
presented	NN	O	O
to	NN	O	O
hospital	NN	O	O
after	NN	O	O
six	NN	O	O
hours	NN	O	O
with	NN	O	O
mild	NN	O	O
hypotension	NN	O	B-Disease
and	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
activated	NN	O	O
charcoal	NN	O	O
and	NN	O	O
intravenous	NN	O	O
fluids	NN	O	O
.	NN	O	O

Eighteen	NN	O	O
hours	NN	O	O
after	NN	O	O
the	NN	O	O
overdose	NN	O	B-Disease
he	NN	O	O
had	NN	O	O
two	NN	O	O
generalised	NN	O	O
tonic	NN	O	B-Disease
-	NN	O	I-Disease
clonic	NN	O	I-Disease
seizures	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
patient	NN	O	O
remained	NN	O	O
unresponsive	NN	O	O
with	NN	O	O
junctional	NN	O	O
bradycardia	NN	O	B-Disease
,	NN	O	O
unrecordable	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
and	NN	O	O
then	NN	O	O
became	NN	O	O
asystolic	NN	O	B-Disease
.	NN	O	O

He	NN	O	O
was	NN	O	O
resuscitated	NN	O	O
with	NN	O	O
high	NN	O	O
dose	NN	O	O
(	NN	O	O
13.5	NN	O	O
g	NN	O	O
)	NN	O	O
intravenous	NN	O	O
calcium	NN	O	B-Chemical
and	NN	O	O
adrenaline	NN	O	B-Chemical
(	NN	O	O
epinephrine	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

He	NN	O	O
required	NN	O	O
inotropic	NN	O	O
support	NN	O	O
and	NN	O	O
temporary	NN	O	O
pacing	NN	O	O
over	NN	O	O
the	NN	O	O
next	NN	O	O
48	NN	O	O
hours	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
suggests	NN	O	O
there	NN	O	O
is	NN	O	O
a	NN	O	O
role	NN	O	O
for	NN	O	O
aggressive	NN	O	O
high	NN	O	O
dose	NN	O	O
intravenous	NN	O	O
calcium	NN	O	B-Chemical
therapy	NN	O	O
in	NN	O	O
severe	NN	O	O
diltiazem	NN	O	B-Chemical
overdose	NN	O	B-Disease
,	NN	O	O
particularly	NN	O	O
with	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
asystole	NN	O	B-Disease
.	NN	O	O

It	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
early	NN	O	O
in	NN	O	O
cases	NN	O	O
of	NN	O	O
cardiac	NN	O	B-Disease
arrest	NN	O	I-Disease
after	NN	O	O
diltiazem	NN	O	B-Chemical
overdose	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
case	NN	O	O
also	NN	O	O
highlights	NN	O	O
the	NN	O	O
problems	NN	O	O
with	NN	O	O
delayed	NN	O	O
toxicity	NN	O	B-Disease
when	NN	O	O
whole	NN	O	O
bowel	NN	O	O
irrigation	NN	O	O
is	NN	O	O
not	NN	O	O
administered	NN	O	O
.	NN	O	O


-DOCSTART- (6699841)

Renal	NN	O	B-Disease
papillary	NN	O	I-Disease
necrosis	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
naproxen	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
31	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
,	NN	O	O
who	NN	O	O
had	NN	O	O
previously	NN	O	O
been	NN	O	O
treated	NN	O	O
with	NN	O	O
sulindac	NN	O	B-Chemical
,	NN	O	O
fenoprofen	NN	O	B-Chemical
calcium	NN	O	I-Chemical
,	NN	O	O
high	NN	O	O
dose	NN	O	O
salicylates	NN	O	B-Chemical
and	NN	O	O
gold	NN	O	B-Chemical
salts	NN	O	O
,	NN	O	O
developed	NN	O	O
renal	NN	O	B-Disease
papillary	NN	O	I-Disease
necrosis	NN	O	I-Disease
(	NN	O	O
RPN	NN	O	B-Disease
)	NN	O	O
4	NN	O	O
months	NN	O	O
after	NN	O	O
institution	NN	O	O
of	NN	O	O
naproxen	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

No	NN	O	O
other	NN	O	O
factor	NN	O	O
predisposing	NN	O	O
to	NN	O	O
RPN	NN	O	B-Disease
could	NN	O	O
be	NN	O	O
discovered	NN	O	O
.	NN	O	O

Sulindac	NN	O	B-Chemical
was	NN	O	O
substituted	NN	O	O
for	NN	O	O
naproxen	NN	O	B-Chemical
and	NN	O	O
no	NN	O	O
further	NN	O	O
adverse	NN	O	O
renal	NN	O	O
effects	NN	O	O
occurred	NN	O	O
over	NN	O	O
the	NN	O	O
next	NN	O	O
12	NN	O	O
months	NN	O	O
.	NN	O	O

We	NN	O	O
review	NN	O	O
previous	NN	O	O
reports	NN	O	O
linking	NN	O	O
RPN	NN	O	B-Disease
to	NN	O	O
antiinflammatory	NN	O	O
drug	NN	O	O
use	NN	O	O
and	NN	O	O
discuss	NN	O	O
possible	NN	O	O
advantages	NN	O	O
of	NN	O	O
sulindac	NN	O	B-Chemical
in	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
experienced	NN	O	O
renal	NN	O	B-Disease
toxicity	NN	O	I-Disease
from	NN	O	O
other	NN	O	O
antiinflammatory	NN	O	O
agents	NN	O	O
.	NN	O	O


-DOCSTART- (6127992)

Adverse	NN	O	O
interaction	NN	O	O
between	NN	O	O
beta	NN	O	B-Chemical
-	NN	O	I-Chemical
adrenergic	NN	O	I-Chemical
blocking	NN	O	I-Chemical
drugs	NN	O	I-Chemical
and	NN	O	O
verapamil	NN	O	B-Chemical
-	NN	O	O
-	NN	O	O
report	NN	O	O
of	NN	O	O
three	NN	O	O
cases	NN	O	O
.	NN	O	O

Three	NN	O	O
patients	NN	O	O
with	NN	O	O
ischaemic	NN	O	B-Disease
heart	NN	O	I-Disease
disease	NN	O	I-Disease
developed	NN	O	O
profound	NN	O	O
cardiac	NN	O	B-Disease
failure	NN	O	I-Disease
,	NN	O	O
hypotension	NN	O	B-Disease
and	NN	O	O
bradycardia	NN	O	B-Disease
during	NN	O	O
combined	NN	O	O
therapy	NN	O	O
with	NN	O	O
verapamil	NN	O	B-Chemical
and	NN	O	O
beta	NN	O	B-Chemical
-	NN	O	I-Chemical
adrenergic	NN	O	I-Chemical
blocking	NN	O	I-Chemical
drugs	NN	O	I-Chemical
.	NN	O	O

This	NN	O	O
clinical	NN	O	O
picture	NN	O	O
resolved	NN	O	O
completely	NN	O	O
with	NN	O	O
cessation	NN	O	O
of	NN	O	O
the	NN	O	O
combined	NN	O	O
therapy	NN	O	O
.	NN	O	O

Baseline	NN	O	O
left	NN	O	O
ventricular	NN	O	O
function	NN	O	O
,	NN	O	O
assessed	NN	O	O
by	NN	O	O
cardiac	NN	O	O
catheterisation	NN	O	O
or	NN	O	O
nuclear	NN	O	O
angiography	NN	O	O
,	NN	O	O
was	NN	O	O
normal	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
and	NN	O	O
only	NN	O	O
mildly	NN	O	O
reduced	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
.	NN	O	O

Simultaneously	NN	O	O
administration	NN	O	O
of	NN	O	O
beta	NN	O	B-Chemical
-	NN	O	I-Chemical
adrenergic	NN	O	I-Chemical
blocking	NN	O	I-Chemical
drugs	NN	O	I-Chemical
and	NN	O	O
verapamil	NN	O	B-Chemical
may	NN	O	O
result	NN	O	O
in	NN	O	O
profound	NN	O	O
adverse	NN	O	O
interactions	NN	O	O
and	NN	O	O
should	NN	O	O
only	NN	O	O
be	NN	O	O
administered	NN	O	O
with	NN	O	O
great	NN	O	O
caution	NN	O	O
.	NN	O	O


-DOCSTART- (6115999)

Adverse	NN	O	O
reactions	NN	O	O
to	NN	O	O
bendrofluazide	NN	O	B-Chemical
and	NN	O	O
propranolol	NN	O	B-Chemical
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
mild	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O

Report	NN	O	O
of	NN	O	O
Medical	NN	O	O
Research	NN	O	O
Council	NN	O	O
Working	NN	O	O
Party	NN	O	O
on	NN	O	O
Mild	NN	O	O
to	NN	O	O
Moderate	NN	O	O
Hypertension	NN	O	B-Disease
.	NN	O	O

Participants	NN	O	O
in	NN	O	O
the	NN	O	O
Medical	NN	O	O
Research	NN	O	O
Council	NN	O	O
treatment	NN	O	O
trial	NN	O	O
for	NN	O	O
mild	NN	O	O
hypertension	NN	O	B-Disease
are	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
one	NN	O	O
of	NN	O	O
four	NN	O	O
treatment	NN	O	O
groups	NN	O	O
:	NN	O	O
bendrofluazide	NN	O	B-Chemical
,	NN	O	O
propranolol	NN	O	B-Chemical
,	NN	O	O
or	NN	O	O
a	NN	O	O
placebo	NN	O	O
for	NN	O	O
either	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
trial	NN	O	O
is	NN	O	O
single	NN	O	O
-	NN	O	O
blind	NN	O	O
.	NN	O	O

23	NN	O	O
582	NN	O	O
patient	NN	O	O
-	NN	O	O
years	NN	O	O
of	NN	O	O
observation	NN	O	O
have	NN	O	O
been	NN	O	O
completed	NN	O	O
so	NN	O	O
far	NN	O	O
,	NN	O	O
10	NN	O	O
684	NN	O	O
on	NN	O	O
active	NN	O	O
drugs	NN	O	O
and	NN	O	O
12	NN	O	O
898	NN	O	O
on	NN	O	O
placebos	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
show	NN	O	O
an	NN	O	O
association	NN	O	O
between	NN	O	O
bendrofluazide	NN	O	B-Chemical
treatment	NN	O	O
and	NN	O	O
impotence	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
impotence	NN	O	B-Disease
also	NN	O	O
occurred	NN	O	O
more	NN	O	O
frequently	NN	O	O
in	NN	O	O
patients	NN	O	O
taking	NN	O	O
propranolol	NN	O	B-Chemical
than	NN	O	O
in	NN	O	O
those	NN	O	O
taking	NN	O	O
placebos	NN	O	O
.	NN	O	O

Other	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
significantly	NN	O	O
linked	NN	O	O
with	NN	O	O
active	NN	O	O
drugs	NN	O	O
include	NN	O	O
impaired	NN	O	B-Disease
glucose	NN	O	I-Disease
tolerance	NN	O	I-Disease
in	NN	O	O
men	NN	O	O
and	NN	O	O
women	NN	O	O
and	NN	O	O
gout	NN	O	B-Disease
in	NN	O	O
men	NN	O	O
,	NN	O	O
associated	NN	O	O
with	NN	O	O
bendrofluazide	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
and	NN	O	O
Raynaud	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
phenomenon	NN	O	I-Disease
and	NN	O	O
dyspnoea	NN	O	B-Disease
in	NN	O	O
men	NN	O	O
and	NN	O	O
women	NN	O	O
taking	NN	O	O
propranolol	NN	O	B-Chemical
.	NN	O	O

No	NN	O	O
corneal	NN	O	B-Disease
disease	NN	O	I-Disease
is	NN	O	O
known	NN	O	O
to	NN	O	O
have	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
propranolol	NN	O	B-Chemical
group	NN	O	O
.	NN	O	O

Mean	NN	O	O
serum	NN	O	O
potassium	NN	O	B-Chemical
level	NN	O	O
fell	NN	O	O
,	NN	O	O
and	NN	O	O
urea	NN	O	B-Chemical
and	NN	O	O
uric	NN	O	B-Chemical
acid	NN	O	I-Chemical
levels	NN	O	O
rose	NN	O	O
,	NN	O	O
in	NN	O	O
men	NN	O	O
and	NN	O	O
women	NN	O	O
taking	NN	O	O
bendrofluazide	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
the	NN	O	O
propranolol	NN	O	B-Chemical
group	NN	O	O
,	NN	O	O
serum	NN	O	O
potassium	NN	O	B-Chemical
and	NN	O	O
uric	NN	O	B-Chemical
acid	NN	O	I-Chemical
levels	NN	O	O
rose	NN	O	O
in	NN	O	O
both	NN	O	O
sexes	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
urea	NN	O	B-Chemical
level	NN	O	O
rose	NN	O	O
significantly	NN	O	O
in	NN	O	O
women	NN	O	O
only	NN	O	O
.	NN	O	O


-DOCSTART- (18086064)

Dexmedetomidine	NN	O	B-Chemical
and	NN	O	O
cardiac	NN	O	O
protection	NN	O	O
for	NN	O	O
non	NN	O	O
-	NN	O	O
cardiac	NN	O	O
surgery	NN	O	O
:	NN	O	O
a	NN	O	O
meta	NN	O	O
-	NN	O	O
analysis	NN	O	O
of	NN	O	O
randomised	NN	O	O
controlled	NN	O	O
trials	NN	O	O
.	NN	O	O

We	NN	O	O
conducted	NN	O	O
a	NN	O	O
systematic	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
dexmedetomidine	NN	O	B-Chemical
on	NN	O	O
cardiac	NN	O	O
outcomes	NN	O	O
following	NN	O	O
non	NN	O	O
-	NN	O	O
cardiac	NN	O	O
surgery	NN	O	O
.	NN	O	O

We	NN	O	O
included	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomised	NN	O	O
peri	NN	O	O
-	NN	O	O
operative	NN	O	O
studies	NN	O	O
of	NN	O	O
dexmedetomidine	NN	O	B-Chemical
that	NN	O	O
reported	NN	O	O
mortality	NN	O	O
,	NN	O	O
cardiac	NN	O	O
morbidity	NN	O	O
or	NN	O	O
adverse	NN	O	O
drug	NN	O	O
events	NN	O	O
.	NN	O	O

A	NN	O	O
PubMed	NN	O	O
Central	NN	O	O
and	NN	O	O
EMBASE	NN	O	O
search	NN	O	O
was	NN	O	O
conducted	NN	O	O
up	NN	O	O
to	NN	O	O
July	NN	O	O
2007	NN	O	O
.	NN	O	O

The	NN	O	O
reference	NN	O	O
lists	NN	O	O
of	NN	O	O
identified	NN	O	O
papers	NN	O	O
were	NN	O	O
examined	NN	O	O
for	NN	O	O
further	NN	O	O
trials	NN	O	O
.	NN	O	O

Of	NN	O	O
425	NN	O	O
studies	NN	O	O
identified	NN	O	O
,	NN	O	O
20	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
meta	NN	O	O
-	NN	O	O
analysis	NN	O	O
(	NN	O	O
840	NN	O	O
patients	NN	O	O
)	NN	O	O
.	NN	O	O

Dexmedetomidine	NN	O	B-Chemical
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
trend	NN	O	O
towards	NN	O	O
improved	NN	O	O
cardiac	NN	O	O
outcomes	NN	O	O
;	NN	O	O
all	NN	O	O
-	NN	O	O
cause	NN	O	O
mortality	NN	O	O
(	NN	O	O
OR	NN	O	O
0.27	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
0.01	NN	O	O
-	NN	O	O
7.13	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.44	NN	O	O
)	NN	O	O
,	NN	O	O
non	NN	O	O
-	NN	O	O
fatal	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
(	NN	O	O
OR	NN	O	O
0.26	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
0.04	NN	O	O
-	NN	O	O
1.60	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.14	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
myocardial	NN	O	B-Disease
ischaemia	NN	O	I-Disease
(	NN	O	O
OR	NN	O	O
0.65	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
0.26	NN	O	O
-	NN	O	O
1.63	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.36	NN	O	O
)	NN	O	O
.	NN	O	O

Peri	NN	O	O
-	NN	O	O
operative	NN	O	O
hypotension	NN	O	B-Disease
(	NN	O	O
26%	NN	O	O
,	NN	O	O
OR	NN	O	O
3.80	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
1.91	NN	O	O
-	NN	O	O
7.54	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.0001	NN	O	O
)	NN	O	O
and	NN	O	O
bradycardia	NN	O	B-Disease
(	NN	O	O
17%	NN	O	O
,	NN	O	O
OR	NN	O	O
5.45	NN	O	O
,	NN	O	O
95%	NN	O	O
CI	NN	O	O
2.98	NN	O	O
-	NN	O	O
9.95	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.00001	NN	O	O
)	NN	O	O
were	NN	O	O
significantly	NN	O	O
increased	NN	O	O
.	NN	O	O

An	NN	O	O
anticholinergic	NN	O	O
did	NN	O	O
not	NN	O	O
reduce	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
bradycardia	NN	O	B-Disease
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.43	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
randomised	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
trial	NN	O	O
of	NN	O	O
dexmedetomidine	NN	O	B-Chemical
is	NN	O	O
warranted	NN	O	O
.	NN	O	O


-DOCSTART- (12739036)

Differential	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
high	NN	O	O
serum	NN	O	O
creatine	NN	O	B-Chemical
kinase	NN	O	O
levels	NN	O	O
in	NN	O	O
systemic	NN	O	B-Disease
lupus	NN	O	I-Disease
erythematosus	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
clinical	NN	O	O
and	NN	O	O
bioptic	NN	O	O
findings	NN	O	O
for	NN	O	O
a	NN	O	O
57	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
severe	NN	O	O
chloroquine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
myopathy	NN	O	B-Disease
.	NN	O	O

Since	NN	O	O
1989	NN	O	O
,	NN	O	O
she	NN	O	O
had	NN	O	O
been	NN	O	O
suffering	NN	O	O
from	NN	O	O
systemic	NN	O	B-Disease
lupus	NN	O	I-Disease
erythematosus	NN	O	I-Disease
(	NN	O	O
SLE	NN	O	B-Disease
)	NN	O	O
with	NN	O	O
renal	NN	O	B-Disease
involvement	NN	O	I-Disease
and	NN	O	O
undergone	NN	O	O
periods	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
azathioprine	NN	O	B-Chemical
and	NN	O	O
cyclophosphamide	NN	O	B-Chemical
.	NN	O	O

Additional	NN	O	O
therapy	NN	O	O
with	NN	O	O
chloroquine	NN	O	B-Chemical
(	NN	O	O
CQ	NN	O	B-Chemical
)	NN	O	O
was	NN	O	O
started	NN	O	O
because	NN	O	O
of	NN	O	O
arthralgia	NN	O	B-Disease
.	NN	O	O

At	NN	O	O
the	NN	O	O
same	NN	O	O
time	NN	O	O
,	NN	O	O
slightly	NN	O	O
increased	NN	O	O
creatine	NN	O	B-Chemical
kinase	NN	O	O
(	NN	O	O
CK	NN	O	O
)	NN	O	O
levels	NN	O	O
were	NN	O	O
noted	NN	O	O
.	NN	O	O

Myositis	NN	O	B-Disease
was	NN	O	O
suspected	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
steroids	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
CK	NN	O	O
increase	NN	O	O
persisted	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
and	NN	O	O
she	NN	O	O
developed	NN	O	O
progressive	NN	O	O
muscular	NN	O	B-Disease
weakness	NN	O	I-Disease
and	NN	O	O
muscular	NN	O	B-Disease
atrophy	NN	O	I-Disease
.	NN	O	O

Routine	NN	O	O
controls	NN	O	O
revealed	NN	O	O
markedly	NN	O	O
elevated	NN	O	O
CK	NN	O	O
levels	NN	O	O
of	NN	O	O
1	NN	O	O
,	NN	O	O
700	NN	O	O
U	NN	O	O
/	NN	O	O
l	NN	O	O
.	NN	O	O

The	NN	O	O
neurological	NN	O	O
and	NN	O	O
electrophysiological	NN	O	O
findings	NN	O	O
were	NN	O	O
not	NN	O	O
typical	NN	O	O
of	NN	O	O
myositis	NN	O	B-Disease
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
muscle	NN	O	O
biopsy	NN	O	O
of	NN	O	O
the	NN	O	O
deltoid	NN	O	O
muscle	NN	O	O
was	NN	O	O
performed	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
exclude	NN	O	O
polymyositis	NN	O	B-Disease
or	NN	O	O
toxic	NN	O	O
myopathy	NN	O	B-Disease
.	NN	O	O

As	NN	O	O
it	NN	O	O
revealed	NN	O	O
chloroquine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
myopathy	NN	O	B-Disease
,	NN	O	O
medication	NN	O	O
was	NN	O	O
stopped	NN	O	O
.	NN	O	O

Discriminating	NN	O	O
between	NN	O	O
primary	NN	O	O
SLE	NN	O	B-Disease
-	NN	O	O
induced	NN	O	O
affection	NN	O	B-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
musculoskeletal	NN	O	I-Disease
system	NN	O	I-Disease
and	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
side	NN	O	O
effects	NN	O	O
is	NN	O	O
important	NN	O	O
for	NN	O	O
appropriate	NN	O	O
treatment	NN	O	O
of	NN	O	O
SLE	NN	O	B-Disease
patients	NN	O	O
.	NN	O	O


-DOCSTART- (12093990)

Intravenous	NN	O	O
ribavirin	NN	O	B-Chemical
treatment	NN	O	O
for	NN	O	O
severe	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
in	NN	O	O
immunocompromised	NN	O	O
children	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Adenovirus	NN	O	O
is	NN	O	O
an	NN	O	O
important	NN	O	O
cause	NN	O	O
of	NN	O	O
morbidity	NN	O	O
and	NN	O	O
mortality	NN	O	O
in	NN	O	O
the	NN	O	O
immunocompromised	NN	O	O
host	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
severe	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
in	NN	O	O
pediatrics	NN	O	O
is	NN	O	O
increasing	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
growing	NN	O	O
numbers	NN	O	O
of	NN	O	O
immunocompromised	NN	O	O
children	NN	O	O
,	NN	O	O
where	NN	O	O
case	NN	O	O
fatality	NN	O	O
rates	NN	O	O
as	NN	O	O
high	NN	O	O
as	NN	O	O
50%	NN	O	O
to	NN	O	O
80%	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

There	NN	O	O
are	NN	O	O
no	NN	O	O
approved	NN	O	O
antiviral	NN	O	O
agents	NN	O	O
with	NN	O	O
proven	NN	O	O
efficacy	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
severe	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
nor	NN	O	O
are	NN	O	O
there	NN	O	O
any	NN	O	O
prospective	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
trials	NN	O	O
of	NN	O	O
potentially	NN	O	O
useful	NN	O	O
anti	NN	O	O
-	NN	O	O
adenovirus	NN	O	O
therapies	NN	O	O
.	NN	O	O

Apparent	NN	O	O
clinical	NN	O	O
success	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
severe	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
is	NN	O	O
limited	NN	O	O
to	NN	O	O
a	NN	O	O
few	NN	O	O
case	NN	O	O
reports	NN	O	O
and	NN	O	O
small	NN	O	O
series	NN	O	O
.	NN	O	O

Experience	NN	O	O
is	NN	O	O
greatest	NN	O	O
with	NN	O	O
intravenous	NN	O	O
ribavirin	NN	O	B-Chemical
and	NN	O	O
cidofovir	NN	O	B-Chemical
.	NN	O	O

Ribavirin	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
guanosine	NN	O	B-Chemical
analogue	NN	O	O
,	NN	O	O
has	NN	O	O
broad	NN	O	O
antiviral	NN	O	O
activity	NN	O	O
against	NN	O	O
both	NN	O	O
RNA	NN	O	O
and	NN	O	O
DNA	NN	O	O
viruses	NN	O	O
,	NN	O	O
including	NN	O	O
documented	NN	O	O
activity	NN	O	O
against	NN	O	O
adenovirus	NN	O	O
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

Ribavirin	NN	O	B-Chemical
is	NN	O	O
licensed	NN	O	O
in	NN	O	O
aerosol	NN	O	O
form	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
respiratory	NN	O	B-Disease
syncytial	NN	O	I-Disease
virus	NN	O	I-Disease
infection	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
orally	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
interferon	NN	O	O
to	NN	O	O
treat	NN	O	O
hepatitis	NN	O	B-Disease
C	NN	O	I-Disease
.	NN	O	O

Intravenous	NN	O	O
ribavirin	NN	O	B-Chemical
is	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
choice	NN	O	O
for	NN	O	O
infection	NN	O	B-Disease
with	NN	O	I-Disease
hemorrhagic	NN	O	I-Disease
fever	NN	O	I-Disease
viruses	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
adverse	NN	O	O
effect	NN	O	O
of	NN	O	O
intravenous	NN	O	O
ribavirin	NN	O	B-Chemical
is	NN	O	O
reversible	NN	O	O
mild	NN	O	O
anemia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
use	NN	O	O
of	NN	O	O
cidofovir	NN	O	B-Chemical
in	NN	O	O
severe	NN	O	O
adenovirus	NN	O	B-Disease
infection	NN	O	I-Disease
has	NN	O	O
been	NN	O	O
limited	NN	O	O
by	NN	O	O
adverse	NN	O	O
effects	NN	O	O
,	NN	O	O
the	NN	O	O
most	NN	O	O
significant	NN	O	O
of	NN	O	O
which	NN	O	O
is	NN	O	O
nephrotoxicity	NN	O	B-Disease
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
We	NN	O	O
report	NN	O	O
our	NN	O	O
experience	NN	O	O
with	NN	O	O
intravenous	NN	O	O
ribavirin	NN	O	B-Chemical
therapy	NN	O	O
for	NN	O	O
severe	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
series	NN	O	O
of	NN	O	O
immunocompromised	NN	O	O
children	NN	O	O
and	NN	O	O
review	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
/	NN	O	O
METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
retrospectively	NN	O	O
reviewed	NN	O	O
the	NN	O	O
medical	NN	O	O
records	NN	O	O
of	NN	O	O
5	NN	O	O
children	NN	O	O
treated	NN	O	O
with	NN	O	O
intravenous	NN	O	O
ribavirin	NN	O	B-Chemical
for	NN	O	O
documented	NN	O	O
severe	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
developed	NN	O	O
adenovirus	NN	O	O
hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
after	NN	O	O
cardiac	NN	O	O
and	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplants	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplant	NN	O	O
patient	NN	O	O
also	NN	O	O
received	NN	O	O
intravenous	NN	O	O
cidofovir	NN	O	B-Chemical
for	NN	O	O
progressive	NN	O	O
disseminated	NN	O	O
disease	NN	O	O
.	NN	O	O

An	NN	O	O
additional	NN	O	O
3	NN	O	O
children	NN	O	O
developed	NN	O	O
adenovirus	NN	O	B-Disease
pneumonia	NN	O	I-Disease
;	NN	O	O
2	NN	O	O
were	NN	O	O
neonates	NN	O	O
,	NN	O	O
1	NN	O	O
of	NN	O	O
whom	NN	O	O
had	NN	O	O
partial	NN	O	O
DiGeorge	NN	O	B-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
remaining	NN	O	O
infant	NN	O	O
had	NN	O	O
recently	NN	O	O
undergone	NN	O	O
a	NN	O	O
cardiac	NN	O	O
transplant	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
ribavirin	NN	O	B-Chemical
was	NN	O	O
administered	NN	O	O
on	NN	O	O
a	NN	O	O
compassionate	NN	O	O
-	NN	O	O
use	NN	O	O
protocol	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Complete	NN	O	O
clinical	NN	O	O
recovery	NN	O	O
followed	NN	O	O
later	NN	O	O
by	NN	O	O
viral	NN	O	O
clearance	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
2	NN	O	O
children	NN	O	O
:	NN	O	O
the	NN	O	O
cardiac	NN	O	O
transplant	NN	O	O
recipient	NN	O	O
with	NN	O	O
adenovirus	NN	O	O
hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
and	NN	O	O
the	NN	O	O
immunocompetent	NN	O	O
neonate	NN	O	O
with	NN	O	O
adenovirus	NN	O	B-Disease
pneumonia	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
remaining	NN	O	O
3	NN	O	O
children	NN	O	O
died	NN	O	O
of	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

Intravenous	NN	O	O
ribavirin	NN	O	B-Chemical
therapy	NN	O	O
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
.	NN	O	O

Use	NN	O	O
of	NN	O	O
cidofovir	NN	O	B-Chemical
in	NN	O	O
1	NN	O	O
child	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
progressive	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
and	NN	O	O
neutropenia	NN	O	B-Disease
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
Our	NN	O	O
series	NN	O	O
of	NN	O	O
patients	NN	O	O
is	NN	O	O
representative	NN	O	O
of	NN	O	O
the	NN	O	O
spectrum	NN	O	O
of	NN	O	O
immunocompromised	NN	O	O
children	NN	O	O
at	NN	O	O
greatest	NN	O	O
risk	NN	O	O
for	NN	O	O
severe	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
namely	NN	O	O
solid	NN	O	O
-	NN	O	O
organ	NN	O	O
and	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
,	NN	O	O
neonates	NN	O	O
,	NN	O	O
and	NN	O	O
children	NN	O	O
with	NN	O	O
immunodeficiency	NN	O	B-Disease
.	NN	O	O

Although	NN	O	O
intravenous	NN	O	O
ribavirin	NN	O	B-Chemical
was	NN	O	O
not	NN	O	O
effective	NN	O	O
for	NN	O	O
all	NN	O	O
children	NN	O	O
with	NN	O	O
severe	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
in	NN	O	O
this	NN	O	O
series	NN	O	O
or	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
,	NN	O	O
therapy	NN	O	O
is	NN	O	O
unlikely	NN	O	O
to	NN	O	O
be	NN	O	O
of	NN	O	O
benefit	NN	O	O
if	NN	O	O
begun	NN	O	O
late	NN	O	O
in	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
the	NN	O	O
infection	NN	O	B-Disease
.	NN	O	O

Early	NN	O	O
identification	NN	O	O
,	NN	O	O
eg	NN	O	O
by	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
of	NN	O	O
those	NN	O	O
patients	NN	O	O
at	NN	O	O
risk	NN	O	O
of	NN	O	O
disseminated	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
may	NN	O	O
permit	NN	O	O
earlier	NN	O	O
antiviral	NN	O	O
treatment	NN	O	O
and	NN	O	O
better	NN	O	O
evaluation	NN	O	O
of	NN	O	O
therapeutic	NN	O	O
response	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Two	NN	O	O
of	NN	O	O
5	NN	O	O
children	NN	O	O
with	NN	O	O
severe	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
treated	NN	O	O
with	NN	O	O
intravenous	NN	O	O
ribavirin	NN	O	B-Chemical
recovered	NN	O	O
.	NN	O	O

The	NN	O	O
availability	NN	O	O
of	NN	O	O
newer	NN	O	O
rapid	NN	O	O
diagnostic	NN	O	O
techniques	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
,	NN	O	O
may	NN	O	O
make	NN	O	O
earlier	NN	O	O
,	NN	O	O
more	NN	O	O
effective	NN	O	O
treatment	NN	O	O
of	NN	O	O
adenovirus	NN	O	B-Disease
infection	NN	O	I-Disease
possible	NN	O	O
.	NN	O	O

Given	NN	O	O
the	NN	O	O
seriousness	NN	O	O
and	NN	O	O
increasing	NN	O	O
prevalence	NN	O	O
of	NN	O	O
adenovirus	NN	O	B-Disease
disease	NN	O	I-Disease
in	NN	O	O
certain	NN	O	O
hosts	NN	O	O
,	NN	O	O
especially	NN	O	O
children	NN	O	O
,	NN	O	O
a	NN	O	O
large	NN	O	O
,	NN	O	O
multicenter	NN	O	O
clinical	NN	O	O
trial	NN	O	O
of	NN	O	O
potentially	NN	O	O
useful	NN	O	O
anti	NN	O	O
-	NN	O	O
adenoviral	NN	O	O
therapies	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
intravenous	NN	O	O
ribavirin	NN	O	B-Chemical
,	NN	O	O
is	NN	O	O
clearly	NN	O	O
required	NN	O	O
to	NN	O	O
demonstrate	NN	O	O
the	NN	O	O
most	NN	O	O
effective	NN	O	O
and	NN	O	O
least	NN	O	O
toxic	NN	O	O
therapy	NN	O	O
.	NN	O	O


-DOCSTART- (3962737)

Hepatotoxicity	NN	O	B-Disease
of	NN	O	O
amiodarone	NN	O	B-Chemical
.	NN	O	O

Amiodarone	NN	O	B-Chemical
has	NN	O	O
proved	NN	O	O
very	NN	O	O
effective	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
otherwise	NN	O	O
resistant	NN	O	O
cardiac	NN	O	O
tachyarrhythmias	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
use	NN	O	O
of	NN	O	O
amiodarone	NN	O	B-Chemical
has	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
been	NN	O	O
limited	NN	O	O
due	NN	O	O
to	NN	O	O
its	NN	O	O
serious	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
.	NN	O	O

A	NN	O	O
patient	NN	O	O
with	NN	O	O
cholestatic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
amiodarone	NN	O	B-Chemical
treatment	NN	O	O
is	NN	O	O
presented	NN	O	O
below	NN	O	O
and	NN	O	O
a	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
hepatotoxicity	NN	O	B-Disease
of	NN	O	O
amiodarone	NN	O	B-Chemical
is	NN	O	O
given	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
solid	NN	O	O
evidence	NN	O	O
exists	NN	O	O
of	NN	O	O
hepatic	NN	O	B-Disease
injury	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
amiodarone	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
including	NN	O	O
steatosis	NN	O	B-Disease
,	NN	O	O
alterations	NN	O	O
resembling	NN	O	O
alcoholic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
,	NN	O	O
cholestatic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
and	NN	O	O
micronodular	NN	O	O
cirrhosis	NN	O	B-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
liver	NN	O	I-Disease
.	NN	O	O

Patients	NN	O	O
receiving	NN	O	O
amiodarone	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
regularly	NN	O	O
screened	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
hepatic	NN	O	O
enzyme	NN	O	O
levels	NN	O	O
.	NN	O	O

Therapy	NN	O	O
should	NN	O	O
be	NN	O	O
discontinued	NN	O	O
on	NN	O	O
the	NN	O	O
suspicion	NN	O	O
of	NN	O	O
cholestatic	NN	O	B-Disease
injury	NN	O	I-Disease
or	NN	O	O
hepatomegaly	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (2716967)

Catalepsy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
combinations	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
and	NN	O	O
morphine	NN	O	B-Chemical
:	NN	O	O
potentiation	NN	O	O
,	NN	O	O
antagonism	NN	O	O
,	NN	O	O
tolerance	NN	O	O
and	NN	O	O
cross	NN	O	O
-	NN	O	O
tolerance	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
both	NN	O	O
ketamine	NN	O	B-Chemical
and	NN	O	O
morphine	NN	O	B-Chemical
induced	NN	O	O
analgesia	NN	O	B-Disease
and	NN	O	O
catalepsy	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
with	NN	O	O
ketamine	NN	O	B-Chemical
produced	NN	O	O
cross	NN	O	O
-	NN	O	O
tolerance	NN	O	O
to	NN	O	O
morphine	NN	O	B-Chemical
,	NN	O	O
whereas	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
morphine	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
induce	NN	O	O
cross	NN	O	O
-	NN	O	O
tolerance	NN	O	O
to	NN	O	O
ketamine	NN	O	B-Chemical
but	NN	O	O
rather	NN	O	O
augmented	NN	O	O
the	NN	O	O
cataleptic	NN	O	B-Disease
response	NN	O	O
;	NN	O	O
this	NN	O	O
augmentation	NN	O	O
was	NN	O	O
attributed	NN	O	O
to	NN	O	O
residual	NN	O	O
morphine	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
brain	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
studies	NN	O	O
explored	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
the	NN	O	O
loss	NN	O	O
of	NN	O	O
righting	NN	O	O
reflex	NN	O	O
induced	NN	O	O
by	NN	O	O
sub	NN	O	O
-	NN	O	O
effective	NN	O	O
doses	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
and	NN	O	O
morphine	NN	O	B-Chemical
,	NN	O	O
administered	NN	O	O
simultaneously	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
mutual	NN	O	O
potentiation	NN	O	O
between	NN	O	O
sub	NN	O	O
-	NN	O	O
effective	NN	O	O
doses	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
and	NN	O	O
morphine	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
sub	NN	O	O
-	NN	O	O
effective	NN	O	O
doses	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
partly	NN	O	O
antagonized	NN	O	O
fully	NN	O	O
-	NN	O	O
effective	NN	O	O
doses	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
.	NN	O	O

Latency	NN	O	O
to	NN	O	O
the	NN	O	O
loss	NN	O	O
of	NN	O	O
righting	NN	O	O
reflex	NN	O	O
,	NN	O	O
rigidity	NN	O	B-Disease
and	NN	O	O
behavior	NN	O	O
on	NN	O	O
recovery	NN	O	O
,	NN	O	O
reflected	NN	O	O
the	NN	O	O
relative	NN	O	O
predominance	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
or	NN	O	O
morphine	NN	O	B-Chemical
in	NN	O	O
each	NN	O	O
combination	NN	O	O
.	NN	O	O

Naloxone	NN	O	B-Chemical
inhibited	NN	O	O
the	NN	O	O
induced	NN	O	O
cataleptic	NN	O	B-Disease
effects	NN	O	O
.	NN	O	O

The	NN	O	O
degree	NN	O	O
and	NN	O	O
time	NN	O	O
course	NN	O	O
of	NN	O	O
development	NN	O	O
of	NN	O	O
tolerance	NN	O	O
to	NN	O	O
daily	NN	O	O
administration	NN	O	O
of	NN	O	O
sub	NN	O	O
-	NN	O	O
effective	NN	O	O
dose	NN	O	O
combinations	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
and	NN	O	O
morphine	NN	O	B-Chemical
were	NN	O	O
similar	NN	O	O
.	NN	O	O

Rats	NN	O	O
,	NN	O	O
tolerant	NN	O	O
to	NN	O	O
ketamine	NN	O	B-Chemical
-	NN	O	O
dominant	NN	O	O
combinations	NN	O	O
,	NN	O	O
were	NN	O	O
cross	NN	O	O
-	NN	O	O
tolerant	NN	O	O
to	NN	O	O
both	NN	O	O
drugs	NN	O	O
,	NN	O	O
while	NN	O	O
those	NN	O	O
tolerant	NN	O	O
to	NN	O	O
morphine	NN	O	B-Chemical
-	NN	O	O
dominant	NN	O	O
combinations	NN	O	O
were	NN	O	O
cross	NN	O	O
-	NN	O	O
tolerant	NN	O	O
to	NN	O	O
morphine	NN	O	B-Chemical
but	NN	O	O
showed	NN	O	O
either	NN	O	O
no	NN	O	O
cross	NN	O	O
-	NN	O	O
tolerance	NN	O	O
or	NN	O	O
an	NN	O	O
augmented	NN	O	O
response	NN	O	O
to	NN	O	O
ketamine	NN	O	B-Chemical
.	NN	O	O

While	NN	O	O
the	NN	O	O
mutual	NN	O	O
potentiation	NN	O	O
,	NN	O	O
antagonism	NN	O	O
and	NN	O	O
tolerance	NN	O	O
suggest	NN	O	O
common	NN	O	O
mechanisms	NN	O	O
for	NN	O	O
the	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
,	NN	O	O
differences	NN	O	O
in	NN	O	O
latency	NN	O	O
,	NN	O	O
rigidity	NN	O	B-Disease
and	NN	O	O
behavior	NN	O	O
,	NN	O	O
asymmetry	NN	O	O
of	NN	O	O
cross	NN	O	O
-	NN	O	O
tolerance	NN	O	O
and	NN	O	O
a	NN	O	O
widely	NN	O	O
-	NN	O	O
different	NN	O	O
ID50	NN	O	O
for	NN	O	O
naloxone	NN	O	B-Chemical
would	NN	O	O
argue	NN	O	O
against	NN	O	O
an	NN	O	O
action	NN	O	O
at	NN	O	O
a	NN	O	O
single	NN	O	O
opioid	NN	O	O
site	NN	O	O
.	NN	O	O


-DOCSTART- (19642243)

Acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
with	NN	O	O
AIDS	NN	O	B-Disease
on	NN	O	O
tenofovir	NN	O	B-Chemical
while	NN	O	O
receiving	NN	O	O
prolonged	NN	O	O
vancomycin	NN	O	B-Chemical
course	NN	O	O
for	NN	O	O
osteomyelitis	NN	O	B-Disease
.	NN	O	O

Renal	NN	O	B-Disease
failure	NN	O	I-Disease
developed	NN	O	O
after	NN	O	O
a	NN	O	O
prolonged	NN	O	O
course	NN	O	O
of	NN	O	O
vancomycin	NN	O	B-Chemical
therapy	NN	O	O
in	NN	O	O
2	NN	O	O
patients	NN	O	O
who	NN	O	O
were	NN	O	O
receiving	NN	O	O
tenofovir	NN	O	B-Chemical
disoproxil	NN	O	I-Chemical
fumarate	NN	O	I-Chemical
as	NN	O	O
part	NN	O	O
of	NN	O	O
an	NN	O	O
antiretroviral	NN	O	O
regimen	NN	O	O
.	NN	O	O

Tenofovir	NN	O	B-Chemical
has	NN	O	O
been	NN	O	O
implicated	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
Fanconi	NN	O	B-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
renal	NN	O	B-Disease
insufficiency	NN	O	I-Disease
because	NN	O	O
of	NN	O	O
its	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
proximal	NN	O	O
renal	NN	O	O
tubule	NN	O	O
.	NN	O	O

Vancomycin	NN	O	B-Chemical
nephrotoxicity	NN	O	B-Disease
is	NN	O	O
infrequent	NN	O	O
but	NN	O	O
may	NN	O	O
result	NN	O	O
from	NN	O	O
coadministration	NN	O	O
with	NN	O	O
a	NN	O	O
nephrotoxic	NN	O	B-Disease
agent	NN	O	O
.	NN	O	O

Clinicians	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
that	NN	O	O
tenofovir	NN	O	B-Chemical
may	NN	O	O
raise	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
during	NN	O	O
prolonged	NN	O	O
administration	NN	O	O
of	NN	O	O
vancomycin	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (17682013)

Delayed	NN	O	O
leukoencephalopathy	NN	O	B-Disease
with	NN	O	O
stroke	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
presentation	NN	O	O
in	NN	O	O
chemotherapy	NN	O	O
recipients	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
A	NN	O	O
transient	NN	O	O
leukoencephalopathy	NN	O	B-Disease
mimicking	NN	O	O
cerebrovascular	NN	O	B-Disease
accident	NN	O	I-Disease
has	NN	O	O
been	NN	O	O
described	NN	O	O
as	NN	O	O
a	NN	O	O
complication	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
,	NN	O	O
most	NN	O	O
commonly	NN	O	O
in	NN	O	O
recipients	NN	O	O
of	NN	O	O
intrathecal	NN	O	O
methotrexate	NN	O	B-Chemical
for	NN	O	O
childhood	NN	O	O
leukaemia	NN	O	B-Disease
.	NN	O	O

Recently	NN	O	O
published	NN	O	O
neuroimaging	NN	O	O
data	NN	O	O
suggest	NN	O	O
a	NN	O	O
common	NN	O	O
pathophysiology	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
agents	NN	O	O
and	NN	O	O
modes	NN	O	O
of	NN	O	O
administration	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
reviewed	NN	O	O
the	NN	O	O
medical	NN	O	O
literature	NN	O	O
for	NN	O	O
single	NN	O	O
reports	NN	O	O
and	NN	O	O
case	NN	O	O
series	NN	O	O
of	NN	O	O
patients	NN	O	O
presenting	NN	O	O
with	NN	O	O
stroke	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
episodes	NN	O	O
while	NN	O	O
receiving	NN	O	O
systemic	NN	O	O
or	NN	O	O
intrathecal	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

We	NN	O	O
only	NN	O	O
included	NN	O	O
studies	NN	O	O
providing	NN	O	O
detailed	NN	O	O
neuroimaging	NN	O	O
data	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
cerebrovascular	NN	O	B-Disease
accidents	NN	O	I-Disease
were	NN	O	O
excluded	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
We	NN	O	O
identified	NN	O	O
27	NN	O	O
reports	NN	O	O
of	NN	O	O
toxic	NN	O	O
leukoencephalopathy	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
methotrexate	NN	O	B-Chemical
(	NN	O	O
intrathecal	NN	O	O
,	NN	O	O
systemic	NN	O	O
)	NN	O	O
,	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
fluorouracil	NN	O	I-Chemical
and	NN	O	O
its	NN	O	O
derivative	NN	O	O
carmofur	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
capecitabine	NN	O	B-Chemical
.	NN	O	O

Diffusion	NN	O	O
weighted	NN	O	O
imaging	NN	O	O
(	NN	O	O
DWI	NN	O	O
)	NN	O	O
of	NN	O	O
all	NN	O	O
patients	NN	O	O
revealed	NN	O	O
well	NN	O	O
demarcated	NN	O	O
hyperintense	NN	O	O
lesions	NN	O	B-Disease
within	NN	O	I-Disease
the	NN	O	I-Disease
subcortical	NN	O	I-Disease
white	NN	O	I-Disease
matter	NN	O	I-Disease
of	NN	O	O
the	NN	O	O
cerebral	NN	O	O
hemispheres	NN	O	O
and	NN	O	O
the	NN	O	O
corpus	NN	O	O
callosum	NN	O	O
,	NN	O	O
corresponding	NN	O	O
to	NN	O	O
areas	NN	O	O
of	NN	O	O
decreased	NN	O	O
proton	NN	O	O
diffusion	NN	O	O
on	NN	O	O
apparent	NN	O	O
diffusion	NN	O	O
coefficient	NN	O	O
(	NN	O	O
ADC	NN	O	O
)	NN	O	O
maps	NN	O	O
(	NN	O	O
available	NN	O	O
in	NN	O	O
21	NN	O	O
/	NN	O	O
27	NN	O	O
patients	NN	O	O
)	NN	O	O
.	NN	O	O

Lesions	NN	O	O
exceeded	NN	O	O
the	NN	O	O
confines	NN	O	O
of	NN	O	O
adjacent	NN	O	O
vascular	NN	O	O
territories	NN	O	O
.	NN	O	O

Complete	NN	O	O
resolution	NN	O	O
of	NN	O	O
symptoms	NN	O	O
within	NN	O	O
1	NN	O	O
-	NN	O	O
4	NN	O	O
days	NN	O	O
was	NN	O	O
accompanied	NN	O	O
by	NN	O	O
normalisation	NN	O	O
of	NN	O	O
ADC	NN	O	O
abnormalities	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
fluid	NN	O	O
attenuated	NN	O	O
inversion	NN	O	O
recovery	NN	O	O
(	NN	O	O
FLAIR	NN	O	O
)	NN	O	O
sequences	NN	O	O
frequently	NN	O	O
revealed	NN	O	O
persistent	NN	O	O
white	NN	O	B-Disease
matter	NN	O	I-Disease
abnormalities	NN	O	I-Disease
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Several	NN	O	O
pathophysiological	NN	O	O
models	NN	O	O
of	NN	O	O
delayed	NN	O	O
leukoencephalopathy	NN	O	B-Disease
after	NN	O	O
exposure	NN	O	O
to	NN	O	O
intrathecal	NN	O	O
or	NN	O	O
systemic	NN	O	O
chemotherapy	NN	O	O
have	NN	O	O
been	NN	O	O
proposed	NN	O	O
.	NN	O	O

DWI	NN	O	O
findings	NN	O	O
in	NN	O	O
this	NN	O	O
cohort	NN	O	O
are	NN	O	O
indicative	NN	O	O
of	NN	O	O
cytotoxic	NN	O	B-Disease
oedema	NN	O	I-Disease
within	NN	O	I-Disease
cerebral	NN	O	I-Disease
white	NN	O	I-Disease
matter	NN	O	I-Disease
and	NN	O	O
lend	NN	O	O
support	NN	O	O
to	NN	O	O
an	NN	O	O
at	NN	O	O
least	NN	O	O
partially	NN	O	O
reversible	NN	O	O
metabolic	NN	O	O
derangement	NN	O	O
as	NN	O	O
the	NN	O	O
basis	NN	O	O
for	NN	O	O
this	NN	O	O
syndrome	NN	O	O
.	NN	O	O


-DOCSTART- (16725121)

Down	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
norepinephrine	NN	O	B-Chemical
transporter	NN	O	O
function	NN	O	O
induced	NN	O	O
by	NN	O	O
chronic	NN	O	O
administration	NN	O	O
of	NN	O	O
desipramine	NN	O	B-Chemical
linking	NN	O	O
to	NN	O	O
the	NN	O	O
alteration	NN	O	O
of	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
local	NN	O	O
-	NN	O	O
anesthetics	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
and	NN	O	O
the	NN	O	O
counteraction	NN	O	O
by	NN	O	O
co	NN	O	O
-	NN	O	O
administration	NN	O	O
with	NN	O	O
local	NN	O	O
anesthetics	NN	O	O
.	NN	O	O

Alterations	NN	O	O
of	NN	O	O
norepinephrine	NN	O	B-Chemical
transporter	NN	O	O
(	NN	O	O
NET	NN	O	O
)	NN	O	O
function	NN	O	O
by	NN	O	O
chronic	NN	O	O
inhibition	NN	O	O
of	NN	O	O
NET	NN	O	O
in	NN	O	O
relation	NN	O	O
to	NN	O	O
sensitization	NN	O	O
to	NN	O	O
seizures	NN	O	B-Disease
induce	NN	O	O
by	NN	O	O
cocaine	NN	O	B-Chemical
and	NN	O	O
local	NN	O	O
anesthetics	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Daily	NN	O	O
administration	NN	O	O
of	NN	O	O
desipramine	NN	O	B-Chemical
,	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
the	NN	O	O
NET	NN	O	O
,	NN	O	O
for	NN	O	O
5	NN	O	O
days	NN	O	O
decreased	NN	O	O
[	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
H	NN	O	O
]	NN	O	O
norepinephrine	NN	O	B-Chemical
uptake	NN	O	O
in	NN	O	O
the	NN	O	O
P2	NN	O	O
fractions	NN	O	O
of	NN	O	O
hippocampus	NN	O	O
but	NN	O	O
not	NN	O	O
cortex	NN	O	O
,	NN	O	O
striatum	NN	O	O
or	NN	O	O
amygdalae	NN	O	O
.	NN	O	O

Co	NN	O	O
-	NN	O	O
administration	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
,	NN	O	O
bupivacaine	NN	O	B-Chemical
or	NN	O	O
tricaine	NN	O	B-Chemical
with	NN	O	O
desipramine	NN	O	B-Chemical
reversed	NN	O	O
this	NN	O	O
effect	NN	O	O
.	NN	O	O

Daily	NN	O	O
treatment	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
increased	NN	O	O
[	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
H	NN	O	O
]	NN	O	O
norepinephrine	NN	O	B-Chemical
uptake	NN	O	O
into	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
.	NN	O	O

Daily	NN	O	O
administration	NN	O	O
of	NN	O	O
desipramine	NN	O	B-Chemical
increased	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
appearance	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
and	NN	O	O
decreased	NN	O	O
that	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
.	NN	O	O

Co	NN	O	O
-	NN	O	O
administration	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
with	NN	O	O
desipramine	NN	O	B-Chemical
reversed	NN	O	O
the	NN	O	O
changes	NN	O	O
of	NN	O	O
convulsive	NN	O	B-Disease
activity	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
and	NN	O	O
cocaine	NN	O	B-Chemical
induced	NN	O	O
by	NN	O	O
repeated	NN	O	O
administration	NN	O	O
of	NN	O	O
desipramine	NN	O	B-Chemical
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
down	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
hippocampal	NN	O	O
NET	NN	O	O
induced	NN	O	O
by	NN	O	O
chronic	NN	O	O
administration	NN	O	O
of	NN	O	O
desipramine	NN	O	B-Chemical
may	NN	O	O
be	NN	O	O
relevant	NN	O	O
to	NN	O	O
desipramine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
sensitization	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
convulsions	NN	O	B-Disease
.	NN	O	O

Inhibition	NN	O	O
of	NN	O	O
Na	NN	O	B-Chemical
(	NN	O	O
+	NN	O	O
)	NN	O	O
channels	NN	O	O
by	NN	O	O
local	NN	O	O
anesthetics	NN	O	O
may	NN	O	O
regulate	NN	O	O
desipramine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
down	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
NET	NN	O	O
function	NN	O	O
.	NN	O	O

Repeated	NN	O	O
administration	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
induces	NN	O	O
up	NN	O	O
-	NN	O	O
regulation	NN	O	O
of	NN	O	O
hippocampal	NN	O	O
NET	NN	O	O
function	NN	O	O
.	NN	O	O

Desipramine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
sensitization	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
seizures	NN	O	B-Disease
may	NN	O	O
have	NN	O	O
a	NN	O	O
mechanism	NN	O	O
distinct	NN	O	O
from	NN	O	O
kindling	NN	O	O
resulting	NN	O	O
from	NN	O	O
repeated	NN	O	O
administration	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (16629641)

Definition	NN	O	O
and	NN	O	O
management	NN	O	O
of	NN	O	O
anemia	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
infected	NN	O	B-Disease
with	NN	O	I-Disease
hepatitis	NN	O	I-Disease
C	NN	O	I-Disease
virus	NN	O	I-Disease
.	NN	O	O

Chronic	NN	O	B-Disease
infection	NN	O	I-Disease
with	NN	O	I-Disease
hepatitis	NN	O	I-Disease
C	NN	O	I-Disease
virus	NN	O	I-Disease
(	NN	O	O
HCV	NN	O	O
)	NN	O	O
can	NN	O	O
progress	NN	O	O
to	NN	O	O
cirrhosis	NN	O	B-Disease
,	NN	O	O
hepatocellular	NN	O	B-Disease
carcinoma	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
end	NN	O	B-Disease
-	NN	O	I-Disease
stage	NN	O	I-Disease
liver	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
current	NN	O	O
best	NN	O	O
treatment	NN	O	O
for	NN	O	O
HCV	NN	O	B-Disease
infection	NN	O	I-Disease
is	NN	O	O
combination	NN	O	O
therapy	NN	O	O
with	NN	O	O
pegylated	NN	O	O
interferon	NN	O	B-Chemical
and	NN	O	O
ribavirin	NN	O	B-Chemical
.	NN	O	O

Although	NN	O	O
this	NN	O	O
regimen	NN	O	O
produces	NN	O	O
sustained	NN	O	O
virologic	NN	O	O
responses	NN	O	O
(	NN	O	O
SVRs	NN	O	O
)	NN	O	O
in	NN	O	O
approximately	NN	O	O
50%	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
it	NN	O	O
can	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
potentially	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
.	NN	O	O

Hemoglobin	NN	O	O
concentrations	NN	O	O
decrease	NN	O	O
mainly	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hemolysis	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
this	NN	O	O
anemia	NN	O	B-Disease
can	NN	O	O
be	NN	O	O
problematic	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
HCV	NN	O	B-Disease
infection	NN	O	I-Disease
,	NN	O	O
especially	NN	O	O
those	NN	O	O
who	NN	O	O
have	NN	O	O
comorbid	NN	O	O
renal	NN	O	B-Disease
or	NN	O	I-Disease
cardiovascular	NN	O	I-Disease
disorders	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
general	NN	O	O
,	NN	O	O
anemia	NN	O	B-Disease
can	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
morbidity	NN	O	O
and	NN	O	O
mortality	NN	O	O
,	NN	O	O
and	NN	O	O
may	NN	O	O
have	NN	O	O
negative	NN	O	O
effects	NN	O	O
on	NN	O	O
cerebral	NN	O	O
function	NN	O	O
and	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
.	NN	O	O

Although	NN	O	O
ribavirin	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
anemia	NN	O	B-Disease
can	NN	O	O
be	NN	O	O
reversed	NN	O	O
by	NN	O	O
dose	NN	O	O
reduction	NN	O	O
or	NN	O	O
discontinuation	NN	O	O
,	NN	O	O
this	NN	O	O
approach	NN	O	O
compromises	NN	O	O
outcomes	NN	O	O
by	NN	O	O
significantly	NN	O	O
decreasing	NN	O	O
SVR	NN	O	O
rates	NN	O	O
.	NN	O	O

Recombinant	NN	O	O
human	NN	O	O
erythropoietin	NN	O	O
has	NN	O	O
been	NN	O	O
used	NN	O	O
to	NN	O	O
manage	NN	O	O
ribavirin	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
anemia	NN	O	B-Disease
but	NN	O	O
has	NN	O	O
other	NN	O	O
potential	NN	O	O
disadvantages	NN	O	O
.	NN	O	O

Viramidine	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
liver	NN	O	O
-	NN	O	O
targeting	NN	O	O
prodrug	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
,	NN	O	O
has	NN	O	O
the	NN	O	O
potential	NN	O	O
to	NN	O	O
maintain	NN	O	O
the	NN	O	O
virologic	NN	O	O
efficacy	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
while	NN	O	O
decreasing	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
C	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (16006300)

Calcium	NN	O	B-Chemical
carbonate	NN	O	I-Chemical
toxicity	NN	O	B-Disease
:	NN	O	O
the	NN	O	O
updated	NN	O	O
milk	NN	O	B-Disease
-	NN	O	I-Disease
alkali	NN	O	I-Disease
syndrome	NN	O	I-Disease
;	NN	O	O
report	NN	O	O
of	NN	O	O
3	NN	O	O
cases	NN	O	O
and	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
describe	NN	O	O
3	NN	O	O
patients	NN	O	O
with	NN	O	O
calcium	NN	O	B-Chemical
carbonate	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
hypercalcemia	NN	O	B-Disease
and	NN	O	O
gain	NN	O	O
insights	NN	O	O
into	NN	O	O
the	NN	O	O
cause	NN	O	O
and	NN	O	O
management	NN	O	O
of	NN	O	O
the	NN	O	O
milk	NN	O	B-Disease
-	NN	O	I-Disease
alkali	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
report	NN	O	O
the	NN	O	O
clinical	NN	O	O
and	NN	O	O
laboratory	NN	O	O
data	NN	O	O
in	NN	O	O
3	NN	O	O
patients	NN	O	O
who	NN	O	O
presented	NN	O	O
with	NN	O	O
severe	NN	O	O
hypercalcemia	NN	O	B-Disease
(	NN	O	O
corrected	NN	O	O
serum	NN	O	O
calcium	NN	O	B-Chemical
>	NN	O	O
or	NN	O	O
=	NN	O	O
14	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
)	NN	O	O
and	NN	O	O
review	NN	O	O
the	NN	O	O
pertinent	NN	O	O
literature	NN	O	O
on	NN	O	O
milk	NN	O	B-Disease
-	NN	O	I-Disease
alkali	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
3	NN	O	O
patients	NN	O	O
had	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
insufficiency	NN	O	I-Disease
,	NN	O	O
relative	NN	O	O
metabolic	NN	O	B-Disease
alkalosis	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
low	NN	O	O
parathyroid	NN	O	O
hormone	NN	O	O
(	NN	O	O
PTH	NN	O	O
)	NN	O	O
,	NN	O	O
PTH	NN	O	O
-	NN	O	O
related	NN	O	O
peptide	NN	O	O
,	NN	O	O
and	NN	O	O
1	NN	O	B-Chemical
,	NN	O	I-Chemical
25	NN	O	I-Chemical
-	NN	O	I-Chemical
dihydroxyvitamin	NN	O	I-Chemical
D	NN	O	I-Chemical
concentrations	NN	O	O
.	NN	O	O

No	NN	O	O
malignant	NN	O	O
lesion	NN	O	O
was	NN	O	O
found	NN	O	O
.	NN	O	O

Treatment	NN	O	O
included	NN	O	O
aggressive	NN	O	O
hydration	NN	O	O
and	NN	O	O
varied	NN	O	O
amounts	NN	O	O
of	NN	O	O
furosemide	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
2	NN	O	O
patients	NN	O	O
with	NN	O	O
the	NN	O	O
higher	NN	O	O
serum	NN	O	O
calcium	NN	O	B-Chemical
concentrations	NN	O	O
received	NN	O	O
pamidronate	NN	O	B-Chemical
intravenously	NN	O	O
(	NN	O	O
60	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
,	NN	O	O
which	NN	O	O
caused	NN	O	O
severe	NN	O	O
hypocalcemia	NN	O	B-Disease
.	NN	O	O

Of	NN	O	O
the	NN	O	O
3	NN	O	O
patients	NN	O	O
,	NN	O	O
2	NN	O	O
were	NN	O	O
ingesting	NN	O	O
acceptable	NN	O	O
doses	NN	O	O
of	NN	O	O
elemental	NN	O	O
calcium	NN	O	B-Chemical
(	NN	O	O
1	NN	O	O
g	NN	O	O
and	NN	O	O
2	NN	O	O
g	NN	O	O
daily	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
form	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
carbonate	NN	O	I-Chemical
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
our	NN	O	O
highlighted	NN	O	O
cases	NN	O	O
,	NN	O	O
we	NN	O	O
review	NN	O	O
the	NN	O	O
history	NN	O	O
,	NN	O	O
classification	NN	O	O
,	NN	O	O
pathophysiologic	NN	O	O
features	NN	O	O
,	NN	O	O
and	NN	O	O
treatment	NN	O	O
of	NN	O	O
milk	NN	O	B-Disease
-	NN	O	I-Disease
alkali	NN	O	I-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
summarize	NN	O	O
the	NN	O	O
cases	NN	O	O
reported	NN	O	O
from	NN	O	O
early	NN	O	O
1995	NN	O	O
to	NN	O	O
November	NN	O	O
2003	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Milk	NN	O	B-Disease
-	NN	O	I-Disease
alkali	NN	O	I-Disease
syndrome	NN	O	I-Disease
may	NN	O	O
be	NN	O	O
a	NN	O	O
common	NN	O	O
cause	NN	O	O
of	NN	O	O
unexplained	NN	O	O
hypercalcemia	NN	O	B-Disease
and	NN	O	O
can	NN	O	O
be	NN	O	O
precipitated	NN	O	O
by	NN	O	O
small	NN	O	O
amounts	NN	O	O
of	NN	O	O
orally	NN	O	O
ingested	NN	O	O
calcium	NN	O	B-Chemical
carbonate	NN	O	I-Chemical
in	NN	O	O
susceptible	NN	O	O
persons	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
hydration	NN	O	O
,	NN	O	O
furosemide	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
calcium	NN	O	B-Chemical
and	NN	O	O
vitamin	NN	O	B-Chemical
D	NN	O	I-Chemical
source	NN	O	O
is	NN	O	O
adequate	NN	O	O
.	NN	O	O

Pamidronate	NN	O	B-Chemical
treatment	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
considerable	NN	O	O
risk	NN	O	O
for	NN	O	O
hypocalcemia	NN	O	B-Disease
,	NN	O	O
even	NN	O	O
in	NN	O	O
cases	NN	O	O
of	NN	O	O
initially	NN	O	O
severe	NN	O	O
hypercalcemia	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (11705128)

Management	NN	O	O
strategies	NN	O	O
for	NN	O	O
ribavirin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
hepatitis	NN	O	B-Disease
C	NN	O	I-Disease
:	NN	O	O
clinical	NN	O	O
and	NN	O	O
economic	NN	O	O
implications	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
Recently	NN	O	O
published	NN	O	O
studies	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
increased	NN	O	O
efficacy	NN	O	O
and	NN	O	O
cost	NN	O	O
-	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
combination	NN	O	O
therapy	NN	O	O
with	NN	O	O
interferon	NN	O	O
and	NN	O	O
alpha	NN	O	O
-	NN	O	O
2b	NN	O	O
/	NN	O	O
ribavirin	NN	O	B-Chemical
compared	NN	O	O
with	NN	O	O
interferon	NN	O	B-Chemical
-	NN	O	I-Chemical
alpha	NN	O	I-Chemical
monotherapy	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
chronic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
C	NN	O	I-Disease
(	NN	O	O
CHC	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Combination	NN	O	O
therapy	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
clinically	NN	O	O
important	NN	O	O
adverse	NN	O	O
effect	NN	O	O
:	NN	O	O
ribavirin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
(	NN	O	O
RIHA	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
direct	NN	O	O
health	NN	O	O
-	NN	O	O
care	NN	O	O
costs	NN	O	O
and	NN	O	O
management	NN	O	O
of	NN	O	O
RIHA	NN	O	B-Disease
during	NN	O	O
treatment	NN	O	O
of	NN	O	O
CHC	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
clinical	NN	O	O
trial	NN	O	O
setting	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
systematic	NN	O	O
literature	NN	O	O
review	NN	O	O
was	NN	O	O
conducted	NN	O	O
to	NN	O	O
synthesize	NN	O	O
information	NN	O	O
on	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
management	NN	O	O
of	NN	O	O
RIHA	NN	O	B-Disease
.	NN	O	O

Decision	NN	O	O
-	NN	O	O
analytic	NN	O	O
techniques	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
estimate	NN	O	O
the	NN	O	O
cost	NN	O	O
of	NN	O	O
treating	NN	O	O
RIHA	NN	O	B-Disease
.	NN	O	O

Uncertainty	NN	O	O
was	NN	O	O
evaluated	NN	O	O
using	NN	O	O
sensitivity	NN	O	O
analyses	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
RIHA	NN	O	B-Disease
,	NN	O	O
defined	NN	O	O
as	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
hemoglobin	NN	O	O
to	NN	O	O
less	NN	O	O
than	NN	O	O
100	NN	O	O
g	NN	O	O
/	NN	O	O
L	NN	O	O
,	NN	O	O
occurs	NN	O	O
in	NN	O	O
approximately	NN	O	O
7%	NN	O	O
to	NN	O	O
9%	NN	O	O
of	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
combination	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
standard	NN	O	O
of	NN	O	O
care	NN	O	O
for	NN	O	O
management	NN	O	O
of	NN	O	O
RIHA	NN	O	B-Disease
is	NN	O	O
reduction	NN	O	O
or	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
ribavirin	NN	O	B-Chemical
dosage	NN	O	O
.	NN	O	O

We	NN	O	O
estimated	NN	O	O
the	NN	O	O
direct	NN	O	O
cost	NN	O	O
of	NN	O	O
treating	NN	O	O
clinically	NN	O	O
significant	NN	O	O
RIHA	NN	O	B-Disease
to	NN	O	O
be	NN	O	O
170	NN	O	O
per	NN	O	O
patient	NN	O	O
receiving	NN	O	O
combination	NN	O	O
therapy	NN	O	O
per	NN	O	O
48	NN	O	O
-	NN	O	O
week	NN	O	O
treatment	NN	O	O
course	NN	O	O
(	NN	O	O
range	NN	O	O
68	NN	O	O
-	NN	O	O
692	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
the	NN	O	O
one	NN	O	O
-	NN	O	O
way	NN	O	O
sensitivity	NN	O	O
analyses	NN	O	O
ranged	NN	O	O
from	NN	O	O
57	NN	O	O
to	NN	O	O
317	NN	O	O
.	NN	O	O

In	NN	O	O
comparison	NN	O	O
,	NN	O	O
the	NN	O	O
cost	NN	O	O
of	NN	O	O
48	NN	O	O
weeks	NN	O	O
of	NN	O	O
combination	NN	O	O
therapy	NN	O	O
is	NN	O	O
16	NN	O	O
,	NN	O	O
459	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
direct	NN	O	O
cost	NN	O	O
of	NN	O	O
treating	NN	O	O
clinically	NN	O	O
significant	NN	O	O
RIHA	NN	O	B-Disease
is	NN	O	O
1%	NN	O	O
(	NN	O	O
170	NN	O	O
/	NN	O	O
16	NN	O	O
,	NN	O	O
459	NN	O	O
)	NN	O	O
of	NN	O	O
drug	NN	O	O
treatment	NN	O	O
costs	NN	O	O
.	NN	O	O

Questions	NN	O	O
remain	NN	O	O
about	NN	O	O
the	NN	O	O
optimal	NN	O	O
dose	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
RIHA	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
real	NN	O	O
-	NN	O	O
world	NN	O	O
population	NN	O	O
.	NN	O	O

Despite	NN	O	O
these	NN	O	O
uncertainties	NN	O	O
,	NN	O	O
this	NN	O	O
initial	NN	O	O
evaluation	NN	O	O
of	NN	O	O
the	NN	O	O
direct	NN	O	O
cost	NN	O	O
of	NN	O	O
treating	NN	O	O
RIHA	NN	O	B-Disease
provides	NN	O	O
an	NN	O	O
estimate	NN	O	O
of	NN	O	O
the	NN	O	O
cost	NN	O	O
and	NN	O	O
management	NN	O	O
implications	NN	O	O
of	NN	O	O
this	NN	O	O
clinically	NN	O	O
important	NN	O	O
adverse	NN	O	O
effect	NN	O	O
.	NN	O	O


-DOCSTART- (6540303)

Effects	NN	O	O
of	NN	O	O
amine	NN	O	B-Chemical
pretreatment	NN	O	O
on	NN	O	O
ketamine	NN	O	B-Chemical
catatonia	NN	O	B-Disease
in	NN	O	O
pinealectomized	NN	O	O
or	NN	O	O
hypophysectomized	NN	O	O
animals	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
studies	NN	O	O
were	NN	O	O
designed	NN	O	O
to	NN	O	O
clarify	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
catecholamines	NN	O	B-Chemical
and	NN	O	O
pineal	NN	O	O
idolamines	NN	O	O
on	NN	O	O
ketamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catatonia	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
intact	NN	O	O
,	NN	O	O
pinealectomized	NN	O	O
or	NN	O	O
hypophysectomized	NN	O	O
chick	NN	O	O
and	NN	O	O
rat	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
pinealectomized	NN	O	O
chick	NN	O	O
,	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
dopamine	NN	O	B-Chemical
increased	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
catatonia	NN	O	B-Disease
(	NN	O	O
DOC	NN	O	O
)	NN	O	O
after	NN	O	O
ketamine	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
norepinephrine	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
.	NN	O	O

The	NN	O	O
pineal	NN	O	O
indolamines	NN	O	O
exhibited	NN	O	O
mixed	NN	O	O
actions	NN	O	O
.	NN	O	O

Serotonin	NN	O	B-Chemical
and	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
acetyl	NN	O	I-Chemical
serotonin	NN	O	I-Chemical
which	NN	O	O
augmented	NN	O	O
ketamine	NN	O	B-Chemical
DOC	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
do	NN	O	O
so	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
the	NN	O	O
pineal	NN	O	O
gland	NN	O	O
,	NN	O	O
whereas	NN	O	O
melatonin	NN	O	B-Chemical
potentiated	NN	O	O
the	NN	O	O
ketamine	NN	O	B-Chemical
DOC	NN	O	O
in	NN	O	O
both	NN	O	O
the	NN	O	O
intact	NN	O	O
and	NN	O	O
pinealectomized	NN	O	O
chick	NN	O	O
.	NN	O	O

Ketamine	NN	O	B-Chemical
was	NN	O	O
more	NN	O	O
potent	NN	O	O
in	NN	O	O
the	NN	O	O
hypophysectomized	NN	O	O
chick	NN	O	O
and	NN	O	O
the	NN	O	O
circadian	NN	O	O
rhythm	NN	O	O
noted	NN	O	O
in	NN	O	O
the	NN	O	O
intact	NN	O	O
chick	NN	O	O
was	NN	O	O
absent	NN	O	O
;	NN	O	O
furthermore	NN	O	O
,	NN	O	O
melatonin	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
augment	NN	O	O
the	NN	O	O
ketamine	NN	O	B-Chemical
DOC	NN	O	O
whereas	NN	O	O
dopamine	NN	O	B-Chemical
continued	NN	O	O
to	NN	O	O
do	NN	O	O
so	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
did	NN	O	O
not	NN	O	O
demonstrate	NN	O	O
a	NN	O	O
species	NN	O	O
difference	NN	O	O
regarding	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
amines	NN	O	B-Chemical
on	NN	O	O
the	NN	O	O
pineal	NN	O	O
in	NN	O	O
spite	NN	O	O
of	NN	O	O
the	NN	O	O
immature	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
in	NN	O	O
the	NN	O	O
young	NN	O	O
chick	NN	O	O
and	NN	O	O
the	NN	O	O
intact	NN	O	O
barrier	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
these	NN	O	O
data	NN	O	O
indicate	NN	O	O
a	NN	O	O
direct	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
pituitary	NN	O	O
in	NN	O	O
the	NN	O	O
augmentation	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
DOC	NN	O	O
induced	NN	O	O
by	NN	O	O
melatonin	NN	O	B-Chemical
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
dopamine	NN	O	B-Chemical
appeared	NN	O	O
to	NN	O	O
act	NN	O	O
on	NN	O	O
systems	NN	O	O
more	NN	O	O
closely	NN	O	O
involved	NN	O	O
with	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
catatonia	NN	O	B-Disease
rather	NN	O	O
than	NN	O	O
directly	NN	O	O
on	NN	O	O
the	NN	O	O
pituitary	NN	O	O
.	NN	O	O


-DOCSTART- (3057041)

Multicenter	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
multiple	NN	O	O
-	NN	O	O
dose	NN	O	O
,	NN	O	O
parallel	NN	O	O
-	NN	O	O
groups	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
trial	NN	O	O
of	NN	O	O
azelastine	NN	O	B-Chemical
,	NN	O	O
chlorpheniramine	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
placebo	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
spring	NN	O	B-Disease
allergic	NN	O	I-Disease
rhinitis	NN	O	I-Disease
.	NN	O	O

Azelastine	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
novel	NN	O	O
antiallergic	NN	O	O
medication	NN	O	O
,	NN	O	O
was	NN	O	O
compared	NN	O	O
with	NN	O	O
chlorpheniramine	NN	O	B-Chemical
maleate	NN	O	I-Chemical
and	NN	O	O
placebo	NN	O	O
for	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
spring	NN	O	B-Disease
allergic	NN	O	I-Disease
rhinitis	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
multicenter	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
multiple	NN	O	O
-	NN	O	O
dose	NN	O	O
,	NN	O	O
parallel	NN	O	O
-	NN	O	O
groups	NN	O	O
study	NN	O	O
.	NN	O	O

One	NN	O	O
hundred	NN	O	O
fifty	NN	O	O
-	NN	O	O
five	NN	O	O
subjects	NN	O	O
participated	NN	O	O
.	NN	O	O

Subjects	NN	O	O
ranged	NN	O	O
in	NN	O	O
age	NN	O	O
from	NN	O	O
18	NN	O	O
to	NN	O	O
60	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
and	NN	O	O
had	NN	O	O
at	NN	O	O
least	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
year	NN	O	O
history	NN	O	O
of	NN	O	O
spring	NN	O	B-Disease
allergic	NN	O	I-Disease
rhinitis	NN	O	I-Disease
,	NN	O	O
confirmed	NN	O	O
by	NN	O	O
positive	NN	O	O
skin	NN	O	O
test	NN	O	O
to	NN	O	O
spring	NN	O	O
aeroallergens	NN	O	O
.	NN	O	O

Medications	NN	O	O
were	NN	O	O
given	NN	O	O
four	NN	O	O
times	NN	O	O
daily	NN	O	O
;	NN	O	O
the	NN	O	O
azelastine	NN	O	B-Chemical
groups	NN	O	O
received	NN	O	O
0.5	NN	O	O
,	NN	O	O
1.0	NN	O	O
,	NN	O	O
or	NN	O	O
2.0	NN	O	O
mg	NN	O	O
in	NN	O	O
the	NN	O	O
morning	NN	O	O
and	NN	O	O
evening	NN	O	O
with	NN	O	O
placebo	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
and	NN	O	O
late	NN	O	O
afternoon	NN	O	O
;	NN	O	O
the	NN	O	O
chlorpheniramine	NN	O	B-Chemical
group	NN	O	O
received	NN	O	O
4.0	NN	O	O
mg	NN	O	O
four	NN	O	O
times	NN	O	O
daily	NN	O	O
.	NN	O	O

Daily	NN	O	O
subject	NN	O	O
symptom	NN	O	O
cards	NN	O	O
were	NN	O	O
completed	NN	O	O
during	NN	O	O
a	NN	O	O
screening	NN	O	O
period	NN	O	O
to	NN	O	O
assess	NN	O	O
pretreatment	NN	O	O
symptoms	NN	O	O
and	NN	O	O
during	NN	O	O
a	NN	O	O
4	NN	O	O
-	NN	O	O
week	NN	O	O
treatment	NN	O	O
period	NN	O	O
while	NN	O	O
subjects	NN	O	O
received	NN	O	O
study	NN	O	O
medications	NN	O	O
.	NN	O	O

Individual	NN	O	O
symptoms	NN	O	O
,	NN	O	O
total	NN	O	O
symptoms	NN	O	O
,	NN	O	O
and	NN	O	O
major	NN	O	O
symptoms	NN	O	O
were	NN	O	O
compared	NN	O	O
to	NN	O	O
determine	NN	O	O
efficacy	NN	O	O
of	NN	O	O
medication	NN	O	O
.	NN	O	O

Elicited	NN	O	O
,	NN	O	O
volunteered	NN	O	O
,	NN	O	O
and	NN	O	O
observed	NN	O	O
adverse	NN	O	O
experiences	NN	O	O
were	NN	O	O
recorded	NN	O	O
for	NN	O	O
each	NN	O	O
subject	NN	O	O
and	NN	O	O
compared	NN	O	O
among	NN	O	O
groups	NN	O	O
.	NN	O	O

Vital	NN	O	O
signs	NN	O	O
,	NN	O	O
body	NN	O	O
weights	NN	O	O
,	NN	O	O
serum	NN	O	O
chemistry	NN	O	O
values	NN	O	O
,	NN	O	O
complete	NN	O	O
blood	NN	O	O
cell	NN	O	O
counts	NN	O	O
,	NN	O	O
urine	NN	O	O
studies	NN	O	O
,	NN	O	O
and	NN	O	O
electrocardiograms	NN	O	O
were	NN	O	O
obtained	NN	O	O
for	NN	O	O
each	NN	O	O
subject	NN	O	O
and	NN	O	O
compared	NN	O	O
among	NN	O	O
groups	NN	O	O
.	NN	O	O

Symptoms	NN	O	O
relief	NN	O	O
in	NN	O	O
the	NN	O	O
group	NN	O	O
receiving	NN	O	O
the	NN	O	O
highest	NN	O	O
concentration	NN	O	O
of	NN	O	O
azelastine	NN	O	B-Chemical
(	NN	O	O
2.0	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
)	NN	O	O
was	NN	O	O
statistically	NN	O	O
greater	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
during	NN	O	O
all	NN	O	O
weeks	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

Lower	NN	O	O
doses	NN	O	O
of	NN	O	O
azelastine	NN	O	B-Chemical
were	NN	O	O
statistically	NN	O	O
more	NN	O	O
effective	NN	O	O
than	NN	O	O
placebo	NN	O	O
only	NN	O	O
during	NN	O	O
portions	NN	O	O
of	NN	O	O
the	NN	O	O
first	NN	O	O
3	NN	O	O
weeks	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
although	NN	O	O
the	NN	O	O
chlorpheniramine	NN	O	B-Chemical
group	NN	O	O
did	NN	O	O
have	NN	O	O
fewer	NN	O	O
symptoms	NN	O	O
than	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
during	NN	O	O
the	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
difference	NN	O	O
never	NN	O	O
reached	NN	O	O
statistical	NN	O	O
significance	NN	O	O
during	NN	O	O
any	NN	O	O
week	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
serious	NN	O	O
side	NN	O	O
effects	NN	O	O
in	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
groups	NN	O	O
.	NN	O	O

Drowsiness	NN	O	B-Disease
and	NN	O	O
altered	NN	O	B-Disease
taste	NN	O	I-Disease
perception	NN	O	I-Disease
were	NN	O	O
increased	NN	O	O
significantly	NN	O	O
over	NN	O	O
placebo	NN	O	O
only	NN	O	O
in	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
azelastine	NN	O	B-Chemical
group	NN	O	O
.	NN	O	O

Azelastine	NN	O	B-Chemical
appears	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
safe	NN	O	O
,	NN	O	O
efficacious	NN	O	O
medication	NN	O	O
for	NN	O	O
seasonal	NN	O	B-Disease
allergic	NN	O	I-Disease
rhinitis	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (625456)

Obsolete	NN	O	O
but	NN	O	O
dangerous	NN	O	O
antacid	NN	O	O
preparations	NN	O	O
.	NN	O	O

One	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	O
hypercalcaemia	NN	O	B-Disease
and	NN	O	O
two	NN	O	O
of	NN	O	O
recurrent	NN	O	O
nephrolithiasis	NN	O	B-Disease
are	NN	O	O
reported	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
regularly	NN	O	O
consumed	NN	O	O
large	NN	O	O
amounts	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
carbon	NN	O	I-Chemical
-	NN	O	I-Chemical
ate	NN	O	I-Chemical
-	NN	O	O
sodium	NN	O	B-Chemical
bicarbonate	NN	O	I-Chemical
powders	NN	O	O
for	NN	O	O
more	NN	O	O
than	NN	O	O
20	NN	O	O
years	NN	O	O
.	NN	O	O

The	NN	O	O
powders	NN	O	O
had	NN	O	O
been	NN	O	O
obtained	NN	O	O
from	NN	O	O
pharmacists	NN	O	O
unknown	NN	O	O
to	NN	O	O
the	NN	O	O
patients	NN	O	O
'	NN	O	O
medical	NN	O	O
practitioners	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
suggested	NN	O	O
that	NN	O	O
these	NN	O	O
preparations	NN	O	O
were	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
problems	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
such	NN	O	O
powders	NN	O	O
should	NN	O	O
no	NN	O	O
longer	NN	O	O
be	NN	O	O
freely	NN	O	O
obtainable	NN	O	O
.	NN	O	O


-DOCSTART- (7910951)

Prolonged	NN	O	O
paralysis	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
nondepolarizing	NN	O	B-Chemical
neuromuscular	NN	O	I-Chemical
blocking	NN	O	I-Chemical
agents	NN	O	I-Chemical
and	NN	O	O
corticosteroids	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
nondepolarizing	NN	O	B-Chemical
neuromuscular	NN	O	I-Chemical
blocking	NN	O	I-Chemical
agents	NN	O	I-Chemical
(	NN	O	O
ND	NN	O	B-Chemical
-	NN	O	I-Chemical
NMBA	NN	O	I-Chemical
)	NN	O	O
has	NN	O	O
recently	NN	O	O
been	NN	O	O
implicated	NN	O	O
as	NN	O	O
a	NN	O	O
cause	NN	O	O
of	NN	O	O
prolonged	NN	O	O
muscle	NN	O	B-Disease
weakness	NN	O	I-Disease
,	NN	O	O
although	NN	O	O
the	NN	O	O
site	NN	O	O
of	NN	O	O
the	NN	O	O
lesion	NN	O	O
and	NN	O	O
the	NN	O	O
predisposing	NN	O	O
factors	NN	O	O
have	NN	O	O
been	NN	O	O
unclear	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
3	NN	O	O
patients	NN	O	O
(	NN	O	O
age	NN	O	O
37	NN	O	O
-	NN	O	O
52	NN	O	O
years	NN	O	O
)	NN	O	O
with	NN	O	O
acute	NN	O	O
respiratory	NN	O	B-Disease
insufficiency	NN	O	I-Disease
who	NN	O	O
developed	NN	O	O
prolonged	NN	O	O
weakness	NN	O	B-Disease
following	NN	O	O
the	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
ND	NN	O	B-Chemical
-	NN	O	I-Chemical
NMBAs	NN	O	I-Chemical
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
also	NN	O	O
received	NN	O	O
intravenous	NN	O	O
corticosteroids	NN	O	B-Chemical
.	NN	O	O

Renal	NN	O	O
function	NN	O	O
was	NN	O	O
normal	NN	O	O
but	NN	O	O
hepatic	NN	O	O
function	NN	O	O
was	NN	O	O
impaired	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
all	NN	O	O
had	NN	O	O
acidosis	NN	O	B-Disease
.	NN	O	O

Electrophysiologic	NN	O	O
studies	NN	O	O
revealed	NN	O	O
low	NN	O	O
amplitude	NN	O	O
compound	NN	O	O
motor	NN	O	O
action	NN	O	O
potentials	NN	O	O
,	NN	O	O
normal	NN	O	O
sensory	NN	O	O
studies	NN	O	O
,	NN	O	O
and	NN	O	O
fibrillations	NN	O	O
.	NN	O	O

Repetitive	NN	O	O
stimulation	NN	O	O
at	NN	O	O
2	NN	O	O
Hz	NN	O	O
showed	NN	O	O
a	NN	O	O
decremental	NN	O	O
response	NN	O	O
in	NN	O	O
2	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
serum	NN	O	O
vecuronium	NN	O	B-Chemical
level	NN	O	O
measured	NN	O	O
in	NN	O	O
1	NN	O	O
patient	NN	O	O
14	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
drug	NN	O	O
had	NN	O	O
been	NN	O	O
discontinued	NN	O	O
was	NN	O	O
172	NN	O	O
ng	NN	O	O
/	NN	O	O
mL	NN	O	O
.	NN	O	O

A	NN	O	O
muscle	NN	O	O
biopsy	NN	O	O
in	NN	O	O
this	NN	O	O
patient	NN	O	O
showed	NN	O	O
loss	NN	O	B-Disease
of	NN	O	I-Disease
thick	NN	O	I-Disease
,	NN	O	I-Disease
myosin	NN	O	I-Disease
filaments	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
weakness	NN	O	B-Disease
in	NN	O	O
these	NN	O	O
patients	NN	O	O
is	NN	O	O
due	NN	O	O
to	NN	O	O
pathology	NN	O	B-Disease
at	NN	O	I-Disease
both	NN	O	I-Disease
the	NN	O	I-Disease
neuromuscular	NN	O	I-Disease
junction	NN	O	I-Disease
(	NN	O	O
most	NN	O	O
likely	NN	O	O
due	NN	O	O
to	NN	O	O
ND	NN	O	B-Chemical
-	NN	O	I-Chemical
NMBA	NN	O	I-Chemical
)	NN	O	O
and	NN	O	O
muscle	NN	O	O
(	NN	O	O
most	NN	O	O
likely	NN	O	O
due	NN	O	O
to	NN	O	O
corticosteroids	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

Hepatic	NN	O	B-Disease
dysfunction	NN	O	I-Disease
and	NN	O	O
acidosis	NN	O	B-Disease
are	NN	O	O
contributing	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O


-DOCSTART- (7752389)

Prostaglandin	NN	O	B-Chemical
E2	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
bladder	NN	O	B-Disease
hyperactivity	NN	O	I-Disease
in	NN	O	O
normal	NN	O	O
,	NN	O	O
conscious	NN	O	O
rats	NN	O	O
:	NN	O	O
involvement	NN	O	O
of	NN	O	O
tachykinins	NN	O	B-Chemical
?	NN	O	O
In	NN	O	O
normal	NN	O	O
conscious	NN	O	O
rats	NN	O	O
investigated	NN	O	O
by	NN	O	O
continuous	NN	O	O
cystometry	NN	O	O
,	NN	O	O
intravesically	NN	O	O
instilled	NN	O	O
prostaglandin	NN	O	B-Chemical
(	NN	O	I-Chemical
PG	NN	O	I-Chemical
)	NN	O	I-Chemical
E2	NN	O	I-Chemical
facilitated	NN	O	O
micturition	NN	O	O
and	NN	O	O
increased	NN	O	O
basal	NN	O	O
intravesical	NN	O	O
pressure	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
was	NN	O	O
attenuated	NN	O	O
by	NN	O	O
both	NN	O	O
the	NN	O	O
NK1	NN	O	O
receptor	NN	O	O
selective	NN	O	O
antagonist	NN	O	O
RP	NN	O	B-Chemical
67	NN	O	I-Chemical
,	NN	O	I-Chemical
580	NN	O	I-Chemical
and	NN	O	O
the	NN	O	O
NK2	NN	O	O
receptor	NN	O	O
selective	NN	O	O
antagonist	NN	O	O
SR	NN	O	B-Chemical
48	NN	O	I-Chemical
,	NN	O	I-Chemical
968	NN	O	I-Chemical
,	NN	O	O
given	NN	O	O
intra	NN	O	O
-	NN	O	O
arterially	NN	O	O
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
it	NN	O	O
was	NN	O	O
mediated	NN	O	O
by	NN	O	O
stimulation	NN	O	O
of	NN	O	O
both	NN	O	O
NK1	NN	O	O
and	NN	O	O
NK2	NN	O	O
receptors	NN	O	O
.	NN	O	O

Intra	NN	O	O
-	NN	O	O
arterially	NN	O	O
given	NN	O	O
PGE2	NN	O	B-Chemical
produced	NN	O	O
a	NN	O	O
distinct	NN	O	O
increase	NN	O	O
in	NN	O	O
bladder	NN	O	O
pressure	NN	O	O
before	NN	O	O
initiating	NN	O	O
a	NN	O	O
micturition	NN	O	O
reflex	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
the	NN	O	O
PG	NN	O	B-Chemical
had	NN	O	O
a	NN	O	O
direct	NN	O	O
contractant	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
detrusor	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
intra	NN	O	O
-	NN	O	O
arterial	NN	O	O
PGE2	NN	O	B-Chemical
could	NN	O	O
not	NN	O	O
be	NN	O	O
blocked	NN	O	O
by	NN	O	O
intra	NN	O	O
-	NN	O	O
arterial	NN	O	O
RP	NN	O	B-Chemical
67	NN	O	I-Chemical
,	NN	O	I-Chemical
580	NN	O	I-Chemical
or	NN	O	O
SR	NN	O	B-Chemical
48	NN	O	I-Chemical
,	NN	O	I-Chemical
968	NN	O	I-Chemical
,	NN	O	O
which	NN	O	O
opens	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
the	NN	O	O
micturition	NN	O	O
reflex	NN	O	O
elicited	NN	O	O
by	NN	O	O
intra	NN	O	O
-	NN	O	O
arterial	NN	O	O
PGE2	NN	O	B-Chemical
was	NN	O	O
mediated	NN	O	O
by	NN	O	O
pathways	NN	O	O
other	NN	O	O
than	NN	O	O
the	NN	O	O
reflex	NN	O	O
initiated	NN	O	O
when	NN	O	O
the	NN	O	O
PG	NN	O	B-Chemical
was	NN	O	O
given	NN	O	O
intravesically	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
results	NN	O	O
thus	NN	O	O
suggest	NN	O	O
that	NN	O	O
intra	NN	O	O
-	NN	O	O
arterial	NN	O	O
PGE2	NN	O	B-Chemical
,	NN	O	O
given	NN	O	O
near	NN	O	O
the	NN	O	O
bladder	NN	O	O
,	NN	O	O
may	NN	O	O
initiate	NN	O	O
micturition	NN	O	O
in	NN	O	O
the	NN	O	O
normal	NN	O	O
rat	NN	O	O
chiefly	NN	O	O
by	NN	O	O
directly	NN	O	O
contracting	NN	O	O
the	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
of	NN	O	O
the	NN	O	O
detrusor	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
when	NN	O	O
given	NN	O	O
intravesically	NN	O	O
,	NN	O	O
PGE2	NN	O	B-Chemical
may	NN	O	O
stimulate	NN	O	O
micturition	NN	O	O
by	NN	O	O
releasing	NN	O	O
tachykinins	NN	O	B-Chemical
from	NN	O	O
nerves	NN	O	O
in	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
immediately	NN	O	O
below	NN	O	O
the	NN	O	O
urothelium	NN	O	O
.	NN	O	O

These	NN	O	O
tachykinins	NN	O	B-Chemical
,	NN	O	O
in	NN	O	O
turn	NN	O	O
,	NN	O	O
initiate	NN	O	O
a	NN	O	O
micturition	NN	O	O
reflex	NN	O	O
by	NN	O	O
stimulating	NN	O	O
NK1	NN	O	O
and	NN	O	O
NK2	NN	O	O
receptors	NN	O	O
.	NN	O	O

Prostanoids	NN	O	B-Chemical
may	NN	O	O
,	NN	O	O
via	NN	O	O
release	NN	O	O
of	NN	O	O
tachykinins	NN	O	B-Chemical
,	NN	O	O
contribute	NN	O	O
to	NN	O	O
both	NN	O	O
urge	NN	O	O
and	NN	O	O
bladder	NN	O	B-Disease
hyperactivity	NN	O	I-Disease
seen	NN	O	O
in	NN	O	O
inflammatory	NN	O	O
conditions	NN	O	O
of	NN	O	O
the	NN	O	O
lower	NN	O	O
urinary	NN	O	O
tract	NN	O	O
.	NN	O	O


-DOCSTART- (6942642)

Thiazide	NN	O	B-Chemical
diuretics	NN	O	O
,	NN	O	O
hypokalemia	NN	O	B-Disease
and	NN	O	O
cardiac	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
.	NN	O	O

Thiazide	NN	O	B-Chemical
diuretics	NN	O	O
are	NN	O	O
widely	NN	O	O
accepted	NN	O	O
as	NN	O	O
the	NN	O	O
cornerstone	NN	O	O
of	NN	O	O
antihypertensive	NN	O	O
treatment	NN	O	O
programs	NN	O	O
.	NN	O	O

Hypokalemia	NN	O	B-Disease
is	NN	O	O
a	NN	O	O
commonly	NN	O	O
encountered	NN	O	O
metabolic	NN	O	O
consequence	NN	O	O
of	NN	O	O
chronic	NN	O	O
thiazide	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

We	NN	O	O
treated	NN	O	O
38	NN	O	O
patients	NN	O	O
(	NN	O	O
22	NN	O	O
low	NN	O	O
renin	NN	O	O
,	NN	O	O
16	NN	O	O
normal	NN	O	O
renin	NN	O	O
)	NN	O	O
with	NN	O	O
moderate	NN	O	O
diastolic	NN	O	B-Disease
hypertension	NN	O	I-Disease
with	NN	O	O
hydrochlorothiazide	NN	O	B-Chemical
(	NN	O	O
HCTC	NN	O	B-Chemical
)	NN	O	O
administered	NN	O	O
on	NN	O	O
a	NN	O	O
twice	NN	O	O
daily	NN	O	O
schedule	NN	O	O
.	NN	O	O

Initial	NN	O	O
dose	NN	O	O
was	NN	O	O
50	NN	O	O
mg	NN	O	O
and	NN	O	O
the	NN	O	O
dose	NN	O	O
was	NN	O	O
increased	NN	O	O
at	NN	O	O
monthly	NN	O	O
intervals	NN	O	O
to	NN	O	O
100	NN	O	O
mg	NN	O	O
,	NN	O	O
150	NN	O	O
mg	NN	O	O
and	NN	O	O
200	NN	O	O
mg	NN	O	O
daily	NN	O	O
until	NN	O	O
blood	NN	O	O
pressure	NN	O	O
normalized	NN	O	O
.	NN	O	O

The	NN	O	O
serum	NN	O	O
K	NN	O	B-Chemical
during	NN	O	O
the	NN	O	O
control	NN	O	O
period	NN	O	O
was	NN	O	O
4.5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.2	NN	O	O
mEq	NN	O	O
/	NN	O	O
l	NN	O	O
an	NN	O	O
on	NN	O	O
50	NN	O	O
,	NN	O	O
100	NN	O	O
,	NN	O	O
150	NN	O	O
and	NN	O	O
200	NN	O	O
mg	NN	O	O
HCTZ	NN	O	B-Chemical
daily	NN	O	O
3.9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.3	NN	O	O
,	NN	O	O
3.4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.2	NN	O	O
,	NN	O	O
2.9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.2	NN	O	O
,	NN	O	O
and	NN	O	O
2.4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.3	NN	O	O
mEq	NN	O	O
/	NN	O	O
l	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Corresponding	NN	O	O
figures	NN	O	O
for	NN	O	O
whole	NN	O	O
body	NN	O	O
K	NN	O	B-Chemical
were	NN	O	O
4107	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
208	NN	O	O
,	NN	O	O
3722	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
319	NN	O	O
,	NN	O	O
3628	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
257	NN	O	O
,	NN	O	O
3551	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
336	NN	O	O
,	NN	O	O
and	NN	O	O
3269	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
380	NN	O	O
mEq	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

In	NN	O	O
13	NN	O	O
patients	NN	O	O
we	NN	O	O
observed	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
HCTZ	NN	O	B-Chemical
therapy	NN	O	O
(	NN	O	O
100	NN	O	O
mg	NN	O	O
daily	NN	O	O
)	NN	O	O
on	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
PVC	NN	O	O
'	NN	O	O
s	NN	O	O
during	NN	O	O
rest	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
during	NN	O	O
static	NN	O	O
and	NN	O	O
dynamic	NN	O	O
exercise	NN	O	O
.	NN	O	O

During	NN	O	O
rest	NN	O	O
we	NN	O	O
observed	NN	O	O
0.6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.08	NN	O	O
PVC	NN	O	O
beats	NN	O	O
/	NN	O	O
min	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SEM	NN	O	O
and	NN	O	O
during	NN	O	O
static	NN	O	O
and	NN	O	O
dynamic	NN	O	O
exercise	NN	O	O
0.6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.06	NN	O	O
and	NN	O	O
0.8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.15	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Corresponding	NN	O	O
figures	NN	O	O
during	NN	O	O
HCTZ	NN	O	B-Chemical
therapy	NN	O	O
100	NN	O	O
mg	NN	O	O
daily	NN	O	O
were	NN	O	O
1.4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.1	NN	O	O
,	NN	O	O
3.6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.7	NN	O	O
and	NN	O	O
5.7	NN	O	O
4	NN	O	O
/	NN	O	O
-	NN	O	O
0.8	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
occurrence	NN	O	O
of	NN	O	O
PVC	NN	O	O
'	NN	O	O
s	NN	O	O
correlated	NN	O	O
significantly	NN	O	O
with	NN	O	O
the	NN	O	O
fall	NN	O	O
in	NN	O	O
serum	NN	O	O
K	NN	O	B-Chemical
+	NN	O	O
observed	NN	O	O
r	NN	O	O
=	NN	O	O
0.72	NN	O	O
,	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
we	NN	O	O
found	NN	O	O
that	NN	O	O
thiazide	NN	O	B-Chemical
diuretics	NN	O	O
cause	NN	O	O
hypokalemia	NN	O	B-Disease
and	NN	O	O
depletion	NN	O	O
of	NN	O	O
body	NN	O	O
potassium	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
more	NN	O	O
profound	NN	O	O
hypokalemia	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
greater	NN	O	O
the	NN	O	O
propensity	NN	O	O
for	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
PVC	NN	O	O
'	NN	O	O
s	NN	O	O
.	NN	O	O


-DOCSTART- (3732088)

Diuretics	NN	O	O
,	NN	O	O
potassium	NN	O	B-Chemical
and	NN	O	O
arrhythmias	NN	O	B-Disease
in	NN	O	O
hypertensive	NN	O	B-Disease
coronary	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

It	NN	O	O
has	NN	O	O
been	NN	O	O
proposed	NN	O	O
that	NN	O	O
modest	NN	O	O
changes	NN	O	O
in	NN	O	O
plasma	NN	O	O
potassium	NN	O	B-Chemical
can	NN	O	O
alter	NN	O	O
the	NN	O	O
tendency	NN	O	O
towards	NN	O	O
cardiac	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
.	NN	O	O

If	NN	O	O
this	NN	O	O
were	NN	O	O
so	NN	O	O
,	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
might	NN	O	O
be	NN	O	O
especially	NN	O	O
susceptible	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
myocardial	NN	O	O
electrical	NN	O	O
excitability	NN	O	O
was	NN	O	O
measured	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
mild	NN	O	O
essential	NN	O	O
hypertension	NN	O	B-Disease
and	NN	O	O
known	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
after	NN	O	O
8	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
a	NN	O	O
potassium	NN	O	B-Chemical
-	NN	O	O
conserving	NN	O	O
diuretic	NN	O	O
(	NN	O	O
amiloride	NN	O	B-Chemical
)	NN	O	O
and	NN	O	O
a	NN	O	O
similar	NN	O	O
period	NN	O	O
on	NN	O	O
a	NN	O	O
potassium	NN	O	B-Chemical
-	NN	O	O
losing	NN	O	O
diuretic	NN	O	O
(	NN	O	O
chlorthalidone	NN	O	B-Chemical
)	NN	O	O
in	NN	O	O
a	NN	O	O
randomised	NN	O	O
study	NN	O	O
.	NN	O	O

Plasma	NN	O	O
potassium	NN	O	B-Chemical
concentrations	NN	O	O
were	NN	O	O
on	NN	O	O
average	NN	O	O
1	NN	O	O
mmol	NN	O	O
/	NN	O	O
L	NN	O	O
lower	NN	O	O
during	NN	O	O
the	NN	O	O
chlorthalidone	NN	O	B-Chemical
phase	NN	O	O
compared	NN	O	O
to	NN	O	O
amiloride	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
volume	NN	O	O
states	NN	O	O
as	NN	O	O
assessed	NN	O	O
by	NN	O	O
bodyweight	NN	O	O
,	NN	O	O
plasma	NN	O	O
renin	NN	O	O
and	NN	O	O
noradrenaline	NN	O	B-Chemical
(	NN	O	O
norepinephrine	NN	O	B-Chemical
)	NN	O	O
concentrations	NN	O	O
were	NN	O	O
similar	NN	O	O
on	NN	O	O
the	NN	O	O
2	NN	O	O
regimens	NN	O	O
.	NN	O	O

Compared	NN	O	O
to	NN	O	O
amiloride	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
chlorthalidone	NN	O	B-Chemical
phase	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
frequency	NN	O	O
of	NN	O	O
ventricular	NN	O	B-Disease
ectopic	NN	O	I-Disease
beats	NN	O	I-Disease
(	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
Holter	NN	O	O
monitoring	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
higher	NN	O	O
Lown	NN	O	O
grading	NN	O	O
,	NN	O	O
increased	NN	O	O
upslope	NN	O	O
and	NN	O	O
duration	NN	O	O
of	NN	O	O
the	NN	O	O
monophasic	NN	O	O
action	NN	O	O
potential	NN	O	O
,	NN	O	O
prolonged	NN	O	O
ventricular	NN	O	O
effective	NN	O	O
refractory	NN	O	O
period	NN	O	O
,	NN	O	O
and	NN	O	O
increased	NN	O	O
electrical	NN	O	O
instability	NN	O	O
during	NN	O	O
programmed	NN	O	O
ventricular	NN	O	O
stimulation	NN	O	O
.	NN	O	O

The	NN	O	O
above	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
because	NN	O	O
potassium	NN	O	B-Chemical
-	NN	O	O
losing	NN	O	O
diuretic	NN	O	O
therapy	NN	O	O
can	NN	O	O
increase	NN	O	O
myocardial	NN	O	O
electrical	NN	O	O
excitability	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
ischaemic	NN	O	B-Disease
heart	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
even	NN	O	O
minor	NN	O	O
falls	NN	O	O
in	NN	O	O
plasma	NN	O	O
potassium	NN	O	B-Chemical
concentrations	NN	O	O
are	NN	O	O
probably	NN	O	O
best	NN	O	O
avoided	NN	O	O
in	NN	O	O
such	NN	O	O
patients	NN	O	O
.	NN	O	O


-DOCSTART- (2893236)

GABA	NN	O	B-Chemical
involvement	NN	O	O
in	NN	O	O
naloxone	NN	O	B-Chemical
induced	NN	O	O
reversal	NN	O	O
of	NN	O	O
respiratory	NN	O	B-Disease
paralysis	NN	O	I-Disease
produced	NN	O	O
by	NN	O	O
thiopental	NN	O	B-Chemical
.	NN	O	O

No	NN	O	O
agent	NN	O	O
is	NN	O	O
yet	NN	O	O
available	NN	O	O
to	NN	O	O
reverse	NN	O	O
respiratory	NN	O	B-Disease
paralysis	NN	O	I-Disease
produced	NN	O	O
by	NN	O	O
CNS	NN	O	O
depressants	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
general	NN	O	O
anesthetics	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
naloxone	NN	O	B-Chemical
reversed	NN	O	O
respiratory	NN	O	B-Disease
paralysis	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
thiopental	NN	O	B-Chemical
in	NN	O	O
rats	NN	O	O
.	NN	O	O

25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.v.	NN	O	O
thiopental	NN	O	B-Chemical
produced	NN	O	O
anesthesia	NN	O	O
without	NN	O	O
altering	NN	O	O
respiratory	NN	O	O
rate	NN	O	O
,	NN	O	O
increased	NN	O	O
GABA	NN	O	B-Chemical
,	NN	O	O
decreased	NN	O	O
glutamate	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
aspartate	NN	O	B-Chemical
or	NN	O	O
glycine	NN	O	B-Chemical
levels	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
in	NN	O	O
rat	NN	O	O
cortex	NN	O	O
and	NN	O	O
brain	NN	O	O
stem	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
of	NN	O	O
rats	NN	O	O
with	NN	O	O
thiosemicarbazide	NN	O	B-Chemical
for	NN	O	O
30	NN	O	O
minutes	NN	O	O
abolished	NN	O	O
the	NN	O	O
anesthetic	NN	O	O
action	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
respiratory	NN	O	O
depressant	NN	O	O
action	NN	O	O
of	NN	O	O
thiopental	NN	O	B-Chemical
.	NN	O	O

50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.v.	NN	O	O
thiopental	NN	O	B-Chemical
produced	NN	O	O
respiratory	NN	O	B-Disease
arrest	NN	O	I-Disease
with	NN	O	O
further	NN	O	O
increase	NN	O	O
in	NN	O	O
GABA	NN	O	B-Chemical
and	NN	O	O
decrease	NN	O	O
in	NN	O	O
glutamate	NN	O	B-Chemical
again	NN	O	O
in	NN	O	O
cortex	NN	O	O
and	NN	O	O
brain	NN	O	O
stem	NN	O	O
without	NN	O	O
affecting	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
amino	NN	O	B-Chemical
acids	NN	O	I-Chemical
studied	NN	O	O
in	NN	O	O
four	NN	O	O
regions	NN	O	O
of	NN	O	O
rat	NN	O	O
brain	NN	O	O
.	NN	O	O

Naloxone	NN	O	B-Chemical
(	NN	O	O
2.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.v.	NN	O	O
)	NN	O	O
reversed	NN	O	O
respiratory	NN	O	B-Disease
paralysis	NN	O	I-Disease
,	NN	O	O
glutamate	NN	O	B-Chemical
and	NN	O	O
GABA	NN	O	B-Chemical
levels	NN	O	O
to	NN	O	O
control	NN	O	O
values	NN	O	O
in	NN	O	O
brain	NN	O	O
stem	NN	O	O
and	NN	O	O
cortex	NN	O	O
with	NN	O	O
no	NN	O	O
changes	NN	O	O
in	NN	O	O
caudate	NN	O	O
or	NN	O	O
cerebellum	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
naloxone	NN	O	B-Chemical
reverses	NN	O	O
respiratory	NN	O	B-Disease
paralysis	NN	O	I-Disease
produced	NN	O	O
by	NN	O	O
thiopental	NN	O	B-Chemical
and	NN	O	O
involves	NN	O	O
GABA	NN	O	B-Chemical
in	NN	O	O
its	NN	O	O
action	NN	O	O
.	NN	O	O


-DOCSTART- (2533791)

National	NN	O	O
project	NN	O	O
on	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
mother	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
infant	NN	O	O
infection	NN	O	B-Disease
by	NN	O	I-Disease
hepatitis	NN	O	I-Disease
B	NN	O	I-Disease
virus	NN	O	I-Disease
in	NN	O	O
Japan	NN	O	O
.	NN	O	O

In	NN	O	O
Japan	NN	O	O
,	NN	O	O
a	NN	O	O
nationwide	NN	O	O
prevention	NN	O	O
program	NN	O	O
against	NN	O	O
mother	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
infant	NN	O	O
infection	NN	O	B-Disease
by	NN	O	I-Disease
hepatitis	NN	O	I-Disease
B	NN	O	I-Disease
virus	NN	O	I-Disease
(	NN	O	O
HBV	NN	O	O
)	NN	O	O
started	NN	O	O
in	NN	O	O
1985	NN	O	O
.	NN	O	O

This	NN	O	O
program	NN	O	O
consists	NN	O	O
of	NN	O	O
double	NN	O	O
screenings	NN	O	O
of	NN	O	O
pregnant	NN	O	O
women	NN	O	O
and	NN	O	O
prophylactic	NN	O	O
treatment	NN	O	O
to	NN	O	O
the	NN	O	O
infants	NN	O	O
born	NN	O	O
to	NN	O	O
both	NN	O	O
hepatitis	NN	O	B-Chemical
B	NN	O	I-Chemical
surface	NN	O	I-Chemical
antigen	NN	O	I-Chemical
(	NN	O	O
HBsAg	NN	O	B-Chemical
)	NN	O	O
and	NN	O	O
hepatitis	NN	O	B-Chemical
B	NN	O	I-Chemical
e	NN	O	I-Chemical
antigen	NN	O	I-Chemical
(	NN	O	O
HBeAg	NN	O	B-Chemical
)	NN	O	O
positive	NN	O	O
mothers	NN	O	O
.	NN	O	O

These	NN	O	O
infants	NN	O	O
are	NN	O	O
treated	NN	O	O
with	NN	O	O
two	NN	O	O
injections	NN	O	O
of	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
immune	NN	O	O
globulin	NN	O	O
(	NN	O	O
HBIG	NN	O	O
)	NN	O	O
and	NN	O	O
at	NN	O	O
least	NN	O	O
three	NN	O	O
injections	NN	O	O
of	NN	O	O
plasma	NN	O	O
derived	NN	O	O
hepatitis	NN	O	B-Chemical
B	NN	O	I-Chemical
vaccine	NN	O	I-Chemical
.	NN	O	O

We	NN	O	O
sent	NN	O	O
questionnaires	NN	O	O
about	NN	O	O
the	NN	O	O
numbers	NN	O	O
of	NN	O	O
each	NN	O	O
procedure	NN	O	O
or	NN	O	O
examination	NN	O	O
during	NN	O	O
nine	NN	O	O
months	NN	O	O
of	NN	O	O
investigation	NN	O	O
period	NN	O	O
to	NN	O	O
each	NN	O	O
local	NN	O	O
government	NN	O	O
in	NN	O	O
1986	NN	O	O
and	NN	O	O
1987	NN	O	O
.	NN	O	O

93.4%	NN	O	O
pregnant	NN	O	O
women	NN	O	O
had	NN	O	O
the	NN	O	O
chance	NN	O	O
to	NN	O	O
be	NN	O	O
examined	NN	O	O
for	NN	O	O
HBsAg	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
the	NN	O	O
positive	NN	O	O
rate	NN	O	O
was	NN	O	O
1.4	NN	O	O
to	NN	O	O
1.5%	NN	O	O
.	NN	O	O

The	NN	O	O
HBeAg	NN	O	B-Chemical
positive	NN	O	O
rate	NN	O	O
in	NN	O	O
HBsAg	NN	O	B-Chemical
positive	NN	O	O
was	NN	O	O
23	NN	O	O
to	NN	O	O
26%	NN	O	O
.	NN	O	O

The	NN	O	O
HBsAg	NN	O	B-Chemical
positive	NN	O	O
rate	NN	O	O
in	NN	O	O
neonates	NN	O	O
and	NN	O	O
in	NN	O	O
infants	NN	O	O
before	NN	O	O
two	NN	O	O
months	NN	O	O
were	NN	O	O
3%	NN	O	O
and	NN	O	O
2%	NN	O	O
respectively	NN	O	O
.	NN	O	O

Some	NN	O	O
problems	NN	O	O
may	NN	O	O
arise	NN	O	O
,	NN	O	O
because	NN	O	O
27	NN	O	O
to	NN	O	O
30%	NN	O	O
of	NN	O	O
infants	NN	O	O
need	NN	O	O
the	NN	O	O
fourth	NN	O	O
vaccination	NN	O	O
in	NN	O	O
some	NN	O	O
restricted	NN	O	O
areas	NN	O	O
.	NN	O	O


-DOCSTART- (2322844)

Nociceptive	NN	O	O
effects	NN	O	O
induced	NN	O	O
by	NN	O	O
intrathecal	NN	O	O
administration	NN	O	O
of	NN	O	O
prostaglandin	NN	O	B-Chemical
D2	NN	O	I-Chemical
,	NN	O	I-Chemical
E2	NN	O	I-Chemical
,	NN	O	I-Chemical
or	NN	O	I-Chemical
F2	NN	O	I-Chemical
alpha	NN	O	I-Chemical
to	NN	O	O
conscious	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
intrathecal	NN	O	O
administration	NN	O	O
of	NN	O	O
prostaglandins	NN	O	B-Chemical
on	NN	O	O
pain	NN	O	B-Disease
responses	NN	O	O
in	NN	O	O
conscious	NN	O	O
mice	NN	O	O
were	NN	O	O
evaluated	NN	O	O
by	NN	O	O
using	NN	O	O
hot	NN	O	O
plate	NN	O	O
and	NN	O	O
acetic	NN	O	B-Chemical
acid	NN	O	I-Chemical
writhing	NN	O	O
tests	NN	O	O
.	NN	O	O

Prostaglandin	NN	O	B-Chemical
D2	NN	O	I-Chemical
(	NN	O	O
0.5	NN	O	O
-	NN	O	O
3	NN	O	O
ng	NN	O	O
/	NN	O	O
mouse	NN	O	O
)	NN	O	O
had	NN	O	O
a	NN	O	O
hyperalgesic	NN	O	B-Disease
action	NN	O	O
on	NN	O	O
the	NN	O	O
response	NN	O	O
to	NN	O	O
a	NN	O	O
hot	NN	O	O
plate	NN	O	O
during	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
60	NN	O	O
min	NN	O	O
period	NN	O	O
after	NN	O	O
injection	NN	O	O
.	NN	O	O

Prostaglandin	NN	O	B-Chemical
E2	NN	O	I-Chemical
showed	NN	O	O
a	NN	O	O
hyperalgesic	NN	O	B-Disease
effect	NN	O	O
at	NN	O	O
doses	NN	O	O
of	NN	O	O
1	NN	O	O
pg	NN	O	B-Chemical
to	NN	O	O
10	NN	O	O
ng	NN	O	O
/	NN	O	O
mouse	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
effect	NN	O	O
lasted	NN	O	O
shorter	NN	O	O
(	NN	O	O
3	NN	O	O
-	NN	O	O
30	NN	O	O
min	NN	O	O
)	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
prostaglandin	NN	O	B-Chemical
D2	NN	O	I-Chemical
.	NN	O	O

Similar	NN	O	O
results	NN	O	O
were	NN	O	O
obtained	NN	O	O
by	NN	O	O
acetic	NN	O	B-Chemical
acid	NN	O	I-Chemical
writhing	NN	O	O
tests	NN	O	O
.	NN	O	O

The	NN	O	O
hyperalgesic	NN	O	B-Disease
effect	NN	O	O
of	NN	O	O
prostaglandin	NN	O	B-Chemical
D2	NN	O	I-Chemical
was	NN	O	O
blocked	NN	O	O
by	NN	O	O
simultaneous	NN	O	O
injection	NN	O	O
of	NN	O	O
a	NN	O	O
substance	NN	O	O
P	NN	O	O
antagonist	NN	O	O
(	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
100	NN	O	O
ng	NN	O	O
)	NN	O	O
but	NN	O	O
not	NN	O	O
by	NN	O	O
AH6809	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
prostanoid	NN	O	O
EP1	NN	O	O
-	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
.	NN	O	O

Conversely	NN	O	O
,	NN	O	O
prostaglandin	NN	O	B-Chemical
E2	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
hyperalgesia	NN	O	B-Disease
was	NN	O	O
blocked	NN	O	O
by	NN	O	O
AH6809	NN	O	B-Chemical
(	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
500	NN	O	O
ng	NN	O	O
)	NN	O	O
but	NN	O	O
not	NN	O	O
by	NN	O	O
the	NN	O	O
substance	NN	O	O
P	NN	O	O
antagonist	NN	O	O
.	NN	O	O

Prostaglandin	NN	O	B-Chemical
F2	NN	O	I-Chemical
alpha	NN	O	I-Chemical
had	NN	O	O
little	NN	O	O
effect	NN	O	O
on	NN	O	O
pain	NN	O	B-Disease
responses	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
both	NN	O	O
prostaglandin	NN	O	B-Chemical
D2	NN	O	I-Chemical
and	NN	O	O
prostaglandin	NN	O	B-Chemical
E2	NN	O	I-Chemical
exert	NN	O	O
hyperalgesia	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
spinal	NN	O	O
cord	NN	O	O
,	NN	O	O
but	NN	O	O
in	NN	O	O
different	NN	O	O
ways	NN	O	O
.	NN	O	O


-DOCSTART- (20552622)

Swallowing	NN	O	O
-	NN	O	O
induced	NN	O	O
atrial	NN	O	B-Disease
tachyarrhythmia	NN	O	I-Disease
triggered	NN	O	O
by	NN	O	O
salbutamol	NN	O	B-Chemical
:	NN	O	O
case	NN	O	O
report	NN	O	O
and	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

CASE	NN	O	O
:	NN	O	O
A	NN	O	O
49	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
patient	NN	O	O
experienced	NN	O	O
chest	NN	O	O
discomfort	NN	O	O
while	NN	O	O
swallowing	NN	O	O
.	NN	O	O

On	NN	O	O
electrocardiogram	NN	O	O
,	NN	O	O
episodes	NN	O	O
of	NN	O	O
atrial	NN	O	B-Disease
tachyarrhythmia	NN	O	I-Disease
were	NN	O	O
recorded	NN	O	O
immediately	NN	O	O
after	NN	O	O
swallowing	NN	O	O
;	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
Holter	NN	O	O
monitoring	NN	O	O
recorded	NN	O	O
several	NN	O	O
events	NN	O	O
.	NN	O	O

The	NN	O	O
arrhythmia	NN	O	B-Disease
resolved	NN	O	O
after	NN	O	O
therapy	NN	O	O
with	NN	O	O
atenolol	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
recurred	NN	O	O
a	NN	O	O
year	NN	O	O
later	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
noticed	NN	O	O
that	NN	O	O
before	NN	O	O
these	NN	O	O
episodes	NN	O	O
he	NN	O	O
had	NN	O	O
been	NN	O	O
using	NN	O	O
an	NN	O	O
inhalator	NN	O	O
of	NN	O	O
salbutamol	NN	O	B-Chemical
.	NN	O	O

After	NN	O	O
stopping	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
agonist	NN	O	O
,	NN	O	O
and	NN	O	O
after	NN	O	O
a	NN	O	O
week	NN	O	O
with	NN	O	O
the	NN	O	O
atenolol	NN	O	B-Chemical
,	NN	O	O
the	NN	O	O
arrhythmia	NN	O	B-Disease
disappeared	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
Swallowing	NN	O	O
-	NN	O	O
induced	NN	O	O
atrial	NN	O	B-Disease
tachyarrhythmia	NN	O	I-Disease
(	NN	O	O
SIAT	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
rare	NN	O	O
phenomenon	NN	O	O
.	NN	O	O

Fewer	NN	O	O
than	NN	O	O
50	NN	O	O
cases	NN	O	O
of	NN	O	O
SIAT	NN	O	B-Disease
have	NN	O	O
been	NN	O	O
described	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

This	NN	O	O
article	NN	O	O
summarizes	NN	O	O
all	NN	O	O
the	NN	O	O
cases	NN	O	O
published	NN	O	O
,	NN	O	O
creating	NN	O	O
a	NN	O	O
comprehensive	NN	O	O
review	NN	O	O
of	NN	O	O
the	NN	O	O
current	NN	O	O
knowledge	NN	O	O
and	NN	O	O
approach	NN	O	O
to	NN	O	O
SIAT	NN	O	B-Disease
.	NN	O	O

It	NN	O	O
discusses	NN	O	O
demographics	NN	O	O
,	NN	O	O
clinical	NN	O	O
characteristics	NN	O	O
and	NN	O	O
types	NN	O	O
of	NN	O	O
arrhythmia	NN	O	B-Disease
,	NN	O	O
postulated	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
SIAT	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
different	NN	O	O
treatment	NN	O	O
possibilities	NN	O	O
such	NN	O	O
as	NN	O	O
medications	NN	O	O
,	NN	O	O
surgery	NN	O	O
,	NN	O	O
and	NN	O	O
radiofrequency	NN	O	O
catheter	NN	O	O
ablation	NN	O	O
(	NN	O	O
RFCA	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Salbutamol	NN	O	B-Chemical
is	NN	O	O
presented	NN	O	O
here	NN	O	O
as	NN	O	O
a	NN	O	O
possible	NN	O	O
trigger	NN	O	O
for	NN	O	O
SIAT	NN	O	B-Disease
.	NN	O	O

Although	NN	O	O
it	NN	O	O
is	NN	O	O
difficult	NN	O	O
to	NN	O	O
define	NN	O	O
causality	NN	O	O
in	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
logical	NN	O	O
to	NN	O	O
think	NN	O	O
that	NN	O	O
a	NN	O	O
beta	NN	O	O
-	NN	O	O
agonist	NN	O	O
like	NN	O	O
salbutamol	NN	O	B-Chemical
(	NN	O	O
known	NN	O	O
to	NN	O	O
induce	NN	O	O
tachycardia	NN	O	B-Disease
)	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
trigger	NN	O	O
of	NN	O	O
adrenergic	NN	O	O
reflexes	NN	O	O
originating	NN	O	O
in	NN	O	O
the	NN	O	O
esophagus	NN	O	O
while	NN	O	O
swallowing	NN	O	O
and	NN	O	O
that	NN	O	O
a	NN	O	O
beta	NN	O	O
-	NN	O	O
blocker	NN	O	O
such	NN	O	O
as	NN	O	O
atenolol	NN	O	B-Chemical
(	NN	O	O
that	NN	O	O
blocks	NN	O	O
the	NN	O	O
adrenergic	NN	O	O
activity	NN	O	O
)	NN	O	O
may	NN	O	O
relieve	NN	O	O
it	NN	O	O
.	NN	O	O


-DOCSTART- (20510337)

Coenzyme	NN	O	B-Chemical
Q10	NN	O	I-Chemical
treatment	NN	O	O
ameliorates	NN	O	O
acute	NN	O	O
cisplatin	NN	O	B-Chemical
nephrotoxicity	NN	O	B-Disease
in	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
nephroprotective	NN	O	O
effect	NN	O	O
of	NN	O	O
coenzyme	NN	O	B-Chemical
Q10	NN	O	I-Chemical
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
mice	NN	O	O
with	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
injury	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
a	NN	O	O
single	NN	O	O
i.p.	NN	O	O
injection	NN	O	O
of	NN	O	O
cisplatin	NN	O	B-Chemical
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

Coenzyme	NN	O	B-Chemical
Q10	NN	O	I-Chemical
treatment	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
i.p.	NN	O	O
)	NN	O	O
was	NN	O	O
applied	NN	O	O
for	NN	O	O
6	NN	O	O
consecutive	NN	O	O
days	NN	O	O
,	NN	O	O
starting	NN	O	O
1	NN	O	O
day	NN	O	O
before	NN	O	O
cisplatin	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

Coenzyme	NN	O	B-Chemical
Q10	NN	O	I-Chemical
significantly	NN	O	O
reduced	NN	O	O
blood	NN	O	B-Chemical
urea	NN	O	I-Chemical
nitrogen	NN	O	I-Chemical
and	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
levels	NN	O	O
which	NN	O	O
were	NN	O	O
increased	NN	O	O
by	NN	O	O
cisplatin	NN	O	B-Chemical
.	NN	O	O

Coenzyme	NN	O	B-Chemical
Q10	NN	O	I-Chemical
significantly	NN	O	O
compensated	NN	O	O
deficits	NN	O	O
in	NN	O	O
the	NN	O	O
antioxidant	NN	O	O
defense	NN	O	O
mechanisms	NN	O	O
(	NN	O	O
reduced	NN	O	B-Chemical
glutathione	NN	O	I-Chemical
level	NN	O	O
and	NN	O	O
superoxide	NN	O	B-Chemical
dismutase	NN	O	O
activity	NN	O	O
)	NN	O	O
,	NN	O	O
suppressed	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
,	NN	O	O
decreased	NN	O	O
the	NN	O	O
elevations	NN	O	O
of	NN	O	O
tumor	NN	O	B-Disease
necrosis	NN	O	B-Disease
factor	NN	O	O
-	NN	O	O
alpha	NN	O	O
,	NN	O	O
nitric	NN	O	B-Chemical
oxide	NN	O	I-Chemical
and	NN	O	O
platinum	NN	O	B-Chemical
ion	NN	O	O
concentration	NN	O	O
,	NN	O	O
and	NN	O	O
attenuated	NN	O	O
the	NN	O	O
reductions	NN	O	O
of	NN	O	O
selenium	NN	O	B-Chemical
and	NN	O	O
zinc	NN	O	B-Chemical
ions	NN	O	O
in	NN	O	O
renal	NN	O	O
tissue	NN	O	O
resulted	NN	O	O
from	NN	O	O
cisplatin	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
histopathological	NN	O	O
renal	NN	O	B-Disease
tissue	NN	O	I-Disease
damage	NN	O	I-Disease
mediated	NN	O	O
by	NN	O	O
cisplatin	NN	O	B-Chemical
was	NN	O	O
ameliorated	NN	O	O
by	NN	O	O
coenzyme	NN	O	B-Chemical
Q10	NN	O	I-Chemical
treatment	NN	O	O
.	NN	O	O

Immunohistochemical	NN	O	O
analysis	NN	O	O
revealed	NN	O	O
that	NN	O	O
coenzyme	NN	O	B-Chemical
Q10	NN	O	I-Chemical
significantly	NN	O	O
decreased	NN	O	O
the	NN	O	O
cisplatin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
overexpression	NN	O	O
of	NN	O	O
inducible	NN	O	O
nitric	NN	O	B-Chemical
oxide	NN	O	I-Chemical
synthase	NN	O	O
,	NN	O	O
nuclear	NN	O	O
factor	NN	O	O
-	NN	O	O
kappaB	NN	O	O
,	NN	O	O
caspase	NN	O	O
-	NN	O	O
3	NN	O	O
and	NN	O	O
p53	NN	O	O
in	NN	O	O
renal	NN	O	O
tissue	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
concluded	NN	O	O
that	NN	O	O
coenzyme	NN	O	B-Chemical
Q10	NN	O	I-Chemical
represents	NN	O	O
a	NN	O	O
potential	NN	O	O
therapeutic	NN	O	O
option	NN	O	O
to	NN	O	O
protect	NN	O	O
against	NN	O	O
acute	NN	O	O
cisplatin	NN	O	B-Chemical
nephrotoxicity	NN	O	B-Disease
commonly	NN	O	O
encountered	NN	O	O
in	NN	O	O
clinical	NN	O	O
practice	NN	O	O
.	NN	O	O


-DOCSTART- (20164825)

Metformin	NN	O	B-Chemical
prevents	NN	O	O
experimental	NN	O	O
gentamicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B-Disease
by	NN	O	O
a	NN	O	O
mitochondria	NN	O	O
-	NN	O	O
dependent	NN	O	O
pathway	NN	O	O
.	NN	O	O

The	NN	O	O
antidiabetic	NN	O	O
drug	NN	O	O
metformin	NN	O	B-Chemical
can	NN	O	O
diminish	NN	O	O
apoptosis	NN	O	O
induced	NN	O	O
by	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
in	NN	O	O
endothelial	NN	O	O
cells	NN	O	O
and	NN	O	O
prevent	NN	O	O
vascular	NN	O	B-Disease
dysfunction	NN	O	I-Disease
even	NN	O	O
in	NN	O	O
nondiabetic	NN	O	O
patients	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
tested	NN	O	O
whether	NN	O	O
it	NN	O	O
has	NN	O	O
a	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
in	NN	O	O
a	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
gentamicin	NN	O	B-Chemical
toxicity	NN	O	B-Disease
.	NN	O	O

Mitochondrial	NN	O	O
analysis	NN	O	O
,	NN	O	O
respiration	NN	O	O
intensity	NN	O	O
,	NN	O	O
levels	NN	O	O
of	NN	O	O
reactive	NN	O	O
oxygen	NN	O	B-Chemical
species	NN	O	O
,	NN	O	O
permeability	NN	O	O
transition	NN	O	O
,	NN	O	O
and	NN	O	O
cytochrome	NN	O	O
c	NN	O	O
release	NN	O	O
were	NN	O	O
assessed	NN	O	O
3	NN	O	O
and	NN	O	O
6	NN	O	O
days	NN	O	O
after	NN	O	O
gentamicin	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

Metformin	NN	O	B-Chemical
treatment	NN	O	O
fully	NN	O	O
blocked	NN	O	O
gentamicin	NN	O	B-Chemical
-	NN	O	O
mediated	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
was	NN	O	O
accompanied	NN	O	O
by	NN	O	O
a	NN	O	O
lower	NN	O	O
activity	NN	O	O
of	NN	O	O
N	NN	O	O
-	NN	O	O
acetyl	NN	O	O
-	NN	O	O
beta	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
glucosaminidase	NN	O	O
,	NN	O	O
together	NN	O	O
with	NN	O	O
a	NN	O	O
decrease	NN	O	O
of	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
and	NN	O	O
increase	NN	O	O
of	NN	O	O
antioxidant	NN	O	O
systems	NN	O	O
.	NN	O	O

Metformin	NN	O	B-Chemical
also	NN	O	O
protected	NN	O	O
the	NN	O	O
kidney	NN	O	O
from	NN	O	O
histological	NN	O	O
damage	NN	O	O
6	NN	O	O
days	NN	O	O
after	NN	O	O
gentamicin	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

These	NN	O	O
in	NN	O	O
vivo	NN	O	O
markers	NN	O	O
of	NN	O	O
kidney	NN	O	B-Disease
dysfunction	NN	O	I-Disease
and	NN	O	O
their	NN	O	O
correction	NN	O	O
by	NN	O	O
metformin	NN	O	B-Chemical
were	NN	O	O
complemented	NN	O	O
by	NN	O	O
in	NN	O	O
vitro	NN	O	O
studies	NN	O	O
of	NN	O	O
mitochondrial	NN	O	O
function	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
gentamicin	NN	O	B-Chemical
treatment	NN	O	O
depleted	NN	O	O
respiratory	NN	O	O
components	NN	O	O
(	NN	O	O
cytochrome	NN	O	O
c	NN	O	O
,	NN	O	O
NADH	NN	O	O
)	NN	O	O
,	NN	O	O
probably	NN	O	O
due	NN	O	O
to	NN	O	O
the	NN	O	O
opening	NN	O	O
of	NN	O	O
mitochondrial	NN	O	O
transition	NN	O	O
pores	NN	O	O
.	NN	O	O

These	NN	O	O
injuries	NN	O	O
,	NN	O	O
partly	NN	O	O
mediated	NN	O	O
by	NN	O	O
a	NN	O	O
rise	NN	O	O
in	NN	O	O
reactive	NN	O	O
oxygen	NN	O	B-Chemical
species	NN	O	O
from	NN	O	O
the	NN	O	O
electron	NN	O	O
transfer	NN	O	O
chain	NN	O	O
,	NN	O	O
were	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
by	NN	O	O
metformin	NN	O	B-Chemical
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
our	NN	O	O
study	NN	O	O
suggests	NN	O	O
that	NN	O	O
pleiotropic	NN	O	O
effects	NN	O	O
of	NN	O	O
metformin	NN	O	B-Chemical
can	NN	O	O
lessen	NN	O	O
gentamicin	NN	O	B-Chemical
nephrotoxicity	NN	O	B-Disease
and	NN	O	O
improve	NN	O	O
mitochondrial	NN	O	O
homeostasis	NN	O	O
.	NN	O	O


-DOCSTART- (20042557)

Sedation	NN	O	O
depth	NN	O	O
during	NN	O	O
spinal	NN	O	O
anesthesia	NN	O	O
and	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
postoperative	NN	O	B-Disease
delirium	NN	O	I-Disease
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
hip	NN	O	B-Disease
fracture	NN	O	I-Disease
repair	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
whether	NN	O	O
limiting	NN	O	O
intraoperative	NN	O	O
sedation	NN	O	O
depth	NN	O	O
during	NN	O	O
spinal	NN	O	O
anesthesia	NN	O	O
for	NN	O	O
hip	NN	O	B-Disease
fracture	NN	O	I-Disease
repair	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
can	NN	O	O
decrease	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
postoperative	NN	O	B-Disease
delirium	NN	O	I-Disease
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
performed	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
randomized	NN	O	O
controlled	NN	O	O
trial	NN	O	O
at	NN	O	O
an	NN	O	O
academic	NN	O	O
medical	NN	O	O
center	NN	O	O
of	NN	O	O
elderly	NN	O	O
patients	NN	O	O
(	NN	O	O
>or=65	NN	O	O
years	NN	O	O
)	NN	O	O
without	NN	O	O
preoperative	NN	O	O
delirium	NN	O	B-Disease
or	NN	O	O
severe	NN	O	O
dementia	NN	O	B-Disease
who	NN	O	O
underwent	NN	O	O
hip	NN	O	B-Disease
fracture	NN	O	I-Disease
repair	NN	O	O
under	NN	O	O
spinal	NN	O	O
anesthesia	NN	O	O
with	NN	O	O
propofol	NN	O	B-Chemical
sedation	NN	O	O
.	NN	O	O

Sedation	NN	O	O
depth	NN	O	O
was	NN	O	O
titrated	NN	O	O
using	NN	O	O
processed	NN	O	O
electroencephalography	NN	O	O
with	NN	O	O
the	NN	O	O
bispectral	NN	O	O
index	NN	O	O
(	NN	O	O
BIS	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
deep	NN	O	O
(	NN	O	O
BIS	NN	O	O
,	NN	O	O
approximately	NN	O	O
50	NN	O	O
)	NN	O	O
or	NN	O	O
light	NN	O	O
(	NN	O	O
BIS	NN	O	O
,	NN	O	O
>or=80	NN	O	O
)	NN	O	O
sedation	NN	O	O
.	NN	O	O

Postoperative	NN	O	B-Disease
delirium	NN	O	I-Disease
was	NN	O	O
assessed	NN	O	O
as	NN	O	O
defined	NN	O	O
by	NN	O	O
Diagnostic	NN	O	O
and	NN	O	O
Statistical	NN	O	O
Manual	NN	O	O
of	NN	O	O
Mental	NN	O	B-Disease
Disorders	NN	O	I-Disease
(	NN	O	O
Third	NN	O	O
Edition	NN	O	O
Revised	NN	O	O
)	NN	O	O
criteria	NN	O	O
using	NN	O	O
the	NN	O	O
Confusion	NN	O	O
Assessment	NN	O	O
Method	NN	O	O
beginning	NN	O	O
at	NN	O	O
any	NN	O	O
time	NN	O	O
from	NN	O	O
the	NN	O	O
second	NN	O	O
day	NN	O	O
after	NN	O	O
surgery	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
From	NN	O	O
April	NN	O	O
2	NN	O	O
,	NN	O	O
2005	NN	O	O
,	NN	O	O
through	NN	O	O
October	NN	O	O
30	NN	O	O
,	NN	O	O
2008	NN	O	O
,	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
114	NN	O	O
patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
.	NN	O	O

The	NN	O	O
prevalence	NN	O	O
of	NN	O	O
postoperative	NN	O	B-Disease
delirium	NN	O	I-Disease
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
light	NN	O	O
sedation	NN	O	O
group	NN	O	O
(	NN	O	O
11	NN	O	O
/	NN	O	O
57	NN	O	O
[	NN	O	O
19%	NN	O	O
]	NN	O	O
vs	NN	O	O
23	NN	O	O
/	NN	O	O
57	NN	O	O
[	NN	O	O
40%	NN	O	O
]	NN	O	O
in	NN	O	O
the	NN	O	O
deep	NN	O	O
sedation	NN	O	O
group	NN	O	O
;	NN	O	O
P=.02	NN	O	O
)	NN	O	O
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
1	NN	O	O
incident	NN	O	O
of	NN	O	O
delirium	NN	O	B-Disease
will	NN	O	O
be	NN	O	O
prevented	NN	O	O
for	NN	O	O
every	NN	O	O
4.7	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
light	NN	O	O
sedation	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
number	NN	O	O
of	NN	O	O
days	NN	O	O
of	NN	O	O
delirium	NN	O	B-Disease
during	NN	O	O
hospitalization	NN	O	O
was	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
light	NN	O	O
sedation	NN	O	O
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
deep	NN	O	O
sedation	NN	O	O
group	NN	O	O
(	NN	O	O
0.5+	NN	O	O
/	NN	O	O
-	NN	O	O
1.5	NN	O	O
days	NN	O	O
vs	NN	O	O
1.4+	NN	O	O
/	NN	O	O
-	NN	O	O
4.0	NN	O	O
days	NN	O	O
;	NN	O	O
P=.01	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
use	NN	O	O
of	NN	O	O
light	NN	O	O
propofol	NN	O	B-Chemical
sedation	NN	O	O
decreased	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
postoperative	NN	O	B-Disease
delirium	NN	O	I-Disease
by	NN	O	O
50%	NN	O	O
compared	NN	O	O
with	NN	O	O
deep	NN	O	O
sedation	NN	O	O
.	NN	O	O

Limiting	NN	O	O
depth	NN	O	O
of	NN	O	O
sedation	NN	O	O
during	NN	O	O
spinal	NN	O	O
anesthesia	NN	O	O
is	NN	O	O
a	NN	O	O
simple	NN	O	O
,	NN	O	O
safe	NN	O	O
,	NN	O	O
and	NN	O	O
cost	NN	O	O
-	NN	O	O
effective	NN	O	O
intervention	NN	O	O
for	NN	O	O
preventing	NN	O	O
postoperative	NN	O	B-Disease
delirium	NN	O	I-Disease
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
that	NN	O	O
could	NN	O	O
be	NN	O	O
widely	NN	O	O
and	NN	O	O
readily	NN	O	O
adopted	NN	O	O
.	NN	O	O


-DOCSTART- (19944333)

Sorafenib	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
spasm	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
65	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
advanced	NN	O	O
renal	NN	O	B-Disease
cell	NN	O	I-Disease
carcinoma	NN	O	I-Disease
was	NN	O	O
admitted	NN	O	O
due	NN	O	O
to	NN	O	O
continuing	NN	O	O
chest	NN	O	B-Disease
pain	NN	O	I-Disease
at	NN	O	O
rest	NN	O	O
.	NN	O	O

Two	NN	O	O
weeks	NN	O	O
before	NN	O	O
his	NN	O	O
admission	NN	O	O
,	NN	O	O
sorafenib	NN	O	B-Chemical
had	NN	O	O
been	NN	O	O
started	NN	O	O
.	NN	O	O

He	NN	O	O
was	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
non	NN	O	O
-	NN	O	O
ST	NN	O	O
-	NN	O	O
elevation	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
by	NN	O	O
laboratory	NN	O	O
data	NN	O	O
and	NN	O	O
electrocardiogram	NN	O	O
.	NN	O	O

Enhanced	NN	O	O
heart	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
imaging	NN	O	O
also	NN	O	O
showed	NN	O	O
subendocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
stenosis	NN	O	O
in	NN	O	O
coronary	NN	O	O
arteries	NN	O	O
on	NN	O	O
angiography	NN	O	O
.	NN	O	O

Coronary	NN	O	B-Disease
artery	NN	O	I-Disease
spasm	NN	O	I-Disease
was	NN	O	O
induced	NN	O	O
by	NN	O	O
a	NN	O	O
provocative	NN	O	O
test	NN	O	O
.	NN	O	O

Cessation	NN	O	O
of	NN	O	O
sorafenib	NN	O	B-Chemical
and	NN	O	O
administration	NN	O	O
of	NN	O	O
Ca	NN	O	B-Chemical
-	NN	O	O
channel	NN	O	O
blocker	NN	O	O
and	NN	O	O
nitrates	NN	O	B-Chemical
ameliorated	NN	O	O
his	NN	O	O
symptoms	NN	O	O
,	NN	O	O
but	NN	O	O
relapse	NN	O	O
occurred	NN	O	O
after	NN	O	O
resumption	NN	O	O
of	NN	O	O
sorafenib	NN	O	B-Chemical
.	NN	O	O

Addition	NN	O	O
of	NN	O	O
oral	NN	O	O
nicorandil	NN	O	B-Chemical
reduced	NN	O	O
his	NN	O	O
symptoms	NN	O	O
and	NN	O	O
maintained	NN	O	O
stable	NN	O	B-Disease
angina	NN	O	I-Disease
status	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
of	NN	O	O
sorafenib	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
spasm	NN	O	I-Disease
.	NN	O	O

Sorafenib	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
multikinase	NN	O	O
inhibitor	NN	O	O
that	NN	O	O
targets	NN	O	O
signaling	NN	O	O
pathways	NN	O	O
necessary	NN	O	O
for	NN	O	O
cellular	NN	O	O
proliferation	NN	O	O
and	NN	O	O
survival	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
the	NN	O	O
Rho	NN	O	O
/	NN	O	O
ROCK	NN	O	O
pathway	NN	O	O
has	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
spasm	NN	O	I-Disease
.	NN	O	O

Our	NN	O	O
report	NN	O	O
may	NN	O	O
show	NN	O	O
an	NN	O	O
adverse	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
Rho	NN	O	O
/	NN	O	O
ROCK	NN	O	O
pathway	NN	O	O
by	NN	O	O
sorafenib	NN	O	B-Chemical
use	NN	O	O
.	NN	O	O


-DOCSTART- (17975693)

Anxiogenic	NN	O	O
potential	NN	O	O
of	NN	O	O
ciprofloxacin	NN	O	B-Chemical
and	NN	O	O
norfloxacin	NN	O	B-Chemical
in	NN	O	O
rats	NN	O	O
.	NN	O	O

INTRODUCTION	NN	O	O
:	NN	O	O
The	NN	O	O
possible	NN	O	O
anxiogenic	NN	O	O
effects	NN	O	O
of	NN	O	O
fluoroquinolones	NN	O	B-Chemical
,	NN	O	O
namely	NN	O	O
ciprofloxacin	NN	O	B-Chemical
and	NN	O	O
norfloxacin	NN	O	B-Chemical
,	NN	O	O
were	NN	O	O
investigated	NN	O	O
in	NN	O	O
adult	NN	O	O
Charles	NN	O	O
Foster	NN	O	O
albino	NN	O	O
rats	NN	O	O
of	NN	O	O
either	NN	O	O
sex	NN	O	O
,	NN	O	O
weighing	NN	O	O
150	NN	O	O
-	NN	O	O
200	NN	O	O
g	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
drugs	NN	O	O
were	NN	O	O
given	NN	O	O
orally	NN	O	O
,	NN	O	O
in	NN	O	O
doses	NN	O	O
of	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
for	NN	O	O
five	NN	O	O
consecutive	NN	O	O
days	NN	O	O
and	NN	O	O
the	NN	O	O
experiments	NN	O	O
were	NN	O	O
performed	NN	O	O
on	NN	O	O
the	NN	O	O
fifth	NN	O	O
day	NN	O	O
.	NN	O	O

The	NN	O	O
tests	NN	O	O
included	NN	O	O
open	NN	O	O
-	NN	O	O
field	NN	O	O
exploratory	NN	O	O
behaviour	NN	O	O
,	NN	O	O
elevated	NN	O	O
plus	NN	O	O
maze	NN	O	O
and	NN	O	O
elevated	NN	O	O
zero	NN	O	O
maze	NN	O	O
,	NN	O	O
social	NN	O	O
interaction	NN	O	O
and	NN	O	O
novelty	NN	O	O
-	NN	O	O
suppressed	NN	O	O
feeding	NN	O	O
latency	NN	O	O
behaviour	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
ciprofloxacin	NN	O	B-Chemical
-	NN	O	O
and	NN	O	O
norfloxacin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
showed	NN	O	O
anxious	NN	O	B-Disease
behaviour	NN	O	I-Disease
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
control	NN	O	O
rats	NN	O	O
in	NN	O	O
all	NN	O	O
the	NN	O	O
parameters	NN	O	O
studied	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
ciprofloxacin	NN	O	B-Chemical
-	NN	O	O
and	NN	O	O
norfloxacin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
significantly	NN	O	O
from	NN	O	O
each	NN	O	O
other	NN	O	O
in	NN	O	O
various	NN	O	O
behavioural	NN	O	O
parameters	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
present	NN	O	O
experimental	NN	O	O
findings	NN	O	O
substantiate	NN	O	O
the	NN	O	O
clinically	NN	O	O
observed	NN	O	O
anxiogenic	NN	O	O
potential	NN	O	O
of	NN	O	O
ciprofloxacin	NN	O	B-Chemical
and	NN	O	O
norfloxacin	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (17943461)

Myocardial	NN	O	O
Fas	NN	O	O
ligand	NN	O	O
expression	NN	O	O
increases	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
AZT	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B-Disease
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Dilated	NN	O	B-Disease
cardiomyopathy	NN	O	I-Disease
(	NN	O	O
DCM	NN	O	B-Disease
)	NN	O	O
and	NN	O	O
myocarditis	NN	O	B-Disease
occur	NN	O	O
in	NN	O	O
many	NN	O	O
HIV	NN	O	B-Disease
-	NN	O	I-Disease
infected	NN	O	I-Disease
individuals	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
symptomatic	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
in	NN	O	O
up	NN	O	O
to	NN	O	O
5%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Highly	NN	O	O
active	NN	O	O
antiretroviral	NN	O	O
therapy	NN	O	O
(	NN	O	O
HAART	NN	O	O
)	NN	O	O
has	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
morbidity	NN	O	O
and	NN	O	O
mortality	NN	O	O
of	NN	O	O
acquired	NN	O	B-Disease
immunodeficiency	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
AIDS	NN	O	B-Disease
)	NN	O	O
,	NN	O	O
but	NN	O	O
has	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
cardiac	NN	O	B-Disease
and	NN	O	I-Disease
skeletal	NN	O	I-Disease
myopathies	NN	O	I-Disease
.	NN	O	O

METHODS	NN	O	O
AND	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
In	NN	O	O
order	NN	O	O
to	NN	O	O
investigate	NN	O	O
whether	NN	O	O
the	NN	O	O
HAART	NN	O	O
component	NN	O	O
zidovudine	NN	O	B-Chemical
(	NN	O	O
3	NN	O	B-Chemical
'	NN	O	I-Chemical
-	NN	O	I-Chemical
azido	NN	O	I-Chemical
-	NN	O	I-Chemical
2	NN	O	I-Chemical
'	NN	O	I-Chemical
,	NN	O	I-Chemical
3	NN	O	I-Chemical
'	NN	O	I-Chemical
-	NN	O	I-Chemical
deoxythymidine	NN	O	I-Chemical
;	NN	O	O
AZT	NN	O	B-Chemical
)	NN	O	O
triggers	NN	O	O
the	NN	O	O
Fas	NN	O	O
-	NN	O	O
dependent	NN	O	O
cell	NN	O	O
-	NN	O	O
death	NN	O	O
pathway	NN	O	O
and	NN	O	O
cause	NN	O	O
cytoskeletal	NN	O	O
disruption	NN	O	O
in	NN	O	O
a	NN	O	O
murine	NN	O	O
model	NN	O	O
of	NN	O	O
DCM	NN	O	B-Disease
,	NN	O	O
8	NN	O	O
-	NN	O	O
week	NN	O	O
-	NN	O	O
old	NN	O	O
transgenic	NN	O	O
(	NN	O	O
expressing	NN	O	O
Fas	NN	O	O
ligand	NN	O	O
in	NN	O	O
the	NN	O	O
myocardium	NN	O	O
:	NN	O	O
FasL	NN	O	O
Tg	NN	O	O
)	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
transgenic	NN	O	O
(	NN	O	O
NTg	NN	O	O
)	NN	O	O
mice	NN	O	O
received	NN	O	O
water	NN	O	O
ad	NN	O	O
libitum	NN	O	O
containing	NN	O	O
different	NN	O	O
concentrations	NN	O	O
of	NN	O	O
AZT	NN	O	B-Chemical
(	NN	O	O
0	NN	O	O
,	NN	O	O
0.07	NN	O	O
,	NN	O	O
0.2	NN	O	O
,	NN	O	O
and	NN	O	O
0.7	NN	O	O
mg	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
6	NN	O	O
weeks	NN	O	O
,	NN	O	O
cardiac	NN	O	O
function	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
echocardiography	NN	O	O
and	NN	O	O
morphology	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
histopathologic	NN	O	O
and	NN	O	O
immunohistochemical	NN	O	O
methods	NN	O	O
.	NN	O	O

NTg	NN	O	O
and	NN	O	O
untreated	NN	O	O
FasL	NN	O	O
Tg	NN	O	O
mice	NN	O	O
showed	NN	O	O
little	NN	O	O
or	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
cardiac	NN	O	O
structure	NN	O	O
or	NN	O	O
function	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
AZT	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
FasL	NN	O	O
Tg	NN	O	O
mice	NN	O	O
developed	NN	O	O
cardiac	NN	O	B-Disease
dilation	NN	O	I-Disease
and	NN	O	O
depressed	NN	O	O
cardiac	NN	O	O
function	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
,	NN	O	O
with	NN	O	O
concomitant	NN	O	O
inflammatory	NN	O	O
infiltration	NN	O	O
of	NN	O	O
both	NN	O	O
ventricles	NN	O	O
.	NN	O	O

These	NN	O	O
changes	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
sarcolemmal	NN	O	O
expression	NN	O	O
of	NN	O	O
Fas	NN	O	O
and	NN	O	O
FasL	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
increased	NN	O	O
activation	NN	O	O
of	NN	O	O
caspase	NN	O	O
3	NN	O	O
,	NN	O	O
translocation	NN	O	O
of	NN	O	O
calpain	NN	O	O
1	NN	O	O
to	NN	O	O
the	NN	O	O
sarcolemma	NN	O	O
and	NN	O	O
sarcomere	NN	O	O
,	NN	O	O
and	NN	O	O
increased	NN	O	O
numbers	NN	O	O
of	NN	O	O
cells	NN	O	O
undergoing	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

These	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
changes	NN	O	O
in	NN	O	O
dystrophin	NN	O	O
and	NN	O	O
cardiac	NN	O	O
troponin	NN	O	O
I	NN	O	O
localization	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
loss	NN	O	O
of	NN	O	O
sarcolemmal	NN	O	O
integrity	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
expression	NN	O	O
of	NN	O	O
Fas	NN	O	O
ligand	NN	O	O
in	NN	O	O
the	NN	O	O
myocardium	NN	O	O
,	NN	O	O
as	NN	O	O
identified	NN	O	O
in	NN	O	O
HIV	NN	O	O
-	NN	O	O
positive	NN	O	O
patients	NN	O	O
,	NN	O	O
might	NN	O	O
increase	NN	O	O
the	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
HAART	NN	O	O
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
activation	NN	O	O
of	NN	O	O
apoptotic	NN	O	O
pathways	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
cardiac	NN	O	B-Disease
dilation	NN	O	I-Disease
and	NN	O	I-Disease
dysfunction	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (17074608)

Valproate	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
chorea	NN	O	B-Disease
and	NN	O	O
encephalopathy	NN	O	B-Disease
in	NN	O	O
atypical	NN	O	O
nonketotic	NN	O	B-Disease
hyperglycinemia	NN	O	I-Disease
.	NN	O	O

Nonketotic	NN	O	B-Disease
hyperglycinemia	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
disorder	NN	O	B-Disease
of	NN	O	I-Disease
amino	NN	O	I-Disease
acid	NN	O	I-Disease
metabolism	NN	O	I-Disease
in	NN	O	O
which	NN	O	O
a	NN	O	O
defect	NN	O	O
in	NN	O	O
the	NN	O	O
glycine	NN	O	B-Chemical
cleavage	NN	O	O
system	NN	O	O
leads	NN	O	O
to	NN	O	O
an	NN	O	O
accumulation	NN	O	O
of	NN	O	O
glycine	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
brain	NN	O	O
and	NN	O	O
other	NN	O	O
body	NN	O	O
compartments	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
classical	NN	O	O
form	NN	O	O
it	NN	O	O
presents	NN	O	O
as	NN	O	O
neonatal	NN	O	O
apnea	NN	O	B-Disease
,	NN	O	O
intractable	NN	O	O
seizures	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
hypotonia	NN	O	B-Disease
,	NN	O	O
followed	NN	O	O
by	NN	O	O
significant	NN	O	O
psychomotor	NN	O	B-Disease
retardation	NN	O	I-Disease
.	NN	O	O

An	NN	O	O
important	NN	O	O
subset	NN	O	O
of	NN	O	O
children	NN	O	O
with	NN	O	O
nonketotic	NN	O	B-Disease
hyperglycinemia	NN	O	I-Disease
are	NN	O	O
atypical	NN	O	O
variants	NN	O	O
who	NN	O	O
present	NN	O	O
in	NN	O	O
a	NN	O	O
heterogeneous	NN	O	O
manner	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
describes	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
mild	NN	O	O
language	NN	O	B-Disease
delay	NN	O	I-Disease
and	NN	O	O
mental	NN	O	B-Disease
retardation	NN	O	I-Disease
,	NN	O	O
who	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
nonketotic	NN	O	B-Disease
hyperglycinemia	NN	O	I-Disease
following	NN	O	O
her	NN	O	O
presentation	NN	O	O
with	NN	O	O
acute	NN	O	O
encephalopathy	NN	O	B-Disease
and	NN	O	O
chorea	NN	O	B-Disease
shortly	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
valproate	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O


-DOCSTART- (16364460)

Microinjection	NN	O	O
of	NN	O	O
ritanserin	NN	O	B-Chemical
into	NN	O	O
the	NN	O	O
CA1	NN	O	O
region	NN	O	O
of	NN	O	O
hippocampus	NN	O	O
improves	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B-Disease
in	NN	O	O
adult	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
ritanserin	NN	O	B-Chemical
(	NN	O	O
5	NN	O	O
-	NN	O	O
HT2	NN	O	O
antagonist	NN	O	O
)	NN	O	O
on	NN	O	O
scopolamine	NN	O	B-Chemical
(	NN	O	O
muscarinic	NN	O	O
cholinergic	NN	O	O
antagonist	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B-Disease
in	NN	O	O
Morris	NN	O	O
water	NN	O	O
maze	NN	O	O
(	NN	O	O
MWM	NN	O	O
)	NN	O	O
was	NN	O	O
investigated	NN	O	O
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
eight	NN	O	O
groups	NN	O	O
and	NN	O	O
bilaterally	NN	O	O
cannulated	NN	O	O
into	NN	O	O
CA1	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
.	NN	O	O

One	NN	O	O
week	NN	O	O
later	NN	O	O
,	NN	O	O
they	NN	O	O
received	NN	O	O
repeatedly	NN	O	O
vehicles	NN	O	O
(	NN	O	O
saline	NN	O	O
,	NN	O	O
DMSO	NN	O	B-Chemical
,	NN	O	O
saline+DMSO	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
scopolamine	NN	O	B-Chemical
(	NN	O	O
2	NN	O	O
microg	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
saline	NN	O	O
/	NN	O	O
side	NN	O	O
;	NN	O	O
30	NN	O	O
min	NN	O	O
before	NN	O	O
training	NN	O	O
)	NN	O	O
,	NN	O	O
ritanserin	NN	O	B-Chemical
(	NN	O	O
2	NN	O	O
,	NN	O	O
4	NN	O	O
and	NN	O	O
8	NN	O	O
microg	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
DMSO	NN	O	B-Chemical
/	NN	O	O
side	NN	O	O
;	NN	O	O
20	NN	O	O
min	NN	O	O
before	NN	O	O
training	NN	O	O
)	NN	O	O
and	NN	O	O
scopolamine	NN	O	B-Chemical
(	NN	O	O
2	NN	O	O
microg	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
;	NN	O	O
30	NN	O	O
min	NN	O	O
before	NN	O	O
ritanserin	NN	O	B-Chemical
injection	NN	O	O
)	NN	O	O
+ritanserin	NN	O	B-Chemical
(	NN	O	O
4	NN	O	O
microg	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
DMSO	NN	O	B-Chemical
)	NN	O	O
through	NN	O	O
cannulae	NN	O	O
each	NN	O	O
day	NN	O	O
.	NN	O	O

Animals	NN	O	O
were	NN	O	O
tested	NN	O	O
for	NN	O	O
four	NN	O	O
consecutive	NN	O	O
days	NN	O	O
(	NN	O	O
4	NN	O	O
trial	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
in	NN	O	O
MWM	NN	O	O
during	NN	O	O
which	NN	O	O
the	NN	O	O
position	NN	O	O
of	NN	O	O
hidden	NN	O	O
platform	NN	O	O
was	NN	O	O
unchanged	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
fifth	NN	O	O
day	NN	O	O
,	NN	O	O
the	NN	O	O
platform	NN	O	O
was	NN	O	O
elevated	NN	O	O
above	NN	O	O
the	NN	O	O
water	NN	O	O
surface	NN	O	O
in	NN	O	O
another	NN	O	O
position	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
function	NN	O	O
of	NN	O	O
motor	NN	O	O
,	NN	O	O
motivational	NN	O	O
and	NN	O	O
visual	NN	O	O
systems	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
escape	NN	O	O
latencies	NN	O	O
and	NN	O	O
traveled	NN	O	O
distances	NN	O	O
to	NN	O	O
find	NN	O	O
platform	NN	O	O
in	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
group	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
saline	NN	O	O
group	NN	O	O
.	NN	O	O

Ritanserin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
(	NN	O	O
4	NN	O	O
microg	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
/	NN	O	O
side	NN	O	O
)	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
mentioned	NN	O	O
parameters	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
DMSO	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
group	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
scopolamine	NN	O	B-Chemical
and	NN	O	O
ritanserin	NN	O	B-Chemical
co	NN	O	O
-	NN	O	O
administration	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
escape	NN	O	O
latencies	NN	O	O
and	NN	O	O
traveled	NN	O	O
distances	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
show	NN	O	O
that	NN	O	O
microinjection	NN	O	O
of	NN	O	O
ritanserin	NN	O	B-Chemical
into	NN	O	O
the	NN	O	O
CA1	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
improves	NN	O	O
the	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (15579441)

Hypoxia	NN	O	B-Disease
in	NN	O	O
renal	NN	O	B-Disease
disease	NN	O	I-Disease
with	NN	O	O
proteinuria	NN	O	B-Disease
and	NN	O	O
/	NN	O	O
or	NN	O	O
glomerular	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O

Despite	NN	O	O
the	NN	O	O
increasing	NN	O	O
need	NN	O	O
to	NN	O	O
identify	NN	O	O
and	NN	O	O
quantify	NN	O	O
tissue	NN	O	O
oxygenation	NN	O	O
at	NN	O	O
the	NN	O	O
cellular	NN	O	O
level	NN	O	O
,	NN	O	O
relatively	NN	O	O
few	NN	O	O
methods	NN	O	O
have	NN	O	O
been	NN	O	O
available	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
we	NN	O	O
developed	NN	O	O
a	NN	O	O
new	NN	O	O
hypoxia	NN	O	B-Disease
-	NN	O	O
responsive	NN	O	O
reporter	NN	O	O
vector	NN	O	O
using	NN	O	O
a	NN	O	O
hypoxia	NN	O	B-Disease
-	NN	O	O
responsive	NN	O	O
element	NN	O	O
of	NN	O	O
the	NN	O	O
5	NN	O	O
'	NN	O	O
vascular	NN	O	O
endothelial	NN	O	O
growth	NN	O	O
factor	NN	O	O
untranslated	NN	O	O
region	NN	O	O
and	NN	O	O
generated	NN	O	O
a	NN	O	O
novel	NN	O	O
hypoxia	NN	O	B-Disease
-	NN	O	O
sensing	NN	O	O
transgenic	NN	O	O
rat	NN	O	O
.	NN	O	O

We	NN	O	O
then	NN	O	O
applied	NN	O	O
this	NN	O	O
animal	NN	O	O
model	NN	O	O
to	NN	O	O
the	NN	O	O
detection	NN	O	O
of	NN	O	O
tubulointerstitial	NN	O	O
hypoxia	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
diseased	NN	O	B-Disease
kidney	NN	O	I-Disease
.	NN	O	O

With	NN	O	O
this	NN	O	O
model	NN	O	O
,	NN	O	O
we	NN	O	O
were	NN	O	O
able	NN	O	O
to	NN	O	O
identify	NN	O	O
diffuse	NN	O	O
cortical	NN	O	O
hypoxia	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
focal	NN	O	O
and	NN	O	O
segmental	NN	O	O
hypoxia	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
remnant	NN	O	O
kidney	NN	O	O
model	NN	O	O
.	NN	O	O

Expression	NN	O	O
of	NN	O	O
the	NN	O	O
hypoxia	NN	O	B-Disease
-	NN	O	O
responsive	NN	O	O
transgene	NN	O	O
increased	NN	O	O
throughout	NN	O	O
the	NN	O	O
observation	NN	O	O
period	NN	O	O
,	NN	O	O
reaching	NN	O	O
2.2	NN	O	O
-	NN	O	O
fold	NN	O	O
at	NN	O	O
2	NN	O	O
weeks	NN	O	O
in	NN	O	O
the	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
model	NN	O	O
and	NN	O	O
2.6	NN	O	O
-	NN	O	O
fold	NN	O	O
at	NN	O	O
4	NN	O	O
weeks	NN	O	O
in	NN	O	O
the	NN	O	O
remnant	NN	O	O
kidney	NN	O	O
model	NN	O	O
,	NN	O	O
whereas	NN	O	O
that	NN	O	O
of	NN	O	O
vascular	NN	O	O
endothelial	NN	O	O
growth	NN	O	O
factor	NN	O	O
showed	NN	O	O
a	NN	O	O
mild	NN	O	O
decrease	NN	O	O
,	NN	O	O
reflecting	NN	O	O
distinct	NN	O	O
behaviors	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
genes	NN	O	O
.	NN	O	O

The	NN	O	O
degree	NN	O	O
of	NN	O	O
hypoxia	NN	O	B-Disease
showed	NN	O	O
a	NN	O	O
positive	NN	O	O
correlation	NN	O	O
with	NN	O	O
microscopic	NN	O	O
tubulointerstitial	NN	O	B-Disease
injury	NN	O	I-Disease
in	NN	O	O
both	NN	O	O
models	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
we	NN	O	O
identified	NN	O	O
the	NN	O	O
localization	NN	O	O
of	NN	O	O
proliferating	NN	O	O
cell	NN	O	O
nuclear	NN	O	O
antigen	NN	O	O
-	NN	O	O
positive	NN	O	O
,	NN	O	O
ED	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
positive	NN	O	O
,	NN	O	O
and	NN	O	O
terminal	NN	O	O
dUTP	NN	O	O
nick	NN	O	O
-	NN	O	O
end	NN	O	O
labeled	NN	O	O
-	NN	O	O
positive	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
hypoxic	NN	O	B-Disease
cortical	NN	O	O
area	NN	O	O
in	NN	O	O
the	NN	O	O
remnant	NN	O	O
kidney	NN	O	O
model	NN	O	O
.	NN	O	O

We	NN	O	O
propose	NN	O	O
here	NN	O	O
a	NN	O	O
possible	NN	O	O
pathological	NN	O	O
tie	NN	O	O
between	NN	O	O
chronic	NN	O	O
tubulointerstitial	NN	O	O
hypoxia	NN	O	B-Disease
and	NN	O	O
progressive	NN	O	O
glomerular	NN	O	B-Disease
diseases	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (15517007)

Consensus	NN	O	O
statement	NN	O	O
concerning	NN	O	O
cardiotoxicity	NN	O	B-Disease
occurring	NN	O	O
during	NN	O	O
haematopoietic	NN	O	O
stem	NN	O	O
cell	NN	O	O
transplantation	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
autoimmune	NN	O	B-Disease
diseases	NN	O	I-Disease
,	NN	O	O
with	NN	O	O
special	NN	O	O
reference	NN	O	O
to	NN	O	O
systemic	NN	O	B-Disease
sclerosis	NN	O	I-Disease
and	NN	O	O
multiple	NN	O	B-Disease
sclerosis	NN	O	I-Disease
.	NN	O	O

Autologous	NN	O	O
haematopoietic	NN	O	O
stem	NN	O	O
cell	NN	O	O
transplantation	NN	O	O
is	NN	O	O
now	NN	O	O
a	NN	O	O
feasible	NN	O	O
and	NN	O	O
effective	NN	O	O
treatment	NN	O	O
for	NN	O	O
selected	NN	O	O
patients	NN	O	O
with	NN	O	O
severe	NN	O	O
autoimmune	NN	O	B-Disease
diseases	NN	O	I-Disease
.	NN	O	O

Worldwide	NN	O	O
,	NN	O	O
over	NN	O	O
650	NN	O	O
patients	NN	O	O
have	NN	O	O
been	NN	O	O
transplanted	NN	O	O
in	NN	O	O
the	NN	O	O
context	NN	O	O
of	NN	O	O
phase	NN	O	O
I	NN	O	O
and	NN	O	O
II	NN	O	O
clinical	NN	O	O
trials	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
are	NN	O	O
encouraging	NN	O	O
enough	NN	O	O
to	NN	O	O
begin	NN	O	O
randomised	NN	O	O
phase	NN	O	O
III	NN	O	O
trials	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
as	NN	O	O
predicted	NN	O	O
,	NN	O	O
significant	NN	O	O
transplant	NN	O	O
-	NN	O	O
related	NN	O	O
morbidity	NN	O	O
and	NN	O	O
mortality	NN	O	O
have	NN	O	O
been	NN	O	O
observed	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
primarily	NN	O	O
due	NN	O	O
to	NN	O	O
complications	NN	O	O
related	NN	O	O
to	NN	O	O
either	NN	O	O
the	NN	O	O
stage	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
at	NN	O	O
transplant	NN	O	O
or	NN	O	O
due	NN	O	O
to	NN	O	O
infections	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
deaths	NN	O	O
related	NN	O	O
to	NN	O	O
cardiac	NN	O	B-Disease
toxicity	NN	O	I-Disease
is	NN	O	O
low	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
caution	NN	O	O
is	NN	O	O
required	NN	O	O
when	NN	O	O
cyclophosphamide	NN	O	B-Chemical
or	NN	O	O
anthracyclines	NN	O	B-Chemical
such	NN	O	O
as	NN	O	O
mitoxantrone	NN	O	B-Chemical
are	NN	O	O
used	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
possible	NN	O	O
underlying	NN	O	O
heart	NN	O	B-Disease
damage	NN	O	I-Disease
,	NN	O	O
for	NN	O	O
example	NN	O	O
,	NN	O	O
systemic	NN	O	B-Disease
sclerosis	NN	O	I-Disease
patients	NN	O	O
.	NN	O	O

In	NN	O	O
November	NN	O	O
2002	NN	O	O
,	NN	O	O
a	NN	O	O
meeting	NN	O	O
was	NN	O	O
held	NN	O	O
in	NN	O	O
Florence	NN	O	O
,	NN	O	O
bringing	NN	O	O
together	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
experts	NN	O	O
in	NN	O	O
various	NN	O	O
fields	NN	O	O
,	NN	O	O
including	NN	O	O
rheumatology	NN	O	O
,	NN	O	O
cardiology	NN	O	O
,	NN	O	O
neurology	NN	O	O
,	NN	O	O
pharmacology	NN	O	O
and	NN	O	O
transplantation	NN	O	O
medicine	NN	O	O
.	NN	O	O

The	NN	O	O
object	NN	O	O
of	NN	O	O
the	NN	O	O
meeting	NN	O	O
was	NN	O	O
to	NN	O	O
analyse	NN	O	O
existing	NN	O	O
data	NN	O	O
,	NN	O	O
both	NN	O	O
published	NN	O	O
or	NN	O	O
available	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
European	NN	O	O
Group	NN	O	O
for	NN	O	O
Blood	NN	O	O
and	NN	O	O
Marrow	NN	O	O
Transplantation	NN	O	O
autoimmune	NN	O	B-Disease
disease	NN	O	I-Disease
database	NN	O	O
,	NN	O	O
and	NN	O	O
to	NN	O	O
propose	NN	O	O
a	NN	O	O
safe	NN	O	O
approach	NN	O	O
to	NN	O	O
such	NN	O	O
patients	NN	O	O
.	NN	O	O

A	NN	O	O
full	NN	O	O
cardiological	NN	O	O
assessment	NN	O	O
before	NN	O	O
and	NN	O	O
during	NN	O	O
the	NN	O	O
transplant	NN	O	O
emerged	NN	O	O
as	NN	O	O
the	NN	O	O
major	NN	O	O
recommendation	NN	O	O
.	NN	O	O


-DOCSTART- (12180796)

Immunohistochemical	NN	O	O
study	NN	O	O
on	NN	O	O
inducible	NN	O	O
type	NN	O	O
of	NN	O	O
nitric	NN	O	B-Chemical
oxide	NN	O	I-Chemical
(	NN	O	O
iNOS	NN	O	O
)	NN	O	O
,	NN	O	O
basic	NN	O	O
fibroblast	NN	O	O
growth	NN	O	O
factor	NN	O	O
(	NN	O	O
bFGF	NN	O	O
)	NN	O	O
and	NN	O	O
tumor	NN	O	B-Disease
growth	NN	O	O
factor	NN	O	O
-	NN	O	O
beta1	NN	O	O
(	NN	O	O
TGF	NN	O	O
-	NN	O	O
beta1	NN	O	O
)	NN	O	O
in	NN	O	O
arteritis	NN	O	B-Disease
induced	NN	O	O
in	NN	O	O
rats	NN	O	O
by	NN	O	O
fenoldopam	NN	O	B-Chemical
and	NN	O	O
theophylline	NN	O	B-Chemical
,	NN	O	O
vasodilators	NN	O	O
.	NN	O	O

Arteritis	NN	O	B-Disease
induced	NN	O	O
in	NN	O	O
rats	NN	O	O
by	NN	O	O
vasodilators	NN	O	O
,	NN	O	O
fenoldopam	NN	O	B-Chemical
and	NN	O	O
theophylline	NN	O	B-Chemical
,	NN	O	O
was	NN	O	O
examined	NN	O	O
immunohistochemically	NN	O	O
for	NN	O	O
expressions	NN	O	O
of	NN	O	O
inducible	NN	O	O
type	NN	O	O
of	NN	O	O
nitric	NN	O	B-Chemical
oxide	NN	O	I-Chemical
synthase	NN	O	O
(	NN	O	O
iNOS	NN	O	O
)	NN	O	O
,	NN	O	O
basic	NN	O	O
fibroblast	NN	O	O
growth	NN	O	O
factor	NN	O	O
(	NN	O	O
bFGF	NN	O	O
)	NN	O	O
and	NN	O	O
tumor	NN	O	B-Disease
growth	NN	O	O
factor	NN	O	O
-	NN	O	O
beta1	NN	O	O
(	NN	O	O
TGF	NN	O	O
-	NN	O	O
beta1	NN	O	O
)	NN	O	O
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
administered	NN	O	O
fenoldopam	NN	O	B-Chemical
for	NN	O	O
24	NN	O	O
hours	NN	O	O
by	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
following	NN	O	O
repeated	NN	O	O
daily	NN	O	O
oral	NN	O	O
administrations	NN	O	O
of	NN	O	O
theophylline	NN	O	B-Chemical
.	NN	O	O

Irrespective	NN	O	O
of	NN	O	O
theophylline	NN	O	B-Chemical
administration	NN	O	O
,	NN	O	O
iNOS	NN	O	O
antigens	NN	O	O
were	NN	O	O
remarkably	NN	O	O
abundant	NN	O	O
in	NN	O	O
ED	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
positive	NN	O	O
cells	NN	O	O
on	NN	O	O
day	NN	O	O
5	NN	O	O
and	NN	O	O
8	NN	O	O
post	NN	O	O
-	NN	O	O
fenoldopam	NN	O	B-Chemical
-	NN	O	O
infusion	NN	O	O
(	NN	O	O
DPI	NN	O	O
)	NN	O	O
;	NN	O	O
bFGF	NN	O	O
antigens	NN	O	O
were	NN	O	O
remarkably	NN	O	O
abundant	NN	O	O
in	NN	O	O
ED	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
positive	NN	O	O
cells	NN	O	O
on	NN	O	O
1	NN	O	O
and	NN	O	O
3	NN	O	O
DPI	NN	O	O
;	NN	O	O
TGF	NN	O	O
-	NN	O	O
beta1	NN	O	O
antigens	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
ED	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
positive	NN	O	O
cells	NN	O	O
on	NN	O	O
and	NN	O	O
after	NN	O	O
5	NN	O	O
DPI	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
peak	NN	O	O
expression	NN	O	O
of	NN	O	O
iNOS	NN	O	O
antigen	NN	O	O
was	NN	O	O
followed	NN	O	O
by	NN	O	O
that	NN	O	O
of	NN	O	O
bFGF	NN	O	O
antigen	NN	O	O
,	NN	O	O
and	NN	O	O
bFGF	NN	O	O
may	NN	O	O
have	NN	O	O
a	NN	O	O
suppressive	NN	O	O
effect	NN	O	O
on	NN	O	O
iNOS	NN	O	O
expression	NN	O	O
in	NN	O	O
these	NN	O	O
rat	NN	O	O
arteritis	NN	O	B-Disease
models	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
TGF	NN	O	O
-	NN	O	O
beta1	NN	O	O
was	NN	O	O
not	NN	O	O
considered	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
suppressive	NN	O	O
effect	NN	O	O
on	NN	O	O
iNOS	NN	O	O
expression	NN	O	O
in	NN	O	O
these	NN	O	O
models	NN	O	O
.	NN	O	O


-DOCSTART- (12109865)

Low	NN	O	B-Chemical
-	NN	O	I-Chemical
molecular	NN	O	I-Chemical
-	NN	O	I-Chemical
weight	NN	O	I-Chemical
heparin	NN	O	I-Chemical
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
mechanical	NN	O	O
heart	NN	O	O
valves	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
interruption	NN	O	O
of	NN	O	O
oral	NN	O	O
anticoagulant	NN	O	O
(	NN	O	O
OAC	NN	O	O
)	NN	O	O
administration	NN	O	O
is	NN	O	O
sometimes	NN	O	O
indicated	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
mechanical	NN	O	O
heart	NN	O	O
valves	NN	O	O
,	NN	O	O
mainly	NN	O	O
before	NN	O	O
noncardiac	NN	O	O
surgery	NN	O	O
,	NN	O	O
non	NN	O	O
-	NN	O	O
surgical	NN	O	O
interventions	NN	O	O
,	NN	O	O
and	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

Unfractionated	NN	O	B-Chemical
heparin	NN	O	I-Chemical
(	NN	O	O
UH	NN	O	B-Chemical
)	NN	O	O
is	NN	O	O
currently	NN	O	O
the	NN	O	O
substitute	NN	O	O
for	NN	O	O
selected	NN	O	O
patients	NN	O	O
.	NN	O	O

Low	NN	O	B-Chemical
-	NN	O	I-Chemical
molecular	NN	O	I-Chemical
-	NN	O	I-Chemical
weight	NN	O	I-Chemical
heparin	NN	O	I-Chemical
(	NN	O	O
LMWH	NN	O	B-Chemical
)	NN	O	O
offers	NN	O	O
theoretical	NN	O	O
advantages	NN	O	O
over	NN	O	O
UH	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
is	NN	O	O
not	NN	O	O
currently	NN	O	O
considered	NN	O	O
in	NN	O	O
clinical	NN	O	O
guidelines	NN	O	O
as	NN	O	O
an	NN	O	O
alternative	NN	O	O
to	NN	O	O
UH	NN	O	B-Chemical
in	NN	O	O
patients	NN	O	O
with	NN	O	O
prosthetic	NN	O	O
valves	NN	O	O
.	NN	O	O

HYPOTHESIS	NN	O	O
:	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
review	NN	O	O
the	NN	O	O
data	NN	O	O
accumulated	NN	O	O
so	NN	O	O
far	NN	O	O
on	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
LMWH	NN	O	B-Chemical
in	NN	O	O
this	NN	O	O
patient	NN	O	O
population	NN	O	O
and	NN	O	O
to	NN	O	O
discuss	NN	O	O
its	NN	O	O
applicability	NN	O	O
in	NN	O	O
common	NN	O	O
practice	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
For	NN	O	O
this	NN	O	O
paper	NN	O	O
,	NN	O	O
the	NN	O	O
current	NN	O	O
medical	NN	O	O
literature	NN	O	O
on	NN	O	O
LMWH	NN	O	B-Chemical
in	NN	O	O
patients	NN	O	O
with	NN	O	O
mechanical	NN	O	O
heart	NN	O	O
valves	NN	O	O
was	NN	O	O
extensively	NN	O	O
reviewed	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
There	NN	O	O
were	NN	O	O
eight	NN	O	O
series	NN	O	O
and	NN	O	O
six	NN	O	O
case	NN	O	O
reports	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
studies	NN	O	O
was	NN	O	O
randomized	NN	O	O
,	NN	O	O
and	NN	O	O
only	NN	O	O
one	NN	O	O
was	NN	O	O
prospective	NN	O	O
.	NN	O	O

Data	NN	O	O
to	NN	O	O
establish	NN	O	O
the	NN	O	O
thromboembolic	NN	O	B-Disease
risk	NN	O	O
were	NN	O	O
incomplete	NN	O	O
.	NN	O	O

After	NN	O	O
excluding	NN	O	O
case	NN	O	O
reports	NN	O	O
,	NN	O	O
the	NN	O	O
following	NN	O	O
groups	NN	O	O
were	NN	O	O
constructed	NN	O	O
:	NN	O	O
(	NN	O	O
a	NN	O	O
)	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
administration	NN	O	O
,	NN	O	O
after	NN	O	O
valve	NN	O	O
insertion	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
212	NN	O	O
)	NN	O	O
;	NN	O	O
(	NN	O	O
b	NN	O	O
)	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
,	NN	O	O
perioperative	NN	O	O
(	NN	O	O
noncardiac	NN	O	O
)	NN	O	O
/	NN	O	O
periprocedural	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
114	NN	O	O
)	NN	O	O
;	NN	O	O
(	NN	O	O
c	NN	O	O
)	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
,	NN	O	O
due	NN	O	O
to	NN	O	O
intolerance	NN	O	O
to	NN	O	O
OAC	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
16	NN	O	O
)	NN	O	O
;	NN	O	O
(	NN	O	O
d	NN	O	O
)	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
,	NN	O	O
in	NN	O	O
pregnancy	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
rate	NN	O	O
of	NN	O	O
thromboembolism	NN	O	B-Disease
was	NN	O	O
0.9%	NN	O	O
for	NN	O	O
all	NN	O	O
the	NN	O	O
studies	NN	O	O
and	NN	O	O
0.5	NN	O	O
,	NN	O	O
0	NN	O	O
,	NN	O	O
20	NN	O	O
,	NN	O	O
and	NN	O	O
0%	NN	O	O
in	NN	O	O
groups	NN	O	O
a	NN	O	O
,	NN	O	O
b	NN	O	O
,	NN	O	O
c	NN	O	O
,	NN	O	O
and	NN	O	O
d	NN	O	O
,	NN	O	O
respectively	NN	O	O
;	NN	O	O
for	NN	O	O
hemorrhage	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
overall	NN	O	O
rate	NN	O	O
was	NN	O	O
3.4%	NN	O	O
(	NN	O	O
3.8	NN	O	O
,	NN	O	O
2.6	NN	O	O
,	NN	O	O
10	NN	O	O
,	NN	O	O
and	NN	O	O
0%	NN	O	O
for	NN	O	O
the	NN	O	O
respective	NN	O	O
groups	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
patients	NN	O	O
with	NN	O	O
mechanical	NN	O	O
heart	NN	O	O
valves	NN	O	O
,	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
LMWH	NN	O	B-Chemical
therapy	NN	O	O
compares	NN	O	O
favorably	NN	O	O
with	NN	O	O
UH	NN	O	B-Chemical
.	NN	O	O

Data	NN	O	O
on	NN	O	O
mid	NN	O	O
-	NN	O	O
and	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
LMWH	NN	O	B-Chemical
administration	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
are	NN	O	O
sparse	NN	O	O
.	NN	O	O

Further	NN	O	O
randomized	NN	O	O
studies	NN	O	O
are	NN	O	O
needed	NN	O	O
to	NN	O	O
confirm	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
precise	NN	O	O
indications	NN	O	O
for	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
LMWH	NN	O	B-Chemical
in	NN	O	O
patients	NN	O	O
with	NN	O	O
mechanical	NN	O	O
heart	NN	O	O
valves	NN	O	O
.	NN	O	O


-DOCSTART- (12042105)

Topiramate	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
nephrolithiasis	NN	O	B-Disease
.	NN	O	O

Topiramate	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
recently	NN	O	O
developed	NN	O	O
antiepileptic	NN	O	O
medication	NN	O	O
that	NN	O	O
is	NN	O	O
becoming	NN	O	O
more	NN	O	O
widely	NN	O	O
prescribed	NN	O	O
because	NN	O	O
of	NN	O	O
its	NN	O	O
efficacy	NN	O	O
in	NN	O	O
treating	NN	O	O
refractory	NN	O	B-Disease
seizures	NN	O	I-Disease
.	NN	O	O

Urologists	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
that	NN	O	O
this	NN	O	O
medication	NN	O	O
can	NN	O	O
cause	NN	O	O
metabolic	NN	O	B-Disease
acidosis	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
secondary	NN	O	O
to	NN	O	O
inhibition	NN	O	O
of	NN	O	O
carbonic	NN	O	O
anhydrase	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
a	NN	O	O
distal	NN	O	O
tubular	NN	O	O
acidification	NN	O	O
defect	NN	O	O
may	NN	O	O
result	NN	O	O
,	NN	O	O
thus	NN	O	O
impairing	NN	O	O
the	NN	O	O
normal	NN	O	O
compensatory	NN	O	O
drop	NN	O	O
in	NN	O	O
urine	NN	O	O
pH	NN	O	O
.	NN	O	O

These	NN	O	O
factors	NN	O	O
can	NN	O	O
lead	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
phosphate	NN	O	I-Chemical
nephrolithiasis	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
first	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
topiramate	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
nephrolithiasis	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
urologic	NN	O	O
literature	NN	O	O
.	NN	O	O


-DOCSTART- (11868798)

Spironolactone	NN	O	B-Chemical
:	NN	O	O
is	NN	O	O
it	NN	O	O
a	NN	O	O
novel	NN	O	O
drug	NN	O	O
for	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
amphotericin	NN	O	B-Chemical
B	NN	O	I-Chemical
-	NN	O	O
related	NN	O	O
hypokalemia	NN	O	B-Disease
in	NN	O	O
cancer	NN	O	B-Disease
patients?	NN	O	O
OBJECTIVE	NN	O	O
:	NN	O	O
Nephrotoxicity	NN	O	B-Disease
is	NN	O	O
the	NN	O	O
major	NN	O	O
adverse	NN	O	O
effect	NN	O	O
of	NN	O	O
amphotericin	NN	O	B-Chemical
B	NN	O	I-Chemical
(	NN	O	O
AmB	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
often	NN	O	O
limiting	NN	O	O
administration	NN	O	O
of	NN	O	O
full	NN	O	O
dosage	NN	O	O
.	NN	O	O

Selective	NN	O	O
distal	NN	O	O
tubular	NN	O	O
epithelial	NN	O	O
toxicity	NN	O	B-Disease
seems	NN	O	O
to	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
profound	NN	O	O
potassium	NN	O	B-Chemical
wasting	NN	O	O
that	NN	O	O
is	NN	O	O
a	NN	O	O
major	NN	O	O
clinical	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
AmB	NN	O	B-Chemical
.	NN	O	O

Potassium	NN	O	B-Chemical
depletion	NN	O	O
also	NN	O	O
potentiates	NN	O	O
the	NN	O	O
tubular	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
AmB	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
spironolactone	NN	O	B-Chemical
to	NN	O	O
reduce	NN	O	O
potassium	NN	O	B-Chemical
requirements	NN	O	O
and	NN	O	O
to	NN	O	O
prevent	NN	O	O
hypokalemia	NN	O	B-Disease
in	NN	O	O
neutropenic	NN	O	B-Disease
patients	NN	O	O
on	NN	O	O
AmB	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
In	NN	O	O
this	NN	O	O
study	NN	O	O
26	NN	O	O
patients	NN	O	O
with	NN	O	O
various	NN	O	O
hematological	NN	O	B-Disease
disorders	NN	O	I-Disease
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
intravenous	NN	O	O
AmB	NN	O	B-Chemical
alone	NN	O	O
or	NN	O	O
AmB	NN	O	B-Chemical
and	NN	O	O
oral	NN	O	O
spironolactone	NN	O	B-Chemical
100	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
when	NN	O	O
developing	NN	O	O
a	NN	O	O
proven	NN	O	O
or	NN	O	O
suspected	NN	O	O
fungal	NN	O	B-Disease
infection	NN	O	I-Disease
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Patients	NN	O	O
receiving	NN	O	O
concomitant	NN	O	O
AmB	NN	O	B-Chemical
and	NN	O	O
spironolactone	NN	O	B-Chemical
had	NN	O	O
significantly	NN	O	O
higher	NN	O	O
plasma	NN	O	O
potassium	NN	O	B-Chemical
levels	NN	O	O
than	NN	O	O
those	NN	O	O
receiving	NN	O	O
AmB	NN	O	B-Chemical
alone	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.0027	NN	O	O
)	NN	O	O
.	NN	O	O

Those	NN	O	O
patients	NN	O	O
receiving	NN	O	O
AmB	NN	O	B-Chemical
and	NN	O	O
spironolactone	NN	O	B-Chemical
required	NN	O	O
significantly	NN	O	O
less	NN	O	O
potassium	NN	O	B-Chemical
supplementation	NN	O	O
to	NN	O	O
maintain	NN	O	O
their	NN	O	O
plasma	NN	O	O
potassium	NN	O	B-Chemical
within	NN	O	O
the	NN	O	O
normal	NN	O	O
range	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.022	NN	O	O
)	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
urinary	NN	O	O
potassium	NN	O	B-Chemical
losses	NN	O	O
were	NN	O	O
significantly	NN	O	O
less	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
AmB	NN	O	B-Chemical
and	NN	O	O
spironolactone	NN	O	B-Chemical
than	NN	O	O
those	NN	O	O
receiving	NN	O	O
AmB	NN	O	B-Chemical
alone	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.040	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
showed	NN	O	O
that	NN	O	O
spironolactone	NN	O	B-Chemical
can	NN	O	O
reduce	NN	O	O
potassium	NN	O	B-Chemical
requirements	NN	O	O
and	NN	O	O
prevent	NN	O	O
hypokalemia	NN	O	B-Disease
by	NN	O	O
reducing	NN	O	O
urinary	NN	O	O
potassium	NN	O	B-Chemical
loss	NN	O	O
in	NN	O	O
neutropenic	NN	O	B-Disease
patients	NN	O	O
on	NN	O	O
AmB	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O


-DOCSTART- (11860278)

Dopamine	NN	O	B-Chemical
D2	NN	O	O
receptor	NN	O	O
signaling	NN	O	O
controls	NN	O	O
neuronal	NN	O	O
cell	NN	O	O
death	NN	O	O
induced	NN	O	O
by	NN	O	O
muscarinic	NN	O	O
and	NN	O	O
glutamatergic	NN	O	O
drugs	NN	O	O
.	NN	O	O

Dopamine	NN	O	B-Chemical
(	NN	O	O
DA	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
through	NN	O	O
D1	NN	O	O
/	NN	O	O
D2	NN	O	O
receptor	NN	O	O
-	NN	O	O
mediated	NN	O	O
signaling	NN	O	O
,	NN	O	O
plays	NN	O	O
a	NN	O	O
major	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
of	NN	O	O
epileptic	NN	O	B-Disease
seizures	NN	O	I-Disease
arising	NN	O	O
in	NN	O	O
the	NN	O	O
limbic	NN	O	O
system	NN	O	O
.	NN	O	O

Excitotoxicity	NN	O	B-Disease
leading	NN	O	O
to	NN	O	O
neuronal	NN	O	O
cell	NN	O	O
death	NN	O	O
in	NN	O	O
the	NN	O	O
affected	NN	O	O
areas	NN	O	O
is	NN	O	O
a	NN	O	O
major	NN	O	O
consequence	NN	O	O
of	NN	O	O
seizures	NN	O	B-Disease
at	NN	O	O
the	NN	O	O
cellular	NN	O	O
level	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
respect	NN	O	O
,	NN	O	O
little	NN	O	O
is	NN	O	O
known	NN	O	O
about	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
DA	NN	O	B-Chemical
receptors	NN	O	O
in	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
epilepsy	NN	O	B-Disease
-	NN	O	O
induced	NN	O	O
neuronal	NN	O	O
cell	NN	O	O
death	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
analyze	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
seizures	NN	O	B-Disease
and	NN	O	O
neurotoxicity	NN	O	B-Disease
in	NN	O	O
D2R	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
treated	NN	O	O
with	NN	O	O
the	NN	O	O
cholinergic	NN	O	O
agonist	NN	O	O
pilocarpine	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
compared	NN	O	O
these	NN	O	O
results	NN	O	O
with	NN	O	O
those	NN	O	O
previously	NN	O	O
obtained	NN	O	O
with	NN	O	O
kainic	NN	O	B-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
KA	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
a	NN	O	O
potent	NN	O	O
glutamate	NN	O	B-Chemical
agonist	NN	O	O
.	NN	O	O

Importantly	NN	O	O
,	NN	O	O
D2R	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
develop	NN	O	O
seizures	NN	O	B-Disease
at	NN	O	O
doses	NN	O	O
of	NN	O	O
both	NN	O	O
drugs	NN	O	O
that	NN	O	O
are	NN	O	O
not	NN	O	O
epileptogenic	NN	O	O
for	NN	O	O
WT	NN	O	O
littermates	NN	O	O
and	NN	O	O
show	NN	O	O
greater	NN	O	O
neurotoxicity	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
pilocarpine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
result	NN	O	O
in	NN	O	O
a	NN	O	O
more	NN	O	O
widespread	NN	O	O
neuronal	NN	O	O
death	NN	O	O
in	NN	O	O
both	NN	O	O
WT	NN	O	O
and	NN	O	O
D2R	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
brains	NN	O	O
in	NN	O	O
comparison	NN	O	O
to	NN	O	O
KA	NN	O	B-Chemical
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
D2R	NN	O	O
lowers	NN	O	O
the	NN	O	O
threshold	NN	O	O
for	NN	O	O
seizures	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
both	NN	O	O
glutamate	NN	O	B-Chemical
and	NN	O	O
acetylcholine	NN	O	B-Chemical
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
the	NN	O	O
dopaminergic	NN	O	O
control	NN	O	O
of	NN	O	O
epilepsy	NN	O	B-Disease
-	NN	O	O
induced	NN	O	O
neurodegeneration	NN	O	B-Disease
seems	NN	O	O
to	NN	O	O
be	NN	O	O
mediated	NN	O	O
by	NN	O	O
distinct	NN	O	O
interactions	NN	O	O
of	NN	O	O
D2R	NN	O	O
signaling	NN	O	O
with	NN	O	O
these	NN	O	O
two	NN	O	O
neurotransmitters	NN	O	O
.	NN	O	O


-DOCSTART- (11838826)

Treatment	NN	O	O
of	NN	O	O
risperidone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperprolactinemia	NN	O	B-Disease
with	NN	O	O
a	NN	O	O
dopamine	NN	O	B-Chemical
agonist	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Risperidone	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
potent	NN	O	O
antagonist	NN	O	O
of	NN	O	O
both	NN	O	O
serotonergic	NN	O	O
(	NN	O	O
5HT2A	NN	O	O
)	NN	O	O
and	NN	O	O
dopaminergic	NN	O	O
D2	NN	O	O
receptors	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
hyperprolactinemia	NN	O	B-Disease
in	NN	O	O
adults	NN	O	O
and	NN	O	O
children	NN	O	O
.	NN	O	O

Chronically	NN	O	O
elevated	NN	O	O
prolactin	NN	O	O
levels	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
prolactinomas	NN	O	B-Disease
may	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
arrested	NN	O	O
growth	NN	O	O
and	NN	O	O
development	NN	O	O
resulting	NN	O	O
in	NN	O	O
either	NN	O	O
delayed	NN	O	B-Disease
puberty	NN	O	I-Disease
or	NN	O	O
short	NN	O	O
stature	NN	O	O
.	NN	O	O

These	NN	O	O
possibilities	NN	O	O
stress	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
developing	NN	O	O
a	NN	O	O
safe	NN	O	O
and	NN	O	O
effective	NN	O	O
approach	NN	O	O
to	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hyperprolactinemia	NN	O	B-Disease
in	NN	O	O
youth	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
successful	NN	O	O
treatment	NN	O	O
of	NN	O	O
risperidone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperprolactinemia	NN	O	B-Disease
with	NN	O	O
cabergoline	NN	O	B-Chemical
in	NN	O	O
youth	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
undertook	NN	O	O
a	NN	O	O
retrospective	NN	O	O
case	NN	O	O
review	NN	O	O
of	NN	O	O
four	NN	O	O
children	NN	O	O
with	NN	O	O
risperidone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperprolactinemia	NN	O	B-Disease
treated	NN	O	O
with	NN	O	O
cabergoline	NN	O	B-Chemical
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Four	NN	O	O
males	NN	O	O
(	NN	O	O
age	NN	O	O
6	NN	O	O
-	NN	O	O
11	NN	O	O
years	NN	O	O
)	NN	O	O
with	NN	O	O
Diagnostic	NN	O	O
and	NN	O	O
Statistical	NN	O	O
Manual	NN	O	O
of	NN	O	O
Mental	NN	O	B-Disease
Disorders	NN	O	I-Disease
(	NN	O	O
fourth	NN	O	O
edition	NN	O	O
)	NN	O	O
bipolar	NN	O	B-Disease
disorder	NN	O	I-Disease
or	NN	O	O
psychoses	NN	O	B-Disease
,	NN	O	O
with	NN	O	O
risperidone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
elevations	NN	O	O
in	NN	O	O
serum	NN	O	O
prolactin	NN	O	O
levels	NN	O	O
(	NN	O	O
57.5	NN	O	O
-	NN	O	O
129	NN	O	O
ng	NN	O	O
/	NN	O	O
mL	NN	O	O
,	NN	O	O
normal	NN	O	O
5	NN	O	O
-	NN	O	O
15	NN	O	O
ng	NN	O	O
/	NN	O	O
mL	NN	O	O
)	NN	O	O
,	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
cabergoline	NN	O	B-Chemical
(	NN	O	O
mean	NN	O	O
dose	NN	O	O
2.13	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.09	NN	O	O
mg	NN	O	O
/	NN	O	O
week	NN	O	O
)	NN	O	O
.	NN	O	O

When	NN	O	O
serum	NN	O	O
prolactin	NN	O	O
levels	NN	O	O
normalized	NN	O	O
in	NN	O	O
all	NN	O	O
four	NN	O	O
subjects	NN	O	O
(	NN	O	O
mean	NN	O	O
11.2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
10.9	NN	O	O
ng	NN	O	O
/	NN	O	O
mL	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
cabergoline	NN	O	B-Chemical
dose	NN	O	O
was	NN	O	O
reduced	NN	O	O
to	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
week	NN	O	O
in	NN	O	O
three	NN	O	O
of	NN	O	O
four	NN	O	O
subjects	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
duration	NN	O	O
of	NN	O	O
therapy	NN	O	O
with	NN	O	O
cabergoline	NN	O	B-Chemical
was	NN	O	O
523.5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
129.7	NN	O	O
days	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
mean	NN	O	O
duration	NN	O	O
of	NN	O	O
therapy	NN	O	O
with	NN	O	O
risperidone	NN	O	B-Chemical
was	NN	O	O
788.5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
162.5	NN	O	O
days	NN	O	O
.	NN	O	O

Cabergoline	NN	O	B-Chemical
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
without	NN	O	O
adverse	NN	O	O
effects	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Cabergoline	NN	O	B-Chemical
may	NN	O	O
be	NN	O	O
useful	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
risperidone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperprolactinemia	NN	O	B-Disease
in	NN	O	O
youth	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
further	NN	O	O
research	NN	O	O
is	NN	O	O
needed	NN	O	O
.	NN	O	O


-DOCSTART- (11467664)

Cholestatic	NN	O	B-Disease
jaundice	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
metformin	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
cholestatic	NN	O	B-Disease
jaundice	NN	O	I-Disease
shortly	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
metformin	NN	O	B-Chemical
hydrochloride	NN	O	I-Chemical
.	NN	O	O

Ultrasound	NN	O	O
of	NN	O	O
the	NN	O	O
liver	NN	O	O
and	NN	O	O
abdominal	NN	O	O
CT	NN	O	O
were	NN	O	O
normal	NN	O	O
.	NN	O	O

An	NN	O	O
ERCP	NN	O	O
showed	NN	O	O
normal	NN	O	O
biliary	NN	O	O
anatomy	NN	O	O
.	NN	O	O

A	NN	O	O
percutaneous	NN	O	O
liver	NN	O	O
biopsy	NN	O	O
was	NN	O	O
obtained	NN	O	O
showing	NN	O	O
marked	NN	O	O
cholestasis	NN	O	B-Disease
,	NN	O	O
with	NN	O	O
portal	NN	O	O
edema	NN	O	B-Disease
,	NN	O	O
ductular	NN	O	O
proliferation	NN	O	O
,	NN	O	O
and	NN	O	O
acute	NN	O	O
inflammation	NN	O	B-Disease
.	NN	O	O

Metformin	NN	O	B-Chemical
hydrochloride	NN	O	I-Chemical
was	NN	O	O
discontinued	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
jaundice	NN	O	B-Disease
resolved	NN	O	O
slowly	NN	O	O
over	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
several	NN	O	O
months	NN	O	O
.	NN	O	O

Given	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
his	NN	O	O
jaundice	NN	O	B-Disease
2	NN	O	O
wk	NN	O	O
after	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
metformin	NN	O	B-Chemical
,	NN	O	O
we	NN	O	O
believe	NN	O	O
that	NN	O	O
this	NN	O	O
case	NN	O	O
represents	NN	O	O
an	NN	O	O
example	NN	O	O
of	NN	O	O
metformin	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
hepatotoxicity	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
first	NN	O	O
such	NN	O	O
case	NN	O	O
reported	NN	O	O
.	NN	O	O


-DOCSTART- (11077455)

Electro	NN	O	O
-	NN	O	O
oculography	NN	O	O
,	NN	O	O
electroretinography	NN	O	O
,	NN	O	O
visual	NN	O	O
evoked	NN	O	O
potentials	NN	O	O
,	NN	O	O
and	NN	O	O
multifocal	NN	O	O
electroretinography	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
vigabatrin	NN	O	B-Chemical
-	NN	O	O
attributed	NN	O	O
visual	NN	O	B-Disease
field	NN	O	I-Disease
constriction	NN	O	I-Disease
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
Symptomatic	NN	O	O
visual	NN	O	B-Disease
field	NN	O	I-Disease
constriction	NN	O	I-Disease
thought	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
vigabatrin	NN	O	B-Chemical
has	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

The	NN	O	O
current	NN	O	O
study	NN	O	O
investigated	NN	O	O
the	NN	O	O
visual	NN	O	O
fields	NN	O	O
and	NN	O	O
visual	NN	O	O
electrophysiology	NN	O	O
of	NN	O	O
eight	NN	O	O
patients	NN	O	O
with	NN	O	O
known	NN	O	O
vigabatrin	NN	O	B-Chemical
-	NN	O	O
attributed	NN	O	O
visual	NN	O	B-Disease
field	NN	O	I-Disease
loss	NN	O	I-Disease
,	NN	O	O
three	NN	O	O
of	NN	O	O
whom	NN	O	O
were	NN	O	O
reported	NN	O	O
previously	NN	O	O
.	NN	O	O

Six	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
no	NN	O	O
longer	NN	O	O
receiving	NN	O	O
vigabatrin	NN	O	B-Chemical
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
central	NN	O	O
and	NN	O	O
peripheral	NN	O	O
fields	NN	O	O
were	NN	O	O
examined	NN	O	O
with	NN	O	O
the	NN	O	O
Humphrey	NN	O	O
Visual	NN	O	O
Field	NN	O	O
Analyzer	NN	O	O
.	NN	O	O

Full	NN	O	O
visual	NN	O	O
electrophysiology	NN	O	O
,	NN	O	O
including	NN	O	O
flash	NN	O	O
electroretinography	NN	O	O
(	NN	O	O
ERG	NN	O	O
)	NN	O	O
,	NN	O	O
pattern	NN	O	O
electroretinography	NN	O	O
,	NN	O	O
multifocal	NN	O	O
ERG	NN	O	O
using	NN	O	O
the	NN	O	O
VERIS	NN	O	O
system	NN	O	O
,	NN	O	O
electro	NN	O	O
-	NN	O	O
oculography	NN	O	O
,	NN	O	O
and	NN	O	O
flash	NN	O	O
and	NN	O	O
pattern	NN	O	O
visual	NN	O	O
evoked	NN	O	O
potentials	NN	O	O
,	NN	O	O
was	NN	O	O
undertaken	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Seven	NN	O	O
patients	NN	O	O
showed	NN	O	O
marked	NN	O	O
visual	NN	O	B-Disease
field	NN	O	I-Disease
constriction	NN	O	I-Disease
with	NN	O	O
some	NN	O	O
sparing	NN	O	O
of	NN	O	O
the	NN	O	O
temporal	NN	O	O
visual	NN	O	O
field	NN	O	O
.	NN	O	O

The	NN	O	O
eighth	NN	O	O
exhibited	NN	O	O
concentric	NN	O	O
constriction	NN	O	O
.	NN	O	O

Most	NN	O	O
electrophysiological	NN	O	O
responses	NN	O	O
were	NN	O	O
usually	NN	O	O
just	NN	O	O
within	NN	O	O
normal	NN	O	O
limits	NN	O	O
;	NN	O	O
two	NN	O	O
patients	NN	O	O
had	NN	O	O
subnormal	NN	O	O
Arden	NN	O	O
electro	NN	O	O
-	NN	O	O
oculography	NN	O	O
indices	NN	O	O
;	NN	O	O
and	NN	O	O
one	NN	O	O
patient	NN	O	O
showed	NN	O	O
an	NN	O	O
abnormally	NN	O	O
delayed	NN	O	O
photopic	NN	O	O
b	NN	O	O
wave	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
five	NN	O	O
patients	NN	O	O
showed	NN	O	O
delayed	NN	O	O
30	NN	O	O
-	NN	O	O
Hz	NN	O	O
flicker	NN	O	O
b	NN	O	O
waves	NN	O	O
,	NN	O	O
and	NN	O	O
seven	NN	O	O
patients	NN	O	O
showed	NN	O	O
delayed	NN	O	O
oscillatory	NN	O	O
potentials	NN	O	O
.	NN	O	O

Multifocal	NN	O	O
ERG	NN	O	O
showed	NN	O	O
abnormalities	NN	O	O
that	NN	O	O
sometimes	NN	O	O
correlated	NN	O	O
with	NN	O	O
the	NN	O	O
visual	NN	O	O
field	NN	O	O
appearance	NN	O	O
and	NN	O	O
confirmed	NN	O	O
that	NN	O	O
the	NN	O	O
deficit	NN	O	O
occurs	NN	O	O
at	NN	O	O
the	NN	O	O
retinal	NN	O	O
level	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Marked	NN	O	O
visual	NN	O	B-Disease
field	NN	O	I-Disease
constriction	NN	O	I-Disease
appears	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
vigabatrin	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
field	NN	O	O
defects	NN	O	O
and	NN	O	O
some	NN	O	O
electrophysiological	NN	O	O
abnormalities	NN	O	O
persist	NN	O	O
when	NN	O	O
vigabatrin	NN	O	B-Chemical
therapy	NN	O	O
is	NN	O	O
withdrawn	NN	O	O
.	NN	O	O


-DOCSTART- (11063349)

Conversion	NN	O	O
to	NN	O	O
rapamycin	NN	O	B-Chemical
immunosuppression	NN	O	O
in	NN	O	O
renal	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
:	NN	O	O
report	NN	O	O
of	NN	O	O
an	NN	O	O
initial	NN	O	O
experience	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
is	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
RAPA	NN	O	B-Chemical
conversion	NN	O	O
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
cyclosporine	NN	O	B-Chemical
(	NN	O	O
CsA	NN	O	B-Chemical
)	NN	O	O
or	NN	O	O
tacrolimus	NN	O	B-Chemical
(	NN	O	O
Tac	NN	O	B-Chemical
)	NN	O	O
toxicity	NN	O	B-Disease
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Twenty	NN	O	O
renal	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
were	NN	O	O
switched	NN	O	O
to	NN	O	O
fixed	NN	O	O
dose	NN	O	O
rapamycin	NN	O	B-Chemical
(	NN	O	O
RAPA	NN	O	B-Chemical
)	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
0	NN	O	O
to	NN	O	O
204	NN	O	O
months	NN	O	O
posttransplant	NN	O	O
.	NN	O	O

Drug	NN	O	O
monitoring	NN	O	O
was	NN	O	O
not	NN	O	O
initially	NN	O	O
used	NN	O	O
to	NN	O	O
adjust	NN	O	O
doses	NN	O	O
.	NN	O	O

The	NN	O	O
indications	NN	O	O
for	NN	O	O
switch	NN	O	O
were	NN	O	O
chronic	NN	O	O
CsA	NN	O	B-Chemical
or	NN	O	O
Tac	NN	O	B-Chemical
nephrotoxicity	NN	O	B-Disease
(	NN	O	O
12	NN	O	O
)	NN	O	O
,	NN	O	O
acute	NN	O	O
CsA	NN	O	B-Chemical
or	NN	O	O
Tac	NN	O	B-Chemical
toxicity	NN	O	B-Disease
(	NN	O	O
3	NN	O	O
)	NN	O	O
,	NN	O	O
severe	NN	O	O
facial	NN	O	B-Disease
dysmorphism	NN	O	I-Disease
(	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
posttransplant	NN	O	B-Disease
lymphoproliferative	NN	O	I-Disease
disorder	NN	O	I-Disease
(	NN	O	O
PTLD	NN	O	B-Disease
)	NN	O	O
in	NN	O	O
remission	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
hepatotoxicity	NN	O	B-Disease
in	NN	O	O
1	NN	O	O
.	NN	O	O

Follow	NN	O	O
-	NN	O	O
up	NN	O	O
is	NN	O	O
7	NN	O	O
to	NN	O	O
24	NN	O	O
months	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
In	NN	O	O
the	NN	O	O
12	NN	O	O
patients	NN	O	O
switched	NN	O	O
because	NN	O	O
of	NN	O	O
chronic	NN	O	O
nephrotoxicity	NN	O	B-Disease
there	NN	O	O
was	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
[	NN	O	O
233+	NN	O	O
/	NN	O	O
-	NN	O	O
34	NN	O	O
to	NN	O	O
210+	NN	O	O
/	NN	O	O
-	NN	O	O
56	NN	O	O
micromol	NN	O	O
/	NN	O	O
liter	NN	O	O
(	NN	O	O
P<0.05	NN	O	O
)	NN	O	O
at	NN	O	O
6	NN	O	O
months	NN	O	O
]	NN	O	O
.	NN	O	O

Facial	NN	O	B-Disease
dysmorphism	NN	O	I-Disease
improved	NN	O	O
in	NN	O	O
two	NN	O	O
patients	NN	O	O
.	NN	O	O

No	NN	O	O
relapse	NN	O	O
of	NN	O	O
PTLD	NN	O	B-Disease
was	NN	O	O
observed	NN	O	O
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
developed	NN	O	O
pneumonia	NN	O	B-Disease
(	NN	O	O
two	NN	O	O
Pneumocystis	NN	O	B-Disease
carinii	NN	O	I-Disease
pneumonia	NN	O	I-Disease
,	NN	O	O
one	NN	O	O
infectious	NN	O	B-Disease
mononucleosis	NN	O	I-Disease
with	NN	O	O
polyclonal	NN	O	O
PTLD	NN	O	B-Disease
lung	NN	O	O
infiltrate	NN	O	O
)	NN	O	O
and	NN	O	O
two	NN	O	O
had	NN	O	O
bronchiolitis	NN	O	B-Disease
obliterans	NN	O	I-Disease
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
deaths	NN	O	O
.	NN	O	O

RAPA	NN	O	B-Chemical
was	NN	O	O
discontinued	NN	O	O
in	NN	O	O
four	NN	O	O
patients	NN	O	O
,	NN	O	O
because	NN	O	O
of	NN	O	O
pneumonia	NN	O	B-Disease
in	NN	O	O
two	NN	O	O
,	NN	O	O
PTLD	NN	O	B-Disease
in	NN	O	O
one	NN	O	O
,	NN	O	O
and	NN	O	O
oral	NN	O	O
aphtous	NN	O	B-Disease
ulcers	NN	O	I-Disease
in	NN	O	O
one	NN	O	O
.	NN	O	O

RAPA	NN	O	B-Chemical
levels	NN	O	O
were	NN	O	O
high	NN	O	O
(	NN	O	O
>15	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
in	NN	O	O
7	NN	O	O
of	NN	O	O
13	NN	O	O
(	NN	O	O
54%	NN	O	O
)	NN	O	O
patients	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
RAPA	NN	O	B-Chemical
conversion	NN	O	O
provides	NN	O	O
adequate	NN	O	O
immunosuppression	NN	O	O
to	NN	O	O
enable	NN	O	O
CsA	NN	O	B-Chemical
withdrawal	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
when	NN	O	O
converting	NN	O	O
patients	NN	O	O
to	NN	O	O
RAPA	NN	O	B-Chemical
drug	NN	O	O
levels	NN	O	O
should	NN	O	O
be	NN	O	O
monitored	NN	O	O
to	NN	O	O
avoid	NN	O	O
over	NN	O	O
-	NN	O	O
immunosuppression	NN	O	O
and	NN	O	O
adequate	NN	O	O
antiviral	NN	O	O
and	NN	O	O
Pneumocystis	NN	O	B-Disease
carinii	NN	O	I-Disease
pneumonia	NN	O	I-Disease
prophylaxis	NN	O	O
should	NN	O	O
be	NN	O	O
given	NN	O	O
.	NN	O	O


-DOCSTART- (10091616)

Worsening	NN	O	O
of	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
by	NN	O	O
motor	NN	O	O
and	NN	O	O
mental	NN	O	O
tasks	NN	O	O
.	NN	O	O

Ten	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
with	NN	O	O
disabling	NN	O	O
dyskinesia	NN	O	B-Disease
were	NN	O	O
included	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
mental	NN	O	O
(	NN	O	O
mental	NN	O	O
calculation	NN	O	O
)	NN	O	O
and	NN	O	O
motor	NN	O	O
(	NN	O	O
flexion	NN	O	O
/	NN	O	O
extension	NN	O	O
of	NN	O	O
right	NN	O	O
fingers	NN	O	O
,	NN	O	O
flexion	NN	O	O
/	NN	O	O
extension	NN	O	O
of	NN	O	O
left	NN	O	O
fingers	NN	O	O
,	NN	O	O
flexion	NN	O	O
/	NN	O	O
extension	NN	O	O
of	NN	O	O
the	NN	O	O
neck	NN	O	O
,	NN	O	O
speaking	NN	O	O
aloud	NN	O	O
)	NN	O	O
tasks	NN	O	O
on	NN	O	O
the	NN	O	O
worsening	NN	O	O
of	NN	O	O
peak	NN	O	O
-	NN	O	O
dose	NN	O	O
dyskinesia	NN	O	B-Disease
following	NN	O	O
administration	NN	O	O
of	NN	O	O
an	NN	O	O
effective	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
apomorphine	NN	O	B-Chemical
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
the	NN	O	O
score	NN	O	O
at	NN	O	O
rest	NN	O	O
(	NN	O	O
1.3+	NN	O	O
/	NN	O	O
-	NN	O	O
0.3	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
significant	NN	O	O
aggravation	NN	O	O
of	NN	O	O
the	NN	O	O
dyskinesia	NN	O	B-Disease
score	NN	O	O
was	NN	O	O
observed	NN	O	O
during	NN	O	O
speaking	NN	O	O
aloud	NN	O	O
(	NN	O	O
5.2+	NN	O	O
/	NN	O	O
-	NN	O	O
1.1	NN	O	O
,	NN	O	O
p<0.05	NN	O	O
)	NN	O	O
,	NN	O	O
movements	NN	O	O
of	NN	O	O
right	NN	O	O
(	NN	O	O
4.5+	NN	O	O
/	NN	O	O
-	NN	O	O
1.0	NN	O	O
,	NN	O	O
p<0.05	NN	O	O
)	NN	O	O
and	NN	O	O
left	NN	O	O
(	NN	O	O
3.7+	NN	O	O
/	NN	O	O
-	NN	O	O
0.8	NN	O	O
,	NN	O	O
p<0.05	NN	O	O
)	NN	O	O
fingers	NN	O	O
,	NN	O	O
movements	NN	O	O
of	NN	O	O
the	NN	O	O
neck	NN	O	O
(	NN	O	O
5.1+	NN	O	O
/	NN	O	O
-	NN	O	O
1.0	NN	O	O
,	NN	O	O
p<0.05	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
mental	NN	O	O
calculation	NN	O	O
(	NN	O	O
3.1+	NN	O	O
/	NN	O	O
-	NN	O	O
1.0	NN	O	O
,	NN	O	O
p<0.05	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
activation	NN	O	O
tasks	NN	O	O
such	NN	O	O
as	NN	O	O
"	NN	O	O
speaking	NN	O	O
aloud	NN	O	O
"	NN	O	O
could	NN	O	O
be	NN	O	O
used	NN	O	O
for	NN	O	O
objective	NN	O	O
assessment	NN	O	O
of	NN	O	O
dyskinesia	NN	O	B-Disease
severity	NN	O	O
.	NN	O	O


-DOCSTART- (9952311)

Structural	NN	O	B-Disease
and	NN	O	I-Disease
functional	NN	O	I-Disease
impairment	NN	O	I-Disease
of	NN	O	I-Disease
mitochondria	NN	O	I-Disease
in	NN	O	O
adriamycin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B-Disease
in	NN	O	O
mice	NN	O	O
:	NN	O	O
suppression	NN	O	O
of	NN	O	O
cytochrome	NN	O	O
c	NN	O	O
oxidase	NN	O	O
II	NN	O	O
gene	NN	O	O
expression	NN	O	O
.	NN	O	O

The	NN	O	O
use	NN	O	O
of	NN	O	O
adriamycin	NN	O	B-Chemical
(	NN	O	O
ADR	NN	O	B-Chemical
)	NN	O	O
in	NN	O	O
cancer	NN	O	B-Disease
chemotherapy	NN	O	O
has	NN	O	O
been	NN	O	O
limited	NN	O	O
due	NN	O	O
to	NN	O	O
its	NN	O	O
cumulative	NN	O	O
cardiovascular	NN	O	B-Disease
toxicity	NN	O	I-Disease
.	NN	O	O

Earlier	NN	O	O
observations	NN	O	O
that	NN	O	O
ADR	NN	O	B-Chemical
interacts	NN	O	O
with	NN	O	O
mitochondrial	NN	O	O
cytochrome	NN	O	O
c	NN	O	O
oxidase	NN	O	O
(	NN	O	O
COX	NN	O	O
)	NN	O	O
and	NN	O	O
suppresses	NN	O	O
its	NN	O	O
enzyme	NN	O	O
activity	NN	O	O
led	NN	O	O
us	NN	O	O
to	NN	O	O
investigate	NN	O	O
ADR	NN	O	B-Chemical
'	NN	O	O
s	NN	O	O
action	NN	O	O
on	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
functions	NN	O	O
and	NN	O	O
heart	NN	O	O
mitochondrial	NN	O	O
morphology	NN	O	O
in	NN	O	O
Balb	NN	O	O
-	NN	O	O
c	NN	O	O
mice	NN	O	O
i.p.	NN	O	O
treated	NN	O	O
with	NN	O	O
ADR	NN	O	B-Chemical
for	NN	O	O
several	NN	O	O
weeks	NN	O	O
.	NN	O	O

At	NN	O	O
various	NN	O	O
times	NN	O	O
during	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
animals	NN	O	O
were	NN	O	O
assessed	NN	O	O
for	NN	O	O
cardiovascular	NN	O	O
functions	NN	O	O
by	NN	O	O
electrocardiography	NN	O	O
and	NN	O	O
for	NN	O	O
heart	NN	O	O
tissue	NN	O	O
damage	NN	O	O
by	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
.	NN	O	O

In	NN	O	O
parallel	NN	O	O
,	NN	O	O
total	NN	O	O
RNA	NN	O	O
was	NN	O	O
extracted	NN	O	O
from	NN	O	O
samples	NN	O	O
of	NN	O	O
dissected	NN	O	O
heart	NN	O	O
and	NN	O	O
analyzed	NN	O	O
by	NN	O	O
Northern	NN	O	O
blot	NN	O	O
hybridization	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
steady	NN	O	O
-	NN	O	O
state	NN	O	O
level	NN	O	O
of	NN	O	O
three	NN	O	O
RNA	NN	O	O
transcripts	NN	O	O
encoded	NN	O	O
by	NN	O	O
the	NN	O	O
COXII	NN	O	O
,	NN	O	O
COXIII	NN	O	O
,	NN	O	O
and	NN	O	O
COXIV	NN	O	O
genes	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
samples	NN	O	O
obtained	NN	O	O
from	NN	O	O
the	NN	O	O
liver	NN	O	O
of	NN	O	O
the	NN	O	O
same	NN	O	O
animals	NN	O	O
were	NN	O	O
analyzed	NN	O	O
for	NN	O	O
comparative	NN	O	O
studies	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
indicated	NN	O	O
that	NN	O	O
1	NN	O	O
)	NN	O	O
treatment	NN	O	O
of	NN	O	O
mice	NN	O	O
with	NN	O	O
ADR	NN	O	B-Chemical
caused	NN	O	O
cardiovascular	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
characterized	NN	O	O
by	NN	O	O
bradycardia	NN	O	B-Disease
,	NN	O	O
extension	NN	O	O
of	NN	O	O
ventricular	NN	O	O
depolarization	NN	O	O
time	NN	O	O
(	NN	O	O
tQRS	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
failure	NN	O	O
of	NN	O	O
QRS	NN	O	O
at	NN	O	O
high	NN	O	O
concentrations	NN	O	O
(	NN	O	O
10	NN	O	O
-	NN	O	O
14	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
weight	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
)	NN	O	O
;	NN	O	O
2	NN	O	O
)	NN	O	O
the	NN	O	O
heart	NN	O	O
mitochondria	NN	O	O
underwent	NN	O	O
swelling	NN	O	B-Disease
,	NN	O	O
fusion	NN	O	O
,	NN	O	O
dissolution	NN	O	O
,	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
disruption	NN	O	O
of	NN	O	O
mitochondrial	NN	O	O
cristae	NN	O	O
after	NN	O	O
several	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Such	NN	O	O
abnormalities	NN	O	O
were	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
mitochondria	NN	O	O
of	NN	O	O
liver	NN	O	O
tissue	NN	O	O
;	NN	O	O
and	NN	O	O
3	NN	O	O
)	NN	O	O
among	NN	O	O
the	NN	O	O
three	NN	O	O
genes	NN	O	O
of	NN	O	O
COX	NN	O	O
enzyme	NN	O	O
examined	NN	O	O
,	NN	O	O
only	NN	O	O
COXII	NN	O	O
gene	NN	O	O
expression	NN	O	O
was	NN	O	O
suppressed	NN	O	O
by	NN	O	O
ADR	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
mainly	NN	O	O
after	NN	O	O
8	NN	O	O
weeks	NN	O	O
in	NN	O	O
both	NN	O	O
heart	NN	O	O
and	NN	O	O
liver	NN	O	O
.	NN	O	O

Knowing	NN	O	O
that	NN	O	O
heart	NN	O	O
mitochondria	NN	O	O
represent	NN	O	O
almost	NN	O	O
40%	NN	O	O
of	NN	O	O
heart	NN	O	O
muscle	NN	O	O
by	NN	O	O
weight	NN	O	O
,	NN	O	O
we	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
deteriorating	NN	O	O
effects	NN	O	O
of	NN	O	O
ADR	NN	O	B-Chemical
on	NN	O	O
cardiovascular	NN	O	O
function	NN	O	O
involve	NN	O	O
mitochondrial	NN	O	B-Disease
structural	NN	O	I-Disease
and	NN	O	I-Disease
functional	NN	O	I-Disease
impairment	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (9915601)

Enhanced	NN	O	O
bradycardia	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
antagonists	NN	O	O
in	NN	O	O
rats	NN	O	O
pretreated	NN	O	O
with	NN	O	O
isoniazid	NN	O	B-Chemical
.	NN	O	O

High	NN	O	O
doses	NN	O	O
of	NN	O	O
isoniazid	NN	O	B-Chemical
increase	NN	O	O
hypotension	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
vasodilators	NN	O	O
and	NN	O	O
change	NN	O	O
the	NN	O	O
accompanying	NN	O	O
reflex	NN	O	O
tachycardia	NN	O	B-Disease
to	NN	O	O
bradycardia	NN	O	B-Disease
,	NN	O	O
an	NN	O	O
interaction	NN	O	O
attributed	NN	O	O
to	NN	O	O
decreased	NN	O	O
synthesis	NN	O	O
of	NN	O	O
brain	NN	O	O
gamma	NN	O	B-Chemical
-	NN	O	I-Chemical
aminobutyric	NN	O	I-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
GABA	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
possible	NN	O	O
enhancement	NN	O	O
by	NN	O	O
isoniazid	NN	O	B-Chemical
of	NN	O	O
bradycardia	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
antagonists	NN	O	O
was	NN	O	O
determined	NN	O	O
in	NN	O	O
rats	NN	O	O
anaesthetised	NN	O	O
with	NN	O	O
chloralose	NN	O	B-Chemical
-	NN	O	O
urethane	NN	O	B-Chemical
.	NN	O	O

Isoniazid	NN	O	B-Chemical
significantly	NN	O	O
increased	NN	O	O
bradycardia	NN	O	B-Disease
after	NN	O	O
propranolol	NN	O	B-Chemical
,	NN	O	O
pindolol	NN	O	B-Chemical
,	NN	O	O
labetalol	NN	O	B-Chemical
and	NN	O	O
atenolol	NN	O	B-Chemical
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
after	NN	O	O
clonidine	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
not	NN	O	O
after	NN	O	O
hexamethonium	NN	O	B-Chemical
or	NN	O	O
carbachol	NN	O	B-Chemical
.	NN	O	O

Enhancement	NN	O	O
was	NN	O	O
not	NN	O	O
observed	NN	O	O
in	NN	O	O
rats	NN	O	O
pretreated	NN	O	O
with	NN	O	O
methylatropine	NN	O	B-Chemical
or	NN	O	O
previously	NN	O	O
vagotomised	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
are	NN	O	O
compatible	NN	O	O
with	NN	O	O
interference	NN	O	O
by	NN	O	O
isoniazid	NN	O	B-Chemical
with	NN	O	O
GABAergic	NN	O	O
inhibition	NN	O	O
of	NN	O	O
cardiac	NN	O	O
parasympathetic	NN	O	O
tone	NN	O	O
.	NN	O	O

Such	NN	O	O
interference	NN	O	O
could	NN	O	O
be	NN	O	O
exerted	NN	O	O
centrally	NN	O	O
,	NN	O	O
possibly	NN	O	O
at	NN	O	O
the	NN	O	O
nucleus	NN	O	O
ambiguus	NN	O	O
,	NN	O	O
or	NN	O	O
peripherally	NN	O	O
at	NN	O	O
the	NN	O	O
sinus	NN	O	O
node	NN	O	O
.	NN	O	O


-DOCSTART- (9758264)

Epileptogenic	NN	O	O
activity	NN	O	O
of	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
after	NN	O	O
drug	NN	O	O
induces	NN	O	O
SLE	NN	O	B-Disease
(	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
and	NN	O	O
epilepsy	NN	O	B-Disease
)	NN	O	O
OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
study	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
-	NN	O	O
containing	NN	O	O
multivitamin	NN	O	O
supplementation	NN	O	O
in	NN	O	O
epileptic	NN	O	B-Disease
women	NN	O	O
before	NN	O	O
and	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
rate	NN	O	O
of	NN	O	O
structural	NN	O	O
birth	NN	O	B-Disease
defects	NN	O	I-Disease
and	NN	O	O
epilepsy	NN	O	B-Disease
-	NN	O	O
related	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

STUDY	NN	O	O
DESIGN	NN	O	O
:	NN	O	O
First	NN	O	O
a	NN	O	O
randomised	NN	O	O
trial	NN	O	O
,	NN	O	O
later	NN	O	O
periconception	NN	O	O
care	NN	O	O
including	NN	O	O
in	NN	O	O
total	NN	O	O
12225	NN	O	O
females	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Of	NN	O	O
60	NN	O	O
epileptic	NN	O	B-Disease
women	NN	O	O
with	NN	O	O
periconceptional	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
0.8	NN	O	O
mg	NN	O	O
)	NN	O	O
-	NN	O	O
containing	NN	O	O
multivitamin	NN	O	O
supplementation	NN	O	O
,	NN	O	O
no	NN	O	O
one	NN	O	O
developed	NN	O	O
epilepsy	NN	O	B-Disease
-	NN	O	O
related	NN	O	O
side	NN	O	O
effects	NN	O	O
during	NN	O	O
the	NN	O	O
periconception	NN	O	O
period	NN	O	O
.	NN	O	O

One	NN	O	O
epileptic	NN	O	B-Disease
woman	NN	O	O
delivered	NN	O	O
a	NN	O	O
newborn	NN	O	O
with	NN	O	O
cleft	NN	O	B-Disease
lip	NN	O	I-Disease
and	NN	O	I-Disease
palate	NN	O	I-Disease
.	NN	O	O

Another	NN	O	O
patient	NN	O	O
exhibited	NN	O	O
with	NN	O	O
a	NN	O	O
cluster	NN	O	O
of	NN	O	O
seizures	NN	O	B-Disease
after	NN	O	O
the	NN	O	O
periconception	NN	O	O
period	NN	O	O
using	NN	O	O
another	NN	O	O
multivitamin	NN	O	O
.	NN	O	O

This	NN	O	O
22	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
epileptic	NN	O	B-Disease
woman	NN	O	O
was	NN	O	O
treated	NN	O	O
continuously	NN	O	O
by	NN	O	O
carbamazepine	NN	O	B-Chemical
and	NN	O	O
a	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
1	NN	O	O
mg	NN	O	O
)	NN	O	O
-	NN	O	O
containing	NN	O	O
multivitamin	NN	O	O
from	NN	O	O
the	NN	O	O
20th	NN	O	O
week	NN	O	O
of	NN	O	O
gestation	NN	O	O
.	NN	O	O

She	NN	O	O
developed	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
and	NN	O	O
later	NN	O	O
symptoms	NN	O	O
of	NN	O	O
systemic	NN	O	B-Disease
lupus	NN	O	I-Disease
erythematodes	NN	O	I-Disease
.	NN	O	O

Her	NN	O	O
pregnancy	NN	O	O
ended	NN	O	O
with	NN	O	O
stillbirth	NN	O	B-Disease
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
epileptic	NN	O	B-Disease
pregnant	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
autoimmune	NN	O	B-Disease
disease	NN	O	I-Disease
(	NN	O	O
probably	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
lupus	NN	O	B-Disease
)	NN	O	O
could	NN	O	O
damage	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
,	NN	O	O
therefore	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
dose	NN	O	O
(	NN	O	O
>	NN	O	O
or	NN	O	O
=1	NN	O	O
mg	NN	O	O
)	NN	O	O
of	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
triggered	NN	O	O
a	NN	O	O
cluster	NN	O	O
of	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

Physiological	NN	O	O
dose	NN	O	O
(	NN	O	O
<1	NN	O	O
mg	NN	O	O
)	NN	O	O
of	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
both	NN	O	O
in	NN	O	O
healthy	NN	O	O
and	NN	O	O
60	NN	O	O
epileptic	NN	O	B-Disease
women	NN	O	O
,	NN	O	O
all	NN	O	O
without	NN	O	O
any	NN	O	O
autoimmune	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
did	NN	O	O
not	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
epileptic	NN	O	B-Disease
seizures	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (9669632)

Effects	NN	O	O
of	NN	O	O
cisapride	NN	O	B-Chemical
on	NN	O	O
symptoms	NN	O	O
and	NN	O	O
postcibal	NN	O	O
small	NN	O	O
-	NN	O	O
bowel	NN	O	O
motor	NN	O	O
function	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
irritable	NN	O	B-Disease
bowel	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Irritable	NN	O	B-Disease
bowel	NN	O	I-Disease
syndrome	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
common	NN	O	O
cause	NN	O	O
of	NN	O	O
abdominal	NN	O	B-Disease
pain	NN	O	I-Disease
and	NN	O	O
discomfort	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
disordered	NN	O	B-Disease
gastrointestinal	NN	O	I-Disease
motility	NN	O	I-Disease
.	NN	O	O

Our	NN	O	O
aim	NN	O	O
was	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
treatment	NN	O	O
with	NN	O	O
a	NN	O	O
prokinetic	NN	O	O
agent	NN	O	O
,	NN	O	O
cisapride	NN	O	B-Chemical
,	NN	O	O
on	NN	O	O
postprandial	NN	O	O
jejunal	NN	O	O
motility	NN	O	O
and	NN	O	O
symptoms	NN	O	O
in	NN	O	O
the	NN	O	O
irritable	NN	O	B-Disease
bowel	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
IBS	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Thirty	NN	O	O
-	NN	O	O
eight	NN	O	O
patients	NN	O	O
with	NN	O	O
IBS	NN	O	B-Disease
(	NN	O	O
constipation	NN	O	B-Disease
-	NN	O	O
predominant	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
17	NN	O	O
;	NN	O	O
diarrhoea	NN	O	B-Disease
-	NN	O	O
predominant	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
21	NN	O	O
)	NN	O	O
underwent	NN	O	O
24	NN	O	O
-	NN	O	O
h	NN	O	O
ambulatory	NN	O	O
jejunal	NN	O	O
manometry	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
12	NN	O	O
week	NN	O	O
'	NN	O	O
s	NN	O	O
treatment	NN	O	O
[	NN	O	O
cisapride	NN	O	B-Chemical
,	NN	O	O
5	NN	O	O
mg	NN	O	O
three	NN	O	O
times	NN	O	O
daily	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
19	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
19	NN	O	O
)	NN	O	O
]	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
In	NN	O	O
diarrhoea	NN	O	B-Disease
-	NN	O	O
predominant	NN	O	O
patients	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
contraction	NN	O	O
characteristics	NN	O	O
were	NN	O	O
observed	NN	O	O
between	NN	O	O
the	NN	O	O
cisapride	NN	O	B-Chemical
and	NN	O	O
placebo	NN	O	O
groups	NN	O	O
.	NN	O	O

In	NN	O	O
cisapride	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
diarrhoea	NN	O	B-Disease
-	NN	O	O
predominant	NN	O	O
patients	NN	O	O
the	NN	O	O
mean	NN	O	O
contraction	NN	O	O
amplitude	NN	O	O
was	NN	O	O
higher	NN	O	O
(	NN	O	O
29.3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3.2	NN	O	O
versus	NN	O	O
24.9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.6	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
cisapride	NN	O	B-Chemical
versus	NN	O	O
placebo	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
;	NN	O	O
pretreatment	NN	O	O
,	NN	O	O
25.7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6.0	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
mean	NN	O	O
contraction	NN	O	O
duration	NN	O	O
longer	NN	O	O
(	NN	O	O
3.4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.2	NN	O	O
versus	NN	O	O
3.0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.2	NN	O	O
sec	NN	O	O
,	NN	O	O
cisapride	NN	O	B-Chemical
versus	NN	O	O
placebo	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
;	NN	O	O
pretreatment	NN	O	O
,	NN	O	O
3.1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.5	NN	O	O
sec	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
mean	NN	O	O
contraction	NN	O	O
frequency	NN	O	O
lower	NN	O	O
(	NN	O	O
2.0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.2	NN	O	O
versus	NN	O	O
2.5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.4	NN	O	O
cont.	NN	O	O
/	NN	O	O
min	NN	O	O
,	NN	O	O
cisapride	NN	O	B-Chemical
versus	NN	O	O
placebo	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
;	NN	O	O
pretreatment	NN	O	O
,	NN	O	O
2.5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.1	NN	O	O
cont.	NN	O	O
/	NN	O	O
min	NN	O	O
]	NN	O	O
than	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
placebo	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
differences	NN	O	O
in	NN	O	O
jejunal	NN	O	O
motility	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
constipation	NN	O	B-Disease
-	NN	O	O
predominant	NN	O	O
IBS	NN	O	B-Disease
group	NN	O	O
.	NN	O	O

Symptoms	NN	O	O
were	NN	O	O
assessed	NN	O	O
by	NN	O	O
using	NN	O	O
a	NN	O	O
visual	NN	O	O
analogue	NN	O	O
scale	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
treatment	NN	O	O
.	NN	O	O

Symptom	NN	O	O
scores	NN	O	O
relating	NN	O	O
to	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
constipation	NN	O	B-Disease
were	NN	O	O
lower	NN	O	O
in	NN	O	O
cisapride	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
constipation	NN	O	B-Disease
-	NN	O	O
predominant	NN	O	O
IBS	NN	O	B-Disease
patients	NN	O	O
[	NN	O	O
score	NN	O	O
,	NN	O	O
54	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
versus	NN	O	O
67	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
14	NN	O	O
mm	NN	O	O
,	NN	O	O
cisapride	NN	O	B-Chemical
versus	NN	O	O
placebo	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
;	NN	O	O
pretreatment	NN	O	O
,	NN	O	O
62	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
19	NN	O	O
mm	NN	O	O
]	NN	O	O
.	NN	O	O

Diarrhoea	NN	O	B-Disease
-	NN	O	O
predominant	NN	O	O
IBS	NN	O	B-Disease
patients	NN	O	O
had	NN	O	O
a	NN	O	O
higher	NN	O	O
pain	NN	O	B-Disease
score	NN	O	O
after	NN	O	O
cisapride	NN	O	B-Chemical
therapy	NN	O	O
[	NN	O	O
score	NN	O	O
,	NN	O	O
55	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
15	NN	O	O
versus	NN	O	O
34	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
12	NN	O	O
mm	NN	O	O
,	NN	O	O
cisapride	NN	O	B-Chemical
versus	NN	O	O
placebo	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
;	NN	O	O
pretreatment	NN	O	O
,	NN	O	O
67	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
19	NN	O	O
mm	NN	O	O
]	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Cisapride	NN	O	B-Chemical
affects	NN	O	O
jejunal	NN	O	O
contraction	NN	O	O
characteristics	NN	O	O
and	NN	O	O
some	NN	O	O
symptoms	NN	O	O
in	NN	O	O
IBS	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (9326871)

Clarithromycin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
ventricular	NN	O	B-Disease
tachycardia	NN	O	I-Disease
.	NN	O	O

Clarithromycin	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
relatively	NN	O	O
new	NN	O	O
macrolide	NN	O	B-Chemical
antibiotic	NN	O	O
that	NN	O	O
offers	NN	O	O
twice	NN	O	O
-	NN	O	O
daily	NN	O	O
dosing	NN	O	O
.	NN	O	O

It	NN	O	O
differs	NN	O	O
from	NN	O	O
erythromycin	NN	O	B-Chemical
only	NN	O	O
in	NN	O	O
the	NN	O	O
methylation	NN	O	O
of	NN	O	O
the	NN	O	O
hydroxyl	NN	O	O
group	NN	O	O
at	NN	O	O
position	NN	O	O
6	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
side	NN	O	O
-	NN	O	O
effect	NN	O	O
profile	NN	O	O
of	NN	O	O
erythromycin	NN	O	B-Chemical
is	NN	O	O
established	NN	O	O
,	NN	O	O
including	NN	O	O
gastroenteritis	NN	O	B-Disease
and	NN	O	O
interactions	NN	O	O
with	NN	O	O
other	NN	O	O
drugs	NN	O	O
subject	NN	O	O
to	NN	O	O
hepatic	NN	O	O
mixed	NN	O	O
-	NN	O	O
function	NN	O	O
oxidase	NN	O	O
metabolism	NN	O	O
,	NN	O	O
experience	NN	O	O
with	NN	O	O
the	NN	O	O
newer	NN	O	O
macrolides	NN	O	B-Chemical
is	NN	O	O
still	NN	O	O
being	NN	O	O
recorded	NN	O	O
.	NN	O	O

Cardiotoxicity	NN	O	B-Disease
has	NN	O	O
been	NN	O	O
demonstrated	NN	O	O
after	NN	O	O
both	NN	O	O
intravenous	NN	O	O
and	NN	O	O
oral	NN	O	O
administration	NN	O	O
of	NN	O	O
erythromycin	NN	O	B-Chemical
but	NN	O	O
has	NN	O	O
never	NN	O	O
been	NN	O	O
reported	NN	O	O
with	NN	O	O
the	NN	O	O
newer	NN	O	O
macrolides	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
ventricular	NN	O	B-Disease
dysrhythmias	NN	O	I-Disease
that	NN	O	O
occurred	NN	O	O
after	NN	O	O
six	NN	O	O
therapeutic	NN	O	O
doses	NN	O	O
of	NN	O	O
clarithromycin	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
dysrhythmias	NN	O	B-Disease
resolved	NN	O	O
after	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O


-DOCSTART- (9226773)

Persistent	NN	O	O
nephrogenic	NN	O	B-Disease
diabetes	NN	O	I-Disease
insipidus	NN	O	I-Disease
following	NN	O	O
lithium	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
severe	NN	O	O
hypernatraemic	NN	O	O
dehydration	NN	O	B-Disease
following	NN	O	O
a	NN	O	O
head	NN	O	B-Disease
injury	NN	O	I-Disease
.	NN	O	O

Ten	NN	O	O
years	NN	O	O
previously	NN	O	O
he	NN	O	O
had	NN	O	O
been	NN	O	O
diagnosed	NN	O	O
to	NN	O	O
have	NN	O	O
lithium	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
nephrogenic	NN	O	B-Disease
diabetes	NN	O	I-Disease
insipidus	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
lithium	NN	O	B-Chemical
therapy	NN	O	O
had	NN	O	O
been	NN	O	O
discontinued	NN	O	O
.	NN	O	O

He	NN	O	O
remained	NN	O	O
thirsty	NN	O	O
and	NN	O	O
polyuric	NN	O	B-Disease
despite	NN	O	O
cessation	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
and	NN	O	O
investigations	NN	O	O
on	NN	O	O
admission	NN	O	O
showed	NN	O	O
him	NN	O	O
to	NN	O	O
have	NN	O	O
normal	NN	O	O
osmoregulated	NN	O	O
thirst	NN	O	O
and	NN	O	O
vasopressin	NN	O	B-Chemical
secretion	NN	O	O
,	NN	O	O
with	NN	O	O
clear	NN	O	O
evidence	NN	O	O
of	NN	O	O
nephrogenic	NN	O	B-Disease
diabetes	NN	O	I-Disease
insipidus	NN	O	I-Disease
.	NN	O	O

Lithium	NN	O	B-Chemical
induced	NN	O	O
nephrogenic	NN	O	B-Disease
diabetes	NN	O	I-Disease
insipidus	NN	O	I-Disease
is	NN	O	O
considered	NN	O	O
to	NN	O	O
be	NN	O	O
reversible	NN	O	O
on	NN	O	O
cessation	NN	O	O
of	NN	O	O
therapy	NN	O	O
but	NN	O	O
polyuria	NN	O	B-Disease
persisted	NN	O	O
in	NN	O	O
this	NN	O	O
patient	NN	O	O
for	NN	O	O
ten	NN	O	O
years	NN	O	O
after	NN	O	O
lithium	NN	O	B-Chemical
was	NN	O	O
stopped	NN	O	O
.	NN	O	O

We	NN	O	O
discuss	NN	O	O
the	NN	O	O
possible	NN	O	O
renal	NN	O	O
mechanisms	NN	O	O
and	NN	O	O
the	NN	O	O
implications	NN	O	O
for	NN	O	O
management	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
lithium	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
nephrogenic	NN	O	B-Disease
diabetes	NN	O	I-Disease
insipidus	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (8600333)

Late	NN	O	O
cardiotoxicity	NN	O	B-Disease
after	NN	O	O
treatment	NN	O	O
for	NN	O	O
a	NN	O	O
malignant	NN	O	O
bone	NN	O	B-Disease
tumor	NN	O	I-Disease
.	NN	O	O

Cardiac	NN	O	O
function	NN	O	O
was	NN	O	O
assessed	NN	O	O
in	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
survivors	NN	O	O
of	NN	O	O
malignant	NN	O	O
bone	NN	O	B-Disease
tumors	NN	O	I-Disease
who	NN	O	O
were	NN	O	O
treated	NN	O	O
according	NN	O	O
to	NN	O	O
Rosen	NN	O	B-Chemical
'	NN	O	I-Chemical
s	NN	O	I-Chemical
T5	NN	O	I-Chemical
or	NN	O	I-Chemical
T10	NN	O	I-Chemical
protocol	NN	O	I-Chemical
,	NN	O	O
both	NN	O	O
including	NN	O	O
doxorubicin	NN	O	B-Chemical
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
one	NN	O	O
patients	NN	O	O
,	NN	O	O
age	NN	O	O
10	NN	O	O
-	NN	O	O
45	NN	O	O
years	NN	O	O
(	NN	O	O
median	NN	O	O
age	NN	O	O
17.8	NN	O	O
years	NN	O	O
)	NN	O	O
were	NN	O	O
evaluated	NN	O	O
2.3	NN	O	O
-	NN	O	O
14.1	NN	O	O
years	NN	O	O
(	NN	O	O
median	NN	O	O
8.9	NN	O	O
years	NN	O	O
)	NN	O	O
following	NN	O	O
completion	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Cumulative	NN	O	O
doses	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
were	NN	O	O
225	NN	O	O
-	NN	O	O
550	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
(	NN	O	O
median	NN	O	O
dose	NN	O	O
360	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
evaluation	NN	O	O
consisted	NN	O	O
of	NN	O	O
a	NN	O	O
history	NN	O	O
,	NN	O	O
physical	NN	O	O
examination	NN	O	O
,	NN	O	O
electrocardiogram	NN	O	O
(	NN	O	O
ECG	NN	O	O
)	NN	O	O
,	NN	O	O
signal	NN	O	O
averaged	NN	O	O
ECG	NN	O	O
,	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
ambulatory	NN	O	O
ECG	NN	O	O
,	NN	O	O
echocardiography	NN	O	O
and	NN	O	O
radionuclide	NN	O	O
angiography	NN	O	O
.	NN	O	O

Eighteen	NN	O	O
of	NN	O	O
31	NN	O	O
(	NN	O	O
58%	NN	O	O
)	NN	O	O
patients	NN	O	O
showed	NN	O	O
cardiac	NN	O	B-Disease
toxicity	NN	O	I-Disease
,	NN	O	O
defined	NN	O	O
as	NN	O	O
having	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
of	NN	O	O
the	NN	O	O
following	NN	O	O
abnormalities	NN	O	O
:	NN	O	O
late	NN	O	O
potentials	NN	O	O
,	NN	O	O
complex	NN	O	O
ventricular	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
,	NN	O	O
left	NN	O	O
ventricular	NN	O	B-Disease
dilation	NN	O	I-Disease
,	NN	O	O
decreased	NN	O	O
shortening	NN	O	O
fraction	NN	O	O
,	NN	O	O
or	NN	O	O
decreased	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
cardiac	NN	O	B-Disease
abnormalities	NN	O	I-Disease
increased	NN	O	O
with	NN	O	O
length	NN	O	O
of	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
(	NN	O	O
P<	NN	O	O
or	NN	O	O
=	NN	O	O
.05	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
correlation	NN	O	O
could	NN	O	O
be	NN	O	O
demonstrated	NN	O	O
between	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
and	NN	O	O
cardiac	NN	O	O
status	NN	O	O
,	NN	O	O
except	NN	O	O
for	NN	O	O
heart	NN	O	O
rate	NN	O	O
variability	NN	O	O
.	NN	O	O

When	NN	O	O
adjusted	NN	O	O
to	NN	O	O
body	NN	O	O
surface	NN	O	O
area	NN	O	O
,	NN	O	O
the	NN	O	O
left	NN	O	O
ventricular	NN	O	O
posterior	NN	O	O
wall	NN	O	O
thickness	NN	O	O
(	NN	O	O
LVPW	NN	O	O
index	NN	O	O
)	NN	O	O
was	NN	O	O
decreased	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B-Disease
is	NN	O	O
high	NN	O	O
and	NN	O	O
increases	NN	O	O
with	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
,	NN	O	O
irrespective	NN	O	O
of	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
.	NN	O	O

Life	NN	O	O
-	NN	O	O
long	NN	O	O
cardiac	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
is	NN	O	O
warranted	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
our	NN	O	O
study	NN	O	O
suggest	NN	O	O
that	NN	O	O
heart	NN	O	O
rate	NN	O	O
variability	NN	O	O
and	NN	O	O
LVPW	NN	O	O
index	NN	O	O
could	NN	O	O
be	NN	O	O
sensitive	NN	O	O
indicators	NN	O	O
for	NN	O	O
cardiotoxicity	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (8514073)

Venous	NN	O	B-Disease
complications	NN	O	I-Disease
of	NN	O	O
midazolam	NN	O	B-Chemical
versus	NN	O	O
diazepam	NN	O	B-Chemical
.	NN	O	O

Although	NN	O	O
some	NN	O	O
studies	NN	O	O
have	NN	O	O
suggested	NN	O	O
fewer	NN	O	O
venous	NN	O	B-Disease
complications	NN	O	I-Disease
are	NN	O	O
associated	NN	O	O
with	NN	O	O
midazolam	NN	O	B-Chemical
than	NN	O	O
with	NN	O	O
diazepam	NN	O	B-Chemical
for	NN	O	O
endoscopic	NN	O	O
procedures	NN	O	O
,	NN	O	O
this	NN	O	O
variable	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
well	NN	O	O
documented	NN	O	O
.	NN	O	O

We	NN	O	O
prospectively	NN	O	O
evaluated	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
venous	NN	O	B-Disease
complications	NN	O	I-Disease
after	NN	O	O
intravenous	NN	O	O
injection	NN	O	O
of	NN	O	O
diazepam	NN	O	B-Chemical
or	NN	O	O
midazolam	NN	O	B-Chemical
in	NN	O	O
122	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
colonoscopy	NN	O	O
and	NN	O	O
esophagogastroduodenoscopy	NN	O	O
.	NN	O	O

Overall	NN	O	O
,	NN	O	O
venous	NN	O	B-Disease
complications	NN	O	I-Disease
were	NN	O	O
more	NN	O	O
frequent	NN	O	O
with	NN	O	O
diazepam	NN	O	B-Chemical
(	NN	O	O
22	NN	O	O
of	NN	O	O
62	NN	O	O
patients	NN	O	O
)	NN	O	O
than	NN	O	O
with	NN	O	O
midazolam	NN	O	B-Chemical
(	NN	O	O
4	NN	O	O
of	NN	O	O
60	NN	O	O
patients	NN	O	O
)	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
palpable	NN	O	O
venous	NN	O	O
cord	NN	O	O
was	NN	O	O
present	NN	O	O
in	NN	O	O
23%	NN	O	O
(	NN	O	O
14	NN	O	O
of	NN	O	O
62	NN	O	O
)	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
diazepam	NN	O	B-Chemical
group	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
2%	NN	O	O
(	NN	O	O
1	NN	O	O
of	NN	O	O
60	NN	O	O
patients	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
midazolam	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.002	NN	O	O
)	NN	O	O
.	NN	O	O

Pain	NN	O	B-Disease
at	NN	O	O
the	NN	O	O
injection	NN	O	O
site	NN	O	O
occurred	NN	O	O
in	NN	O	O
35%	NN	O	O
(	NN	O	O
22	NN	O	O
of	NN	O	O
62	NN	O	O
)	NN	O	O
of	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
diazepam	NN	O	B-Chemical
group	NN	O	O
compared	NN	O	O
with	NN	O	O
7%	NN	O	O
(	NN	O	O
4	NN	O	O
of	NN	O	O
60	NN	O	O
patients	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
midazolam	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

Swelling	NN	O	B-Disease
and	NN	O	O
warmth	NN	O	O
at	NN	O	O
the	NN	O	O
injection	NN	O	O
site	NN	O	O
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

Smoking	NN	O	O
,	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drug	NN	O	O
use	NN	O	O
,	NN	O	O
intravenous	NN	O	O
catheter	NN	O	O
site	NN	O	O
,	NN	O	O
dwell	NN	O	O
time	NN	O	O
of	NN	O	O
the	NN	O	O
needle	NN	O	O
,	NN	O	O
alcohol	NN	O	B-Chemical
use	NN	O	O
,	NN	O	O
and	NN	O	O
pain	NN	O	B-Disease
during	NN	O	O
the	NN	O	O
injection	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
venous	NN	O	B-Disease
complications	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (8492347)

Tetany	NN	O	B-Disease
and	NN	O	O
rhabdomyolysis	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
surreptitious	NN	O	O
furosemide	NN	O	B-Chemical
-	NN	O	O
-	NN	O	O
importance	NN	O	O
of	NN	O	O
magnesium	NN	O	B-Chemical
supplementation	NN	O	O
.	NN	O	O

Diuretics	NN	O	O
may	NN	O	O
induce	NN	O	O
hypokalemia	NN	O	B-Disease
,	NN	O	O
hypocalcemia	NN	O	B-Disease
and	NN	O	O
hypomagnesemia	NN	O	B-Disease
.	NN	O	O

While	NN	O	O
severe	NN	O	O
hypokalemia	NN	O	B-Disease
may	NN	O	O
cause	NN	O	O
muscle	NN	O	B-Disease
weakness	NN	O	I-Disease
,	NN	O	O
severe	NN	O	O
hypomagnesemia	NN	O	B-Disease
is	NN	O	O
associated	NN	O	O
with	NN	O	O
muscle	NN	O	B-Disease
spasms	NN	O	I-Disease
and	NN	O	O
tetany	NN	O	B-Disease
which	NN	O	O
cannot	NN	O	O
be	NN	O	O
corrected	NN	O	O
by	NN	O	O
potassium	NN	O	B-Chemical
and	NN	O	O
calcium	NN	O	B-Chemical
supplementation	NN	O	O
alone	NN	O	O
(	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
)	NN	O	O
.	NN	O	O

Surreptitious	NN	O	O
diuretic	NN	O	O
ingestion	NN	O	O
has	NN	O	O
been	NN	O	O
described	NN	O	O
,	NN	O	O
mainly	NN	O	O
in	NN	O	O
women	NN	O	O
who	NN	O	O
are	NN	O	O
concerned	NN	O	O
that	NN	O	O
they	NN	O	O
are	NN	O	O
obese	NN	O	B-Disease
or	NN	O	O
edematous	NN	O	B-Disease
.	NN	O	O

Symptomatic	NN	O	O
hypokalemia	NN	O	B-Disease
has	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
such	NN	O	O
patients	NN	O	O
(	NN	O	O
3	NN	O	O
-	NN	O	O
7	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
one	NN	O	O
case	NN	O	O
hypocalcemia	NN	O	B-Disease
was	NN	O	O
observed	NN	O	O
(	NN	O	O
8	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
magnesium	NN	O	B-Chemical
depletion	NN	O	O
were	NN	O	O
not	NN	O	O
noted	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O


-DOCSTART- (8410199)

Loss	NN	O	O
of	NN	O	O
glutamate	NN	O	B-Chemical
decarboxylase	NN	O	O
mRNA	NN	O	O
-	NN	O	O
containing	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
following	NN	O	O
pilocarpine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
situ	NN	O	O
hybridization	NN	O	O
methods	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
glutamic	NN	O	B-Chemical
acid	NN	O	I-Chemical
decarboxylase	NN	O	O
(	NN	O	O
GAD	NN	O	O
)	NN	O	O
mRNA	NN	O	O
-	NN	O	O
containing	NN	O	O
neurons	NN	O	O
within	NN	O	O
the	NN	O	O
hilus	NN	O	O
of	NN	O	O
the	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
are	NN	O	O
vulnerable	NN	O	O
to	NN	O	O
seizure	NN	O	B-Disease
-	NN	O	O
induced	NN	O	O
damage	NN	O	O
in	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
chronic	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
were	NN	O	O
injected	NN	O	O
intraperitoneally	NN	O	O
with	NN	O	O
pilocarpine	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
the	NN	O	O
hippocampal	NN	O	O
formation	NN	O	O
was	NN	O	O
studied	NN	O	O
histologically	NN	O	O
at	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
4	NN	O	O
,	NN	O	O
and	NN	O	O
8	NN	O	O
week	NN	O	O
intervals	NN	O	O
after	NN	O	O
pilocarpine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
situ	NN	O	O
hybridization	NN	O	O
histochemistry	NN	O	O
,	NN	O	O
using	NN	O	O
a	NN	O	O
digoxigenin	NN	O	B-Chemical
-	NN	O	O
labeled	NN	O	O
GAD	NN	O	O
cRNA	NN	O	O
probe	NN	O	O
,	NN	O	O
demonstrated	NN	O	O
a	NN	O	O
substantial	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
GAD	NN	O	O
mRNA	NN	O	O
-	NN	O	O
containing	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
hilus	NN	O	O
of	NN	O	O
the	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
in	NN	O	O
the	NN	O	O
pilocarpine	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
controls	NN	O	O
at	NN	O	O
all	NN	O	O
time	NN	O	O
intervals	NN	O	O
.	NN	O	O

Additional	NN	O	O
neuronanatomical	NN	O	O
studies	NN	O	O
,	NN	O	O
including	NN	O	O
cresyl	NN	O	B-Chemical
violet	NN	O	I-Chemical
staining	NN	O	O
,	NN	O	O
neuronal	NN	O	B-Disease
degeneration	NN	O	I-Disease
methods	NN	O	O
,	NN	O	O
and	NN	O	O
histochemical	NN	O	O
localization	NN	O	O
of	NN	O	O
glial	NN	O	O
fibrillary	NN	O	O
acidic	NN	O	O
protein	NN	O	O
,	NN	O	O
suggested	NN	O	O
that	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
GAD	NN	O	O
mRNA	NN	O	O
-	NN	O	O
containing	NN	O	O
neurons	NN	O	O
was	NN	O	O
related	NN	O	O
to	NN	O	O
neuronal	NN	O	B-Disease
loss	NN	O	I-Disease
rather	NN	O	O
than	NN	O	O
to	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
GAD	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
.	NN	O	O

The	NN	O	O
loss	NN	O	O
of	NN	O	O
GAD	NN	O	O
mRNA	NN	O	O
-	NN	O	O
containing	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
hilus	NN	O	O
contrasted	NN	O	O
with	NN	O	O
the	NN	O	O
relative	NN	O	O
preservation	NN	O	O
of	NN	O	O
labeled	NN	O	O
putative	NN	O	O
basket	NN	O	O
cells	NN	O	O
along	NN	O	O
the	NN	O	O
inner	NN	O	O
margin	NN	O	O
of	NN	O	O
the	NN	O	O
granule	NN	O	O
cell	NN	O	O
layer	NN	O	O
.	NN	O	O

Quantitative	NN	O	O
analyses	NN	O	O
of	NN	O	O
labeled	NN	O	O
neurons	NN	O	O
in	NN	O	O
three	NN	O	O
regions	NN	O	O
of	NN	O	O
the	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
in	NN	O	O
the	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
week	NN	O	O
groups	NN	O	O
showed	NN	O	O
statistically	NN	O	O
significant	NN	O	O
decreases	NN	O	O
in	NN	O	O
the	NN	O	O
mean	NN	O	O
number	NN	O	O
of	NN	O	O
GAD	NN	O	O
mRNA	NN	O	O
-	NN	O	O
containing	NN	O	O
neurons	NN	O	O
in	NN	O	O
the	NN	O	O
hilus	NN	O	O
of	NN	O	O
both	NN	O	O
groups	NN	O	O
of	NN	O	O
experimental	NN	O	O
animals	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
differences	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
molecular	NN	O	O
layer	NN	O	O
or	NN	O	O
the	NN	O	O
granule	NN	O	O
cell	NN	O	O
layer	NN	O	O
,	NN	O	O
which	NN	O	O
included	NN	O	O
labeled	NN	O	O
neurons	NN	O	O
along	NN	O	O
the	NN	O	O
lower	NN	O	O
margin	NN	O	O
of	NN	O	O
the	NN	O	O
granule	NN	O	O
cell	NN	O	O
layer	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
,	NN	O	O
in	NN	O	O
this	NN	O	O
model	NN	O	O
,	NN	O	O
a	NN	O	O
subpopulation	NN	O	O
of	NN	O	O
GAD	NN	O	O
mRNA	NN	O	O
-	NN	O	O
containing	NN	O	O
neurons	NN	O	O
within	NN	O	O
the	NN	O	O
dentate	NN	O	O
gyrus	NN	O	O
is	NN	O	O
selectively	NN	O	O
vulnerable	NN	O	O
to	NN	O	O
seizure	NN	O	B-Disease
-	NN	O	O
induced	NN	O	O
damage	NN	O	O
.	NN	O	O

Such	NN	O	O
differential	NN	O	O
vulnerability	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
another	NN	O	O
indication	NN	O	O
of	NN	O	O
the	NN	O	O
heterogeneity	NN	O	O
of	NN	O	O
GABA	NN	O	B-Chemical
neurons	NN	O	O
.	NN	O	O


-DOCSTART- (7791169)

Protective	NN	O	O
effect	NN	O	O
of	NN	O	O
misoprostol	NN	O	B-Chemical
on	NN	O	O
indomethacin	NN	O	B-Chemical
induced	NN	O	O
renal	NN	O	B-Disease
dysfunction	NN	O	I-Disease
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
possible	NN	O	O
protective	NN	O	O
effects	NN	O	O
of	NN	O	O
misoprostol	NN	O	B-Chemical
on	NN	O	O
renal	NN	O	O
function	NN	O	O
in	NN	O	O
hospitalized	NN	O	O
elderly	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
indomethacin	NN	O	B-Chemical
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Forty	NN	O	O
-	NN	O	O
five	NN	O	O
hospitalized	NN	O	O
elderly	NN	O	O
patients	NN	O	O
(	NN	O	O
>	NN	O	O
65	NN	O	O
years	NN	O	O
old	NN	O	O
)	NN	O	O
who	NN	O	O
required	NN	O	O
therapy	NN	O	O
with	NN	O	O
nonsteroidal	NN	O	O
antiinflammatory	NN	O	O
drugs	NN	O	O
(	NN	O	O
NSAID	NN	O	O
)	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
indomethacin	NN	O	B-Chemical
,	NN	O	O
150	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
(	NN	O	O
Group	NN	O	O
A	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
indomethacin	NN	O	B-Chemical
150	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
plus	NN	O	O
misoprostol	NN	O	B-Chemical
at	NN	O	O
0.6	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
(	NN	O	O
Group	NN	O	O
B	NN	O	O
)	NN	O	O
.	NN	O	O

Laboratory	NN	O	O
variables	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
[	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
,	NN	O	O
blood	NN	O	B-Chemical
urea	NN	O	I-Chemical
nitrogen	NN	O	I-Chemical
(	NN	O	O
BUN	NN	O	B-Chemical
)	NN	O	O
and	NN	O	O
electrolytes	NN	O	O
]	NN	O	O
were	NN	O	O
evaluated	NN	O	O
before	NN	O	O
initiation	NN	O	O
of	NN	O	O
therapy	NN	O	O
and	NN	O	O
every	NN	O	O
2	NN	O	O
days	NN	O	O
,	NN	O	O
until	NN	O	O
termination	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
(	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
at	NN	O	O
least	NN	O	O
6	NN	O	O
days	NN	O	O
)	NN	O	O
.	NN	O	O

Response	NN	O	O
to	NN	O	O
treatment	NN	O	O
was	NN	O	O
estimated	NN	O	O
by	NN	O	O
the	NN	O	O
visual	NN	O	O
analog	NN	O	O
scale	NN	O	O
for	NN	O	O
severity	NN	O	O
of	NN	O	O
pain	NN	O	B-Disease
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Forty	NN	O	O
-	NN	O	O
two	NN	O	O
patients	NN	O	O
completed	NN	O	O
the	NN	O	O
study	NN	O	O
,	NN	O	O
22	NN	O	O
in	NN	O	O
Group	NN	O	O
A	NN	O	O
and	NN	O	O
20	NN	O	O
in	NN	O	O
Group	NN	O	O
B	NN	O	O
.	NN	O	O

BUN	NN	O	B-Chemical
and	NN	O	O
creatinine	NN	O	B-Chemical
increased	NN	O	O
by	NN	O	O
>	NN	O	O
50%	NN	O	O
of	NN	O	O
baseline	NN	O	O
levels	NN	O	O
in	NN	O	O
54	NN	O	O
and	NN	O	O
45%	NN	O	O
of	NN	O	O
Group	NN	O	O
A	NN	O	O
patients	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
compared	NN	O	O
to	NN	O	O
only	NN	O	O
20	NN	O	O
and	NN	O	O
10%	NN	O	O
of	NN	O	O
Group	NN	O	O
B	NN	O	O
patients	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Potassium	NN	O	B-Chemical
(	NN	O	O
K	NN	O	B-Chemical
)	NN	O	O
increment	NN	O	O
of	NN	O	O
0.6	NN	O	O
mEq	NN	O	O
/	NN	O	O
l	NN	O	O
or	NN	O	O
more	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
50%	NN	O	O
of	NN	O	O
Group	NN	O	O
A	NN	O	O
,	NN	O	O
but	NN	O	O
in	NN	O	O
only	NN	O	O
15%	NN	O	O
of	NN	O	O
Group	NN	O	O
B	NN	O	O
patients	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
increments	NN	O	O
in	NN	O	O
BUN	NN	O	B-Chemical
,	NN	O	O
creatinine	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
K	NN	O	B-Chemical
were	NN	O	O
reduced	NN	O	O
by	NN	O	O
63	NN	O	O
,	NN	O	O
80	NN	O	O
,	NN	O	O
and	NN	O	O
42%	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
in	NN	O	O
Group	NN	O	O
B	NN	O	O
patients	NN	O	O
compared	NN	O	O
to	NN	O	O
Group	NN	O	O
A	NN	O	O
.	NN	O	O

Response	NN	O	O
to	NN	O	O
treatment	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
significantly	NN	O	O
between	NN	O	O
the	NN	O	O
2	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Hospitalized	NN	O	O
elderly	NN	O	O
patients	NN	O	O
are	NN	O	O
at	NN	O	O
risk	NN	O	O
for	NN	O	O
developing	NN	O	O
indomethacin	NN	O	B-Chemical
related	NN	O	O
renal	NN	O	B-Disease
dysfunction	NN	O	I-Disease
.	NN	O	O

Addition	NN	O	O
of	NN	O	O
misoprostol	NN	O	B-Chemical
can	NN	O	O
minimize	NN	O	O
this	NN	O	O
renal	NN	O	B-Disease
impairment	NN	O	I-Disease
without	NN	O	O
affecting	NN	O	O
pain	NN	O	B-Disease
control	NN	O	O
.	NN	O	O


-DOCSTART- (6728084)

Nephrotoxic	NN	O	B-Disease
effects	NN	O	O
of	NN	O	O
aminoglycoside	NN	O	B-Chemical
treatment	NN	O	O
on	NN	O	O
renal	NN	O	O
protein	NN	O	O
reabsorption	NN	O	O
and	NN	O	O
accumulation	NN	O	O
.	NN	O	O

To	NN	O	O
quantify	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
gentamicin	NN	O	B-Chemical
,	NN	O	O
kanamycin	NN	O	B-Chemical
and	NN	O	O
netilmicin	NN	O	B-Chemical
on	NN	O	O
renal	NN	O	O
protein	NN	O	O
reabsorption	NN	O	O
and	NN	O	O
accumulation	NN	O	O
,	NN	O	O
these	NN	O	O
drugs	NN	O	O
were	NN	O	O
administered	NN	O	O
to	NN	O	O
rats	NN	O	O
intraperitoneally	NN	O	O
(	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
for	NN	O	O
7	NN	O	O
,	NN	O	O
14	NN	O	O
or	NN	O	O
21	NN	O	O
days	NN	O	O
.	NN	O	O

Scanning	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
of	NN	O	O
the	NN	O	O
glomerular	NN	O	O
endothelia	NN	O	O
,	NN	O	O
urinary	NN	O	O
measurements	NN	O	O
of	NN	O	O
sodium	NN	O	B-Chemical
,	NN	O	O
potassium	NN	O	B-Chemical
,	NN	O	O
endogenous	NN	O	O
lysozyme	NN	O	O
,	NN	O	O
N	NN	O	O
-	NN	O	O
acetyl	NN	O	O
-	NN	O	O
beta	NN	O	O
-	NN	O	O
D	NN	O	O
-	NN	O	O
glucosaminidase	NN	O	O
(	NN	O	O
NAG	NN	O	O
)	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
clearance	NN	O	O
and	NN	O	O
accumulation	NN	O	O
experiments	NN	O	O
after	NN	O	O
i.v.	NN	O	O
administration	NN	O	O
of	NN	O	O
egg	NN	O	O
-	NN	O	O
white	NN	O	O
lysozyme	NN	O	O
and	NN	O	O
measurements	NN	O	O
of	NN	O	O
inulin	NN	O	O
clearance	NN	O	O
(	NN	O	O
GFR	NN	O	O
)	NN	O	O
were	NN	O	O
done	NN	O	O
in	NN	O	O
each	NN	O	O
treatment	NN	O	O
group	NN	O	O
.	NN	O	O

Gentamicin	NN	O	B-Chemical
administration	NN	O	O
decreased	NN	O	O
diameter	NN	O	O
,	NN	O	O
density	NN	O	O
and	NN	O	O
shape	NN	O	O
of	NN	O	O
endothelial	NN	O	O
fenestrae	NN	O	O
.	NN	O	O

Kanamycin	NN	O	B-Chemical
and	NN	O	O
netilmicin	NN	O	B-Chemical
appeared	NN	O	O
to	NN	O	O
have	NN	O	O
no	NN	O	O
effect	NN	O	O
at	NN	O	O
the	NN	O	O
dose	NN	O	O
used	NN	O	O
.	NN	O	O

All	NN	O	O
three	NN	O	O
aminoglycosides	NN	O	B-Chemical
decreased	NN	O	O
GFR	NN	O	O
and	NN	O	O
increased	NN	O	O
urinary	NN	O	O
excretion	NN	O	O
of	NN	O	O
sodium	NN	O	B-Chemical
and	NN	O	O
potassium	NN	O	B-Chemical
.	NN	O	O

While	NN	O	O
gentamicin	NN	O	B-Chemical
and	NN	O	O
kanamycin	NN	O	B-Chemical
decreased	NN	O	O
the	NN	O	O
percentage	NN	O	O
reabsorption	NN	O	O
and	NN	O	O
accumulation	NN	O	O
of	NN	O	O
lysozyme	NN	O	O
after	NN	O	O
i.v.	NN	O	O
administration	NN	O	O
of	NN	O	O
egg	NN	O	O
-	NN	O	O
white	NN	O	O
lysozyme	NN	O	O
netilmicin	NN	O	B-Chemical
had	NN	O	O
no	NN	O	O
effect	NN	O	O
.	NN	O	O

Daily	NN	O	O
excretion	NN	O	O
of	NN	O	O
total	NN	O	O
protein	NN	O	O
,	NN	O	O
endogenous	NN	O	O
lysozyme	NN	O	O
and	NN	O	O
NAG	NN	O	O
increased	NN	O	O
only	NN	O	O
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
kanamycin	NN	O	B-Chemical
and	NN	O	O
gentamicin	NN	O	B-Chemical
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
aminoglycosides	NN	O	B-Chemical
may	NN	O	O
act	NN	O	O
as	NN	O	O
nephrotoxicants	NN	O	O
at	NN	O	O
glomerular	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
tubular	NN	O	O
level	NN	O	O
inducing	NN	O	O
impairment	NN	O	B-Disease
of	NN	O	I-Disease
renal	NN	O	I-Disease
reabsorption	NN	O	I-Disease
and	NN	O	O
accumulation	NN	O	O
of	NN	O	O
proteins	NN	O	O
.	NN	O	O


-DOCSTART- (6111982)

Pharmacology	NN	O	O
of	NN	O	O
GYKI	NN	O	B-Chemical
-	NN	O	I-Chemical
41	NN	O	I-Chemical
099	NN	O	I-Chemical
(	NN	O	O
chlorpropanol	NN	O	B-Chemical
,	NN	O	O
Tobanum	NN	O	B-Chemical
)	NN	O	O
a	NN	O	O
new	NN	O	O
potent	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
antagonist	NN	O	O
.	NN	O	O

The	NN	O	O
compound	NN	O	O
GYKI	NN	O	B-Chemical
-	NN	O	I-Chemical
41	NN	O	I-Chemical
099	NN	O	I-Chemical
,	NN	O	O
as	NN	O	O
a	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
antagonist	NN	O	O
,	NN	O	O
is	NN	O	O
3	NN	O	O
-	NN	O	O
8	NN	O	O
times	NN	O	O
more	NN	O	O
potent	NN	O	O
than	NN	O	O
propranolol	NN	O	B-Chemical
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

Its	NN	O	O
antiarrhythmic	NN	O	O
effectiveness	NN	O	O
surpasses	NN	O	O
that	NN	O	O
of	NN	O	O
propranolol	NN	O	B-Chemical
and	NN	O	O
pindolol	NN	O	B-Chemical
inhibiting	NN	O	O
the	NN	O	O
ouabain	NN	O	B-Chemical
arrhythmia	NN	O	B-Disease
in	NN	O	O
dogs	NN	O	O
and	NN	O	O
cats	NN	O	O
.	NN	O	O

GYKI	NN	O	B-Chemical
-	NN	O	I-Chemical
41	NN	O	I-Chemical
900	NN	O	I-Chemical
has	NN	O	O
a	NN	O	O
negligible	NN	O	O
cardiodepressant	NN	O	O
activity	NN	O	O
;	NN	O	O
it	NN	O	O
is	NN	O	O
not	NN	O	O
cardioselective	NN	O	O
.	NN	O	O

The	NN	O	O
compound	NN	O	O
shows	NN	O	O
a	NN	O	O
rapid	NN	O	O
and	NN	O	O
long	NN	O	O
lasting	NN	O	O
effect	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
prolonged	NN	O	O
elimination	NN	O	O
of	NN	O	O
the	NN	O	O
radioactivity	NN	O	O
after	NN	O	O
the	NN	O	O
injection	NN	O	O
of	NN	O	O
14C	NN	O	B-Chemical
-	NN	O	I-Chemical
41	NN	O	I-Chemical
099	NN	O	I-Chemical
to	NN	O	O
rats	NN	O	O
and	NN	O	O
dogs	NN	O	O
.	NN	O	O

The	NN	O	O
half	NN	O	O
life	NN	O	O
of	NN	O	O
the	NN	O	O
unlabeled	NN	O	O
substance	NN	O	O
in	NN	O	O
humans	NN	O	O
was	NN	O	O
more	NN	O	O
than	NN	O	O
10	NN	O	O
hours	NN	O	O
.	NN	O	O


-DOCSTART- (3123611)

Chorea	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
oral	NN	O	B-Chemical
contraception	NN	O	I-Chemical
.	NN	O	O

Three	NN	O	O
patients	NN	O	O
developed	NN	O	O
chorea	NN	O	B-Disease
while	NN	O	O
receiving	NN	O	O
oral	NN	O	B-Chemical
contraceptives	NN	O	I-Chemical
.	NN	O	O

Two	NN	O	O
were	NN	O	O
young	NN	O	O
patients	NN	O	O
whose	NN	O	O
chorea	NN	O	B-Disease
developed	NN	O	O
long	NN	O	O
after	NN	O	O
treatment	NN	O	O
had	NN	O	O
been	NN	O	O
started	NN	O	O
and	NN	O	O
disappeared	NN	O	O
soon	NN	O	O
after	NN	O	O
it	NN	O	O
had	NN	O	O
been	NN	O	O
discontinued	NN	O	O
.	NN	O	O

The	NN	O	O
third	NN	O	O
patient	NN	O	O
had	NN	O	O
acute	NN	O	O
amphetamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
chorea	NN	O	B-Disease
after	NN	O	O
prolonged	NN	O	O
oral	NN	O	B-Chemical
contraception	NN	O	I-Chemical
.	NN	O	O

Prolonged	NN	O	O
administration	NN	O	O
of	NN	O	O
female	NN	O	O
sex	NN	O	O
hormones	NN	O	O
is	NN	O	O
a	NN	O	O
possible	NN	O	O
cause	NN	O	O
of	NN	O	O
chorea	NN	O	B-Disease
in	NN	O	O
women	NN	O	O
who	NN	O	O
have	NN	O	O
not	NN	O	O
previously	NN	O	O
had	NN	O	O
chorea	NN	O	B-Disease
or	NN	O	O
rheumatic	NN	O	B-Disease
fever	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (761833)

Reversal	NN	O	O
of	NN	O	O
ammonia	NN	O	B-Chemical
coma	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
by	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
:	NN	O	O
a	NN	O	O
peripheral	NN	O	O
effect	NN	O	O
.	NN	O	O

Ammonia	NN	O	B-Chemical
coma	NN	O	B-Disease
was	NN	O	O
produced	NN	O	O
in	NN	O	O
rats	NN	O	O
within	NN	O	O
10	NN	O	O
to	NN	O	O
15	NN	O	O
minutes	NN	O	O
of	NN	O	O
an	NN	O	O
intraperitonealinjection	NN	O	O
of	NN	O	O
1.7	NN	O	O
mmol	NN	O	O
NH4CL	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
coma	NN	O	B-Disease
was	NN	O	O
prevented	NN	O	O
with	NN	O	O
1.68	NN	O	O
mmol	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
given	NN	O	O
by	NN	O	O
gastric	NN	O	O
intubation	NN	O	O
15	NN	O	O
minutes	NN	O	O
before	NN	O	O
the	NN	O	O
ammonium	NN	O	B-Chemical
salt	NN	O	I-Chemical
injection	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
was	NN	O	O
correlated	NN	O	O
with	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
blood	NN	O	O
and	NN	O	O
brain	NN	O	O
ammonia	NN	O	B-Chemical
,	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
brain	NN	O	O
dopamine	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
renal	NN	O	O
excretion	NN	O	O
of	NN	O	O
ammonia	NN	O	B-Chemical
and	NN	O	O
urea	NN	O	B-Chemical
.	NN	O	O

Intraventricular	NN	O	O
infusion	NN	O	O
of	NN	O	O
dopamine	NN	O	B-Chemical
sufficient	NN	O	O
to	NN	O	O
raise	NN	O	O
the	NN	O	O
brain	NN	O	O
dopamine	NN	O	B-Chemical
to	NN	O	O
the	NN	O	O
same	NN	O	O
extent	NN	O	O
did	NN	O	O
not	NN	O	O
prevent	NN	O	O
the	NN	O	O
ammonia	NN	O	B-Chemical
coma	NN	O	B-Disease
nor	NN	O	O
affect	NN	O	O
the	NN	O	O
blood	NN	O	O
and	NN	O	O
brain	NN	O	O
ammonia	NN	O	B-Chemical
concentrations	NN	O	O
.	NN	O	O

Bilateral	NN	O	O
nephrectomy	NN	O	O
eliminated	NN	O	O
the	NN	O	O
beneficial	NN	O	O
effect	NN	O	O
of	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
on	NN	O	O
blood	NN	O	O
and	NN	O	O
brain	NN	O	O
ammonia	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
ammonia	NN	O	B-Chemical
coma	NN	O	B-Disease
was	NN	O	O
not	NN	O	O
prevented	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
the	NN	O	O
reduction	NN	O	O
in	NN	O	O
blood	NN	O	O
and	NN	O	O
brain	NN	O	O
ammonia	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
ammonia	NN	O	B-Chemical
coma	NN	O	B-Disease
after	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
,	NN	O	O
can	NN	O	O
be	NN	O	O
accounted	NN	O	O
for	NN	O	O
by	NN	O	O
the	NN	O	O
peripheral	NN	O	O
effect	NN	O	O
of	NN	O	O
dopamine	NN	O	B-Chemical
on	NN	O	O
renal	NN	O	O
function	NN	O	O
rather	NN	O	O
than	NN	O	O
its	NN	O	O
central	NN	O	O
action	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
provide	NN	O	O
a	NN	O	O
reasonable	NN	O	O
explanation	NN	O	O
for	NN	O	O
the	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
observed	NN	O	O
in	NN	O	O
some	NN	O	O
encephalopathic	NN	O	B-Disease
patients	NN	O	O
receiving	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
.	NN	O	O


-DOCSTART- (18589141)

Heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Unfractionated	NN	O	B-Chemical
heparin	NN	O	I-Chemical
sodium	NN	O	I-Chemical
(	NN	O	O
UFH	NN	O	B-Chemical
)	NN	O	O
or	NN	O	O
low	NN	O	B-Chemical
-	NN	O	I-Chemical
molecular	NN	O	I-Chemical
weight	NN	O	I-Chemical
heparin	NN	O	I-Chemical
(	NN	O	O
LMWH	NN	O	O
)	NN	O	O
is	NN	O	O
used	NN	O	O
in	NN	O	O
anticoagulant	NN	O	O
protocols	NN	O	O
at	NN	O	O
several	NN	O	O
institutions	NN	O	O
to	NN	O	O
prevent	NN	O	O
thrombosis	NN	O	B-Disease
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

Heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
(	NN	O	O
HIT	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
an	NN	O	O
adverse	NN	O	O
immune	NN	O	O
-	NN	O	O
mediated	NN	O	O
reaction	NN	O	O
to	NN	O	O
heparin	NN	O	B-Chemical
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
platelet	NN	O	O
count	NN	O	O
decreases	NN	O	O
of	NN	O	O
more	NN	O	O
than	NN	O	O
50%	NN	O	O
.	NN	O	O

The	NN	O	O
frequencies	NN	O	O
of	NN	O	O
HIT	NN	O	B-Disease
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
and	NN	O	O
platelet	NN	O	O
factor	NN	O	O
4	NN	O	O
/	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
reactive	NN	O	O
antibody	NN	O	O
(	NN	O	O
HIT	NN	O	B-Disease
antibody	NN	O	O
)	NN	O	O
positivity	NN	O	O
in	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
patients	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
are	NN	O	O
unknown	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
32	NN	O	O
men	NN	O	O
and	NN	O	O
20	NN	O	O
women	NN	O	O
underwent	NN	O	O
living	NN	O	O
donor	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

We	NN	O	O
started	NN	O	O
LMWH	NN	O	O
(	NN	O	O
25	NN	O	O
IU	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
h	NN	O	O
)	NN	O	O
on	NN	O	O
postoperative	NN	O	O
day	NN	O	O
(	NN	O	O
POD	NN	O	O
)	NN	O	O
1	NN	O	O
,	NN	O	O
switching	NN	O	O
to	NN	O	O
UFH	NN	O	B-Chemical
(	NN	O	O
5000	NN	O	O
U	NN	O	O
/	NN	O	O
d	NN	O	O
)	NN	O	O
on	NN	O	O
POD	NN	O	O
2	NN	O	O
or	NN	O	O
3	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
of	NN	O	O
UFH	NN	O	B-Chemical
was	NN	O	O
changed	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
activated	NN	O	O
clotting	NN	O	O
time	NN	O	O
level	NN	O	O
.	NN	O	O

HIT	NN	O	B-Disease
antibody	NN	O	O
levels	NN	O	O
were	NN	O	O
measured	NN	O	O
the	NN	O	O
day	NN	O	O
before	NN	O	O
surgery	NN	O	O
and	NN	O	O
on	NN	O	O
POD	NN	O	O
7	NN	O	O
and	NN	O	O
14	NN	O	O
.	NN	O	O

Platelet	NN	O	O
count	NN	O	O
was	NN	O	O
measured	NN	O	O
daily	NN	O	O
for	NN	O	O
3	NN	O	O
weeks	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
average	NN	O	O
platelet	NN	O	O
counts	NN	O	O
preoperatively	NN	O	O
,	NN	O	O
and	NN	O	O
on	NN	O	O
POD	NN	O	O
7	NN	O	O
,	NN	O	O
14	NN	O	O
,	NN	O	O
and	NN	O	O
21	NN	O	O
were	NN	O	O
65	NN	O	O
,	NN	O	O
88	NN	O	O
,	NN	O	O
149	NN	O	O
,	NN	O	O
and	NN	O	O
169	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
/	NN	O	O
L	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
developed	NN	O	O
hepatic	NN	O	O
artery	NN	O	O
thrombosis	NN	O	B-Disease
on	NN	O	O
POD	NN	O	O
11	NN	O	O
and	NN	O	O
19	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
although	NN	O	O
they	NN	O	O
were	NN	O	O
HIT	NN	O	B-Disease
antibody	NN	O	O
-	NN	O	O
negative	NN	O	O
and	NN	O	O
their	NN	O	O
platelet	NN	O	O
counts	NN	O	O
were	NN	O	O
stable	NN	O	O
.	NN	O	O

In	NN	O	O
2	NN	O	O
other	NN	O	O
patients	NN	O	O
,	NN	O	O
the	NN	O	O
platelet	NN	O	O
count	NN	O	O
decreased	NN	O	O
suddenly	NN	O	O
from	NN	O	O
107	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
/	NN	O	O
L	NN	O	O
on	NN	O	O
POD	NN	O	O
4	NN	O	O
to	NN	O	O
65	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
/	NN	O	O
L	NN	O	O
on	NN	O	O
POD	NN	O	O
6	NN	O	O
and	NN	O	O
from	NN	O	O
76	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
/	NN	O	O
L	NN	O	O
on	NN	O	O
POD	NN	O	O
7	NN	O	O
to	NN	O	O
33	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
/	NN	O	O
L	NN	O	O
on	NN	O	O
POD	NN	O	O
9	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
platelet	NN	O	B-Disease
aggregation	NN	O	I-Disease
test	NN	O	O
was	NN	O	O
negative	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
percentage	NN	O	O
of	NN	O	O
HIT	NN	O	B-Disease
antibody	NN	O	O
-	NN	O	O
positive	NN	O	O
patients	NN	O	O
was	NN	O	O
0.5%	NN	O	O
preoperatively	NN	O	O
,	NN	O	O
5.6%	NN	O	O
on	NN	O	O
POD	NN	O	O
7	NN	O	O
,	NN	O	O
and	NN	O	O
5.6%	NN	O	O
on	NN	O	O
POD	NN	O	O
14	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
subjects	NN	O	O
/	NN	O	O
patients	NN	O	O
developed	NN	O	O
UFH	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
HIT	NN	O	B-Disease
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
our	NN	O	O
series	NN	O	O
,	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
HIT	NN	O	B-Disease
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
was	NN	O	O
uncommon	NN	O	O
.	NN	O	O


-DOCSTART- (16418614)

PTU	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
vasculitis	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
girl	NN	O	O
with	NN	O	O
Turner	NN	O	B-Disease
Syndrome	NN	O	I-Disease
and	NN	O	O
Graves	NN	O	B-Disease
'	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

Palpable	NN	O	O
purpura	NN	O	B-Disease
is	NN	O	O
a	NN	O	O
concerning	NN	O	O
clinical	NN	O	O
finding	NN	O	O
in	NN	O	O
pediatric	NN	O	O
patients	NN	O	O
and	NN	O	O
can	NN	O	O
have	NN	O	O
many	NN	O	O
causes	NN	O	O
,	NN	O	O
including	NN	O	O
infectious	NN	O	O
and	NN	O	O
autoimmune	NN	O	O
processes	NN	O	O
.	NN	O	O

A	NN	O	O
rare	NN	O	O
cause	NN	O	O
,	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
vasculitis	NN	O	B-Disease
,	NN	O	O
may	NN	O	O
result	NN	O	O
from	NN	O	O
the	NN	O	O
production	NN	O	O
of	NN	O	O
antineutrophil	NN	O	O
cytoplasmic	NN	O	O
antibodies	NN	O	O
(	NN	O	O
ANCAs	NN	O	O
)	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
a	NN	O	O
medication	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
girl	NN	O	O
with	NN	O	O
Turner	NN	O	B-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
Graves	NN	O	B-Disease
'	NN	O	I-Disease
disease	NN	O	I-Disease
who	NN	O	O
presented	NN	O	O
with	NN	O	O
palpable	NN	O	O
purpuric	NN	O	B-Disease
lesions	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
propylthiouracil	NN	O	B-Chemical
(	NN	O	O
PTU	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
associated	NN	O	O
vasculitis	NN	O	B-Disease
was	NN	O	O
made	NN	O	O
by	NN	O	O
observation	NN	O	O
of	NN	O	O
consistent	NN	O	O
clinical	NN	O	O
features	NN	O	O
,	NN	O	O
the	NN	O	O
detection	NN	O	O
of	NN	O	O
elevated	NN	O	O
ANA	NN	O	O
and	NN	O	O
ANCA	NN	O	O
in	NN	O	O
the	NN	O	O
blood	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
observed	NN	O	O
clinical	NN	O	O
resolution	NN	O	O
of	NN	O	O
symptoms	NN	O	O
following	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
PTU	NN	O	B-Chemical
.	NN	O	O

Subsequent	NN	O	O
treatment	NN	O	O
of	NN	O	O
persistent	NN	O	O
hyperthyroidism	NN	O	B-Disease
with	NN	O	O
radioablation	NN	O	O
did	NN	O	O
not	NN	O	O
result	NN	O	O
in	NN	O	O
an	NN	O	O
exacerbation	NN	O	O
of	NN	O	O
the	NN	O	O
vasculitis	NN	O	B-Disease
,	NN	O	O
a	NN	O	O
complication	NN	O	O
described	NN	O	O
in	NN	O	O
prior	NN	O	O
case	NN	O	O
reports	NN	O	O
.	NN	O	O


-DOCSTART- (15893386)

Succinylcholine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
masseter	NN	O	B-Disease
muscle	NN	O	I-Disease
rigidity	NN	O	I-Disease
during	NN	O	O
bronchoscopic	NN	O	O
removal	NN	O	O
of	NN	O	O
a	NN	O	O
tracheal	NN	O	O
foreign	NN	O	O
body	NN	O	O
.	NN	O	O

Masseter	NN	O	B-Disease
muscle	NN	O	I-Disease
rigidity	NN	O	I-Disease
during	NN	O	O
general	NN	O	O
anesthesia	NN	O	O
is	NN	O	O
considered	NN	O	O
an	NN	O	O
early	NN	O	O
warning	NN	O	O
sign	NN	O	O
of	NN	O	O
a	NN	O	O
possible	NN	O	O
episode	NN	O	O
of	NN	O	O
malignant	NN	O	B-Disease
hyperthermia	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
decision	NN	O	O
whether	NN	O	O
to	NN	O	O
continue	NN	O	O
or	NN	O	O
discontinue	NN	O	O
the	NN	O	O
procedure	NN	O	O
depends	NN	O	O
on	NN	O	O
the	NN	O	O
urgency	NN	O	O
of	NN	O	O
the	NN	O	O
surgery	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
masseter	NN	O	B-Disease
muscle	NN	O	I-Disease
rigidity	NN	O	I-Disease
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
describe	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
severe	NN	O	O
masseter	NN	O	B-Disease
muscle	NN	O	I-Disease
rigidity	NN	O	I-Disease
(	NN	O	O
jaw	NN	O	B-Disease
of	NN	O	I-Disease
steel	NN	O	I-Disease
)	NN	O	O
after	NN	O	O
succinylcholine	NN	O	B-Chemical
(	NN	O	O
Sch	NN	O	B-Chemical
)	NN	O	O
administration	NN	O	O
during	NN	O	O
general	NN	O	O
anesthetic	NN	O	O
management	NN	O	O
for	NN	O	O
rigid	NN	O	O
bronchoscopic	NN	O	O
removal	NN	O	O
of	NN	O	O
a	NN	O	O
tracheal	NN	O	O
foreign	NN	O	O
body	NN	O	O
.	NN	O	O

Anesthesia	NN	O	O
was	NN	O	O
continued	NN	O	O
uneventfully	NN	O	O
with	NN	O	O
propofol	NN	O	B-Chemical
infusion	NN	O	O
while	NN	O	O
all	NN	O	O
facilities	NN	O	O
were	NN	O	O
available	NN	O	O
to	NN	O	O
detect	NN	O	O
and	NN	O	O
treat	NN	O	O
malignant	NN	O	B-Disease
hyperthermia	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (15814210)

Minor	NN	O	O
neurological	NN	O	B-Disease
dysfunction	NN	O	I-Disease
,	NN	O	O
cognitive	NN	O	O
development	NN	O	O
,	NN	O	O
and	NN	O	O
somatic	NN	O	O
development	NN	O	O
at	NN	O	O
the	NN	O	O
age	NN	O	O
of	NN	O	O
3	NN	O	O
to	NN	O	O
7	NN	O	O
years	NN	O	O
after	NN	O	O
dexamethasone	NN	O	B-Chemical
treatment	NN	O	O
in	NN	O	O
very	NN	O	O
-	NN	O	O
low	NN	O	O
birth	NN	O	O
-	NN	O	O
weight	NN	O	O
infants	NN	O	O
.	NN	O	O

The	NN	O	O
objective	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
assess	NN	O	O
minor	NN	O	O
neurological	NN	O	B-Disease
dysfunction	NN	O	I-Disease
,	NN	O	O
cognitive	NN	O	O
development	NN	O	O
,	NN	O	O
and	NN	O	O
somatic	NN	O	O
development	NN	O	O
after	NN	O	O
dexamethasone	NN	O	B-Chemical
therapy	NN	O	O
in	NN	O	O
very	NN	O	O
-	NN	O	O
low	NN	O	O
-	NN	O	O
birthweight	NN	O	O
infants	NN	O	O
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
three	NN	O	O
children	NN	O	O
after	NN	O	O
dexamethasone	NN	O	B-Chemical
treatment	NN	O	O
were	NN	O	O
matched	NN	O	O
to	NN	O	O
33	NN	O	O
children	NN	O	O
without	NN	O	O
dexamethasone	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

Data	NN	O	O
were	NN	O	O
assessed	NN	O	O
at	NN	O	O
the	NN	O	O
age	NN	O	O
of	NN	O	O
3	NN	O	O
-	NN	O	O
7	NN	O	O
years	NN	O	O
.	NN	O	O

Dexamethasone	NN	O	B-Chemical
was	NN	O	O
started	NN	O	O
between	NN	O	O
the	NN	O	O
7th	NN	O	O
and	NN	O	O
the	NN	O	O
28th	NN	O	O
day	NN	O	O
of	NN	O	O
life	NN	O	O
over	NN	O	O
7	NN	O	O
days	NN	O	O
with	NN	O	O
a	NN	O	O
total	NN	O	O
dose	NN	O	O
of	NN	O	O
2.35	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
.	NN	O	O

Exclusion	NN	O	O
criteria	NN	O	O
were	NN	O	O
asphyxia	NN	O	B-Disease
,	NN	O	O
malformations	NN	O	B-Disease
,	NN	O	O
major	NN	O	O
surgical	NN	O	O
interventions	NN	O	O
,	NN	O	O
small	NN	O	O
for	NN	O	O
gestational	NN	O	O
age	NN	O	O
,	NN	O	O
intraventricular	NN	O	O
haemorrhage	NN	O	B-Disease
grades	NN	O	O
III	NN	O	O
and	NN	O	O
IV	NN	O	O
,	NN	O	O
periventricular	NN	O	B-Disease
leukomalacia	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
severe	NN	O	O
psychomotor	NN	O	B-Disease
retardation	NN	O	I-Disease
.	NN	O	O

Each	NN	O	O
child	NN	O	O
was	NN	O	O
examined	NN	O	O
by	NN	O	O
a	NN	O	O
neuropediatrician	NN	O	O
for	NN	O	O
minor	NN	O	O
neurological	NN	O	B-Disease
dysfunctions	NN	O	I-Disease
and	NN	O	O
tested	NN	O	O
by	NN	O	O
a	NN	O	O
psychologist	NN	O	O
for	NN	O	O
cognitive	NN	O	O
development	NN	O	O
with	NN	O	O
a	NN	O	O
Kaufman	NN	O	O
Assessment	NN	O	O
Battery	NN	O	O
for	NN	O	O
Children	NN	O	O
and	NN	O	O
a	NN	O	O
Draw	NN	O	O
-	NN	O	O
a	NN	O	O
-	NN	O	O
Man	NN	O	O
Test	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
differences	NN	O	O
in	NN	O	O
demographic	NN	O	O
data	NN	O	O
,	NN	O	O
growth	NN	O	O
,	NN	O	O
and	NN	O	O
socio	NN	O	O
-	NN	O	O
economic	NN	O	O
status	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

Fine	NN	O	O
motor	NN	O	O
skills	NN	O	O
and	NN	O	O
gross	NN	O	O
motor	NN	O	O
function	NN	O	O
were	NN	O	O
significantly	NN	O	O
better	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
p<0.01	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
Draw	NN	O	O
-	NN	O	O
a	NN	O	O
-	NN	O	O
Man	NN	O	O
Test	NN	O	O
,	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
showed	NN	O	O
better	NN	O	O
results	NN	O	O
(	NN	O	O
p<0.001	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
differences	NN	O	O
in	NN	O	O
development	NN	O	O
of	NN	O	O
speech	NN	O	O
,	NN	O	O
social	NN	O	O
development	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
Kaufman	NN	O	O
Assessment	NN	O	O
Battery	NN	O	O
for	NN	O	O
Children	NN	O	O
.	NN	O	O

After	NN	O	O
dexamethasone	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
children	NN	O	O
showed	NN	O	O
a	NN	O	O
higher	NN	O	O
rate	NN	O	O
of	NN	O	O
minor	NN	O	O
neurological	NN	O	B-Disease
dysfunctions	NN	O	I-Disease
.	NN	O	O

Neurological	NN	O	O
development	NN	O	O
was	NN	O	O
affected	NN	O	O
even	NN	O	O
without	NN	O	O
neurological	NN	O	O
diagnosis	NN	O	O
.	NN	O	O

Further	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
studies	NN	O	O
will	NN	O	O
be	NN	O	O
necessary	NN	O	O
to	NN	O	O
fully	NN	O	O
evaluate	NN	O	O
the	NN	O	O
impact	NN	O	O
of	NN	O	O
dexamethasone	NN	O	B-Chemical
on	NN	O	O
neurological	NN	O	O
and	NN	O	O
cognitive	NN	O	O
development	NN	O	O
.	NN	O	O


-DOCSTART- (11912119)

Force	NN	O	O
overflow	NN	O	O
and	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
in	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
assessed	NN	O	O
force	NN	O	O
coordination	NN	O	O
of	NN	O	O
the	NN	O	O
hand	NN	O	O
in	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
and	NN	O	O
its	NN	O	O
relationship	NN	O	O
to	NN	O	O
motor	NN	O	O
complications	NN	O	O
of	NN	O	O
levodopa	NN	O	B-Chemical
therapy	NN	O	O
,	NN	O	O
particularly	NN	O	O
to	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
(	NN	O	O
LID	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

We	NN	O	O
studied	NN	O	O
two	NN	O	O
groups	NN	O	O
of	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
patients	NN	O	O
with	NN	O	O
(	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
+	NN	O	O
LID	NN	O	B-Disease
,	NN	O	O
n	NN	O	O
=	NN	O	O
23	NN	O	O
)	NN	O	O
and	NN	O	O
without	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
(	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
-	NN	O	O
LID	NN	O	B-Disease
,	NN	O	O
n	NN	O	O
=	NN	O	O
10	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
age	NN	O	O
-	NN	O	O
matched	NN	O	O
healthy	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
motor	NN	O	O
score	NN	O	O
of	NN	O	O
the	NN	O	O
Unified	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
Disease	NN	O	I-Disease
Rating	NN	O	O
Scale	NN	O	O
,	NN	O	O
a	NN	O	O
dyskinesia	NN	O	B-Disease
score	NN	O	O
and	NN	O	O
force	NN	O	O
in	NN	O	O
a	NN	O	O
grip	NN	O	O
-	NN	O	O
lift	NN	O	O
paradigm	NN	O	O
were	NN	O	O
assessed	NN	O	O
ON	NN	O	O
and	NN	O	O
OFF	NN	O	O
levodopa	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
pathological	NN	O	O
increase	NN	O	O
of	NN	O	O
forces	NN	O	O
was	NN	O	O
seen	NN	O	O
in	NN	O	O
ON	NN	O	O
-	NN	O	O
state	NN	O	O
in	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
+	NN	O	O
LID	NN	O	B-Disease
only	NN	O	O
.	NN	O	O

In	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
+	NN	O	O
LID	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
force	NN	O	O
involved	NN	O	O
in	NN	O	O
pressing	NN	O	O
down	NN	O	O
the	NN	O	O
object	NN	O	O
before	NN	O	O
lifting	NN	O	O
was	NN	O	O
significantly	NN	O	O
increased	NN	O	O
by	NN	O	O
levodopa	NN	O	B-Chemical
(	NN	O	O
by	NN	O	O
61%	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

An	NN	O	O
overshooting	NN	O	O
of	NN	O	O
peak	NN	O	O
grip	NN	O	O
force	NN	O	O
by	NN	O	O
51%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
and	NN	O	O
of	NN	O	O
static	NN	O	O
grip	NN	O	O
force	NN	O	O
by	NN	O	O
45%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
ON	NN	O	O
-	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
OFF	NN	O	O
-	NN	O	O
drug	NN	O	O
condition	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
no	NN	O	O
excessive	NN	O	O
force	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
-	NN	O	O
LID	NN	O	B-Disease
.	NN	O	O

Peak	NN	O	O
grip	NN	O	O
force	NN	O	O
in	NN	O	O
ON	NN	O	O
-	NN	O	O
state	NN	O	O
was	NN	O	O
140%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
higher	NN	O	O
in	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
+	NN	O	O
LID	NN	O	B-Disease
than	NN	O	O
in	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
-	NN	O	O
LID	NN	O	B-Disease
,	NN	O	O
while	NN	O	O
static	NN	O	O
grip	NN	O	O
force	NN	O	O
was	NN	O	O
increased	NN	O	O
by	NN	O	O
138%	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
between	NN	O	O
groups	NN	O	O
.	NN	O	O

Severity	NN	O	O
of	NN	O	O
peak	NN	O	O
-	NN	O	O
dose	NN	O	O
dyskinesias	NN	O	B-Disease
was	NN	O	O
strongly	NN	O	O
correlated	NN	O	O
with	NN	O	O
grip	NN	O	O
force	NN	O	O
in	NN	O	O
ON	NN	O	O
-	NN	O	O
state	NN	O	O
(	NN	O	O
r	NN	O	O
=	NN	O	O
0.79	NN	O	O
with	NN	O	O
peak	NN	O	O
force	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
correlation	NN	O	O
was	NN	O	O
observed	NN	O	O
between	NN	O	O
forces	NN	O	O
and	NN	O	O
the	NN	O	O
motor	NN	O	O
score	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
with	NN	O	O
the	NN	O	O
daily	NN	O	O
dose	NN	O	O
of	NN	O	O
dopaminergic	NN	O	O
medication	NN	O	O
.	NN	O	O

Force	NN	O	O
excess	NN	O	O
was	NN	O	O
only	NN	O	O
observed	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
LID	NN	O	B-Disease
and	NN	O	O
motor	NN	O	O
fluctuations	NN	O	O
.	NN	O	O

A	NN	O	O
close	NN	O	O
relationship	NN	O	O
was	NN	O	O
seen	NN	O	O
between	NN	O	O
the	NN	O	O
overshooting	NN	O	O
of	NN	O	O
forces	NN	O	O
and	NN	O	O
dyskinesias	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
ON	NN	O	O
-	NN	O	O
drug	NN	O	O
condition	NN	O	O
.	NN	O	O

We	NN	O	O
postulate	NN	O	O
that	NN	O	O
both	NN	O	O
LID	NN	O	B-Disease
and	NN	O	O
grip	NN	O	O
force	NN	O	O
excess	NN	O	O
share	NN	O	O
common	NN	O	O
pathophysiological	NN	O	O
mechanisms	NN	O	O
related	NN	O	O
to	NN	O	O
motor	NN	O	O
fluctuations	NN	O	O
.	NN	O	O


-DOCSTART- (9105126)

Postinfarction	NN	O	O
ventricular	NN	O	B-Disease
septal	NN	O	I-Disease
defect	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
steroid	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Two	NN	O	O
cases	NN	O	O
of	NN	O	O
postinfarction	NN	O	O
ventricular	NN	O	B-Disease
septal	NN	O	I-Disease
rupture	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
on	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
steroid	NN	O	B-Chemical
therapy	NN	O	O
are	NN	O	O
presented	NN	O	O
and	NN	O	O
the	NN	O	O
favourable	NN	O	O
outcome	NN	O	O
in	NN	O	O
both	NN	O	O
cases	NN	O	O
described	NN	O	O
.	NN	O	O

A	NN	O	O
possible	NN	O	O
association	NN	O	O
between	NN	O	O
steroid	NN	O	B-Chemical
therapy	NN	O	O
and	NN	O	O
subsequent	NN	O	O
postinfarction	NN	O	O
septal	NN	O	B-Disease
rupture	NN	O	I-Disease
is	NN	O	O
discussed	NN	O	O
.	NN	O	O


-DOCSTART- (8599504)

Angioedema	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
droperidol	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

Angioedema	NN	O	B-Disease
,	NN	O	O
also	NN	O	O
known	NN	O	O
as	NN	O	O
angioneurotic	NN	O	B-Disease
edema	NN	O	I-Disease
or	NN	O	O
Quincke	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
is	NN	O	O
a	NN	O	O
well	NN	O	O
-	NN	O	O
demarcated	NN	O	O
,	NN	O	O
localized	NN	O	O
edema	NN	O	B-Disease
involving	NN	O	O
the	NN	O	O
subcutaneous	NN	O	O
tissues	NN	O	O
that	NN	O	O
may	NN	O	O
cause	NN	O	O
upper	NN	O	B-Disease
-	NN	O	I-Disease
airway	NN	O	I-Disease
obstruction	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
previously	NN	O	O
healthy	NN	O	O
19	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
no	NN	O	O
known	NN	O	O
drug	NN	O	B-Disease
allergies	NN	O	I-Disease
in	NN	O	O
whom	NN	O	O
angioedema	NN	O	B-Disease
with	NN	O	O
significant	NN	O	O
tongue	NN	O	B-Disease
swelling	NN	O	I-Disease
and	NN	O	O
protrusion	NN	O	O
developed	NN	O	O
within	NN	O	O
10	NN	O	O
minutes	NN	O	O
of	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
single	NN	O	O
IV	NN	O	O
dose	NN	O	O
of	NN	O	O
droperidol	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (8546130)

Clarithromycin	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
visual	NN	O	B-Disease
hallucinations	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
chronic	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
on	NN	O	O
continuous	NN	O	O
ambulatory	NN	O	O
peritoneal	NN	O	O
dialysis	NN	O	O
.	NN	O	O

Visual	NN	O	B-Disease
hallucinations	NN	O	I-Disease
are	NN	O	O
a	NN	O	O
rare	NN	O	O
event	NN	O	O
in	NN	O	O
chronic	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
and	NN	O	O
not	NN	O	O
related	NN	O	O
to	NN	O	O
uremia	NN	O	B-Disease
per	NN	O	O
se	NN	O	O
.	NN	O	O

Unreported	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
is	NN	O	O
visual	NN	O	B-Disease
hallucinations	NN	O	I-Disease
occurring	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
the	NN	O	O
new	NN	O	O
macrolide	NN	O	B-Chemical
antibiotic	NN	O	O
,	NN	O	O
clarithromycin	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
describe	NN	O	O
such	NN	O	O
a	NN	O	O
case	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
end	NN	O	B-Disease
-	NN	O	I-Disease
stage	NN	O	I-Disease
renal	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
ESRD	NN	O	B-Disease
)	NN	O	O
maintained	NN	O	O
on	NN	O	O
continuous	NN	O	O
ambulatory	NN	O	O
peritoneal	NN	O	O
dialysis	NN	O	O
(	NN	O	O
CAPD	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
combination	NN	O	O
of	NN	O	O
a	NN	O	O
relatively	NN	O	O
high	NN	O	O
dose	NN	O	O
of	NN	O	O
clarithromycin	NN	O	B-Chemical
in	NN	O	O
face	NN	O	O
of	NN	O	O
chronic	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
functionally	NN	O	O
anephric	NN	O	O
patient	NN	O	O
,	NN	O	O
with	NN	O	O
underlying	NN	O	O
aluminum	NN	O	B-Chemical
intoxication	NN	O	O
,	NN	O	O
may	NN	O	O
have	NN	O	O
facilitated	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
this	NN	O	O
neurotoxic	NN	O	B-Disease
side	NN	O	O
effect	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
important	NN	O	O
to	NN	O	O
understand	NN	O	O
the	NN	O	O
pharmacokinetics	NN	O	O
of	NN	O	O
medications	NN	O	O
in	NN	O	O
face	NN	O	O
of	NN	O	O
chronic	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
,	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
drug	NN	O	O
interactions	NN	O	O
,	NN	O	O
and	NN	O	O
how	NN	O	O
these	NN	O	O
factors	NN	O	O
should	NN	O	O
help	NN	O	O
guide	NN	O	O
medication	NN	O	O
therapy	NN	O	O
in	NN	O	O
the	NN	O	O
ESRD	NN	O	B-Disease
patient	NN	O	O
.	NN	O	O


-DOCSTART- (7724492)

Acute	NN	O	O
renal	NN	O	B-Disease
toxicity	NN	O	I-Disease
of	NN	O	O
doxorubicin	NN	O	B-Chemical
(	NN	O	O
adriamycin	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
loaded	NN	O	O
cyanoacrylate	NN	O	B-Chemical
nanoparticles	NN	O	O
.	NN	O	O

Acute	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
loaded	NN	O	O
nanoparticle	NN	O	O
(	NN	O	O
DXNP	NN	O	O
)	NN	O	O
renal	NN	O	B-Disease
toxicity	NN	O	I-Disease
was	NN	O	O
explored	NN	O	O
in	NN	O	O
both	NN	O	O
normal	NN	O	O
rats	NN	O	O
and	NN	O	O
rats	NN	O	O
with	NN	O	O
experimental	NN	O	O
glomerulonephritis	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
normal	NN	O	O
rats	NN	O	O
,	NN	O	O
2	NN	O	O
/	NN	O	O
6	NN	O	O
rats	NN	O	O
given	NN	O	O
free	NN	O	O
doxorubicin	NN	O	B-Chemical
(	NN	O	O
DX	NN	O	B-Chemical
)	NN	O	O
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
died	NN	O	O
within	NN	O	O
one	NN	O	O
week	NN	O	O
,	NN	O	O
whereas	NN	O	O
all	NN	O	O
control	NN	O	O
animals	NN	O	O
and	NN	O	O
all	NN	O	O
rats	NN	O	O
having	NN	O	O
received	NN	O	O
free	NN	O	O
NP	NN	O	O
or	NN	O	O
DXNP	NN	O	O
survived	NN	O	O
.	NN	O	O

A	NN	O	O
3	NN	O	O
times	NN	O	O
higher	NN	O	O
proteinuria	NN	O	B-Disease
appeared	NN	O	O
in	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
DXNP	NN	O	O
than	NN	O	O
in	NN	O	O
those	NN	O	O
treated	NN	O	O
with	NN	O	O
DX	NN	O	B-Chemical
.	NN	O	O

Free	NN	O	O
NP	NN	O	O
did	NN	O	O
not	NN	O	O
provoke	NN	O	O
any	NN	O	O
proteinuria	NN	O	B-Disease
.	NN	O	O

Two	NN	O	O
hr	NN	O	O
post	NN	O	O
-	NN	O	O
injection	NN	O	O
,	NN	O	O
DXNP	NN	O	O
was	NN	O	O
2.7	NN	O	O
times	NN	O	O
more	NN	O	O
concentrated	NN	O	O
in	NN	O	O
kidneys	NN	O	O
than	NN	O	O
free	NN	O	O
DX	NN	O	B-Chemical
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.025	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
rats	NN	O	O
with	NN	O	O
immune	NN	O	O
experimental	NN	O	O
glomerulonephritis	NN	O	B-Disease
,	NN	O	O
5	NN	O	O
/	NN	O	O
6	NN	O	O
rats	NN	O	O
given	NN	O	O
DX	NN	O	B-Chemical
died	NN	O	O
within	NN	O	O
7	NN	O	O
days	NN	O	O
,	NN	O	O
in	NN	O	O
contrast	NN	O	O
to	NN	O	O
animals	NN	O	O
treated	NN	O	O
by	NN	O	O
DXNP	NN	O	O
,	NN	O	O
NP	NN	O	O
,	NN	O	O
or	NN	O	O
untreated	NN	O	O
,	NN	O	O
which	NN	O	O
all	NN	O	O
survived	NN	O	O
.	NN	O	O

Proteinuria	NN	O	B-Disease
appeared	NN	O	O
in	NN	O	O
all	NN	O	O
series	NN	O	O
,	NN	O	O
but	NN	O	O
was	NN	O	O
2	NN	O	O
-	NN	O	O
5	NN	O	O
times	NN	O	O
more	NN	O	O
intense	NN	O	O
(	NN	O	O
p	NN	O	O
>	NN	O	O
0.001	NN	O	O
)	NN	O	O
and	NN	O	O
prolonged	NN	O	O
after	NN	O	O
doxorubicin	NN	O	B-Chemical
treatment	NN	O	O
(	NN	O	O
400	NN	O	O
-	NN	O	O
700	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
,	NN	O	O
without	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
DXNP	NN	O	O
and	NN	O	O
DX	NN	O	B-Chemical
.	NN	O	O

Rats	NN	O	O
treated	NN	O	O
by	NN	O	O
unloaded	NN	O	O
NP	NN	O	O
behaved	NN	O	O
as	NN	O	O
controls	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
,	NN	O	O
in	NN	O	O
these	NN	O	O
experimental	NN	O	O
conditions	NN	O	O
,	NN	O	O
DXNP	NN	O	O
killed	NN	O	O
less	NN	O	O
animals	NN	O	O
than	NN	O	O
free	NN	O	O
DX	NN	O	B-Chemical
,	NN	O	O
despite	NN	O	O
of	NN	O	O
an	NN	O	O
enhanced	NN	O	O
renal	NN	O	B-Disease
toxicity	NN	O	I-Disease
of	NN	O	O
the	NN	O	O
former	NN	O	O
.	NN	O	O

Both	NN	O	O
effects	NN	O	O
(	NN	O	O
better	NN	O	O
survival	NN	O	O
and	NN	O	O
nephrosis	NN	O	B-Disease
)	NN	O	O
are	NN	O	O
most	NN	O	O
probably	NN	O	O
related	NN	O	O
to	NN	O	O
an	NN	O	O
enhanced	NN	O	O
capture	NN	O	O
of	NN	O	O
DXNP	NN	O	O
by	NN	O	O
cells	NN	O	O
of	NN	O	O
the	NN	O	O
mononuclear	NN	O	O
phagocyte	NN	O	O
system	NN	O	O
,	NN	O	O
including	NN	O	O
mesangial	NN	O	O
cells	NN	O	O
.	NN	O	O


-DOCSTART- (7619765)

Etoposide	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
occurrence	NN	O	O
of	NN	O	O
a	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
is	NN	O	O
reported	NN	O	O
after	NN	O	O
chemotherapy	NN	O	O
containing	NN	O	O
etoposide	NN	O	B-Chemical
,	NN	O	O
in	NN	O	O
a	NN	O	O
man	NN	O	O
with	NN	O	O
no	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
coronary	NN	O	B-Disease
heart	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

Possible	NN	O	O
causal	NN	O	O
mechanisms	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O


-DOCSTART- (7416947)

Subjective	NN	O	O
assessment	NN	O	O
of	NN	O	O
sexual	NN	O	B-Disease
dysfunction	NN	O	I-Disease
of	NN	O	O
patients	NN	O	O
on	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
administration	NN	O	O
of	NN	O	O
digoxin	NN	O	B-Chemical
.	NN	O	O

Various	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
male	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
received	NN	O	O
digoxin	NN	O	B-Chemical
on	NN	O	O
a	NN	O	O
longterm	NN	O	O
basis	NN	O	O
have	NN	O	O
increased	NN	O	O
levels	NN	O	O
of	NN	O	O
serum	NN	O	O
estrogen	NN	O	B-Chemical
and	NN	O	O
decreased	NN	O	O
levels	NN	O	O
of	NN	O	O
plasma	NN	O	O
testosterone	NN	O	B-Chemical
and	NN	O	O
luteinizing	NN	O	O
hormone	NN	O	O
(	NN	O	O
LH	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
links	NN	O	O
between	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
administration	NN	O	O
of	NN	O	O
digoxin	NN	O	B-Chemical
therapy	NN	O	O
and	NN	O	O
sexual	NN	O	O
behavior	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
digoxin	NN	O	B-Chemical
on	NN	O	O
plasma	NN	O	O
levels	NN	O	O
of	NN	O	O
estradiol	NN	O	B-Chemical
,	NN	O	O
testosterone	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
LH	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
and	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
without	NN	O	O
digoxin	NN	O	B-Chemical
)	NN	O	O
were	NN	O	O
of	NN	O	O
similar	NN	O	O
cardiac	NN	O	O
functional	NN	O	O
capacity	NN	O	O
and	NN	O	O
age	NN	O	O
(	NN	O	O
25	NN	O	O
-	NN	O	O
40	NN	O	O
years	NN	O	O
)	NN	O	O
and	NN	O	O
were	NN	O	O
randomly	NN	O	O
selected	NN	O	O
from	NN	O	O
the	NN	O	O
rheumatic	NN	O	B-Disease
heart	NN	O	I-Disease
disease	NN	O	I-Disease
patients	NN	O	O
.	NN	O	O

A	NN	O	O
subjective	NN	O	O
assessment	NN	O	O
of	NN	O	O
sexual	NN	O	O
behavior	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
and	NN	O	O
control	NN	O	O
groups	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
,	NN	O	O
using	NN	O	O
parameters	NN	O	O
such	NN	O	O
as	NN	O	O
sexual	NN	O	O
desire	NN	O	O
,	NN	O	O
sexual	NN	O	O
excitement	NN	O	O
,	NN	O	O
and	NN	O	O
frequency	NN	O	O
of	NN	O	O
sexual	NN	O	O
relations	NN	O	O
.	NN	O	O

Personal	NN	O	O
interviews	NN	O	O
and	NN	O	O
a	NN	O	O
questionnaire	NN	O	O
were	NN	O	O
also	NN	O	O
used	NN	O	O
for	NN	O	O
the	NN	O	O
evaluation	NN	O	O
of	NN	O	O
sexual	NN	O	O
behavior	NN	O	O
.	NN	O	O

The	NN	O	O
findings	NN	O	O
support	NN	O	O
the	NN	O	O
reports	NN	O	O
concerning	NN	O	O
digoxin	NN	O	B-Chemical
effect	NN	O	O
on	NN	O	O
plasma	NN	O	O
estradiol	NN	O	B-Chemical
,	NN	O	O
testosterone	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
LH	NN	O	O
.	NN	O	O

The	NN	O	O
differences	NN	O	O
in	NN	O	O
the	NN	O	O
means	NN	O	O
were	NN	O	O
significant	NN	O	O
.	NN	O	O

Tests	NN	O	O
used	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
changes	NN	O	O
in	NN	O	O
sexual	NN	O	O
behavior	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	B-Disease
in	NN	O	I-Disease
sexual	NN	O	I-Disease
desire	NN	O	I-Disease
,	NN	O	O
sexual	NN	O	O
excitement	NN	O	O
phase	NN	O	O
(	NN	O	O
erection	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
frequency	NN	O	O
of	NN	O	O
sexual	NN	O	O
relations	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
group	NN	O	O
.	NN	O	O


-DOCSTART- (7263204)

Fatal	NN	O	O
aplastic	NN	O	B-Disease
anemia	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
indomethacin	NN	O	B-Chemical
-	NN	O	O
-	NN	O	O
lymphocyte	NN	O	O
transformation	NN	O	O
tests	NN	O	O
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

Although	NN	O	O
indomethacin	NN	O	B-Chemical
has	NN	O	O
been	NN	O	O
implicated	NN	O	O
as	NN	O	O
a	NN	O	O
possible	NN	O	O
cause	NN	O	O
of	NN	O	O
aplastic	NN	O	B-Disease
anemia	NN	O	I-Disease
on	NN	O	O
the	NN	O	O
basis	NN	O	O
of	NN	O	O
a	NN	O	O
few	NN	O	O
clinical	NN	O	O
observations	NN	O	O
,	NN	O	O
its	NN	O	O
role	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
definitely	NN	O	O
established	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
fatal	NN	O	O
aplastic	NN	O	B-Disease
anemia	NN	O	I-Disease
is	NN	O	O
described	NN	O	O
in	NN	O	O
which	NN	O	O
no	NN	O	O
drugs	NN	O	O
other	NN	O	O
than	NN	O	O
allopurinol	NN	O	B-Chemical
and	NN	O	O
indomethacin	NN	O	B-Chemical
were	NN	O	O
given	NN	O	O
.	NN	O	O

Indomethacin	NN	O	B-Chemical
was	NN	O	O
first	NN	O	O
given	NN	O	O
four	NN	O	O
weeks	NN	O	O
prior	NN	O	O
to	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
symptoms	NN	O	O
.	NN	O	O

A	NN	O	O
positive	NN	O	O
lymphocyte	NN	O	O
transformation	NN	O	O
test	NN	O	O
with	NN	O	O
indomethacin	NN	O	B-Chemical
in	NN	O	O
vitro	NN	O	O
further	NN	O	O
substantiates	NN	O	O
the	NN	O	O
potential	NN	O	O
role	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
in	NN	O	O
causing	NN	O	O
aplastic	NN	O	B-Disease
anemia	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
susceptible	NN	O	O
patient	NN	O	O
.	NN	O	O

Fortunately	NN	O	O
,	NN	O	O
this	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
very	NN	O	O
rare	NN	O	O
complication	NN	O	O
.	NN	O	O


-DOCSTART- (7066357)

Plasma	NN	O	O
and	NN	O	O
urinary	NN	O	O
lipids	NN	O	O
and	NN	O	O
lipoproteins	NN	O	O
during	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
induced	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
by	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
ascertain	NN	O	O
whether	NN	O	O
the	NN	O	O
alterations	NN	O	O
of	NN	O	O
plasma	NN	O	O
lipoproteins	NN	O	O
found	NN	O	O
in	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
were	NN	O	O
due	NN	O	O
to	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
per	NN	O	O
se	NN	O	O
,	NN	O	O
or	NN	O	O
,	NN	O	O
at	NN	O	O
least	NN	O	O
in	NN	O	O
part	NN	O	O
,	NN	O	O
to	NN	O	O
the	NN	O	O
aminonucleoside	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
changes	NN	O	O
in	NN	O	O
plasma	NN	O	O
and	NN	O	O
urinary	NN	O	O
lipoproteins	NN	O	O
during	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
(	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
subsequent	NN	O	O
development	NN	O	O
of	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Since	NN	O	O
massive	NN	O	O
albuminuria	NN	O	B-Disease
occurred	NN	O	O
after	NN	O	O
6	NN	O	O
days	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
time	NN	O	O
-	NN	O	O
course	NN	O	O
study	NN	O	O
was	NN	O	O
divided	NN	O	O
into	NN	O	O
two	NN	O	O
stages	NN	O	O
:	NN	O	O
pre	NN	O	O
-	NN	O	O
nephrotic	NN	O	B-Disease
stage	NN	O	O
(	NN	O	O
day	NN	O	O
1	NN	O	O
-	NN	O	O
5	NN	O	O
)	NN	O	O
and	NN	O	O
nephrotic	NN	O	B-Disease
stage	NN	O	O
(	NN	O	O
day	NN	O	O
6	NN	O	O
-	NN	O	O
11	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
pre	NN	O	O
-	NN	O	O
nephrotic	NN	O	B-Disease
stage	NN	O	O
the	NN	O	O
plasma	NN	O	O
level	NN	O	O
of	NN	O	O
fatty	NN	O	B-Chemical
acids	NN	O	I-Chemical
,	NN	O	O
triacylglycerol	NN	O	B-Chemical
and	NN	O	O
VLDL	NN	O	O
decreased	NN	O	O
while	NN	O	O
that	NN	O	O
of	NN	O	O
phospholipid	NN	O	O
,	NN	O	O
cholesteryl	NN	O	B-Chemical
esters	NN	O	I-Chemical
and	NN	O	O
HDL	NN	O	O
remained	NN	O	O
constant	NN	O	O
.	NN	O	O

Plasma	NN	O	O
apolipoprotein	NN	O	O
A	NN	O	O
-	NN	O	O
I	NN	O	O
tended	NN	O	O
to	NN	O	O
increase	NN	O	O
(	NN	O	O
40%	NN	O	O
increase	NN	O	O
at	NN	O	O
day	NN	O	O
5	NN	O	O
)	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
beginning	NN	O	O
of	NN	O	O
nephrotic	NN	O	B-Disease
stage	NN	O	O
(	NN	O	O
day	NN	O	O
6	NN	O	O
)	NN	O	O
the	NN	O	O
concentration	NN	O	O
of	NN	O	O
plasma	NN	O	O
albumin	NN	O	O
dropped	NN	O	O
to	NN	O	O
a	NN	O	O
very	NN	O	O
low	NN	O	O
level	NN	O	O
,	NN	O	O
while	NN	O	O
that	NN	O	O
of	NN	O	O
apolipoprotein	NN	O	O
A	NN	O	O
-	NN	O	O
I	NN	O	O
increased	NN	O	O
abruptly	NN	O	O
(	NN	O	O
4	NN	O	O
-	NN	O	O
fold	NN	O	O
increase	NN	O	O
)	NN	O	O
and	NN	O	O
continued	NN	O	O
to	NN	O	O
rise	NN	O	O
,	NN	O	O
although	NN	O	O
less	NN	O	O
steeply	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
following	NN	O	O
days	NN	O	O
.	NN	O	O

The	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
of	NN	O	O
HDL	NN	O	O
followed	NN	O	O
the	NN	O	O
same	NN	O	O
pattern	NN	O	O
.	NN	O	O

Plasma	NN	O	O
VLDL	NN	O	O
and	NN	O	O
LDL	NN	O	O
increased	NN	O	O
at	NN	O	O
a	NN	O	O
later	NN	O	O
stage	NN	O	O
(	NN	O	O
day	NN	O	O
9	NN	O	O
)	NN	O	O
.	NN	O	O

Plasma	NN	O	O
apolipoprotein	NN	O	O
A	NN	O	O
-	NN	O	O
I	NN	O	O
was	NN	O	O
found	NN	O	O
not	NN	O	O
only	NN	O	O
in	NN	O	O
HDL	NN	O	O
(	NN	O	O
1.063	NN	O	O
-	NN	O	O
1.210	NN	O	O
g	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
but	NN	O	O
also	NN	O	O
in	NN	O	O
the	NN	O	O
LDL	NN	O	O
density	NN	O	O
class	NN	O	O
(	NN	O	O
1.025	NN	O	O
-	NN	O	O
1.050	NN	O	O
g	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
pre	NN	O	O
-	NN	O	O
nephrotic	NN	O	B-Disease
stage	NN	O	O
lipoproteinuria	NN	O	O
was	NN	O	O
negligible	NN	O	O
,	NN	O	O
while	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
nephrotic	NN	O	B-Disease
stage	NN	O	O
the	NN	O	O
urinary	NN	O	O
loss	NN	O	O
of	NN	O	O
plasma	NN	O	O
lipoproteins	NN	O	O
consisted	NN	O	O
mainly	NN	O	O
of	NN	O	O
HDL	NN	O	O
.	NN	O	O

These	NN	O	O
observations	NN	O	O
indicate	NN	O	O
that	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
alters	NN	O	O
plasma	NN	O	O
lipoproteins	NN	O	O
by	NN	O	O
lowering	NN	O	O
VLDL	NN	O	O
and	NN	O	O
increasing	NN	O	O
HDL	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
likely	NN	O	O
that	NN	O	O
the	NN	O	O
early	NN	O	O
and	NN	O	O
striking	NN	O	O
increase	NN	O	O
of	NN	O	O
plasma	NN	O	O
HDL	NN	O	O
found	NN	O	O
in	NN	O	O
nephrotic	NN	O	B-Disease
rats	NN	O	O
is	NN	O	O
related	NN	O	O
to	NN	O	O
a	NN	O	O
direct	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
on	NN	O	O
HDL	NN	O	O
metabolism	NN	O	O
.	NN	O	O


-DOCSTART- (7007443)

Circulating	NN	O	O
lysosomal	NN	O	O
enzymes	NN	O	O
and	NN	O	O
acute	NN	O	B-Disease
hepatic	NN	O	I-Disease
necrosis	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
activities	NN	O	O
of	NN	O	O
the	NN	O	O
lysosomal	NN	O	O
enzymes	NN	O	O
acid	NN	O	O
and	NN	O	O
neutral	NN	O	O
protease	NN	O	O
,	NN	O	O
N	NN	O	O
-	NN	O	O
acetylglucosaminidase	NN	O	O
,	NN	O	O
and	NN	O	O
acid	NN	O	O
phosphatase	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
the	NN	O	O
serum	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
fulminant	NN	O	B-Disease
hepatic	NN	O	I-Disease
failure	NN	O	I-Disease
.	NN	O	O

Acid	NN	O	O
protease	NN	O	O
(	NN	O	O
cathepsin	NN	O	O
D	NN	O	O
)	NN	O	O
activity	NN	O	O
was	NN	O	O
increased	NN	O	O
about	NN	O	O
tenfold	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
died	NN	O	O
and	NN	O	O
nearly	NN	O	O
fourfold	NN	O	O
in	NN	O	O
those	NN	O	O
who	NN	O	O
survived	NN	O	O
fulminant	NN	O	B-Disease
hepatic	NN	O	I-Disease
failure	NN	O	I-Disease
after	NN	O	O
paracetamol	NN	O	B-Chemical
overdose	NN	O	B-Disease
,	NN	O	O
whereas	NN	O	O
activities	NN	O	O
were	NN	O	O
increased	NN	O	O
equally	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
fulminant	NN	O	B-Disease
hepatic	NN	O	I-Disease
failure	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
viral	NN	O	B-Disease
hepatitis	NN	O	I-Disease
whether	NN	O	O
or	NN	O	O
not	NN	O	O
they	NN	O	O
survived	NN	O	O
.	NN	O	O

A	NN	O	O
correlation	NN	O	O
was	NN	O	O
found	NN	O	O
between	NN	O	O
serum	NN	O	O
acid	NN	O	O
protease	NN	O	O
activity	NN	O	O
and	NN	O	O
prothrombin	NN	O	O
time	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
cathepsin	NN	O	O
D	NN	O	O
activity	NN	O	O
was	NN	O	O
sustained	NN	O	O
over	NN	O	O
several	NN	O	O
days	NN	O	O
compared	NN	O	O
with	NN	O	O
aspartate	NN	O	B-Chemical
aminotransferase	NN	O	O
,	NN	O	O
which	NN	O	O
showed	NN	O	O
a	NN	O	O
sharp	NN	O	O
early	NN	O	O
peak	NN	O	O
and	NN	O	O
then	NN	O	O
a	NN	O	O
fall	NN	O	O
.	NN	O	O

Circulating	NN	O	O
lysosomal	NN	O	O
proteases	NN	O	O
can	NN	O	O
damage	NN	O	O
other	NN	O	O
organs	NN	O	O
,	NN	O	O
and	NN	O	O
measurement	NN	O	O
of	NN	O	O
their	NN	O	O
activity	NN	O	O
may	NN	O	O
therefore	NN	O	O
be	NN	O	O
of	NN	O	O
added	NN	O	O
value	NN	O	O
in	NN	O	O
assessing	NN	O	O
prognosis	NN	O	O
in	NN	O	O
this	NN	O	O
condition	NN	O	O
.	NN	O	O


-DOCSTART- (3762968)

Transketolase	NN	O	O
abnormality	NN	O	O
in	NN	O	O
tolazamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
Wernicke	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
encephalopathy	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
studied	NN	O	O
a	NN	O	O
thiamine	NN	O	B-Chemical
-	NN	O	O
dependent	NN	O	O
enzyme	NN	O	O
,	NN	O	O
transketolase	NN	O	O
,	NN	O	O
from	NN	O	O
fibroblasts	NN	O	O
of	NN	O	O
a	NN	O	O
diabetic	NN	O	B-Disease
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
Wernicke	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
encephalopathy	NN	O	I-Disease
when	NN	O	O
treated	NN	O	O
with	NN	O	O
tolazamide	NN	O	B-Chemical
,	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
delineate	NN	O	O
if	NN	O	O
this	NN	O	O
patient	NN	O	O
also	NN	O	O
had	NN	O	O
transketolase	NN	O	O
abnormality	NN	O	O
[	NN	O	O
high	NN	O	O
Km	NN	O	O
for	NN	O	O
thiamine	NN	O	B-Chemical
pyrophosphate	NN	O	I-Chemical
(	NN	O	O
TPP	NN	O	B-Chemical
)	NN	O	O
]	NN	O	O
,	NN	O	O
as	NN	O	O
previously	NN	O	O
reported	NN	O	O
in	NN	O	O
postalcoholic	NN	O	O
Wernicke	NN	O	B-Disease
-	NN	O	I-Disease
Korsakoff	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
this	NN	O	O
patient	NN	O	O
,	NN	O	O
we	NN	O	O
also	NN	O	O
studied	NN	O	O
this	NN	O	O
enzyme	NN	O	O
from	NN	O	O
three	NN	O	O
diabetic	NN	O	B-Disease
kindreds	NN	O	O
without	NN	O	O
any	NN	O	O
history	NN	O	O
of	NN	O	O
Wernicke	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
encephalopathy	NN	O	I-Disease
and	NN	O	O
from	NN	O	O
four	NN	O	O
normal	NN	O	O
controls	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
that	NN	O	O
the	NN	O	O
above	NN	O	O
-	NN	O	O
mentioned	NN	O	O
patient	NN	O	O
and	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
diabetic	NN	O	B-Disease
kindreds	NN	O	O
with	NN	O	O
no	NN	O	O
history	NN	O	O
of	NN	O	O
Wernicke	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
encephalopathy	NN	O	I-Disease
had	NN	O	O
abnormal	NN	O	O
transketolase	NN	O	O
as	NN	O	O
determined	NN	O	O
by	NN	O	O
its	NN	O	O
Km	NN	O	O
for	NN	O	O
TPP	NN	O	B-Chemical
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
a	NN	O	O
similarity	NN	O	O
between	NN	O	O
postalcoholic	NN	O	O
Wernicke	NN	O	B-Disease
-	NN	O	I-Disease
Korsakoff	NN	O	I-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
the	NN	O	O
patient	NN	O	O
with	NN	O	O
tolazamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
Wernicke	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
encephalopathy	NN	O	I-Disease
from	NN	O	O
the	NN	O	O
standpoint	NN	O	O
of	NN	O	O
transketolase	NN	O	O
abnormality	NN	O	O
.	NN	O	O


-DOCSTART- (3413271)

Mechanisms	NN	O	O
of	NN	O	O
myocardial	NN	O	B-Disease
ischemia	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
epinephrine	NN	O	B-Chemical
:	NN	O	O
comparison	NN	O	O
with	NN	O	O
exercise	NN	O	O
-	NN	O	O
induced	NN	O	O
ischemia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
role	NN	O	O
of	NN	O	O
epinephrine	NN	O	B-Chemical
in	NN	O	O
eliciting	NN	O	O
myocardial	NN	O	B-Disease
ischemia	NN	O	I-Disease
was	NN	O	O
examined	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

Objective	NN	O	O
signs	NN	O	O
of	NN	O	O
ischemia	NN	O	B-Disease
and	NN	O	O
factors	NN	O	O
increasing	NN	O	O
myocardial	NN	O	O
oxygen	NN	O	B-Chemical
consumption	NN	O	O
were	NN	O	O
compared	NN	O	O
during	NN	O	O
epinephrine	NN	O	B-Chemical
infusion	NN	O	O
and	NN	O	O
supine	NN	O	O
bicycle	NN	O	O
exercise	NN	O	O
.	NN	O	O

Both	NN	O	O
epinephrine	NN	O	B-Chemical
and	NN	O	O
exercise	NN	O	O
produced	NN	O	O
myocardial	NN	O	B-Disease
ischemia	NN	O	I-Disease
as	NN	O	O
evidenced	NN	O	O
by	NN	O	O
ST	NN	O	O
segment	NN	O	O
depression	NN	O	B-Disease
and	NN	O	O
angina	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
myocardial	NN	O	B-Disease
ischemia	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
epinephrine	NN	O	B-Chemical
were	NN	O	O
significantly	NN	O	O
different	NN	O	O
from	NN	O	O
those	NN	O	O
of	NN	O	O
exercise	NN	O	O
.	NN	O	O

Exercise	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B-Disease
ischemia	NN	O	I-Disease
was	NN	O	O
marked	NN	O	O
predominantly	NN	O	O
by	NN	O	O
increased	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
rate	NN	O	O
-	NN	O	O
pressure	NN	O	O
product	NN	O	O
with	NN	O	O
a	NN	O	O
minor	NN	O	O
contribution	NN	O	O
of	NN	O	O
end	NN	O	O
-	NN	O	O
diastolic	NN	O	O
volume	NN	O	O
,	NN	O	O
while	NN	O	O
epinephrine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
ischemia	NN	O	B-Disease
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
a	NN	O	O
marked	NN	O	O
increase	NN	O	O
in	NN	O	O
contractility	NN	O	O
and	NN	O	O
a	NN	O	O
less	NN	O	O
pronounced	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
rate	NN	O	O
-	NN	O	O
pressure	NN	O	O
product	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
ischemia	NN	O	B-Disease
produced	NN	O	O
by	NN	O	O
epinephrine	NN	O	B-Chemical
,	NN	O	O
as	NN	O	O
may	NN	O	O
occur	NN	O	O
during	NN	O	O
states	NN	O	O
of	NN	O	O
emotional	NN	O	O
distress	NN	O	O
,	NN	O	O
has	NN	O	O
a	NN	O	O
mechanism	NN	O	O
distinct	NN	O	O
from	NN	O	O
that	NN	O	O
due	NN	O	O
to	NN	O	O
physical	NN	O	O
exertion	NN	O	O
.	NN	O	O


-DOCSTART- (3088349)

Transient	NN	O	O
contralateral	NN	O	B-Disease
rotation	NN	O	I-Disease
following	NN	O	O
unilateral	NN	O	O
substantia	NN	O	B-Disease
nigra	NN	O	I-Disease
lesion	NN	O	I-Disease
reflects	NN	O	O
susceptibility	NN	O	O
of	NN	O	O
the	NN	O	O
nigrostriatal	NN	O	O
system	NN	O	O
to	NN	O	O
exhaustion	NN	O	O
by	NN	O	O
amphetamine	NN	O	B-Chemical
.	NN	O	O

Following	NN	O	O
unilateral	NN	O	O
6	NN	O	B-Chemical
-	NN	O	I-Chemical
OHDA	NN	O	I-Chemical
induced	NN	O	O
SN	NN	O	B-Disease
lesion	NN	O	I-Disease
,	NN	O	O
a	NN	O	O
transient	NN	O	O
period	NN	O	O
of	NN	O	O
contralateral	NN	O	B-Disease
rotation	NN	O	I-Disease
has	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
precede	NN	O	O
the	NN	O	O
predominant	NN	O	O
ipsilateral	NN	O	B-Disease
circling	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
clarify	NN	O	O
the	NN	O	O
nature	NN	O	O
of	NN	O	O
this	NN	O	O
initial	NN	O	O
contralateral	NN	O	B-Disease
rotation	NN	O	I-Disease
we	NN	O	O
examined	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
recovery	NN	O	O
period	NN	O	O
after	NN	O	O
the	NN	O	O
lesion	NN	O	O
,	NN	O	O
on	NN	O	O
amphetamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
rotational	NN	O	B-Disease
behavior	NN	O	I-Disease
.	NN	O	O

Three	NN	O	O
days	NN	O	O
post	NN	O	O
lesion	NN	O	O
,	NN	O	O
most	NN	O	O
rats	NN	O	O
circled	NN	O	O
predominantly	NN	O	O
contralaterally	NN	O	O
to	NN	O	O
the	NN	O	O
lesion	NN	O	O
.	NN	O	O

Such	NN	O	O
contralateral	NN	O	B-Disease
rotation	NN	O	I-Disease
may	NN	O	O
result	NN	O	O
from	NN	O	O
either	NN	O	O
degeneration	NN	O	O
-	NN	O	O
induced	NN	O	O
breakdown	NN	O	O
of	NN	O	O
the	NN	O	O
DA	NN	O	O
pool	NN	O	O
,	NN	O	O
or	NN	O	O
lesion	NN	O	O
-	NN	O	O
induced	NN	O	O
increase	NN	O	O
of	NN	O	O
DA	NN	O	O
turnover	NN	O	O
in	NN	O	O
the	NN	O	O
spared	NN	O	O
neurons	NN	O	O
.	NN	O	O

A	NN	O	O
substantial	NN	O	O
degree	NN	O	O
of	NN	O	O
contralateral	NN	O	O
preference	NN	O	O
was	NN	O	O
still	NN	O	O
evident	NN	O	O
when	NN	O	O
amphetamine	NN	O	B-Chemical
was	NN	O	O
administered	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
24	NN	O	O
days	NN	O	O
after	NN	O	O
lesioning	NN	O	O
,	NN	O	O
indicating	NN	O	O
involvement	NN	O	O
of	NN	O	O
spared	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
contralateral	NN	O	B-Disease
rotation	NN	O	I-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
regardless	NN	O	O
of	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
recovery	NN	O	O
(	NN	O	O
and	NN	O	O
irrespective	NN	O	O
of	NN	O	O
either	NN	O	O
lesion	NN	O	O
volume	NN	O	O
,	NN	O	O
amphetamine	NN	O	B-Chemical
dose	NN	O	O
,	NN	O	O
or	NN	O	O
post	NN	O	O
-	NN	O	O
lesion	NN	O	O
motor	NN	O	O
exercise	NN	O	O
)	NN	O	O
,	NN	O	O
amphetamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
rotation	NN	O	B-Disease
tended	NN	O	O
to	NN	O	O
become	NN	O	O
gradually	NN	O	O
more	NN	O	O
ipsilateral	NN	O	O
as	NN	O	O
the	NN	O	O
observation	NN	O	O
session	NN	O	O
progressed	NN	O	O
,	NN	O	O
and	NN	O	O
all	NN	O	O
rats	NN	O	O
circled	NN	O	O
ipsilaterally	NN	O	O
to	NN	O	O
the	NN	O	O
lesion	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
further	NN	O	O
amphetamine	NN	O	B-Chemical
injections	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
amphetamine	NN	O	B-Chemical
has	NN	O	O
an	NN	O	O
irreversible	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
post	NN	O	O
-	NN	O	O
lesion	NN	O	O
DA	NN	O	O
pool	NN	O	O
contributing	NN	O	O
to	NN	O	O
contralateral	NN	O	B-Disease
rotation	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (3001299)

Thyroid	NN	O	O
function	NN	O	O
and	NN	O	O
urine	NN	O	O
-	NN	O	O
concentrating	NN	O	O
ability	NN	O	O
during	NN	O	O
lithium	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

It	NN	O	O
has	NN	O	O
been	NN	O	O
suggested	NN	O	O
that	NN	O	O
adenylate	NN	O	O
cyclase	NN	O	O
inhibition	NN	O	O
may	NN	O	O
be	NN	O	O
important	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
both	NN	O	O
nephrogenic	NN	O	B-Disease
diabetes	NN	O	I-Disease
insipidus	NN	O	I-Disease
and	NN	O	O
hypothyroidism	NN	O	B-Disease
during	NN	O	O
lithium	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

We	NN	O	O
measured	NN	O	O
serum	NN	O	O
thyroxine	NN	O	B-Chemical
and	NN	O	O
urine	NN	O	O
-	NN	O	O
concentrating	NN	O	O
ability	NN	O	O
(	NN	O	O
Umax	NN	O	O
)	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
desmopressin	NN	O	O
(	NN	O	O
DDAVP	NN	O	O
)	NN	O	O
in	NN	O	O
85	NN	O	O
patients	NN	O	O
receiving	NN	O	O
lithium	NN	O	B-Chemical
.	NN	O	O

Hypothyroidism	NN	O	B-Disease
developed	NN	O	O
in	NN	O	O
eight	NN	O	O
patients	NN	O	O
while	NN	O	O
they	NN	O	O
were	NN	O	O
taking	NN	O	O
lithium	NN	O	B-Chemical
.	NN	O	O

Impaired	NN	O	O
Umax	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
both	NN	O	O
euthyroid	NN	O	O
and	NN	O	O
hypothyroid	NN	O	B-Disease
patients	NN	O	O
while	NN	O	O
some	NN	O	O
hypothyroid	NN	O	B-Disease
patients	NN	O	O
concentrated	NN	O	O
their	NN	O	O
urine	NN	O	O
well	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
the	NN	O	O
dominant	NN	O	O
mechanisms	NN	O	O
by	NN	O	O
which	NN	O	O
lithium	NN	O	B-Chemical
exerts	NN	O	O
these	NN	O	O
two	NN	O	O
effects	NN	O	O
are	NN	O	O
different	NN	O	O
.	NN	O	O


-DOCSTART- (2004015)

Sensitivity	NN	O	O
of	NN	O	O
erythroid	NN	O	O
progenitor	NN	O	O
colonies	NN	O	O
to	NN	O	O
erythropoietin	NN	O	O
in	NN	O	O
azidothymidine	NN	O	B-Chemical
treated	NN	O	O
immunodeficient	NN	O	B-Disease
mice	NN	O	O
.	NN	O	O

The	NN	O	O
anaemia	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
3	NN	O	B-Chemical
'	NN	O	I-Chemical
-	NN	O	I-Chemical
azido	NN	O	I-Chemical
-	NN	O	I-Chemical
3	NN	O	I-Chemical
'	NN	O	I-Chemical
dideoxythymidine	NN	O	I-Chemical
(	NN	O	O
AZT	NN	O	B-Chemical
)	NN	O	O
is	NN	O	O
poorly	NN	O	O
understood	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
used	NN	O	O
a	NN	O	O
murine	NN	O	O
model	NN	O	O
of	NN	O	O
AIDS	NN	O	B-Disease
,	NN	O	O
infection	NN	O	B-Disease
of	NN	O	O
female	NN	O	O
C57BL	NN	O	O
/	NN	O	O
6	NN	O	O
mice	NN	O	O
with	NN	O	O
LP	NN	O	O
-	NN	O	O
BM5	NN	O	O
murine	NN	O	O
leukaemia	NN	O	B-Disease
(	NN	O	O
MuLV	NN	O	O
)	NN	O	O
virus	NN	O	O
,	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
AZT	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
anaemia	NN	O	B-Disease
is	NN	O	O
due	NN	O	O
,	NN	O	O
in	NN	O	O
part	NN	O	O
,	NN	O	O
to	NN	O	O
decreased	NN	O	O
responsiveness	NN	O	O
of	NN	O	O
erythropoietic	NN	O	O
precursors	NN	O	O
(	NN	O	O
BFU	NN	O	O
-	NN	O	O
e	NN	O	O
)	NN	O	O
to	NN	O	O
erythropoietin	NN	O	O
(	NN	O	O
EPO	NN	O	O
)	NN	O	O
.	NN	O	O

Mice	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
stage	NN	O	O
of	NN	O	O
LP	NN	O	O
-	NN	O	O
BM5	NN	O	O
MuLV	NN	O	O
disease	NN	O	O
were	NN	O	O
given	NN	O	O
AZT	NN	O	B-Chemical
in	NN	O	O
their	NN	O	O
drinking	NN	O	O
water	NN	O	O
at	NN	O	O
1.0	NN	O	O
and	NN	O	O
2.5	NN	O	O
mg	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O

AZT	NN	O	B-Chemical
produced	NN	O	O
anaemia	NN	O	B-Disease
in	NN	O	O
both	NN	O	O
groups	NN	O	O
,	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
fashion	NN	O	O
.	NN	O	O

Despite	NN	O	O
the	NN	O	O
anaemia	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
splenic	NN	O	O
and	NN	O	O
bone	NN	O	O
marrow	NN	O	O
BFU	NN	O	O
-	NN	O	O
e	NN	O	O
in	NN	O	O
AZT	NN	O	B-Chemical
treated	NN	O	O
mice	NN	O	O
increased	NN	O	O
up	NN	O	O
to	NN	O	O
five	NN	O	O
-	NN	O	O
fold	NN	O	O
over	NN	O	O
levels	NN	O	O
observed	NN	O	O
in	NN	O	O
infected	NN	O	O
untreated	NN	O	O
animals	NN	O	O
after	NN	O	O
15	NN	O	O
d	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Colony	NN	O	O
formation	NN	O	O
by	NN	O	O
splenic	NN	O	O
and	NN	O	O
bone	NN	O	O
marrow	NN	O	O
BFUe	NN	O	O
was	NN	O	O
stimulated	NN	O	O
at	NN	O	O
lower	NN	O	O
concentrations	NN	O	O
of	NN	O	O
EPO	NN	O	O
in	NN	O	O
mice	NN	O	O
receiving	NN	O	O
AZT	NN	O	B-Chemical
for	NN	O	O
15	NN	O	O
d	NN	O	O
than	NN	O	O
for	NN	O	O
infected	NN	O	O
,	NN	O	O
untreated	NN	O	O
mice	NN	O	O
.	NN	O	O

By	NN	O	O
day	NN	O	O
30	NN	O	O
,	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
both	NN	O	O
splenic	NN	O	O
and	NN	O	O
bone	NN	O	O
marrow	NN	O	O
BFU	NN	O	O
-	NN	O	O
e	NN	O	O
of	NN	O	O
treated	NN	O	O
animals	NN	O	O
returned	NN	O	O
to	NN	O	O
that	NN	O	O
observed	NN	O	O
from	NN	O	O
cells	NN	O	O
of	NN	O	O
infected	NN	O	O
untreated	NN	O	O
animals	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
plasma	NN	O	O
levels	NN	O	O
of	NN	O	O
EPO	NN	O	O
observed	NN	O	O
in	NN	O	O
AZT	NN	O	B-Chemical
treated	NN	O	O
mice	NN	O	O
were	NN	O	O
appropriate	NN	O	O
for	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
anaemia	NN	O	B-Disease
observed	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
phenylhydrazine	NN	O	B-Chemical
(	NN	O	O
PHZ	NN	O	B-Chemical
)	NN	O	O
treated	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
numbers	NN	O	O
of	NN	O	O
BFU	NN	O	O
-	NN	O	O
e	NN	O	O
and	NN	O	O
the	NN	O	O
percentage	NN	O	O
of	NN	O	O
bone	NN	O	O
marrow	NN	O	O
erythroblasts	NN	O	O
observed	NN	O	O
were	NN	O	O
comparable	NN	O	O
in	NN	O	O
AZT	NN	O	B-Chemical
and	NN	O	O
PHZ	NN	O	B-Chemical
treated	NN	O	O
mice	NN	O	O
with	NN	O	O
similar	NN	O	O
degrees	NN	O	O
of	NN	O	O
anaemia	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
reticulocytosis	NN	O	B-Disease
was	NN	O	O
inappropriate	NN	O	O
for	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
anaemia	NN	O	B-Disease
observed	NN	O	O
in	NN	O	O
AZT	NN	O	B-Chemical
treated	NN	O	O
infected	NN	O	O
mice	NN	O	O
.	NN	O	O

AZT	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
peripheral	NN	O	O
anaemia	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
face	NN	O	O
of	NN	O	O
increased	NN	O	O
numbers	NN	O	O
of	NN	O	O
BFU	NN	O	O
-	NN	O	O
e	NN	O	O
and	NN	O	O
increased	NN	O	O
levels	NN	O	O
of	NN	O	O
plasma	NN	O	O
EPO	NN	O	O
suggest	NN	O	O
a	NN	O	O
lesion	NN	O	O
in	NN	O	O
terminal	NN	O	O
differentiation	NN	O	O
.	NN	O	O


-DOCSTART- (1732442)

Detection	NN	O	O
of	NN	O	O
abnormal	NN	O	O
cardiac	NN	O	O
adrenergic	NN	O	O
neuron	NN	O	O
activity	NN	O	O
in	NN	O	O
adriamycin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B-Disease
with	NN	O	O
iodine	NN	O	B-Chemical
-	NN	O	I-Chemical
125	NN	O	I-Chemical
-	NN	O	I-Chemical
metaiodobenzylguanidine	NN	O	I-Chemical
.	NN	O	O

Radiolabeled	NN	O	B-Chemical
metaiodobenzylguanidine	NN	O	I-Chemical
(	NN	O	O
MIBG	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
an	NN	O	O
analog	NN	O	O
of	NN	O	O
norepinephrine	NN	O	B-Chemical
(	NN	O	O
NE	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
serves	NN	O	O
as	NN	O	O
an	NN	O	O
index	NN	O	O
of	NN	O	O
adrenergic	NN	O	O
neuron	NN	O	O
integrity	NN	O	O
and	NN	O	O
function	NN	O	O
.	NN	O	O

Using	NN	O	O
a	NN	O	O
rat	NN	O	O
model	NN	O	O
of	NN	O	O
adriamycin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B-Disease
,	NN	O	O
we	NN	O	O
tested	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
abnormal	NN	O	O
cardiac	NN	O	O
adrenergic	NN	O	O
neuron	NN	O	O
activity	NN	O	O
may	NN	O	O
appear	NN	O	O
and	NN	O	O
be	NN	O	O
exacerbated	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
in	NN	O	O
adriamycin	NN	O	B-Chemical
cardiomyopathy	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
degree	NN	O	O
of	NN	O	O
vacuolar	NN	O	B-Disease
degeneration	NN	O	I-Disease
of	NN	O	I-Disease
myocardial	NN	O	I-Disease
cells	NN	O	I-Disease
was	NN	O	O
analyzed	NN	O	O
in	NN	O	O
relation	NN	O	O
to	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
adriamycin	NN	O	B-Chemical
treatment	NN	O	O
(	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
once	NN	O	O
a	NN	O	O
week	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
abnormalities	NN	O	O
or	NN	O	O
only	NN	O	O
isolated	NN	O	O
degeneration	NN	O	O
in	NN	O	O
the	NN	O	O
1	NN	O	O
-	NN	O	O
or	NN	O	O
2	NN	O	O
-	NN	O	O
wk	NN	O	O
treatment	NN	O	O
groups	NN	O	O
,	NN	O	O
isolated	NN	O	O
or	NN	O	O
scattered	NN	O	O
degeneration	NN	O	O
in	NN	O	O
half	NN	O	O
of	NN	O	O
the	NN	O	O
3	NN	O	O
-	NN	O	O
wk	NN	O	O
group	NN	O	O
,	NN	O	O
frequent	NN	O	O
scattered	NN	O	O
degeneration	NN	O	O
in	NN	O	O
the	NN	O	O
4	NN	O	O
-	NN	O	O
wk	NN	O	O
group	NN	O	O
,	NN	O	O
scattered	NN	O	O
or	NN	O	O
focal	NN	O	O
degeneration	NN	O	O
in	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
wk	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
extensive	NN	O	O
degeneration	NN	O	O
in	NN	O	O
the	NN	O	O
8	NN	O	O
-	NN	O	O
wk	NN	O	O
group	NN	O	O
.	NN	O	O

Myocardial	NN	O	O
accumulation	NN	O	O
of	NN	O	O
[	NN	O	O
125I	NN	O	O
]	NN	O	O
MIBG	NN	O	B-Chemical
4	NN	O	O
hr	NN	O	O
after	NN	O	O
intravenous	NN	O	O
injection	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
between	NN	O	O
the	NN	O	O
controls	NN	O	O
and	NN	O	O
the	NN	O	O
groups	NN	O	O
treated	NN	O	O
3	NN	O	O
wk	NN	O	O
or	NN	O	O
less	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
4	NN	O	O
-	NN	O	O
wk	NN	O	O
group	NN	O	O
had	NN	O	O
a	NN	O	O
slightly	NN	O	O
lower	NN	O	O
accumulation	NN	O	O
in	NN	O	O
the	NN	O	O
right	NN	O	O
ventricular	NN	O	O
wall	NN	O	O
(	NN	O	O
82%	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
)	NN	O	O
and	NN	O	O
significantly	NN	O	O
lower	NN	O	O
accumulation	NN	O	O
in	NN	O	O
the	NN	O	O
left	NN	O	O
ventricular	NN	O	O
wall	NN	O	O
(	NN	O	O
about	NN	O	O
66%	NN	O	O
of	NN	O	O
the	NN	O	O
control	NN	O	O
:	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
5	NN	O	O
-	NN	O	O
wk	NN	O	O
group	NN	O	O
,	NN	O	O
MIBG	NN	O	B-Chemical
accumulation	NN	O	O
in	NN	O	O
the	NN	O	O
right	NN	O	O
and	NN	O	O
left	NN	O	O
ventricular	NN	O	O
wall	NN	O	O
was	NN	O	O
35%	NN	O	O
and	NN	O	O
27%	NN	O	O
of	NN	O	O
that	NN	O	O
in	NN	O	O
controls	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
8	NN	O	O
-	NN	O	O
wk	NN	O	O
group	NN	O	O
,	NN	O	O
MIBG	NN	O	B-Chemical
accumulation	NN	O	O
in	NN	O	O
the	NN	O	O
right	NN	O	O
and	NN	O	O
left	NN	O	O
ventricular	NN	O	O
wall	NN	O	O
was	NN	O	O
18%	NN	O	O
and	NN	O	O
14%	NN	O	O
of	NN	O	O
that	NN	O	O
in	NN	O	O
controls	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
p	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
MIBG	NN	O	B-Chemical
accumulation	NN	O	O
in	NN	O	O
the	NN	O	O
myocardium	NN	O	O
decreased	NN	O	O
in	NN	O	O
an	NN	O	O
adriamycin	NN	O	B-Chemical
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

The	NN	O	O
appearance	NN	O	O
of	NN	O	O
impaired	NN	O	O
cardiac	NN	O	O
adrenergic	NN	O	O
neuron	NN	O	O
activity	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
slight	NN	O	O
myocardial	NN	O	B-Disease
impairment	NN	O	I-Disease
(	NN	O	O
scattered	NN	O	O
or	NN	O	O
focal	NN	O	O
vacuolar	NN	O	B-Disease
degeneration	NN	O	I-Disease
)	NN	O	O
indicates	NN	O	O
that	NN	O	O
MIBG	NN	O	B-Chemical
scintigraphy	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
useful	NN	O	O
method	NN	O	O
for	NN	O	O
detection	NN	O	O
of	NN	O	O
adriamycin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (1423339)

Amnestic	NN	O	B-Disease
syndrome	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
propranolol	NN	O	B-Chemical
toxicity	NN	O	B-Disease
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

An	NN	O	O
elderly	NN	O	O
woman	NN	O	O
developed	NN	O	O
an	NN	O	O
Alzheimer	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
subacute	NN	O	O
dementia	NN	O	B-Disease
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
propranolol	NN	O	B-Chemical
toxicity	NN	O	B-Disease
.	NN	O	O

Analysis	NN	O	O
of	NN	O	O
the	NN	O	O
manifestations	NN	O	O
showed	NN	O	O
that	NN	O	O
severe	NN	O	O
impairment	NN	O	O
of	NN	O	O
memory	NN	O	O
accounted	NN	O	O
for	NN	O	O
virtually	NN	O	O
all	NN	O	O
of	NN	O	O
the	NN	O	O
abnormalities	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
evidence	NN	O	O
that	NN	O	O
cerebral	NN	O	O
reactions	NN	O	O
to	NN	O	O
drug	NN	O	O
toxicity	NN	O	B-Disease
can	NN	O	O
exhibit	NN	O	O
patterns	NN	O	O
that	NN	O	O
suggest	NN	O	O
highly	NN	O	O
selective	NN	O	O
involvement	NN	O	O
of	NN	O	O
functional	NN	O	O
subdivisions	NN	O	O
of	NN	O	O
the	NN	O	O
brain	NN	O	O
.	NN	O	O


-DOCSTART- (921394)

Biphasic	NN	O	O
response	NN	O	O
of	NN	O	O
the	NN	O	O
SA	NN	O	O
node	NN	O	O
of	NN	O	O
the	NN	O	O
dog	NN	O	O
heart	NN	O	O
in	NN	O	O
vivo	NN	O	O
to	NN	O	O
selective	NN	O	O
administration	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
on	NN	O	O
the	NN	O	O
SA	NN	O	O
node	NN	O	O
of	NN	O	O
the	NN	O	O
dog	NN	O	O
heart	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
vivo	NN	O	O
using	NN	O	O
a	NN	O	O
selective	NN	O	O
perfusion	NN	O	O
technique	NN	O	O
of	NN	O	O
the	NN	O	O
SA	NN	O	O
node	NN	O	O
artery	NN	O	O
.	NN	O	O

Injections	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
in	NN	O	O
doses	NN	O	O
from	NN	O	O
100	NN	O	O
microgram	NN	O	O
to	NN	O	O
3	NN	O	O
mg	NN	O	O
into	NN	O	O
the	NN	O	O
artery	NN	O	O
produced	NN	O	O
a	NN	O	O
depression	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
SA	NN	O	O
nodal	NN	O	O
activity	NN	O	O
by	NN	O	O
a	NN	O	O
direct	NN	O	O
action	NN	O	O
.	NN	O	O

This	NN	O	O
depression	NN	O	B-Disease
was	NN	O	O
followed	NN	O	O
by	NN	O	O
the	NN	O	O
sudden	NN	O	O
appearance	NN	O	O
of	NN	O	O
a	NN	O	O
stimulatory	NN	O	O
phase	NN	O	O
.	NN	O	O

Bilateral	NN	O	O
vagotomy	NN	O	O
and	NN	O	O
sympathectomy	NN	O	O
or	NN	O	O
prior	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
ganglion	NN	O	O
blocker	NN	O	O
failed	NN	O	O
to	NN	O	O
inhibit	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
the	NN	O	O
ketamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
tachycardia	NN	O	B-Disease
,	NN	O	O
while	NN	O	O
it	NN	O	O
was	NN	O	O
completely	NN	O	O
abolished	NN	O	O
in	NN	O	O
the	NN	O	O
reserpinized	NN	O	O
dogs	NN	O	O
or	NN	O	O
by	NN	O	O
a	NN	O	O
prior	NN	O	O
injection	NN	O	O
of	NN	O	O
a	NN	O	O
beta	NN	O	O
-	NN	O	O
blocking	NN	O	O
agent	NN	O	O
into	NN	O	O
the	NN	O	O
SA	NN	O	O
node	NN	O	O
artery	NN	O	O
.	NN	O	O

This	NN	O	O
may	NN	O	O
indicate	NN	O	O
that	NN	O	O
an	NN	O	O
activation	NN	O	O
of	NN	O	O
the	NN	O	O
peripheral	NN	O	O
adrenergic	NN	O	O
mechanism	NN	O	O
plays	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
the	NN	O	O
excitatory	NN	O	O
effect	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
injected	NN	O	O
in	NN	O	O
the	NN	O	O
SA	NN	O	O
node	NN	O	O
artery	NN	O	O
.	NN	O	O


-DOCSTART- (871943)

The	NN	O	O
use	NN	O	O
of	NN	O	O
serum	NN	O	O
cholinesterase	NN	O	O
in	NN	O	O
succinylcholine	NN	O	B-Chemical
apnoea	NN	O	B-Disease
.	NN	O	O

Fifteen	NN	O	O
patients	NN	O	O
demonstrating	NN	O	O
unexpected	NN	O	O
prolonged	NN	O	O
apnoea	NN	O	B-Disease
lasting	NN	O	O
several	NN	O	O
hours	NN	O	O
after	NN	O	O
succinylcholine	NN	O	B-Chemical
have	NN	O	O
been	NN	O	O
treated	NN	O	O
by	NN	O	O
a	NN	O	O
new	NN	O	O
preparation	NN	O	O
of	NN	O	O
human	NN	O	O
serum	NN	O	O
cholinesterase	NN	O	O
.	NN	O	O

Adequate	NN	O	O
spontaneous	NN	O	O
respiration	NN	O	O
was	NN	O	O
re	NN	O	O
-	NN	O	O
established	NN	O	O
in	NN	O	O
an	NN	O	O
average	NN	O	O
period	NN	O	O
of	NN	O	O
ten	NN	O	O
minutes	NN	O	O
after	NN	O	O
the	NN	O	O
injection	NN	O	O
.	NN	O	O

In	NN	O	O
12	NN	O	O
patients	NN	O	O
biochemical	NN	O	O
genetic	NN	O	O
examinations	NN	O	O
confirmed	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
an	NN	O	O
atypical	NN	O	O
serum	NN	O	O
cholinesterase	NN	O	O
.	NN	O	O

In	NN	O	O
three	NN	O	O
patients	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
usual	NN	O	O
variants	NN	O	O
were	NN	O	O
found	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
therefore	NN	O	O
supposed	NN	O	O
that	NN	O	O
other	NN	O	O
unknown	NN	O	O
variants	NN	O	O
of	NN	O	O
serum	NN	O	O
cholinesterase	NN	O	O
exist	NN	O	O
which	NN	O	O
cannot	NN	O	O
hydrolyze	NN	O	O
succinylcholine	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
use	NN	O	O
of	NN	O	O
serum	NN	O	O
cholinesterase	NN	O	O
in	NN	O	O
succinylcholine	NN	O	B-Chemical
apnoea	NN	O	B-Disease
provided	NN	O	O
considerable	NN	O	O
relief	NN	O	O
to	NN	O	O
both	NN	O	O
patient	NN	O	O
and	NN	O	O
anaesthetist	NN	O	O
.	NN	O	O


-DOCSTART- (1355091)

Orthostatic	NN	O	B-Disease
hypotension	NN	O	I-Disease
occurs	NN	O	O
following	NN	O	O
alpha	NN	O	O
2	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
blockade	NN	O	O
in	NN	O	O
chronic	NN	O	O
prazosin	NN	O	B-Chemical
-	NN	O	O
pretreated	NN	O	O
conscious	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B-Disease
rats	NN	O	O
.	NN	O	O

1	NN	O	O
.	NN	O	O

Studies	NN	O	O
were	NN	O	O
performed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
whether	NN	O	O
chronic	NN	O	O
prazosin	NN	O	B-Chemical
treatment	NN	O	O
alters	NN	O	O
the	NN	O	O
alpha	NN	O	O
2	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
function	NN	O	O
for	NN	O	O
orthostatic	NN	O	O
control	NN	O	O
of	NN	O	O
arterial	NN	O	O
blood	NN	O	O
pressure	NN	O	O
in	NN	O	O
conscious	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B-Disease
rats	NN	O	O
(	NN	O	O
SHR	NN	O	O
)	NN	O	O
.	NN	O	O

2	NN	O	O
.	NN	O	O

Conscious	NN	O	O
SHR	NN	O	O
(	NN	O	O
male	NN	O	O
300	NN	O	O
-	NN	O	O
350	NN	O	O
g	NN	O	O
)	NN	O	O
were	NN	O	O
subjected	NN	O	O
to	NN	O	O
90	NN	O	O
degrees	NN	O	O
head	NN	O	O
-	NN	O	O
up	NN	O	O
tilts	NN	O	O
for	NN	O	O
60	NN	O	O
s	NN	O	O
following	NN	O	O
acute	NN	O	O
administration	NN	O	O
of	NN	O	O
prazosin	NN	O	B-Chemical
(	NN	O	O
0.1	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i.p.	NN	O	O
)	NN	O	O
or	NN	O	O
rauwolscine	NN	O	B-Chemical
(	NN	O	O
3	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i.v.	NN	O	O
)	NN	O	O
.	NN	O	O

Orthostatic	NN	O	B-Disease
hypotension	NN	O	I-Disease
was	NN	O	O
determined	NN	O	O
by	NN	O	O
the	NN	O	O
average	NN	O	O
decrease	NN	O	O
(	NN	O	O
%	NN	O	O
)	NN	O	O
in	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
(	NN	O	O
MAP	NN	O	O
femoral	NN	O	O
)	NN	O	O
over	NN	O	O
the	NN	O	O
60	NN	O	O
-	NN	O	O
s	NN	O	O
tilt	NN	O	O
period	NN	O	O
.	NN	O	O

The	NN	O	O
basal	NN	O	O
MAP	NN	O	O
of	NN	O	O
conscious	NN	O	O
SHR	NN	O	O
was	NN	O	O
reduced	NN	O	O
to	NN	O	O
a	NN	O	O
similar	NN	O	O
extent	NN	O	O
by	NN	O	O
prazosin	NN	O	B-Chemical
(	NN	O	O
-	NN	O	O
23%	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
26%	NN	O	O
MAP	NN	O	O
)	NN	O	O
and	NN	O	O
rauwolscine	NN	O	B-Chemical
(	NN	O	O
-	NN	O	O
16%	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
33%	NN	O	O
MAP	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
head	NN	O	O
-	NN	O	O
up	NN	O	O
tilt	NN	O	O
induced	NN	O	O
orthostatic	NN	O	B-Disease
hypotension	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
SHR	NN	O	O
treated	NN	O	O
with	NN	O	O
prazosin	NN	O	B-Chemical
(	NN	O	O
-	NN	O	O
16%	NN	O	O
MAP	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
SHR	NN	O	O
treated	NN	O	O
with	NN	O	O
rauwolscine	NN	O	B-Chemical
(	NN	O	O
less	NN	O	O
than	NN	O	O
+2%	NN	O	O
MAP	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
.	NN	O	O

3	NN	O	O
.	NN	O	O

Conscious	NN	O	O
SHR	NN	O	O
were	NN	O	O
treated	NN	O	O
for	NN	O	O
4	NN	O	O
days	NN	O	O
with	NN	O	O
prazosin	NN	O	B-Chemical
at	NN	O	O
2	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
day	NN	O	O
-	NN	O	O
1	NN	O	O
i.p.	NN	O	O
for	NN	O	O
chronic	NN	O	O
alpha	NN	O	O
1	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
blockade	NN	O	O
.	NN	O	O

MAP	NN	O	O
in	NN	O	O
conscious	NN	O	O
SHR	NN	O	O
after	NN	O	O
chronic	NN	O	O
prazosin	NN	O	B-Chemical
treatment	NN	O	O
was	NN	O	O
14%	NN	O	O
lower	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
untreated	NN	O	O
SHR	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
8	NN	O	O
)	NN	O	O
.	NN	O	O

Head	NN	O	O
-	NN	O	O
up	NN	O	O
tilts	NN	O	O
in	NN	O	O
these	NN	O	O
rats	NN	O	O
did	NN	O	O
not	NN	O	O
produce	NN	O	O
orthostatic	NN	O	B-Disease
hypotension	NN	O	I-Disease
when	NN	O	O
performed	NN	O	O
either	NN	O	O
prior	NN	O	O
to	NN	O	O
or	NN	O	O
after	NN	O	O
acute	NN	O	O
dosing	NN	O	O
of	NN	O	O
prazosin	NN	O	B-Chemical
(	NN	O	O
0.1	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i.p.	NN	O	O
)	NN	O	O
.	NN	O	O

Conversely	NN	O	O
,	NN	O	O
administration	NN	O	O
of	NN	O	O
rauwolscine	NN	O	B-Chemical
(	NN	O	O
3	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i.v.	NN	O	O
)	NN	O	O
in	NN	O	O
chronic	NN	O	O
prazosin	NN	O	B-Chemical
treated	NN	O	O
SHR	NN	O	O
decreased	NN	O	O
the	NN	O	O
basal	NN	O	O
MAP	NN	O	O
by	NN	O	O
12	NN	O	O
-	NN	O	O
31%	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
subsequent	NN	O	O
tilts	NN	O	O
induced	NN	O	O
further	NN	O	O
drops	NN	O	O
of	NN	O	O
MAP	NN	O	O
by	NN	O	O
19	NN	O	O
-	NN	O	O
23%	NN	O	O
in	NN	O	O
these	NN	O	O
rats	NN	O	O
.	NN	O	O

4	NN	O	O
.	NN	O	O

The	NN	O	O
pressor	NN	O	O
responses	NN	O	O
and	NN	O	O
bradycardia	NN	O	B-Disease
to	NN	O	O
the	NN	O	O
alpha	NN	O	O
1	NN	O	O
-	NN	O	O
agonist	NN	O	O
cirazoline	NN	O	B-Chemical
(	NN	O	O
0.6	NN	O	O
and	NN	O	O
2	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i.v.	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
alpha	NN	O	O
2	NN	O	O
-	NN	O	O
agonist	NN	O	O
Abbott	NN	O	B-Chemical
-	NN	O	I-Chemical
53693	NN	O	I-Chemical
(	NN	O	O
1	NN	O	O
and	NN	O	O
3	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i.v.	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
noradrenaline	NN	O	B-Chemical
(	NN	O	O
0.1	NN	O	O
and	NN	O	O
1.0	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
i.v.	NN	O	O
)	NN	O	O
were	NN	O	O
determined	NN	O	O
in	NN	O	O
conscious	NN	O	O
SHR	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
chronic	NN	O	O
prazosin	NN	O	B-Chemical
pretreatment	NN	O	O
.	NN	O	O

Both	NN	O	O
the	NN	O	O
pressor	NN	O	O
and	NN	O	O
bradycardia	NN	O	B-Disease
effects	NN	O	O
of	NN	O	O
cirazoline	NN	O	B-Chemical
were	NN	O	O
abolished	NN	O	O
in	NN	O	O
chronic	NN	O	O
prazosin	NN	O	B-Chemical
treated	NN	O	O
SHR	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
)	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
untreated	NN	O	O
SHR	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
4	NN	O	O
)	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
the	NN	O	O
pressor	NN	O	O
effects	NN	O	O
of	NN	O	O
Abbott	NN	O	B-Chemical
-	NN	O	I-Chemical
53693	NN	O	I-Chemical
were	NN	O	O
similar	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
of	NN	O	O
SHR	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
accompanying	NN	O	O
bradycardia	NN	O	B-Disease
was	NN	O	O
greater	NN	O	O
in	NN	O	O
SHR	NN	O	O
with	NN	O	O
chronic	NN	O	O
prazosin	NN	O	B-Chemical
treatment	NN	O	O
than	NN	O	O
without	NN	O	O
such	NN	O	O
treatment	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
bradycardia	NN	O	B-Disease
that	NN	O	O
accompanied	NN	O	O
the	NN	O	O
noradrenaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
pressor	NN	O	O
effect	NN	O	O
in	NN	O	O
SHR	NN	O	O
was	NN	O	O
similar	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
chronic	NN	O	O
prazosin	NN	O	B-Chemical
treatment	NN	O	O
despite	NN	O	O
a	NN	O	O
47	NN	O	O
-	NN	O	O
71%	NN	O	O
reduction	NN	O	O
of	NN	O	O
the	NN	O	O
pressor	NN	O	O
effect	NN	O	O
in	NN	O	O
chronic	NN	O	O
alpha	NN	O	O
1	NN	O	O
-	NN	O	O
receptor	NN	O	O
blocked	NN	O	O
SHR.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
400	NN	O	O
WORDS	NN	O	O
)	NN	O	O

-DOCSTART- (8638876)

Coexistence	NN	O	O
of	NN	O	O
cerebral	NN	O	B-Disease
venous	NN	O	I-Disease
sinus	NN	O	I-Disease
and	NN	O	I-Disease
internal	NN	O	I-Disease
carotid	NN	O	I-Disease
artery	NN	O	I-Disease
thrombosis	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
exogenous	NN	O	O
sex	NN	O	O
hormones	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

A	NN	O	O
forty	NN	O	O
-	NN	O	O
six	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
premenopausal	NN	O	O
woman	NN	O	O
developed	NN	O	O
headache	NN	O	B-Disease
,	NN	O	O
nausea	NN	O	B-Disease
and	NN	O	O
vomiting	NN	O	B-Disease
,	NN	O	O
left	NN	O	O
hemiparesis	NN	O	B-Disease
and	NN	O	O
seizure	NN	O	B-Disease
two	NN	O	O
days	NN	O	O
after	NN	O	O
parenteral	NN	O	O
use	NN	O	O
of	NN	O	O
progesterone	NN	O	B-Chemical
and	NN	O	O
estradiol	NN	O	B-Chemical
.	NN	O	O

Diabetes	NN	O	B-Disease
mellitus	NN	O	I-Disease
(	NN	O	O
DM	NN	O	B-Disease
)	NN	O	O
was	NN	O	O
found	NN	O	O
during	NN	O	O
admission	NN	O	O
.	NN	O	O

Computed	NN	O	O
tomography	NN	O	O
showed	NN	O	O
a	NN	O	O
hemorrhagic	NN	O	B-Disease
infarct	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
right	NN	O	O
frontal	NN	O	O
lobe	NN	O	O
and	NN	O	O
increased	NN	O	O
density	NN	O	O
in	NN	O	O
the	NN	O	O
superior	NN	O	O
sagittal	NN	O	O
sinus	NN	O	O
(	NN	O	O
SSS	NN	O	O
)	NN	O	O
.	NN	O	O

Left	NN	O	O
carotid	NN	O	O
angiography	NN	O	O
found	NN	O	O
occlusion	NN	O	B-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
left	NN	O	I-Disease
internal	NN	O	I-Disease
carotid	NN	O	I-Disease
artery	NN	O	I-Disease
(	NN	O	O
ICA	NN	O	O
)	NN	O	O
.	NN	O	O

Right	NN	O	O
carotid	NN	O	O
angiograms	NN	O	O
failed	NN	O	O
to	NN	O	O
show	NN	O	O
the	NN	O	O
SSS	NN	O	O
and	NN	O	O
inferior	NN	O	O
sagittal	NN	O	O
sinus	NN	O	O
,	NN	O	O
suggestive	NN	O	O
of	NN	O	O
venous	NN	O	B-Disease
sinus	NN	O	I-Disease
thrombosis	NN	O	I-Disease
.	NN	O	O

Coexistence	NN	O	O
of	NN	O	O
the	NN	O	O
cerebral	NN	O	B-Disease
artery	NN	O	I-Disease
and	NN	O	I-Disease
the	NN	O	I-Disease
venous	NN	O	I-Disease
sinus	NN	O	I-Disease
occlusion	NN	O	I-Disease
has	NN	O	O
been	NN	O	O
described	NN	O	O
infrequently	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
case	NN	O	O
,	NN	O	O
the	NN	O	O
authors	NN	O	O
postulate	NN	O	O
that	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
estradiol	NN	O	B-Chemical
and	NN	O	O
progesterone	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
underlying	NN	O	O
DM	NN	O	B-Disease
increased	NN	O	O
vascular	NN	O	O
thrombogenicity	NN	O	O
,	NN	O	O
which	NN	O	O
provided	NN	O	O
a	NN	O	O
common	NN	O	O
denominator	NN	O	O
for	NN	O	O
thrombosis	NN	O	B-Disease
of	NN	O	I-Disease
both	NN	O	I-Disease
the	NN	O	I-Disease
ICA	NN	O	I-Disease
and	NN	O	I-Disease
the	NN	O	I-Disease
venous	NN	O	I-Disease
sinus	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (1628552)

Chloroquine	NN	O	B-Chemical
related	NN	O	O
complete	NN	O	O
heart	NN	O	B-Disease
block	NN	O	I-Disease
with	NN	O	O
blindness	NN	O	B-Disease
:	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

A	NN	O	O
27	NN	O	O
-	NN	O	O
year	NN	O	O
old	NN	O	O
African	NN	O	O
woman	NN	O	O
with	NN	O	O
history	NN	O	O
of	NN	O	O
regular	NN	O	O
chloroquine	NN	O	B-Chemical
ingestion	NN	O	O
presented	NN	O	O
with	NN	O	O
progressive	NN	O	O
deterioration	NN	O	B-Disease
of	NN	O	I-Disease
vision	NN	O	I-Disease
,	NN	O	O
easy	NN	O	O
fatiguability	NN	O	B-Disease
,	NN	O	O
dyspnoea	NN	O	B-Disease
,	NN	O	O
dizziness	NN	O	B-Disease
progressing	NN	O	O
to	NN	O	O
syncopal	NN	O	B-Disease
attacks	NN	O	I-Disease
.	NN	O	O

Ophthalmological	NN	O	O
assessment	NN	O	O
revealed	NN	O	O
features	NN	O	O
of	NN	O	O
chloroquine	NN	O	B-Chemical
retinopathy	NN	O	B-Disease
,	NN	O	O
cardiac	NN	O	O
assessment	NN	O	O
revealed	NN	O	O
features	NN	O	O
of	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
and	NN	O	O
a	NN	O	O
complete	NN	O	O
heart	NN	O	B-Disease
block	NN	O	I-Disease
with	NN	O	O
right	NN	O	B-Disease
bundle	NN	O	I-Disease
branch	NN	O	I-Disease
block	NN	O	I-Disease
pattern	NN	O	O
.	NN	O	O

The	NN	O	O
heart	NN	O	B-Disease
block	NN	O	I-Disease
was	NN	O	O
treated	NN	O	O
by	NN	O	O
pacemaker	NN	O	O
insertion	NN	O	O
and	NN	O	O
the	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
resolved	NN	O	O
spontaneously	NN	O	O
following	NN	O	O
chloroquine	NN	O	B-Chemical
discontinuation	NN	O	O
.	NN	O	O

She	NN	O	O
however	NN	O	O
remains	NN	O	O
blind	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (11524350)

Systemic	NN	O	O
toxicity	NN	O	B-Disease
and	NN	O	O
resuscitation	NN	O	O
in	NN	O	O
bupivacaine	NN	O	B-Chemical
-	NN	O	O
,	NN	O	O
levobupivacaine	NN	O	B-Chemical
-	NN	O	O
,	NN	O	O
or	NN	O	O
ropivacaine	NN	O	B-Chemical
-	NN	O	O
infused	NN	O	O
rats	NN	O	O
.	NN	O	O

We	NN	O	O
compared	NN	O	O
the	NN	O	O
systemic	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
bupivacaine	NN	O	B-Chemical
,	NN	O	O
levobupivacaine	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
ropivacaine	NN	O	B-Chemical
in	NN	O	O
anesthetized	NN	O	O
rats	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
compared	NN	O	O
the	NN	O	O
ability	NN	O	O
to	NN	O	O
resuscitate	NN	O	O
rats	NN	O	O
after	NN	O	O
lethal	NN	O	O
doses	NN	O	O
of	NN	O	O
these	NN	O	O
local	NN	O	O
anesthetics	NN	O	O
.	NN	O	O

Bupivacaine	NN	O	B-Chemical
,	NN	O	O
levobupivacaine	NN	O	B-Chemical
,	NN	O	O
or	NN	O	O
ropivacaine	NN	O	B-Chemical
was	NN	O	O
infused	NN	O	O
at	NN	O	O
a	NN	O	O
rate	NN	O	O
of	NN	O	O
2	NN	O	O
mg	NN	O	O
.	NN	O	O

kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

min	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
while	NN	O	O
electrocardiogram	NN	O	O
,	NN	O	O
electroencephalogram	NN	O	O
,	NN	O	O
and	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
were	NN	O	O
continuously	NN	O	O
monitored	NN	O	O
.	NN	O	O

When	NN	O	O
asystole	NN	O	B-Disease
was	NN	O	O
recorded	NN	O	O
,	NN	O	O
drug	NN	O	O
infusion	NN	O	O
was	NN	O	O
stopped	NN	O	O
and	NN	O	O
a	NN	O	O
resuscitation	NN	O	O
sequence	NN	O	O
was	NN	O	O
begun	NN	O	O
.	NN	O	O

Epinephrine	NN	O	B-Chemical
0.01	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
was	NN	O	O
administered	NN	O	O
at	NN	O	O
1	NN	O	O
-	NN	O	O
min	NN	O	O
intervals	NN	O	O
while	NN	O	O
external	NN	O	O
cardiac	NN	O	O
compressions	NN	O	O
were	NN	O	O
applied	NN	O	O
.	NN	O	O

Resuscitation	NN	O	O
was	NN	O	O
considered	NN	O	O
successful	NN	O	O
when	NN	O	O
a	NN	O	O
systolic	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
>	NN	O	O
or	NN	O	O
=100	NN	O	O
mm	NN	O	O
Hg	NN	O	O
was	NN	O	O
achieved	NN	O	O
within	NN	O	O
5	NN	O	O
min	NN	O	O
.	NN	O	O

The	NN	O	O
cumulative	NN	O	O
doses	NN	O	O
of	NN	O	O
levobupivacaine	NN	O	B-Chemical
and	NN	O	O
ropivacaine	NN	O	B-Chemical
that	NN	O	O
produced	NN	O	O
seizures	NN	O	B-Disease
were	NN	O	O
similar	NN	O	O
and	NN	O	O
were	NN	O	O
larger	NN	O	O
than	NN	O	O
those	NN	O	O
of	NN	O	O
bupivacaine	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
cumulative	NN	O	O
doses	NN	O	O
of	NN	O	O
levobupivacaine	NN	O	B-Chemical
that	NN	O	O
produced	NN	O	O
dysrhythmias	NN	O	B-Disease
and	NN	O	O
asystole	NN	O	B-Disease
were	NN	O	O
smaller	NN	O	O
than	NN	O	O
the	NN	O	O
corresponding	NN	O	O
doses	NN	O	O
of	NN	O	O
ropivacaine	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
they	NN	O	O
were	NN	O	O
larger	NN	O	O
than	NN	O	O
those	NN	O	O
of	NN	O	O
bupivacaine	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
successful	NN	O	O
resuscitations	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
among	NN	O	O
groups	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
a	NN	O	O
smaller	NN	O	O
dose	NN	O	O
of	NN	O	O
epinephrine	NN	O	B-Chemical
was	NN	O	O
required	NN	O	O
in	NN	O	O
the	NN	O	O
Ropivacaine	NN	O	B-Chemical
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
groups	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
systemic	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
levobupivacaine	NN	O	B-Chemical
is	NN	O	O
intermediate	NN	O	O
between	NN	O	O
that	NN	O	O
of	NN	O	O
ropivacaine	NN	O	B-Chemical
and	NN	O	O
bupivacaine	NN	O	B-Chemical
when	NN	O	O
administered	NN	O	O
at	NN	O	O
the	NN	O	O
same	NN	O	O
rate	NN	O	O
and	NN	O	O
that	NN	O	O
ropivacaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiac	NN	O	B-Disease
arrest	NN	O	I-Disease
appears	NN	O	O
to	NN	O	O
be	NN	O	O
more	NN	O	O
susceptible	NN	O	O
to	NN	O	O
treatment	NN	O	O
than	NN	O	O
that	NN	O	O
induced	NN	O	O
by	NN	O	O
bupivacaine	NN	O	B-Chemical
or	NN	O	O
levobupivacaine	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (10027919)

22	NN	O	B-Chemical
-	NN	O	I-Chemical
oxacalcitriol	NN	O	I-Chemical
suppresses	NN	O	O
secondary	NN	O	B-Disease
hyperparathyroidism	NN	O	I-Disease
without	NN	O	O
inducing	NN	O	O
low	NN	O	B-Disease
bone	NN	O	I-Disease
turnover	NN	O	I-Disease
in	NN	O	O
dogs	NN	O	O
with	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Calcitriol	NN	O	B-Chemical
therapy	NN	O	O
suppresses	NN	O	O
serum	NN	O	O
levels	NN	O	O
of	NN	O	O
parathyroid	NN	O	O
hormone	NN	O	O
(	NN	O	O
PTH	NN	O	O
)	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
but	NN	O	O
has	NN	O	O
several	NN	O	O
drawbacks	NN	O	O
,	NN	O	O
including	NN	O	O
hypercalcemia	NN	O	B-Disease
and	NN	O	O
/	NN	O	O
or	NN	O	O
marked	NN	O	O
suppression	NN	O	B-Disease
of	NN	O	I-Disease
bone	NN	O	I-Disease
turnover	NN	O	I-Disease
,	NN	O	O
which	NN	O	O
may	NN	O	O
lead	NN	O	O
to	NN	O	O
adynamic	NN	O	B-Disease
bone	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
new	NN	O	O
vitamin	NN	O	B-Chemical
D	NN	O	I-Chemical
analogue	NN	O	O
,	NN	O	O
22	NN	O	B-Chemical
-	NN	O	I-Chemical
oxacalcitriol	NN	O	I-Chemical
(	NN	O	O
OCT	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
have	NN	O	O
promising	NN	O	O
characteristics	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
OCT	NN	O	B-Chemical
on	NN	O	O
serum	NN	O	O
PTH	NN	O	O
levels	NN	O	O
and	NN	O	O
bone	NN	O	O
turnover	NN	O	O
in	NN	O	O
states	NN	O	O
of	NN	O	O
normal	NN	O	O
or	NN	O	O
impaired	NN	O	B-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Sixty	NN	O	O
dogs	NN	O	O
were	NN	O	O
either	NN	O	O
nephrectomized	NN	O	O
(	NN	O	O
Nx	NN	O	O
,	NN	O	O
N	NN	O	O
=	NN	O	O
38	NN	O	O
)	NN	O	O
or	NN	O	O
sham	NN	O	O
-	NN	O	O
operated	NN	O	O
(	NN	O	O
Sham	NN	O	O
,	NN	O	O
N	NN	O	O
=	NN	O	O
22	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
animals	NN	O	O
received	NN	O	O
supplemental	NN	O	O
phosphate	NN	O	B-Chemical
to	NN	O	O
enhance	NN	O	O
PTH	NN	O	O
secretion	NN	O	O
.	NN	O	O

Fourteen	NN	O	O
weeks	NN	O	O
after	NN	O	O
the	NN	O	O
start	NN	O	O
of	NN	O	O
phosphate	NN	O	B-Chemical
supplementation	NN	O	O
,	NN	O	O
half	NN	O	O
of	NN	O	O
the	NN	O	O
Nx	NN	O	O
and	NN	O	O
Sham	NN	O	O
dogs	NN	O	O
received	NN	O	O
doses	NN	O	O
of	NN	O	O
OCT	NN	O	B-Chemical
(	NN	O	O
three	NN	O	O
times	NN	O	O
per	NN	O	O
week	NN	O	O
)	NN	O	O
;	NN	O	O
the	NN	O	O
other	NN	O	O
half	NN	O	O
were	NN	O	O
given	NN	O	O
vehicle	NN	O	O
for	NN	O	O
60	NN	O	O
weeks	NN	O	O
.	NN	O	O

Thereafter	NN	O	O
,	NN	O	O
the	NN	O	O
treatment	NN	O	O
modalities	NN	O	O
for	NN	O	O
a	NN	O	O
subset	NN	O	O
of	NN	O	O
animals	NN	O	O
were	NN	O	O
crossed	NN	O	O
over	NN	O	O
for	NN	O	O
an	NN	O	O
additional	NN	O	O
eight	NN	O	O
months	NN	O	O
.	NN	O	O

Biochemical	NN	O	O
and	NN	O	O
hormonal	NN	O	O
indices	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
and	NN	O	O
bone	NN	O	O
metabolism	NN	O	O
were	NN	O	O
measured	NN	O	O
throughout	NN	O	O
the	NN	O	O
study	NN	O	O
,	NN	O	O
and	NN	O	O
bone	NN	O	O
biopsies	NN	O	O
were	NN	O	O
done	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
60	NN	O	O
weeks	NN	O	O
after	NN	O	O
OCT	NN	O	B-Chemical
or	NN	O	O
vehicle	NN	O	O
treatment	NN	O	O
,	NN	O	O
and	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
crossover	NN	O	O
period	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
In	NN	O	O
Nx	NN	O	O
dogs	NN	O	O
,	NN	O	O
OCT	NN	O	B-Chemical
significantly	NN	O	O
decreased	NN	O	O
serum	NN	O	O
PTH	NN	O	O
levels	NN	O	O
soon	NN	O	O
after	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
insufficiency	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
long	NN	O	O
-	NN	O	O
standing	NN	O	O
secondary	NN	O	B-Disease
hyperparathyroidism	NN	O	I-Disease
,	NN	O	O
OCT	NN	O	B-Chemical
(	NN	O	O
0.03	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
stabilized	NN	O	O
serum	NN	O	O
PTH	NN	O	O
levels	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
months	NN	O	O
.	NN	O	O

Serum	NN	O	O
PTH	NN	O	O
levels	NN	O	O
rose	NN	O	O
thereafter	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
rise	NN	O	O
was	NN	O	O
less	NN	O	O
pronounced	NN	O	O
compared	NN	O	O
with	NN	O	O
baseline	NN	O	O
than	NN	O	O
the	NN	O	O
rise	NN	O	O
seen	NN	O	O
in	NN	O	O
Nx	NN	O	O
control	NN	O	O
.	NN	O	O

These	NN	O	O
effects	NN	O	O
were	NN	O	O
accompanied	NN	O	O
by	NN	O	O
episodes	NN	O	O
of	NN	O	O
hypercalcemia	NN	O	B-Disease
and	NN	O	O
hyperphosphatemia	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
animals	NN	O	O
with	NN	O	O
normal	NN	O	O
renal	NN	O	O
function	NN	O	O
,	NN	O	O
OCT	NN	O	B-Chemical
induced	NN	O	O
a	NN	O	O
transient	NN	O	O
decrease	NN	O	O
in	NN	O	O
serum	NN	O	O
PTH	NN	O	O
levels	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
0.1	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
not	NN	O	O
sustained	NN	O	O
with	NN	O	O
lowering	NN	O	O
of	NN	O	O
the	NN	O	O
doses	NN	O	O
.	NN	O	O

In	NN	O	O
Nx	NN	O	O
dogs	NN	O	O
,	NN	O	O
OCT	NN	O	B-Chemical
reversed	NN	O	O
abnormal	NN	O	O
bone	NN	O	O
formation	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
woven	NN	O	B-Disease
osteoid	NN	O	I-Disease
and	NN	O	O
fibrosis	NN	O	B-Disease
,	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
significantly	NN	O	O
alter	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
bone	NN	O	O
turnover	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
OCT	NN	O	B-Chemical
improved	NN	O	O
mineralization	NN	O	O
lag	NN	O	O
time	NN	O	O
,	NN	O	O
(	NN	O	O
that	NN	O	O
is	NN	O	O
,	NN	O	O
the	NN	O	O
rate	NN	O	O
at	NN	O	O
which	NN	O	O
osteoid	NN	O	O
mineralizes	NN	O	O
)	NN	O	O
in	NN	O	O
both	NN	O	O
Nx	NN	O	O
and	NN	O	O
Sham	NN	O	O
dogs	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
These	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
even	NN	O	O
though	NN	O	O
OCT	NN	O	B-Chemical
does	NN	O	O
not	NN	O	O
completely	NN	O	O
prevent	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
hypercalcemia	NN	O	B-Disease
in	NN	O	O
experimental	NN	O	O
dogs	NN	O	O
with	NN	O	O
renal	NN	O	B-Disease
insufficiency	NN	O	I-Disease
,	NN	O	O
it	NN	O	O
may	NN	O	O
be	NN	O	O
of	NN	O	O
use	NN	O	O
in	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
secondary	NN	O	B-Disease
hyperparathyroidism	NN	O	I-Disease
because	NN	O	O
it	NN	O	O
does	NN	O	O
not	NN	O	O
induce	NN	O	O
low	NN	O	B-Disease
bone	NN	O	I-Disease
turnover	NN	O	I-Disease
and	NN	O	O
,	NN	O	O
therefore	NN	O	O
,	NN	O	O
does	NN	O	O
not	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
adynamic	NN	O	B-Disease
bone	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (8643966)

Chemotherapy	NN	O	O
of	NN	O	O
advanced	NN	O	O
inoperable	NN	O	O
non	NN	O	B-Disease
-	NN	O	I-Disease
small	NN	O	I-Disease
cell	NN	O	I-Disease
lung	NN	O	I-Disease
cancer	NN	O	I-Disease
with	NN	O	O
paclitaxel	NN	O	B-Chemical
:	NN	O	O
a	NN	O	O
phase	NN	O	O
II	NN	O	O
trial	NN	O	O
.	NN	O	O

Paclitaxel	NN	O	B-Chemical
(	NN	O	O
Taxol	NN	O	B-Chemical
;	NN	O	O
Bristol	NN	O	O
-	NN	O	O
Myers	NN	O	O
Squibb	NN	O	O
Company	NN	O	O
,	NN	O	O
Princeton	NN	O	O
,	NN	O	O
NJ	NN	O	O
)	NN	O	O
has	NN	O	O
demonstrated	NN	O	O
significant	NN	O	O
antineoplastic	NN	O	O
activity	NN	O	O
against	NN	O	O
different	NN	O	O
tumor	NN	O	B-Disease
types	NN	O	O
,	NN	O	O
notably	NN	O	O
ovarian	NN	O	B-Disease
and	NN	O	I-Disease
breast	NN	O	I-Disease
carcinoma	NN	O	I-Disease
.	NN	O	O

Two	NN	O	O
phase	NN	O	O
II	NN	O	O
trials	NN	O	O
of	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
paclitaxel	NN	O	B-Chemical
infusions	NN	O	O
in	NN	O	O
chemotherapy	NN	O	O
-	NN	O	O
naive	NN	O	O
patients	NN	O	O
with	NN	O	O
stage	NN	O	O
IIIB	NN	O	O
or	NN	O	O
IV	NN	O	O
non	NN	O	B-Disease
-	NN	O	I-Disease
small	NN	O	I-Disease
cell	NN	O	I-Disease
lung	NN	O	I-Disease
cancer	NN	O	I-Disease
(	NN	O	O
NSCLC	NN	O	B-Disease
)	NN	O	O
reported	NN	O	O
response	NN	O	O
rates	NN	O	O
of	NN	O	O
21%	NN	O	O
and	NN	O	O
24%	NN	O	O
.	NN	O	O

Leukopenia	NN	O	B-Disease
was	NN	O	O
dose	NN	O	O
limiting	NN	O	O
:	NN	O	O
as	NN	O	O
many	NN	O	O
as	NN	O	O
62.5%	NN	O	O
of	NN	O	O
patients	NN	O	O
experienced	NN	O	O
grade	NN	O	O
4	NN	O	O
leukopenia	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
hour	NN	O	O
paclitaxel	NN	O	B-Chemical
infusion	NN	O	O
in	NN	O	O
a	NN	O	O
phase	NN	O	O
II	NN	O	O
trial	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
inoperable	NN	O	O
stage	NN	O	O
IIIB	NN	O	O
or	NN	O	O
IV	NN	O	O
NSCLC	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
58	NN	O	O
patients	NN	O	O
treated	NN	O	O
(	NN	O	O
41	NN	O	O
men	NN	O	O
and	NN	O	O
17	NN	O	O
women	NN	O	O
)	NN	O	O
had	NN	O	O
a	NN	O	O
median	NN	O	O
age	NN	O	O
of	NN	O	O
59	NN	O	O
years	NN	O	O
(	NN	O	O
age	NN	O	O
range	NN	O	O
,	NN	O	O
25	NN	O	O
to	NN	O	O
75	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
performance	NN	O	O
status	NN	O	O
of	NN	O	O
0	NN	O	O
through	NN	O	O
2	NN	O	O
.	NN	O	O

Most	NN	O	O
patients	NN	O	O
(	NN	O	O
72.4%	NN	O	O
)	NN	O	O
had	NN	O	O
stage	NN	O	O
IV	NN	O	O
NSCLC	NN	O	B-Disease
.	NN	O	O

Paclitaxel	NN	O	B-Chemical
225	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
was	NN	O	O
infused	NN	O	O
over	NN	O	O
3	NN	O	O
hours	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
with	NN	O	O
standard	NN	O	O
prophylactic	NN	O	O
premedication	NN	O	O
.	NN	O	O

Of	NN	O	O
50	NN	O	O
patients	NN	O	O
evaluable	NN	O	O
for	NN	O	O
response	NN	O	O
,	NN	O	O
12	NN	O	O
(	NN	O	O
24%	NN	O	O
)	NN	O	O
had	NN	O	O
partial	NN	O	O
remission	NN	O	O
,	NN	O	O
26	NN	O	O
(	NN	O	O
52%	NN	O	O
)	NN	O	O
had	NN	O	O
no	NN	O	O
change	NN	O	O
,	NN	O	O
and	NN	O	O
12	NN	O	O
had	NN	O	O
disease	NN	O	O
progression	NN	O	O
(	NN	O	O
24%	NN	O	O
)	NN	O	O
.	NN	O	O

Hematologic	NN	O	O
toxicities	NN	O	B-Disease
were	NN	O	O
mild	NN	O	O
:	NN	O	O
only	NN	O	O
one	NN	O	O
patient	NN	O	O
(	NN	O	O
2%	NN	O	O
)	NN	O	O
developed	NN	O	O
grade	NN	O	O
3	NN	O	O
or	NN	O	O
4	NN	O	O
neutropenia	NN	O	B-Disease
,	NN	O	O
while	NN	O	O
29%	NN	O	O
had	NN	O	O
grade	NN	O	O
1	NN	O	O
or	NN	O	O
2	NN	O	O
.	NN	O	O

Grade	NN	O	O
1	NN	O	O
or	NN	O	O
2	NN	O	O
polyneuropathy	NN	O	B-Disease
affected	NN	O	O
56%	NN	O	O
of	NN	O	O
patients	NN	O	O
while	NN	O	O
only	NN	O	O
one	NN	O	O
(	NN	O	O
2%	NN	O	O
)	NN	O	O
experienced	NN	O	O
severe	NN	O	O
polyneuropathy	NN	O	B-Disease
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
grade	NN	O	O
1	NN	O	O
or	NN	O	O
2	NN	O	O
myalgia	NN	O	B-Disease
/	NN	O	O
arthralgia	NN	O	B-Disease
was	NN	O	O
observed	NN	O	O
in	NN	O	O
63.2%	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
but	NN	O	O
only	NN	O	O
14.3%	NN	O	O
experienced	NN	O	O
grade	NN	O	O
3	NN	O	O
or	NN	O	O
4	NN	O	O
.	NN	O	O

Nausea	NN	O	B-Disease
and	NN	O	O
vomiting	NN	O	B-Disease
were	NN	O	O
infrequent	NN	O	O
,	NN	O	O
with	NN	O	O
14%	NN	O	O
of	NN	O	O
patients	NN	O	O
experiencing	NN	O	O
grade	NN	O	O
1	NN	O	O
or	NN	O	O
2	NN	O	O
and	NN	O	O
only	NN	O	O
2%	NN	O	O
experiencing	NN	O	O
grade	NN	O	O
3	NN	O	O
or	NN	O	O
4	NN	O	O
.	NN	O	O

Paclitaxel	NN	O	B-Chemical
is	NN	O	O
thus	NN	O	O
an	NN	O	O
active	NN	O	O
single	NN	O	O
agent	NN	O	O
in	NN	O	O
this	NN	O	O
patient	NN	O	O
population	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
hour	NN	O	O
infusion	NN	O	O
proving	NN	O	O
comparably	NN	O	O
effective	NN	O	O
to	NN	O	O
a	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
infusion	NN	O	O
and	NN	O	O
superior	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
hematologic	NN	O	O
and	NN	O	O
nonhematologic	NN	O	O
toxicity	NN	O	B-Disease
.	NN	O	O

Further	NN	O	O
phase	NN	O	O
II	NN	O	O
studies	NN	O	O
with	NN	O	O
paclitaxel	NN	O	B-Chemical
combined	NN	O	O
with	NN	O	O
other	NN	O	O
drugs	NN	O	O
active	NN	O	O
against	NN	O	O
NSCLC	NN	O	B-Disease
are	NN	O	O
indicated	NN	O	O
,	NN	O	O
and	NN	O	O
phase	NN	O	O
III	NN	O	O
studies	NN	O	O
comparing	NN	O	O
paclitaxel	NN	O	B-Chemical
with	NN	O	O
standard	NN	O	O
chemotherapy	NN	O	O
remain	NN	O	O
to	NN	O	O
be	NN	O	O
completed	NN	O	O
.	NN	O	O


-DOCSTART- (6695415)

Cerebral	NN	O	B-Disease
hemorrhage	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
phenylpropanolamine	NN	O	B-Chemical
in	NN	O	O
combination	NN	O	O
with	NN	O	O
caffeine	NN	O	B-Chemical
.	NN	O	O

Phenylpropanolamine	NN	O	B-Chemical
(	NN	O	O
PPA	NN	O	B-Chemical
)	NN	O	O
is	NN	O	O
a	NN	O	O
drug	NN	O	O
that	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
serious	NN	O	O
side	NN	O	O
effects	NN	O	O
including	NN	O	O
stroke	NN	O	B-Disease
.	NN	O	O

It	NN	O	O
is	NN	O	O
often	NN	O	O
combined	NN	O	O
with	NN	O	O
caffeine	NN	O	B-Chemical
in	NN	O	O
diet	NN	O	O
preparations	NN	O	O
and	NN	O	O
"	NN	O	O
look	NN	O	O
-	NN	O	O
alike	NN	O	O
"	NN	O	O
pills	NN	O	O
.	NN	O	O

In	NN	O	O
order	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
PPA	NN	O	B-Chemical
/	NN	O	O
caffeine	NN	O	B-Chemical
can	NN	O	O
lead	NN	O	O
to	NN	O	O
stroke	NN	O	B-Disease
in	NN	O	O
normotensive	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
hypertensive	NN	O	B-Disease
rats	NN	O	O
,	NN	O	O
we	NN	O	O
administered	NN	O	O
the	NN	O	O
combination	NN	O	O
in	NN	O	O
six	NN	O	O
times	NN	O	O
the	NN	O	O
allowed	NN	O	O
human	NN	O	O
dose	NN	O	O
calculated	NN	O	O
on	NN	O	O
a	NN	O	O
per	NN	O	O
weight	NN	O	O
basis	NN	O	O
for	NN	O	O
the	NN	O	O
rats	NN	O	O
two	NN	O	O
times	NN	O	O
per	NN	O	O
day	NN	O	O
for	NN	O	O
five	NN	O	O
days	NN	O	O
.	NN	O	O

Subarachnoid	NN	O	B-Disease
and	NN	O	I-Disease
cerebral	NN	O	I-Disease
hemorrhage	NN	O	I-Disease
was	NN	O	O
noted	NN	O	O
in	NN	O	O
18%	NN	O	O
of	NN	O	O
the	NN	O	O
hypertensive	NN	O	B-Disease
rats	NN	O	O
.	NN	O	O

A	NN	O	O
single	NN	O	O
PPA	NN	O	B-Chemical
/	NN	O	O
caffeine	NN	O	B-Chemical
administration	NN	O	O
(	NN	O	O
same	NN	O	O
dose	NN	O	O
)	NN	O	O
lead	NN	O	O
to	NN	O	O
acute	NN	O	O
hypertension	NN	O	B-Disease
in	NN	O	O
both	NN	O	O
the	NN	O	O
normotensive	NN	O	O
and	NN	O	O
hypertensive	NN	O	B-Disease
animals	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
PPA	NN	O	B-Chemical
/	NN	O	O
caffeine	NN	O	B-Chemical
can	NN	O	O
lead	NN	O	O
to	NN	O	O
cerebral	NN	O	B-Disease
hemorrhage	NN	O	I-Disease
in	NN	O	O
previously	NN	O	O
hypertensive	NN	O	B-Disease
animals	NN	O	O
when	NN	O	O
administered	NN	O	O
in	NN	O	O
greater	NN	O	O
than	NN	O	O
the	NN	O	O
allowed	NN	O	O
dosage	NN	O	O
.	NN	O	O

An	NN	O	O
acute	NN	O	O
elevation	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
may	NN	O	O
be	NN	O	O
a	NN	O	O
contributing	NN	O	O
factor	NN	O	O
.	NN	O	O


-DOCSTART- (6637851)

Long	NN	O	O
-	NN	O	O
term	NN	O	O
efficacy	NN	O	O
and	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
amiodarone	NN	O	B-Chemical
therapy	NN	O	O
for	NN	O	O
ventricular	NN	O	B-Disease
tachycardia	NN	O	I-Disease
or	NN	O	O
ventricular	NN	O	B-Disease
fibrillation	NN	O	I-Disease
.	NN	O	O

Amiodarone	NN	O	B-Chemical
was	NN	O	O
administered	NN	O	O
to	NN	O	O
154	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
sustained	NN	O	O
,	NN	O	O
symptomatic	NN	O	O
ventricular	NN	O	B-Disease
tachycardia	NN	O	I-Disease
(	NN	O	O
VT	NN	O	B-Disease
)	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
118	NN	O	O
)	NN	O	O
or	NN	O	O
a	NN	O	O
cardiac	NN	O	B-Disease
arrest	NN	O	I-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
36	NN	O	O
)	NN	O	O
and	NN	O	O
who	NN	O	O
were	NN	O	O
refractory	NN	O	O
to	NN	O	O
conventional	NN	O	O
antiarrhythmic	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
loading	NN	O	O
dose	NN	O	O
was	NN	O	O
800	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
6	NN	O	O
weeks	NN	O	O
and	NN	O	O
the	NN	O	O
maintenance	NN	O	O
dose	NN	O	O
was	NN	O	O
600	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
.	NN	O	O

Sixty	NN	O	O
-	NN	O	O
nine	NN	O	O
percent	NN	O	O
of	NN	O	O
patients	NN	O	O
continued	NN	O	O
treatment	NN	O	O
with	NN	O	O
amiodarone	NN	O	B-Chemical
and	NN	O	O
had	NN	O	O
no	NN	O	O
recurrence	NN	O	O
of	NN	O	O
symptomatic	NN	O	O
VT	NN	O	B-Disease
or	NN	O	O
ventricular	NN	O	B-Disease
fibrillation	NN	O	I-Disease
(	NN	O	O
VF	NN	O	B-Disease
)	NN	O	O
over	NN	O	O
a	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
6	NN	O	O
to	NN	O	O
52	NN	O	O
months	NN	O	O
(	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
standard	NN	O	O
deviation	NN	O	O
14.2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8.2	NN	O	O
)	NN	O	O
.	NN	O	O

Six	NN	O	O
percent	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
nonfatal	NN	O	O
recurrence	NN	O	O
of	NN	O	O
VT	NN	O	B-Disease
and	NN	O	O
were	NN	O	O
successfully	NN	O	O
managed	NN	O	O
by	NN	O	O
continuing	NN	O	O
amiodarone	NN	O	B-Chemical
at	NN	O	O
a	NN	O	O
higher	NN	O	O
dose	NN	O	O
or	NN	O	O
by	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
a	NN	O	O
conventional	NN	O	O
antiarrhythmic	NN	O	O
drug	NN	O	O
.	NN	O	O

One	NN	O	O
or	NN	O	O
more	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reactions	NN	O	O
occurred	NN	O	O
in	NN	O	O
51%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Adverse	NN	O	O
effects	NN	O	O
forced	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
amiodarone	NN	O	B-Chemical
in	NN	O	O
41%	NN	O	O
and	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
amiodarone	NN	O	B-Chemical
in	NN	O	O
10%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
symptomatic	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
were	NN	O	O
tremor	NN	O	B-Disease
or	NN	O	O
ataxia	NN	O	B-Disease
(	NN	O	O
35%	NN	O	O
)	NN	O	O
,	NN	O	O
nausea	NN	O	B-Disease
and	NN	O	O
anorexia	NN	O	B-Disease
(	NN	O	O
8%	NN	O	O
)	NN	O	O
,	NN	O	O
visual	NN	O	B-Disease
halos	NN	O	I-Disease
or	NN	O	I-Disease
blurring	NN	O	I-Disease
(	NN	O	O
6%	NN	O	O
)	NN	O	O
,	NN	O	O
thyroid	NN	O	B-Disease
function	NN	O	I-Disease
abnormalities	NN	O	I-Disease
(	NN	O	O
6%	NN	O	O
)	NN	O	O
and	NN	O	O
pulmonary	NN	O	B-Disease
interstitial	NN	O	I-Disease
infiltrates	NN	O	I-Disease
(	NN	O	O
5%	NN	O	O
)	NN	O	O
.	NN	O	O

Although	NN	O	O
large	NN	O	O
-	NN	O	O
dose	NN	O	O
amiodarone	NN	O	B-Chemical
is	NN	O	O
highly	NN	O	O
effective	NN	O	O
in	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
treatment	NN	O	O
of	NN	O	O
VT	NN	O	B-Disease
or	NN	O	O
VF	NN	O	B-Disease
refractory	NN	O	O
to	NN	O	O
conventional	NN	O	O
antiarrhythmic	NN	O	O
drugs	NN	O	O
,	NN	O	O
it	NN	O	O
causes	NN	O	O
significant	NN	O	O
toxicity	NN	O	B-Disease
in	NN	O	O
approximately	NN	O	O
50%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
when	NN	O	O
the	NN	O	O
dose	NN	O	O
is	NN	O	O
adjusted	NN	O	O
based	NN	O	O
on	NN	O	O
clinical	NN	O	O
response	NN	O	O
or	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
adverse	NN	O	O
effects	NN	O	O
,	NN	O	O
75%	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
VT	NN	O	B-Disease
or	NN	O	O
VF	NN	O	B-Disease
can	NN	O	O
be	NN	O	O
successfully	NN	O	O
managed	NN	O	O
with	NN	O	O
amiodarone	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (8800187)

Effect	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
and	NN	O	O
4	NN	O	B-Chemical
-	NN	O	I-Chemical
aminopyridine	NN	O	I-Chemical
therapy	NN	O	O
on	NN	O	O
desipramine	NN	O	B-Chemical
toxicity	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Hypotension	NN	O	B-Disease
is	NN	O	O
a	NN	O	O
major	NN	O	O
contributor	NN	O	O
to	NN	O	O
mortality	NN	O	O
in	NN	O	O
tricyclic	NN	O	O
antidepressant	NN	O	O
overdose	NN	O	B-Disease
.	NN	O	O

Recent	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
tricyclic	NN	O	O
antidepressants	NN	O	O
inhibit	NN	O	O
calcium	NN	O	B-Chemical
influx	NN	O	O
in	NN	O	O
some	NN	O	O
tissues	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
addressed	NN	O	O
the	NN	O	O
potential	NN	O	O
role	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
channel	NN	O	O
blockade	NN	O	O
in	NN	O	O
tricyclic	NN	O	O
antidepressant	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Two	NN	O	O
interventions	NN	O	O
were	NN	O	O
studied	NN	O	O
that	NN	O	O
have	NN	O	O
been	NN	O	O
shown	NN	O	O
previously	NN	O	O
to	NN	O	O
improve	NN	O	O
blood	NN	O	O
pressure	NN	O	O
with	NN	O	O
calcium	NN	O	B-Chemical
channel	NN	O	O
blocker	NN	O	O
overdose	NN	O	B-Disease
.	NN	O	O

CaCl2	NN	O	B-Chemical
and	NN	O	O
4	NN	O	B-Chemical
-	NN	O	I-Chemical
aminopyridine	NN	O	I-Chemical
.	NN	O	O

Anesthetized	NN	O	O
rats	NN	O	O
received	NN	O	O
the	NN	O	O
tricyclic	NN	O	O
antidepressant	NN	O	O
desipramine	NN	O	B-Chemical
IP	NN	O	O
to	NN	O	O
produce	NN	O	O
hypotension	NN	O	B-Disease
,	NN	O	O
QRS	NN	O	O
prolongation	NN	O	O
,	NN	O	O
and	NN	O	O
bradycardia	NN	O	B-Disease
.	NN	O	O

Fifteen	NN	O	O
min	NN	O	O
later	NN	O	O
,	NN	O	O
animals	NN	O	O
received	NN	O	O
CaCl2	NN	O	B-Chemical
,	NN	O	O
NaHCO3	NN	O	B-Chemical
,	NN	O	O
or	NN	O	O
saline	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
second	NN	O	O
experiment	NN	O	O
,	NN	O	O
rats	NN	O	O
received	NN	O	O
tricyclic	NN	O	O
antidepressant	NN	O	O
desipramine	NN	O	B-Chemical
IP	NN	O	O
followed	NN	O	O
in	NN	O	O
15	NN	O	O
min	NN	O	O
by	NN	O	O
4	NN	O	B-Chemical
-	NN	O	I-Chemical
aminopyridine	NN	O	I-Chemical
or	NN	O	O
saline	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
NaHCO3	NN	O	B-Chemical
briefly	NN	O	O
(	NN	O	O
5	NN	O	O
min	NN	O	O
)	NN	O	O
reversed	NN	O	O
hypotension	NN	O	B-Disease
and	NN	O	O
QRS	NN	O	O
prolongation	NN	O	O
.	NN	O	O

CaCl2	NN	O	B-Chemical
and	NN	O	O
4	NN	O	B-Chemical
-	NN	O	I-Chemical
aminopyridine	NN	O	I-Chemical
failed	NN	O	O
to	NN	O	O
improve	NN	O	O
blood	NN	O	O
pressure	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
ventricular	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.004	NN	O	O
)	NN	O	O
and	NN	O	O
seizures	NN	O	B-Disease
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.03	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
CaCl2	NN	O	B-Chemical
group	NN	O	O
was	NN	O	O
higher	NN	O	O
than	NN	O	O
the	NN	O	O
other	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
administration	NN	O	O
of	NN	O	O
CaCl2	NN	O	B-Chemical
or	NN	O	O
4	NN	O	B-Chemical
-	NN	O	I-Chemical
aminopyridine	NN	O	I-Chemical
did	NN	O	O
not	NN	O	O
reverse	NN	O	O
tricyclic	NN	O	O
antidepressant	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

CaCl2	NN	O	B-Chemical
therapy	NN	O	O
may	NN	O	O
possibly	NN	O	O
worsen	NN	O	O
both	NN	O	O
cardiovascular	NN	O	B-Disease
and	NN	O	I-Disease
central	NN	O	I-Disease
nervous	NN	O	I-Disease
system	NN	O	I-Disease
toxicity	NN	O	I-Disease
.	NN	O	O

These	NN	O	O
findings	NN	O	O
do	NN	O	O
not	NN	O	O
support	NN	O	O
a	NN	O	O
role	NN	O	O
for	NN	O	O
calcium	NN	O	B-Chemical
channel	NN	O	O
inhibition	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
tricyclic	NN	O	O
antidepressant	NN	O	O
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (7707116)

Phase	NN	O	O
I	NN	O	O
trial	NN	O	O
of	NN	O	O
13	NN	O	B-Chemical
-	NN	O	I-Chemical
cis	NN	O	I-Chemical
-	NN	O	I-Chemical
retinoic	NN	O	I-Chemical
acid	NN	O	I-Chemical
in	NN	O	O
children	NN	O	O
with	NN	O	O
neuroblastoma	NN	O	B-Disease
following	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
Treatment	NN	O	O
of	NN	O	O
neuroblastoma	NN	O	B-Disease
cell	NN	O	O
lines	NN	O	O
with	NN	O	O
13	NN	O	B-Chemical
-	NN	O	I-Chemical
cis	NN	O	I-Chemical
-	NN	O	I-Chemical
retinoic	NN	O	I-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
cis	NN	O	B-Chemical
-	NN	O	I-Chemical
RA	NN	O	I-Chemical
)	NN	O	O
can	NN	O	O
cause	NN	O	O
sustained	NN	O	O
inhibition	NN	O	O
of	NN	O	O
proliferation	NN	O	O
.	NN	O	O

Since	NN	O	O
cis	NN	O	B-Chemical
-	NN	O	I-Chemical
RA	NN	O	I-Chemical
has	NN	O	O
demonstrated	NN	O	O
clinical	NN	O	O
responses	NN	O	O
in	NN	O	O
neuroblastoma	NN	O	B-Disease
patients	NN	O	O
,	NN	O	O
it	NN	O	O
may	NN	O	O
be	NN	O	O
effective	NN	O	O
in	NN	O	O
preventing	NN	O	O
relapse	NN	O	O
after	NN	O	O
cytotoxic	NN	O	O
therapy	NN	O	O
.	NN	O	O

This	NN	O	O
phase	NN	O	O
I	NN	O	O
trial	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
maximal	NN	O	O
-	NN	O	O
tolerated	NN	O	O
dosage	NN	O	O
(	NN	O	O
MTD	NN	O	O
)	NN	O	O
,	NN	O	O
toxicities	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
pharmacokinetics	NN	O	O
of	NN	O	O
cis	NN	O	B-Chemical
-	NN	O	I-Chemical
RA	NN	O	I-Chemical
administered	NN	O	O
on	NN	O	O
an	NN	O	O
intermittent	NN	O	O
schedule	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
neuroblastoma	NN	O	B-Disease
following	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
(	NN	O	O
BMT	NN	O	O
)	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Fifty	NN	O	O
-	NN	O	O
one	NN	O	O
assessable	NN	O	O
patients	NN	O	O
,	NN	O	O
2	NN	O	O
to	NN	O	O
12	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
,	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
oral	NN	O	O
cis	NN	O	B-Chemical
-	NN	O	I-Chemical
RA	NN	O	I-Chemical
administered	NN	O	O
in	NN	O	O
two	NN	O	O
equally	NN	O	O
divided	NN	O	O
doses	NN	O	O
daily	NN	O	O
for	NN	O	O
2	NN	O	O
weeks	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
week	NN	O	O
rest	NN	O	O
period	NN	O	O
,	NN	O	O
for	NN	O	O
up	NN	O	O
to	NN	O	O
12	NN	O	O
courses	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
was	NN	O	O
escalated	NN	O	O
from	NN	O	O
100	NN	O	O
to	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
d	NN	O	O
until	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
toxicity	NN	O	B-Disease
(	NN	O	O
DLT	NN	O	O
)	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

A	NN	O	O
single	NN	O	O
intrapatient	NN	O	O
dose	NN	O	O
escalation	NN	O	O
was	NN	O	O
permitted	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
MTD	NN	O	O
of	NN	O	O
cis	NN	O	B-Chemical
-	NN	O	I-Chemical
RA	NN	O	I-Chemical
was	NN	O	O
160	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
d	NN	O	O
.	NN	O	O

Dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
toxicities	NN	O	B-Disease
in	NN	O	O
six	NN	O	O
of	NN	O	O
nine	NN	O	O
patients	NN	O	O
at	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
d	NN	O	O
included	NN	O	O
hypercalcemia	NN	O	B-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
3	NN	O	O
)	NN	O	O
,	NN	O	O
rash	NN	O	B-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
anemia	NN	O	B-Disease
/	NN	O	O
thrombocytopenia	NN	O	B-Disease
/	NN	O	O
emesis	NN	O	B-Disease
/	NN	O	O
rash	NN	O	B-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

All	NN	O	O
toxicities	NN	O	B-Disease
resolved	NN	O	O
after	NN	O	O
cis	NN	O	B-Chemical
-	NN	O	I-Chemical
RA	NN	O	I-Chemical
was	NN	O	O
discontinued	NN	O	O
.	NN	O	O

Three	NN	O	O
complete	NN	O	O
responses	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
marrow	NN	O	O
metastases	NN	O	B-Disease
.	NN	O	O

Serum	NN	O	O
levels	NN	O	O
of	NN	O	O
7.4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3.0	NN	O	O
mumol	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
peak	NN	O	O
)	NN	O	O
and	NN	O	O
4.0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.8	NN	O	O
mumol	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
trough	NN	O	O
)	NN	O	O
at	NN	O	O
the	NN	O	O
MTD	NN	O	O
were	NN	O	O
maintained	NN	O	O
during	NN	O	O
14	NN	O	O
days	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
DLT	NN	O	O
correlated	NN	O	O
with	NN	O	O
serum	NN	O	O
levels	NN	O	O
>	NN	O	O
or	NN	O	O
=	NN	O	O
10	NN	O	O
mumol	NN	O	O
/	NN	O	O
L	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
MTD	NN	O	O
of	NN	O	O
cis	NN	O	B-Chemical
-	NN	O	I-Chemical
RA	NN	O	I-Chemical
given	NN	O	O
on	NN	O	O
this	NN	O	O
intermittent	NN	O	O
schedule	NN	O	O
was	NN	O	O
160	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
d	NN	O	O
.	NN	O	O

Serum	NN	O	O
levels	NN	O	O
known	NN	O	O
to	NN	O	O
be	NN	O	O
effective	NN	O	O
against	NN	O	O
neuroblastoma	NN	O	B-Disease
in	NN	O	O
vitro	NN	O	O
were	NN	O	O
achieved	NN	O	O
at	NN	O	O
this	NN	O	O
dose	NN	O	O
.	NN	O	O

The	NN	O	O
DLT	NN	O	O
included	NN	O	O
hypercalcemia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
predicted	NN	O	O
by	NN	O	O
serum	NN	O	O
cis	NN	O	B-Chemical
-	NN	O	I-Chemical
RA	NN	O	I-Chemical
levels	NN	O	O
.	NN	O	O

Monitoring	NN	O	O
of	NN	O	O
serum	NN	O	O
calcium	NN	O	B-Chemical
and	NN	O	O
cis	NN	O	B-Chemical
-	NN	O	I-Chemical
RA	NN	O	I-Chemical
levels	NN	O	O
is	NN	O	O
indicated	NN	O	O
in	NN	O	O
future	NN	O	O
trials	NN	O	O
.	NN	O	O


-DOCSTART- (6892185)

Effect	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
on	NN	O	O
gross	NN	O	O
behavioural	NN	O	O
changes	NN	O	O
produced	NN	O	O
by	NN	O	O
carbachol	NN	O	B-Chemical
and	NN	O	O
eserine	NN	O	B-Chemical
in	NN	O	O
cats	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
injected	NN	O	O
into	NN	O	O
the	NN	O	O
cerebral	NN	O	O
ventricles	NN	O	O
of	NN	O	O
group	NN	O	O
-	NN	O	O
housed	NN	O	O
unanaesthetized	NN	O	O
cats	NN	O	O
upon	NN	O	O
vocalization	NN	O	O
(	NN	O	O
rage	NN	O	O
,	NN	O	O
hissing	NN	O	O
and	NN	O	O
snarling	NN	O	O
)	NN	O	O
,	NN	O	O
fighting	NN	O	O
(	NN	O	O
attack	NN	O	O
with	NN	O	O
paws	NN	O	O
and	NN	O	O
claws	NN	O	O
,	NN	O	O
defense	NN	O	O
with	NN	O	O
paws	NN	O	O
and	NN	O	O
claws	NN	O	O
and	NN	O	O
biting	NN	O	O
)	NN	O	O
,	NN	O	O
mydriasis	NN	O	B-Disease
,	NN	O	O
tremor	NN	O	B-Disease
and	NN	O	O
clonic	NN	O	B-Disease
-	NN	O	I-Disease
tonic	NN	O	I-Disease
convulsions	NN	O	I-Disease
produced	NN	O	O
by	NN	O	O
carbachol	NN	O	B-Chemical
and	NN	O	O
eserine	NN	O	B-Chemical
injected	NN	O	O
similarly	NN	O	O
was	NN	O	O
investigated	NN	O	O
.	NN	O	O

Calcium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
depressed	NN	O	O
or	NN	O	O
almost	NN	O	O
completely	NN	O	O
abolished	NN	O	O
the	NN	O	O
vocalization	NN	O	O
and	NN	O	O
fighting	NN	O	O
due	NN	O	O
to	NN	O	O
carbachol	NN	O	B-Chemical
and	NN	O	O
eserine	NN	O	B-Chemical
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
mydriasis	NN	O	B-Disease
,	NN	O	O
tremor	NN	O	B-Disease
and	NN	O	O
clonic	NN	O	B-Disease
-	NN	O	I-Disease
tonic	NN	O	I-Disease
convulsions	NN	O	I-Disease
evoked	NN	O	O
by	NN	O	O
carbachol	NN	O	B-Chemical
and	NN	O	O
eserine	NN	O	B-Chemical
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
changed	NN	O	O
by	NN	O	O
calcium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
.	NN	O	O

It	NN	O	O
is	NN	O	O
apparent	NN	O	O
that	NN	O	O
calcium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
can	NN	O	O
"	NN	O	O
dissociate	NN	O	O
"	NN	O	O
vocalization	NN	O	O
and	NN	O	O
fighting	NN	O	O
from	NN	O	O
autonomic	NN	O	O
and	NN	O	O
motor	NN	O	O
phenomena	NN	O	O
such	NN	O	O
as	NN	O	O
mydriasis	NN	O	B-Disease
,	NN	O	O
tremor	NN	O	B-Disease
and	NN	O	O
clonic	NN	O	B-Disease
-	NN	O	I-Disease
tonic	NN	O	I-Disease
convulsions	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
carbachol	NN	O	B-Chemical
and	NN	O	O
eserine	NN	O	B-Chemical
.	NN	O	O

Calcium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
inhibited	NN	O	O
the	NN	O	O
vocalization	NN	O	O
and	NN	O	O
fighting	NN	O	O
produced	NN	O	O
by	NN	O	O
carbachol	NN	O	B-Chemical
and	NN	O	O
eserine	NN	O	B-Chemical
most	NN	O	O
probably	NN	O	O
by	NN	O	O
a	NN	O	O
nonspecific	NN	O	O
stabilizing	NN	O	O
action	NN	O	O
on	NN	O	O
central	NN	O	O
muscarinic	NN	O	O
cholinoceptive	NN	O	O
sites	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
further	NN	O	O
support	NN	O	O
the	NN	O	O
view	NN	O	O
that	NN	O	O
calcium	NN	O	B-Chemical
ions	NN	O	O
in	NN	O	O
excess	NN	O	O
have	NN	O	O
an	NN	O	O
atropine	NN	O	B-Chemical
-	NN	O	O
like	NN	O	O
action	NN	O	O
also	NN	O	O
in	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
.	NN	O	O


-DOCSTART- (6216862)

Multiple	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
penicillamine	NN	O	B-Chemical
therapy	NN	O	O
in	NN	O	O
one	NN	O	O
patient	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
.	NN	O	O

Skin	NN	O	B-Disease
rashes	NN	O	I-Disease
,	NN	O	O
proteinuria	NN	O	B-Disease
,	NN	O	O
systemic	NN	O	B-Disease
lupus	NN	O	I-Disease
erythematosus	NN	O	I-Disease
,	NN	O	O
polymyositis	NN	O	B-Disease
and	NN	O	O
myasthenia	NN	O	B-Disease
gravis	NN	O	I-Disease
have	NN	O	O
all	NN	O	O
been	NN	O	O
recorded	NN	O	O
as	NN	O	O
complications	NN	O	O
of	NN	O	O
penicillamine	NN	O	B-Chemical
therapy	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
patient	NN	O	O
who	NN	O	O
had	NN	O	O
developed	NN	O	O
all	NN	O	O
5	NN	O	O
is	NN	O	O
now	NN	O	O
described	NN	O	O
.	NN	O	O

The	NN	O	O
skin	NN	O	B-Disease
lesion	NN	O	I-Disease
resembled	NN	O	O
elastosis	NN	O	B-Disease
perforans	NN	O	I-Disease
serpiginosa	NN	O	I-Disease
,	NN	O	O
which	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
as	NN	O	O
a	NN	O	O
rare	NN	O	O
side	NN	O	O
effect	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
Wilson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
but	NN	O	O
not	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
treated	NN	O	O
with	NN	O	O
penicillamine	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (2004)

Electrocardiographic	NN	O	O
changes	NN	O	O
and	NN	O	O
cardiac	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
psychotropic	NN	O	O
drugs	NN	O	O
.	NN	O	O

Eight	NN	O	O
patients	NN	O	O
had	NN	O	O
cardiac	NN	O	O
manifestations	NN	O	O
that	NN	O	O
were	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
in	NN	O	O
five	NN	O	O
while	NN	O	O
taking	NN	O	O
psychotropic	NN	O	O
drugs	NN	O	O
,	NN	O	O
either	NN	O	O
phenothiazines	NN	O	B-Chemical
or	NN	O	O
tricyclic	NN	O	O
antidepressants	NN	O	O
.	NN	O	O

Although	NN	O	O
most	NN	O	O
patients	NN	O	O
were	NN	O	O
receiving	NN	O	O
several	NN	O	O
drugs	NN	O	O
,	NN	O	O
Mellaril	NN	O	B-Chemical
(	NN	O	O
thioridazine	NN	O	B-Chemical
)	NN	O	O
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
five	NN	O	O
cases	NN	O	O
of	NN	O	O
ventricular	NN	O	B-Disease
tachycardia	NN	O	I-Disease
,	NN	O	O
one	NN	O	O
of	NN	O	O
which	NN	O	O
was	NN	O	O
fatal	NN	O	O
in	NN	O	O
a	NN	O	O
35	NN	O	O
year	NN	O	O
old	NN	O	O
woman	NN	O	O
.	NN	O	O

Supraventricular	NN	O	B-Disease
tachycardia	NN	O	I-Disease
developed	NN	O	O
in	NN	O	O
one	NN	O	O
patient	NN	O	O
receiving	NN	O	O
Thorazine	NN	O	B-Chemical
(	NN	O	O
chlorpromazine	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

Aventyl	NN	O	B-Chemical
(	NN	O	O
nortriptyline	NN	O	B-Chemical
)	NN	O	O
and	NN	O	O
Elavil	NN	O	B-Chemical
(	NN	O	O
amitriptyline	NN	O	B-Chemical
)	NN	O	O
each	NN	O	O
produced	NN	O	O
left	NN	O	B-Disease
bundle	NN	O	I-Disease
branch	NN	O	I-Disease
block	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
73	NN	O	O
year	NN	O	O
old	NN	O	O
woman	NN	O	O
.	NN	O	O

Electrocardiographic	NN	O	O
T	NN	O	O
and	NN	O	O
U	NN	O	O
wave	NN	O	O
abnormalities	NN	O	O
were	NN	O	O
present	NN	O	O
in	NN	O	O
most	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
ventricular	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
responded	NN	O	O
to	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
and	NN	O	O
to	NN	O	O
direct	NN	O	O
current	NN	O	O
electric	NN	O	O
shock	NN	O	O
;	NN	O	O
ventricular	NN	O	O
pacing	NN	O	O
was	NN	O	O
required	NN	O	O
in	NN	O	O
some	NN	O	O
instances	NN	O	O
and	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
propranolol	NN	O	B-Chemical
combined	NN	O	O
with	NN	O	O
ventricular	NN	O	O
pacing	NN	O	O
in	NN	O	O
one	NN	O	O
.	NN	O	O

The	NN	O	O
tachyarrhythmias	NN	O	B-Disease
generally	NN	O	O
subsided	NN	O	O
within	NN	O	O
48	NN	O	O
hours	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
drugs	NN	O	O
was	NN	O	O
stopped	NN	O	O
.	NN	O	O

Five	NN	O	O
of	NN	O	O
the	NN	O	O
eight	NN	O	O
patients	NN	O	O
were	NN	O	O
50	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
or	NN	O	O
younger	NN	O	O
;	NN	O	O
only	NN	O	O
one	NN	O	O
clearly	NN	O	O
had	NN	O	O
antecedent	NN	O	O
heart	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

Major	NN	O	O
cardiac	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
are	NN	O	O
a	NN	O	O
potential	NN	O	O
hazard	NN	O	O
in	NN	O	O
patients	NN	O	O
without	NN	O	O
heart	NN	O	B-Disease
disease	NN	O	I-Disease
who	NN	O	O
are	NN	O	O
receiving	NN	O	O
customary	NN	O	O
therapeutic	NN	O	O
doses	NN	O	O
of	NN	O	O
psychotropic	NN	O	O
drugs	NN	O	O
.	NN	O	O

A	NN	O	O
prospective	NN	O	O
clinical	NN	O	O
trial	NN	O	O
is	NN	O	O
suggested	NN	O	O
to	NN	O	O
quantify	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
cardiac	NN	O	B-Disease
complications	NN	O	I-Disease
to	NN	O	O
patients	NN	O	O
receiving	NN	O	O
phenothiazines	NN	O	B-Chemical
or	NN	O	O
tricyclic	NN	O	O
antidepressant	NN	O	O
drugs	NN	O	O
.	NN	O	O


-DOCSTART- (6118280)

Serotonergic	NN	O	O
drugs	NN	O	O
,	NN	O	O
benzodiazepines	NN	O	B-Chemical
and	NN	O	O
baclofen	NN	O	B-Chemical
block	NN	O	O
muscimol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
myoclonic	NN	O	B-Disease
jerks	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
strain	NN	O	O
of	NN	O	O
mice	NN	O	O
.	NN	O	O

In	NN	O	O
male	NN	O	O
Swiss	NN	O	O
mice	NN	O	O
,	NN	O	O
muscimol	NN	O	B-Chemical
produced	NN	O	O
myoclonic	NN	O	B-Disease
jerks	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
(	NN	O	O
i.p.	NN	O	O
)	NN	O	O
dose	NN	O	O
induced	NN	O	O
this	NN	O	O
response	NN	O	O
in	NN	O	O
all	NN	O	O
of	NN	O	O
the	NN	O	O
mice	NN	O	O
tested	NN	O	O
and	NN	O	O
the	NN	O	O
peak	NN	O	O
response	NN	O	O
of	NN	O	O
73	NN	O	O
jerks	NN	O	O
per	NN	O	O
min	NN	O	O
was	NN	O	O
observed	NN	O	O
between	NN	O	O
27	NN	O	O
and	NN	O	O
45	NN	O	O
min	NN	O	O
.	NN	O	O

Increasing	NN	O	O
the	NN	O	O
brain	NN	O	O
serotonin	NN	O	B-Chemical
levels	NN	O	O
by	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxytryptophan	NN	O	I-Chemical
(	NN	O	O
80	NN	O	O
-	NN	O	O
160	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
a	NN	O	O
peripheral	NN	O	O
decarboxylase	NN	O	O
inhibitor	NN	O	O
resulted	NN	O	O
in	NN	O	O
an	NN	O	O
inhibition	NN	O	O
of	NN	O	O
the	NN	O	O
muscimol	NN	O	B-Chemical
effect	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
in	NN	O	O
a	NN	O	O
similar	NN	O	O
experiment	NN	O	O
l	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
(	NN	O	O
80	NN	O	O
-	NN	O	O
160	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
without	NN	O	O
effect	NN	O	O
.	NN	O	O

In	NN	O	O
doses	NN	O	O
of	NN	O	O
3	NN	O	O
-	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
the	NN	O	O
serotonin	NN	O	B-Chemical
receptor	NN	O	O
agonist	NN	O	O
MK	NN	O	B-Chemical
-	NN	O	I-Chemical
212	NN	O	I-Chemical
caused	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
blockade	NN	O	O
of	NN	O	O
the	NN	O	O
response	NN	O	O
of	NN	O	O
muscimol	NN	O	B-Chemical
.	NN	O	O

Of	NN	O	O
the	NN	O	O
benzodiazepines	NN	O	B-Chemical
,	NN	O	O
clonazepam	NN	O	B-Chemical
(	NN	O	O
0.1	NN	O	O
-	NN	O	O
0.3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
several	NN	O	O
fold	NN	O	O
more	NN	O	O
potent	NN	O	O
than	NN	O	O
diazepam	NN	O	B-Chemical
(	NN	O	O
0.3	NN	O	O
-	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
in	NN	O	O
blocking	NN	O	O
the	NN	O	O
myoclonic	NN	O	B-Disease
jerks	NN	O	I-Disease
.	NN	O	O

While	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
baclofen	NN	O	B-Chemical
(	NN	O	O
1	NN	O	O
-	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
proved	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
effective	NN	O	O
antagonist	NN	O	O
of	NN	O	O
muscimol	NN	O	B-Chemical
,	NN	O	O
its	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
isomer	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
lacked	NN	O	O
this	NN	O	O
property	NN	O	O
.	NN	O	O

Considering	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HTP	NN	O	I-Chemical
and	NN	O	O
the	NN	O	O
benzodiazepines	NN	O	B-Chemical
have	NN	O	O
been	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
beneficial	NN	O	O
in	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
clinical	NN	O	O
myoclonus	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
muscimol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
myoclonus	NN	O	B-Disease
seems	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
satisfactory	NN	O	O
animal	NN	O	O
model	NN	O	O
that	NN	O	O
may	NN	O	O
prove	NN	O	O
useful	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
new	NN	O	O
drug	NN	O	O
treatments	NN	O	O
for	NN	O	O
this	NN	O	O
condition	NN	O	O
.	NN	O	O

Our	NN	O	O
present	NN	O	O
study	NN	O	O
indicated	NN	O	O
the	NN	O	O
possible	NN	O	O
value	NN	O	O
of	NN	O	O
MK	NN	O	B-Chemical
-	NN	O	I-Chemical
212	NN	O	I-Chemical
and	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
baclofen	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
clinical	NN	O	O
myoclonus	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (3703509)

Hyperglycemic	NN	O	B-Disease
acidotic	NN	O	I-Disease
coma	NN	O	I-Disease
and	NN	O	O
death	NN	O	O
in	NN	O	O
Kearns	NN	O	B-Disease
-	NN	O	I-Disease
Sayre	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
paper	NN	O	O
presents	NN	O	O
the	NN	O	O
clinical	NN	O	O
and	NN	O	O
metabolic	NN	O	O
findings	NN	O	O
in	NN	O	O
two	NN	O	O
young	NN	O	O
boys	NN	O	O
with	NN	O	O
long	NN	O	O
-	NN	O	O
standing	NN	O	O
Kearns	NN	O	B-Disease
-	NN	O	I-Disease
Sayre	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Following	NN	O	O
short	NN	O	O
exposure	NN	O	O
to	NN	O	O
oral	NN	O	O
prednisone	NN	O	B-Chemical
,	NN	O	O
both	NN	O	O
boys	NN	O	O
developed	NN	O	O
lethargy	NN	O	B-Disease
,	NN	O	O
increasing	NN	O	O
somnolence	NN	O	B-Disease
,	NN	O	O
polydipsia	NN	O	B-Disease
,	NN	O	O
polyphagia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
polyuria	NN	O	B-Disease
.	NN	O	O

Both	NN	O	O
presented	NN	O	O
in	NN	O	O
the	NN	O	O
emergency	NN	O	O
room	NN	O	O
with	NN	O	O
profound	NN	O	O
coma	NN	O	B-Disease
,	NN	O	O
hypotension	NN	O	B-Disease
,	NN	O	O
severe	NN	O	O
hyperglycemia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
acidosis	NN	O	B-Disease
.	NN	O	O

Nonketotic	NN	O	O
lactic	NN	O	B-Disease
acidosis	NN	O	I-Disease
was	NN	O	O
present	NN	O	O
in	NN	O	O
one	NN	O	O
and	NN	O	O
ketosis	NN	O	B-Disease
without	NN	O	O
a	NN	O	O
known	NN	O	O
serum	NN	O	O
lactate	NN	O	B-Chemical
level	NN	O	O
was	NN	O	O
present	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
.	NN	O	O

Respiratory	NN	O	B-Disease
failure	NN	O	I-Disease
rapidly	NN	O	O
ensued	NN	O	O
and	NN	O	O
both	NN	O	O
patients	NN	O	O
expired	NN	O	O
in	NN	O	O
spite	NN	O	O
of	NN	O	O
efforts	NN	O	O
at	NN	O	O
resuscitation	NN	O	O
.	NN	O	O

We	NN	O	O
believe	NN	O	O
these	NN	O	O
two	NN	O	O
cases	NN	O	O
represent	NN	O	O
a	NN	O	O
newly	NN	O	O
described	NN	O	O
and	NN	O	O
catastrophic	NN	O	O
metabolic	NN	O	B-Disease
-	NN	O	I-Disease
endocrine	NN	O	I-Disease
failure	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
Kearns	NN	O	B-Disease
-	NN	O	I-Disease
Sayre	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (20683499)

Effects	NN	O	O
of	NN	O	O
active	NN	O	O
constituents	NN	O	O
of	NN	O	O
Crocus	NN	O	O
sativus	NN	O	O
L.	NN	O	O
,	NN	O	O
crocin	NN	O	B-Chemical
on	NN	O	O
streptozocin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
model	NN	O	O
of	NN	O	O
sporadic	NN	O	O
Alzheimer	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
in	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
involvement	NN	O	O
of	NN	O	O
water	NN	O	O
-	NN	O	O
soluble	NN	O	O
carotenoids	NN	O	B-Chemical
,	NN	O	O
crocins	NN	O	B-Chemical
,	NN	O	O
as	NN	O	O
the	NN	O	O
main	NN	O	O
and	NN	O	O
active	NN	O	O
components	NN	O	O
of	NN	O	O
Crocus	NN	O	O
sativus	NN	O	O
L	NN	O	O
.	NN	O	O

extract	NN	O	O
in	NN	O	O
learning	NN	O	O
and	NN	O	O
memory	NN	O	O
processes	NN	O	O
has	NN	O	O
been	NN	O	O
proposed	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
crocins	NN	O	B-Chemical
on	NN	O	O
sporadic	NN	O	O
Alzheimer	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
intracerebroventricular	NN	O	O
(	NN	O	O
icv	NN	O	O
)	NN	O	O
streptozocin	NN	O	B-Chemical
(	NN	O	O
STZ	NN	O	B-Chemical
)	NN	O	O
in	NN	O	O
male	NN	O	O
rats	NN	O	O
was	NN	O	O
investigated	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Male	NN	O	O
adult	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
90	NN	O	O
and	NN	O	O
260	NN	O	O
-	NN	O	O
290	NN	O	O
g	NN	O	O
)	NN	O	O
were	NN	O	O
divided	NN	O	O
into	NN	O	O
1	NN	O	O
,	NN	O	O
control	NN	O	O
;	NN	O	O
2	NN	O	O
and	NN	O	O
3	NN	O	O
,	NN	O	O
crocins	NN	O	B-Chemical
(	NN	O	O
15	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
;	NN	O	O
4	NN	O	O
,	NN	O	O
STZ	NN	O	B-Chemical
;	NN	O	O
5	NN	O	O
and	NN	O	O
6	NN	O	O
,	NN	O	O
STZ	NN	O	B-Chemical
+	NN	O	O
crocins	NN	O	B-Chemical
(	NN	O	O
15	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
groups	NN	O	O
.	NN	O	O

In	NN	O	O
Alzheimer	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
groups	NN	O	O
,	NN	O	O
rats	NN	O	O
were	NN	O	O
injected	NN	O	O
with	NN	O	O
STZ	NN	O	B-Chemical
-	NN	O	O
icv	NN	O	O
bilaterally	NN	O	O
(	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
in	NN	O	O
first	NN	O	O
day	NN	O	O
and	NN	O	O
3	NN	O	O
days	NN	O	O
later	NN	O	O
,	NN	O	O
a	NN	O	O
similar	NN	O	O
STZ	NN	O	B-Chemical
-	NN	O	O
icv	NN	O	O
application	NN	O	O
was	NN	O	O
repeated	NN	O	O
.	NN	O	O

In	NN	O	O
STZ	NN	O	B-Chemical
+	NN	O	O
crocin	NN	O	B-Chemical
animal	NN	O	O
groups	NN	O	O
,	NN	O	O
crocin	NN	O	B-Chemical
was	NN	O	O
applied	NN	O	O
in	NN	O	O
doses	NN	O	O
of	NN	O	O
15	NN	O	O
and	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.p.	NN	O	O
,	NN	O	O
one	NN	O	O
day	NN	O	O
pre	NN	O	O
-	NN	O	O
surgery	NN	O	O
and	NN	O	O
continued	NN	O	O
for	NN	O	O
three	NN	O	O
weeks	NN	O	O
.	NN	O	O

Prescription	NN	O	O
of	NN	O	O
crocin	NN	O	B-Chemical
in	NN	O	O
each	NN	O	O
dose	NN	O	O
was	NN	O	O
repeated	NN	O	O
once	NN	O	O
for	NN	O	O
two	NN	O	O
days	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
learning	NN	O	O
and	NN	O	O
memory	NN	O	O
performance	NN	O	O
was	NN	O	O
assessed	NN	O	O
using	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
paradigm	NN	O	O
,	NN	O	O
and	NN	O	O
for	NN	O	O
spatial	NN	O	O
cognition	NN	O	O
evaluation	NN	O	O
,	NN	O	O
Y	NN	O	O
-	NN	O	O
maze	NN	O	O
task	NN	O	O
was	NN	O	O
used	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
It	NN	O	O
was	NN	O	O
found	NN	O	O
out	NN	O	O
that	NN	O	O
crocin	NN	O	B-Chemical
(	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
-	NN	O	O
treated	NN	O	O
STZ	NN	O	B-Chemical
-	NN	O	O
injected	NN	O	O
rats	NN	O	O
show	NN	O	O
higher	NN	O	O
correct	NN	O	O
choices	NN	O	O
and	NN	O	O
lower	NN	O	O
errors	NN	O	O
in	NN	O	O
Y	NN	O	O
-	NN	O	O
maze	NN	O	O
than	NN	O	O
vehicle	NN	O	O
-	NN	O	O
treated	NN	O	O
STZ	NN	O	B-Chemical
-	NN	O	O
injected	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
crocin	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
mentioned	NN	O	O
dose	NN	O	O
could	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
learning	NN	O	B-Disease
and	NN	O	I-Disease
memory	NN	O	I-Disease
impairment	NN	O	I-Disease
in	NN	O	O
treated	NN	O	O
STZ	NN	O	B-Chemical
-	NN	O	O
injected	NN	O	O
group	NN	O	O
in	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
test	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Therefore	NN	O	O
,	NN	O	O
these	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
crocin	NN	O	B-Chemical
(	NN	O	O
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
in	NN	O	O
antagonizing	NN	O	O
the	NN	O	O
cognitive	NN	O	B-Disease
deficits	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
STZ	NN	O	B-Chemical
-	NN	O	O
icv	NN	O	O
in	NN	O	O
rats	NN	O	O
and	NN	O	O
its	NN	O	O
potential	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
neurodegenerative	NN	O	B-Disease
diseases	NN	O	I-Disease
such	NN	O	O
as	NN	O	O
Alzheimer	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (20466178)

Rosaceiform	NN	O	O
dermatitis	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
topical	NN	O	O
tacrolimus	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
herein	NN	O	O
3	NN	O	O
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
rosacea	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
dermatitis	NN	O	B-Disease
eruptions	NN	O	B-Disease
while	NN	O	O
using	NN	O	O
0.03%	NN	O	O
or	NN	O	O
0.1%	NN	O	O
tacrolimus	NN	O	B-Chemical
ointment	NN	O	O
for	NN	O	O
facial	NN	O	B-Disease
dermatitis	NN	O	I-Disease
.	NN	O	O

Skin	NN	O	O
biopsy	NN	O	O
specimens	NN	O	O
showed	NN	O	O
telangiectasia	NN	O	B-Disease
and	NN	O	O
noncaseating	NN	O	O
epithelioid	NN	O	O
granulomatous	NN	O	O
tissue	NN	O	O
formation	NN	O	O
in	NN	O	O
the	NN	O	O
papillary	NN	O	O
to	NN	O	O
mid	NN	O	O
dermis	NN	O	O
.	NN	O	O

Continuous	NN	O	O
topical	NN	O	O
use	NN	O	O
of	NN	O	O
immunomodulators	NN	O	O
such	NN	O	O
as	NN	O	O
tacrolimus	NN	O	B-Chemical
or	NN	O	O
pimecrolimus	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
regarded	NN	O	O
as	NN	O	O
a	NN	O	O
potential	NN	O	O
cause	NN	O	O
of	NN	O	O
rosaceiform	NN	O	O
dermatitis	NN	O	B-Disease
,	NN	O	O
although	NN	O	O
many	NN	O	O
cases	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O


-DOCSTART- (19944736)

A	NN	O	O
novel	NN	O	O
animal	NN	O	O
model	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
a	NN	O	O
drug	NN	O	O
delivery	NN	O	O
system	NN	O	O
to	NN	O	O
promote	NN	O	O
the	NN	O	O
passage	NN	O	O
through	NN	O	O
the	NN	O	O
BBB	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
investigation	NN	O	O
was	NN	O	O
to	NN	O	O
explore	NN	O	O
the	NN	O	O
potentiality	NN	O	O
of	NN	O	O
a	NN	O	O
novel	NN	O	O
animal	NN	O	O
model	NN	O	O
to	NN	O	O
be	NN	O	O
used	NN	O	O
for	NN	O	O
the	NN	O	O
in	NN	O	O
vivo	NN	O	O
evaluation	NN	O	O
of	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
a	NN	O	O
drug	NN	O	O
delivery	NN	O	O
system	NN	O	O
to	NN	O	O
promote	NN	O	O
the	NN	O	O
passage	NN	O	O
through	NN	O	O
the	NN	O	O
blood	NN	O	O
-	NN	O	O
brain	NN	O	O
barrier	NN	O	O
(	NN	O	O
BBB	NN	O	O
)	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
to	NN	O	O
improve	NN	O	O
the	NN	O	O
brain	NN	O	O
localization	NN	O	O
of	NN	O	O
a	NN	O	O
bioactive	NN	O	O
compound	NN	O	O
.	NN	O	O

A	NN	O	O
Tween	NN	O	O
80	NN	O	O
-	NN	O	O
coated	NN	O	O
poly	NN	O	B-Chemical
-	NN	O	I-Chemical
L	NN	O	I-Chemical
-	NN	O	I-Chemical
lactid	NN	O	I-Chemical
acid	NN	O	I-Chemical
nanoparticles	NN	O	O
was	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
colloidal	NN	O	O
drug	NN	O	O
delivery	NN	O	O
system	NN	O	O
,	NN	O	O
able	NN	O	O
to	NN	O	O
trespass	NN	O	O
the	NN	O	O
BBB	NN	O	O
.	NN	O	O

Tacrine	NN	O	B-Chemical
,	NN	O	O
administered	NN	O	O
in	NN	O	O
LiCl	NN	O	B-Chemical
pre	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
,	NN	O	O
induces	NN	O	O
electrocorticographic	NN	O	O
seizures	NN	O	B-Disease
and	NN	O	O
delayed	NN	O	O
hippocampal	NN	O	B-Disease
damage	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
toxic	NN	O	O
effects	NN	O	O
of	NN	O	O
tacrine	NN	O	B-Chemical
-	NN	O	O
loaded	NN	O	O
poly	NN	O	B-Chemical
-	NN	O	I-Chemical
L	NN	O	I-Chemical
-	NN	O	I-Chemical
lactid	NN	O	I-Chemical
acid	NN	O	I-Chemical
nanoparticles	NN	O	O
(	NN	O	O
5mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
saline	NN	O	O
solution	NN	O	O
of	NN	O	O
tacrine	NN	O	B-Chemical
(	NN	O	O
5mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
an	NN	O	O
empty	NN	O	O
colloidal	NN	O	O
nanoparticle	NN	O	O
suspension	NN	O	O
were	NN	O	O
compared	NN	O	O
following	NN	O	O
i.p.	NN	O	O
administration	NN	O	O
in	NN	O	O
LiCl	NN	O	B-Chemical
-	NN	O	O
pre	NN	O	O
-	NN	O	O
treated	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

All	NN	O	O
the	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
tacrine	NN	O	B-Chemical
-	NN	O	O
loaded	NN	O	O
nanoparticles	NN	O	O
showed	NN	O	O
an	NN	O	O
earlier	NN	O	O
outcome	NN	O	O
of	NN	O	O
CNS	NN	O	O
adverse	NN	O	O
symptoms	NN	O	O
,	NN	O	O
i.e.	NN	O	O
epileptic	NN	O	B-Disease
onset	NN	O	O
,	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
those	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
the	NN	O	O
free	NN	O	O
compound	NN	O	O
(	NN	O	O
10	NN	O	O
min	NN	O	O
vs	NN	O	O
.	NN	O	O

22	NN	O	O
min	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
tacrine	NN	O	B-Chemical
-	NN	O	O
loaded	NN	O	O
nanoparticles	NN	O	O
administration	NN	O	O
induced	NN	O	O
damage	NN	O	B-Disease
of	NN	O	I-Disease
neuronal	NN	O	I-Disease
cells	NN	O	I-Disease
in	NN	O	O
CA1	NN	O	O
field	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
in	NN	O	O
all	NN	O	O
treated	NN	O	O
animals	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
saline	NN	O	O
solution	NN	O	O
of	NN	O	O
tacrine	NN	O	B-Chemical
only	NN	O	O
in	NN	O	O
60%	NN	O	O
of	NN	O	O
animals	NN	O	O
.	NN	O	O

Empty	NN	O	O
nanoparticles	NN	O	O
provided	NN	O	O
similar	NN	O	O
results	NN	O	O
to	NN	O	O
control	NN	O	O
(	NN	O	O
saline	NN	O	O
-	NN	O	O
treated	NN	O	O
)	NN	O	O
group	NN	O	O
of	NN	O	O
animals	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
the	NN	O	O
evaluation	NN	O	O
of	NN	O	O
time	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
onset	NN	O	O
of	NN	O	O
symptoms	NN	O	O
and	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
neurodegenerative	NN	O	O
processes	NN	O	O
induced	NN	O	O
by	NN	O	O
the	NN	O	O
tacrine	NN	O	B-Chemical
-	NN	O	O
lithium	NN	O	B-Chemical
model	NN	O	O
of	NN	O	O
epilepsy	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
rat	NN	O	O
,	NN	O	O
could	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
evaluate	NN	O	O
preliminarily	NN	O	O
the	NN	O	O
capability	NN	O	O
of	NN	O	O
a	NN	O	O
drug	NN	O	O
delivery	NN	O	O
system	NN	O	O
to	NN	O	O
trespass	NN	O	O
(	NN	O	O
or	NN	O	O
not	NN	O	O
)	NN	O	O
the	NN	O	O
BBB	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O


-DOCSTART- (19721134)

The	NN	O	O
antiarrhythmic	NN	O	O
effect	NN	O	O
and	NN	O	O
possible	NN	O	O
ionic	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
pilocarpine	NN	O	B-Chemical
on	NN	O	O
animal	NN	O	O
models	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
pilocarpine	NN	O	B-Chemical
and	NN	O	O
explore	NN	O	O
the	NN	O	O
underlying	NN	O	O
ionic	NN	O	O
mechanism	NN	O	O
,	NN	O	O
using	NN	O	O
both	NN	O	O
aconitine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
rat	NN	O	O
and	NN	O	O
ouabain	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
guinea	NN	O	O
pig	NN	O	O
arrhythmia	NN	O	B-Disease
models	NN	O	O
.	NN	O	O

Confocal	NN	O	O
microscopy	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
measure	NN	O	O
intracellular	NN	O	O
free	NN	O	O
-	NN	O	O
calcium	NN	O	B-Chemical
concentrations	NN	O	O
(	NN	O	O
[	NN	O	O
Ca	NN	O	B-Chemical
(	NN	O	O
2+	NN	O	O
)	NN	O	O
]	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
)	NN	O	O
in	NN	O	O
isolated	NN	O	O
myocytes	NN	O	O
.	NN	O	O

The	NN	O	O
current	NN	O	O
data	NN	O	O
showed	NN	O	O
that	NN	O	O
pilocarpine	NN	O	B-Chemical
significantly	NN	O	O
delayed	NN	O	O
onset	NN	O	O
of	NN	O	O
arrhythmias	NN	O	B-Disease
,	NN	O	O
decreased	NN	O	O
the	NN	O	O
time	NN	O	O
course	NN	O	O
of	NN	O	O
ventricular	NN	O	B-Disease
tachycardia	NN	O	I-Disease
and	NN	O	I-Disease
fibrillation	NN	O	I-Disease
,	NN	O	O
reduced	NN	O	O
arrhythmia	NN	O	B-Disease
score	NN	O	O
,	NN	O	O
and	NN	O	O
increased	NN	O	O
the	NN	O	O
survival	NN	O	O
time	NN	O	O
of	NN	O	O
arrhythmic	NN	O	B-Disease
rats	NN	O	O
and	NN	O	O
guinea	NN	O	O
pigs	NN	O	O
.	NN	O	O

[	NN	O	O
Ca	NN	O	B-Chemical
(	NN	O	O
2+	NN	O	O
)	NN	O	O
]	NN	O	O
(	NN	O	O
i	NN	O	O
)	NN	O	O
overload	NN	O	O
induced	NN	O	O
by	NN	O	O
aconitine	NN	O	B-Chemical
or	NN	O	O
ouabain	NN	O	B-Chemical
was	NN	O	O
reduced	NN	O	O
in	NN	O	O
isolated	NN	O	O
myocytes	NN	O	O
pretreated	NN	O	O
with	NN	O	O
pilocarpine	NN	O	B-Chemical
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
M	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
-	NN	O	O
muscarinic	NN	O	O
acetylcholine	NN	O	B-Chemical
receptor	NN	O	O
(	NN	O	O
mAChR	NN	O	O
)	NN	O	O
antagonist	NN	O	O
4	NN	O	B-Chemical
-	NN	O	I-Chemical
DAMP	NN	O	I-Chemical
(	NN	O	O
4	NN	O	B-Chemical
-	NN	O	I-Chemical
diphenylacetoxy	NN	O	I-Chemical
-	NN	O	I-Chemical
N	NN	O	I-Chemical
-	NN	O	I-Chemical
methylpiperidine	NN	O	I-Chemical
-	NN	O	I-Chemical
methiodide	NN	O	I-Chemical
)	NN	O	O
partially	NN	O	O
abolished	NN	O	O
the	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
of	NN	O	O
pilocarpine	NN	O	B-Chemical
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
pilocarpine	NN	O	B-Chemical
produced	NN	O	O
antiarrhythmic	NN	O	O
actions	NN	O	O
on	NN	O	O
arrhythmic	NN	O	B-Disease
rat	NN	O	O
and	NN	O	O
guinea	NN	O	O
pig	NN	O	O
models	NN	O	O
induced	NN	O	O
by	NN	O	O
aconitine	NN	O	B-Chemical
or	NN	O	O
ouabain	NN	O	B-Chemical
via	NN	O	O
stimulating	NN	O	O
the	NN	O	O
cardiac	NN	O	O
M	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
-	NN	O	O
mAChR	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
improvement	NN	O	O
of	NN	O	O
Ca	NN	O	B-Chemical
(	NN	O	O
2+	NN	O	O
)	NN	O	O
handling	NN	O	O
.	NN	O	O


-DOCSTART- (17786501)

Disulfiram	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
transient	NN	O	O
optic	NN	O	B-Disease
and	NN	O	I-Disease
peripheral	NN	O	I-Disease
neuropathy	NN	O	I-Disease
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
optic	NN	O	B-Disease
and	NN	O	I-Disease
peripheral	NN	O	I-Disease
neuropathy	NN	O	I-Disease
after	NN	O	O
chronic	NN	O	O
use	NN	O	O
of	NN	O	O
disulfiram	NN	O	B-Chemical
for	NN	O	O
alcohol	NN	O	B-Disease
dependence	NN	O	I-Disease
management	NN	O	O
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
57	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
presented	NN	O	O
with	NN	O	O
gradual	NN	O	O
loss	NN	O	B-Disease
of	NN	O	I-Disease
vision	NN	O	I-Disease
in	NN	O	O
both	NN	O	O
eyes	NN	O	O
with	NN	O	O
intermittent	NN	O	O
headaches	NN	O	B-Disease
for	NN	O	O
2	NN	O	O
months	NN	O	O
.	NN	O	O

He	NN	O	O
also	NN	O	O
complained	NN	O	O
of	NN	O	O
paraesthesia	NN	O	B-Disease
with	NN	O	O
numbness	NN	O	B-Disease
in	NN	O	O
both	NN	O	O
feet	NN	O	O
.	NN	O	O

His	NN	O	O
vision	NN	O	O
was	NN	O	O
6	NN	O	O
/	NN	O	O
15	NN	O	O
and	NN	O	O
2	NN	O	O
/	NN	O	O
60	NN	O	O
in	NN	O	O
the	NN	O	O
right	NN	O	O
and	NN	O	O
left	NN	O	O
eyes	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Fundoscopy	NN	O	O
revealed	NN	O	O
bilaterally	NN	O	O
swollen	NN	O	O
optic	NN	O	O
nerve	NN	O	O
heads	NN	O	O
.	NN	O	O

Visual	NN	O	O
field	NN	O	O
testing	NN	O	O
confirmed	NN	O	O
bilateral	NN	O	O
central	NN	O	O
-	NN	O	O
caecal	NN	O	O
scotomata	NN	O	B-Disease
.	NN	O	O

He	NN	O	O
had	NN	O	O
been	NN	O	O
taking	NN	O	O
disulfiram	NN	O	B-Chemical
for	NN	O	O
alcohol	NN	O	B-Disease
dependence	NN	O	I-Disease
for	NN	O	O
the	NN	O	O
preceding	NN	O	O
3	NN	O	O
years	NN	O	O
.	NN	O	O

Disulfiram	NN	O	B-Chemical
discontinuation	NN	O	O
lead	NN	O	O
to	NN	O	O
an	NN	O	O
immediate	NN	O	O
symptomatic	NN	O	O
improvement	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Physicians	NN	O	O
initiating	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
disulfiram	NN	O	B-Chemical
therapy	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
these	NN	O	O
adverse	NN	O	O
effects	NN	O	O
.	NN	O	O

They	NN	O	O
should	NN	O	O
recommend	NN	O	O
annual	NN	O	O
ophthalmic	NN	O	O
reviews	NN	O	O
with	NN	O	O
visual	NN	O	O
field	NN	O	O
testing	NN	O	O
.	NN	O	O

Patients	NN	O	O
should	NN	O	O
be	NN	O	O
reassured	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
the	NN	O	O
reversibility	NN	O	O
of	NN	O	O
these	NN	O	O
adverse	NN	O	O
effects	NN	O	O
.	NN	O	O


-DOCSTART- (16960342)

Sustained	NN	O	O
clinical	NN	O	O
improvement	NN	O	O
of	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
decompensated	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
virus	NN	O	O
-	NN	O	O
related	NN	O	O
cirrhosis	NN	O	B-Disease
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
lamivudine	NN	O	B-Chemical
monotherapy	NN	O	O
.	NN	O	O

Hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
virus	NN	O	I-Disease
(	NN	O	I-Disease
HBV	NN	O	I-Disease
)	NN	O	I-Disease
infection	NN	O	I-Disease
,	NN	O	O
which	NN	O	O
causes	NN	O	O
liver	NN	O	B-Disease
cirrhosis	NN	O	I-Disease
and	NN	O	O
hepatocellular	NN	O	B-Disease
carcinoma	NN	O	I-Disease
,	NN	O	O
remains	NN	O	O
a	NN	O	O
major	NN	O	O
health	NN	O	O
problem	NN	O	O
in	NN	O	O
Asian	NN	O	O
countries	NN	O	O
.	NN	O	O

Recent	NN	O	O
development	NN	O	O
of	NN	O	O
vaccine	NN	O	O
for	NN	O	O
prevention	NN	O	O
is	NN	O	O
reported	NN	O	O
to	NN	O	O
be	NN	O	O
successful	NN	O	O
in	NN	O	O
reducing	NN	O	O
the	NN	O	O
size	NN	O	O
of	NN	O	O
chronically	NN	O	O
infected	NN	O	O
carriers	NN	O	O
,	NN	O	O
although	NN	O	O
the	NN	O	O
standard	NN	O	O
medical	NN	O	O
therapies	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
established	NN	O	O
up	NN	O	O
to	NN	O	O
now	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
report	NN	O	O
,	NN	O	O
we	NN	O	O
encountered	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
decompensated	NN	O	O
HBV	NN	O	O
-	NN	O	O
related	NN	O	O
cirrhosis	NN	O	B-Disease
who	NN	O	O
exhibited	NN	O	O
the	NN	O	O
dramatic	NN	O	O
improvements	NN	O	O
after	NN	O	O
antiviral	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
a	NN	O	O
50	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
.	NN	O	O

Previous	NN	O	O
conventional	NN	O	O
medical	NN	O	O
treatments	NN	O	O
were	NN	O	O
not	NN	O	O
effective	NN	O	O
for	NN	O	O
this	NN	O	O
patient	NN	O	O
,	NN	O	O
thus	NN	O	O
this	NN	O	O
patient	NN	O	O
had	NN	O	O
been	NN	O	O
referred	NN	O	O
to	NN	O	O
our	NN	O	O
hospital	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
lamivudine	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
reverse	NN	O	O
transcriptase	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
for	NN	O	O
23	NN	O	O
months	NN	O	O
dramatically	NN	O	O
improved	NN	O	O
her	NN	O	O
liver	NN	O	O
severity	NN	O	O
.	NN	O	O

During	NN	O	O
this	NN	O	O
period	NN	O	O
,	NN	O	O
no	NN	O	O
drug	NN	O	O
resistant	NN	O	O
mutant	NN	O	O
HBV	NN	O	O
emerged	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
serum	NN	O	O
HBV	NN	O	O
-	NN	O	O
DNA	NN	O	O
level	NN	O	O
was	NN	O	O
continuously	NN	O	O
suppressed	NN	O	O
.	NN	O	O

These	NN	O	O
virological	NN	O	O
responses	NN	O	O
were	NN	O	O
also	NN	O	O
maintained	NN	O	O
even	NN	O	O
after	NN	O	O
the	NN	O	O
antiviral	NN	O	O
therapy	NN	O	O
was	NN	O	O
discontinued	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
both	NN	O	O
hepatitis	NN	O	B-Chemical
B	NN	O	I-Chemical
surface	NN	O	I-Chemical
antigen	NN	O	I-Chemical
and	NN	O	I-Chemical
e	NN	O	I-Chemical
antigen	NN	O	I-Chemical
were	NN	O	O
observed	NN	O	O
to	NN	O	O
have	NN	O	O
disappeared	NN	O	O
in	NN	O	O
this	NN	O	O
patient	NN	O	O
.	NN	O	O

The	NN	O	O
administration	NN	O	O
of	NN	O	O
lamivudine	NN	O	B-Chemical
to	NN	O	O
patients	NN	O	O
with	NN	O	O
HBV	NN	O	O
-	NN	O	O
related	NN	O	O
cirrhosis	NN	O	B-Disease
,	NN	O	O
like	NN	O	O
our	NN	O	O
present	NN	O	O
case	NN	O	O
,	NN	O	O
should	NN	O	O
be	NN	O	O
considered	NN	O	O
as	NN	O	O
an	NN	O	O
initial	NN	O	O
medical	NN	O	O
therapeutic	NN	O	O
option	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
countries	NN	O	O
where	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
is	NN	O	O
not	NN	O	O
reliably	NN	O	O
available	NN	O	O
.	NN	O	O


-DOCSTART- (11226639)

Dual	NN	O	O
effects	NN	O	O
of	NN	O	O
melatonin	NN	O	B-Chemical
on	NN	O	O
barbiturate	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
narcosis	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Melatonin	NN	O	B-Chemical
affects	NN	O	O
the	NN	O	O
circadian	NN	O	O
sleep	NN	O	O
/	NN	O	O
wake	NN	O	O
cycle	NN	O	O
,	NN	O	O
but	NN	O	O
it	NN	O	O
is	NN	O	O
not	NN	O	O
clear	NN	O	O
whether	NN	O	O
it	NN	O	O
may	NN	O	O
influence	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
narcosis	NN	O	B-Disease
.	NN	O	O

Sodium	NN	O	B-Chemical
thiopenthal	NN	O	I-Chemical
was	NN	O	O
administered	NN	O	O
intraperitoneally	NN	O	O
into	NN	O	O
male	NN	O	O
rats	NN	O	O
pre	NN	O	O
-	NN	O	O
treated	NN	O	O
with	NN	O	O
melatonin	NN	O	B-Chemical
(	NN	O	O
0.05	NN	O	O
,	NN	O	O
0.5	NN	O	O
,	NN	O	O
5	NN	O	O
and	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

Melatonin	NN	O	B-Chemical
pre	NN	O	O
-	NN	O	O
treatment	NN	O	O
affected	NN	O	O
in	NN	O	O
a	NN	O	O
dual	NN	O	O
manner	NN	O	O
barbiturate	NN	O	B-Chemical
narcosis	NN	O	B-Disease
,	NN	O	O
however	NN	O	O
,	NN	O	O
no	NN	O	O
dose	NN	O	O
-	NN	O	O
effect	NN	O	O
correlation	NN	O	O
was	NN	O	O
found	NN	O	O
.	NN	O	O

In	NN	O	O
particular	NN	O	O
,	NN	O	O
low	NN	O	O
doses	NN	O	O
reduced	NN	O	O
the	NN	O	O
latency	NN	O	O
to	NN	O	O
and	NN	O	O
prolonged	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
barbiturate	NN	O	B-Chemical
narcosis	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
highest	NN	O	O
dose	NN	O	O
of	NN	O	O
melatonin	NN	O	B-Chemical
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
caused	NN	O	O
a	NN	O	O
paradoxical	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
latency	NN	O	O
and	NN	O	O
produced	NN	O	O
a	NN	O	O
sustained	NN	O	O
reduction	NN	O	O
of	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
narcosis	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
mortality	NN	O	O
rate	NN	O	O
.	NN	O	O

Melatonin	NN	O	B-Chemical
0.5	NN	O	O
and	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
influenced	NN	O	O
the	NN	O	O
duration	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
latency	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
-	NN	O	O
or	NN	O	O
diazepam	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
narcosis	NN	O	B-Disease
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
the	NN	O	O
dual	NN	O	O
action	NN	O	O
of	NN	O	O
melatonin	NN	O	B-Chemical
on	NN	O	O
pharmacological	NN	O	O
narcosis	NN	O	B-Disease
seems	NN	O	O
to	NN	O	O
be	NN	O	O
specific	NN	O	O
for	NN	O	O
the	NN	O	O
barbiturate	NN	O	B-Chemical
mechanism	NN	O	O
of	NN	O	O
action	NN	O	O
.	NN	O	O


-DOCSTART- (9228650)

Effects	NN	O	O
of	NN	O	O
NIK	NN	O	B-Chemical
-	NN	O	I-Chemical
247	NN	O	I-Chemical
on	NN	O	O
cholinesterase	NN	O	O
and	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
NIK	NN	O	B-Chemical
-	NN	O	I-Chemical
247	NN	O	I-Chemical
on	NN	O	O
cholinesterase	NN	O	O
,	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B-Disease
and	NN	O	O
spontaneous	NN	O	O
movement	NN	O	O
were	NN	O	O
examined	NN	O	O
and	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
of	NN	O	O
the	NN	O	O
well	NN	O	O
-	NN	O	O
known	NN	O	O
cholinesterase	NN	O	O
inhibitors	NN	O	O
tacrine	NN	O	B-Chemical
and	NN	O	O
E	NN	O	B-Chemical
-	NN	O	I-Chemical
2020	NN	O	I-Chemical
.	NN	O	O

NIK	NN	O	B-Chemical
-	NN	O	I-Chemical
247	NN	O	I-Chemical
,	NN	O	O
tacrine	NN	O	B-Chemical
and	NN	O	O
E	NN	O	B-Chemical
-	NN	O	I-Chemical
2020	NN	O	I-Chemical
all	NN	O	O
strongly	NN	O	O
inhibited	NN	O	O
acetylcholinesterase	NN	O	O
(	NN	O	O
AChE	NN	O	O
)	NN	O	O
in	NN	O	O
human	NN	O	O
red	NN	O	O
blood	NN	O	O
cells	NN	O	O
(	NN	O	O
IC50s	NN	O	O
=	NN	O	O
1.0	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
6	NN	O	O
)	NN	O	O
,	NN	O	O
2.9	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
7	NN	O	O
)	NN	O	O
and	NN	O	O
3.7	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
8	NN	O	O
)	NN	O	O
M	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
NIK	NN	O	B-Chemical
-	NN	O	I-Chemical
247	NN	O	I-Chemical
and	NN	O	O
tacrine	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
not	NN	O	O
E	NN	O	B-Chemical
-	NN	O	I-Chemical
2020	NN	O	I-Chemical
,	NN	O	O
strongly	NN	O	O
inhibited	NN	O	O
butyrylcholinestrase	NN	O	O
(	NN	O	O
BuChE	NN	O	O
)	NN	O	O
in	NN	O	O
human	NN	O	O
serum	NN	O	O
.	NN	O	O

All	NN	O	O
three	NN	O	O
drugs	NN	O	O
produced	NN	O	O
mixed	NN	O	O
inhibition	NN	O	O
of	NN	O	O
AChE	NN	O	O
activity	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
the	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
of	NN	O	O
NIK	NN	O	B-Chemical
-	NN	O	I-Chemical
247	NN	O	I-Chemical
on	NN	O	O
AChE	NN	O	O
was	NN	O	O
reversible	NN	O	O
.	NN	O	O

All	NN	O	O
compounds	NN	O	O
at	NN	O	O
0.1	NN	O	O
-	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
p.o.	NN	O	O
significantly	NN	O	O
improved	NN	O	O
the	NN	O	O
amnesia	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
scopolamine	NN	O	B-Chemical
(	NN	O	O
0.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
s.c.	NN	O	O
)	NN	O	O
in	NN	O	O
rats	NN	O	O
performing	NN	O	O
a	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
.	NN	O	O

The	NN	O	O
three	NN	O	O
compounds	NN	O	O
at	NN	O	O
1	NN	O	O
and	NN	O	O
3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
p.o.	NN	O	O
did	NN	O	O
not	NN	O	O
significantly	NN	O	O
decrease	NN	O	O
spontaneous	NN	O	O
movement	NN	O	O
by	NN	O	O
rats	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
NIK	NN	O	B-Chemical
-	NN	O	I-Chemical
247	NN	O	I-Chemical
at	NN	O	O
a	NN	O	O
low	NN	O	O
dose	NN	O	O
(	NN	O	O
0.1	NN	O	O
-	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
p.o.	NN	O	O
)	NN	O	O
improves	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B-Disease
but	NN	O	O
does	NN	O	O
not	NN	O	O
affect	NN	O	O
spontaneous	NN	O	O
movement	NN	O	O
.	NN	O	O

The	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
NIK	NN	O	B-Chemical
-	NN	O	I-Chemical
247	NN	O	I-Chemical
may	NN	O	O
be	NN	O	O
a	NN	O	O
useful	NN	O	O
drug	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
Alzheimer	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (8766220)

Nightmares	NN	O	O
and	NN	O	O
hallucinations	NN	O	B-Disease
after	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
intake	NN	O	O
of	NN	O	O
tramadol	NN	O	B-Chemical
combined	NN	O	O
with	NN	O	O
antidepressants	NN	O	O
.	NN	O	O

Tramadol	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
weak	NN	O	O
opioid	NN	O	O
with	NN	O	O
effects	NN	O	O
on	NN	O	O
adrenergic	NN	O	O
and	NN	O	O
serotonergic	NN	O	O
neurotransmission	NN	O	O
that	NN	O	O
is	NN	O	O
used	NN	O	O
to	NN	O	O
treat	NN	O	O
cancer	NN	O	B-Disease
pain	NN	O	B-Disease
and	NN	O	O
chronic	NN	O	O
non	NN	O	O
malignant	NN	O	O
pain	NN	O	B-Disease
.	NN	O	O

This	NN	O	O
drug	NN	O	O
was	NN	O	O
initiated	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
paroxetine	NN	O	B-Chemical
and	NN	O	O
dosulepine	NN	O	B-Chemical
hydrochloride	NN	O	I-Chemical
in	NN	O	O
a	NN	O	O
tetraparetic	NN	O	B-Disease
patient	NN	O	O
with	NN	O	O
chronic	NN	O	B-Disease
pain	NN	O	I-Disease
.	NN	O	O

Fifty	NN	O	O
-	NN	O	O
six	NN	O	O
days	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
the	NN	O	O
patient	NN	O	O
presented	NN	O	O
hallucinations	NN	O	B-Disease
that	NN	O	O
only	NN	O	O
stopped	NN	O	O
after	NN	O	O
the	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
psycho	NN	O	O
-	NN	O	O
active	NN	O	O
drugs	NN	O	O
and	NN	O	O
tramadol	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
case	NN	O	O
report	NN	O	O
questions	NN	O	O
the	NN	O	O
long	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
pain	NN	O	B-Disease
killers	NN	O	O
combined	NN	O	O
with	NN	O	O
psycho	NN	O	O
-	NN	O	O
active	NN	O	O
drugs	NN	O	O
in	NN	O	O
chronic	NN	O	O
non	NN	O	O
malignant	NN	O	O
pain	NN	O	B-Disease
,	NN	O	O
especially	NN	O	O
if	NN	O	O
pain	NN	O	B-Disease
is	NN	O	O
under	NN	O	O
control	NN	O	O
.	NN	O	O


-DOCSTART- (8441146)

Apparent	NN	O	O
cure	NN	O	O
of	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
by	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
sustained	NN	O	O
remissions	NN	O	O
and	NN	O	O
possible	NN	O	O
cure	NN	O	O
of	NN	O	O
severe	NN	O	O
erosive	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
(	NN	O	O
RA	NN	O	B-Disease
)	NN	O	O
by	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
(	NN	O	O
BMT	NN	O	O
)	NN	O	O
in	NN	O	O
2	NN	O	O
patients	NN	O	O
.	NN	O	O

BMT	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
treat	NN	O	O
severe	NN	O	O
aplastic	NN	O	B-Disease
anemia	NN	O	I-Disease
which	NN	O	O
was	NN	O	O
caused	NN	O	O
by	NN	O	O
gold	NN	O	B-Chemical
in	NN	O	O
one	NN	O	O
case	NN	O	O
and	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
in	NN	O	O
the	NN	O	O
other	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
8	NN	O	O
and	NN	O	O
6	NN	O	O
years	NN	O	O
since	NN	O	O
the	NN	O	O
transplants	NN	O	O
(	NN	O	O
representing	NN	O	O
8	NN	O	O
and	NN	O	O
4	NN	O	O
years	NN	O	O
since	NN	O	O
cessation	NN	O	O
of	NN	O	O
all	NN	O	O
immunosuppressive	NN	O	O
therapy	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
RA	NN	O	B-Disease
in	NN	O	O
each	NN	O	O
case	NN	O	O
has	NN	O	O
been	NN	O	O
completely	NN	O	O
quiescent	NN	O	O
.	NN	O	O

Although	NN	O	O
short	NN	O	O
term	NN	O	O
remission	NN	O	O
of	NN	O	O
severe	NN	O	O
RA	NN	O	B-Disease
following	NN	O	O
BMT	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
,	NN	O	O
these	NN	O	O
are	NN	O	O
the	NN	O	O
first	NN	O	O
cases	NN	O	O
for	NN	O	O
which	NN	O	O
prolonged	NN	O	O
followup	NN	O	O
has	NN	O	O
been	NN	O	O
available	NN	O	O
.	NN	O	O

This	NN	O	O
experience	NN	O	O
raises	NN	O	O
the	NN	O	O
question	NN	O	O
of	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
BMT	NN	O	O
itself	NN	O	O
as	NN	O	O
a	NN	O	O
therapeutic	NN	O	O
option	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
uncontrolled	NN	O	O
destructive	NN	O	O
synovitis	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (3653576)

Urinary	NN	O	O
enzymes	NN	O	O
and	NN	O	O
protein	NN	O	O
patterns	NN	O	O
as	NN	O	O
indicators	NN	O	O
of	NN	O	O
injury	NN	O	B-Disease
to	NN	O	I-Disease
different	NN	O	I-Disease
regions	NN	O	I-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
kidney	NN	O	I-Disease
.	NN	O	O

Acute	NN	O	B-Disease
experimental	NN	O	I-Disease
models	NN	O	I-Disease
of	NN	O	I-Disease
renal	NN	O	I-Disease
damage	NN	O	I-Disease
to	NN	O	O
the	NN	O	O
proximal	NN	O	O
tubular	NN	O	O
,	NN	O	O
glomerular	NN	O	O
,	NN	O	O
and	NN	O	O
papillary	NN	O	O
regions	NN	O	O
of	NN	O	O
the	NN	O	O
rat	NN	O	O
were	NN	O	O
produced	NN	O	O
by	NN	O	O
administration	NN	O	O
of	NN	O	O
hexachloro	NN	O	B-Chemical
-	NN	O	I-Chemical
1	NN	O	I-Chemical
:	NN	O	I-Chemical
3	NN	O	I-Chemical
-	NN	O	I-Chemical
butadiene	NN	O	I-Chemical
(	NN	O	O
HCBD	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
(	NN	O	O
PAN	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
and	NN	O	O
2	NN	O	B-Chemical
-	NN	O	I-Chemical
bromoethylamine	NN	O	I-Chemical
(	NN	O	O
BEA	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Several	NN	O	O
routine	NN	O	O
indicators	NN	O	O
of	NN	O	O
nephrotoxicity	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
enzymes	NN	O	O
alkaline	NN	O	O
phosphatase	NN	O	O
and	NN	O	O
N	NN	O	O
-	NN	O	O
acetyl	NN	O	O
-	NN	O	O
beta	NN	O	O
-	NN	O	O
glucosaminidase	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
molecular	NN	O	O
weight	NN	O	O
of	NN	O	O
protein	NN	O	B-Disease
excretion	NN	O	I-Disease
were	NN	O	O
determined	NN	O	O
on	NN	O	O
urine	NN	O	O
samples	NN	O	O
.	NN	O	O

Tubular	NN	O	O
damage	NN	O	O
produced	NN	O	O
by	NN	O	O
HCBD	NN	O	B-Chemical
or	NN	O	O
BEA	NN	O	B-Chemical
was	NN	O	O
discriminated	NN	O	O
both	NN	O	O
quantitatively	NN	O	O
and	NN	O	O
qualitatively	NN	O	O
from	NN	O	O
glomerular	NN	O	B-Disease
damage	NN	O	I-Disease
produced	NN	O	O
by	NN	O	O
PAN	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
latter	NN	O	O
was	NN	O	O
characterized	NN	O	O
by	NN	O	O
a	NN	O	O
pronounced	NN	O	O
increase	NN	O	O
in	NN	O	O
protein	NN	O	B-Disease
excretion	NN	O	I-Disease
,	NN	O	O
especially	NN	O	O
proteins	NN	O	O
with	NN	O	O
molecular	NN	O	O
weight	NN	O	O
greater	NN	O	O
than	NN	O	O
40	NN	O	O
,	NN	O	O
000	NN	O	O
Da	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
protein	NN	O	B-Disease
excretion	NN	O	I-Disease
in	NN	O	O
tubular	NN	O	O
damage	NN	O	O
was	NN	O	O
raised	NN	O	O
only	NN	O	O
slightly	NN	O	O
and	NN	O	O
characterized	NN	O	O
by	NN	O	O
excretion	NN	O	B-Disease
of	NN	O	I-Disease
proteins	NN	O	I-Disease
of	NN	O	O
a	NN	O	O
wide	NN	O	O
range	NN	O	O
of	NN	O	O
molecular	NN	O	O
weights	NN	O	O
.	NN	O	O

Proximal	NN	O	O
tubular	NN	O	O
damage	NN	O	O
caused	NN	O	O
by	NN	O	O
HCBD	NN	O	B-Chemical
and	NN	O	O
papillary	NN	O	O
damage	NN	O	O
caused	NN	O	O
by	NN	O	O
BEA	NN	O	B-Chemical
were	NN	O	O
distinguished	NN	O	O
both	NN	O	O
by	NN	O	O
conventional	NN	O	O
urinalysis	NN	O	O
(	NN	O	O
volume	NN	O	O
and	NN	O	O
specific	NN	O	O
gravity	NN	O	O
)	NN	O	O
and	NN	O	O
by	NN	O	O
measurement	NN	O	O
of	NN	O	O
the	NN	O	O
two	NN	O	O
urinary	NN	O	O
enzymes	NN	O	O
.	NN	O	O

Alkaline	NN	O	O
phosphatase	NN	O	O
and	NN	O	O
glucose	NN	O	B-Chemical
were	NN	O	O
markedly	NN	O	O
and	NN	O	O
transiently	NN	O	O
elevated	NN	O	O
in	NN	O	O
proximal	NN	O	O
tubular	NN	O	O
damage	NN	O	O
and	NN	O	O
N	NN	O	O
-	NN	O	O
acetyl	NN	O	O
-	NN	O	O
beta	NN	O	O
-	NN	O	O
glucosaminidase	NN	O	O
showed	NN	O	O
a	NN	O	O
sustained	NN	O	O
elevation	NN	O	O
in	NN	O	O
papillary	NN	O	O
damage	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
both	NN	O	O
selective	NN	O	O
urinary	NN	O	O
enzymes	NN	O	O
and	NN	O	O
the	NN	O	O
molecular	NN	O	O
weight	NN	O	O
pattern	NN	O	O
of	NN	O	O
urinary	NN	O	O
proteins	NN	O	O
can	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
provide	NN	O	O
diagnostic	NN	O	O
information	NN	O	O
about	NN	O	O
the	NN	O	O
possible	NN	O	O
site	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
damage	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (2750819)

Neuromuscular	NN	O	B-Disease
blockade	NN	O	I-Disease
with	NN	O	O
magnesium	NN	O	B-Chemical
sulfate	NN	O	I-Chemical
and	NN	O	O
nifedipine	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
patient	NN	O	O
who	NN	O	O
received	NN	O	O
tocolysis	NN	O	O
with	NN	O	O
nifedipine	NN	O	B-Chemical
developed	NN	O	O
neuromuscular	NN	O	B-Disease
blockade	NN	O	I-Disease
after	NN	O	O
500	NN	O	O
mg	NN	O	O
of	NN	O	O
magnesium	NN	O	B-Chemical
sulfate	NN	O	I-Chemical
was	NN	O	O
administered	NN	O	O
.	NN	O	O

This	NN	O	O
reaction	NN	O	O
demonstrates	NN	O	O
that	NN	O	O
nifedipine	NN	O	B-Chemical
can	NN	O	O
seriously	NN	O	O
potentiate	NN	O	O
the	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
magnesium	NN	O	B-Chemical
.	NN	O	O

Caution	NN	O	O
should	NN	O	O
be	NN	O	O
exercised	NN	O	O
when	NN	O	O
these	NN	O	O
two	NN	O	O
tocolytics	NN	O	O
are	NN	O	O
combined	NN	O	O
.	NN	O	O


-DOCSTART- (1899352)

Ifosfamide	NN	O	B-Chemical
continuous	NN	O	O
infusion	NN	O	O
without	NN	O	O
mesna	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
phase	NN	O	O
I	NN	O	O
trial	NN	O	O
of	NN	O	O
a	NN	O	O
14	NN	O	O
-	NN	O	O
day	NN	O	O
cycle	NN	O	O
.	NN	O	O

Twenty	NN	O	O
patients	NN	O	O
received	NN	O	O
27	NN	O	O
courses	NN	O	O
of	NN	O	O
ifosfamide	NN	O	B-Chemical
administered	NN	O	O
as	NN	O	O
a	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
for	NN	O	O
14	NN	O	O
days	NN	O	O
without	NN	O	O
Mesna	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
goal	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
deliver	NN	O	O
a	NN	O	O
dose	NN	O	O
rate	NN	O	O
and	NN	O	O
total	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
of	NN	O	O
ifosfamide	NN	O	B-Chemical
that	NN	O	O
would	NN	O	O
be	NN	O	O
comparable	NN	O	O
to	NN	O	O
standard	NN	O	O
bolus	NN	O	O
or	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
infusions	NN	O	O
administered	NN	O	O
with	NN	O	O
Mesna	NN	O	B-Chemical
.	NN	O	O

Dose	NN	O	O
escalations	NN	O	O
proceeded	NN	O	O
from	NN	O	O
200	NN	O	O
to	NN	O	O
300	NN	O	O
,	NN	O	O
400	NN	O	O
,	NN	O	O
450	NN	O	O
,	NN	O	O
500	NN	O	O
,	NN	O	O
and	NN	O	O
550	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
d	NN	O	O
.	NN	O	O

Four	NN	O	O
patients	NN	O	O
developed	NN	O	O
transient	NN	O	O
microscopic	NN	O	O
hematuria	NN	O	B-Disease
at	NN	O	O
400	NN	O	O
,	NN	O	O
450	NN	O	O
,	NN	O	O
and	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
d	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
instances	NN	O	O
of	NN	O	O
macroscopic	NN	O	O
hematuria	NN	O	B-Disease
.	NN	O	O

At	NN	O	O
550	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
d	NN	O	O
,	NN	O	O
three	NN	O	O
patients	NN	O	O
experienced	NN	O	O
nonurologic	NN	O	O
toxicity	NN	O	B-Disease
;	NN	O	O
confusion	NN	O	B-Disease
(	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
nausea	NN	O	B-Disease
(	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
Grade	NN	O	O
2	NN	O	O
leukopenia	NN	O	B-Disease
(	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
recommended	NN	O	O
dose	NN	O	O
of	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
/	NN	O	O
d	NN	O	O
delivers	NN	O	O
a	NN	O	O
total	NN	O	O
dose	NN	O	O
of	NN	O	O
7	NN	O	O
g	NN	O	O
/	NN	O	O
m2	NN	O	O
per	NN	O	O
cycle	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
comparable	NN	O	O
to	NN	O	O
that	NN	O	O
delivered	NN	O	O
in	NN	O	O
clinical	NN	O	O
practice	NN	O	O
for	NN	O	O
bolus	NN	O	O
or	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
infusion	NN	O	O
.	NN	O	O

Because	NN	O	O
few	NN	O	O
patients	NN	O	O
received	NN	O	O
multiple	NN	O	O
courses	NN	O	O
over	NN	O	O
time	NN	O	O
,	NN	O	O
the	NN	O	O
cumulative	NN	O	O
effects	NN	O	O
are	NN	O	O
indeterminate	NN	O	O
in	NN	O	O
the	NN	O	O
present	NN	O	O
trial	NN	O	O
.	NN	O	O

The	NN	O	O
frequency	NN	O	O
and	NN	O	O
predictability	NN	O	O
of	NN	O	O
hematuria	NN	O	B-Disease
are	NN	O	O
not	NN	O	O
precise	NN	O	O
,	NN	O	O
and	NN	O	O
at	NN	O	O
least	NN	O	O
daily	NN	O	O
monitoring	NN	O	O
by	NN	O	O
urine	NN	O	O
Hematest	NN	O	O
is	NN	O	O
essential	NN	O	O
,	NN	O	O
adding	NN	O	O
Mesna	NN	O	B-Chemical
to	NN	O	O
the	NN	O	O
infusate	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
persistent	NN	O	O
hematuria	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
protracted	NN	O	O
infusion	NN	O	O
schedule	NN	O	O
for	NN	O	O
ifosfamide	NN	O	B-Chemical
permits	NN	O	O
convenient	NN	O	O
outpatient	NN	O	O
administration	NN	O	O
without	NN	O	O
Mesna	NN	O	B-Chemical
and	NN	O	O
reduces	NN	O	O
the	NN	O	O
drug	NN	O	O
cost	NN	O	O
of	NN	O	O
clinical	NN	O	O
usage	NN	O	O
of	NN	O	O
this	NN	O	O
agent	NN	O	O
by	NN	O	O
up	NN	O	O
to	NN	O	O
890	NN	O	O
per	NN	O	O
cycle	NN	O	O
.	NN	O	O

Clinical	NN	O	O
activity	NN	O	O
was	NN	O	O
demonstrated	NN	O	O
in	NN	O	O
a	NN	O	O
single	NN	O	O
patient	NN	O	O
,	NN	O	O
but	NN	O	O
a	NN	O	O
comparative	NN	O	O
trial	NN	O	O
of	NN	O	O
standard	NN	O	O
bolus	NN	O	O
schedules	NN	O	O
with	NN	O	O
the	NN	O	O
protracted	NN	O	O
infusion	NN	O	O
schedule	NN	O	O
will	NN	O	O
be	NN	O	O
necessary	NN	O	O
to	NN	O	O
determine	NN	O	O
if	NN	O	O
the	NN	O	O
clinical	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
is	NN	O	O
maintained	NN	O	O
.	NN	O	O


-DOCSTART- (18161408)

Myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
in	NN	O	O
pregnancy	NN	O	O
associated	NN	O	O
with	NN	O	O
clomiphene	NN	O	B-Chemical
citrate	NN	O	I-Chemical
for	NN	O	O
ovulation	NN	O	O
induction	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Clomiphene	NN	O	B-Chemical
citrate	NN	O	I-Chemical
(	NN	O	O
CC	NN	O	B-Chemical
)	NN	O	O
is	NN	O	O
commonly	NN	O	O
prescribed	NN	O	O
for	NN	O	O
ovulation	NN	O	O
induction	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
considered	NN	O	O
safe	NN	O	O
,	NN	O	O
with	NN	O	O
minimal	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Thromboembolism	NN	O	B-Disease
is	NN	O	O
a	NN	O	O
rare	NN	O	O
but	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
complication	NN	O	O
that	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
after	NN	O	O
ovulation	NN	O	O
induction	NN	O	O
with	NN	O	O
CC	NN	O	B-Chemical
.	NN	O	O

Spontaneous	NN	O	O
coronary	NN	O	B-Disease
thrombosis	NN	O	I-Disease
or	NN	O	O
thromboembolism	NN	O	B-Disease
with	NN	O	O
subsequent	NN	O	O
clot	NN	O	O
lysis	NN	O	O
has	NN	O	O
been	NN	O	O
suggested	NN	O	O
as	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
causes	NN	O	O
of	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
(	NN	O	O
MI	NN	O	B-Disease
)	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
subsequently	NN	O	O
normal	NN	O	O
coronary	NN	O	O
angiogram	NN	O	O
.	NN	O	O

CASE	NN	O	O
:	NN	O	O
A	NN	O	O
33	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
a	NN	O	O
5	NN	O	O
-	NN	O	O
week	NN	O	O
gestation	NN	O	O
had	NN	O	O
recently	NN	O	O
received	NN	O	O
CC	NN	O	B-Chemical
for	NN	O	O
ovulation	NN	O	O
induction	NN	O	O
and	NN	O	O
presented	NN	O	O
with	NN	O	O
chest	NN	O	B-Disease
pain	NN	O	I-Disease
.	NN	O	O

An	NN	O	O
electrocardiogram	NN	O	O
showed	NN	O	O
a	NN	O	O
lateral	NN	O	O
and	NN	O	O
anterior	NN	O	O
wall	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
.	NN	O	O

Cardiac	NN	O	O
enzymes	NN	O	O
showed	NN	O	O
a	NN	O	O
peak	NN	O	O
rise	NN	O	O
in	NN	O	O
troponin	NN	O	O
I	NN	O	O
to	NN	O	O
9.10	NN	O	O
ng	NN	O	O
/	NN	O	O
mL	NN	O	O
.	NN	O	O

An	NN	O	O
initial	NN	O	O
exercise	NN	O	O
stress	NN	O	O
test	NN	O	O
was	NN	O	O
normal	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
admission	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
at	NN	O	O
high	NN	O	O
risk	NN	O	O
of	NN	O	O
radiation	NN	O	B-Disease
injury	NN	O	I-Disease
to	NN	O	O
the	NN	O	O
fetus	NN	O	O
,	NN	O	O
so	NN	O	O
a	NN	O	O
coronary	NN	O	O
angiogram	NN	O	O
was	NN	O	O
postponed	NN	O	O
until	NN	O	O
the	NN	O	O
second	NN	O	O
trimester	NN	O	O
.	NN	O	O

It	NN	O	O
showed	NN	O	O
normal	NN	O	O
coronary	NN	O	O
vessels	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
This	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
first	NN	O	O
reported	NN	O	O
case	NN	O	O
documenting	NN	O	O
a	NN	O	O
possible	NN	O	O
association	NN	O	O
between	NN	O	O
CC	NN	O	B-Chemical
and	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
.	NN	O	O

Thrombosis	NN	O	B-Disease
might	NN	O	O
be	NN	O	O
a	NN	O	O
rare	NN	O	O
but	NN	O	O
hazardous	NN	O	O
complication	NN	O	O
of	NN	O	O
CC	NN	O	B-Chemical
.	NN	O	O

Given	NN	O	O
this	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
complication	NN	O	O
,	NN	O	O
appropriate	NN	O	O
prophylactic	NN	O	O
measures	NN	O	O
should	NN	O	O
be	NN	O	O
used	NN	O	O
in	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
woman	NN	O	O
undergoing	NN	O	O
ovarian	NN	O	O
stimulation	NN	O	O
.	NN	O	O


-DOCSTART- (17574447)

Hepatonecrosis	NN	O	B-Disease
and	NN	O	O
cholangitis	NN	O	B-Disease
related	NN	O	O
to	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
phenobarbital	NN	O	B-Chemical
therapy	NN	O	O
:	NN	O	O
an	NN	O	O
autopsy	NN	O	O
report	NN	O	O
of	NN	O	O
two	NN	O	O
patients	NN	O	O
.	NN	O	O

Phenobarbital	NN	O	B-Chemical
(	NN	O	O
PB	NN	O	B-Chemical
)	NN	O	O
has	NN	O	O
a	NN	O	O
reputation	NN	O	O
for	NN	O	O
safety	NN	O	O
,	NN	O	O
and	NN	O	O
it	NN	O	O
is	NN	O	O
commonly	NN	O	O
believed	NN	O	O
that	NN	O	O
PB	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
increases	NN	O	O
in	NN	O	O
serum	NN	O	O
aminotransferase	NN	O	O
levels	NN	O	O
do	NN	O	O
not	NN	O	O
indicate	NN	O	O
or	NN	O	O
predict	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
significant	NN	O	O
chronic	NN	O	O
liver	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

Here	NN	O	O
we	NN	O	O
report	NN	O	O
of	NN	O	O
two	NN	O	O
adult	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
long	NN	O	O
history	NN	O	O
of	NN	O	O
epilepsy	NN	O	B-Disease
treated	NN	O	O
with	NN	O	O
PB	NN	O	B-Chemical
who	NN	O	O
died	NN	O	O
suddenly	NN	O	O
:	NN	O	O
one	NN	O	O
as	NN	O	O
consequence	NN	O	O
of	NN	O	O
cardiac	NN	O	B-Disease
arrest	NN	O	I-Disease
,	NN	O	O
the	NN	O	O
other	NN	O	O
of	NN	O	O
acute	NN	O	O
bronchopneumonia	NN	O	B-Disease
.	NN	O	O

At	NN	O	O
autopsy	NN	O	O
,	NN	O	O
analysis	NN	O	O
of	NN	O	O
liver	NN	O	O
parenchyma	NN	O	O
revealed	NN	O	O
rich	NN	O	O
portal	NN	O	O
inflammatory	NN	O	O
infiltrate	NN	O	O
,	NN	O	O
which	NN	O	O
consisted	NN	O	O
of	NN	O	O
mixed	NN	O	O
eosinophil	NN	O	O
and	NN	O	O
monocyte	NN	O	O
cells	NN	O	O
,	NN	O	O
associated	NN	O	O
with	NN	O	O
several	NN	O	O
foci	NN	O	O
of	NN	O	O
necrosis	NN	O	B-Disease
surrounded	NN	O	O
by	NN	O	O
a	NN	O	O
hard	NN	O	O
ring	NN	O	O
of	NN	O	O
non	NN	O	O
-	NN	O	O
specific	NN	O	O
granulomatous	NN	O	O
tissue	NN	O	O
.	NN	O	O

Inflammatory	NN	O	O
reactions	NN	O	O
of	NN	O	O
internal	NN	O	O
and	NN	O	O
external	NN	O	O
hepatic	NN	O	O
biliary	NN	O	O
ducts	NN	O	O
were	NN	O	O
also	NN	O	O
seen	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
illustrate	NN	O	O
that	NN	O	O
PB	NN	O	B-Chemical
may	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
chronic	NN	O	O
liver	NN	O	B-Disease
damage	NN	O	I-Disease
,	NN	O	O
which	NN	O	O
may	NN	O	O
lead	NN	O	O
to	NN	O	O
more	NN	O	O
serious	NN	O	O
and	NN	O	O
deleterious	NN	O	O
consequences	NN	O	O
.	NN	O	O

For	NN	O	O
this	NN	O	O
reason	NN	O	O
,	NN	O	O
each	NN	O	O
clinician	NN	O	O
should	NN	O	O
recognize	NN	O	O
this	NN	O	O
entity	NN	O	O
in	NN	O	O
the	NN	O	O
differential	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
PB	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
asymptomatic	NN	O	O
chronic	NN	O	B-Disease
hepatic	NN	O	I-Disease
enzyme	NN	O	I-Disease
dysfunction	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (16710500)

Ethambutol	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
.	NN	O	O

INTRODUCTION	NN	O	O
:	NN	O	O
Ethambutol	NN	O	B-Chemical
is	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
tuberculosis	NN	O	B-Disease
,	NN	O	O
which	NN	O	O
is	NN	O	O
still	NN	O	O
prevalent	NN	O	O
in	NN	O	O
Southeast	NN	O	O
Asia	NN	O	O
,	NN	O	O
and	NN	O	O
can	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
permanent	NN	O	O
visual	NN	O	B-Disease
loss	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
report	NN	O	O
3	NN	O	O
cases	NN	O	O
which	NN	O	O
presented	NN	O	O
with	NN	O	O
bitemporal	NN	O	B-Disease
hemianopia	NN	O	I-Disease
.	NN	O	O

CLINICAL	NN	O	O
PICTURE	NN	O	O
:	NN	O	O
Three	NN	O	O
patients	NN	O	O
with	NN	O	O
ethambutol	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
toxic	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
are	NN	O	O
described	NN	O	O
.	NN	O	O

All	NN	O	O
3	NN	O	O
patients	NN	O	O
had	NN	O	O
loss	NN	O	B-Disease
of	NN	O	I-Disease
central	NN	O	I-Disease
visual	NN	O	I-Disease
acuity	NN	O	I-Disease
,	NN	O	I-Disease
colour	NN	O	I-Disease
vision	NN	O	I-Disease
(	NN	O	I-Disease
Ishihara	NN	O	I-Disease
)	NN	O	I-Disease
and	NN	O	I-Disease
visual	NN	O	I-Disease
field	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
visual	NN	O	B-Disease
field	NN	O	I-Disease
loss	NN	O	I-Disease
had	NN	O	O
a	NN	O	O
bitemporal	NN	O	O
flavour	NN	O	O
,	NN	O	O
suggesting	NN	O	O
involvement	NN	O	O
of	NN	O	O
the	NN	O	O
optic	NN	O	O
chiasm	NN	O	O
.	NN	O	O

TREATMENT	NN	O	O
:	NN	O	O
Despite	NN	O	O
stopping	NN	O	O
ethambutol	NN	O	B-Chemical
on	NN	O	O
diagnosis	NN	O	O
,	NN	O	O
visual	NN	O	O
function	NN	O	O
continued	NN	O	O
to	NN	O	O
deteriorate	NN	O	O
for	NN	O	O
a	NN	O	O
few	NN	O	O
months	NN	O	O
.	NN	O	O

Subsequent	NN	O	O
improvement	NN	O	O
was	NN	O	O
mild	NN	O	O
in	NN	O	O
2	NN	O	O
cases	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
third	NN	O	O
case	NN	O	O
,	NN	O	O
visual	NN	O	O
acuity	NN	O	O
and	NN	O	O
colour	NN	O	O
vision	NN	O	O
normalised	NN	O	O
but	NN	O	O
the	NN	O	O
optic	NN	O	O
discs	NN	O	O
were	NN	O	O
pale	NN	O	O
.	NN	O	O

OUTCOME	NN	O	O
:	NN	O	O
All	NN	O	O
3	NN	O	O
patients	NN	O	O
had	NN	O	O
some	NN	O	O
permanent	NN	O	O
loss	NN	O	B-Disease
of	NN	O	I-Disease
visual	NN	O	I-Disease
function	NN	O	I-Disease
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Ethambutol	NN	O	B-Chemical
usage	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
permanent	NN	O	O
visual	NN	O	B-Disease
loss	NN	O	I-Disease
and	NN	O	O
should	NN	O	O
be	NN	O	O
avoided	NN	O	O
if	NN	O	O
possible	NN	O	O
or	NN	O	O
used	NN	O	O
with	NN	O	O
caution	NN	O	O
and	NN	O	O
proper	NN	O	O
ophthalmological	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

The	NN	O	O
author	NN	O	O
postulates	NN	O	O
that	NN	O	O
in	NN	O	O
cases	NN	O	O
of	NN	O	O
ethambutol	NN	O	B-Chemical
associated	NN	O	O
chiasmopathy	NN	O	O
,	NN	O	O
ethambutol	NN	O	B-Chemical
may	NN	O	O
initially	NN	O	O
affect	NN	O	O
the	NN	O	O
optic	NN	O	O
nerves	NN	O	O
and	NN	O	O
subsequently	NN	O	O
progress	NN	O	O
to	NN	O	O
involve	NN	O	O
the	NN	O	O
optic	NN	O	O
chiasm	NN	O	O
.	NN	O	O


-DOCSTART- (11694026)

Tolerability	NN	O	O
of	NN	O	O
nimesulide	NN	O	B-Chemical
and	NN	O	O
paracetamol	NN	O	B-Chemical
in	NN	O	O
patients	NN	O	O
with	NN	O	O
NSAID	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
urticaria	NN	O	B-Disease
/	NN	O	O
angioedema	NN	O	B-Disease
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
evaluated	NN	O	O
the	NN	O	O
tolerance	NN	O	O
of	NN	O	O
nimesulide	NN	O	B-Chemical
and	NN	O	O
paracetamol	NN	O	B-Chemical
in	NN	O	O
subjects	NN	O	O
with	NN	O	O
cutaneous	NN	O	O
,	NN	O	O
respiratory	NN	O	O
and	NN	O	O
anaphylactoid	NN	O	O
reactions	NN	O	O
induced	NN	O	O
by	NN	O	O
nonsteroidal	NN	O	B-Chemical
anti	NN	O	I-Chemical
-	NN	O	I-Chemical
inflammatory	NN	O	I-Chemical
drugs	NN	O	I-Chemical
(	NN	O	O
NSAIDs	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
we	NN	O	O
investigated	NN	O	O
tolerability	NN	O	O
and	NN	O	O
reliability	NN	O	O
of	NN	O	O
nimesulide	NN	O	B-Chemical
and	NN	O	O
paracetamol	NN	O	B-Chemical
in	NN	O	O
a	NN	O	O
very	NN	O	O
large	NN	O	O
number	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
an	NN	O	O
exclusive	NN	O	O
well	NN	O	O
-	NN	O	O
documented	NN	O	O
history	NN	O	O
of	NN	O	O
NSAID	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
urticaria	NN	O	B-Disease
/	NN	O	O
angioedema	NN	O	B-Disease
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
we	NN	O	O
evaluated	NN	O	O
whether	NN	O	O
some	NN	O	O
factors	NN	O	O
have	NN	O	O
the	NN	O	O
potential	NN	O	O
to	NN	O	O
increase	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
reaction	NN	O	O
to	NN	O	O
paracetamol	NN	O	B-Chemical
and	NN	O	O
nimesulide	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
single	NN	O	O
-	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
oral	NN	O	O
challenge	NN	O	O
procedure	NN	O	O
with	NN	O	O
nimesulide	NN	O	B-Chemical
or	NN	O	O
paracetamol	NN	O	B-Chemical
was	NN	O	O
applied	NN	O	O
to	NN	O	O
829	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
NSAID	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
urticaria	NN	O	B-Disease
/	NN	O	O
angioedema	NN	O	B-Disease
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
75	NN	O	O
/	NN	O	O
829	NN	O	O
(	NN	O	O
9.4%	NN	O	O
)	NN	O	O
patients	NN	O	O
experienced	NN	O	O
reactions	NN	O	O
to	NN	O	O
nimesulide	NN	O	B-Chemical
or	NN	O	O
paracetamol	NN	O	B-Chemical
.	NN	O	O

Of	NN	O	O
the	NN	O	O
715	NN	O	O
patients	NN	O	O
tested	NN	O	O
with	NN	O	O
nimesulide	NN	O	B-Chemical
62	NN	O	O
(	NN	O	O
8.6%	NN	O	O
)	NN	O	O
showed	NN	O	O
a	NN	O	O
positive	NN	O	O
test	NN	O	O
,	NN	O	O
while	NN	O	O
of	NN	O	O
114	NN	O	O
subjects	NN	O	O
submitted	NN	O	O
to	NN	O	O
the	NN	O	O
challenge	NN	O	O
with	NN	O	O
paracetamol	NN	O	B-Chemical
,	NN	O	O
13	NN	O	O
(	NN	O	O
9.6%	NN	O	O
)	NN	O	O
did	NN	O	O
not	NN	O	O
tolerate	NN	O	O
this	NN	O	O
drug	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
18.28%	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
chronic	NN	O	O
urticaria	NN	O	B-Disease
and	NN	O	O
11.8%	NN	O	O
of	NN	O	O
subjects	NN	O	O
with	NN	O	O
an	NN	O	O
history	NN	O	O
of	NN	O	O
NSAID	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
urticaria	NN	O	B-Disease
/	NN	O	O
angioedema	NN	O	B-Disease
or	NN	O	O
angioedema	NN	O	B-Disease
alone	NN	O	O
(	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
chronic	NN	O	O
urticaria	NN	O	B-Disease
)	NN	O	O
resulted	NN	O	O
to	NN	O	O
be	NN	O	O
intolerant	NN	O	O
to	NN	O	O
alternative	NN	O	O
drugs	NN	O	O
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
our	NN	O	O
results	NN	O	O
confirm	NN	O	O
the	NN	O	O
good	NN	O	O
tolerability	NN	O	O
of	NN	O	O
nimesulide	NN	O	B-Chemical
and	NN	O	O
paracetamol	NN	O	B-Chemical
in	NN	O	O
patients	NN	O	O
who	NN	O	O
experienced	NN	O	O
urticaria	NN	O	B-Disease
/	NN	O	O
angioedema	NN	O	B-Disease
caused	NN	O	O
by	NN	O	O
NSAIDs	NN	O	B-Chemical
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
reaction	NN	O	O
to	NN	O	O
these	NN	O	O
alternative	NN	O	O
study	NN	O	O
drugs	NN	O	O
is	NN	O	O
statistically	NN	O	O
increased	NN	O	O
by	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
chronic	NN	O	O
urticaria	NN	O	B-Disease
and	NN	O	O
,	NN	O	O
above	NN	O	O
all	NN	O	O
,	NN	O	O
by	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
NSAID	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
angioedema	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (11282081)

Effects	NN	O	O
of	NN	O	O
verapamil	NN	O	B-Chemical
on	NN	O	O
atrial	NN	O	B-Disease
fibrillation	NN	O	I-Disease
and	NN	O	O
its	NN	O	O
electrophysiological	NN	O	O
determinants	NN	O	O
in	NN	O	O
dogs	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Atrial	NN	O	B-Disease
tachycardia	NN	O	I-Disease
-	NN	O	O
induced	NN	O	O
remodeling	NN	O	O
promotes	NN	O	O
the	NN	O	O
occurrence	NN	O	O
and	NN	O	O
maintenance	NN	O	O
of	NN	O	O
atrial	NN	O	B-Disease
fibrillation	NN	O	I-Disease
(	NN	O	O
AF	NN	O	B-Disease
)	NN	O	O
and	NN	O	O
decreases	NN	O	O
L	NN	O	O
-	NN	O	O
type	NN	O	O
Ca	NN	O	B-Chemical
(	NN	O	O
2+	NN	O	O
)	NN	O	O
current	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
also	NN	O	O
a	NN	O	O
clinical	NN	O	O
suggestion	NN	O	O
that	NN	O	O
acute	NN	O	O
L	NN	O	O
-	NN	O	O
type	NN	O	O
Ca	NN	O	B-Chemical
(	NN	O	O
2	NN	O	O
)	NN	O	O
channel	NN	O	O
blockade	NN	O	O
can	NN	O	O
promote	NN	O	O
AF	NN	O	B-Disease
,	NN	O	O
consistent	NN	O	O
with	NN	O	O
an	NN	O	O
AF	NN	O	B-Disease
promoting	NN	O	O
effect	NN	O	O
of	NN	O	O
Ca	NN	O	B-Chemical
(	NN	O	O
2+	NN	O	O
)	NN	O	O
channel	NN	O	O
inhibition	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
potential	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
AF	NN	O	B-Disease
promotion	NN	O	O
by	NN	O	O
Ca	NN	O	B-Chemical
(	NN	O	O
2+	NN	O	O
)	NN	O	O
channel	NN	O	O
blockers	NN	O	O
,	NN	O	O
we	NN	O	O
administered	NN	O	O
verapamil	NN	O	B-Chemical
to	NN	O	O
morphine	NN	O	B-Chemical
-	NN	O	O
chloralose	NN	O	B-Chemical
anesthetized	NN	O	O
dogs	NN	O	O
.	NN	O	O

Diltiazem	NN	O	B-Chemical
was	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
comparison	NN	O	O
drug	NN	O	O
and	NN	O	O
autonomic	NN	O	O
blockade	NN	O	O
with	NN	O	O
atropine	NN	O	B-Chemical
and	NN	O	O
nadolol	NN	O	B-Chemical
was	NN	O	O
applied	NN	O	O
in	NN	O	O
some	NN	O	O
experiments	NN	O	O
.	NN	O	O

Epicardial	NN	O	O
mapping	NN	O	O
with	NN	O	O
240	NN	O	O
epicardial	NN	O	O
electrodes	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
evaluate	NN	O	O
activation	NN	O	O
during	NN	O	O
AF	NN	O	B-Disease
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Verapamil	NN	O	B-Chemical
caused	NN	O	O
AF	NN	O	B-Disease
promotion	NN	O	O
in	NN	O	O
six	NN	O	O
dogs	NN	O	O
,	NN	O	O
increasing	NN	O	O
mean	NN	O	O
duration	NN	O	O
of	NN	O	O
AF	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
burst	NN	O	O
pacing	NN	O	O
,	NN	O	O
from	NN	O	O
8+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
s	NN	O	O
(	NN	O	O
mean+	NN	O	O
/	NN	O	O
-	NN	O	O
S.E.	NN	O	O
)	NN	O	O
to	NN	O	O
95+	NN	O	O
/	NN	O	O
-	NN	O	O
39	NN	O	O
s	NN	O	O
(	NN	O	O
P<0.01	NN	O	O
vs	NN	O	O
.	NN	O	O

control	NN	O	O
)	NN	O	O
at	NN	O	O
a	NN	O	O
loading	NN	O	O
dose	NN	O	O
of	NN	O	O
0.1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
and	NN	O	O
228+	NN	O	O
/	NN	O	O
-	NN	O	O
101	NN	O	O
s	NN	O	O
(	NN	O	O
P<0.0005	NN	O	O
vs	NN	O	O
.	NN	O	O

control	NN	O	O
)	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
0.2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Underlying	NN	O	O
electrophysiological	NN	O	O
mechanisms	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
detail	NN	O	O
in	NN	O	O
five	NN	O	O
additional	NN	O	O
dogs	NN	O	O
under	NN	O	O
control	NN	O	O
conditions	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
the	NN	O	O
higher	NN	O	O
dose	NN	O	O
of	NN	O	O
verapamil	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
these	NN	O	O
experiments	NN	O	O
,	NN	O	O
verapamil	NN	O	B-Chemical
shortened	NN	O	O
mean	NN	O	O
effective	NN	O	O
refractory	NN	O	O
period	NN	O	O
(	NN	O	O
ERP	NN	O	O
)	NN	O	O
from	NN	O	O
122+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
to	NN	O	O
114+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
ms	NN	O	O
(	NN	O	O
P<0.02	NN	O	O
)	NN	O	O
at	NN	O	O
a	NN	O	O
cycle	NN	O	O
length	NN	O	O
of	NN	O	O
300	NN	O	O
ms	NN	O	O
,	NN	O	O
decreased	NN	O	O
ERP	NN	O	O
heterogeneity	NN	O	O
(	NN	O	O
from	NN	O	O
15+	NN	O	O
/	NN	O	O
-	NN	O	O
1	NN	O	O
to	NN	O	O
10+	NN	O	O
/	NN	O	O
-	NN	O	O
1%	NN	O	O
,	NN	O	O
P<0.05	NN	O	O
)	NN	O	O
,	NN	O	O
heterogeneously	NN	O	O
accelerated	NN	O	O
atrial	NN	O	O
conduction	NN	O	O
and	NN	O	O
decreased	NN	O	O
the	NN	O	O
cycle	NN	O	O
length	NN	O	O
of	NN	O	O
AF	NN	O	B-Disease
(	NN	O	O
94+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
to	NN	O	O
84+	NN	O	O
/	NN	O	O
-	NN	O	O
3	NN	O	O
ms	NN	O	O
,	NN	O	O
P<0.005	NN	O	O
)	NN	O	O
.	NN	O	O

Diltiazem	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
affect	NN	O	O
ERP	NN	O	O
,	NN	O	O
AF	NN	O	B-Disease
cycle	NN	O	O
length	NN	O	O
or	NN	O	O
AF	NN	O	B-Disease
duration	NN	O	O
,	NN	O	O
but	NN	O	O
produced	NN	O	O
conduction	NN	O	O
acceleration	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
caused	NN	O	O
by	NN	O	O
verapamil	NN	O	B-Chemical
(	NN	O	O
n=5	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
autonomic	NN	O	O
blockade	NN	O	O
,	NN	O	O
verapamil	NN	O	B-Chemical
failed	NN	O	O
to	NN	O	O
promote	NN	O	O
AF	NN	O	B-Disease
and	NN	O	O
increased	NN	O	O
,	NN	O	O
rather	NN	O	O
than	NN	O	O
decreasing	NN	O	O
,	NN	O	O
refractoriness	NN	O	O
.	NN	O	O

Neither	NN	O	O
verapamil	NN	O	B-Chemical
nor	NN	O	O
diltiazem	NN	O	B-Chemical
affected	NN	O	O
atrial	NN	O	O
conduction	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
autonomic	NN	O	O
blockade	NN	O	O
.	NN	O	O

Epicardial	NN	O	O
mapping	NN	O	O
suggested	NN	O	O
that	NN	O	O
verapamil	NN	O	B-Chemical
promoted	NN	O	O
AF	NN	O	B-Disease
by	NN	O	O
increasing	NN	O	O
the	NN	O	O
number	NN	O	O
of	NN	O	O
simultaneous	NN	O	O
wavefronts	NN	O	O
reflected	NN	O	O
by	NN	O	O
separate	NN	O	O
zones	NN	O	O
of	NN	O	O
reactivation	NN	O	O
in	NN	O	O
each	NN	O	O
cycle	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Verapamil	NN	O	B-Chemical
promotes	NN	O	O
AF	NN	O	B-Disease
in	NN	O	O
normal	NN	O	O
dogs	NN	O	O
by	NN	O	O
promoting	NN	O	O
multiple	NN	O	O
circuit	NN	O	O
reentry	NN	O	O
,	NN	O	O
an	NN	O	O
effect	NN	O	O
dependent	NN	O	O
on	NN	O	O
intact	NN	O	O
autonomic	NN	O	O
tone	NN	O	O
and	NN	O	O
not	NN	O	O
shared	NN	O	O
by	NN	O	O
diltiazem	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (10074612)

Hypotension	NN	O	B-Disease
,	NN	O	O
bradycardia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
asystole	NN	O	B-Disease
after	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
intravenous	NN	O	O
methylprednisolone	NN	O	B-Chemical
in	NN	O	O
a	NN	O	O
monitored	NN	O	O
patient	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
hypotension	NN	O	B-Disease
,	NN	O	O
bradycardia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
asystole	NN	O	B-Disease
after	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
methylprednisolone	NN	O	B-Chemical
in	NN	O	O
a	NN	O	O
73	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
patient	NN	O	O
who	NN	O	O
underwent	NN	O	O
electrocardiographic	NN	O	O
(	NN	O	O
ECG	NN	O	O
)	NN	O	O
monitoring	NN	O	O
throughout	NN	O	O
the	NN	O	O
episode	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
ischemic	NN	O	B-Disease
cardiac	NN	O	B-Disease
disease	NN	O	I-Disease
9	NN	O	O
years	NN	O	O
earlier	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
admitted	NN	O	O
with	NN	O	O
a	NN	O	O
pulmonary	NN	O	B-Disease
-	NN	O	I-Disease
renal	NN	O	I-Disease
syndrome	NN	O	I-Disease
with	NN	O	O
hemoptysis	NN	O	B-Disease
,	NN	O	O
rapidly	NN	O	O
progressive	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
hypoxemia	NN	O	B-Disease
that	NN	O	O
required	NN	O	O
mechanical	NN	O	O
ventilation	NN	O	O
in	NN	O	O
the	NN	O	O
intensive	NN	O	O
care	NN	O	O
unit	NN	O	O
.	NN	O	O

After	NN	O	O
receiving	NN	O	O
advanced	NN	O	O
cardiopulmonary	NN	O	O
resuscitation	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
recovered	NN	O	O
cardiac	NN	O	O
rhythm	NN	O	O
.	NN	O	O

The	NN	O	O
ECG	NN	O	O
showed	NN	O	O
a	NN	O	O
junctional	NN	O	O
rhythm	NN	O	O
without	NN	O	O
ventricular	NN	O	B-Disease
arrhythmia	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
study	NN	O	O
reviews	NN	O	O
the	NN	O	O
current	NN	O	O
proposed	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
sudden	NN	O	B-Disease
death	NN	O	I-Disease
after	NN	O	O
a	NN	O	O
high	NN	O	O
dose	NN	O	O
of	NN	O	O
intravenous	NN	O	O
methylprednisolone	NN	O	B-Chemical
(	NN	O	O
IVMP	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

These	NN	O	O
mechanisms	NN	O	O
are	NN	O	O
not	NN	O	O
well	NN	O	O
understood	NN	O	O
because	NN	O	O
,	NN	O	O
in	NN	O	O
most	NN	O	O
cases	NN	O	O
,	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
not	NN	O	O
monitored	NN	O	O
at	NN	O	O
the	NN	O	O
moment	NN	O	O
of	NN	O	O
the	NN	O	O
event	NN	O	O
.	NN	O	O

Rapid	NN	O	O
infusion	NN	O	O
and	NN	O	O
underlying	NN	O	O
cardiac	NN	O	B-Disease
disease	NN	O	I-Disease
were	NN	O	O
important	NN	O	O
risk	NN	O	O
factors	NN	O	O
in	NN	O	O
the	NN	O	O
case	NN	O	O
reported	NN	O	O
here	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
authors	NN	O	O
discount	NN	O	O
ventricular	NN	O	B-Disease
arrhythmia	NN	O	I-Disease
as	NN	O	O
the	NN	O	O
main	NN	O	O
mechanism	NN	O	O
.	NN	O	O


-DOCSTART- (9209318)

Lifetime	NN	O	O
treatment	NN	O	O
of	NN	O	O
mice	NN	O	O
with	NN	O	O
azidothymidine	NN	O	B-Chemical
(	NN	O	O
AZT	NN	O	B-Chemical
)	NN	O	O
produces	NN	O	O
myelodysplasia	NN	O	B-Disease
.	NN	O	O

AZT	NN	O	B-Chemical
has	NN	O	O
induced	NN	O	O
a	NN	O	O
macrocytic	NN	O	B-Disease
anemia	NN	O	I-Disease
in	NN	O	O
AIDS	NN	O	B-Disease
patients	NN	O	O
on	NN	O	O
long	NN	O	O
term	NN	O	O
AZT	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
generally	NN	O	O
assumed	NN	O	O
that	NN	O	O
DNA	NN	O	O
elongation	NN	O	O
is	NN	O	O
stopped	NN	O	O
by	NN	O	O
the	NN	O	O
insertion	NN	O	O
of	NN	O	O
AZT	NN	O	B-Chemical
into	NN	O	O
the	NN	O	O
chain	NN	O	O
in	NN	O	O
place	NN	O	O
of	NN	O	O
thymidine	NN	O	B-Chemical
thus	NN	O	O
preventing	NN	O	O
the	NN	O	O
phosphate	NN	O	B-Chemical
hydroxyl	NN	O	O
linkages	NN	O	O
and	NN	O	O
therefore	NN	O	O
suppresses	NN	O	O
hemopoietic	NN	O	O
progenitor	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
in	NN	O	O
an	NN	O	O
early	NN	O	O
stage	NN	O	O
of	NN	O	O
differentiation	NN	O	O
.	NN	O	O

CBA	NN	O	O
/	NN	O	O
Ca	NN	O	O
male	NN	O	O
mice	NN	O	O
started	NN	O	O
on	NN	O	O
AZT	NN	O	B-Chemical
0.75	NN	O	O
mg	NN	O	O
/	NN	O	O
ml	NN	O	O
H2O	NN	O	O
at	NN	O	O
84	NN	O	O
days	NN	O	O
of	NN	O	O
age	NN	O	O
and	NN	O	O
kept	NN	O	O
on	NN	O	O
it	NN	O	O
for	NN	O	O
687	NN	O	O
days	NN	O	O
when	NN	O	O
dosage	NN	O	O
reduced	NN	O	O
to	NN	O	O
0.5	NN	O	O
mg	NN	O	O
/	NN	O	O
ml	NN	O	O
H2O	NN	O	O
for	NN	O	O
a	NN	O	O
group	NN	O	O
,	NN	O	O
another	NN	O	O
group	NN	O	O
removed	NN	O	O
from	NN	O	O
AZT	NN	O	B-Chemical
to	NN	O	O
see	NN	O	O
recovery	NN	O	O
,	NN	O	O
and	NN	O	O
third	NN	O	O
group	NN	O	O
remained	NN	O	O
on	NN	O	O
0.75	NN	O	O
mg	NN	O	O
.	NN	O	O

At	NN	O	O
687	NN	O	O
days	NN	O	O
mice	NN	O	O
that	NN	O	O
had	NN	O	O
been	NN	O	O
on	NN	O	O
0.75	NN	O	O
mg	NN	O	O
had	NN	O	O
average	NN	O	O
platelet	NN	O	O
counts	NN	O	O
of	NN	O	O
2.5	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
.	NN	O	O

Histological	NN	O	O
examination	NN	O	O
on	NN	O	O
9	NN	O	O
of	NN	O	O
10	NN	O	O
mice	NN	O	O
with	NN	O	O
such	NN	O	O
thrombocytopenia	NN	O	B-Disease
showed	NN	O	O
changes	NN	O	O
compatible	NN	O	O
with	NN	O	O
myelodysplastic	NN	O	B-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
MDS	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

A	NN	O	O
variety	NN	O	O
of	NN	O	O
histological	NN	O	O
patterns	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
hypocellular	NN	O	O
myelodysplasia	NN	O	B-Disease
,	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
hypersegmented	NN	O	O
myelodysplastic	NN	O	B-Disease
granulocytosis	NN	O	O
,	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
hypercellular	NN	O	O
marrow	NN	O	O
with	NN	O	O
abnormal	NN	O	O
megakaryocytes	NN	O	O
with	NN	O	O
bizarre	NN	O	O
nuclei	NN	O	O
,	NN	O	O
one	NN	O	O
case	NN	O	O
of	NN	O	O
megakaryocytic	NN	O	O
myelosis	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
hyperplastic	NN	O	B-Disease
marrow	NN	O	I-Disease
,	NN	O	O
dysmyelopoiesis	NN	O	B-Disease
and	NN	O	O
a	NN	O	O
hypocellular	NN	O	B-Disease
marrow	NN	O	I-Disease
and	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
myelodysplasia	NN	O	B-Disease
with	NN	O	O
dyserythropoiesis	NN	O	B-Disease
,	NN	O	O
hemosiderosis	NN	O	B-Disease
and	NN	O	O
a	NN	O	O
hypocellular	NN	O	B-Disease
marrow	NN	O	I-Disease
.	NN	O	O

Above	NN	O	O
mentioned	NN	O	O
AZT	NN	O	B-Chemical
incorporation	NN	O	O
may	NN	O	O
have	NN	O	O
induced	NN	O	O
an	NN	O	O
ineffective	NN	O	O
hemopoiesis	NN	O	O
in	NN	O	O
the	NN	O	O
primitive	NN	O	O
hemopoietic	NN	O	O
progenitor	NN	O	O
cells	NN	O	O
,	NN	O	O
which	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
be	NN	O	O
seen	NN	O	O
commonly	NN	O	O
in	NN	O	O
the	NN	O	O
myelodysplastic	NN	O	B-Disease
syndrome	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (8742498)

Influence	NN	O	O
of	NN	O	O
diet	NN	O	O
free	NN	O	O
of	NN	O	O
NAD	NN	O	B-Chemical
-	NN	O	O
precursors	NN	O	O
on	NN	O	O
acetaminophen	NN	O	B-Chemical
hepatotoxicity	NN	O	B-Disease
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
we	NN	O	O
demonstrated	NN	O	O
the	NN	O	O
hepatoprotective	NN	O	O
effects	NN	O	O
of	NN	O	O
nicotinic	NN	O	B-Chemical
acid	NN	O	I-Chemical
amide	NN	O	I-Chemical
,	NN	O	O
a	NN	O	O
selective	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
poly	NN	O	B-Chemical
(	NN	O	I-Chemical
ADP	NN	O	I-Chemical
-	NN	O	I-Chemical
ribose	NN	O	I-Chemical
)	NN	O	I-Chemical
polymerase	NN	O	O
(	NN	O	O
PARP	NN	O	O
;	NN	O	O
EC	NN	O	O
2.4.2.30	NN	O	O
)	NN	O	O
on	NN	O	O
mice	NN	O	O
suffering	NN	O	O
from	NN	O	O
acetaminophen	NN	O	B-Chemical
(	NN	O	O
AAP	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
hepatitis	NN	O	B-Disease
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
the	NN	O	O
AAP	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
liver	NN	O	B-Disease
injury	NN	O	I-Disease
involves	NN	O	O
a	NN	O	O
step	NN	O	O
which	NN	O	O
depends	NN	O	O
on	NN	O	O
adenoribosylation	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
investigates	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
diet	NN	O	O
free	NN	O	O
of	NN	O	O
precursors	NN	O	O
of	NN	O	O
NAD	NN	O	B-Chemical
,	NN	O	O
the	NN	O	O
substrate	NN	O	O
on	NN	O	O
which	NN	O	O
PARP	NN	O	O
acts	NN	O	O
,	NN	O	O
in	NN	O	O
female	NN	O	O
NMRI	NN	O	O
mice	NN	O	O
with	NN	O	O
AAP	NN	O	B-Chemical
hepatitis	NN	O	B-Disease
and	NN	O	O
evaluates	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
simultaneous	NN	O	O
ethanol	NN	O	B-Chemical
consumption	NN	O	O
in	NN	O	O
these	NN	O	O
animals	NN	O	O
.	NN	O	O

Liver	NN	O	B-Disease
injuries	NN	O	I-Disease
were	NN	O	O
quantified	NN	O	O
as	NN	O	O
serum	NN	O	O
activities	NN	O	O
of	NN	O	O
glutamate	NN	O	B-Chemical
-	NN	O	O
oxaloacetate	NN	O	B-Chemical
transaminase	NN	O	O
(	NN	O	O
GOT	NN	O	O
)	NN	O	O
and	NN	O	O
glutamate	NN	O	B-Chemical
-	NN	O	O
pyruvate	NN	O	B-Chemical
transaminase	NN	O	O
(	NN	O	O
GPT	NN	O	O
)	NN	O	O
.	NN	O	O

While	NN	O	O
AAP	NN	O	B-Chemical
caused	NN	O	O
a	NN	O	O
117	NN	O	O
-	NN	O	O
fold	NN	O	O
elevation	NN	O	O
of	NN	O	O
serum	NN	O	O
transaminase	NN	O	O
activities	NN	O	O
in	NN	O	O
mice	NN	O	O
kept	NN	O	O
on	NN	O	O
a	NN	O	O
standard	NN	O	O
laboratory	NN	O	O
diet	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
significantly	NN	O	O
exacerbated	NN	O	O
by	NN	O	O
ethanol	NN	O	B-Chemical
and	NN	O	O
inhibited	NN	O	O
by	NN	O	O
nicotinic	NN	O	B-Chemical
acid	NN	O	I-Chemical
amide	NN	O	I-Chemical
(	NN	O	O
NAA	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
adverse	NN	O	O
effects	NN	O	O
were	NN	O	O
noted	NN	O	O
in	NN	O	O
animals	NN	O	O
fed	NN	O	O
a	NN	O	O
diet	NN	O	O
free	NN	O	O
of	NN	O	O
precursors	NN	O	O
of	NN	O	O
NAD	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
these	NN	O	O
animals	NN	O	O
,	NN	O	O
only	NN	O	O
minor	NN	O	O
increases	NN	O	O
of	NN	O	O
serum	NN	O	O
transaminase	NN	O	O
activities	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
AAP	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
unlike	NN	O	O
the	NN	O	O
exacerbation	NN	O	O
caused	NN	O	O
by	NN	O	O
ethanol	NN	O	B-Chemical
in	NN	O	O
mice	NN	O	O
on	NN	O	O
a	NN	O	O
standard	NN	O	O
diet	NN	O	O
,	NN	O	O
the	NN	O	O
liver	NN	O	B-Disease
damage	NN	O	I-Disease
was	NN	O	O
inhibited	NN	O	O
by	NN	O	O
50%	NN	O	O
by	NN	O	O
ethanol	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
further	NN	O	O
64%	NN	O	O
reduction	NN	O	O
of	NN	O	O
hepatitis	NN	O	B-Disease
was	NN	O	O
observed	NN	O	O
,	NN	O	O
when	NN	O	O
NAA	NN	O	B-Chemical
was	NN	O	O
given	NN	O	O
to	NN	O	O
ethanol	NN	O	B-Chemical
/	NN	O	O
AAP	NN	O	B-Chemical
-	NN	O	O
mice	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
provide	NN	O	O
evidence	NN	O	O
that	NN	O	O
the	NN	O	O
AAP	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hepatitis	NN	O	B-Disease
and	NN	O	O
its	NN	O	O
exacerbation	NN	O	O
by	NN	O	O
ethanol	NN	O	B-Chemical
can	NN	O	O
either	NN	O	O
be	NN	O	O
reduced	NN	O	O
by	NN	O	O
end	NN	O	O
-	NN	O	O
product	NN	O	O
inhibition	NN	O	O
of	NN	O	O
PARP	NN	O	O
by	NN	O	O
NAA	NN	O	B-Chemical
or	NN	O	O
by	NN	O	O
dietary	NN	O	O
depletion	NN	O	O
of	NN	O	O
the	NN	O	O
enzyme	NN	O	O
'	NN	O	O
s	NN	O	O
substrate	NN	O	O
NAD	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
see	NN	O	O
the	NN	O	O
main	NN	O	O
application	NN	O	O
of	NN	O	O
NAA	NN	O	B-Chemical
as	NN	O	O
for	NN	O	O
the	NN	O	O
combinational	NN	O	O
use	NN	O	O
in	NN	O	O
pharmaceutical	NN	O	O
preparations	NN	O	O
of	NN	O	O
acetaminophen	NN	O	B-Chemical
in	NN	O	O
order	NN	O	O
to	NN	O	O
avoid	NN	O	O
hepatic	NN	O	B-Disease
damage	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
this	NN	O	O
widely	NN	O	O
used	NN	O	O
analgesic	NN	O	O
.	NN	O	O


-DOCSTART- (2435991)

Antiarrhythmic	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
of	NN	O	O
cibenzoline	NN	O	B-Chemical
on	NN	O	O
canine	NN	O	O
ventricular	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
.	NN	O	O

Using	NN	O	O
two	NN	O	O
-	NN	O	O
stage	NN	O	O
coronary	NN	O	O
ligation	NN	O	O
-	NN	O	O
,	NN	O	O
digitalis	NN	O	B-Chemical
-	NN	O	O
,	NN	O	O
and	NN	O	O
adrenaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
canine	NN	O	O
ventricular	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
,	NN	O	O
antiarrhythmic	NN	O	O
effects	NN	O	O
of	NN	O	O
cibenzoline	NN	O	B-Chemical
were	NN	O	O
examined	NN	O	O
and	NN	O	O
the	NN	O	O
minimum	NN	O	O
effective	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
for	NN	O	O
each	NN	O	O
arrhythmia	NN	O	B-Disease
model	NN	O	O
was	NN	O	O
determined	NN	O	O
.	NN	O	O

Cibenzoline	NN	O	B-Chemical
suppressed	NN	O	O
all	NN	O	O
the	NN	O	O
arrhythmias	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
the	NN	O	O
minimum	NN	O	O
effective	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
for	NN	O	O
arrhythmias	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
24	NN	O	O
-	NN	O	O
h	NN	O	O
coronary	NN	O	O
ligation	NN	O	O
,	NN	O	O
48	NN	O	O
-	NN	O	O
h	NN	O	O
coronary	NN	O	O
ligation	NN	O	O
,	NN	O	O
digitalis	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
adrenaline	NN	O	B-Chemical
were	NN	O	O
1.9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.9	NN	O	O
(	NN	O	O
by	NN	O	O
8	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
)	NN	O	O
,	NN	O	O
1.6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.5	NN	O	O
(	NN	O	O
by	NN	O	O
8	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
)	NN	O	O
,	NN	O	O
0.6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.2	NN	O	O
(	NN	O	O
by	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
3.5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.3	NN	O	O
(	NN	O	O
by	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
)	NN	O	O
micrograms	NN	O	O
/	NN	O	O
ml	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SDM	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
-	NN	O	O
7	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
concentration	NN	O	O
for	NN	O	O
adrenaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
arrhythmia	NN	O	B-Disease
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
than	NN	O	O
those	NN	O	O
for	NN	O	O
the	NN	O	O
other	NN	O	O
types	NN	O	O
of	NN	O	O
arrhythmias	NN	O	B-Disease
.	NN	O	O

This	NN	O	O
pharmacological	NN	O	O
profile	NN	O	O
is	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
of	NN	O	O
mexiletine	NN	O	B-Chemical
and	NN	O	O
tocainide	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
all	NN	O	O
three	NN	O	O
drugs	NN	O	O
have	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
(	NN	O	O
CNS	NN	O	O
)	NN	O	O
stimulant	NN	O	O
action	NN	O	O
.	NN	O	O

Because	NN	O	O
cibenzoline	NN	O	B-Chemical
had	NN	O	O
only	NN	O	O
weak	NN	O	O
hypotensive	NN	O	B-Disease
and	NN	O	O
sinus	NN	O	O
node	NN	O	O
depressive	NN	O	B-Disease
effects	NN	O	O
and	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
orally	NN	O	O
active	NN	O	O
when	NN	O	O
given	NN	O	O
to	NN	O	O
coronary	NN	O	O
ligation	NN	O	O
arrhythmia	NN	O	B-Disease
dogs	NN	O	O
,	NN	O	O
its	NN	O	O
clinical	NN	O	O
usefulness	NN	O	O
is	NN	O	O
expected	NN	O	O
.	NN	O	O


-DOCSTART- (950631)

Immunopathology	NN	O	O
of	NN	O	O
penicillamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
glomerular	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

Four	NN	O	O
patients	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
developed	NN	O	O
heavy	NN	O	O
proteinuria	NN	O	B-Disease
after	NN	O	O
five	NN	O	O
to	NN	O	O
12	NN	O	O
months	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
.	NN	O	O

Light	NN	O	O
microscopy	NN	O	O
of	NN	O	O
renal	NN	O	O
biopsy	NN	O	O
samples	NN	O	O
showed	NN	O	O
minimal	NN	O	O
glomerular	NN	O	O
capillary	NN	O	O
wall	NN	O	O
thickening	NN	O	O
and	NN	O	O
mesangial	NN	O	O
matrix	NN	O	O
increase	NN	O	O
,	NN	O	O
or	NN	O	O
no	NN	O	O
departure	NN	O	O
from	NN	O	O
normal	NN	O	O
.	NN	O	O

Electron	NN	O	O
microscopy	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
revealed	NN	O	O
subepithelial	NN	O	O
electron	NN	O	O
-	NN	O	O
dense	NN	O	O
deposits	NN	O	O
,	NN	O	O
fusion	NN	O	O
of	NN	O	O
epithelial	NN	O	O
cell	NN	O	O
foot	NN	O	O
processes	NN	O	O
,	NN	O	O
and	NN	O	O
evidence	NN	O	O
of	NN	O	O
mesangial	NN	O	O
cell	NN	O	O
hyperactivity	NN	O	O
.	NN	O	O

Immunofluorescence	NN	O	O
microscopy	NN	O	O
demonstrated	NN	O	O
granular	NN	O	O
capillary	NN	O	O
wall	NN	O	O
deposits	NN	O	O
of	NN	O	O
IgG	NN	O	O
and	NN	O	O
C3	NN	O	O
.	NN	O	O

The	NN	O	O
findings	NN	O	O
were	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
in	NN	O	O
early	NN	O	O
membranous	NN	O	B-Disease
glomerulonephritis	NN	O	I-Disease
,	NN	O	O
differences	NN	O	O
being	NN	O	O
observed	NN	O	O
however	NN	O	O
in	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
staining	NN	O	O
for	NN	O	O
the	NN	O	O
early	NN	O	O
-	NN	O	O
acting	NN	O	O
complement	NN	O	O
components	NN	O	O
C1q	NN	O	O
and	NN	O	O
C4	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
tentatively	NN	O	O
concluded	NN	O	O
that	NN	O	O
complement	NN	O	O
was	NN	O	O
activated	NN	O	O
by	NN	O	O
the	NN	O	O
classical	NN	O	O
pathway	NN	O	O
.	NN	O	O


-DOCSTART- (663266)

Ventricular	NN	O	B-Disease
fibrillation	NN	O	I-Disease
from	NN	O	O
diatrizoate	NN	O	B-Chemical
with	NN	O	O
and	NN	O	O
without	NN	O	O
chelating	NN	O	O
agents	NN	O	O
.	NN	O	O

The	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
Renografin	NN	O	B-Chemical
76%	NN	O	I-Chemical
was	NN	O	O
compared	NN	O	O
with	NN	O	O
that	NN	O	O
of	NN	O	O
Hypaque	NN	O	B-Chemical
76%	NN	O	I-Chemical
by	NN	O	O
selective	NN	O	O
injection	NN	O	O
of	NN	O	O
each	NN	O	O
into	NN	O	O
the	NN	O	O
right	NN	O	O
coronary	NN	O	O
artery	NN	O	O
of	NN	O	O
dogs	NN	O	O
.	NN	O	O

Renografin	NN	O	B-Chemical
contains	NN	O	O
the	NN	O	O
chelating	NN	O	O
agents	NN	O	O
sodium	NN	O	B-Chemical
citrate	NN	O	I-Chemical
and	NN	O	O
disodium	NN	O	B-Chemical
edetate	NN	O	I-Chemical
,	NN	O	O
while	NN	O	O
Hypaque	NN	O	B-Chemical
contains	NN	O	O
calcium	NN	O	B-Chemical
disodium	NN	O	I-Chemical
edetate	NN	O	I-Chemical
and	NN	O	O
no	NN	O	O
sodium	NN	O	B-Chemical
citrate	NN	O	I-Chemical
.	NN	O	O

Ventricular	NN	O	B-Disease
fibrillation	NN	O	I-Disease
occurred	NN	O	O
significantly	NN	O	O
more	NN	O	O
often	NN	O	O
with	NN	O	O
Renografin	NN	O	B-Chemical
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
chelating	NN	O	O
agents	NN	O	O
contribute	NN	O	O
to	NN	O	O
toxicity	NN	O	B-Disease
in	NN	O	O
coronary	NN	O	O
angiography	NN	O	O
.	NN	O	O


-DOCSTART- (19319147)

Rapid	NN	O	O
reversal	NN	O	O
of	NN	O	O
anticoagulation	NN	O	O
reduces	NN	O	O
hemorrhage	NN	O	B-Disease
volume	NN	O	O
in	NN	O	O
a	NN	O	O
mouse	NN	O	O
model	NN	O	O
of	NN	O	O
warfarin	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
intracerebral	NN	O	B-Disease
hemorrhage	NN	O	I-Disease
.	NN	O	O

Warfarin	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
intracerebral	NN	O	B-Disease
hemorrhage	NN	O	I-Disease
(	NN	O	O
W	NN	O	O
-	NN	O	O
ICH	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
severe	NN	O	O
type	NN	O	O
of	NN	O	O
stroke	NN	O	B-Disease
.	NN	O	O

There	NN	O	O
is	NN	O	O
no	NN	O	O
consensus	NN	O	O
on	NN	O	O
the	NN	O	O
optimal	NN	O	O
treatment	NN	O	O
for	NN	O	O
W	NN	O	O
-	NN	O	O
ICH	NN	O	B-Disease
.	NN	O	O

Using	NN	O	O
a	NN	O	O
mouse	NN	O	O
model	NN	O	O
,	NN	O	O
we	NN	O	O
tested	NN	O	O
whether	NN	O	O
the	NN	O	O
rapid	NN	O	O
reversal	NN	O	O
of	NN	O	O
anticoagulation	NN	O	O
using	NN	O	O
human	NN	O	O
prothrombin	NN	O	B-Chemical
complex	NN	O	I-Chemical
concentrate	NN	O	I-Chemical
(	NN	O	O
PCC	NN	O	B-Chemical
)	NN	O	O
can	NN	O	O
reduce	NN	O	O
hemorrhagic	NN	O	O
blood	NN	O	O
volume	NN	O	O
.	NN	O	O

Male	NN	O	O
CD	NN	O	O
-	NN	O	O
1	NN	O	O
mice	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
warfarin	NN	O	B-Chemical
(	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
over	NN	O	O
24	NN	O	O
h	NN	O	O
)	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
a	NN	O	O
mean	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
s.d.	NN	O	O
)	NN	O	O
International	NN	O	O
Normalized	NN	O	O
Ratio	NN	O	O
of	NN	O	O
3.5+	NN	O	O
/	NN	O	O
-	NN	O	O
0.9	NN	O	O
.	NN	O	O

First	NN	O	O
,	NN	O	O
we	NN	O	O
showed	NN	O	O
that	NN	O	O
an	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
human	NN	O	O
PCC	NN	O	B-Chemical
rapidly	NN	O	O
reversed	NN	O	O
anticoagulation	NN	O	O
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Second	NN	O	O
,	NN	O	O
a	NN	O	O
stereotactic	NN	O	O
injection	NN	O	O
of	NN	O	O
collagenase	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
induce	NN	O	O
hemorrhage	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
right	NN	O	O
striatum	NN	O	O
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
five	NN	O	O
minutes	NN	O	O
later	NN	O	O
,	NN	O	O
the	NN	O	O
animals	NN	O	O
were	NN	O	O
randomly	NN	O	O
treated	NN	O	O
with	NN	O	O
PCC	NN	O	B-Chemical
(	NN	O	O
100	NN	O	O
U	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
or	NN	O	O
saline	NN	O	O
i.v.	NN	O	O
(	NN	O	O
n=12	NN	O	O
per	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
four	NN	O	O
hours	NN	O	O
after	NN	O	O
hemorrhage	NN	O	B-Disease
induction	NN	O	O
,	NN	O	O
hemorrhagic	NN	O	O
blood	NN	O	O
volume	NN	O	O
was	NN	O	O
quantified	NN	O	O
using	NN	O	O
a	NN	O	O
photometric	NN	O	O
hemoglobin	NN	O	O
assay	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
hemorrhagic	NN	O	O
blood	NN	O	O
volume	NN	O	O
was	NN	O	O
reduced	NN	O	O
in	NN	O	O
PCC	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
(	NN	O	O
6.5+	NN	O	O
/	NN	O	O
-	NN	O	O
3.1	NN	O	O
microL	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
saline	NN	O	O
controls	NN	O	O
(	NN	O	O
15.3+	NN	O	O
/	NN	O	O
-	NN	O	O
11.2	NN	O	O
microL	NN	O	O
,	NN	O	O
P=0.015	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
saline	NN	O	O
group	NN	O	O
,	NN	O	O
45%	NN	O	O
of	NN	O	O
the	NN	O	O
mice	NN	O	O
developed	NN	O	O
large	NN	O	O
hematomas	NN	O	B-Disease
(	NN	O	O
i.e.	NN	O	O
,	NN	O	O
>15	NN	O	O
microL	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
such	NN	O	O
extensive	NN	O	O
lesions	NN	O	O
were	NN	O	O
never	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
PCC	NN	O	B-Chemical
group	NN	O	O
.	NN	O	O

We	NN	O	O
provide	NN	O	O
experimental	NN	O	O
data	NN	O	O
suggesting	NN	O	O
PCC	NN	O	B-Chemical
to	NN	O	O
be	NN	O	O
an	NN	O	O
effective	NN	O	O
acute	NN	O	O
treatment	NN	O	O
for	NN	O	O
W	NN	O	O
-	NN	O	O
ICH	NN	O	B-Disease
in	NN	O	O
terms	NN	O	O
of	NN	O	O
reducing	NN	O	O
hemorrhagic	NN	O	O
blood	NN	O	O
volume	NN	O	O
.	NN	O	O

Future	NN	O	O
studies	NN	O	O
are	NN	O	O
needed	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
potential	NN	O	O
emerging	NN	O	O
from	NN	O	O
our	NN	O	O
finding	NN	O	O
for	NN	O	O
human	NN	O	O
W	NN	O	O
-	NN	O	O
ICH	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (16634859)

Impact	NN	O	O
of	NN	O	O
alcohol	NN	O	B-Chemical
exposure	NN	O	O
after	NN	O	O
pregnancy	NN	O	O
recognition	NN	O	O
on	NN	O	O
ultrasonographic	NN	O	O
fetal	NN	O	O
growth	NN	O	O
measures	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
More	NN	O	O
than	NN	O	O
3	NN	O	O
decades	NN	O	O
after	NN	O	O
Jones	NN	O	O
and	NN	O	O
Smith	NN	O	O
(	NN	O	O
1973	NN	O	O
)	NN	O	O
reported	NN	O	O
on	NN	O	O
the	NN	O	O
devastation	NN	O	O
caused	NN	O	O
by	NN	O	O
alcohol	NN	O	B-Chemical
exposure	NN	O	O
on	NN	O	O
fetal	NN	O	O
development	NN	O	O
,	NN	O	O
the	NN	O	O
rates	NN	O	O
of	NN	O	O
heavy	NN	O	O
drinking	NN	O	O
during	NN	O	O
pregnancy	NN	O	O
remain	NN	O	O
relatively	NN	O	O
unchanged	NN	O	O
.	NN	O	O

Early	NN	O	O
identification	NN	O	O
of	NN	O	O
fetal	NN	O	O
alcohol	NN	O	B-Chemical
exposure	NN	O	O
and	NN	O	O
maternal	NN	O	O
abstinence	NN	O	O
led	NN	O	O
to	NN	O	O
better	NN	O	O
infant	NN	O	O
outcomes	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
examined	NN	O	O
the	NN	O	O
utility	NN	O	O
of	NN	O	O
biometry	NN	O	O
for	NN	O	O
detecting	NN	O	O
alcohol	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
fetal	NN	O	O
growth	NN	O	B-Disease
impairment	NN	O	I-Disease
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
obtained	NN	O	O
fetal	NN	O	O
ultrasound	NN	O	O
measures	NN	O	O
from	NN	O	O
routine	NN	O	O
ultrasound	NN	O	O
examinations	NN	O	O
for	NN	O	O
167	NN	O	O
pregnant	NN	O	O
hazardous	NN	O	O
drinkers	NN	O	O
who	NN	O	O
were	NN	O	O
enrolled	NN	O	O
in	NN	O	O
a	NN	O	O
brief	NN	O	O
alcohol	NN	O	B-Chemical
intervention	NN	O	O
study	NN	O	O
.	NN	O	O

The	NN	O	O
fetal	NN	O	O
measures	NN	O	O
for	NN	O	O
women	NN	O	O
who	NN	O	O
quit	NN	O	O
after	NN	O	O
learning	NN	O	O
of	NN	O	O
their	NN	O	O
pregnancies	NN	O	O
were	NN	O	O
compared	NN	O	O
with	NN	O	O
measures	NN	O	O
for	NN	O	O
women	NN	O	O
who	NN	O	O
continued	NN	O	O
some	NN	O	O
drinking	NN	O	O
throughout	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
their	NN	O	O
pregnancies	NN	O	O
.	NN	O	O

Because	NN	O	O
intensity	NN	O	O
of	NN	O	O
alcohol	NN	O	B-Chemical
consumption	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
poorer	NN	O	O
fetal	NN	O	O
outcomes	NN	O	O
,	NN	O	O
separate	NN	O	O
analyses	NN	O	O
were	NN	O	O
conducted	NN	O	O
for	NN	O	O
the	NN	O	O
heavy	NN	O	O
(	NN	O	O
average	NN	O	O
of	NN	O	O
>or=5	NN	O	O
drinks	NN	O	O
per	NN	O	O
drinking	NN	O	O
day	NN	O	O
)	NN	O	O
alcohol	NN	O	B-Chemical
consumers	NN	O	O
.	NN	O	O

Fetal	NN	O	O
measures	NN	O	O
from	NN	O	O
the	NN	O	O
heavy	NN	O	O
-	NN	O	O
exposed	NN	O	O
fetuses	NN	O	O
were	NN	O	O
also	NN	O	O
compared	NN	O	O
with	NN	O	O
measures	NN	O	O
from	NN	O	O
a	NN	O	O
nondrinking	NN	O	O
group	NN	O	O
that	NN	O	O
was	NN	O	O
representative	NN	O	O
of	NN	O	O
normal	NN	O	O
,	NN	O	O
uncomplicated	NN	O	O
pregnancies	NN	O	O
from	NN	O	O
our	NN	O	O
clinics	NN	O	O
.	NN	O	O

Analyses	NN	O	O
of	NN	O	O
covariance	NN	O	O
were	NN	O	O
used	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
there	NN	O	O
were	NN	O	O
differences	NN	O	O
between	NN	O	O
groups	NN	O	O
after	NN	O	O
controlling	NN	O	O
for	NN	O	O
influences	NN	O	O
of	NN	O	O
gestational	NN	O	O
age	NN	O	O
and	NN	O	O
drug	NN	O	B-Disease
abuse	NN	O	I-Disease
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Nearly	NN	O	O
half	NN	O	O
of	NN	O	O
the	NN	O	O
pregnant	NN	O	O
drinkers	NN	O	O
abstained	NN	O	O
after	NN	O	O
learning	NN	O	O
of	NN	O	O
their	NN	O	O
pregnancies	NN	O	O
.	NN	O	O

When	NN	O	O
women	NN	O	O
reportedly	NN	O	O
quit	NN	O	O
drinking	NN	O	O
early	NN	O	O
in	NN	O	O
their	NN	O	O
pregnancies	NN	O	O
,	NN	O	O
fetal	NN	O	O
growth	NN	O	O
measures	NN	O	O
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
from	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
alcohol	NN	O	B-Chemical
-	NN	O	O
exposed	NN	O	O
group	NN	O	O
,	NN	O	O
regardless	NN	O	O
of	NN	O	O
prior	NN	O	O
drinking	NN	O	O
patterns	NN	O	O
.	NN	O	O

Any	NN	O	O
alcohol	NN	O	B-Chemical
consumption	NN	O	O
postpregnancy	NN	O	O
recognition	NN	O	O
among	NN	O	O
the	NN	O	O
heavy	NN	O	O
drinkers	NN	O	O
resulted	NN	O	O
in	NN	O	O
reduced	NN	O	B-Disease
cerebellar	NN	O	I-Disease
growth	NN	O	I-Disease
as	NN	O	O
well	NN	O	O
as	NN	O	O
decreased	NN	O	B-Disease
cranial	NN	O	I-Disease
to	NN	O	I-Disease
body	NN	O	I-Disease
growth	NN	O	I-Disease
in	NN	O	O
comparison	NN	O	O
with	NN	O	O
women	NN	O	O
who	NN	O	O
either	NN	O	O
quit	NN	O	O
drinking	NN	O	O
or	NN	O	O
who	NN	O	O
were	NN	O	O
nondrinkers	NN	O	O
.	NN	O	O

Amphetamine	NN	O	B-Chemical
abuse	NN	O	O
was	NN	O	O
predictive	NN	O	O
of	NN	O	O
larger	NN	O	O
cranial	NN	O	O
to	NN	O	O
body	NN	O	O
growth	NN	O	O
ratios	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Alterations	NN	O	O
in	NN	O	O
fetal	NN	O	O
biometric	NN	O	O
measurements	NN	O	O
were	NN	O	O
observed	NN	O	O
among	NN	O	O
the	NN	O	O
heavy	NN	O	O
drinkers	NN	O	O
only	NN	O	O
when	NN	O	O
they	NN	O	O
continued	NN	O	O
drinking	NN	O	O
after	NN	O	O
becoming	NN	O	O
aware	NN	O	O
of	NN	O	O
their	NN	O	O
pregnancies	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
reliance	NN	O	O
on	NN	O	O
self	NN	O	O
-	NN	O	O
reported	NN	O	O
drinking	NN	O	O
is	NN	O	O
a	NN	O	O
limitation	NN	O	O
in	NN	O	O
this	NN	O	O
study	NN	O	O
,	NN	O	O
these	NN	O	O
findings	NN	O	O
support	NN	O	O
the	NN	O	O
benefits	NN	O	O
of	NN	O	O
early	NN	O	O
abstinence	NN	O	O
and	NN	O	O
the	NN	O	O
potential	NN	O	O
for	NN	O	O
ultrasound	NN	O	O
examinations	NN	O	O
in	NN	O	O
the	NN	O	O
detection	NN	O	O
of	NN	O	O
fetal	NN	O	O
alcohol	NN	O	B-Chemical
effects	NN	O	O
.	NN	O	O


-DOCSTART- (16471092)

Urinary	NN	O	O
symptoms	NN	O	O
and	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
changes	NN	O	O
in	NN	O	O
Thai	NN	O	O
women	NN	O	O
with	NN	O	O
overactive	NN	O	B-Disease
bladder	NN	O	I-Disease
after	NN	O	O
tolterodine	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
study	NN	O	O
the	NN	O	O
urinary	NN	O	O
symptoms	NN	O	O
and	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
changes	NN	O	O
in	NN	O	O
Thai	NN	O	O
women	NN	O	O
with	NN	O	O
overactive	NN	O	B-Disease
bladder	NN	O	I-Disease
(	NN	O	O
OAB	NN	O	B-Disease
)	NN	O	O
after	NN	O	O
tolterodine	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

MATERIAL	NN	O	O
AND	NN	O	O
METHOD	NN	O	O
:	NN	O	O
Thirty	NN	O	O
women	NN	O	O
(	NN	O	O
aged	NN	O	O
30	NN	O	O
-	NN	O	O
77	NN	O	O
years	NN	O	O
)	NN	O	O
diagnosed	NN	O	O
as	NN	O	O
having	NN	O	O
OAB	NN	O	B-Disease
at	NN	O	O
the	NN	O	O
Gynecology	NN	O	O
Clinic	NN	O	O
,	NN	O	O
King	NN	O	O
Chulalongkorn	NN	O	O
Memorial	NN	O	O
Hospital	NN	O	O
from	NN	O	O
January	NN	O	O
to	NN	O	O
April	NN	O	O
2004	NN	O	O
were	NN	O	O
included	NN	O	O
in	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
.	NN	O	O

Tolterodine	NN	O	B-Chemical
2	NN	O	O
mg	NN	O	O
,	NN	O	O
twice	NN	O	O
daily	NN	O	O
was	NN	O	O
given	NN	O	O
.	NN	O	O

After	NN	O	O
8	NN	O	O
weeks	NN	O	O
treatment	NN	O	O
,	NN	O	O
changes	NN	O	O
in	NN	O	O
micturition	NN	O	O
diary	NN	O	O
variables	NN	O	O
and	NN	O	O
tolerability	NN	O	O
were	NN	O	O
determined	NN	O	O
.	NN	O	O

Short	NN	O	O
form	NN	O	O
36	NN	O	O
(	NN	O	O
SF36	NN	O	O
)	NN	O	O
questionaires	NN	O	O
(	NN	O	O
Thai	NN	O	O
version	NN	O	O
)	NN	O	O
were	NN	O	O
given	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
8	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
At	NN	O	O
8	NN	O	O
weeks	NN	O	O
,	NN	O	O
all	NN	O	O
micturition	NN	O	O
per	NN	O	O
day	NN	O	O
decreased	NN	O	O
from	NN	O	O
16	NN	O	O
.	NN	O	O

7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5	NN	O	O
.	NN	O	O

3	NN	O	O
to	NN	O	O
6	NN	O	O
.	NN	O	O

7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.4	NN	O	O
times	NN	O	O
per	NN	O	O
day	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
nocturia	NN	O	B-Disease
episodes	NN	O	O
decreased	NN	O	O
from	NN	O	O
5.4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4.2	NN	O	O
to	NN	O	O
1.1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.0	NN	O	O
times	NN	O	O
per	NN	O	O
night	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
side	NN	O	O
effect	NN	O	O
was	NN	O	O
dry	NN	O	B-Disease
month	NN	O	I-Disease
in	NN	O	O
5	NN	O	O
cases	NN	O	O
(	NN	O	O
16.7%	NN	O	O
)	NN	O	O
with	NN	O	O
2	NN	O	O
cases	NN	O	O
reporting	NN	O	O
a	NN	O	O
moderate	NN	O	O
degree	NN	O	O
and	NN	O	O
1	NN	O	O
case	NN	O	O
with	NN	O	O
severe	NN	O	O
degree	NN	O	O
.	NN	O	O

Only	NN	O	O
one	NN	O	O
case	NN	O	O
(	NN	O	O
3.3%	NN	O	O
)	NN	O	O
withdrew	NN	O	O
from	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
severe	NN	O	O
dry	NN	O	B-Disease
mouth	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
SF	NN	O	O
-	NN	O	O
36	NN	O	O
scores	NN	O	O
changed	NN	O	O
significantly	NN	O	O
in	NN	O	O
the	NN	O	O
domains	NN	O	O
of	NN	O	O
physical	NN	O	O
functioning	NN	O	O
,	NN	O	O
role	NN	O	O
function	NN	O	O
emotional	NN	O	O
,	NN	O	O
social	NN	O	O
function	NN	O	O
and	NN	O	O
mental	NN	O	O
heath	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Tolterodine	NN	O	B-Chemical
was	NN	O	O
well	NN	O	O
tolerated	NN	O	O
and	NN	O	O
its	NN	O	O
effects	NN	O	O
improved	NN	O	O
the	NN	O	O
quality	NN	O	O
of	NN	O	O
life	NN	O	O
in	NN	O	O
Thai	NN	O	O
women	NN	O	O
with	NN	O	O
OAB	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (16174948)

Absence	NN	O	O
of	NN	O	O
acute	NN	O	O
cerebral	NN	O	O
vasoconstriction	NN	O	O
after	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
subarachnoid	NN	O	B-Disease
hemorrhage	NN	O	I-Disease
.	NN	O	O

INTRODUCTION	NN	O	O
:	NN	O	O
Cocaine	NN	O	B-Chemical
use	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
neurovascular	NN	O	B-Disease
complications	NN	O	I-Disease
,	NN	O	O
including	NN	O	O
arterial	NN	O	O
vasoconstriction	NN	O	O
and	NN	O	O
vasculitis	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
are	NN	O	O
few	NN	O	O
studies	NN	O	O
of	NN	O	O
angiographic	NN	O	O
effects	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
on	NN	O	O
human	NN	O	O
cerebral	NN	O	O
arteries	NN	O	O
.	NN	O	O

Information	NN	O	O
on	NN	O	O
these	NN	O	O
effects	NN	O	O
could	NN	O	O
be	NN	O	O
obtained	NN	O	O
from	NN	O	O
angiograms	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
subarachnoid	NN	O	B-Disease
hemorrhage	NN	O	I-Disease
(	NN	O	O
SAH	NN	O	B-Disease
)	NN	O	O
who	NN	O	O
underwent	NN	O	O
angiography	NN	O	O
shortly	NN	O	O
after	NN	O	O
cocaine	NN	O	B-Chemical
use	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
screened	NN	O	O
patients	NN	O	O
with	NN	O	O
SAH	NN	O	B-Disease
retrospectively	NN	O	O
and	NN	O	O
identified	NN	O	O
those	NN	O	O
with	NN	O	O
positive	NN	O	O
urine	NN	O	O
toxicology	NN	O	O
for	NN	O	O
cocaine	NN	O	B-Chemical
or	NN	O	O
its	NN	O	O
metabolites	NN	O	O
.	NN	O	O

Quantitative	NN	O	O
arterial	NN	O	O
diameter	NN	O	O
measurements	NN	O	O
from	NN	O	O
angiograms	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
were	NN	O	O
compared	NN	O	O
to	NN	O	O
measurements	NN	O	O
from	NN	O	O
control	NN	O	O
patients	NN	O	O
with	NN	O	O
SAH	NN	O	B-Disease
who	NN	O	O
were	NN	O	O
matched	NN	O	O
for	NN	O	O
factors	NN	O	O
known	NN	O	O
to	NN	O	O
influence	NN	O	O
arterial	NN	O	O
diameter	NN	O	O
.	NN	O	O

Qualitative	NN	O	O
comparisons	NN	O	O
of	NN	O	O
small	NN	O	O
artery	NN	O	O
changes	NN	O	O
also	NN	O	O
were	NN	O	O
made	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Thirteen	NN	O	O
patients	NN	O	O
with	NN	O	O
positive	NN	O	O
cocaine	NN	O	B-Chemical
toxicology	NN	O	O
were	NN	O	O
compared	NN	O	O
to	NN	O	O
26	NN	O	O
controls	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
groups	NN	O	O
in	NN	O	O
the	NN	O	O
mean	NN	O	O
diameters	NN	O	O
of	NN	O	O
the	NN	O	O
intradural	NN	O	O
internal	NN	O	O
carotid	NN	O	O
,	NN	O	O
sphenoidal	NN	O	O
segment	NN	O	O
of	NN	O	O
the	NN	O	O
middle	NN	O	O
cerebral	NN	O	O
,	NN	O	O
precommunicating	NN	O	O
segment	NN	O	O
of	NN	O	O
the	NN	O	O
anterior	NN	O	O
cerebral	NN	O	O
,	NN	O	O
or	NN	O	O
basilar	NN	O	O
arteries	NN	O	O
(	NN	O	O
p	NN	O	O
greater	NN	O	O
than	NN	O	O
0.05	NN	O	O
for	NN	O	O
all	NN	O	O
comparisons	NN	O	O
,	NN	O	O
unpaired	NN	O	O
t	NN	O	O
-	NN	O	O
tests	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
also	NN	O	O
were	NN	O	O
no	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
groups	NN	O	O
when	NN	O	O
expressing	NN	O	O
diameters	NN	O	O
as	NN	O	O
the	NN	O	O
sum	NN	O	O
of	NN	O	O
the	NN	O	O
precommunicating	NN	O	O
segment	NN	O	O
of	NN	O	O
the	NN	O	O
anterior	NN	O	O
cerebral	NN	O	O
+	NN	O	O
sphenoidal	NN	O	O
segment	NN	O	O
of	NN	O	O
the	NN	O	O
middle	NN	O	O
cerebral	NN	O	O
+	NN	O	O
supraclinoid	NN	O	O
internal	NN	O	O
carotid	NN	O	O
artery	NN	O	O
+	NN	O	O
basilar	NN	O	O
artery	NN	O	O
divided	NN	O	O
by	NN	O	O
the	NN	O	O
diameter	NN	O	O
of	NN	O	O
the	NN	O	O
petrous	NN	O	O
internal	NN	O	O
carotid	NN	O	O
artery	NN	O	O
(	NN	O	O
p	NN	O	O
greater	NN	O	O
than	NN	O	O
0.05	NN	O	O
,	NN	O	O
unpaired	NN	O	O
t	NN	O	O
-	NN	O	O
tests	NN	O	O
)	NN	O	O
.	NN	O	O

Qualitative	NN	O	O
assessments	NN	O	O
showed	NN	O	O
two	NN	O	O
arterial	NN	O	O
irregularities	NN	O	O
in	NN	O	O
the	NN	O	O
distal	NN	O	O
vasculature	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
No	NN	O	O
quantitative	NN	O	O
evidence	NN	O	O
for	NN	O	O
narrowing	NN	O	O
of	NN	O	O
large	NN	O	O
cerebral	NN	O	O
arteries	NN	O	O
or	NN	O	O
qualitative	NN	O	O
angiographic	NN	O	O
evidence	NN	O	O
for	NN	O	O
distal	NN	O	O
narrowing	NN	O	O
or	NN	O	O
vasculitis	NN	O	B-Disease
could	NN	O	O
be	NN	O	O
found	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
underwent	NN	O	O
angiography	NN	O	O
after	NN	O	O
aneurysmal	NN	O	B-Disease
SAH	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
cocaine	NN	O	B-Chemical
use	NN	O	O
.	NN	O	O


-DOCSTART- (15042318)

Atrial	NN	O	B-Disease
fibrillation	NN	O	I-Disease
following	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
stage	NN	O	O
IIIE	NN	O	O
diffuse	NN	O	O
large	NN	O	O
B	NN	O	O
-	NN	O	O
cell	NN	O	O
gastric	NN	O	B-Disease
lymphoma	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
(	NN	O	O
Steinert	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
)	NN	O	O
.	NN	O	O

The	NN	O	O
authors	NN	O	O
describe	NN	O	O
the	NN	O	O
unusual	NN	O	O
association	NN	O	O
between	NN	O	O
diffuse	NN	O	O
B	NN	O	O
-	NN	O	O
cell	NN	O	O
gastric	NN	O	B-Disease
lymphoma	NN	O	I-Disease
and	NN	O	O
myotonic	NN	O	B-Disease
dystrophy	NN	O	I-Disease
,	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
form	NN	O	O
of	NN	O	O
adult	NN	O	O
muscular	NN	O	B-Disease
dystrophy	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
sudden	NN	O	O
atrial	NN	O	B-Disease
fibrillation	NN	O	I-Disease
following	NN	O	O
one	NN	O	O
cycle	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
based	NN	O	O
chemotherapy	NN	O	O
in	NN	O	O
the	NN	O	O
same	NN	O	O
patient	NN	O	O
.	NN	O	O

Atrial	NN	O	B-Disease
fibrillation	NN	O	I-Disease
or	NN	O	O
other	NN	O	O
cardiac	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
are	NN	O	O
unusual	NN	O	O
complications	NN	O	O
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O

The	NN	O	O
cardiac	NN	O	B-Disease
toxicity	NN	O	I-Disease
intrinsically	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
aggressive	NN	O	O
chemotherapy	NN	O	O
employed	NN	O	O
could	NN	O	O
function	NN	O	O
as	NN	O	O
a	NN	O	O
triggering	NN	O	O
factor	NN	O	O
for	NN	O	O
the	NN	O	O
arrhythmia	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
predisposed	NN	O	O
myocardium	NN	O	O
of	NN	O	O
this	NN	O	O
patient	NN	O	O
.	NN	O	O


-DOCSTART- (12448656)

A	NN	O	O
phase	NN	O	O
II	NN	O	O
study	NN	O	O
of	NN	O	O
thalidomide	NN	O	B-Chemical
in	NN	O	O
advanced	NN	O	O
metastatic	NN	O	O
renal	NN	O	B-Disease
cell	NN	O	I-Disease
carcinoma	NN	O	I-Disease
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
toxicity	NN	O	B-Disease
and	NN	O	O
activity	NN	O	O
of	NN	O	O
thalidomide	NN	O	B-Chemical
in	NN	O	O
patients	NN	O	O
with	NN	O	O
advanced	NN	O	O
metastatic	NN	O	O
renal	NN	O	B-Disease
cell	NN	O	I-Disease
cancer	NN	O	I-Disease
and	NN	O	O
to	NN	O	O
measure	NN	O	O
changes	NN	O	O
of	NN	O	O
one	NN	O	O
angiogenic	NN	O	O
factor	NN	O	O
,	NN	O	O
vascular	NN	O	O
endothelial	NN	O	O
growth	NN	O	O
factor	NN	O	O
(	NN	O	O
VEGF	NN	O	O
)	NN	O	O
165	NN	O	O
,	NN	O	O
with	NN	O	O
therapy	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
29	NN	O	O
patients	NN	O	O
were	NN	O	O
enrolled	NN	O	O
on	NN	O	O
a	NN	O	O
study	NN	O	O
of	NN	O	O
thalidomide	NN	O	B-Chemical
using	NN	O	O
an	NN	O	O
intra	NN	O	O
-	NN	O	O
patient	NN	O	O
dose	NN	O	O
escalation	NN	O	O
schedule	NN	O	O
.	NN	O	O

Patients	NN	O	O
began	NN	O	O
thalidomide	NN	O	B-Chemical
at	NN	O	O
400	NN	O	O
mg	NN	O	O
/	NN	O	O
d	NN	O	O
and	NN	O	O
escalated	NN	O	O
as	NN	O	O
tolerated	NN	O	O
to	NN	O	O
1200	NN	O	O
mg	NN	O	O
/	NN	O	O
d	NN	O	O
by	NN	O	O
day	NN	O	O
54	NN	O	O
.	NN	O	O

Fifty	NN	O	O
-	NN	O	O
nine	NN	O	O
per	NN	O	O
cent	NN	O	O
of	NN	O	O
patients	NN	O	O
had	NN	O	O
had	NN	O	O
previous	NN	O	O
therapy	NN	O	O
with	NN	O	O
IL	NN	O	O
-	NN	O	O
2	NN	O	O
and	NN	O	O
52%	NN	O	O
were	NN	O	O
performance	NN	O	O
status	NN	O	O
2	NN	O	O
or	NN	O	O
3	NN	O	O
.	NN	O	O

Systemic	NN	O	O
plasma	NN	O	O
VEGF165	NN	O	O
levels	NN	O	O
were	NN	O	O
measured	NN	O	O
by	NN	O	O
dual	NN	O	O
monoclonal	NN	O	O
ELISA	NN	O	O
in	NN	O	O
8	NN	O	O
patients	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
24	NN	O	O
patients	NN	O	O
were	NN	O	O
evaluable	NN	O	O
for	NN	O	O
response	NN	O	O
with	NN	O	O
one	NN	O	O
partial	NN	O	O
response	NN	O	O
of	NN	O	O
11	NN	O	O
months	NN	O	O
duration	NN	O	O
of	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
hepatic	NN	O	O
and	NN	O	O
pulmonary	NN	O	O
metastases	NN	O	B-Disease
(	NN	O	O
4%	NN	O	O
)	NN	O	O
,	NN	O	O
one	NN	O	O
minor	NN	O	O
response	NN	O	O
,	NN	O	O
and	NN	O	O
2	NN	O	O
patients	NN	O	O
stable	NN	O	O
for	NN	O	O
over	NN	O	O
6	NN	O	O
months	NN	O	O
.	NN	O	O

Somnolence	NN	O	B-Disease
and	NN	O	O
constipation	NN	O	B-Disease
were	NN	O	O
prominent	NN	O	O
toxicities	NN	O	B-Disease
and	NN	O	O
most	NN	O	O
patients	NN	O	O
could	NN	O	O
not	NN	O	O
tolerate	NN	O	O
the	NN	O	O
1200	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
dose	NN	O	O
level	NN	O	O
.	NN	O	O

Systemic	NN	O	O
plasma	NN	O	O
VEGF165	NN	O	O
levels	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
with	NN	O	O
therapy	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
These	NN	O	O
results	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
a	NN	O	O
low	NN	O	O
level	NN	O	O
of	NN	O	O
activity	NN	O	O
of	NN	O	O
thalidomide	NN	O	B-Chemical
in	NN	O	O
renal	NN	O	B-Disease
cell	NN	O	I-Disease
carcinoma	NN	O	I-Disease
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
doses	NN	O	O
over	NN	O	O
800	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
was	NN	O	O
difficult	NN	O	O
to	NN	O	O
achieve	NN	O	O
in	NN	O	O
this	NN	O	O
patient	NN	O	O
population	NN	O	O
,	NN	O	O
however	NN	O	O
lower	NN	O	O
doses	NN	O	O
were	NN	O	O
practical	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
-	NN	O	O
response	NN	O	O
relationship	NN	O	O
,	NN	O	O
if	NN	O	O
any	NN	O	O
,	NN	O	O
of	NN	O	O
thalidomide	NN	O	B-Chemical
for	NN	O	O
renal	NN	O	B-Disease
cell	NN	O	I-Disease
carcinoma	NN	O	I-Disease
is	NN	O	O
unclear	NN	O	O
.	NN	O	O


-DOCSTART- (12231232)

The	NN	O	O
striatum	NN	O	O
as	NN	O	O
a	NN	O	O
target	NN	O	O
for	NN	O	O
anti	NN	O	O
-	NN	O	O
rigor	NN	O	O
effects	NN	O	O
of	NN	O	O
an	NN	O	O
antagonist	NN	O	O
of	NN	O	O
mGluR1	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
an	NN	O	O
agonist	NN	O	O
of	NN	O	O
group	NN	O	O
II	NN	O	O
metabotropic	NN	O	O
glutamate	NN	O	B-Chemical
receptors	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
find	NN	O	O
out	NN	O	O
whether	NN	O	O
the	NN	O	O
metabotropic	NN	O	O
receptor	NN	O	O
1	NN	O	O
(	NN	O	O
mGluR1	NN	O	O
)	NN	O	O
and	NN	O	O
group	NN	O	O
II	NN	O	O
mGluRs	NN	O	O
,	NN	O	O
localized	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
,	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
antiparkinsonian	NN	O	O
-	NN	O	O
like	NN	O	O
effects	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Haloperidol	NN	O	B-Chemical
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
ip	NN	O	O
)	NN	O	O
induced	NN	O	O
parkinsonian	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
,	NN	O	O
measured	NN	O	O
as	NN	O	O
an	NN	O	O
increased	NN	O	O
resistance	NN	O	O
of	NN	O	O
a	NN	O	O
rat	NN	O	O
'	NN	O	O
s	NN	O	O
hind	NN	O	O
foot	NN	O	O
to	NN	O	O
passive	NN	O	O
flexion	NN	O	O
and	NN	O	O
extension	NN	O	O
at	NN	O	O
the	NN	O	O
ankle	NN	O	O
joint	NN	O	O
.	NN	O	O

(	NN	O	B-Chemical
RS	NN	O	I-Chemical
)	NN	O	I-Chemical
-	NN	O	I-Chemical
1	NN	O	I-Chemical
-	NN	O	I-Chemical
aminoindan	NN	O	I-Chemical
-	NN	O	I-Chemical
1	NN	O	I-Chemical
,	NN	O	I-Chemical
5	NN	O	I-Chemical
-	NN	O	I-Chemical
dicarboxylic	NN	O	I-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
AIDA	NN	O	B-Chemical
;	NN	O	O
0.5	NN	O	O
-	NN	O	O
15	NN	O	O
microg	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
potent	NN	O	O
and	NN	O	O
selective	NN	O	O
mGluR1	NN	O	O
antagonist	NN	O	O
,	NN	O	O
or	NN	O	O
(	NN	O	B-Chemical
2R	NN	O	I-Chemical
,	NN	O	I-Chemical
4R	NN	O	I-Chemical
)	NN	O	I-Chemical
-	NN	O	I-Chemical
4	NN	O	I-Chemical
-	NN	O	I-Chemical
aminopyrrolidine	NN	O	I-Chemical
-	NN	O	I-Chemical
2	NN	O	I-Chemical
,	NN	O	I-Chemical
4	NN	O	I-Chemical
-	NN	O	I-Chemical
dicarboxylate	NN	O	I-Chemical
(	NN	O	O
2R	NN	O	B-Chemical
,	NN	O	I-Chemical
4R	NN	O	I-Chemical
-	NN	O	I-Chemical
APDC	NN	O	I-Chemical
;	NN	O	O
7.5	NN	O	O
-	NN	O	O
15	NN	O	O
microg	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
selective	NN	O	O
group	NN	O	O
II	NN	O	O
agonist	NN	O	O
,	NN	O	O
was	NN	O	O
injected	NN	O	O
bilaterally	NN	O	O
into	NN	O	O
the	NN	O	O
striatum	NN	O	O
of	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
.	NN	O	O

AIDA	NN	O	B-Chemical
in	NN	O	O
doses	NN	O	O
of	NN	O	O
7.5	NN	O	O
-	NN	O	O
15	NN	O	O
microg	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
diminished	NN	O	O
the	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
2R	NN	O	B-Chemical
,	NN	O	I-Chemical
4R	NN	O	I-Chemical
-	NN	O	I-Chemical
APDC	NN	O	I-Chemical
injections	NN	O	O
were	NN	O	O
ineffective	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
results	NN	O	O
may	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
blockade	NN	O	O
of	NN	O	O
striatal	NN	O	O
mGluR1	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
stimulation	NN	O	O
of	NN	O	O
group	NN	O	O
II	NN	O	O
mGluRs	NN	O	O
,	NN	O	O
may	NN	O	O
ameliorate	NN	O	O
parkinsonian	NN	O	B-Disease
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (11847945)

Acute	NN	O	O
cholestatic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
after	NN	O	O
exposure	NN	O	O
to	NN	O	O
isoflurane	NN	O	B-Chemical
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
acute	NN	O	O
cholestatic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
following	NN	O	O
exposure	NN	O	O
to	NN	O	O
the	NN	O	O
inhalational	NN	O	O
anesthetic	NN	O	O
isoflurane	NN	O	B-Chemical
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
70	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
healthy	NN	O	O
woman	NN	O	O
from	NN	O	O
Iraq	NN	O	O
developed	NN	O	O
acute	NN	O	O
cholestatic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
3	NN	O	O
weeks	NN	O	O
following	NN	O	O
repair	NN	O	O
of	NN	O	O
the	NN	O	O
right	NN	O	O
rotator	NN	O	O
cuff	NN	O	O
under	NN	O	O
general	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
evidence	NN	O	O
for	NN	O	O
viral	NN	O	O
,	NN	O	O
autoimmune	NN	O	O
,	NN	O	O
or	NN	O	O
metabolic	NN	O	O
causes	NN	O	O
of	NN	O	O
hepatitis	NN	O	B-Disease
.	NN	O	O

No	NN	O	O
other	NN	O	O
medications	NN	O	O
were	NN	O	O
involved	NN	O	O
except	NN	O	O
for	NN	O	O
dipyrone	NN	O	B-Chemical
for	NN	O	O
analgesia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
alanine	NN	O	B-Chemical
aminotransferase	NN	O	O
was	NN	O	O
elevated	NN	O	O
to	NN	O	O
a	NN	O	O
peak	NN	O	O
concentration	NN	O	O
of	NN	O	O
1533	NN	O	O
U	NN	O	O
/	NN	O	O
L	NN	O	O
and	NN	O	O
the	NN	O	O
serum	NN	O	O
bilirubin	NN	O	B-Chemical
reached	NN	O	O
a	NN	O	O
peak	NN	O	O
of	NN	O	O
17.0	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
slow	NN	O	O
improvement	NN	O	O
over	NN	O	O
4	NN	O	O
months	NN	O	O
.	NN	O	O

Accidental	NN	O	O
reexposure	NN	O	O
by	NN	O	O
the	NN	O	O
patient	NN	O	O
to	NN	O	O
dipyrone	NN	O	B-Chemical
was	NN	O	O
uneventful	NN	O	O
.	NN	O	O

DISCUSSION	NN	O	O
:	NN	O	O
The	NN	O	O
clinical	NN	O	O
and	NN	O	O
histologic	NN	O	O
picture	NN	O	O
of	NN	O	O
this	NN	O	O
case	NN	O	O
resembles	NN	O	O
halothane	NN	O	B-Disease
hepatitis	NN	O	I-Disease
,	NN	O	O
which	NN	O	O
has	NN	O	O
a	NN	O	O
significant	NN	O	O
mortality	NN	O	O
rate	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Isoflurane	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
common	NN	O	O
anesthetic	NN	O	O
agent	NN	O	O
,	NN	O	O
can	NN	O	O
cause	NN	O	O
severe	NN	O	O
cholestatic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (11284996)

Calcitonin	NN	O	O
gene	NN	O	O
-	NN	O	O
related	NN	O	O
peptide	NN	O	O
levels	NN	O	O
during	NN	O	O
nitric	NN	O	B-Chemical
oxide	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
headache	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	O
tension	NN	O	B-Disease
-	NN	O	I-Disease
type	NN	O	I-Disease
headache	NN	O	I-Disease
.	NN	O	O

It	NN	O	O
has	NN	O	O
been	NN	O	O
proposed	NN	O	O
that	NN	O	O
nitric	NN	O	B-Chemical
oxide	NN	O	I-Chemical
(	NN	O	O
NO	NN	O	B-Chemical
)	NN	O	O
induced	NN	O	O
headache	NN	O	B-Disease
in	NN	O	O
primary	NN	O	B-Disease
headaches	NN	O	I-Disease
may	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
release	NN	O	O
of	NN	O	O
calcitonin	NN	O	O
gene	NN	O	O
-	NN	O	O
related	NN	O	O
peptide	NN	O	O
(	NN	O	O
CGRP	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
we	NN	O	O
aimed	NN	O	O
to	NN	O	O
investigate	NN	O	O
plasma	NN	O	O
levels	NN	O	O
of	NN	O	O
CGRP	NN	O	O
during	NN	O	O
headache	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
the	NN	O	O
NO	NN	O	B-Chemical
donor	NN	O	O
glyceryl	NN	O	B-Chemical
trinitrate	NN	O	I-Chemical
(	NN	O	O
GTN	NN	O	B-Chemical
)	NN	O	O
in	NN	O	O
16	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	O
tension	NN	O	B-Disease
-	NN	O	I-Disease
type	NN	O	I-Disease
headache	NN	O	I-Disease
and	NN	O	O
16	NN	O	O
healthy	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
subjects	NN	O	O
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
receive	NN	O	O
0.5	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
GTN	NN	O	B-Chemical
or	NN	O	O
placebo	NN	O	O
over	NN	O	O
20	NN	O	O
min	NN	O	O
on	NN	O	O
two	NN	O	O
headache	NN	O	B-Disease
-	NN	O	O
free	NN	O	O
days	NN	O	O
.	NN	O	O

Blood	NN	O	O
samples	NN	O	O
were	NN	O	O
collected	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
10	NN	O	O
,	NN	O	O
20	NN	O	O
and	NN	O	O
60	NN	O	O
min	NN	O	O
after	NN	O	O
start	NN	O	O
of	NN	O	O
infusion	NN	O	O
.	NN	O	O

Both	NN	O	O
patients	NN	O	O
and	NN	O	O
controls	NN	O	O
developed	NN	O	O
significantly	NN	O	O
stronger	NN	O	O
immediate	NN	O	O
headache	NN	O	B-Disease
on	NN	O	O
the	NN	O	O
GTN	NN	O	B-Chemical
day	NN	O	O
than	NN	O	O
on	NN	O	O
the	NN	O	O
placebo	NN	O	O
day	NN	O	O
and	NN	O	O
the	NN	O	O
headache	NN	O	B-Disease
was	NN	O	O
significantly	NN	O	O
more	NN	O	O
pronounced	NN	O	O
in	NN	O	O
patients	NN	O	O
than	NN	O	O
in	NN	O	O
controls	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
difference	NN	O	O
between	NN	O	O
the	NN	O	O
area	NN	O	O
under	NN	O	O
the	NN	O	O
CGRP	NN	O	O
curve	NN	O	O
(	NN	O	O
AUCCGRP	NN	O	O
)	NN	O	O
on	NN	O	O
GTN	NN	O	B-Chemical
vs	NN	O	O
.	NN	O	O

placebo	NN	O	O
day	NN	O	O
in	NN	O	O
either	NN	O	O
patients	NN	O	O
(	NN	O	O
P=0.65	NN	O	O
)	NN	O	O
or	NN	O	O
controls	NN	O	O
(	NN	O	O
P=0.48	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
AUCCGRP	NN	O	O
recorded	NN	O	O
on	NN	O	O
the	NN	O	O
GTN	NN	O	B-Chemical
day	NN	O	O
did	NN	O	O
not	NN	O	O
differ	NN	O	O
between	NN	O	O
patients	NN	O	O
and	NN	O	O
controls	NN	O	O
(	NN	O	O
P=0.36	NN	O	O
)	NN	O	O
.	NN	O	O

Both	NN	O	O
in	NN	O	O
patients	NN	O	O
and	NN	O	O
controls	NN	O	O
,	NN	O	O
CGRP	NN	O	O
levels	NN	O	O
changed	NN	O	O
significantly	NN	O	O
over	NN	O	O
time	NN	O	O
,	NN	O	O
on	NN	O	O
both	NN	O	O
the	NN	O	O
GTN	NN	O	B-Chemical
and	NN	O	O
placebo	NN	O	O
days	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
indicates	NN	O	O
that	NN	O	O
NO	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
immediate	NN	O	O
headache	NN	O	B-Disease
is	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
release	NN	O	O
of	NN	O	O
CGRP	NN	O	O
.	NN	O	O


-DOCSTART- (11078231)

Myocardial	NN	O	B-Disease
ischemia	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
spasm	NN	O	I-Disease
during	NN	O	O
dobutamine	NN	O	B-Chemical
stress	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

Dobutamine	NN	O	B-Chemical
stress	NN	O	O
echocardiography	NN	O	O
(	NN	O	O
DSE	NN	O	O
)	NN	O	O
is	NN	O	O
a	NN	O	O
useful	NN	O	O
and	NN	O	O
safe	NN	O	O
provocation	NN	O	O
test	NN	O	O
for	NN	O	O
myocardial	NN	O	B-Disease
ischemia	NN	O	I-Disease
.	NN	O	O

Until	NN	O	O
now	NN	O	O
,	NN	O	O
the	NN	O	O
test	NN	O	O
has	NN	O	O
been	NN	O	O
focused	NN	O	O
only	NN	O	O
on	NN	O	O
the	NN	O	O
organic	NN	O	O
lesion	NN	O	O
in	NN	O	O
the	NN	O	O
coronary	NN	O	O
artery	NN	O	O
,	NN	O	O
and	NN	O	O
positive	NN	O	O
DSE	NN	O	O
has	NN	O	O
indicated	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
significant	NN	O	O
fixed	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
stenosis	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
is	NN	O	O
to	NN	O	O
examine	NN	O	O
whether	NN	O	O
myocardial	NN	O	B-Disease
ischemia	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
coronary	NN	O	B-Disease
spasm	NN	O	I-Disease
is	NN	O	O
induced	NN	O	O
by	NN	O	O
dobutamine	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
performed	NN	O	O
DSE	NN	O	O
on	NN	O	O
51	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B-Disease
spastic	NN	O	I-Disease
angina	NN	O	I-Disease
but	NN	O	O
without	NN	O	O
significant	NN	O	O
fixed	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
stenosis	NN	O	I-Disease
.	NN	O	O

All	NN	O	O
patients	NN	O	O
had	NN	O	O
anginal	NN	O	B-Disease
attacks	NN	O	O
at	NN	O	O
rest	NN	O	O
with	NN	O	O
ST	NN	O	O
elevation	NN	O	O
on	NN	O	O
the	NN	O	O
electrocardiogram	NN	O	O
(	NN	O	O
variant	NN	O	B-Disease
angina	NN	O	I-Disease
)	NN	O	O
.	NN	O	O

Coronary	NN	O	O
spasm	NN	O	O
was	NN	O	O
induced	NN	O	O
by	NN	O	O
intracoronary	NN	O	O
injection	NN	O	O
of	NN	O	O
acetylcholine	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
no	NN	O	O
fixed	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
stenosis	NN	O	I-Disease
was	NN	O	O
documented	NN	O	O
on	NN	O	O
angiograms	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
.	NN	O	O

DSE	NN	O	O
was	NN	O	O
performed	NN	O	O
with	NN	O	O
intravenous	NN	O	O
dobutamine	NN	O	B-Chemical
infusion	NN	O	O
with	NN	O	O
an	NN	O	O
incremental	NN	O	O
doses	NN	O	O
of	NN	O	O
5	NN	O	O
,	NN	O	O
10	NN	O	O
,	NN	O	O
20	NN	O	O
,	NN	O	O
30	NN	O	O
,	NN	O	O
and	NN	O	O
40	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
every	NN	O	O
5	NN	O	O
minutes	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
51	NN	O	O
patients	NN	O	O
,	NN	O	O
7	NN	O	O
patients	NN	O	O
showed	NN	O	O
asynergy	NN	O	O
with	NN	O	O
ST	NN	O	O
elevation	NN	O	O
.	NN	O	O

All	NN	O	O
7	NN	O	O
patients	NN	O	O
(	NN	O	O
13.7%	NN	O	O
)	NN	O	O
had	NN	O	O
chest	NN	O	B-Disease
pain	NN	O	I-Disease
during	NN	O	O
asynergy	NN	O	O
,	NN	O	O
and	NN	O	O
both	NN	O	O
chest	NN	O	B-Disease
pain	NN	O	I-Disease
and	NN	O	O
electrocardiographic	NN	O	O
changes	NN	O	O
were	NN	O	O
preceded	NN	O	O
by	NN	O	O
asynergy	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
indicate	NN	O	O
that	NN	O	O
dobutamine	NN	O	B-Chemical
can	NN	O	O
provoke	NN	O	O
coronary	NN	O	B-Disease
spasm	NN	O	I-Disease
in	NN	O	O
some	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B-Disease
spastic	NN	O	I-Disease
angina	NN	O	I-Disease
.	NN	O	O

When	NN	O	O
DSE	NN	O	O
is	NN	O	O
performed	NN	O	O
to	NN	O	O
evaluate	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
not	NN	O	O
only	NN	O	O
fixed	NN	O	O
coronary	NN	O	B-Disease
stenosis	NN	O	I-Disease
,	NN	O	O
but	NN	O	O
also	NN	O	O
coronary	NN	O	B-Disease
spasm	NN	O	I-Disease
should	NN	O	O
be	NN	O	O
considered	NN	O	O
as	NN	O	O
a	NN	O	O
genesis	NN	O	O
of	NN	O	O
asynergy	NN	O	O
.	NN	O	O


-DOCSTART- (10523326)

Nitric	NN	O	B-Chemical
oxide	NN	O	I-Chemical
synthase	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
lead	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
recently	NN	O	O
showed	NN	O	O
elevated	NN	O	O
reactive	NN	O	O
oxygen	NN	O	B-Chemical
species	NN	O	O
(	NN	O	O
ROS	NN	O	O
)	NN	O	O
,	NN	O	O
reduced	NN	O	O
urinary	NN	O	O
excretion	NN	O	O
of	NN	O	O
NO	NN	O	B-Chemical
metabolites	NN	O	O
(	NN	O	O
NOx	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
increased	NN	O	O
NO	NN	O	B-Chemical
sequestration	NN	O	O
as	NN	O	O
nitrotyrosine	NN	O	B-Chemical
in	NN	O	O
various	NN	O	O
tissues	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
lead	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
designed	NN	O	O
to	NN	O	O
discern	NN	O	O
whether	NN	O	O
the	NN	O	O
reduction	NN	O	O
in	NN	O	O
urinary	NN	O	O
NOx	NN	O	O
in	NN	O	O
lead	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B-Disease
is	NN	O	O
,	NN	O	O
in	NN	O	O
part	NN	O	O
,	NN	O	O
due	NN	O	O
to	NN	O	O
depressed	NN	O	O
NO	NN	O	B-Chemical
synthase	NN	O	O
(	NN	O	O
NOS	NN	O	O
)	NN	O	O
expression	NN	O	O
.	NN	O	O

Male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
a	NN	O	O
lead	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
group	NN	O	O
(	NN	O	O
given	NN	O	O
lead	NN	O	B-Chemical
acetate	NN	O	I-Chemical
,	NN	O	O
100	NN	O	O
ppm	NN	O	O
,	NN	O	O
in	NN	O	O
drinking	NN	O	O
water	NN	O	O
and	NN	O	O
regular	NN	O	O
rat	NN	O	O
chow	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
group	NN	O	O
given	NN	O	O
lead	NN	O	B-Chemical
and	NN	O	O
vitamin	NN	O	B-Chemical
E	NN	O	I-Chemical
-	NN	O	O
fortified	NN	O	O
chow	NN	O	O
,	NN	O	O
or	NN	O	O
a	NN	O	O
normal	NN	O	O
control	NN	O	O
group	NN	O	O
given	NN	O	O
either	NN	O	O
regular	NN	O	O
food	NN	O	O
and	NN	O	O
water	NN	O	O
or	NN	O	O
vitamin	NN	O	B-Chemical
E	NN	O	I-Chemical
-	NN	O	O
fortified	NN	O	O
food	NN	O	O
for	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

Tail	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
urinary	NN	O	O
NOx	NN	O	O
excretion	NN	O	O
,	NN	O	O
plasma	NN	O	O
malondialdehyde	NN	O	B-Chemical
(	NN	O	O
MDA	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
and	NN	O	O
endothelial	NN	O	O
and	NN	O	O
inducible	NN	O	O
NOS	NN	O	O
(	NN	O	O
eNOS	NN	O	O
and	NN	O	O
iNOS	NN	O	O
)	NN	O	O
isotypes	NN	O	O
in	NN	O	O
the	NN	O	O
aorta	NN	O	O
and	NN	O	O
kidney	NN	O	O
were	NN	O	O
measured	NN	O	O
.	NN	O	O

The	NN	O	O
lead	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
group	NN	O	O
exhibited	NN	O	O
a	NN	O	O
rise	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
plasma	NN	O	O
MDA	NN	O	B-Chemical
concentration	NN	O	O
,	NN	O	O
a	NN	O	O
fall	NN	O	O
in	NN	O	O
urinary	NN	O	O
NOx	NN	O	O
excretion	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
paradoxical	NN	O	O
rise	NN	O	O
in	NN	O	O
vascular	NN	O	O
and	NN	O	O
renal	NN	O	O
tissue	NN	O	O
eNOS	NN	O	O
and	NN	O	O
iNOS	NN	O	O
expression	NN	O	O
.	NN	O	O

Vitamin	NN	O	B-Chemical
E	NN	O	I-Chemical
supplementation	NN	O	O
ameliorated	NN	O	O
hypertension	NN	O	B-Disease
,	NN	O	O
lowered	NN	O	O
plasma	NN	O	O
MDA	NN	O	B-Chemical
concentration	NN	O	O
,	NN	O	O
and	NN	O	O
raised	NN	O	O
urinary	NN	O	O
NOx	NN	O	O
excretion	NN	O	O
while	NN	O	O
significantly	NN	O	O
lowering	NN	O	O
vascular	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
renal	NN	O	O
,	NN	O	O
tissue	NN	O	O
eNOS	NN	O	O
and	NN	O	O
iNOS	NN	O	O
expression	NN	O	O
.	NN	O	O

Vitamin	NN	O	B-Chemical
E	NN	O	I-Chemical
supplementation	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
either	NN	O	O
blood	NN	O	O
pressure	NN	O	O
,	NN	O	O
plasma	NN	O	O
MDA	NN	O	B-Chemical
,	NN	O	O
or	NN	O	O
NOS	NN	O	O
expression	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
also	NN	O	O
revealed	NN	O	O
significant	NN	O	O
inhibition	NN	O	O
of	NN	O	O
NOS	NN	O	O
enzymatic	NN	O	O
activity	NN	O	O
by	NN	O	O
lead	NN	O	B-Chemical
in	NN	O	O
cell	NN	O	O
-	NN	O	O
free	NN	O	O
preparations	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
lead	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B-Disease
in	NN	O	O
this	NN	O	O
model	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
compensatory	NN	O	O
upregulation	NN	O	O
of	NN	O	O
renal	NN	O	O
and	NN	O	O
vascular	NN	O	O
eNOS	NN	O	O
and	NN	O	O
iNOS	NN	O	O
expression	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
,	NN	O	O
in	NN	O	O
part	NN	O	O
,	NN	O	O
due	NN	O	O
to	NN	O	O
ROS	NN	O	O
-	NN	O	O
mediated	NN	O	O
NO	NN	O	B-Chemical
inactivation	NN	O	O
,	NN	O	O
lead	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
inhibition	NN	O	O
of	NN	O	O
NOS	NN	O	O
activity	NN	O	O
,	NN	O	O
and	NN	O	O
perhaps	NN	O	O
stimulatory	NN	O	O
actions	NN	O	O
of	NN	O	O
increased	NN	O	O
shear	NN	O	O
stress	NN	O	O
associated	NN	O	O
with	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (9867728)

Risk	NN	O	O
for	NN	O	O
valvular	NN	O	B-Disease
heart	NN	O	I-Disease
disease	NN	O	I-Disease
among	NN	O	O
users	NN	O	O
of	NN	O	O
fenfluramine	NN	O	B-Chemical
and	NN	O	O
dexfenfluramine	NN	O	B-Chemical
who	NN	O	O
underwent	NN	O	O
echocardiography	NN	O	O
before	NN	O	O
use	NN	O	O
of	NN	O	O
medication	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Because	NN	O	O
uncontrolled	NN	O	O
echocardiographic	NN	O	O
surveys	NN	O	O
suggested	NN	O	O
that	NN	O	O
up	NN	O	O
to	NN	O	O
30%	NN	O	O
to	NN	O	O
38%	NN	O	O
of	NN	O	O
users	NN	O	O
of	NN	O	O
fenfluramine	NN	O	B-Chemical
and	NN	O	O
dexfenfluramine	NN	O	B-Chemical
had	NN	O	O
valvular	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
these	NN	O	O
drugs	NN	O	O
were	NN	O	O
withdrawn	NN	O	O
from	NN	O	O
the	NN	O	O
market	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
the	NN	O	O
risk	NN	O	O
for	NN	O	O
new	NN	O	O
or	NN	O	O
worsening	NN	O	O
valvular	NN	O	B-Disease
abnormalities	NN	O	I-Disease
among	NN	O	O
users	NN	O	O
of	NN	O	O
fenfluramine	NN	O	B-Chemical
or	NN	O	O
dexfenfluramine	NN	O	B-Chemical
who	NN	O	O
underwent	NN	O	O
echocardiography	NN	O	O
before	NN	O	O
they	NN	O	O
began	NN	O	O
to	NN	O	O
take	NN	O	O
these	NN	O	O
medications	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Cohort	NN	O	O
study	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
Academic	NN	O	O
primary	NN	O	O
care	NN	O	O
practices	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
:	NN	O	O
46	NN	O	O
patients	NN	O	O
who	NN	O	O
used	NN	O	O
fenfluramine	NN	O	B-Chemical
or	NN	O	O
dexfenfluramine	NN	O	B-Chemical
for	NN	O	O
14	NN	O	O
days	NN	O	O
or	NN	O	O
more	NN	O	O
and	NN	O	O
had	NN	O	O
echocardiograms	NN	O	O
obtained	NN	O	O
before	NN	O	O
therapy	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
:	NN	O	O
Follow	NN	O	O
-	NN	O	O
up	NN	O	O
echocardiography	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
outcome	NN	O	O
was	NN	O	O
new	NN	O	O
or	NN	O	O
worsening	NN	O	O
valvulopathy	NN	O	B-Disease
,	NN	O	O
defined	NN	O	O
as	NN	O	O
progression	NN	O	O
of	NN	O	O
either	NN	O	O
aortic	NN	O	B-Disease
or	NN	O	I-Disease
mitral	NN	O	I-Disease
regurgitation	NN	O	I-Disease
by	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
degree	NN	O	O
of	NN	O	O
severity	NN	O	O
and	NN	O	O
disease	NN	O	O
that	NN	O	O
met	NN	O	O
U.S.	NN	O	O
Food	NN	O	O
and	NN	O	O
Drug	NN	O	O
Administration	NN	O	O
criteria	NN	O	O
(	NN	O	O
at	NN	O	O
least	NN	O	O
mild	NN	O	O
aortic	NN	O	B-Disease
regurgitation	NN	O	I-Disease
or	NN	O	O
moderate	NN	O	O
mitral	NN	O	B-Disease
regurgitation	NN	O	I-Disease
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Two	NN	O	O
patients	NN	O	O
(	NN	O	O
4.3%	NN	O	O
[	NN	O	O
95%	NN	O	O
CI	NN	O	O
,	NN	O	O
0.6%	NN	O	O
to	NN	O	O
14.8%	NN	O	O
]	NN	O	O
)	NN	O	O
receiving	NN	O	O
fenfluramine	NN	O	B-Chemical
-	NN	O	O
phentermine	NN	O	B-Chemical
developed	NN	O	O
valvular	NN	O	B-Disease
heart	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

One	NN	O	O
had	NN	O	O
baseline	NN	O	O
bicuspid	NN	O	B-Disease
aortic	NN	O	I-Disease
valve	NN	O	I-Disease
and	NN	O	O
mild	NN	O	O
aortic	NN	O	B-Disease
regurgitation	NN	O	I-Disease
that	NN	O	O
progressed	NN	O	O
to	NN	O	O
moderate	NN	O	O
regurgitation	NN	O	O
.	NN	O	O

The	NN	O	O
second	NN	O	O
patient	NN	O	O
developed	NN	O	O
new	NN	O	O
moderate	NN	O	O
aortic	NN	O	B-Disease
insufficiency	NN	O	I-Disease
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Users	NN	O	O
of	NN	O	O
diet	NN	O	O
medications	NN	O	O
are	NN	O	O
at	NN	O	O
risk	NN	O	O
for	NN	O	O
valvular	NN	O	B-Disease
heart	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
incidence	NN	O	O
may	NN	O	O
be	NN	O	O
lower	NN	O	O
than	NN	O	O
that	NN	O	O
reported	NN	O	O
previously	NN	O	O
.	NN	O	O


-DOCSTART- (9636837)

Carboplatin	NN	O	B-Chemical
toxic	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
peripheral	NN	O	O
nervous	NN	O	O
system	NN	O	O
of	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
most	NN	O	O
striking	NN	O	O
of	NN	O	O
carboplatin	NN	O	B-Chemical
'	NN	O	O
s	NN	O	O
advantages	NN	O	O
(	NN	O	O
CBDCA	NN	O	B-Chemical
)	NN	O	O
over	NN	O	O
cisplatin	NN	O	B-Chemical
(	NN	O	O
CDDP	NN	O	B-Chemical
)	NN	O	O
is	NN	O	O
its	NN	O	O
markedly	NN	O	O
reduced	NN	O	O
rate	NN	O	O
of	NN	O	O
neurotoxic	NN	O	B-Disease
effects	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
CBDCA	NN	O	B-Chemical
higher	NN	O	O
-	NN	O	O
intensity	NN	O	O
schedules	NN	O	O
and	NN	O	O
the	NN	O	O
association	NN	O	O
with	NN	O	O
other	NN	O	O
neurotoxic	NN	O	B-Disease
drugs	NN	O	O
in	NN	O	O
polychemotherapy	NN	O	O
may	NN	O	O
cause	NN	O	O
some	NN	O	O
concern	NN	O	O
about	NN	O	O
its	NN	O	O
safety	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
peripheral	NN	O	B-Disease
nervous	NN	O	I-Disease
system	NN	O	I-Disease
damage	NN	O	I-Disease
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Two	NN	O	O
different	NN	O	O
schedules	NN	O	O
of	NN	O	O
CBDCA	NN	O	B-Chemical
administration	NN	O	O
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
and	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.p.	NN	O	O
twice	NN	O	O
a	NN	O	O
week	NN	O	O
for	NN	O	O
nine	NN	O	O
times	NN	O	O
)	NN	O	O
were	NN	O	O
evaluated	NN	O	O
in	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

Neurotoxicity	NN	O	B-Disease
was	NN	O	O
assessed	NN	O	O
for	NN	O	O
behavioral	NN	O	O
(	NN	O	O
tail	NN	O	O
-	NN	O	O
flick	NN	O	O
test	NN	O	O
)	NN	O	O
,	NN	O	O
neurophysiological	NN	O	O
(	NN	O	O
nerve	NN	O	O
conduction	NN	O	O
velocity	NN	O	O
in	NN	O	O
the	NN	O	O
tail	NN	O	O
nerve	NN	O	O
)	NN	O	O
,	NN	O	O
morphological	NN	O	O
,	NN	O	O
morphometrical	NN	O	O
and	NN	O	O
analytical	NN	O	O
effects	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
CBDCA	NN	O	B-Chemical
administration	NN	O	O
induced	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
peripheral	NN	O	B-Disease
neurotoxicity	NN	O	I-Disease
.	NN	O	O

Pain	NN	O	B-Disease
perception	NN	O	O
and	NN	O	O
nerve	NN	O	O
conduction	NN	O	O
velocity	NN	O	O
in	NN	O	O
the	NN	O	O
tail	NN	O	O
were	NN	O	O
significantly	NN	O	O
impaired	NN	O	O
,	NN	O	O
particularly	NN	O	O
after	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
dorsal	NN	O	O
root	NN	O	O
ganglia	NN	O	O
sensory	NN	O	O
neurons	NN	O	O
and	NN	O	O
,	NN	O	O
to	NN	O	O
a	NN	O	O
lesser	NN	O	O
extent	NN	O	O
,	NN	O	O
satellite	NN	O	O
cells	NN	O	O
showed	NN	O	O
the	NN	O	O
same	NN	O	O
changes	NN	O	O
as	NN	O	O
those	NN	O	O
induced	NN	O	O
by	NN	O	O
CDDP	NN	O	B-Chemical
,	NN	O	O
mainly	NN	O	O
affecting	NN	O	O
the	NN	O	O
nucleus	NN	O	O
and	NN	O	O
nucleolus	NN	O	O
of	NN	O	O
ganglionic	NN	O	O
sensory	NN	O	O
neurons	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
significant	NN	O	O
amounts	NN	O	O
of	NN	O	O
platinum	NN	O	B-Chemical
were	NN	O	O
detected	NN	O	O
in	NN	O	O
the	NN	O	O
dorsal	NN	O	O
root	NN	O	O
ganglia	NN	O	O
and	NN	O	O
kidney	NN	O	O
after	NN	O	O
CBDCA	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
CBDCA	NN	O	B-Chemical
is	NN	O	O
neurotoxic	NN	O	B-Disease
in	NN	O	O
our	NN	O	O
model	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
type	NN	O	O
of	NN	O	O
pathological	NN	O	O
changes	NN	O	O
it	NN	O	O
induces	NN	O	O
are	NN	O	O
so	NN	O	O
closely	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
caused	NN	O	O
by	NN	O	O
CDDP	NN	O	B-Chemical
that	NN	O	O
it	NN	O	O
is	NN	O	O
probable	NN	O	O
that	NN	O	O
neurotoxicity	NN	O	B-Disease
is	NN	O	O
induced	NN	O	O
in	NN	O	O
the	NN	O	O
two	NN	O	O
drugs	NN	O	O
by	NN	O	O
the	NN	O	O
same	NN	O	O
mechanism	NN	O	O
.	NN	O	O

This	NN	O	O
model	NN	O	O
can	NN	O	O
be	NN	O	O
used	NN	O	O
alone	NN	O	O
or	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
other	NN	O	O
drugs	NN	O	O
to	NN	O	O
explore	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
CBDCA	NN	O	B-Chemical
on	NN	O	O
the	NN	O	O
peripheral	NN	O	O
nervous	NN	O	O
system	NN	O	O
.	NN	O	O


-DOCSTART- (9579567)

Iatrogenic	NN	O	O
risks	NN	O	O
of	NN	O	O
endometrial	NN	O	B-Disease
carcinoma	NN	O	I-Disease
after	NN	O	O
treatment	NN	O	O
for	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
large	NN	O	O
French	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
.	NN	O	O

F	NN	O	O
d	NN	O	O
ration	NN	O	O
Nationale	NN	O	O
des	NN	O	O
Centres	NN	O	O
de	NN	O	O
Lutte	NN	O	O
Contre	NN	O	O
le	NN	O	O
Cancer	NN	O	O
(	NN	O	O
FNCLCC	NN	O	O
)	NN	O	O
.	NN	O	O

Since	NN	O	O
tamoxifen	NN	O	B-Chemical
is	NN	O	O
widely	NN	O	O
used	NN	O	O
in	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
treatment	NN	O	O
and	NN	O	O
has	NN	O	O
been	NN	O	O
proposed	NN	O	O
for	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
,	NN	O	O
its	NN	O	O
endometrial	NN	O	O
iatrogenic	NN	O	O
effects	NN	O	O
must	NN	O	O
be	NN	O	O
carefully	NN	O	O
examined	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
investigated	NN	O	O
the	NN	O	O
association	NN	O	O
between	NN	O	O
endometrial	NN	O	B-Disease
cancer	NN	O	I-Disease
and	NN	O	O
tamoxifen	NN	O	B-Chemical
use	NN	O	O
or	NN	O	O
other	NN	O	O
treatments	NN	O	O
in	NN	O	O
women	NN	O	O
treated	NN	O	O
for	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
.	NN	O	O

Cases	NN	O	O
of	NN	O	O
endometrial	NN	O	B-Disease
cancer	NN	O	I-Disease
diagnosed	NN	O	O
after	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
135	NN	O	O
)	NN	O	O
and	NN	O	O
467	NN	O	O
controls	NN	O	O
matched	NN	O	O
for	NN	O	O
age	NN	O	O
,	NN	O	O
year	NN	O	O
of	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
and	NN	O	O
hospital	NN	O	O
and	NN	O	O
survival	NN	O	O
time	NN	O	O
with	NN	O	O
an	NN	O	O
intact	NN	O	O
uterus	NN	O	O
were	NN	O	O
included	NN	O	O
.	NN	O	O

Women	NN	O	O
who	NN	O	O
had	NN	O	O
received	NN	O	O
tamoxifen	NN	O	B-Chemical
were	NN	O	O
significantly	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
endometrial	NN	O	B-Disease
cancer	NN	O	I-Disease
diagnosed	NN	O	O
than	NN	O	O
those	NN	O	O
who	NN	O	O
had	NN	O	O
not	NN	O	O
(	NN	O	O
crude	NN	O	O
relative	NN	O	O
risk	NN	O	O
=	NN	O	O
4.9	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.0001	NN	O	O
)	NN	O	O
.	NN	O	O

Univariate	NN	O	O
and	NN	O	O
adjusted	NN	O	O
analyses	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
risk	NN	O	O
increased	NN	O	O
with	NN	O	O
the	NN	O	O
length	NN	O	O
of	NN	O	O
treatment	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.0001	NN	O	O
)	NN	O	O
or	NN	O	O
the	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
of	NN	O	O
tamoxifen	NN	O	B-Chemical
received	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.0001	NN	O	O
)	NN	O	O
,	NN	O	O
irrespective	NN	O	O
of	NN	O	O
the	NN	O	O
daily	NN	O	O
dose	NN	O	O
.	NN	O	O

Women	NN	O	O
who	NN	O	O
had	NN	O	O
undergone	NN	O	O
pelvic	NN	O	O
radiotherapy	NN	O	O
also	NN	O	O
had	NN	O	O
a	NN	O	O
higher	NN	O	O
risk	NN	O	O
(	NN	O	O
crude	NN	O	O
relative	NN	O	O
risk	NN	O	O
=	NN	O	O
7.8	NN	O	O
,	NN	O	O
p	NN	O	O
=	NN	O	O
0.0001	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
adjusting	NN	O	O
for	NN	O	O
confounding	NN	O	O
factors	NN	O	O
,	NN	O	O
the	NN	O	O
risk	NN	O	O
was	NN	O	O
higher	NN	O	O
for	NN	O	O
tamoxifen	NN	O	B-Chemical
users	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.0012	NN	O	O
)	NN	O	O
,	NN	O	O
treatment	NN	O	O
for	NN	O	O
more	NN	O	O
than	NN	O	O
3	NN	O	O
years	NN	O	O
(	NN	O	O
all	NN	O	O
p	NN	O	O
<	NN	O	O
0.03	NN	O	O
)	NN	O	O
and	NN	O	O
pelvic	NN	O	O
radiotherapy	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.012	NN	O	O
)	NN	O	O
.	NN	O	O

Women	NN	O	O
who	NN	O	O
had	NN	O	O
endometrial	NN	O	B-Disease
cancer	NN	O	I-Disease
and	NN	O	O
had	NN	O	O
received	NN	O	O
tamoxifen	NN	O	B-Chemical
had	NN	O	O
more	NN	O	O
advanced	NN	O	B-Disease
disease	NN	O	I-Disease
and	NN	O	O
poorer	NN	O	O
prognosis	NN	O	O
than	NN	O	O
those	NN	O	O
with	NN	O	O
endometrial	NN	O	B-Disease
cancer	NN	O	I-Disease
who	NN	O	O
had	NN	O	O
not	NN	O	O
received	NN	O	O
this	NN	O	O
treatment	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
a	NN	O	O
causal	NN	O	O
role	NN	O	O
of	NN	O	O
tamoxifen	NN	O	B-Chemical
in	NN	O	O
endometrial	NN	O	B-Disease
cancer	NN	O	I-Disease
,	NN	O	O
particularly	NN	O	O
when	NN	O	O
used	NN	O	O
as	NN	O	O
currently	NN	O	O
proposed	NN	O	O
for	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
prevention	NN	O	O
.	NN	O	O

Pelvic	NN	O	O
radiotherapy	NN	O	O
may	NN	O	O
be	NN	O	O
an	NN	O	O
additional	NN	O	O
iatrogenic	NN	O	O
factor	NN	O	O
for	NN	O	O
women	NN	O	O
with	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

Endometrial	NN	O	B-Disease
cancers	NN	O	I-Disease
diagnosed	NN	O	O
in	NN	O	O
women	NN	O	O
treated	NN	O	O
with	NN	O	O
tamoxifen	NN	O	B-Chemical
have	NN	O	O
poorer	NN	O	O
prognosis	NN	O	O
.	NN	O	O

Women	NN	O	O
who	NN	O	O
receive	NN	O	O
tamoxifen	NN	O	B-Chemical
for	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
should	NN	O	O
be	NN	O	O
offered	NN	O	O
gynaecological	NN	O	O
surveillance	NN	O	O
during	NN	O	O
and	NN	O	O
after	NN	O	O
treatment	NN	O	O
.	NN	O	O

A	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
evaluation	NN	O	O
of	NN	O	O
the	NN	O	O
risk	NN	O	O
-	NN	O	O
benefit	NN	O	O
ratio	NN	O	O
of	NN	O	O
tamoxifen	NN	O	B-Chemical
as	NN	O	O
a	NN	O	O
preventive	NN	O	O
treatment	NN	O	O
for	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
is	NN	O	O
clearly	NN	O	O
warranted	NN	O	O
.	NN	O	O


-DOCSTART- (9205462)

Granulosa	NN	O	B-Disease
cell	NN	O	I-Disease
tumor	NN	O	I-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
ovary	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
antecedent	NN	O	O
tamoxifen	NN	O	B-Chemical
use	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Increased	NN	O	O
attention	NN	O	O
has	NN	O	O
been	NN	O	O
focused	NN	O	O
recently	NN	O	O
on	NN	O	O
the	NN	O	O
estrogenic	NN	O	O
effects	NN	O	O
of	NN	O	O
tamoxifen	NN	O	B-Chemical
.	NN	O	O

Review	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
reveals	NN	O	O
an	NN	O	O
association	NN	O	O
between	NN	O	O
tamoxifen	NN	O	B-Chemical
use	NN	O	O
and	NN	O	O
gynecologic	NN	O	O
tumors	NN	O	B-Disease
.	NN	O	O

CASE	NN	O	O
:	NN	O	O
A	NN	O	O
52	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
postmenopausal	NN	O	O
woman	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
tamoxifen	NN	O	B-Chemical
for	NN	O	O
stage	NN	O	O
II	NN	O	O
estrogen	NN	O	B-Chemical
receptor	NN	O	O
-	NN	O	O
positive	NN	O	O
breast	NN	O	B-Disease
carcinoma	NN	O	I-Disease
.	NN	O	O

Her	NN	O	O
aspartate	NN	O	B-Chemical
transaminase	NN	O	O
and	NN	O	O
alanine	NN	O	B-Chemical
transaminase	NN	O	O
levels	NN	O	O
increase	NN	O	O
markedly	NN	O	O
after	NN	O	O
6	NN	O	O
months	NN	O	O
of	NN	O	O
tamoxifen	NN	O	B-Chemical
use	NN	O	O
.	NN	O	O

After	NN	O	O
an	NN	O	O
additional	NN	O	O
17	NN	O	O
months	NN	O	O
of	NN	O	O
elevated	NN	O	O
serum	NN	O	O
transaminases	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
stage	NN	O	O
Ic	NN	O	O
granulosa	NN	O	B-Disease
cell	NN	O	I-Disease
tumor	NN	O	I-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
ovary	NN	O	I-Disease
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Patients	NN	O	O
with	NN	O	O
tamoxifen	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
liver	NN	O	B-Disease
dysfunction	NN	O	I-Disease
may	NN	O	O
be	NN	O	O
at	NN	O	O
increased	NN	O	O
risk	NN	O	O
for	NN	O	O
granulosa	NN	O	B-Disease
cell	NN	O	I-Disease
tumors	NN	O	I-Disease
because	NN	O	O
of	NN	O	O
alterations	NN	O	O
in	NN	O	O
tamoxifen	NN	O	B-Chemical
metabolism	NN	O	O
.	NN	O	O


-DOCSTART- (9098464)

A	NN	O	O
murine	NN	O	O
model	NN	O	O
of	NN	O	O
adenomyosis	NN	O	B-Disease
:	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
hyperprolactinemia	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
fluoxetine	NN	O	B-Chemical
hydrochloride	NN	O	I-Chemical
,	NN	O	O
a	NN	O	O
selective	NN	O	O
serotonin	NN	O	B-Chemical
reuptake	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
on	NN	O	O
adenomyosis	NN	O	B-Disease
induction	NN	O	O
in	NN	O	O
Wistar	NN	O	O
albino	NN	O	O
rats	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
whether	NN	O	O
fluoxetine	NN	O	B-Chemical
given	NN	O	O
to	NN	O	O
castrated	NN	O	O
and	NN	O	O
noncastrated	NN	O	O
rats	NN	O	O
caused	NN	O	O
hyperprolactinemia	NN	O	B-Disease
and	NN	O	O
its	NN	O	O
effects	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
adenomyosis	NN	O	B-Disease
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Fluoxetine	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
serotonin	NN	O	B-Chemical
reuptake	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
was	NN	O	O
given	NN	O	O
to	NN	O	O
Wistar	NN	O	O
Albino	NN	O	O
rats	NN	O	O
for	NN	O	O
98	NN	O	O
days	NN	O	O
to	NN	O	O
produce	NN	O	O
hyperprolactinemia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
drug	NN	O	O
was	NN	O	O
given	NN	O	O
to	NN	O	O
two	NN	O	O
groups	NN	O	O
consisting	NN	O	O
of	NN	O	O
castrated	NN	O	O
and	NN	O	O
noncastrated	NN	O	O
rats	NN	O	O
and	NN	O	O
compared	NN	O	O
to	NN	O	O
two	NN	O	O
groups	NN	O	O
of	NN	O	O
castrated	NN	O	O
and	NN	O	O
noncastrated	NN	O	O
controls	NN	O	O
.	NN	O	O

Prolactin	NN	O	O
levels	NN	O	O
were	NN	O	O
measured	NN	O	O
and	NN	O	O
the	NN	O	O
uteri	NN	O	O
of	NN	O	O
the	NN	O	O
rats	NN	O	O
were	NN	O	O
removed	NN	O	O
for	NN	O	O
histopathological	NN	O	O
analysis	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
98	NN	O	O
days	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
Marmara	NN	O	O
University	NN	O	O
School	NN	O	O
of	NN	O	O
Medicine	NN	O	O
,	NN	O	O
Department	NN	O	O
of	NN	O	O
Histology	NN	O	O
and	NN	O	O
Embryology	NN	O	O
,	NN	O	O
Zeynep	NN	O	O
Kamil	NN	O	O
Women	NN	O	O
and	NN	O	O
Children	NN	O	O
'	NN	O	O
s	NN	O	O
Hospital	NN	O	O
.	NN	O	O

MAIN	NN	O	O
OUTCOME	NN	O	O
MEASURES	NN	O	O
:	NN	O	O
Serum	NN	O	O
prolactin	NN	O	O
levels	NN	O	O
,	NN	O	O
uterine	NN	O	O
histopathology	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
prolactin	NN	O	O
levels	NN	O	O
of	NN	O	O
castrated	NN	O	O
and	NN	O	O
noncastrated	NN	O	O
groups	NN	O	O
treated	NN	O	O
with	NN	O	O
fluoxetine	NN	O	B-Chemical
were	NN	O	O
statistically	NN	O	O
significantly	NN	O	O
higher	NN	O	O
when	NN	O	O
compared	NN	O	O
to	NN	O	O
their	NN	O	O
respective	NN	O	O
control	NN	O	O
groups	NN	O	O
.	NN	O	O

Histological	NN	O	O
studies	NN	O	O
revealed	NN	O	O
11	NN	O	O
cases	NN	O	O
of	NN	O	O
adenomyosis	NN	O	B-Disease
,	NN	O	O
all	NN	O	O
within	NN	O	O
the	NN	O	O
noncastrated	NN	O	O
group	NN	O	O
receiving	NN	O	O
fluoxetine	NN	O	B-Chemical
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
It	NN	O	O
was	NN	O	O
suggested	NN	O	O
that	NN	O	O
high	NN	O	O
serum	NN	O	O
prolactin	NN	O	O
levels	NN	O	O
cause	NN	O	O
degeneration	NN	O	O
of	NN	O	O
myometrial	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
ovarian	NN	O	O
steroids	NN	O	B-Chemical
that	NN	O	O
results	NN	O	O
in	NN	O	O
a	NN	O	O
myometrial	NN	O	O
invasion	NN	O	O
by	NN	O	O
endometrial	NN	O	O
stroma	NN	O	O
.	NN	O	O

This	NN	O	O
invasion	NN	O	O
eventually	NN	O	O
progresses	NN	O	O
to	NN	O	O
adenomyosis	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (8424298)

Effects	NN	O	O
of	NN	O	O
deliberate	NN	O	O
hypotension	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
labetalol	NN	O	B-Chemical
with	NN	O	O
isoflurane	NN	O	B-Chemical
on	NN	O	O
neuropsychological	NN	O	O
function	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
deliberate	NN	O	O
hypotension	NN	O	B-Disease
on	NN	O	O
brain	NN	O	O
function	NN	O	O
measured	NN	O	O
by	NN	O	O
neuropsychological	NN	O	O
tests	NN	O	O
was	NN	O	O
studied	NN	O	O
in	NN	O	O
41	NN	O	O
adult	NN	O	O
patients	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
four	NN	O	O
patients	NN	O	O
were	NN	O	O
anaesthetized	NN	O	O
for	NN	O	O
middle	NN	O	O
-	NN	O	O
ear	NN	O	O
surgery	NN	O	O
with	NN	O	O
deliberate	NN	O	O
hypotension	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
labetalol	NN	O	B-Chemical
with	NN	O	O
isoflurane	NN	O	B-Chemical
(	NN	O	O
hypotensive	NN	O	B-Disease
group	NN	O	O
)	NN	O	O
.	NN	O	O

Seventeen	NN	O	O
patients	NN	O	O
without	NN	O	O
hypotension	NN	O	B-Disease
served	NN	O	O
as	NN	O	O
a	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
was	NN	O	O
77	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
mmHg	NN	O	O
(	NN	O	O
10.3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.3	NN	O	O
kPa	NN	O	O
)	NN	O	O
before	NN	O	O
hypotension	NN	O	B-Disease
and	NN	O	O
50	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0	NN	O	O
mmHg	NN	O	O
(	NN	O	O
6.7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.0	NN	O	O
kPa	NN	O	O
)	NN	O	O
during	NN	O	O
hypotension	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
hypotensive	NN	O	B-Disease
group	NN	O	O
,	NN	O	O
and	NN	O	O
86	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2	NN	O	O
mmHg	NN	O	O
(	NN	O	O
11.5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.3	NN	O	O
kPa	NN	O	O
)	NN	O	O
during	NN	O	O
anaesthesia	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
following	NN	O	O
psychological	NN	O	O
tests	NN	O	O
were	NN	O	O
performed	NN	O	O
:	NN	O	O
four	NN	O	O
subtests	NN	O	O
of	NN	O	O
the	NN	O	O
Wechsler	NN	O	O
Adult	NN	O	O
Intelligence	NN	O	O
Scale	NN	O	O
(	NN	O	O
similarities	NN	O	O
,	NN	O	O
digit	NN	O	O
span	NN	O	O
,	NN	O	O
vocabulary	NN	O	O
and	NN	O	O
digit	NN	O	O
symbol	NN	O	O
)	NN	O	O
,	NN	O	O
Trail	NN	O	O
-	NN	O	O
Making	NN	O	O
tests	NN	O	O
A	NN	O	O
and	NN	O	O
B	NN	O	O
,	NN	O	O
Zung	NN	O	O
tests	NN	O	O
(	NN	O	O
self	NN	O	O
-	NN	O	O
rating	NN	O	O
anxiety	NN	O	B-Disease
scale	NN	O	O
and	NN	O	O
self	NN	O	O
-	NN	O	O
rating	NN	O	O
depression	NN	O	B-Disease
scale	NN	O	O
)	NN	O	O
and	NN	O	O
two	NN	O	O
-	NN	O	O
part	NN	O	O
memory	NN	O	O
test	NN	O	O
battery	NN	O	O
with	NN	O	O
immediate	NN	O	O
and	NN	O	O
delayed	NN	O	O
recall	NN	O	O
.	NN	O	O

The	NN	O	O
tests	NN	O	O
were	NN	O	O
performed	NN	O	O
preoperatively	NN	O	O
and	NN	O	O
2	NN	O	O
days	NN	O	O
postoperatively	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
statistically	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
groups	NN	O	O
in	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
tests	NN	O	O
in	NN	O	O
the	NN	O	O
changes	NN	O	O
from	NN	O	O
preoperative	NN	O	O
value	NN	O	O
to	NN	O	O
postoperative	NN	O	O
value	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
hypotension	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
labetalol	NN	O	B-Chemical
with	NN	O	O
isoflurane	NN	O	B-Chemical
has	NN	O	O
no	NN	O	O
significant	NN	O	O
harmful	NN	O	O
effects	NN	O	O
on	NN	O	O
mental	NN	O	O
functions	NN	O	O
compared	NN	O	O
to	NN	O	O
normotensive	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O


-DOCSTART- (7880714)

Auditory	NN	O	O
disturbance	NN	O	O
associated	NN	O	O
with	NN	O	O
interscalene	NN	O	O
brachial	NN	O	O
plexus	NN	O	O
block	NN	O	O
.	NN	O	O

We	NN	O	O
performed	NN	O	O
an	NN	O	O
audiometric	NN	O	O
study	NN	O	O
in	NN	O	O
20	NN	O	O
patients	NN	O	O
who	NN	O	O
underwent	NN	O	O
surgery	NN	O	O
of	NN	O	O
the	NN	O	O
shoulder	NN	O	O
region	NN	O	O
under	NN	O	O
an	NN	O	O
interscalene	NN	O	O
brachial	NN	O	O
plexus	NN	O	O
block	NN	O	O
(	NN	O	O
IBPB	NN	O	O
)	NN	O	O
.	NN	O	O

Bupivacaine	NN	O	B-Chemical
0.75%	NN	O	O
with	NN	O	O
adrenaline	NN	O	B-Chemical
was	NN	O	O
given	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
24	NN	O	O
-	NN	O	O
hr	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
0.25%	NN	O	O
bupivacaine	NN	O	B-Chemical
.	NN	O	O

Three	NN	O	O
audiometric	NN	O	O
threshold	NN	O	O
measurements	NN	O	O
(	NN	O	O
0.25	NN	O	O
-	NN	O	O
18	NN	O	O
kHz	NN	O	O
)	NN	O	O
were	NN	O	O
made	NN	O	O
:	NN	O	O
the	NN	O	O
first	NN	O	O
before	NN	O	O
IBPB	NN	O	O
,	NN	O	O
the	NN	O	O
second	NN	O	O
2	NN	O	O
-	NN	O	O
6	NN	O	O
h	NN	O	O
after	NN	O	O
surgery	NN	O	O
and	NN	O	O
the	NN	O	O
third	NN	O	O
on	NN	O	O
the	NN	O	O
first	NN	O	O
day	NN	O	O
after	NN	O	O
operation	NN	O	O
.	NN	O	O

In	NN	O	O
four	NN	O	O
patients	NN	O	O
hearing	NN	O	B-Disease
impairment	NN	O	I-Disease
on	NN	O	O
the	NN	O	O
side	NN	O	O
of	NN	O	O
the	NN	O	O
block	NN	O	O
was	NN	O	O
demonstrated	NN	O	O
after	NN	O	O
operation	NN	O	O
,	NN	O	O
in	NN	O	O
three	NN	O	O
measurements	NN	O	O
on	NN	O	O
the	NN	O	O
day	NN	O	O
of	NN	O	O
surgery	NN	O	O
and	NN	O	O
in	NN	O	O
one	NN	O	O
on	NN	O	O
the	NN	O	O
following	NN	O	O
day	NN	O	O
.	NN	O	O

The	NN	O	O
frequencies	NN	O	O
at	NN	O	O
which	NN	O	O
the	NN	O	O
impairment	NN	O	O
occurred	NN	O	O
varied	NN	O	O
between	NN	O	O
patients	NN	O	O
;	NN	O	O
in	NN	O	O
one	NN	O	O
only	NN	O	O
low	NN	O	O
frequencies	NN	O	O
(	NN	O	O
0.25	NN	O	O
-	NN	O	O
0.5	NN	O	O
kHz	NN	O	O
)	NN	O	O
were	NN	O	O
involved	NN	O	O
.	NN	O	O

The	NN	O	O
maximum	NN	O	O
change	NN	O	O
in	NN	O	O
threshold	NN	O	O
was	NN	O	O
35	NN	O	O
dB	NN	O	O
at	NN	O	O
6	NN	O	O
kHz	NN	O	O
measured	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
continuous	NN	O	O
infusion	NN	O	O
of	NN	O	O
bupivacaine	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
patient	NN	O	O
had	NN	O	O
hearing	NN	O	O
threshold	NN	O	O
changes	NN	O	O
(	NN	O	O
15	NN	O	O
-	NN	O	O
20	NN	O	O
dB	NN	O	O
)	NN	O	O
at	NN	O	O
6	NN	O	O
-	NN	O	O
10	NN	O	O
kHz	NN	O	O
on	NN	O	O
the	NN	O	O
opposite	NN	O	O
side	NN	O	O
also	NN	O	O
.	NN	O	O

IBPB	NN	O	O
may	NN	O	O
cause	NN	O	O
transient	NN	O	O
auditory	NN	O	B-Disease
dysfunction	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
ipsilateral	NN	O	O
ear	NN	O	O
,	NN	O	O
possibly	NN	O	O
via	NN	O	O
an	NN	O	O
effect	NN	O	O
on	NN	O	O
sympathetic	NN	O	O
innervation	NN	O	O
.	NN	O	O


-DOCSTART- (7102237)

Midazolam	NN	O	B-Chemical
compared	NN	O	O
with	NN	O	O
thiopentone	NN	O	B-Chemical
as	NN	O	O
an	NN	O	O
induction	NN	O	O
agent	NN	O	O
.	NN	O	O

In	NN	O	O
patients	NN	O	O
premedicated	NN	O	O
with	NN	O	O
scopolamine	NN	O	B-Chemical
+	NN	O	O
morphine	NN	O	B-Chemical
(	NN	O	O
+5	NN	O	O
mg	NN	O	O
nitrazepam	NN	O	B-Chemical
the	NN	O	O
evening	NN	O	O
before	NN	O	O
surgery	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
sleep	NN	O	O
-	NN	O	O
inducing	NN	O	O
effect	NN	O	O
of	NN	O	O
midazolam	NN	O	B-Chemical
0.15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
was	NN	O	O
clearly	NN	O	O
slower	NN	O	O
in	NN	O	O
onset	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
thiopentone	NN	O	B-Chemical
4.67	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
Somewhat	NN	O	O
fewer	NN	O	O
cardiovascular	NN	O	O
and	NN	O	O
local	NN	O	O
sequelae	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
midazolam	NN	O	B-Chemical
group	NN	O	O
,	NN	O	O
but	NN	O	O
,	NN	O	O
although	NN	O	O
apnoea	NN	O	B-Disease
occurred	NN	O	O
less	NN	O	O
often	NN	O	O
in	NN	O	O
the	NN	O	O
midazolam	NN	O	B-Chemical
group	NN	O	O
it	NN	O	O
lasted	NN	O	O
longer	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
whole	NN	O	O
,	NN	O	O
the	NN	O	O
differences	NN	O	O
between	NN	O	O
midazolam	NN	O	B-Chemical
and	NN	O	O
thiopentone	NN	O	B-Chemical
had	NN	O	O
no	NN	O	O
apparent	NN	O	O
clinical	NN	O	O
consequences	NN	O	O
.	NN	O	O

Midazolam	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
new	NN	O	O
alternative	NN	O	O
agent	NN	O	O
for	NN	O	O
induction	NN	O	O
in	NN	O	O
combination	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O


-DOCSTART- (6769133)

Cardiotoxic	NN	O	B-Disease
and	NN	O	O
possible	NN	O	O
leukemogenic	NN	O	O
effects	NN	O	O
of	NN	O	O
adriamycin	NN	O	B-Chemical
in	NN	O	O
nonhuman	NN	O	O
primates	NN	O	O
.	NN	O	O

10	NN	O	O
monkeys	NN	O	O
(	NN	O	O
macaques	NN	O	O
)	NN	O	O
received	NN	O	O
adriamycin	NN	O	B-Chemical
by	NN	O	O
monthly	NN	O	O
intravenous	NN	O	O
injections	NN	O	O
at	NN	O	O
12	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

8	NN	O	O
of	NN	O	O
the	NN	O	O
10	NN	O	O
monkeys	NN	O	O
developed	NN	O	O
congestive	NN	O	B-Disease
heart	NN	O	I-Disease
failure	NN	O	I-Disease
at	NN	O	O
an	NN	O	O
average	NN	O	O
cumulative	NN	O	O
adriamycin	NN	O	B-Chemical
dose	NN	O	O
(	NN	O	O
310	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
)	NN	O	O
well	NN	O	O
below	NN	O	O
that	NN	O	O
considered	NN	O	O
the	NN	O	O
safe	NN	O	O
upper	NN	O	O
limit	NN	O	O
(	NN	O	O
550	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
)	NN	O	O
in	NN	O	O
man	NN	O	O
.	NN	O	O

Histologically	NN	O	O
,	NN	O	O
the	NN	O	O
myocardial	NN	O	B-Disease
lesions	NN	O	I-Disease
resembled	NN	O	O
those	NN	O	O
found	NN	O	O
in	NN	O	O
human	NN	O	O
anthracycline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B-Disease
.	NN	O	O

1	NN	O	O
of	NN	O	O
the	NN	O	O
10	NN	O	O
monkeys	NN	O	O
developed	NN	O	O
acute	NN	O	B-Disease
myeloblastic	NN	O	I-Disease
leukemia	NN	O	I-Disease
after	NN	O	O
receiving	NN	O	O
324	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
of	NN	O	O
adriamycin	NN	O	B-Chemical
;	NN	O	O
the	NN	O	O
10th	NN	O	O
monkey	NN	O	O
is	NN	O	O
alive	NN	O	O
and	NN	O	O
well	NN	O	O
26	NN	O	O
months	NN	O	O
after	NN	O	O
the	NN	O	O
last	NN	O	O
dose	NN	O	O
of	NN	O	O
drug	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
adriamycin	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
more	NN	O	O
potent	NN	O	O
cardiotoxin	NN	O	O
in	NN	O	O
monkeys	NN	O	O
than	NN	O	O
in	NN	O	O
man	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
leukemia	NN	O	B-Disease
may	NN	O	O
be	NN	O	O
a	NN	O	O
consequence	NN	O	O
of	NN	O	O
prolonged	NN	O	O
treatment	NN	O	O
with	NN	O	O
this	NN	O	O
drug	NN	O	O
.	NN	O	O


-DOCSTART- (6292680)

Doxorubicin	NN	O	B-Chemical
cardiomyopathy	NN	O	B-Disease
in	NN	O	O
children	NN	O	O
with	NN	O	O
left	NN	O	O
-	NN	O	O
sided	NN	O	O
Wilms	NN	O	B-Disease
tumor	NN	O	I-Disease
.	NN	O	O

Two	NN	O	O
children	NN	O	O
with	NN	O	O
Wilms	NN	O	B-Disease
tumor	NN	O	I-Disease
of	NN	O	O
the	NN	O	O
left	NN	O	O
kidney	NN	O	O
experienced	NN	O	O
severe	NN	O	O
anthracycline	NN	O	B-Chemical
cardiomyopathy	NN	O	B-Disease
after	NN	O	O
irradiation	NN	O	O
to	NN	O	O
the	NN	O	O
tumor	NN	O	B-Disease
bed	NN	O	O
and	NN	O	O
conventional	NN	O	O
dosage	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
cardiomyopathy	NN	O	B-Disease
is	NN	O	O
attributed	NN	O	O
1	NN	O	O
)	NN	O	O
to	NN	O	O
the	NN	O	O
fact	NN	O	O
that	NN	O	O
radiation	NN	O	O
fields	NN	O	O
for	NN	O	O
left	NN	O	O
Wilms	NN	O	B-Disease
tumor	NN	O	I-Disease
include	NN	O	O
the	NN	O	O
lower	NN	O	O
portion	NN	O	O
of	NN	O	O
the	NN	O	O
heart	NN	O	O
and	NN	O	O
2	NN	O	O
)	NN	O	O
to	NN	O	O
the	NN	O	O
interaction	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
and	NN	O	O
irradiation	NN	O	O
on	NN	O	O
cardiac	NN	O	O
muscle	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
recommended	NN	O	O
that	NN	O	O
doxorubicin	NN	O	B-Chemical
dosage	NN	O	O
be	NN	O	O
sharply	NN	O	O
restricted	NN	O	O
in	NN	O	O
children	NN	O	O
with	NN	O	O
Wilms	NN	O	B-Disease
tumor	NN	O	I-Disease
of	NN	O	O
the	NN	O	O
left	NN	O	O
kidney	NN	O	O
who	NN	O	O
receive	NN	O	O
postoperative	NN	O	O
irradiation	NN	O	O
.	NN	O	O


-DOCSTART- (3969369)

Promotional	NN	O	O
effects	NN	O	O
of	NN	O	O
testosterone	NN	O	B-Chemical
and	NN	O	O
dietary	NN	O	O
fat	NN	O	O
on	NN	O	O
prostate	NN	O	O
carcinogenesis	NN	O	B-Disease
in	NN	O	O
genetically	NN	O	O
susceptible	NN	O	O
rats	NN	O	O
.	NN	O	O

Germfree	NN	O	O
(	NN	O	O
GF	NN	O	O
)	NN	O	O
Lobund	NN	O	O
strain	NN	O	O
Wistar	NN	O	O
(	NN	O	O
LW	NN	O	O
)	NN	O	O
rats	NN	O	O
,	NN	O	O
fed	NN	O	O
vegetable	NN	O	O
diet	NN	O	O
L	NN	O	O
-	NN	O	O
485	NN	O	O
,	NN	O	O
have	NN	O	O
developed	NN	O	O
prostate	NN	O	B-Disease
adenocarcinomas	NN	O	I-Disease
spontaneously	NN	O	O
(	NN	O	O
10%	NN	O	O
incidence	NN	O	O
)	NN	O	O
at	NN	O	O
average	NN	O	O
age	NN	O	O
34	NN	O	O
months	NN	O	O
.	NN	O	O

Conventional	NN	O	O
LW	NN	O	O
rats	NN	O	O
,	NN	O	O
implanted	NN	O	O
with	NN	O	O
testosterone	NN	O	B-Chemical
at	NN	O	O
age	NN	O	O
4	NN	O	O
months	NN	O	O
,	NN	O	O
developed	NN	O	O
a	NN	O	O
higher	NN	O	O
incidence	NN	O	O
of	NN	O	O
prostate	NN	O	B-Disease
cancer	NN	O	I-Disease
after	NN	O	O
an	NN	O	O
average	NN	O	O
interval	NN	O	O
of	NN	O	O
14	NN	O	O
months	NN	O	O
:	NN	O	O
24%	NN	O	O
had	NN	O	O
developed	NN	O	O
gross	NN	O	O
tumors	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
40%	NN	O	O
when	NN	O	O
it	NN	O	O
included	NN	O	O
microscopic	NN	O	O
tumors	NN	O	B-Disease
.	NN	O	O

Preliminary	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
testosterone	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
LW	NN	O	O
rats	NN	O	O
that	NN	O	O
were	NN	O	O
fed	NN	O	O
the	NN	O	O
same	NN	O	O
diet	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
supplemented	NN	O	O
with	NN	O	O
corn	NN	O	O
oil	NN	O	O
up	NN	O	O
to	NN	O	O
20%	NN	O	O
fat	NN	O	O
,	NN	O	O
developed	NN	O	O
prostate	NN	O	B-Disease
cancer	NN	O	I-Disease
after	NN	O	O
intervals	NN	O	O
of	NN	O	O
6	NN	O	O
-	NN	O	O
12	NN	O	O
months	NN	O	O
.	NN	O	O

Aged	NN	O	O
GF	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
(	NN	O	O
SD	NN	O	O
)	NN	O	O
rats	NN	O	O
have	NN	O	O
not	NN	O	O
developed	NN	O	O
prostate	NN	O	B-Disease
cancer	NN	O	I-Disease
spontaneously	NN	O	O
.	NN	O	O

Conventional	NN	O	O
SD	NN	O	O
rats	NN	O	O
fed	NN	O	O
diet	NN	O	O
L	NN	O	O
-	NN	O	O
485	NN	O	O
and	NN	O	O
treated	NN	O	O
with	NN	O	O
testosterone	NN	O	B-Chemical
developed	NN	O	O
only	NN	O	O
prostatitis	NN	O	B-Disease
.	NN	O	O

Experimental	NN	O	O
designs	NN	O	O
should	NN	O	O
consider	NN	O	O
genetic	NN	O	O
susceptibility	NN	O	O
as	NN	O	O
a	NN	O	O
basic	NN	O	O
prerequisite	NN	O	O
for	NN	O	O
studies	NN	O	O
on	NN	O	O
experimental	NN	O	O
prostate	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (3108839)

Mitomycin	NN	O	B-Chemical
C	NN	O	I-Chemical
associated	NN	O	O
hemolytic	NN	O	B-Disease
uremic	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Mitomycin	NN	O	B-Chemical
C	NN	O	I-Chemical
associated	NN	O	O
Hemolytic	NN	O	B-Disease
Uremic	NN	O	I-Disease
Syndrome	NN	O	I-Disease
(	NN	O	O
HUS	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
potentially	NN	O	O
fatal	NN	O	O
but	NN	O	O
uncommon	NN	O	O
condition	NN	O	O
that	NN	O	O
is	NN	O	O
not	NN	O	O
yet	NN	O	O
widely	NN	O	O
recognised	NN	O	O
.	NN	O	O

It	NN	O	O
consists	NN	O	O
of	NN	O	O
microangiopathic	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
,	NN	O	O
thrombocytopenia	NN	O	B-Disease
and	NN	O	O
progressive	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
mitomycin	NN	O	B-Chemical
C	NN	O	I-Chemical
treatment	NN	O	O
and	NN	O	O
affects	NN	O	O
about	NN	O	O
10%	NN	O	O
of	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
this	NN	O	O
agent	NN	O	O
.	NN	O	O

The	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
usually	NN	O	O
develops	NN	O	O
about	NN	O	O
8	NN	O	O
-	NN	O	O
10	NN	O	O
mth	NN	O	O
after	NN	O	O
start	NN	O	O
of	NN	O	O
mitomycin	NN	O	B-Chemical
C	NN	O	I-Chemical
treatment	NN	O	O
and	NN	O	O
the	NN	O	O
mortality	NN	O	O
is	NN	O	O
approximately	NN	O	O
60%	NN	O	O
from	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
or	NN	O	O
pulmonary	NN	O	B-Disease
edema	NN	O	I-Disease
.	NN	O	O

Renal	NN	O	B-Disease
lesions	NN	O	I-Disease
are	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
seen	NN	O	O
in	NN	O	O
idiopathic	NN	O	O
HUS	NN	O	B-Disease
and	NN	O	O
include	NN	O	O
arteriolar	NN	O	O
fibrin	NN	O	O
thrombi	NN	O	B-Disease
,	NN	O	O
expanded	NN	O	O
subendothelial	NN	O	O
zones	NN	O	O
in	NN	O	O
glomerular	NN	O	O
capillary	NN	O	O
walls	NN	O	O
,	NN	O	O
ischemic	NN	O	B-Disease
wrinkling	NN	O	O
of	NN	O	O
glomerular	NN	O	O
basement	NN	O	O
membranes	NN	O	O
and	NN	O	O
mesangiolysis	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
of	NN	O	O
action	NN	O	O
is	NN	O	O
postulated	NN	O	O
as	NN	O	O
mitomycin	NN	O	B-Chemical
C	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
endothelial	NN	O	O
cell	NN	O	O
damage	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
the	NN	O	O
clinical	NN	O	O
course	NN	O	O
and	NN	O	O
pathological	NN	O	O
findings	NN	O	O
in	NN	O	O
a	NN	O	O
65	NN	O	O
yr	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
gastric	NN	O	B-Disease
adenocarcinoma	NN	O	I-Disease
who	NN	O	O
developed	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
and	NN	O	O
thrombocytopenia	NN	O	B-Disease
while	NN	O	O
on	NN	O	O
treatment	NN	O	O
with	NN	O	O
mitomycin	NN	O	B-Chemical
C	NN	O	I-Chemical
and	NN	O	O
died	NN	O	O
in	NN	O	O
pulmonary	NN	O	B-Disease
edema	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (2466960)

Continuous	NN	O	O
ambulatory	NN	O	O
ECG	NN	O	O
monitoring	NN	O	O
during	NN	O	O
fluorouracil	NN	O	B-Chemical
therapy	NN	O	O
:	NN	O	O
a	NN	O	O
prospective	NN	O	O
study	NN	O	O
.	NN	O	O

Although	NN	O	O
there	NN	O	O
have	NN	O	O
been	NN	O	O
anecdotal	NN	O	O
reports	NN	O	O
of	NN	O	O
cardiac	NN	O	B-Disease
toxicity	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
fluorouracil	NN	O	B-Chemical
(	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
)	NN	O	O
therapy	NN	O	O
,	NN	O	O
this	NN	O	O
phenomenon	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
studied	NN	O	O
in	NN	O	O
a	NN	O	O
systematic	NN	O	O
fashion	NN	O	O
.	NN	O	O

We	NN	O	O
prospectively	NN	O	O
performed	NN	O	O
continuous	NN	O	O
ambulatory	NN	O	O
ECG	NN	O	O
monitoring	NN	O	O
on	NN	O	O
25	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
infusion	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
solid	NN	O	O
tumors	NN	O	B-Disease
in	NN	O	O
order	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
ischemic	NN	O	B-Disease
ST	NN	O	O
changes	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
monitored	NN	O	O
for	NN	O	O
23	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
hours	NN	O	O
before	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
infusion	NN	O	O
,	NN	O	O
and	NN	O	O
98	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
9	NN	O	O
hours	NN	O	O
during	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
infusion	NN	O	O
.	NN	O	O

Anginal	NN	O	B-Disease
episodes	NN	O	O
were	NN	O	O
rare	NN	O	O
:	NN	O	O
only	NN	O	O
one	NN	O	O
patient	NN	O	O
had	NN	O	O
angina	NN	O	B-Disease
(	NN	O	O
during	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
infusion	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
asymptomatic	NN	O	O
ST	NN	O	O
changes	NN	O	O
(	NN	O	O
greater	NN	O	O
than	NN	O	O
or	NN	O	O
equal	NN	O	O
to	NN	O	O
1	NN	O	O
mm	NN	O	O
ST	NN	O	O
deviation	NN	O	O
)	NN	O	O
were	NN	O	O
common	NN	O	O
:	NN	O	O
six	NN	O	O
of	NN	O	O
25	NN	O	O
patients	NN	O	O
(	NN	O	O
24%	NN	O	O
)	NN	O	O
had	NN	O	O
ST	NN	O	O
changes	NN	O	O
before	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
infusion	NN	O	O
v	NN	O	O
17	NN	O	O
(	NN	O	O
68%	NN	O	O
)	NN	O	O
during	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
infusion	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
.002	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
ischemic	NN	O	B-Disease
episodes	NN	O	O
per	NN	O	O
patient	NN	O	O
per	NN	O	O
hour	NN	O	O
was	NN	O	O
0.05	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.02	NN	O	O
prior	NN	O	O
to	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
infusion	NN	O	O
v	NN	O	O
0.13	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.03	NN	O	O
during	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
infusion	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
.001	NN	O	O
)	NN	O	O
;	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
ECG	NN	O	O
changes	NN	O	O
was	NN	O	O
0.6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.3	NN	O	O
minutes	NN	O	O
per	NN	O	O
patient	NN	O	O
per	NN	O	O
hour	NN	O	O
before	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
v	NN	O	O
1.9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.5	NN	O	O
minutes	NN	O	O
per	NN	O	O
patient	NN	O	O
per	NN	O	O
hour	NN	O	O
during	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
.01	NN	O	O
)	NN	O	O
.	NN	O	O

ECG	NN	O	O
changes	NN	O	O
were	NN	O	O
more	NN	O	O
common	NN	O	O
among	NN	O	O
patients	NN	O	O
with	NN	O	O
known	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

There	NN	O	O
were	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
sudden	NN	O	B-Disease
death	NN	O	I-Disease
,	NN	O	O
both	NN	O	O
of	NN	O	O
which	NN	O	O
occurred	NN	O	O
at	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
chemotherapy	NN	O	O
course	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
infusion	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
silent	NN	O	O
ST	NN	O	O
segment	NN	O	O
deviation	NN	O	O
suggestive	NN	O	O
of	NN	O	O
ischemia	NN	O	B-Disease
,	NN	O	O
particularly	NN	O	O
among	NN	O	O
patients	NN	O	O
with	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
and	NN	O	O
clinical	NN	O	O
significance	NN	O	O
of	NN	O	O
these	NN	O	O
ECG	NN	O	O
changes	NN	O	O
remain	NN	O	O
to	NN	O	O
be	NN	O	O
determined	NN	O	O
.	NN	O	O


-DOCSTART- (2320800)

Lethal	NN	O	O
anuria	NN	O	B-Disease
complicating	NN	O	O
high	NN	O	O
dose	NN	O	O
ifosfamide	NN	O	B-Chemical
chemotherapy	NN	O	O
in	NN	O	O
a	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
patient	NN	O	O
with	NN	O	O
an	NN	O	O
impaired	NN	O	B-Disease
renal	NN	O	I-Disease
function	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
sixty	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
advanced	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
,	NN	O	O
previously	NN	O	O
treated	NN	O	O
with	NN	O	O
cisplatin	NN	O	B-Chemical
,	NN	O	O
developed	NN	O	O
an	NN	O	O
irreversible	NN	O	O
lethal	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
with	NN	O	O
anuria	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
day	NN	O	O
after	NN	O	O
5	NN	O	O
g	NN	O	O
/	NN	O	O
m2	NN	O	O
bolus	NN	O	O
ifosfamide	NN	O	B-Chemical
.	NN	O	O

Postrenal	NN	O	B-Disease
failure	NN	O	I-Disease
was	NN	O	O
excluded	NN	O	O
by	NN	O	O
echography	NN	O	O
.	NN	O	O

A	NN	O	O
prerenal	NN	O	O
component	NN	O	O
could	NN	O	O
have	NN	O	O
contributed	NN	O	O
to	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
because	NN	O	O
of	NN	O	O
a	NN	O	O
transient	NN	O	O
hypotension	NN	O	B-Disease
,	NN	O	O
due	NN	O	O
to	NN	O	O
an	NN	O	O
increasing	NN	O	O
ascitis	NN	O	O
,	NN	O	O
occurring	NN	O	O
just	NN	O	O
before	NN	O	O
anuria	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
correction	NN	O	O
of	NN	O	O
the	NN	O	O
hemodynamic	NN	O	O
parameters	NN	O	O
did	NN	O	O
not	NN	O	O
improve	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

Ifosfamide	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
known	NN	O	O
nephrotoxic	NN	O	B-Disease
drug	NN	O	O
with	NN	O	O
demonstrated	NN	O	O
tubulopathies	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
strongly	NN	O	O
suspect	NN	O	O
that	NN	O	O
this	NN	O	O
lethal	NN	O	O
anuria	NN	O	B-Disease
was	NN	O	O
mainly	NN	O	O
due	NN	O	O
to	NN	O	O
ifosfamide	NN	O	B-Chemical
,	NN	O	O
occurring	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
having	NN	O	O
received	NN	O	O
previous	NN	O	O
cisplatin	NN	O	B-Chemical
chemotherapy	NN	O	O
and	NN	O	O
with	NN	O	O
poor	NN	O	O
kidney	NN	O	O
perfusion	NN	O	O
due	NN	O	O
to	NN	O	O
transient	NN	O	O
hypotension	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
recommend	NN	O	O
careful	NN	O	O
use	NN	O	O
of	NN	O	O
ifosfamide	NN	O	B-Chemical
in	NN	O	O
patients	NN	O	O
pretreated	NN	O	O
with	NN	O	O
nephrotoxic	NN	O	B-Disease
chemotherapy	NN	O	O
and	NN	O	O
inadequate	NN	O	O
renal	NN	O	O
perfusion	NN	O	O
.	NN	O	O


-DOCSTART- (2220369)

Central	NN	O	O
vein	NN	O	B-Disease
thrombosis	NN	O	I-Disease
and	NN	O	O
topical	NN	O	O
dipivalyl	NN	O	B-Chemical
epinephrine	NN	O	I-Chemical
.	NN	O	O

A	NN	O	O
report	NN	O	O
is	NN	O	O
given	NN	O	O
on	NN	O	O
an	NN	O	O
83	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
female	NN	O	O
who	NN	O	O
acquired	NN	O	O
central	NN	O	O
vein	NN	O	B-Disease
thrombosis	NN	O	I-Disease
in	NN	O	O
her	NN	O	O
seeing	NN	O	O
eye	NN	O	O
one	NN	O	O
day	NN	O	O
after	NN	O	O
having	NN	O	O
started	NN	O	O
topical	NN	O	O
medication	NN	O	O
with	NN	O	O
dipivalyl	NN	O	B-Chemical
epinephrine	NN	O	I-Chemical
for	NN	O	O
advanced	NN	O	O
glaucoma	NN	O	B-Disease
discovered	NN	O	O
in	NN	O	O
the	NN	O	O
other	NN	O	O
eye	NN	O	O
.	NN	O	O

From	NN	O	O
present	NN	O	O
knowledge	NN	O	O
about	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
adrenergic	NN	O	O
eye	NN	O	O
drops	NN	O	O
on	NN	O	O
ocular	NN	O	O
blood	NN	O	O
circulation	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
difficult	NN	O	O
to	NN	O	O
suggest	NN	O	O
an	NN	O	O
association	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
events	NN	O	O
,	NN	O	O
which	NN	O	O
may	NN	O	O
be	NN	O	O
coincidental	NN	O	O
only	NN	O	O
.	NN	O	O


-DOCSTART- (326460)

Amelioration	NN	O	O
of	NN	O	O
bendrofluazide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypokalemia	NN	O	B-Disease
by	NN	O	O
timolol	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
beta	NN	O	O
adrenergic	NN	O	O
blocking	NN	O	O
drug	NN	O	O
,	NN	O	O
timolol	NN	O	B-Chemical
,	NN	O	O
tended	NN	O	O
to	NN	O	O
correct	NN	O	O
the	NN	O	O
hypokalemia	NN	O	B-Disease
of	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
bendrofluazide	NN	O	B-Chemical
treatment	NN	O	O
in	NN	O	O
6	NN	O	O
healthy	NN	O	O
male	NN	O	O
subjects	NN	O	O
and	NN	O	O
although	NN	O	O
the	NN	O	O
effect	NN	O	O
was	NN	O	O
small	NN	O	O
it	NN	O	O
was	NN	O	O
significant	NN	O	O
.	NN	O	O

Timolol	NN	O	B-Chemical
also	NN	O	O
reduced	NN	O	O
the	NN	O	O
rise	NN	O	O
in	NN	O	O
plasma	NN	O	O
aldosterone	NN	O	B-Chemical
and	NN	O	O
urine	NN	O	O
potassium	NN	O	B-Chemical
excretion	NN	O	O
following	NN	O	O
bendrofluazide	NN	O	B-Chemical
and	NN	O	O
increased	NN	O	O
the	NN	O	O
urine	NN	O	O
sodium	NN	O	B-Chemical
/	NN	O	O
potassium	NN	O	B-Chemical
ratio	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
a	NN	O	O
shift	NN	O	O
of	NN	O	O
potassium	NN	O	B-Chemical
from	NN	O	O
the	NN	O	O
intracellular	NN	O	O
to	NN	O	O
the	NN	O	O
extracellular	NN	O	O
space	NN	O	O
.	NN	O	O


-DOCSTART- (20331935)

A	NN	O	O
cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
evaluation	NN	O	O
of	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
risperidone	NN	O	B-Chemical
and	NN	O	O
selective	NN	O	O
serotonin	NN	O	B-Chemical
reuptake	NN	O	O
inhibitors	NN	O	O
on	NN	O	O
bone	NN	O	O
mineral	NN	O	O
density	NN	O	O
in	NN	O	O
boys	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
risperidone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperprolactinemia	NN	O	B-Disease
on	NN	O	O
trabecular	NN	O	O
bone	NN	O	O
mineral	NN	O	O
density	NN	O	O
(	NN	O	O
BMD	NN	O	O
)	NN	O	O
in	NN	O	O
children	NN	O	O
and	NN	O	O
adolescents	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
Medically	NN	O	O
healthy	NN	O	O
7	NN	O	O
-	NN	O	O
to	NN	O	O
17	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
males	NN	O	O
chronically	NN	O	O
treated	NN	O	O
,	NN	O	O
in	NN	O	O
a	NN	O	O
naturalistic	NN	O	O
setting	NN	O	O
,	NN	O	O
with	NN	O	O
risperidone	NN	O	B-Chemical
were	NN	O	O
recruited	NN	O	O
for	NN	O	O
this	NN	O	O
cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
study	NN	O	O
through	NN	O	O
child	NN	O	O
psychiatry	NN	O	O
outpatient	NN	O	O
clinics	NN	O	O
between	NN	O	O
November	NN	O	O
2005	NN	O	O
and	NN	O	O
June	NN	O	O
2007	NN	O	O
.	NN	O	O

Anthropometric	NN	O	O
measurements	NN	O	O
and	NN	O	O
laboratory	NN	O	O
testing	NN	O	O
were	NN	O	O
conducted	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
diagnoses	NN	O	O
were	NN	O	O
based	NN	O	O
on	NN	O	O
chart	NN	O	O
review	NN	O	O
,	NN	O	O
and	NN	O	O
developmental	NN	O	O
and	NN	O	O
treatment	NN	O	O
history	NN	O	O
was	NN	O	O
obtained	NN	O	O
from	NN	O	O
the	NN	O	O
medical	NN	O	O
record	NN	O	O
.	NN	O	O

Volumetric	NN	O	O
BMD	NN	O	O
of	NN	O	O
the	NN	O	O
ultradistal	NN	O	O
radius	NN	O	O
was	NN	O	O
measured	NN	O	O
using	NN	O	O
peripheral	NN	O	O
quantitative	NN	O	O
computed	NN	O	O
tomography	NN	O	O
,	NN	O	O
and	NN	O	O
areal	NN	O	O
BMD	NN	O	O
of	NN	O	O
the	NN	O	O
lumbar	NN	O	O
spine	NN	O	O
was	NN	O	O
estimated	NN	O	O
using	NN	O	O
dual	NN	O	O
-	NN	O	O
energy	NN	O	O
x	NN	O	O
-	NN	O	O
ray	NN	O	O
absorptiometry	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Hyperprolactinemia	NN	O	B-Disease
was	NN	O	O
present	NN	O	O
in	NN	O	O
49%	NN	O	O
of	NN	O	O
83	NN	O	O
boys	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
41	NN	O	O
)	NN	O	O
treated	NN	O	O
with	NN	O	O
risperidone	NN	O	B-Chemical
for	NN	O	O
a	NN	O	O
mean	NN	O	O
of	NN	O	O
2.9	NN	O	O
years	NN	O	O
.	NN	O	O

Serum	NN	O	O
testosterone	NN	O	B-Chemical
concentration	NN	O	O
increased	NN	O	O
with	NN	O	O
pubertal	NN	O	O
status	NN	O	O
but	NN	O	O
was	NN	O	O
not	NN	O	O
affected	NN	O	O
by	NN	O	O
hyperprolactinemia	NN	O	B-Disease
.	NN	O	O

As	NN	O	O
expected	NN	O	O
,	NN	O	O
bone	NN	O	O
mineral	NN	O	O
content	NN	O	O
and	NN	O	O
BMD	NN	O	O
increased	NN	O	O
with	NN	O	O
sexual	NN	O	O
maturity	NN	O	O
.	NN	O	O

After	NN	O	O
adjusting	NN	O	O
for	NN	O	O
the	NN	O	O
stage	NN	O	O
of	NN	O	O
sexual	NN	O	O
development	NN	O	O
and	NN	O	O
height	NN	O	O
and	NN	O	O
BMI	NN	O	O
z	NN	O	O
scores	NN	O	O
,	NN	O	O
serum	NN	O	O
prolactin	NN	O	O
was	NN	O	O
negatively	NN	O	O
associated	NN	O	O
with	NN	O	O
trabecular	NN	O	O
volumetric	NN	O	O
BMD	NN	O	O
at	NN	O	O
the	NN	O	O
ultradistal	NN	O	O
radius	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.03	NN	O	O
)	NN	O	O
.	NN	O	O

Controlling	NN	O	O
for	NN	O	O
relevant	NN	O	O
covariates	NN	O	O
,	NN	O	O
we	NN	O	O
also	NN	O	O
found	NN	O	O
treatment	NN	O	O
with	NN	O	O
selective	NN	O	O
serotonin	NN	O	B-Chemical
reuptake	NN	O	O
inhibitors	NN	O	O
(	NN	O	O
SSRIs	NN	O	O
)	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
lower	NN	O	O
trabecular	NN	O	O
BMD	NN	O	O
at	NN	O	O
the	NN	O	O
radius	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.03	NN	O	O
)	NN	O	O
and	NN	O	O
BMD	NN	O	O
z	NN	O	O
score	NN	O	O
at	NN	O	O
the	NN	O	O
lumbar	NN	O	O
spine	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
became	NN	O	O
more	NN	O	O
marked	NN	O	O
when	NN	O	O
the	NN	O	O
analysis	NN	O	O
was	NN	O	O
restricted	NN	O	O
to	NN	O	O
non	NN	O	O
-	NN	O	O
Hispanic	NN	O	O
white	NN	O	O
patients	NN	O	O
.	NN	O	O

Of	NN	O	O
13	NN	O	O
documented	NN	O	O
fractures	NN	O	B-Disease
,	NN	O	O
3	NN	O	O
occurred	NN	O	O
after	NN	O	O
risperidone	NN	O	B-Chemical
and	NN	O	O
SSRIs	NN	O	O
were	NN	O	O
started	NN	O	O
,	NN	O	O
and	NN	O	O
none	NN	O	O
occurred	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
hyperprolactinemia	NN	O	B-Disease
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
study	NN	O	O
to	NN	O	O
link	NN	O	O
risperidone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperprolactinemia	NN	O	B-Disease
and	NN	O	O
SSRI	NN	O	O
treatment	NN	O	O
to	NN	O	O
lower	NN	O	O
BMD	NN	O	O
in	NN	O	O
children	NN	O	O
and	NN	O	O
adolescents	NN	O	O
.	NN	O	O

Future	NN	O	O
research	NN	O	O
should	NN	O	O
evaluate	NN	O	O
the	NN	O	O
longitudinal	NN	O	O
course	NN	O	O
of	NN	O	O
this	NN	O	O
adverse	NN	O	O
event	NN	O	O
to	NN	O	O
determine	NN	O	O
its	NN	O	O
temporal	NN	O	O
stability	NN	O	O
and	NN	O	O
whether	NN	O	O
a	NN	O	O
higher	NN	O	O
fracture	NN	O	O
rate	NN	O	O
ensues	NN	O	O
.	NN	O	O


-DOCSTART- (19707748)

Seizures	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
levofloxacin	NN	O	B-Chemical
:	NN	O	O
case	NN	O	O
presentation	NN	O	O
and	NN	O	O
literature	NN	O	O
review	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
We	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
seizures	NN	O	B-Disease
shortly	NN	O	O
after	NN	O	O
initiating	NN	O	O
treatment	NN	O	O
with	NN	O	O
levofloxacin	NN	O	B-Chemical
and	NN	O	O
to	NN	O	O
discuss	NN	O	O
the	NN	O	O
potential	NN	O	O
drug	NN	O	O
-	NN	O	O
drug	NN	O	O
interactions	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
cytochrome	NN	O	O
P450	NN	O	O
(	NN	O	O
CYP	NN	O	O
)	NN	O	O
1A2	NN	O	O
in	NN	O	O
this	NN	O	O
case	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
in	NN	O	O
other	NN	O	O
cases	NN	O	O
,	NN	O	O
of	NN	O	O
levofloxacin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Several	NN	O	O
biomedical	NN	O	O
databases	NN	O	O
were	NN	O	O
searched	NN	O	O
including	NN	O	O
MEDLINE	NN	O	O
,	NN	O	O
Cochrane	NN	O	O
and	NN	O	O
Ovid	NN	O	O
.	NN	O	O

The	NN	O	O
main	NN	O	O
search	NN	O	O
terms	NN	O	O
utilized	NN	O	O
were	NN	O	O
case	NN	O	O
report	NN	O	O
and	NN	O	O
levofloxacin	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
search	NN	O	O
was	NN	O	O
limited	NN	O	O
to	NN	O	O
studies	NN	O	O
published	NN	O	O
in	NN	O	O
English	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Six	NN	O	O
cases	NN	O	O
of	NN	O	O
levofloxacin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
have	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

Drug	NN	O	O
-	NN	O	O
drug	NN	O	O
interactions	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
CYP1A2	NN	O	O
by	NN	O	O
levofloxacin	NN	O	B-Chemical
are	NN	O	O
likely	NN	O	O
involved	NN	O	O
in	NN	O	O
the	NN	O	O
clinical	NN	O	O
outcome	NN	O	O
of	NN	O	O
these	NN	O	O
cases	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Clinicians	NN	O	O
are	NN	O	O
exhorted	NN	O	O
to	NN	O	O
pay	NN	O	O
close	NN	O	O
attention	NN	O	O
when	NN	O	O
initiating	NN	O	O
levofloxacin	NN	O	B-Chemical
therapy	NN	O	O
in	NN	O	O
patients	NN	O	O
taking	NN	O	O
medications	NN	O	O
with	NN	O	O
epileptogenic	NN	O	O
properties	NN	O	O
that	NN	O	O
are	NN	O	O
CYP1A2	NN	O	O
substrates	NN	O	O
.	NN	O	O


-DOCSTART- (19692487)

Mice	NN	O	O
lacking	NN	O	O
mPGES	NN	O	O
-	NN	O	O
1	NN	O	O
are	NN	O	O
resistant	NN	O	O
to	NN	O	O
lithium	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
polyuria	NN	O	B-Disease
.	NN	O	O

Cyclooxygenase	NN	O	O
-	NN	O	O
2	NN	O	O
activity	NN	O	O
is	NN	O	O
required	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
polyuria	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
involvement	NN	O	O
of	NN	O	O
a	NN	O	O
specific	NN	O	O
,	NN	O	O
terminal	NN	O	O
prostaglandin	NN	O	B-Chemical
(	NN	O	O
PG	NN	O	B-Chemical
)	NN	O	O
isomerase	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
evaluated	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
undertaken	NN	O	O
to	NN	O	O
assess	NN	O	O
lithium	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
polyuria	NN	O	B-Disease
in	NN	O	O
mice	NN	O	O
deficient	NN	O	O
in	NN	O	O
microsomal	NN	O	O
prostaglandin	NN	O	B-Chemical
E	NN	O	I-Chemical
synthase	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
mPGES	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
2	NN	O	O
-	NN	O	O
wk	NN	O	O
administration	NN	O	O
of	NN	O	O
LiCl	NN	O	B-Chemical
(	NN	O	O
4	NN	O	O
mmol.kg	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.day	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
ip	NN	O	O
)	NN	O	O
in	NN	O	O
mPGES	NN	O	O
-	NN	O	O
1	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
mice	NN	O	O
led	NN	O	O
to	NN	O	O
a	NN	O	O
marked	NN	O	O
polyuria	NN	O	B-Disease
with	NN	O	O
hyposmotic	NN	O	O
urine	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
elevated	NN	O	O
renal	NN	O	O
mPGES	NN	O	O
-	NN	O	O
1	NN	O	O
protein	NN	O	O
expression	NN	O	O
and	NN	O	O
increased	NN	O	O
urine	NN	O	O
PGE	NN	O	B-Chemical
(	NN	O	I-Chemical
2	NN	O	I-Chemical
)	NN	O	I-Chemical
excretion	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
mPGES	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
were	NN	O	O
largely	NN	O	O
resistant	NN	O	O
to	NN	O	O
lithium	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
polyuria	NN	O	B-Disease
and	NN	O	O
a	NN	O	O
urine	NN	O	O
concentrating	NN	O	O
defect	NN	O	O
,	NN	O	O
accompanied	NN	O	O
by	NN	O	O
nearly	NN	O	O
complete	NN	O	O
blockade	NN	O	O
of	NN	O	O
high	NN	O	O
urine	NN	O	O
PGE	NN	O	B-Chemical
(	NN	O	I-Chemical
2	NN	O	I-Chemical
)	NN	O	I-Chemical
and	NN	O	O
cAMP	NN	O	O
output	NN	O	O
.	NN	O	O

Immunoblotting	NN	O	O
,	NN	O	O
immunohistochemistry	NN	O	O
,	NN	O	O
and	NN	O	O
quantitative	NN	O	O
(	NN	O	O
q	NN	O	O
)	NN	O	O
RT	NN	O	O
-	NN	O	O
PCR	NN	O	O
consistently	NN	O	O
detected	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
aquaporin	NN	O	O
-	NN	O	O
2	NN	O	O
(	NN	O	O
AQP2	NN	O	O
)	NN	O	O
protein	NN	O	O
expression	NN	O	O
in	NN	O	O
both	NN	O	O
the	NN	O	O
renal	NN	O	O
cortex	NN	O	O
and	NN	O	O
medulla	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
mice	NN	O	O
.	NN	O	O

This	NN	O	O
decrease	NN	O	O
was	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
in	NN	O	O
the	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
.	NN	O	O

qRT	NN	O	O
-	NN	O	O
PCR	NN	O	O
detected	NN	O	O
similar	NN	O	O
patterns	NN	O	O
of	NN	O	O
changes	NN	O	O
in	NN	O	O
AQP2	NN	O	O
mRNA	NN	O	O
in	NN	O	O
the	NN	O	O
medulla	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
cortex	NN	O	O
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
the	NN	O	O
total	NN	O	O
protein	NN	O	O
abundance	NN	O	O
of	NN	O	O
the	NN	O	O
Na	NN	O	B-Chemical
-	NN	O	O
K	NN	O	B-Chemical
-	NN	O	O
2Cl	NN	O	B-Chemical
cotransporter	NN	O	O
(	NN	O	O
NKCC2	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
medulla	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
cortex	NN	O	O
of	NN	O	O
the	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
mice	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
by	NN	O	O
lithium	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
dowregulation	NN	O	O
of	NN	O	O
renal	NN	O	O
medullary	NN	O	O
NKCC2	NN	O	O
expression	NN	O	O
was	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
in	NN	O	O
the	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
mPGES	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
derived	NN	O	O
PGE	NN	O	B-Chemical
(	NN	O	I-Chemical
2	NN	O	I-Chemical
)	NN	O	I-Chemical
mediates	NN	O	O
lithium	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
polyuria	NN	O	B-Disease
likely	NN	O	O
via	NN	O	O
inhibition	NN	O	O
of	NN	O	O
AQP2	NN	O	O
and	NN	O	O
NKCC2	NN	O	O
expression	NN	O	O
.	NN	O	O


-DOCSTART- (19289093)

Identification	NN	O	O
of	NN	O	O
a	NN	O	O
simple	NN	O	O
and	NN	O	O
sensitive	NN	O	O
microplate	NN	O	O
method	NN	O	O
for	NN	O	O
the	NN	O	O
detection	NN	O	O
of	NN	O	O
oversulfated	NN	O	O
chondroitin	NN	O	B-Chemical
sulfate	NN	O	I-Chemical
in	NN	O	O
heparin	NN	O	B-Chemical
products	NN	O	O
.	NN	O	O

Heparin	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
commonly	NN	O	O
implemented	NN	O	O
anticoagulant	NN	O	O
used	NN	O	O
to	NN	O	O
treat	NN	O	O
critically	NN	O	O
ill	NN	O	O
patients	NN	O	O
.	NN	O	O

Recently	NN	O	O
,	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
commercial	NN	O	O
lots	NN	O	O
of	NN	O	O
heparin	NN	O	B-Chemical
products	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
contaminated	NN	O	O
with	NN	O	O
an	NN	O	O
oversulfated	NN	O	O
chondroitin	NN	O	B-Chemical
sulfate	NN	O	I-Chemical
(	NN	O	O
OSCS	NN	O	O
)	NN	O	O
derivative	NN	O	O
that	NN	O	O
could	NN	O	O
elicit	NN	O	O
a	NN	O	O
hypotensive	NN	O	B-Disease
response	NN	O	O
in	NN	O	O
pigs	NN	O	O
following	NN	O	O
a	NN	O	O
single	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
infusion	NN	O	O
.	NN	O	O

Using	NN	O	O
both	NN	O	O
contaminated	NN	O	O
heparin	NN	O	B-Chemical
products	NN	O	O
and	NN	O	O
the	NN	O	O
synthetically	NN	O	O
produced	NN	O	O
derivative	NN	O	O
,	NN	O	O
we	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
OSCS	NN	O	O
produces	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
hypotension	NN	O	B-Disease
in	NN	O	O
pigs	NN	O	O
.	NN	O	O

The	NN	O	O
no	NN	O	O
observed	NN	O	O
effect	NN	O	O
level	NN	O	O
(	NN	O	O
NOEL	NN	O	O
)	NN	O	O
for	NN	O	O
this	NN	O	O
contaminant	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
approximately	NN	O	O
1mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
corresponding	NN	O	O
to	NN	O	O
a	NN	O	O
contamination	NN	O	O
level	NN	O	O
of	NN	O	O
approximately	NN	O	O
3%	NN	O	O
.	NN	O	O

We	NN	O	O
also	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
OSCS	NN	O	O
can	NN	O	O
be	NN	O	O
identified	NN	O	O
in	NN	O	O
heparin	NN	O	B-Chemical
products	NN	O	O
using	NN	O	O
a	NN	O	O
simple	NN	O	O
,	NN	O	O
inexpensive	NN	O	O
,	NN	O	O
commercially	NN	O	O
available	NN	O	O
heparin	NN	O	B-Chemical
enzyme	NN	O	O
immunoassay	NN	O	O
(	NN	O	O
EIA	NN	O	O
)	NN	O	O
kit	NN	O	O
that	NN	O	O
has	NN	O	O
a	NN	O	O
limit	NN	O	O
of	NN	O	O
detection	NN	O	O
of	NN	O	O
approximately	NN	O	O
0.1%	NN	O	O
,	NN	O	O
well	NN	O	O
below	NN	O	O
the	NN	O	O
NOEL	NN	O	O
.	NN	O	O

This	NN	O	O
kit	NN	O	O
may	NN	O	O
provide	NN	O	O
a	NN	O	O
useful	NN	O	O
method	NN	O	O
to	NN	O	O
test	NN	O	O
heparin	NN	O	B-Chemical
products	NN	O	O
for	NN	O	O
contamination	NN	O	O
with	NN	O	O
oversulfated	NN	O	O
GAG	NN	O	O
derivatives	NN	O	O
.	NN	O	O


-DOCSTART- (18627295)

Doxorubicin	NN	O	B-Chemical
cardiomyopathy	NN	O	B-Disease
-	NN	O	O
induced	NN	O	O
inflammation	NN	O	B-Disease
and	NN	O	O
apoptosis	NN	O	O
are	NN	O	O
attenuated	NN	O	O
by	NN	O	O
gene	NN	O	O
deletion	NN	O	O
of	NN	O	O
the	NN	O	O
kinin	NN	O	O
B1	NN	O	O
receptor	NN	O	O
.	NN	O	O

Clinical	NN	O	O
use	NN	O	O
of	NN	O	O
the	NN	O	O
anthracycline	NN	O	B-Chemical
doxorubicin	NN	O	B-Chemical
(	NN	O	O
DOX	NN	O	B-Chemical
)	NN	O	O
is	NN	O	O
limited	NN	O	O
by	NN	O	O
its	NN	O	O
cardiotoxic	NN	O	B-Disease
effects	NN	O	O
,	NN	O	O
which	NN	O	O
are	NN	O	O
attributed	NN	O	O
to	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

To	NN	O	O
elucidate	NN	O	O
the	NN	O	O
possible	NN	O	O
role	NN	O	O
of	NN	O	O
the	NN	O	O
kinin	NN	O	O
B1	NN	O	O
receptor	NN	O	O
(	NN	O	O
B1R	NN	O	O
)	NN	O	O
during	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
DOX	NN	O	B-Chemical
cardiomyopathy	NN	O	B-Disease
,	NN	O	O
we	NN	O	O
studied	NN	O	O
B1R	NN	O	O
knockout	NN	O	O
mice	NN	O	O
(	NN	O	O
B1R	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
)	NN	O	O
by	NN	O	O
investigating	NN	O	O
cardiac	NN	O	O
inflammation	NN	O	B-Disease
and	NN	O	O
apoptosis	NN	O	O
after	NN	O	O
induction	NN	O	O
of	NN	O	O
DOX	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiomyopathy	NN	O	B-Disease
.	NN	O	O

DOX	NN	O	B-Chemical
control	NN	O	O
mice	NN	O	O
showed	NN	O	O
cardiac	NN	O	B-Disease
dysfunction	NN	O	I-Disease
measured	NN	O	O
by	NN	O	O
pressure	NN	O	O
-	NN	O	O
volume	NN	O	O
loops	NN	O	O
in	NN	O	O
vivo	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
reduced	NN	O	O
activation	NN	O	O
state	NN	O	O
of	NN	O	O
AKT	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
an	NN	O	O
increased	NN	O	O
bax	NN	O	O
/	NN	O	O
bcl2	NN	O	O
ratio	NN	O	O
in	NN	O	O
Western	NN	O	O
blots	NN	O	O
,	NN	O	O
indicating	NN	O	O
cardiac	NN	O	B-Disease
apoptosis	NN	O	I-Disease
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
of	NN	O	O
the	NN	O	O
proinflammatory	NN	O	O
cytokine	NN	O	O
interleukin	NN	O	O
6	NN	O	O
were	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
cardiac	NN	O	O
tissue	NN	O	O
.	NN	O	O

In	NN	O	O
DOX	NN	O	B-Chemical
B1R	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
,	NN	O	O
cardiac	NN	O	B-Disease
dysfunction	NN	O	I-Disease
was	NN	O	O
improved	NN	O	O
compared	NN	O	O
to	NN	O	O
DOX	NN	O	B-Chemical
control	NN	O	O
mice	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
normalization	NN	O	O
of	NN	O	O
the	NN	O	O
bax	NN	O	O
/	NN	O	O
bcl	NN	O	O
-	NN	O	O
2	NN	O	O
ratio	NN	O	O
and	NN	O	O
interleukin	NN	O	O
6	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
AKT	NN	O	O
activation	NN	O	O
state	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
suggest	NN	O	O
that	NN	O	O
B1R	NN	O	O
is	NN	O	O
detrimental	NN	O	O
in	NN	O	O
DOX	NN	O	B-Chemical
cardiomyopathy	NN	O	B-Disease
in	NN	O	O
that	NN	O	O
it	NN	O	O
mediates	NN	O	O
the	NN	O	O
inflammatory	NN	O	O
response	NN	O	O
and	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

These	NN	O	O
insights	NN	O	O
might	NN	O	O
have	NN	O	O
useful	NN	O	O
implications	NN	O	O
for	NN	O	O
future	NN	O	O
studies	NN	O	O
utilizing	NN	O	O
B1R	NN	O	O
antagonists	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
human	NN	O	O
DOX	NN	O	B-Chemical
cardiomyopathy	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (18405372)

Hepatotoxicity	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
sulfasalazine	NN	O	B-Chemical
in	NN	O	O
inflammatory	NN	O	O
arthritis	NN	O	B-Disease
:	NN	O	O
A	NN	O	O
case	NN	O	O
series	NN	O	O
from	NN	O	O
a	NN	O	O
local	NN	O	O
surveillance	NN	O	O
of	NN	O	O
serious	NN	O	O
adverse	NN	O	O
events	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Spontaneous	NN	O	O
reporting	NN	O	O
systems	NN	O	O
for	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reactions	NN	O	O
(	NN	O	O
ADRs	NN	O	O
)	NN	O	O
are	NN	O	O
handicapped	NN	O	O
by	NN	O	O
under	NN	O	O
-	NN	O	O
reporting	NN	O	O
and	NN	O	O
limited	NN	O	O
detail	NN	O	O
on	NN	O	O
individual	NN	O	O
cases	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
an	NN	O	O
investigation	NN	O	O
from	NN	O	O
a	NN	O	O
local	NN	O	O
surveillance	NN	O	O
for	NN	O	O
serious	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reactions	NN	O	O
associated	NN	O	O
with	NN	O	O
disease	NN	O	O
modifying	NN	O	O
anti	NN	O	O
-	NN	O	O
rheumatic	NN	O	O
drugs	NN	O	O
that	NN	O	O
was	NN	O	O
triggered	NN	O	O
by	NN	O	O
the	NN	O	O
occurrence	NN	O	O
of	NN	O	O
liver	NN	O	B-Disease
failure	NN	O	I-Disease
in	NN	O	O
two	NN	O	O
of	NN	O	O
our	NN	O	O
patients	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Serious	NN	O	O
ADR	NN	O	O
reports	NN	O	O
have	NN	O	O
been	NN	O	O
solicited	NN	O	O
from	NN	O	O
local	NN	O	O
clinicians	NN	O	O
by	NN	O	O
regular	NN	O	O
postcards	NN	O	O
over	NN	O	O
the	NN	O	O
past	NN	O	O
seven	NN	O	O
years	NN	O	O
.	NN	O	O

Patients	NN	O	O
'	NN	O	O
,	NN	O	O
who	NN	O	O
had	NN	O	O
hepatotoxicity	NN	O	B-Disease
on	NN	O	O
sulfasalazine	NN	O	B-Chemical
and	NN	O	O
met	NN	O	O
a	NN	O	O
definition	NN	O	O
of	NN	O	O
a	NN	O	O
serious	NN	O	O
ADR	NN	O	O
,	NN	O	O
were	NN	O	O
identified	NN	O	O
.	NN	O	O

Two	NN	O	O
clinicians	NN	O	O
reviewed	NN	O	O
structured	NN	O	O
case	NN	O	O
reports	NN	O	O
and	NN	O	O
assessed	NN	O	O
causality	NN	O	O
by	NN	O	O
consensus	NN	O	O
and	NN	O	O
by	NN	O	O
using	NN	O	O
a	NN	O	O
causality	NN	O	O
assessment	NN	O	O
instrument	NN	O	O
.	NN	O	O

The	NN	O	O
likely	NN	O	O
frequency	NN	O	O
of	NN	O	O
hepatotoxicity	NN	O	B-Disease
with	NN	O	O
sulfasalazine	NN	O	B-Chemical
was	NN	O	O
estimated	NN	O	O
by	NN	O	O
making	NN	O	O
a	NN	O	O
series	NN	O	O
of	NN	O	O
conservative	NN	O	O
assumptions	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Ten	NN	O	O
cases	NN	O	O
were	NN	O	O
identified	NN	O	O
:	NN	O	O
eight	NN	O	O
occurred	NN	O	O
during	NN	O	O
surveillance	NN	O	O
.	NN	O	O

Eight	NN	O	O
patients	NN	O	O
were	NN	O	O
hospitalised	NN	O	O
,	NN	O	O
two	NN	O	O
in	NN	O	O
hepatic	NN	O	B-Disease
failure	NN	O	I-Disease
-	NN	O	O
one	NN	O	O
died	NN	O	O
after	NN	O	O
a	NN	O	O
liver	NN	O	O
transplant	NN	O	O
.	NN	O	O

All	NN	O	O
but	NN	O	O
one	NN	O	O
event	NN	O	O
occurred	NN	O	O
within	NN	O	O
6	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

Seven	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
skin	NN	O	B-Disease
rash	NN	O	I-Disease
,	NN	O	O
three	NN	O	O
eosinophilia	NN	O	B-Disease
and	NN	O	O
one	NN	O	O
interstitial	NN	O	B-Disease
nephritis	NN	O	I-Disease
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
were	NN	O	O
of	NN	O	O
Black	NN	O	O
British	NN	O	O
of	NN	O	O
African	NN	O	O
or	NN	O	O
Caribbean	NN	O	O
descent	NN	O	O
.	NN	O	O

Liver	NN	O	O
enzymes	NN	O	O
showed	NN	O	O
a	NN	O	O
hepatocellular	NN	O	O
pattern	NN	O	O
in	NN	O	O
four	NN	O	O
cases	NN	O	O
and	NN	O	O
a	NN	O	O
mixed	NN	O	O
pattern	NN	O	O
in	NN	O	O
six	NN	O	O
.	NN	O	O

Drug	NN	O	O
-	NN	O	O
related	NN	O	O
hepatotoxicity	NN	O	B-Disease
was	NN	O	O
judged	NN	O	O
probable	NN	O	O
or	NN	O	O
highly	NN	O	O
probable	NN	O	O
in	NN	O	O
8	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
likely	NN	O	O
frequency	NN	O	O
of	NN	O	O
serious	NN	O	O
hepatotoxicity	NN	O	B-Disease
with	NN	O	O
sulfasalazine	NN	O	B-Chemical
was	NN	O	O
estimated	NN	O	O
at	NN	O	O
0.4%	NN	O	O
of	NN	O	O
treated	NN	O	O
patients	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Serious	NN	O	O
hepatotoxicity	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
sulfasalazine	NN	O	B-Chemical
appears	NN	O	O
to	NN	O	O
be	NN	O	O
under	NN	O	O
-	NN	O	O
appreciated	NN	O	O
and	NN	O	O
intensive	NN	O	O
monitoring	NN	O	O
and	NN	O	O
vigilance	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
6	NN	O	O
weeks	NN	O	O
of	NN	O	O
treatment	NN	O	O
is	NN	O	O
especially	NN	O	O
important	NN	O	O
.	NN	O	O


-DOCSTART- (18356633)

An	NN	O	O
evaluation	NN	O	O
of	NN	O	O
amikacin	NN	O	B-Chemical
nephrotoxicity	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
hematology	NN	O	O
/	NN	O	O
oncology	NN	O	O
population	NN	O	O
.	NN	O	O

Amikacin	NN	O	B-Chemical
is	NN	O	O
an	NN	O	O
aminoglycoside	NN	O	B-Chemical
commonly	NN	O	O
used	NN	O	O
to	NN	O	O
provide	NN	O	O
empirical	NN	O	O
double	NN	O	O
gram	NN	O	O
-	NN	O	O
negative	NN	O	O
treatment	NN	O	O
for	NN	O	O
febrile	NN	O	B-Disease
neutropenia	NN	O	I-Disease
and	NN	O	O
other	NN	O	O
suspected	NN	O	O
infections	NN	O	B-Disease
.	NN	O	O

Strategies	NN	O	O
of	NN	O	O
extended	NN	O	O
-	NN	O	O
interval	NN	O	O
and	NN	O	O
conventional	NN	O	O
dosing	NN	O	O
have	NN	O	O
been	NN	O	O
utilized	NN	O	O
extensively	NN	O	O
in	NN	O	O
the	NN	O	O
general	NN	O	O
medical	NN	O	O
population	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
data	NN	O	O
are	NN	O	O
lacking	NN	O	O
to	NN	O	O
support	NN	O	O
a	NN	O	O
dosing	NN	O	O
strategy	NN	O	O
in	NN	O	O
the	NN	O	O
hematology	NN	O	O
/	NN	O	O
oncology	NN	O	O
population	NN	O	O
.	NN	O	O

To	NN	O	O
evaluate	NN	O	O
amikacin	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
nephrotoxicity	NN	O	B-Disease
in	NN	O	O
an	NN	O	O
adult	NN	O	O
hematology	NN	O	O
/	NN	O	O
oncology	NN	O	O
population	NN	O	O
,	NN	O	O
a	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
trial	NN	O	O
was	NN	O	O
conducted	NN	O	O
at	NN	O	O
a	NN	O	O
university	NN	O	O
-	NN	O	O
affiliated	NN	O	O
medical	NN	O	O
center	NN	O	O
.	NN	O	O

Forty	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
diagnosis	NN	O	O
consistent	NN	O	O
with	NN	O	O
a	NN	O	O
hematologic	NN	O	B-Disease
/	NN	O	I-Disease
oncologic	NN	O	I-Disease
disorder	NN	O	I-Disease
that	NN	O	O
required	NN	O	O
treatment	NN	O	O
with	NN	O	O
an	NN	O	O
aminoglycoside	NN	O	B-Chemical
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
either	NN	O	O
conventional	NN	O	O
or	NN	O	O
extended	NN	O	O
-	NN	O	O
interval	NN	O	O
amikacin	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
occurrence	NN	O	O
of	NN	O	O
nephrotoxicity	NN	O	B-Disease
by	NN	O	O
means	NN	O	O
of	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
and	NN	O	O
evaluation	NN	O	O
of	NN	O	O
efficacy	NN	O	O
via	NN	O	O
amikacin	NN	O	B-Chemical
serum	NN	O	O
concentrations	NN	O	O
with	NN	O	O
respective	NN	O	O
pathogens	NN	O	O
were	NN	O	O
assessed	NN	O	O
.	NN	O	O

The	NN	O	O
occurrence	NN	O	O
of	NN	O	O
nephrotoxicity	NN	O	B-Disease
was	NN	O	O
similar	NN	O	O
between	NN	O	O
the	NN	O	O
conventional	NN	O	O
and	NN	O	O
extended	NN	O	O
-	NN	O	O
interval	NN	O	O
groups	NN	O	O
,	NN	O	O
at	NN	O	O
10%	NN	O	O
and	NN	O	O
5%	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
1.00	NN	O	O
)	NN	O	O
.	NN	O	O

Six	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
conventional	NN	O	O
group	NN	O	O
had	NN	O	O
a	NN	O	O
positive	NN	O	O
culture	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
none	NN	O	O
in	NN	O	O
the	NN	O	O
extended	NN	O	O
-	NN	O	O
interval	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.002	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
occurrence	NN	O	O
of	NN	O	O
nephrotoxicity	NN	O	B-Disease
was	NN	O	O
similar	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
dosing	NN	O	O
regimens	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
distribution	NN	O	O
of	NN	O	O
risk	NN	O	O
factors	NN	O	O
was	NN	O	O
variable	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

Efficacy	NN	O	O
could	NN	O	O
not	NN	O	O
be	NN	O	O
assessed	NN	O	O
.	NN	O	O


-DOCSTART- (16574713)

Memory	NN	O	O
function	NN	O	O
and	NN	O	O
serotonin	NN	O	B-Chemical
transporter	NN	O	O
promoter	NN	O	O
gene	NN	O	O
polymorphism	NN	O	O
in	NN	O	O
ecstasy	NN	O	B-Chemical
(	NN	O	O
MDMA	NN	O	B-Chemical
)	NN	O	O
users	NN	O	O
.	NN	O	O

Although	NN	O	O
3	NN	O	B-Chemical
,	NN	O	I-Chemical
4	NN	O	I-Chemical
-	NN	O	I-Chemical
methylenedioxymethamphetamine	NN	O	I-Chemical
(	NN	O	O
MDMA	NN	O	B-Chemical
or	NN	O	O
ecstasy	NN	O	B-Chemical
)	NN	O	O
has	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
damage	NN	O	O
brain	NN	O	O
serotonin	NN	O	B-Chemical
(	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
)	NN	O	O
neurons	NN	O	O
in	NN	O	O
animals	NN	O	O
and	NN	O	O
possibly	NN	O	O
humans	NN	O	O
,	NN	O	O
little	NN	O	O
is	NN	O	O
known	NN	O	O
about	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
consequences	NN	O	O
of	NN	O	O
MDMA	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
neurotoxic	NN	O	B-Disease
lesions	NN	O	I-Disease
on	NN	O	O
functions	NN	O	O
in	NN	O	O
which	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
is	NN	O	O
involved	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
cognitive	NN	O	O
function	NN	O	O
.	NN	O	O

Because	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
transporters	NN	O	O
play	NN	O	O
a	NN	O	O
key	NN	O	O
element	NN	O	O
in	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
synaptic	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
transmission	NN	O	O
it	NN	O	O
may	NN	O	O
be	NN	O	O
important	NN	O	O
to	NN	O	O
control	NN	O	O
for	NN	O	O
the	NN	O	O
potential	NN	O	O
covariance	NN	O	O
effect	NN	O	O
of	NN	O	O
a	NN	O	O
polymorphism	NN	O	O
in	NN	O	O
the	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
transporter	NN	O	O
promoter	NN	O	O
gene	NN	O	O
region	NN	O	O
(	NN	O	O
5	NN	O	O
-	NN	O	O
HTTLPR	NN	O	O
)	NN	O	O
when	NN	O	O
studying	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
MDMA	NN	O	B-Chemical
as	NN	O	O
well	NN	O	O
as	NN	O	O
cognitive	NN	O	O
functioning	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
moderate	NN	O	O
and	NN	O	O
heavy	NN	O	O
MDMA	NN	O	B-Chemical
use	NN	O	O
on	NN	O	O
cognitive	NN	O	O
function	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
abstention	NN	O	O
from	NN	O	O
MDMA	NN	O	B-Chemical
,	NN	O	O
in	NN	O	O
subjects	NN	O	O
genotyped	NN	O	O
for	NN	O	O
5	NN	O	O
-	NN	O	O
HTTLPR	NN	O	O
.	NN	O	O

A	NN	O	O
second	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
these	NN	O	O
effects	NN	O	O
differ	NN	O	O
for	NN	O	O
females	NN	O	O
and	NN	O	O
males	NN	O	O
.	NN	O	O

Fifteen	NN	O	O
moderate	NN	O	O
MDMA	NN	O	B-Chemical
users	NN	O	O
(	NN	O	O
<55	NN	O	O
lifetime	NN	O	O
tablets	NN	O	O
)	NN	O	O
,	NN	O	O
22	NN	O	O
heavy	NN	O	O
MDMA	NN	O	B-Chemical
+	NN	O	O
users	NN	O	O
(	NN	O	O
>55	NN	O	O
lifetime	NN	O	O
tablets	NN	O	O
)	NN	O	O
,	NN	O	O
16	NN	O	O
ex	NN	O	O
-	NN	O	O
MDMA	NN	O	B-Chemical
+	NN	O	O
users	NN	O	O
(	NN	O	O
last	NN	O	O
tablet	NN	O	O
>	NN	O	O
1	NN	O	O
year	NN	O	O
ago	NN	O	O
)	NN	O	O
and	NN	O	O
13	NN	O	O
controls	NN	O	O
were	NN	O	O
compared	NN	O	O
on	NN	O	O
a	NN	O	O
battery	NN	O	O
of	NN	O	O
neuropsychological	NN	O	O
tests	NN	O	O
.	NN	O	O

DNA	NN	O	O
from	NN	O	O
peripheral	NN	O	O
nuclear	NN	O	O
blood	NN	O	O
cells	NN	O	O
was	NN	O	O
genotyped	NN	O	O
for	NN	O	O
5	NN	O	O
-	NN	O	O
HTTLPR	NN	O	O
using	NN	O	O
standard	NN	O	O
polymerase	NN	O	O
chain	NN	O	O
reaction	NN	O	O
methods.A	NN	O	O
significant	NN	O	O
group	NN	O	O
effect	NN	O	O
was	NN	O	O
observed	NN	O	O
only	NN	O	O
on	NN	O	O
memory	NN	O	O
function	NN	O	O
tasks	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.04	NN	O	O
)	NN	O	O
but	NN	O	O
not	NN	O	O
on	NN	O	O
reaction	NN	O	O
times	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.61	NN	O	O
)	NN	O	O
or	NN	O	O
attention	NN	O	O
/	NN	O	O
executive	NN	O	O
functioning	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.59	NN	O	O
)	NN	O	O
.	NN	O	O

Heavy	NN	O	O
and	NN	O	O
ex	NN	O	O
-	NN	O	O
MDMA	NN	O	B-Chemical
+	NN	O	O
users	NN	O	O
performed	NN	O	O
significantly	NN	O	O
poorer	NN	O	O
on	NN	O	O
memory	NN	O	O
tasks	NN	O	O
than	NN	O	O
controls	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
memory	NN	O	B-Disease
impairment	NN	O	I-Disease
was	NN	O	O
observed	NN	O	O
in	NN	O	O
moderate	NN	O	O
MDMA	NN	O	B-Chemical
users	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
effect	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
HTTLPR	NN	O	O
or	NN	O	O
gender	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O

While	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
MDMA	NN	O	B-Chemical
in	NN	O	O
quantities	NN	O	O
that	NN	O	O
may	NN	O	O
be	NN	O	O
considered	NN	O	O
"	NN	O	O
moderate	NN	O	O
"	NN	O	O
is	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
impaired	NN	O	B-Disease
memory	NN	O	I-Disease
functioning	NN	O	I-Disease
,	NN	O	O
heavy	NN	O	O
use	NN	O	O
of	NN	O	O
MDMA	NN	O	B-Chemical
use	NN	O	O
may	NN	O	O
lead	NN	O	O
to	NN	O	O
long	NN	O	O
lasting	NN	O	O
memory	NN	O	B-Disease
impairments	NN	O	I-Disease
.	NN	O	O

No	NN	O	O
effect	NN	O	O
of	NN	O	O
5	NN	O	O
-	NN	O	O
HTTLPR	NN	O	O
or	NN	O	O
gender	NN	O	O
on	NN	O	O
memory	NN	O	O
function	NN	O	O
or	NN	O	O
MDMA	NN	O	B-Chemical
use	NN	O	O
was	NN	O	O
observed	NN	O	O
.	NN	O	O


-DOCSTART- (15638391)

Aging	NN	O	O
process	NN	O	O
of	NN	O	O
epithelial	NN	O	O
cells	NN	O	O
of	NN	O	O
the	NN	O	O
rat	NN	O	O
prostate	NN	O	O
lateral	NN	O	O
lobe	NN	O	O
in	NN	O	O
experimental	NN	O	O
hyperprolactinemia	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
haloperidol	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
hyperprolactinemia	NN	O	B-Disease
,	NN	O	O
induced	NN	O	O
by	NN	O	O
haloperidol	NN	O	B-Chemical
(	NN	O	O
HAL	NN	O	B-Chemical
)	NN	O	O
on	NN	O	O
age	NN	O	O
related	NN	O	O
morphology	NN	O	O
and	NN	O	O
function	NN	O	O
changes	NN	O	O
of	NN	O	O
epithelial	NN	O	O
cells	NN	O	O
in	NN	O	O
rat	NN	O	O
prostate	NN	O	O
lateral	NN	O	O
lobe	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
was	NN	O	O
performed	NN	O	O
on	NN	O	O
sexually	NN	O	O
mature	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

Serum	NN	O	O
concentrations	NN	O	O
of	NN	O	O
prolactin	NN	O	O
(	NN	O	O
PRL	NN	O	B-Chemical
)	NN	O	O
and	NN	O	O
testosterone	NN	O	B-Chemical
(	NN	O	O
T	NN	O	B-Chemical
)	NN	O	O
were	NN	O	O
measured	NN	O	O
.	NN	O	O

Tissue	NN	O	O
sections	NN	O	O
were	NN	O	O
evaluated	NN	O	O
with	NN	O	O
light	NN	O	O
and	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
.	NN	O	O

Immunohistochemical	NN	O	O
reactions	NN	O	O
for	NN	O	O
Anti	NN	O	O
-	NN	O	O
Proliferating	NN	O	O
Cell	NN	O	O
Nuclear	NN	O	O
Antigen	NN	O	O
(	NN	O	O
PCNA	NN	O	O
)	NN	O	O
were	NN	O	O
performed	NN	O	O
.	NN	O	O

In	NN	O	O
rats	NN	O	O
of	NN	O	O
the	NN	O	O
experimental	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
mean	NN	O	O
concentration	NN	O	O
of	NN	O	O
:	NN	O	O
PRL	NN	O	B-Chemical
was	NN	O	O
more	NN	O	O
than	NN	O	O
twice	NN	O	O
higher	NN	O	O
,	NN	O	O
whereas	NN	O	O
T	NN	O	B-Chemical
concentration	NN	O	O
was	NN	O	O
almost	NN	O	O
twice	NN	O	O
lower	NN	O	O
than	NN	O	O
that	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
.	NN	O	O

Light	NN	O	O
microscopy	NN	O	O
visualized	NN	O	O
the	NN	O	O
following	NN	O	O
:	NN	O	O
hypertrophy	NN	O	B-Disease
and	NN	O	O
epithelium	NN	O	O
hyperplasia	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
glandular	NN	O	O
ducts	NN	O	O
,	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
PCNA	NN	O	O
expression	NN	O	O
.	NN	O	O

Electron	NN	O	O
microscopy	NN	O	O
revealed	NN	O	O
changes	NN	O	O
in	NN	O	O
columnar	NN	O	O
epithelial	NN	O	O
cells	NN	O	O
,	NN	O	O
concerning	NN	O	O
organelles	NN	O	O
,	NN	O	O
engaged	NN	O	O
in	NN	O	O
protein	NN	O	O
synthesis	NN	O	O
and	NN	O	O
secretion	NN	O	O
.	NN	O	O


-DOCSTART- (15531665)

Does	NN	O	O
supplemental	NN	O	O
vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
increase	NN	O	O
cardiovascular	NN	O	B-Disease
disease	NN	O	I-Disease
risk	NN	O	O
in	NN	O	O
women	NN	O	O
with	NN	O	O
diabetes	NN	O	B-Disease
?	NN	O	O
BACKGROUND	NN	O	O
:	NN	O	O
Vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
acts	NN	O	O
as	NN	O	O
a	NN	O	O
potent	NN	O	O
antioxidant	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
it	NN	O	O
can	NN	O	O
also	NN	O	O
be	NN	O	O
a	NN	O	O
prooxidant	NN	O	O
and	NN	O	O
glycate	NN	O	O
protein	NN	O	O
under	NN	O	O
certain	NN	O	O
circumstances	NN	O	O
in	NN	O	O
vitro	NN	O	O
.	NN	O	O

These	NN	O	O
observations	NN	O	O
led	NN	O	O
us	NN	O	O
to	NN	O	O
hypothesize	NN	O	O
that	NN	O	O
a	NN	O	O
high	NN	O	O
intake	NN	O	O
of	NN	O	O
vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
in	NN	O	O
diabetic	NN	O	B-Disease
persons	NN	O	O
might	NN	O	O
promote	NN	O	O
atherosclerosis	NN	O	B-Disease
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
objective	NN	O	O
was	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
relation	NN	O	O
between	NN	O	O
vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
intake	NN	O	O
and	NN	O	O
mortality	NN	O	O
from	NN	O	O
cardiovascular	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
We	NN	O	O
studied	NN	O	O
the	NN	O	O
relation	NN	O	O
between	NN	O	O
vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
intake	NN	O	O
and	NN	O	O
mortality	NN	O	O
from	NN	O	O
total	NN	O	O
cardiovascular	NN	O	B-Disease
disease	NN	O	I-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
281	NN	O	O
)	NN	O	O
,	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
175	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
stroke	NN	O	B-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
57	NN	O	O
)	NN	O	O
in	NN	O	O
1923	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
who	NN	O	O
reported	NN	O	O
being	NN	O	O
diabetic	NN	O	B-Disease
at	NN	O	O
baseline	NN	O	O
.	NN	O	O

Diet	NN	O	O
was	NN	O	O
assessed	NN	O	O
with	NN	O	O
a	NN	O	O
food	NN	O	O
-	NN	O	O
frequency	NN	O	O
questionnaire	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
and	NN	O	O
subjects	NN	O	O
initially	NN	O	O
free	NN	O	O
of	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
were	NN	O	O
prospectively	NN	O	O
followed	NN	O	O
for	NN	O	O
15	NN	O	O
y	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
After	NN	O	O
adjustment	NN	O	O
for	NN	O	O
cardiovascular	NN	O	B-Disease
disease	NN	O	I-Disease
risk	NN	O	O
factors	NN	O	O
,	NN	O	O
type	NN	O	O
of	NN	O	O
diabetes	NN	O	B-Disease
medication	NN	O	O
used	NN	O	O
,	NN	O	O
duration	NN	O	O
of	NN	O	O
diabetes	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
intakes	NN	O	O
of	NN	O	O
folate	NN	O	B-Chemical
,	NN	O	O
vitamin	NN	O	B-Chemical
E	NN	O	I-Chemical
,	NN	O	O
and	NN	O	O
beta	NN	O	B-Chemical
-	NN	O	I-Chemical
carotene	NN	O	I-Chemical
,	NN	O	O
the	NN	O	O
adjusted	NN	O	O
relative	NN	O	O
risks	NN	O	O
of	NN	O	O
total	NN	O	O
cardiovascular	NN	O	B-Disease
disease	NN	O	I-Disease
mortality	NN	O	O
were	NN	O	O
1.0	NN	O	O
,	NN	O	O
0.97	NN	O	O
,	NN	O	O
1.11	NN	O	O
,	NN	O	O
1.47	NN	O	O
,	NN	O	O
and	NN	O	O
1.84	NN	O	O
(	NN	O	O
P	NN	O	O
for	NN	O	O
trend	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
across	NN	O	O
quintiles	NN	O	O
of	NN	O	O
total	NN	O	O
vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
intake	NN	O	O
from	NN	O	O
food	NN	O	O
and	NN	O	O
supplements	NN	O	O
.	NN	O	O

Adjusted	NN	O	O
relative	NN	O	O
risks	NN	O	O
of	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
were	NN	O	O
1.0	NN	O	O
,	NN	O	O
0.81	NN	O	O
,	NN	O	O
0.99	NN	O	O
,	NN	O	O
1.26	NN	O	O
,	NN	O	O
and	NN	O	O
1.91	NN	O	O
(	NN	O	O
P	NN	O	O
for	NN	O	O
trend	NN	O	O
=	NN	O	O
0.01	NN	O	O
)	NN	O	O
and	NN	O	O
of	NN	O	O
stroke	NN	O	B-Disease
were	NN	O	O
1.0	NN	O	O
,	NN	O	O
0.52	NN	O	O
,	NN	O	O
1.23	NN	O	O
,	NN	O	O
2.22	NN	O	O
,	NN	O	O
and	NN	O	O
2.57	NN	O	O
(	NN	O	O
P	NN	O	O
for	NN	O	O
trend	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

When	NN	O	O
dietary	NN	O	O
and	NN	O	O
supplemental	NN	O	O
vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
were	NN	O	O
analyzed	NN	O	O
separately	NN	O	O
,	NN	O	O
only	NN	O	O
supplemental	NN	O	O
vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
showed	NN	O	O
a	NN	O	O
positive	NN	O	O
association	NN	O	O
with	NN	O	O
mortality	NN	O	O
endpoints	NN	O	O
.	NN	O	O

Vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
intake	NN	O	O
was	NN	O	O
unrelated	NN	O	O
to	NN	O	O
mortality	NN	O	O
from	NN	O	O
cardiovascular	NN	O	B-Disease
disease	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
nondiabetic	NN	O	O
subjects	NN	O	O
at	NN	O	O
baseline	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
A	NN	O	O
high	NN	O	O
vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
intake	NN	O	O
from	NN	O	O
supplements	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
cardiovascular	NN	O	B-Disease
disease	NN	O	I-Disease
mortality	NN	O	O
in	NN	O	O
postmenopausal	NN	O	O
women	NN	O	O
with	NN	O	O
diabetes	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (12851669)

Absolute	NN	O	O
and	NN	O	O
attributable	NN	O	O
risk	NN	O	O
of	NN	O	O
venous	NN	O	B-Disease
thromboembolism	NN	O	I-Disease
in	NN	O	O
women	NN	O	O
on	NN	O	O
combined	NN	O	O
cyproterone	NN	O	B-Chemical
acetate	NN	O	I-Chemical
and	NN	O	O
ethinylestradiol	NN	O	B-Chemical
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
achieve	NN	O	O
absolute	NN	O	O
risk	NN	O	O
estimates	NN	O	O
of	NN	O	O
venous	NN	O	B-Disease
thromboembolism	NN	O	I-Disease
(	NN	O	O
VTE	NN	O	B-Disease
)	NN	O	O
among	NN	O	O
women	NN	O	O
on	NN	O	O
cyproterone	NN	O	B-Chemical
acetate	NN	O	I-Chemical
plus	NN	O	O
ethinylestradiol	NN	O	B-Chemical
(	NN	O	O
CPA	NN	O	B-Chemical
/	NN	O	O
EE	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
and	NN	O	O
among	NN	O	O
women	NN	O	O
on	NN	O	O
combined	NN	O	B-Chemical
oral	NN	O	I-Chemical
contraceptives	NN	O	I-Chemical
(	NN	O	O
COCs	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
From	NN	O	O
the	NN	O	O
Danish	NN	O	O
National	NN	O	O
Register	NN	O	O
of	NN	O	O
Patients	NN	O	O
(	NN	O	O
NRP	NN	O	O
)	NN	O	O
,	NN	O	O
1996	NN	O	O
to	NN	O	O
1998	NN	O	O
,	NN	O	O
the	NN	O	O
records	NN	O	O
of	NN	O	O
1.1	NN	O	O
million	NN	O	O
Danish	NN	O	O
women	NN	O	O
,	NN	O	O
ages	NN	O	O
15	NN	O	O
to	NN	O	O
44	NN	O	O
years	NN	O	O
,	NN	O	O
were	NN	O	O
searched	NN	O	O
for	NN	O	O
evidence	NN	O	O
of	NN	O	O
VTE	NN	O	B-Disease
.	NN	O	O

COC	NN	O	B-Chemical
use	NN	O	O
was	NN	O	O
ascertained	NN	O	O
through	NN	O	O
mailed	NN	O	O
questionnaires	NN	O	O
.	NN	O	O

Sales	NN	O	O
statistics	NN	O	O
of	NN	O	O
COCs	NN	O	B-Chemical
and	NN	O	O
CPA	NN	O	B-Chemical
/	NN	O	O
EE	NN	O	B-Chemical
were	NN	O	O
provided	NN	O	O
through	NN	O	O
Danish	NN	O	O
Drug	NN	O	O
Statistics	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
During	NN	O	O
the	NN	O	O
time	NN	O	O
frame	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
,	NN	O	O
330	NN	O	O
women	NN	O	O
were	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
had	NN	O	O
VTE	NN	O	B-Disease
while	NN	O	O
on	NN	O	O
COCs	NN	O	B-Chemical
.	NN	O	O

Of	NN	O	O
these	NN	O	O
women	NN	O	O
,	NN	O	O
67	NN	O	O
were	NN	O	O
on	NN	O	O
levonorgestrel	NN	O	B-Chemical
-	NN	O	O
containing	NN	O	O
COCs	NN	O	B-Chemical
.	NN	O	O

Eleven	NN	O	O
were	NN	O	O
on	NN	O	O
CPA	NN	O	B-Chemical
/	NN	O	O
EE	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
corresponding	NN	O	O
absolute	NN	O	O
risk	NN	O	O
of	NN	O	O
VTE	NN	O	B-Disease
was	NN	O	O
3.4	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
3.1	NN	O	O
-	NN	O	O
3.8	NN	O	O
)	NN	O	O
per	NN	O	O
10	NN	O	O
000	NN	O	O
women	NN	O	O
years	NN	O	O
among	NN	O	O
the	NN	O	O
women	NN	O	O
on	NN	O	O
COCs	NN	O	B-Chemical
,	NN	O	O
4.2	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
3.2	NN	O	O
-	NN	O	O
5.2	NN	O	O
)	NN	O	O
per	NN	O	O
10	NN	O	O
000	NN	O	O
women	NN	O	O
years	NN	O	O
among	NN	O	O
women	NN	O	O
on	NN	O	O
levonorgestrel	NN	O	B-Chemical
-	NN	O	O
containing	NN	O	O
COCs	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
3.1	NN	O	O
(	NN	O	O
range	NN	O	O
,	NN	O	O
1.3	NN	O	O
-	NN	O	O
4.9	NN	O	O
)	NN	O	O
per	NN	O	O
10	NN	O	O
000	NN	O	O
women	NN	O	O
years	NN	O	O
among	NN	O	O
the	NN	O	O
women	NN	O	O
on	NN	O	O
CPA	NN	O	B-Chemical
/	NN	O	O
EE	NN	O	B-Chemical
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
the	NN	O	O
absolute	NN	O	O
risk	NN	O	O
of	NN	O	O
VTE	NN	O	B-Disease
among	NN	O	O
Danish	NN	O	O
women	NN	O	O
on	NN	O	O
COCs	NN	O	B-Chemical
is	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
among	NN	O	O
women	NN	O	O
taking	NN	O	O
CPA	NN	O	B-Chemical
/	NN	O	O
EE	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (12842176)

Effect	NN	O	O
of	NN	O	O
lindane	NN	O	B-Chemical
on	NN	O	O
hepatic	NN	O	O
and	NN	O	O
brain	NN	O	O
cytochrome	NN	O	O
P450s	NN	O	O
and	NN	O	O
influence	NN	O	O
of	NN	O	O
P450	NN	O	O
modulation	NN	O	O
in	NN	O	O
lindane	NN	O	B-Chemical
induced	NN	O	O
neurotoxicity	NN	O	B-Disease
.	NN	O	O

Oral	NN	O	O
administration	NN	O	O
of	NN	O	O
lindane	NN	O	B-Chemical
(	NN	O	O
2.5	NN	O	O
,	NN	O	O
5	NN	O	O
,	NN	O	O
10	NN	O	O
and	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
body	NN	O	O
weight	NN	O	O
)	NN	O	O
for	NN	O	O
5	NN	O	O
days	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
produce	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
P450	NN	O	O
dependent	NN	O	O
7	NN	O	O
-	NN	O	O
ethoxyresorufin	NN	O	O
-	NN	O	O
O	NN	O	O
-	NN	O	O
deethylase	NN	O	O
(	NN	O	O
EROD	NN	O	O
)	NN	O	O
,	NN	O	O
7	NN	O	O
-	NN	O	O
pentoxyresorufin	NN	O	O
-	NN	O	O
O	NN	O	O
-	NN	O	O
dealkylase	NN	O	O
(	NN	O	O
PROD	NN	O	O
)	NN	O	O
and	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
nitrosodimethylamine	NN	O	I-Chemical
demethylase	NN	O	O
(	NN	O	O
NDMA	NN	O	B-Chemical
-	NN	O	O
d	NN	O	O
)	NN	O	O
in	NN	O	O
rat	NN	O	O
brain	NN	O	O
and	NN	O	O
liver	NN	O	O
.	NN	O	O

A	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
hepatic	NN	O	O
and	NN	O	O
brain	NN	O	O
P450	NN	O	O
monooxygenases	NN	O	O
was	NN	O	O
also	NN	O	O
observed	NN	O	O
when	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
exposure	NN	O	O
of	NN	O	O
low	NN	O	O
dose	NN	O	O
(	NN	O	O
2.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
of	NN	O	O
lindane	NN	O	B-Chemical
was	NN	O	O
increased	NN	O	O
from	NN	O	O
5	NN	O	O
days	NN	O	O
to	NN	O	O
15	NN	O	O
or	NN	O	O
21	NN	O	O
days	NN	O	O
.	NN	O	O

As	NN	O	O
observed	NN	O	O
with	NN	O	O
different	NN	O	O
doses	NN	O	O
,	NN	O	O
the	NN	O	O
magnitude	NN	O	O
of	NN	O	O
induction	NN	O	O
in	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
P450	NN	O	O
monooxygenases	NN	O	O
was	NN	O	O
several	NN	O	O
fold	NN	O	O
higher	NN	O	O
in	NN	O	O
liver	NN	O	O
microsomes	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
brain	NN	O	O
.	NN	O	O

Western	NN	O	O
blotting	NN	O	O
studies	NN	O	O
have	NN	O	O
indicated	NN	O	O
that	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
P450	NN	O	O
enzymes	NN	O	O
could	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
expression	NN	O	O
of	NN	O	O
P450	NN	O	O
1A1	NN	O	O
/	NN	O	O
1A2	NN	O	O
,	NN	O	O
2B1	NN	O	O
/	NN	O	O
2B2	NN	O	O
and	NN	O	O
2E1	NN	O	O
isoenzymes	NN	O	O
.	NN	O	O

In	NN	O	O
vitro	NN	O	O
studies	NN	O	O
using	NN	O	O
organic	NN	O	O
inhibitors	NN	O	O
specific	NN	O	O
for	NN	O	O
individual	NN	O	O
P450	NN	O	O
isoenzymes	NN	O	O
and	NN	O	O
antibody	NN	O	O
inhibition	NN	O	O
experiments	NN	O	O
have	NN	O	O
further	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
PROD	NN	O	O
,	NN	O	O
EROD	NN	O	O
and	NN	O	O
NDMA	NN	O	B-Chemical
-	NN	O	O
d	NN	O	O
are	NN	O	O
due	NN	O	O
to	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
levels	NN	O	O
of	NN	O	O
P450	NN	O	O
2B1	NN	O	O
/	NN	O	O
2B2	NN	O	O
,	NN	O	O
1A1	NN	O	O
/	NN	O	O
1A2	NN	O	O
and	NN	O	O
2E1	NN	O	O
isoenzymes	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Induction	NN	O	O
studies	NN	O	O
have	NN	O	O
further	NN	O	O
shown	NN	O	O
that	NN	O	O
while	NN	O	O
pretreatment	NN	O	O
of	NN	O	O
3	NN	O	B-Chemical
-	NN	O	I-Chemical
methylcholanthrene	NN	O	I-Chemical
(	NN	O	O
MC	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
an	NN	O	O
inducer	NN	O	O
of	NN	O	O
P4501A1	NN	O	O
/	NN	O	O
1A2	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
produce	NN	O	O
any	NN	O	O
significant	NN	O	O
effect	NN	O	O
in	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
lindane	NN	O	B-Chemical
induced	NN	O	O
convulsions	NN	O	B-Disease
,	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
phenobarbital	NN	O	B-Chemical
(	NN	O	O
PB	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
inducer	NN	O	O
of	NN	O	O
P450	NN	O	O
2B1	NN	O	O
/	NN	O	O
2B2	NN	O	O
or	NN	O	O
ethanol	NN	O	B-Chemical
,	NN	O	O
an	NN	O	O
inducer	NN	O	O
of	NN	O	O
P450	NN	O	O
2E1	NN	O	O
catalysed	NN	O	O
reactions	NN	O	O
,	NN	O	O
significantly	NN	O	O
increased	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
lindane	NN	O	B-Chemical
induced	NN	O	O
convulsions	NN	O	B-Disease
.	NN	O	O

Similarly	NN	O	O
,	NN	O	O
when	NN	O	O
the	NN	O	O
P450	NN	O	O
-	NN	O	O
mediated	NN	O	O
metabolism	NN	O	O
of	NN	O	O
lindane	NN	O	B-Chemical
was	NN	O	O
blocked	NN	O	O
by	NN	O	O
cobalt	NN	O	B-Chemical
chloride	NN	O	I-Chemical
incidence	NN	O	O
of	NN	O	O
convulsions	NN	O	B-Disease
was	NN	O	O
increased	NN	O	O
in	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
lindane	NN	O	B-Chemical
indicating	NN	O	O
that	NN	O	O
lindane	NN	O	B-Chemical
per	NN	O	O
se	NN	O	O
or	NN	O	O
its	NN	O	O
metabolites	NN	O	O
formed	NN	O	O
by	NN	O	O
PB	NN	O	O
or	NN	O	O
ethanol	NN	O	B-Chemical
inducible	NN	O	O
P450	NN	O	O
isoenzymes	NN	O	O
are	NN	O	O
involved	NN	O	O
in	NN	O	O
its	NN	O	O
neurobehavioral	NN	O	O
toxicity	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (12745515)

Seizure	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
sleep	NN	O	B-Disease
deprivation	NN	O	I-Disease
and	NN	O	O
sustained	NN	O	O
-	NN	O	O
release	NN	O	O
bupropion	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
case	NN	O	O
report	NN	O	O
describes	NN	O	O
a	NN	O	O
generalized	NN	O	O
seizure	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
sustained	NN	O	O
-	NN	O	O
release	NN	O	O
bupropion	NN	O	B-Chemical
use	NN	O	O
and	NN	O	O
sleep	NN	O	B-Disease
deprivation	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
subject	NN	O	O
,	NN	O	O
a	NN	O	O
31	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
female	NN	O	O
smoker	NN	O	O
,	NN	O	O
was	NN	O	O
participating	NN	O	O
in	NN	O	O
a	NN	O	O
clinical	NN	O	O
trial	NN	O	O
evaluating	NN	O	O
an	NN	O	O
investigational	NN	O	O
medication	NN	O	O
for	NN	O	O
smoking	NN	O	O
cessation	NN	O	O
that	NN	O	O
used	NN	O	O
sustained	NN	O	O
-	NN	O	O
release	NN	O	O
bupropion	NN	O	B-Chemical
as	NN	O	O
an	NN	O	O
active	NN	O	O
control	NN	O	O
.	NN	O	O

After	NN	O	O
5	NN	O	O
weeks	NN	O	O
of	NN	O	O
bupropion	NN	O	B-Chemical
use	NN	O	O
,	NN	O	O
the	NN	O	O
subject	NN	O	O
experienced	NN	O	O
a	NN	O	O
generalized	NN	O	O
tonic	NN	O	O
clonic	NN	O	O
seizure	NN	O	B-Disease
after	NN	O	O
staying	NN	O	O
up	NN	O	O
nearly	NN	O	O
all	NN	O	O
night	NN	O	O
packing	NN	O	O
and	NN	O	O
moving	NN	O	O
to	NN	O	O
a	NN	O	O
new	NN	O	O
residence	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
had	NN	O	O
no	NN	O	O
other	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
sleep	NN	O	B-Disease
deprivation	NN	O	I-Disease
may	NN	O	O
add	NN	O	O
to	NN	O	O
the	NN	O	O
risk	NN	O	O
of	NN	O	O
bupropion	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (12571256)

Nephrotoxic	NN	O	B-Disease
effects	NN	O	O
in	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
angiography	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
The	NN	O	O
use	NN	O	O
of	NN	O	O
iodinated	NN	O	O
contrast	NN	O	O
medium	NN	O	O
can	NN	O	O
result	NN	O	O
in	NN	O	O
nephropathy	NN	O	B-Disease
.	NN	O	O

Whether	NN	O	O
iso	NN	O	O
-	NN	O	O
osmolar	NN	O	O
contrast	NN	O	O
medium	NN	O	O
is	NN	O	O
less	NN	O	O
nephrotoxic	NN	O	B-Disease
than	NN	O	O
low	NN	O	O
-	NN	O	O
osmolar	NN	O	O
contrast	NN	O	O
medium	NN	O	O
in	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
patients	NN	O	O
is	NN	O	O
uncertain	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
conducted	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
prospective	NN	O	O
,	NN	O	O
multicenter	NN	O	O
study	NN	O	O
comparing	NN	O	O
the	NN	O	O
nephrotoxic	NN	O	B-Disease
effects	NN	O	O
of	NN	O	O
an	NN	O	O
iso	NN	O	O
-	NN	O	O
osmolar	NN	O	O
,	NN	O	O
dimeric	NN	O	O
,	NN	O	O
nonionic	NN	O	O
contrast	NN	O	O
medium	NN	O	O
,	NN	O	O
iodixanol	NN	O	B-Chemical
,	NN	O	O
with	NN	O	O
those	NN	O	O
of	NN	O	O
a	NN	O	O
low	NN	O	O
-	NN	O	O
osmolar	NN	O	O
,	NN	O	O
nonionic	NN	O	O
,	NN	O	O
monomeric	NN	O	O
contrast	NN	O	O
medium	NN	O	O
,	NN	O	O
iohexol	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
study	NN	O	O
involved	NN	O	O
129	NN	O	O
patients	NN	O	O
with	NN	O	O
diabetes	NN	O	B-Disease
with	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
concentrations	NN	O	O
of	NN	O	O
1.5	NN	O	O
to	NN	O	O
3.5	NN	O	O
mg	NN	O	O
per	NN	O	O
deciliter	NN	O	O
who	NN	O	O
underwent	NN	O	O
coronary	NN	O	O
or	NN	O	O
aortofemoral	NN	O	O
angiography	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
end	NN	O	O
point	NN	O	O
was	NN	O	O
the	NN	O	O
peak	NN	O	O
increase	NN	O	O
from	NN	O	O
base	NN	O	O
line	NN	O	O
in	NN	O	O
the	NN	O	O
creatinine	NN	O	B-Chemical
concentration	NN	O	O
during	NN	O	O
the	NN	O	O
three	NN	O	O
days	NN	O	O
after	NN	O	O
angiography	NN	O	O
.	NN	O	O

Other	NN	O	O
end	NN	O	O
points	NN	O	O
were	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
creatinine	NN	O	B-Chemical
concentration	NN	O	O
of	NN	O	O
0.5	NN	O	O
mg	NN	O	O
per	NN	O	O
deciliter	NN	O	O
or	NN	O	O
more	NN	O	O
,	NN	O	O
an	NN	O	O
increase	NN	O	O
of	NN	O	O
1.0	NN	O	O
mg	NN	O	O
per	NN	O	O
deciliter	NN	O	O
or	NN	O	O
more	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
change	NN	O	O
in	NN	O	O
the	NN	O	O
creatinine	NN	O	B-Chemical
concentration	NN	O	O
from	NN	O	O
day	NN	O	O
0	NN	O	O
to	NN	O	O
day	NN	O	O
7	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
creatinine	NN	O	B-Chemical
concentration	NN	O	O
increased	NN	O	O
significantly	NN	O	O
less	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
received	NN	O	O
iodixanol	NN	O	B-Chemical
.	NN	O	O

From	NN	O	O
day	NN	O	O
0	NN	O	O
to	NN	O	O
day	NN	O	O
3	NN	O	O
,	NN	O	O
the	NN	O	O
mean	NN	O	O
peak	NN	O	O
increase	NN	O	O
in	NN	O	O
creatinine	NN	O	B-Chemical
was	NN	O	O
0.13	NN	O	O
mg	NN	O	O
per	NN	O	O
deciliter	NN	O	O
in	NN	O	O
the	NN	O	O
iodixanol	NN	O	B-Chemical
group	NN	O	O
and	NN	O	O
0.55	NN	O	O
mg	NN	O	O
per	NN	O	O
deciliter	NN	O	O
in	NN	O	O
the	NN	O	O
iohexol	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
P=0.001	NN	O	O
;	NN	O	O
the	NN	O	O
increase	NN	O	O
with	NN	O	O
iodixanol	NN	O	B-Chemical
minus	NN	O	O
the	NN	O	O
increase	NN	O	O
with	NN	O	O
iohexol	NN	O	B-Chemical
,	NN	O	O
-	NN	O	O
0.42	NN	O	O
mg	NN	O	O
per	NN	O	O
deciliter	NN	O	O
[	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
-	NN	O	O
0.73	NN	O	O
to	NN	O	O
-	NN	O	O
0.22	NN	O	O
]	NN	O	O
)	NN	O	O
.	NN	O	O

Two	NN	O	O
of	NN	O	O
the	NN	O	O
64	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
iodixanol	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
3	NN	O	O
percent	NN	O	O
)	NN	O	O
had	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
creatinine	NN	O	B-Chemical
concentration	NN	O	O
of	NN	O	O
0.5	NN	O	O
mg	NN	O	O
per	NN	O	O
deciliter	NN	O	O
or	NN	O	O
more	NN	O	O
,	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
17	NN	O	O
of	NN	O	O
the	NN	O	O
65	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
iohexol	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
26	NN	O	O
percent	NN	O	O
)	NN	O	O
(	NN	O	O
P=0.002	NN	O	O
;	NN	O	O
odds	NN	O	O
ratio	NN	O	O
for	NN	O	O
such	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
iodixanol	NN	O	B-Chemical
group	NN	O	O
,	NN	O	O
0.09	NN	O	O
[	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
0.02	NN	O	O
to	NN	O	O
0.41	NN	O	O
]	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
patient	NN	O	O
receiving	NN	O	O
iodixanol	NN	O	B-Chemical
had	NN	O	O
an	NN	O	O
increase	NN	O	O
of	NN	O	O
1.0	NN	O	O
mg	NN	O	O
per	NN	O	O
deciliter	NN	O	O
or	NN	O	O
more	NN	O	O
,	NN	O	O
but	NN	O	O
10	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
iohexol	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
15	NN	O	O
percent	NN	O	O
)	NN	O	O
did	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
change	NN	O	O
in	NN	O	O
the	NN	O	O
creatinine	NN	O	B-Chemical
concentration	NN	O	O
from	NN	O	O
day	NN	O	O
0	NN	O	O
to	NN	O	O
day	NN	O	O
7	NN	O	O
was	NN	O	O
0.07	NN	O	O
mg	NN	O	O
per	NN	O	O
deciliter	NN	O	O
in	NN	O	O
the	NN	O	O
iodixanol	NN	O	B-Chemical
group	NN	O	O
and	NN	O	O
0.24	NN	O	O
mg	NN	O	O
per	NN	O	O
deciliter	NN	O	O
in	NN	O	O
the	NN	O	O
iohexol	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
P=0.003	NN	O	O
;	NN	O	O
value	NN	O	O
in	NN	O	O
the	NN	O	O
iodixanol	NN	O	B-Chemical
group	NN	O	O
minus	NN	O	O
the	NN	O	O
value	NN	O	O
in	NN	O	O
the	NN	O	O
iohexol	NN	O	B-Chemical
group	NN	O	O
,	NN	O	O
-	NN	O	O
0.17	NN	O	O
mg	NN	O	O
per	NN	O	O
deciliter	NN	O	O
[	NN	O	O
95	NN	O	O
percent	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
-	NN	O	O
0.34	NN	O	O
to	NN	O	O
-	NN	O	O
0.07	NN	O	O
]	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Nephropathy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
contrast	NN	O	O
medium	NN	O	O
may	NN	O	O
be	NN	O	O
less	NN	O	O
likely	NN	O	O
to	NN	O	O
develop	NN	O	O
in	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
patients	NN	O	O
when	NN	O	O
iodixanol	NN	O	B-Chemical
is	NN	O	O
used	NN	O	O
rather	NN	O	O
than	NN	O	O
a	NN	O	O
low	NN	O	O
-	NN	O	O
osmolar	NN	O	O
,	NN	O	O
nonionic	NN	O	O
contrast	NN	O	O
medium	NN	O	O
.	NN	O	O


-DOCSTART- (9514561)

Experimental	NN	O	O
cranial	NN	O	O
pain	NN	O	B-Disease
elicited	NN	O	O
by	NN	O	O
capsaicin	NN	O	B-Chemical
:	NN	O	O
a	NN	O	O
PET	NN	O	O
study	NN	O	O
.	NN	O	O

Using	NN	O	O
a	NN	O	O
positron	NN	O	O
emission	NN	O	O
tomography	NN	O	O
(	NN	O	O
PET	NN	O	O
)	NN	O	O
study	NN	O	O
it	NN	O	O
was	NN	O	O
shown	NN	O	O
recently	NN	O	O
that	NN	O	O
in	NN	O	O
migraine	NN	O	B-Disease
without	NN	O	O
aura	NN	O	O
certain	NN	O	O
areas	NN	O	O
in	NN	O	O
the	NN	O	O
brain	NN	O	O
stem	NN	O	O
were	NN	O	O
activated	NN	O	O
during	NN	O	O
the	NN	O	O
headache	NN	O	B-Disease
state	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
the	NN	O	O
headache	NN	O	B-Disease
free	NN	O	O
interval	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
suggested	NN	O	O
that	NN	O	O
this	NN	O	O
brain	NN	O	O
stem	NN	O	O
activation	NN	O	O
is	NN	O	O
inherent	NN	O	O
to	NN	O	O
the	NN	O	O
migraine	NN	O	B-Disease
attack	NN	O	O
itself	NN	O	O
and	NN	O	O
represents	NN	O	O
the	NN	O	O
so	NN	O	O
called	NN	O	O
'	NN	O	O
migraine	NN	O	B-Disease
generator	NN	O	O
'	NN	O	O
.	NN	O	O

To	NN	O	O
test	NN	O	O
this	NN	O	O
hypothesis	NN	O	O
we	NN	O	O
performed	NN	O	O
an	NN	O	O
experimental	NN	O	O
pain	NN	O	B-Disease
study	NN	O	O
in	NN	O	O
seven	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
,	NN	O	O
using	NN	O	O
the	NN	O	O
same	NN	O	O
positioning	NN	O	O
in	NN	O	O
the	NN	O	O
PET	NN	O	O
scanner	NN	O	O
as	NN	O	O
in	NN	O	O
the	NN	O	O
migraine	NN	O	B-Disease
patients	NN	O	O
.	NN	O	O

A	NN	O	O
small	NN	O	O
amount	NN	O	O
of	NN	O	O
capsaicin	NN	O	B-Chemical
was	NN	O	O
administered	NN	O	O
subcutaneously	NN	O	O
in	NN	O	O
the	NN	O	O
right	NN	O	O
forehead	NN	O	O
to	NN	O	O
evoke	NN	O	O
a	NN	O	O
burning	NN	O	O
painful	NN	O	B-Disease
sensation	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
division	NN	O	O
of	NN	O	O
the	NN	O	O
trigeminal	NN	O	O
nerve	NN	O	O
.	NN	O	O

Increases	NN	O	O
of	NN	O	O
regional	NN	O	O
cerebral	NN	O	O
blood	NN	O	O
flow	NN	O	O
(	NN	O	O
rCBF	NN	O	O
)	NN	O	O
were	NN	O	O
found	NN	O	O
bilaterally	NN	O	O
in	NN	O	O
the	NN	O	O
insula	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
anterior	NN	O	O
cingulate	NN	O	O
cortex	NN	O	O
,	NN	O	O
the	NN	O	O
cavernous	NN	O	O
sinus	NN	O	O
and	NN	O	O
the	NN	O	O
cerebellum	NN	O	O
.	NN	O	O

Using	NN	O	O
the	NN	O	O
same	NN	O	O
stereotactic	NN	O	O
space	NN	O	O
limits	NN	O	O
as	NN	O	O
in	NN	O	O
the	NN	O	O
above	NN	O	O
mentioned	NN	O	O
migraine	NN	O	B-Disease
study	NN	O	O
no	NN	O	O
brain	NN	O	O
stem	NN	O	O
activation	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
acute	NN	O	O
pain	NN	O	B-Disease
state	NN	O	O
compared	NN	O	O
to	NN	O	O
the	NN	O	O
pain	NN	O	B-Disease
free	NN	O	O
state	NN	O	O
.	NN	O	O

The	NN	O	O
increase	NN	O	O
of	NN	O	O
activation	NN	O	O
in	NN	O	O
the	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
cavernous	NN	O	O
sinus	NN	O	O
however	NN	O	O
,	NN	O	O
suggests	NN	O	O
that	NN	O	O
this	NN	O	O
structure	NN	O	O
is	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
involved	NN	O	O
in	NN	O	O
trigeminal	NN	O	O
transmitted	NN	O	O
pain	NN	O	B-Disease
as	NN	O	O
such	NN	O	O
,	NN	O	O
rather	NN	O	O
than	NN	O	O
in	NN	O	O
a	NN	O	O
specific	NN	O	O
type	NN	O	O
of	NN	O	O
headache	NN	O	B-Disease
as	NN	O	O
was	NN	O	O
suggested	NN	O	O
for	NN	O	O
cluster	NN	O	B-Disease
headache	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (9165568)

Neuroleptic	NN	O	B-Disease
malignant	NN	O	I-Disease
syndrome	NN	O	I-Disease
with	NN	O	O
risperidone	NN	O	B-Chemical
.	NN	O	O

Neuroleptic	NN	O	B-Disease
malignant	NN	O	I-Disease
syndrome	NN	O	I-Disease
is	NN	O	O
thought	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
dopamine	NN	O	B-Chemical
D2	NN	O	O
receptor	NN	O	O
blockade	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
of	NN	O	O
the	NN	O	O
basal	NN	O	O
ganglia	NN	O	O
.	NN	O	O

Risperidone	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
benzisoxazole	NN	O	B-Chemical
derivative	NN	O	O
antipsychotic	NN	O	O
,	NN	O	O
has	NN	O	O
high	NN	O	O
serotonin	NN	O	B-Chemical
5	NN	O	O
-	NN	O	O
HT2	NN	O	O
receptor	NN	O	O
blockade	NN	O	O
and	NN	O	O
dose	NN	O	O
-	NN	O	O
related	NN	O	O
D2	NN	O	O
receptor	NN	O	O
blockade	NN	O	O
.	NN	O	O

The	NN	O	O
high	NN	O	O
ratio	NN	O	O
is	NN	O	O
believed	NN	O	O
to	NN	O	O
impart	NN	O	O
the	NN	O	O
low	NN	O	O
frequency	NN	O	O
of	NN	O	O
extrapyramidal	NN	O	B-Disease
symptoms	NN	O	I-Disease
with	NN	O	O
risperidone	NN	O	B-Chemical
at	NN	O	O
low	NN	O	O
dosages	NN	O	O
.	NN	O	O

With	NN	O	O
this	NN	O	O
low	NN	O	O
frequency	NN	O	O
of	NN	O	O
extrapyramidal	NN	O	B-Disease
symptoms	NN	O	I-Disease
,	NN	O	O
it	NN	O	O
was	NN	O	O
thought	NN	O	O
the	NN	O	O
frequency	NN	O	O
of	NN	O	O
neuroleptic	NN	O	B-Disease
malignant	NN	O	I-Disease
syndrome	NN	O	I-Disease
might	NN	O	O
also	NN	O	O
be	NN	O	O
lowered	NN	O	O
.	NN	O	O

A	NN	O	O
73	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
developed	NN	O	O
neuroleptic	NN	O	B-Disease
malignant	NN	O	I-Disease
syndrome	NN	O	I-Disease
after	NN	O	O
monotherapy	NN	O	O
with	NN	O	O
risperidone	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
syndrome	NN	O	O
reversed	NN	O	O
after	NN	O	O
discontinuing	NN	O	O
risperidone	NN	O	B-Chemical
and	NN	O	O
starting	NN	O	O
treatment	NN	O	O
with	NN	O	O
dantrolene	NN	O	B-Chemical
and	NN	O	O
bromocriptine	NN	O	B-Chemical
.	NN	O	O

It	NN	O	O
appears	NN	O	O
that	NN	O	O
the	NN	O	O
protection	NN	O	O
from	NN	O	O
extrapyramidal	NN	O	O
side	NN	O	O
effects	NN	O	O
observed	NN	O	O
with	NN	O	O
risperidone	NN	O	B-Chemical
does	NN	O	O
not	NN	O	O
ensure	NN	O	O
protection	NN	O	O
from	NN	O	O
neuroleptic	NN	O	B-Disease
malignant	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (9154656)

Hepatic	NN	O	O
and	NN	O	O
extrahepatic	NN	O	O
angiotensinogen	NN	O	O
gene	NN	O	O
expression	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
acute	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Plasma	NN	O	O
concentration	NN	O	O
and	NN	O	O
urine	NN	O	O
excretion	NN	O	O
of	NN	O	O
the	NN	O	O
renin	NN	O	O
-	NN	O	O
angiotensin	NN	O	B-Chemical
system	NN	O	O
proteins	NN	O	O
are	NN	O	O
altered	NN	O	O
in	NN	O	O
rats	NN	O	O
with	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
NS	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
work	NN	O	O
the	NN	O	O
messenger	NN	O	O
ribonucleic	NN	O	O
acid	NN	O	O
(	NN	O	O
mRNA	NN	O	O
)	NN	O	O
levels	NN	O	O
of	NN	O	O
angiotensinogen	NN	O	O
(	NN	O	O
Ao	NN	O	O
)	NN	O	O
were	NN	O	O
analyzed	NN	O	O
with	NN	O	O
the	NN	O	O
slot	NN	O	O
-	NN	O	O
blot	NN	O	O
hybridization	NN	O	O
technique	NN	O	O
in	NN	O	O
liver	NN	O	O
and	NN	O	O
other	NN	O	O
extrahepatic	NN	O	O
tissues	NN	O	O
:	NN	O	O
kidney	NN	O	O
,	NN	O	O
heart	NN	O	O
,	NN	O	O
brain	NN	O	O
,	NN	O	O
and	NN	O	O
adrenal	NN	O	O
gland	NN	O	O
from	NN	O	O
control	NN	O	O
,	NN	O	O
nephrotic	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
pair	NN	O	O
-	NN	O	O
fed	NN	O	O
(	NN	O	O
PF	NN	O	O
)	NN	O	O
rats	NN	O	O
.	NN	O	O

NS	NN	O	B-Disease
was	NN	O	O
induced	NN	O	O
by	NN	O	O
a	NN	O	O
single	NN	O	O
injection	NN	O	O
of	NN	O	O
puromycin	NN	O	B-Chemical
amino	NN	O	I-Chemical
-	NN	O	I-Chemical
nucleoside	NN	O	I-Chemical
(	NN	O	O
PAN	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

Although	NN	O	O
a	NN	O	O
great	NN	O	O
urinary	NN	O	O
excretion	NN	O	O
and	NN	O	O
half	NN	O	O
-	NN	O	O
normal	NN	O	O
plasma	NN	O	O
levels	NN	O	O
of	NN	O	O
Ao	NN	O	O
were	NN	O	O
observed	NN	O	O
on	NN	O	O
day	NN	O	O
6	NN	O	O
after	NN	O	O
PAN	NN	O	B-Chemical
injection	NN	O	O
,	NN	O	O
when	NN	O	O
NS	NN	O	B-Disease
was	NN	O	O
clearly	NN	O	O
established	NN	O	O
,	NN	O	O
hepatic	NN	O	O
Ao	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
the	NN	O	O
Ao	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
did	NN	O	O
not	NN	O	O
change	NN	O	O
in	NN	O	O
any	NN	O	O
of	NN	O	O
the	NN	O	O
extrahepatic	NN	O	O
tissues	NN	O	O
studied	NN	O	O
on	NN	O	O
day	NN	O	O
6	NN	O	O
,	NN	O	O
nor	NN	O	O
did	NN	O	O
its	NN	O	O
hepatic	NN	O	O
levels	NN	O	O
at	NN	O	O
days	NN	O	O
1	NN	O	O
,	NN	O	O
3	NN	O	O
,	NN	O	O
5	NN	O	O
,	NN	O	O
or	NN	O	O
7	NN	O	O
after	NN	O	O
PAN	NN	O	B-Chemical
injection	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
hepatic	NN	O	O
and	NN	O	O
extrahepatic	NN	O	O
Ao	NN	O	O
mRNA	NN	O	O
levels	NN	O	O
are	NN	O	O
unaltered	NN	O	O
during	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
the	NN	O	O
acute	NN	O	O
NS	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
PAN	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (8911359)

Cyclophosphamide	NN	O	B-Chemical
associated	NN	O	O
bladder	NN	O	B-Disease
cancer	NN	O	I-Disease
-	NN	O	O
-	NN	O	O
a	NN	O	O
highly	NN	O	O
aggressive	NN	O	O
disease	NN	O	O
:	NN	O	O
analysis	NN	O	O
of	NN	O	O
12	NN	O	O
cases	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
We	NN	O	O
gained	NN	O	O
knowledge	NN	O	O
of	NN	O	O
the	NN	O	O
etiology	NN	O	O
,	NN	O	O
treatment	NN	O	O
and	NN	O	O
prevention	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	B-Chemical
associated	NN	O	O
urothelial	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
medical	NN	O	O
records	NN	O	O
of	NN	O	O
6	NN	O	O
men	NN	O	O
and	NN	O	O
6	NN	O	O
women	NN	O	O
(	NN	O	O
mean	NN	O	O
age	NN	O	O
55	NN	O	O
years	NN	O	O
)	NN	O	O
with	NN	O	O
cyclophosphamide	NN	O	B-Chemical
associated	NN	O	O
bladder	NN	O	B-Disease
cancer	NN	O	I-Disease
were	NN	O	O
reviewed	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
All	NN	O	O
tumors	NN	O	B-Disease
were	NN	O	O
grade	NN	O	O
3	NN	O	O
or	NN	O	O
4	NN	O	O
transitional	NN	O	O
cell	NN	O	O
carcinoma	NN	O	B-Disease
.	NN	O	O

Of	NN	O	O
the	NN	O	O
5	NN	O	O
patients	NN	O	O
initially	NN	O	O
treated	NN	O	O
with	NN	O	O
endoscopic	NN	O	O
resection	NN	O	O
alone	NN	O	O
only	NN	O	O
1	NN	O	O
is	NN	O	O
alive	NN	O	O
without	NN	O	O
disease	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
6	NN	O	O
patients	NN	O	O
who	NN	O	O
underwent	NN	O	O
early	NN	O	O
cystectomy	NN	O	O
4	NN	O	O
were	NN	O	O
alive	NN	O	O
at	NN	O	O
24	NN	O	O
to	NN	O	O
111	NN	O	O
months	NN	O	O
.	NN	O	O

The	NN	O	O
remaining	NN	O	O
patient	NN	O	O
with	NN	O	O
extensive	NN	O	O
cancer	NN	O	B-Disease
underwent	NN	O	O
partial	NN	O	O
cystectomy	NN	O	O
for	NN	O	O
palliation	NN	O	O
and	NN	O	O
died	NN	O	O
3	NN	O	O
months	NN	O	O
later	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Cyclophosphamide	NN	O	B-Chemical
associated	NN	O	O
bladder	NN	O	B-Disease
tumor	NN	O	I-Disease
is	NN	O	O
an	NN	O	O
aggressive	NN	O	O
disease	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
survival	NN	O	O
is	NN	O	O
possible	NN	O	O
when	NN	O	O
radical	NN	O	O
cystectomy	NN	O	O
is	NN	O	O
performed	NN	O	O
for	NN	O	O
bladder	NN	O	B-Disease
tumors	NN	O	I-Disease
with	NN	O	O
any	NN	O	O
sign	NN	O	O
of	NN	O	O
invasion	NN	O	O
and	NN	O	O
for	NN	O	O
recurrent	NN	O	O
high	NN	O	O
grade	NN	O	O
disease	NN	O	O
,	NN	O	O
even	NN	O	O
when	NN	O	O
noninvasive	NN	O	O
.	NN	O	O


-DOCSTART- (8686832)

Leg	NN	O	B-Disease
and	NN	O	I-Disease
back	NN	O	I-Disease
pain	NN	O	I-Disease
after	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
involving	NN	O	O
hyperbaric	NN	O	O
5%	NN	O	O
lignocaine	NN	O	B-Chemical
.	NN	O	O

Fifty	NN	O	O
-	NN	O	O
four	NN	O	O
patients	NN	O	O
,	NN	O	O
aged	NN	O	O
27	NN	O	O
-	NN	O	O
90	NN	O	O
years	NN	O	O
,	NN	O	O
who	NN	O	O
were	NN	O	O
given	NN	O	O
lignocaine	NN	O	B-Chemical
5%	NN	O	O
in	NN	O	O
6.8%	NN	O	O
glucose	NN	O	B-Chemical
solution	NN	O	O
for	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
were	NN	O	O
studied	NN	O	O
.	NN	O	O

Thirteen	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
experienced	NN	O	O
pain	NN	O	B-Disease
in	NN	O	I-Disease
the	NN	O	I-Disease
legs	NN	O	I-Disease
and	NN	O	I-Disease
/	NN	O	I-Disease
or	NN	O	I-Disease
back	NN	O	I-Disease
after	NN	O	O
recovery	NN	O	O
from	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
affected	NN	O	O
were	NN	O	O
younger	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
site	NN	O	O
of	NN	O	O
the	NN	O	O
dural	NN	O	O
puncture	NN	O	O
was	NN	O	O
higher	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
than	NN	O	O
those	NN	O	O
individuals	NN	O	O
without	NN	O	O
pain	NN	O	B-Disease
.	NN	O	O

Five	NN	O	O
of	NN	O	O
the	NN	O	O
13	NN	O	O
patients	NN	O	O
(	NN	O	O
38%	NN	O	O
)	NN	O	O
with	NN	O	O
pain	NN	O	B-Disease
and	NN	O	O
seven	NN	O	O
of	NN	O	O
the	NN	O	O
41	NN	O	O
patients	NN	O	O
(	NN	O	O
17%	NN	O	O
)	NN	O	O
without	NN	O	O
pain	NN	O	B-Disease
admitted	NN	O	O
to	NN	O	O
a	NN	O	O
high	NN	O	O
alcohol	NN	O	B-Chemical
intake	NN	O	O
,	NN	O	O
which	NN	O	O
might	NN	O	O
be	NN	O	O
a	NN	O	O
contributing	NN	O	O
factor	NN	O	O
.	NN	O	O

Leg	NN	O	B-Disease
and	NN	O	I-Disease
/	NN	O	I-Disease
or	NN	O	I-Disease
back	NN	O	I-Disease
pain	NN	O	I-Disease
is	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
intrathecal	NN	O	O
use	NN	O	O
of	NN	O	O
hyperbaric	NN	O	O
5%	NN	O	O
lignocaine	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (8607407)

Acute	NN	O	O
blood	NN	O	O
pressure	NN	O	O
elevations	NN	O	O
with	NN	O	O
caffeine	NN	O	B-Chemical
in	NN	O	O
men	NN	O	O
with	NN	O	O
borderline	NN	O	O
systemic	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O

Whether	NN	O	O
the	NN	O	O
vasoconstrictive	NN	O	O
actions	NN	O	O
of	NN	O	O
caffeine	NN	O	B-Chemical
are	NN	O	O
enhanced	NN	O	O
in	NN	O	O
hypertensive	NN	O	B-Disease
persons	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
demonstrated	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
caffeine	NN	O	B-Chemical
(	NN	O	O
3.3	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
versus	NN	O	O
placebo	NN	O	O
was	NN	O	O
tested	NN	O	O
in	NN	O	O
48	NN	O	O
healthy	NN	O	O
men	NN	O	O
(	NN	O	O
aged	NN	O	O
20	NN	O	O
to	NN	O	O
35	NN	O	O
years	NN	O	O
)	NN	O	O
selected	NN	O	O
after	NN	O	O
screening	NN	O	O
on	NN	O	O
2	NN	O	O
separate	NN	O	O
occasions	NN	O	O
.	NN	O	O

Borderline	NN	O	O
hypertensive	NN	O	B-Disease
men	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
24	NN	O	O
)	NN	O	O
were	NN	O	O
selected	NN	O	O
with	NN	O	O
screening	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
BP	NN	O	O
)	NN	O	O
of	NN	O	O
140	NN	O	O
to	NN	O	O
160	NN	O	O
mm	NN	O	O
Hg	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
diastolic	NN	O	O
BP	NN	O	O
90	NN	O	O
to	NN	O	O
99	NN	O	O
mm	NN	O	O
Hg	NN	O	O
.	NN	O	O

Low	NN	O	O
-	NN	O	O
risk	NN	O	O
controls	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
24	NN	O	O
)	NN	O	O
reported	NN	O	O
no	NN	O	O
parental	NN	O	O
history	NN	O	O
of	NN	O	O
hypertension	NN	O	B-Disease
and	NN	O	O
had	NN	O	O
screening	NN	O	O
BP	NN	O	O
<	NN	O	O
130	NN	O	O
/	NN	O	O
85	NN	O	O
mm	NN	O	O
Hg	NN	O	O
.	NN	O	O

Participants	NN	O	O
were	NN	O	O
then	NN	O	O
tested	NN	O	O
on	NN	O	O
2	NN	O	O
occasions	NN	O	O
after	NN	O	O
12	NN	O	O
-	NN	O	O
hour	NN	O	O
abstinence	NN	O	O
from	NN	O	O
caffeine	NN	O	B-Chemical
in	NN	O	O
each	NN	O	O
of	NN	O	O
2	NN	O	O
protocols	NN	O	O
;	NN	O	O
this	NN	O	O
required	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
4	NN	O	O
laboratory	NN	O	O
visits	NN	O	O
.	NN	O	O

Caffeine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
changes	NN	O	O
in	NN	O	O
diastolic	NN	O	O
BP	NN	O	O
were	NN	O	O
2	NN	O	O
to	NN	O	O
3	NN	O	O
times	NN	O	O
larger	NN	O	O
in	NN	O	O
borderline	NN	O	O
subjects	NN	O	O
than	NN	O	O
in	NN	O	O
controls	NN	O	O
(	NN	O	O
+8.4	NN	O	O
vs	NN	O	O
+3.8	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.0001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
were	NN	O	O
attributable	NN	O	O
to	NN	O	O
larger	NN	O	O
changes	NN	O	O
in	NN	O	O
impedance	NN	O	O
-	NN	O	O
derived	NN	O	O
measures	NN	O	O
of	NN	O	O
systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
(	NN	O	O
+135	NN	O	O
vs	NN	O	O
+45	NN	O	O
dynes.s.cm	NN	O	O
-	NN	O	O
5	NN	O	O
,	NN	O	O
p	NN	O	O
<	NN	O	O
0.004	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
were	NN	O	O
consistent	NN	O	O
and	NN	O	O
reached	NN	O	O
significance	NN	O	O
in	NN	O	O
both	NN	O	O
protocols	NN	O	O
.	NN	O	O

The	NN	O	O
percentage	NN	O	O
of	NN	O	O
borderline	NN	O	O
subjects	NN	O	O
in	NN	O	O
whom	NN	O	O
diastolic	NN	O	O
BP	NN	O	O
changes	NN	O	O
exceeded	NN	O	O
the	NN	O	O
median	NN	O	O
control	NN	O	O
response	NN	O	O
was	NN	O	O
96%	NN	O	O
.	NN	O	O

Consequently	NN	O	O
,	NN	O	O
whereas	NN	O	O
all	NN	O	O
participants	NN	O	O
exhibited	NN	O	O
normotensive	NN	O	O
levels	NN	O	O
during	NN	O	O
the	NN	O	O
resting	NN	O	O
predrug	NN	O	O
baseline	NN	O	O
,	NN	O	O
33%	NN	O	O
of	NN	O	O
borderline	NN	O	O
subjects	NN	O	O
achieved	NN	O	O
hypertensive	NN	O	B-Disease
BP	NN	O	O
levels	NN	O	O
after	NN	O	O
caffeine	NN	O	B-Chemical
ingestion	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
in	NN	O	O
borderline	NN	O	O
hypertensive	NN	O	B-Disease
men	NN	O	O
,	NN	O	O
exaggerated	NN	O	O
responses	NN	O	O
to	NN	O	O
caffeine	NN	O	B-Chemical
were	NN	O	O
:	NN	O	O
selective	NN	O	O
for	NN	O	O
diastolic	NN	O	O
BP	NN	O	O
,	NN	O	O
consistent	NN	O	O
with	NN	O	O
greater	NN	O	O
vasoconstriction	NN	O	O
,	NN	O	O
replicated	NN	O	O
in	NN	O	O
2	NN	O	O
protocols	NN	O	O
,	NN	O	O
and	NN	O	O
representative	NN	O	O
of	NN	O	O
nearly	NN	O	O
all	NN	O	O
borderline	NN	O	O
hypertensives	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
suspect	NN	O	O
that	NN	O	O
the	NN	O	O
potential	NN	O	O
for	NN	O	O
caffeine	NN	O	B-Chemical
to	NN	O	O
stabilize	NN	O	O
high	NN	O	O
resistance	NN	O	O
states	NN	O	O
in	NN	O	O
susceptible	NN	O	O
persons	NN	O	O
suggests	NN	O	O
that	NN	O	O
its	NN	O	O
use	NN	O	O
may	NN	O	O
facilitate	NN	O	O
their	NN	O	O
disease	NN	O	O
progression	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
hinder	NN	O	O
accurate	NN	O	O
diagnosis	NN	O	O
and	NN	O	O
treatment	NN	O	O
.	NN	O	O


-DOCSTART- (8111719)

Hallucinations	NN	O	B-Disease
and	NN	O	O
ifosfamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B-Disease
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Hallucinations	NN	O	B-Disease
as	NN	O	O
a	NN	O	O
symptom	NN	O	O
of	NN	O	O
central	NN	O	O
neurotoxicity	NN	O	B-Disease
are	NN	O	O
a	NN	O	O
known	NN	O	O
but	NN	O	O
poorly	NN	O	O
described	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
ifosfamide	NN	O	B-Chemical
.	NN	O	O

Most	NN	O	O
cases	NN	O	O
of	NN	O	O
ifosfamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hallucinations	NN	O	B-Disease
have	NN	O	O
been	NN	O	O
reported	NN	O	O
with	NN	O	O
other	NN	O	O
mental	NN	O	O
status	NN	O	O
changes	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
authors	NN	O	O
interviewed	NN	O	O
six	NN	O	O
persons	NN	O	O
with	NN	O	O
ifosfamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hallucinations	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
a	NN	O	O
clear	NN	O	O
sensorium	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
were	NN	O	O
receiving	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
ifosfamide	NN	O	B-Chemical
as	NN	O	O
part	NN	O	O
of	NN	O	O
their	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplant	NN	O	O
procedure	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Hallucinations	NN	O	B-Disease
occurred	NN	O	O
only	NN	O	O
when	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
eyes	NN	O	O
were	NN	O	O
closed	NN	O	O
and	NN	O	O
,	NN	O	O
in	NN	O	O
all	NN	O	O
but	NN	O	O
one	NN	O	O
case	NN	O	O
,	NN	O	O
were	NN	O	O
reported	NN	O	O
as	NN	O	O
disturbing	NN	O	O
or	NN	O	O
frightening	NN	O	O
.	NN	O	O

Underreporting	NN	O	O
of	NN	O	O
these	NN	O	O
hallucinations	NN	O	B-Disease
by	NN	O	O
patients	NN	O	O
is	NN	O	O
likely	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Hallucinations	NN	O	B-Disease
may	NN	O	O
be	NN	O	O
the	NN	O	O
sole	NN	O	O
or	NN	O	O
first	NN	O	O
manifestation	NN	O	O
of	NN	O	O
neurotoxicity	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
may	NN	O	O
be	NN	O	O
dose	NN	O	O
and	NN	O	O
infusion	NN	O	O
-	NN	O	O
time	NN	O	O
related	NN	O	O
.	NN	O	O

The	NN	O	O
clinician	NN	O	O
should	NN	O	O
be	NN	O	O
alerted	NN	O	O
for	NN	O	O
possible	NN	O	O
ifosfamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hallucinations	NN	O	B-Disease
,	NN	O	O
which	NN	O	O
may	NN	O	O
occur	NN	O	O
without	NN	O	O
other	NN	O	O
signs	NN	O	O
of	NN	O	O
neurotoxicity	NN	O	B-Disease
.	NN	O	O

"	NN	O	O
Eyes	NN	O	O
-	NN	O	O
closed	NN	O	O
"	NN	O	O
hallucinatory	NN	O	B-Disease
experiences	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
an	NN	O	O
unusual	NN	O	O
feature	NN	O	O
of	NN	O	O
this	NN	O	O
presentation	NN	O	O
.	NN	O	O

Patients	NN	O	O
anxious	NN	O	O
about	NN	O	O
this	NN	O	O
experience	NN	O	O
respond	NN	O	O
well	NN	O	O
to	NN	O	O
support	NN	O	O
and	NN	O	O
education	NN	O	O
about	NN	O	O
this	NN	O	O
occurrence	NN	O	O
.	NN	O	O

Optimal	NN	O	O
pharmacologic	NN	O	O
management	NN	O	O
of	NN	O	O
disturbed	NN	O	O
patients	NN	O	O
is	NN	O	O
unclear	NN	O	O
.	NN	O	O

If	NN	O	O
agitation	NN	O	B-Disease
becomes	NN	O	O
marked	NN	O	O
,	NN	O	O
high	NN	O	O
-	NN	O	O
potency	NN	O	O
neuroleptics	NN	O	O
(	NN	O	O
i.e.	NN	O	O
,	NN	O	O
haloperidol	NN	O	B-Chemical
)	NN	O	O
may	NN	O	O
be	NN	O	O
effective	NN	O	O
.	NN	O	O


-DOCSTART- (7059267)

Chlorpropamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
65	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
adult	NN	O	B-Disease
-	NN	O	I-Disease
onset	NN	O	I-Disease
diabetes	NN	O	I-Disease
treated	NN	O	O
with	NN	O	O
chlorpropamide	NN	O	B-Chemical
(	NN	O	O
Diabenese	NN	O	B-Chemical
)	NN	O	O
had	NN	O	O
a	NN	O	O
toxic	NN	O	B-Disease
optic	NN	O	I-Disease
neuropathy	NN	O	I-Disease
that	NN	O	O
resolved	NN	O	O
with	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
chlorpropamide	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Visual	NN	O	B-Disease
loss	NN	O	I-Disease
occurs	NN	O	O
in	NN	O	O
diabetics	NN	O	B-Disease
for	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
reasons	NN	O	O
,	NN	O	O
and	NN	O	O
accurate	NN	O	O
diagnosis	NN	O	O
is	NN	O	O
necessary	NN	O	O
to	NN	O	O
institute	NN	O	O
appropriate	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
possibility	NN	O	O
of	NN	O	O
a	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
optic	NN	O	B-Disease
neuropathy	NN	O	I-Disease
should	NN	O	O
be	NN	O	O
considered	NN	O	O
in	NN	O	O
the	NN	O	O
differential	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
visual	NN	O	B-Disease
loss	NN	O	I-Disease
in	NN	O	O
diabetics	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (6381653)

Levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesia	NN	O	B-Disease
and	NN	O	O
thalamotomy	NN	O	O
.	NN	O	O

Levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesia	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
limbs	NN	O	O
in	NN	O	O
thirteen	NN	O	O
cases	NN	O	O
of	NN	O	O
Parkinsonism	NN	O	B-Disease
,	NN	O	O
which	NN	O	O
was	NN	O	O
choreic	NN	O	O
,	NN	O	O
ballistic	NN	O	O
or	NN	O	O
dystonic	NN	O	B-Disease
in	NN	O	O
type	NN	O	O
,	NN	O	O
was	NN	O	O
alleviated	NN	O	O
almost	NN	O	O
completely	NN	O	O
by	NN	O	O
stereotaxic	NN	O	O
surgery	NN	O	O
using	NN	O	O
a	NN	O	O
microelectrode	NN	O	O
technique	NN	O	O
for	NN	O	O
the	NN	O	O
ventralis	NN	O	O
oralis	NN	O	O
anterior	NN	O	O
and	NN	O	O
posterior	NN	O	O
nuclei	NN	O	O
of	NN	O	O
the	NN	O	O
thalamus	NN	O	O
,	NN	O	O
but	NN	O	O
much	NN	O	O
less	NN	O	O
by	NN	O	O
the	NN	O	O
ventralis	NN	O	O
intermedius	NN	O	O
nucleus	NN	O	O
.	NN	O	O

Control	NN	O	O
of	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
by	NN	O	O
thalamic	NN	O	B-Disease
lesions	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
routine	NN	O	O
treatment	NN	O	O
of	NN	O	O
Parkinsonism	NN	O	B-Disease
is	NN	O	O
discussed	NN	O	O
.	NN	O	O


-DOCSTART- (3950060)

Factors	NN	O	O
associated	NN	O	O
with	NN	O	O
nephrotoxicity	NN	O	B-Disease
and	NN	O	O
clinical	NN	O	O
outcome	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
amikacin	NN	O	B-Chemical
.	NN	O	O

Data	NN	O	O
from	NN	O	O
60	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
amikacin	NN	O	B-Chemical
were	NN	O	O
analyzed	NN	O	O
for	NN	O	O
factors	NN	O	O
associated	NN	O	O
with	NN	O	O
nephrotoxicity	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
42	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
,	NN	O	O
data	NN	O	O
were	NN	O	O
examined	NN	O	O
for	NN	O	O
factors	NN	O	O
associated	NN	O	O
with	NN	O	O
clinical	NN	O	O
outcome	NN	O	O
.	NN	O	O

Variables	NN	O	O
evaluated	NN	O	O
included	NN	O	O
patient	NN	O	O
weight	NN	O	O
,	NN	O	O
age	NN	O	O
,	NN	O	O
sex	NN	O	O
,	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
level	NN	O	O
,	NN	O	O
creatinine	NN	O	B-Chemical
clearance	NN	O	O
,	NN	O	O
duration	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
total	NN	O	O
dose	NN	O	O
,	NN	O	O
mean	NN	O	O
daily	NN	O	O
dose	NN	O	O
,	NN	O	O
organism	NN	O	O
minimum	NN	O	O
inhibitory	NN	O	O
concentration	NN	O	O
(	NN	O	O
MIC	NN	O	O
)	NN	O	O
,	NN	O	O
mean	NN	O	O
peak	NN	O	O
levels	NN	O	O
,	NN	O	O
mean	NN	O	O
trough	NN	O	O
levels	NN	O	O
,	NN	O	O
mean	NN	O	O
area	NN	O	O
under	NN	O	O
the	NN	O	O
serum	NN	O	O
concentration	NN	O	O
-	NN	O	O
time	NN	O	O
curve	NN	O	O
(	NN	O	O
AUC	NN	O	O
)	NN	O	O
,	NN	O	O
total	NN	O	O
AUC	NN	O	O
,	NN	O	O
mean	NN	O	O
AUC	NN	O	O
greater	NN	O	O
than	NN	O	O
MIC	NN	O	O
,	NN	O	O
total	NN	O	O
AUC	NN	O	O
greater	NN	O	O
than	NN	O	O
MIC	NN	O	O
,	NN	O	O
mean	NN	O	O
Schumacher	NN	O	O
'	NN	O	O
s	NN	O	O
intensity	NN	O	O
factor	NN	O	O
(	NN	O	O
IF	NN	O	O
)	NN	O	O
,	NN	O	O
total	NN	O	O
IF	NN	O	O
,	NN	O	O
In	NN	O	O
(	NN	O	O
mean	NN	O	O
maximum	NN	O	O
concentration	NN	O	O
[	NN	O	O
Cmax	NN	O	O
]	NN	O	O
/	NN	O	O
MIC	NN	O	O
)	NN	O	O
.	NN	O	O

Model	NN	O	O
-	NN	O	O
dependent	NN	O	O
pharmacokinetic	NN	O	O
parameters	NN	O	O
were	NN	O	O
calculated	NN	O	O
by	NN	O	O
computer	NN	O	O
based	NN	O	O
on	NN	O	O
a	NN	O	O
one	NN	O	O
-	NN	O	O
compartment	NN	O	O
model	NN	O	O
.	NN	O	O

When	NN	O	O
the	NN	O	O
parameters	NN	O	O
were	NN	O	O
examined	NN	O	O
individually	NN	O	O
,	NN	O	O
duration	NN	O	O
of	NN	O	O
therapy	NN	O	O
and	NN	O	O
total	NN	O	O
AUC	NN	O	O
correlated	NN	O	O
significantly	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
.05	NN	O	O
)	NN	O	O
with	NN	O	O
nephrotoxicity	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
a	NN	O	O
stepwise	NN	O	O
discriminant	NN	O	O
function	NN	O	O
analysis	NN	O	O
identified	NN	O	O
only	NN	O	O
duration	NN	O	O
of	NN	O	O
therapy	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
.001	NN	O	O
)	NN	O	O
as	NN	O	O
an	NN	O	O
important	NN	O	O
factor	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
this	NN	O	O
model	NN	O	O
and	NN	O	O
on	NN	O	O
Bayes	NN	O	O
'	NN	O	O
theorem	NN	O	O
,	NN	O	O
the	NN	O	O
predictive	NN	O	O
accuracy	NN	O	O
of	NN	O	O
identifying	NN	O	O
"	NN	O	O
nephrotoxic	NN	O	B-Disease
"	NN	O	O
patients	NN	O	O
increased	NN	O	O
from	NN	O	O
0.17	NN	O	O
to	NN	O	O
0.39	NN	O	O
.	NN	O	O

When	NN	O	O
examined	NN	O	O
individually	NN	O	O
,	NN	O	O
mean	NN	O	O
IF	NN	O	O
,	NN	O	O
MIC	NN	O	O
,	NN	O	O
total	NN	O	O
dose	NN	O	O
,	NN	O	O
mean	NN	O	O
daily	NN	O	O
dose	NN	O	O
,	NN	O	O
and	NN	O	O
ln	NN	O	O
(	NN	O	O
mean	NN	O	O
Cmax	NN	O	O
/	NN	O	O
MIC	NN	O	O
)	NN	O	O
correlated	NN	O	O
significantly	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
.05	NN	O	O
)	NN	O	O
with	NN	O	O
cure	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
a	NN	O	O
simultaneous	NN	O	O
multivariable	NN	O	O
analysis	NN	O	O
identified	NN	O	O
IF	NN	O	O
,	NN	O	O
MIC	NN	O	O
,	NN	O	O
and	NN	O	O
total	NN	O	O
dose	NN	O	O
according	NN	O	O
to	NN	O	O
one	NN	O	O
model	NN	O	O
and	NN	O	O
ln	NN	O	O
(	NN	O	O
mean	NN	O	O
Cmax	NN	O	O
/	NN	O	O
MIC	NN	O	O
)	NN	O	O
according	NN	O	O
to	NN	O	O
a	NN	O	O
second	NN	O	O
statistical	NN	O	O
model	NN	O	O
of	NN	O	O
parameters	NN	O	O
selected	NN	O	O
to	NN	O	O
have	NN	O	O
the	NN	O	O
greatest	NN	O	O
prospective	NN	O	O
value	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
Bayes	NN	O	O
'	NN	O	O
theorem	NN	O	O
and	NN	O	O
the	NN	O	O
first	NN	O	O
model	NN	O	O
,	NN	O	O
the	NN	O	O
predictive	NN	O	O
accuracy	NN	O	O
of	NN	O	O
identifying	NN	O	O
patients	NN	O	O
not	NN	O	O
cured	NN	O	O
increased	NN	O	O
from	NN	O	O
0.19	NN	O	O
to	NN	O	O
0.83	NN	O	O
.	NN	O	O

For	NN	O	O
the	NN	O	O
second	NN	O	O
model	NN	O	O
,	NN	O	O
the	NN	O	O
predictive	NN	O	O
accuracy	NN	O	O
increased	NN	O	O
from	NN	O	O
0.19	NN	O	O
to	NN	O	O
0.50.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

-DOCSTART- (3311455)

Cardiac	NN	O	O
transplantation	NN	O	O
:	NN	O	O
improved	NN	O	O
quality	NN	O	O
of	NN	O	O
survival	NN	O	O
with	NN	O	O
a	NN	O	O
modified	NN	O	O
immunosuppressive	NN	O	O
protocol	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
on	NN	O	O
renal	NN	O	O
function	NN	O	O
on	NN	O	O
two	NN	O	O
different	NN	O	O
immunosuppressive	NN	O	O
protocols	NN	O	O
were	NN	O	O
evaluated	NN	O	O
retrospectively	NN	O	O
in	NN	O	O
two	NN	O	O
subsequent	NN	O	O
groups	NN	O	O
of	NN	O	O
heart	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
.	NN	O	O

In	NN	O	O
group	NN	O	O
I	NN	O	O
,	NN	O	O
cyclosporine	NN	O	B-Chemical
was	NN	O	O
given	NN	O	O
before	NN	O	O
the	NN	O	O
procedure	NN	O	O
at	NN	O	O
a	NN	O	O
loading	NN	O	O
dose	NN	O	O
of	NN	O	O
17.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
and	NN	O	O
then	NN	O	O
continued	NN	O	O
after	NN	O	O
the	NN	O	O
procedure	NN	O	O
to	NN	O	O
keep	NN	O	O
a	NN	O	O
whole	NN	O	O
blood	NN	O	O
level	NN	O	O
about	NN	O	O
1000	NN	O	O
ng	NN	O	O
/	NN	O	O
ml	NN	O	O
.	NN	O	O

In	NN	O	O
group	NN	O	O
II	NN	O	O
,	NN	O	O
cyclosporine	NN	O	B-Chemical
was	NN	O	O
started	NN	O	O
only	NN	O	O
after	NN	O	O
the	NN	O	O
procedure	NN	O	O
at	NN	O	O
a	NN	O	O
lower	NN	O	O
dosage	NN	O	O
and	NN	O	O
was	NN	O	O
complemented	NN	O	O
by	NN	O	O
azathioprine	NN	O	B-Chemical
,	NN	O	O
which	NN	O	O
was	NN	O	O
used	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
postoperative	NN	O	O
week	NN	O	O
.	NN	O	O

Group	NN	O	O
II	NN	O	O
showed	NN	O	O
a	NN	O	O
better	NN	O	O
perioperative	NN	O	O
renal	NN	O	O
function	NN	O	O
as	NN	O	O
determined	NN	O	O
by	NN	O	O
serum	NN	O	O
blood	NN	O	O
urea	NN	O	B-Chemical
nitrogen	NN	O	I-Chemical
and	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
levels	NN	O	O
.	NN	O	O

Group	NN	O	O
II	NN	O	O
also	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
of	NN	O	O
chronic	NN	O	O
nephrotoxicity	NN	O	B-Disease
secondary	NN	O	O
to	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
therapy	NN	O	O
with	NN	O	O
cyclosporine	NN	O	B-Chemical
.	NN	O	O

Despite	NN	O	O
this	NN	O	O
improvement	NN	O	O
in	NN	O	O
late	NN	O	O
renal	NN	O	O
function	NN	O	O
,	NN	O	O
group	NN	O	O
II	NN	O	O
still	NN	O	O
shows	NN	O	O
a	NN	O	O
slow	NN	O	O
rise	NN	O	O
in	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
think	NN	O	O
that	NN	O	O
even	NN	O	O
these	NN	O	O
lower	NN	O	O
dosages	NN	O	O
of	NN	O	O
cyclosporine	NN	O	B-Chemical
can	NN	O	O
cause	NN	O	O
chronic	NN	O	O
nephrotoxicity	NN	O	B-Disease
and	NN	O	O
that	NN	O	O
further	NN	O	O
modification	NN	O	O
of	NN	O	O
the	NN	O	O
immunosuppressive	NN	O	O
regimen	NN	O	O
is	NN	O	O
required	NN	O	O
to	NN	O	O
completely	NN	O	O
abolish	NN	O	O
this	NN	O	O
toxic	NN	O	O
side	NN	O	O
effect	NN	O	O
.	NN	O	O


-DOCSTART- (2051906)

Reversible	NN	O	O
cholestasis	NN	O	B-Disease
with	NN	O	O
bile	NN	O	B-Disease
duct	NN	O	I-Disease
injury	NN	O	I-Disease
following	NN	O	O
azathioprine	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

A	NN	O	O
67	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
patient	NN	O	O
,	NN	O	O
with	NN	O	O
primary	NN	O	O
polymyositis	NN	O	B-Disease
and	NN	O	O
without	NN	O	O
previous	NN	O	O
evidence	NN	O	O
of	NN	O	O
liver	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
developed	NN	O	O
clinical	NN	O	O
and	NN	O	O
biochemical	NN	O	O
features	NN	O	O
of	NN	O	O
severe	NN	O	O
cholestasis	NN	O	B-Disease
3	NN	O	O
months	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
azathioprine	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Liver	NN	O	O
biopsy	NN	O	O
showed	NN	O	O
cholestasis	NN	O	B-Disease
with	NN	O	O
both	NN	O	O
cytological	NN	O	O
and	NN	O	O
architectural	NN	O	O
alterations	NN	O	O
of	NN	O	O
interlobular	NN	O	O
bile	NN	O	O
ducts	NN	O	O
.	NN	O	O

Azathioprine	NN	O	B-Chemical
withdrawal	NN	O	O
resulted	NN	O	O
after	NN	O	O
7	NN	O	O
weeks	NN	O	O
in	NN	O	O
the	NN	O	O
resolution	NN	O	O
of	NN	O	O
clinical	NN	O	O
and	NN	O	O
biochemical	NN	O	O
abnormalities	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
believed	NN	O	O
that	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
reported	NN	O	O
case	NN	O	O
of	NN	O	O
reversible	NN	O	O
azathioprine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cholestasis	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
histological	NN	O	O
evidence	NN	O	O
of	NN	O	O
bile	NN	O	B-Disease
duct	NN	O	I-Disease
injury	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (2021202)

Renal	NN	O	O
function	NN	O	O
and	NN	O	O
hemodynamics	NN	O	O
during	NN	O	O
prolonged	NN	O	O
isoflurane	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
in	NN	O	O
humans	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
isoflurane	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
on	NN	O	O
glomerular	NN	O	O
function	NN	O	O
and	NN	O	O
renal	NN	O	O
blood	NN	O	O
flow	NN	O	O
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
20	NN	O	O
human	NN	O	O
subjects	NN	O	O
.	NN	O	O

Glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
(	NN	O	O
GFR	NN	O	O
)	NN	O	O
and	NN	O	O
effective	NN	O	O
renal	NN	O	O
plasma	NN	O	O
flow	NN	O	O
(	NN	O	O
ERPF	NN	O	O
)	NN	O	O
were	NN	O	O
measured	NN	O	O
by	NN	O	O
inulin	NN	O	O
and	NN	O	O
para	NN	O	B-Chemical
-	NN	O	I-Chemical
aminohippurate	NN	O	I-Chemical
(	NN	O	O
PAH	NN	O	B-Chemical
)	NN	O	O
clearance	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Anesthesia	NN	O	O
was	NN	O	O
maintained	NN	O	O
with	NN	O	O
fentanyl	NN	O	B-Chemical
,	NN	O	O
nitrous	NN	O	B-Chemical
oxide	NN	O	I-Chemical
,	NN	O	O
oxygen	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
isoflurane	NN	O	B-Chemical
.	NN	O	O

Hypotension	NN	O	B-Disease
was	NN	O	O
induced	NN	O	O
for	NN	O	O
236.9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
15.1	NN	O	O
min	NN	O	O
by	NN	O	O
increasing	NN	O	O
the	NN	O	O
isoflurane	NN	O	B-Chemical
inspired	NN	O	O
concentration	NN	O	O
to	NN	O	O
maintain	NN	O	O
a	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
of	NN	O	O
59.8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.4	NN	O	O
mmHg	NN	O	O
.	NN	O	O

GFR	NN	O	O
and	NN	O	O
ERPF	NN	O	O
decreased	NN	O	O
with	NN	O	O
the	NN	O	O
induction	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
but	NN	O	O
not	NN	O	O
significantly	NN	O	O
more	NN	O	O
during	NN	O	O
hypotension	NN	O	B-Disease
.	NN	O	O

Postoperatively	NN	O	O
,	NN	O	O
ERPF	NN	O	O
returned	NN	O	O
to	NN	O	O
preoperative	NN	O	O
values	NN	O	O
,	NN	O	O
whereas	NN	O	O
GFR	NN	O	O
was	NN	O	O
higher	NN	O	O
than	NN	O	O
preoperative	NN	O	O
values	NN	O	O
.	NN	O	O

Renal	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
increased	NN	O	O
during	NN	O	O
anesthesia	NN	O	O
but	NN	O	O
decreased	NN	O	O
when	NN	O	O
hypotension	NN	O	B-Disease
was	NN	O	O
induced	NN	O	O
,	NN	O	O
allowing	NN	O	O
the	NN	O	O
maintenance	NN	O	O
of	NN	O	O
renal	NN	O	O
blood	NN	O	O
flow	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
renal	NN	O	O
compensatory	NN	O	O
mechanisms	NN	O	O
are	NN	O	O
preserved	NN	O	O
during	NN	O	O
isoflurane	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
and	NN	O	O
that	NN	O	O
renal	NN	O	O
function	NN	O	O
and	NN	O	O
hemodynamics	NN	O	O
quickly	NN	O	O
return	NN	O	O
to	NN	O	O
normal	NN	O	O
when	NN	O	O
normotension	NN	O	O
is	NN	O	O
resumed	NN	O	O
.	NN	O	O


-DOCSTART- (1848636)

Debrisoquine	NN	O	B-Chemical
phenotype	NN	O	O
and	NN	O	O
the	NN	O	O
pharmacokinetics	NN	O	O
and	NN	O	O
beta	NN	O	O
-	NN	O	O
2	NN	O	O
receptor	NN	O	O
pharmacodynamics	NN	O	O
of	NN	O	O
metoprolol	NN	O	B-Chemical
and	NN	O	O
its	NN	O	O
enantiomers	NN	O	O
.	NN	O	O

The	NN	O	O
metabolism	NN	O	O
of	NN	O	O
the	NN	O	O
cardioselective	NN	O	O
beta	NN	O	O
-	NN	O	O
blocker	NN	O	O
metoprolol	NN	O	B-Chemical
is	NN	O	O
under	NN	O	O
genetic	NN	O	O
control	NN	O	O
of	NN	O	O
the	NN	O	O
debrisoquine	NN	O	B-Chemical
/	NN	O	O
sparteine	NN	O	B-Chemical
type	NN	O	O
.	NN	O	O

The	NN	O	O
two	NN	O	O
metabolic	NN	O	O
phenotypes	NN	O	O
,	NN	O	O
extensive	NN	O	O
(	NN	O	O
EM	NN	O	O
)	NN	O	O
and	NN	O	O
poor	NN	O	O
metabolizers	NN	O	O
(	NN	O	O
PM	NN	O	O
)	NN	O	O
,	NN	O	O
show	NN	O	O
different	NN	O	O
stereoselective	NN	O	O
metabolism	NN	O	O
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
apparently	NN	O	O
higher	NN	O	O
beta	NN	O	O
-	NN	O	O
1	NN	O	O
adrenoceptor	NN	O	O
antagonistic	NN	O	O
potency	NN	O	O
of	NN	O	O
racemic	NN	O	O
metoprolol	NN	O	B-Chemical
in	NN	O	O
EMs	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
if	NN	O	O
the	NN	O	O
latter	NN	O	O
also	NN	O	O
applies	NN	O	O
to	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
2	NN	O	O
adrenoceptor	NN	O	O
antagonism	NN	O	O
by	NN	O	O
metoprolol	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
drug	NN	O	O
effect	NN	O	O
studied	NN	O	O
was	NN	O	O
the	NN	O	O
antagonism	NN	O	O
by	NN	O	O
metoprolol	NN	O	B-Chemical
of	NN	O	O
terbutaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypokalemia	NN	O	B-Disease
.	NN	O	O

By	NN	O	O
using	NN	O	O
pharmacokinetic	NN	O	O
pharmacodynamic	NN	O	O
modeling	NN	O	O
the	NN	O	O
pharmacodynamics	NN	O	O
of	NN	O	O
racemic	NN	O	O
metoprolol	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
active	NN	O	O
S	NN	O	O
-	NN	O	O
isomer	NN	O	O
,	NN	O	O
were	NN	O	O
quantitated	NN	O	O
in	NN	O	O
EMs	NN	O	O
and	NN	O	O
PMs	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
IC50	NN	O	O
values	NN	O	O
,	NN	O	O
representing	NN	O	O
metoprolol	NN	O	B-Chemical
plasma	NN	O	O
concentrations	NN	O	O
resulting	NN	O	O
in	NN	O	O
half	NN	O	O
-	NN	O	O
maximum	NN	O	O
receptor	NN	O	O
occupancy	NN	O	O
.	NN	O	O

Six	NN	O	O
EMs	NN	O	O
received	NN	O	O
0.5	NN	O	O
mg	NN	O	O
of	NN	O	O
terbutaline	NN	O	B-Chemical
s.c.	NN	O	O
on	NN	O	O
two	NN	O	O
different	NN	O	O
occasions	NN	O	O
:	NN	O	O
1	NN	O	O
)	NN	O	O
1	NN	O	O
hr	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
placebo	NN	O	O
and	NN	O	O
2	NN	O	O
)	NN	O	O
1	NN	O	O
hr	NN	O	O
after	NN	O	O
150	NN	O	O
mg	NN	O	O
of	NN	O	O
metoprolol	NN	O	B-Chemical
p.o.	NN	O	O
Five	NN	O	O
PMs	NN	O	O
were	NN	O	O
studied	NN	O	O
according	NN	O	O
to	NN	O	O
the	NN	O	O
same	NN	O	O
protocol	NN	O	O
,	NN	O	O
except	NN	O	O
for	NN	O	O
a	NN	O	O
higher	NN	O	O
terbutaline	NN	O	B-Chemical
dose	NN	O	O
(	NN	O	O
0.75	NN	O	O
mg	NN	O	O
)	NN	O	O
on	NN	O	O
day	NN	O	O
2	NN	O	O
.	NN	O	O

Blood	NN	O	O
samples	NN	O	O
for	NN	O	O
the	NN	O	O
analysis	NN	O	O
of	NN	O	O
plasma	NN	O	O
potassium	NN	O	B-Chemical
,	NN	O	O
terbutaline	NN	O	B-Chemical
,	NN	O	O
metoprolol	NN	O	B-Chemical
(	NN	O	O
racemic	NN	O	O
,	NN	O	O
R	NN	O	O
-	NN	O	O
and	NN	O	O
S	NN	O	O
-	NN	O	O
isomer	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxymetoprolol	NN	O	I-Chemical
concentrations	NN	O	O
were	NN	O	O
taken	NN	O	O
at	NN	O	O
regular	NN	O	O
time	NN	O	O
intervals	NN	O	O
,	NN	O	O
during	NN	O	O
8	NN	O	O
hr	NN	O	O
after	NN	O	O
metoprolol	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
PMs	NN	O	O
,	NN	O	O
metoprolol	NN	O	B-Chemical
increased	NN	O	O
the	NN	O	O
terbutaline	NN	O	B-Chemical
area	NN	O	O
under	NN	O	O
the	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
vs	NN	O	O
.	NN	O	O

time	NN	O	O
curve	NN	O	O
(	NN	O	O
+67%	NN	O	O
)	NN	O	O
.	NN	O	O

Higher	NN	O	O
metoprolol	NN	O	B-Chemical
/	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxymetoprolol	NN	O	I-Chemical
ratios	NN	O	O
in	NN	O	O
PMs	NN	O	O
were	NN	O	O
predictive	NN	O	O
for	NN	O	O
higher	NN	O	O
R	NN	O	O
-	NN	O	O
/	NN	O	O
S	NN	O	O
-	NN	O	O
isomer	NN	O	O
ratios	NN	O	O
of	NN	O	O
unchanged	NN	O	O
drug	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
a	NN	O	O
difference	NN	O	O
in	NN	O	O
metoprolol	NN	O	B-Chemical
potency	NN	O	O
with	NN	O	O
higher	NN	O	O
racemic	NN	O	O
metoprolol	NN	O	B-Chemical
IC50	NN	O	O
values	NN	O	O
in	NN	O	O
PMs	NN	O	O
(	NN	O	O
72	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
ng.ml	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
than	NN	O	O
EMs	NN	O	O
(	NN	O	O
42	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
ng.ml	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
.001	NN	O	O
)	NN	O	O
.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

-DOCSTART- (1445986)

Cefotetan	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
immune	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
.	NN	O	O

Immune	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
a	NN	O	O
drug	NN	O	O
-	NN	O	O
adsorption	NN	O	O
mechanism	NN	O	O
has	NN	O	O
been	NN	O	O
described	NN	O	O
primarily	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
penicillins	NN	O	B-Chemical
and	NN	O	O
first	NN	O	O
-	NN	O	O
generation	NN	O	O
cephalosporins	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
anemia	NN	O	B-Disease
while	NN	O	O
receiving	NN	O	O
intravenous	NN	O	O
cefotetan	NN	O	B-Chemical
.	NN	O	O

Cefotetan	NN	O	B-Chemical
-	NN	O	O
dependent	NN	O	O
antibodies	NN	O	O
were	NN	O	O
detected	NN	O	O
in	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
serum	NN	O	O
and	NN	O	O
in	NN	O	O
an	NN	O	O
eluate	NN	O	O
prepared	NN	O	O
from	NN	O	O
his	NN	O	O
red	NN	O	O
blood	NN	O	O
cells	NN	O	O
.	NN	O	O

The	NN	O	O
eluate	NN	O	O
also	NN	O	O
reacted	NN	O	O
weakly	NN	O	O
with	NN	O	O
red	NN	O	O
blood	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
cefotetan	NN	O	B-Chemical
,	NN	O	O
suggesting	NN	O	O
the	NN	O	O
concomitant	NN	O	O
formation	NN	O	O
of	NN	O	O
warm	NN	O	O
-	NN	O	O
reactive	NN	O	O
autoantibodies	NN	O	O
.	NN	O	O

These	NN	O	O
observations	NN	O	O
,	NN	O	O
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
clinical	NN	O	O
and	NN	O	O
laboratory	NN	O	O
evidence	NN	O	O
of	NN	O	O
extravascular	NN	O	O
hemolysis	NN	O	B-Disease
,	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
,	NN	O	O
possibly	NN	O	O
involving	NN	O	O
both	NN	O	O
drug	NN	O	O
-	NN	O	O
adsorption	NN	O	O
and	NN	O	O
autoantibody	NN	O	O
formation	NN	O	O
mechanisms	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
emphasizes	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
increased	NN	O	O
awareness	NN	O	O
of	NN	O	O
hemolytic	NN	O	O
reactions	NN	O	O
to	NN	O	O
all	NN	O	O
cephalosporins	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (982002)

Acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
subsequent	NN	O	O
to	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
rifampicin	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
study	NN	O	O
of	NN	O	O
cases	NN	O	O
reported	NN	O	O
earlier	NN	O	O
.	NN	O	O

A	NN	O	O
clinical	NN	O	O
presentation	NN	O	O
is	NN	O	O
made	NN	O	O
of	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
3	NN	O	O
year	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
of	NN	O	O
six	NN	O	O
cases	NN	O	O
of	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
that	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
earlier	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
had	NN	O	O
developed	NN	O	O
transient	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
after	NN	O	O
the	NN	O	O
intermittent	NN	O	O
administration	NN	O	O
of	NN	O	O
rifampicin	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
stage	NN	O	O
of	NN	O	O
olig	NN	O	O
-	NN	O	O
anuria	NN	O	B-Disease
lasted	NN	O	O
for	NN	O	O
1	NN	O	O
-	NN	O	O
3	NN	O	O
weeks	NN	O	O
,	NN	O	O
and	NN	O	O
five	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
treated	NN	O	O
by	NN	O	O
hemodialysis	NN	O	O
.	NN	O	O

Two	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
died	NN	O	O
due	NN	O	O
to	NN	O	O
unrelated	NN	O	O
causes	NN	O	O
during	NN	O	O
the	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
.	NN	O	O

The	NN	O	O
four	NN	O	O
patients	NN	O	O
re	NN	O	O
-	NN	O	O
examined	NN	O	O
were	NN	O	O
clinically	NN	O	O
cured	NN	O	O
.	NN	O	O

Pathologic	NN	O	O
findings	NN	O	O
by	NN	O	O
light	NN	O	O
microscopy	NN	O	O
and	NN	O	O
immunofluorescence	NN	O	O
at	NN	O	O
biopsy	NN	O	O
were	NN	O	O
scarce	NN	O	O
.	NN	O	O

Nothing	NN	O	O
abnormal	NN	O	O
was	NN	O	O
seen	NN	O	O
by	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
in	NN	O	O
two	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
studied	NN	O	O
.	NN	O	O

Renal	NN	O	O
function	NN	O	O
was	NN	O	O
normal	NN	O	O
.	NN	O	O

In	NN	O	O
three	NN	O	O
cases	NN	O	O
the	NN	O	O
excretion	NN	O	O
at	NN	O	O
131I	NN	O	O
-	NN	O	O
hippuran	NN	O	O
renography	NN	O	O
was	NN	O	O
slightly	NN	O	O
slowed	NN	O	O
.	NN	O	O

Although	NN	O	O
in	NN	O	O
the	NN	O	O
acute	NN	O	O
stage	NN	O	O
the	NN	O	O
renal	NN	O	B-Disease
lesions	NN	O	I-Disease
histologically	NN	O	O
appeared	NN	O	O
toxic	NN	O	O
,	NN	O	O
evidence	NN	O	O
suggestive	NN	O	O
of	NN	O	O
an	NN	O	O
immunological	NN	O	O
mechanism	NN	O	O
cannot	NN	O	O
be	NN	O	O
excluded	NN	O	O
.	NN	O	O


-DOCSTART- (343678)

Type	NN	O	B-Disease
B	NN	O	I-Disease
hepatitis	NN	O	I-Disease
after	NN	O	O
needle	NN	O	O
-	NN	O	O
stick	NN	O	O
exposure	NN	O	O
:	NN	O	O
prevention	NN	O	O
with	NN	O	O
hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
immune	NN	O	O
globulin	NN	O	O
.	NN	O	O

Final	NN	O	O
report	NN	O	O
of	NN	O	O
the	NN	O	O
Veterans	NN	O	O
Administration	NN	O	O
Cooperative	NN	O	O
Study	NN	O	O
.	NN	O	O

Hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
immune	NN	O	O
globulin	NN	O	O
(	NN	O	O
HBIG	NN	O	O
)	NN	O	O
and	NN	O	O
immune	NN	O	O
serum	NN	O	O
globulin	NN	O	O
(	NN	O	O
ISG	NN	O	O
)	NN	O	O
were	NN	O	O
examined	NN	O	O
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
trial	NN	O	O
to	NN	O	O
assess	NN	O	O
their	NN	O	O
relative	NN	O	O
efficacies	NN	O	O
in	NN	O	O
preventing	NN	O	O
type	NN	O	B-Disease
B	NN	O	I-Disease
hepatitis	NN	O	I-Disease
after	NN	O	O
needle	NN	O	O
-	NN	O	O
stick	NN	O	O
exposure	NN	O	O
to	NN	O	O
hepatitis	NN	O	B-Chemical
B	NN	O	I-Chemical
surface	NN	O	I-Chemical
antigen	NN	O	I-Chemical
(	NN	O	O
HBsAG	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
positive	NN	O	O
donors	NN	O	O
.	NN	O	O

Clinical	NN	O	O
hepatitis	NN	O	B-Disease
developed	NN	O	O
in	NN	O	O
1.4%	NN	O	O
of	NN	O	O
HBIG	NN	O	O
and	NN	O	O
in	NN	O	O
5.9%	NN	O	O
of	NN	O	O
ISG	NN	O	O
recipients	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.016	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
seroconversion	NN	O	O
(	NN	O	O
anti	NN	O	O
-	NN	O	O
HBs	NN	O	O
)	NN	O	O
occurred	NN	O	O
in	NN	O	O
5.6%	NN	O	O
and	NN	O	O
20.7%	NN	O	O
of	NN	O	O
them	NN	O	O
respectively	NN	O	O
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

Mild	NN	O	O
and	NN	O	O
transient	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
were	NN	O	O
noted	NN	O	O
in	NN	O	O
3.0%	NN	O	O
of	NN	O	O
ISG	NN	O	O
and	NN	O	O
in	NN	O	O
3.2%	NN	O	O
of	NN	O	O
HBIG	NN	O	O
recipients	NN	O	O
.	NN	O	O

Available	NN	O	O
donor	NN	O	O
sera	NN	O	O
were	NN	O	O
examined	NN	O	O
for	NN	O	O
DNA	NN	O	O
polymerase	NN	O	O
(	NN	O	O
DNAP	NN	O	O
)	NN	O	O
and	NN	O	O
e	NN	O	O
antigen	NN	O	O
and	NN	O	O
antibody	NN	O	O
(	NN	O	O
HBeAg	NN	O	B-Chemical
;	NN	O	O
anti	NN	O	O
-	NN	O	O
HBE	NN	O	O
)	NN	O	O
.	NN	O	O

Both	NN	O	O
DNAP	NN	O	O
and	NN	O	O
HBeAg	NN	O	B-Chemical
showed	NN	O	O
a	NN	O	O
highly	NN	O	O
statistically	NN	O	O
significant	NN	O	O
correlation	NN	O	O
with	NN	O	O
the	NN	O	O
infectivity	NN	O	O
of	NN	O	O
HBsAg	NN	O	B-Chemical
-	NN	O	O
positive	NN	O	O
donors	NN	O	O
.	NN	O	O

Hepatitis	NN	O	B-Disease
B	NN	O	I-Disease
immune	NN	O	O
globulin	NN	O	O
remained	NN	O	O
significantly	NN	O	O
superior	NN	O	O
to	NN	O	O
ISG	NN	O	O
in	NN	O	O
preventing	NN	O	O
type	NN	O	B-Disease
B	NN	O	I-Disease
hepatitis	NN	O	I-Disease
even	NN	O	O
when	NN	O	O
the	NN	O	O
analysis	NN	O	O
was	NN	O	O
confined	NN	O	O
to	NN	O	O
these	NN	O	O
two	NN	O	O
high	NN	O	O
-	NN	O	O
risk	NN	O	O
subgroups	NN	O	O
.	NN	O	O

The	NN	O	O
efficacy	NN	O	O
of	NN	O	O
ISG	NN	O	O
in	NN	O	O
preventing	NN	O	O
type	NN	O	B-Disease
B	NN	O	I-Disease
hepatitis	NN	O	I-Disease
cannot	NN	O	O
be	NN	O	O
ascertained	NN	O	O
because	NN	O	O
a	NN	O	O
true	NN	O	O
placebo	NN	O	O
group	NN	O	O
was	NN	O	O
not	NN	O	O
included	NN	O	O
.	NN	O	O


-DOCSTART- (8888541)

Serotonin	NN	O	B-Disease
syndrome	NN	O	I-Disease
from	NN	O	O
venlafaxine	NN	O	B-Chemical
-	NN	O	O
tranylcypromine	NN	O	B-Chemical
interaction	NN	O	O
.	NN	O	O

Excessive	NN	O	O
stimulation	NN	O	O
of	NN	O	O
serotonin	NN	O	B-Chemical
5HT1A	NN	O	O
receptors	NN	O	O
causes	NN	O	O
a	NN	O	O
syndrome	NN	O	O
of	NN	O	O
serotonin	NN	O	B-Chemical
excess	NN	O	O
that	NN	O	O
consists	NN	O	O
of	NN	O	O
shivering	NN	O	O
,	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
,	NN	O	O
salivation	NN	O	B-Disease
,	NN	O	O
confusion	NN	O	B-Disease
,	NN	O	O
agitation	NN	O	B-Disease
and	NN	O	O
hyperthermia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
most	NN	O	O
common	NN	O	O
cause	NN	O	O
of	NN	O	O
this	NN	O	O
syndrome	NN	O	O
is	NN	O	O
an	NN	O	O
interaction	NN	O	O
between	NN	O	O
a	NN	O	O
monoamine	NN	O	O
oxidase	NN	O	O
inhibitor	NN	O	O
(	NN	O	O
MAOI	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
specific	NN	O	O
serotonin	NN	O	B-Chemical
reuptake	NN	O	O
inhibitor	NN	O	O
.	NN	O	O

Venlafaxine	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
new	NN	O	O
antidepressant	NN	O	O
agent	NN	O	O
that	NN	O	O
inhibits	NN	O	O
the	NN	O	O
reuptake	NN	O	O
of	NN	O	O
serotonin	NN	O	B-Chemical
and	NN	O	O
norepinephrine	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
venlafaxine	NN	O	B-Chemical
-	NN	O	O
MAOI	NN	O	O
interaction	NN	O	O
that	NN	O	O
resulted	NN	O	O
in	NN	O	O
the	NN	O	O
serotonin	NN	O	B-Disease
syndrome	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
23	NN	O	O
-	NN	O	O
y	NN	O	O
-	NN	O	O
old	NN	O	O
male	NN	O	O
who	NN	O	O
was	NN	O	O
taking	NN	O	O
tranylcypromine	NN	O	B-Chemical
for	NN	O	O
depression	NN	O	B-Disease
.	NN	O	O

He	NN	O	O
had	NN	O	O
been	NN	O	O
well	NN	O	O
until	NN	O	O
the	NN	O	O
morning	NN	O	O
of	NN	O	O
presentation	NN	O	O
when	NN	O	O
he	NN	O	O
took	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
tab	NN	O	O
of	NN	O	O
venlafaxine	NN	O	B-Chemical
.	NN	O	O

Within	NN	O	O
2	NN	O	O
h	NN	O	O
he	NN	O	O
became	NN	O	O
confused	NN	O	O
with	NN	O	O
jerking	NN	O	O
movements	NN	O	O
of	NN	O	O
his	NN	O	O
extremities	NN	O	O
,	NN	O	O
tremors	NN	O	B-Disease
and	NN	O	O
rigidity	NN	O	B-Disease
.	NN	O	O

He	NN	O	O
was	NN	O	O
brought	NN	O	O
directly	NN	O	O
to	NN	O	O
a	NN	O	O
hospital	NN	O	O
where	NN	O	O
he	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
agitated	NN	O	O
and	NN	O	O
confused	NN	O	O
with	NN	O	O
shivering	NN	O	O
,	NN	O	O
myoclonic	NN	O	B-Disease
jerks	NN	O	I-Disease
,	NN	O	O
rigidity	NN	O	B-Disease
,	NN	O	O
salivation	NN	O	B-Disease
and	NN	O	O
diaphoresis	NN	O	O
.	NN	O	O

His	NN	O	O
pupils	NN	O	O
were	NN	O	O
7	NN	O	O
mm	NN	O	O
and	NN	O	O
sluggishly	NN	O	O
reactive	NN	O	O
to	NN	O	O
light	NN	O	O
.	NN	O	O

Vital	NN	O	O
signs	NN	O	O
were	NN	O	O
:	NN	O	O
blood	NN	O	O
pressure	NN	O	O
120	NN	O	O
/	NN	O	O
67	NN	O	O
mm	NN	O	O
Hg	NN	O	O
,	NN	O	O
heart	NN	O	O
rate	NN	O	O
127	NN	O	O
/	NN	O	O
min	NN	O	O
,	NN	O	O
respiratory	NN	O	O
rate	NN	O	O
28	NN	O	O
/	NN	O	O
min	NN	O	O
,	NN	O	O
and	NN	O	O
temperature	NN	O	O
97	NN	O	O
F	NN	O	O
.	NN	O	O

After	NN	O	O
180	NN	O	O
mg	NN	O	O
of	NN	O	O
diazepam	NN	O	B-Chemical
i.v.	NN	O	O
he	NN	O	O
remained	NN	O	O
tremulous	NN	O	O
with	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
and	NN	O	O
clenched	NN	O	O
jaws	NN	O	O
.	NN	O	O

He	NN	O	O
was	NN	O	O
intubated	NN	O	O
for	NN	O	O
airway	NN	O	O
protection	NN	O	O
and	NN	O	O
because	NN	O	O
of	NN	O	O
hypoventilation	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
was	NN	O	O
paralyzed	NN	O	B-Disease
to	NN	O	O
control	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
.	NN	O	O

His	NN	O	O
subsequent	NN	O	O
course	NN	O	O
was	NN	O	O
remarkable	NN	O	O
for	NN	O	O
non	NN	O	O
-	NN	O	O
immune	NN	O	O
thrombocytopenia	NN	O	B-Disease
which	NN	O	O
resolved	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
maximal	NN	O	O
temperature	NN	O	O
was	NN	O	O
101.2	NN	O	O
F	NN	O	O
and	NN	O	O
his	NN	O	O
CPK	NN	O	O
remained	NN	O	O
<	NN	O	O
500	NN	O	O
units	NN	O	O
/	NN	O	O
L	NN	O	O
with	NN	O	O
no	NN	O	O
other	NN	O	O
evidence	NN	O	O
of	NN	O	O
rhabdomyolysis	NN	O	B-Disease
.	NN	O	O

His	NN	O	O
mental	NN	O	O
status	NN	O	O
normalized	NN	O	O
and	NN	O	O
he	NN	O	O
was	NN	O	O
transferred	NN	O	O
to	NN	O	O
a	NN	O	O
psychiatry	NN	O	O
ward	NN	O	O
.	NN	O	O

This	NN	O	O
patient	NN	O	O
survived	NN	O	O
without	NN	O	O
sequelae	NN	O	O
due	NN	O	O
to	NN	O	O
the	NN	O	O
aggressive	NN	O	O
sedation	NN	O	O
and	NN	O	O
neuromuscular	NN	O	O
paralysis	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (8106150)

Effect	NN	O	O
of	NN	O	O
nondopaminergic	NN	O	O
drugs	NN	O	O
on	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
in	NN	O	O
MPTP	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
monkeys	NN	O	O
.	NN	O	O

A	NN	O	O
group	NN	O	O
of	NN	O	O
four	NN	O	O
monkeys	NN	O	O
was	NN	O	O
rendered	NN	O	O
parkinsonian	NN	O	B-Disease
with	NN	O	O
the	NN	O	O
toxin	NN	O	O
MPTP	NN	O	B-Chemical
.	NN	O	O

They	NN	O	O
were	NN	O	O
then	NN	O	O
treated	NN	O	O
chronically	NN	O	O
with	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
DOPA	NN	O	I-Chemical
/	NN	O	I-Chemical
benserazide	NN	O	I-Chemical
50	NN	O	O
/	NN	O	O
12.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
given	NN	O	O
orally	NN	O	O
daily	NN	O	O
for	NN	O	O
2	NN	O	O
months	NN	O	O
.	NN	O	O

This	NN	O	O
dose	NN	O	O
produced	NN	O	O
a	NN	O	O
striking	NN	O	O
antiparkinsonian	NN	O	O
effect	NN	O	O
,	NN	O	O
but	NN	O	O
all	NN	O	O
animals	NN	O	O
manifested	NN	O	O
dyskinesia	NN	O	B-Disease
.	NN	O	O

A	NN	O	O
series	NN	O	O
of	NN	O	O
agents	NN	O	O
acting	NN	O	O
primarily	NN	O	O
on	NN	O	O
neurotransmitters	NN	O	O
other	NN	O	O
than	NN	O	O
dopamine	NN	O	B-Chemical
were	NN	O	O
then	NN	O	O
tested	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
DOPA	NN	O	I-Chemical
to	NN	O	O
see	NN	O	O
if	NN	O	O
the	NN	O	O
dyskinetic	NN	O	B-Disease
movements	NN	O	O
would	NN	O	O
be	NN	O	O
modified	NN	O	O
.	NN	O	O

Several	NN	O	O
drugs	NN	O	O
,	NN	O	O
including	NN	O	O
clonidine	NN	O	B-Chemical
,	NN	O	O
physostigmine	NN	O	B-Chemical
,	NN	O	O
methysergide	NN	O	B-Chemical
,	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
MDOT	NN	O	I-Chemical
,	NN	O	O
propranolol	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
MK	NN	O	B-Chemical
-	NN	O	I-Chemical
801	NN	O	I-Chemical
,	NN	O	O
markedly	NN	O	O
reduced	NN	O	O
the	NN	O	O
dyskinetic	NN	O	B-Disease
movements	NN	O	O
but	NN	O	O
at	NN	O	O
the	NN	O	O
cost	NN	O	O
of	NN	O	O
a	NN	O	O
return	NN	O	O
of	NN	O	O
parkinsonian	NN	O	B-Disease
symptomatology	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
yohimbine	NN	O	B-Chemical
and	NN	O	O
meperidine	NN	O	B-Chemical
reduced	NN	O	O
predominantly	NN	O	O
the	NN	O	O
dyskinetic	NN	O	B-Disease
movements	NN	O	O
.	NN	O	O

Baclofen	NN	O	B-Chemical
was	NN	O	O
also	NN	O	O
useful	NN	O	O
in	NN	O	O
one	NN	O	O
monkey	NN	O	O
against	NN	O	O
a	NN	O	O
more	NN	O	O
dystonic	NN	O	B-Disease
form	NN	O	O
of	NN	O	O
dyskinesia	NN	O	B-Disease
.	NN	O	O

Atropine	NN	O	B-Chemical
converted	NN	O	O
the	NN	O	O
dystonic	NN	O	B-Disease
movements	NN	O	O
into	NN	O	O
chorea	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (21418164)

CCNU	NN	O	B-Chemical
(	NN	O	O
lomustine	NN	O	B-Chemical
)	NN	O	O
toxicity	NN	O	B-Disease
in	NN	O	O
dogs	NN	O	O
:	NN	O	O
a	NN	O	O
retrospective	NN	O	O
study	NN	O	O
(	NN	O	O
2002	NN	O	O
-	NN	O	O
07	NN	O	O
)	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
describe	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
haematological	NN	O	B-Disease
,	NN	O	I-Disease
renal	NN	O	I-Disease
,	NN	O	I-Disease
hepatic	NN	O	I-Disease
and	NN	O	I-Disease
gastrointestinal	NN	O	I-Disease
toxicities	NN	O	I-Disease
in	NN	O	O
tumour	NN	O	O
-	NN	O	O
bearing	NN	O	O
dogs	NN	O	O
receiving	NN	O	O
1	NN	O	B-Chemical
-	NN	O	I-Chemical
(	NN	O	I-Chemical
2	NN	O	I-Chemical
-	NN	O	I-Chemical
chloroethyl	NN	O	I-Chemical
)	NN	O	I-Chemical
-	NN	O	I-Chemical
3	NN	O	I-Chemical
-	NN	O	I-Chemical
cyclohexyl	NN	O	I-Chemical
-	NN	O	I-Chemical
1	NN	O	I-Chemical
-	NN	O	I-Chemical
nitrosourea	NN	O	I-Chemical
(	NN	O	O
CCNU	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
The	NN	O	O
medical	NN	O	O
records	NN	O	O
of	NN	O	O
206	NN	O	O
dogs	NN	O	O
that	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
CCNU	NN	O	B-Chemical
at	NN	O	O
the	NN	O	O
Melbourne	NN	O	O
Veterinary	NN	O	O
Specialist	NN	O	O
Centre	NN	O	O
between	NN	O	O
February	NN	O	O
2002	NN	O	O
and	NN	O	O
December	NN	O	O
2007	NN	O	O
were	NN	O	O
retrospectively	NN	O	O
evaluated	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Of	NN	O	O
the	NN	O	O
206	NN	O	O
dogs	NN	O	O
treated	NN	O	O
with	NN	O	O
CCNU	NN	O	B-Chemical
,	NN	O	O
185	NN	O	O
met	NN	O	O
the	NN	O	O
inclusion	NN	O	O
criteria	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
one	NN	O	O
class	NN	O	O
of	NN	O	O
toxicity	NN	O	B-Disease
.	NN	O	O

CCNU	NN	O	B-Chemical
was	NN	O	O
used	NN	O	O
most	NN	O	O
commonly	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
lymphoma	NN	O	B-Disease
,	NN	O	O
mast	NN	O	B-Disease
cell	NN	O	I-Disease
tumour	NN	O	I-Disease
,	NN	O	O
brain	NN	O	B-Disease
tumour	NN	O	I-Disease
,	NN	O	O
histiocytic	NN	O	B-Disease
tumours	NN	O	I-Disease
and	NN	O	O
epitheliotropic	NN	O	B-Disease
lymphoma	NN	O	I-Disease
.	NN	O	O

Throughout	NN	O	O
treatment	NN	O	O
,	NN	O	O
56.9%	NN	O	O
of	NN	O	O
dogs	NN	O	O
experienced	NN	O	O
neutropenia	NN	O	B-Disease
,	NN	O	O
34.2%	NN	O	O
experienced	NN	O	O
anaemia	NN	O	B-Disease
and	NN	O	O
14.2%	NN	O	O
experienced	NN	O	O
thrombocytopenia	NN	O	B-Disease
.	NN	O	O

Gastrointestinal	NN	O	B-Disease
toxicosis	NN	O	I-Disease
was	NN	O	O
detected	NN	O	O
in	NN	O	O
37.8%	NN	O	O
of	NN	O	O
dogs	NN	O	O
,	NN	O	O
the	NN	O	O
most	NN	O	O
common	NN	O	O
sign	NN	O	O
of	NN	O	O
which	NN	O	O
was	NN	O	O
vomiting	NN	O	B-Disease
(	NN	O	O
24.3%	NN	O	O
)	NN	O	O
.	NN	O	O

Potential	NN	O	O
renal	NN	O	O
toxicity	NN	O	B-Disease
and	NN	O	O
elevated	NN	O	O
alanine	NN	O	B-Chemical
transaminase	NN	O	O
(	NN	O	O
ALT	NN	O	O
)	NN	O	O
concentration	NN	O	O
were	NN	O	O
reported	NN	O	O
in	NN	O	O
12.2%	NN	O	O
and	NN	O	O
48.8%	NN	O	O
of	NN	O	O
dogs	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
hepatic	NN	O	B-Disease
failure	NN	O	I-Disease
was	NN	O	O
1.2%	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
CCNU	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
toxicity	NN	O	B-Disease
in	NN	O	O
dogs	NN	O	O
is	NN	O	O
common	NN	O	O
,	NN	O	O
but	NN	O	O
is	NN	O	O
usually	NN	O	O
not	NN	O	O
life	NN	O	O
threatening	NN	O	O
.	NN	O	O


-DOCSTART- (9121607)

Neuroactive	NN	O	O
steroids	NN	O	B-Chemical
protect	NN	O	O
against	NN	O	O
pilocarpine	NN	O	B-Chemical
-	NN	O	O
and	NN	O	O
kainic	NN	O	B-Chemical
acid	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
limbic	NN	O	O
seizures	NN	O	B-Disease
and	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Several	NN	O	O
structurally	NN	O	O
related	NN	O	O
metabolites	NN	O	O
of	NN	O	O
progesterone	NN	O	B-Chemical
(	NN	O	O
3	NN	O	B-Chemical
alpha	NN	O	I-Chemical
-	NN	O	I-Chemical
hydroxy	NN	O	I-Chemical
pregnane	NN	O	I-Chemical
-	NN	O	I-Chemical
20	NN	O	I-Chemical
-	NN	O	I-Chemical
ones	NN	O	I-Chemical
)	NN	O	O
and	NN	O	O
deoxycorticosterone	NN	O	B-Chemical
(	NN	O	O
3	NN	O	B-Chemical
alpha	NN	O	I-Chemical
-	NN	O	I-Chemical
hydroxy	NN	O	I-Chemical
pregnane	NN	O	I-Chemical
-	NN	O	I-Chemical
21	NN	O	I-Chemical
-	NN	O	I-Chemical
diol	NN	O	I-Chemical
-	NN	O	I-Chemical
20	NN	O	I-Chemical
-	NN	O	I-Chemical
ones	NN	O	I-Chemical
)	NN	O	O
and	NN	O	O
their	NN	O	O
3	NN	O	O
beta	NN	O	O
-	NN	O	O
epimers	NN	O	O
were	NN	O	O
evaluated	NN	O	O
for	NN	O	O
protective	NN	O	O
activity	NN	O	O
against	NN	O	O
pilocarpine	NN	O	B-Chemical
-	NN	O	O
,	NN	O	O
kainic	NN	O	B-Chemical
acid	NN	O	I-Chemical
-	NN	O	O
and	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
-	NN	O	I-Chemical
D	NN	O	I-Chemical
-	NN	O	I-Chemical
aspartate	NN	O	I-Chemical
(	NN	O	O
NMDA	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Steroids	NN	O	B-Chemical
with	NN	O	O
the	NN	O	O
3	NN	O	O
-	NN	O	O
hydroxy	NN	O	O
group	NN	O	O
in	NN	O	O
the	NN	O	O
alpha	NN	O	O
-	NN	O	O
position	NN	O	O
and	NN	O	O
5	NN	O	O
-	NN	O	O
H	NN	O	O
in	NN	O	O
the	NN	O	O
alpha	NN	O	O
-	NN	O	O
or	NN	O	O
beta	NN	O	O
-	NN	O	O
configurations	NN	O	O
were	NN	O	O
highly	NN	O	O
effective	NN	O	O
in	NN	O	O
protecting	NN	O	O
against	NN	O	O
pilocarpine	NN	O	B-Chemical
(	NN	O	O
416	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
s.c.	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
limbic	NN	O	O
motor	NN	O	O
seizures	NN	O	B-Disease
and	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
(	NN	O	O
ED50	NN	O	O
values	NN	O	O
,	NN	O	O
7.0	NN	O	O
-	NN	O	O
18.7	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.p.	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
corresponding	NN	O	O
epimers	NN	O	O
with	NN	O	O
the	NN	O	O
3	NN	O	O
-	NN	O	O
hydroxy	NN	O	O
group	NN	O	O
in	NN	O	O
the	NN	O	O
beta	NN	O	O
-	NN	O	O
position	NN	O	O
were	NN	O	O
also	NN	O	O
effective	NN	O	O
but	NN	O	O
less	NN	O	O
potent	NN	O	O
(	NN	O	O
ED50	NN	O	O
values	NN	O	O
,	NN	O	O
33.8	NN	O	O
-	NN	O	O
63.5	NN	O	O
,	NN	O	O
i.p.	NN	O	O
)	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
neuroactive	NN	O	O
steroids	NN	O	B-Chemical
were	NN	O	O
considerably	NN	O	O
less	NN	O	O
potent	NN	O	O
than	NN	O	O
the	NN	O	O
benzodiazepine	NN	O	B-Chemical
clonazepam	NN	O	B-Chemical
in	NN	O	O
protecting	NN	O	O
against	NN	O	O
pilocarpine	NN	O	B-Chemical
seizures	NN	O	B-Disease
,	NN	O	O
steroids	NN	O	B-Chemical
with	NN	O	O
the	NN	O	O
5	NN	O	O
alpha	NN	O	O
,	NN	O	O
3	NN	O	O
alpha	NN	O	O
-	NN	O	O
configuration	NN	O	O
had	NN	O	O
comparable	NN	O	O
or	NN	O	O
higher	NN	O	O
protective	NN	O	O
index	NN	O	O
values	NN	O	O
(	NN	O	O
TD50	NN	O	O
for	NN	O	O
motor	NN	O	O
impairment	NN	O	O
divided	NN	O	O
by	NN	O	O
ED50	NN	O	O
for	NN	O	O
seizure	NN	O	B-Disease
protection	NN	O	O
)	NN	O	O
than	NN	O	O
clonazepam	NN	O	B-Chemical
,	NN	O	O
indicating	NN	O	O
that	NN	O	O
some	NN	O	O
neuroactive	NN	O	O
steroids	NN	O	B-Chemical
may	NN	O	O
have	NN	O	O
lower	NN	O	O
relative	NN	O	O
toxicity	NN	O	B-Disease
.	NN	O	O

Steroids	NN	O	B-Chemical
with	NN	O	O
the	NN	O	O
5	NN	O	O
alpha	NN	O	O
,	NN	O	O
3	NN	O	O
alpha	NN	O	O
-	NN	O	O
or	NN	O	O
5	NN	O	O
beta	NN	O	O
,	NN	O	O
3	NN	O	O
alpha	NN	O	O
-	NN	O	O
configurations	NN	O	O
also	NN	O	O
produced	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
delay	NN	O	O
in	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
limbic	NN	O	O
seizures	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
kainic	NN	O	B-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
32	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
s.c.	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
completely	NN	O	O
protect	NN	O	O
against	NN	O	O
the	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
when	NN	O	O
a	NN	O	O
second	NN	O	O
dose	NN	O	O
of	NN	O	O
the	NN	O	O
steroid	NN	O	B-Chemical
was	NN	O	O
administered	NN	O	O
1	NN	O	O
hr	NN	O	O
after	NN	O	O
the	NN	O	O
first	NN	O	O
dose	NN	O	O
,	NN	O	O
complete	NN	O	O
protection	NN	O	O
from	NN	O	O
the	NN	O	O
kainic	NN	O	B-Chemical
acid	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
limbic	NN	O	O
seizures	NN	O	B-Disease
and	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
was	NN	O	O
obtained	NN	O	O
.	NN	O	O

The	NN	O	O
steroids	NN	O	B-Chemical
also	NN	O	O
caused	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
delay	NN	O	O
in	NN	O	O
NMDA	NN	O	B-Chemical
(	NN	O	O
257	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
s.c.	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
lethality	NN	O	O
,	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
completely	NN	O	O
protect	NN	O	O
against	NN	O	O
NMDA	NN	O	B-Chemical
seizures	NN	O	B-Disease
or	NN	O	O
lethality	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
neuroactive	NN	O	O
steroids	NN	O	B-Chemical
are	NN	O	O
highly	NN	O	O
effective	NN	O	O
in	NN	O	O
protecting	NN	O	O
against	NN	O	O
pilocarpine	NN	O	B-Chemical
-	NN	O	O
and	NN	O	O
kainic	NN	O	B-Chemical
acid	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
and	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
in	NN	O	O
mice	NN	O	O
,	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
of	NN	O	O
utility	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
some	NN	O	O
forms	NN	O	O
of	NN	O	O
status	NN	O	B-Disease
epilepticus	NN	O	I-Disease
in	NN	O	O
humans	NN	O	O
.	NN	O	O


-DOCSTART- (7905523)

The	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
combination	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
butyl	NN	O	I-Chemical
-	NN	O	I-Chemical
deoxynojirimycin	NN	O	I-Chemical
(	NN	O	O
SC	NN	O	B-Chemical
-	NN	O	I-Chemical
48334	NN	O	I-Chemical
)	NN	O	O
and	NN	O	O
zidovudine	NN	O	B-Chemical
in	NN	O	O
patients	NN	O	O
with	NN	O	O
HIV	NN	O	B-Disease
-	NN	O	I-Disease
1	NN	O	I-Disease
infection	NN	O	I-Disease
and	NN	O	O
200	NN	O	O
-	NN	O	O
500	NN	O	O
CD4	NN	O	O
cells	NN	O	O
/	NN	O	O
mm3	NN	O	O
.	NN	O	O

We	NN	O	O
conducted	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
randomized	NN	O	O
phase	NN	O	O
II	NN	O	O
study	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
activity	NN	O	O
of	NN	O	O
combination	NN	O	O
therapy	NN	O	O
with	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
butyl	NN	O	I-Chemical
-	NN	O	I-Chemical
deoxynojirimycin	NN	O	I-Chemical
(	NN	O	O
SC	NN	O	B-Chemical
-	NN	O	I-Chemical
48334	NN	O	I-Chemical
)	NN	O	O
(	NN	O	O
an	NN	O	O
alpha	NN	O	O
-	NN	O	O
glucosidase	NN	O	O
I	NN	O	O
inhibitor	NN	O	O
)	NN	O	O
and	NN	O	O
zidovudine	NN	O	B-Chemical
versus	NN	O	O
zidovudine	NN	O	B-Chemical
alone	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
200	NN	O	O
to	NN	O	O
500	NN	O	O
CD4	NN	O	O
cells	NN	O	O
/	NN	O	O
mm3	NN	O	O
who	NN	O	O
tolerated	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
12	NN	O	O
weeks	NN	O	O
of	NN	O	O
prior	NN	O	O
zidovudine	NN	O	B-Chemical
therapy	NN	O	O
received	NN	O	O
SC	NN	O	B-Chemical
-	NN	O	I-Chemical
48334	NN	O	I-Chemical
(	NN	O	O
1000	NN	O	O
mg	NN	O	O
every	NN	O	O
8	NN	O	O
h	NN	O	O
)	NN	O	O
and	NN	O	O
zidovudine	NN	O	B-Chemical
(	NN	O	O
100	NN	O	O
mg	NN	O	O
every	NN	O	O
8	NN	O	O
h	NN	O	O
)	NN	O	O
or	NN	O	O
zidovudine	NN	O	B-Chemical
and	NN	O	O
placebo	NN	O	O
.	NN	O	O

Sixty	NN	O	O
patients	NN	O	O
received	NN	O	O
combination	NN	O	O
therapy	NN	O	O
and	NN	O	O
58	NN	O	O
,	NN	O	O
zidovudine	NN	O	B-Chemical
and	NN	O	O
placebo	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
three	NN	O	O
patients	NN	O	O
(	NN	O	O
38%	NN	O	O
)	NN	O	O
and	NN	O	O
15	NN	O	O
(	NN	O	O
26%	NN	O	O
)	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
combination	NN	O	O
and	NN	O	O
zidovudine	NN	O	B-Chemical
groups	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
discontinued	NN	O	O
therapy	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.15	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
SC	NN	O	B-Chemical
-	NN	O	I-Chemical
48334	NN	O	I-Chemical
steady	NN	O	O
-	NN	O	O
state	NN	O	O
trough	NN	O	O
level	NN	O	O
(	NN	O	O
4.04	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.99	NN	O	O
micrograms	NN	O	O
/	NN	O	O
ml	NN	O	O
)	NN	O	O
was	NN	O	O
below	NN	O	O
the	NN	O	O
in	NN	O	O
vitro	NN	O	O
inhibitory	NN	O	O
concentration	NN	O	O
for	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	B-Disease
virus	NN	O	O
(	NN	O	O
HIV	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
mean	NN	O	O
increase	NN	O	O
in	NN	O	O
CD4	NN	O	O
cells	NN	O	O
at	NN	O	O
week	NN	O	O
4	NN	O	O
was	NN	O	O
73.8	NN	O	O
cells	NN	O	O
/	NN	O	O
mm3	NN	O	O
and	NN	O	O
52.4	NN	O	O
cells	NN	O	O
/	NN	O	O
mm3	NN	O	O
for	NN	O	O
the	NN	O	O
combination	NN	O	O
and	NN	O	O
zidovudine	NN	O	B-Chemical
groups	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
p	NN	O	O
>	NN	O	O
0.36	NN	O	O
)	NN	O	O
.	NN	O	O

For	NN	O	O
patients	NN	O	O
with	NN	O	O
prior	NN	O	O
zidovudine	NN	O	B-Chemical
therapy	NN	O	O
,	NN	O	O
the	NN	O	O
mean	NN	O	O
change	NN	O	O
in	NN	O	O
CD4	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
combination	NN	O	O
and	NN	O	O
zidovudine	NN	O	B-Chemical
groups	NN	O	O
was	NN	O	O
63.7	NN	O	O
cells	NN	O	O
/	NN	O	O
mm3	NN	O	O
and	NN	O	O
4.9	NN	O	O
cells	NN	O	O
/	NN	O	O
mm3	NN	O	O
at	NN	O	O
week	NN	O	O
8	NN	O	O
and	NN	O	O
6.8	NN	O	O
cells	NN	O	O
/	NN	O	O
mm3	NN	O	O
and	NN	O	O
-	NN	O	O
45.1	NN	O	O
cells	NN	O	O
/	NN	O	O
mm3	NN	O	O
at	NN	O	O
week	NN	O	O
16	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
number	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
suppression	NN	O	O
of	NN	O	O
HIV	NN	O	O
p24	NN	O	O
antigenemia	NN	O	O
in	NN	O	O
the	NN	O	O
combination	NN	O	O
and	NN	O	O
zidovudine	NN	O	B-Chemical
groups	NN	O	O
was	NN	O	O
six	NN	O	O
(	NN	O	O
40%	NN	O	O
)	NN	O	O
and	NN	O	O
two	NN	O	O
(	NN	O	O
11%	NN	O	O
)	NN	O	O
at	NN	O	O
week	NN	O	O
4	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.10	NN	O	O
)	NN	O	O
and	NN	O	O
five	NN	O	O
(	NN	O	O
45%	NN	O	O
)	NN	O	O
and	NN	O	O
two	NN	O	O
(	NN	O	O
14%	NN	O	O
)	NN	O	O
at	NN	O	O
week	NN	O	O
24	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.08	NN	O	O
)	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Diarrhea	NN	O	B-Disease
,	NN	O	O
flatulence	NN	O	B-Disease
,	NN	O	O
abdominal	NN	O	B-Disease
pain	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
weight	NN	O	B-Disease
loss	NN	O	I-Disease
were	NN	O	O
common	NN	O	O
for	NN	O	O
combination	NN	O	O
recipients.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

-DOCSTART- (3431591)

Recent	NN	O	O
preclinical	NN	O	O
and	NN	O	O
clinical	NN	O	O
studies	NN	O	O
with	NN	O	O
the	NN	O	O
thymidylate	NN	O	O
synthase	NN	O	O
inhibitor	NN	O	O
N10	NN	O	B-Chemical
-	NN	O	I-Chemical
propargyl	NN	O	I-Chemical
-	NN	O	I-Chemical
5	NN	O	I-Chemical
,	NN	O	I-Chemical
8	NN	O	I-Chemical
-	NN	O	I-Chemical
dideazafolic	NN	O	I-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
CB	NN	O	B-Chemical
3717	NN	O	I-Chemical
)	NN	O	O
.	NN	O	O

CB	NN	O	B-Chemical
3717	NN	O	I-Chemical
,	NN	O	O
N10	NN	O	B-Chemical
-	NN	O	I-Chemical
propargyl	NN	O	I-Chemical
-	NN	O	I-Chemical
5	NN	O	I-Chemical
,	NN	O	I-Chemical
8	NN	O	I-Chemical
-	NN	O	I-Chemical
dideazafolic	NN	O	I-Chemical
acid	NN	O	I-Chemical
,	NN	O	O
is	NN	O	O
a	NN	O	O
tight	NN	O	O
-	NN	O	O
binding	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
thymidylate	NN	O	O
synthase	NN	O	O
(	NN	O	O
TS	NN	O	O
)	NN	O	O
whose	NN	O	O
cytotoxicity	NN	O	B-Disease
is	NN	O	O
mediated	NN	O	O
solely	NN	O	O
through	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
this	NN	O	O
enzyme	NN	O	O
.	NN	O	O

Recent	NN	O	O
preclinical	NN	O	O
studies	NN	O	O
have	NN	O	O
focused	NN	O	O
on	NN	O	O
the	NN	O	O
intracellular	NN	O	O
formation	NN	O	O
of	NN	O	O
CB	NN	O	B-Chemical
3717	NN	O	I-Chemical
polyglutamates	NN	O	O
.	NN	O	O

Following	NN	O	O
a	NN	O	O
12	NN	O	O
-	NN	O	O
hour	NN	O	O
exposure	NN	O	O
of	NN	O	O
L1210	NN	O	O
cells	NN	O	O
to	NN	O	O
50	NN	O	O
microM	NN	O	O
[	NN	O	O
3H	NN	O	O
]	NN	O	O
CB	NN	O	B-Chemical
3717	NN	O	I-Chemical
,	NN	O	O
30%	NN	O	O
of	NN	O	O
the	NN	O	O
extractable	NN	O	O
radioactivity	NN	O	O
could	NN	O	O
be	NN	O	O
accounted	NN	O	O
for	NN	O	O
as	NN	O	O
CB	NN	O	B-Chemical
3717	NN	O	I-Chemical
tetra	NN	O	O
-	NN	O	O
and	NN	O	O
pentaglutamate	NN	O	O
,	NN	O	O
as	NN	O	O
determined	NN	O	O
by	NN	O	O
high	NN	O	O
-	NN	O	O
pressure	NN	O	O
liquid	NN	O	O
chromatography	NN	O	O
(	NN	O	O
HPLC	NN	O	O
)	NN	O	O
analyses	NN	O	O
.	NN	O	O

As	NN	O	O
inhibitors	NN	O	O
of	NN	O	O
isolated	NN	O	O
L1210	NN	O	O
TS	NN	O	O
,	NN	O	O
CB	NN	O	O
3717	NN	O	O
di	NN	O	O
-	NN	O	O
,	NN	O	O
tri	NN	O	O
-	NN	O	O
,	NN	O	O
tetra	NN	O	O
-	NN	O	O
and	NN	O	O
pentaglutamate	NN	O	O
are	NN	O	O
26	NN	O	O
-	NN	O	O
,	NN	O	O
87	NN	O	O
-	NN	O	O
,	NN	O	O
119	NN	O	O
-	NN	O	O
and	NN	O	O
114	NN	O	O
-	NN	O	O
fold	NN	O	O
more	NN	O	O
potent	NN	O	O
than	NN	O	O
CB	NN	O	B-Chemical
3717	NN	O	I-Chemical
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
and	NN	O	O
their	NN	O	O
formation	NN	O	O
may	NN	O	O
,	NN	O	O
therefore	NN	O	O
,	NN	O	O
be	NN	O	O
an	NN	O	O
important	NN	O	O
determinant	NN	O	O
of	NN	O	O
CB	NN	O	B-Chemical
3717	NN	O	I-Chemical
cytotoxicity	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
early	NN	O	O
clinical	NN	O	O
studies	NN	O	O
with	NN	O	O
CB	NN	O	B-Chemical
3717	NN	O	I-Chemical
,	NN	O	O
activity	NN	O	O
has	NN	O	O
been	NN	O	O
seen	NN	O	O
in	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
,	NN	O	O
ovarian	NN	O	B-Disease
cancer	NN	O	I-Disease
,	NN	O	O
hepatoma	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
mesothelioma	NN	O	B-Disease
.	NN	O	O

Toxicities	NN	O	B-Disease
included	NN	O	O
hepatotoxicity	NN	O	B-Disease
,	NN	O	O
malaise	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
dose	NN	O	O
-	NN	O	O
limiting	NN	O	O
nephrotoxicity	NN	O	B-Disease
.	NN	O	O

This	NN	O	O
latter	NN	O	O
effect	NN	O	O
is	NN	O	O
thought	NN	O	O
to	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
drug	NN	O	O
precipitation	NN	O	O
within	NN	O	O
the	NN	O	O
renal	NN	O	O
tubule	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
the	NN	O	O
poor	NN	O	O
solubility	NN	O	O
of	NN	O	O
CB	NN	O	B-Chemical
3717	NN	O	I-Chemical
under	NN	O	O
acidic	NN	O	O
conditions	NN	O	O
.	NN	O	O

In	NN	O	O
an	NN	O	O
attempt	NN	O	O
to	NN	O	O
overcome	NN	O	O
this	NN	O	O
problem	NN	O	O
,	NN	O	O
a	NN	O	O
clinical	NN	O	O
trial	NN	O	O
of	NN	O	O
CB	NN	O	B-Chemical
3717	NN	O	I-Chemical
administered	NN	O	O
with	NN	O	O
alkaline	NN	O	O
diuresis	NN	O	O
is	NN	O	O
under	NN	O	O
way	NN	O	O
.	NN	O	O

Preliminary	NN	O	O
results	NN	O	O
at	NN	O	O
400	NN	O	O
and	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
suggest	NN	O	O
that	NN	O	O
a	NN	O	O
reduction	NN	O	O
in	NN	O	O
nephrotoxicity	NN	O	B-Disease
may	NN	O	O
have	NN	O	O
been	NN	O	O
achieved	NN	O	O
with	NN	O	O
only	NN	O	O
1	NN	O	O
instance	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
toxicity	NN	O	I-Disease
in	NN	O	O
10	NN	O	O
patients	NN	O	O
.	NN	O	O

Hepatotoxicity	NN	O	B-Disease
and	NN	O	O
malaise	NN	O	B-Disease
are	NN	O	O
again	NN	O	O
the	NN	O	O
most	NN	O	O
frequent	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Evidence	NN	O	O
of	NN	O	O
antitumor	NN	O	O
activity	NN	O	O
has	NN	O	O
been	NN	O	O
seen	NN	O	O
in	NN	O	O
3	NN	O	O
patients	NN	O	O
.	NN	O	O

Pharmacokinetic	NN	O	O
investigations	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
alkaline	NN	O	O
diuresis	NN	O	O
does	NN	O	O
not	NN	O	O
alter	NN	O	O
CB	NN	O	B-Chemical
3717	NN	O	I-Chemical
plasma	NN	O	O
levels	NN	O	O
or	NN	O	O
urinary	NN	O	O
excretion	NN	O	O
and	NN	O	O
that	NN	O	O
satisfactory	NN	O	O
urinary	NN	O	O
alkalinization	NN	O	O
can	NN	O	O
be	NN	O	O
readily	NN	O	O
achieved	NN	O	O
.	NN	O	O


-DOCSTART- (33969)

Ethopropazine	NN	O	B-Chemical
and	NN	O	O
benztropine	NN	O	B-Chemical
in	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
parkinsonism	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
a	NN	O	O
12	NN	O	O
-	NN	O	O
week	NN	O	O
controlled	NN	O	O
study	NN	O	O
ethopropazine	NN	O	B-Chemical
was	NN	O	O
compared	NN	O	O
to	NN	O	O
benztropine	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
parkinsonism	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
fluphenazine	NN	O	B-Chemical
enanthate	NN	O	I-Chemical
in	NN	O	O
60	NN	O	O
schizophrenic	NN	O	B-Disease
outpatients	NN	O	O
.	NN	O	O

Ethopropazine	NN	O	B-Chemical
and	NN	O	O
benztropine	NN	O	B-Chemical
were	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
equally	NN	O	O
effective	NN	O	O
in	NN	O	O
controlling	NN	O	O
parkinsonian	NN	O	B-Disease
symptoms	NN	O	I-Disease
and	NN	O	O
were	NN	O	O
as	NN	O	O
efficacious	NN	O	O
as	NN	O	O
procyclidine	NN	O	B-Chemical
,	NN	O	O
their	NN	O	O
previous	NN	O	O
antiparkinsonian	NN	O	O
drug	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
benztropine	NN	O	B-Chemical
treated	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
tardive	NN	O	B-Disease
dyskinesia	NN	O	I-Disease
compared	NN	O	O
to	NN	O	O
their	NN	O	O
condition	NN	O	O
during	NN	O	O
procyclindine	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
and	NN	O	O
significantly	NN	O	O
more	NN	O	O
anxiety	NN	O	B-Disease
and	NN	O	O
depression	NN	O	B-Disease
than	NN	O	O
ethopropazine	NN	O	B-Chemical
treated	NN	O	O
patients	NN	O	O
.	NN	O	O

This	NN	O	O
suggests	NN	O	O
that	NN	O	O
benztropine	NN	O	B-Chemical
is	NN	O	O
not	NN	O	O
the	NN	O	O
anticholinergic	NN	O	O
drug	NN	O	O
of	NN	O	O
choice	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
parkinsonian	NN	O	B-Disease
symptoms	NN	O	I-Disease
,	NN	O	O
because	NN	O	O
of	NN	O	O
its	NN	O	O
more	NN	O	O
toxic	NN	O	O
central	NN	O	O
and	NN	O	O
peripheral	NN	O	O
atropinic	NN	O	O
effect	NN	O	O
.	NN	O	O


-DOCSTART- (16844102)

Effect	NN	O	O
of	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
tocopherol	NN	O	I-Chemical
and	NN	O	O
deferoxamine	NN	O	B-Chemical
on	NN	O	O
methamphetamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B-Disease
.	NN	O	O

Methamphetamine	NN	O	B-Chemical
(	NN	O	O
MA	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
dopaminergic	NN	O	O
neurotoxicity	NN	O	B-Disease
is	NN	O	O
believed	NN	O	O
to	NN	O	O
be	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
increased	NN	O	O
formation	NN	O	O
of	NN	O	O
free	NN	O	O
radicals	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
examined	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
tocopherol	NN	O	I-Chemical
(	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
TC	NN	O	I-Chemical
)	NN	O	O
,	NN	O	O
a	NN	O	O
scavenger	NN	O	O
of	NN	O	O
reactive	NN	O	O
oxygen	NN	O	B-Chemical
species	NN	O	O
,	NN	O	O
and	NN	O	O
deferoxamine	NN	O	B-Chemical
(	NN	O	O
DFO	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
an	NN	O	O
iron	NN	O	B-Chemical
chelator	NN	O	O
,	NN	O	O
on	NN	O	O
the	NN	O	O
MA	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B-Disease
.	NN	O	O

Male	NN	O	O
rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
MA	NN	O	B-Chemical
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
every	NN	O	O
2	NN	O	O
h	NN	O	O
for	NN	O	O
four	NN	O	O
injections	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
rat	NN	O	O
received	NN	O	O
either	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
TC	NN	O	I-Chemical
(	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
intraperitoneally	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
and	NN	O	O
30	NN	O	O
min	NN	O	O
prior	NN	O	O
to	NN	O	O
MA	NN	O	B-Chemical
administration	NN	O	O
or	NN	O	O
DFO	NN	O	B-Chemical
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
subcutaneously	NN	O	O
30	NN	O	O
min	NN	O	O
before	NN	O	O
MA	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

The	NN	O	O
concentrations	NN	O	O
of	NN	O	O
dopamine	NN	O	B-Chemical
(	NN	O	O
DA	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
serotonin	NN	O	B-Chemical
and	NN	O	O
their	NN	O	O
metabolites	NN	O	O
decreased	NN	O	O
significantly	NN	O	O
after	NN	O	O
MA	NN	O	B-Chemical
administration	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
inhibited	NN	O	O
by	NN	O	O
the	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
TC	NN	O	I-Chemical
and	NN	O	O
DFO	NN	O	B-Chemical
pretreatment	NN	O	O
.	NN	O	O

alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
TC	NN	O	I-Chemical
and	NN	O	O
DFO	NN	O	B-Chemical
attenuated	NN	O	O
the	NN	O	O
MA	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperthermia	NN	O	B-Disease
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
alterations	NN	O	O
in	NN	O	O
the	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
.	NN	O	O

The	NN	O	O
level	NN	O	O
of	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
was	NN	O	O
higher	NN	O	O
and	NN	O	O
the	NN	O	O
reduced	NN	O	O
glutathione	NN	O	B-Chemical
concentration	NN	O	O
was	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
MA	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

These	NN	O	O
changes	NN	O	O
were	NN	O	O
significantly	NN	O	O
attenuated	NN	O	O
by	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
TC	NN	O	I-Chemical
and	NN	O	O
DFO	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
suggests	NN	O	O
that	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
TC	NN	O	I-Chemical
and	NN	O	O
DFO	NN	O	B-Chemical
ameliorate	NN	O	O
the	NN	O	O
MA	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
neuronal	NN	O	B-Disease
damage	NN	O	I-Disease
by	NN	O	O
decreasing	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
.	NN	O	O


-DOCSTART- (14633084)

Use	NN	O	O
of	NN	O	O
dexamethasone	NN	O	B-Chemical
with	NN	O	O
mesna	NN	O	B-Chemical
for	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
ifosfamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
Hemorrhagic	NN	O	B-Disease
cystitis	NN	O	I-Disease
(	NN	O	O
HC	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
limiting	NN	O	O
side	NN	O	O
-	NN	O	O
effect	NN	O	O
of	NN	O	O
chemotherapy	NN	O	O
with	NN	O	O
ifosfamide	NN	O	B-Chemical
(	NN	O	O
IFS	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
study	NN	O	O
presented	NN	O	O
here	NN	O	O
,	NN	O	O
we	NN	O	O
investigated	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
dexamethasone	NN	O	B-Chemical
in	NN	O	O
combination	NN	O	O
with	NN	O	O
mesna	NN	O	B-Chemical
for	NN	O	O
the	NN	O	O
prevention	NN	O	O
of	NN	O	O
IFS	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
HC	NN	O	B-Disease
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
(	NN	O	O
150	NN	O	O
-	NN	O	O
200	NN	O	O
g	NN	O	O
;	NN	O	O
6	NN	O	O
rats	NN	O	O
per	NN	O	O
group	NN	O	O
)	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
saline	NN	O	O
or	NN	O	O
mesna	NN	O	B-Chemical
5	NN	O	O
min	NN	O	O
(	NN	O	O
i.p.	NN	O	O
)	NN	O	O
before	NN	O	O
and	NN	O	O
2	NN	O	O
and	NN	O	O
6	NN	O	O
h	NN	O	O
after	NN	O	O
(	NN	O	O
v.o.	NN	O	O
)	NN	O	O
administration	NN	O	O
of	NN	O	O
IFS	NN	O	B-Chemical
.	NN	O	O

One	NN	O	O
,	NN	O	O
two	NN	O	O
or	NN	O	O
three	NN	O	O
doses	NN	O	O
of	NN	O	O
mesna	NN	O	B-Chemical
were	NN	O	O
replaced	NN	O	O
with	NN	O	O
dexamethasone	NN	O	B-Chemical
alone	NN	O	O
or	NN	O	O
with	NN	O	O
dexamethasone	NN	O	B-Chemical
plus	NN	O	O
mesna	NN	O	B-Chemical
.	NN	O	O

Cystitis	NN	O	B-Disease
was	NN	O	O
evaluated	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
its	NN	O	O
induction	NN	O	O
by	NN	O	O
the	NN	O	O
changes	NN	O	O
in	NN	O	O
bladder	NN	O	O
wet	NN	O	O
weight	NN	O	O
and	NN	O	O
by	NN	O	O
macroscopic	NN	O	O
and	NN	O	O
microscopic	NN	O	O
analysis	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
replacement	NN	O	O
of	NN	O	O
the	NN	O	O
last	NN	O	O
dose	NN	O	O
or	NN	O	O
the	NN	O	O
last	NN	O	O
two	NN	O	O
doses	NN	O	O
of	NN	O	O
mesna	NN	O	B-Chemical
with	NN	O	O
dexamethasone	NN	O	B-Chemical
reduced	NN	O	O
the	NN	O	O
increase	NN	O	O
in	NN	O	O
bladder	NN	O	O
wet	NN	O	O
weight	NN	O	O
induced	NN	O	O
by	NN	O	O
IFS	NN	O	B-Chemical
by	NN	O	O
84.79%	NN	O	O
and	NN	O	O
89.13%	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
it	NN	O	O
almost	NN	O	O
abolished	NN	O	O
the	NN	O	O
macroscopic	NN	O	O
and	NN	O	O
microscopic	NN	O	O
alterations	NN	O	O
induced	NN	O	O
by	NN	O	O
IFS	NN	O	B-Chemical
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
the	NN	O	O
addition	NN	O	O
of	NN	O	O
dexamethasone	NN	O	B-Chemical
to	NN	O	O
the	NN	O	O
last	NN	O	O
two	NN	O	O
doses	NN	O	O
of	NN	O	O
mesna	NN	O	B-Chemical
was	NN	O	O
more	NN	O	O
efficient	NN	O	O
than	NN	O	O
three	NN	O	O
doses	NN	O	O
of	NN	O	O
mesna	NN	O	B-Chemical
alone	NN	O	O
when	NN	O	O
evaluated	NN	O	O
microscopically	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Dexamethasone	NN	O	B-Chemical
in	NN	O	O
combination	NN	O	O
with	NN	O	O
mesna	NN	O	B-Chemical
was	NN	O	O
efficient	NN	O	O
in	NN	O	O
blocking	NN	O	O
IFS	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
HC	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
replacement	NN	O	O
of	NN	O	O
last	NN	O	O
two	NN	O	O
doses	NN	O	O
of	NN	O	O
mesna	NN	O	B-Chemical
with	NN	O	O
saline	NN	O	O
or	NN	O	O
all	NN	O	O
of	NN	O	O
the	NN	O	O
mesna	NN	O	B-Chemical
doses	NN	O	O
with	NN	O	O
dexamethasone	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
prevent	NN	O	O
HC	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (11999899)

Behavioral	NN	O	O
effects	NN	O	O
of	NN	O	O
MK	NN	O	B-Chemical
-	NN	O	I-Chemical
801	NN	O	I-Chemical
on	NN	O	O
reserpine	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
mice	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
dizocilpine	NN	O	B-Chemical
(	NN	O	O
MK	NN	O	B-Chemical
-	NN	O	I-Chemical
801	NN	O	I-Chemical
)	NN	O	O
,	NN	O	O
a	NN	O	O
noncompetitive	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
-	NN	O	I-Chemical
D	NN	O	I-Chemical
-	NN	O	I-Chemical
aspartate	NN	O	I-Chemical
(	NN	O	O
NMDA	NN	O	B-Chemical
)	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
were	NN	O	O
studied	NN	O	O
on	NN	O	O
dopamine	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
behaviors	NN	O	O
induced	NN	O	O
by	NN	O	O
reserpine	NN	O	B-Chemical
treatments	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
focuses	NN	O	O
on	NN	O	O
behavioral	NN	O	O
syndromes	NN	O	O
that	NN	O	O
may	NN	O	O
used	NN	O	O
as	NN	O	O
models	NN	O	O
for	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
or	NN	O	O
tardive	NN	O	B-Disease
dyskinesia	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
its	NN	O	O
response	NN	O	O
after	NN	O	O
glutamatergic	NN	O	O
blockage	NN	O	O
.	NN	O	O

Reserpine	NN	O	B-Chemical
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
administered	NN	O	O
once	NN	O	O
every	NN	O	O
other	NN	O	O
day	NN	O	O
for	NN	O	O
4	NN	O	O
days	NN	O	O
,	NN	O	O
produced	NN	O	O
increases	NN	O	O
in	NN	O	O
orofacial	NN	O	B-Disease
dyskinesia	NN	O	I-Disease
,	NN	O	O
tongue	NN	O	O
protrusion	NN	O	O
and	NN	O	O
vacuous	NN	O	O
chewing	NN	O	O
in	NN	O	O
mice	NN	O	O
,	NN	O	O
which	NN	O	O
are	NN	O	O
signs	NN	O	O
indicative	NN	O	O
of	NN	O	O
tardive	NN	O	B-Disease
dyskinesia	NN	O	I-Disease
.	NN	O	O

Reserpine	NN	O	B-Chemical
also	NN	O	O
produced	NN	O	O
tremor	NN	O	B-Disease
and	NN	O	O
catalepsy	NN	O	B-Disease
,	NN	O	O
which	NN	O	O
are	NN	O	O
signs	NN	O	O
suggestive	NN	O	O
of	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

MK	NN	O	B-Chemical
-	NN	O	I-Chemical
801	NN	O	I-Chemical
(	NN	O	O
0.1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
administered	NN	O	O
30	NN	O	O
min	NN	O	O
before	NN	O	O
the	NN	O	O
observation	NN	O	O
test	NN	O	O
,	NN	O	O
prevented	NN	O	O
the	NN	O	O
vacuous	NN	O	O
chewing	NN	O	O
movements	NN	O	O
,	NN	O	O
tongue	NN	O	O
protrusions	NN	O	O
and	NN	O	O
catalepsy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
reserpine	NN	O	B-Chemical
.	NN	O	O

However	NN	O	O
,	NN	O	O
MK	NN	O	B-Chemical
-	NN	O	I-Chemical
801	NN	O	I-Chemical
injection	NN	O	O
produced	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
of	NN	O	O
tremor	NN	O	B-Disease
in	NN	O	O
reserpine	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
mice	NN	O	O
.	NN	O	O

Reserpine	NN	O	B-Chemical
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
administered	NN	O	O
90	NN	O	O
min	NN	O	O
before	NN	O	O
the	NN	O	O
test	NN	O	O
and	NN	O	O
followed	NN	O	O
by	NN	O	O
apomophine	NN	O	B-Chemical
injection	NN	O	O
(	NN	O	O
0.1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
5	NN	O	O
min	NN	O	O
before	NN	O	O
the	NN	O	O
test	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
produce	NN	O	O
oral	NN	O	B-Disease
dyskinesia	NN	O	I-Disease
in	NN	O	O
mice	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
reserpine	NN	O	B-Chemical
induced	NN	O	O
increases	NN	O	O
in	NN	O	O
tremor	NN	O	B-Disease
and	NN	O	O
catalepsy	NN	O	B-Disease
compared	NN	O	O
to	NN	O	O
control	NN	O	O
mice	NN	O	O
.	NN	O	O

MK	NN	O	B-Chemical
-	NN	O	I-Chemical
801	NN	O	I-Chemical
(	NN	O	O
0.1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
administration	NN	O	O
attenuated	NN	O	O
the	NN	O	O
catalepsy	NN	O	B-Disease
and	NN	O	O
tremor	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
reserpine	NN	O	B-Chemical
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
reserpine	NN	O	B-Chemical
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
24	NN	O	O
h	NN	O	O
before	NN	O	O
the	NN	O	O
observation	NN	O	O
test	NN	O	O
produced	NN	O	O
increases	NN	O	O
in	NN	O	O
vacuous	NN	O	O
chewing	NN	O	O
movements	NN	O	O
and	NN	O	O
tongue	NN	O	O
protrusion	NN	O	O
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
increases	NN	O	O
in	NN	O	O
tremor	NN	O	B-Disease
and	NN	O	O
catalepsy	NN	O	B-Disease
,	NN	O	O
whereas	NN	O	O
MK	NN	O	B-Chemical
-	NN	O	I-Chemical
801	NN	O	I-Chemical
(	NN	O	O
0.1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
injection	NN	O	O
90	NN	O	O
min	NN	O	O
before	NN	O	O
the	NN	O	O
test	NN	O	O
reversed	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
reserpine	NN	O	B-Chemical
.	NN	O	O

These	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
reserpine	NN	O	B-Chemical
produces	NN	O	O
different	NN	O	O
and	NN	O	O
abnormal	NN	O	B-Disease
movements	NN	O	I-Disease
,	NN	O	O
which	NN	O	O
are	NN	O	O
related	NN	O	O
to	NN	O	O
dose	NN	O	O
and	NN	O	O
schedule	NN	O	O
employed	NN	O	O
and	NN	O	O
can	NN	O	O
be	NN	O	O
considered	NN	O	O
as	NN	O	O
parkinsonian	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
and	NN	O	O
tardive	NN	O	B-Disease
dsykinesia	NN	O	I-Disease
signs	NN	O	O
.	NN	O	O

The	NN	O	O
glutamatergic	NN	O	O
blockage	NN	O	O
produced	NN	O	O
by	NN	O	O
NMDA	NN	O	B-Chemical
can	NN	O	O
restore	NN	O	O
these	NN	O	O
signs	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
vacuous	NN	O	O
chewing	NN	O	O
movements	NN	O	O
,	NN	O	O
tongue	NN	O	O
protrusions	NN	O	O
,	NN	O	O
catalepsy	NN	O	B-Disease
and	NN	O	O
tremor	NN	O	B-Disease
according	NN	O	O
to	NN	O	O
the	NN	O	O
employed	NN	O	O
model	NN	O	O
.	NN	O	O


-DOCSTART- (9431903)

Effect	NN	O	O
of	NN	O	O
glyceryl	NN	O	B-Chemical
trinitrate	NN	O	I-Chemical
on	NN	O	O
the	NN	O	O
sphincter	NN	O	B-Disease
of	NN	O	I-Disease
Oddi	NN	O	I-Disease
spasm	NN	O	I-Disease
evoked	NN	O	O
by	NN	O	O
prostigmine	NN	O	B-Chemical
-	NN	O	O
morphine	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
In	NN	O	O
this	NN	O	O
study	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
glyceryl	NN	O	B-Chemical
trinitrate	NN	O	I-Chemical
on	NN	O	O
the	NN	O	O
prostigmine	NN	O	B-Chemical
-	NN	O	O
morphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
sphincter	NN	O	B-Disease
of	NN	O	I-Disease
Oddi	NN	O	I-Disease
spasm	NN	O	I-Disease
was	NN	O	O
evaluated	NN	O	O
in	NN	O	O
nine	NN	O	O
female	NN	O	O
patients	NN	O	O
with	NN	O	O
sphincter	NN	O	B-Disease
of	NN	O	I-Disease
Oddi	NN	O	I-Disease
dyskinesia	NN	O	I-Disease
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
Sphincter	NN	O	B-Disease
of	NN	O	I-Disease
Oddi	NN	O	I-Disease
spasm	NN	O	I-Disease
was	NN	O	O
induced	NN	O	O
by	NN	O	O
prostigmine	NN	O	B-Chemical
-	NN	O	O
morphine	NN	O	B-Chemical
administration	NN	O	O
(	NN	O	O
0.5	NN	O	O
mg	NN	O	O
prostigmine	NN	O	B-Chemical
intramuscularly	NN	O	O
and	NN	O	O
10	NN	O	O
mg	NN	O	O
morphine	NN	O	B-Chemical
subcutaneously	NN	O	O
)	NN	O	O
and	NN	O	O
visualized	NN	O	O
by	NN	O	O
quantitative	NN	O	O
hepatobiliary	NN	O	O
scintigraphy	NN	O	O
.	NN	O	O

The	NN	O	O
entire	NN	O	O
procedure	NN	O	O
was	NN	O	O
repeated	NN	O	O
during	NN	O	O
glyceryl	NN	O	B-Chemical
trinitrate	NN	O	I-Chemical
infusion	NN	O	O
(	NN	O	O
Nitrolingual	NN	O	B-Chemical
1	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
for	NN	O	O
120	NN	O	O
min	NN	O	O
)	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Prostigmine	NN	O	B-Chemical
-	NN	O	O
morphine	NN	O	B-Chemical
provocation	NN	O	O
caused	NN	O	O
significant	NN	O	O
increases	NN	O	O
in	NN	O	O
the	NN	O	O
time	NN	O	O
to	NN	O	O
peak	NN	O	O
activity	NN	O	O
(	NN	O	O
Tmax	NN	O	O
)	NN	O	O
over	NN	O	O
the	NN	O	O
hepatic	NN	O	O
hilum	NN	O	O
(	NN	O	O
HH	NN	O	O
:	NN	O	O
34.33	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5.05	NN	O	O
vs	NN	O	O
.	NN	O	O

22.77	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3.26	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
common	NN	O	O
bile	NN	O	O
duct	NN	O	O
(	NN	O	O
CBD	NN	O	O
:	NN	O	O
60.44	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5.99	NN	O	O
vs	NN	O	O
.	NN	O	O

40.0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.88	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
half	NN	O	O
-	NN	O	O
time	NN	O	O
of	NN	O	O
excretion	NN	O	O
(	NN	O	O
T1	NN	O	O
/	NN	O	O
2	NN	O	O
)	NN	O	O
over	NN	O	O
the	NN	O	O
liver	NN	O	O
parenchyma	NN	O	O
(	NN	O	O
LP	NN	O	O
:	NN	O	O
120.04	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
16.01	NN	O	O
vs	NN	O	O
.	NN	O	O

27.37	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.19	NN	O	O
)	NN	O	O
,	NN	O	O
HH	NN	O	O
(	NN	O	O
117.61	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
14.71	NN	O	O
vs	NN	O	O
.	NN	O	O

31.85	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3.99	NN	O	O
)	NN	O	O
and	NN	O	O
CBD	NN	O	O
(	NN	O	O
158.11	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
9.18	NN	O	O
vs	NN	O	O
.	NN	O	O

40.1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6.24	NN	O	O
)	NN	O	O
,	NN	O	O
indicating	NN	O	O
a	NN	O	O
complete	NN	O	O
spasm	NN	O	B-Disease
at	NN	O	O
the	NN	O	O
level	NN	O	O
of	NN	O	O
the	NN	O	O
sphincter	NN	O	O
of	NN	O	O
Oddi	NN	O	O
.	NN	O	O

Glyceryl	NN	O	B-Chemical
trinitrate	NN	O	I-Chemical
infusion	NN	O	O
completely	NN	O	O
normalized	NN	O	O
the	NN	O	O
prostigmine	NN	O	B-Chemical
-	NN	O	O
morphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
alterations	NN	O	O
in	NN	O	O
these	NN	O	O
quantitative	NN	O	O
parameters	NN	O	O
(	NN	O	O
TmaX	NN	O	O
over	NN	O	O
the	NN	O	O
LP	NN	O	O
:	NN	O	O
11.33	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.13	NN	O	O
;	NN	O	O
over	NN	O	O
the	NN	O	O
HH	NN	O	O
:	NN	O	O
18.88	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.48	NN	O	O
;	NN	O	O
and	NN	O	O
over	NN	O	O
the	NN	O	O
CBD	NN	O	O
:	NN	O	O
36.22	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.92	NN	O	O
;	NN	O	O
and	NN	O	O
T1	NN	O	O
/	NN	O	O
2	NN	O	O
over	NN	O	O
the	NN	O	O
LP	NN	O	O
:	NN	O	O
28.21	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.83	NN	O	O
;	NN	O	O
over	NN	O	O
the	NN	O	O
HH	NN	O	O
:	NN	O	O
33.42	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3.10	NN	O	O
;	NN	O	O
and	NN	O	O
over	NN	O	O
the	NN	O	O
CBD	NN	O	O
:	NN	O	O
41.66	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
6.33	NN	O	O
)	NN	O	O
,	NN	O	O
suggesting	NN	O	O
an	NN	O	O
effective	NN	O	O
sphincter	NN	O	O
-	NN	O	O
relaxing	NN	O	O
effect	NN	O	O
of	NN	O	O
glyceryl	NN	O	B-Chemical
trinitrate	NN	O	I-Chemical
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
These	NN	O	O
results	NN	O	O
provide	NN	O	O
the	NN	O	O
first	NN	O	O
evidence	NN	O	O
of	NN	O	O
the	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
glyceryl	NN	O	B-Chemical
trinitrate	NN	O	I-Chemical
on	NN	O	O
the	NN	O	O
morphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
sphincter	NN	O	B-Disease
of	NN	O	I-Disease
Oddi	NN	O	I-Disease
spasm	NN	O	I-Disease
in	NN	O	O
humans	NN	O	O
.	NN	O	O

Since	NN	O	O
glyceryl	NN	O	B-Chemical
trinitrate	NN	O	I-Chemical
is	NN	O	O
able	NN	O	O
to	NN	O	O
overcome	NN	O	O
even	NN	O	O
the	NN	O	O
drastic	NN	O	O
effect	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
,	NN	O	O
it	NN	O	O
might	NN	O	O
be	NN	O	O
of	NN	O	O
relevance	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
sphincter	NN	O	B-Disease
of	NN	O	I-Disease
Oddi	NN	O	I-Disease
dyskinesia	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (8665051)

Effects	NN	O	O
of	NN	O	O
acute	NN	O	O
steroid	NN	O	B-Chemical
administration	NN	O	O
on	NN	O	O
ventilatory	NN	O	O
and	NN	O	O
peripheral	NN	O	O
muscles	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Occasional	NN	O	O
case	NN	O	O
reports	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
acute	NN	O	O
myopathy	NN	O	B-Disease
may	NN	O	O
occur	NN	O	O
in	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
massive	NN	O	O
doses	NN	O	O
of	NN	O	O
corticosteroids	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
of	NN	O	O
this	NN	O	O
myopathy	NN	O	B-Disease
is	NN	O	O
poorly	NN	O	O
understood	NN	O	O
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
60	NN	O	O
male	NN	O	O
rats	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
receive	NN	O	O
daily	NN	O	O
injection	NN	O	O
of	NN	O	O
saline	NN	O	O
(	NN	O	O
C	NN	O	O
)	NN	O	O
,	NN	O	O
methylprednisolone	NN	O	B-Chemical
(	NN	O	O
M	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
or	NN	O	O
triamcinolone	NN	O	B-Chemical
(	NN	O	O
T	NN	O	B-Chemical
)	NN	O	O
80	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
d	NN	O	O
for	NN	O	O
5	NN	O	O
d	NN	O	O
.	NN	O	O

Nutritional	NN	O	O
intake	NN	O	O
,	NN	O	O
measured	NN	O	O
daily	NN	O	O
in	NN	O	O
15	NN	O	O
animals	NN	O	O
,	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	B-Disease
of	NN	O	I-Disease
food	NN	O	I-Disease
intake	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
steroid	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
groups	NN	O	O
(	NN	O	O
-	NN	O	O
50	NN	O	O
and	NN	O	O
-	NN	O	O
79%	NN	O	O
in	NN	O	O
M	NN	O	B-Chemical
and	NN	O	O
T	NN	O	B-Chemical
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
similar	NN	O	O
loss	NN	O	B-Disease
in	NN	O	I-Disease
body	NN	O	I-Disease
weight	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
the	NN	O	O
45	NN	O	O
remaining	NN	O	O
animals	NN	O	O
,	NN	O	O
diaphragm	NN	O	O
contractility	NN	O	O
and	NN	O	O
histopathologic	NN	O	O
features	NN	O	O
of	NN	O	O
several	NN	O	O
muscles	NN	O	O
were	NN	O	O
studied	NN	O	O
.	NN	O	O

Weights	NN	O	O
of	NN	O	O
respiratory	NN	O	O
and	NN	O	O
peripheral	NN	O	O
muscles	NN	O	O
were	NN	O	O
similarly	NN	O	O
decreased	NN	O	O
after	NN	O	O
steroid	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

Maximal	NN	O	O
twitches	NN	O	O
of	NN	O	O
the	NN	O	O
diaphragm	NN	O	O
were	NN	O	O
lower	NN	O	O
in	NN	O	O
the	NN	O	O
C	NN	O	O
group	NN	O	O
(	NN	O	O
653	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
174	NN	O	O
g	NN	O	O
/	NN	O	O
cm	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
M	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
837	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
171	NN	O	O
g	NN	O	O
/	NN	O	O
cm	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
;	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
T	NN	O	B-Chemical
group	NN	O	O
(	NN	O	O
765	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
145	NN	O	O
g	NN	O	O
/	NN	O	O
cm	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
NS	NN	O	O
)	NN	O	O
.	NN	O	O

Half	NN	O	O
-	NN	O	O
relaxation	NN	O	O
time	NN	O	O
was	NN	O	O
prolonged	NN	O	O
in	NN	O	O
both	NN	O	O
steroid	NN	O	B-Chemical
groups	NN	O	O
,	NN	O	O
and	NN	O	O
time	NN	O	O
to	NN	O	O
peak	NN	O	O
tension	NN	O	O
was	NN	O	O
longer	NN	O	O
with	NN	O	O
M	NN	O	B-Chemical
,	NN	O	O
whereas	NN	O	O
tetanic	NN	O	B-Disease
tensions	NN	O	O
were	NN	O	O
similar	NN	O	O
.	NN	O	O

Steroid	NN	O	B-Chemical
treatment	NN	O	O
also	NN	O	O
induced	NN	O	O
a	NN	O	O
leftward	NN	O	O
shift	NN	O	O
of	NN	O	O
the	NN	O	O
force	NN	O	O
-	NN	O	O
frequency	NN	O	O
curve	NN	O	O
at	NN	O	O
25	NN	O	O
and	NN	O	O
50	NN	O	O
Hz	NN	O	O
when	NN	O	O
compared	NN	O	O
with	NN	O	O
saline	NN	O	O
treatment	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

ATPase	NN	O	O
staining	NN	O	O
of	NN	O	O
the	NN	O	O
diaphragm	NN	O	O
,	NN	O	O
scalenus	NN	O	O
medius	NN	O	O
,	NN	O	O
and	NN	O	O
gastrocnemius	NN	O	O
showed	NN	O	O
type	NN	O	O
IIb	NN	O	O
fiber	NN	O	O
atrophy	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
steroid	NN	O	B-Chemical
groups	NN	O	O
and	NN	O	O
also	NN	O	O
diaphragmatic	NN	O	O
type	NN	O	O
IIa	NN	O	O
atrophy	NN	O	B-Disease
with	NN	O	O
T	NN	O	B-Chemical
,	NN	O	O
whereas	NN	O	O
histologic	NN	O	O
examinations	NN	O	O
revealed	NN	O	O
a	NN	O	O
normal	NN	O	O
muscular	NN	O	O
pattern	NN	O	O
with	NN	O	O
absence	NN	O	O
of	NN	O	O
necrosis	NN	O	B-Disease
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
a	NN	O	O
pair	NN	O	O
-	NN	O	O
fed	NN	O	O
(	NN	O	O
PF	NN	O	O
)	NN	O	O
study	NN	O	O
,	NN	O	O
performed	NN	O	O
in	NN	O	O
18	NN	O	O
rats	NN	O	O
(	NN	O	O
C	NN	O	O
,	NN	O	O
T	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
PF	NN	O	O
)	NN	O	O
,	NN	O	O
showed	NN	O	O
that	NN	O	O
muscle	NN	O	B-Disease
atrophy	NN	O	I-Disease
was	NN	O	O
considerably	NN	O	O
less	NN	O	O
pronounced	NN	O	O
in	NN	O	O
PF	NN	O	O
animals	NN	O	O
than	NN	O	O
in	NN	O	O
T	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
treatment	NN	O	O
with	NN	O	O
massive	NN	O	O
doses	NN	O	O
of	NN	O	O
steroids	NN	O	B-Chemical
induced	NN	O	O
severe	NN	O	O
respiratory	NN	O	O
and	NN	O	O
limb	NN	O	O
muscle	NN	O	O
wasting	NN	O	O
;	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
both	NN	O	O
types	NN	O	O
of	NN	O	O
steroids	NN	O	B-Chemical
induced	NN	O	O
predominantly	NN	O	O
type	NN	O	O
IIb	NN	O	O
atrophy	NN	O	B-Disease
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
the	NN	O	O
expected	NN	O	O
alterations	NN	O	O
in	NN	O	O
diaphragm	NN	O	O
contractile	NN	O	O
properties	NN	O	O
;	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
neither	NN	O	O
steroid	NN	O	B-Chemical
caused	NN	O	O
muscle	NN	O	O
necrosis	NN	O	B-Disease
;	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
type	NN	O	O
IIb	NN	O	O
atrophy	NN	O	B-Disease
was	NN	O	O
not	NN	O	O
caused	NN	O	O
by	NN	O	O
acute	NN	O	O
nutritional	NN	O	O
deprivation	NN	O	O
alone	NN	O	O
.	NN	O	O


-DOCSTART- (7785794)

Refractory	NN	O	O
cardiogenic	NN	O	B-Disease
shock	NN	O	I-Disease
and	NN	O	O
complete	NN	O	O
heart	NN	O	B-Disease
block	NN	O	I-Disease
after	NN	O	O
verapamil	NN	O	B-Chemical
SR	NN	O	O
and	NN	O	O
metoprolol	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

A	NN	O	O
seventy	NN	O	O
-	NN	O	O
eight	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
presented	NN	O	O
with	NN	O	O
complete	NN	O	O
heart	NN	O	B-Disease
block	NN	O	I-Disease
and	NN	O	O
refractory	NN	O	O
hypotension	NN	O	B-Disease
two	NN	O	O
days	NN	O	O
after	NN	O	O
a	NN	O	O
therapeutic	NN	O	O
dose	NN	O	O
of	NN	O	O
sustained	NN	O	O
-	NN	O	O
release	NN	O	O
verapamil	NN	O	B-Chemical
with	NN	O	O
concomitant	NN	O	O
use	NN	O	O
of	NN	O	O
metoprolol	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
patient	NN	O	O
continued	NN	O	O
to	NN	O	O
remain	NN	O	O
hypotensive	NN	O	B-Disease
with	NN	O	O
complete	NN	O	O
heart	NN	O	B-Disease
block	NN	O	I-Disease
,	NN	O	O
even	NN	O	O
with	NN	O	O
multiple	NN	O	O
uses	NN	O	O
of	NN	O	O
intravenous	NN	O	O
atropine	NN	O	B-Chemical
as	NN	O	O
well	NN	O	O
as	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
pressor	NN	O	O
agents	NN	O	O
such	NN	O	O
as	NN	O	O
dopamine	NN	O	B-Chemical
and	NN	O	O
dobutamine	NN	O	B-Chemical
.	NN	O	O

However	NN	O	O
,	NN	O	O
shortly	NN	O	O
after	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
intravenous	NN	O	O
calcium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
,	NN	O	O
the	NN	O	O
refractory	NN	O	O
hypotension	NN	O	B-Disease
and	NN	O	O
complete	NN	O	O
heart	NN	O	B-Disease
block	NN	O	I-Disease
resolved	NN	O	O
.	NN	O	O


-DOCSTART- (8958188)

A	NN	O	O
phase	NN	O	O
I	NN	O	O
clinical	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
antipurine	NN	O	B-Chemical
antifolate	NN	O	O
lometrexol	NN	O	B-Chemical
(	NN	O	O
DDATHF	NN	O	B-Chemical
)	NN	O	O
given	NN	O	O
with	NN	O	O
oral	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
.	NN	O	O

Lometrexol	NN	O	B-Chemical
is	NN	O	O
an	NN	O	O
antifolate	NN	O	O
which	NN	O	O
inhibits	NN	O	O
glycinamide	NN	O	B-Chemical
ribonucleotide	NN	O	I-Chemical
formyltransferase	NN	O	O
(	NN	O	O
GARFT	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
enzyme	NN	O	O
essential	NN	O	O
for	NN	O	O
de	NN	O	O
novo	NN	O	O
purine	NN	O	B-Chemical
synthesis	NN	O	O
.	NN	O	O

Extensive	NN	O	O
experimental	NN	O	O
and	NN	O	O
limited	NN	O	O
clinical	NN	O	O
data	NN	O	O
have	NN	O	O
shown	NN	O	O
that	NN	O	O
lometrexol	NN	O	B-Chemical
has	NN	O	O
activity	NN	O	O
against	NN	O	O
tumours	NN	O	B-Disease
which	NN	O	O
are	NN	O	O
refractory	NN	O	O
to	NN	O	O
other	NN	O	O
drugs	NN	O	O
,	NN	O	O
notably	NN	O	O
methotrexate	NN	O	B-Chemical
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
initial	NN	O	O
clinical	NN	O	O
development	NN	O	O
of	NN	O	O
lometrexol	NN	O	B-Chemical
was	NN	O	O
curtailed	NN	O	O
because	NN	O	O
of	NN	O	O
severe	NN	O	O
and	NN	O	O
cumulative	NN	O	O
antiproliferative	NN	O	O
toxicities	NN	O	B-Disease
.	NN	O	O

Preclinical	NN	O	O
murine	NN	O	O
studies	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
the	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
lometrexol	NN	O	B-Chemical
can	NN	O	O
be	NN	O	O
prevented	NN	O	O
by	NN	O	O
low	NN	O	O
dose	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
administration	NN	O	O
,	NN	O	O
i.e.	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
prior	NN	O	O
to	NN	O	O
and	NN	O	O
7	NN	O	O
days	NN	O	O
following	NN	O	O
a	NN	O	O
single	NN	O	O
bolus	NN	O	O
dose	NN	O	O
.	NN	O	O

This	NN	O	O
observation	NN	O	O
prompted	NN	O	O
a	NN	O	O
Phase	NN	O	O
I	NN	O	O
clinical	NN	O	O
study	NN	O	O
of	NN	O	O
lometrexol	NN	O	B-Chemical
given	NN	O	O
with	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
supplementation	NN	O	O
which	NN	O	O
has	NN	O	O
confirmed	NN	O	O
that	NN	O	O
the	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
lometrexol	NN	O	B-Chemical
can	NN	O	O
be	NN	O	O
markedly	NN	O	O
reduced	NN	O	O
by	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
supplementation	NN	O	O
.	NN	O	O

Thrombocytopenia	NN	O	B-Disease
and	NN	O	O
mucositis	NN	O	B-Disease
were	NN	O	O
the	NN	O	O
major	NN	O	O
toxicities	NN	O	B-Disease
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
clear	NN	O	O
relationship	NN	O	O
between	NN	O	O
clinical	NN	O	O
toxicity	NN	O	B-Disease
and	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
plasma	NN	O	O
folate	NN	O	B-Chemical
elevation	NN	O	O
.	NN	O	O

Associated	NN	O	O
studies	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
lometrexol	NN	O	B-Chemical
plasma	NN	O	O
pharmacokinetics	NN	O	O
were	NN	O	O
not	NN	O	O
altered	NN	O	O
by	NN	O	O
folic	NN	O	B-Chemical
acid	NN	O	I-Chemical
administration	NN	O	O
indicating	NN	O	O
that	NN	O	O
supplementation	NN	O	O
is	NN	O	O
unlikely	NN	O	O
to	NN	O	O
reduce	NN	O	O
toxicity	NN	O	B-Disease
by	NN	O	O
enhancing	NN	O	O
lometrexol	NN	O	B-Chemical
plasma	NN	O	O
clearance	NN	O	O
.	NN	O	O

The	NN	O	O
work	NN	O	O
described	NN	O	O
in	NN	O	O
this	NN	O	O
report	NN	O	O
has	NN	O	O
identified	NN	O	O
for	NN	O	O
the	NN	O	O
first	NN	O	O
time	NN	O	O
a	NN	O	O
clinically	NN	O	O
acceptable	NN	O	O
schedule	NN	O	O
for	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
a	NN	O	O
GARFT	NN	O	O
inhibitor	NN	O	O
.	NN	O	O

This	NN	O	O
information	NN	O	O
will	NN	O	O
facilitate	NN	O	O
the	NN	O	O
future	NN	O	O
evaluation	NN	O	O
of	NN	O	O
this	NN	O	O
class	NN	O	O
of	NN	O	O
compounds	NN	O	O
in	NN	O	O
cancer	NN	O	B-Disease
therapy	NN	O	O
.	NN	O	O


-DOCSTART- (2557556)

Involvement	NN	O	O
of	NN	O	O
the	NN	O	O
mu	NN	O	O
-	NN	O	O
opiate	NN	O	O
receptor	NN	O	O
in	NN	O	O
peripheral	NN	O	O
analgesia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
intradermal	NN	O	O
injection	NN	O	O
of	NN	O	O
mu	NN	O	O
(	NN	O	O
morphine	NN	O	B-Chemical
,	NN	O	O
Tyr	NN	O	B-Chemical
-	NN	O	I-Chemical
D	NN	O	I-Chemical
-	NN	O	I-Chemical
Ala	NN	O	I-Chemical
-	NN	O	I-Chemical
Gly	NN	O	I-Chemical
-	NN	O	I-Chemical
NMe	NN	O	I-Chemical
-	NN	O	I-Chemical
Phe	NN	O	I-Chemical
-	NN	O	I-Chemical
Gly	NN	O	I-Chemical
-	NN	O	I-Chemical
ol	NN	O	I-Chemical
and	NN	O	O
morphiceptin	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
kappa	NN	O	O
(	NN	O	O
trans	NN	O	B-Chemical
-	NN	O	I-Chemical
3	NN	O	I-Chemical
,	NN	O	I-Chemical
4	NN	O	I-Chemical
-	NN	O	I-Chemical
dichloro	NN	O	I-Chemical
-	NN	O	I-Chemical
N	NN	O	I-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
-	NN	O	I-Chemical
N	NN	O	I-Chemical
[	NN	O	I-Chemical
2	NN	O	I-Chemical
-	NN	O	I-Chemical
(	NN	O	I-Chemical
1	NN	O	I-Chemical
-	NN	O	I-Chemical
pyrrolidinyl	NN	O	I-Chemical
)	NN	O	I-Chemical
cyclohexyl	NN	O	I-Chemical
]	NN	O	I-Chemical
benzeneactemide	NN	O	I-Chemical
)	NN	O	O
and	NN	O	O
delta	NN	O	O
(	NN	O	O
[	NN	O	B-Chemical
D	NN	O	I-Chemical
-	NN	O	I-Chemical
Pen2.5	NN	O	I-Chemical
]	NN	O	I-Chemical
-	NN	O	I-Chemical
enkephalin	NN	O	I-Chemical
and	NN	O	O
[	NN	O	B-Chemical
D	NN	O	I-Chemical
-	NN	O	I-Chemical
Ser2	NN	O	I-Chemical
]	NN	O	I-Chemical
-	NN	O	I-Chemical
[	NN	O	I-Chemical
Leu	NN	O	I-Chemical
]	NN	O	I-Chemical
enkephalin	NN	O	I-Chemical
-	NN	O	I-Chemical
Thr	NN	O	I-Chemical
)	NN	O	O
selective	NN	O	O
opioid	NN	O	O
-	NN	O	O
agonists	NN	O	O
,	NN	O	O
by	NN	O	O
themselves	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
significantly	NN	O	O
affect	NN	O	O
the	NN	O	O
mechanical	NN	O	O
nociceptive	NN	O	O
threshold	NN	O	O
in	NN	O	O
the	NN	O	O
hindpaw	NN	O	O
of	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Intradermal	NN	O	O
injection	NN	O	O
of	NN	O	O
mu	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
delta	NN	O	O
or	NN	O	O
kappa	NN	O	O
opioid	NN	O	O
-	NN	O	O
agonists	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
produced	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
inhibition	NN	O	O
of	NN	O	O
prostaglandin	NN	O	B-Chemical
E2	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
hyperalgesia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
analgesic	NN	O	O
effect	NN	O	O
of	NN	O	O
the	NN	O	O
mu	NN	O	O
-	NN	O	O
agonist	NN	O	O
morphine	NN	O	B-Chemical
was	NN	O	O
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
antagonized	NN	O	O
by	NN	O	O
naloxone	NN	O	B-Chemical
and	NN	O	O
prevented	NN	O	O
by	NN	O	O
co	NN	O	O
-	NN	O	O
injection	NN	O	O
of	NN	O	O
pertussis	NN	O	O
toxin	NN	O	O
.	NN	O	O

Morphine	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
alter	NN	O	O
the	NN	O	O
hyperalgesia	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
8	NN	O	B-Chemical
-	NN	O	I-Chemical
bromo	NN	O	I-Chemical
cyclic	NN	O	I-Chemical
adenosine	NN	O	I-Chemical
monophosphate	NN	O	I-Chemical
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
the	NN	O	O
analgesic	NN	O	O
action	NN	O	O
of	NN	O	O
opioids	NN	O	O
on	NN	O	O
the	NN	O	O
peripheral	NN	O	O
terminals	NN	O	O
of	NN	O	O
primary	NN	O	O
afferents	NN	O	O
is	NN	O	O
via	NN	O	O
a	NN	O	O
binding	NN	O	O
site	NN	O	O
with	NN	O	O
characteristics	NN	O	O
of	NN	O	O
the	NN	O	O
mu	NN	O	O
-	NN	O	O
opioid	NN	O	O
receptor	NN	O	O
and	NN	O	O
that	NN	O	O
this	NN	O	O
action	NN	O	O
is	NN	O	O
mediated	NN	O	O
by	NN	O	O
inhibition	NN	O	O
of	NN	O	O
the	NN	O	O
cyclic	NN	O	B-Chemical
adenosine	NN	O	I-Chemical
monophosphate	NN	O	I-Chemical
second	NN	O	O
messenger	NN	O	O
system	NN	O	O
.	NN	O	O


-DOCSTART- (15580403)

Adequate	NN	O	O
timing	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
reduction	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
hemolysis	NN	O	B-Disease
during	NN	O	O
combination	NN	O	O
therapy	NN	O	O
of	NN	O	O
interferon	NN	O	B-Chemical
and	NN	O	O
ribavirin	NN	O	B-Chemical
for	NN	O	O
chronic	NN	O	B-Disease
hepatitis	NN	O	I-Disease
C	NN	O	I-Disease
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
is	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
major	NN	O	O
adverse	NN	O	O
events	NN	O	O
of	NN	O	O
the	NN	O	O
combination	NN	O	O
therapy	NN	O	O
of	NN	O	O
interferon	NN	O	B-Chemical
and	NN	O	O
ribavirin	NN	O	B-Chemical
.	NN	O	O

Because	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
,	NN	O	O
dose	NN	O	O
reduction	NN	O	O
is	NN	O	O
a	NN	O	O
common	NN	O	O
event	NN	O	O
in	NN	O	O
this	NN	O	O
therapy	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
clinical	NN	O	O
retrospective	NN	O	O
cohort	NN	O	O
study	NN	O	O
we	NN	O	O
have	NN	O	O
examined	NN	O	O
the	NN	O	O
suitable	NN	O	O
timing	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
reduction	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
hemolysis	NN	O	B-Disease
during	NN	O	O
combination	NN	O	O
therapy	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Thirty	NN	O	O
-	NN	O	O
seven	NN	O	O
of	NN	O	O
160	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
HCV	NN	O	O
-	NN	O	O
genotype	NN	O	O
1b	NN	O	O
,	NN	O	O
had	NN	O	O
high	NN	O	O
virus	NN	O	O
load	NN	O	O
,	NN	O	O
and	NN	O	O
received	NN	O	O
24	NN	O	O
-	NN	O	O
week	NN	O	O
combination	NN	O	O
therapy	NN	O	O
developed	NN	O	O
anemia	NN	O	B-Disease
with	NN	O	O
hemoglobin	NN	O	O
level	NN	O	O
<10	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
or	NN	O	O
anemia	NN	O	B-Disease
-	NN	O	O
related	NN	O	O
signs	NN	O	O
during	NN	O	O
therapy	NN	O	O
.	NN	O	O

After	NN	O	O
that	NN	O	O
,	NN	O	O
these	NN	O	O
37	NN	O	O
patients	NN	O	O
were	NN	O	O
reduced	NN	O	O
one	NN	O	O
tablet	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
(	NN	O	O
200	NN	O	O
mg	NN	O	O
)	NN	O	O
per	NN	O	O
day	NN	O	O
.	NN	O	O

After	NN	O	O
reduction	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
,	NN	O	O
27	NN	O	O
of	NN	O	O
37	NN	O	O
patients	NN	O	O
could	NN	O	O
continue	NN	O	O
combination	NN	O	O
therapy	NN	O	O
for	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
24	NN	O	O
weeks	NN	O	O
(	NN	O	O
group	NN	O	O
A	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
10	NN	O	O
of	NN	O	O
37	NN	O	O
patients	NN	O	O
with	NN	O	O
reduction	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
could	NN	O	O
not	NN	O	O
continue	NN	O	O
combination	NN	O	O
therapy	NN	O	O
because	NN	O	O
their	NN	O	O
<8.5	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
hemoglobin	NN	O	O
values	NN	O	O
decreased	NN	O	O
to	NN	O	O
or	NN	O	O
anemia	NN	O	B-Disease
-	NN	O	O
related	NN	O	O
severe	NN	O	O
side	NN	O	O
effects	NN	O	O
occurred	NN	O	O
(	NN	O	O
group	NN	O	O
B	NN	O	O
)	NN	O	O
.	NN	O	O

We	NN	O	O
assessed	NN	O	O
the	NN	O	O
final	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
after	NN	O	O
reduction	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
in	NN	O	O
groups	NN	O	O
A	NN	O	O
and	NN	O	O
B	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
sustained	NN	O	O
virological	NN	O	O
response	NN	O	O
(	NN	O	O
SVR	NN	O	O
)	NN	O	O
was	NN	O	O
29.6%	NN	O	O
(	NN	O	O
8	NN	O	O
/	NN	O	O
27	NN	O	O
)	NN	O	O
in	NN	O	O
group	NN	O	O
A	NN	O	O
and	NN	O	O
10%	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
10	NN	O	O
)	NN	O	O
in	NN	O	O
group	NN	O	O
B	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

A	NN	O	O
34.4%	NN	O	O
(	NN	O	O
12	NN	O	O
/	NN	O	O
27	NN	O	O
)	NN	O	O
of	NN	O	O
SVR	NN	O	O
+	NN	O	O
biological	NN	O	O
response	NN	O	O
in	NN	O	O
group	NN	O	O
A	NN	O	O
was	NN	O	O
higher	NN	O	O
than	NN	O	O
10%	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
10	NN	O	O
)	NN	O	O
in	NN	O	O
group	NN	O	O
B	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.051	NN	O	O
)	NN	O	O
,	NN	O	O
with	NN	O	O
slight	NN	O	O
significance	NN	O	O
.	NN	O	O

With	NN	O	O
respect	NN	O	O
to	NN	O	O
hemoglobin	NN	O	O
level	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
reduction	NN	O	O
,	NN	O	O
a	NN	O	O
rate	NN	O	O
of	NN	O	O
continuation	NN	O	O
of	NN	O	O
therapy	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
>	NN	O	O
or	NN	O	O
=10	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
hemoglobin	NN	O	O
was	NN	O	O
higher	NN	O	O
than	NN	O	O
that	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
<10	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.036	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Reduction	NN	O	O
of	NN	O	O
ribavirin	NN	O	B-Chemical
at	NN	O	O
hemoglobin	NN	O	O
level	NN	O	O
>	NN	O	O
or	NN	O	O
=10	NN	O	O
g	NN	O	O
/	NN	O	O
dl	NN	O	O
is	NN	O	O
suitable	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
efficacy	NN	O	O
and	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O


-DOCSTART- (15075188)

Increased	NN	O	O
expression	NN	O	O
and	NN	O	O
apical	NN	O	O
targeting	NN	O	O
of	NN	O	O
renal	NN	O	O
ENaC	NN	O	O
subunits	NN	O	O
in	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
is	NN	O	O
often	NN	O	O
accompanied	NN	O	O
by	NN	O	O
sodium	NN	O	B-Chemical
retention	NN	O	O
and	NN	O	O
generalized	NN	O	O
edema	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
molecular	NN	O	O
basis	NN	O	O
for	NN	O	O
the	NN	O	O
decreased	NN	O	O
renal	NN	O	O
sodium	NN	O	B-Chemical
excretion	NN	O	O
remains	NN	O	O
undefined	NN	O	O
.	NN	O	O

We	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
epithelial	NN	O	O
Na	NN	O	B-Chemical
channel	NN	O	O
(	NN	O	O
ENaC	NN	O	O
)	NN	O	O
subunit	NN	O	O
dysregulation	NN	O	O
may	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
increased	NN	O	O
sodium	NN	O	B-Chemical
retention	NN	O	O
.	NN	O	O

An	NN	O	O
experimental	NN	O	O
group	NN	O	O
of	NN	O	O
rats	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
(	NN	O	O
PAN	NN	O	B-Chemical
;	NN	O	O
180	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
iv	NN	O	O
)	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
received	NN	O	O
only	NN	O	O
vehicle	NN	O	O
.	NN	O	O

After	NN	O	O
7	NN	O	O
days	NN	O	O
,	NN	O	O
PAN	NN	O	B-Chemical
treatment	NN	O	O
induced	NN	O	O
significant	NN	O	O
proteinuria	NN	O	B-Disease
,	NN	O	O
hypoalbuminemia	NN	O	B-Disease
,	NN	O	O
decreased	NN	O	O
urinary	NN	O	O
sodium	NN	O	B-Chemical
excretion	NN	O	O
,	NN	O	O
and	NN	O	O
extensive	NN	O	O
ascites	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
protein	NN	O	O
abundance	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
ENaC	NN	O	O
and	NN	O	O
beta	NN	O	O
-	NN	O	O
ENaC	NN	O	O
was	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
inner	NN	O	O
stripe	NN	O	O
of	NN	O	O
the	NN	O	O
outer	NN	O	O
medulla	NN	O	O
(	NN	O	O
ISOM	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
inner	NN	O	O
medulla	NN	O	O
(	NN	O	O
IM	NN	O	O
)	NN	O	O
but	NN	O	O
was	NN	O	O
not	NN	O	O
altered	NN	O	O
in	NN	O	O
the	NN	O	O
cortex	NN	O	O
.	NN	O	O

gamma	NN	O	O
-	NN	O	O
ENaC	NN	O	O
abundance	NN	O	O
was	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
cortex	NN	O	O
,	NN	O	O
ISOM	NN	O	O
,	NN	O	O
and	NN	O	O
IM	NN	O	O
.	NN	O	O

Immunoperoxidase	NN	O	O
brightfield	NN	O	O
-	NN	O	O
and	NN	O	O
laser	NN	O	O
-	NN	O	O
scanning	NN	O	O
confocal	NN	O	O
fluorescence	NN	O	O
microscopy	NN	O	O
demonstrated	NN	O	O
increased	NN	O	O
targeting	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
ENaC	NN	O	O
,	NN	O	O
beta	NN	O	O
-	NN	O	O
ENaC	NN	O	O
,	NN	O	O
and	NN	O	O
gamma	NN	O	O
-	NN	O	O
ENaC	NN	O	O
subunits	NN	O	O
to	NN	O	O
the	NN	O	O
apical	NN	O	O
plasma	NN	O	O
membrane	NN	O	O
in	NN	O	O
the	NN	O	O
distal	NN	O	O
convoluted	NN	O	O
tubule	NN	O	O
(	NN	O	O
DCT2	NN	O	O
)	NN	O	O
,	NN	O	O
connecting	NN	O	O
tubule	NN	O	O
,	NN	O	O
and	NN	O	O
cortical	NN	O	O
and	NN	O	O
medullary	NN	O	O
collecting	NN	O	O
duct	NN	O	O
segments	NN	O	O
.	NN	O	O

Immunoelectron	NN	O	O
microscopy	NN	O	O
further	NN	O	O
revealed	NN	O	O
an	NN	O	O
increased	NN	O	O
labeling	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
ENaC	NN	O	O
in	NN	O	O
the	NN	O	O
apical	NN	O	O
plasma	NN	O	O
membrane	NN	O	O
of	NN	O	O
cortical	NN	O	O
collecting	NN	O	O
duct	NN	O	O
principal	NN	O	O
cells	NN	O	O
of	NN	O	O
PAN	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
,	NN	O	O
indicating	NN	O	O
enhanced	NN	O	O
apical	NN	O	O
targeting	NN	O	O
of	NN	O	O
alpha	NN	O	O
-	NN	O	O
ENaC	NN	O	O
subunits	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
protein	NN	O	O
abundances	NN	O	O
of	NN	O	O
Na	NN	O	B-Chemical
(	NN	O	O
+	NN	O	O
)	NN	O	O
/	NN	O	O
H	NN	O	B-Chemical
(	NN	O	O
+	NN	O	O
)	NN	O	O
exchanger	NN	O	O
type	NN	O	O
3	NN	O	O
(	NN	O	O
NHE3	NN	O	O
)	NN	O	O
,	NN	O	O
Na	NN	O	B-Chemical
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
K	NN	O	B-Chemical
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
2Cl	NN	O	B-Chemical
(	NN	O	O
-	NN	O	O
)	NN	O	O
cotransporter	NN	O	O
(	NN	O	O
BSC	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
thiazide	NN	O	B-Chemical
-	NN	O	O
sensitive	NN	O	O
Na	NN	O	B-Chemical
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
Cl	NN	O	B-Chemical
(	NN	O	O
-	NN	O	O
)	NN	O	O
cotransporter	NN	O	O
(	NN	O	O
TSC	NN	O	O
)	NN	O	O
were	NN	O	O
decreased	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
the	NN	O	O
abundance	NN	O	O
of	NN	O	O
the	NN	O	O
alpha	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
-	NN	O	O
subunit	NN	O	O
of	NN	O	O
the	NN	O	O
Na	NN	O	B-Chemical
-	NN	O	O
K	NN	O	B-Chemical
-	NN	O	O
ATPase	NN	O	O
was	NN	O	O
decreased	NN	O	O
in	NN	O	O
the	NN	O	O
cortex	NN	O	O
and	NN	O	O
ISOM	NN	O	O
,	NN	O	O
but	NN	O	O
it	NN	O	O
remained	NN	O	O
unchanged	NN	O	O
in	NN	O	O
the	NN	O	O
IM	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
the	NN	O	O
increased	NN	O	O
or	NN	O	O
sustained	NN	O	O
expression	NN	O	O
of	NN	O	O
ENaC	NN	O	O
subunits	NN	O	O
combined	NN	O	O
with	NN	O	O
increased	NN	O	O
apical	NN	O	O
targeting	NN	O	O
in	NN	O	O
the	NN	O	O
DCT2	NN	O	O
,	NN	O	O
connecting	NN	O	O
tubule	NN	O	O
,	NN	O	O
and	NN	O	O
collecting	NN	O	O
duct	NN	O	O
are	NN	O	O
likely	NN	O	O
to	NN	O	O
play	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
the	NN	O	O
sodium	NN	O	B-Chemical
retention	NN	O	O
associated	NN	O	O
with	NN	O	O
PAN	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
decreased	NN	O	O
abundance	NN	O	O
of	NN	O	O
NHE3	NN	O	O
,	NN	O	O
BSC	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
TSC	NN	O	O
,	NN	O	O
and	NN	O	O
Na	NN	O	B-Chemical
-	NN	O	O
K	NN	O	B-Chemical
-	NN	O	O
ATPase	NN	O	O
may	NN	O	O
play	NN	O	O
a	NN	O	O
compensatory	NN	O	O
role	NN	O	O
to	NN	O	O
promote	NN	O	O
sodium	NN	O	B-Chemical
excretion	NN	O	O
.	NN	O	O


-DOCSTART- (14745746)

Does	NN	O	O
hormone	NN	O	O
therapy	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
have	NN	O	O
a	NN	O	O
detrimental	NN	O	B-Disease
effect	NN	O	I-Disease
on	NN	O	I-Disease
memory	NN	O	I-Disease
and	NN	O	I-Disease
cognition	NN	O	I-Disease
?	NN	O	O
A	NN	O	O
pilot	NN	O	O
study	NN	O	O
.	NN	O	O

This	NN	O	O
pilot	NN	O	O
study	NN	O	O
examines	NN	O	O
whether	NN	O	O
hormone	NN	O	O
therapy	NN	O	O
for	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
affects	NN	O	O
cognition	NN	O	O
.	NN	O	O

Patients	NN	O	O
participating	NN	O	O
in	NN	O	O
a	NN	O	O
randomised	NN	O	O
trial	NN	O	O
of	NN	O	O
anastrozole	NN	O	B-Chemical
,	NN	O	O
tamoxifen	NN	O	B-Chemical
alone	NN	O	O
or	NN	O	O
combined	NN	O	O
(	NN	O	O
ATAC	NN	O	O
)	NN	O	O
(	NN	O	O
n=94	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
women	NN	O	O
without	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
(	NN	O	O
n=35	NN	O	O
)	NN	O	O
completed	NN	O	O
a	NN	O	O
battery	NN	O	O
of	NN	O	O
neuropsychological	NN	O	O
measures	NN	O	O
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
patients	NN	O	O
were	NN	O	O
impaired	NN	O	O
on	NN	O	O
a	NN	O	O
processing	NN	O	O
speed	NN	O	O
task	NN	O	O
(	NN	O	O
p=0.032	NN	O	O
)	NN	O	O
and	NN	O	O
on	NN	O	O
a	NN	O	O
measure	NN	O	O
of	NN	O	O
immediate	NN	O	O
verbal	NN	O	O
memory	NN	O	O
(	NN	O	O
p=0.026	NN	O	O
)	NN	O	O
after	NN	O	O
controlling	NN	O	O
for	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
hormone	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
.	NN	O	O

Patient	NN	O	O
group	NN	O	O
performance	NN	O	O
was	NN	O	O
not	NN	O	O
significantly	NN	O	O
related	NN	O	O
to	NN	O	O
length	NN	O	O
of	NN	O	O
treatment	NN	O	O
or	NN	O	O
measures	NN	O	O
of	NN	O	O
psychological	NN	O	O
morbidity	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
showed	NN	O	O
specific	NN	O	O
impairments	NN	O	O
in	NN	O	O
processing	NN	O	O
speed	NN	O	O
and	NN	O	O
verbal	NN	O	O
memory	NN	O	O
in	NN	O	O
women	NN	O	O
receiving	NN	O	O
hormonal	NN	O	O
therapy	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

Verbal	NN	O	O
memory	NN	O	O
may	NN	O	O
be	NN	O	O
especially	NN	O	O
sensitive	NN	O	O
to	NN	O	O
changes	NN	O	O
in	NN	O	O
oestrogen	NN	O	B-Chemical
levels	NN	O	O
,	NN	O	O
a	NN	O	O
finding	NN	O	O
commonly	NN	O	O
reported	NN	O	O
in	NN	O	O
studies	NN	O	O
of	NN	O	O
hormone	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
in	NN	O	O
healthy	NN	O	O
women	NN	O	O
.	NN	O	O

In	NN	O	O
view	NN	O	O
of	NN	O	O
the	NN	O	O
increased	NN	O	O
use	NN	O	O
of	NN	O	O
hormone	NN	O	O
therapies	NN	O	O
in	NN	O	O
an	NN	O	O
adjuvant	NN	O	O
and	NN	O	O
preventative	NN	O	O
setting	NN	O	O
their	NN	O	O
impact	NN	O	O
on	NN	O	O
cognitive	NN	O	O
functioning	NN	O	O
should	NN	O	O
be	NN	O	O
investigated	NN	O	O
more	NN	O	O
thoroughly	NN	O	O
.	NN	O	O


-DOCSTART- (11208990)

Association	NN	O	O
of	NN	O	O
nitric	NN	O	B-Chemical
oxide	NN	O	I-Chemical
production	NN	O	O
and	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
experimental	NN	O	O
nephropathy	NN	O	B-Disease
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
In	NN	O	O
recent	NN	O	O
studies	NN	O	O
increased	NN	O	O
amounts	NN	O	O
of	NN	O	O
nitric	NN	O	B-Chemical
oxide	NN	O	I-Chemical
(	NN	O	O
NO	NN	O	B-Chemical
)	NN	O	O
and	NN	O	O
apoptosis	NN	O	O
have	NN	O	O
been	NN	O	O
implicated	NN	O	O
in	NN	O	O
various	NN	O	O
pathological	NN	O	O
conditions	NN	O	O
in	NN	O	O
the	NN	O	O
kidney	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
studied	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
NO	NN	O	B-Chemical
and	NN	O	O
its	NN	O	O
association	NN	O	O
with	NN	O	O
apoptosis	NN	O	O
in	NN	O	O
an	NN	O	O
experimental	NN	O	O
model	NN	O	O
of	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
a	NN	O	O
single	NN	O	O
injection	NN	O	O
of	NN	O	O
adriamycin	NN	O	B-Chemical
(	NN	O	O
ADR	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
alteration	NN	O	O
in	NN	O	O
the	NN	O	O
NO	NN	O	B-Chemical
pathway	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
measuring	NN	O	O
nitrite	NN	O	B-Chemical
levels	NN	O	O
in	NN	O	O
serum	NN	O	O
/	NN	O	O
urine	NN	O	O
and	NN	O	O
by	NN	O	O
evaluating	NN	O	O
the	NN	O	O
changes	NN	O	O
in	NN	O	O
vascular	NN	O	O
reactivity	NN	O	O
of	NN	O	O
the	NN	O	O
isolated	NN	O	O
perfused	NN	O	O
rat	NN	O	O
kidney	NN	O	O
(	NN	O	O
IPRK	NN	O	O
)	NN	O	O
system	NN	O	O
.	NN	O	O

Rats	NN	O	O
were	NN	O	O
stratified	NN	O	O
into	NN	O	O
control	NN	O	O
groups	NN	O	O
and	NN	O	O
ADR	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
nephropathy	NN	O	B-Disease
groups	NN	O	O
.	NN	O	O

These	NN	O	O
two	NN	O	O
groups	NN	O	O
were	NN	O	O
then	NN	O	O
divided	NN	O	O
into	NN	O	O
:	NN	O	O
group	NN	O	O
1	NN	O	O
,	NN	O	O
animals	NN	O	O
receiving	NN	O	O
saline	NN	O	O
;	NN	O	O
and	NN	O	O
group	NN	O	O
2	NN	O	O
,	NN	O	O
animals	NN	O	O
receiving	NN	O	O
aminoguanidine	NN	O	B-Chemical
(	NN	O	O
AG	NN	O	B-Chemical
)	NN	O	O
which	NN	O	O
is	NN	O	O
a	NN	O	O
specific	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
inducible	NN	O	O
-	NN	O	O
NO	NN	O	B-Chemical
synthase	NN	O	O
.	NN	O	O

On	NN	O	O
day	NN	O	O
21	NN	O	O
,	NN	O	O
rats	NN	O	O
were	NN	O	O
sacrificed	NN	O	O
after	NN	O	O
obtaining	NN	O	O
material	NN	O	O
for	NN	O	O
biochemical	NN	O	O
analysis	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Histopathological	NN	O	O
examination	NN	O	O
of	NN	O	O
the	NN	O	O
kidneys	NN	O	O
of	NN	O	O
rats	NN	O	O
treated	NN	O	O
with	NN	O	O
ADR	NN	O	B-Chemical
revealed	NN	O	O
focal	NN	O	O
areas	NN	O	O
of	NN	O	O
mesangial	NN	O	B-Disease
proliferation	NN	O	I-Disease
and	NN	O	O
mild	NN	O	O
tubulointerstitial	NN	O	B-Disease
inflammation	NN	O	I-Disease
.	NN	O	O

They	NN	O	O
also	NN	O	O
had	NN	O	O
significantly	NN	O	O
higher	NN	O	O
levels	NN	O	O
of	NN	O	O
proteinuria	NN	O	B-Disease
compared	NN	O	O
with	NN	O	O
control	NN	O	O
and	NN	O	O
treatment	NN	O	O
groups	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Urine	NN	O	O
nitrite	NN	O	B-Chemical
levels	NN	O	O
were	NN	O	O
significantly	NN	O	O
increased	NN	O	O
in	NN	O	O
the	NN	O	O
ADR	NN	O	B-Chemical
-	NN	O	O
nephropathy	NN	O	B-Disease
group	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
IPRK	NN	O	O
phenylephrine	NN	O	B-Chemical
and	NN	O	O
acetylcholine	NN	O	B-Chemical
related	NN	O	O
responses	NN	O	O
were	NN	O	O
significantly	NN	O	O
impaired	NN	O	O
in	NN	O	O
the	NN	O	O
ADR	NN	O	B-Chemical
-	NN	O	O
nephropathy	NN	O	B-Disease
group	NN	O	O
.	NN	O	O

Apoptosis	NN	O	O
was	NN	O	O
not	NN	O	O
detected	NN	O	O
in	NN	O	O
controls	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
in	NN	O	O
the	NN	O	O
ADR	NN	O	B-Chemical
-	NN	O	O
nephropathy	NN	O	B-Disease
group	NN	O	O
,	NN	O	O
numerous	NN	O	O
apoptotic	NN	O	O
cells	NN	O	O
were	NN	O	O
identified	NN	O	O
in	NN	O	O
the	NN	O	O
tubulointerstitial	NN	O	O
areas	NN	O	O
.	NN	O	O

Double	NN	O	O
staining	NN	O	O
revealed	NN	O	O
numerous	NN	O	O
interstitial	NN	O	O
apoptotic	NN	O	O
cells	NN	O	O
to	NN	O	O
stain	NN	O	O
for	NN	O	O
ED1	NN	O	O
,	NN	O	O
a	NN	O	O
marker	NN	O	O
for	NN	O	O
monocytes	NN	O	O
/	NN	O	O
macrophages	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
AG	NN	O	B-Chemical
prevented	NN	O	O
the	NN	O	O
impairment	NN	O	O
of	NN	O	O
renal	NN	O	O
vascular	NN	O	O
bed	NN	O	O
responses	NN	O	O
and	NN	O	O
reduced	NN	O	O
both	NN	O	O
urine	NN	O	O
nitrite	NN	O	B-Chemical
levels	NN	O	O
and	NN	O	O
apoptosis	NN	O	O
to	NN	O	O
control	NN	O	O
levels	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
We	NN	O	O
suggest	NN	O	O
that	NN	O	O
interactions	NN	O	O
between	NN	O	O
NO	NN	O	B-Chemical
and	NN	O	O
apoptosis	NN	O	O
are	NN	O	O
important	NN	O	O
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
the	NN	O	O
ADR	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
nephrosis	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (9201797)

The	NN	O	O
attenuating	NN	O	O
effect	NN	O	O
of	NN	O	O
carteolol	NN	O	B-Chemical
hydrochloride	NN	O	I-Chemical
,	NN	O	O
a	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
on	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
known	NN	O	O
that	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
antagonists	NN	O	O
are	NN	O	O
effective	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
akathisia	NN	O	B-Disease
,	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
extrapyramidal	NN	O	O
side	NN	O	O
effects	NN	O	O
that	NN	O	O
occur	NN	O	O
during	NN	O	O
neuroleptic	NN	O	O
treatment	NN	O	O
.	NN	O	O

Neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
,	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
extrapyramidal	NN	O	O
side	NN	O	O
effects	NN	O	O
,	NN	O	O
was	NN	O	O
considered	NN	O	O
suitable	NN	O	O
as	NN	O	O
a	NN	O	O
model	NN	O	O
for	NN	O	O
predicting	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
akathisia	NN	O	B-Disease
in	NN	O	O
humans	NN	O	O
,	NN	O	O
although	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
was	NN	O	O
not	NN	O	O
considered	NN	O	O
a	NN	O	O
specific	NN	O	O
test	NN	O	O
for	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
akathisia	NN	O	B-Disease
.	NN	O	O

Therefore	NN	O	O
,	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
carteolol	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
on	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
were	NN	O	O
behaviorally	NN	O	O
studied	NN	O	O
and	NN	O	O
compared	NN	O	O
with	NN	O	O
those	NN	O	O
of	NN	O	O
propranolol	NN	O	B-Chemical
and	NN	O	O
biperiden	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
muscarinic	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
.	NN	O	O

Carteolol	NN	O	B-Chemical
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
propranolol	NN	O	B-Chemical
and	NN	O	O
biperiden	NN	O	B-Chemical
,	NN	O	O
inhibited	NN	O	O
the	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
of	NN	O	O
carteolol	NN	O	B-Chemical
was	NN	O	O
almost	NN	O	O
comparable	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
propranolol	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
was	NN	O	O
weaker	NN	O	O
than	NN	O	O
that	NN	O	O
of	NN	O	O
biperiden	NN	O	B-Chemical
.	NN	O	O

Carteolol	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
evoke	NN	O	O
postsynaptic	NN	O	O
dopamine	NN	O	B-Chemical
receptor	NN	O	O
-	NN	O	O
stimulating	NN	O	O
behavioral	NN	O	O
signs	NN	O	O
such	NN	O	O
as	NN	O	O
stereotypy	NN	O	O
and	NN	O	O
hyperlocomotion	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Carteolol	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
antagonize	NN	O	O
the	NN	O	O
inhibitory	NN	O	O
effects	NN	O	O
of	NN	O	O
haloperidol	NN	O	B-Chemical
on	NN	O	O
apomorphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
stereotypy	NN	O	O
and	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
carteolol	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
evoke	NN	O	O
5	NN	O	O
-	NN	O	O
HT1A	NN	O	O
receptor	NN	O	O
-	NN	O	O
stimulating	NN	O	O
behavioral	NN	O	O
signs	NN	O	O
such	NN	O	O
as	NN	O	O
flat	NN	O	O
body	NN	O	O
posture	NN	O	O
and	NN	O	O
forepaw	NN	O	O
treading	NN	O	O
and	NN	O	O
did	NN	O	O
not	NN	O	O
inhibit	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxytryptophan	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
head	NN	O	O
twitch	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
carteolol	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
inhibit	NN	O	O
physostigmine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
lethality	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
strongly	NN	O	O
suggest	NN	O	O
that	NN	O	O
carteolol	NN	O	B-Chemical
improves	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
via	NN	O	O
its	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
antagonistic	NN	O	O
activity	NN	O	O
and	NN	O	O
is	NN	O	O
expected	NN	O	O
to	NN	O	O
be	NN	O	O
effective	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
akathisia	NN	O	B-Disease
without	NN	O	O
attenuating	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
antipsychotic	NN	O	O
effects	NN	O	O
due	NN	O	O
to	NN	O	O
its	NN	O	O
postsynaptic	NN	O	O
dopamine	NN	O	B-Chemical
receptor	NN	O	O
antagonistic	NN	O	O
activity	NN	O	O
.	NN	O	O


-DOCSTART- (8267029)

Penicillamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
rapidly	NN	O	O
progressive	NN	O	O
glomerulonephritis	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
67	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
presented	NN	O	O
rapidly	NN	O	O
progressive	NN	O	O
glomerulonephritis	NN	O	B-Disease
(	NN	O	O
RPGN	NN	O	B-Disease
)	NN	O	O
after	NN	O	O
5	NN	O	O
months	NN	O	O
of	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
(	NN	O	O
250	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
treatment	NN	O	O
.	NN	O	O

Light	NN	O	O
microscopy	NN	O	O
study	NN	O	O
showed	NN	O	O
severe	NN	O	O
glomerulonephritis	NN	O	B-Disease
with	NN	O	O
crescent	NN	O	O
formation	NN	O	O
in	NN	O	O
60%	NN	O	O
of	NN	O	O
the	NN	O	O
glomeruli	NN	O	O
and	NN	O	O
infiltration	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
cells	NN	O	O
in	NN	O	O
the	NN	O	O
wall	NN	O	O
of	NN	O	O
an	NN	O	O
arteriole	NN	O	O
.	NN	O	O

Immunofluorescence	NN	O	O
revealed	NN	O	O
scanty	NN	O	O
granular	NN	O	O
IgG	NN	O	O
,	NN	O	O
IgA	NN	O	O
and	NN	O	O
C3	NN	O	O
deposits	NN	O	O
along	NN	O	O
the	NN	O	O
capillary	NN	O	O
walls	NN	O	O
and	NN	O	O
mesangium	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
steroid	NN	O	B-Chemical
pulse	NN	O	O
,	NN	O	O
plasmapheresis	NN	O	O
,	NN	O	O
cyclophosphamide	NN	O	B-Chemical
and	NN	O	O
antiplatelet	NN	O	B-Chemical
agents	NN	O	I-Chemical
.	NN	O	O

A	NN	O	O
complete	NN	O	O
recovery	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
was	NN	O	O
achieved	NN	O	O
in	NN	O	O
a	NN	O	O
few	NN	O	O
weeks	NN	O	O
.	NN	O	O

This	NN	O	O
new	NN	O	O
case	NN	O	O
of	NN	O	O
RPGN	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
treatment	NN	O	O
emphasizes	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
frequent	NN	O	O
monitoring	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
and	NN	O	O
evaluation	NN	O	O
of	NN	O	O
urinary	NN	O	O
sediment	NN	O	O
and	NN	O	O
proteinuria	NN	O	B-Disease
in	NN	O	O
these	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
prompt	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
and	NN	O	O
vigorous	NN	O	O
treatment	NN	O	O
measures	NN	O	O
could	NN	O	O
allow	NN	O	O
for	NN	O	O
a	NN	O	O
good	NN	O	O
prognosis	NN	O	O
as	NN	O	O
in	NN	O	O
this	NN	O	O
case	NN	O	O
.	NN	O	O


-DOCSTART- (2528969)

Nature	NN	O	O
,	NN	O	O
time	NN	O	O
course	NN	O	O
and	NN	O	O
dose	NN	O	O
dependence	NN	O	O
of	NN	O	O
zidovudine	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
side	NN	O	O
effects	NN	O	O
:	NN	O	O
results	NN	O	O
from	NN	O	O
the	NN	O	O
Multicenter	NN	O	O
Canadian	NN	O	O
Azidothymidine	NN	O	B-Chemical
Trial	NN	O	O
.	NN	O	O

To	NN	O	O
characterize	NN	O	O
the	NN	O	O
nature	NN	O	O
,	NN	O	O
time	NN	O	O
course	NN	O	O
and	NN	O	O
dose	NN	O	O
dependency	NN	O	O
of	NN	O	O
zidovudine	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
side	NN	O	O
effects	NN	O	O
,	NN	O	O
we	NN	O	O
undertook	NN	O	O
a	NN	O	O
multicenter	NN	O	O
,	NN	O	O
prospective	NN	O	O
,	NN	O	O
dose	NN	O	O
-	NN	O	O
range	NN	O	O
finding	NN	O	O
study	NN	O	O
.	NN	O	O

Our	NN	O	O
study	NN	O	O
group	NN	O	O
consisted	NN	O	O
of	NN	O	O
74	NN	O	O
HIV	NN	O	O
-	NN	O	O
positive	NN	O	O
homosexual	NN	O	O
men	NN	O	O
belonging	NN	O	O
to	NN	O	O
groups	NN	O	O
II	NN	O	O
B	NN	O	O
,	NN	O	O
III	NN	O	O
and	NN	O	O
IV	NN	O	O
C2	NN	O	O
from	NN	O	O
the	NN	O	O
Centers	NN	O	O
for	NN	O	O
Disease	NN	O	O
Control	NN	O	O
(	NN	O	O
CDC	NN	O	O
)	NN	O	O
classification	NN	O	O
of	NN	O	O
HIV	NN	O	B-Disease
disease	NN	O	I-Disease
.	NN	O	O

Following	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
week	NN	O	O
observation	NN	O	O
period	NN	O	O
,	NN	O	O
volunteers	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
zidovudine	NN	O	B-Chemical
600	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
18	NN	O	O
weeks	NN	O	O
,	NN	O	O
900	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
9	NN	O	O
weeks	NN	O	O
and	NN	O	O
1200	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
9	NN	O	O
weeks	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
washout	NN	O	O
period	NN	O	O
of	NN	O	O
6	NN	O	O
weeks	NN	O	O
after	NN	O	O
which	NN	O	O
they	NN	O	O
were	NN	O	O
re	NN	O	O
-	NN	O	O
started	NN	O	O
on	NN	O	O
1200	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
or	NN	O	O
the	NN	O	O
highest	NN	O	O
tolerated	NN	O	O
dose	NN	O	O
at	NN	O	O
8	NN	O	O
-	NN	O	O
hourly	NN	O	O
intervals	NN	O	O
.	NN	O	O

Subjects	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
4	NN	O	O
-	NN	O	O
hourly	NN	O	O
or	NN	O	O
8	NN	O	O
-	NN	O	O
hourly	NN	O	O
regimens	NN	O	O
within	NN	O	O
CDC	NN	O	O
groups	NN	O	O
while	NN	O	O
taking	NN	O	O
600	NN	O	O
and	NN	O	O
1200	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
.	NN	O	O

Clinical	NN	O	O
and	NN	O	O
laboratory	NN	O	O
evaluations	NN	O	O
were	NN	O	O
performed	NN	O	O
at	NN	O	O
3	NN	O	O
-	NN	O	O
week	NN	O	O
intervals	NN	O	O
.	NN	O	O

Symptomatic	NN	O	O
adverse	NN	O	O
effects	NN	O	O
were	NN	O	O
present	NN	O	O
in	NN	O	O
96%	NN	O	O
of	NN	O	O
subjects	NN	O	O
,	NN	O	O
most	NN	O	O
commonly	NN	O	O
nausea	NN	O	B-Disease
(	NN	O	O
64%	NN	O	O
)	NN	O	O
,	NN	O	O
fatigue	NN	O	B-Disease
(	NN	O	O
55%	NN	O	O
)	NN	O	O
and	NN	O	O
headache	NN	O	B-Disease
(	NN	O	O
49%	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
were	NN	O	O
generally	NN	O	O
self	NN	O	O
-	NN	O	O
limited	NN	O	O
,	NN	O	O
reappearing	NN	O	O
briefly	NN	O	O
at	NN	O	O
each	NN	O	O
dose	NN	O	O
increment	NN	O	O
.	NN	O	O

A	NN	O	O
decrease	NN	O	O
in	NN	O	O
hemoglobin	NN	O	O
occurred	NN	O	O
shortly	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
not	NN	O	O
dose	NN	O	O
dependent	NN	O	O
and	NN	O	O
reversed	NN	O	O
rapidly	NN	O	O
upon	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
treatment	NN	O	O
.	NN	O	O

A	NN	O	O
red	NN	O	O
blood	NN	O	O
cell	NN	O	O
count	NN	O	O
decrease	NN	O	O
,	NN	O	O
a	NN	O	O
mean	NN	O	O
cell	NN	O	O
volume	NN	O	O
increase	NN	O	O
and	NN	O	O
a	NN	O	O
granulocyte	NN	O	O
count	NN	O	O
decrease	NN	O	O
developed	NN	O	O
early	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
independent	NN	O	O
fashion	NN	O	O
,	NN	O	O
reverting	NN	O	O
at	NN	O	O
least	NN	O	O
partially	NN	O	O
during	NN	O	O
the	NN	O	O
washout	NN	O	O
phase	NN	O	O
.	NN	O	O

The	NN	O	O
decrease	NN	O	O
in	NN	O	O
reticulocyte	NN	O	O
count	NN	O	O
was	NN	O	O
dose	NN	O	O
related	NN	O	O
between	NN	O	O
600	NN	O	O
and	NN	O	O
900	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
with	NN	O	O
no	NN	O	O
further	NN	O	O
change	NN	O	O
when	NN	O	O
the	NN	O	O
dose	NN	O	O
was	NN	O	O
escalated	NN	O	O
to	NN	O	O
1200	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
.	NN	O	O

Bone	NN	O	O
marrow	NN	O	O
changes	NN	O	O
occurred	NN	O	O
rapidly	NN	O	O
as	NN	O	O
demonstrated	NN	O	O
by	NN	O	O
megaloblastosis	NN	O	B-Disease
in	NN	O	O
95%	NN	O	O
of	NN	O	O
65	NN	O	O
specimens	NN	O	O
at	NN	O	O
week	NN	O	O
18.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

-DOCSTART- (384871)

Bilateral	NN	O	B-Disease
optic	NN	O	I-Disease
neuropathy	NN	O	I-Disease
due	NN	O	O
to	NN	O	O
combined	NN	O	O
ethambutol	NN	O	B-Chemical
and	NN	O	O
isoniazid	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
40	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
patient	NN	O	O
who	NN	O	O
underwent	NN	O	O
an	NN	O	O
unsuccessful	NN	O	O
cadaver	NN	O	O
kidney	NN	O	O
transplantation	NN	O	O
and	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
ethambutol	NN	O	B-Chemical
and	NN	O	O
isoniazid	NN	O	B-Chemical
is	NN	O	O
reported	NN	O	O
.	NN	O	O

A	NN	O	O
bilateral	NN	O	B-Disease
retrobulbar	NN	O	I-Disease
neuropathy	NN	O	I-Disease
with	NN	O	O
an	NN	O	O
unusual	NN	O	O
central	NN	O	O
bitemporal	NN	O	O
hemianopic	NN	O	O
scotoma	NN	O	B-Disease
was	NN	O	O
found	NN	O	O
.	NN	O	O

Ethambutol	NN	O	B-Chemical
was	NN	O	O
stopped	NN	O	O
and	NN	O	O
only	NN	O	O
small	NN	O	O
improvement	NN	O	O
of	NN	O	O
the	NN	O	O
visual	NN	O	O
acuity	NN	O	O
followed	NN	O	O
.	NN	O	O

Isoniazid	NN	O	B-Chemical
was	NN	O	O
discontinued	NN	O	O
later	NN	O	O
,	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
dramatic	NN	O	O
improvement	NN	O	O
in	NN	O	O
the	NN	O	O
visual	NN	O	O
acuity	NN	O	O
.	NN	O	O

The	NN	O	O
hazards	NN	O	O
of	NN	O	O
optic	NN	O	O
nerve	NN	O	O
toxicity	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
ethambutol	NN	O	B-Chemical
are	NN	O	O
known	NN	O	O
.	NN	O	O

We	NN	O	O
emphasize	NN	O	O
the	NN	O	O
potential	NN	O	O
danger	NN	O	O
in	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
ethambutol	NN	O	B-Chemical
and	NN	O	O
isoniazid	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (133615)

Progestational	NN	O	O
agents	NN	O	O
and	NN	O	O
blood	NN	O	B-Disease
coagulation	NN	O	I-Disease
.	NN	O	O

VII	NN	O	O
.	NN	O	O

Thromboembolic	NN	O	B-Disease
and	NN	O	O
other	NN	O	O
complications	NN	O	O
of	NN	O	O
oral	NN	O	B-Chemical
contraceptive	NN	O	I-Chemical
therapy	NN	O	O
in	NN	O	O
relationship	NN	O	O
to	NN	O	O
pretreatment	NN	O	O
levels	NN	O	O
of	NN	O	O
blood	NN	O	B-Disease
coagulation	NN	O	I-Disease
factors	NN	O	O
:	NN	O	O
summary	NN	O	O
report	NN	O	O
of	NN	O	O
a	NN	O	O
ten	NN	O	O
-	NN	O	O
year	NN	O	O
study	NN	O	O
.	NN	O	O

During	NN	O	O
a	NN	O	O
ten	NN	O	O
-	NN	O	O
year	NN	O	O
period	NN	O	O
,	NN	O	O
348	NN	O	O
women	NN	O	O
were	NN	O	O
studied	NN	O	O
for	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
5	NN	O	O
,	NN	O	O
877	NN	O	O
patient	NN	O	O
months	NN	O	O
in	NN	O	O
four	NN	O	O
separate	NN	O	O
studies	NN	O	O
relating	NN	O	O
oral	NN	O	B-Chemical
contraceptives	NN	O	I-Chemical
to	NN	O	O
changes	NN	O	O
in	NN	O	O
hematologic	NN	O	O
parameters	NN	O	O
.	NN	O	O

Significant	NN	O	O
increases	NN	O	O
in	NN	O	O
certain	NN	O	O
factors	NN	O	O
of	NN	O	O
the	NN	O	O
blood	NN	O	B-Disease
coagulation	NN	O	I-Disease
and	NN	O	O
fibrinolysin	NN	O	O
systems	NN	O	O
(	NN	O	O
factors	NN	O	O
I	NN	O	O
,	NN	O	O
II	NN	O	O
,	NN	O	O
VII	NN	O	O
,	NN	O	O
VIII	NN	O	O
,	NN	O	O
IX	NN	O	O
,	NN	O	O
and	NN	O	O
X	NN	O	O
and	NN	O	O
plasminogen	NN	O	O
)	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
treated	NN	O	O
groups	NN	O	O
.	NN	O	O

Severe	NN	O	O
complications	NN	O	O
developed	NN	O	O
in	NN	O	O
four	NN	O	O
patients	NN	O	O
.	NN	O	O

All	NN	O	O
four	NN	O	O
had	NN	O	O
an	NN	O	O
abnormal	NN	O	O
blood	NN	O	B-Disease
coagulation	NN	O	I-Disease
profile	NN	O	O
,	NN	O	O
suggesting	NN	O	O
"	NN	O	O
hypercoagulability	NN	O	B-Disease
"	NN	O	O
before	NN	O	O
initiation	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

Some	NN	O	O
of	NN	O	O
these	NN	O	O
findings	NN	O	O
represented	NN	O	O
the	NN	O	O
most	NN	O	O
extreme	NN	O	O
abnormalities	NN	O	O
seen	NN	O	O
in	NN	O	O
the	NN	O	O
entire	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
;	NN	O	O
some	NN	O	O
increased	NN	O	O
further	NN	O	O
during	NN	O	O
therapy	NN	O	O
.	NN	O	O

One	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
developed	NN	O	O
a	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
before	NN	O	O
receiving	NN	O	O
any	NN	O	O
medication	NN	O	O
,	NN	O	O
shortly	NN	O	O
after	NN	O	O
the	NN	O	O
base	NN	O	O
-	NN	O	O
line	NN	O	O
values	NN	O	O
were	NN	O	O
obtained	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
developed	NN	O	O
retinopathy	NN	O	B-Disease
19	NN	O	O
months	NN	O	O
after	NN	O	O
she	NN	O	O
began	NN	O	O
therapy	NN	O	O
,	NN	O	O
and	NN	O	O
another	NN	O	O
developed	NN	O	O
thrombophlebitis	NN	O	B-Disease
after	NN	O	O
27	NN	O	O
months	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
fourth	NN	O	O
patient	NN	O	O
developed	NN	O	O
thrombophlebitis	NN	O	B-Disease
14	NN	O	O
days	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
contraceptive	NN	O	O
therapy	NN	O	O
.	NN	O	O

All	NN	O	O
four	NN	O	O
patients	NN	O	O
were	NN	O	O
of	NN	O	O
the	NN	O	O
A	NN	O	O
or	NN	O	O
AB	NN	O	O
blood	NN	O	O
group	NN	O	O
.	NN	O	O

Previous	NN	O	O
studies	NN	O	O
suggested	NN	O	O
the	NN	O	O
possiblility	NN	O	O
of	NN	O	O
increased	NN	O	O
propensity	NN	O	O
for	NN	O	O
thromboembolic	NN	O	B-Disease
episodes	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
possessing	NN	O	O
the	NN	O	O
A	NN	O	O
antigen	NN	O	O
.	NN	O	O

It	NN	O	O
appears	NN	O	O
from	NN	O	O
these	NN	O	O
data	NN	O	O
that	NN	O	O
hematologic	NN	O	O
work	NN	O	O
-	NN	O	O
ups	NN	O	O
may	NN	O	O
be	NN	O	O
useful	NN	O	O
in	NN	O	O
women	NN	O	O
who	NN	O	O
are	NN	O	O
about	NN	O	O
to	NN	O	O
start	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
oral	NN	O	B-Chemical
contraceptive	NN	O	I-Chemical
therapy	NN	O	O
.	NN	O	O


-DOCSTART- (17263743)

Cardiac	NN	O	B-Disease
arrest	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
child	NN	O	O
with	NN	O	O
cerebral	NN	O	B-Disease
palsy	NN	O	I-Disease
undergoing	NN	O	O
sevoflurane	NN	O	B-Chemical
induction	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
after	NN	O	O
preoperative	NN	O	O
clonidine	NN	O	B-Chemical
.	NN	O	O

Clonidine	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
frequently	NN	O	O
administered	NN	O	O
alpha2	NN	O	O
-	NN	O	O
adrenergic	NN	O	O
agonist	NN	O	O
which	NN	O	O
can	NN	O	O
decrease	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
blood	NN	O	O
pressure	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
5	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
child	NN	O	O
with	NN	O	O
cerebral	NN	O	B-Disease
palsy	NN	O	I-Disease
and	NN	O	O
seizure	NN	O	B-Disease
disorder	NN	O	I-Disease
,	NN	O	O
receiving	NN	O	O
clonidine	NN	O	B-Chemical
for	NN	O	O
restlessness	NN	O	B-Disease
,	NN	O	O
who	NN	O	O
presented	NN	O	O
for	NN	O	O
placement	NN	O	O
of	NN	O	O
a	NN	O	O
baclofen	NN	O	B-Chemical
pump	NN	O	O
.	NN	O	O

Without	NN	O	O
the	NN	O	O
knowledge	NN	O	O
of	NN	O	O
the	NN	O	O
medical	NN	O	O
personnel	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
mother	NN	O	O
administered	NN	O	O
three	NN	O	O
doses	NN	O	O
of	NN	O	O
clonidine	NN	O	B-Chemical
during	NN	O	O
the	NN	O	O
evening	NN	O	O
before	NN	O	O
and	NN	O	O
morning	NN	O	O
of	NN	O	O
surgery	NN	O	O
to	NN	O	O
reduce	NN	O	O
anxiety	NN	O	B-Disease
.	NN	O	O

During	NN	O	O
induction	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
developed	NN	O	O
bradycardia	NN	O	B-Disease
and	NN	O	O
hypotension	NN	O	B-Disease
requiring	NN	O	O
cardiac	NN	O	O
resuscitation	NN	O	O
.	NN	O	O

There	NN	O	O
are	NN	O	O
no	NN	O	O
previous	NN	O	O
reports	NN	O	O
of	NN	O	O
clonidine	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
cardiac	NN	O	B-Disease
arrest	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
child	NN	O	O
undergoing	NN	O	O
induction	NN	O	O
of	NN	O	O
anesthesia	NN	O	O
.	NN	O	O


-DOCSTART- (17241657)

Effects	NN	O	O
of	NN	O	O
UMB24	NN	O	B-Chemical
and	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
SM	NN	O	B-Chemical
21	NN	O	I-Chemical
,	NN	O	O
putative	NN	O	O
sigma2	NN	O	O
-	NN	O	O
preferring	NN	O	O
antagonists	NN	O	O
,	NN	O	O
on	NN	O	O
behavioral	NN	O	O
toxic	NN	O	O
and	NN	O	O
stimulant	NN	O	O
effects	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
in	NN	O	O
mice	NN	O	O
.	NN	O	O

Earlier	NN	O	O
studies	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
antagonism	NN	O	O
of	NN	O	O
sigma1	NN	O	O
receptors	NN	O	O
attenuates	NN	O	O
the	NN	O	O
convulsive	NN	O	B-Disease
,	NN	O	O
lethal	NN	O	O
,	NN	O	O
locomotor	NN	O	O
stimulatory	NN	O	O
and	NN	O	O
rewarding	NN	O	O
actions	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
in	NN	O	O
mice	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
contribution	NN	O	O
of	NN	O	O
sigma2	NN	O	O
receptors	NN	O	O
is	NN	O	O
unclear	NN	O	O
because	NN	O	O
experimental	NN	O	O
tools	NN	O	O
to	NN	O	O
selectively	NN	O	O
target	NN	O	O
this	NN	O	O
subtype	NN	O	O
are	NN	O	O
unavailable	NN	O	O
.	NN	O	O

To	NN	O	O
begin	NN	O	O
addressing	NN	O	O
this	NN	O	O
need	NN	O	O
,	NN	O	O
we	NN	O	O
characterized	NN	O	O
UMB24	NN	O	B-Chemical
(	NN	O	O
1	NN	O	B-Chemical
-	NN	O	I-Chemical
(	NN	O	I-Chemical
2	NN	O	I-Chemical
-	NN	O	I-Chemical
phenethyl	NN	O	I-Chemical
)	NN	O	I-Chemical
-	NN	O	I-Chemical
4	NN	O	I-Chemical
-	NN	O	I-Chemical
(	NN	O	I-Chemical
2	NN	O	I-Chemical
-	NN	O	I-Chemical
pyridyl	NN	O	I-Chemical
)	NN	O	I-Chemical
-	NN	O	I-Chemical
piperazine	NN	O	I-Chemical
)	NN	O	O
and	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
SM	NN	O	B-Chemical
21	NN	O	I-Chemical
(	NN	O	O
3alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
tropanyl	NN	O	I-Chemical
-	NN	O	I-Chemical
2	NN	O	I-Chemical
-	NN	O	I-Chemical
(	NN	O	I-Chemical
4	NN	O	I-Chemical
-	NN	O	I-Chemical
chorophenoxy	NN	O	I-Chemical
)	NN	O	I-Chemical
butyrate	NN	O	I-Chemical
)	NN	O	O
in	NN	O	O
receptor	NN	O	O
binding	NN	O	O
and	NN	O	O
behavioral	NN	O	O
studies	NN	O	O
.	NN	O	O

Receptor	NN	O	O
binding	NN	O	O
studies	NN	O	O
confirmed	NN	O	O
that	NN	O	O
UMB24	NN	O	B-Chemical
and	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
SM	NN	O	B-Chemical
21	NN	O	I-Chemical
display	NN	O	O
preferential	NN	O	O
affinity	NN	O	O
for	NN	O	O
sigma2	NN	O	O
over	NN	O	O
sigma1	NN	O	O
receptors	NN	O	O
.	NN	O	O

In	NN	O	O
behavioral	NN	O	O
studies	NN	O	O
,	NN	O	O
pretreatment	NN	O	O
of	NN	O	O
Swiss	NN	O	O
Webster	NN	O	O
mice	NN	O	O
with	NN	O	O
UMB24	NN	O	B-Chemical
or	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
SM	NN	O	B-Chemical
21	NN	O	I-Chemical
significantly	NN	O	O
attenuated	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
and	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
lethality	NN	O	O
.	NN	O	O

When	NN	O	O
administered	NN	O	O
alone	NN	O	O
,	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
SM	NN	O	B-Chemical
21	NN	O	I-Chemical
produced	NN	O	O
no	NN	O	O
significant	NN	O	O
effects	NN	O	O
compared	NN	O	O
to	NN	O	O
control	NN	O	O
injections	NN	O	O
of	NN	O	O
saline	NN	O	O
,	NN	O	O
but	NN	O	O
UMB24	NN	O	B-Chemical
had	NN	O	O
locomotor	NN	O	O
depressant	NN	O	O
actions	NN	O	O
.	NN	O	O

Together	NN	O	O
,	NN	O	O
the	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
sigma2	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
have	NN	O	O
the	NN	O	O
potential	NN	O	O
to	NN	O	O
attenuate	NN	O	O
some	NN	O	O
of	NN	O	O
the	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
further	NN	O	O
development	NN	O	O
of	NN	O	O
more	NN	O	O
selective	NN	O	O
,	NN	O	O
high	NN	O	O
affinity	NN	O	O
ligands	NN	O	O
are	NN	O	O
warranted	NN	O	O
.	NN	O	O


-DOCSTART- (14982270)

Methimazole	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cholestatic	NN	O	B-Disease
jaundice	NN	O	I-Disease
.	NN	O	O

Methimazole	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
widely	NN	O	O
used	NN	O	O
and	NN	O	O
generally	NN	O	O
well	NN	O	O
-	NN	O	O
tolerated	NN	O	O
antithyroid	NN	O	O
agent	NN	O	O
.	NN	O	O

A	NN	O	O
43	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
had	NN	O	O
severe	NN	O	O
jaundice	NN	O	B-Disease
and	NN	O	O
itching	NN	O	B-Disease
1	NN	O	O
month	NN	O	O
after	NN	O	O
receiving	NN	O	O
methimazole	NN	O	B-Chemical
(	NN	O	O
10	NN	O	O
mg	NN	O	O
tid	NN	O	O
)	NN	O	O
and	NN	O	O
propranolol	NN	O	B-Chemical
(	NN	O	O
20	NN	O	O
mg	NN	O	O
tid	NN	O	O
)	NN	O	O
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
hyperthyroidism	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
patient	NN	O	O
continued	NN	O	O
treatment	NN	O	O
for	NN	O	O
another	NN	O	O
4	NN	O	O
days	NN	O	O
after	NN	O	O
the	NN	O	O
appearance	NN	O	O
of	NN	O	O
jaundice	NN	O	B-Disease
until	NN	O	O
she	NN	O	O
finished	NN	O	O
both	NN	O	O
medications	NN	O	O
.	NN	O	O

When	NN	O	O
seen	NN	O	O
at	NN	O	O
the	NN	O	O
emergency	NN	O	O
department	NN	O	O
2	NN	O	O
weeks	NN	O	O
later	NN	O	O
,	NN	O	O
she	NN	O	O
still	NN	O	O
had	NN	O	O
severe	NN	O	O
icterus	NN	O	B-Disease
,	NN	O	O
pruritus	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
hyperbilirubinemia	NN	O	B-Disease
,	NN	O	O
formed	NN	O	O
mainly	NN	O	O
of	NN	O	O
the	NN	O	O
conjugated	NN	O	O
fraction	NN	O	O
.	NN	O	O

Methimazole	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cholestasis	NN	O	B-Disease
was	NN	O	O
diagnosed	NN	O	O
,	NN	O	O
and	NN	O	O
propranolol	NN	O	B-Chemical
therapy	NN	O	O
was	NN	O	O
resumed	NN	O	O
.	NN	O	O

Over	NN	O	O
the	NN	O	O
following	NN	O	O
9	NN	O	O
days	NN	O	O
,	NN	O	O
the	NN	O	O
symptoms	NN	O	O
improved	NN	O	O
and	NN	O	O
plasma	NN	O	O
bilirubin	NN	O	B-Chemical
levels	NN	O	O
were	NN	O	O
normal	NN	O	O
after	NN	O	O
12	NN	O	O
weeks	NN	O	O
without	NN	O	O
methimazole	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
rare	NN	O	O
cases	NN	O	O
within	NN	O	O
the	NN	O	O
first	NN	O	O
few	NN	O	O
weeks	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
this	NN	O	O
drug	NN	O	O
can	NN	O	O
cause	NN	O	O
severe	NN	O	O
and	NN	O	O
reversible	NN	O	O
cholestatic	NN	O	B-Disease
jaundice	NN	O	I-Disease
.	NN	O	O

Physicians	NN	O	O
and	NN	O	O
patients	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
adverse	NN	O	O
effect	NN	O	O
so	NN	O	O
that	NN	O	O
,	NN	O	O
upon	NN	O	O
occurrence	NN	O	O
,	NN	O	O
they	NN	O	O
can	NN	O	O
discontinue	NN	O	O
methimazole	NN	O	B-Chemical
therapy	NN	O	O
and	NN	O	O
avoid	NN	O	O
unnecessary	NN	O	O
invasive	NN	O	O
procedures	NN	O	O
.	NN	O	O


-DOCSTART- (12911170)

Ciprofloxacin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
acute	NN	O	O
interstitial	NN	O	B-Disease
nephritis	NN	O	I-Disease
and	NN	O	O
autoimmune	NN	O	B-Disease
hemolytic	NN	O	I-Disease
anemia	NN	O	I-Disease
.	NN	O	O

Ciprofloxacin	NN	O	B-Chemical
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
several	NN	O	O
side	NN	O	O
effects	NN	O	O
including	NN	O	O
interstitial	NN	O	B-Disease
nephritis	NN	O	I-Disease
and	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
combination	NN	O	O
of	NN	O	O
both	NN	O	O
side	NN	O	O
effects	NN	O	O
is	NN	O	O
extremely	NN	O	O
rare	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
report	NN	O	O
,	NN	O	O
we	NN	O	O
describe	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
ciprofloxacin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
interstitial	NN	O	B-Disease
nephritis	NN	O	I-Disease
and	NN	O	O
autoimmune	NN	O	B-Disease
hemolytic	NN	O	I-Disease
anemia	NN	O	I-Disease
.	NN	O	O

Hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
improved	NN	O	O
after	NN	O	O
stopping	NN	O	O
the	NN	O	O
drug	NN	O	O
and	NN	O	O
initiation	NN	O	O
of	NN	O	O
steroid	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Unfortunately	NN	O	O
,	NN	O	O
acute	NN	O	O
interstitial	NN	O	B-Disease
nephritis	NN	O	I-Disease
was	NN	O	O
irreversible	NN	O	O
and	NN	O	O
the	NN	O	O
patient	NN	O	O
developed	NN	O	O
end	NN	O	B-Disease
-	NN	O	I-Disease
stage	NN	O	I-Disease
renal	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (11195262)

Contribution	NN	O	O
of	NN	O	O
sodium	NN	O	B-Chemical
valproate	NN	O	I-Chemical
to	NN	O	O
the	NN	O	O
syndrome	NN	O	B-Disease
of	NN	O	I-Disease
inappropriate	NN	O	I-Disease
secretion	NN	O	I-Disease
of	NN	O	I-Disease
antidiuretic	NN	O	I-Disease
hormone	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
62	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
who	NN	O	O
was	NN	O	O
administered	NN	O	O
sodium	NN	O	B-Chemical
valproate	NN	O	I-Chemical
(	NN	O	O
VPA	NN	O	B-Chemical
)	NN	O	O
and	NN	O	O
who	NN	O	O
subsequently	NN	O	O
developed	NN	O	O
the	NN	O	O
syndrome	NN	O	B-Disease
of	NN	O	I-Disease
inappropriate	NN	O	I-Disease
secretion	NN	O	I-Disease
of	NN	O	I-Disease
antidiuretic	NN	O	I-Disease
hormone	NN	O	I-Disease
(	NN	O	O
SIADH	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

He	NN	O	O
had	NN	O	O
been	NN	O	O
taking	NN	O	O
VPA	NN	O	B-Chemical
for	NN	O	O
treatment	NN	O	O
of	NN	O	O
idiopathic	NN	O	O
generalized	NN	O	O
tonic	NN	O	B-Disease
-	NN	O	I-Disease
clonic	NN	O	I-Disease
convulsions	NN	O	I-Disease
since	NN	O	O
he	NN	O	O
was	NN	O	O
56	NN	O	O
years	NN	O	O
old	NN	O	O
.	NN	O	O

After	NN	O	O
substituting	NN	O	O
VPA	NN	O	B-Chemical
with	NN	O	O
zonisamide	NN	O	B-Chemical
,	NN	O	O
the	NN	O	O
serum	NN	O	O
sodium	NN	O	B-Chemical
level	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
.	NN	O	O

We	NN	O	O
consider	NN	O	O
this	NN	O	O
episode	NN	O	O
of	NN	O	O
SIADH	NN	O	B-Disease
to	NN	O	O
be	NN	O	O
the	NN	O	O
result	NN	O	O
of	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
factors	NN	O	O
including	NN	O	O
a	NN	O	O
weakness	NN	O	B-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
central	NN	O	I-Disease
nervous	NN	O	I-Disease
system	NN	O	I-Disease
and	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
administration	NN	O	O
of	NN	O	O
VPA	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (10728962)

Vasopressin	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
milrinone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
in	NN	O	O
severe	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
use	NN	O	O
of	NN	O	O
phosphodiesterase	NN	O	O
inhibitors	NN	O	O
such	NN	O	O
as	NN	O	O
milrinone	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
severe	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
is	NN	O	O
frequently	NN	O	O
restricted	NN	O	O
because	NN	O	O
they	NN	O	O
cause	NN	O	O
vasodilation	NN	O	O
and	NN	O	O
hypotension	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
decompensated	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
with	NN	O	O
hypotension	NN	O	B-Disease
after	NN	O	O
treatment	NN	O	O
with	NN	O	O
milrinone	NN	O	B-Chemical
,	NN	O	O
low	NN	O	O
doses	NN	O	O
of	NN	O	O
vasopressin	NN	O	B-Chemical
restored	NN	O	O
blood	NN	O	O
pressure	NN	O	O
without	NN	O	O
inhibiting	NN	O	O
the	NN	O	O
inotropic	NN	O	O
effect	NN	O	O
of	NN	O	O
milrinone	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (7647582)

Halogenated	NN	O	O
anesthetics	NN	O	O
form	NN	O	O
liver	NN	O	O
adducts	NN	O	O
and	NN	O	O
antigens	NN	O	O
that	NN	O	O
cross	NN	O	O
-	NN	O	O
react	NN	O	O
with	NN	O	O
halothane	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
antibodies	NN	O	O
.	NN	O	O

Two	NN	O	O
halogenated	NN	O	O
anesthetics	NN	O	O
,	NN	O	O
enflurane	NN	O	B-Chemical
and	NN	O	O
isoflurane	NN	O	B-Chemical
,	NN	O	O
have	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
an	NN	O	O
allergic	NN	O	O
-	NN	O	O
type	NN	O	O
hepatic	NN	O	B-Disease
injury	NN	O	I-Disease
both	NN	O	O
alone	NN	O	O
and	NN	O	O
following	NN	O	O
previous	NN	O	O
exposure	NN	O	O
to	NN	O	O
halothane	NN	O	B-Chemical
.	NN	O	O

Halothane	NN	O	B-Chemical
hepatitis	NN	O	B-Disease
appears	NN	O	O
to	NN	O	O
involve	NN	O	O
an	NN	O	O
aberrant	NN	O	O
immune	NN	O	O
response	NN	O	O
.	NN	O	O

An	NN	O	O
antibody	NN	O	O
response	NN	O	O
to	NN	O	O
a	NN	O	O
protein	NN	O	O
-	NN	O	O
bound	NN	O	O
biotransformation	NN	O	O
product	NN	O	O
(	NN	O	O
trifluoroacetyl	NN	O	B-Chemical
adduct	NN	O	O
)	NN	O	O
has	NN	O	O
been	NN	O	O
detected	NN	O	O
on	NN	O	O
halothane	NN	O	B-Chemical
hepatitis	NN	O	B-Disease
patients	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
was	NN	O	O
performed	NN	O	O
to	NN	O	O
determine	NN	O	O
cross	NN	O	O
-	NN	O	O
reactivity	NN	O	O
between	NN	O	O
enflurane	NN	O	B-Chemical
and	NN	O	O
isoflurane	NN	O	B-Chemical
with	NN	O	O
the	NN	O	O
hypersensitivity	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
halothane	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
subcellular	NN	O	O
and	NN	O	O
lobular	NN	O	O
production	NN	O	O
of	NN	O	O
hepatic	NN	O	O
neoantigens	NN	O	O
recognized	NN	O	O
by	NN	O	O
halothane	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
antibodies	NN	O	O
following	NN	O	O
enflurane	NN	O	B-Chemical
and	NN	O	O
isoflurane	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
the	NN	O	O
biochemical	NN	O	O
nature	NN	O	O
of	NN	O	O
these	NN	O	O
neoantigens	NN	O	O
was	NN	O	O
investigated	NN	O	O
in	NN	O	O
two	NN	O	O
animal	NN	O	O
models	NN	O	O
.	NN	O	O

Enflurane	NN	O	B-Chemical
administration	NN	O	O
resulted	NN	O	O
in	NN	O	O
neoantigens	NN	O	O
detected	NN	O	O
in	NN	O	O
both	NN	O	O
the	NN	O	O
microsomal	NN	O	O
and	NN	O	O
cytosolic	NN	O	O
fraction	NN	O	O
of	NN	O	O
liver	NN	O	O
homogenates	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
centrilobular	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
liver	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
same	NN	O	O
liver	NN	O	O
,	NN	O	O
biochemical	NN	O	O
analysis	NN	O	O
detected	NN	O	O
fluorinated	NN	O	O
liver	NN	O	O
adducts	NN	O	O
that	NN	O	O
were	NN	O	O
up	NN	O	O
to	NN	O	O
20	NN	O	O
-	NN	O	O
fold	NN	O	O
greater	NN	O	O
in	NN	O	O
guinea	NN	O	O
pigs	NN	O	O
than	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

This	NN	O	O
supports	NN	O	O
and	NN	O	O
extends	NN	O	O
previous	NN	O	O
evidence	NN	O	O
for	NN	O	O
a	NN	O	O
mechanism	NN	O	O
by	NN	O	O
which	NN	O	O
enflurane	NN	O	B-Chemical
and	NN	O	O
/	NN	O	O
or	NN	O	O
isoflurane	NN	O	B-Chemical
could	NN	O	O
produce	NN	O	O
a	NN	O	O
hypersensitivity	NN	O	B-Disease
condition	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
halothane	NN	O	B-Chemical
hepatitis	NN	O	B-Disease
either	NN	O	O
alone	NN	O	O
or	NN	O	O
subsequent	NN	O	O
to	NN	O	O
halothane	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

The	NN	O	O
guinea	NN	O	O
pig	NN	O	O
would	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
useful	NN	O	O
model	NN	O	O
for	NN	O	O
further	NN	O	O
investigations	NN	O	O
of	NN	O	O
the	NN	O	O
immunological	NN	O	O
response	NN	O	O
to	NN	O	O
these	NN	O	O
antigens	NN	O	O
.	NN	O	O


-DOCSTART- (4090988)

Induction	NN	O	O
by	NN	O	O
paracetamol	NN	O	B-Chemical
of	NN	O	O
bladder	NN	O	B-Disease
and	NN	O	I-Disease
liver	NN	O	I-Disease
tumours	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Effects	NN	O	O
on	NN	O	O
hepatocyte	NN	O	O
fine	NN	O	O
structure	NN	O	O
.	NN	O	O

Groups	NN	O	O
of	NN	O	O
male	NN	O	O
and	NN	O	O
female	NN	O	O
inbred	NN	O	O
Leeds	NN	O	O
strain	NN	O	O
rats	NN	O	O
were	NN	O	O
fed	NN	O	O
diets	NN	O	O
containing	NN	O	O
either	NN	O	O
0.5%	NN	O	O
or	NN	O	O
1.0%	NN	O	O
paracetamol	NN	O	B-Chemical
by	NN	O	O
weight	NN	O	O
for	NN	O	O
up	NN	O	O
to	NN	O	O
18	NN	O	O
months	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
1.0%	NN	O	O
dosage	NN	O	O
level	NN	O	O
,	NN	O	O
20%	NN	O	O
of	NN	O	O
rats	NN	O	O
of	NN	O	O
both	NN	O	O
sexes	NN	O	O
developed	NN	O	O
neoplastic	NN	O	O
nodules	NN	O	O
of	NN	O	O
the	NN	O	O
liver	NN	O	O
,	NN	O	O
a	NN	O	O
statistically	NN	O	O
significant	NN	O	O
incidence	NN	O	O
.	NN	O	O

These	NN	O	O
rats	NN	O	O
also	NN	O	O
showed	NN	O	O
gross	NN	O	O
enlargement	NN	O	O
of	NN	O	O
their	NN	O	O
livers	NN	O	O
and	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
foci	NN	O	O
of	NN	O	O
cellular	NN	O	O
alteration	NN	O	O
,	NN	O	O
the	NN	O	O
latter	NN	O	O
also	NN	O	O
being	NN	O	O
observed	NN	O	O
in	NN	O	O
the	NN	O	O
low	NN	O	O
dosage	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

Papillomas	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
transitional	NN	O	O
epithelium	NN	O	O
of	NN	O	O
the	NN	O	O
bladder	NN	O	O
developed	NN	O	O
in	NN	O	O
all	NN	O	O
paracetamol	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
groups	NN	O	O
,	NN	O	O
and	NN	O	O
three	NN	O	O
rats	NN	O	O
bore	NN	O	O
bladder	NN	O	B-Disease
carcinomas	NN	O	I-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
significant	NN	O	O
yields	NN	O	O
of	NN	O	O
bladder	NN	O	B-Disease
tumours	NN	O	I-Disease
were	NN	O	O
only	NN	O	O
obtained	NN	O	O
from	NN	O	O
low	NN	O	O
dosage	NN	O	O
females	NN	O	O
and	NN	O	O
high	NN	O	O
dosage	NN	O	O
males	NN	O	O
.	NN	O	O

Additionally	NN	O	O
,	NN	O	O
20	NN	O	O
to	NN	O	O
25%	NN	O	O
of	NN	O	O
paracetamol	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
developed	NN	O	O
hyperplasia	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
bladder	NN	O	O
epithelium	NN	O	O
,	NN	O	O
which	NN	O	O
was	NN	O	O
not	NN	O	O
coincident	NN	O	O
with	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
bladder	NN	O	B-Disease
calculi	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
low	NN	O	O
yield	NN	O	O
of	NN	O	O
tumours	NN	O	B-Disease
at	NN	O	O
various	NN	O	O
other	NN	O	O
sites	NN	O	O
also	NN	O	O
arose	NN	O	O
following	NN	O	O
paracetamol	NN	O	B-Chemical
feeding	NN	O	O
.	NN	O	O

An	NN	O	O
electron	NN	O	O
microscope	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
livers	NN	O	O
of	NN	O	O
paracetamol	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
revealed	NN	O	O
ultrastructural	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
hepatocytes	NN	O	O
that	NN	O	O
resemble	NN	O	O
those	NN	O	O
that	NN	O	O
result	NN	O	O
from	NN	O	O
exposure	NN	O	O
to	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
known	NN	O	O
hepatocarcinogens	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (4038130)

Rat	NN	O	O
extraocular	NN	O	O
muscle	NN	O	O
regeneration	NN	O	O
.	NN	O	O

Repair	NN	O	O
of	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
-	NN	O	O
induced	NN	O	O
damage	NN	O	O
.	NN	O	O

Local	NN	O	O
anesthetics	NN	O	O
that	NN	O	O
are	NN	O	O
commonly	NN	O	O
used	NN	O	O
in	NN	O	O
ophthalmic	NN	O	O
surgery	NN	O	O
(	NN	O	O
0.75%	NN	O	O
bupivacaine	NN	O	B-Chemical
hydrochloride	NN	O	I-Chemical
,	NN	O	O
2.0%	NN	O	O
mepivacaine	NN	O	B-Chemical
hydrochloride	NN	O	I-Chemical
,	NN	O	O
and	NN	O	O
2.0%	NN	O	O
lidocaine	NN	O	B-Chemical
hydrochloride	NN	O	I-Chemical
plus	NN	O	O
1	NN	O	O
:	NN	O	O
100	NN	O	O
,	NN	O	O
000	NN	O	O
epinephrine	NN	O	B-Chemical
)	NN	O	O
were	NN	O	O
injected	NN	O	O
into	NN	O	O
the	NN	O	O
retrobulbar	NN	O	O
area	NN	O	O
of	NN	O	O
rat	NN	O	O
eyes	NN	O	O
.	NN	O	O

Controls	NN	O	O
were	NN	O	O
injected	NN	O	O
with	NN	O	O
physiological	NN	O	O
saline	NN	O	O
.	NN	O	O

All	NN	O	O
three	NN	O	O
anesthetics	NN	O	O
produced	NN	O	O
massive	NN	O	O
degeneration	NN	O	O
of	NN	O	O
the	NN	O	O
extraocular	NN	O	O
muscles	NN	O	O
.	NN	O	O

Muscle	NN	O	B-Disease
degeneration	NN	O	I-Disease
is	NN	O	O
followed	NN	O	O
by	NN	O	O
regeneration	NN	O	O
of	NN	O	O
the	NN	O	O
damaged	NN	O	O
muscle	NN	O	O
fibers	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
muscle	NN	O	B-Disease
damage	NN	O	I-Disease
,	NN	O	O
severe	NN	O	O
damage	NN	O	O
was	NN	O	O
also	NN	O	O
seen	NN	O	O
in	NN	O	O
harderian	NN	O	O
glands	NN	O	O
,	NN	O	O
especially	NN	O	O
after	NN	O	O
exposure	NN	O	O
to	NN	O	O
mepivacaine	NN	O	B-Chemical
and	NN	O	O
lidocaine	NN	O	B-Chemical
plus	NN	O	O
epinephrine	NN	O	B-Chemical
.	NN	O	O

With	NN	O	O
these	NN	O	O
findings	NN	O	O
in	NN	O	O
rats	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
the	NN	O	O
temporary	NN	O	O
diplopia	NN	O	B-Disease
sometimes	NN	O	O
seen	NN	O	O
in	NN	O	O
patients	NN	O	O
after	NN	O	O
ophthalmic	NN	O	O
surgery	NN	O	O
might	NN	O	O
be	NN	O	O
due	NN	O	O
to	NN	O	O
anesthetic	NN	O	O
-	NN	O	O
induced	NN	O	O
damage	NN	O	O
to	NN	O	O
the	NN	O	O
extraocular	NN	O	O
muscles	NN	O	O
.	NN	O	O


-DOCSTART- (2907585)

Reversal	NN	O	O
of	NN	O	O
neuroleptic	NN	O	O
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
by	NN	O	O
novel	NN	O	O
aryl	NN	O	B-Chemical
-	NN	O	I-Chemical
piperazine	NN	O	I-Chemical
anxiolytic	NN	O	O
drugs	NN	O	O
.	NN	O	O

The	NN	O	O
novel	NN	O	O
anxiolytic	NN	O	O
drug	NN	O	O
,	NN	O	O
buspirone	NN	O	B-Chemical
,	NN	O	O
reverses	NN	O	O
catalepsy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
haloperidol	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
series	NN	O	O
of	NN	O	O
aryl	NN	O	B-Chemical
-	NN	O	I-Chemical
piperazine	NN	O	I-Chemical
analogues	NN	O	O
of	NN	O	O
buspirone	NN	O	B-Chemical
and	NN	O	O
other	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxytryptaminergic	NN	O	I-Chemical
agonists	NN	O	I-Chemical
were	NN	O	O
tested	NN	O	O
for	NN	O	O
their	NN	O	O
ability	NN	O	O
to	NN	O	O
reverse	NN	O	O
haloperidol	NN	O	B-Chemical
induced	NN	O	O
catalepsy	NN	O	B-Disease
.	NN	O	O

Those	NN	O	O
drugs	NN	O	O
with	NN	O	O
strong	NN	O	O
affinity	NN	O	O
for	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxytryptamine	NN	O	I-Chemical
1a	NN	O	O
receptors	NN	O	O
were	NN	O	O
able	NN	O	O
to	NN	O	O
reverse	NN	O	O
catalepsy	NN	O	B-Disease
.	NN	O	O

Drugs	NN	O	O
with	NN	O	O
affinity	NN	O	O
for	NN	O	O
other	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
receptors	NN	O	O
or	NN	O	O
weak	NN	O	O
affinity	NN	O	O
were	NN	O	O
ineffective	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
inhibition	NN	O	O
of	NN	O	O
postsynaptic	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
receptors	NN	O	O
neither	NN	O	O
inhibited	NN	O	O
nor	NN	O	O
potentiated	NN	O	O
reversal	NN	O	O
of	NN	O	O
catalepsy	NN	O	B-Disease
and	NN	O	O
leaves	NN	O	O
open	NN	O	O
the	NN	O	O
question	NN	O	O
as	NN	O	O
to	NN	O	O
the	NN	O	O
site	NN	O	O
or	NN	O	O
mechanism	NN	O	O
for	NN	O	O
this	NN	O	O
effect	NN	O	O
.	NN	O	O


-DOCSTART- (2894433)

Diazepam	NN	O	B-Chemical
facilitates	NN	O	O
reflex	NN	O	O
bradycardia	NN	O	B-Disease
in	NN	O	O
conscious	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
diazepam	NN	O	B-Chemical
on	NN	O	O
cardiovascular	NN	O	O
function	NN	O	O
were	NN	O	O
assessed	NN	O	O
in	NN	O	O
conscious	NN	O	O
rats	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
diazepam	NN	O	B-Chemical
(	NN	O	O
1	NN	O	O
-	NN	O	O
30	NN	O	O
mg	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
produced	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
decrease	NN	O	O
in	NN	O	O
both	NN	O	O
the	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
and	NN	O	O
the	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
reflex	NN	O	O
bradycardia	NN	O	B-Disease
was	NN	O	O
produced	NN	O	O
in	NN	O	O
rats	NN	O	O
by	NN	O	O
intravenous	NN	O	O
infusion	NN	O	O
of	NN	O	O
adrenaline	NN	O	B-Chemical
(	NN	O	O
1.25	NN	O	O
-	NN	O	O
2.5	NN	O	O
micrograms	NN	O	O
kg	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
pretreatment	NN	O	O
of	NN	O	O
the	NN	O	O
rats	NN	O	O
with	NN	O	O
diazepam	NN	O	B-Chemical
,	NN	O	O
although	NN	O	O
causing	NN	O	O
no	NN	O	O
change	NN	O	O
in	NN	O	O
the	NN	O	O
adrenaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
pressor	NN	O	O
effect	NN	O	O
,	NN	O	O
did	NN	O	O
enhance	NN	O	O
the	NN	O	O
adrenaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
reflex	NN	O	O
bradycardia	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
diazepam	NN	O	B-Chemical
enhancement	NN	O	O
of	NN	O	O
adrenaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
reflex	NN	O	O
bradycardia	NN	O	B-Disease
was	NN	O	O
antagonized	NN	O	O
by	NN	O	O
pretreatment	NN	O	O
of	NN	O	O
rats	NN	O	O
with	NN	O	O
an	NN	O	O
intravenous	NN	O	O
dose	NN	O	O
of	NN	O	O
picrotoxin	NN	O	B-Chemical
(	NN	O	O
an	NN	O	O
agent	NN	O	O
blocks	NN	O	O
chloride	NN	O	B-Chemical
channels	NN	O	O
by	NN	O	O
binding	NN	O	O
to	NN	O	O
sites	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
benzodiazepine	NN	O	B-Chemical
-	NN	O	O
GABA	NN	O	B-Chemical
-	NN	O	O
chloride	NN	O	B-Chemical
channel	NN	O	O
macromolecular	NN	O	O
complex	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
diazepam	NN	O	B-Chemical
acts	NN	O	O
through	NN	O	O
the	NN	O	O
benzodiazepine	NN	O	B-Chemical
-	NN	O	O
GABA	NN	O	B-Chemical
-	NN	O	O
chloride	NN	O	B-Chemical
channel	NN	O	O
macromolecular	NN	O	O
complex	NN	O	O
within	NN	O	O
the	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
to	NN	O	O
facilitate	NN	O	O
reflex	NN	O	O
bradycardia	NN	O	B-Disease
mediated	NN	O	O
through	NN	O	O
baroreceptor	NN	O	O
reflexes	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
an	NN	O	O
acute	NN	O	O
increase	NN	O	O
in	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
.	NN	O	O


-DOCSTART- (2790457)

Chronic	NN	O	O
carbamazepine	NN	O	B-Chemical
inhibits	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
seizures	NN	O	B-Disease
kindled	NN	O	O
by	NN	O	O
cocaine	NN	O	B-Chemical
and	NN	O	O
lidocaine	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
carbamazepine	NN	O	B-Chemical
(	NN	O	O
CBZ	NN	O	B-Chemical
)	NN	O	O
treatment	NN	O	O
on	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
-	NN	O	O
kindled	NN	O	O
seizures	NN	O	B-Disease
and	NN	O	O
lethality	NN	O	O
were	NN	O	O
evaluated	NN	O	O
in	NN	O	O
different	NN	O	O
stages	NN	O	O
of	NN	O	O
the	NN	O	O
kindling	NN	O	O
process	NN	O	O
and	NN	O	O
under	NN	O	O
different	NN	O	O
methods	NN	O	O
of	NN	O	O
CBZ	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

Chronic	NN	O	O
oral	NN	O	O
CBZ	NN	O	B-Chemical
inhibited	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
both	NN	O	O
lidocaine	NN	O	B-Chemical
-	NN	O	O
and	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
,	NN	O	O
but	NN	O	O
had	NN	O	O
little	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
fully	NN	O	O
developed	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

Chronic	NN	O	O
CBZ	NN	O	B-Chemical
also	NN	O	O
decreased	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
seizure	NN	O	B-Disease
-	NN	O	O
related	NN	O	O
mortality	NN	O	O
in	NN	O	O
the	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
injected	NN	O	O
rats	NN	O	O
.	NN	O	O

Acute	NN	O	O
CBZ	NN	O	B-Chemical
over	NN	O	O
a	NN	O	O
range	NN	O	O
of	NN	O	O
doses	NN	O	O
(	NN	O	O
15	NN	O	O
-	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
completed	NN	O	O
lidocaine	NN	O	B-Chemical
-	NN	O	O
kindled	NN	O	O
or	NN	O	O
acute	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

Repeated	NN	O	O
i.p.	NN	O	O
injection	NN	O	O
of	NN	O	O
CBZ	NN	O	B-Chemical
(	NN	O	O
15	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
also	NN	O	O
was	NN	O	O
without	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
-	NN	O	O
or	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
kindled	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
differential	NN	O	O
effects	NN	O	O
of	NN	O	O
CBZ	NN	O	B-Chemical
depending	NN	O	O
upon	NN	O	O
stage	NN	O	O
of	NN	O	O
seizure	NN	O	B-Disease
development	NN	O	O
suggest	NN	O	O
that	NN	O	O
distinct	NN	O	O
mechanisms	NN	O	O
underlie	NN	O	O
the	NN	O	O
development	NN	O	O
versus	NN	O	O
maintenance	NN	O	O
of	NN	O	O
local	NN	O	O
anesthetic	NN	O	O
-	NN	O	O
kindled	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
effectiveness	NN	O	O
of	NN	O	O
chronic	NN	O	O
but	NN	O	O
not	NN	O	O
repeated	NN	O	O
,	NN	O	O
intermittent	NN	O	O
injections	NN	O	O
of	NN	O	O
CBZ	NN	O	B-Chemical
suggests	NN	O	O
that	NN	O	O
different	NN	O	O
biochemical	NN	O	O
consequences	NN	O	O
result	NN	O	O
from	NN	O	O
the	NN	O	O
different	NN	O	O
treatment	NN	O	O
regimens	NN	O	O
.	NN	O	O

The	NN	O	O
possible	NN	O	O
utility	NN	O	O
of	NN	O	O
chronic	NN	O	O
CBZ	NN	O	B-Chemical
in	NN	O	O
preventing	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
toxic	NN	O	O
side	NN	O	O
effects	NN	O	O
in	NN	O	O
human	NN	O	O
cocaine	NN	O	B-Chemical
users	NN	O	O
is	NN	O	O
suggested	NN	O	O
by	NN	O	O
these	NN	O	O
data	NN	O	O
,	NN	O	O
but	NN	O	O
remains	NN	O	O
to	NN	O	O
be	NN	O	O
directly	NN	O	O
evaluated	NN	O	O
.	NN	O	O


-DOCSTART- (2334179)

D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
localized	NN	O	B-Disease
scleroderma	NN	O	I-Disease
.	NN	O	O

Localized	NN	O	B-Disease
scleroderma	NN	O	I-Disease
has	NN	O	O
no	NN	O	O
recognized	NN	O	O
internal	NN	O	O
organ	NN	O	O
involvement	NN	O	O
but	NN	O	O
may	NN	O	O
be	NN	O	O
disfiguring	NN	O	O
and	NN	O	O
disabling	NN	O	O
when	NN	O	O
the	NN	O	O
cutaneous	NN	O	O
lesions	NN	O	O
are	NN	O	O
extensive	NN	O	O
or	NN	O	O
affect	NN	O	O
children	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
no	NN	O	O
accepted	NN	O	O
or	NN	O	O
proven	NN	O	O
treatment	NN	O	O
for	NN	O	O
localized	NN	O	B-Disease
scleroderma	NN	O	I-Disease
.	NN	O	O

Case	NN	O	O
reports	NN	O	O
of	NN	O	O
11	NN	O	O
patients	NN	O	O
with	NN	O	O
severe	NN	O	O
,	NN	O	O
extensive	NN	O	O
localized	NN	O	B-Disease
scleroderma	NN	O	I-Disease
who	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
are	NN	O	O
summarized	NN	O	O
in	NN	O	O
this	NN	O	O
article	NN	O	O
.	NN	O	O

This	NN	O	O
drug	NN	O	O
was	NN	O	O
judged	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
favorable	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
disease	NN	O	O
course	NN	O	O
in	NN	O	O
7	NN	O	O
(	NN	O	O
64%	NN	O	O
)	NN	O	O
of	NN	O	O
11	NN	O	O
patients	NN	O	O
.	NN	O	O

Improvement	NN	O	O
began	NN	O	O
within	NN	O	O
3	NN	O	O
to	NN	O	O
6	NN	O	O
months	NN	O	O
and	NN	O	O
consisted	NN	O	O
of	NN	O	O
cessation	NN	O	O
of	NN	O	O
active	NN	O	O
cutaneous	NN	O	O
lesions	NN	O	O
in	NN	O	O
all	NN	O	O
7	NN	O	O
patients	NN	O	O
,	NN	O	O
skin	NN	O	O
softening	NN	O	O
in	NN	O	O
5	NN	O	O
,	NN	O	O
and	NN	O	O
more	NN	O	O
normal	NN	O	O
growth	NN	O	O
of	NN	O	O
the	NN	O	O
affected	NN	O	O
limb	NN	O	O
in	NN	O	O
2	NN	O	O
of	NN	O	O
3	NN	O	O
children	NN	O	O
.	NN	O	O

Joint	NN	O	O
stiffness	NN	O	O
and	NN	O	O
contractures	NN	O	B-Disease
also	NN	O	O
improved	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
of	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
associated	NN	O	O
with	NN	O	O
a	NN	O	O
favorable	NN	O	O
response	NN	O	O
was	NN	O	O
as	NN	O	O
low	NN	O	O
as	NN	O	O
2	NN	O	O
to	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
day	NN	O	O
given	NN	O	O
over	NN	O	O
a	NN	O	O
period	NN	O	O
ranging	NN	O	O
from	NN	O	O
15	NN	O	O
to	NN	O	O
53	NN	O	O
months	NN	O	O
.	NN	O	O

D	NN	O	B-Chemical
-	NN	O	I-Chemical
Penicillamine	NN	O	I-Chemical
caused	NN	O	O
nephrotic	NN	O	B-Disease
syndrome	NN	O	I-Disease
in	NN	O	O
1	NN	O	O
patient	NN	O	O
and	NN	O	O
milder	NN	O	O
reversible	NN	O	O
proteinuria	NN	O	B-Disease
in	NN	O	O
3	NN	O	O
other	NN	O	O
patients	NN	O	O
;	NN	O	O
none	NN	O	O
developed	NN	O	O
renal	NN	O	B-Disease
insufficiency	NN	O	I-Disease
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
may	NN	O	O
be	NN	O	O
effective	NN	O	O
in	NN	O	O
severe	NN	O	O
cases	NN	O	O
of	NN	O	O
localized	NN	O	B-Disease
scleroderma	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (1969772)

Preservation	NN	O	O
of	NN	O	O
renal	NN	O	O
blood	NN	O	O
flow	NN	O	O
during	NN	O	O
hypotension	NN	O	B-Disease
induced	NN	O	O
with	NN	O	O
fenoldopam	NN	O	B-Chemical
in	NN	O	O
dogs	NN	O	O
.	NN	O	O

The	NN	O	O
introduction	NN	O	O
of	NN	O	O
drugs	NN	O	O
that	NN	O	O
could	NN	O	O
induce	NN	O	O
hypotension	NN	O	B-Disease
with	NN	O	O
different	NN	O	O
pharmacological	NN	O	O
actions	NN	O	O
would	NN	O	O
be	NN	O	O
advantageous	NN	O	O
because	NN	O	O
side	NN	O	O
effects	NN	O	O
unique	NN	O	O
to	NN	O	O
a	NN	O	O
specific	NN	O	O
drug	NN	O	O
could	NN	O	O
be	NN	O	O
minimized	NN	O	O
by	NN	O	O
selecting	NN	O	O
appropriate	NN	O	O
therapy	NN	O	O
.	NN	O	O

Specific	NN	O	O
dopamine	NN	O	B-Chemical
-	NN	O	O
1	NN	O	O
,	NN	O	O
(	NN	O	O
DA	NN	O	B-Chemical
1	NN	O	O
)	NN	O	O
and	NN	O	O
dopamine	NN	O	B-Chemical
-	NN	O	O
2	NN	O	O
(	NN	O	O
DA	NN	O	B-Chemical
2	NN	O	O
)	NN	O	O
receptor	NN	O	O
agonists	NN	O	O
are	NN	O	O
now	NN	O	O
under	NN	O	O
clinical	NN	O	O
investigation	NN	O	O
.	NN	O	O

Fenoldopam	NN	O	B-Chemical
mesylate	NN	O	I-Chemical
is	NN	O	O
a	NN	O	O
specific	NN	O	O
DA1	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
that	NN	O	O
lowers	NN	O	O
blood	NN	O	O
pressure	NN	O	O
by	NN	O	O
vasodilatation	NN	O	O
.	NN	O	O

The	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
fenoldopam	NN	O	B-Chemical
could	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
induce	NN	O	O
hypotension	NN	O	B-Disease
and	NN	O	O
preserve	NN	O	O
blood	NN	O	O
flow	NN	O	O
to	NN	O	O
the	NN	O	O
kidney	NN	O	O
was	NN	O	O
tested	NN	O	O
.	NN	O	O

Systemic	NN	O	O
aortic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
renal	NN	O	O
blood	NN	O	O
flow	NN	O	O
were	NN	O	O
measured	NN	O	O
continuously	NN	O	O
with	NN	O	O
a	NN	O	O
carotid	NN	O	O
arterial	NN	O	O
catheter	NN	O	O
and	NN	O	O
an	NN	O	O
electromagnetic	NN	O	O
flow	NN	O	O
probe	NN	O	O
respectively	NN	O	O
,	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
cardiovascular	NN	O	O
and	NN	O	O
renal	NN	O	O
vascular	NN	O	O
effects	NN	O	O
of	NN	O	O
fenoldopam	NN	O	B-Chemical
and	NN	O	O
sodium	NN	O	B-Chemical
nitroprusside	NN	O	B-Chemical
in	NN	O	O
ten	NN	O	O
dogs	NN	O	O
under	NN	O	O
halothane	NN	O	B-Chemical
general	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

Mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
was	NN	O	O
decreased	NN	O	O
30	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
per	NN	O	O
cent	NN	O	O
from	NN	O	O
control	NN	O	O
with	NN	O	O
infusion	NN	O	O
of	NN	O	O
fenoldopam	NN	O	B-Chemical
(	NN	O	O
3.4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2.0	NN	O	O
micrograms.kg	NN	O	O
-	NN	O	O
1.min	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
and	NN	O	O
34	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
4	NN	O	O
per	NN	O	O
cent	NN	O	O
with	NN	O	O
infusion	NN	O	O
of	NN	O	O
sodium	NN	O	B-Chemical
nitroprusside	NN	O	B-Chemical
(	NN	O	O
5.9	NN	O	O
micrograms.kg	NN	O	O
-	NN	O	O
1.min	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
(	NN	O	O
NS	NN	O	O
)	NN	O	O
.	NN	O	O

Renal	NN	O	O
blood	NN	O	O
flow	NN	O	O
(	NN	O	O
RBF	NN	O	O
)	NN	O	O
increased	NN	O	O
during	NN	O	O
fenoldopam	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
11	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
7	NN	O	O
per	NN	O	O
cent	NN	O	O
and	NN	O	O
decreased	NN	O	O
21	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
per	NN	O	O
cent	NN	O	O
during	NN	O	O
sodium	NN	O	B-Chemical
nitroprusside	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

Sodium	NN	O	O
nitroprusside	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
selective	NN	O	O
arteriolar	NN	O	O
and	NN	O	O
venous	NN	O	O
vasodilator	NN	O	O
that	NN	O	O
can	NN	O	O
produce	NN	O	O
redistribution	NN	O	O
of	NN	O	O
blood	NN	O	O
flow	NN	O	O
away	NN	O	O
from	NN	O	O
the	NN	O	O
kidney	NN	O	O
during	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
.	NN	O	O

Fenoldopam	NN	O	O
is	NN	O	O
a	NN	O	O
selective	NN	O	O
dopamine	NN	O	B-Chemical
-	NN	O	O
1	NN	O	O
(	NN	O	O
DA1	NN	O	O
)	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
that	NN	O	O
causes	NN	O	O
vasodilatation	NN	O	O
to	NN	O	O
the	NN	O	O
kidney	NN	O	O
and	NN	O	O
other	NN	O	O
organs	NN	O	O
with	NN	O	O
DA1	NN	O	O
receptors	NN	O	O
and	NN	O	O
preserves	NN	O	O
blood	NN	O	O
flow	NN	O	O
to	NN	O	O
the	NN	O	O
kidney	NN	O	O
during	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (1700207)

Antiarrhythmic	NN	O	O
effects	NN	O	O
of	NN	O	O
optical	NN	O	O
isomers	NN	O	O
of	NN	O	O
cibenzoline	NN	O	B-Chemical
on	NN	O	O
canine	NN	O	O
ventricular	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
.	NN	O	O

Antiarrhythmic	NN	O	O
effects	NN	O	O
of	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
cibenzoline	NN	O	B-Chemical
and	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
cibenzoline	NN	O	B-Chemical
were	NN	O	O
examined	NN	O	O
using	NN	O	O
two	NN	O	O
canine	NN	O	O
ventricular	NN	O	B-Disease
arrhythmia	NN	O	I-Disease
models	NN	O	O
.	NN	O	O

Digitalis	NN	O	B-Chemical
arrhythmia	NN	O	B-Disease
,	NN	O	O
which	NN	O	O
is	NN	O	O
suppressed	NN	O	O
by	NN	O	O
Na	NN	O	B-Chemical
channel	NN	O	O
blockers	NN	O	O
,	NN	O	O
was	NN	O	O
induced	NN	O	O
by	NN	O	O
intermittent	NN	O	O
intravenous	NN	O	O
(	NN	O	O
i.v.	NN	O	O
)	NN	O	O
injection	NN	O	O
of	NN	O	O
ouabain	NN	O	B-Chemical
in	NN	O	O
pentobarbital	NN	O	B-Chemical
-	NN	O	O
anesthetized	NN	O	O
dogs	NN	O	O
.	NN	O	O

Adrenaline	NN	O	B-Disease
arrhythmia	NN	O	I-Disease
,	NN	O	O
which	NN	O	O
is	NN	O	O
suppressed	NN	O	O
by	NN	O	O
Ca	NN	O	B-Chemical
channel	NN	O	O
blockers	NN	O	O
,	NN	O	O
was	NN	O	O
induced	NN	O	O
by	NN	O	O
adrenaline	NN	O	B-Chemical
infusion	NN	O	O
in	NN	O	O
halothane	NN	O	B-Chemical
-	NN	O	O
anesthetized	NN	O	O
dogs	NN	O	O
.	NN	O	O

Ten	NN	O	O
and	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
cibenzoline	NN	O	B-Chemical
suppressed	NN	O	O
digitalis	NN	O	B-Chemical
-	NN	O	O
and	NN	O	O
adrenaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
arrhythmias	NN	O	B-Disease
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

The	NN	O	O
minimum	NN	O	O
effective	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
of	NN	O	O
(	NN	O	O
+	NN	O	O
)	NN	O	O
-	NN	O	O
cibenzoline	NN	O	B-Chemical
for	NN	O	O
digitalis	NN	O	B-Chemical
-	NN	O	O
and	NN	O	O
adrenaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
arrhythmias	NN	O	B-Disease
were	NN	O	O
1.4	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.4	NN	O	O
and	NN	O	O
2.0	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.6	NN	O	O
micrograms	NN	O	O
/	NN	O	O
ml	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
lower	NN	O	O
dose	NN	O	O
of	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
of	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
cibenzoline	NN	O	B-Chemical
suppressed	NN	O	O
the	NN	O	O
digitalis	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
arrhythmia	NN	O	B-Disease
,	NN	O	O
whereas	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
was	NN	O	O
needed	NN	O	O
to	NN	O	O
suppress	NN	O	O
adrenaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
arrhythmias	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
minimum	NN	O	O
effective	NN	O	O
plasma	NN	O	O
concentrations	NN	O	O
of	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
cibenzoline	NN	O	B-Chemical
for	NN	O	O
digitalis	NN	O	B-Chemical
-	NN	O	O
and	NN	O	O
adrenaline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
arrhythmia	NN	O	B-Disease
were	NN	O	O
0.06	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.04	NN	O	O
and	NN	O	O
0.7	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.1	NN	O	O
micrograms	NN	O	O
/	NN	O	O
ml	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
mean	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
6	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
stronger	NN	O	O
antiarrhythmic	NN	O	O
effect	NN	O	O
of	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
cibenzoline	NN	O	B-Chemical
indicates	NN	O	O
that	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
-	NN	O	O
isomer	NN	O	O
may	NN	O	O
have	NN	O	O
an	NN	O	O
effect	NN	O	O
nearly	NN	O	O
5	NN	O	O
-	NN	O	O
20	NN	O	O
times	NN	O	O
stronger	NN	O	O
in	NN	O	O
suppressing	NN	O	O
Na	NN	O	B-Chemical
channels	NN	O	O
,	NN	O	O
but	NN	O	O
effects	NN	O	O
of	NN	O	O
both	NN	O	O
drugs	NN	O	O
on	NN	O	O
Ca	NN	O	B-Chemical
channels	NN	O	O
may	NN	O	O
be	NN	O	O
almost	NN	O	O
equipotent	NN	O	O
.	NN	O	O


-DOCSTART- (19761039)

Effect	NN	O	O
of	NN	O	O
Hibiscus	NN	O	B-Chemical
rosa	NN	O	I-Chemical
sinensis	NN	O	I-Chemical
on	NN	O	O
reserpine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
neurobehavioral	NN	O	O
and	NN	O	O
biochemical	NN	O	O
alterations	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Effect	NN	O	O
of	NN	O	O
methanolic	NN	O	O
extract	NN	O	O
of	NN	O	O
Hibiscus	NN	O	B-Chemical
rosa	NN	O	I-Chemical
sinensis	NN	O	I-Chemical
(	NN	O	O
100	NN	O	O
-	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
was	NN	O	O
studied	NN	O	O
on	NN	O	O
reserpine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
orofacial	NN	O	O
dyskinesia	NN	O	B-Disease
and	NN	O	O
neurochemical	NN	O	O
alterations	NN	O	O
.	NN	O	O

The	NN	O	O
rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
intraperitoneal	NN	O	O
reserpine	NN	O	B-Chemical
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
ip	NN	O	O
)	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
every	NN	O	O
other	NN	O	O
day	NN	O	O
.	NN	O	O

On	NN	O	O
day	NN	O	O
5	NN	O	O
,	NN	O	O
vacuous	NN	O	O
chewing	NN	O	O
movements	NN	O	O
and	NN	O	O
tongue	NN	O	O
protrusions	NN	O	O
were	NN	O	O
counted	NN	O	O
for	NN	O	O
5	NN	O	O
min	NN	O	O
.	NN	O	O

Reserpine	NN	O	B-Chemical
treated	NN	O	O
rats	NN	O	O
significantly	NN	O	O
developed	NN	O	O
vacuous	NN	O	O
chewing	NN	O	O
movements	NN	O	O
and	NN	O	O
tongue	NN	O	O
protrusions	NN	O	O
however	NN	O	O
,	NN	O	O
coadministration	NN	O	O
of	NN	O	O
Hibiscus	NN	O	B-Chemical
rosa	NN	O	I-Chemical
sinensis	NN	O	I-Chemical
roots	NN	O	O
extract	NN	O	O
(	NN	O	O
100	NN	O	O
,	NN	O	O
200	NN	O	O
and	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
per	NN	O	O
orally	NN	O	O
)	NN	O	O
attenuated	NN	O	O
the	NN	O	O
effects	NN	O	O
.	NN	O	O

Biochemical	NN	O	O
analysis	NN	O	O
of	NN	O	O
brain	NN	O	O
revealed	NN	O	O
that	NN	O	O
the	NN	O	O
reserpine	NN	O	B-Chemical
treatment	NN	O	O
significantly	NN	O	O
increased	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
and	NN	O	O
decreased	NN	O	O
levels	NN	O	O
of	NN	O	O
superoxide	NN	O	B-Chemical
dismutase	NN	O	O
(	NN	O	O
SOD	NN	O	O
)	NN	O	O
,	NN	O	O
catalase	NN	O	O
(	NN	O	O
CAT	NN	O	O
)	NN	O	O
and	NN	O	O
glutathione	NN	O	B-Chemical
reductase	NN	O	O
(	NN	O	O
GSH	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
index	NN	O	O
of	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
process	NN	O	O
.	NN	O	O

Coadministration	NN	O	O
of	NN	O	O
extract	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
lipid	NN	O	O
peroxidation	NN	O	O
and	NN	O	O
reversed	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
brain	NN	O	O
SOD	NN	O	O
,	NN	O	O
CAT	NN	O	O
and	NN	O	O
GSH	NN	O	O
levels	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
suggested	NN	O	O
that	NN	O	O
Hibiscus	NN	O	B-Chemical
rosa	NN	O	I-Chemical
sinensis	NN	O	I-Chemical
had	NN	O	O
a	NN	O	O
protective	NN	O	O
role	NN	O	O
against	NN	O	O
reserpine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
orofacial	NN	O	O
dyskinesia	NN	O	B-Disease
and	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
.	NN	O	O


-DOCSTART- (11704023)

Comparison	NN	O	O
of	NN	O	O
aqueous	NN	O	O
and	NN	O	O
gellan	NN	O	O
ophthalmic	NN	O	O
timolol	NN	O	B-Chemical
with	NN	O	O
placebo	NN	O	O
on	NN	O	O
the	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
heart	NN	O	O
rate	NN	O	O
response	NN	O	O
in	NN	O	O
patients	NN	O	O
on	NN	O	O
treatment	NN	O	O
for	NN	O	O
glaucoma	NN	O	B-Disease
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
Topical	NN	O	O
beta	NN	O	O
-	NN	O	O
blocker	NN	O	O
treatment	NN	O	O
is	NN	O	O
routine	NN	O	O
therapy	NN	O	O
in	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
glaucoma	NN	O	B-Disease
.	NN	O	O

Therapy	NN	O	O
results	NN	O	O
in	NN	O	O
systemic	NN	O	O
absorption	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
the	NN	O	O
degree	NN	O	O
of	NN	O	O
reduction	NN	O	O
of	NN	O	O
resting	NN	O	O
and	NN	O	O
peak	NN	O	O
heart	NN	O	O
rate	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
quantified	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
This	NN	O	O
trial	NN	O	O
evaluated	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
placebo	NN	O	O
,	NN	O	O
0.5%	NN	O	O
aqueous	NN	O	O
timolol	NN	O	B-Chemical
(	NN	O	O
timolol	NN	O	B-Chemical
solution	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
0.5%	NN	O	O
timolol	NN	O	B-Chemical
suspension	NN	O	O
that	NN	O	O
forms	NN	O	O
a	NN	O	O
gel	NN	O	O
on	NN	O	O
application	NN	O	O
to	NN	O	O
the	NN	O	O
conjunctiva	NN	O	O
(	NN	O	O
timolol	NN	O	B-Chemical
gellan	NN	O	O
)	NN	O	O
on	NN	O	O
the	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
heart	NN	O	O
rate	NN	O	O
in	NN	O	O
patients	NN	O	O
currently	NN	O	O
being	NN	O	O
treated	NN	O	O
for	NN	O	O
glaucoma	NN	O	B-Disease
to	NN	O	O
quantify	NN	O	O
the	NN	O	O
reduction	NN	O	O
in	NN	O	O
mean	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Forty	NN	O	O
-	NN	O	O
three	NN	O	O
Caucasian	NN	O	O
patients	NN	O	O
with	NN	O	O
primary	NN	O	O
open	NN	O	B-Disease
-	NN	O	I-Disease
angle	NN	O	I-Disease
glaucoma	NN	O	I-Disease
or	NN	O	O
ocular	NN	O	B-Disease
hypertension	NN	O	I-Disease
with	NN	O	O
a	NN	O	O
mean	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
SD	NN	O	O
)	NN	O	O
age	NN	O	O
of	NN	O	O
63	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
8	NN	O	O
)	NN	O	O
years	NN	O	O
were	NN	O	O
randomized	NN	O	O
and	NN	O	O
crossed	NN	O	O
over	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
masked	NN	O	O
manner	NN	O	O
to	NN	O	O
14	NN	O	O
days	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
placebo	NN	O	O
(	NN	O	O
morning	NN	O	O
and	NN	O	O
evening	NN	O	O
in	NN	O	O
both	NN	O	O
eyes	NN	O	O
)	NN	O	O
,	NN	O	O
timolol	NN	O	B-Chemical
solution	NN	O	O
(	NN	O	O
morning	NN	O	O
and	NN	O	O
evening	NN	O	O
in	NN	O	O
both	NN	O	O
eyes	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
timolol	NN	O	B-Chemical
gellan	NN	O	O
(	NN	O	O
morning	NN	O	O
in	NN	O	O
both	NN	O	O
eyes	NN	O	O
with	NN	O	O
placebo	NN	O	O
in	NN	O	O
the	NN	O	O
evening	NN	O	O
)	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
13th	NN	O	O
day	NN	O	O
of	NN	O	O
each	NN	O	O
period	NN	O	O
,	NN	O	O
heart	NN	O	O
rate	NN	O	O
was	NN	O	O
recorded	NN	O	O
continuously	NN	O	O
during	NN	O	O
a	NN	O	O
typical	NN	O	O
,	NN	O	O
ambulant	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
period	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Both	NN	O	O
timolol	NN	O	B-Chemical
solution	NN	O	O
and	NN	O	O
timolol	NN	O	B-Chemical
gellan	NN	O	O
reduced	NN	O	O
the	NN	O	O
mean	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
heart	NN	O	O
rate	NN	O	O
compared	NN	O	O
with	NN	O	O
placebo	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
.001	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
this	NN	O	O
reduction	NN	O	O
was	NN	O	O
most	NN	O	O
pronounced	NN	O	O
during	NN	O	O
the	NN	O	O
daytime	NN	O	O
(	NN	O	O
-	NN	O	O
7.5%	NN	O	O
change	NN	O	O
in	NN	O	O
mean	NN	O	O
heart	NN	O	O
rate	NN	O	O
,	NN	O	O
-	NN	O	O
5.7	NN	O	O
beats	NN	O	O
/	NN	O	O
min	NN	O	O
)	NN	O	O
.	NN	O	O

Timolol	NN	O	B-Chemical
gellan	NN	O	O
showed	NN	O	O
a	NN	O	O
numerically	NN	O	O
but	NN	O	O
not	NN	O	O
significantly	NN	O	O
smaller	NN	O	O
reduction	NN	O	O
in	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
heart	NN	O	O
rate	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
timolol	NN	O	B-Chemical
solution	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
night	NN	O	O
,	NN	O	O
the	NN	O	O
mean	NN	O	O
12	NN	O	O
-	NN	O	O
hour	NN	O	O
heart	NN	O	O
rate	NN	O	O
on	NN	O	O
placebo	NN	O	O
and	NN	O	O
timolol	NN	O	B-Chemical
gellan	NN	O	O
were	NN	O	O
both	NN	O	O
significantly	NN	O	O
less	NN	O	O
than	NN	O	O
on	NN	O	O
timolol	NN	O	B-Chemical
solution	NN	O	O
;	NN	O	O
the	NN	O	O
difference	NN	O	O
between	NN	O	O
solution	NN	O	O
and	NN	O	O
gellan	NN	O	O
treatments	NN	O	O
was	NN	O	O
statistically	NN	O	O
significant	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.01	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Both	NN	O	O
timolol	NN	O	B-Chemical
solution	NN	O	O
and	NN	O	O
timolol	NN	O	B-Chemical
gellan	NN	O	O
decrease	NN	O	O
the	NN	O	O
mean	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
heart	NN	O	O
rate	NN	O	O
compared	NN	O	O
with	NN	O	O
placebo	NN	O	O
.	NN	O	O

This	NN	O	O
response	NN	O	O
was	NN	O	O
most	NN	O	O
pronounced	NN	O	O
during	NN	O	O
the	NN	O	O
active	NN	O	O
daytime	NN	O	O
period	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
quantify	NN	O	O
the	NN	O	O
modest	NN	O	O
bradycardia	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
ophthalmic	NN	O	O
beta	NN	O	O
-	NN	O	O
blocker	NN	O	O
therapy	NN	O	O
in	NN	O	O
a	NN	O	O
typical	NN	O	O
patient	NN	O	O
population	NN	O	O
on	NN	O	O
therapy	NN	O	O
for	NN	O	O
glaucoma	NN	O	B-Disease
.	NN	O	O

Although	NN	O	O
exercise	NN	O	O
performance	NN	O	O
was	NN	O	O
not	NN	O	O
assessed	NN	O	O
in	NN	O	O
this	NN	O	O
trial	NN	O	O
,	NN	O	O
reductions	NN	O	O
of	NN	O	O
this	NN	O	O
magnitude	NN	O	O
should	NN	O	O
not	NN	O	O
have	NN	O	O
substantial	NN	O	O
clinical	NN	O	O
consequences	NN	O	O
.	NN	O	O


-DOCSTART- (19300240)

5	NN	O	B-Chemical
flourouracil	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
apical	NN	O	B-Disease
ballooning	NN	O	I-Disease
syndrome	NN	O	I-Disease
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

The	NN	O	O
apical	NN	O	B-Disease
ballooning	NN	O	I-Disease
syndrome	NN	O	I-Disease
(	NN	O	O
ABS	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
a	NN	O	O
recently	NN	O	O
described	NN	O	O
stress	NN	O	O
-	NN	O	O
mediated	NN	O	O
acute	NN	O	B-Disease
cardiac	NN	O	I-Disease
syndrome	NN	O	I-Disease
characterized	NN	O	O
by	NN	O	O
transient	NN	O	O
wall	NN	O	O
-	NN	O	O
motion	NN	O	O
abnormalities	NN	O	O
involving	NN	O	O
the	NN	O	O
apex	NN	O	O
and	NN	O	O
midventricle	NN	O	O
with	NN	O	O
hyperkinesis	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
basal	NN	O	O
left	NN	O	O
ventricular	NN	O	O
(	NN	O	O
LV	NN	O	O
)	NN	O	O
segments	NN	O	O
without	NN	O	O
obstructive	NN	O	O
epicardial	NN	O	B-Disease
coronary	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

Cardiotoxicity	NN	O	B-Disease
is	NN	O	O
not	NN	O	O
an	NN	O	O
uncommon	NN	O	O
adverse	NN	O	O
effect	NN	O	O
of	NN	O	O
chemotherapeutic	NN	O	O
agents	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
are	NN	O	O
no	NN	O	O
reports	NN	O	O
of	NN	O	O
ABS	NN	O	B-Disease
secondary	NN	O	O
to	NN	O	O
chemotherapeutic	NN	O	O
agents	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
woman	NN	O	O
who	NN	O	O
developed	NN	O	O
the	NN	O	O
syndrome	NN	O	O
after	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
metastatic	NN	O	O
cancer	NN	O	B-Disease
.	NN	O	O

A	NN	O	O
79	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
presented	NN	O	O
with	NN	O	O
typical	NN	O	O
ischemic	NN	O	B-Disease
chest	NN	O	B-Disease
pain	NN	O	I-Disease
,	NN	O	O
elevated	NN	O	O
cardiac	NN	O	O
enzymes	NN	O	O
with	NN	O	O
significant	NN	O	O
ST	NN	O	O
-	NN	O	O
segment	NN	O	O
abnormalities	NN	O	O
on	NN	O	O
her	NN	O	O
electrocardiogram	NN	O	O
.	NN	O	O

She	NN	O	O
underwent	NN	O	O
recent	NN	O	O
chemotherapy	NN	O	O
with	NN	O	O
fluorouracil	NN	O	B-Chemical
for	NN	O	O
metastatic	NN	O	O
colorectal	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

Echocardiography	NN	O	O
revealed	NN	O	O
a	NN	O	O
wall	NN	O	O
-	NN	O	O
motion	NN	O	O
abnormality	NN	O	O
involving	NN	O	O
the	NN	O	O
apical	NN	O	O
and	NN	O	O
periapical	NN	O	O
segments	NN	O	O
which	NN	O	O
appeared	NN	O	O
akinetic	NN	O	B-Disease
.	NN	O	O

Coronary	NN	O	O
angiography	NN	O	O
revealed	NN	O	O
no	NN	O	O
obstructive	NN	O	O
coronary	NN	O	O
lesions	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
stabilized	NN	O	O
with	NN	O	O
medical	NN	O	O
therapy	NN	O	O
.	NN	O	O

Four	NN	O	O
weeks	NN	O	O
later	NN	O	O
she	NN	O	O
remained	NN	O	O
completely	NN	O	O
asymptomatic	NN	O	O
.	NN	O	O

Echocardiogram	NN	O	O
revealed	NN	O	O
a	NN	O	O
normal	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
and	NN	O	O
a	NN	O	O
resolution	NN	O	O
of	NN	O	O
the	NN	O	O
apical	NN	O	O
akinesis	NN	O	B-Disease
.	NN	O	O

Pathogenetic	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
cardiac	NN	O	B-Disease
complications	NN	O	I-Disease
in	NN	O	O
cancer	NN	O	B-Disease
patients	NN	O	O
undergoing	NN	O	O
chemotherapy	NN	O	O
include	NN	O	O
coronary	NN	O	B-Disease
vasospasm	NN	O	I-Disease
,	NN	O	O
endothelial	NN	O	O
damage	NN	O	O
and	NN	O	O
consequent	NN	O	O
thrombus	NN	O	B-Disease
formation	NN	O	O
.	NN	O	O

In	NN	O	O
our	NN	O	O
patient	NN	O	O
,	NN	O	O
both	NN	O	O
supraphysiologic	NN	O	O
levels	NN	O	O
of	NN	O	O
plasma	NN	O	O
catecholamines	NN	O	B-Chemical
and	NN	O	O
stress	NN	O	O
related	NN	O	O
neuropeptides	NN	O	O
caused	NN	O	O
by	NN	O	O
cancer	NN	O	B-Disease
diagnosis	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
chemotherapy	NN	O	O
may	NN	O	O
have	NN	O	O
contributed	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
ABS	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (18006530)

Reduction	NN	O	O
of	NN	O	O
pain	NN	O	B-Disease
during	NN	O	O
induction	NN	O	O
with	NN	O	O
target	NN	O	O
-	NN	O	O
controlled	NN	O	O
propofol	NN	O	B-Chemical
and	NN	O	O
remifentanil	NN	O	B-Chemical
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Pain	NN	O	B-Disease
on	NN	O	O
injection	NN	O	O
of	NN	O	O
propofol	NN	O	B-Chemical
is	NN	O	O
unpleasant	NN	O	O
.	NN	O	O

We	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
propofol	NN	O	B-Chemical
infusion	NN	O	O
pain	NN	O	B-Disease
might	NN	O	O
be	NN	O	O
prevented	NN	O	O
by	NN	O	O
infusing	NN	O	O
remifentanil	NN	O	B-Chemical
before	NN	O	O
starting	NN	O	O
the	NN	O	O
propofol	NN	O	B-Chemical
infusion	NN	O	O
in	NN	O	O
a	NN	O	O
clinical	NN	O	O
setting	NN	O	O
where	NN	O	O
target	NN	O	O
-	NN	O	O
controlled	NN	O	O
infusions	NN	O	O
(	NN	O	O
TCI	NN	O	O
)	NN	O	O
of	NN	O	O
both	NN	O	O
drugs	NN	O	O
were	NN	O	O
used	NN	O	O
.	NN	O	O

A	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
trial	NN	O	O
was	NN	O	O
performed	NN	O	O
to	NN	O	O
determine	NN	O	O
the	NN	O	O
effect	NN	O	O
-	NN	O	O
site	NN	O	O
concentration	NN	O	O
(	NN	O	O
Ce	NN	O	O
)	NN	O	O
of	NN	O	O
remifentanil	NN	O	B-Chemical
to	NN	O	O
prevent	NN	O	O
the	NN	O	O
pain	NN	O	B-Disease
without	NN	O	O
producing	NN	O	O
complications	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
128	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
general	NN	O	O
surgery	NN	O	O
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
receive	NN	O	O
normal	NN	O	O
saline	NN	O	O
(	NN	O	O
control	NN	O	O
)	NN	O	O
or	NN	O	O
remifentanil	NN	O	B-Chemical
to	NN	O	O
a	NN	O	O
target	NN	O	O
Ce	NN	O	O
of	NN	O	O
2	NN	O	O
ng	NN	O	O
ml	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
(	NN	O	O
R2	NN	O	O
)	NN	O	O
,	NN	O	O
4	NN	O	O
ng	NN	O	O
ml	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
(	NN	O	O
R4	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
6	NN	O	O
ng	NN	O	O
ml	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
(	NN	O	O
R6	NN	O	O
)	NN	O	O
administered	NN	O	O
via	NN	O	O
TCI	NN	O	O
.	NN	O	O

After	NN	O	O
the	NN	O	O
target	NN	O	O
Ce	NN	O	O
was	NN	O	O
achieved	NN	O	O
,	NN	O	O
the	NN	O	O
infusion	NN	O	O
of	NN	O	O
propofol	NN	O	B-Chemical
was	NN	O	O
started	NN	O	O
.	NN	O	O

Remifentanil	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
complications	NN	O	O
were	NN	O	O
assessed	NN	O	O
during	NN	O	O
the	NN	O	O
remifentanil	NN	O	B-Chemical
infusion	NN	O	O
,	NN	O	O
and	NN	O	O
pain	NN	O	B-Disease
caused	NN	O	O
by	NN	O	O
propofol	NN	O	B-Chemical
was	NN	O	O
evaluated	NN	O	O
using	NN	O	O
a	NN	O	O
four	NN	O	O
-	NN	O	O
point	NN	O	O
scale	NN	O	O
during	NN	O	O
the	NN	O	O
propofol	NN	O	B-Chemical
infusion	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
incidence	NN	O	O
of	NN	O	O
pain	NN	O	B-Disease
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
in	NN	O	O
Groups	NN	O	O
R4	NN	O	O
and	NN	O	O
R6	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
and	NN	O	O
R2	NN	O	O
groups	NN	O	O
(	NN	O	O
12	NN	O	O
/	NN	O	O
32	NN	O	O
and	NN	O	O
6	NN	O	O
/	NN	O	O
31	NN	O	O
vs	NN	O	O
26	NN	O	O
/	NN	O	O
31	NN	O	O
and	NN	O	O
25	NN	O	O
/	NN	O	O
32	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
P<0.001	NN	O	O
)	NN	O	O
.	NN	O	O

Pain	NN	O	B-Disease
was	NN	O	O
less	NN	O	O
severe	NN	O	O
in	NN	O	O
Groups	NN	O	O
R4	NN	O	O
and	NN	O	O
R6	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
control	NN	O	O
and	NN	O	O
R2	NN	O	O
groups	NN	O	O
(	NN	O	O
P<0.001	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
both	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
pain	NN	O	B-Disease
were	NN	O	O
not	NN	O	O
different	NN	O	O
between	NN	O	O
Groups	NN	O	O
R4	NN	O	O
and	NN	O	O
R6	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
complications	NN	O	O
were	NN	O	O
observed	NN	O	O
during	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
During	NN	O	O
induction	NN	O	O
of	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
TCI	NN	O	O
of	NN	O	O
propofol	NN	O	B-Chemical
and	NN	O	O
remifentanil	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
significant	NN	O	O
reduction	NN	O	O
in	NN	O	O
propofol	NN	O	B-Chemical
infusion	NN	O	O
pain	NN	O	B-Disease
was	NN	O	O
achieved	NN	O	O
without	NN	O	O
significant	NN	O	O
complications	NN	O	O
by	NN	O	O
prior	NN	O	O
administration	NN	O	O
of	NN	O	O
remifentanil	NN	O	B-Chemical
at	NN	O	O
a	NN	O	O
target	NN	O	O
Ce	NN	O	O
of	NN	O	O
4	NN	O	O
ng	NN	O	O
ml	NN	O	O
(	NN	O	O
-	NN	O	O
1	NN	O	O
)	NN	O	O
.	NN	O	O


-DOCSTART- (17702969)

Prenatal	NN	O	O
exposure	NN	O	O
to	NN	O	O
fluoxetine	NN	O	B-Chemical
induces	NN	O	O
fetal	NN	O	B-Disease
pulmonary	NN	O	I-Disease
hypertension	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

RATIONALE	NN	O	O
:	NN	O	O
Fluoxetine	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
selective	NN	O	O
serotonin	NN	O	B-Chemical
reuptake	NN	O	O
inhibitor	NN	O	O
antidepressant	NN	O	O
widely	NN	O	O
used	NN	O	O
by	NN	O	O
pregnant	NN	O	O
women	NN	O	O
.	NN	O	O

Epidemiological	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
fluoxetine	NN	O	B-Chemical
exposure	NN	O	O
prenatally	NN	O	O
increases	NN	O	O
the	NN	O	O
prevalence	NN	O	O
of	NN	O	O
persistent	NN	O	O
pulmonary	NN	O	B-Disease
hypertension	NN	O	I-Disease
syndrome	NN	O	I-Disease
of	NN	O	O
the	NN	O	O
newborn	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
responsible	NN	O	O
for	NN	O	O
this	NN	O	O
effect	NN	O	O
is	NN	O	O
unclear	NN	O	O
and	NN	O	O
paradoxical	NN	O	O
,	NN	O	O
considering	NN	O	O
the	NN	O	O
current	NN	O	O
evidence	NN	O	O
of	NN	O	O
a	NN	O	O
pulmonary	NN	O	B-Disease
hypertension	NN	O	I-Disease
protective	NN	O	O
fluoxetine	NN	O	B-Chemical
effect	NN	O	O
in	NN	O	O
adult	NN	O	O
rodents	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
fluoxetine	NN	O	B-Chemical
effect	NN	O	O
on	NN	O	O
fetal	NN	O	O
rat	NN	O	O
pulmonary	NN	O	O
vascular	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
mechanical	NN	O	O
properties	NN	O	O
and	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
rate	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Pregnant	NN	O	O
rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
fluoxetine	NN	O	B-Chemical
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
from	NN	O	O
Day	NN	O	O
11	NN	O	O
through	NN	O	O
Day	NN	O	O
21	NN	O	O
of	NN	O	O
gestation	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
AND	NN	O	O
MAIN	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
Fetuses	NN	O	O
were	NN	O	O
delivered	NN	O	O
by	NN	O	O
cesarean	NN	O	O
section	NN	O	O
.	NN	O	O

As	NN	O	O
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
,	NN	O	O
fluoxetine	NN	O	B-Chemical
exposure	NN	O	O
resulted	NN	O	O
in	NN	O	O
fetal	NN	O	B-Disease
pulmonary	NN	O	I-Disease
hypertension	NN	O	I-Disease
as	NN	O	O
evidenced	NN	O	O
by	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
weight	NN	O	O
ratio	NN	O	O
of	NN	O	O
the	NN	O	O
right	NN	O	O
ventricle	NN	O	O
to	NN	O	O
the	NN	O	O
left	NN	O	O
ventricle	NN	O	O
plus	NN	O	O
septum	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.02	NN	O	O
)	NN	O	O
and	NN	O	O
by	NN	O	O
an	NN	O	O
increase	NN	O	O
in	NN	O	O
pulmonary	NN	O	O
arterial	NN	O	O
medial	NN	O	O
thickness	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

Postnatal	NN	O	O
mortality	NN	O	O
was	NN	O	O
increased	NN	O	O
among	NN	O	O
experimental	NN	O	O
animals	NN	O	O
,	NN	O	O
and	NN	O	O
arterial	NN	O	O
oxygen	NN	O	B-Chemical
saturation	NN	O	O
was	NN	O	O
96	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1%	NN	O	O
in	NN	O	O
1	NN	O	O
-	NN	O	O
day	NN	O	O
-	NN	O	O
old	NN	O	O
control	NN	O	O
animals	NN	O	O
and	NN	O	O
significantly	NN	O	O
lower	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
in	NN	O	O
fluoxetine	NN	O	B-Chemical
-	NN	O	O
exposed	NN	O	O
pups	NN	O	O
(	NN	O	O
79	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2%	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
vitro	NN	O	O
,	NN	O	O
fluoxetine	NN	O	B-Chemical
induced	NN	O	O
pulmonary	NN	O	O
arterial	NN	O	O
muscle	NN	O	O
contraction	NN	O	O
in	NN	O	O
fetal	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
adult	NN	O	O
,	NN	O	O
animals	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
and	NN	O	O
reduced	NN	O	O
serotonin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
contraction	NN	O	O
at	NN	O	O
both	NN	O	O
ages	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

After	NN	O	O
in	NN	O	O
utero	NN	O	O
exposure	NN	O	O
to	NN	O	O
a	NN	O	O
low	NN	O	O
fluoxetine	NN	O	B-Chemical
concentration	NN	O	O
the	NN	O	O
pulmonary	NN	O	O
arterial	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
cell	NN	O	O
proliferation	NN	O	O
rate	NN	O	O
was	NN	O	O
significantly	NN	O	O
increased	NN	O	O
in	NN	O	O
fetal	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
adult	NN	O	O
,	NN	O	O
cells	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
contrast	NN	O	O
to	NN	O	O
the	NN	O	O
adult	NN	O	O
,	NN	O	O
fluoxetine	NN	O	B-Chemical
exposure	NN	O	O
in	NN	O	O
utero	NN	O	O
induces	NN	O	O
pulmonary	NN	O	B-Disease
hypertension	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
fetal	NN	O	O
rat	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
a	NN	O	O
developmentally	NN	O	O
regulated	NN	O	O
increase	NN	O	O
in	NN	O	O
pulmonary	NN	O	O
vascular	NN	O	O
smooth	NN	O	O
muscle	NN	O	O
proliferation	NN	O	O
.	NN	O	O


-DOCSTART- (17344330)

Syncope	NN	O	B-Disease
and	NN	O	O
QT	NN	O	B-Disease
prolongation	NN	O	I-Disease
among	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
methadone	NN	O	B-Chemical
for	NN	O	O
heroin	NN	O	B-Chemical
dependence	NN	O	O
in	NN	O	O
the	NN	O	O
city	NN	O	O
of	NN	O	O
Copenhagen	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Methadone	NN	O	B-Chemical
is	NN	O	O
prescribed	NN	O	O
to	NN	O	O
heroin	NN	O	B-Chemical
addicts	NN	O	O
to	NN	O	O
decrease	NN	O	O
illicit	NN	O	O
opioid	NN	O	O
use	NN	O	O
.	NN	O	O

Prolongation	NN	O	O
of	NN	O	O
the	NN	O	O
QT	NN	O	O
interval	NN	O	O
in	NN	O	O
the	NN	O	O
ECG	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
(	NN	O	O
TdP	NN	O	B-Disease
)	NN	O	O
has	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
methadone	NN	O	B-Chemical
users	NN	O	O
.	NN	O	O

As	NN	O	O
heroin	NN	O	B-Chemical
addicts	NN	O	O
sometimes	NN	O	O
faint	NN	O	O
while	NN	O	O
using	NN	O	O
illicit	NN	O	O
drugs	NN	O	O
,	NN	O	O
doctors	NN	O	O
might	NN	O	O
attribute	NN	O	O
too	NN	O	O
many	NN	O	O
episodes	NN	O	O
of	NN	O	O
syncope	NN	O	B-Disease
to	NN	O	O
illicit	NN	O	O
drug	NN	O	O
use	NN	O	O
and	NN	O	O
thereby	NN	O	O
underestimate	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
TdP	NN	O	B-Disease
in	NN	O	O
this	NN	O	O
special	NN	O	O
population	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
high	NN	O	O
mortality	NN	O	O
in	NN	O	O
this	NN	O	O
population	NN	O	O
may	NN	O	O
,	NN	O	O
in	NN	O	O
part	NN	O	O
,	NN	O	O
be	NN	O	O
caused	NN	O	O
by	NN	O	O
the	NN	O	O
proarrhythmic	NN	O	O
effect	NN	O	O
of	NN	O	O
methadone	NN	O	B-Chemical
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
In	NN	O	O
this	NN	O	O
cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
study	NN	O	O
interview	NN	O	O
,	NN	O	O
ECGs	NN	O	O
and	NN	O	O
blood	NN	O	O
samples	NN	O	O
were	NN	O	O
collected	NN	O	O
in	NN	O	O
a	NN	O	O
population	NN	O	O
of	NN	O	O
adult	NN	O	O
heroin	NN	O	B-Chemical
addicts	NN	O	O
treated	NN	O	O
with	NN	O	O
methadone	NN	O	B-Chemical
or	NN	O	O
buprenorphine	NN	O	B-Chemical
on	NN	O	O
a	NN	O	O
daily	NN	O	O
basis	NN	O	O
.	NN	O	O

Of	NN	O	O
the	NN	O	O
patients	NN	O	O
at	NN	O	O
the	NN	O	O
Drug	NN	O	O
Addiction	NN	O	O
Service	NN	O	O
in	NN	O	O
the	NN	O	O
municipal	NN	O	O
of	NN	O	O
Copenhagen	NN	O	O
,	NN	O	O
450	NN	O	O
(	NN	O	O
approximately	NN	O	O
52%	NN	O	O
)	NN	O	O
were	NN	O	O
included	NN	O	O
.	NN	O	O

The	NN	O	O
QT	NN	O	O
interval	NN	O	O
was	NN	O	O
estimated	NN	O	O
from	NN	O	O
12	NN	O	O
lead	NN	O	O
ECGs	NN	O	O
.	NN	O	O

All	NN	O	O
participants	NN	O	O
were	NN	O	O
interviewed	NN	O	O
about	NN	O	O
any	NN	O	O
experience	NN	O	O
of	NN	O	O
syncope	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
association	NN	O	O
between	NN	O	O
opioid	NN	O	O
dose	NN	O	O
and	NN	O	O
QT	NN	O	O
,	NN	O	O
and	NN	O	O
methadone	NN	O	B-Chemical
dose	NN	O	O
and	NN	O	O
reporting	NN	O	O
of	NN	O	O
syncope	NN	O	B-Disease
was	NN	O	O
assessed	NN	O	O
using	NN	O	O
multivariate	NN	O	O
linear	NN	O	O
regression	NN	O	O
and	NN	O	O
logistic	NN	O	O
regression	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Methadone	NN	O	B-Chemical
dose	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
longer	NN	O	O
QT	NN	O	O
interval	NN	O	O
of	NN	O	O
0.140	NN	O	O
ms	NN	O	O
/	NN	O	O
mg	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.002	NN	O	O
)	NN	O	O
.	NN	O	O

No	NN	O	O
association	NN	O	O
between	NN	O	O
buprenorphine	NN	O	B-Chemical
and	NN	O	O
QTc	NN	O	O
was	NN	O	O
found	NN	O	O
.	NN	O	O

Among	NN	O	O
the	NN	O	O
subjects	NN	O	O
treated	NN	O	O
with	NN	O	O
methadone	NN	O	B-Chemical
,	NN	O	O
28%	NN	O	O
men	NN	O	O
and	NN	O	O
32%	NN	O	O
women	NN	O	O
had	NN	O	O
prolonged	NN	O	B-Disease
QTc	NN	O	I-Disease
interval	NN	O	I-Disease
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
subjects	NN	O	O
treated	NN	O	O
with	NN	O	O
buprenorphine	NN	O	B-Chemical
had	NN	O	O
QTc	NN	O	O
interval	NN	O	O
>0.440	NN	O	O
s	NN	O	O
(	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
)	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
50	NN	O	O
mg	NN	O	O
higher	NN	O	O
methadone	NN	O	B-Chemical
dose	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
1.2	NN	O	O
(	NN	O	O
95%	NN	O	O
CI	NN	O	O
1.1	NN	O	O
to	NN	O	O
1.4	NN	O	O
)	NN	O	O
times	NN	O	O
higher	NN	O	O
odds	NN	O	O
for	NN	O	O
syncope	NN	O	B-Disease
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Methadone	NN	O	B-Chemical
is	NN	O	O
associated	NN	O	O
with	NN	O	O
QT	NN	O	B-Disease
prolongation	NN	O	I-Disease
and	NN	O	O
higher	NN	O	O
reporting	NN	O	O
of	NN	O	O
syncope	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
population	NN	O	O
of	NN	O	O
heroin	NN	O	B-Chemical
addicts	NN	O	O
.	NN	O	O


-DOCSTART- (16826348)

Peripheral	NN	O	B-Disease
neuropathy	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
cytosine	NN	O	B-Chemical
arabinoside	NN	O	I-Chemical
treatment	NN	O	O
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
acute	NN	O	B-Disease
myeloid	NN	O	I-Disease
leukemia	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
central	NN	O	O
nervous	NN	O	O
system	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
cytosine	NN	O	B-Chemical
arabinoside	NN	O	I-Chemical
is	NN	O	O
well	NN	O	O
recognized	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
cytosine	NN	O	B-Chemical
arabinoside	NN	O	I-Chemical
in	NN	O	O
the	NN	O	O
peripheral	NN	O	O
nervous	NN	O	O
system	NN	O	O
has	NN	O	O
been	NN	O	O
infrequently	NN	O	O
reported	NN	O	O
.	NN	O	O

A	NN	O	O
49	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Japanese	NN	O	O
man	NN	O	O
was	NN	O	O
diagnosed	NN	O	O
with	NN	O	O
acute	NN	O	B-Disease
myeloid	NN	O	I-Disease
leukemia	NN	O	I-Disease
.	NN	O	O

After	NN	O	O
he	NN	O	O
achieved	NN	O	O
complete	NN	O	O
remission	NN	O	O
,	NN	O	O
he	NN	O	O
received	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
cytosine	NN	O	B-Chemical
arabinoside	NN	O	I-Chemical
treatment	NN	O	O
(	NN	O	O
2	NN	O	O
g	NN	O	O
/	NN	O	O
m2	NN	O	O
twice	NN	O	O
a	NN	O	O
day	NN	O	O
for	NN	O	O
5	NN	O	O
days	NN	O	O
;	NN	O	O
total	NN	O	O
,	NN	O	O
20	NN	O	O
g	NN	O	O
/	NN	O	O
m2	NN	O	O
)	NN	O	O
as	NN	O	O
consolidation	NN	O	O
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
first	NN	O	O
course	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
cytosine	NN	O	B-Chemical
arabinoside	NN	O	I-Chemical
resulted	NN	O	O
in	NN	O	O
no	NN	O	O
unusual	NN	O	O
symptoms	NN	O	O
,	NN	O	O
but	NN	O	O
on	NN	O	O
day	NN	O	O
21	NN	O	O
of	NN	O	O
the	NN	O	O
second	NN	O	O
course	NN	O	O
of	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
complained	NN	O	O
of	NN	O	O
numbness	NN	O	B-Disease
in	NN	O	O
his	NN	O	O
right	NN	O	O
foot	NN	O	O
.	NN	O	O

Electromyogram	NN	O	O
and	NN	O	O
nerve	NN	O	O
-	NN	O	O
conduction	NN	O	O
studies	NN	O	O
showed	NN	O	O
peripheral	NN	O	B-Disease
neuropathy	NN	O	I-Disease
in	NN	O	O
both	NN	O	O
peroneal	NN	O	O
nerves	NN	O	O
.	NN	O	O

This	NN	O	O
neuropathy	NN	O	B-Disease
was	NN	O	O
gradually	NN	O	O
resolving	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
after	NN	O	O
the	NN	O	O
patient	NN	O	O
received	NN	O	O
allogeneic	NN	O	O
bone	NN	O	O
marrow	NN	O	O
transplantation	NN	O	O
,	NN	O	O
the	NN	O	O
symptoms	NN	O	O
worsened	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
graft	NN	O	B-Disease
-	NN	O	I-Disease
versus	NN	O	I-Disease
-	NN	O	I-Disease
host	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
the	NN	O	O
symptoms	NN	O	O
subsequently	NN	O	O
responded	NN	O	O
to	NN	O	O
methylprednisolone	NN	O	B-Chemical
.	NN	O	O

Although	NN	O	O
the	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
peripheral	NN	O	B-Disease
neuropathy	NN	O	I-Disease
are	NN	O	O
still	NN	O	O
unclear	NN	O	O
,	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
cytosine	NN	O	B-Chemical
arabinoside	NN	O	I-Chemical
is	NN	O	O
a	NN	O	O
therapy	NN	O	O
that	NN	O	O
is	NN	O	O
potentially	NN	O	O
toxic	NN	O	O
to	NN	O	O
the	NN	O	O
peripheral	NN	O	O
nervous	NN	O	O
system	NN	O	O
,	NN	O	O
and	NN	O	O
auto	NN	O	O
/	NN	O	O
alloimmunity	NN	O	O
may	NN	O	O
play	NN	O	O
an	NN	O	O
important	NN	O	O
role	NN	O	O
in	NN	O	O
these	NN	O	O
mechanisms	NN	O	O
.	NN	O	O


-DOCSTART- (16820346)

Atorvastatin	NN	O	B-Chemical
prevented	NN	O	O
and	NN	O	O
reversed	NN	O	O
dexamethasone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

To	NN	O	O
assess	NN	O	O
the	NN	O	O
antioxidant	NN	O	O
effects	NN	O	O
of	NN	O	O
atorvastatin	NN	O	B-Chemical
(	NN	O	O
atorva	NN	O	B-Chemical
)	NN	O	O
on	NN	O	O
dexamethasone	NN	O	B-Chemical
(	NN	O	O
dex	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B-Disease
,	NN	O	O
60	NN	O	O
male	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
atorva	NN	O	B-Chemical
30	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
or	NN	O	O
tap	NN	O	O
water	NN	O	O
for	NN	O	O
15	NN	O	O
days	NN	O	O
.	NN	O	O

Dex	NN	O	B-Chemical
increased	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
SBP	NN	O	O
)	NN	O	O
from	NN	O	O
109	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.8	NN	O	O
to	NN	O	O
135	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.6	NN	O	O
mmHg	NN	O	O
and	NN	O	O
plasma	NN	O	O
superoxide	NN	O	B-Chemical
(	NN	O	O
5711	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
284.9	NN	O	O
saline	NN	O	O
,	NN	O	O
7931	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
392.8	NN	O	O
U	NN	O	O
/	NN	O	O
ml	NN	O	O
dex	NN	O	B-Chemical
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
prevention	NN	O	O
study	NN	O	O
,	NN	O	O
SBP	NN	O	O
in	NN	O	O
the	NN	O	O
atorva	NN	O	B-Chemical
+	NN	O	O
dex	NN	O	B-Chemical
group	NN	O	O
was	NN	O	O
increased	NN	O	O
from	NN	O	O
115	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.4	NN	O	O
to	NN	O	O
124	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.5	NN	O	O
mmHg	NN	O	O
,	NN	O	O
but	NN	O	O
this	NN	O	O
was	NN	O	O
significantly	NN	O	O
lower	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
dex	NN	O	B-Chemical
-	NN	O	O
only	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
'	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Atorva	NN	O	B-Chemical
reversed	NN	O	O
dex	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B-Disease
(	NN	O	O
129	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.6	NN	O	O
mmHg	NN	O	O
,	NN	O	O
vs	NN	O	O
.	NN	O	O

135	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.6	NN	O	O
mmHg	NN	O	O
P	NN	O	O
'	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
and	NN	O	O
decreased	NN	O	O
plasma	NN	O	O
superoxide	NN	O	B-Chemical
(	NN	O	O
7931	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
392.8	NN	O	O
dex	NN	O	B-Chemical
,	NN	O	O
1187	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
441.2	NN	O	O
atorva	NN	O	B-Chemical
+	NN	O	O
dex	NN	O	B-Chemical
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.0001	NN	O	O
)	NN	O	O
.	NN	O	O

Plasma	NN	O	O
nitrate	NN	O	B-Chemical
/	NN	O	O
nitrite	NN	O	B-Chemical
(	NN	O	O
NOx	NN	O	O
)	NN	O	O
was	NN	O	O
decreased	NN	O	O
in	NN	O	O
dex	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
compared	NN	O	O
to	NN	O	O
saline	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
(	NN	O	O
11.2	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.08	NN	O	O
microm	NN	O	O
,	NN	O	O
15.3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.17	NN	O	O
microm	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Atorva	NN	O	B-Chemical
affected	NN	O	O
neither	NN	O	O
plasma	NN	O	O
NOx	NN	O	O
nor	NN	O	O
thymus	NN	O	O
weight	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
atorvastatin	NN	O	B-Chemical
prevented	NN	O	O
and	NN	O	O
reversed	NN	O	O
dexamethasone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O


-DOCSTART- (15974569)

Two	NN	O	O
prodrugs	NN	O	O
of	NN	O	O
potent	NN	O	O
and	NN	O	O
selective	NN	O	O
GluR5	NN	O	O
kainate	NN	O	B-Chemical
receptor	NN	O	O
antagonists	NN	O	O
actives	NN	O	O
in	NN	O	O
three	NN	O	O
animal	NN	O	O
models	NN	O	O
of	NN	O	O
pain	NN	O	B-Disease
.	NN	O	O

Amino	NN	O	O
acids	NN	O	O
5	NN	O	O
and	NN	O	O
7	NN	O	O
,	NN	O	O
two	NN	O	O
potent	NN	O	O
and	NN	O	O
selective	NN	O	O
competitive	NN	O	O
GluR5	NN	O	O
KA	NN	O	B-Chemical
receptor	NN	O	O
antagonists	NN	O	O
,	NN	O	O
exhibited	NN	O	O
high	NN	O	O
GluR5	NN	O	O
receptor	NN	O	O
affinity	NN	O	O
over	NN	O	O
other	NN	O	O
glutamate	NN	O	B-Chemical
receptors	NN	O	O
.	NN	O	O

Their	NN	O	O
ester	NN	O	O
prodrugs	NN	O	O
6	NN	O	O
and	NN	O	O
8	NN	O	O
were	NN	O	O
orally	NN	O	O
active	NN	O	O
in	NN	O	O
three	NN	O	O
models	NN	O	O
of	NN	O	O
pain	NN	O	B-Disease
:	NN	O	O
reversal	NN	O	O
of	NN	O	O
formalin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
paw	NN	O	O
licking	NN	O	O
,	NN	O	O
carrageenan	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thermal	NN	O	B-Disease
hyperalgesia	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
capsaicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
mechanical	NN	O	B-Disease
hyperalgesia	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (11583940)

Sirolimus	NN	O	B-Chemical
and	NN	O	O
mycophenolate	NN	O	B-Chemical
mofetil	NN	O	I-Chemical
for	NN	O	O
calcineurin	NN	O	O
-	NN	O	O
free	NN	O	O
immunosuppression	NN	O	O
in	NN	O	O
renal	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
.	NN	O	O

Calcineurin	NN	O	O
inhibitors	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
cyclosporine	NN	O	B-Chemical
and	NN	O	O
tacrolimus	NN	O	B-Chemical
,	NN	O	O
have	NN	O	O
been	NN	O	O
available	NN	O	O
for	NN	O	O
almost	NN	O	O
20	NN	O	O
years	NN	O	O
.	NN	O	O

Although	NN	O	O
these	NN	O	O
drugs	NN	O	O
are	NN	O	O
highly	NN	O	O
effective	NN	O	O
and	NN	O	O
represent	NN	O	O
the	NN	O	O
mainstay	NN	O	O
of	NN	O	O
transplant	NN	O	O
immunosuppression	NN	O	O
,	NN	O	O
they	NN	O	O
are	NN	O	O
associated	NN	O	O
with	NN	O	O
acute	NN	O	O
and	NN	O	O
chronic	NN	O	O
nephrotoxicity	NN	O	B-Disease
.	NN	O	O

Acute	NN	O	O
nephrotoxicity	NN	O	B-Disease
,	NN	O	O
which	NN	O	O
occurs	NN	O	O
in	NN	O	O
the	NN	O	O
early	NN	O	O
period	NN	O	O
after	NN	O	O
transplantation	NN	O	O
,	NN	O	O
leads	NN	O	O
to	NN	O	O
a	NN	O	O
higher	NN	O	O
rate	NN	O	O
of	NN	O	O
dialysis	NN	O	O
,	NN	O	O
and	NN	O	O
chronic	NN	O	O
nephrotoxicity	NN	O	B-Disease
may	NN	O	O
eventually	NN	O	O
result	NN	O	O
in	NN	O	O
graft	NN	O	O
loss	NN	O	O
.	NN	O	O

Acute	NN	O	O
and	NN	O	O
chronic	NN	O	O
nephrotoxicity	NN	O	B-Disease
is	NN	O	O
becoming	NN	O	O
more	NN	O	O
common	NN	O	O
as	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
marginal	NN	O	O
kidneys	NN	O	O
for	NN	O	O
transplantation	NN	O	O
increases	NN	O	O
.	NN	O	O

Two	NN	O	O
recently	NN	O	O
available	NN	O	O
immunosuppressive	NN	O	O
agents	NN	O	O
,	NN	O	O
mycophenolate	NN	O	B-Chemical
mofetil	NN	O	I-Chemical
and	NN	O	O
sirolimus	NN	O	B-Chemical
(	NN	O	O
rapamycin	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
have	NN	O	O
no	NN	O	O
nephrotoxicity	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
use	NN	O	O
of	NN	O	O
these	NN	O	O
drugs	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
other	NN	O	O
agents	NN	O	O
has	NN	O	O
led	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
new	NN	O	O
paradigms	NN	O	O
of	NN	O	O
immunosuppressive	NN	O	O
therapy	NN	O	O
.	NN	O	O

This	NN	O	O
paper	NN	O	O
reviews	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
clinical	NN	O	O
trials	NN	O	O
that	NN	O	O
have	NN	O	O
investigated	NN	O	O
these	NN	O	O
new	NN	O	O
approaches	NN	O	O
to	NN	O	O
immunosuppression	NN	O	O
in	NN	O	O
renal	NN	O	O
transplant	NN	O	O
recipients	NN	O	O
.	NN	O	O


-DOCSTART- (11245434)

Erythropoietin	NN	O	O
restores	NN	O	O
the	NN	O	O
anemia	NN	O	B-Disease
-	NN	O	O
induced	NN	O	O
reduction	NN	O	O
in	NN	O	O
cyclophosphamide	NN	O	B-Chemical
cytotoxicity	NN	O	B-Disease
in	NN	O	O
rat	NN	O	O
tumors	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
impact	NN	O	O
of	NN	O	O
anemia	NN	O	B-Disease
prevention	NN	O	O
by	NN	O	O
recombinant	NN	O	O
human	NN	O	O
erythropoietin	NN	O	O
(	NN	O	O
rHuEPO	NN	O	O
)	NN	O	O
treatment	NN	O	O
on	NN	O	O
the	NN	O	O
cytotoxicity	NN	O	B-Disease
of	NN	O	O
cyclophosphamide	NN	O	B-Chemical
in	NN	O	O
solid	NN	O	O
experimental	NN	O	O
tumors	NN	O	B-Disease
.	NN	O	O

Anemia	NN	O	B-Disease
was	NN	O	O
induced	NN	O	O
using	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
carboplatin	NN	O	B-Chemical
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
)	NN	O	O
resulting	NN	O	O
in	NN	O	O
a	NN	O	O
long	NN	O	O
-	NN	O	O
lasting	NN	O	O
reduction	NN	O	O
(	NN	O	O
30%	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
hemoglobin	NN	O	O
concentration	NN	O	O
.	NN	O	O

In	NN	O	O
a	NN	O	O
second	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
anemia	NN	O	B-Disease
was	NN	O	O
prevented	NN	O	O
by	NN	O	O
rHuEPO	NN	O	O
(	NN	O	O
1000	NN	O	O
IU	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
administered	NN	O	O
s.c.	NN	O	O
three	NN	O	O
times	NN	O	O
/	NN	O	O
week	NN	O	O
starting	NN	O	O
7	NN	O	O
days	NN	O	O
before	NN	O	O
carboplatin	NN	O	B-Chemical
application	NN	O	O
.	NN	O	O

Four	NN	O	O
days	NN	O	O
after	NN	O	O
carboplatin	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
tumors	NN	O	B-Disease
(	NN	O	O
DS	NN	O	O
-	NN	O	O
sarcoma	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
rat	NN	O	O
)	NN	O	O
were	NN	O	O
implanted	NN	O	O
s.c.	NN	O	O
onto	NN	O	O
the	NN	O	O
hind	NN	O	O
food	NN	O	O
dorsum	NN	O	O
.	NN	O	O

Neither	NN	O	O
carboplatin	NN	O	B-Chemical
nor	NN	O	O
rHuEPO	NN	O	O
treatment	NN	O	O
influenced	NN	O	O
tumor	NN	O	B-Disease
growth	NN	O	O
rate	NN	O	O
per	NN	O	O
se	NN	O	O
.	NN	O	O

When	NN	O	O
tumors	NN	O	B-Disease
were	NN	O	O
treated	NN	O	O
with	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	B-Chemical
(	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.p.	NN	O	O
)	NN	O	O
5	NN	O	O
days	NN	O	O
after	NN	O	O
implantation	NN	O	O
,	NN	O	O
a	NN	O	O
growth	NN	O	O
delay	NN	O	O
with	NN	O	O
a	NN	O	O
subsequent	NN	O	O
regrowth	NN	O	O
of	NN	O	O
the	NN	O	O
tumors	NN	O	B-Disease
was	NN	O	O
observed	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
anemia	NN	O	B-Disease
group	NN	O	O
,	NN	O	O
the	NN	O	O
growth	NN	O	O
delay	NN	O	O
was	NN	O	O
significantly	NN	O	O
shorter	NN	O	O
compared	NN	O	O
with	NN	O	O
nonanemic	NN	O	O
controls	NN	O	O
(	NN	O	O
13.3	NN	O	O
days	NN	O	O
versus	NN	O	O
8.6	NN	O	O
days	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
group	NN	O	O
where	NN	O	O
anemia	NN	O	B-Disease
was	NN	O	O
prevented	NN	O	O
by	NN	O	O
rHuEPO	NN	O	O
treatment	NN	O	O
,	NN	O	O
growth	NN	O	O
delay	NN	O	O
was	NN	O	O
comparable	NN	O	O
with	NN	O	O
that	NN	O	O
of	NN	O	O
nonanemic	NN	O	O
controls	NN	O	O
(	NN	O	O
13.3	NN	O	O
days	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
chemotherapy	NN	O	O
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B-Disease
reduces	NN	O	O
cytotoxicity	NN	O	B-Disease
of	NN	O	O
cyclophosphamide	NN	O	B-Chemical
in	NN	O	O
tumors	NN	O	B-Disease
,	NN	O	O
whereas	NN	O	O
correction	NN	O	O
of	NN	O	O
anemia	NN	O	B-Disease
by	NN	O	O
rHuEPO	NN	O	O
treatment	NN	O	O
(	NN	O	O
epoetin	NN	O	O
alpha	NN	O	O
)	NN	O	O
increases	NN	O	O
the	NN	O	O
sensitivity	NN	O	O
,	NN	O	O
probably	NN	O	O
as	NN	O	O
a	NN	O	O
result	NN	O	O
of	NN	O	O
an	NN	O	O
improved	NN	O	O
oxygen	NN	O	B-Chemical
supply	NN	O	O
to	NN	O	O
tumor	NN	O	B-Disease
tissue	NN	O	O
.	NN	O	O


-DOCSTART- (11243580)

The	NN	O	O
role	NN	O	O
of	NN	O	O
nitrergic	NN	O	O
system	NN	O	O
in	NN	O	O
lidocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
convulsion	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
mouse	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
nitro	NN	O	I-Chemical
-	NN	O	I-Chemical
L	NN	O	I-Chemical
-	NN	O	I-Chemical
arginine	NN	O	I-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
ester	NN	O	I-Chemical
(	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
NAME	NN	O	I-Chemical
)	NN	O	O
a	NN	O	O
nitric	NN	O	B-Chemical
oxide	NN	O	I-Chemical
(	NN	O	O
NO	NN	O	B-Chemical
)	NN	O	O
synthase	NN	O	O
inhibitor	NN	O	O
and	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
arginine	NN	O	I-Chemical
,	NN	O	O
a	NN	O	O
NO	NN	O	B-Chemical
precursor	NN	O	O
,	NN	O	O
were	NN	O	O
investigated	NN	O	O
on	NN	O	O
lidocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
the	NN	O	O
first	NN	O	O
experiment	NN	O	O
,	NN	O	O
four	NN	O	O
groups	NN	O	O
of	NN	O	O
mice	NN	O	O
received	NN	O	O
physiological	NN	O	O
saline	NN	O	O
(	NN	O	O
0.9%	NN	O	O
)	NN	O	O
,	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
arginine	NN	O	I-Chemical
(	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.p.	NN	O	O
)	NN	O	O
,	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
NAME	NN	O	I-Chemical
(	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.p.	NN	O	O
)	NN	O	O
and	NN	O	O
diazepam	NN	O	B-Chemical
(	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Thirty	NN	O	O
minutes	NN	O	O
after	NN	O	O
these	NN	O	O
injections	NN	O	O
,	NN	O	O
all	NN	O	O
mice	NN	O	O
received	NN	O	O
lidocaine	NN	O	B-Chemical
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.p.	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
second	NN	O	O
experiment	NN	O	O
,	NN	O	O
four	NN	O	O
groups	NN	O	O
of	NN	O	O
mice	NN	O	O
received	NN	O	O
similar	NN	O	O
treatment	NN	O	O
in	NN	O	O
the	NN	O	O
first	NN	O	O
experiment	NN	O	O
,	NN	O	O
and	NN	O	O
30	NN	O	O
min	NN	O	O
after	NN	O	O
these	NN	O	O
injections	NN	O	O
,	NN	O	O
all	NN	O	O
mice	NN	O	O
received	NN	O	O
a	NN	O	O
higher	NN	O	O
dose	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
(	NN	O	O
80	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
.	NN	O	O

L	NN	O	B-Chemical
-	NN	O	I-Chemical
NAME	NN	O	I-Chemical
(	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.p.	NN	O	O
)	NN	O	O
and	NN	O	O
diazepam	NN	O	B-Chemical
(	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
(	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
arginine	NN	O	I-Chemical
treatment	NN	O	O
increased	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
lidocaine	NN	O	B-Chemical
(	NN	O	O
80	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.p.	NN	O	O
)	NN	O	O
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
significantly	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
may	NN	O	O
suggest	NN	O	O
that	NN	O	O
NO	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
proconvulsant	NN	O	O
mediator	NN	O	O
in	NN	O	O
lidocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
convulsions	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (11079278)

Effect	NN	O	O
of	NN	O	O
intravenous	NN	O	O
metoprolol	NN	O	B-Chemical
or	NN	O	O
intravenous	NN	O	O
metoprolol	NN	O	B-Chemical
plus	NN	O	O
glucagon	NN	O	O
on	NN	O	O
dobutamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B-Disease
ischemia	NN	O	I-Disease
.	NN	O	O

STUDY	NN	O	O
OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
metoprolol	NN	O	B-Chemical
on	NN	O	O
dobutamine	NN	O	B-Chemical
stress	NN	O	O
testing	NN	O	O
with	NN	O	O
technetium	NN	O	B-Chemical
-	NN	O	I-Chemical
99m	NN	O	I-Chemical
sestamibi	NN	O	I-Chemical
single	NN	O	O
-	NN	O	O
photon	NN	O	O
emission	NN	O	O
computed	NN	O	O
tomography	NN	O	O
imaging	NN	O	O
and	NN	O	O
ST	NN	O	O
-	NN	O	O
segment	NN	O	O
monitoring	NN	O	O
,	NN	O	O
and	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
impact	NN	O	O
of	NN	O	O
intravenous	NN	O	O
glucagon	NN	O	O
on	NN	O	O
metoprolol	NN	O	B-Chemical
'	NN	O	O
s	NN	O	O
effects	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
Community	NN	O	O
hospital	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
:	NN	O	O
Twenty	NN	O	O
-	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
known	NN	O	O
reversible	NN	O	O
perfusion	NN	O	O
defects	NN	O	O
.	NN	O	O

INTERVENTION	NN	O	O
:	NN	O	O
Patients	NN	O	O
underwent	NN	O	O
dobutamine	NN	O	B-Chemical
stress	NN	O	O
tests	NN	O	O
per	NN	O	O
standard	NN	O	O
protocol	NN	O	O
.	NN	O	O

Before	NN	O	O
dobutamine	NN	O	B-Chemical
was	NN	O	O
begun	NN	O	O
,	NN	O	O
no	NN	O	O
therapy	NN	O	O
was	NN	O	O
given	NN	O	O
during	NN	O	O
the	NN	O	O
first	NN	O	O
visit	NN	O	O
,	NN	O	O
and	NN	O	O
patients	NN	O	O
were	NN	O	O
randomized	NN	O	O
on	NN	O	O
subsequent	NN	O	O
visits	NN	O	O
to	NN	O	O
receive	NN	O	O
metoprolol	NN	O	B-Chemical
or	NN	O	O
metoprolol	NN	O	B-Chemical
plus	NN	O	O
glucagon	NN	O	O
1	NN	O	O
mg	NN	O	O
.	NN	O	O

Metoprolol	NN	O	B-Chemical
was	NN	O	O
dosed	NN	O	O
to	NN	O	O
achieve	NN	O	O
a	NN	O	O
resting	NN	O	O
predobutamine	NN	O	B-Chemical
heart	NN	O	O
rate	NN	O	O
below	NN	O	O
65	NN	O	O
beats	NN	O	O
/	NN	O	O
minute	NN	O	O
or	NN	O	O
a	NN	O	O
total	NN	O	O
intravenous	NN	O	O
dose	NN	O	O
of	NN	O	O
20	NN	O	O
mg	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
AND	NN	O	O
MAIN	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
Metoprolol	NN	O	B-Chemical
reduced	NN	O	O
maximum	NN	O	O
heart	NN	O	O
rate	NN	O	O
31%	NN	O	O
,	NN	O	O
summed	NN	O	O
stress	NN	O	O
scores	NN	O	O
29%	NN	O	O
,	NN	O	O
and	NN	O	O
summed	NN	O	O
difference	NN	O	O
scores	NN	O	O
43%	NN	O	O
versus	NN	O	O
control	NN	O	O
.	NN	O	O

Metoprolol	NN	O	B-Chemical
plus	NN	O	O
glucagon	NN	O	O
also	NN	O	O
reduced	NN	O	O
the	NN	O	O
maximum	NN	O	O
heart	NN	O	O
rate	NN	O	O
29%	NN	O	O
versus	NN	O	O
control	NN	O	O
.	NN	O	O

Summed	NN	O	O
stress	NN	O	O
and	NN	O	O
summed	NN	O	O
difference	NN	O	O
scores	NN	O	O
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
,	NN	O	O
although	NN	O	O
they	NN	O	O
were	NN	O	O
18%	NN	O	O
and	NN	O	O
30%	NN	O	O
lower	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
than	NN	O	O
control	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
differences	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
any	NN	O	O
parameter	NN	O	O
between	NN	O	O
metoprolol	NN	O	B-Chemical
and	NN	O	O
metoprolol	NN	O	B-Chemical
-	NN	O	O
glucagon	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
During	NN	O	O
dobutamine	NN	O	B-Chemical
stress	NN	O	O
testing	NN	O	O
,	NN	O	O
metoprolol	NN	O	B-Chemical
attenuates	NN	O	O
or	NN	O	O
eliminates	NN	O	O
evidence	NN	O	O
of	NN	O	O
myocardial	NN	O	B-Disease
ischemia	NN	O	I-Disease
.	NN	O	O

Glucagon	NN	O	O
1	NN	O	O
mg	NN	O	O
,	NN	O	O
although	NN	O	O
somewhat	NN	O	O
effective	NN	O	O
,	NN	O	O
does	NN	O	O
not	NN	O	O
correct	NN	O	O
this	NN	O	O
effect	NN	O	O
to	NN	O	O
the	NN	O	O
extent	NN	O	O
that	NN	O	O
it	NN	O	O
can	NN	O	O
be	NN	O	O
administered	NN	O	O
clinically	NN	O	O
.	NN	O	O


-DOCSTART- (10910842)

Prednisolone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
muscle	NN	O	B-Disease
dysfunction	NN	O	I-Disease
is	NN	O	O
caused	NN	O	O
more	NN	O	O
by	NN	O	O
atrophy	NN	O	B-Disease
than	NN	O	O
by	NN	O	O
altered	NN	O	O
acetylcholine	NN	O	B-Chemical
receptor	NN	O	O
expression	NN	O	O
.	NN	O	O

Large	NN	O	O
doses	NN	O	O
of	NN	O	O
glucocorticoids	NN	O	O
can	NN	O	O
alter	NN	O	O
muscle	NN	O	O
physiology	NN	O	O
and	NN	O	O
susceptibility	NN	O	O
to	NN	O	O
neuromuscular	NN	O	O
blocking	NN	O	O
drugs	NN	O	O
by	NN	O	O
mechanisms	NN	O	O
not	NN	O	O
clearly	NN	O	O
understood	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
moderate	NN	O	O
and	NN	O	O
large	NN	O	O
doses	NN	O	O
of	NN	O	O
prednisolone	NN	O	B-Chemical
on	NN	O	O
muscle	NN	O	O
function	NN	O	O
and	NN	O	O
pharmacology	NN	O	O
,	NN	O	O
and	NN	O	O
their	NN	O	O
relationship	NN	O	O
to	NN	O	O
changes	NN	O	O
in	NN	O	O
muscle	NN	O	O
size	NN	O	O
and	NN	O	O
acetylcholine	NN	O	B-Chemical
receptor	NN	O	O
(	NN	O	O
AChR	NN	O	O
)	NN	O	O
expression	NN	O	O
.	NN	O	O

With	NN	O	O
institutional	NN	O	O
approval	NN	O	O
,	NN	O	O
35	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
to	NN	O	O
receive	NN	O	O
daily	NN	O	O
subcutaneous	NN	O	O
doses	NN	O	O
of	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
prednisolone	NN	O	B-Chemical
(	NN	O	O
P10	NN	O	O
group	NN	O	O
)	NN	O	O
,	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
prednisolone	NN	O	B-Chemical
(	NN	O	O
P100	NN	O	O
group	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
an	NN	O	O
equal	NN	O	O
volume	NN	O	O
of	NN	O	O
saline	NN	O	O
(	NN	O	O
S	NN	O	O
group	NN	O	O
)	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
.	NN	O	O

A	NN	O	O
fourth	NN	O	O
group	NN	O	O
of	NN	O	O
rats	NN	O	O
was	NN	O	O
pair	NN	O	O
fed	NN	O	O
(	NN	O	O
food	NN	O	O
restricted	NN	O	O
)	NN	O	O
with	NN	O	O
the	NN	O	O
P100	NN	O	O
rats	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
(	NN	O	O
FR	NN	O	O
group	NN	O	O
)	NN	O	O
.	NN	O	O

On	NN	O	O
Day	NN	O	O
8	NN	O	O
,	NN	O	O
the	NN	O	O
nerve	NN	O	O
-	NN	O	O
evoked	NN	O	O
peak	NN	O	O
twitch	NN	O	O
tensions	NN	O	O
,	NN	O	O
tetanic	NN	O	B-Disease
tensions	NN	O	O
,	NN	O	O
and	NN	O	O
fatigability	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
dose	NN	O	O
-	NN	O	O
response	NN	O	O
curves	NN	O	O
of	NN	O	O
d	NN	O	B-Chemical
-	NN	O	I-Chemical
tubocurarine	NN	O	I-Chemical
in	NN	O	O
the	NN	O	O
tibialis	NN	O	O
cranialis	NN	O	O
muscle	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
vivo	NN	O	O
and	NN	O	O
related	NN	O	O
to	NN	O	O
muscle	NN	O	O
mass	NN	O	O
or	NN	O	O
expression	NN	O	O
of	NN	O	O
AChRs	NN	O	O
.	NN	O	O

Rate	NN	O	O
of	NN	O	O
body	NN	O	O
weight	NN	O	O
gain	NN	O	O
was	NN	O	O
depressed	NN	O	O
in	NN	O	O
the	NN	O	O
P100	NN	O	O
,	NN	O	O
FR	NN	O	O
,	NN	O	O
and	NN	O	O
P10	NN	O	O
groups	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
S	NN	O	O
group	NN	O	O
.	NN	O	O

Tibialis	NN	O	O
muscle	NN	O	O
mass	NN	O	O
was	NN	O	O
smaller	NN	O	O
in	NN	O	O
the	NN	O	O
P100	NN	O	O
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
P10	NN	O	O
or	NN	O	O
S	NN	O	O
groups	NN	O	O
.	NN	O	O

The	NN	O	O
evoked	NN	O	O
peak	NN	O	O
twitch	NN	O	O
and	NN	O	O
tetanic	NN	O	B-Disease
tensions	NN	O	O
were	NN	O	O
less	NN	O	O
in	NN	O	O
the	NN	O	O
P100	NN	O	O
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
P10	NN	O	O
or	NN	O	O
S	NN	O	O
groups	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
tension	NN	O	O
per	NN	O	O
milligram	NN	O	O
of	NN	O	O
muscle	NN	O	O
mass	NN	O	O
was	NN	O	O
greater	NN	O	O
in	NN	O	O
the	NN	O	O
P100	NN	O	O
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
S	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
50%	NN	O	O
effective	NN	O	O
dose	NN	O	O
of	NN	O	O
d	NN	O	B-Chemical
-	NN	O	I-Chemical
tubocurarine	NN	O	I-Chemical
(	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
tibialis	NN	O	O
muscle	NN	O	O
was	NN	O	O
smaller	NN	O	O
in	NN	O	O
the	NN	O	O
P10	NN	O	O
(	NN	O	O
33.6	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5.4	NN	O	O
)	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
S	NN	O	O
(	NN	O	O
61.9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
5.0	NN	O	O
)	NN	O	O
or	NN	O	O
the	NN	O	O
P100	NN	O	O
(	NN	O	O
71.3	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
9.6	NN	O	O
)	NN	O	O
groups	NN	O	O
.	NN	O	O

AChR	NN	O	O
expression	NN	O	O
was	NN	O	O
less	NN	O	O
in	NN	O	O
the	NN	O	O
P10	NN	O	O
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
S	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
evoked	NN	O	O
tensions	NN	O	O
correlated	NN	O	O
with	NN	O	O
muscle	NN	O	O
mass	NN	O	O
(	NN	O	O
r	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
=	NN	O	O
0.32	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
not	NN	O	O
with	NN	O	O
expression	NN	O	O
of	NN	O	O
AChR	NN	O	O
.	NN	O	O

The	NN	O	O
50%	NN	O	O
effective	NN	O	O
dose	NN	O	O
of	NN	O	O
d	NN	O	B-Chemical
-	NN	O	I-Chemical
tubocurarine	NN	O	I-Chemical
did	NN	O	O
not	NN	O	O
correlate	NN	O	O
with	NN	O	O
muscle	NN	O	O
mass	NN	O	O
or	NN	O	O
AChR	NN	O	O
expression	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
neuromuscular	NN	O	B-Disease
dysfunction	NN	O	I-Disease
after	NN	O	O
prednisolone	NN	O	B-Chemical
is	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
,	NN	O	O
and	NN	O	O
derives	NN	O	O
primarily	NN	O	O
from	NN	O	O
muscle	NN	O	B-Disease
atrophy	NN	O	I-Disease
and	NN	O	O
derives	NN	O	O
less	NN	O	O
so	NN	O	O
from	NN	O	O
changes	NN	O	O
in	NN	O	O
AChR	NN	O	O
expression	NN	O	O
.	NN	O	O

IMPLICATIONS	NN	O	O
:	NN	O	O
The	NN	O	O
mechanisms	NN	O	O
by	NN	O	O
which	NN	O	O
chronic	NN	O	O
glucocorticoid	NN	O	O
therapy	NN	O	O
alters	NN	O	O
neuromuscular	NN	O	O
physiology	NN	O	O
and	NN	O	O
pharmacology	NN	O	O
are	NN	O	O
unclear	NN	O	O
.	NN	O	O

We	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
observed	NN	O	O
effects	NN	O	O
are	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
and	NN	O	O
derive	NN	O	O
primarily	NN	O	O
from	NN	O	O
muscle	NN	O	B-Disease
atrophy	NN	O	I-Disease
and	NN	O	O
derive	NN	O	O
less	NN	O	O
from	NN	O	O
changes	NN	O	O
in	NN	O	O
acetylcholine	NN	O	B-Chemical
receptor	NN	O	O
expression	NN	O	O
.	NN	O	O


-DOCSTART- (10533019)

Rapid	NN	O	O
reversal	NN	O	O
of	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
diltiazem	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
tetany	NN	O	B-Disease
with	NN	O	O
calcium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
patient	NN	O	O
who	NN	O	O
developed	NN	O	O
tetany	NN	O	B-Disease
with	NN	O	O
sudden	NN	O	O
respiratory	NN	O	B-Disease
arrest	NN	O	I-Disease
after	NN	O	O
the	NN	O	O
infusion	NN	O	O
of	NN	O	O
intravenous	NN	O	O
diltiazem	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
administration	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
rapidly	NN	O	O
resolved	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
tetany	NN	O	B-Disease
with	NN	O	O
prompt	NN	O	O
recovery	NN	O	O
of	NN	O	O
respiratory	NN	O	O
function	NN	O	O
,	NN	O	O
averting	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
more	NN	O	O
aggressive	NN	O	O
airway	NN	O	O
management	NN	O	O
and	NN	O	O
ventilatory	NN	O	O
support	NN	O	O
.	NN	O	O

The	NN	O	O
emergency	NN	O	O
physician	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
that	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
tetany	NN	O	B-Disease
may	NN	O	O
accompany	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
intravenous	NN	O	O
diltiazem	NN	O	B-Chemical
and	NN	O	O
that	NN	O	O
calcium	NN	O	B-Chemical
chloride	NN	O	I-Chemical
may	NN	O	O
be	NN	O	O
a	NN	O	O
rapid	NN	O	O
and	NN	O	O
effective	NN	O	O
remedy	NN	O	O
.	NN	O	O


-DOCSTART- (10414674)

Effects	NN	O	O
of	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
on	NN	O	O
hemostasis	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
aneurysmal	NN	O	B-Disease
subarachnoid	NN	O	I-Disease
hemorrhage	NN	O	I-Disease
.	NN	O	O

Platelet	NN	O	O
function	NN	O	O
is	NN	O	O
impaired	NN	O	O
by	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
(	NN	O	O
NSAIDs	NN	O	O
)	NN	O	O
with	NN	O	O
prominent	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
properties	NN	O	O
.	NN	O	O

Their	NN	O	O
safety	NN	O	O
in	NN	O	O
patients	NN	O	O
undergoing	NN	O	O
intracranial	NN	O	O
surgery	NN	O	O
is	NN	O	O
under	NN	O	O
debate	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
aneurysmal	NN	O	B-Disease
subarachnoid	NN	O	I-Disease
hemorrhage	NN	O	I-Disease
(	NN	O	O
SAH	NN	O	B-Disease
)	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
ketoprofen	NN	O	B-Chemical
,	NN	O	O
100	NN	O	O
mg	NN	O	O
,	NN	O	O
three	NN	O	O
times	NN	O	O
a	NN	O	O
day	NN	O	O
(	NN	O	O
ketoprofen	NN	O	B-Chemical
group	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
9	NN	O	O
)	NN	O	O
or	NN	O	O
a	NN	O	O
weak	NN	O	O
NSAID	NN	O	O
,	NN	O	O
acetaminophen	NN	O	B-Chemical
,	NN	O	O
1	NN	O	O
g	NN	O	O
,	NN	O	O
three	NN	O	O
times	NN	O	O
a	NN	O	O
day	NN	O	O
(	NN	O	O
acetaminophen	NN	O	B-Chemical
group	NN	O	O
,	NN	O	O
n	NN	O	O
=	NN	O	O
9	NN	O	O
)	NN	O	O
starting	NN	O	O
immediately	NN	O	O
after	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
aneurysmal	NN	O	B-Disease
SAH	NN	O	B-Disease
.	NN	O	O

Treatment	NN	O	O
was	NN	O	O
continued	NN	O	O
for	NN	O	O
3	NN	O	O
days	NN	O	O
postoperatively	NN	O	O
.	NN	O	O

Test	NN	O	O
blood	NN	O	O
samples	NN	O	O
were	NN	O	O
taken	NN	O	O
before	NN	O	O
treatment	NN	O	O
and	NN	O	O
surgery	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
on	NN	O	O
the	NN	O	O
first	NN	O	O
,	NN	O	O
third	NN	O	O
,	NN	O	O
and	NN	O	O
fifth	NN	O	O
postoperative	NN	O	O
mornings	NN	O	O
.	NN	O	O

Maximal	NN	O	O
platelet	NN	O	B-Disease
aggregation	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
6	NN	O	O
microM	NN	O	O
of	NN	O	O
adenosine	NN	O	B-Chemical
diphosphate	NN	O	I-Chemical
decreased	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
ketoprofen	NN	O	B-Chemical
.	NN	O	O

Aggregation	NN	O	O
was	NN	O	O
lower	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
ketoprofen	NN	O	B-Chemical
group	NN	O	O
than	NN	O	O
in	NN	O	O
the	NN	O	O
acetaminophen	NN	O	B-Chemical
group	NN	O	O
just	NN	O	O
before	NN	O	O
surgery	NN	O	O
and	NN	O	O
on	NN	O	O
the	NN	O	O
third	NN	O	O
postoperative	NN	O	O
day	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
maximal	NN	O	O
platelet	NN	O	B-Disease
aggregation	NN	O	I-Disease
increased	NN	O	O
in	NN	O	O
the	NN	O	O
acetaminophen	NN	O	B-Chemical
group	NN	O	O
on	NN	O	O
the	NN	O	O
third	NN	O	O
postoperative	NN	O	O
day	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
pretreatment	NN	O	O
platelet	NN	O	B-Disease
aggregation	NN	O	I-Disease
results	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
.05	NN	O	O
)	NN	O	O
.	NN	O	O

One	NN	O	O
patient	NN	O	O
in	NN	O	O
the	NN	O	O
ketoprofen	NN	O	B-Chemical
group	NN	O	O
developed	NN	O	O
a	NN	O	O
postoperative	NN	O	O
intracranial	NN	O	O
hematoma	NN	O	B-Disease
.	NN	O	O

Coagulation	NN	O	O
(	NN	O	O
prothrombin	NN	O	O
time	NN	O	O
[	NN	O	O
PT	NN	O	O
]	NN	O	O
,	NN	O	O
activated	NN	O	O
partial	NN	O	O
thromboplastin	NN	O	O
time	NN	O	O
[	NN	O	O
APPT	NN	O	O
]	NN	O	O
,	NN	O	O
fibrinogen	NN	O	O
concentration	NN	O	O
,	NN	O	O
and	NN	O	O
antithrombin	NN	O	O
III	NN	O	O
[	NN	O	O
AT	NN	O	O
III	NN	O	O
]	NN	O	O
)	NN	O	O
was	NN	O	O
comparable	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

Ketoprofen	NN	O	B-Chemical
but	NN	O	O
not	NN	O	O
acetaminophen	NN	O	B-Chemical
impaired	NN	O	O
platelet	NN	O	O
function	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
SAH	NN	O	B-Disease
.	NN	O	O

If	NN	O	O
ketoprofen	NN	O	B-Chemical
is	NN	O	O
used	NN	O	O
before	NN	O	O
surgery	NN	O	O
on	NN	O	O
cerebral	NN	O	O
artery	NN	O	B-Disease
aneurysms	NN	O	I-Disease
,	NN	O	O
it	NN	O	O
may	NN	O	O
pose	NN	O	O
an	NN	O	O
additional	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	NN	O	O
hemorrhage	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (9523850)

Value	NN	O	O
of	NN	O	O
methylprednisolone	NN	O	B-Chemical
in	NN	O	O
prevention	NN	O	O
of	NN	O	O
the	NN	O	O
arthralgia	NN	O	B-Disease
-	NN	O	O
myalgia	NN	O	B-Disease
syndrome	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
total	NN	O	O
dose	NN	O	O
infusion	NN	O	O
of	NN	O	O
iron	NN	O	B-Chemical
dextran	NN	O	I-Chemical
:	NN	O	O
a	NN	O	O
double	NN	O	O
blind	NN	O	O
randomized	NN	O	O
trial	NN	O	O
.	NN	O	O

The	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
total	NN	O	O
dose	NN	O	O
infusion	NN	O	O
(	NN	O	O
TDI	NN	O	O
)	NN	O	O
of	NN	O	O
iron	NN	O	B-Chemical
dextran	NN	O	I-Chemical
has	NN	O	O
been	NN	O	O
well	NN	O	O
documented	NN	O	O
.	NN	O	O

In	NN	O	O
40%	NN	O	O
of	NN	O	O
treated	NN	O	O
patients	NN	O	O
,	NN	O	O
an	NN	O	O
arthralgia	NN	O	B-Disease
-	NN	O	O
myalgia	NN	O	B-Disease
syndrome	NN	O	O
develops	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
prospective	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
investigate	NN	O	O
whether	NN	O	O
intravenous	NN	O	O
(	NN	O	O
i.v.	NN	O	O
)	NN	O	O
administration	NN	O	O
of	NN	O	O
methylprednisolone	NN	O	B-Chemical
(	NN	O	O
MP	NN	O	B-Chemical
)	NN	O	O
prevents	NN	O	O
this	NN	O	O
complication	NN	O	O
.	NN	O	O

Sixty	NN	O	O
-	NN	O	O
five	NN	O	O
patients	NN	O	O
,	NN	O	O
34	NN	O	O
women	NN	O	O
and	NN	O	O
31	NN	O	O
men	NN	O	O
,	NN	O	O
ages	NN	O	O
36	NN	O	O
to	NN	O	O
80	NN	O	O
years	NN	O	O
,	NN	O	O
received	NN	O	O
either	NN	O	O
normal	NN	O	O
saline	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
TDI	NN	O	O
(	NN	O	O
group	NN	O	O
1	NN	O	O
)	NN	O	O
,	NN	O	O
125	NN	O	O
mg	NN	O	O
i.v.	NN	O	O
MP	NN	O	B-Chemical
before	NN	O	O
and	NN	O	O
saline	NN	O	O
after	NN	O	O
TDI	NN	O	O
(	NN	O	O
group	NN	O	O
2	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
125	NN	O	O
mg	NN	O	O
i.v.	NN	O	O
MP	NN	O	B-Chemical
before	NN	O	O
and	NN	O	O
after	NN	O	O
TDI	NN	O	O
(	NN	O	O
group	NN	O	O
3	NN	O	O
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
observed	NN	O	O
for	NN	O	O
72	NN	O	O
hours	NN	O	O
and	NN	O	O
reactions	NN	O	O
were	NN	O	O
recorded	NN	O	O
and	NN	O	O
graded	NN	O	O
according	NN	O	O
to	NN	O	O
severity	NN	O	O
.	NN	O	O

Fifty	NN	O	O
-	NN	O	O
eight	NN	O	O
percent	NN	O	O
of	NN	O	O
group	NN	O	O
1	NN	O	O
patients	NN	O	O
,	NN	O	O
33%	NN	O	O
of	NN	O	O
group	NN	O	O
2	NN	O	O
,	NN	O	O
and	NN	O	O
26%	NN	O	O
of	NN	O	O
group	NN	O	O
3	NN	O	O
had	NN	O	O
reactions	NN	O	O
to	NN	O	O
TDI	NN	O	O
.	NN	O	O

The	NN	O	O
severity	NN	O	O
of	NN	O	O
reactions	NN	O	O
(	NN	O	O
minimal	NN	O	O
,	NN	O	O
mild	NN	O	O
,	NN	O	O
and	NN	O	O
moderate	NN	O	O
,	NN	O	O
respectively	NN	O	O
)	NN	O	O
was	NN	O	O
as	NN	O	O
follows	NN	O	O
:	NN	O	O
group	NN	O	O
1	NN	O	O
-	NN	O	O
-	NN	O	O
6	NN	O	O
,	NN	O	O
6	NN	O	O
,	NN	O	O
and	NN	O	O
2	NN	O	O
;	NN	O	O
group	NN	O	O
2	NN	O	O
-	NN	O	O
-	NN	O	O
1	NN	O	O
,	NN	O	O
5	NN	O	O
,	NN	O	O
and	NN	O	O
0	NN	O	O
;	NN	O	O
group	NN	O	O
3	NN	O	O
-	NN	O	O
-	NN	O	O
5	NN	O	O
,	NN	O	O
1	NN	O	O
,	NN	O	O
and	NN	O	O
0	NN	O	O
.	NN	O	O

Data	NN	O	O
were	NN	O	O
analyzed	NN	O	O
by	NN	O	O
the	NN	O	O
two	NN	O	O
-	NN	O	O
sided	NN	O	O
Fisher	NN	O	O
'	NN	O	O
s	NN	O	O
exact	NN	O	O
test	NN	O	O
using	NN	O	O
95%	NN	O	O
confidence	NN	O	O
intervals	NN	O	O
with	NN	O	O
the	NN	O	O
approximation	NN	O	O
of	NN	O	O
Woolf	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
administration	NN	O	O
of	NN	O	O
MP	NN	O	B-Chemical
before	NN	O	O
and	NN	O	O
after	NN	O	O
TDI	NN	O	O
reduces	NN	O	O
the	NN	O	O
frequency	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
the	NN	O	O
arthralgia	NN	O	B-Disease
-	NN	O	O
myalgia	NN	O	B-Disease
syndrome	NN	O	O
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
125	NN	O	O
mg	NN	O	O
i.v.	NN	O	O
MP	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
given	NN	O	O
routinely	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
TDI	NN	O	O
of	NN	O	O
iron	NN	O	B-Chemical
dextran	NN	O	I-Chemical
.	NN	O	O


-DOCSTART- (8384253)

Long	NN	O	O
-	NN	O	O
term	NN	O	O
effects	NN	O	O
of	NN	O	O
vincristine	NN	O	B-Chemical
on	NN	O	O
the	NN	O	O
peripheral	NN	O	O
nervous	NN	O	O
system	NN	O	O
.	NN	O	O

Forty	NN	O	O
patients	NN	O	O
with	NN	O	O
Non	NN	O	B-Disease
-	NN	O	I-Disease
Hodgkin	NN	O	I-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
Lymphoma	NN	O	I-Disease
treated	NN	O	O
with	NN	O	O
vincristine	NN	O	B-Chemical
between	NN	O	O
1984	NN	O	O
and	NN	O	O
1990	NN	O	O
(	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
12	NN	O	O
mg	NN	O	O
in	NN	O	O
18	NN	O	O
-	NN	O	O
24	NN	O	O
weeks	NN	O	O
)	NN	O	O
were	NN	O	O
investigated	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
long	NN	O	O
term	NN	O	O
effects	NN	O	O
of	NN	O	O
vincristine	NN	O	B-Chemical
on	NN	O	O
the	NN	O	O
peripheral	NN	O	O
nervous	NN	O	O
system	NN	O	O
.	NN	O	O

The	NN	O	O
patients	NN	O	O
were	NN	O	O
interviewed	NN	O	O
with	NN	O	O
emphasis	NN	O	O
on	NN	O	O
neuropathic	NN	O	B-Disease
symptoms	NN	O	I-Disease
.	NN	O	O

Physical	NN	O	O
and	NN	O	O
quantitative	NN	O	O
sensory	NN	O	O
examination	NN	O	O
with	NN	O	O
determination	NN	O	O
of	NN	O	O
vibratory	NN	O	O
perception	NN	O	O
and	NN	O	O
thermal	NN	O	O
discrimination	NN	O	O
thresholds	NN	O	O
were	NN	O	O
performed	NN	O	O
,	NN	O	O
four	NN	O	O
to	NN	O	O
77	NN	O	O
months	NN	O	O
(	NN	O	O
median	NN	O	O
34	NN	O	O
months	NN	O	O
)	NN	O	O
after	NN	O	O
vincristine	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
seven	NN	O	O
patients	NN	O	O
reported	NN	O	O
neuropathic	NN	O	B-Disease
symptoms	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
13	NN	O	O
of	NN	O	O
these	NN	O	O
27	NN	O	O
patients	NN	O	O
symptoms	NN	O	O
were	NN	O	O
still	NN	O	O
present	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
examination	NN	O	O
.	NN	O	O

In	NN	O	O
these	NN	O	O
patients	NN	O	O
sensory	NN	O	O
signs	NN	O	O
and	NN	O	O
symptoms	NN	O	O
predominated	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
other	NN	O	O
14	NN	O	O
patients	NN	O	O
symptoms	NN	O	O
had	NN	O	O
been	NN	O	O
present	NN	O	O
in	NN	O	O
the	NN	O	O
past	NN	O	O
.	NN	O	O

Symptoms	NN	O	O
persisted	NN	O	O
maximally	NN	O	O
40	NN	O	O
months	NN	O	O
since	NN	O	O
cessation	NN	O	O
of	NN	O	O
therapy	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
age	NN	O	O
difference	NN	O	O
between	NN	O	O
patients	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
complaints	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
examination	NN	O	O
.	NN	O	O

Normal	NN	O	O
reflexes	NN	O	O
were	NN	O	O
found	NN	O	O
in	NN	O	O
two	NN	O	O
third	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

Neuropathic	NN	O	O
complaints	NN	O	O
were	NN	O	O
not	NN	O	O
very	NN	O	O
troublesome	NN	O	O
on	NN	O	O
the	NN	O	O
long	NN	O	O
term	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
with	NN	O	O
the	NN	O	O
above	NN	O	O
mentioned	NN	O	O
vincristine	NN	O	B-Chemical
dose	NN	O	O
schedule	NN	O	O
signs	NN	O	O
and	NN	O	O
symptoms	NN	O	O
of	NN	O	O
vincristine	NN	O	B-Chemical
neuropathy	NN	O	B-Disease
are	NN	O	O
reversible	NN	O	O
for	NN	O	O
a	NN	O	O
great	NN	O	O
deal	NN	O	O
and	NN	O	O
prognosis	NN	O	O
is	NN	O	O
fairly	NN	O	O
good	NN	O	O
.	NN	O	O


-DOCSTART- (8268147)

A	NN	O	O
case	NN	O	O
of	NN	O	O
polymyositis	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
primary	NN	O	B-Disease
biliary	NN	O	I-Disease
cirrhosis	NN	O	I-Disease
treated	NN	O	O
with	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
.	NN	O	O

Although	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
has	NN	O	O
been	NN	O	O
used	NN	O	O
for	NN	O	O
many	NN	O	O
rheumatologic	NN	O	B-Disease
diseases	NN	O	I-Disease
,	NN	O	O
toxicity	NN	O	B-Disease
limits	NN	O	O
its	NN	O	O
usefulness	NN	O	O
in	NN	O	O
many	NN	O	O
patients	NN	O	O
.	NN	O	O

Polymyositis	NN	O	B-Disease
/	NN	O	O
dermatomyositis	NN	O	B-Disease
can	NN	O	O
develop	NN	O	O
as	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
autoimmune	NN	O	O
complications	NN	O	O
of	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
treatment	NN	O	O
,	NN	O	O
but	NN	O	O
its	NN	O	O
exact	NN	O	O
pathogenesis	NN	O	O
remains	NN	O	O
unclear	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
primary	NN	O	B-Disease
biliary	NN	O	I-Disease
cirrhosis	NN	O	I-Disease
,	NN	O	O
who	NN	O	O
developed	NN	O	O
polymyositis	NN	O	B-Disease
while	NN	O	O
receiving	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
therapy	NN	O	O
.	NN	O	O

We	NN	O	O
described	NN	O	O
the	NN	O	O
special	NN	O	O
clinical	NN	O	O
course	NN	O	O
of	NN	O	O
the	NN	O	O
patient	NN	O	O
.	NN	O	O

Patients	NN	O	O
receiving	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
penicillamine	NN	O	I-Chemical
therapy	NN	O	O
should	NN	O	O
be	NN	O	O
followed	NN	O	O
carefully	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
autoimmune	NN	O	O
complications	NN	O	O
like	NN	O	O
polymyositis	NN	O	B-Disease
/	NN	O	O
dermatomyositis	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (8251368)

Photodistributed	NN	O	O
nifedipine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
facial	NN	O	O
telangiectasia	NN	O	B-Disease
.	NN	O	O

Five	NN	O	O
months	NN	O	O
after	NN	O	O
starting	NN	O	O
nifedipine	NN	O	B-Chemical
(	NN	O	O
Adalat	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
two	NN	O	O
patients	NN	O	O
developed	NN	O	O
photodistributed	NN	O	O
facial	NN	O	O
telangiectasia	NN	O	B-Disease
,	NN	O	O
which	NN	O	O
became	NN	O	O
more	NN	O	O
noticeable	NN	O	O
with	NN	O	O
time	NN	O	O
.	NN	O	O

Neither	NN	O	O
patient	NN	O	O
complained	NN	O	O
of	NN	O	O
photosensitivity	NN	O	O
or	NN	O	O
flushing	NN	O	B-Disease
.	NN	O	O

Both	NN	O	O
patients	NN	O	O
reported	NN	O	O
a	NN	O	O
significant	NN	O	O
cosmetic	NN	O	O
improvement	NN	O	O
after	NN	O	O
discontinuing	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

One	NN	O	O
commenced	NN	O	O
the	NN	O	O
closely	NN	O	O
related	NN	O	O
drug	NN	O	O
amlodipine	NN	O	B-Chemical
3	NN	O	O
years	NN	O	O
later	NN	O	O
,	NN	O	O
with	NN	O	O
recurrence	NN	O	O
of	NN	O	O
telangiectasia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
photodistribution	NN	O	O
of	NN	O	O
the	NN	O	O
telangiectasia	NN	O	B-Disease
suggests	NN	O	O
a	NN	O	O
significant	NN	O	O
drug	NN	O	O
/	NN	O	O
light	NN	O	O
interaction	NN	O	O
.	NN	O	O


-DOCSTART- (7542793)

Nephrotoxicity	NN	O	B-Disease
of	NN	O	O
cyclosporin	NN	O	B-Chemical
A	NN	O	I-Chemical
and	NN	O	O
FK506	NN	O	B-Chemical
:	NN	O	O
inhibition	NN	O	O
of	NN	O	O
calcineurin	NN	O	O
phosphatase	NN	O	O
.	NN	O	O

Cyclosporin	NN	O	B-Chemical
A	NN	O	I-Chemical
(	NN	O	O
CsA	NN	O	B-Chemical
;	NN	O	O
50	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
Fujimycine	NN	O	B-Chemical
(	NN	O	O
FK506	NN	O	B-Chemical
;	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
the	NN	O	O
related	NN	O	O
macrolide	NN	O	B-Chemical
immunosuppressant	NN	O	O
rapamycin	NN	O	B-Chemical
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
caused	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
rate	NN	O	O
,	NN	O	O
degenerative	NN	O	O
changes	NN	O	O
of	NN	O	O
proximal	NN	O	O
tubular	NN	O	O
epithelium	NN	O	O
,	NN	O	O
and	NN	O	O
hypertrophy	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
juxtaglomerular	NN	O	O
apparatus	NN	O	O
in	NN	O	O
male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
when	NN	O	O
given	NN	O	O
for	NN	O	O
10	NN	O	O
days	NN	O	O
.	NN	O	O

The	NN	O	O
molecular	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
CsA	NN	O	B-Chemical
and	NN	O	O
FK506	NN	O	B-Chemical
toxicity	NN	O	B-Disease
were	NN	O	O
investigated	NN	O	O
.	NN	O	O

Cyclophilin	NN	O	O
A	NN	O	O
and	NN	O	O
FK506	NN	O	B-Chemical
-	NN	O	O
binding	NN	O	O
protein	NN	O	O
,	NN	O	O
the	NN	O	O
main	NN	O	O
intracytoplasmic	NN	O	O
receptors	NN	O	O
for	NN	O	O
CsA	NN	O	B-Chemical
and	NN	O	O
FK506	NN	O	B-Chemical
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
were	NN	O	O
each	NN	O	O
detected	NN	O	O
in	NN	O	O
renal	NN	O	O
tissue	NN	O	O
extract	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
kidney	NN	O	O
,	NN	O	O
high	NN	O	O
levels	NN	O	O
of	NN	O	O
immunoreactive	NN	O	O
and	NN	O	O
enzymatically	NN	O	O
active	NN	O	O
calcineurin	NN	O	O
were	NN	O	O
found	NN	O	O
which	NN	O	O
were	NN	O	O
inhibited	NN	O	O
by	NN	O	O
the	NN	O	O
immunosuppressants	NN	O	O
CsA	NN	O	B-Chemical
and	NN	O	O
FK506	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
not	NN	O	O
by	NN	O	O
rapamycin	NN	O	B-Chemical
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
specific	NN	O	O
immunophilin	NN	O	O
-	NN	O	O
drug	NN	O	O
-	NN	O	O
calcineurin	NN	O	O
complexes	NN	O	O
formed	NN	O	O
only	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
CsA	NN	O	B-Chemical
and	NN	O	O
FK506	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
not	NN	O	O
rapamycin	NN	O	B-Chemical
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
the	NN	O	O
nephrotoxic	NN	O	B-Disease
effects	NN	O	O
of	NN	O	O
CsA	NN	O	B-Chemical
and	NN	O	O
FK506	NN	O	B-Chemical
is	NN	O	O
likely	NN	O	O
mediated	NN	O	O
through	NN	O	O
binding	NN	O	O
to	NN	O	O
renal	NN	O	O
immunophilin	NN	O	O
and	NN	O	O
inhibiting	NN	O	O
calcineurin	NN	O	O
phosphatase	NN	O	O
.	NN	O	O


-DOCSTART- (7337133)

Massive	NN	O	O
cerebral	NN	O	B-Disease
edema	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
fulminant	NN	O	O
hepatic	NN	O	B-Disease
failure	NN	O	I-Disease
in	NN	O	O
acetaminophen	NN	O	B-Chemical
overdose	NN	O	B-Disease
:	NN	O	O
possible	NN	O	O
role	NN	O	O
of	NN	O	O
cranial	NN	O	O
decompression	NN	O	O
.	NN	O	O

Cerebral	NN	O	B-Disease
edema	NN	O	I-Disease
may	NN	O	O
complicate	NN	O	O
the	NN	O	O
course	NN	O	O
of	NN	O	O
fulminant	NN	O	B-Disease
hepatic	NN	O	I-Disease
failure	NN	O	I-Disease
.	NN	O	O

Response	NN	O	O
to	NN	O	O
conventional	NN	O	O
therapy	NN	O	O
has	NN	O	O
been	NN	O	O
disappointing	NN	O	O
.	NN	O	O

We	NN	O	O
present	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
fatal	NN	O	O
acetaminophen	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
fulminant	NN	O	B-Disease
hepatic	NN	O	I-Disease
failure	NN	O	I-Disease
,	NN	O	O
with	NN	O	O
signs	NN	O	O
and	NN	O	O
symptoms	NN	O	O
of	NN	O	O
cerebral	NN	O	B-Disease
edema	NN	O	I-Disease
,	NN	O	O
unresponsive	NN	O	O
to	NN	O	O
conventional	NN	O	O
medical	NN	O	O
therapy	NN	O	O
.	NN	O	O

Cranial	NN	O	O
decompression	NN	O	O
was	NN	O	O
carried	NN	O	O
out	NN	O	O
.	NN	O	O

A	NN	O	O
justification	NN	O	O
of	NN	O	O
the	NN	O	O
need	NN	O	O
for	NN	O	O
further	NN	O	O
evaluation	NN	O	O
of	NN	O	O
cranial	NN	O	O
decompression	NN	O	O
in	NN	O	O
such	NN	O	O
patients	NN	O	O
is	NN	O	O
presented	NN	O	O
.	NN	O	O


-DOCSTART- (4069770)

Gentamicin	NN	O	B-Chemical
nephropathy	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
neonate	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
and	NN	O	O
autopsy	NN	O	O
findings	NN	O	O
in	NN	O	O
a	NN	O	O
premature	NN	O	O
baby	NN	O	O
who	NN	O	O
died	NN	O	O
of	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
after	NN	O	O
therapy	NN	O	O
with	NN	O	O
gentamicin	NN	O	B-Chemical
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
and	NN	O	O
penicillin	NN	O	B-Chemical
are	NN	O	O
presented	NN	O	O
.	NN	O	O

The	NN	O	O
serum	NN	O	O
gentamicin	NN	O	B-Chemical
concentration	NN	O	O
had	NN	O	O
reached	NN	O	O
toxic	NN	O	O
levels	NN	O	O
when	NN	O	O
anuria	NN	O	B-Disease
developed	NN	O	O
.	NN	O	O

Numerous	NN	O	O
periodic	NN	O	B-Chemical
acid	NN	O	I-Chemical
Schiff	NN	O	O
(	NN	O	O
PAS	NN	O	O
)	NN	O	O
positive	NN	O	O
,	NN	O	O
diastase	NN	O	O
resistant	NN	O	O
cytoplasmic	NN	O	O
inclusion	NN	O	O
bodies	NN	O	O
which	NN	O	O
appeared	NN	O	O
as	NN	O	O
myelin	NN	O	O
figures	NN	O	O
in	NN	O	O
cytosegresomes	NN	O	O
under	NN	O	O
the	NN	O	O
electron	NN	O	O
microscope	NN	O	O
were	NN	O	O
identified	NN	O	O
in	NN	O	O
the	NN	O	O
proximal	NN	O	O
convoluted	NN	O	O
tubules	NN	O	O
.	NN	O	O

The	NN	O	O
pathological	NN	O	O
changes	NN	O	O
induced	NN	O	O
by	NN	O	O
gentamicin	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
human	NN	O	O
neonatal	NN	O	O
kidneys	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
previously	NN	O	O
reported	NN	O	O
.	NN	O	O


-DOCSTART- (3780814)

Anti	NN	O	O
-	NN	O	O
carcinogenic	NN	O	B-Disease
action	NN	O	O
of	NN	O	O
phenobarbital	NN	O	B-Chemical
given	NN	O	O
simultaneously	NN	O	O
with	NN	O	O
diethylnitrosamine	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
work	NN	O	O
has	NN	O	O
been	NN	O	O
planned	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
elucidate	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
phenobarbital	NN	O	B-Chemical
(	NN	O	O
PB	NN	O	B-Chemical
:	NN	O	O
15	NN	O	O
mg	NN	O	O
per	NN	O	O
rat	NN	O	O
of	NN	O	O
ingested	NN	O	O
dose	NN	O	O
)	NN	O	O
on	NN	O	O
carcinogenesis	NN	O	B-Disease
when	NN	O	O
it	NN	O	O
is	NN	O	O
administered	NN	O	O
simultaneously	NN	O	O
with	NN	O	O
diethylnitrosamine	NN	O	B-Chemical
(	NN	O	O
DEN	NN	O	B-Chemical
:	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
.	NN	O	O

Wistar	NN	O	O
rats	NN	O	O
(	NN	O	O
180	NN	O	O
g	NN	O	O
)	NN	O	O
were	NN	O	O
treated	NN	O	O
by	NN	O	O
DEN	NN	O	B-Chemical
alone	NN	O	O
or	NN	O	O
by	NN	O	O
DEN	NN	O	B-Chemical
+	NN	O	O
PB	NN	O	B-Chemical
during	NN	O	O
2	NN	O	O
,	NN	O	O
4	NN	O	O
and	NN	O	O
6	NN	O	O
weeks	NN	O	O
according	NN	O	O
to	NN	O	O
our	NN	O	O
schedule	NN	O	O
for	NN	O	O
hepatocarcinogenesis	NN	O	B-Disease
.	NN	O	O

After	NN	O	O
the	NN	O	O
end	NN	O	O
of	NN	O	O
the	NN	O	O
treatment	NN	O	O
,	NN	O	O
the	NN	O	O
number	NN	O	O
and	NN	O	O
the	NN	O	O
size	NN	O	O
of	NN	O	O
induced	NN	O	O
PAS	NN	O	O
positive	NN	O	O
preneoplastic	NN	O	B-Disease
foci	NN	O	I-Disease
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
when	NN	O	O
PB	NN	O	B-Chemical
was	NN	O	O
given	NN	O	O
simultaneously	NN	O	O
with	NN	O	O
DEN	NN	O	B-Chemical
for	NN	O	O
4	NN	O	O
and	NN	O	O
6	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
mitotic	NN	O	O
inhibition	NN	O	O
and	NN	O	O
the	NN	O	O
production	NN	O	O
of	NN	O	O
micronuclei	NN	O	O
normally	NN	O	O
observed	NN	O	O
after	NN	O	O
partial	NN	O	O
hepatectomy	NN	O	O
in	NN	O	O
DEN	NN	O	B-Chemical
treated	NN	O	O
rats	NN	O	O
were	NN	O	O
also	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
in	NN	O	O
DEN	NN	O	B-Chemical
+	NN	O	O
PB	NN	O	B-Chemical
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

When	NN	O	O
the	NN	O	O
treatment	NN	O	O
last	NN	O	O
only	NN	O	O
2	NN	O	O
weeks	NN	O	O
,	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
PB	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
change	NN	O	O
significantly	NN	O	O
the	NN	O	O
last	NN	O	O
parameters	NN	O	O
.	NN	O	O

In	NN	O	O
DEN	NN	O	B-Chemical
+	NN	O	O
PB	NN	O	B-Chemical
treated	NN	O	O
rats	NN	O	O
,	NN	O	O
the	NN	O	O
survival	NN	O	O
was	NN	O	O
prolonged	NN	O	O
and	NN	O	O
the	NN	O	O
tumor	NN	O	B-Disease
incidence	NN	O	O
decreased	NN	O	O
as	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
results	NN	O	O
obtained	NN	O	O
by	NN	O	O
DEN	NN	O	B-Chemical
alone	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
PB	NN	O	B-Chemical
,	NN	O	O
which	NN	O	O
promotes	NN	O	O
carcinogenesis	NN	O	B-Disease
when	NN	O	O
administered	NN	O	O
after	NN	O	O
the	NN	O	O
DEN	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
reduces	NN	O	O
the	NN	O	O
carcinogen	NN	O	O
effect	NN	O	O
when	NN	O	O
given	NN	O	O
simultaneously	NN	O	O
with	NN	O	O
DEN	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
'	NN	O	O
anti	NN	O	O
-	NN	O	O
carcinogen	NN	O	O
'	NN	O	O
effect	NN	O	O
acts	NN	O	O
on	NN	O	O
the	NN	O	O
initiation	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
on	NN	O	O
the	NN	O	O
promotion	NN	O	O
of	NN	O	O
the	NN	O	O
precancerous	NN	O	B-Disease
lesions	NN	O	I-Disease
.	NN	O	O

Biochemical	NN	O	O
investigations	NN	O	O
are	NN	O	O
in	NN	O	O
progress	NN	O	O
to	NN	O	O
obtain	NN	O	O
more	NN	O	O
information	NN	O	O
about	NN	O	O
this	NN	O	O
'	NN	O	O
paradoxical	NN	O	O
'	NN	O	O
PB	NN	O	B-Chemical
effect	NN	O	O
.	NN	O	O


-DOCSTART- (3780697)

Post	NN	O	O
-	NN	O	O
operative	NN	O	O
rigidity	NN	O	B-Disease
after	NN	O	O
fentanyl	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
of	NN	O	O
thoraco	NN	O	O
-	NN	O	O
abdominal	NN	O	O
rigidity	NN	O	B-Disease
leading	NN	O	O
to	NN	O	O
respiratory	NN	O	B-Disease
failure	NN	O	I-Disease
is	NN	O	O
described	NN	O	O
in	NN	O	O
the	NN	O	O
post	NN	O	O
-	NN	O	O
operative	NN	O	O
period	NN	O	O
in	NN	O	O
an	NN	O	O
elderly	NN	O	O
patient	NN	O	O
who	NN	O	O
received	NN	O	O
a	NN	O	O
moderate	NN	O	O
dose	NN	O	O
of	NN	O	O
fentanyl	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
was	NN	O	O
successfully	NN	O	O
reversed	NN	O	O
by	NN	O	O
naloxone	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
mechanisms	NN	O	O
possibly	NN	O	O
implicated	NN	O	O
in	NN	O	O
this	NN	O	O
accident	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O


-DOCSTART- (3686155)

Postpartum	NN	O	O
psychosis	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
bromocriptine	NN	O	B-Chemical
.	NN	O	O

Two	NN	O	O
multigravida	NN	O	O
patients	NN	O	O
with	NN	O	O
no	NN	O	O
prior	NN	O	O
psychiatric	NN	O	B-Disease
history	NN	O	O
were	NN	O	O
seen	NN	O	O
with	NN	O	O
postpartum	NN	O	O
psychosis	NN	O	B-Disease
,	NN	O	O
having	NN	O	O
received	NN	O	O
bromocriptine	NN	O	B-Chemical
for	NN	O	O
inhibition	NN	O	B-Disease
of	NN	O	I-Disease
lactation	NN	O	I-Disease
.	NN	O	O

Bromocriptine	NN	O	B-Chemical
given	NN	O	O
in	NN	O	O
high	NN	O	O
doses	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
psychosis	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
the	NN	O	O
drug	NN	O	O
for	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

These	NN	O	O
cases	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
bromocriptine	NN	O	B-Chemical
may	NN	O	O
cause	NN	O	O
psychosis	NN	O	B-Disease
even	NN	O	O
when	NN	O	O
given	NN	O	O
in	NN	O	O
low	NN	O	O
doses	NN	O	O
.	NN	O	O


-DOCSTART- (3137399)

A	NN	O	O
prospective	NN	O	O
study	NN	O	O
on	NN	O	O
the	NN	O	O
dose	NN	O	O
dependency	NN	O	O
of	NN	O	O
cardiotoxicity	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
mitomycin	NN	O	B-Chemical
C	NN	O	I-Chemical
.	NN	O	O

Since	NN	O	O
1975	NN	O	O
mitomycin	NN	O	B-Chemical
C	NN	O	I-Chemical
(	NN	O	O
MMC	NN	O	B-Chemical
)	NN	O	O
has	NN	O	O
been	NN	O	O
suggested	NN	O	O
to	NN	O	O
be	NN	O	O
cardiotoxic	NN	O	B-Disease
,	NN	O	O
especially	NN	O	O
when	NN	O	O
combined	NN	O	O
with	NN	O	O
or	NN	O	O
given	NN	O	O
following	NN	O	O
doxorubicin	NN	O	B-Chemical
.	NN	O	O

Data	NN	O	O
on	NN	O	O
dose	NN	O	O
dependency	NN	O	O
or	NN	O	O
incidence	NN	O	O
concerning	NN	O	O
this	NN	O	O
side	NN	O	O
effect	NN	O	O
were	NN	O	O
not	NN	O	O
known	NN	O	O
.	NN	O	O

We	NN	O	O
have	NN	O	O
initiated	NN	O	O
a	NN	O	O
prospective	NN	O	O
study	NN	O	O
to	NN	O	O
obtain	NN	O	O
some	NN	O	O
more	NN	O	O
data	NN	O	O
on	NN	O	O
these	NN	O	O
subjects	NN	O	O
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
four	NN	O	O
MMC	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
patients	NN	O	O
were	NN	O	O
studied	NN	O	O
,	NN	O	O
37	NN	O	O
of	NN	O	O
them	NN	O	O
could	NN	O	O
be	NN	O	O
evaluated	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
were	NN	O	O
studied	NN	O	O
by	NN	O	O
repeated	NN	O	O
physical	NN	O	O
examinations	NN	O	O
,	NN	O	O
chest	NN	O	O
X	NN	O	O
-	NN	O	O
rays	NN	O	O
,	NN	O	O
electro	NN	O	O
-	NN	O	O
and	NN	O	O
echocardiography	NN	O	O
and	NN	O	O
radionuclide	NN	O	O
left	NN	O	O
ventricular	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
(	NN	O	O
EF	NN	O	O
)	NN	O	O
determinations	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
were	NN	O	O
evaluated	NN	O	O
per	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
level	NN	O	O
.	NN	O	O

One	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
developed	NN	O	O
cardiac	NN	O	B-Disease
failure	NN	O	I-Disease
after	NN	O	O
30	NN	O	O
mg	NN	O	O
m	NN	O	O
-	NN	O	O
2	NN	O	O
MMC	NN	O	B-Chemical
and	NN	O	O
only	NN	O	O
150	NN	O	O
mg	NN	O	O
m	NN	O	O
-	NN	O	O
2	NN	O	O
doxorubicin	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
cardiac	NN	O	B-Disease
failure	NN	O	I-Disease
was	NN	O	O
predicted	NN	O	O
by	NN	O	O
a	NN	O	O
drop	NN	O	O
in	NN	O	O
EF	NN	O	O
determined	NN	O	O
during	NN	O	O
a	NN	O	O
cold	NN	O	O
pressor	NN	O	O
test	NN	O	O
.	NN	O	O

None	NN	O	O
of	NN	O	O
the	NN	O	O
other	NN	O	O
patients	NN	O	O
developed	NN	O	O
clinical	NN	O	O
cardiotoxicity	NN	O	B-Disease
,	NN	O	O
nor	NN	O	O
did	NN	O	O
the	NN	O	O
studied	NN	O	O
parameters	NN	O	O
change	NN	O	O
.	NN	O	O

The	NN	O	O
literature	NN	O	O
on	NN	O	O
this	NN	O	O
subject	NN	O	O
was	NN	O	O
also	NN	O	O
reviewed	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
the	NN	O	O
combined	NN	O	O
data	NN	O	O
from	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
and	NN	O	O
the	NN	O	O
literature	NN	O	O
,	NN	O	O
we	NN	O	O
suggest	NN	O	O
that	NN	O	O
MMC	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
cardiotoxicity	NN	O	B-Disease
is	NN	O	O
dose	NN	O	O
dependent	NN	O	O
,	NN	O	O
occurring	NN	O	O
at	NN	O	O
cumulative	NN	O	O
dose	NN	O	O
levels	NN	O	O
of	NN	O	O
30	NN	O	O
mg	NN	O	O
m	NN	O	O
-	NN	O	O
2	NN	O	O
or	NN	O	O
more	NN	O	O
,	NN	O	O
mainly	NN	O	O
in	NN	O	O
patients	NN	O	O
also	NN	O	O
(	NN	O	O
previously	NN	O	O
or	NN	O	O
simultaneously	NN	O	O
)	NN	O	O
treated	NN	O	O
with	NN	O	O
doxorubicin	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
is	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
less	NN	O	O
than	NN	O	O
10%	NN	O	O
even	NN	O	O
for	NN	O	O
this	NN	O	O
risk	NN	O	O
group	NN	O	O
.	NN	O	O


-DOCSTART- (2709684)

Phlorizin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
glycosuria	NN	O	B-Disease
does	NN	O	O
not	NN	O	O
prevent	NN	O	O
gentamicin	NN	O	B-Chemical
nephrotoxicity	NN	O	B-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Because	NN	O	O
rats	NN	O	O
with	NN	O	O
streptozotocin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
diabetes	NN	O	B-Disease
mellitus	NN	O	I-Disease
(	NN	O	O
DM	NN	O	B-Disease
)	NN	O	O
have	NN	O	O
a	NN	O	O
high	NN	O	O
solute	NN	O	O
diuresis	NN	O	O
(	NN	O	O
glycosuria	NN	O	B-Disease
of	NN	O	O
10	NN	O	O
to	NN	O	O
12	NN	O	O
g	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
,	NN	O	O
we	NN	O	O
have	NN	O	O
suggested	NN	O	O
that	NN	O	O
this	NN	O	O
may	NN	O	O
in	NN	O	O
part	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
their	NN	O	O
resistance	NN	O	O
to	NN	O	O
gentamicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
(	NN	O	O
ARF	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

The	NN	O	O
protection	NN	O	O
from	NN	O	O
gentamicin	NN	O	B-Chemical
nephrotoxicity	NN	O	B-Disease
was	NN	O	O
studied	NN	O	O
in	NN	O	O
non	NN	O	O
-	NN	O	O
diabetic	NN	O	B-Disease
rats	NN	O	O
with	NN	O	O
chronic	NN	O	O
solute	NN	O	O
diuresis	NN	O	O
induced	NN	O	O
by	NN	O	O
blockage	NN	O	O
of	NN	O	O
tubular	NN	O	O
glucose	NN	O	B-Chemical
reabsorption	NN	O	O
with	NN	O	O
phlorizin	NN	O	B-Chemical
(	NN	O	O
P	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

DM	NN	O	B-Disease
rats	NN	O	O
with	NN	O	O
mild	NN	O	O
glycosuria	NN	O	B-Disease
(	NN	O	O
similar	NN	O	O
in	NN	O	O
degree	NN	O	O
to	NN	O	O
that	NN	O	O
of	NN	O	O
the	NN	O	O
P	NN	O	B-Chemical
treated	NN	O	O
animals	NN	O	O
)	NN	O	O
were	NN	O	O
also	NN	O	O
studied	NN	O	O
.	NN	O	O

Unanesthetized	NN	O	O
adult	NN	O	O
female	NN	O	O
,	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
were	NN	O	O
divided	NN	O	O
in	NN	O	O
four	NN	O	O
groups	NN	O	O
and	NN	O	O
studied	NN	O	O
for	NN	O	O
15	NN	O	O
days	NN	O	O
.	NN	O	O

Group	NN	O	O
1	NN	O	O
(	NN	O	O
P	NN	O	B-Chemical
alone	NN	O	O
)	NN	O	O
received	NN	O	O
P	NN	O	B-Chemical
,	NN	O	O
360	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
for	NN	O	O
15	NN	O	O
days	NN	O	O
;	NN	O	O
Group	NN	O	O
II	NN	O	O
(	NN	O	O
P	NN	O	B-Chemical
+	NN	O	O
gentamicin	NN	O	B-Chemical
)	NN	O	O
;	NN	O	O
Group	NN	O	O
III	NN	O	O
(	NN	O	O
gentamicin	NN	O	B-Chemical
alone	NN	O	O
)	NN	O	O
and	NN	O	O
Group	NN	O	O
IV	NN	O	O
(	NN	O	O
mild	NN	O	O
DM	NN	O	B-Disease
+	NN	O	O
gentamicin	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

Nephrotoxic	NN	O	B-Disease
doses	NN	O	O
(	NN	O	O
40	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
body	NN	O	O
wt	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
of	NN	O	O
gentamicin	NN	O	B-Chemical
were	NN	O	O
injected	NN	O	O
during	NN	O	O
the	NN	O	O
last	NN	O	O
nine	NN	O	O
days	NN	O	O
of	NN	O	O
study	NN	O	O
to	NN	O	O
the	NN	O	O
animals	NN	O	O
of	NN	O	O
groups	NN	O	O
II	NN	O	O
to	NN	O	O
IV	NN	O	O
.	NN	O	O

In	NN	O	O
Group	NN	O	O
I	NN	O	O
,	NN	O	O
P	NN	O	B-Chemical
induced	NN	O	O
a	NN	O	O
moderate	NN	O	O
and	NN	O	O
stable	NN	O	O
glycosuria	NN	O	B-Disease
(	NN	O	O
3.9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.1	NN	O	O
g	NN	O	O
/	NN	O	O
day	NN	O	O
,	NN	O	O
SE	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
no	NN	O	O
functional	NN	O	O
or	NN	O	O
morphologic	NN	O	O
evidence	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
dysfunction	NN	O	I-Disease
(	NN	O	O
baseline	NN	O	O
CCr	NN	O	O
2.1	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.1	NN	O	O
ml	NN	O	O
/	NN	O	O
min	NN	O	O
,	NN	O	O
undetectable	NN	O	O
lysozymuria	NN	O	O
)	NN	O	O
or	NN	O	O
damage	NN	O	O
(	NN	O	O
tubular	NN	O	B-Disease
necrosis	NN	O	I-Disease
score	NN	O	O
[	NN	O	O
maximum	NN	O	O
4	NN	O	O
]	NN	O	O
,	NN	O	O
zero	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
Group	NN	O	O
II	NN	O	O
,	NN	O	O
P	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
prevent	NN	O	O
gentamicin	NN	O	B-Chemical
-	NN	O	O
ARF	NN	O	B-Disease
(	NN	O	O
maximal	NN	O	O
decrease	NN	O	O
in	NN	O	O
CCr	NN	O	O
at	NN	O	O
day	NN	O	O
9.89%	NN	O	O
,	NN	O	O
P	NN	O	B-Chemical
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
;	NN	O	O
peak	NN	O	O
lysozymuria	NN	O	O
,	NN	O	O
1863	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
321	NN	O	O
micrograms	NN	O	O
/	NN	O	O
day	NN	O	O
;	NN	O	O
and	NN	O	O
tubular	NN	O	B-Disease
necrosis	NN	O	I-Disease
score	NN	O	O
,	NN	O	O
3.9	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.1	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
values	NN	O	O
were	NN	O	O
not	NN	O	O
different	NN	O	O
from	NN	O	O
those	NN	O	O
of	NN	O	O
Group	NN	O	O
III	NN	O	O
:	NN	O	O
maximal	NN	O	O
decrease	NN	O	O
in	NN	O	O
CCr	NN	O	O
73%	NN	O	O
(	NN	O	O
P	NN	O	B-Chemical
less	NN	O	O
than	NN	O	O
0.001	NN	O	O
)	NN	O	O
;	NN	O	O
lysozymuria	NN	O	O
,	NN	O	O
2147	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
701	NN	O	O
micrograms	NN	O	O
/	NN	O	O
day	NN	O	O
;	NN	O	O
tubular	NN	O	B-Disease
necrosis	NN	O	I-Disease
score	NN	O	O
,	NN	O	O
3.8	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.1.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

-DOCSTART- (458486)

Tiapride	NN	O	B-Chemical
in	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
involuntary	NN	O	B-Disease
movements	NN	O	I-Disease
.	NN	O	O

Tiapride	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
substituted	NN	O	O
benzamide	NN	O	B-Chemical
derivative	NN	O	O
closely	NN	O	O
related	NN	O	O
to	NN	O	O
metoclopramide	NN	O	B-Chemical
,	NN	O	O
reduced	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
peak	NN	O	O
dose	NN	O	O
involuntary	NN	O	B-Disease
movements	NN	O	I-Disease
in	NN	O	O
16	NN	O	O
patients	NN	O	O
with	NN	O	O
idiopathic	NN	O	B-Disease
Parkinson	NN	O	I-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
an	NN	O	O
unacceptable	NN	O	O
increase	NN	O	O
in	NN	O	O
disability	NN	O	O
from	NN	O	O
Parkinsonism	NN	O	B-Disease
with	NN	O	O
aggravation	NN	O	O
of	NN	O	O
end	NN	O	O
-	NN	O	O
of	NN	O	O
-	NN	O	O
dose	NN	O	O
akinesia	NN	O	B-Disease
led	NN	O	O
to	NN	O	O
its	NN	O	O
cessation	NN	O	O
in	NN	O	O
14	NN	O	O
patients	NN	O	O
.	NN	O	O

Tiapride	NN	O	B-Chemical
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
early	NN	O	O
morning	NN	O	O
of	NN	O	O
"	NN	O	O
off	NN	O	O
-	NN	O	O
period	NN	O	O
"	NN	O	O
segmental	NN	O	O
dystonia	NN	O	B-Disease
.	NN	O	O

These	NN	O	O
results	NN	O	O
fail	NN	O	O
to	NN	O	O
support	NN	O	O
the	NN	O	O
notion	NN	O	O
that	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
are	NN	O	O
caused	NN	O	O
by	NN	O	O
overstimulation	NN	O	O
of	NN	O	O
a	NN	O	O
separate	NN	O	O
group	NN	O	O
of	NN	O	O
dopamine	NN	O	B-Chemical
receptors	NN	O	O
.	NN	O	O


-DOCSTART- (21294084)

Effects	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampal	NN	O	O
deep	NN	O	O
brain	NN	O	O
stimulation	NN	O	O
on	NN	O	O
cortical	NN	O	O
epileptic	NN	O	B-Disease
discharges	NN	O	O
in	NN	O	O
penicillin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
epilepsy	NN	O	B-Disease
model	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

AIM	NN	O	O
:	NN	O	O
Experimental	NN	O	O
and	NN	O	O
clinical	NN	O	O
studies	NN	O	O
have	NN	O	O
revealed	NN	O	O
that	NN	O	O
hippocampal	NN	O	O
DBS	NN	O	O
can	NN	O	O
control	NN	O	O
epileptic	NN	O	B-Disease
activity	NN	O	O
,	NN	O	O
but	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
action	NN	O	O
is	NN	O	O
obscure	NN	O	O
and	NN	O	O
optimal	NN	O	O
stimulation	NN	O	O
parameters	NN	O	O
are	NN	O	O
not	NN	O	O
clearly	NN	O	O
defined	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
high	NN	O	O
frequency	NN	O	O
hippocampal	NN	O	O
stimulation	NN	O	O
on	NN	O	O
cortical	NN	O	O
epileptic	NN	O	B-Disease
activity	NN	O	O
in	NN	O	O
penicillin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
epilepsy	NN	O	B-Disease
model	NN	O	O
.	NN	O	O

MATERIAL	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Twenty	NN	O	O
-	NN	O	O
five	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
rats	NN	O	O
were	NN	O	O
implanted	NN	O	O
DBS	NN	O	O
electrodes	NN	O	O
.	NN	O	O

In	NN	O	O
group	NN	O	O
-	NN	O	O
1	NN	O	O
(	NN	O	O
n=10	NN	O	O
)	NN	O	O
hippocampal	NN	O	O
DBS	NN	O	O
was	NN	O	O
off	NN	O	O
and	NN	O	O
in	NN	O	O
the	NN	O	O
group	NN	O	O
-	NN	O	O
2	NN	O	O
(	NN	O	O
n=10	NN	O	O
)	NN	O	O
hippocampal	NN	O	O
DBS	NN	O	O
was	NN	O	O
on	NN	O	O
(	NN	O	O
185	NN	O	O
Hz	NN	O	O
,	NN	O	O
0.5V	NN	O	O
,	NN	O	O
1V	NN	O	O
,	NN	O	O
2V	NN	O	O
,	NN	O	O
and	NN	O	O
5V	NN	O	O
for	NN	O	O
60	NN	O	O
sec	NN	O	O
)	NN	O	O
following	NN	O	O
penicillin	NN	O	B-Chemical
G	NN	O	I-Chemical
injection	NN	O	O
intracortically	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
hippocampal	NN	O	O
DBS	NN	O	O
was	NN	O	O
on	NN	O	O
following	NN	O	O
8	NN	O	O
l	NN	O	O
saline	NN	O	O
injection	NN	O	O
intracortically	NN	O	O
.	NN	O	O

EEG	NN	O	O
recordings	NN	O	O
were	NN	O	O
obtained	NN	O	O
before	NN	O	O
and	NN	O	O
15	NN	O	O
minutes	NN	O	O
following	NN	O	O
penicillin	NN	O	B-Chemical
-	NN	O	I-Chemical
G	NN	O	I-Chemical
injection	NN	O	O
,	NN	O	O
and	NN	O	O
at	NN	O	O
10th	NN	O	O
minutes	NN	O	O
following	NN	O	O
each	NN	O	O
stimulus	NN	O	O
for	NN	O	O
analysis	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
frequency	NN	O	O
,	NN	O	O
amplitude	NN	O	O
,	NN	O	O
and	NN	O	O
power	NN	O	O
spectrum	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
High	NN	O	O
frequency	NN	O	O
hippocampal	NN	O	O
DBS	NN	O	O
suppressed	NN	O	O
the	NN	O	O
acute	NN	O	O
penicillin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cortical	NN	O	O
epileptic	NN	O	B-Disease
activity	NN	O	O
independent	NN	O	O
from	NN	O	O
stimulus	NN	O	O
intensity	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
,	NN	O	O
hippocampal	NN	O	O
stimulation	NN	O	O
alone	NN	O	O
lead	NN	O	O
only	NN	O	O
to	NN	O	O
diffuse	NN	O	O
slowing	NN	O	O
of	NN	O	O
cerebral	NN	O	O
bioelectrical	NN	O	O
activity	NN	O	O
at	NN	O	O
5V	NN	O	O
stimulation	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Our	NN	O	O
results	NN	O	O
revealed	NN	O	O
that	NN	O	O
continuous	NN	O	O
high	NN	O	O
frequency	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
hippocampus	NN	O	O
suppressed	NN	O	O
acute	NN	O	O
cortical	NN	O	O
epileptic	NN	O	B-Disease
activity	NN	O	O
effectively	NN	O	O
without	NN	O	O
causing	NN	O	O
secondary	NN	O	O
epileptic	NN	O	B-Disease
discharges	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
are	NN	O	O
important	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
defining	NN	O	O
the	NN	O	O
optimal	NN	O	O
parameters	NN	O	O
of	NN	O	O
hippocampal	NN	O	O
DBS	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
epilepsy	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (20727411)

Neural	NN	O	O
correlates	NN	O	O
of	NN	O	O
S	NN	O	B-Chemical
-	NN	O	I-Chemical
ketamine	NN	O	I-Chemical
induced	NN	O	O
psychosis	NN	O	B-Disease
during	NN	O	O
overt	NN	O	O
continuous	NN	O	O
verbal	NN	O	O
fluency	NN	O	O
.	NN	O	O

The	NN	O	O
glutamatergic	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
-	NN	O	I-Chemical
D	NN	O	I-Chemical
-	NN	O	I-Chemical
aspartate	NN	O	I-Chemical
(	NN	O	O
NMDA	NN	O	B-Chemical
)	NN	O	O
receptor	NN	O	O
has	NN	O	O
been	NN	O	O
implicated	NN	O	O
in	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B-Disease
.	NN	O	O

Administered	NN	O	O
to	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
,	NN	O	O
a	NN	O	O
subanesthetic	NN	O	O
dose	NN	O	O
of	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
competitive	NN	O	O
NMDA	NN	O	B-Chemical
receptor	NN	O	O
antagonist	NN	O	O
ketamine	NN	O	B-Chemical
leads	NN	O	O
to	NN	O	O
psychopathological	NN	O	O
symptoms	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
observed	NN	O	O
in	NN	O	O
schizophrenia	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
schizophrenia	NN	O	B-Disease
,	NN	O	O
ketamine	NN	O	B-Chemical
exacerbates	NN	O	O
the	NN	O	O
core	NN	O	O
symptoms	NN	O	O
of	NN	O	O
illness	NN	O	O
,	NN	O	O
supporting	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
of	NN	O	O
a	NN	O	O
glutamatergic	NN	O	B-Disease
dysfunction	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
a	NN	O	O
counterbalanced	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
study	NN	O	O
design	NN	O	O
,	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
were	NN	O	O
administered	NN	O	O
a	NN	O	O
continuous	NN	O	O
subanesthetic	NN	O	O
S	NN	O	B-Chemical
-	NN	O	I-Chemical
ketamine	NN	O	I-Chemical
infusion	NN	O	O
while	NN	O	O
differences	NN	O	O
in	NN	O	O
BOLD	NN	O	O
responses	NN	O	O
measured	NN	O	O
with	NN	O	O
fMRI	NN	O	O
were	NN	O	O
detected	NN	O	O
.	NN	O	O

During	NN	O	O
the	NN	O	O
scanning	NN	O	O
period	NN	O	O
,	NN	O	O
subjects	NN	O	O
performed	NN	O	O
continuous	NN	O	O
overt	NN	O	O
verbal	NN	O	O
fluency	NN	O	O
tasks	NN	O	O
(	NN	O	O
phonological	NN	O	O
,	NN	O	O
lexical	NN	O	O
and	NN	O	O
semantic	NN	O	O
)	NN	O	O
.	NN	O	O

Ketamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
psychopathological	NN	O	O
symptoms	NN	O	O
were	NN	O	O
assessed	NN	O	O
with	NN	O	O
the	NN	O	O
Positive	NN	O	O
and	NN	O	O
Negative	NN	O	O
Syndrome	NN	O	O
Scale	NN	O	O
(	NN	O	O
PANSS	NN	O	O
)	NN	O	O
.	NN	O	O

Ketamine	NN	O	B-Chemical
elicited	NN	O	O
psychosis	NN	O	B-Disease
like	NN	O	O
psychopathology	NN	O	O
.	NN	O	O

Post	NN	O	O
-	NN	O	O
hoc	NN	O	O
t	NN	O	O
-	NN	O	O
tests	NN	O	O
revealed	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
placebo	NN	O	O
and	NN	O	O
ketamine	NN	O	B-Chemical
for	NN	O	O
the	NN	O	O
amounts	NN	O	O
of	NN	O	O
words	NN	O	O
generated	NN	O	O
during	NN	O	O
lexical	NN	O	O
and	NN	O	O
semantic	NN	O	O
verbal	NN	O	O
fluency	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
phonological	NN	O	O
domain	NN	O	O
remained	NN	O	O
unaffected	NN	O	O
.	NN	O	O

Ketamine	NN	O	B-Chemical
led	NN	O	O
to	NN	O	O
enhanced	NN	O	O
cortical	NN	O	O
activations	NN	O	O
in	NN	O	O
supramarginal	NN	O	O
and	NN	O	O
frontal	NN	O	O
brain	NN	O	O
regions	NN	O	O
for	NN	O	O
phonological	NN	O	O
and	NN	O	O
lexical	NN	O	O
verbal	NN	O	O
fluency	NN	O	O
,	NN	O	O
but	NN	O	O
not	NN	O	O
for	NN	O	O
semantic	NN	O	O
verbal	NN	O	O
fluency	NN	O	O
.	NN	O	O

Ketamine	NN	O	B-Chemical
induces	NN	O	O
activation	NN	O	O
changes	NN	O	O
in	NN	O	O
healthy	NN	O	O
subjects	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
observed	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
schizophrenia	NN	O	B-Disease
,	NN	O	O
particularly	NN	O	O
in	NN	O	O
frontal	NN	O	O
and	NN	O	O
temporal	NN	O	O
brain	NN	O	O
regions	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
provide	NN	O	O
further	NN	O	O
support	NN	O	O
for	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
of	NN	O	O
an	NN	O	O
NMDA	NN	O	B-Chemical
receptor	NN	O	O
dysfunction	NN	O	O
in	NN	O	O
the	NN	O	O
pathophysiology	NN	O	O
of	NN	O	O
schizophrenia	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (20533999)

Dopamine	NN	O	B-Chemical
is	NN	O	O
not	NN	O	O
essential	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
methamphetamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
neurotoxicity	NN	O	B-Disease
.	NN	O	O

It	NN	O	O
is	NN	O	O
widely	NN	O	O
believed	NN	O	O
that	NN	O	O
dopamine	NN	O	B-Chemical
(	NN	O	O
DA	NN	O	B-Chemical
)	NN	O	O
mediates	NN	O	O
methamphetamine	NN	O	B-Chemical
(	NN	O	O
METH	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
toxicity	NN	O	B-Disease
to	NN	O	O
brain	NN	O	O
dopaminergic	NN	O	O
neurons	NN	O	O
,	NN	O	O
because	NN	O	O
drugs	NN	O	O
that	NN	O	O
interfere	NN	O	O
with	NN	O	O
DA	NN	O	B-Chemical
neurotransmission	NN	O	O
decrease	NN	O	O
toxicity	NN	O	B-Disease
,	NN	O	O
whereas	NN	O	O
drugs	NN	O	O
that	NN	O	O
increase	NN	O	O
DA	NN	O	B-Chemical
neurotransmission	NN	O	O
enhance	NN	O	O
toxicity	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
temperature	NN	O	O
effects	NN	O	O
of	NN	O	O
drugs	NN	O	O
that	NN	O	O
have	NN	O	O
been	NN	O	O
used	NN	O	O
to	NN	O	O
manipulate	NN	O	O
brain	NN	O	O
DA	NN	O	B-Chemical
neurotransmission	NN	O	O
confound	NN	O	O
interpretation	NN	O	O
of	NN	O	O
the	NN	O	O
data	NN	O	O
.	NN	O	O

Here	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
recently	NN	O	O
reported	NN	O	O
ability	NN	O	O
of	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dihydroxyphenylalanine	NN	O	I-Chemical
to	NN	O	O
reverse	NN	O	O
the	NN	O	O
protective	NN	O	O
effect	NN	O	O
of	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
-	NN	O	I-Chemical
para	NN	O	I-Chemical
-	NN	O	I-Chemical
tyrosine	NN	O	I-Chemical
on	NN	O	O
METH	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
DA	NN	O	B-Chemical
neurotoxicity	NN	O	B-Disease
is	NN	O	O
also	NN	O	O
confounded	NN	O	O
by	NN	O	O
drug	NN	O	O
effects	NN	O	O
on	NN	O	O
body	NN	O	O
temperature	NN	O	O
.	NN	O	O

Further	NN	O	O
,	NN	O	O
we	NN	O	O
show	NN	O	O
that	NN	O	O
mice	NN	O	O
genetically	NN	O	O
engineered	NN	O	O
to	NN	O	O
be	NN	O	O
deficient	NN	O	O
in	NN	O	O
brain	NN	O	O
DA	NN	O	B-Chemical
develop	NN	O	O
METH	NN	O	B-Chemical
neurotoxicity	NN	O	B-Disease
,	NN	O	O
as	NN	O	O
long	NN	O	O
as	NN	O	O
the	NN	O	O
thermic	NN	O	O
effects	NN	O	O
of	NN	O	O
METH	NN	O	B-Chemical
are	NN	O	O
preserved	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
we	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
mice	NN	O	O
genetically	NN	O	O
engineered	NN	O	O
to	NN	O	O
have	NN	O	O
unilateral	NN	O	O
brain	NN	O	O
DA	NN	O	B-Chemical
deficits	NN	O	O
develop	NN	O	O
METH	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dopaminergic	NN	O	B-Disease
deficits	NN	O	I-Disease
that	NN	O	O
are	NN	O	O
of	NN	O	O
comparable	NN	O	O
magnitude	NN	O	O
on	NN	O	O
both	NN	O	O
sides	NN	O	O
of	NN	O	O
the	NN	O	O
brain	NN	O	O
.	NN	O	O

Taken	NN	O	O
together	NN	O	O
,	NN	O	O
these	NN	O	O
findings	NN	O	O
demonstrate	NN	O	O
that	NN	O	O
DA	NN	O	B-Chemical
is	NN	O	O
not	NN	O	O
essential	NN	O	O
for	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
METH	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dopaminergic	NN	O	O
neurotoxicity	NN	O	B-Disease
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
mechanisms	NN	O	O
independent	NN	O	O
of	NN	O	O
DA	NN	O	B-Chemical
warrant	NN	O	O
more	NN	O	O
intense	NN	O	O
investigation	NN	O	O
.	NN	O	O


-DOCSTART- (20304337)

Brainstem	NN	O	B-Disease
dysgenesis	NN	O	I-Disease
in	NN	O	O
an	NN	O	O
infant	NN	O	O
prenatally	NN	O	O
exposed	NN	O	O
to	NN	O	O
cocaine	NN	O	B-Chemical
.	NN	O	O

Many	NN	O	O
authors	NN	O	O
described	NN	O	O
the	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
fetus	NN	O	O
of	NN	O	O
maternal	NN	O	O
cocaine	NN	O	B-Disease
abuse	NN	O	I-Disease
during	NN	O	O
pregnancy	NN	O	O
.	NN	O	O

Vasoconstriction	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
common	NN	O	O
mechanism	NN	O	O
of	NN	O	O
action	NN	O	O
leading	NN	O	O
to	NN	O	O
a	NN	O	O
wide	NN	O	O
range	NN	O	O
of	NN	O	O
fetal	NN	O	B-Disease
anomalies	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
report	NN	O	O
on	NN	O	O
an	NN	O	O
infant	NN	O	O
with	NN	O	O
multiple	NN	O	B-Disease
cranial	NN	O	I-Disease
-	NN	O	I-Disease
nerve	NN	O	I-Disease
involvement	NN	O	I-Disease
attributable	NN	O	O
to	NN	O	O
brainstem	NN	O	B-Disease
dysgenesis	NN	O	I-Disease
,	NN	O	O
born	NN	O	O
to	NN	O	O
a	NN	O	O
cocaine	NN	O	B-Disease
-	NN	O	I-Disease
addicted	NN	O	I-Disease
mother	NN	O	O
.	NN	O	O


-DOCSTART- (20103708)

The	NN	O	O
protective	NN	O	O
role	NN	O	O
of	NN	O	O
Nrf2	NN	O	O
in	NN	O	O
streptozotocin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
diabetic	NN	O	B-Disease
nephropathy	NN	O	I-Disease
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
Diabetic	NN	O	B-Disease
nephropathy	NN	O	I-Disease
is	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
major	NN	O	O
causes	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
,	NN	O	O
which	NN	O	O
is	NN	O	O
accompanied	NN	O	O
by	NN	O	O
the	NN	O	O
production	NN	O	O
of	NN	O	O
reactive	NN	O	O
oxygen	NN	O	B-Chemical
species	NN	O	O
(	NN	O	O
ROS	NN	O	O
)	NN	O	O
.	NN	O	O

Nrf2	NN	O	O
is	NN	O	O
the	NN	O	O
primary	NN	O	O
transcription	NN	O	O
factor	NN	O	O
that	NN	O	O
controls	NN	O	O
the	NN	O	O
antioxidant	NN	O	O
response	NN	O	O
essential	NN	O	O
for	NN	O	O
maintaining	NN	O	O
cellular	NN	O	O
redox	NN	O	O
homeostasis	NN	O	O
.	NN	O	O

Here	NN	O	O
,	NN	O	O
we	NN	O	O
report	NN	O	O
our	NN	O	O
findings	NN	O	O
demonstrating	NN	O	O
a	NN	O	O
protective	NN	O	O
role	NN	O	O
of	NN	O	O
Nrf2	NN	O	O
against	NN	O	O
diabetic	NN	O	B-Disease
nephropathy	NN	O	I-Disease
.	NN	O	O

RESEARCH	NN	O	O
DESIGN	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
We	NN	O	O
explore	NN	O	O
the	NN	O	O
protective	NN	O	O
role	NN	O	O
of	NN	O	O
Nrf2	NN	O	O
against	NN	O	O
diabetic	NN	O	B-Disease
nephropathy	NN	O	I-Disease
using	NN	O	O
human	NN	O	O
kidney	NN	O	O
biopsy	NN	O	O
tissues	NN	O	O
from	NN	O	O
diabetic	NN	O	B-Disease
nephropathy	NN	O	I-Disease
patients	NN	O	O
,	NN	O	O
a	NN	O	O
streptozotocin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
diabetic	NN	O	B-Disease
nephropathy	NN	O	I-Disease
model	NN	O	O
in	NN	O	O
Nrf2	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
,	NN	O	O
and	NN	O	O
cultured	NN	O	O
human	NN	O	O
mesangial	NN	O	O
cells	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
glomeruli	NN	O	O
of	NN	O	O
human	NN	O	O
diabetic	NN	O	B-Disease
nephropathy	NN	O	I-Disease
patients	NN	O	O
were	NN	O	O
under	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
and	NN	O	O
had	NN	O	O
elevated	NN	O	O
Nrf2	NN	O	O
levels	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
animal	NN	O	O
study	NN	O	O
,	NN	O	O
Nrf2	NN	O	O
was	NN	O	O
demonstrated	NN	O	O
to	NN	O	O
be	NN	O	O
crucial	NN	O	O
in	NN	O	O
ameliorating	NN	O	O
streptozotocin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
renal	NN	O	B-Disease
damage	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
is	NN	O	O
evident	NN	O	O
by	NN	O	O
Nrf2	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
having	NN	O	O
higher	NN	O	O
ROS	NN	O	O
production	NN	O	O
and	NN	O	O
suffering	NN	O	O
from	NN	O	O
greater	NN	O	O
oxidative	NN	O	O
DNA	NN	O	O
damage	NN	O	O
and	NN	O	O
renal	NN	O	B-Disease
injury	NN	O	I-Disease
compared	NN	O	O
with	NN	O	O
Nrf2	NN	O	O
(	NN	O	O
+	NN	O	O
/	NN	O	O
+	NN	O	O
)	NN	O	O
mice	NN	O	O
.	NN	O	O

Mechanistic	NN	O	O
studies	NN	O	O
in	NN	O	O
both	NN	O	O
in	NN	O	O
vivo	NN	O	O
and	NN	O	O
in	NN	O	O
vitro	NN	O	O
systems	NN	O	O
showed	NN	O	O
that	NN	O	O
the	NN	O	O
Nrf2	NN	O	O
-	NN	O	O
mediated	NN	O	O
protection	NN	O	O
against	NN	O	O
diabetic	NN	O	B-Disease
nephropathy	NN	O	I-Disease
is	NN	O	O
,	NN	O	O
at	NN	O	O
least	NN	O	O
,	NN	O	O
partially	NN	O	O
through	NN	O	O
inhibition	NN	O	O
of	NN	O	O
transforming	NN	O	O
growth	NN	O	O
factor	NN	O	O
-	NN	O	O
beta1	NN	O	O
(	NN	O	O
TGF	NN	O	O
-	NN	O	O
beta1	NN	O	O
)	NN	O	O
and	NN	O	O
reduction	NN	O	O
of	NN	O	O
extracellular	NN	O	O
matrix	NN	O	O
production	NN	O	O
.	NN	O	O

In	NN	O	O
human	NN	O	O
renal	NN	O	O
mesangial	NN	O	O
cells	NN	O	O
,	NN	O	O
high	NN	O	O
glucose	NN	O	B-Chemical
induced	NN	O	O
ROS	NN	O	O
production	NN	O	O
and	NN	O	O
activated	NN	O	O
expression	NN	O	O
of	NN	O	O
Nrf2	NN	O	O
and	NN	O	O
its	NN	O	O
downstream	NN	O	O
genes	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
activation	NN	O	O
or	NN	O	O
overexpression	NN	O	O
of	NN	O	O
Nrf2	NN	O	O
inhibited	NN	O	O
the	NN	O	O
promoter	NN	O	O
activity	NN	O	O
of	NN	O	O
TGF	NN	O	O
-	NN	O	O
beta1	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
,	NN	O	O
whereas	NN	O	O
knockdown	NN	O	O
of	NN	O	O
Nrf2	NN	O	O
by	NN	O	O
siRNA	NN	O	O
enhanced	NN	O	O
TGF	NN	O	O
-	NN	O	O
beta1	NN	O	O
transcription	NN	O	O
and	NN	O	O
fibronectin	NN	O	O
production	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
This	NN	O	O
work	NN	O	O
clearly	NN	O	O
indicates	NN	O	O
a	NN	O	O
protective	NN	O	O
role	NN	O	O
of	NN	O	O
Nrf2	NN	O	O
in	NN	O	O
diabetic	NN	O	B-Disease
nephropathy	NN	O	I-Disease
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
dietary	NN	O	O
or	NN	O	O
therapeutic	NN	O	O
activation	NN	O	O
of	NN	O	O
Nrf2	NN	O	O
could	NN	O	O
be	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
strategy	NN	O	O
to	NN	O	O
prevent	NN	O	O
or	NN	O	O
slow	NN	O	O
down	NN	O	O
the	NN	O	O
progression	NN	O	O
of	NN	O	O
diabetic	NN	O	B-Disease
nephropathy	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (19996135)

High	NN	O	O
-	NN	O	O
dose	NN	O	O
tranexamic	NN	O	B-Chemical
Acid	NN	O	I-Chemical
is	NN	O	O
associated	NN	O	O
with	NN	O	O
nonischemic	NN	O	O
clinical	NN	O	O
seizures	NN	O	B-Disease
in	NN	O	O
cardiac	NN	O	O
surgical	NN	O	O
patients	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
In	NN	O	O
2	NN	O	O
separate	NN	O	O
centers	NN	O	O
,	NN	O	O
we	NN	O	O
observed	NN	O	O
a	NN	O	O
notable	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
postoperative	NN	O	O
convulsive	NN	O	B-Disease
seizures	NN	O	B-Disease
from	NN	O	O
1.3%	NN	O	O
to	NN	O	O
3.8%	NN	O	O
in	NN	O	O
patients	NN	O	O
having	NN	O	O
undergone	NN	O	O
major	NN	O	O
cardiac	NN	O	O
surgical	NN	O	O
procedures	NN	O	O
.	NN	O	O

These	NN	O	O
events	NN	O	O
were	NN	O	O
temporally	NN	O	O
coincident	NN	O	O
with	NN	O	O
the	NN	O	O
initial	NN	O	O
use	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
tranexamic	NN	O	B-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
TXA	NN	O	B-Chemical
)	NN	O	O
therapy	NN	O	O
after	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
aprotinin	NN	O	O
from	NN	O	O
general	NN	O	O
clinical	NN	O	O
usage	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
review	NN	O	O
was	NN	O	O
to	NN	O	O
perform	NN	O	O
a	NN	O	O
retrospective	NN	O	O
analysis	NN	O	O
to	NN	O	O
examine	NN	O	O
whether	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
relation	NN	O	O
between	NN	O	O
TXA	NN	O	B-Chemical
usage	NN	O	O
and	NN	O	O
seizures	NN	O	B-Disease
after	NN	O	O
cardiac	NN	O	O
surgery	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
An	NN	O	O
in	NN	O	O
-	NN	O	O
depth	NN	O	O
chart	NN	O	O
review	NN	O	O
was	NN	O	O
undertaken	NN	O	O
in	NN	O	O
all	NN	O	O
24	NN	O	O
patients	NN	O	O
who	NN	O	O
developed	NN	O	O
perioperative	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

Electroencephalographic	NN	O	O
activity	NN	O	O
was	NN	O	O
recorded	NN	O	O
in	NN	O	O
11	NN	O	O
of	NN	O	O
these	NN	O	O
patients	NN	O	O
,	NN	O	O
and	NN	O	O
all	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
formal	NN	O	O
neurological	NN	O	O
evaluation	NN	O	O
and	NN	O	O
brain	NN	O	O
imaging	NN	O	O
studies	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Twenty	NN	O	O
-	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
24	NN	O	O
patients	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
evidence	NN	O	O
of	NN	O	O
new	NN	O	O
cerebral	NN	O	B-Disease
ischemic	NN	O	I-Disease
injury	NN	O	I-Disease
,	NN	O	O
but	NN	O	O
seizures	NN	O	B-Disease
were	NN	O	O
likely	NN	O	O
due	NN	O	O
to	NN	O	O
ischemic	NN	O	B-Disease
brain	NN	O	I-Disease
injury	NN	O	I-Disease
in	NN	O	O
3	NN	O	O
patients	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
with	NN	O	O
seizures	NN	O	B-Disease
did	NN	O	O
not	NN	O	O
have	NN	O	O
permanent	NN	O	O
neurological	NN	O	B-Disease
abnormalities	NN	O	I-Disease
.	NN	O	O

All	NN	O	O
24	NN	O	O
patients	NN	O	O
with	NN	O	O
seizures	NN	O	B-Disease
received	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
TXA	NN	O	B-Chemical
intraoperatively	NN	O	O
ranging	NN	O	O
from	NN	O	O
61	NN	O	O
to	NN	O	O
259	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
had	NN	O	O
a	NN	O	O
mean	NN	O	O
age	NN	O	O
of	NN	O	O
69.9	NN	O	O
years	NN	O	O
,	NN	O	O
and	NN	O	O
21	NN	O	O
of	NN	O	O
24	NN	O	O
had	NN	O	O
undergone	NN	O	O
open	NN	O	O
chamber	NN	O	O
rather	NN	O	O
than	NN	O	O
coronary	NN	O	O
bypass	NN	O	O
procedures	NN	O	O
.	NN	O	O

All	NN	O	O
but	NN	O	O
one	NN	O	O
patient	NN	O	O
were	NN	O	O
managed	NN	O	O
using	NN	O	O
cardiopulmonary	NN	O	O
bypass	NN	O	O
.	NN	O	O

No	NN	O	O
evidence	NN	O	O
of	NN	O	O
brain	NN	O	B-Disease
ischemic	NN	O	I-Disease
,	NN	O	O
metabolic	NN	O	O
,	NN	O	O
or	NN	O	O
hyperthermia	NN	O	B-Disease
-	NN	O	O
induced	NN	O	O
causes	NN	O	O
for	NN	O	O
their	NN	O	O
seizures	NN	O	B-Disease
was	NN	O	O
apparent	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Our	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
use	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
TXA	NN	O	B-Chemical
in	NN	O	O
older	NN	O	O
patients	NN	O	O
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
cardiopulmonary	NN	O	O
bypass	NN	O	O
and	NN	O	O
open	NN	O	O
-	NN	O	O
chamber	NN	O	O
cardiac	NN	O	O
surgery	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
clinical	NN	O	O
seizures	NN	O	B-Disease
in	NN	O	O
susceptible	NN	O	O
patients	NN	O	O
.	NN	O	O


-DOCSTART- (19674115)

Recurrent	NN	O	O
dysosmia	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
pyrazinamide	NN	O	B-Chemical
.	NN	O	O

Pyrazinamide	NN	O	B-Chemical
can	NN	O	O
have	NN	O	O
adverse	NN	O	O
effects	NN	O	O
such	NN	O	O
as	NN	O	O
hepatic	NN	O	B-Disease
toxicity	NN	O	I-Disease
,	NN	O	O
hyperuricemia	NN	O	B-Disease
or	NN	O	O
digestive	NN	O	O
disorders	NN	O	O
.	NN	O	O

In	NN	O	O
rare	NN	O	O
cases	NN	O	O
,	NN	O	O
alterations	NN	O	O
in	NN	O	O
taste	NN	O	O
and	NN	O	O
smell	NN	O	O
function	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
for	NN	O	O
pyrazinamide	NN	O	B-Chemical
when	NN	O	O
combined	NN	O	O
with	NN	O	O
other	NN	O	O
drugs	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
reversible	NN	O	O
olfactory	NN	O	B-Disease
disorder	NN	O	I-Disease
related	NN	O	O
to	NN	O	O
pyrazinamide	NN	O	B-Chemical
in	NN	O	O
a	NN	O	O
woman	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
positive	NN	O	O
rechallenge	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
presented	NN	O	O
every	NN	O	O
day	NN	O	O
a	NN	O	O
sensation	NN	O	O
of	NN	O	O
smelling	NN	O	O
something	NN	O	O
burning	NN	O	O
15	NN	O	O
min	NN	O	O
after	NN	O	O
drug	NN	O	O
intake	NN	O	O
.	NN	O	O

Dysosmia	NN	O	B-Disease
disappeared	NN	O	O
completely	NN	O	O
after	NN	O	O
pyrazinamide	NN	O	B-Chemical
withdrawal	NN	O	O
and	NN	O	O
recurred	NN	O	O
after	NN	O	O
its	NN	O	O
rechallenge	NN	O	O
.	NN	O	O

The	NN	O	O
case	NN	O	O
was	NN	O	O
reported	NN	O	O
to	NN	O	O
the	NN	O	O
Tunisian	NN	O	O
Centre	NN	O	O
of	NN	O	O
Pharmacovigilance	NN	O	O
.	NN	O	O


-DOCSTART- (19139001)

Longitudinal	NN	O	O
assessment	NN	O	O
of	NN	O	O
air	NN	O	O
conduction	NN	O	O
audiograms	NN	O	O
in	NN	O	O
a	NN	O	O
phase	NN	O	O
III	NN	O	O
clinical	NN	O	O
trial	NN	O	O
of	NN	O	O
difluoromethylornithine	NN	O	B-Chemical
and	NN	O	O
sulindac	NN	O	B-Chemical
for	NN	O	O
prevention	NN	O	O
of	NN	O	O
sporadic	NN	O	O
colorectal	NN	O	B-Disease
adenomas	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
phase	NN	O	O
III	NN	O	O
clinical	NN	O	O
trial	NN	O	O
assessed	NN	O	O
the	NN	O	O
recurrence	NN	O	O
of	NN	O	O
adenomatous	NN	O	B-Disease
polyps	NN	O	I-Disease
after	NN	O	O
treatment	NN	O	O
for	NN	O	O
36	NN	O	O
months	NN	O	O
with	NN	O	O
difluoromethylornithine	NN	O	B-Chemical
(	NN	O	O
DFMO	NN	O	B-Chemical
)	NN	O	O
plus	NN	O	O
sulindac	NN	O	B-Chemical
or	NN	O	O
matched	NN	O	O
placebos	NN	O	O
.	NN	O	O

Temporary	NN	O	O
hearing	NN	O	B-Disease
loss	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
known	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
DFMO	NN	O	B-Chemical
,	NN	O	O
thus	NN	O	O
a	NN	O	O
comprehensive	NN	O	O
approach	NN	O	O
was	NN	O	O
developed	NN	O	O
to	NN	O	O
analyze	NN	O	O
serial	NN	O	O
air	NN	O	O
conduction	NN	O	O
audiograms	NN	O	O
.	NN	O	O

The	NN	O	O
generalized	NN	O	O
estimating	NN	O	O
equation	NN	O	O
method	NN	O	O
estimated	NN	O	O
the	NN	O	O
mean	NN	O	O
difference	NN	O	O
between	NN	O	O
treatment	NN	O	O
arms	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
change	NN	O	O
in	NN	O	O
air	NN	O	O
conduction	NN	O	O
pure	NN	O	O
tone	NN	O	O
thresholds	NN	O	O
while	NN	O	O
accounting	NN	O	O
for	NN	O	O
within	NN	O	O
-	NN	O	O
subject	NN	O	O
correlation	NN	O	O
due	NN	O	O
to	NN	O	O
repeated	NN	O	O
measurements	NN	O	O
at	NN	O	O
frequencies	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
290	NN	O	O
subjects	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
an	NN	O	O
average	NN	O	O
difference	NN	O	O
of	NN	O	O
0.50	NN	O	O
dB	NN	O	O
between	NN	O	O
subjects	NN	O	O
treated	NN	O	O
with	NN	O	O
DFMO	NN	O	B-Chemical
plus	NN	O	O
sulindac	NN	O	B-Chemical
compared	NN	O	O
with	NN	O	O
those	NN	O	O
treated	NN	O	O
with	NN	O	O
placebo	NN	O	O
(	NN	O	O
95%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
-	NN	O	O
0.64	NN	O	O
to	NN	O	O
1.63	NN	O	O
dB	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0.39	NN	O	O
)	NN	O	O
,	NN	O	O
adjusted	NN	O	O
for	NN	O	O
baseline	NN	O	O
values	NN	O	O
,	NN	O	O
age	NN	O	O
,	NN	O	O
and	NN	O	O
frequencies	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
normal	NN	O	O
speech	NN	O	O
range	NN	O	O
of	NN	O	O
500	NN	O	O
to	NN	O	O
3	NN	O	O
,	NN	O	O
000	NN	O	O
Hz	NN	O	O
,	NN	O	O
an	NN	O	O
estimated	NN	O	O
difference	NN	O	O
of	NN	O	O
0.99	NN	O	O
dB	NN	O	O
(	NN	O	O
-	NN	O	O
0.17	NN	O	O
to	NN	O	O
2.14	NN	O	O
dB	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0.09	NN	O	O
)	NN	O	O
was	NN	O	O
detected	NN	O	O
.	NN	O	O

Dose	NN	O	O
intensity	NN	O	O
did	NN	O	O
not	NN	O	O
add	NN	O	O
information	NN	O	O
to	NN	O	O
models	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
14	NN	O	O
of	NN	O	O
151	NN	O	O
(	NN	O	O
9.3%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
DFMO	NN	O	B-Chemical
plus	NN	O	O
sulindac	NN	O	B-Chemical
group	NN	O	O
and	NN	O	O
4	NN	O	O
of	NN	O	O
139	NN	O	O
(	NN	O	O
2.9%	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
who	NN	O	O
experienced	NN	O	O
at	NN	O	O
least	NN	O	O
15	NN	O	O
dB	NN	O	O
hearing	NN	O	O
reduction	NN	O	O
from	NN	O	O
baseline	NN	O	O
in	NN	O	O
2	NN	O	O
or	NN	O	O
more	NN	O	O
consecutive	NN	O	O
frequencies	NN	O	O
across	NN	O	O
the	NN	O	O
entire	NN	O	O
range	NN	O	O
tested	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
0.02	NN	O	O
)	NN	O	O
.	NN	O	O

Follow	NN	O	O
-	NN	O	O
up	NN	O	O
air	NN	O	O
conduction	NN	O	O
done	NN	O	O
at	NN	O	O
least	NN	O	O
6	NN	O	O
months	NN	O	O
after	NN	O	O
end	NN	O	O
of	NN	O	O
treatment	NN	O	O
showed	NN	O	O
an	NN	O	O
adjusted	NN	O	O
mean	NN	O	O
difference	NN	O	O
in	NN	O	O
hearing	NN	O	O
thresholds	NN	O	O
of	NN	O	O
1.08	NN	O	O
dB	NN	O	O
(	NN	O	O
-	NN	O	O
0.81	NN	O	O
to	NN	O	O
2.96	NN	O	O
dB	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0.26	NN	O	O
)	NN	O	O
between	NN	O	O
treatment	NN	O	O
arms	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
in	NN	O	O
the	NN	O	O
proportion	NN	O	O
of	NN	O	O
subjects	NN	O	O
in	NN	O	O
the	NN	O	O
DFMO	NN	O	B-Chemical
plus	NN	O	O
sulindac	NN	O	B-Chemical
group	NN	O	O
who	NN	O	O
experienced	NN	O	O
clinically	NN	O	O
significant	NN	O	O
hearing	NN	O	B-Disease
loss	NN	O	I-Disease
compared	NN	O	O
with	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
.	NN	O	O

The	NN	O	O
estimated	NN	O	O
attributable	NN	O	O
risk	NN	O	O
of	NN	O	O
ototoxicity	NN	O	B-Disease
from	NN	O	O
exposure	NN	O	O
to	NN	O	O
the	NN	O	O
drug	NN	O	O
is	NN	O	O
8.4%	NN	O	O
(	NN	O	O
95%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
-	NN	O	O
2.0%	NN	O	O
to	NN	O	O
18.8%	NN	O	O
;	NN	O	O
P	NN	O	O
=	NN	O	O
0.12	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
a	NN	O	O
<2	NN	O	O
dB	NN	O	O
difference	NN	O	O
in	NN	O	O
mean	NN	O	O
threshold	NN	O	O
for	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
DFMO	NN	O	B-Chemical
plus	NN	O	O
sulindac	NN	O	B-Chemical
compared	NN	O	O
with	NN	O	O
those	NN	O	O
treated	NN	O	O
with	NN	O	O
placebo	NN	O	O
.	NN	O	O


-DOCSTART- (18239197)

Increased	NN	O	O
mental	NN	O	B-Disease
slowing	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
the	NN	O	O
APOE	NN	O	O
epsilon4	NN	O	O
allele	NN	O	O
after	NN	O	O
trihexyphenidyl	NN	O	B-Chemical
oral	NN	O	O
anticholinergic	NN	O	O
challenge	NN	O	O
in	NN	O	O
healthy	NN	O	O
elderly	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
The	NN	O	O
objectives	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
were	NN	O	O
to	NN	O	O
examine	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
APOE	NN	O	O
epsilon4	NN	O	O
and	NN	O	O
subjective	NN	O	O
effects	NN	O	O
of	NN	O	O
trihexyphenidyl	NN	O	B-Chemical
on	NN	O	O
measures	NN	O	O
reflecting	NN	O	O
sedation	NN	O	O
and	NN	O	O
confusion	NN	O	B-Disease
and	NN	O	O
to	NN	O	O
investigate	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
trihexyphenidyl	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
subjective	NN	O	O
effects	NN	O	O
and	NN	O	O
objective	NN	O	O
memory	NN	O	O
performance	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
study	NN	O	O
comprised	NN	O	O
24	NN	O	O
cognitively	NN	O	O
intact	NN	O	O
,	NN	O	O
health	NN	O	O
elderly	NN	O	O
adults	NN	O	O
(	NN	O	O
12	NN	O	O
APOE	NN	O	O
epsilon4	NN	O	O
carriers	NN	O	O
)	NN	O	O
at	NN	O	O
an	NN	O	O
outpatient	NN	O	O
geriatric	NN	O	O
psychiatry	NN	O	O
research	NN	O	O
clinic	NN	O	O
.	NN	O	O

This	NN	O	O
was	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
,	NN	O	O
three	NN	O	O
-	NN	O	O
way	NN	O	O
,	NN	O	O
crossover	NN	O	O
experimental	NN	O	O
design	NN	O	O
.	NN	O	O

All	NN	O	O
participants	NN	O	O
received	NN	O	O
1.0	NN	O	O
mg	NN	O	O
or	NN	O	O
2.0	NN	O	O
mg	NN	O	O
trihexyphenidyl	NN	O	B-Chemical
or	NN	O	O
placebo	NN	O	O
administered	NN	O	O
in	NN	O	O
counterbalanced	NN	O	O
sequences	NN	O	O
over	NN	O	O
a	NN	O	O
period	NN	O	O
of	NN	O	O
three	NN	O	O
consecutive	NN	O	O
weeks	NN	O	O
.	NN	O	O

Bond	NN	O	O
and	NN	O	O
Lader	NN	O	O
'	NN	O	O
s	NN	O	O
visual	NN	O	O
analog	NN	O	O
scales	NN	O	O
and	NN	O	O
alternate	NN	O	O
versions	NN	O	O
of	NN	O	O
the	NN	O	O
Buschke	NN	O	O
Selective	NN	O	O
Reminding	NN	O	O
Test	NN	O	O
were	NN	O	O
administered	NN	O	O
in	NN	O	O
a	NN	O	O
repeated	NN	O	O
measures	NN	O	O
design	NN	O	O
at	NN	O	O
baseline	NN	O	O
,	NN	O	O
1	NN	O	O
,	NN	O	O
2.5	NN	O	O
,	NN	O	O
and	NN	O	O
5	NN	O	O
hours	NN	O	O
postdrug	NN	O	O
administration	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
2.0	NN	O	O
-	NN	O	O
mg	NN	O	O
oral	NN	O	O
dose	NN	O	O
of	NN	O	O
trihexyphenidyl	NN	O	B-Chemical
resulted	NN	O	O
in	NN	O	O
increased	NN	O	O
subjective	NN	O	O
ratings	NN	O	O
of	NN	O	O
mental	NN	O	B-Disease
slowness	NN	O	I-Disease
in	NN	O	O
carriers	NN	O	O
of	NN	O	O
the	NN	O	O
APOE	NN	O	O
epsilon4	NN	O	O
allele	NN	O	O
only	NN	O	O
.	NN	O	O

Drug	NN	O	O
effects	NN	O	O
as	NN	O	O
determined	NN	O	O
by	NN	O	O
difference	NN	O	O
scores	NN	O	O
between	NN	O	O
2.0	NN	O	O
mg	NN	O	O
trihexyphenidyl	NN	O	B-Chemical
and	NN	O	O
placebo	NN	O	O
on	NN	O	O
ratings	NN	O	O
of	NN	O	O
mental	NN	O	B-Disease
slowness	NN	O	I-Disease
significantly	NN	O	O
correlated	NN	O	O
with	NN	O	O
total	NN	O	O
and	NN	O	O
delayed	NN	O	O
recall	NN	O	O
on	NN	O	O
the	NN	O	O
Buschke	NN	O	O
Selective	NN	O	O
Reminding	NN	O	O
Test	NN	O	O
in	NN	O	O
carriers	NN	O	O
of	NN	O	O
the	NN	O	O
APOE	NN	O	O
epsilon4	NN	O	O
allele	NN	O	O
only	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
no	NN	O	O
significant	NN	O	O
effects	NN	O	O
were	NN	O	O
found	NN	O	O
with	NN	O	O
other	NN	O	O
visual	NN	O	O
analog	NN	O	O
scales	NN	O	O
reflecting	NN	O	O
subjective	NN	O	O
sedation	NN	O	O
and	NN	O	O
clear	NN	O	O
-	NN	O	O
headedness	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
The	NN	O	O
epsilon4	NN	O	O
allele	NN	O	O
in	NN	O	O
healthy	NN	O	O
elderly	NN	O	O
was	NN	O	O
associated	NN	O	O
with	NN	O	O
increased	NN	O	O
subjective	NN	O	O
mental	NN	O	B-Disease
slowing	NN	O	I-Disease
after	NN	O	O
trihexyphenidyl	NN	O	B-Chemical
anticholinergic	NN	O	O
challenge	NN	O	O
.	NN	O	O


-DOCSTART- (17194457)

Behavioral	NN	O	O
effects	NN	O	O
of	NN	O	O
pubertal	NN	O	O
anabolic	NN	O	O
androgenic	NN	O	O
steroid	NN	O	B-Chemical
exposure	NN	O	O
in	NN	O	O
male	NN	O	O
rats	NN	O	O
with	NN	O	O
low	NN	O	O
serotonin	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
goal	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
interactive	NN	O	O
effects	NN	O	O
of	NN	O	O
chronic	NN	O	O
anabolic	NN	O	O
androgenic	NN	O	O
steroid	NN	O	B-Chemical
(	NN	O	O
AAS	NN	O	O
)	NN	O	O
exposure	NN	O	O
and	NN	O	O
brain	NN	O	O
serotonin	NN	O	B-Chemical
(	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxytryptamine	NN	O	I-Chemical
,	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
)	NN	O	O
depletion	NN	O	O
on	NN	O	O
behavior	NN	O	O
of	NN	O	O
pubertal	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

Serotonin	NN	O	B-Chemical
was	NN	O	O
depleted	NN	O	O
beginning	NN	O	O
on	NN	O	O
postnatal	NN	O	O
day	NN	O	O
26	NN	O	O
with	NN	O	O
parachlorophenylalanine	NN	O	B-Chemical
(	NN	O	O
PCPA	NN	O	B-Chemical
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
every	NN	O	O
other	NN	O	O
day	NN	O	O
)	NN	O	O
;	NN	O	O
controls	NN	O	O
received	NN	O	O
saline	NN	O	O
.	NN	O	O

At	NN	O	O
puberty	NN	O	O
(	NN	O	O
P40	NN	O	O
)	NN	O	O
,	NN	O	O
half	NN	O	O
the	NN	O	O
PCPA	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
and	NN	O	O
half	NN	O	O
the	NN	O	O
saline	NN	O	O
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
began	NN	O	O
treatment	NN	O	O
with	NN	O	O
testosterone	NN	O	B-Chemical
(	NN	O	O
T	NN	O	B-Chemical
,	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
5	NN	O	O
days	NN	O	O
/	NN	O	O
week	NN	O	O
)	NN	O	O
.	NN	O	O

Behavioral	NN	O	O
measures	NN	O	O
included	NN	O	O
locomotion	NN	O	O
,	NN	O	O
irritability	NN	O	B-Disease
,	NN	O	O
copulation	NN	O	O
,	NN	O	O
partner	NN	O	O
preference	NN	O	O
,	NN	O	O
and	NN	O	O
aggression	NN	O	B-Disease
.	NN	O	O

Animals	NN	O	O
were	NN	O	O
tested	NN	O	O
for	NN	O	O
aggression	NN	O	B-Disease
in	NN	O	O
their	NN	O	O
home	NN	O	O
cage	NN	O	O
,	NN	O	O
both	NN	O	O
with	NN	O	O
and	NN	O	O
without	NN	O	O
physical	NN	O	O
provocation	NN	O	O
(	NN	O	O
mild	NN	O	O
tail	NN	O	O
pinch	NN	O	O
)	NN	O	O
.	NN	O	O

Brain	NN	O	O
levels	NN	O	O
of	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
and	NN	O	O
its	NN	O	O
metabolite	NN	O	O
,	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxyindoleacetic	NN	O	I-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HIAA	NN	O	I-Chemical
)	NN	O	O
,	NN	O	O
were	NN	O	O
determined	NN	O	O
using	NN	O	O
HPLC	NN	O	O
.	NN	O	O

PCPA	NN	O	B-Chemical
significantly	NN	O	O
and	NN	O	O
substantially	NN	O	O
depleted	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
and	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HIAA	NN	O	I-Chemical
in	NN	O	O
all	NN	O	O
brain	NN	O	O
regions	NN	O	O
examined	NN	O	O
.	NN	O	O

Chronic	NN	O	O
T	NN	O	B-Chemical
treatment	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
and	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HIAA	NN	O	I-Chemical
in	NN	O	O
certain	NN	O	O
brain	NN	O	O
areas	NN	O	O
,	NN	O	O
but	NN	O	O
to	NN	O	O
a	NN	O	O
much	NN	O	O
lesser	NN	O	O
extent	NN	O	O
than	NN	O	O
PCPA	NN	O	B-Chemical
.	NN	O	O

Chronic	NN	O	O
exposure	NN	O	O
to	NN	O	O
PCPA	NN	O	B-Chemical
alone	NN	O	O
significantly	NN	O	O
decreased	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
and	NN	O	O
increased	NN	O	O
irritability	NN	O	B-Disease
but	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
sexual	NN	O	O
behavior	NN	O	O
,	NN	O	O
partner	NN	O	O
preference	NN	O	O
,	NN	O	O
or	NN	O	O
aggression	NN	O	B-Disease
.	NN	O	O

T	NN	O	B-Chemical
alone	NN	O	O
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
locomotion	NN	O	O
,	NN	O	O
irritability	NN	O	B-Disease
,	NN	O	O
or	NN	O	O
sexual	NN	O	O
behavior	NN	O	O
but	NN	O	O
increased	NN	O	O
partner	NN	O	O
preference	NN	O	O
and	NN	O	O
aggression	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
most	NN	O	O
striking	NN	O	O
effect	NN	O	O
of	NN	O	O
combining	NN	O	O
T	NN	O	B-Chemical
+PCPA	NN	O	B-Chemical
was	NN	O	O
a	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
attack	NN	O	O
frequency	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
a	NN	O	O
significant	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
latency	NN	O	O
to	NN	O	O
attack	NN	O	O
,	NN	O	O
particularly	NN	O	O
following	NN	O	O
physical	NN	O	O
provocation	NN	O	O
.	NN	O	O

Based	NN	O	O
on	NN	O	O
these	NN	O	O
data	NN	O	O
,	NN	O	O
it	NN	O	O
can	NN	O	O
be	NN	O	O
speculated	NN	O	O
that	NN	O	O
pubertal	NN	O	O
AAS	NN	O	O
users	NN	O	O
with	NN	O	O
low	NN	O	O
central	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
may	NN	O	O
be	NN	O	O
especially	NN	O	O
prone	NN	O	O
to	NN	O	O
exhibit	NN	O	O
aggressive	NN	O	B-Disease
behavior	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (16132524)

Intracavitary	NN	O	O
chemotherapy	NN	O	O
(	NN	O	O
paclitaxel	NN	O	B-Chemical
/	NN	O	O
carboplatin	NN	O	B-Chemical
liquid	NN	O	O
crystalline	NN	O	O
cubic	NN	O	O
phases	NN	O	O
)	NN	O	O
for	NN	O	O
recurrent	NN	O	O
glioblastoma	NN	O	B-Disease
-	NN	O	O
-	NN	O	O
clinical	NN	O	O
observations	NN	O	O
.	NN	O	O

Human	NN	O	O
malignant	NN	O	O
brain	NN	O	B-Disease
tumors	NN	O	I-Disease
have	NN	O	O
a	NN	O	O
poor	NN	O	O
prognosis	NN	O	O
in	NN	O	O
spite	NN	O	O
of	NN	O	O
surgery	NN	O	O
and	NN	O	O
radiation	NN	O	O
therapy	NN	O	O
.	NN	O	O

Cubic	NN	O	O
phases	NN	O	O
consist	NN	O	O
of	NN	O	O
curved	NN	O	O
biocontinuous	NN	O	O
lipid	NN	O	O
bilayers	NN	O	O
,	NN	O	O
separating	NN	O	O
two	NN	O	O
congruent	NN	O	O
networks	NN	O	O
of	NN	O	O
water	NN	O	O
channels	NN	O	O
.	NN	O	O

Used	NN	O	O
as	NN	O	O
a	NN	O	O
host	NN	O	O
for	NN	O	O
cytotoxic	NN	O	O
drugs	NN	O	O
,	NN	O	O
the	NN	O	O
gel	NN	O	O
-	NN	O	O
like	NN	O	O
matrix	NN	O	O
can	NN	O	O
easily	NN	O	O
be	NN	O	O
applied	NN	O	O
to	NN	O	O
the	NN	O	O
walls	NN	O	O
of	NN	O	O
a	NN	O	O
surgical	NN	O	O
resection	NN	O	O
cavity	NN	O	O
.	NN	O	O

For	NN	O	O
human	NN	O	O
glioblastoma	NN	O	B-Disease
recurrences	NN	O	O
,	NN	O	O
the	NN	O	O
feasibility	NN	O	O
,	NN	O	O
safety	NN	O	O
,	NN	O	O
and	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
surgical	NN	O	O
intracavitary	NN	O	O
application	NN	O	O
of	NN	O	O
paclitaxel	NN	O	B-Chemical
and	NN	O	O
carboplatin	NN	O	B-Chemical
encapsulated	NN	O	O
by	NN	O	O
liquid	NN	O	O
crystalline	NN	O	O
cubic	NN	O	O
phases	NN	O	O
are	NN	O	O
examined	NN	O	O
in	NN	O	O
a	NN	O	O
pilot	NN	O	O
study	NN	O	O
.	NN	O	O

A	NN	O	O
total	NN	O	O
of	NN	O	O
12	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
recurrence	NN	O	O
of	NN	O	O
a	NN	O	O
glioblastoma	NN	O	B-Disease
multiforme	NN	O	O
underwent	NN	O	O
re	NN	O	O
-	NN	O	O
resection	NN	O	O
and	NN	O	O
received	NN	O	O
an	NN	O	O
intracavitary	NN	O	O
application	NN	O	O
of	NN	O	O
paclitaxel	NN	O	B-Chemical
and	NN	O	O
carboplatin	NN	O	B-Chemical
cubic	NN	O	O
phases	NN	O	O
in	NN	O	O
different	NN	O	O
dosages	NN	O	O
.	NN	O	O

Six	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
received	NN	O	O
more	NN	O	O
than	NN	O	O
15	NN	O	O
mg	NN	O	O
paclitaxel	NN	O	B-Chemical
and	NN	O	O
suffered	NN	O	O
from	NN	O	O
moderate	NN	O	O
to	NN	O	O
severe	NN	O	O
brain	NN	O	B-Disease
edema	NN	O	I-Disease
,	NN	O	O
while	NN	O	O
the	NN	O	O
remaining	NN	O	O
patients	NN	O	O
received	NN	O	O
only	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
15	NN	O	O
mg	NN	O	O
paclitaxel	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
the	NN	O	O
latter	NN	O	O
group	NN	O	O
,	NN	O	O
brain	NN	O	B-Disease
edema	NN	O	I-Disease
was	NN	O	O
markedly	NN	O	O
reduced	NN	O	O
and	NN	O	O
dealt	NN	O	O
medically	NN	O	O
.	NN	O	O

Intracavitary	NN	O	O
chemotherapy	NN	O	O
in	NN	O	O
recurrent	NN	O	O
glioblastoma	NN	O	B-Disease
using	NN	O	O
cubic	NN	O	O
phases	NN	O	O
is	NN	O	O
feasible	NN	O	O
and	NN	O	O
safe	NN	O	O
,	NN	O	O
yet	NN	O	O
the	NN	O	O
clinical	NN	O	O
benefit	NN	O	O
remains	NN	O	O
to	NN	O	O
be	NN	O	O
examined	NN	O	O
in	NN	O	O
a	NN	O	O
clinical	NN	O	O
phase	NN	O	O
II	NN	O	O
study	NN	O	O
.	NN	O	O


-DOCSTART- (12907924)

Methylphenidate	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
obsessive	NN	O	B-Disease
-	NN	O	I-Disease
compulsive	NN	O	I-Disease
symptoms	NN	O	I-Disease
in	NN	O	O
an	NN	O	O
elderly	NN	O	O
man	NN	O	O
.	NN	O	O

An	NN	O	O
82	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
treatment	NN	O	B-Disease
-	NN	O	I-Disease
resistant	NN	O	I-Disease
depression	NN	O	I-Disease
and	NN	O	O
early	NN	O	O
Alzheimer	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
was	NN	O	O
started	NN	O	O
on	NN	O	O
methylphenidate	NN	O	B-Chemical
.	NN	O	O

Significant	NN	O	O
obsessive	NN	O	B-Disease
-	NN	O	I-Disease
compulsive	NN	O	I-Disease
behavior	NN	O	I-Disease
ensued	NN	O	O
but	NN	O	O
diminished	NN	O	O
over	NN	O	O
several	NN	O	O
weeks	NN	O	O
when	NN	O	O
methylphenidate	NN	O	B-Chemical
was	NN	O	O
replaced	NN	O	O
by	NN	O	O
fluvoxamine	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
patient	NN	O	O
had	NN	O	O
no	NN	O	O
prior	NN	O	O
psychiatric	NN	O	B-Disease
history	NN	O	O
,	NN	O	O
but	NN	O	O
he	NN	O	O
had	NN	O	O
a	NN	O	O
sister	NN	O	O
with	NN	O	O
obsessive	NN	O	B-Disease
-	NN	O	I-Disease
compulsive	NN	O	I-Disease
disorder	NN	O	I-Disease
.	NN	O	O

It	NN	O	O
appears	NN	O	O
that	NN	O	O
methylphenidate	NN	O	B-Chemical
precipitated	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
pathological	NN	O	O
behavior	NN	O	O
.	NN	O	O


-DOCSTART- (12139551)

Cardiac	NN	O	B-Disease
arrest	NN	O	I-Disease
after	NN	O	O
intravenous	NN	O	O
metoclopramide	NN	O	B-Chemical
-	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
five	NN	O	O
repeated	NN	O	O
injections	NN	O	O
of	NN	O	O
metoclopramide	NN	O	B-Chemical
causing	NN	O	O
five	NN	O	O
episodes	NN	O	O
of	NN	O	O
cardiac	NN	O	B-Disease
arrest	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
patient	NN	O	O
where	NN	O	O
intravenous	NN	O	O
injection	NN	O	O
of	NN	O	O
metoclopramide	NN	O	B-Chemical
was	NN	O	O
immediately	NN	O	O
followed	NN	O	O
by	NN	O	O
asystole	NN	O	B-Disease
repeatedly	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
received	NN	O	O
metoclopramide	NN	O	B-Chemical
10	NN	O	O
mg	NN	O	O
i.v.	NN	O	O
five	NN	O	O
times	NN	O	O
during	NN	O	O
48	NN	O	O
h	NN	O	O
.	NN	O	O

After	NN	O	O
interviewing	NN	O	O
the	NN	O	O
attending	NN	O	O
nurses	NN	O	O
and	NN	O	O
reviewing	NN	O	O
the	NN	O	O
written	NN	O	O
documentation	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
clear	NN	O	O
that	NN	O	O
every	NN	O	O
administration	NN	O	O
of	NN	O	O
metoclopramide	NN	O	B-Chemical
was	NN	O	O
immediately	NN	O	O
(	NN	O	O
within	NN	O	O
s	NN	O	O
)	NN	O	O
followed	NN	O	O
by	NN	O	O
asystole	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
asystole	NN	O	B-Disease
lasted	NN	O	O
15	NN	O	O
-	NN	O	O
30	NN	O	O
s	NN	O	O
on	NN	O	O
four	NN	O	O
occasions	NN	O	O
,	NN	O	O
on	NN	O	O
one	NN	O	O
occasion	NN	O	O
it	NN	O	O
lasted	NN	O	O
2	NN	O	O
min	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
received	NN	O	O
atropine	NN	O	B-Chemical
0.5	NN	O	O
-	NN	O	O
1	NN	O	O
mg	NN	O	O
and	NN	O	O
chest	NN	O	O
compressions	NN	O	O
,	NN	O	O
before	NN	O	O
sinus	NN	O	O
rhythm	NN	O	O
again	NN	O	O
took	NN	O	O
over	NN	O	O
.	NN	O	O

We	NN	O	O
interpret	NN	O	O
this	NN	O	O
as	NN	O	O
episodes	NN	O	O
of	NN	O	O
cardiac	NN	O	B-Disease
arrest	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
metoclopramide	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
rapid	NN	O	O
injection	NN	O	O
via	NN	O	O
the	NN	O	O
central	NN	O	O
venous	NN	O	O
route	NN	O	O
and	NN	O	O
the	NN	O	O
concomitant	NN	O	O
tapering	NN	O	O
of	NN	O	O
dopamine	NN	O	B-Chemical
infusion	NN	O	O
might	NN	O	O
have	NN	O	O
contributed	NN	O	O
in	NN	O	O
precipitating	NN	O	O
the	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reaction	NN	O	O
.	NN	O	O


-DOCSTART- (10411803)

Severe	NN	O	O
immune	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
prophylactic	NN	O	O
use	NN	O	O
of	NN	O	O
cefotetan	NN	O	B-Chemical
in	NN	O	O
obstetric	NN	O	O
and	NN	O	O
gynecologic	NN	O	O
procedures	NN	O	O
.	NN	O	O

Second	NN	O	O
-	NN	O	O
and	NN	O	O
third	NN	O	O
-	NN	O	O
generation	NN	O	O
cephalosporins	NN	O	B-Chemical
,	NN	O	O
especially	NN	O	O
cefotetan	NN	O	B-Chemical
,	NN	O	O
are	NN	O	O
increasingly	NN	O	O
associated	NN	O	O
with	NN	O	O
severe	NN	O	O
,	NN	O	O
sometimes	NN	O	O
fatal	NN	O	O
immune	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
noticed	NN	O	O
that	NN	O	O
10	NN	O	O
of	NN	O	O
our	NN	O	O
35	NN	O	O
cases	NN	O	O
of	NN	O	O
cefotetan	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hemolytic	NN	O	B-Disease
anemias	NN	O	I-Disease
were	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
received	NN	O	O
cefotetan	NN	O	B-Chemical
prophylactically	NN	O	O
for	NN	O	O
obstetric	NN	O	O
and	NN	O	O
gynecologic	NN	O	O
procedures	NN	O	O
.	NN	O	O

Eight	NN	O	O
of	NN	O	O
these	NN	O	O
cases	NN	O	O
of	NN	O	O
severe	NN	O	O
immune	NN	O	O
hemolytic	NN	O	B-Disease
anemia	NN	O	I-Disease
are	NN	O	O
described	NN	O	O
.	NN	O	O


-DOCSTART- (10225068)

Cauda	NN	O	B-Disease
equina	NN	O	I-Disease
syndrome	NN	O	I-Disease
after	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
hyperbaric	NN	O	O
5%	NN	O	O
lignocaine	NN	O	B-Chemical
:	NN	O	O
a	NN	O	O
review	NN	O	O
of	NN	O	O
six	NN	O	O
cases	NN	O	O
of	NN	O	O
cauda	NN	O	B-Disease
equina	NN	O	I-Disease
syndrome	NN	O	I-Disease
reported	NN	O	O
to	NN	O	O
the	NN	O	O
Swedish	NN	O	O
Pharmaceutical	NN	O	O
Insurance	NN	O	O
1993	NN	O	O
-	NN	O	O
1997	NN	O	O
.	NN	O	O

Six	NN	O	O
cases	NN	O	O
of	NN	O	O
cauda	NN	O	B-Disease
equina	NN	O	I-Disease
syndrome	NN	O	I-Disease
with	NN	O	O
varying	NN	O	O
severity	NN	O	O
were	NN	O	O
reported	NN	O	O
to	NN	O	O
the	NN	O	O
Swedish	NN	O	O
Pharmaceutical	NN	O	O
Insurance	NN	O	O
during	NN	O	O
the	NN	O	O
period	NN	O	O
1993	NN	O	O
-	NN	O	O
1997	NN	O	O
.	NN	O	O

All	NN	O	O
were	NN	O	O
associated	NN	O	O
with	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
using	NN	O	O
hyperbaric	NN	O	O
5%	NN	O	O
lignocaine	NN	O	B-Chemical
.	NN	O	O

Five	NN	O	O
cases	NN	O	O
had	NN	O	O
single	NN	O	O
-	NN	O	O
shot	NN	O	O
spinal	NN	O	O
anaesthesia	NN	O	O
and	NN	O	O
one	NN	O	O
had	NN	O	O
a	NN	O	O
repeat	NN	O	O
spinal	NN	O	O
anaesthetic	NN	O	O
due	NN	O	O
to	NN	O	O
inadequate	NN	O	O
block	NN	O	O
.	NN	O	O

The	NN	O	O
dose	NN	O	O
of	NN	O	O
hyperbaric	NN	O	O
5%	NN	O	O
lignocaine	NN	O	B-Chemical
administered	NN	O	O
ranged	NN	O	O
from	NN	O	O
60	NN	O	O
to	NN	O	O
120	NN	O	O
mg	NN	O	O
.	NN	O	O

Three	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
were	NN	O	O
most	NN	O	O
likely	NN	O	O
caused	NN	O	O
by	NN	O	O
direct	NN	O	O
neurotoxicity	NN	O	B-Disease
of	NN	O	O
hyperbaric	NN	O	O
5%	NN	O	O
lignocaine	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
the	NN	O	O
other	NN	O	O
3	NN	O	O
cases	NN	O	O
,	NN	O	O
direct	NN	O	O
neurotoxicity	NN	O	B-Disease
was	NN	O	O
also	NN	O	O
probable	NN	O	O
,	NN	O	O
but	NN	O	O
unfortunately	NN	O	O
radiological	NN	O	O
investigations	NN	O	O
were	NN	O	O
not	NN	O	O
done	NN	O	O
to	NN	O	O
definitely	NN	O	O
exclude	NN	O	O
a	NN	O	O
compressive	NN	O	O
aetiology	NN	O	O
.	NN	O	O

All	NN	O	O
cases	NN	O	O
sustained	NN	O	O
permanent	NN	O	O
neurological	NN	O	B-Disease
deficits	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
recommend	NN	O	O
that	NN	O	O
hyperbaric	NN	O	O
lignocaine	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
administered	NN	O	O
in	NN	O	O
concentrations	NN	O	O
not	NN	O	O
greater	NN	O	O
than	NN	O	O
2%	NN	O	O
and	NN	O	O
at	NN	O	O
a	NN	O	O
total	NN	O	O
dose	NN	O	O
preferably	NN	O	O
not	NN	O	O
exceeding	NN	O	O
60	NN	O	O
mg	NN	O	O
.	NN	O	O


-DOCSTART- (9549528)

Cortical	NN	O	O
motor	NN	O	O
overactivation	NN	O	O
in	NN	O	O
parkinsonian	NN	O	B-Disease
patients	NN	O	O
with	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
peak	NN	O	O
-	NN	O	O
dose	NN	O	O
dyskinesia	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
have	NN	O	O
studied	NN	O	O
the	NN	O	O
regional	NN	O	O
cerebral	NN	O	O
blood	NN	O	O
flow	NN	O	O
(	NN	O	O
rCBF	NN	O	O
)	NN	O	O
changes	NN	O	O
induced	NN	O	O
by	NN	O	O
the	NN	O	O
execution	NN	O	O
of	NN	O	O
a	NN	O	O
finger	NN	O	O
-	NN	O	O
to	NN	O	O
-	NN	O	O
thumb	NN	O	O
opposition	NN	O	O
motor	NN	O	O
task	NN	O	O
in	NN	O	O
the	NN	O	O
supplementary	NN	O	O
and	NN	O	O
primary	NN	O	O
motor	NN	O	O
cortex	NN	O	O
of	NN	O	O
two	NN	O	O
groups	NN	O	O
of	NN	O	O
parkinsonian	NN	O	B-Disease
patients	NN	O	O
on	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
medication	NN	O	O
,	NN	O	O
the	NN	O	O
first	NN	O	O
one	NN	O	O
without	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
induced	NN	O	O
dyskinesia	NN	O	B-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
23	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
other	NN	O	O
with	NN	O	O
moderate	NN	O	O
peak	NN	O	O
-	NN	O	O
dose	NN	O	O
dyskinesia	NN	O	B-Disease
(	NN	O	O
n	NN	O	O
=	NN	O	O
15	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
of	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
14	NN	O	O
normal	NN	O	O
subjects	NN	O	O
.	NN	O	O

Single	NN	O	O
photon	NN	O	O
emission	NN	O	O
tomography	NN	O	O
with	NN	O	O
i.v.	NN	O	O
133Xe	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
measure	NN	O	O
the	NN	O	O
rCBF	NN	O	O
changes	NN	O	O
.	NN	O	O

The	NN	O	O
dyskinetic	NN	O	B-Disease
parkinsonian	NN	O	B-Disease
patients	NN	O	O
exhibited	NN	O	O
a	NN	O	O
pattern	NN	O	O
of	NN	O	O
response	NN	O	O
which	NN	O	O
was	NN	O	O
markedly	NN	O	O
different	NN	O	O
from	NN	O	O
those	NN	O	O
of	NN	O	O
the	NN	O	O
normal	NN	O	O
subjects	NN	O	O
and	NN	O	O
non	NN	O	O
-	NN	O	O
dyskinetic	NN	O	B-Disease
parkinsonian	NN	O	B-Disease
patients	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
significant	NN	O	O
overactivation	NN	O	O
in	NN	O	O
the	NN	O	O
supplementary	NN	O	O
motor	NN	O	O
area	NN	O	O
and	NN	O	O
the	NN	O	O
ipsi	NN	O	O
-	NN	O	O
and	NN	O	O
contralateral	NN	O	O
primary	NN	O	O
motor	NN	O	O
areas	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
are	NN	O	O
compatible	NN	O	O
with	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
an	NN	O	O
hyperkinetic	NN	O	B-Disease
abnormal	NN	O	B-Disease
involuntary	NN	O	I-Disease
movement	NN	O	I-Disease
,	NN	O	O
like	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
dopa	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
peak	NN	O	O
dose	NN	O	O
dyskinesia	NN	O	B-Disease
,	NN	O	O
is	NN	O	O
due	NN	O	O
to	NN	O	O
a	NN	O	O
disinhibition	NN	O	O
of	NN	O	O
the	NN	O	O
primary	NN	O	O
and	NN	O	O
associated	NN	O	O
motor	NN	O	O
cortex	NN	O	O
secondary	NN	O	O
to	NN	O	O
an	NN	O	O
excessive	NN	O	O
outflow	NN	O	O
of	NN	O	O
the	NN	O	O
pallidothalamocortical	NN	O	O
motor	NN	O	O
loop	NN	O	O
.	NN	O	O


-DOCSTART- (7843916)

Dexamethasone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
ocular	NN	O	B-Disease
hypertension	NN	O	I-Disease
in	NN	O	O
perfusion	NN	O	O
-	NN	O	O
cultured	NN	O	O
human	NN	O	O
eyes	NN	O	O
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
Glucocorticoid	NN	O	O
administration	NN	O	O
can	NN	O	O
lead	NN	O	O
to	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
ocular	NN	O	B-Disease
hypertension	NN	O	I-Disease
and	NN	O	O
corticosteroid	NN	O	B-Disease
glaucoma	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
subset	NN	O	O
of	NN	O	O
the	NN	O	O
population	NN	O	O
through	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
aqueous	NN	O	O
humor	NN	O	O
outflow	NN	O	O
facility	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
determine	NN	O	O
whether	NN	O	O
glucocorticoid	NN	O	O
treatment	NN	O	O
can	NN	O	O
directly	NN	O	O
affect	NN	O	O
the	NN	O	O
outflow	NN	O	O
facility	NN	O	O
of	NN	O	O
isolated	NN	O	O
,	NN	O	O
perfusion	NN	O	O
-	NN	O	O
cultured	NN	O	O
human	NN	O	O
eyes	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
anterior	NN	O	O
segments	NN	O	O
of	NN	O	O
human	NN	O	O
donor	NN	O	O
eyes	NN	O	O
from	NN	O	O
regional	NN	O	O
eye	NN	O	O
banks	NN	O	O
were	NN	O	O
placed	NN	O	O
in	NN	O	O
a	NN	O	O
constant	NN	O	O
flow	NN	O	O
,	NN	O	O
variable	NN	O	O
pressure	NN	O	O
perfusion	NN	O	O
culture	NN	O	O
system	NN	O	O
.	NN	O	O

Paired	NN	O	O
eyes	NN	O	O
were	NN	O	O
perfused	NN	O	O
in	NN	O	O
serum	NN	O	O
-	NN	O	O
free	NN	O	O
media	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
10	NN	O	O
(	NN	O	O
-	NN	O	O
7	NN	O	O
)	NN	O	O
M	NN	O	O
dexamethasone	NN	O	B-Chemical
for	NN	O	O
12	NN	O	O
days	NN	O	O
.	NN	O	O

Intraocular	NN	O	O
pressure	NN	O	O
was	NN	O	O
monitored	NN	O	O
daily	NN	O	O
.	NN	O	O

After	NN	O	O
incubation	NN	O	O
,	NN	O	O
the	NN	O	O
eyes	NN	O	O
were	NN	O	O
morphologically	NN	O	O
characterized	NN	O	O
by	NN	O	O
light	NN	O	O
microscopy	NN	O	O
,	NN	O	O
transmission	NN	O	O
and	NN	O	O
scanning	NN	O	O
electron	NN	O	O
microscopy	NN	O	O
,	NN	O	O
and	NN	O	O
scanning	NN	O	O
laser	NN	O	O
confocal	NN	O	O
microscopy	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
significant	NN	O	O
increase	NN	O	O
in	NN	O	O
intraocular	NN	O	O
pressure	NN	O	O
developed	NN	O	O
in	NN	O	O
13	NN	O	O
of	NN	O	O
the	NN	O	O
44	NN	O	O
pairs	NN	O	O
of	NN	O	O
eyes	NN	O	O
perfused	NN	O	O
with	NN	O	O
dexamethasone	NN	O	B-Chemical
with	NN	O	O
an	NN	O	O
average	NN	O	O
pressure	NN	O	O
rise	NN	O	O
of	NN	O	O
17.5	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3.8	NN	O	O
mm	NN	O	O
Hg	NN	O	O
after	NN	O	O
12	NN	O	O
days	NN	O	O
of	NN	O	O
dexamethasone	NN	O	B-Chemical
exposure	NN	O	O
.	NN	O	O

The	NN	O	O
contralateral	NN	O	O
control	NN	O	O
eyes	NN	O	O
,	NN	O	O
which	NN	O	O
did	NN	O	O
not	NN	O	O
receive	NN	O	O
dexamethasone	NN	O	B-Chemical
,	NN	O	O
maintained	NN	O	O
a	NN	O	O
stable	NN	O	O
intraocular	NN	O	O
pressure	NN	O	O
during	NN	O	O
the	NN	O	O
same	NN	O	O
period	NN	O	O
.	NN	O	O

The	NN	O	O
outflow	NN	O	O
pathway	NN	O	O
of	NN	O	O
the	NN	O	O
untreated	NN	O	O
eyes	NN	O	O
appeared	NN	O	O
morphologically	NN	O	O
normal	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
dexamethasone	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
hypertensive	NN	O	B-Disease
eyes	NN	O	I-Disease
had	NN	O	O
thickened	NN	O	O
trabecular	NN	O	O
beams	NN	O	O
,	NN	O	O
decreased	NN	O	O
intertrabecular	NN	O	O
spaces	NN	O	O
,	NN	O	O
thickened	NN	O	O
juxtacanalicular	NN	O	O
tissue	NN	O	O
,	NN	O	O
activated	NN	O	O
trabecular	NN	O	O
meshwork	NN	O	O
cells	NN	O	O
,	NN	O	O
and	NN	O	O
increased	NN	O	O
amounts	NN	O	O
of	NN	O	O
amorphogranular	NN	O	O
extracellular	NN	O	O
material	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
the	NN	O	O
juxtacanalicular	NN	O	O
tissue	NN	O	O
and	NN	O	O
beneath	NN	O	O
the	NN	O	O
endothelial	NN	O	O
lining	NN	O	O
of	NN	O	O
the	NN	O	O
canal	NN	O	O
of	NN	O	O
Schlemm	NN	O	O
.	NN	O	O

The	NN	O	O
dexamethasone	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
nonresponder	NN	O	O
eyes	NN	O	O
appeared	NN	O	O
to	NN	O	O
be	NN	O	O
morphologically	NN	O	O
similar	NN	O	O
to	NN	O	O
the	NN	O	O
untreated	NN	O	O
eyes	NN	O	O
,	NN	O	O
although	NN	O	O
several	NN	O	O
subtle	NN	O	O
dexamethasone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
morphologic	NN	O	O
changes	NN	O	O
were	NN	O	O
evident	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Dexamethasone	NN	O	B-Chemical
treatment	NN	O	O
of	NN	O	O
isolated	NN	O	O
,	NN	O	O
perfusion	NN	O	O
-	NN	O	O
cultured	NN	O	O
human	NN	O	O
eyes	NN	O	O
led	NN	O	O
to	NN	O	O
the	NN	O	O
generation	NN	O	O
of	NN	O	O
ocular	NN	O	B-Disease
hypertension	NN	O	I-Disease
in	NN	O	O
approximately	NN	O	O
30%	NN	O	O
of	NN	O	O
the	NN	O	O
dexamethasone	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
eyes	NN	O	O
.	NN	O	O

Steroid	NN	O	B-Chemical
treatment	NN	O	O
resulted	NN	O	O
in	NN	O	O
morphologic	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
trabecular	NN	O	O
meshwork	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
reported	NN	O	O
for	NN	O	O
corticosteroid	NN	O	B-Disease
glaucoma	NN	O	I-Disease
and	NN	O	O
open	NN	O	B-Disease
angle	NN	O	I-Disease
glaucoma	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
system	NN	O	O
may	NN	O	O
provide	NN	O	O
an	NN	O	O
acute	NN	O	O
model	NN	O	O
in	NN	O	O
which	NN	O	O
to	NN	O	O
study	NN	O	O
the	NN	O	O
pathogenic	NN	O	O
mechanisms	NN	O	O
involved	NN	O	O
in	NN	O	O
steroid	NN	O	B-Disease
glaucoma	NN	O	I-Disease
and	NN	O	O
primary	NN	O	B-Disease
open	NN	O	I-Disease
angle	NN	O	I-Disease
glaucoma	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (7803371)

Cognitive	NN	O	B-Disease
deterioration	NN	O	I-Disease
from	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
abuse	NN	O	O
of	NN	O	O
dextromethorphan	NN	O	B-Chemical
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

Dextromethorphan	NN	O	B-Chemical
(	NN	O	O
DM	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
the	NN	O	O
dextrorotatory	NN	O	O
isomer	NN	O	O
of	NN	O	O
3	NN	O	B-Chemical
-	NN	O	I-Chemical
hydroxy	NN	O	I-Chemical
-	NN	O	I-Chemical
N	NN	O	I-Chemical
-	NN	O	I-Chemical
methylmorphinan	NN	O	I-Chemical
,	NN	O	O
is	NN	O	O
the	NN	O	O
main	NN	O	O
ingredient	NN	O	O
in	NN	O	O
a	NN	O	O
number	NN	O	O
of	NN	O	O
widely	NN	O	O
available	NN	O	O
,	NN	O	O
over	NN	O	O
-	NN	O	O
the	NN	O	O
-	NN	O	O
counter	NN	O	O
antitussives	NN	O	O
.	NN	O	O

Initial	NN	O	O
studies	NN	O	O
(	NN	O	O
Bornstein	NN	O	O
1968	NN	O	O
)	NN	O	O
showed	NN	O	O
that	NN	O	O
it	NN	O	O
possessed	NN	O	O
no	NN	O	O
respiratory	NN	O	O
suppressant	NN	O	O
effects	NN	O	O
and	NN	O	O
no	NN	O	O
addiction	NN	O	O
liability	NN	O	O
.	NN	O	O

Subsequently	NN	O	O
,	NN	O	O
however	NN	O	O
,	NN	O	O
several	NN	O	O
articles	NN	O	O
reporting	NN	O	O
abuse	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
have	NN	O	O
appeared	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

The	NN	O	O
drug	NN	O	O
is	NN	O	O
known	NN	O	O
to	NN	O	O
cause	NN	O	O
a	NN	O	O
variety	NN	O	O
of	NN	O	O
acute	NN	O	O
toxic	NN	O	O
effects	NN	O	O
,	NN	O	O
ranging	NN	O	O
from	NN	O	O
nausea	NN	O	B-Disease
,	NN	O	O
restlessness	NN	O	B-Disease
,	NN	O	O
insomnia	NN	O	B-Disease
,	NN	O	O
ataxia	NN	O	B-Disease
,	NN	O	O
slurred	NN	O	O
speech	NN	O	O
and	NN	O	O
nystagmus	NN	O	B-Disease
to	NN	O	O
mood	NN	O	O
changes	NN	O	O
,	NN	O	O
perceptual	NN	O	O
alterations	NN	O	O
,	NN	O	O
inattention	NN	O	O
,	NN	O	O
disorientation	NN	O	O
and	NN	O	O
aggressive	NN	O	B-Disease
behavior	NN	O	I-Disease
(	NN	O	O
Rammer	NN	O	O
et	NN	O	O
al	NN	O	O
1988	NN	O	O
;	NN	O	O
Katona	NN	O	O
and	NN	O	O
Watson	NN	O	O
1986	NN	O	O
;	NN	O	O
Isbell	NN	O	O
and	NN	O	O
Fraser	NN	O	O
1953	NN	O	O
;	NN	O	O
Devlin	NN	O	O
et	NN	O	O
al	NN	O	O
1985	NN	O	O
;	NN	O	O
McCarthy	NN	O	O
1971	NN	O	O
;	NN	O	O
Dodds	NN	O	O
and	NN	O	O
Revai	NN	O	O
1967	NN	O	O
;	NN	O	O
Degkwitz	NN	O	O
1964	NN	O	O
;	NN	O	O
Hildebrand	NN	O	O
et	NN	O	O
al	NN	O	O
1989	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
have	NN	O	O
also	NN	O	O
been	NN	O	O
two	NN	O	O
reported	NN	O	O
fatalities	NN	O	O
from	NN	O	O
DM	NN	O	B-Chemical
overdoses	NN	O	O
(	NN	O	O
Fleming	NN	O	O
1986	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
are	NN	O	O
no	NN	O	O
reports	NN	O	O
describing	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
chronic	NN	O	O
abuse	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
describes	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
cognitive	NN	O	B-Disease
deterioration	NN	O	I-Disease
resulting	NN	O	O
from	NN	O	O
prolonged	NN	O	O
use	NN	O	O
of	NN	O	O
DM	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (7437994)

Long	NN	O	O
-	NN	O	O
term	NN	O	O
lithium	NN	O	B-Chemical
treatment	NN	O	O
and	NN	O	O
the	NN	O	O
kidney	NN	O	O
.	NN	O	O

Interim	NN	O	O
report	NN	O	O
on	NN	O	O
fifty	NN	O	O
patients	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
a	NN	O	O
report	NN	O	O
on	NN	O	O
the	NN	O	O
first	NN	O	O
part	NN	O	O
of	NN	O	O
our	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
lithium	NN	O	B-Chemical
treatment	NN	O	O
on	NN	O	O
the	NN	O	O
kidney	NN	O	O
.	NN	O	O

Creatinine	NN	O	B-Chemical
clearance	NN	O	O
,	NN	O	O
maximum	NN	O	O
urinary	NN	O	O
osmolality	NN	O	O
and	NN	O	O
24	NN	O	O
hour	NN	O	O
urine	NN	O	O
volume	NN	O	O
have	NN	O	O
been	NN	O	O
tested	NN	O	O
in	NN	O	O
50	NN	O	O
affectively	NN	O	O
ill	NN	O	O
patients	NN	O	O
who	NN	O	O
have	NN	O	O
been	NN	O	O
on	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
lithium	NN	O	B-Chemical
for	NN	O	O
more	NN	O	O
than	NN	O	O
one	NN	O	O
year	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
have	NN	O	O
been	NN	O	O
compared	NN	O	O
with	NN	O	O
norms	NN	O	O
and	NN	O	O
with	NN	O	O
values	NN	O	O
of	NN	O	O
the	NN	O	O
same	NN	O	O
tests	NN	O	O
from	NN	O	O
screening	NN	O	O
prior	NN	O	O
to	NN	O	O
lithium	NN	O	B-Chemical
,	NN	O	O
available	NN	O	O
for	NN	O	O
most	NN	O	O
of	NN	O	O
our	NN	O	O
patients	NN	O	O
.	NN	O	O

No	NN	O	O
evidence	NN	O	O
was	NN	O	O
found	NN	O	O
for	NN	O	O
any	NN	O	O
reduction	NN	O	O
of	NN	O	O
glomerular	NN	O	O
filtration	NN	O	O
during	NN	O	O
lithium	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

Low	NN	O	O
clearance	NN	O	O
values	NN	O	O
found	NN	O	O
in	NN	O	O
several	NN	O	O
patients	NN	O	O
could	NN	O	O
be	NN	O	O
accounted	NN	O	O
for	NN	O	O
by	NN	O	O
their	NN	O	O
age	NN	O	O
and	NN	O	O
their	NN	O	O
pre	NN	O	O
-	NN	O	O
lithium	NN	O	B-Chemical
values	NN	O	O
.	NN	O	O

Urinary	NN	O	O
concentration	NN	O	O
defect	NN	O	O
appeared	NN	O	O
frequent	NN	O	O
but	NN	O	O
the	NN	O	O
extent	NN	O	O
of	NN	O	O
the	NN	O	O
impairment	NN	O	O
is	NN	O	O
difficult	NN	O	O
to	NN	O	O
assess	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
uncertainty	NN	O	O
about	NN	O	O
the	NN	O	O
norms	NN	O	O
applicable	NN	O	O
to	NN	O	O
this	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

The	NN	O	O
concentration	NN	O	O
defect	NN	O	O
appeared	NN	O	O
reversible	NN	O	O
,	NN	O	O
at	NN	O	O
least	NN	O	O
in	NN	O	O
part	NN	O	O
.	NN	O	O

Polyuria	NN	O	B-Disease
above	NN	O	O
3	NN	O	O
litres	NN	O	O
/	NN	O	O
24	NN	O	O
hours	NN	O	O
was	NN	O	O
found	NN	O	O
in	NN	O	O
10%	NN	O	O
of	NN	O	O
patients	NN	O	O
.	NN	O	O

An	NN	O	O
attempt	NN	O	O
is	NN	O	O
made	NN	O	O
to	NN	O	O
draw	NN	O	O
practical	NN	O	O
conclusions	NN	O	O
from	NN	O	O
the	NN	O	O
preliminary	NN	O	O
findings	NN	O	O
.	NN	O	O


-DOCSTART- (6496797)

Complete	NN	O	O
heart	NN	O	B-Disease
block	NN	O	I-Disease
following	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
trazodone	NN	O	B-Chemical
.	NN	O	O

Forty	NN	O	O
minutes	NN	O	O
after	NN	O	O
receiving	NN	O	O
a	NN	O	O
single	NN	O	O
starting	NN	O	O
dose	NN	O	O
of	NN	O	O
trazodone	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
patient	NN	O	O
developed	NN	O	O
complete	NN	O	O
heart	NN	O	B-Disease
block	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
case	NN	O	O
illustrates	NN	O	O
that	NN	O	O
,	NN	O	O
despite	NN	O	O
the	NN	O	O
results	NN	O	O
of	NN	O	O
earlier	NN	O	O
studies	NN	O	O
,	NN	O	O
trazodone	NN	O	B-Chemical
'	NN	O	O
s	NN	O	O
effect	NN	O	O
on	NN	O	O
cardiac	NN	O	O
conduction	NN	O	O
may	NN	O	O
be	NN	O	O
severe	NN	O	O
in	NN	O	O
individuals	NN	O	O
at	NN	O	O
risk	NN	O	O
for	NN	O	O
conduction	NN	O	O
delay	NN	O	O
.	NN	O	O


-DOCSTART- (3411101)

Quinidine	NN	O	B-Chemical
phenylethylbarbiturate	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
fulminant	NN	O	O
hepatitis	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
pregnant	NN	O	O
woman	NN	O	O
.	NN	O	O

A	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
19	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
Laotian	NN	O	O
patient	NN	O	O
affected	NN	O	O
by	NN	O	O
fulminant	NN	O	O
hepatitis	NN	O	B-Disease
during	NN	O	O
the	NN	O	O
third	NN	O	O
trimester	NN	O	O
of	NN	O	O
her	NN	O	O
pregnancy	NN	O	O
after	NN	O	O
a	NN	O	O
1	NN	O	O
-	NN	O	O
month	NN	O	O
administration	NN	O	O
of	NN	O	O
quinidine	NN	O	B-Chemical
phenylethylbarbiturate	NN	O	I-Chemical
.	NN	O	O

After	NN	O	O
delivery	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
underwent	NN	O	O
orthotopic	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
was	NN	O	O
in	NN	O	O
good	NN	O	O
condition	NN	O	O
16	NN	O	O
months	NN	O	O
after	NN	O	O
liver	NN	O	O
transplantation	NN	O	O
.	NN	O	O

Quinidine	NN	O	B-Chemical
itself	NN	O	O
or	NN	O	O
phenylethylbarbiturate	NN	O	B-Chemical
may	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
fulminant	NN	O	O
hepatitis	NN	O	B-Disease
in	NN	O	O
this	NN	O	O
patient	NN	O	O
.	NN	O	O


-DOCSTART- (2598570)

The	NN	O	O
epidemiology	NN	O	O
of	NN	O	O
the	NN	O	O
acute	NN	O	O
flank	NN	O	B-Disease
pain	NN	O	I-Disease
syndrome	NN	O	O
from	NN	O	O
suprofen	NN	O	B-Chemical
.	NN	O	O

Suprofen	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
new	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drug	NN	O	O
,	NN	O	O
was	NN	O	O
marketed	NN	O	O
in	NN	O	O
early	NN	O	O
1986	NN	O	O
as	NN	O	O
an	NN	O	O
analgesic	NN	O	O
agent	NN	O	O
.	NN	O	O

Until	NN	O	O
physicians	NN	O	O
began	NN	O	O
reporting	NN	O	O
an	NN	O	O
unusual	NN	O	O
acute	NN	O	O
flank	NN	O	B-Disease
pain	NN	O	I-Disease
syndrome	NN	O	O
to	NN	O	O
the	NN	O	O
spontaneous	NN	O	O
reporting	NN	O	O
system	NN	O	O
,	NN	O	O
700	NN	O	O
,	NN	O	O
000	NN	O	O
persons	NN	O	O
used	NN	O	O
the	NN	O	O
drug	NN	O	O
in	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
.	NN	O	O

Through	NN	O	O
August	NN	O	O
1986	NN	O	O
,	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
163	NN	O	O
cases	NN	O	O
of	NN	O	O
this	NN	O	O
syndrome	NN	O	O
were	NN	O	O
reported	NN	O	O
.	NN	O	O

To	NN	O	O
elucidate	NN	O	O
the	NN	O	O
epidemiology	NN	O	O
of	NN	O	O
the	NN	O	O
syndrome	NN	O	O
,	NN	O	O
a	NN	O	O
case	NN	O	O
-	NN	O	O
control	NN	O	O
study	NN	O	O
was	NN	O	O
performed	NN	O	O
,	NN	O	O
comparing	NN	O	O
62	NN	O	O
of	NN	O	O
the	NN	O	O
case	NN	O	O
patients	NN	O	O
who	NN	O	O
had	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
the	NN	O	O
spontaneous	NN	O	O
reporting	NN	O	O
system	NN	O	O
to	NN	O	O
185	NN	O	O
suprofen	NN	O	B-Chemical
-	NN	O	O
exposed	NN	O	O
control	NN	O	O
subjects	NN	O	O
who	NN	O	O
did	NN	O	O
not	NN	O	O
have	NN	O	O
the	NN	O	O
syndrome	NN	O	O
.	NN	O	O

Case	NN	O	O
patients	NN	O	O
were	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
be	NN	O	O
men	NN	O	O
(	NN	O	O
odds	NN	O	O
ratio	NN	O	O
,	NN	O	O
3.8	NN	O	O
;	NN	O	O
95%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
1.2	NN	O	O
-	NN	O	O
12.1	NN	O	O
)	NN	O	O
,	NN	O	O
suffer	NN	O	O
from	NN	O	O
hay	NN	O	B-Disease
fever	NN	O	I-Disease
and	NN	O	O
asthma	NN	O	B-Disease
(	NN	O	O
odds	NN	O	O
ratio	NN	O	O
,	NN	O	O
3.4	NN	O	O
;	NN	O	O
95%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
1.0	NN	O	O
-	NN	O	O
11.9	NN	O	O
)	NN	O	O
;	NN	O	O
to	NN	O	O
participate	NN	O	O
in	NN	O	O
regular	NN	O	O
exercise	NN	O	O
(	NN	O	O
odds	NN	O	O
ratio	NN	O	O
,	NN	O	O
5.9	NN	O	O
;	NN	O	O
95%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
1.1	NN	O	O
-	NN	O	O
30.7	NN	O	O
)	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
Nautilus	NN	O	O
equipment	NN	O	O
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.02	NN	O	O
)	NN	O	O
;	NN	O	O
and	NN	O	O
to	NN	O	O
use	NN	O	O
alcohol	NN	O	B-Chemical
(	NN	O	O
odds	NN	O	O
ratio	NN	O	O
,	NN	O	O
4.4	NN	O	O
;	NN	O	O
95%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
1.1	NN	O	O
-	NN	O	O
17.5	NN	O	O
)	NN	O	O
.	NN	O	O

Possible	NN	O	O
risk	NN	O	O
factors	NN	O	O
included	NN	O	O
young	NN	O	O
age	NN	O	O
,	NN	O	O
concurrent	NN	O	O
use	NN	O	O
of	NN	O	O
other	NN	O	O
analgesic	NN	O	O
agents	NN	O	O
(	NN	O	O
especially	NN	O	O
ibuprofen	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
preexisting	NN	O	O
renal	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
kidney	NN	O	B-Disease
stones	NN	O	I-Disease
,	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
gout	NN	O	B-Disease
,	NN	O	O
a	NN	O	O
recent	NN	O	O
increase	NN	O	O
in	NN	O	O
activity	NN	O	O
,	NN	O	O
a	NN	O	O
recent	NN	O	O
increase	NN	O	O
in	NN	O	O
sun	NN	O	O
exposure	NN	O	O
,	NN	O	O
and	NN	O	O
residence	NN	O	O
in	NN	O	O
the	NN	O	O
Sunbelt	NN	O	O
.	NN	O	O

These	NN	O	O
were	NN	O	O
findings	NN	O	O
that	NN	O	O
were	NN	O	O
suggestive	NN	O	O
but	NN	O	O
did	NN	O	O
not	NN	O	O
reach	NN	O	O
conventional	NN	O	O
statistical	NN	O	O
significance	NN	O	O
.	NN	O	O

These	NN	O	O
findings	NN	O	O
are	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
postulated	NN	O	O
mechanism	NN	O	O
for	NN	O	O
this	NN	O	O
unusual	NN	O	O
syndrome	NN	O	O
:	NN	O	O
acute	NN	O	O
diffuse	NN	O	O
crystallization	NN	O	O
of	NN	O	O
uric	NN	O	B-Chemical
acid	NN	O	I-Chemical
in	NN	O	O
renal	NN	O	O
tubules	NN	O	O
.	NN	O	O


-DOCSTART- (1415380)

Hemolytic	NN	O	B-Disease
-	NN	O	I-Disease
uremic	NN	O	I-Disease
syndrome	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
ingestion	NN	O	O
of	NN	O	O
quinine	NN	O	B-Chemical
.	NN	O	O

Hemolytic	NN	O	B-Disease
-	NN	O	I-Disease
uremic	NN	O	I-Disease
syndrome	NN	O	I-Disease
following	NN	O	O
quinine	NN	O	B-Chemical
ingestion	NN	O	O
is	NN	O	O
a	NN	O	O
newly	NN	O	O
described	NN	O	O
phenomenon	NN	O	O
,	NN	O	O
with	NN	O	O
just	NN	O	O
two	NN	O	O
previous	NN	O	O
descriptions	NN	O	O
of	NN	O	O
4	NN	O	O
cases	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
a	NN	O	O
5th	NN	O	O
case	NN	O	O
.	NN	O	O

The	NN	O	O
reaction	NN	O	O
may	NN	O	O
be	NN	O	O
mediated	NN	O	O
by	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
antibodies	NN	O	O
reactive	NN	O	O
against	NN	O	O
platelets	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
quinine	NN	O	B-Chemical
.	NN	O	O

Treatment	NN	O	O
has	NN	O	O
included	NN	O	O
use	NN	O	O
of	NN	O	O
plasma	NN	O	O
exchange	NN	O	O
,	NN	O	O
prednisone	NN	O	B-Chemical
,	NN	O	O
aspirin	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
dipyridamole	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
patients	NN	O	O
have	NN	O	O
all	NN	O	O
regained	NN	O	O
some	NN	O	O
degree	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
unclear	NN	O	O
whether	NN	O	O
pharmacological	NN	O	O
treatment	NN	O	O
or	NN	O	O
spontaneous	NN	O	O
resolution	NN	O	O
is	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
improvement	NN	O	O
.	NN	O	O

Quinine	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
hemolytic	NN	O	B-Disease
-	NN	O	I-Disease
uremic	NN	O	I-Disease
syndrome	NN	O	I-Disease
probably	NN	O	O
occurs	NN	O	O
more	NN	O	O
often	NN	O	O
than	NN	O	O
is	NN	O	O
recognized	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
important	NN	O	O
to	NN	O	O
recognize	NN	O	O
this	NN	O	O
reaction	NN	O	O
when	NN	O	O
it	NN	O	O
occurs	NN	O	O
and	NN	O	O
to	NN	O	O
avoid	NN	O	O
further	NN	O	O
quinine	NN	O	B-Chemical
exposure	NN	O	O
,	NN	O	O
since	NN	O	O
the	NN	O	O
reaction	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
recurrent	NN	O	O
.	NN	O	O


-DOCSTART- (1255900)

Pyeloureteral	NN	O	O
filling	NN	O	O
defects	NN	O	O
associated	NN	O	O
with	NN	O	O
systemic	NN	O	O
anticoagulation	NN	O	O
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

The	NN	O	O
etiology	NN	O	O
of	NN	O	O
pyeloureteritis	NN	O	B-Disease
cystica	NN	O	I-Disease
has	NN	O	O
long	NN	O	O
been	NN	O	O
attributed	NN	O	O
to	NN	O	O
chronic	NN	O	O
infection	NN	O	B-Disease
and	NN	O	O
inflammation	NN	O	B-Disease
.	NN	O	O

A	NN	O	O
case	NN	O	O
is	NN	O	O
presented	NN	O	O
that	NN	O	O
is	NN	O	O
unique	NN	O	O
in	NN	O	O
that	NN	O	O
the	NN	O	O
acute	NN	O	O
onset	NN	O	O
and	NN	O	O
the	NN	O	O
rapid	NN	O	O
resolution	NN	O	O
of	NN	O	O
pyeloureteral	NN	O	O
filling	NN	O	O
defects	NN	O	O
in	NN	O	O
this	NN	O	O
patient	NN	O	O
were	NN	O	O
documented	NN	O	O
by	NN	O	O
radiography	NN	O	O
.	NN	O	O

There	NN	O	O
is	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
antecedent	NN	O	O
or	NN	O	O
concurrent	NN	O	O
infection	NN	O	B-Disease
in	NN	O	O
this	NN	O	O
patient	NN	O	O
.	NN	O	O

The	NN	O	O
disease	NN	O	O
occurred	NN	O	O
subsequent	NN	O	O
to	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
heparin	NN	O	B-Chemical
therapy	NN	O	O
for	NN	O	O
suspected	NN	O	O
pelvic	NN	O	O
thrombophlebitis	NN	O	B-Disease
and	NN	O	O
cleared	NN	O	O
rapidly	NN	O	O
subsequent	NN	O	O
to	NN	O	O
its	NN	O	O
discontinuation	NN	O	O
.	NN	O	O

The	NN	O	O
rate	NN	O	O
of	NN	O	O
resolution	NN	O	O
of	NN	O	O
the	NN	O	O
radiographic	NN	O	O
findings	NN	O	O
may	NN	O	O
be	NN	O	O
helpful	NN	O	O
in	NN	O	O
distinguishing	NN	O	O
between	NN	O	O
true	NN	O	O
pyeloureteritis	NN	O	B-Disease
cystica	NN	O	I-Disease
and	NN	O	O
submucosal	NN	O	B-Disease
hemorrhage	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (85485)

Changes	NN	O	O
in	NN	O	O
peroxisomes	NN	O	O
in	NN	O	O
preneoplastic	NN	O	O
liver	NN	O	O
and	NN	O	O
hepatoma	NN	O	B-Disease
of	NN	O	O
mice	NN	O	O
induced	NN	O	O
by	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
benzene	NN	O	I-Chemical
hexachloride	NN	O	I-Chemical
.	NN	O	O

Peroxisomes	NN	O	O
in	NN	O	O
hepatomas	NN	O	B-Disease
and	NN	O	O
hyperplastic	NN	O	O
preneoplastic	NN	O	O
liver	NN	O	B-Disease
lesions	NN	O	I-Disease
induced	NN	O	O
in	NN	O	O
mice	NN	O	O
by	NN	O	O
500	NN	O	O
ppm	NN	O	O
alpha	NN	O	B-Chemical
-	NN	O	I-Chemical
benzene	NN	O	I-Chemical
hexachloride	NN	O	I-Chemical
were	NN	O	O
examined	NN	O	O
histochemically	NN	O	O
and	NN	O	O
electron	NN	O	O
microscopically	NN	O	O
.	NN	O	O

Although	NN	O	O
most	NN	O	O
of	NN	O	O
the	NN	O	O
hepatomas	NN	O	B-Disease
were	NN	O	O
well	NN	O	O
-	NN	O	O
differentiated	NN	O	O
tumors	NN	O	B-Disease
and	NN	O	O
contained	NN	O	O
a	NN	O	O
considerable	NN	O	O
number	NN	O	O
of	NN	O	O
peroxisomes	NN	O	O
,	NN	O	O
the	NN	O	O
tumor	NN	O	B-Disease
cells	NN	O	O
did	NN	O	O
not	NN	O	O
respond	NN	O	O
to	NN	O	O
ethyl	NN	O	B-Chemical
-	NN	O	I-Chemical
alpha	NN	O	I-Chemical
-	NN	O	I-Chemical
p	NN	O	I-Chemical
-	NN	O	I-Chemical
chlorophenoxyisobutyrate	NN	O	I-Chemical
with	NN	O	O
proliferation	NN	O	O
of	NN	O	O
peroxisomes	NN	O	O
.	NN	O	O

At	NN	O	O
the	NN	O	O
16th	NN	O	O
week	NN	O	O
of	NN	O	O
carcinogen	NN	O	O
feeding	NN	O	O
,	NN	O	O
hyperplastic	NN	O	O
nodules	NN	O	O
appeared	NN	O	O
and	NN	O	O
advanced	NN	O	O
to	NN	O	O
further	NN	O	O
stages	NN	O	O
.	NN	O	O

A	NN	O	O
majority	NN	O	O
of	NN	O	O
the	NN	O	O
nodules	NN	O	O
showed	NN	O	O
a	NN	O	O
considerable	NN	O	O
number	NN	O	O
of	NN	O	O
peroxisomes	NN	O	O
and	NN	O	O
the	NN	O	O
inductive	NN	O	O
proliferation	NN	O	O
of	NN	O	O
peroxisomes	NN	O	O
.	NN	O	O

Within	NN	O	O
the	NN	O	O
nodules	NN	O	O
,	NN	O	O
foci	NN	O	O
of	NN	O	O
proliferation	NN	O	O
of	NN	O	O
the	NN	O	O
cells	NN	O	O
that	NN	O	O
showed	NN	O	O
no	NN	O	O
inducibility	NN	O	O
of	NN	O	O
proliferation	NN	O	O
of	NN	O	O
peroxisomes	NN	O	O
appeared	NN	O	O
.	NN	O	O

These	NN	O	O
cells	NN	O	O
proliferated	NN	O	O
further	NN	O	O
,	NN	O	O
replacing	NN	O	O
the	NN	O	O
most	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
nodules	NN	O	O
,	NN	O	O
and	NN	O	O
with	NN	O	O
this	NN	O	O
process	NN	O	O
hepatomas	NN	O	B-Disease
appeared	NN	O	O
to	NN	O	O
have	NN	O	O
been	NN	O	O
formed	NN	O	O
.	NN	O	O

No	NN	O	O
abnormal	NN	O	O
matrical	NN	O	O
inclusions	NN	O	O
of	NN	O	O
peroxisomes	NN	O	O
were	NN	O	O
formed	NN	O	O
in	NN	O	O
the	NN	O	O
cells	NN	O	O
of	NN	O	O
hyperplastic	NN	O	O
nodules	NN	O	O
by	NN	O	O
ethyl	NN	O	B-Chemical
-	NN	O	I-Chemical
alpha	NN	O	I-Chemical
-	NN	O	I-Chemical
p	NN	O	I-Chemical
-	NN	O	I-Chemical
chlorophenoxyisobutyrate	NN	O	I-Chemical
unlike	NN	O	O
in	NN	O	O
the	NN	O	O
case	NN	O	O
of	NN	O	O
rats	NN	O	O
.	NN	O	O


-DOCSTART- (48362)

Quinidine	NN	O	B-Chemical
hepatitis	NN	O	B-Disease
.	NN	O	O

Long	NN	O	O
-	NN	O	O
term	NN	O	O
administration	NN	O	O
of	NN	O	O
quinidine	NN	O	B-Chemical
was	NN	O	O
associated	NN	O	O
with	NN	O	O
persistent	NN	O	O
elevation	NN	O	O
of	NN	O	O
serum	NN	O	O
concentrations	NN	O	O
of	NN	O	O
SGOT	NN	O	O
,	NN	O	O
lactic	NN	O	B-Chemical
acid	NN	O	I-Chemical
dehydrogenase	NN	O	O
,	NN	O	O
and	NN	O	O
alkaline	NN	O	O
phosphatase	NN	O	O
.	NN	O	O

Liver	NN	O	O
biopsy	NN	O	O
showed	NN	O	O
active	NN	O	O
hepatitis	NN	O	B-Disease
.	NN	O	O

Discontinuance	NN	O	O
of	NN	O	O
quinidine	NN	O	B-Chemical
therapy	NN	O	O
led	NN	O	O
to	NN	O	O
normalization	NN	O	O
of	NN	O	O
liver	NN	O	O
function	NN	O	O
tests	NN	O	O
.	NN	O	O

A	NN	O	O
challenge	NN	O	O
dose	NN	O	O
of	NN	O	O
quinidine	NN	O	B-Chemical
caused	NN	O	O
clinical	NN	O	O
symptoms	NN	O	O
and	NN	O	O
abrupt	NN	O	O
elevation	NN	O	O
of	NN	O	O
SGOT	NN	O	O
,	NN	O	O
alkaline	NN	O	O
phosphatase	NN	O	O
,	NN	O	O
and	NN	O	O
lactic	NN	O	B-Chemical
acid	NN	O	I-Chemical
dehydrogenase	NN	O	O
values	NN	O	O
.	NN	O	O

We	NN	O	O
concluded	NN	O	O
that	NN	O	O
this	NN	O	O
patient	NN	O	O
had	NN	O	O
quinidine	NN	O	B-Chemical
hepatotoxicity	NN	O	B-Disease
and	NN	O	O
believe	NN	O	O
that	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
reported	NN	O	O
with	NN	O	O
liver	NN	O	O
biopsy	NN	O	O
documentation	NN	O	O
.	NN	O	O

This	NN	O	O
report	NN	O	O
also	NN	O	O
suggests	NN	O	O
that	NN	O	O
,	NN	O	O
even	NN	O	O
after	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
administration	NN	O	O
,	NN	O	O
the	NN	O	O
hepatic	NN	O	B-Disease
toxicity	NN	O	I-Disease
is	NN	O	O
reversible	NN	O	O
.	NN	O	O


-DOCSTART- (9067481)

Cholesteryl	NN	O	B-Chemical
hemisuccinate	NN	O	I-Chemical
treatment	NN	O	O
protects	NN	O	O
rodents	NN	O	O
from	NN	O	O
the	NN	O	O
toxic	NN	O	O
effects	NN	O	O
of	NN	O	O
acetaminophen	NN	O	B-Chemical
,	NN	O	O
adriamycin	NN	O	B-Chemical
,	NN	O	O
carbon	NN	O	B-Chemical
tetrachloride	NN	O	I-Chemical
,	NN	O	O
chloroform	NN	O	B-Chemical
and	NN	O	O
galactosamine	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
addition	NN	O	O
to	NN	O	O
its	NN	O	O
use	NN	O	O
as	NN	O	O
a	NN	O	O
stabilizer	NN	O	O
/	NN	O	O
rigidifier	NN	O	O
of	NN	O	O
membranes	NN	O	O
,	NN	O	O
cholesteryl	NN	O	B-Chemical
hemisuccinate	NN	O	I-Chemical
,	NN	O	O
tris	NN	O	B-Chemical
salt	NN	O	I-Chemical
(	NN	O	O
CS	NN	O	B-Chemical
)	NN	O	O
administration	NN	O	O
has	NN	O	O
also	NN	O	O
been	NN	O	O
shown	NN	O	O
to	NN	O	O
protect	NN	O	O
rats	NN	O	O
from	NN	O	O
the	NN	O	O
hepatotoxic	NN	O	B-Disease
effects	NN	O	O
of	NN	O	O
carbon	NN	O	B-Chemical
tetrachloride	NN	O	I-Chemical
(	NN	O	O
CCl4	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

To	NN	O	O
further	NN	O	O
our	NN	O	O
understanding	NN	O	O
of	NN	O	O
the	NN	O	O
mechanism	NN	O	O
of	NN	O	O
CS	NN	O	B-Chemical
cytoprotection	NN	O	O
,	NN	O	O
we	NN	O	O
examined	NN	O	O
in	NN	O	O
rats	NN	O	O
and	NN	O	O
mice	NN	O	O
the	NN	O	O
protective	NN	O	O
abilities	NN	O	O
of	NN	O	O
CS	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
hydrolyzable	NN	O	O
ether	NN	O	O
form	NN	O	O
of	NN	O	O
CS	NN	O	B-Chemical
,	NN	O	O
gamma	NN	O	B-Chemical
-	NN	O	I-Chemical
cholesteryloxybutyric	NN	O	I-Chemical
acid	NN	O	I-Chemical
,	NN	O	O
tris	NN	O	B-Chemical
salt	NN	O	I-Chemical
(	NN	O	O
CSE	NN	O	B-Chemical
)	NN	O	O
against	NN	O	O
acetaminophen	NN	O	B-Chemical
-	NN	O	O
,	NN	O	O
adriamycin	NN	O	B-Chemical
-	NN	O	O
,	NN	O	O
carbon	NN	O	B-Chemical
tetrachloride	NN	O	I-Chemical
-	NN	O	O
,	NN	O	O
chloroform	NN	O	B-Chemical
-	NN	O	O
and	NN	O	O
galactosamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
toxicity	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
results	NN	O	O
of	NN	O	O
these	NN	O	O
studies	NN	O	O
demonstrated	NN	O	O
that	NN	O	O
CS	NN	O	B-Chemical
-	NN	O	O
mediated	NN	O	O
protection	NN	O	O
is	NN	O	O
not	NN	O	O
selective	NN	O	O
for	NN	O	O
a	NN	O	O
particular	NN	O	O
species	NN	O	O
,	NN	O	O
organ	NN	O	O
system	NN	O	O
or	NN	O	O
toxic	NN	O	O
chemical	NN	O	O
.	NN	O	O

A	NN	O	O
24	NN	O	O
-	NN	O	O
h	NN	O	O
pretreatment	NN	O	O
of	NN	O	O
both	NN	O	O
rats	NN	O	O
and	NN	O	O
mice	NN	O	O
with	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
CS	NN	O	B-Chemical
(	NN	O	O
100mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.p.	NN	O	O
)	NN	O	O
,	NN	O	O
resulted	NN	O	O
in	NN	O	O
significant	NN	O	O
protection	NN	O	O
against	NN	O	O
the	NN	O	O
hepatotoxic	NN	O	B-Disease
effects	NN	O	O
of	NN	O	O
CCl4	NN	O	B-Chemical
,	NN	O	O
CHCl3	NN	O	B-Chemical
,	NN	O	O
acetaminophen	NN	O	B-Chemical
and	NN	O	O
galactosamine	NN	O	B-Chemical
and	NN	O	O
against	NN	O	O
the	NN	O	O
lethal	NN	O	O
(	NN	O	O
and	NN	O	O
presumably	NN	O	O
cardiotoxic	NN	O	B-Disease
)	NN	O	O
effect	NN	O	O
of	NN	O	O
adriamycin	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

Maximal	NN	O	O
CS	NN	O	B-Chemical
-	NN	O	O
mediated	NN	O	O
protection	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
experimental	NN	O	O
animals	NN	O	O
pretreated	NN	O	O
24	NN	O	O
h	NN	O	O
prior	NN	O	O
to	NN	O	O
the	NN	O	O
toxic	NN	O	O
insult	NN	O	O
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
CS	NN	O	B-Chemical
intervenes	NN	O	O
in	NN	O	O
a	NN	O	O
critical	NN	O	O
cellular	NN	O	O
event	NN	O	O
that	NN	O	O
is	NN	O	O
an	NN	O	O
important	NN	O	O
common	NN	O	O
pathway	NN	O	O
to	NN	O	O
toxic	NN	O	O
cell	NN	O	O
death	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
of	NN	O	O
CS	NN	O	B-Chemical
protection	NN	O	O
does	NN	O	O
not	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
dependent	NN	O	O
on	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
chemical	NN	O	O
bioactivation	NN	O	O
to	NN	O	O
a	NN	O	O
toxic	NN	O	O
reactive	NN	O	O
intermediate	NN	O	O
(	NN	O	O
in	NN	O	O
light	NN	O	O
of	NN	O	O
the	NN	O	O
protection	NN	O	O
observed	NN	O	O
against	NN	O	O
galactosamine	NN	O	B-Chemical
hepatotoxicity	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
based	NN	O	O
on	NN	O	O
the	NN	O	O
data	NN	O	O
presented	NN	O	O
,	NN	O	O
we	NN	O	O
can	NN	O	O
not	NN	O	O
exclude	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
CS	NN	O	B-Chemical
administration	NN	O	O
inhibits	NN	O	O
chemical	NN	O	O
bioactivation	NN	O	O
.	NN	O	O

Our	NN	O	O
findings	NN	O	O
do	NN	O	O
suggest	NN	O	O
that	NN	O	O
CS	NN	O	B-Chemical
-	NN	O	O
mediated	NN	O	O
protection	NN	O	O
is	NN	O	O
dependent	NN	O	O
on	NN	O	O
the	NN	O	O
action	NN	O	O
of	NN	O	O
the	NN	O	O
intact	NN	O	O
anionic	NN	O	O
CS	NN	O	B-Chemical
molecule	NN	O	O
(	NN	O	O
non	NN	O	O
-	NN	O	O
hydrolyzable	NN	O	O
CSE	NN	O	B-Chemical
was	NN	O	O
as	NN	O	O
protective	NN	O	O
as	NN	O	O
CS	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
whose	NN	O	O
mechanism	NN	O	O
has	NN	O	O
yet	NN	O	O
to	NN	O	O
be	NN	O	O
defined	NN	O	O
.	NN	O	O


-DOCSTART- (19274460)

DSMM	NN	O	O
XI	NN	O	O
study	NN	O	O
:	NN	O	O
dose	NN	O	O
definition	NN	O	O
for	NN	O	O
intravenous	NN	O	O
cyclophosphamide	NN	O	B-Chemical
in	NN	O	O
combination	NN	O	O
with	NN	O	O
bortezomib	NN	O	B-Chemical
/	NN	O	O
dexamethasone	NN	O	B-Chemical
for	NN	O	O
remission	NN	O	O
induction	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
newly	NN	O	O
diagnosed	NN	O	O
myeloma	NN	O	B-Disease
.	NN	O	O

A	NN	O	O
clinical	NN	O	O
trial	NN	O	O
was	NN	O	O
initiated	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
recommended	NN	O	O
dose	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	B-Chemical
in	NN	O	O
combination	NN	O	O
with	NN	O	O
bortezomib	NN	O	B-Chemical
and	NN	O	O
dexamethasone	NN	O	B-Chemical
as	NN	O	O
induction	NN	O	O
treatment	NN	O	O
before	NN	O	O
stem	NN	O	O
cell	NN	O	O
transplantation	NN	O	O
for	NN	O	O
younger	NN	O	O
patients	NN	O	O
with	NN	O	O
newly	NN	O	O
diagnosed	NN	O	O
multiple	NN	O	B-Disease
myeloma	NN	O	I-Disease
(	NN	O	O
MM	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Thirty	NN	O	O
patients	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
three	NN	O	O
21	NN	O	O
-	NN	O	O
day	NN	O	O
cycles	NN	O	O
of	NN	O	O
bortezomib	NN	O	B-Chemical
1.3	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
on	NN	O	O
days	NN	O	O
1	NN	O	O
,	NN	O	O
4	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
and	NN	O	O
11	NN	O	O
plus	NN	O	O
dexamethasone	NN	O	B-Chemical
40	NN	O	O
mg	NN	O	O
on	NN	O	O
the	NN	O	O
day	NN	O	O
of	NN	O	O
bortezomib	NN	O	B-Chemical
injection	NN	O	O
and	NN	O	O
the	NN	O	O
day	NN	O	O
after	NN	O	O
plus	NN	O	O
cyclophosphamide	NN	O	B-Chemical
at	NN	O	O
900	NN	O	O
,	NN	O	O
1	NN	O	O
,	NN	O	O
200	NN	O	O
,	NN	O	O
or	NN	O	O
1	NN	O	O
,	NN	O	O
500	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
on	NN	O	O
day	NN	O	O
1	NN	O	O
.	NN	O	O

The	NN	O	O
maximum	NN	O	O
tolerated	NN	O	O
dose	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	B-Chemical
was	NN	O	O
defined	NN	O	O
as	NN	O	O
900	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
.	NN	O	O

At	NN	O	O
this	NN	O	O
dose	NN	O	O
level	NN	O	O
,	NN	O	O
92%	NN	O	O
of	NN	O	O
patients	NN	O	O
achieved	NN	O	O
at	NN	O	O
least	NN	O	O
a	NN	O	O
partial	NN	O	O
response	NN	O	O
.	NN	O	O

The	NN	O	O
overall	NN	O	O
response	NN	O	O
rate	NN	O	O
[	NN	O	O
complete	NN	O	O
response	NN	O	O
(	NN	O	O
CR	NN	O	O
)	NN	O	O
plus	NN	O	O
partial	NN	O	O
response	NN	O	O
(	NN	O	O
PR	NN	O	O
)	NN	O	O
]	NN	O	O
across	NN	O	O
all	NN	O	O
dose	NN	O	O
levels	NN	O	O
was	NN	O	O
77%	NN	O	O
,	NN	O	O
with	NN	O	O
a	NN	O	O
10%	NN	O	O
CR	NN	O	O
rate	NN	O	O
.	NN	O	O

No	NN	O	O
patient	NN	O	O
experienced	NN	O	O
progressive	NN	O	O
disease	NN	O	O
.	NN	O	O

The	NN	O	O
most	NN	O	O
frequent	NN	O	O
adverse	NN	O	O
events	NN	O	O
were	NN	O	O
hematological	NN	O	B-Disease
and	NN	O	I-Disease
gastrointestinal	NN	O	I-Disease
toxicities	NN	O	I-Disease
as	NN	O	O
well	NN	O	O
as	NN	O	O
neuropathy	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
bortezomib	NN	O	B-Chemical
in	NN	O	O
combination	NN	O	O
with	NN	O	O
cyclophosphamide	NN	O	B-Chemical
at	NN	O	O
900	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
and	NN	O	O
dexamethasone	NN	O	B-Chemical
is	NN	O	O
an	NN	O	O
effective	NN	O	O
induction	NN	O	O
treatment	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
newly	NN	O	O
diagnosed	NN	O	O
MM	NN	O	B-Disease
that	NN	O	O
warrants	NN	O	O
further	NN	O	O
investigation	NN	O	O
.	NN	O	O


-DOCSTART- (18201582)

Results	NN	O	O
of	NN	O	O
a	NN	O	O
comparative	NN	O	O
,	NN	O	O
phase	NN	O	O
III	NN	O	O
,	NN	O	O
12	NN	O	O
-	NN	O	O
week	NN	O	O
,	NN	O	O
multicenter	NN	O	O
,	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
assessment	NN	O	O
of	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
tolerability	NN	O	O
of	NN	O	O
a	NN	O	O
fixed	NN	O	O
-	NN	O	O
dose	NN	O	O
combination	NN	O	O
of	NN	O	O
telmisartan	NN	O	B-Chemical
and	NN	O	O
amlodipine	NN	O	B-Chemical
versus	NN	O	O
amlodipine	NN	O	B-Chemical
monotherapy	NN	O	O
in	NN	O	O
Indian	NN	O	O
adults	NN	O	O
with	NN	O	O
stage	NN	O	O
II	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
tolerability	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
fixed	NN	O	O
-	NN	O	O
dose	NN	O	O
combination	NN	O	O
(	NN	O	O
FDC	NN	O	O
)	NN	O	O
of	NN	O	O
telmisartan	NN	O	B-Chemical
40	NN	O	O
mg	NN	O	O
+	NN	O	O
amlodipine	NN	O	B-Chemical
5	NN	O	O
mg	NN	O	O
(	NN	O	O
T+A	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
amlodipine	NN	O	B-Chemical
5	NN	O	O
-	NN	O	O
mg	NN	O	O
monotherapy	NN	O	O
(	NN	O	O
A	NN	O	O
)	NN	O	O
in	NN	O	O
adult	NN	O	O
Indian	NN	O	O
patients	NN	O	O
with	NN	O	O
stage	NN	O	O
II	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
This	NN	O	O
comparative	NN	O	O
,	NN	O	O
Phase	NN	O	O
III	NN	O	O
,	NN	O	O
12	NN	O	O
-	NN	O	O
week	NN	O	O
,	NN	O	O
multicenter	NN	O	O
,	NN	O	O
prospective	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
study	NN	O	O
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
Indian	NN	O	O
patients	NN	O	O
aged	NN	O	O
18	NN	O	O
to	NN	O	O
65	NN	O	O
years	NN	O	O
with	NN	O	O
established	NN	O	O
stage	NN	O	O
II	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
oral	NN	O	O
FDC	NN	O	O
of	NN	O	O
T+A	NN	O	O
or	NN	O	O
A	NN	O	O
QD	NN	O	O
before	NN	O	O
breakfast	NN	O	O
for	NN	O	O
12	NN	O	O
weeks	NN	O	O
;	NN	O	O
blood	NN	O	O
pressure	NN	O	O
(	NN	O	O
BP	NN	O	O
)	NN	O	O
and	NN	O	O
heart	NN	O	O
rate	NN	O	O
were	NN	O	O
measured	NN	O	O
in	NN	O	O
the	NN	O	O
sitting	NN	O	O
position	NN	O	O
.	NN	O	O

Primary	NN	O	O
efficacy	NN	O	O
end	NN	O	O
points	NN	O	O
were	NN	O	O
reduction	NN	O	O
in	NN	O	O
clinical	NN	O	O
systolic	NN	O	O
BP	NN	O	O
(	NN	O	O
SBP	NN	O	O
)	NN	O	O
/	NN	O	O
diastolic	NN	O	O
BP	NN	O	O
(	NN	O	O
DBP	NN	O	O
)	NN	O	O
from	NN	O	O
baseline	NN	O	O
to	NN	O	O
study	NN	O	O
end	NN	O	O
and	NN	O	O
number	NN	O	O
of	NN	O	O
responders	NN	O	O
(	NN	O	O
ie	NN	O	O
,	NN	O	O
patients	NN	O	O
who	NN	O	O
achieved	NN	O	O
target	NN	O	O
SBP	NN	O	O
/	NN	O	O
DBP	NN	O	O
<130	NN	O	O
/	NN	O	O
<80	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
at	NN	O	O
end	NN	O	O
of	NN	O	O
study	NN	O	O
.	NN	O	O

Tolerability	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
treatment	NN	O	O
-	NN	O	O
emergent	NN	O	O
adverse	NN	O	O
events	NN	O	O
,	NN	O	O
identified	NN	O	O
using	NN	O	O
physical	NN	O	O
examination	NN	O	O
,	NN	O	O
laboratory	NN	O	O
analysis	NN	O	O
,	NN	O	O
and	NN	O	O
electrocardiography	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
A	NN	O	O
total	NN	O	O
of	NN	O	O
210	NN	O	O
patients	NN	O	O
were	NN	O	O
enrolled	NN	O	O
in	NN	O	O
the	NN	O	O
study	NN	O	O
;	NN	O	O
203	NN	O	O
patients	NN	O	O
(	NN	O	O
143	NN	O	O
men	NN	O	O
,	NN	O	O
60	NN	O	O
women	NN	O	O
)	NN	O	O
completed	NN	O	O
the	NN	O	O
study	NN	O	O
while	NN	O	O
7	NN	O	O
were	NN	O	O
lost	NN	O	O
to	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
(	NN	O	O
4	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
T+A	NN	O	O
group	NN	O	O
and	NN	O	O
3	NN	O	O
in	NN	O	O
the	NN	O	O
A	NN	O	O
group	NN	O	O
)	NN	O	O
and	NN	O	O
considered	NN	O	O
with	NN	O	O
-	NN	O	O
drawn	NN	O	O
.	NN	O	O

At	NN	O	O
study	NN	O	O
end	NN	O	O
,	NN	O	O
statistically	NN	O	O
significant	NN	O	O
percentage	NN	O	O
reductions	NN	O	O
from	NN	O	O
baseline	NN	O	O
within	NN	O	O
groups	NN	O	O
and	NN	O	O
between	NN	O	O
groups	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
SBP	NN	O	O
(	NN	O	O
T+A	NN	O	O
[	NN	O	O
-	NN	O	O
27.4%	NN	O	O
]	NN	O	O
;	NN	O	O
A	NN	O	O
[	NN	O	O
-	NN	O	O
16.6%	NN	O	O
]	NN	O	O
)	NN	O	O
and	NN	O	O
DBP	NN	O	O
(	NN	O	O
T+A	NN	O	O
[	NN	O	O
-	NN	O	O
20.1%	NN	O	O
]	NN	O	O
;	NN	O	O
A	NN	O	O
[	NN	O	O
-	NN	O	O
13.3%	NN	O	O
]	NN	O	O
)	NN	O	O
(	NN	O	O
all	NN	O	O
,	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Response	NN	O	O
rates	NN	O	O
were	NN	O	O
87.3%	NN	O	O
(	NN	O	O
89	NN	O	O
/	NN	O	O
102	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
T+A	NN	O	O
group	NN	O	O
and	NN	O	O
69.3%	NN	O	O
(	NN	O	O
70	NN	O	O
/	NN	O	O
101	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
A	NN	O	O
group	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
prevalences	NN	O	O
of	NN	O	O
adverse	NN	O	O
events	NN	O	O
were	NN	O	O
not	NN	O	O
significantly	NN	O	O
different	NN	O	O
between	NN	O	O
the	NN	O	O
2	NN	O	O
treatment	NN	O	O
groups	NN	O	O
(	NN	O	O
T+A	NN	O	O
,	NN	O	O
16.0%	NN	O	O
[	NN	O	O
17	NN	O	O
/	NN	O	O
106	NN	O	O
]	NN	O	O
;	NN	O	O
A	NN	O	O
,	NN	O	O
15.4%	NN	O	O
[	NN	O	O
16	NN	O	O
/	NN	O	O
104	NN	O	O
]	NN	O	O
)	NN	O	O
.	NN	O	O

Peripheral	NN	O	O
edema	NN	O	B-Disease
was	NN	O	O
reported	NN	O	O
in	NN	O	O
8.5%	NN	O	O
patients	NN	O	O
(	NN	O	O
9	NN	O	O
/	NN	O	O
106	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
T+A	NN	O	O
group	NN	O	O
compared	NN	O	O
with	NN	O	O
13.5%	NN	O	O
(	NN	O	O
14	NN	O	O
/	NN	O	O
104	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
A	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
cough	NN	O	B-Disease
was	NN	O	O
reported	NN	O	O
in	NN	O	O
3.8%	NN	O	O
patients	NN	O	O
(	NN	O	O
4	NN	O	O
/	NN	O	O
106	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
T+A	NN	O	O
group	NN	O	O
and	NN	O	O
1.0%	NN	O	O
(	NN	O	O
1	NN	O	O
/	NN	O	O
104	NN	O	O
)	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
A	NN	O	O
group	NN	O	O
;	NN	O	O
these	NN	O	O
differences	NN	O	O
did	NN	O	O
not	NN	O	O
reach	NN	O	O
statistical	NN	O	O
significance	NN	O	O
.	NN	O	O

The	NN	O	O
incidences	NN	O	O
of	NN	O	O
headache	NN	O	B-Disease
,	NN	O	O
dizziness	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
diarrhea	NN	O	B-Disease
were	NN	O	O
similar	NN	O	O
between	NN	O	O
the	NN	O	O
2	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Among	NN	O	O
these	NN	O	O
Indian	NN	O	O
patients	NN	O	O
with	NN	O	O
stage	NN	O	O
II	NN	O	O
hypertension	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
FDC	NN	O	O
of	NN	O	O
T+A	NN	O	O
was	NN	O	O
found	NN	O	O
to	NN	O	O
be	NN	O	O
significantly	NN	O	O
more	NN	O	O
effective	NN	O	O
,	NN	O	O
with	NN	O	O
regard	NN	O	O
to	NN	O	O
BP	NN	O	O
reductions	NN	O	O
,	NN	O	O
than	NN	O	O
A	NN	O	O
,	NN	O	O
and	NN	O	O
both	NN	O	O
treatments	NN	O	O
were	NN	O	O
well	NN	O	O
tolerated	NN	O	O
.	NN	O	O


-DOCSTART- (11337188)

Cutaneous	NN	O	B-Disease
leucocytoclastic	NN	O	I-Disease
vasculitis	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
oxacillin	NN	O	B-Chemical
.	NN	O	O

A	NN	O	O
67	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
who	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
oxacillin	NN	O	B-Chemical
for	NN	O	O
one	NN	O	O
week	NN	O	O
because	NN	O	O
of	NN	O	O
Staphylococcus	NN	O	B-Disease
aureus	NN	O	I-Disease
bacteremia	NN	O	I-Disease
,	NN	O	O
developed	NN	O	O
renal	NN	O	B-Disease
failure	NN	O	I-Disease
and	NN	O	O
diffuse	NN	O	O
,	NN	O	O
symmetric	NN	O	O
,	NN	O	O
palpable	NN	O	O
purpuric	NN	O	B-Disease
lesions	NN	O	I-Disease
on	NN	O	O
his	NN	O	O
feet	NN	O	O
.	NN	O	O

Necrotic	NN	O	B-Disease
blisters	NN	O	I-Disease
were	NN	O	O
noted	NN	O	O
on	NN	O	O
his	NN	O	O
fingers	NN	O	O
.	NN	O	O

Skin	NN	O	O
biopsies	NN	O	O
showed	NN	O	O
findings	NN	O	O
diagnostic	NN	O	O
of	NN	O	O
leucocytoclastic	NN	O	B-Disease
vasculitis	NN	O	I-Disease
.	NN	O	O

Oxacillin	NN	O	B-Chemical
was	NN	O	O
discontinued	NN	O	O
and	NN	O	O
patient	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
corticosteroids	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
rash	NN	O	B-Disease
disappeared	NN	O	O
after	NN	O	O
three	NN	O	O
weeks	NN	O	O
and	NN	O	O
renal	NN	O	O
function	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
.	NN	O	O

Leucocytoclastic	NN	O	B-Disease
vasculitis	NN	O	I-Disease
presents	NN	O	O
as	NN	O	O
palpable	NN	O	O
purpura	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
lower	NN	O	O
extremities	NN	O	O
often	NN	O	O
accompanied	NN	O	O
by	NN	O	O
abdominal	NN	O	B-Disease
pain	NN	O	I-Disease
,	NN	O	O
arthralgia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
renal	NN	O	B-Disease
involvement	NN	O	I-Disease
.	NN	O	O

Etiologic	NN	O	O
factors	NN	O	O
or	NN	O	O
associated	NN	O	O
disorders	NN	O	O
include	NN	O	O
infections	NN	O	B-Disease
,	NN	O	O
medications	NN	O	O
,	NN	O	O
collagen	NN	O	B-Disease
vascular	NN	O	I-Disease
disease	NN	O	I-Disease
and	NN	O	O
neoplasia	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
in	NN	O	O
half	NN	O	O
of	NN	O	O
the	NN	O	O
cases	NN	O	O
no	NN	O	O
etiologic	NN	O	O
factor	NN	O	O
is	NN	O	O
identified	NN	O	O
.	NN	O	O

Usually	NN	O	O
it	NN	O	O
is	NN	O	O
a	NN	O	O
self	NN	O	O
-	NN	O	O
limited	NN	O	O
disorder	NN	O	O
,	NN	O	O
but	NN	O	O
corticosteroid	NN	O	B-Chemical
therapy	NN	O	O
may	NN	O	O
be	NN	O	O
needed	NN	O	O
in	NN	O	O
life	NN	O	O
-	NN	O	O
threatening	NN	O	O
cases	NN	O	O
since	NN	O	O
early	NN	O	O
treatment	NN	O	O
with	NN	O	O
corticosteroids	NN	O	B-Chemical
in	NN	O	O
severe	NN	O	O
cases	NN	O	O
can	NN	O	O
prevent	NN	O	O
complications	NN	O	O
.	NN	O	O

Oxacillin	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
included	NN	O	O
among	NN	O	O
the	NN	O	O
drugs	NN	O	O
that	NN	O	O
can	NN	O	O
cause	NN	O	O
leucocytoclastic	NN	O	B-Disease
vasculitis	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (6308526)

Naloxazone	NN	O	B-Chemical
pretreatment	NN	O	O
modifies	NN	O	O
cardiorespiratory	NN	O	O
,	NN	O	O
temperature	NN	O	O
,	NN	O	O
and	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
.	NN	O	O

Behavioral	NN	O	O
and	NN	O	O
cardiorespiratory	NN	O	O
responses	NN	O	O
to	NN	O	O
a	NN	O	O
lethal	NN	O	O
dose	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
were	NN	O	O
evaluated	NN	O	O
in	NN	O	O
rats	NN	O	O
pretreated	NN	O	O
with	NN	O	O
saline	NN	O	O
or	NN	O	O
naloxazone	NN	O	B-Chemical
,	NN	O	O
an	NN	O	O
antagonist	NN	O	O
of	NN	O	O
high	NN	O	O
-	NN	O	O
affinity	NN	O	O
mu	NN	O	O
1	NN	O	O
opioid	NN	O	O
receptors	NN	O	O
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
naloxazone	NN	O	B-Chemical
significantly	NN	O	O
blocked	NN	O	O
morphine	NN	O	B-Chemical
analgesia	NN	O	B-Disease
,	NN	O	O
catalepsy	NN	O	B-Disease
and	NN	O	O
hypothermia	NN	O	B-Disease
at	NN	O	O
a	NN	O	O
dose	NN	O	O
which	NN	O	O
completely	NN	O	O
eliminated	NN	O	O
high	NN	O	O
-	NN	O	O
affinity	NN	O	O
binding	NN	O	O
in	NN	O	O
brain	NN	O	O
membranes	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
naloxazone	NN	O	B-Chemical
significantly	NN	O	O
attenuated	NN	O	O
the	NN	O	O
morphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
and	NN	O	O
respiratory	NN	O	B-Disease
depression	NN	O	I-Disease
,	NN	O	O
whereas	NN	O	O
morphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
bradycardia	NN	O	B-Disease
was	NN	O	O
less	NN	O	O
affected	NN	O	O
.	NN	O	O

Results	NN	O	O
indicate	NN	O	O
that	NN	O	O
subpopulations	NN	O	O
of	NN	O	O
mu	NN	O	O
receptors	NN	O	O
may	NN	O	O
mediate	NN	O	O
selective	NN	O	O
behavioral	NN	O	O
and	NN	O	O
cardiorespiratory	NN	O	O
responses	NN	O	O
to	NN	O	O
morphine	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (15897593)

Dexrazoxane	NN	O	B-Chemical
protects	NN	O	O
against	NN	O	O
myelosuppression	NN	O	B-Disease
from	NN	O	O
the	NN	O	O
DNA	NN	O	O
cleavage	NN	O	O
-	NN	O	O
enhancing	NN	O	O
drugs	NN	O	O
etoposide	NN	O	B-Chemical
and	NN	O	O
daunorubicin	NN	O	B-Chemical
but	NN	O	O
not	NN	O	O
doxorubicin	NN	O	B-Chemical
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
The	NN	O	O
anthracyclines	NN	O	B-Chemical
daunorubicin	NN	O	B-Chemical
and	NN	O	O
doxorubicin	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
epipodophyllotoxin	NN	O	B-Chemical
etoposide	NN	O	B-Chemical
are	NN	O	O
potent	NN	O	O
DNA	NN	O	O
cleavage	NN	O	O
-	NN	O	O
enhancing	NN	O	O
drugs	NN	O	O
that	NN	O	O
are	NN	O	O
widely	NN	O	O
used	NN	O	O
in	NN	O	O
clinical	NN	O	O
oncology	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
myelosuppression	NN	O	B-Disease
and	NN	O	O
cardiac	NN	O	B-Disease
toxicity	NN	O	I-Disease
limit	NN	O	O
their	NN	O	O
use	NN	O	O
.	NN	O	O

Dexrazoxane	NN	O	B-Chemical
(	NN	O	O
ICRF	NN	O	B-Chemical
-	NN	O	I-Chemical
187	NN	O	I-Chemical
)	NN	O	O
is	NN	O	O
recommended	NN	O	O
for	NN	O	O
protection	NN	O	O
against	NN	O	O
anthracycline	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B-Disease
.	NN	O	O

EXPERIMENTAL	NN	O	O
DESIGN	NN	O	O
:	NN	O	O
Because	NN	O	O
of	NN	O	O
their	NN	O	O
widespread	NN	O	O
use	NN	O	O
,	NN	O	O
the	NN	O	O
hematologic	NN	O	B-Disease
toxicity	NN	O	I-Disease
following	NN	O	O
coadministration	NN	O	O
of	NN	O	O
dexrazoxane	NN	O	B-Chemical
and	NN	O	O
these	NN	O	O
three	NN	O	O
structurally	NN	O	O
different	NN	O	O
DNA	NN	O	O
cleavage	NN	O	O
enhancers	NN	O	O
was	NN	O	O
investigated	NN	O	O
:	NN	O	O
Sensitivity	NN	O	O
of	NN	O	O
human	NN	O	O
and	NN	O	O
murine	NN	O	O
blood	NN	O	O
progenitor	NN	O	O
cells	NN	O	O
to	NN	O	O
etoposide	NN	O	B-Chemical
,	NN	O	O
daunorubicin	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
doxorubicin	NN	O	B-Chemical
+	NN	O	O
/	NN	O	O
-	NN	O	O
dexrazoxane	NN	O	B-Chemical
was	NN	O	O
determined	NN	O	O
in	NN	O	O
granulocyte	NN	O	O
-	NN	O	O
macrophage	NN	O	O
colony	NN	O	O
forming	NN	O	O
assays	NN	O	O
.	NN	O	O

Likewise	NN	O	O
,	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
B6D2F1	NN	O	O
mice	NN	O	O
were	NN	O	O
treated	NN	O	O
with	NN	O	O
etoposide	NN	O	B-Chemical
,	NN	O	O
daunorubicin	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
doxorubicin	NN	O	B-Chemical
,	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
dexrazoxane	NN	O	B-Chemical
over	NN	O	O
a	NN	O	O
wide	NN	O	O
range	NN	O	O
of	NN	O	O
doses	NN	O	O
:	NN	O	O
posttreatment	NN	O	O
,	NN	O	O
a	NN	O	O
full	NN	O	O
hematologic	NN	O	O
evaluation	NN	O	O
was	NN	O	O
done	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Nontoxic	NN	O	O
doses	NN	O	O
of	NN	O	O
dexrazoxane	NN	O	B-Chemical
reduced	NN	O	O
myelosuppression	NN	O	B-Disease
and	NN	O	O
weight	NN	O	B-Disease
loss	NN	O	I-Disease
from	NN	O	O
daunorubicin	NN	O	B-Chemical
and	NN	O	O
etoposide	NN	O	B-Chemical
in	NN	O	O
mice	NN	O	O
and	NN	O	O
antagonized	NN	O	O
their	NN	O	O
antiproliferative	NN	O	O
effects	NN	O	O
in	NN	O	O
the	NN	O	O
colony	NN	O	O
assay	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
dexrazoxane	NN	O	B-Chemical
neither	NN	O	O
reduced	NN	O	O
myelosuppression	NN	O	B-Disease
,	NN	O	O
weight	NN	O	B-Disease
loss	NN	O	I-Disease
,	NN	O	O
nor	NN	O	O
the	NN	O	O
in	NN	O	O
vitro	NN	O	O
cytotoxicity	NN	O	B-Disease
from	NN	O	O
doxorubicin	NN	O	B-Chemical
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Although	NN	O	O
our	NN	O	O
findings	NN	O	O
support	NN	O	O
the	NN	O	O
observation	NN	O	O
that	NN	O	O
dexrazoxane	NN	O	B-Chemical
reduces	NN	O	O
neither	NN	O	O
hematologic	NN	O	O
activity	NN	O	O
nor	NN	O	O
antitumor	NN	O	O
activity	NN	O	O
from	NN	O	O
doxorubicin	NN	O	B-Chemical
clinically	NN	O	O
,	NN	O	O
the	NN	O	O
potent	NN	O	O
antagonism	NN	O	O
of	NN	O	O
daunorubicin	NN	O	B-Chemical
activity	NN	O	O
raises	NN	O	O
concern	NN	O	O
;	NN	O	O
a	NN	O	O
possible	NN	O	O
interference	NN	O	O
with	NN	O	O
anticancer	NN	O	O
efficacy	NN	O	O
certainly	NN	O	O
would	NN	O	O
call	NN	O	O
for	NN	O	O
renewed	NN	O	O
attention	NN	O	O
.	NN	O	O

Our	NN	O	O
data	NN	O	O
also	NN	O	O
suggest	NN	O	O
that	NN	O	O
significant	NN	O	O
etoposide	NN	O	B-Chemical
dose	NN	O	O
escalation	NN	O	O
is	NN	O	O
perhaps	NN	O	O
possible	NN	O	O
by	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
dexrazoxane	NN	O	B-Chemical
.	NN	O	O

Clinical	NN	O	O
trials	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
brain	NN	O	O
metastases	NN	O	B-Disease
combining	NN	O	O
dexrazoxane	NN	O	B-Chemical
and	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
etoposide	NN	O	B-Chemical
is	NN	O	O
ongoing	NN	O	O
with	NN	O	O
the	NN	O	O
aim	NN	O	O
of	NN	O	O
improving	NN	O	O
efficacy	NN	O	O
without	NN	O	O
aggravating	NN	O	O
hematologic	NN	O	B-Disease
toxicity	NN	O	I-Disease
.	NN	O	O

If	NN	O	O
successful	NN	O	O
,	NN	O	O
this	NN	O	O
represents	NN	O	O
an	NN	O	O
exciting	NN	O	O
mechanism	NN	O	O
for	NN	O	O
pharmacologic	NN	O	O
regulation	NN	O	O
of	NN	O	O
side	NN	O	O
effects	NN	O	O
from	NN	O	O
cytotoxic	NN	O	O
chemotherapy	NN	O	O
.	NN	O	O


-DOCSTART- (6817363)

Effects	NN	O	O
of	NN	O	O
the	NN	O	O
novel	NN	O	O
compound	NN	O	O
aniracetam	NN	O	B-Chemical
(	NN	O	O
Ro	NN	O	B-Chemical
13	NN	O	I-Chemical
-	NN	O	I-Chemical
5057	NN	O	I-Chemical
)	NN	O	O
upon	NN	O	O
impaired	NN	O	B-Disease
learning	NN	O	I-Disease
and	NN	O	I-Disease
memory	NN	O	I-Disease
in	NN	O	O
rodents	NN	O	O
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
aniracetam	NN	O	B-Chemical
(	NN	O	O
Ro	NN	O	B-Chemical
13	NN	O	I-Chemical
-	NN	O	I-Chemical
5057	NN	O	I-Chemical
,	NN	O	O
1	NN	O	B-Chemical
-	NN	O	I-Chemical
anisoyl	NN	O	I-Chemical
-	NN	O	I-Chemical
2	NN	O	I-Chemical
-	NN	O	I-Chemical
pyrrolidinone	NN	O	I-Chemical
)	NN	O	O
was	NN	O	O
studied	NN	O	O
on	NN	O	O
various	NN	O	O
forms	NN	O	O
of	NN	O	O
experimentally	NN	O	O
impaired	NN	O	B-Disease
cognitive	NN	O	I-Disease
functions	NN	O	I-Disease
(	NN	O	O
learning	NN	O	O
and	NN	O	O
memory	NN	O	O
)	NN	O	O
in	NN	O	O
rodents	NN	O	O
and	NN	O	O
produced	NN	O	O
the	NN	O	O
following	NN	O	O
effects	NN	O	O
:	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
almost	NN	O	O
complete	NN	O	O
prevention	NN	O	O
of	NN	O	O
the	NN	O	O
incapacity	NN	O	O
to	NN	O	O
learn	NN	O	O
a	NN	O	O
discrete	NN	O	O
escape	NN	O	O
response	NN	O	O
in	NN	O	O
rats	NN	O	O
exposed	NN	O	O
to	NN	O	O
sublethal	NN	O	O
hypercapnia	NN	O	B-Disease
immediately	NN	O	O
before	NN	O	O
the	NN	O	O
acquisition	NN	O	O
session	NN	O	O
;	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
partial	NN	O	O
(	NN	O	O
rats	NN	O	O
)	NN	O	O
or	NN	O	O
complete	NN	O	O
(	NN	O	O
mice	NN	O	O
)	NN	O	O
prevention	NN	O	O
of	NN	O	O
the	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
amnesia	NN	O	B-Disease
for	NN	O	O
a	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
;	NN	O	O
(	NN	O	O
3	NN	O	O
)	NN	O	O
complete	NN	O	O
protection	NN	O	O
against	NN	O	O
amnesia	NN	O	B-Disease
for	NN	O	O
a	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
in	NN	O	O
rats	NN	O	O
submitted	NN	O	O
to	NN	O	O
electroconvulsive	NN	O	O
shock	NN	O	O
immediately	NN	O	O
after	NN	O	O
avoidance	NN	O	O
acquisition	NN	O	O
;	NN	O	O
(	NN	O	O
4	NN	O	O
)	NN	O	O
prevention	NN	O	O
of	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
retention	NN	O	O
-	NN	O	O
or	NN	O	O
retrieval	NN	O	O
-	NN	O	O
deficit	NN	O	O
for	NN	O	O
a	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
induced	NN	O	O
in	NN	O	O
rats	NN	O	O
and	NN	O	O
mice	NN	O	O
by	NN	O	O
chloramphenicol	NN	O	B-Chemical
or	NN	O	O
cycloheximide	NN	O	B-Chemical
administered	NN	O	O
immediately	NN	O	O
after	NN	O	O
acquisition	NN	O	O
;	NN	O	O
(	NN	O	O
5	NN	O	O
)	NN	O	O
reversal	NN	O	O
,	NN	O	O
when	NN	O	O
administered	NN	O	O
as	NN	O	O
late	NN	O	O
as	NN	O	O
1	NN	O	O
h	NN	O	O
before	NN	O	O
the	NN	O	O
retention	NN	O	O
test	NN	O	O
,	NN	O	O
of	NN	O	O
the	NN	O	O
deficit	NN	O	O
in	NN	O	O
retention	NN	O	O
or	NN	O	O
retrieval	NN	O	O
of	NN	O	O
a	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
induced	NN	O	O
by	NN	O	O
cycloheximide	NN	O	B-Chemical
injected	NN	O	O
2	NN	O	O
days	NN	O	O
previously	NN	O	O
;	NN	O	O
(	NN	O	O
6	NN	O	O
)	NN	O	O
prevention	NN	O	O
of	NN	O	O
the	NN	O	O
deficit	NN	O	O
in	NN	O	O
the	NN	O	O
retrieval	NN	O	O
of	NN	O	O
an	NN	O	O
active	NN	O	O
avoidance	NN	O	O
task	NN	O	O
induced	NN	O	O
in	NN	O	O
mice	NN	O	O
by	NN	O	O
subconvulsant	NN	O	O
electroshock	NN	O	O
or	NN	O	O
hypercapnia	NN	O	B-Disease
applied	NN	O	O
immediately	NN	O	O
before	NN	O	O
retrieval	NN	O	O
testing	NN	O	O
(	NN	O	O
24	NN	O	O
h	NN	O	O
after	NN	O	O
acquisition	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
improvements	NN	O	O
or	NN	O	O
normalizations	NN	O	O
of	NN	O	O
impaired	NN	O	B-Disease
cognitive	NN	O	I-Disease
functions	NN	O	I-Disease
were	NN	O	O
seen	NN	O	O
at	NN	O	O
oral	NN	O	O
aniracetam	NN	O	B-Chemical
doses	NN	O	O
of	NN	O	O
10	NN	O	O
-	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

Generally	NN	O	O
,	NN	O	O
the	NN	O	O
dose	NN	O	O
-	NN	O	O
response	NN	O	O
curves	NN	O	O
were	NN	O	O
bell	NN	O	O
-	NN	O	O
shaped	NN	O	O
.	NN	O	O

The	NN	O	O
mechanisms	NN	O	O
underlying	NN	O	O
the	NN	O	O
activity	NN	O	O
of	NN	O	O
aniracetam	NN	O	B-Chemical
and	NN	O	O
its	NN	O	O
'	NN	O	O
therapeutic	NN	O	O
window	NN	O	O
'	NN	O	O
are	NN	O	O
unknown	NN	O	O
.	NN	O	O

Piracetam	NN	O	B-Chemical
,	NN	O	O
another	NN	O	O
pyrrolidinone	NN	O	B-Chemical
derivative	NN	O	O
was	NN	O	O
used	NN	O	O
for	NN	O	O
comparison	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
active	NN	O	O
only	NN	O	O
in	NN	O	O
six	NN	O	O
of	NN	O	O
nine	NN	O	O
tests	NN	O	O
and	NN	O	O
had	NN	O	O
about	NN	O	O
one	NN	O	O
-	NN	O	O
tenth	NN	O	O
the	NN	O	O
potency	NN	O	O
of	NN	O	O
aniracetam	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
aniracetam	NN	O	B-Chemical
improves	NN	O	O
cognitive	NN	O	O
functions	NN	O	O
which	NN	O	O
are	NN	O	O
impaired	NN	O	O
by	NN	O	O
different	NN	O	O
procedure	NN	O	O
and	NN	O	O
in	NN	O	O
different	NN	O	O
phases	NN	O	O
of	NN	O	O
the	NN	O	O
learning	NN	O	O
and	NN	O	O
memory	NN	O	O
process	NN	O	O
.	NN	O	O


-DOCSTART- (11900788)

Nicotine	NN	O	B-Chemical
potentiation	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
catalepsy	NN	O	B-Disease
in	NN	O	O
mice	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
effects	NN	O	O
of	NN	O	O
nicotine	NN	O	B-Chemical
on	NN	O	O
catalepsy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
morphine	NN	O	B-Chemical
in	NN	O	O
mice	NN	O	O
have	NN	O	O
been	NN	O	O
investigated	NN	O	O
.	NN	O	O

Morphine	NN	O	B-Chemical
but	NN	O	O
not	NN	O	O
nicotine	NN	O	B-Chemical
induced	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
catalepsy	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
response	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
was	NN	O	O
potentiated	NN	O	O
by	NN	O	O
nicotine	NN	O	B-Chemical
.	NN	O	O

Intraperitoneal	NN	O	O
administration	NN	O	O
of	NN	O	O
atropine	NN	O	B-Chemical
,	NN	O	O
naloxone	NN	O	B-Chemical
,	NN	O	O
mecamylamine	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
hexamethonium	NN	O	B-Chemical
to	NN	O	O
mice	NN	O	O
reduced	NN	O	O
catalepsy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
a	NN	O	O
combination	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
with	NN	O	O
nicotine	NN	O	B-Chemical
.	NN	O	O

Intracerebroventricular	NN	O	O
injection	NN	O	O
of	NN	O	O
atropine	NN	O	B-Chemical
,	NN	O	O
hexamethonium	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
naloxone	NN	O	B-Chemical
also	NN	O	O
decreased	NN	O	O
catalepsy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
morphine	NN	O	B-Chemical
plus	NN	O	O
nicotine	NN	O	B-Chemical
.	NN	O	O

Intraperitoneal	NN	O	O
administration	NN	O	O
of	NN	O	O
atropine	NN	O	B-Chemical
,	NN	O	O
but	NN	O	O
not	NN	O	O
intraperitoneal	NN	O	O
or	NN	O	O
intracerebroventricular	NN	O	O
injection	NN	O	O
of	NN	O	O
hexamethonium	NN	O	B-Chemical
,	NN	O	O
decreased	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
.	NN	O	O

It	NN	O	O
was	NN	O	O
concluded	NN	O	O
that	NN	O	O
morphine	NN	O	B-Chemical
catalepsy	NN	O	B-Disease
can	NN	O	O
be	NN	O	O
elicited	NN	O	O
by	NN	O	O
opioid	NN	O	O
and	NN	O	O
cholinergic	NN	O	O
receptors	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
potentiation	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
induced	NN	O	O
by	NN	O	O
nicotine	NN	O	B-Chemical
may	NN	O	O
also	NN	O	O
be	NN	O	O
mediated	NN	O	O
through	NN	O	O
cholinergic	NN	O	O
receptor	NN	O	O
mechanisms	NN	O	O
.	NN	O	O


-DOCSTART- (11230490)

Reduced	NN	O	O
cardiotoxicity	NN	O	B-Disease
and	NN	O	O
preserved	NN	O	O
antitumor	NN	O	O
efficacy	NN	O	O
of	NN	O	O
liposome	NN	O	O
-	NN	O	O
encapsulated	NN	O	O
doxorubicin	NN	O	B-Chemical
and	NN	O	O
cyclophosphamide	NN	O	B-Chemical
compared	NN	O	O
with	NN	O	O
conventional	NN	O	O
doxorubicin	NN	O	B-Chemical
and	NN	O	O
cyclophosphamide	NN	O	B-Chemical
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
,	NN	O	O
multicenter	NN	O	O
trial	NN	O	O
of	NN	O	O
metastatic	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
determine	NN	O	O
whether	NN	O	O
Myocet	NN	O	B-Chemical
(	NN	O	O
liposome	NN	O	O
-	NN	O	O
encapsulated	NN	O	O
doxorubicin	NN	O	B-Chemical
;	NN	O	O
The	NN	O	O
Liposome	NN	O	O
Company	NN	O	O
,	NN	O	O
Elan	NN	O	O
Corporation	NN	O	O
,	NN	O	O
Princeton	NN	O	O
,	NN	O	O
NJ	NN	O	O
)	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
cyclophosphamide	NN	O	B-Chemical
significantly	NN	O	O
reduces	NN	O	O
doxorubicin	NN	O	B-Chemical
cardiotoxicity	NN	O	B-Disease
while	NN	O	O
providing	NN	O	O
comparable	NN	O	O
antitumor	NN	O	O
efficacy	NN	O	O
in	NN	O	O
first	NN	O	O
-	NN	O	O
line	NN	O	O
treatment	NN	O	O
of	NN	O	O
metastatic	NN	O	O
breast	NN	O	B-Disease
cancer	NN	O	I-Disease
(	NN	O	O
MBC	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
Two	NN	O	O
hundred	NN	O	O
ninety	NN	O	O
-	NN	O	O
seven	NN	O	O
patients	NN	O	O
with	NN	O	O
MBC	NN	O	B-Disease
and	NN	O	O
no	NN	O	O
prior	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
metastatic	NN	O	O
disease	NN	O	O
were	NN	O	O
randomized	NN	O	O
to	NN	O	O
receive	NN	O	O
either	NN	O	O
60	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
of	NN	O	O
Myocet	NN	O	B-Chemical
(	NN	O	O
M	NN	O	O
)	NN	O	O
or	NN	O	O
conventional	NN	O	O
doxorubicin	NN	O	B-Chemical
(	NN	O	O
A	NN	O	O
)	NN	O	O
,	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
600	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
of	NN	O	O
cyclophosphamide	NN	O	B-Chemical
(	NN	O	O
C	NN	O	O
)	NN	O	O
,	NN	O	O
every	NN	O	O
3	NN	O	O
weeks	NN	O	O
until	NN	O	O
disease	NN	O	O
progression	NN	O	O
or	NN	O	O
unacceptable	NN	O	O
toxicity	NN	O	B-Disease
.	NN	O	O

Cardiotoxicity	NN	O	B-Disease
was	NN	O	O
defined	NN	O	O
by	NN	O	O
reductions	NN	O	O
in	NN	O	O
left	NN	O	O
-	NN	O	O
ventricular	NN	O	O
ejection	NN	O	O
fraction	NN	O	O
,	NN	O	O
assessed	NN	O	O
by	NN	O	O
serial	NN	O	O
multigated	NN	O	O
radionuclide	NN	O	O
angiography	NN	O	O
scans	NN	O	O
,	NN	O	O
or	NN	O	O
congestive	NN	O	B-Disease
heart	NN	O	I-Disease
failure	NN	O	I-Disease
(	NN	O	O
CHF	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

Antitumor	NN	O	O
efficacy	NN	O	O
was	NN	O	O
assessed	NN	O	O
by	NN	O	O
objective	NN	O	O
tumor	NN	O	B-Disease
response	NN	O	O
rates	NN	O	O
(	NN	O	O
World	NN	O	O
Health	NN	O	O
Organization	NN	O	O
criteria	NN	O	O
)	NN	O	O
,	NN	O	O
time	NN	O	O
to	NN	O	O
progression	NN	O	O
,	NN	O	O
and	NN	O	O
survival	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Six	NN	O	O
percent	NN	O	O
of	NN	O	O
MC	NN	O	O
patients	NN	O	O
versus	NN	O	O
21%	NN	O	O
(	NN	O	O
including	NN	O	O
five	NN	O	O
cases	NN	O	O
of	NN	O	O
CHF	NN	O	B-Disease
)	NN	O	O
of	NN	O	O
AC	NN	O	O
patients	NN	O	O
developed	NN	O	O
cardiotoxicity	NN	O	B-Disease
(	NN	O	O
P	NN	O	O
=.0002	NN	O	O
)	NN	O	O
.	NN	O	O

Median	NN	O	O
cumulative	NN	O	O
doxorubicin	NN	O	B-Chemical
dose	NN	O	O
at	NN	O	O
onset	NN	O	O
was	NN	O	O
more	NN	O	O
than	NN	O	O
2	NN	O	O
,	NN	O	O
220	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
for	NN	O	O
MC	NN	O	O
versus	NN	O	O
480	NN	O	O
mg	NN	O	O
/	NN	O	O
m	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
for	NN	O	O
AC	NN	O	O
(	NN	O	O
P	NN	O	O
=.0001	NN	O	O
,	NN	O	O
hazard	NN	O	O
ratio	NN	O	O
,	NN	O	O
5.04	NN	O	O
)	NN	O	O
.	NN	O	O

MC	NN	O	O
patients	NN	O	O
also	NN	O	O
experienced	NN	O	O
less	NN	O	O
grade	NN	O	O
4	NN	O	O
neutropenia	NN	O	B-Disease
.	NN	O	O

Antitumor	NN	O	O
efficacy	NN	O	O
of	NN	O	O
MC	NN	O	O
versus	NN	O	O
AC	NN	O	O
was	NN	O	O
comparable	NN	O	O
:	NN	O	O
objective	NN	O	O
response	NN	O	O
rates	NN	O	O
,	NN	O	O
43%	NN	O	O
versus	NN	O	O
43%	NN	O	O
;	NN	O	O
median	NN	O	O
time	NN	O	O
to	NN	O	O
progression	NN	O	O
,	NN	O	O
5.1%	NN	O	O
versus	NN	O	O
5.5	NN	O	O
months	NN	O	O
;	NN	O	O
median	NN	O	O
time	NN	O	O
to	NN	O	O
treatment	NN	O	O
failure	NN	O	O
,	NN	O	O
4.6	NN	O	O
versus	NN	O	O
4.4	NN	O	O
months	NN	O	O
;	NN	O	O
and	NN	O	O
median	NN	O	O
survival	NN	O	O
,	NN	O	O
19	NN	O	O
versus	NN	O	O
16	NN	O	O
months	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Myocet	NN	O	B-Chemical
improves	NN	O	O
the	NN	O	O
therapeutic	NN	O	O
index	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
by	NN	O	O
significantly	NN	O	O
reducing	NN	O	O
cardiotoxicity	NN	O	B-Disease
and	NN	O	O
grade	NN	O	O
4	NN	O	O
neutropenia	NN	O	B-Disease
and	NN	O	O
provides	NN	O	O
comparable	NN	O	O
antitumor	NN	O	O
efficacy	NN	O	O
,	NN	O	O
when	NN	O	O
used	NN	O	O
in	NN	O	O
combination	NN	O	O
with	NN	O	O
cyclophosphamide	NN	O	B-Chemical
as	NN	O	O
first	NN	O	O
-	NN	O	O
line	NN	O	O
therapy	NN	O	O
for	NN	O	O
MBC	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (2594614)

Protective	NN	O	O
effect	NN	O	O
of	NN	O	O
a	NN	O	O
specific	NN	O	O
platelet	NN	O	O
-	NN	O	O
activating	NN	O	O
factor	NN	O	O
antagonist	NN	O	O
,	NN	O	O
BN	NN	O	B-Chemical
52021	NN	O	I-Chemical
,	NN	O	O
on	NN	O	O
bupivacaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiovascular	NN	O	B-Disease
impairments	NN	O	I-Disease
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
the	NN	O	O
local	NN	O	O
anaesthetic	NN	O	O
bupivacaine	NN	O	B-Chemical
(	NN	O	O
1.5	NN	O	O
or	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
i.v.	NN	O	O
)	NN	O	O
to	NN	O	O
rats	NN	O	O
elicited	NN	O	O
a	NN	O	O
marked	NN	O	O
decrease	NN	O	B-Disease
of	NN	O	I-Disease
mean	NN	O	I-Disease
arterial	NN	O	I-Disease
blood	NN	O	I-Disease
pressure	NN	O	I-Disease
(	NN	O	I-Disease
MBP	NN	O	I-Disease
)	NN	O	I-Disease
and	NN	O	I-Disease
heart	NN	O	I-Disease
rate	NN	O	I-Disease
(	NN	O	I-Disease
HR	NN	O	I-Disease
)	NN	O	I-Disease
leading	NN	O	O
to	NN	O	O
death	NN	O	O
(	NN	O	O
in	NN	O	O
67%	NN	O	O
or	NN	O	O
90%	NN	O	O
of	NN	O	O
animals	NN	O	O
respectively	NN	O	O
)	NN	O	O
.	NN	O	O

Intravenous	NN	O	O
injection	NN	O	O
of	NN	O	O
the	NN	O	O
specific	NN	O	O
platelet	NN	O	O
-	NN	O	O
activating	NN	O	O
factor	NN	O	O
(	NN	O	O
PAF	NN	O	O
)	NN	O	O
antagonist	NN	O	O
BN	NN	O	B-Chemical
52021	NN	O	I-Chemical
(	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
30	NN	O	O
min	NN	O	O
before	NN	O	O
bupivacaine	NN	O	B-Chemical
administration	NN	O	O
(	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
)	NN	O	O
suppressed	NN	O	O
both	NN	O	O
the	NN	O	O
decrease	NN	O	B-Disease
of	NN	O	I-Disease
MBP	NN	O	I-Disease
and	NN	O	I-Disease
HR	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
doses	NN	O	O
of	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
BN	NN	O	B-Chemical
52021	NN	O	I-Chemical
given	NN	O	O
30	NN	O	O
min	NN	O	O
before	NN	O	O
or	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
administered	NN	O	O
5	NN	O	O
min	NN	O	O
before	NN	O	O
i.v.	NN	O	O
injection	NN	O	O
of	NN	O	O
bupivacaine	NN	O	B-Chemical
were	NN	O	O
ineffective	NN	O	O
.	NN	O	O

When	NN	O	O
BN	NN	O	B-Chemical
52021	NN	O	I-Chemical
(	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.v.	NN	O	O
)	NN	O	O
was	NN	O	O
injected	NN	O	O
immediately	NN	O	O
after	NN	O	O
bupivacaine	NN	O	B-Chemical
(	NN	O	O
2	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
a	NN	O	O
partial	NN	O	O
reversion	NN	O	O
of	NN	O	O
the	NN	O	O
decrease	NN	O	B-Disease
of	NN	O	I-Disease
MBP	NN	O	I-Disease
and	NN	O	I-Disease
HR	NN	O	I-Disease
was	NN	O	O
observed	NN	O	O
,	NN	O	O
whereas	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
was	NN	O	O
ineffective	NN	O	O
.	NN	O	O

A	NN	O	O
partial	NN	O	O
recovery	NN	O	O
of	NN	O	O
bupivacaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
ECG	NN	O	O
alterations	NN	O	O
was	NN	O	O
observed	NN	O	O
after	NN	O	O
pretreatment	NN	O	O
of	NN	O	O
the	NN	O	O
rats	NN	O	O
with	NN	O	O
BN	NN	O	B-Chemical
52021	NN	O	I-Chemical
.	NN	O	O

Since	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
BN	NN	O	B-Chemical
52021	NN	O	I-Chemical
,	NN	O	O
at	NN	O	O
all	NN	O	O
doses	NN	O	O
studied	NN	O	O
,	NN	O	O
did	NN	O	O
not	NN	O	O
alter	NN	O	O
MBP	NN	O	O
and	NN	O	O
HR	NN	O	O
at	NN	O	O
the	NN	O	O
doses	NN	O	O
used	NN	O	O
,	NN	O	O
the	NN	O	O
bulk	NN	O	O
of	NN	O	O
these	NN	O	O
results	NN	O	O
clearly	NN	O	O
demonstrate	NN	O	O
a	NN	O	O
protective	NN	O	O
action	NN	O	O
of	NN	O	O
BN	NN	O	B-Chemical
52021	NN	O	I-Chemical
,	NN	O	O
a	NN	O	O
specific	NN	O	O
antagonist	NN	O	O
of	NN	O	O
PAF	NN	O	O
,	NN	O	O
against	NN	O	O
bupivacaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiovascular	NN	O	B-Disease
toxicity	NN	O	I-Disease
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
consistent	NN	O	O
with	NN	O	O
its	NN	O	O
direct	NN	O	O
effect	NN	O	O
on	NN	O	O
heart	NN	O	O
,	NN	O	O
PAF	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
implicated	NN	O	O
in	NN	O	O
bupivacaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiovascular	NN	O	B-Disease
alterations	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (2257294)

Benzylacyclouridine	NN	O	B-Chemical
reverses	NN	O	O
azidothymidine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
marrow	NN	O	B-Disease
suppression	NN	O	I-Disease
without	NN	O	O
impairment	NN	O	O
of	NN	O	O
anti	NN	O	O
-	NN	O	O
human	NN	O	O
immunodeficiency	NN	O	B-Disease
virus	NN	O	O
activity	NN	O	O
.	NN	O	O

Increased	NN	O	O
extracellular	NN	O	O
concentrations	NN	O	O
of	NN	O	O
uridine	NN	O	B-Chemical
(	NN	O	O
Urd	NN	O	B-Chemical
)	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
reduce	NN	O	O
,	NN	O	O
in	NN	O	O
vitro	NN	O	O
,	NN	O	O
azidothymidine	NN	O	B-Chemical
(	NN	O	O
AZT	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
inhibition	NN	O	O
of	NN	O	O
human	NN	O	O
granulocyte	NN	O	O
-	NN	O	O
macrophage	NN	O	O
progenitor	NN	O	O
cells	NN	O	O
without	NN	O	O
impairment	NN	O	O
of	NN	O	O
its	NN	O	O
antihuman	NN	O	O
immunodeficiency	NN	O	B-Disease
virus	NN	O	O
(	NN	O	O
HIV	NN	O	O
)	NN	O	O
activity	NN	O	O
.	NN	O	O

Because	NN	O	O
of	NN	O	O
the	NN	O	O
clinical	NN	O	O
toxicities	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
chronic	NN	O	O
Urd	NN	O	B-Chemical
administration	NN	O	O
,	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
benzylacyclouridine	NN	O	B-Chemical
(	NN	O	O
BAU	NN	O	B-Chemical
)	NN	O	O
to	NN	O	O
effect	NN	O	O
,	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
AZT	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B-Disease
and	NN	O	O
leukopenia	NN	O	B-Disease
was	NN	O	O
assessed	NN	O	O
.	NN	O	O

This	NN	O	O
agent	NN	O	O
inhibits	NN	O	O
Urd	NN	O	B-Chemical
catabolism	NN	O	O
and	NN	O	O
,	NN	O	O
in	NN	O	O
vivo	NN	O	O
,	NN	O	O
increases	NN	O	O
the	NN	O	O
plasma	NN	O	O
concentration	NN	O	O
of	NN	O	O
Urd	NN	O	B-Chemical
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
,	NN	O	O
without	NN	O	O
Urd	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
toxicity	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
mice	NN	O	O
rendered	NN	O	O
anemic	NN	O	B-Disease
and	NN	O	O
leukopenic	NN	O	B-Disease
by	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
AZT	NN	O	B-Chemical
for	NN	O	O
28	NN	O	O
days	NN	O	O
in	NN	O	O
drinking	NN	O	O
water	NN	O	O
(	NN	O	O
1.5	NN	O	O
mg	NN	O	O
/	NN	O	O
mL	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
continued	NN	O	O
administration	NN	O	O
of	NN	O	O
AZT	NN	O	B-Chemical
plus	NN	O	O
daily	NN	O	O
BAU	NN	O	B-Chemical
(	NN	O	O
300	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
,	NN	O	O
orally	NN	O	O
)	NN	O	O
partially	NN	O	O
reversed	NN	O	O
AZT	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
anemia	NN	O	B-Disease
and	NN	O	O
leukopenia	NN	O	B-Disease
(	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
.05	NN	O	O
)	NN	O	O
,	NN	O	O
increased	NN	O	O
peripheral	NN	O	O
reticulocytes	NN	O	O
(	NN	O	O
to	NN	O	O
4.9%	NN	O	O
,	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
.01	NN	O	O
)	NN	O	O
,	NN	O	O
increased	NN	O	O
cellularity	NN	O	O
in	NN	O	O
the	NN	O	O
marrow	NN	O	O
,	NN	O	O
and	NN	O	O
improved	NN	O	O
megaloblastosis	NN	O	B-Disease
.	NN	O	O

When	NN	O	O
coadministered	NN	O	O
with	NN	O	O
AZT	NN	O	B-Chemical
from	NN	O	O
the	NN	O	O
onset	NN	O	O
of	NN	O	O
drug	NN	O	O
administration	NN	O	O
,	NN	O	O
BAU	NN	O	B-Chemical
reduced	NN	O	O
AZT	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
marrow	NN	O	B-Disease
toxicity	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
vitro	NN	O	O
,	NN	O	O
at	NN	O	O
a	NN	O	O
concentration	NN	O	O
of	NN	O	O
100	NN	O	O
mumol	NN	O	O
/	NN	O	O
L	NN	O	O
,	NN	O	O
BAU	NN	O	B-Chemical
possesses	NN	O	O
minimal	NN	O	O
anti	NN	O	O
-	NN	O	O
HIV	NN	O	O
activity	NN	O	O
and	NN	O	O
has	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
AZT	NN	O	B-Chemical
to	NN	O	O
reverse	NN	O	O
the	NN	O	O
HIV	NN	O	O
-	NN	O	O
induced	NN	O	O
cytopathic	NN	O	O
effect	NN	O	O
in	NN	O	O
MT4	NN	O	O
cells	NN	O	O
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
and	NN	O	O
biochemical	NN	O	O
implications	NN	O	O
of	NN	O	O
these	NN	O	O
findings	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O


-DOCSTART- (10840460)

Cyclophosphamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B-Disease
in	NN	O	O
freely	NN	O	O
-	NN	O	O
moving	NN	O	O
conscious	NN	O	O
rats	NN	O	O
:	NN	O	O
behavioral	NN	O	O
approach	NN	O	O
to	NN	O	O
a	NN	O	O
new	NN	O	O
model	NN	O	O
of	NN	O	O
visceral	NN	O	B-Disease
pain	NN	O	I-Disease
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
To	NN	O	O
develop	NN	O	O
a	NN	O	O
model	NN	O	O
of	NN	O	O
visceral	NN	O	B-Disease
pain	NN	O	I-Disease
in	NN	O	O
rats	NN	O	O
using	NN	O	O
a	NN	O	O
behavioral	NN	O	O
approach	NN	O	O
.	NN	O	O

Cyclophosphamide	NN	O	B-Chemical
(	NN	O	O
CP	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
an	NN	O	O
antitumoral	NN	O	O
agent	NN	O	O
known	NN	O	O
to	NN	O	O
produce	NN	O	O
toxic	NN	O	O
effects	NN	O	O
on	NN	O	O
the	NN	O	O
bladder	NN	O	O
wall	NN	O	O
through	NN	O	O
its	NN	O	O
main	NN	O	O
toxic	NN	O	O
metabolite	NN	O	O
acrolein	NN	O	B-Chemical
,	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
induce	NN	O	O
cystitis	NN	O	B-Disease
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
CP	NN	O	B-Chemical
was	NN	O	O
administered	NN	O	O
at	NN	O	O
doses	NN	O	O
of	NN	O	O
50	NN	O	O
,	NN	O	O
100	NN	O	O
and	NN	O	O
200	NN	O	O
mg.	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

i.p.	NN	O	O
to	NN	O	O
male	NN	O	O
rats	NN	O	O
,	NN	O	O
and	NN	O	O
their	NN	O	O
behavior	NN	O	O
observed	NN	O	O
and	NN	O	O
scored	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
(	NN	O	O
0.5	NN	O	O
to	NN	O	O
4	NN	O	O
mg.	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

i.v.	NN	O	O
)	NN	O	O
on	NN	O	O
CP	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
behavioral	NN	O	O
modifications	NN	O	O
were	NN	O	O
tested	NN	O	O
administered	NN	O	O
alone	NN	O	O
and	NN	O	O
after	NN	O	O
naloxone	NN	O	B-Chemical
(	NN	O	O
1	NN	O	O
mg.	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

s.c.	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
90	NN	O	O
minutes	NN	O	O
after	NN	O	O
CP	NN	O	B-Chemical
injection	NN	O	O
,	NN	O	O
that	NN	O	O
is	NN	O	O
,	NN	O	O
at	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
administration	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
,	NN	O	O
the	NN	O	O
bladder	NN	O	O
was	NN	O	O
removed	NN	O	O
in	NN	O	O
some	NN	O	O
rats	NN	O	O
for	NN	O	O
histological	NN	O	O
examination	NN	O	O
.	NN	O	O

Finally	NN	O	O
,	NN	O	O
to	NN	O	O
show	NN	O	O
that	NN	O	O
the	NN	O	O
bladder	NN	O	O
is	NN	O	O
essential	NN	O	O
for	NN	O	O
the	NN	O	O
CP	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
behavioral	NN	O	O
modifications	NN	O	O
,	NN	O	O
female	NN	O	O
rats	NN	O	O
also	NN	O	O
received	NN	O	O
CP	NN	O	B-Chemical
at	NN	O	O
doses	NN	O	O
of	NN	O	O
200	NN	O	O
mg.	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

i.p.	NN	O	O
and	NN	O	O
of	NN	O	O
20	NN	O	O
mg	NN	O	O
.	NN	O	O

by	NN	O	O
the	NN	O	O
intravesical	NN	O	O
route	NN	O	O
,	NN	O	O
and	NN	O	O
acrolein	NN	O	B-Chemical
at	NN	O	O
doses	NN	O	O
of	NN	O	O
0.5	NN	O	O
mg	NN	O	O
.	NN	O	O

by	NN	O	O
the	NN	O	O
intravesical	NN	O	O
route	NN	O	O
and	NN	O	O
of	NN	O	O
5	NN	O	O
mg.	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

i.v.	NN	O	O
RESULTS	NN	O	O
:	NN	O	O
CP	NN	O	B-Chemical
dose	NN	O	O
-	NN	O	O
relatedly	NN	O	O
induced	NN	O	O
marked	NN	O	O
behavioral	NN	O	O
modifications	NN	O	O
in	NN	O	O
male	NN	O	O
rats	NN	O	O
:	NN	O	O
breathing	NN	O	O
rate	NN	O	O
decrease	NN	O	O
,	NN	O	O
closing	NN	O	O
of	NN	O	O
the	NN	O	O
eyes	NN	O	O
and	NN	O	O
occurrence	NN	O	O
of	NN	O	O
specific	NN	O	O
postures	NN	O	O
.	NN	O	O

Morphine	NN	O	B-Chemical
dose	NN	O	O
-	NN	O	O
dependently	NN	O	O
reversed	NN	O	O
these	NN	O	O
behavioral	NN	O	B-Disease
disorders	NN	O	I-Disease
.	NN	O	O

A	NN	O	O
dose	NN	O	O
of	NN	O	O
0.5	NN	O	O
mg.	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

produced	NN	O	O
a	NN	O	O
reduction	NN	O	O
of	NN	O	O
almost	NN	O	O
50%	NN	O	O
of	NN	O	O
the	NN	O	O
behavioral	NN	O	O
score	NN	O	O
induced	NN	O	O
by	NN	O	O
CP	NN	O	B-Chemical
200	NN	O	O
mg.	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

This	NN	O	O
effect	NN	O	O
was	NN	O	O
completely	NN	O	O
prevented	NN	O	O
by	NN	O	O
pretreatment	NN	O	O
with	NN	O	O
naloxone	NN	O	B-Chemical
.	NN	O	O

At	NN	O	O
the	NN	O	O
time	NN	O	O
of	NN	O	O
administration	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
,	NN	O	O
histological	NN	O	O
modifications	NN	O	O
of	NN	O	O
the	NN	O	O
bladder	NN	O	O
wall	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
chorionic	NN	O	O
and	NN	O	O
muscle	NN	O	O
layer	NN	O	O
edema	NN	O	B-Disease
,	NN	O	O
were	NN	O	O
observed	NN	O	O
.	NN	O	O

In	NN	O	O
female	NN	O	O
rats	NN	O	O
,	NN	O	O
CP	NN	O	B-Chemical
200	NN	O	O
mg.	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

i.p.	NN	O	O
produced	NN	O	O
the	NN	O	O
same	NN	O	O
marked	NN	O	O
behavioral	NN	O	O
modifications	NN	O	O
as	NN	O	O
those	NN	O	O
observed	NN	O	O
in	NN	O	O
male	NN	O	O
rats	NN	O	O
.	NN	O	O

Administered	NN	O	O
at	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
20	NN	O	O
mg	NN	O	O
.	NN	O	O

intravesically	NN	O	O
,	NN	O	O
CP	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
produce	NN	O	O
any	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
,	NN	O	O
whereas	NN	O	O
acrolein	NN	O	B-Chemical
at	NN	O	O
0.5	NN	O	O
mg	NN	O	O
.	NN	O	O

intravesically	NN	O	O
induced	NN	O	O
behavioral	NN	O	O
modifications	NN	O	O
identical	NN	O	O
to	NN	O	O
those	NN	O	O
under	NN	O	O
CP	NN	O	B-Chemical
200	NN	O	O
mg.	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

i.p.	NN	O	O
,	NN	O	O
with	NN	O	O
the	NN	O	O
same	NN	O	O
maximal	NN	O	O
levels	NN	O	O
.	NN	O	O

Conversely	NN	O	O
,	NN	O	O
acrolein	NN	O	B-Chemical
5	NN	O	O
mg.	NN	O	O
/	NN	O	O
kg	NN	O	O
.	NN	O	O

i.v.	NN	O	O
did	NN	O	O
not	NN	O	O
produce	NN	O	O
any	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
at	NN	O	O
all	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Overall	NN	O	O
,	NN	O	O
these	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
this	NN	O	O
experimental	NN	O	O
model	NN	O	O
of	NN	O	O
CP	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B-Disease
may	NN	O	O
be	NN	O	O
an	NN	O	O
interesting	NN	O	O
new	NN	O	O
behavioral	NN	O	O
model	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
visceral	NN	O	B-Disease
pain	NN	O	I-Disease
,	NN	O	O
allowing	NN	O	O
a	NN	O	O
better	NN	O	O
understanding	NN	O	O
of	NN	O	O
these	NN	O	O
painful	NN	O	B-Disease
syndromes	NN	O	I-Disease
and	NN	O	O
thus	NN	O	O
a	NN	O	O
better	NN	O	O
therapeutic	NN	O	O
approach	NN	O	O
to	NN	O	O
them	NN	O	O
.	NN	O	O


-DOCSTART- (8278214)

Hyperalgesia	NN	O	B-Disease
and	NN	O	O
myoclonus	NN	O	B-Disease
in	NN	O	O
terminal	NN	O	O
cancer	NN	O	B-Disease
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
continuous	NN	O	O
intravenous	NN	O	O
morphine	NN	O	B-Chemical
.	NN	O	O

Eight	NN	O	O
cancer	NN	O	B-Disease
patients	NN	O	O
in	NN	O	O
the	NN	O	O
terminal	NN	O	O
stages	NN	O	O
of	NN	O	O
the	NN	O	O
disease	NN	O	O
treated	NN	O	O
with	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
intravenous	NN	O	O
morphine	NN	O	B-Chemical
developed	NN	O	O
hyperalgesia	NN	O	B-Disease
.	NN	O	O

All	NN	O	O
cases	NN	O	O
were	NN	O	O
retrospectively	NN	O	O
sampled	NN	O	O
from	NN	O	O
three	NN	O	O
different	NN	O	O
hospitals	NN	O	O
in	NN	O	O
Copenhagen	NN	O	O
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
developed	NN	O	O
universal	NN	O	O
hyperalgesia	NN	O	B-Disease
and	NN	O	O
hyperesthesia	NN	O	B-Disease
which	NN	O	O
in	NN	O	O
2	NN	O	O
cases	NN	O	O
were	NN	O	O
accompanied	NN	O	O
by	NN	O	O
myoclonus	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
3	NN	O	O
patients	NN	O	O
a	NN	O	O
pre	NN	O	O
-	NN	O	O
existing	NN	O	O
neuralgia	NN	O	B-Disease
increased	NN	O	O
to	NN	O	O
excruciating	NN	O	O
intensity	NN	O	O
and	NN	O	O
in	NN	O	O
2	NN	O	O
of	NN	O	O
these	NN	O	O
cases	NN	O	O
myoclonus	NN	O	B-Disease
occurred	NN	O	O
simultaneously	NN	O	O
.	NN	O	O

Although	NN	O	O
only	NN	O	O
few	NN	O	O
clinical	NN	O	O
descriptions	NN	O	O
of	NN	O	O
the	NN	O	O
relationship	NN	O	O
between	NN	O	O
hyperalgesia	NN	O	B-Disease
/	NN	O	O
myoclonus	NN	O	B-Disease
and	NN	O	O
high	NN	O	O
doses	NN	O	O
of	NN	O	O
morphine	NN	O	B-Chemical
are	NN	O	O
available	NN	O	O
,	NN	O	O
experimental	NN	O	O
support	NN	O	O
from	NN	O	O
animal	NN	O	O
studies	NN	O	O
indicates	NN	O	O
that	NN	O	O
morphine	NN	O	B-Chemical
,	NN	O	O
or	NN	O	O
its	NN	O	O
metabolites	NN	O	O
,	NN	O	O
plays	NN	O	O
a	NN	O	O
causative	NN	O	O
role	NN	O	O
for	NN	O	O
the	NN	O	O
observed	NN	O	O
behavioural	NN	O	O
syndrome	NN	O	O
.	NN	O	O

The	NN	O	O
possible	NN	O	O
mechanisms	NN	O	O
are	NN	O	O
discussed	NN	O	O
and	NN	O	O
treatment	NN	O	O
proposals	NN	O	O
given	NN	O	O
suggesting	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
more	NN	O	O
efficacious	NN	O	O
opioids	NN	O	O
with	NN	O	O
less	NN	O	O
excitatory	NN	O	O
potency	NN	O	O
in	NN	O	O
these	NN	O	O
situations	NN	O	O
.	NN	O	O


-DOCSTART- (3934126)

A	NN	O	O
prospective	NN	O	O
study	NN	O	O
of	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
associated	NN	O	O
with	NN	O	O
vancomycin	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

A	NN	O	O
prospective	NN	O	O
evaluation	NN	O	O
of	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
vancomycin	NN	O	B-Chemical
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
54	NN	O	O
consecutive	NN	O	O
patients	NN	O	O
over	NN	O	O
a	NN	O	O
16	NN	O	O
-	NN	O	O
month	NN	O	O
period	NN	O	O
.	NN	O	O

Vancomycin	NN	O	B-Chemical
was	NN	O	O
curative	NN	O	O
in	NN	O	O
95%	NN	O	O
of	NN	O	O
43	NN	O	O
patients	NN	O	O
with	NN	O	O
proven	NN	O	O
infection	NN	O	B-Disease
.	NN	O	O

Drugs	NN	O	O
were	NN	O	O
ceased	NN	O	O
in	NN	O	O
six	NN	O	O
patients	NN	O	O
because	NN	O	O
of	NN	O	O
adverse	NN	O	O
reactions	NN	O	O
;	NN	O	O
in	NN	O	O
three	NN	O	O
of	NN	O	O
these	NN	O	O
vancomycin	NN	O	B-Chemical
was	NN	O	O
considered	NN	O	O
the	NN	O	O
likely	NN	O	O
cause	NN	O	O
.	NN	O	O

Reactions	NN	O	O
included	NN	O	O
thrombophlebitis	NN	O	B-Disease
(	NN	O	O
20	NN	O	O
of	NN	O	O
54	NN	O	O
patients	NN	O	O
)	NN	O	O
,	NN	O	O
rash	NN	O	B-Disease
(	NN	O	O
4	NN	O	O
of	NN	O	O
54	NN	O	O
)	NN	O	O
,	NN	O	O
nephrotoxicity	NN	O	B-Disease
(	NN	O	O
4	NN	O	O
of	NN	O	O
50	NN	O	O
)	NN	O	O
,	NN	O	O
proteinuria	NN	O	B-Disease
(	NN	O	O
1	NN	O	O
of	NN	O	O
50	NN	O	O
)	NN	O	O
and	NN	O	O
ototoxicity	NN	O	B-Disease
(	NN	O	O
1	NN	O	O
of	NN	O	O
11	NN	O	O
patients	NN	O	O
tested	NN	O	O
by	NN	O	O
audiometry	NN	O	O
)	NN	O	O
.	NN	O	O

Thrombophlebitis	NN	O	B-Disease
occurred	NN	O	O
only	NN	O	O
with	NN	O	O
infusion	NN	O	O
through	NN	O	O
peripheral	NN	O	O
cannulae	NN	O	O
;	NN	O	O
nephrotoxicity	NN	O	B-Disease
and	NN	O	O
ototoxicity	NN	O	B-Disease
were	NN	O	O
confined	NN	O	O
to	NN	O	O
patients	NN	O	O
receiving	NN	O	O
an	NN	O	O
aminoglycoside	NN	O	B-Chemical
plus	NN	O	O
vancomycin	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
conclude	NN	O	O
that	NN	O	O
vancomycin	NN	O	B-Chemical
,	NN	O	O
administered	NN	O	O
appropriately	NN	O	O
,	NN	O	O
constitutes	NN	O	O
safe	NN	O	O
,	NN	O	O
effective	NN	O	O
therapy	NN	O	O
for	NN	O	O
infections	NN	O	B-Disease
caused	NN	O	O
by	NN	O	O
susceptible	NN	O	O
bacteria	NN	O	O
.	NN	O	O


-DOCSTART- (1687392)

Blockade	NN	O	O
of	NN	O	O
both	NN	O	O
D	NN	O	O
-	NN	O	O
1	NN	O	O
and	NN	O	O
D	NN	O	O
-	NN	O	O
2	NN	O	O
dopamine	NN	O	B-Chemical
receptors	NN	O	O
may	NN	O	O
induce	NN	O	O
catalepsy	NN	O	B-Disease
in	NN	O	O
mice	NN	O	O
.	NN	O	O

1	NN	O	O
.	NN	O	O

The	NN	O	O
catalepsy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
dopamine	NN	O	B-Chemical
antagonists	NN	O	O
has	NN	O	O
been	NN	O	O
tested	NN	O	O
and	NN	O	O
the	NN	O	O
possible	NN	O	O
dopamine	NN	O	B-Chemical
subtypes	NN	O	O
involved	NN	O	O
in	NN	O	O
catalepsy	NN	O	B-Disease
was	NN	O	O
determined	NN	O	O
.	NN	O	O

2	NN	O	O
.	NN	O	O

Dopamine	NN	O	B-Chemical
antagonist	NN	O	O
fluphenazine	NN	O	B-Chemical
,	NN	O	O
D	NN	O	O
-	NN	O	O
1	NN	O	O
antagonist	NN	O	O
SCH	NN	O	B-Chemical
23390	NN	O	I-Chemical
or	NN	O	O
D	NN	O	O
-	NN	O	O
2	NN	O	O
antagonist	NN	O	O
sulpiride	NN	O	B-Chemical
induced	NN	O	O
catalepsy	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
fluphenazine	NN	O	B-Chemical
and	NN	O	O
sulpiride	NN	O	B-Chemical
was	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
.	NN	O	O

Combination	NN	O	O
of	NN	O	O
SCH	NN	O	B-Chemical
23390	NN	O	I-Chemical
with	NN	O	O
sulpiride	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
induce	NN	O	O
catalepsy	NN	O	B-Disease
potentiation	NN	O	O
.	NN	O	O

3	NN	O	O
.	NN	O	O

D	NN	O	O
-	NN	O	O
1	NN	O	O
agonist	NN	O	O
SKF	NN	O	B-Chemical
38393	NN	O	I-Chemical
or	NN	O	O
D	NN	O	O
-	NN	O	O
2	NN	O	O
agonist	NN	O	O
quinpirole	NN	O	B-Chemical
decreased	NN	O	O
the	NN	O	O
catalepsy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
fluphenazine	NN	O	B-Chemical
,	NN	O	O
SCH	NN	O	B-Chemical
23390	NN	O	I-Chemical
or	NN	O	O
sulpiride	NN	O	B-Chemical
.	NN	O	O

4	NN	O	O
.	NN	O	O

Combination	NN	O	O
of	NN	O	O
SKF	NN	O	B-Chemical
38393	NN	O	I-Chemical
with	NN	O	O
quinpirole	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
cause	NN	O	O
potentiated	NN	O	O
inhibitory	NN	O	O
effect	NN	O	O
on	NN	O	O
catalepsy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
dopamine	NN	O	B-Chemical
antagonists	NN	O	O
.	NN	O	O

5	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
may	NN	O	O
indicate	NN	O	O
that	NN	O	O
although	NN	O	O
D	NN	O	O
-	NN	O	O
2	NN	O	O
receptor	NN	O	O
blockade	NN	O	O
is	NN	O	O
involved	NN	O	O
in	NN	O	O
catalepsy	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
D	NN	O	O
-	NN	O	O
1	NN	O	O
receptor	NN	O	O
may	NN	O	O
plan	NN	O	O
a	NN	O	O
role	NN	O	O
.	NN	O	O


-DOCSTART- (19719056)

Dextran	NN	O	B-Chemical
-	NN	O	O
etodolac	NN	O	B-Chemical
conjugates	NN	O	O
:	NN	O	O
synthesis	NN	O	O
,	NN	O	O
in	NN	O	O
vitro	NN	O	O
and	NN	O	O
in	NN	O	O
vivo	NN	O	O
evaluation	NN	O	O
.	NN	O	O

Etodolac	NN	O	B-Chemical
(	NN	O	O
E	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
is	NN	O	O
a	NN	O	O
non	NN	O	O
-	NN	O	O
narcotic	NN	O	O
analgesic	NN	O	O
and	NN	O	O
antiinflammatory	NN	O	O
drug	NN	O	O
.	NN	O	O

A	NN	O	O
biodegradable	NN	O	O
polymer	NN	O	O
dextran	NN	O	B-Chemical
has	NN	O	O
been	NN	O	O
utilized	NN	O	O
as	NN	O	O
a	NN	O	O
carrier	NN	O	O
for	NN	O	O
synthesis	NN	O	O
of	NN	O	O
etodolac	NN	O	B-Chemical
-	NN	O	O
dextran	NN	O	B-Chemical
conjugates	NN	O	O
(	NN	O	O
ED	NN	O	O
)	NN	O	O
to	NN	O	O
improve	NN	O	O
its	NN	O	O
aqueous	NN	O	O
solubility	NN	O	O
and	NN	O	O
reduce	NN	O	O
gastrointestinal	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

An	NN	O	O
activated	NN	O	O
moiety	NN	O	O
,	NN	O	O
i.e.	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
acylimidazole	NN	O	I-Chemical
derivative	NN	O	O
of	NN	O	O
etodolac	NN	O	B-Chemical
(	NN	O	O
EAI	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
was	NN	O	O
condensed	NN	O	O
with	NN	O	O
the	NN	O	O
polysaccharide	NN	O	O
polymer	NN	O	O
dextran	NN	O	B-Chemical
of	NN	O	O
different	NN	O	O
molecular	NN	O	O
weights	NN	O	O
(	NN	O	O
40000	NN	O	O
,	NN	O	O
60000	NN	O	O
,	NN	O	O
110000	NN	O	O
and	NN	O	O
200000	NN	O	O
)	NN	O	O
.	NN	O	O

IR	NN	O	O
spectral	NN	O	O
data	NN	O	O
confirmed	NN	O	O
formation	NN	O	O
of	NN	O	O
ester	NN	O	O
bonding	NN	O	O
in	NN	O	O
the	NN	O	O
conjugates	NN	O	O
.	NN	O	O

Etodolac	NN	O	B-Chemical
contents	NN	O	O
were	NN	O	O
evaluated	NN	O	O
by	NN	O	O
UV	NN	O	O
-	NN	O	O
spectrophotometric	NN	O	O
analysis	NN	O	O
.	NN	O	O

The	NN	O	O
molecular	NN	O	O
weights	NN	O	O
were	NN	O	O
determined	NN	O	O
by	NN	O	O
measuring	NN	O	O
viscosity	NN	O	O
using	NN	O	O
the	NN	O	O
Mark	NN	O	O
-	NN	O	O
Howink	NN	O	O
-	NN	O	O
Sakurada	NN	O	O
equation	NN	O	O
.	NN	O	O

In	NN	O	O
vitro	NN	O	O
hydrolysis	NN	O	O
of	NN	O	O
ED	NN	O	O
was	NN	O	O
done	NN	O	O
in	NN	O	O
aqueous	NN	O	O
buffers	NN	O	O
(	NN	O	O
pH	NN	O	O
1.2	NN	O	O
,	NN	O	O
7.4	NN	O	O
,	NN	O	O
9	NN	O	O
)	NN	O	O
and	NN	O	O
in	NN	O	O
80%	NN	O	O
(	NN	O	O
v	NN	O	O
/	NN	O	O
v	NN	O	O
)	NN	O	O
human	NN	O	O
plasma	NN	O	O
(	NN	O	O
pH	NN	O	O
7.4	NN	O	O
)	NN	O	O
.	NN	O	O

At	NN	O	O
pH	NN	O	O
9	NN	O	O
,	NN	O	O
a	NN	O	O
higher	NN	O	O
rate	NN	O	O
of	NN	O	O
etodolac	NN	O	B-Chemical
release	NN	O	O
from	NN	O	O
ED	NN	O	O
was	NN	O	O
observed	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
aqueous	NN	O	O
buffer	NN	O	O
of	NN	O	O
pH	NN	O	O
7.4	NN	O	O
and	NN	O	O
80%	NN	O	O
human	NN	O	O
plasma	NN	O	O
(	NN	O	O
pH	NN	O	O
7.4	NN	O	O
)	NN	O	O
,	NN	O	O
following	NN	O	O
first	NN	O	O
-	NN	O	O
order	NN	O	O
kinetics	NN	O	O
.	NN	O	O

In	NN	O	O
vivo	NN	O	O
investigations	NN	O	O
were	NN	O	O
performed	NN	O	O
in	NN	O	O
animals	NN	O	O
.	NN	O	O

Acute	NN	O	O
analgesic	NN	O	O
and	NN	O	O
antiinflammatory	NN	O	O
activities	NN	O	O
were	NN	O	O
ascertained	NN	O	O
using	NN	O	O
acetic	NN	O	B-Chemical
acid	NN	O	I-Chemical
induced	NN	O	O
writhing	NN	O	B-Disease
model	NN	O	O
(	NN	O	O
mice	NN	O	O
)	NN	O	O
and	NN	O	O
carrageenan	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
rat	NN	O	O
paw	NN	O	O
edema	NN	O	B-Disease
model	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

In	NN	O	O
comparison	NN	O	O
to	NN	O	O
control	NN	O	O
,	NN	O	O
E	NN	O	B-Chemical
and	NN	O	O
ED1	NN	O	O
-	NN	O	O
ED4	NN	O	O
showed	NN	O	O
highly	NN	O	O
significant	NN	O	O
analgesic	NN	O	O
and	NN	O	O
antiinflammatory	NN	O	O
activities	NN	O	O
(	NN	O	O
p	NN	O	O
<0.001	NN	O	O
)	NN	O	O
.	NN	O	O

Biological	NN	O	O
evaluation	NN	O	O
suggested	NN	O	O
that	NN	O	O
conjugates	NN	O	O
(	NN	O	O
ED1	NN	O	O
-	NN	O	O
ED4	NN	O	O
)	NN	O	O
retained	NN	O	O
comparable	NN	O	O
analgesic	NN	O	O
and	NN	O	O
antiinflammatory	NN	O	O
activities	NN	O	O
with	NN	O	O
remarkably	NN	O	O
reduced	NN	O	O
ulcerogenicity	NN	O	O
as	NN	O	O
compared	NN	O	O
to	NN	O	O
their	NN	O	O
parent	NN	O	O
drug	NN	O	O
-	NN	O	O
-	NN	O	O
etodolac	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (15266362)

Hypersensitivity	NN	O	B-Disease
myocarditis	NN	O	B-Disease
complicating	NN	O	O
hypertrophic	NN	O	B-Disease
cardiomyopathy	NN	O	I-Disease
heart	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
report	NN	O	O
describes	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
eosinophilic	NN	O	B-Disease
myocarditis	NN	O	I-Disease
complicating	NN	O	O
hypertrophic	NN	O	B-Disease
cardiomyopathy	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
47	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
female	NN	O	O
patient	NN	O	O
,	NN	O	O
known	NN	O	O
to	NN	O	O
have	NN	O	O
hypertrophic	NN	O	B-Disease
cardiomyopathy	NN	O	I-Disease
,	NN	O	O
was	NN	O	O
admitted	NN	O	O
with	NN	O	O
biventricular	NN	O	B-Disease
failure	NN	O	I-Disease
and	NN	O	O
managed	NN	O	O
aggressively	NN	O	O
with	NN	O	O
dobutamine	NN	O	B-Chemical
infusion	NN	O	O
and	NN	O	O
other	NN	O	O
drugs	NN	O	O
while	NN	O	O
being	NN	O	O
assessed	NN	O	O
for	NN	O	O
heart	NN	O	O
transplantation	NN	O	O
.	NN	O	O

On	NN	O	O
transthoracic	NN	O	O
echocardiogram	NN	O	O
,	NN	O	O
she	NN	O	O
had	NN	O	O
moderate	NN	O	O
left	NN	O	B-Disease
ventricular	NN	O	I-Disease
dysfunction	NN	O	I-Disease
with	NN	O	O
regional	NN	O	O
variability	NN	O	O
and	NN	O	O
moderate	NN	O	O
mitral	NN	O	B-Disease
regurgitation	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
recipient	NN	O	O
'	NN	O	O
s	NN	O	O
heart	NN	O	O
showed	NN	O	O
the	NN	O	O
features	NN	O	O
of	NN	O	O
apical	NN	O	O
hypertrophic	NN	O	B-Disease
cardiomyopathy	NN	O	I-Disease
and	NN	O	O
myocarditis	NN	O	B-Disease
with	NN	O	O
abundant	NN	O	O
eosinophils	NN	O	O
.	NN	O	O

Myocarditis	NN	O	B-Disease
is	NN	O	O
rare	NN	O	O
and	NN	O	O
eosinophilic	NN	O	B-Disease
myocarditis	NN	O	I-Disease
is	NN	O	O
rarer	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
likely	NN	O	O
that	NN	O	O
the	NN	O	O
hypersensitivity	NN	O	B-Disease
(	NN	O	O
eosinophilic	NN	O	B-Disease
)	NN	O	O
myocarditis	NN	O	B-Disease
was	NN	O	O
related	NN	O	O
to	NN	O	O
dobutamine	NN	O	B-Chemical
infusion	NN	O	O
therapy	NN	O	O
.	NN	O	O

Eosinophilic	NN	O	B-Disease
myocarditis	NN	O	I-Disease
has	NN	O	O
been	NN	O	O
reported	NN	O	O
with	NN	O	O
an	NN	O	O
incidence	NN	O	O
of	NN	O	O
2.4%	NN	O	O
to	NN	O	O
7.2%	NN	O	O
in	NN	O	O
explanted	NN	O	O
hearts	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
multidrug	NN	O	O
therapy	NN	O	O
.	NN	O	O


-DOCSTART- (14648024)

All	NN	O	B-Chemical
-	NN	O	I-Chemical
trans	NN	O	I-Chemical
-	NN	O	I-Chemical
retinoic	NN	O	I-Chemical
acid	NN	O	I-Chemical
-	NN	O	O
induced	NN	O	O
erythema	NN	O	B-Disease
nodosum	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B-Disease
promyelocytic	NN	O	I-Disease
leukemia	NN	O	I-Disease
.	NN	O	O

Erythema	NN	O	B-Disease
nodosum	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
all	NN	O	B-Chemical
-	NN	O	I-Chemical
trans	NN	O	I-Chemical
-	NN	O	I-Chemical
retinoic	NN	O	I-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
ATRA	NN	O	B-Chemical
)	NN	O	O
for	NN	O	O
acute	NN	O	B-Disease
promyelocytic	NN	O	I-Disease
leukemia	NN	O	I-Disease
(	NN	O	O
APL	NN	O	B-Disease
)	NN	O	O
is	NN	O	O
very	NN	O	O
rare	NN	O	O
.	NN	O	O

We	NN	O	O
describe	NN	O	O
four	NN	O	O
patients	NN	O	O
with	NN	O	O
classic	NN	O	O
APL	NN	O	B-Disease
who	NN	O	O
developed	NN	O	O
erythema	NN	O	B-Disease
nodosum	NN	O	I-Disease
during	NN	O	O
ATRA	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Fever	NN	O	B-Disease
and	NN	O	O
subsequent	NN	O	O
multiple	NN	O	O
painful	NN	O	B-Disease
erythematous	NN	O	B-Disease
nodules	NN	O	I-Disease
over	NN	O	O
extremities	NN	O	O
developed	NN	O	O
on	NN	O	O
D11	NN	O	O
,	NN	O	O
D16	NN	O	O
,	NN	O	O
D17	NN	O	O
,	NN	O	O
and	NN	O	O
D19	NN	O	O
,	NN	O	O
respectively	NN	O	O
,	NN	O	O
after	NN	O	O
ATRA	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

The	NN	O	O
skin	NN	O	O
biopsy	NN	O	O
taken	NN	O	O
from	NN	O	O
each	NN	O	O
patient	NN	O	O
was	NN	O	O
consistent	NN	O	O
with	NN	O	O
erythema	NN	O	B-Disease
nodosum	NN	O	I-Disease
.	NN	O	O

All	NN	O	O
patients	NN	O	O
received	NN	O	O
short	NN	O	O
course	NN	O	O
of	NN	O	O
steroids	NN	O	B-Chemical
.	NN	O	O

Fever	NN	O	B-Disease
subsided	NN	O	O
rapidly	NN	O	O
and	NN	O	O
the	NN	O	O
skin	NN	O	O
lesions	NN	O	O
regressed	NN	O	O
completely	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
achieved	NN	O	O
complete	NN	O	O
remission	NN	O	O
without	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
ATRA	NN	O	B-Chemical
.	NN	O	O

ATRA	NN	O	B-Chemical
seemed	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
most	NN	O	O
possible	NN	O	O
etiology	NN	O	O
of	NN	O	O
erythema	NN	O	B-Disease
nodosum	NN	O	I-Disease
in	NN	O	O
our	NN	O	O
patients	NN	O	O
.	NN	O	O

Short	NN	O	O
-	NN	O	O
term	NN	O	O
use	NN	O	O
of	NN	O	O
steroid	NN	O	B-Chemical
is	NN	O	O
very	NN	O	O
effective	NN	O	O
in	NN	O	O
ATRA	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
erythema	NN	O	B-Disease
nodosum	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (11827497)

Delayed	NN	O	O
-	NN	O	O
onset	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
presents	NN	O	O
5	NN	O	O
to	NN	O	O
12	NN	O	O
days	NN	O	O
after	NN	O	O
heparin	NN	O	B-Chemical
exposure	NN	O	O
,	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
arterial	NN	O	B-Disease
or	NN	O	I-Disease
venous	NN	O	I-Disease
thromboemboli	NN	O	I-Disease
.	NN	O	O

Delayed	NN	O	O
recognition	NN	O	O
and	NN	O	O
treatment	NN	O	O
of	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
contribute	NN	O	O
to	NN	O	O
poor	NN	O	O
patient	NN	O	O
outcomes	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
describe	NN	O	O
and	NN	O	O
increase	NN	O	O
awareness	NN	O	O
of	NN	O	O
a	NN	O	O
clinical	NN	O	O
scenario	NN	O	O
in	NN	O	O
which	NN	O	O
the	NN	O	O
onset	NN	O	O
or	NN	O	O
manifestations	NN	O	O
of	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
are	NN	O	O
delayed	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Retrospective	NN	O	O
case	NN	O	O
series	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
Three	NN	O	O
large	NN	O	O
urban	NN	O	O
hospitals	NN	O	O
(	NN	O	O
with	NN	O	O
active	NN	O	O
cardiovascular	NN	O	O
surgery	NN	O	O
programs	NN	O	O
)	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
:	NN	O	O
14	NN	O	O
patients	NN	O	O
seen	NN	O	O
over	NN	O	O
a	NN	O	O
3	NN	O	O
-	NN	O	O
year	NN	O	O
period	NN	O	O
in	NN	O	O
whom	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
became	NN	O	O
apparent	NN	O	O
on	NN	O	O
delayed	NN	O	O
presentation	NN	O	O
with	NN	O	O
thromboembolic	NN	O	B-Disease
complications	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
:	NN	O	O
Platelet	NN	O	O
counts	NN	O	O
,	NN	O	O
onset	NN	O	O
of	NN	O	O
objectively	NN	O	O
determined	NN	O	O
thromboembolism	NN	O	B-Disease
,	NN	O	O
results	NN	O	O
of	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
platelet	NN	O	O
factor	NN	O	O
4	NN	O	O
antibody	NN	O	O
tests	NN	O	O
,	NN	O	O
and	NN	O	O
outcomes	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Patients	NN	O	O
went	NN	O	O
home	NN	O	O
after	NN	O	O
hospitalizations	NN	O	O
that	NN	O	O
had	NN	O	O
included	NN	O	O
heparin	NN	O	B-Chemical
exposure	NN	O	O
-	NN	O	O
-	NN	O	O
in	NN	O	O
most	NN	O	O
cases	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
thrombocytopenia	NN	O	B-Disease
recognized	NN	O	O
-	NN	O	O
-	NN	O	O
only	NN	O	O
to	NN	O	O
return	NN	O	O
to	NN	O	O
the	NN	O	O
hospital	NN	O	O
(	NN	O	O
median	NN	O	O
,	NN	O	O
day	NN	O	O
14	NN	O	O
)	NN	O	O
with	NN	O	O
thromboembolic	NN	O	B-Disease
complications	NN	O	O
.	NN	O	O

Thromboemboli	NN	O	B-Disease
were	NN	O	O
venous	NN	O	O
(	NN	O	O
12	NN	O	O
patients	NN	O	O
,	NN	O	O
7	NN	O	O
with	NN	O	O
pulmonary	NN	O	B-Disease
emboli	NN	O	I-Disease
)	NN	O	O
or	NN	O	O
arterial	NN	O	O
(	NN	O	O
4	NN	O	O
patients	NN	O	O
)	NN	O	O
or	NN	O	O
both	NN	O	O
.	NN	O	O

Platelet	NN	O	O
counts	NN	O	O
were	NN	O	O
mildly	NN	O	O
decreased	NN	O	O
in	NN	O	O
all	NN	O	O
but	NN	O	O
2	NN	O	O
patients	NN	O	O
on	NN	O	O
second	NN	O	O
presentation	NN	O	O
.	NN	O	O

On	NN	O	O
readmission	NN	O	O
,	NN	O	O
11	NN	O	O
patients	NN	O	O
received	NN	O	O
therapeutic	NN	O	O
heparin	NN	O	B-Chemical
,	NN	O	O
which	NN	O	O
worsened	NN	O	O
the	NN	O	O
patients	NN	O	O
'	NN	O	O
clinical	NN	O	O
condition	NN	O	O
and	NN	O	O
,	NN	O	O
in	NN	O	O
all	NN	O	O
11	NN	O	O
cases	NN	O	O
,	NN	O	O
decreased	NN	O	O
the	NN	O	O
platelet	NN	O	O
count	NN	O	O
(	NN	O	O
mean	NN	O	O
at	NN	O	O
readmission	NN	O	O
,	NN	O	O
143	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
cells	NN	O	O
/	NN	O	O
L	NN	O	O
;	NN	O	O
mean	NN	O	O
nadir	NN	O	O
after	NN	O	O
heparin	NN	O	B-Chemical
re	NN	O	O
-	NN	O	O
exposure	NN	O	O
,	NN	O	O
39	NN	O	O
x	NN	O	O
10	NN	O	O
(	NN	O	O
9	NN	O	O
)	NN	O	O
cells	NN	O	O
/	NN	O	O
L	NN	O	O
)	NN	O	O
.	NN	O	O

Results	NN	O	O
of	NN	O	O
serologic	NN	O	O
tests	NN	O	O
for	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
antibodies	NN	O	O
were	NN	O	O
positive	NN	O	O
in	NN	O	O
all	NN	O	O
patients	NN	O	O
.	NN	O	O

Subsequent	NN	O	O
treatments	NN	O	O
included	NN	O	O
alternative	NN	O	O
anticoagulants	NN	O	O
(	NN	O	O
11	NN	O	O
patients	NN	O	O
)	NN	O	O
,	NN	O	O
thrombolytic	NN	O	O
drugs	NN	O	O
(	NN	O	O
3	NN	O	O
patients	NN	O	O
)	NN	O	O
,	NN	O	O
inferior	NN	O	O
vena	NN	O	O
cava	NN	O	O
filters	NN	O	O
(	NN	O	O
3	NN	O	O
patients	NN	O	O
)	NN	O	O
and	NN	O	O
,	NN	O	O
eventually	NN	O	O
,	NN	O	O
warfarin	NN	O	B-Chemical
(	NN	O	O
11	NN	O	O
patients	NN	O	O
)	NN	O	O
.	NN	O	O

Three	NN	O	O
patients	NN	O	O
died	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Delayed	NN	O	O
-	NN	O	O
onset	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
is	NN	O	O
increasingly	NN	O	O
being	NN	O	O
recognized	NN	O	O
.	NN	O	O

To	NN	O	O
avoid	NN	O	O
disastrous	NN	O	O
outcomes	NN	O	O
,	NN	O	O
physicians	NN	O	O
must	NN	O	O
consider	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
whenever	NN	O	O
a	NN	O	O
recently	NN	O	O
hospitalized	NN	O	O
patient	NN	O	O
returns	NN	O	O
with	NN	O	O
thromboembolism	NN	O	B-Disease
;	NN	O	O
therapy	NN	O	O
with	NN	O	O
alternative	NN	O	O
anticoagulants	NN	O	O
,	NN	O	O
not	NN	O	O
heparin	NN	O	B-Chemical
,	NN	O	O
should	NN	O	O
be	NN	O	O
initiated	NN	O	O
.	NN	O	O


-DOCSTART- (8841157)

Valsartan	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
new	NN	O	O
angiotensin	NN	O	B-Chemical
II	NN	O	I-Chemical
antagonist	NN	O	O
for	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
essential	NN	O	O
hypertension	NN	O	B-Disease
:	NN	O	O
a	NN	O	O
comparative	NN	O	O
study	NN	O	O
of	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
against	NN	O	O
amlodipine	NN	O	B-Chemical
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
compare	NN	O	O
the	NN	O	O
antihypertensive	NN	O	O
efficacy	NN	O	O
of	NN	O	O
a	NN	O	O
new	NN	O	O
angiotensin	NN	O	B-Chemical
II	NN	O	I-Chemical
antagonist	NN	O	O
,	NN	O	O
valsartan	NN	O	B-Chemical
,	NN	O	O
with	NN	O	O
a	NN	O	O
reference	NN	O	O
therapy	NN	O	O
,	NN	O	O
amlodipine	NN	O	B-Chemical
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
One	NN	O	O
hundred	NN	O	O
sixty	NN	O	O
-	NN	O	O
eight	NN	O	O
adult	NN	O	O
outpatients	NN	O	O
with	NN	O	O
mild	NN	O	O
to	NN	O	O
moderate	NN	O	O
hypertension	NN	O	B-Disease
were	NN	O	O
randomly	NN	O	O
allocated	NN	O	O
in	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
fashion	NN	O	O
and	NN	O	O
equal	NN	O	O
number	NN	O	O
to	NN	O	O
receive	NN	O	O
80	NN	O	O
mg	NN	O	O
valsartan	NN	O	B-Chemical
or	NN	O	O
5	NN	O	O
mg	NN	O	O
amlodipine	NN	O	B-Chemical
for	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

After	NN	O	O
8	NN	O	O
weeks	NN	O	O
of	NN	O	O
therapy	NN	O	O
,	NN	O	O
in	NN	O	O
patients	NN	O	O
whose	NN	O	O
blood	NN	O	O
pressure	NN	O	O
remained	NN	O	O
uncontrolled	NN	O	O
,	NN	O	O
5	NN	O	O
mg	NN	O	O
amlodipine	NN	O	B-Chemical
was	NN	O	O
added	NN	O	O
to	NN	O	O
the	NN	O	O
initial	NN	O	O
therapy	NN	O	O
.	NN	O	O

Patients	NN	O	O
were	NN	O	O
assessed	NN	O	O
at	NN	O	O
4	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
and	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

The	NN	O	O
primary	NN	O	O
efficacy	NN	O	O
variable	NN	O	O
was	NN	O	O
change	NN	O	O
from	NN	O	O
baseline	NN	O	O
in	NN	O	O
mean	NN	O	O
sitting	NN	O	O
diastolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
at	NN	O	O
8	NN	O	O
weeks	NN	O	O
.	NN	O	O

Secondary	NN	O	O
variables	NN	O	O
included	NN	O	O
change	NN	O	O
in	NN	O	O
sitting	NN	O	O
systolic	NN	O	O
blood	NN	O	O
pressure	NN	O	O
and	NN	O	O
responder	NN	O	O
rates	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Both	NN	O	O
valsartan	NN	O	B-Chemical
and	NN	O	O
amlodipine	NN	O	B-Chemical
were	NN	O	O
effective	NN	O	O
at	NN	O	O
lowering	NN	O	O
blood	NN	O	O
pressure	NN	O	O
at	NN	O	O
4	NN	O	O
,	NN	O	O
8	NN	O	O
,	NN	O	O
and	NN	O	O
12	NN	O	O
weeks	NN	O	O
.	NN	O	O

Similar	NN	O	O
decreases	NN	O	O
were	NN	O	O
observed	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
,	NN	O	O
with	NN	O	O
no	NN	O	O
statistically	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
groups	NN	O	O
for	NN	O	O
any	NN	O	O
variable	NN	O	O
analyzed	NN	O	O
.	NN	O	O

For	NN	O	O
the	NN	O	O
primary	NN	O	O
variable	NN	O	O
the	NN	O	O
difference	NN	O	O
was	NN	O	O
0.5	NN	O	O
mm	NN	O	O
Hg	NN	O	O
in	NN	O	O
favor	NN	O	O
of	NN	O	O
valsartan	NN	O	B-Chemical
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.68	NN	O	O
;	NN	O	O
95%	NN	O	O
confidence	NN	O	O
interval	NN	O	O
,	NN	O	O
-	NN	O	O
2.7	NN	O	O
to	NN	O	O
1.7	NN	O	O
)	NN	O	O
.	NN	O	O

Responder	NN	O	O
rates	NN	O	O
at	NN	O	O
8	NN	O	O
weeks	NN	O	O
were	NN	O	O
66.7%	NN	O	O
for	NN	O	O
valsartan	NN	O	B-Chemical
and	NN	O	O
60.2%	NN	O	O
for	NN	O	O
amlodipine	NN	O	B-Chemical
(	NN	O	O
p	NN	O	O
=	NN	O	O
0.39	NN	O	O
)	NN	O	O
.	NN	O	O

Both	NN	O	O
treatments	NN	O	O
were	NN	O	O
well	NN	O	O
tolerated	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
related	NN	O	O
dependent	NN	O	O
edema	NN	O	B-Disease
was	NN	O	O
somewhat	NN	O	O
higher	NN	O	O
in	NN	O	O
the	NN	O	O
amlodipine	NN	O	B-Chemical
group	NN	O	O
,	NN	O	O
particularly	NN	O	O
at	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
10	NN	O	O
mg	NN	O	O
per	NN	O	O
day	NN	O	O
(	NN	O	O
2.4%	NN	O	O
for	NN	O	O
80	NN	O	O
mg	NN	O	O
valsartan	NN	O	B-Chemical
;	NN	O	O
3.6%	NN	O	O
for	NN	O	O
5	NN	O	O
mg	NN	O	O
amlodipine	NN	O	B-Chemical
;	NN	O	O
0%	NN	O	O
for	NN	O	O
valsartan	NN	O	B-Chemical
plus	NN	O	O
5	NN	O	O
mg	NN	O	O
amlodipine	NN	O	B-Chemical
;	NN	O	O
14.3%	NN	O	O
for	NN	O	O
10	NN	O	O
mg	NN	O	O
amlodipine	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
The	NN	O	O
data	NN	O	O
show	NN	O	O
that	NN	O	O
valsartan	NN	O	B-Chemical
is	NN	O	O
at	NN	O	O
least	NN	O	O
as	NN	O	O
effective	NN	O	O
as	NN	O	O
amlodipine	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
mild	NN	O	O
to	NN	O	O
moderate	NN	O	O
hypertension	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
results	NN	O	O
also	NN	O	O
show	NN	O	O
valsartan	NN	O	B-Chemical
to	NN	O	O
be	NN	O	O
well	NN	O	O
tolerated	NN	O	O
and	NN	O	O
suggest	NN	O	O
that	NN	O	O
it	NN	O	O
is	NN	O	O
not	NN	O	O
associated	NN	O	O
with	NN	O	O
side	NN	O	O
effects	NN	O	O
characteristic	NN	O	O
of	NN	O	O
this	NN	O	O
comparator	NN	O	O
class	NN	O	O
,	NN	O	O
dihydropyridine	NN	O	B-Chemical
calcium	NN	O	B-Chemical
antagonists	NN	O	O
.	NN	O	O


-DOCSTART- (8045270)

KF17837	NN	O	B-Chemical
:	NN	O	O
a	NN	O	O
novel	NN	O	O
selective	NN	O	O
adenosine	NN	O	B-Chemical
A2A	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
with	NN	O	O
anticataleptic	NN	O	O
activity	NN	O	O
.	NN	O	O

KF17837	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
novel	NN	O	O
selective	NN	O	O
adenosine	NN	O	B-Chemical
A2A	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
.	NN	O	O

Oral	NN	O	O
administration	NN	O	O
of	NN	O	O
KF17837	NN	O	B-Chemical
(	NN	O	O
2.5	NN	O	O
,	NN	O	O
10.0	NN	O	O
and	NN	O	O
30.0	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
significantly	NN	O	O
ameliorated	NN	O	O
the	NN	O	O
cataleptic	NN	O	B-Disease
responses	NN	O	O
induced	NN	O	O
by	NN	O	O
intracerebroventricular	NN	O	O
administration	NN	O	O
of	NN	O	O
an	NN	O	O
adenosine	NN	O	B-Chemical
A2A	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
,	NN	O	O
CGS	NN	O	B-Chemical
21680	NN	O	I-Chemical
(	NN	O	O
10	NN	O	O
micrograms	NN	O	O
)	NN	O	O
,	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
manner	NN	O	O
.	NN	O	O

KF17837	NN	O	B-Chemical
also	NN	O	O
reduced	NN	O	O
the	NN	O	O
catalepsy	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
haloperidol	NN	O	B-Chemical
(	NN	O	O
1	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.p.	NN	O	O
)	NN	O	O
and	NN	O	O
by	NN	O	O
reserpine	NN	O	B-Chemical
(	NN	O	O
5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.p.	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
anticataleptic	NN	O	O
effects	NN	O	O
were	NN	O	O
exhibited	NN	O	O
dose	NN	O	O
dependently	NN	O	O
at	NN	O	O
doses	NN	O	O
from	NN	O	O
0.625	NN	O	O
and	NN	O	O
2.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
p.o.	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
KF17837	NN	O	B-Chemical
(	NN	O	O
0.625	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
p.o.	NN	O	O
)	NN	O	O
potentiated	NN	O	O
the	NN	O	O
anticataleptic	NN	O	O
effects	NN	O	O
of	NN	O	O
a	NN	O	O
subthreshold	NN	O	O
dose	NN	O	O
of	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
3	NN	O	I-Chemical
,	NN	O	I-Chemical
4	NN	O	I-Chemical
-	NN	O	I-Chemical
dihydroxyphenylalanine	NN	O	I-Chemical
(	NN	O	O
L	NN	O	B-Chemical
-	NN	O	I-Chemical
DOPA	NN	O	I-Chemical
;	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.p.	NN	O	O
)	NN	O	O
plus	NN	O	O
benserazide	NN	O	B-Chemical
(	NN	O	O
6.25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.p.	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggested	NN	O	O
that	NN	O	O
KF17837	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
centrally	NN	O	O
active	NN	O	O
adenosine	NN	O	B-Chemical
A2A	NN	O	O
receptor	NN	O	O
antagonist	NN	O	O
and	NN	O	O
that	NN	O	O
the	NN	O	O
dopaminergic	NN	O	O
function	NN	O	O
of	NN	O	O
the	NN	O	O
nigrostriatal	NN	O	O
pathway	NN	O	O
is	NN	O	O
potentiated	NN	O	O
by	NN	O	O
adenosine	NN	O	B-Chemical
A2A	NN	O	O
receptor	NN	O	O
antagonists	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
KF17837	NN	O	B-Chemical
may	NN	O	O
be	NN	O	O
a	NN	O	O
useful	NN	O	O
drug	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
parkinsonism	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (2576810)

Some	NN	O	O
central	NN	O	O
effects	NN	O	O
of	NN	O	O
repeated	NN	O	O
treatment	NN	O	O
with	NN	O	O
fluvoxamine	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
repeated	NN	O	O
treatment	NN	O	O
with	NN	O	O
fluvoxamine	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
selective	NN	O	O
serotonin	NN	O	B-Chemical
uptake	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
on	NN	O	O
behavioral	NN	O	O
effects	NN	O	O
of	NN	O	O
dopaminomimetics	NN	O	O
and	NN	O	O
methoxamine	NN	O	B-Chemical
and	NN	O	O
on	NN	O	O
the	NN	O	O
animal	NN	O	O
behavior	NN	O	O
in	NN	O	O
the	NN	O	O
"	NN	O	O
behavioral	NN	O	O
despair	NN	O	O
"	NN	O	O
test	NN	O	O
.	NN	O	O

A	NN	O	O
repeated	NN	O	O
treatment	NN	O	O
with	NN	O	O
fluvoxamine	NN	O	B-Chemical
(	NN	O	O
twice	NN	O	O
daily	NN	O	O
for	NN	O	O
14	NN	O	O
days	NN	O	O
)	NN	O	O
potentiated	NN	O	O
in	NN	O	O
mice	NN	O	O
and	NN	O	O
in	NN	O	O
rats	NN	O	O
(	NN	O	O
weaker	NN	O	O
)	NN	O	O
the	NN	O	O
amphetamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hyperactivity	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
hyperactivity	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
nomifensine	NN	O	B-Chemical
in	NN	O	O
mice	NN	O	O
remained	NN	O	O
unaffected	NN	O	O
by	NN	O	O
fluvoxamine	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
stimulation	NN	O	O
of	NN	O	O
locomotor	NN	O	O
activity	NN	O	O
by	NN	O	O
intracerebroventricularly	NN	O	O
administered	NN	O	O
methoxamine	NN	O	B-Chemical
was	NN	O	O
not	NN	O	O
affected	NN	O	O
by	NN	O	O
repeated	NN	O	O
treatment	NN	O	O
with	NN	O	O
fluvoxamine	NN	O	B-Chemical
.	NN	O	O

Given	NN	O	O
three	NN	O	O
times	NN	O	O
fluvoxamine	NN	O	B-Chemical
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
immobilization	NN	O	O
time	NN	O	O
in	NN	O	O
the	NN	O	O
"	NN	O	O
behavioral	NN	O	O
despair	NN	O	O
"	NN	O	O
test	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
results	NN	O	O
indicate	NN	O	O
that	NN	O	O
fluvoxamine	NN	O	B-Chemical
given	NN	O	O
repeatedly	NN	O	O
acts	NN	O	O
differently	NN	O	O
than	NN	O	O
citalopram	NN	O	B-Chemical
,	NN	O	O
another	NN	O	O
selective	NN	O	O
serotonin	NN	O	B-Chemical
uptake	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
and	NN	O	O
differs	NN	O	O
also	NN	O	O
from	NN	O	O
other	NN	O	O
antidepressant	NN	O	O
drugs	NN	O	O
.	NN	O	O


-DOCSTART- (20635749)

Severe	NN	O	O
congestive	NN	O	B-Disease
heart	NN	O	I-Disease
failure	NN	O	I-Disease
patient	NN	O	O
on	NN	O	O
amiodarone	NN	O	B-Chemical
presenting	NN	O	O
with	NN	O	O
myxedemic	NN	O	B-Disease
coma	NN	O	I-Disease
:	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
a	NN	O	O
case	NN	O	O
report	NN	O	O
of	NN	O	O
myxedema	NN	O	B-Disease
coma	NN	O	I-Disease
secondary	NN	O	O
to	NN	O	O
amiodarone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypothyroidism	NN	O	B-Disease
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
severe	NN	O	O
congestive	NN	O	B-Disease
heart	NN	O	I-Disease
failure	NN	O	I-Disease
(	NN	O	O
CHF	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
and	NN	O	O
after	NN	O	O
reviewing	NN	O	O
the	NN	O	O
literature	NN	O	O
there	NN	O	O
is	NN	O	O
one	NN	O	O
case	NN	O	O
report	NN	O	O
of	NN	O	O
myxedema	NN	O	B-Disease
coma	NN	O	I-Disease
during	NN	O	O
long	NN	O	O
term	NN	O	O
amiodarone	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O

Myxedema	NN	O	B-Disease
coma	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
life	NN	O	O
threatening	NN	O	O
condition	NN	O	O
that	NN	O	O
carries	NN	O	O
a	NN	O	O
mortality	NN	O	O
reaching	NN	O	O
as	NN	O	O
high	NN	O	O
as	NN	O	O
20%	NN	O	O
with	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
condition	NN	O	O
is	NN	O	O
treated	NN	O	O
with	NN	O	O
intravenous	NN	O	O
thyroxine	NN	O	B-Chemical
(	NN	O	O
T4	NN	O	B-Chemical
)	NN	O	O
or	NN	O	O
intravenous	NN	O	O
tri	NN	O	B-Chemical
-	NN	O	I-Chemical
iodo	NN	O	I-Chemical
-	NN	O	I-Chemical
thyronine	NN	O	I-Chemical
(	NN	O	O
T3	NN	O	B-Chemical
)	NN	O	O
.	NN	O	O

Patients	NN	O	O
with	NN	O	O
CHF	NN	O	B-Disease
on	NN	O	O
amiodarone	NN	O	B-Chemical
may	NN	O	O
suffer	NN	O	O
serious	NN	O	O
morbidity	NN	O	O
and	NN	O	O
mortality	NN	O	O
from	NN	O	O
hypothyroidism	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
thus	NN	O	O
may	NN	O	O
deserve	NN	O	O
closer	NN	O	O
follow	NN	O	O
up	NN	O	O
for	NN	O	O
thyroid	NN	O	O
stimulating	NN	O	O
hormone	NN	O	O
(	NN	O	O
TSH	NN	O	O
)	NN	O	O
levels	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
report	NN	O	O
carries	NN	O	O
an	NN	O	O
important	NN	O	O
clinical	NN	O	O
application	NN	O	O
given	NN	O	O
the	NN	O	O
frequent	NN	O	O
usage	NN	O	O
of	NN	O	O
amiodarone	NN	O	B-Chemical
among	NN	O	O
CHF	NN	O	B-Disease
patients	NN	O	O
.	NN	O	O

The	NN	O	O
myriad	NN	O	O
clinical	NN	O	O
presentation	NN	O	O
of	NN	O	O
myxedema	NN	O	B-Disease
coma	NN	O	I-Disease
and	NN	O	O
its	NN	O	O
serious	NN	O	O
morbidity	NN	O	O
and	NN	O	O
mortality	NN	O	O
stresses	NN	O	O
the	NN	O	O
need	NN	O	O
to	NN	O	O
suspect	NN	O	O
this	NN	O	O
clinical	NN	O	O
syndrome	NN	O	O
among	NN	O	O
CHF	NN	O	B-Disease
patients	NN	O	O
presenting	NN	O	O
with	NN	O	O
hypotension	NN	O	B-Disease
,	NN	O	O
weakness	NN	O	B-Disease
or	NN	O	O
other	NN	O	O
unexplained	NN	O	O
symptoms	NN	O	O
.	NN	O	O


-DOCSTART- (20394767)

Fear	NN	O	O
-	NN	O	O
potentiated	NN	O	O
startle	NN	O	B-Disease
,	NN	O	O
but	NN	O	O
not	NN	O	O
light	NN	O	O
-	NN	O	O
enhanced	NN	O	O
startle	NN	O	B-Disease
,	NN	O	O
is	NN	O	O
enhanced	NN	O	O
by	NN	O	O
anxiogenic	NN	O	O
drugs	NN	O	O
.	NN	O	O

RATIONALE	NN	O	O
AND	NN	O	O
OBJECTIVES	NN	O	O
:	NN	O	O
The	NN	O	O
light	NN	O	O
-	NN	O	O
enhanced	NN	O	O
startle	NN	O	B-Disease
paradigm	NN	O	O
(	NN	O	O
LES	NN	O	O
)	NN	O	O
is	NN	O	O
suggested	NN	O	O
to	NN	O	O
model	NN	O	O
anxiety	NN	O	B-Disease
,	NN	O	O
because	NN	O	O
of	NN	O	O
the	NN	O	O
non	NN	O	O
-	NN	O	O
specific	NN	O	O
cue	NN	O	O
and	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
effect	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
the	NN	O	O
fear	NN	O	O
-	NN	O	O
potentiated	NN	O	O
startle	NN	O	B-Disease
(	NN	O	O
FPS	NN	O	O
)	NN	O	O
is	NN	O	O
suggested	NN	O	O
to	NN	O	O
model	NN	O	O
conditioned	NN	O	O
fear	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
pharmacological	NN	O	O
profiles	NN	O	O
of	NN	O	O
these	NN	O	O
two	NN	O	O
paradigms	NN	O	O
are	NN	O	O
very	NN	O	O
similar	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
investigated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
putative	NN	O	O
anxiogenic	NN	O	O
drugs	NN	O	O
on	NN	O	O
LES	NN	O	O
and	NN	O	O
FPS	NN	O	O
and	NN	O	O
aimed	NN	O	O
at	NN	O	O
determining	NN	O	O
the	NN	O	O
sensitivity	NN	O	O
of	NN	O	O
LES	NN	O	O
for	NN	O	O
anxiogenic	NN	O	O
drugs	NN	O	O
and	NN	O	O
to	NN	O	O
potentially	NN	O	O
showing	NN	O	O
a	NN	O	O
pharmacological	NN	O	O
differentiation	NN	O	O
between	NN	O	O
these	NN	O	O
two	NN	O	O
paradigms	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Male	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
received	NN	O	O
each	NN	O	O
dose	NN	O	O
of	NN	O	O
the	NN	O	O
alpha	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
antagonist	NN	O	O
yohimbine	NN	O	B-Chemical
(	NN	O	O
0.25	NN	O	O
-	NN	O	O
1.0mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
HT	NN	O	I-Chemical
(	NN	O	O
2C	NN	O	O
)	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
m	NN	O	B-Chemical
-	NN	O	I-Chemical
chlorophenylpiperazine	NN	O	I-Chemical
(	NN	O	O
mCPP	NN	O	B-Chemical
,	NN	O	O
0.5	NN	O	O
-	NN	O	O
2.0mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
or	NN	O	O
the	NN	O	O
GABA	NN	O	B-Chemical
(	NN	O	O
A	NN	O	O
)	NN	O	O
inverse	NN	O	O
receptor	NN	O	O
agonist	NN	O	O
pentylenetetrazole	NN	O	B-Chemical
(	NN	O	O
PTZ	NN	O	B-Chemical
,	NN	O	O
3	NN	O	O
-	NN	O	O
30mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
were	NN	O	O
subsequently	NN	O	O
tested	NN	O	O
in	NN	O	O
either	NN	O	O
LES	NN	O	O
or	NN	O	O
FPS	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
None	NN	O	O
of	NN	O	O
the	NN	O	O
drugs	NN	O	O
enhanced	NN	O	O
LES	NN	O	O
,	NN	O	O
whereas	NN	O	O
mCPP	NN	O	B-Chemical
increased	NN	O	O
percentage	NN	O	O
FPS	NN	O	O
and	NN	O	O
yohimbine	NN	O	B-Chemical
increased	NN	O	O
absolute	NN	O	O
FPS	NN	O	O
values	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
yohimbine	NN	O	B-Chemical
increased	NN	O	O
baseline	NN	O	O
startle	NN	O	B-Disease
amplitude	NN	O	O
in	NN	O	O
the	NN	O	O
LES	NN	O	O
,	NN	O	O
while	NN	O	O
mCPP	NN	O	B-Chemical
suppressed	NN	O	O
baseline	NN	O	O
startle	NN	O	B-Disease
in	NN	O	O
both	NN	O	O
the	NN	O	O
LES	NN	O	O
and	NN	O	O
FPS	NN	O	O
and	NN	O	O
PTZ	NN	O	B-Chemical
suppressed	NN	O	O
baseline	NN	O	O
startle	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
FPS	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
In	NN	O	O
contrast	NN	O	O
to	NN	O	O
findings	NN	O	O
in	NN	O	O
the	NN	O	O
FPS	NN	O	O
paradigm	NN	O	O
,	NN	O	O
none	NN	O	O
of	NN	O	O
the	NN	O	O
drugs	NN	O	O
were	NN	O	O
able	NN	O	O
to	NN	O	O
exacerbate	NN	O	O
the	NN	O	O
LES	NN	O	O
response	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
a	NN	O	O
clear	NN	O	O
pharmacological	NN	O	O
differentiation	NN	O	O
was	NN	O	O
found	NN	O	O
between	NN	O	O
LES	NN	O	O
and	NN	O	O
FPS	NN	O	O
.	NN	O	O


-DOCSTART- (19203554)

Proteinase	NN	O	O
3	NN	O	O
-	NN	O	O
antineutrophil	NN	O	O
cytoplasmic	NN	O	O
antibody	NN	O	O
-	NN	O	O
(	NN	O	O
PR3	NN	O	O
-	NN	O	O
ANCA	NN	O	O
)	NN	O	O
positive	NN	O	O
necrotizing	NN	O	O
glomerulonephritis	NN	O	B-Disease
after	NN	O	O
restarting	NN	O	O
sulphasalazine	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

A	NN	O	O
59	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
ulcerative	NN	O	B-Disease
colitis	NN	O	I-Disease
developed	NN	O	O
red	NN	O	B-Disease
eyes	NN	O	I-Disease
,	NN	O	O
pleural	NN	O	B-Disease
effusion	NN	O	I-Disease
,	NN	O	O
eosinophilia	NN	O	B-Disease
and	NN	O	O
urinary	NN	O	B-Disease
abnormalities	NN	O	I-Disease
after	NN	O	O
restarting	NN	O	O
of	NN	O	O
sulphasalazine	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

Light	NN	O	O
microscopy	NN	O	O
of	NN	O	O
a	NN	O	O
kidney	NN	O	O
biopsy	NN	O	O
revealed	NN	O	O
segmental	NN	O	B-Disease
necrotizing	NN	O	I-Disease
glomerulonephritis	NN	O	I-Disease
without	NN	O	O
deposition	NN	O	O
of	NN	O	O
immunoglobulin	NN	O	O
or	NN	O	O
complement	NN	O	O
.	NN	O	O

Proteinase	NN	O	O
3	NN	O	O
-	NN	O	O
antineutrophil	NN	O	O
cytoplasmic	NN	O	O
antibody	NN	O	O
(	NN	O	O
PR3	NN	O	O
-	NN	O	O
ANCA	NN	O	O
)	NN	O	O
titer	NN	O	O
was	NN	O	O
elevated	NN	O	O
at	NN	O	O
183	NN	O	O
ELISA	NN	O	O
units	NN	O	O
(	NN	O	O
EU	NN	O	O
)	NN	O	O
in	NN	O	O
sera	NN	O	O
(	NN	O	O
normal	NN	O	O
range	NN	O	O
less	NN	O	O
than	NN	O	O
10	NN	O	O
EU	NN	O	O
)	NN	O	O
,	NN	O	O
myeloperoxidase	NN	O	O
-	NN	O	O
ANCA	NN	O	O
was	NN	O	O
negative	NN	O	O
.	NN	O	O

PR3	NN	O	O
-	NN	O	O
ANCA	NN	O	O
titer	NN	O	O
was	NN	O	O
250	NN	O	O
and	NN	O	O
1	NN	O	O
,	NN	O	O
070	NN	O	O
EU	NN	O	O
in	NN	O	O
pleural	NN	O	B-Disease
effusions	NN	O	I-Disease
on	NN	O	O
right	NN	O	O
and	NN	O	O
left	NN	O	O
side	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Although	NN	O	O
cessation	NN	O	O
of	NN	O	O
sulphasalazine	NN	O	B-Chemical
treatment	NN	O	O
resulted	NN	O	O
in	NN	O	O
improvements	NN	O	O
in	NN	O	O
fever	NN	O	B-Disease
,	NN	O	O
red	NN	O	B-Disease
eyes	NN	O	I-Disease
,	NN	O	O
chest	NN	O	B-Disease
pain	NN	O	I-Disease
,	NN	O	O
titer	NN	O	O
of	NN	O	O
C	NN	O	O
-	NN	O	O
reactive	NN	O	O
protein	NN	O	O
and	NN	O	O
volume	NN	O	O
of	NN	O	O
the	NN	O	O
pleural	NN	O	B-Disease
effusions	NN	O	I-Disease
,	NN	O	O
we	NN	O	O
initiated	NN	O	O
steroid	NN	O	B-Chemical
therapy	NN	O	O
,	NN	O	O
because	NN	O	O
PR3	NN	O	O
-	NN	O	O
ANCA	NN	O	O
titer	NN	O	O
rose	NN	O	O
to	NN	O	O
320	NN	O	O
EU	NN	O	O
,	NN	O	O
eosinophil	NN	O	O
count	NN	O	O
increased	NN	O	O
to	NN	O	O
1	NN	O	O
,	NN	O	O
100	NN	O	O
cells	NN	O	O
/	NN	O	O
microl	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
pleural	NN	O	B-Disease
effusion	NN	O	I-Disease
remained	NN	O	O
.	NN	O	O

One	NN	O	O
month	NN	O	O
after	NN	O	O
steroid	NN	O	B-Chemical
therapy	NN	O	O
,	NN	O	O
the	NN	O	O
pleural	NN	O	B-Disease
effusion	NN	O	I-Disease
disappeared	NN	O	O
,	NN	O	O
and	NN	O	O
PR3	NN	O	O
-	NN	O	O
ANCA	NN	O	O
titer	NN	O	O
normalized	NN	O	O
3	NN	O	O
months	NN	O	O
later	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
suggests	NN	O	O
that	NN	O	O
sulphasalazine	NN	O	B-Chemical
can	NN	O	O
induce	NN	O	O
PR3	NN	O	O
-	NN	O	O
ANCA	NN	O	O
-	NN	O	O
positive	NN	O	O
necrotizing	NN	O	O
glomerulonephritis	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (17049862)

Is	NN	O	O
phenytoin	NN	O	B-Chemical
administration	NN	O	O
safe	NN	O	O
in	NN	O	O
a	NN	O	O
hypothermic	NN	O	B-Disease
child?	NN	O	O
A	NN	O	O
male	NN	O	O
neonate	NN	O	O
with	NN	O	O
a	NN	O	O
Chiari	NN	O	B-Disease
malformation	NN	O	I-Disease
and	NN	O	O
a	NN	O	O
leaking	NN	O	O
myelomeningocoele	NN	O	O
underwent	NN	O	O
ventriculoperitoneal	NN	O	O
shunt	NN	O	O
insertion	NN	O	O
followed	NN	O	O
by	NN	O	O
repair	NN	O	O
of	NN	O	O
myelomeningocoele	NN	O	O
.	NN	O	O

During	NN	O	O
anaesthesia	NN	O	O
and	NN	O	O
surgery	NN	O	O
,	NN	O	O
he	NN	O	O
inadvertently	NN	O	O
became	NN	O	O
moderately	NN	O	O
hypothermic	NN	O	B-Disease
.	NN	O	O

Intravenous	NN	O	O
phenytoin	NN	O	B-Chemical
was	NN	O	O
administered	NN	O	O
during	NN	O	O
the	NN	O	O
later	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
surgery	NN	O	O
for	NN	O	O
seizure	NN	O	B-Disease
prophylaxis	NN	O	O
.	NN	O	O

Following	NN	O	O
phenytoin	NN	O	B-Chemical
administration	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
developed	NN	O	O
acute	NN	O	O
severe	NN	O	O
bradycardia	NN	O	B-Disease
,	NN	O	O
refractory	NN	O	O
to	NN	O	O
atropine	NN	O	B-Chemical
and	NN	O	O
adrenaline	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
cardiac	NN	O	O
depressant	NN	O	O
actions	NN	O	O
of	NN	O	O
phenytoin	NN	O	B-Chemical
and	NN	O	O
hypothermia	NN	O	B-Disease
can	NN	O	O
be	NN	O	O
additive	NN	O	O
.	NN	O	O

Administration	NN	O	O
of	NN	O	O
phenytoin	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
hypothermia	NN	O	B-Disease
may	NN	O	O
lead	NN	O	O
to	NN	O	O
an	NN	O	O
adverse	NN	O	O
cardiac	NN	O	O
event	NN	O	O
in	NN	O	O
children	NN	O	O
.	NN	O	O

As	NN	O	O
phenytoin	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
commonly	NN	O	O
used	NN	O	O
drug	NN	O	O
,	NN	O	O
clinicians	NN	O	O
need	NN	O	O
to	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
interaction	NN	O	O
.	NN	O	O


-DOCSTART- (16225977)

Amisulpride	NN	O	B-Chemical
related	NN	O	O
tic	NN	O	B-Disease
-	NN	O	I-Disease
like	NN	O	I-Disease
symptoms	NN	O	I-Disease
in	NN	O	O
an	NN	O	O
adolescent	NN	O	O
schizophrenic	NN	O	B-Disease
.	NN	O	O

Tic	NN	O	B-Disease
disorders	NN	O	I-Disease
can	NN	O	O
be	NN	O	O
effectively	NN	O	O
treated	NN	O	O
by	NN	O	O
atypical	NN	O	O
antipsychotics	NN	O	O
such	NN	O	O
as	NN	O	O
risperidone	NN	O	B-Chemical
,	NN	O	O
olanzapine	NN	O	B-Chemical
and	NN	O	O
ziprasidone	NN	O	B-Chemical
.	NN	O	O

However	NN	O	O
,	NN	O	O
there	NN	O	O
are	NN	O	O
two	NN	O	O
case	NN	O	O
reports	NN	O	O
that	NN	O	O
show	NN	O	O
tic	NN	O	B-Disease
-	NN	O	I-Disease
like	NN	O	I-Disease
symptoms	NN	O	I-Disease
,	NN	O	O
including	NN	O	O
motor	NN	O	O
and	NN	O	O
phonic	NN	O	O
variants	NN	O	O
,	NN	O	O
occurring	NN	O	O
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
quetiapine	NN	O	B-Chemical
or	NN	O	O
clozapine	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
present	NN	O	O
a	NN	O	O
15	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
girl	NN	O	O
schizophrenic	NN	O	B-Disease
who	NN	O	O
developed	NN	O	O
frequent	NN	O	O
involuntary	NN	O	B-Disease
eye	NN	O	I-Disease
-	NN	O	I-Disease
blinking	NN	O	I-Disease
movements	NN	O	I-Disease
after	NN	O	O
5	NN	O	O
months	NN	O	O
of	NN	O	O
amisulpride	NN	O	B-Chemical
treatment	NN	O	O
(	NN	O	O
1000	NN	O	O
mg	NN	O	O
per	NN	O	O
day	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
tic	NN	O	B-Disease
-	NN	O	I-Disease
like	NN	O	I-Disease
symptoms	NN	O	I-Disease
resolved	NN	O	O
completely	NN	O	O
after	NN	O	O
we	NN	O	O
reduced	NN	O	O
the	NN	O	O
dose	NN	O	O
of	NN	O	O
amisulpride	NN	O	B-Chemical
down	NN	O	O
to	NN	O	O
800	NN	O	O
mg	NN	O	O
per	NN	O	O
day	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
her	NN	O	O
psychosis	NN	O	B-Disease
recurred	NN	O	O
after	NN	O	O
the	NN	O	O
dose	NN	O	O
reduction	NN	O	O
.	NN	O	O

We	NN	O	O
then	NN	O	O
placed	NN	O	O
her	NN	O	O
on	NN	O	O
an	NN	O	O
additional	NN	O	O
100	NN	O	O
mg	NN	O	O
per	NN	O	O
day	NN	O	O
of	NN	O	O
quetiapine	NN	O	B-Chemical
.	NN	O	O

She	NN	O	O
has	NN	O	O
been	NN	O	O
in	NN	O	O
complete	NN	O	O
remission	NN	O	O
under	NN	O	O
the	NN	O	O
combined	NN	O	O
medications	NN	O	O
for	NN	O	O
more	NN	O	O
than	NN	O	O
one	NN	O	O
year	NN	O	O
and	NN	O	O
maintains	NN	O	O
a	NN	O	O
fair	NN	O	O
role	NN	O	O
function	NN	O	O
.	NN	O	O

No	NN	O	O
more	NN	O	O
tic	NN	O	B-Disease
-	NN	O	I-Disease
like	NN	O	I-Disease
symptoms	NN	O	I-Disease
or	NN	O	O
other	NN	O	O
side	NN	O	O
effects	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
.	NN	O	O

Together	NN	O	O
with	NN	O	O
previously	NN	O	O
reported	NN	O	O
cases	NN	O	O
,	NN	O	O
our	NN	O	O
patient	NN	O	O
suggests	NN	O	O
that	NN	O	O
tic	NN	O	B-Disease
-	NN	O	I-Disease
like	NN	O	I-Disease
symptoms	NN	O	I-Disease
might	NN	O	O
occur	NN	O	O
in	NN	O	O
certain	NN	O	O
vulnerable	NN	O	O
individuals	NN	O	O
during	NN	O	O
treatment	NN	O	O
with	NN	O	O
atypical	NN	O	O
antipsychotics	NN	O	O
such	NN	O	O
as	NN	O	O
quetiapine	NN	O	B-Chemical
,	NN	O	O
clozapine	NN	O	B-Chemical
,	NN	O	O
or	NN	O	O
amisulpride	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (12852481)

Comparison	NN	O	O
of	NN	O	O
developmental	NN	O	O
toxicology	NN	O	O
of	NN	O	O
aspirin	NN	O	B-Chemical
(	NN	O	O
acetylsalicylic	NN	O	B-Chemical
acid	NN	O	I-Chemical
)	NN	O	O
in	NN	O	O
rats	NN	O	O
using	NN	O	O
selected	NN	O	O
dosing	NN	O	O
paradigms	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Analysis	NN	O	O
of	NN	O	O
the	NN	O	O
literature	NN	O	O
for	NN	O	O
nonsteroidal	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
drugs	NN	O	O
(	NN	O	O
NSAIDs	NN	O	O
)	NN	O	O
suggests	NN	O	O
that	NN	O	O
a	NN	O	O
low	NN	O	O
incidence	NN	O	O
of	NN	O	O
developmental	NN	O	B-Disease
anomalies	NN	O	I-Disease
occurs	NN	O	O
in	NN	O	O
rats	NN	O	O
given	NN	O	O
NSAIDs	NN	O	O
on	NN	O	O
specific	NN	O	O
days	NN	O	O
during	NN	O	O
organogenesis	NN	O	O
.	NN	O	O

Aspirin	NN	O	B-Chemical
(	NN	O	O
acetylsalicylic	NN	O	B-Chemical
acid	NN	O	I-Chemical
[	NN	O	O
ASA	NN	O	B-Chemical
]	NN	O	O
)	NN	O	O
,	NN	O	O
an	NN	O	O
irreversible	NN	O	O
cyclooxygenase	NN	O	O
1	NN	O	O
and	NN	O	O
2	NN	O	O
inhibitor	NN	O	O
,	NN	O	O
induces	NN	O	O
developmental	NN	O	B-Disease
anomalies	NN	O	I-Disease
when	NN	O	O
administered	NN	O	O
to	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
on	NN	O	O
gestational	NN	O	O
day	NN	O	O
(	NN	O	O
GD	NN	O	O
)	NN	O	O
9	NN	O	O
,	NN	O	O
10	NN	O	O
,	NN	O	O
or	NN	O	O
11	NN	O	O
(	NN	O	O
Kimmel	NN	O	O
CA	NN	O	O
,	NN	O	O
Wilson	NN	O	O
JG	NN	O	O
,	NN	O	O
Schumacher	NN	O	O
HJ	NN	O	O
.	NN	O	O

Teratology	NN	O	O
4	NN	O	O
:	NN	O	O
15	NN	O	O
-	NN	O	O
24	NN	O	O
,	NN	O	O
1971	NN	O	O
)	NN	O	O
.	NN	O	O

There	NN	O	O
are	NN	O	O
no	NN	O	O
published	NN	O	O
ASA	NN	O	B-Chemical
studies	NN	O	O
using	NN	O	O
the	NN	O	O
multiple	NN	O	O
dosing	NN	O	O
paradigm	NN	O	O
of	NN	O	O
GDs	NN	O	O
6	NN	O	O
to	NN	O	O
17	NN	O	O
.	NN	O	O

Objectives	NN	O	O
of	NN	O	O
the	NN	O	O
current	NN	O	O
study	NN	O	O
were	NN	O	O
to	NN	O	O
compare	NN	O	O
results	NN	O	O
between	NN	O	O
Sprague	NN	O	O
-	NN	O	O
Dawley	NN	O	O
(	NN	O	O
SD	NN	O	O
)	NN	O	O
and	NN	O	O
Wistar	NN	O	O
strains	NN	O	O
when	NN	O	O
ASA	NN	O	B-Chemical
is	NN	O	O
administered	NN	O	O
on	NN	O	O
GD	NN	O	O
9	NN	O	O
,	NN	O	O
10	NN	O	O
,	NN	O	O
or	NN	O	O
11	NN	O	O
;	NN	O	O
to	NN	O	O
compare	NN	O	O
the	NN	O	O
malformation	NN	O	O
patterns	NN	O	O
following	NN	O	O
single	NN	O	O
and	NN	O	O
multiple	NN	O	O
dosings	NN	O	O
during	NN	O	O
organogenesis	NN	O	O
in	NN	O	O
SD	NN	O	O
rats	NN	O	O
;	NN	O	O
and	NN	O	O
to	NN	O	O
test	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
maternal	NN	O	O
gastrointestinal	NN	O	B-Disease
toxicity	NN	O	I-Disease
confounds	NN	O	O
the	NN	O	O
detection	NN	O	O
of	NN	O	O
low	NN	O	O
incidence	NN	O	O
malformations	NN	O	B-Disease
with	NN	O	O
ASA	NN	O	B-Chemical
when	NN	O	O
a	NN	O	O
multiple	NN	O	O
dosing	NN	O	O
paradigm	NN	O	O
is	NN	O	O
used	NN	O	O
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
ASA	NN	O	B-Chemical
was	NN	O	O
administered	NN	O	O
as	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
on	NN	O	O
GD	NN	O	O
9	NN	O	O
(	NN	O	O
0	NN	O	O
,	NN	O	O
250	NN	O	O
,	NN	O	O
500	NN	O	O
,	NN	O	O
or	NN	O	O
625	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
10	NN	O	O
(	NN	O	O
0	NN	O	O
,	NN	O	O
500	NN	O	O
,	NN	O	O
625	NN	O	O
,	NN	O	O
or	NN	O	O
750	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
,	NN	O	O
or	NN	O	O
11	NN	O	O
(	NN	O	O
0	NN	O	O
,	NN	O	O
500	NN	O	O
,	NN	O	O
750	NN	O	O
,	NN	O	O
or	NN	O	O
1000	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
)	NN	O	O
and	NN	O	O
from	NN	O	O
GD	NN	O	O
6	NN	O	O
to	NN	O	O
GD	NN	O	O
17	NN	O	O
(	NN	O	O
0	NN	O	O
,	NN	O	O
50	NN	O	O
,	NN	O	O
125	NN	O	O
,	NN	O	O
or	NN	O	O
250	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
a	NN	O	O
day	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
multiple	NN	O	O
dose	NN	O	O
study	NN	O	O
to	NN	O	O
SD	NN	O	O
rats	NN	O	O
.	NN	O	O

Animals	NN	O	O
were	NN	O	O
killed	NN	O	O
on	NN	O	O
GD	NN	O	O
21	NN	O	O
,	NN	O	O
and	NN	O	O
fetuses	NN	O	O
were	NN	O	O
examined	NN	O	O
viscerally	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
The	NN	O	O
literature	NN	O	O
evaluation	NN	O	O
suggested	NN	O	O
that	NN	O	O
NSAIDs	NN	O	O
induce	NN	O	O
ventricular	NN	O	B-Disease
septal	NN	O	I-Disease
defects	NN	O	I-Disease
(	NN	O	O
VSDs	NN	O	B-Disease
)	NN	O	O
and	NN	O	O
midline	NN	O	B-Disease
defects	NN	O	I-Disease
(	NN	O	O
MDs	NN	O	B-Disease
)	NN	O	O
in	NN	O	O
rats	NN	O	O
and	NN	O	O
diaphragmatic	NN	O	B-Disease
hernia	NN	O	I-Disease
(	NN	O	O
DH	NN	O	B-Disease
)	NN	O	O
,	NN	O	O
MDs	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
VSDs	NN	O	B-Disease
in	NN	O	O
rabbits	NN	O	O
(	NN	O	O
Cook	NN	O	O
JC	NN	O	O
et	NN	O	O
al.	NN	O	O
,	NN	O	O
2003	NN	O	O
)	NN	O	O
;	NN	O	O
hence	NN	O	O
,	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
focused	NN	O	O
on	NN	O	O
these	NN	O	O
malformations	NN	O	B-Disease
,	NN	O	O
even	NN	O	O
though	NN	O	O
ASA	NN	O	B-Chemical
induces	NN	O	O
several	NN	O	O
other	NN	O	O
low	NN	O	O
-	NN	O	O
incidence	NN	O	O
malformations	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
single	NN	O	O
dose	NN	O	O
studies	NN	O	O
,	NN	O	O
DH	NN	O	B-Disease
,	NN	O	O
MD	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
VSD	NN	O	B-Disease
were	NN	O	O
induced	NN	O	O
on	NN	O	O
GDs	NN	O	O
9	NN	O	O
and	NN	O	O
10	NN	O	O
.	NN	O	O

VSD	NN	O	B-Disease
also	NN	O	O
was	NN	O	O
noted	NN	O	O
following	NN	O	O
treatment	NN	O	O
on	NN	O	O
GD	NN	O	O
11	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
DH	NN	O	B-Disease
and	NN	O	O
MD	NN	O	B-Disease
were	NN	O	O
noted	NN	O	O
in	NN	O	O
the	NN	O	O
multiple	NN	O	O
dose	NN	O	O
study	NN	O	O
design	NN	O	O
only	NN	O	O
in	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
VSD	NN	O	B-Disease
was	NN	O	O
noted	NN	O	O
across	NN	O	O
all	NN	O	O
dose	NN	O	O
groups	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
High	NN	O	O
concordance	NN	O	O
in	NN	O	O
major	NN	O	O
developmental	NN	O	B-Disease
anomalies	NN	O	I-Disease
between	NN	O	O
Wistar	NN	O	O
and	NN	O	O
SD	NN	O	O
rats	NN	O	O
were	NN	O	O
noted	NN	O	O
with	NN	O	O
the	NN	O	O
exception	NN	O	O
of	NN	O	O
VSD	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
SD	NN	O	O
rats	NN	O	O
and	NN	O	O
hydrocephalus	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
.	NN	O	O

Variations	NN	O	O
and	NN	O	O
malformations	NN	O	B-Disease
were	NN	O	O
similar	NN	O	O
when	NN	O	O
ASA	NN	O	B-Chemical
was	NN	O	O
administered	NN	O	O
as	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
or	NN	O	O
during	NN	O	O
the	NN	O	O
period	NN	O	O
of	NN	O	O
organogenesis	NN	O	O
(	NN	O	O
GDs	NN	O	O
6	NN	O	O
to	NN	O	O
17	NN	O	O
)	NN	O	O
.	NN	O	O

It	NN	O	O
was	NN	O	O
also	NN	O	O
evident	NN	O	O
that	NN	O	O
,	NN	O	O
by	NN	O	O
titrating	NN	O	O
the	NN	O	O
dose	NN	O	O
to	NN	O	O
achieve	NN	O	O
a	NN	O	O
maximum	NN	O	O
tolerated	NN	O	O
dose	NN	O	O
,	NN	O	O
malformations	NN	O	B-Disease
that	NN	O	O
normally	NN	O	O
occur	NN	O	O
at	NN	O	O
low	NN	O	O
incidence	NN	O	O
,	NN	O	O
as	NN	O	O
reported	NN	O	O
from	NN	O	O
previous	NN	O	O
single	NN	O	O
dose	NN	O	O
studies	NN	O	O
,	NN	O	O
could	NN	O	O
also	NN	O	O
be	NN	O	O
induced	NN	O	O
with	NN	O	O
ASA	NN	O	B-Chemical
given	NN	O	O
at	NN	O	O
multiple	NN	O	O
doses	NN	O	O
.	NN	O	O


-DOCSTART- (11858397)

Torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
metoclopramide	NN	O	B-Chemical
in	NN	O	O
an	NN	O	O
elderly	NN	O	O
woman	NN	O	O
with	NN	O	O
preexisting	NN	O	O
complete	NN	O	O
left	NN	O	B-Disease
bundle	NN	O	I-Disease
branch	NN	O	I-Disease
block	NN	O	I-Disease
.	NN	O	O

There	NN	O	O
is	NN	O	O
a	NN	O	O
growing	NN	O	O
list	NN	O	O
of	NN	O	O
drugs	NN	O	O
implicated	NN	O	O
in	NN	O	O
acquired	NN	O	O
long	NN	O	B-Disease
QT	NN	O	I-Disease
syndrome	NN	O	I-Disease
and	NN	O	O
torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
the	NN	O	O
torsadogenic	NN	O	O
potential	NN	O	O
of	NN	O	O
metoclopramide	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
commonly	NN	O	O
used	NN	O	O
antiemetic	NN	O	O
and	NN	O	O
prokinetic	NN	O	O
drug	NN	O	O
,	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
,	NN	O	O
despite	NN	O	O
its	NN	O	O
chemical	NN	O	O
similarity	NN	O	O
to	NN	O	O
procainamide	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
report	NN	O	O
on	NN	O	O
a	NN	O	O
92	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
with	NN	O	O
preexisting	NN	O	O
complete	NN	O	O
left	NN	O	B-Disease
bundle	NN	O	I-Disease
branch	NN	O	I-Disease
block	NN	O	I-Disease
who	NN	O	O
developed	NN	O	O
torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
after	NN	O	O
intravenous	NN	O	O
and	NN	O	O
oral	NN	O	O
administration	NN	O	O
of	NN	O	O
metoclopramide	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
patient	NN	O	O
also	NN	O	O
developed	NN	O	O
torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
when	NN	O	O
cisapride	NN	O	B-Chemical
and	NN	O	O
erythromycin	NN	O	B-Chemical
were	NN	O	O
given	NN	O	O
simultaneously	NN	O	O
.	NN	O	O

These	NN	O	O
two	NN	O	O
episodes	NN	O	O
were	NN	O	O
suppressed	NN	O	O
successfully	NN	O	O
after	NN	O	O
discontinuing	NN	O	O
the	NN	O	O
offending	NN	O	O
drugs	NN	O	O
and	NN	O	O
administering	NN	O	O
class	NN	O	O
IB	NN	O	O
drugs	NN	O	O
.	NN	O	O

This	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
documentation	NN	O	O
that	NN	O	O
metoclopramide	NN	O	B-Chemical
provokes	NN	O	O
torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
clinically	NN	O	O
.	NN	O	O

Metoclopramide	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
used	NN	O	O
cautiously	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
risk	NN	O	O
of	NN	O	O
torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (11009181)

Apomorphine	NN	O	B-Chemical
:	NN	O	O
an	NN	O	O
underutilized	NN	O	O
therapy	NN	O	O
for	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

Apomorphine	NN	O	B-Chemical
was	NN	O	O
the	NN	O	O
first	NN	O	O
dopaminergic	NN	O	O
drug	NN	O	O
ever	NN	O	O
used	NN	O	O
to	NN	O	O
treat	NN	O	O
symptoms	NN	O	O
of	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
.	NN	O	O

While	NN	O	O
powerful	NN	O	O
antiparkinsonian	NN	O	O
effects	NN	O	O
had	NN	O	O
been	NN	O	O
observed	NN	O	O
as	NN	O	O
early	NN	O	O
as	NN	O	O
1951	NN	O	O
,	NN	O	O
the	NN	O	O
potential	NN	O	O
of	NN	O	O
treating	NN	O	O
fluctuating	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
by	NN	O	O
subcutaneous	NN	O	O
administration	NN	O	O
of	NN	O	O
apomorphine	NN	O	B-Chemical
has	NN	O	O
only	NN	O	O
recently	NN	O	O
become	NN	O	O
the	NN	O	O
subject	NN	O	O
of	NN	O	O
systematic	NN	O	O
study	NN	O	O
.	NN	O	O

A	NN	O	O
number	NN	O	O
of	NN	O	O
small	NN	O	O
scale	NN	O	O
clinical	NN	O	O
trials	NN	O	O
have	NN	O	O
unequivocally	NN	O	O
shown	NN	O	O
that	NN	O	O
intermittent	NN	O	O
subcutaneous	NN	O	O
apomorphine	NN	O	B-Chemical
injections	NN	O	O
produce	NN	O	O
antiparkinsonian	NN	O	O
benefit	NN	O	O
close	NN	O	O
if	NN	O	O
not	NN	O	O
identical	NN	O	O
to	NN	O	O
that	NN	O	O
seen	NN	O	O
with	NN	O	O
levodopa	NN	O	B-Chemical
and	NN	O	O
that	NN	O	O
apomorphine	NN	O	B-Chemical
rescue	NN	O	O
injections	NN	O	O
can	NN	O	O
reliably	NN	O	O
revert	NN	O	O
off	NN	O	O
-	NN	O	O
periods	NN	O	O
even	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
complex	NN	O	O
on	NN	O	O
-	NN	O	O
off	NN	O	O
motor	NN	O	O
swings	NN	O	O
.	NN	O	O

Continuous	NN	O	O
subcutaneous	NN	O	O
apomorphine	NN	O	B-Chemical
infusions	NN	O	O
can	NN	O	O
reduce	NN	O	O
daily	NN	O	O
off	NN	O	O
-	NN	O	O
time	NN	O	O
by	NN	O	O
more	NN	O	O
than	NN	O	O
50%	NN	O	O
in	NN	O	O
this	NN	O	O
group	NN	O	O
of	NN	O	O
patients	NN	O	O
,	NN	O	O
which	NN	O	O
appears	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
stronger	NN	O	O
effect	NN	O	O
than	NN	O	O
that	NN	O	O
generally	NN	O	O
seen	NN	O	O
with	NN	O	O
add	NN	O	O
-	NN	O	O
on	NN	O	O
therapy	NN	O	O
with	NN	O	O
oral	NN	O	O
dopamine	NN	O	B-Chemical
agonists	NN	O	O
or	NN	O	O
COMT	NN	O	O
inhibitors	NN	O	O
.	NN	O	O

Extended	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
studies	NN	O	O
of	NN	O	O
up	NN	O	O
to	NN	O	O
8	NN	O	O
years	NN	O	O
have	NN	O	O
demonstrated	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
persistence	NN	O	O
of	NN	O	O
apomorphine	NN	O	B-Chemical
efficacy	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
convincing	NN	O	O
clinical	NN	O	O
evidence	NN	O	O
that	NN	O	O
monotherapy	NN	O	O
with	NN	O	O
continuous	NN	O	O
subcutaneous	NN	O	O
apomorphine	NN	O	B-Chemical
infusions	NN	O	O
is	NN	O	O
associated	NN	O	O
with	NN	O	O
marked	NN	O	O
reductions	NN	O	O
of	NN	O	O
preexisting	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
main	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
subcutaneous	NN	O	O
apomorphine	NN	O	B-Chemical
treatment	NN	O	O
are	NN	O	O
related	NN	O	O
to	NN	O	O
cutaneous	NN	O	O
tolerability	NN	O	O
problems	NN	O	O
,	NN	O	O
whereas	NN	O	O
sedation	NN	O	O
and	NN	O	O
psychiatric	NN	O	B-Disease
complications	NN	O	O
play	NN	O	O
a	NN	O	O
lesser	NN	O	O
role	NN	O	O
.	NN	O	O

Given	NN	O	O
the	NN	O	O
marked	NN	O	O
degree	NN	O	O
of	NN	O	O
efficacy	NN	O	O
of	NN	O	O
subcutaneous	NN	O	O
apomorphine	NN	O	B-Chemical
treatment	NN	O	O
in	NN	O	O
fluctuating	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
this	NN	O	O
approach	NN	O	O
seems	NN	O	O
to	NN	O	O
deserve	NN	O	O
more	NN	O	O
widespread	NN	O	O
clinical	NN	O	O
use	NN	O	O
.	NN	O	O


-DOCSTART- (8988571)

Fatal	NN	O	O
excited	NN	O	O
delirium	NN	O	B-Disease
following	NN	O	O
cocaine	NN	O	B-Chemical
use	NN	O	O
:	NN	O	O
epidemiologic	NN	O	O
findings	NN	O	O
provide	NN	O	O
new	NN	O	O
evidence	NN	O	O
for	NN	O	O
mechanisms	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
toxicity	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
describe	NN	O	O
an	NN	O	O
outbreak	NN	O	O
of	NN	O	O
deaths	NN	O	O
from	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
excited	NN	O	O
delirium	NN	O	B-Disease
(	NN	O	O
EDDs	NN	O	B-Disease
)	NN	O	O
in	NN	O	O
Dade	NN	O	O
County	NN	O	O
,	NN	O	O
Florida	NN	O	O
between	NN	O	O
1979	NN	O	O
and	NN	O	O
1990	NN	O	O
.	NN	O	O

From	NN	O	O
a	NN	O	O
registry	NN	O	O
of	NN	O	O
all	NN	O	O
cocaine	NN	O	B-Chemical
-	NN	O	O
related	NN	O	O
deaths	NN	O	O
in	NN	O	O
Dade	NN	O	O
County	NN	O	O
,	NN	O	O
Florida	NN	O	O
,	NN	O	O
from	NN	O	O
1969	NN	O	O
-	NN	O	O
1990	NN	O	O
,	NN	O	O
58	NN	O	O
EDDs	NN	O	B-Disease
were	NN	O	O
compared	NN	O	O
with	NN	O	O
125	NN	O	O
victims	NN	O	O
of	NN	O	O
accidental	NN	O	O
cocaine	NN	O	B-Chemical
overdose	NN	O	B-Disease
without	NN	O	O
excited	NN	O	O
delirium	NN	O	B-Disease
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
controls	NN	O	O
,	NN	O	O
EDDs	NN	O	B-Disease
were	NN	O	O
more	NN	O	O
frequently	NN	O	O
black	NN	O	O
,	NN	O	O
male	NN	O	O
,	NN	O	O
and	NN	O	O
younger	NN	O	O
.	NN	O	O

They	NN	O	O
were	NN	O	O
less	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
a	NN	O	O
low	NN	O	O
body	NN	O	O
mass	NN	O	O
index	NN	O	O
,	NN	O	O
and	NN	O	O
more	NN	O	O
likely	NN	O	O
to	NN	O	O
have	NN	O	O
died	NN	O	O
in	NN	O	O
police	NN	O	O
custody	NN	O	O
,	NN	O	O
to	NN	O	O
have	NN	O	O
received	NN	O	O
medical	NN	O	O
treatment	NN	O	O
immediately	NN	O	O
before	NN	O	O
death	NN	O	O
,	NN	O	O
to	NN	O	O
have	NN	O	O
survived	NN	O	O
for	NN	O	O
a	NN	O	O
longer	NN	O	O
period	NN	O	O
,	NN	O	O
to	NN	O	O
have	NN	O	O
developed	NN	O	O
hyperthermia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
to	NN	O	O
have	NN	O	O
died	NN	O	O
in	NN	O	O
summer	NN	O	O
months	NN	O	O
.	NN	O	O

EDDs	NN	O	B-Disease
had	NN	O	O
concentrations	NN	O	O
of	NN	O	O
cocaine	NN	O	B-Chemical
and	NN	O	O
benzoylecgonine	NN	O	B-Chemical
in	NN	O	O
autopsy	NN	O	O
blood	NN	O	O
that	NN	O	O
were	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
for	NN	O	O
controls	NN	O	O
.	NN	O	O

The	NN	O	O
epidemiologic	NN	O	O
findings	NN	O	O
are	NN	O	O
most	NN	O	O
consistent	NN	O	O
with	NN	O	O
the	NN	O	O
hypothesis	NN	O	O
that	NN	O	O
chronic	NN	O	O
cocaine	NN	O	B-Chemical
use	NN	O	O
disrupts	NN	O	O
dopaminergic	NN	O	O
function	NN	O	O
and	NN	O	O
,	NN	O	O
when	NN	O	O
coupled	NN	O	O
with	NN	O	O
recent	NN	O	O
cocaine	NN	O	B-Chemical
use	NN	O	O
,	NN	O	O
may	NN	O	O
precipitate	NN	O	O
agitation	NN	O	B-Disease
,	NN	O	O
delirium	NN	O	B-Disease
,	NN	O	O
aberrant	NN	O	O
thermoregulation	NN	O	O
,	NN	O	O
rhabdomyolysis	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
sudden	NN	O	B-Disease
death	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (6615052)

Heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
,	NN	O	O
thrombosis	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
hemorrhage	NN	O	B-Disease
.	NN	O	O

Sixty	NN	O	O
-	NN	O	O
two	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
thrombocytopenia	NN	O	B-Disease
are	NN	O	O
reported	NN	O	O
.	NN	O	O

Clinical	NN	O	O
manifestations	NN	O	O
of	NN	O	O
this	NN	O	O
disorder	NN	O	O
include	NN	O	O
hemorrhage	NN	O	B-Disease
or	NN	O	O
,	NN	O	O
more	NN	O	O
frequently	NN	O	O
,	NN	O	O
thromboembolic	NN	O	B-Disease
events	NN	O	O
in	NN	O	O
patients	NN	O	O
receiving	NN	O	O
heparin	NN	O	B-Chemical
.	NN	O	O

Laboratory	NN	O	O
testing	NN	O	O
has	NN	O	O
revealed	NN	O	O
a	NN	O	B-Disease
falling	NN	O	I-Disease
platelet	NN	O	I-Disease
count	NN	O	I-Disease
,	NN	O	O
increased	NN	O	O
resistance	NN	O	O
to	NN	O	O
heparin	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
aggregation	NN	O	O
of	NN	O	O
platelets	NN	O	O
by	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
plasma	NN	O	O
when	NN	O	O
heparin	NN	O	B-Chemical
is	NN	O	O
added	NN	O	O
.	NN	O	O

Immunologic	NN	O	O
testing	NN	O	O
has	NN	O	O
demonstrated	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
a	NN	O	O
heparin	NN	O	B-Chemical
-	NN	O	O
dependent	NN	O	O
platelet	NN	O	O
membrane	NN	O	O
antibody	NN	O	O
.	NN	O	O

The	NN	O	O
20	NN	O	O
deaths	NN	O	O
,	NN	O	O
52	NN	O	O
hemorrhagic	NN	O	B-Disease
and	NN	O	I-Disease
thromboembolic	NN	O	I-Disease
complications	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
21	NN	O	O
surgical	NN	O	O
procedures	NN	O	O
to	NN	O	O
manage	NN	O	O
the	NN	O	O
complications	NN	O	O
confirm	NN	O	O
the	NN	O	O
seriousness	NN	O	O
of	NN	O	O
the	NN	O	O
disorder	NN	O	O
.	NN	O	O

Specific	NN	O	O
risk	NN	O	O
factors	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
identified	NN	O	O
;	NN	O	O
therefore	NN	O	O
,	NN	O	O
all	NN	O	O
patients	NN	O	O
receiving	NN	O	O
heparin	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
monitored	NN	O	O
.	NN	O	O

If	NN	O	O
the	NN	O	O
platelet	NN	O	O
count	NN	O	O
falls	NN	O	O
to	NN	O	O
less	NN	O	O
than	NN	O	O
100	NN	O	O
,	NN	O	O
000	NN	O	O
/	NN	O	O
mm3	NN	O	O
,	NN	O	O
while	NN	O	O
the	NN	O	O
patient	NN	O	O
is	NN	O	O
receiving	NN	O	O
heparin	NN	O	B-Chemical
,	NN	O	O
platelet	NN	O	B-Disease
aggregation	NN	O	I-Disease
testing	NN	O	O
,	NN	O	O
using	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
plasma	NN	O	O
,	NN	O	O
is	NN	O	O
indicated	NN	O	O
.	NN	O	O

Management	NN	O	O
consists	NN	O	O
of	NN	O	O
cessation	NN	O	O
of	NN	O	O
heparin	NN	O	B-Chemical
,	NN	O	O
platelet	NN	O	O
anti	NN	O	O
-	NN	O	O
aggregating	NN	O	O
agents	NN	O	O
,	NN	O	O
and	NN	O	O
alternate	NN	O	O
forms	NN	O	O
of	NN	O	O
anticoagulation	NN	O	O
when	NN	O	O
indicated	NN	O	O
.	NN	O	O


-DOCSTART- (3952818)

Cardiac	NN	O	B-Disease
toxicity	NN	O	I-Disease
of	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
fluorouracil	NN	O	I-Chemical
.	NN	O	O

Report	NN	O	O
of	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
spontaneous	NN	O	O
angina	NN	O	B-Disease
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
colon	NN	O	B-Disease
carcinoma	NN	O	I-Disease
and	NN	O	O
liver	NN	O	O
metastasis	NN	O	B-Disease
who	NN	O	O
presented	NN	O	O
chest	NN	O	B-Disease
pain	NN	O	I-Disease
after	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
fluorouracil	NN	O	I-Chemical
(	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
)	NN	O	O
administration	NN	O	O
.	NN	O	O

Clinical	NN	O	O
electrocardiographic	NN	O	O
evolution	NN	O	O
was	NN	O	O
similar	NN	O	O
to	NN	O	O
that	NN	O	O
observed	NN	O	O
in	NN	O	O
Prinzmetal	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
angina	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
chest	NN	O	B-Disease
pain	NN	O	I-Disease
promptly	NN	O	O
resolved	NN	O	O
with	NN	O	O
nifedipine	NN	O	B-Chemical
.	NN	O	O

These	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
coronary	NN	O	B-Disease
spasm	NN	O	I-Disease
may	NN	O	O
be	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
cardiotoxicity	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
,	NN	O	O
and	NN	O	O
that	NN	O	O
calcium	NN	O	B-Chemical
antagonists	NN	O	O
may	NN	O	O
probably	NN	O	O
be	NN	O	O
used	NN	O	O
in	NN	O	O
the	NN	O	O
prevention	NN	O	O
or	NN	O	O
treatment	NN	O	O
of	NN	O	O
5	NN	O	B-Chemical
-	NN	O	I-Chemical
FU	NN	O	I-Chemical
cardiotoxicity	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (3084782)

Toxicity	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
remission	NN	O	O
inducing	NN	O	O
drugs	NN	O	O
in	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
.	NN	O	O

Association	NN	O	O
with	NN	O	O
HLA	NN	O	O
-	NN	O	O
B35	NN	O	O
and	NN	O	O
Cw4	NN	O	O
antigens	NN	O	O
.	NN	O	O

Twenty	NN	O	O
-	NN	O	O
five	NN	O	O
patients	NN	O	O
with	NN	O	O
rheumatoid	NN	O	B-Disease
arthritis	NN	O	I-Disease
(	NN	O	O
RA	NN	O	B-Disease
)	NN	O	O
who	NN	O	O
developed	NN	O	O
toxicity	NN	O	B-Disease
while	NN	O	O
taking	NN	O	O
remission	NN	O	O
inducing	NN	O	O
drugs	NN	O	O
and	NN	O	O
30	NN	O	O
without	NN	O	O
toxicity	NN	O	B-Disease
were	NN	O	O
studied	NN	O	O
for	NN	O	O
possible	NN	O	O
associations	NN	O	O
with	NN	O	O
class	NN	O	O
I	NN	O	O
and	NN	O	O
II	NN	O	O
HLA	NN	O	O
antigens	NN	O	O
.	NN	O	O

A	NN	O	O
strong	NN	O	O
association	NN	O	O
has	NN	O	O
been	NN	O	O
found	NN	O	O
between	NN	O	O
nephritis	NN	O	B-Disease
and	NN	O	O
dermatitis	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
Tiopronin	NN	O	B-Chemical
(	NN	O	O
a	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
Penicillamine	NN	O	I-Chemical
like	NN	O	O
compound	NN	O	O
)	NN	O	O
and	NN	O	O
class	NN	O	O
I	NN	O	O
antigens	NN	O	O
B35	NN	O	O
-	NN	O	O
Cw4	NN	O	O
,	NN	O	O
and	NN	O	O
between	NN	O	O
dermatitis	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
gold	NN	O	B-Chemical
thiosulphate	NN	O	B-Chemical
and	NN	O	O
B35	NN	O	O
.	NN	O	O

Compared	NN	O	O
to	NN	O	O
healthy	NN	O	O
controls	NN	O	O
a	NN	O	O
lower	NN	O	O
DR5	NN	O	O
frequency	NN	O	O
was	NN	O	O
observed	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
RA	NN	O	B-Disease
except	NN	O	O
for	NN	O	O
the	NN	O	O
Tiopronin	NN	O	B-Chemical
related	NN	O	O
nephritis	NN	O	B-Disease
group	NN	O	O
.	NN	O	O


-DOCSTART- (430165)

Transient	NN	O	O
hemiparesis	NN	O	B-Disease
:	NN	O	O
a	NN	O	O
rare	NN	O	O
manifestation	NN	O	O
of	NN	O	O
diphenylhydantoin	NN	O	B-Chemical
toxicity	NN	O	B-Disease
.	NN	O	O

Report	NN	O	O
of	NN	O	O
two	NN	O	O
cases	NN	O	O
.	NN	O	O

Among	NN	O	O
the	NN	O	O
common	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
diphenylhydantoin	NN	O	B-Chemical
(	NN	O	O
DPH	NN	O	B-Chemical
)	NN	O	O
overdose	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
most	NN	O	O
frequently	NN	O	O
encountered	NN	O	O
neurological	NN	O	O
signs	NN	O	O
are	NN	O	O
those	NN	O	O
of	NN	O	O
cerebellar	NN	O	B-Disease
dysfunction	NN	O	I-Disease
.	NN	O	O

Very	NN	O	O
rarely	NN	O	O
,	NN	O	O
the	NN	O	O
toxic	NN	O	O
neurological	NN	O	O
manifestations	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
are	NN	O	O
of	NN	O	O
cerebral	NN	O	O
origin	NN	O	O
.	NN	O	O

Two	NN	O	O
patients	NN	O	O
are	NN	O	O
presented	NN	O	O
who	NN	O	O
suffered	NN	O	O
progressive	NN	O	O
hemiparesis	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
DPH	NN	O	B-Chemical
overdose	NN	O	B-Disease
.	NN	O	O

Both	NN	O	O
had	NN	O	O
brain	NN	O	O
surgery	NN	O	O
before	NN	O	O
DPH	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
assumed	NN	O	O
that	NN	O	O
patients	NN	O	O
with	NN	O	O
some	NN	O	O
cerebral	NN	O	B-Disease
damage	NN	O	I-Disease
are	NN	O	O
liable	NN	O	O
to	NN	O	O
manifest	NN	O	O
DPH	NN	O	B-Chemical
toxicity	NN	O	B-Disease
as	NN	O	O
focal	NN	O	O
neurological	NN	O	O
signs	NN	O	O
.	NN	O	O


-DOCSTART- (16600756)

Nerve	NN	O	O
growth	NN	O	O
factor	NN	O	O
and	NN	O	O
prostaglandins	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
urine	NN	O	O
of	NN	O	O
female	NN	O	O
patients	NN	O	O
with	NN	O	O
overactive	NN	O	B-Disease
bladder	NN	O	I-Disease
.	NN	O	O

PURPOSE	NN	O	O
:	NN	O	O
NGF	NN	O	O
and	NN	O	O
PGs	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
bladder	NN	O	O
can	NN	O	O
be	NN	O	O
affected	NN	O	O
by	NN	O	O
pathological	NN	O	O
changes	NN	O	O
in	NN	O	O
the	NN	O	O
bladder	NN	O	O
and	NN	O	O
these	NN	O	O
changes	NN	O	O
can	NN	O	O
be	NN	O	O
detected	NN	O	O
in	NN	O	O
urine	NN	O	O
.	NN	O	O

We	NN	O	O
investigated	NN	O	O
changes	NN	O	O
in	NN	O	O
urinary	NN	O	O
NGF	NN	O	O
and	NN	O	O
PGs	NN	O	B-Chemical
in	NN	O	O
women	NN	O	O
with	NN	O	O
OAB	NN	O	B-Disease
.	NN	O	O

MATERIALS	NN	O	O
AND	NN	O	O
METHODS	NN	O	O
:	NN	O	O
The	NN	O	O
study	NN	O	O
groups	NN	O	O
included	NN	O	O
65	NN	O	O
women	NN	O	O
with	NN	O	O
OAB	NN	O	B-Disease
and	NN	O	O
20	NN	O	O
without	NN	O	O
bladder	NN	O	O
symptoms	NN	O	O
who	NN	O	O
served	NN	O	O
as	NN	O	O
controls	NN	O	O
.	NN	O	O

Evaluation	NN	O	O
included	NN	O	O
patient	NN	O	O
history	NN	O	O
,	NN	O	O
urinalysis	NN	O	O
,	NN	O	O
a	NN	O	O
voiding	NN	O	O
diary	NN	O	O
and	NN	O	O
urodynamic	NN	O	O
studies	NN	O	O
.	NN	O	O

Urine	NN	O	O
samples	NN	O	O
were	NN	O	O
collected	NN	O	O
.	NN	O	O

NGF	NN	O	O
,	NN	O	O
PGE2	NN	O	B-Chemical
,	NN	O	O
PGF2alpha	NN	O	B-Chemical
and	NN	O	O
PGI2	NN	O	B-Chemical
were	NN	O	O
measured	NN	O	O
using	NN	O	O
enzyme	NN	O	O
-	NN	O	O
linked	NN	O	O
immunosorbent	NN	O	O
assay	NN	O	O
and	NN	O	O
compared	NN	O	O
between	NN	O	O
the	NN	O	O
groups	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
correlations	NN	O	O
between	NN	O	O
urinary	NN	O	O
NGF	NN	O	O
and	NN	O	O
PG	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
urodynamic	NN	O	O
parameters	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
OAB	NN	O	B-Disease
were	NN	O	O
examined	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Urinary	NN	O	O
NGF	NN	O	O
,	NN	O	O
PGE2	NN	O	B-Chemical
and	NN	O	O
PGF2alpha	NN	O	B-Chemical
were	NN	O	O
significantly	NN	O	O
increased	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
OAB	NN	O	B-Disease
compared	NN	O	O
with	NN	O	O
controls	NN	O	O
(	NN	O	O
p	NN	O	O
<0.05	NN	O	O
)	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
urinary	NN	O	O
PGI2	NN	O	B-Chemical
was	NN	O	O
not	NN	O	O
different	NN	O	O
between	NN	O	O
controls	NN	O	O
and	NN	O	O
patients	NN	O	O
with	NN	O	O
OAB	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
patients	NN	O	O
with	NN	O	O
OAB	NN	O	B-Disease
urinary	NN	O	O
PGE2	NN	O	B-Chemical
positively	NN	O	O
correlated	NN	O	O
with	NN	O	O
volume	NN	O	O
at	NN	O	O
first	NN	O	O
desire	NN	O	O
to	NN	O	O
void	NN	O	O
and	NN	O	O
maximum	NN	O	O
cystometric	NN	O	O
capacity	NN	O	O
(	NN	O	O
p	NN	O	O
<0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Urinary	NN	O	O
NGF	NN	O	O
,	NN	O	O
PGF2alpha	NN	O	B-Chemical
and	NN	O	O
PGI2	NN	O	B-Chemical
did	NN	O	O
not	NN	O	O
correlate	NN	O	O
with	NN	O	O
urodynamic	NN	O	O
parameters	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
OAB	NN	O	B-Disease
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
NGF	NN	O	O
and	NN	O	O
PGs	NN	O	B-Chemical
have	NN	O	O
important	NN	O	O
roles	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
OAB	NN	O	B-Disease
symptoms	NN	O	O
in	NN	O	O
female	NN	O	O
patients	NN	O	O
.	NN	O	O

Urinary	NN	O	O
levels	NN	O	O
of	NN	O	O
these	NN	O	O
factors	NN	O	O
may	NN	O	O
be	NN	O	O
used	NN	O	O
as	NN	O	O
markers	NN	O	O
to	NN	O	O
evaluate	NN	O	O
OAB	NN	O	B-Disease
symptoms	NN	O	O
.	NN	O	O


-DOCSTART- (15686794)

Acute	NN	O	O
low	NN	O	B-Disease
back	NN	O	I-Disease
pain	NN	O	I-Disease
during	NN	O	O
intravenous	NN	O	O
administration	NN	O	O
of	NN	O	O
amiodarone	NN	O	B-Chemical
:	NN	O	O
a	NN	O	O
report	NN	O	O
of	NN	O	O
two	NN	O	O
cases	NN	O	O
.	NN	O	O

Amiodarone	NN	O	B-Chemical
represents	NN	O	O
an	NN	O	O
effective	NN	O	O
antiarrhythmic	NN	O	O
drug	NN	O	O
for	NN	O	O
cardioversion	NN	O	O
of	NN	O	O
recent	NN	O	O
-	NN	O	O
onset	NN	O	O
atrial	NN	O	B-Disease
fibrillation	NN	O	I-Disease
(	NN	O	O
AF	NN	O	B-Disease
)	NN	O	O
and	NN	O	O
maintenance	NN	O	O
of	NN	O	O
sinus	NN	O	O
rhythm	NN	O	O
.	NN	O	O

We	NN	O	O
briefly	NN	O	O
describe	NN	O	O
two	NN	O	O
patients	NN	O	O
suffering	NN	O	O
from	NN	O	O
recent	NN	O	O
-	NN	O	O
onset	NN	O	O
atrial	NN	O	B-Disease
fibrillation	NN	O	I-Disease
,	NN	O	O
who	NN	O	O
experienced	NN	O	O
an	NN	O	O
acute	NN	O	O
devastating	NN	O	O
low	NN	O	B-Disease
back	NN	O	I-Disease
pain	NN	O	I-Disease
a	NN	O	O
few	NN	O	O
minutes	NN	O	O
after	NN	O	O
initiation	NN	O	O
of	NN	O	O
intravenous	NN	O	O
amiodarone	NN	O	B-Chemical
loading	NN	O	O
.	NN	O	O

Notably	NN	O	O
,	NN	O	O
this	NN	O	O
side	NN	O	O
effect	NN	O	O
has	NN	O	O
not	NN	O	O
been	NN	O	O
ever	NN	O	O
reported	NN	O	O
in	NN	O	O
the	NN	O	O
medical	NN	O	O
literature	NN	O	O
.	NN	O	O

Clinicians	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
of	NN	O	O
this	NN	O	O
reaction	NN	O	O
since	NN	O	O
prompt	NN	O	O
termination	NN	O	O
of	NN	O	O
parenteral	NN	O	O
administration	NN	O	O
leads	NN	O	O
to	NN	O	O
complete	NN	O	O
resolution	NN	O	O
.	NN	O	O


-DOCSTART- (12760988)

Postoperative	NN	O	B-Disease
myalgia	NN	O	I-Disease
after	NN	O	O
succinylcholine	NN	O	B-Chemical
:	NN	O	O
no	NN	O	O
evidence	NN	O	O
for	NN	O	O
an	NN	O	O
inflammatory	NN	O	O
origin	NN	O	O
.	NN	O	O

A	NN	O	O
common	NN	O	O
side	NN	O	O
effect	NN	O	O
associated	NN	O	O
with	NN	O	O
succinylcholine	NN	O	B-Chemical
is	NN	O	O
postoperative	NN	O	B-Disease
myalgia	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
this	NN	O	O
myalgia	NN	O	B-Disease
is	NN	O	O
still	NN	O	O
unclear	NN	O	O
;	NN	O	O
inflammation	NN	O	B-Disease
has	NN	O	O
been	NN	O	O
suggested	NN	O	O
but	NN	O	O
without	NN	O	O
convincing	NN	O	O
evidence	NN	O	O
.	NN	O	O

We	NN	O	O
designed	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
to	NN	O	O
investigate	NN	O	O
whether	NN	O	O
an	NN	O	O
inflammatory	NN	O	O
reaction	NN	O	O
contributes	NN	O	O
to	NN	O	O
this	NN	O	O
myalgia	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
succinylcholine	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
myalgia	NN	O	B-Disease
was	NN	O	O
determined	NN	O	O
in	NN	O	O
64	NN	O	O
patients	NN	O	O
pretreated	NN	O	O
with	NN	O	O
saline	NN	O	O
or	NN	O	O
dexamethasone	NN	O	B-Chemical
before	NN	O	O
succinylcholine	NN	O	B-Chemical
(	NN	O	O
n	NN	O	O
=	NN	O	O
32	NN	O	O
for	NN	O	O
each	NN	O	O
)	NN	O	O
.	NN	O	O

Incidence	NN	O	O
and	NN	O	O
severity	NN	O	O
of	NN	O	O
myalgia	NN	O	B-Disease
did	NN	O	O
not	NN	O	O
differ	NN	O	O
significantly	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
:	NN	O	O
15	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
dexamethasone	NN	O	B-Chemical
group	NN	O	O
complained	NN	O	O
of	NN	O	O
myalgia	NN	O	B-Disease
compared	NN	O	O
with	NN	O	O
18	NN	O	O
patients	NN	O	O
in	NN	O	O
the	NN	O	O
saline	NN	O	O
group	NN	O	O
,	NN	O	O
and	NN	O	O
severe	NN	O	O
myalgia	NN	O	B-Disease
was	NN	O	O
reported	NN	O	O
by	NN	O	O
five	NN	O	O
patients	NN	O	O
and	NN	O	O
three	NN	O	O
patients	NN	O	O
,	NN	O	O
respectively	NN	O	O
(	NN	O	O
not	NN	O	O
significant	NN	O	O
)	NN	O	O
.	NN	O	O

At	NN	O	O
48	NN	O	O
h	NN	O	O
after	NN	O	O
surgery	NN	O	O
,	NN	O	O
12	NN	O	O
patients	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
still	NN	O	O
suffered	NN	O	O
from	NN	O	O
myalgia	NN	O	B-Disease
(	NN	O	O
not	NN	O	O
significant	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
interleukin	NN	O	O
-	NN	O	O
6	NN	O	O
(	NN	O	O
IL	NN	O	O
-	NN	O	O
6	NN	O	O
)	NN	O	O
as	NN	O	O
an	NN	O	O
early	NN	O	O
marker	NN	O	O
of	NN	O	O
inflammation	NN	O	B-Disease
was	NN	O	O
assessed	NN	O	O
in	NN	O	O
a	NN	O	O
subgroup	NN	O	O
of	NN	O	O
10	NN	O	O
patients	NN	O	O
pretreated	NN	O	O
with	NN	O	O
saline	NN	O	O
.	NN	O	O

We	NN	O	O
found	NN	O	O
an	NN	O	O
increase	NN	O	O
of	NN	O	O
IL	NN	O	O
-	NN	O	O
6	NN	O	O
for	NN	O	O
only	NN	O	O
three	NN	O	O
patients	NN	O	O
,	NN	O	O
but	NN	O	O
only	NN	O	O
one	NN	O	O
patient	NN	O	O
reported	NN	O	O
myalgia	NN	O	B-Disease
;	NN	O	O
no	NN	O	O
relationship	NN	O	O
between	NN	O	O
myalgia	NN	O	B-Disease
and	NN	O	O
the	NN	O	O
increase	NN	O	O
of	NN	O	O
IL	NN	O	O
-	NN	O	O
6	NN	O	O
was	NN	O	O
found	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
there	NN	O	O
is	NN	O	O
no	NN	O	O
evidence	NN	O	O
for	NN	O	O
an	NN	O	O
inflammatory	NN	O	O
origin	NN	O	O
of	NN	O	O
succinylcholine	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
myalgia	NN	O	B-Disease
.	NN	O	O

IMPLICATIONS	NN	O	O
:	NN	O	O
Administration	NN	O	O
of	NN	O	O
dexamethasone	NN	O	B-Chemical
before	NN	O	O
succinylcholine	NN	O	B-Chemical
was	NN	O	O
not	NN	O	O
effective	NN	O	O
in	NN	O	O
decreasing	NN	O	O
the	NN	O	O
incidence	NN	O	O
or	NN	O	O
the	NN	O	O
severity	NN	O	O
of	NN	O	O
succinylcholine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
postoperative	NN	O	B-Disease
myalgia	NN	O	I-Disease
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
relationship	NN	O	O
between	NN	O	O
postoperative	NN	O	B-Disease
myalgia	NN	O	I-Disease
and	NN	O	O
time	NN	O	O
course	NN	O	O
of	NN	O	O
interleukin	NN	O	O
-	NN	O	O
6	NN	O	O
concentrations	NN	O	O
,	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
inflammation	NN	O	B-Disease
.	NN	O	O

Pretreatment	NN	O	O
with	NN	O	O
dexamethasone	NN	O	B-Chemical
is	NN	O	O
not	NN	O	O
justified	NN	O	O
to	NN	O	O
prevent	NN	O	O
postoperative	NN	O	B-Disease
myalgia	NN	O	I-Disease
after	NN	O	O
succinylcholine	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (12691807)

Levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
oromandibular	NN	O	O
dystonia	NN	O	B-Disease
in	NN	O	O
progressive	NN	O	B-Disease
supranuclear	NN	O	I-Disease
palsy	NN	O	I-Disease
.	NN	O	O

Levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
have	NN	O	O
been	NN	O	O
reported	NN	O	O
in	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
and	NN	O	O
multiple	NN	O	B-Disease
system	NN	O	I-Disease
atrophy	NN	O	I-Disease
.	NN	O	O

Cranial	NN	O	O
dystonias	NN	O	B-Disease
are	NN	O	O
rare	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
progressive	NN	O	B-Disease
supranuclear	NN	O	I-Disease
palsy	NN	O	I-Disease
(	NN	O	O
PSP	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
report	NN	O	O
we	NN	O	O
describe	NN	O	O
an	NN	O	O
unusual	NN	O	O
case	NN	O	O
of	NN	O	O
reversible	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
Oromandibular	NN	O	B-Disease
dystonia	NN	O	I-Disease
(	NN	O	O
OMD	NN	O	B-Disease
)	NN	O	O
in	NN	O	O
a	NN	O	O
PSP	NN	O	B-Disease
patient	NN	O	O
to	NN	O	O
highlight	NN	O	O
the	NN	O	O
importance	NN	O	O
of	NN	O	O
recognizing	NN	O	O
this	NN	O	O
drug	NN	O	O
related	NN	O	O
complication	NN	O	O
in	NN	O	O
the	NN	O	O
management	NN	O	O
of	NN	O	O
PSP	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
discuss	NN	O	O
the	NN	O	O
possible	NN	O	O
underlying	NN	O	O
pathophysiology	NN	O	O
.	NN	O	O


-DOCSTART- (12600698)

Protective	NN	O	O
effect	NN	O	O
of	NN	O	O
edaravone	NN	O	B-Chemical
against	NN	O	O
streptomycin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
vestibulotoxicity	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
guinea	NN	O	O
pig	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
investigated	NN	O	O
alleviation	NN	O	O
of	NN	O	O
streptomycin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
vestibulotoxicity	NN	O	B-Disease
by	NN	O	O
edaravone	NN	O	B-Chemical
in	NN	O	O
guinea	NN	O	O
pigs	NN	O	O
.	NN	O	O

Edaravone	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
free	NN	O	O
radical	NN	O	O
scavenger	NN	O	O
,	NN	O	O
has	NN	O	O
potent	NN	O	O
free	NN	O	O
radical	NN	O	O
quenching	NN	O	O
action	NN	O	O
and	NN	O	O
is	NN	O	O
used	NN	O	O
in	NN	O	O
clinical	NN	O	O
practice	NN	O	O
to	NN	O	O
treat	NN	O	O
cerebral	NN	O	B-Disease
infarction	NN	O	I-Disease
.	NN	O	O

Streptomycin	NN	O	B-Chemical
was	NN	O	O
administered	NN	O	O
to	NN	O	O
the	NN	O	O
inner	NN	O	O
ear	NN	O	O
by	NN	O	O
osmotic	NN	O	O
pump	NN	O	O
for	NN	O	O
24	NN	O	O
h	NN	O	O
,	NN	O	O
and	NN	O	O
edaravone	NN	O	B-Chemical
(	NN	O	O
n=8	NN	O	O
)	NN	O	O
or	NN	O	O
saline	NN	O	O
(	NN	O	O
n=6	NN	O	O
)	NN	O	O
was	NN	O	O
intraperitoneally	NN	O	O
injected	NN	O	O
once	NN	O	O
a	NN	O	O
day	NN	O	O
for	NN	O	O
7	NN	O	O
days	NN	O	O
.	NN	O	O

We	NN	O	O
observed	NN	O	O
horizontal	NN	O	O
vestibulo	NN	O	O
-	NN	O	O
ocular	NN	O	O
reflex	NN	O	O
as	NN	O	O
a	NN	O	O
marker	NN	O	O
of	NN	O	O
postoperative	NN	O	O
vestibular	NN	O	O
function	NN	O	O
.	NN	O	O

Animals	NN	O	O
injected	NN	O	O
with	NN	O	O
saline	NN	O	O
showed	NN	O	O
statistically	NN	O	O
smaller	NN	O	O
gains	NN	O	O
than	NN	O	O
those	NN	O	O
injected	NN	O	O
with	NN	O	O
edaravone	NN	O	B-Chemical
.	NN	O	O

These	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
edaravone	NN	O	B-Chemical
suppresses	NN	O	O
streptomycin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
vestibulotoxicity	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (12091028)

Ketamine	NN	O	B-Chemical
in	NN	O	O
war	NN	O	O
/	NN	O	O
tropical	NN	O	O
surgery	NN	O	O
(	NN	O	O
a	NN	O	O
final	NN	O	O
tribute	NN	O	O
to	NN	O	O
the	NN	O	O
racemic	NN	O	O
mixture	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
technique	NN	O	O
of	NN	O	O
continuous	NN	O	O
intravenous	NN	O	O
anaesthesia	NN	O	O
with	NN	O	O
ketamine	NN	O	B-Chemical
was	NN	O	O
used	NN	O	O
successfully	NN	O	O
during	NN	O	O
the	NN	O	O
Somalia	NN	O	O
civil	NN	O	O
war	NN	O	O
in	NN	O	O
1994	NN	O	O
and	NN	O	O
in	NN	O	O
north	NN	O	O
Uganda	NN	O	O
in	NN	O	O
1999	NN	O	O
for	NN	O	O
64	NN	O	O
operations	NN	O	O
in	NN	O	O
62	NN	O	O
patients	NN	O	O
,	NN	O	O
aged	NN	O	O
from	NN	O	O
6	NN	O	O
weeks	NN	O	O
to	NN	O	O
70	NN	O	O
years	NN	O	O
,	NN	O	O
undergoing	NN	O	O
limb	NN	O	O
and	NN	O	O
abdominal	NN	O	O
surgery	NN	O	O
including	NN	O	O
caesarian	NN	O	O
sections	NN	O	O
and	NN	O	O
interventions	NN	O	O
in	NN	O	O
neonates	NN	O	O
.	NN	O	O

Operations	NN	O	O
lasting	NN	O	O
up	NN	O	O
to	NN	O	O
2h	NN	O	O
could	NN	O	O
be	NN	O	O
performed	NN	O	O
in	NN	O	O
the	NN	O	O
absence	NN	O	O
of	NN	O	O
sophisticated	NN	O	O
equipment	NN	O	O
such	NN	O	O
as	NN	O	O
pulse	NN	O	O
oximeters	NN	O	O
or	NN	O	O
ventilators	NN	O	O
in	NN	O	O
patients	NN	O	O
on	NN	O	O
spontaneous	NN	O	O
ventilation	NN	O	O
breathing	NN	O	O
air	NN	O	O
/	NN	O	O
oxygen	NN	O	B-Chemical
only	NN	O	O
.	NN	O	O

After	NN	O	O
premedication	NN	O	O
with	NN	O	O
diazepam	NN	O	B-Chemical
,	NN	O	O
glycopyrrolate	NN	O	B-Chemical
and	NN	O	O
local	NN	O	O
anaesthesia	NN	O	O
,	NN	O	O
and	NN	O	O
induction	NN	O	O
with	NN	O	O
standard	NN	O	O
doses	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
maintenance	NN	O	O
dose	NN	O	O
of	NN	O	O
10	NN	O	O
-	NN	O	O
20	NN	O	O
microg	NN	O	O
/	NN	O	O
kg	NN	O	O
/	NN	O	O
min	NN	O	O
of	NN	O	O
ketamine	NN	O	B-Chemical
proved	NN	O	O
safe	NN	O	O
and	NN	O	O
effective	NN	O	O
.	NN	O	O

Emphasis	NN	O	O
was	NN	O	O
placed	NN	O	O
on	NN	O	O
bedside	NN	O	O
clinical	NN	O	O
monitoring	NN	O	O
,	NN	O	O
relying	NN	O	O
heavily	NN	O	O
on	NN	O	O
the	NN	O	O
heart	NN	O	O
rate	NN	O	O
.	NN	O	O

Diazepam	NN	O	B-Chemical
,	NN	O	O
unless	NN	O	O
contraindicated	NN	O	O
or	NN	O	O
risky	NN	O	O
,	NN	O	O
remains	NN	O	O
the	NN	O	O
only	NN	O	O
necessary	NN	O	O
complementary	NN	O	O
drug	NN	O	O
to	NN	O	O
ketamine	NN	O	B-Chemical
as	NN	O	O
it	NN	O	O
buffers	NN	O	O
its	NN	O	O
cardiovascular	NN	O	O
response	NN	O	O
and	NN	O	O
decreases	NN	O	O
the	NN	O	O
duration	NN	O	O
and	NN	O	O
intensity	NN	O	O
of	NN	O	O
operative	NN	O	O
and	NN	O	O
postoperative	NN	O	O
hallucinations	NN	O	B-Disease
.	NN	O	O

Local	NN	O	O
anaesthetic	NN	O	O
blocks	NN	O	O
were	NN	O	O
useful	NN	O	O
in	NN	O	O
decreasing	NN	O	O
the	NN	O	O
requirement	NN	O	O
for	NN	O	O
postoperative	NN	O	O
analgesia	NN	O	B-Disease
.	NN	O	O

An	NN	O	O
antisialogue	NN	O	O
was	NN	O	O
usually	NN	O	O
unnecessary	NN	O	O
in	NN	O	O
operations	NN	O	O
lasting	NN	O	O
up	NN	O	O
to	NN	O	O
2	NN	O	O
h	NN	O	O
,	NN	O	O
glycopyrrolate	NN	O	B-Chemical
being	NN	O	O
the	NN	O	O
best	NN	O	O
choice	NN	O	O
for	NN	O	O
its	NN	O	O
lowest	NN	O	O
psychotropic	NN	O	O
and	NN	O	O
chronotropic	NN	O	O
effects	NN	O	O
,	NN	O	O
especially	NN	O	O
in	NN	O	O
a	NN	O	O
hot	NN	O	O
climate	NN	O	O
.	NN	O	O

Experience	NN	O	O
in	NN	O	O
war	NN	O	O
/	NN	O	O
tropical	NN	O	O
settings	NN	O	O
suggests	NN	O	O
this	NN	O	O
technique	NN	O	O
could	NN	O	O
be	NN	O	O
useful	NN	O	O
in	NN	O	O
civilian	NN	O	O
contexts	NN	O	O
such	NN	O	O
as	NN	O	O
outdoor	NN	O	O
life	NN	O	O
-	NN	O	O
saving	NN	O	O
emergency	NN	O	O
surgery	NN	O	O
or	NN	O	O
in	NN	O	O
mass	NN	O	O
casualties	NN	O	O
where	NN	O	O
,	NN	O	O
e.g.	NN	O	O
amputation	NN	O	O
and	NN	O	O
rapid	NN	O	O
extrication	NN	O	O
were	NN	O	O
required	NN	O	O
.	NN	O	O


-DOCSTART- (11860495)

Steroid	NN	O	B-Chemical
structure	NN	O	O
and	NN	O	O
pharmacological	NN	O	O
properties	NN	O	O
determine	NN	O	O
the	NN	O	O
anti	NN	O	O
-	NN	O	O
amnesic	NN	O	B-Disease
effects	NN	O	O
of	NN	O	O
pregnenolone	NN	O	B-Chemical
sulphate	NN	O	I-Chemical
in	NN	O	O
the	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

Pregnenolone	NN	O	B-Chemical
sulphate	NN	O	I-Chemical
(	NN	O	O
PREGS	NN	O	B-Chemical
)	NN	O	O
has	NN	O	O
generated	NN	O	O
interest	NN	O	O
as	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
most	NN	O	O
potent	NN	O	O
memory	NN	O	O
-	NN	O	O
enhancing	NN	O	O
neurosteroids	NN	O	O
to	NN	O	O
be	NN	O	O
examined	NN	O	O
in	NN	O	O
rodent	NN	O	O
learning	NN	O	O
studies	NN	O	O
,	NN	O	O
with	NN	O	O
particular	NN	O	O
importance	NN	O	O
in	NN	O	O
the	NN	O	O
ageing	NN	O	O
process	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
by	NN	O	O
which	NN	O	O
this	NN	O	O
endogenous	NN	O	O
steroid	NN	O	B-Chemical
enhances	NN	O	O
memory	NN	O	O
formation	NN	O	O
is	NN	O	O
hypothesized	NN	O	O
to	NN	O	O
involve	NN	O	O
actions	NN	O	O
on	NN	O	O
glutamatergic	NN	O	O
and	NN	O	O
GABAergic	NN	O	O
systems	NN	O	O
.	NN	O	O

This	NN	O	O
hypothesis	NN	O	O
stems	NN	O	O
from	NN	O	O
findings	NN	O	O
that	NN	O	O
PREGS	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
potent	NN	O	O
positive	NN	O	O
modulator	NN	O	O
of	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
methyl	NN	O	I-Chemical
-	NN	O	I-Chemical
d	NN	O	I-Chemical
-	NN	O	I-Chemical
aspartate	NN	O	I-Chemical
receptors	NN	O	O
(	NN	O	O
NMDARs	NN	O	O
)	NN	O	O
and	NN	O	O
a	NN	O	O
negative	NN	O	O
modulator	NN	O	O
of	NN	O	O
gamma	NN	O	B-Chemical
-	NN	O	I-Chemical
aminobutyric	NN	O	I-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
A	NN	O	O
)	NN	O	O
receptors	NN	O	O
(	NN	O	O
GABA	NN	O	B-Chemical
(	NN	O	O
A	NN	O	O
)	NN	O	O
Rs	NN	O	O
)	NN	O	O
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
PREGS	NN	O	B-Chemical
is	NN	O	O
able	NN	O	O
to	NN	O	O
reverse	NN	O	O
the	NN	O	O
amnesic	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
effects	NN	O	O
of	NN	O	O
NMDAR	NN	O	O
and	NN	O	O
GABA	NN	O	B-Chemical
(	NN	O	O
A	NN	O	O
)	NN	O	O
R	NN	O	O
ligands	NN	O	O
.	NN	O	O

To	NN	O	O
investigate	NN	O	O
this	NN	O	O
hypothesis	NN	O	O
,	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
in	NN	O	O
rats	NN	O	O
examined	NN	O	O
the	NN	O	O
memory	NN	O	O
-	NN	O	O
altering	NN	O	O
abilities	NN	O	O
of	NN	O	O
structural	NN	O	O
analogs	NN	O	O
of	NN	O	O
PREGS	NN	O	B-Chemical
,	NN	O	O
which	NN	O	O
differ	NN	O	O
in	NN	O	O
their	NN	O	O
modulation	NN	O	O
of	NN	O	O
NMDAR	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
GABA	NN	O	B-Chemical
(	NN	O	O
A	NN	O	O
)	NN	O	O
R	NN	O	O
function	NN	O	O
.	NN	O	O

The	NN	O	O
analogs	NN	O	O
tested	NN	O	O
were	NN	O	O
:	NN	O	O
11	NN	O	B-Chemical
-	NN	O	I-Chemical
ketopregnenolone	NN	O	I-Chemical
sulphate	NN	O	I-Chemical
(	NN	O	O
an	NN	O	O
agent	NN	O	O
that	NN	O	O
is	NN	O	O
inactive	NN	O	O
at	NN	O	O
GABA	NN	O	B-Chemical
(	NN	O	O
A	NN	O	O
)	NN	O	O
Rs	NN	O	O
and	NN	O	O
NMDARs	NN	O	O
)	NN	O	O
,	NN	O	O
epipregnanolone	NN	O	B-Chemical
(	NN	O	I-Chemical
[	NN	O	I-Chemical
3beta	NN	O	I-Chemical
-	NN	O	I-Chemical
hydroxy	NN	O	I-Chemical
-	NN	O	I-Chemical
5beta	NN	O	I-Chemical
-	NN	O	I-Chemical
pregnan	NN	O	I-Chemical
-	NN	O	I-Chemical
20	NN	O	I-Chemical
-	NN	O	I-Chemical
one	NN	O	I-Chemical
]	NN	O	I-Chemical
sulphate	NN	O	I-Chemical
,	NN	O	O
an	NN	O	O
inhibitor	NN	O	O
of	NN	O	O
both	NN	O	O
GABA	NN	O	B-Chemical
(	NN	O	O
A	NN	O	O
)	NN	O	O
Rs	NN	O	O
and	NN	O	O
NMDARs	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
a	NN	O	O
newly	NN	O	O
synthesized	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
PREGS	NN	O	B-Chemical
enantiomer	NN	O	O
(	NN	O	O
which	NN	O	O
is	NN	O	O
identical	NN	O	O
to	NN	O	O
PREGS	NN	O	B-Chemical
in	NN	O	O
effects	NN	O	O
on	NN	O	O
GABA	NN	O	B-Chemical
(	NN	O	O
A	NN	O	O
)	NN	O	O
Rs	NN	O	O
and	NN	O	O
NMDARs	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
memory	NN	O	O
-	NN	O	O
enhancing	NN	O	O
effects	NN	O	O
of	NN	O	O
PREGS	NN	O	B-Chemical
and	NN	O	O
its	NN	O	O
analogs	NN	O	O
were	NN	O	O
tested	NN	O	O
in	NN	O	O
the	NN	O	O
passive	NN	O	O
avoidance	NN	O	O
task	NN	O	O
using	NN	O	O
the	NN	O	O
model	NN	O	O
of	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B-Disease
.	NN	O	O

Both	NN	O	O
PREGS	NN	O	B-Chemical
and	NN	O	O
its	NN	O	O
(	NN	O	O
-	NN	O	O
)	NN	O	O
enantiomer	NN	O	O
blocked	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
scopolamine	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
results	NN	O	O
show	NN	O	O
that	NN	O	O
,	NN	O	O
unlike	NN	O	O
PREGS	NN	O	B-Chemical
,	NN	O	O
11	NN	O	B-Chemical
-	NN	O	I-Chemical
ketopregnenolone	NN	O	I-Chemical
sulphate	NN	O	I-Chemical
and	NN	O	O
epipregnanolone	NN	O	B-Chemical
sulphate	NN	O	I-Chemical
failed	NN	O	O
to	NN	O	O
block	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
scopolamine	NN	O	B-Chemical
,	NN	O	O
suggesting	NN	O	O
that	NN	O	O
altering	NN	O	O
the	NN	O	O
modulation	NN	O	O
of	NN	O	O
NMDA	NN	O	B-Chemical
receptors	NN	O	O
diminishes	NN	O	O
the	NN	O	O
memory	NN	O	O
-	NN	O	O
enhancing	NN	O	O
effects	NN	O	O
of	NN	O	O
PREGS	NN	O	B-Chemical
.	NN	O	O

Moreover	NN	O	O
,	NN	O	O
enantioselectivity	NN	O	O
was	NN	O	O
demonstrated	NN	O	O
by	NN	O	O
the	NN	O	O
ability	NN	O	O
of	NN	O	O
natural	NN	O	O
PREGS	NN	O	B-Chemical
to	NN	O	O
be	NN	O	O
an	NN	O	O
order	NN	O	O
of	NN	O	O
magnitude	NN	O	O
more	NN	O	O
effective	NN	O	O
than	NN	O	O
its	NN	O	O
synthetic	NN	O	O
enantiomer	NN	O	O
in	NN	O	O
reversing	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
amnesia	NN	O	B-Disease
.	NN	O	O

These	NN	O	O
results	NN	O	O
identify	NN	O	O
a	NN	O	O
novel	NN	O	O
neuropharmacological	NN	O	O
site	NN	O	O
for	NN	O	O
the	NN	O	O
modulation	NN	O	O
of	NN	O	O
memory	NN	O	O
processes	NN	O	O
by	NN	O	O
neuroactive	NN	O	O
steroids	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (11752998)

Preliminary	NN	O	O
efficacy	NN	O	O
assessment	NN	O	O
of	NN	O	O
intrathecal	NN	O	O
injection	NN	O	O
of	NN	O	O
an	NN	O	O
American	NN	O	O
formulation	NN	O	O
of	NN	O	O
adenosine	NN	O	B-Chemical
in	NN	O	O
humans	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Preclinical	NN	O	O
studies	NN	O	O
of	NN	O	O
intrathecal	NN	O	O
adenosine	NN	O	B-Chemical
suggest	NN	O	O
it	NN	O	O
may	NN	O	O
be	NN	O	O
effective	NN	O	O
in	NN	O	O
the	NN	O	O
treatment	NN	O	O
of	NN	O	O
acute	NN	O	B-Disease
and	NN	O	I-Disease
chronic	NN	O	I-Disease
pain	NN	O	I-Disease
in	NN	O	O
humans	NN	O	O
,	NN	O	O
and	NN	O	O
preliminary	NN	O	O
studies	NN	O	O
in	NN	O	O
volunteers	NN	O	O
and	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
Swedish	NN	O	O
formulation	NN	O	O
of	NN	O	O
adenosine	NN	O	B-Chemical
suggests	NN	O	O
it	NN	O	O
may	NN	O	O
be	NN	O	O
effective	NN	O	O
in	NN	O	O
hypersensitivity	NN	O	B-Disease
states	NN	O	O
but	NN	O	O
not	NN	O	O
with	NN	O	O
acute	NN	O	O
noxious	NN	O	O
stimulation	NN	O	O
.	NN	O	O

The	NN	O	O
purpose	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
screen	NN	O	O
for	NN	O	O
efficacy	NN	O	O
of	NN	O	O
a	NN	O	O
different	NN	O	O
formulation	NN	O	O
of	NN	O	O
adenosine	NN	O	B-Chemical
marketed	NN	O	O
in	NN	O	O
the	NN	O	O
US	NN	O	O
,	NN	O	O
using	NN	O	O
both	NN	O	O
acute	NN	O	O
noxious	NN	O	O
stimulation	NN	O	O
and	NN	O	O
capsaicin	NN	O	B-Chemical
-	NN	O	O
evoked	NN	O	O
mechanical	NN	O	O
hypersensitivity	NN	O	B-Disease
.	NN	O	O

METHODS	NN	O	O
:	NN	O	O
Following	NN	O	O
Food	NN	O	O
and	NN	O	O
Drug	NN	O	O
Administration	NN	O	O
and	NN	O	O
institutional	NN	O	O
review	NN	O	O
board	NN	O	O
approval	NN	O	O
and	NN	O	O
written	NN	O	O
informed	NN	O	O
consent	NN	O	O
,	NN	O	O
65	NN	O	O
volunteers	NN	O	O
were	NN	O	O
studied	NN	O	O
in	NN	O	O
two	NN	O	O
trials	NN	O	O
:	NN	O	O
an	NN	O	O
open	NN	O	O
-	NN	O	O
label	NN	O	O
,	NN	O	O
dose	NN	O	O
-	NN	O	O
escalating	NN	O	O
trial	NN	O	O
with	NN	O	O
intrathecal	NN	O	O
adenosine	NN	O	B-Chemical
doses	NN	O	O
of	NN	O	O
0.25	NN	O	O
-	NN	O	O
2.0	NN	O	O
mg	NN	O	O
and	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
trial	NN	O	O
of	NN	O	O
adenosine	NN	O	B-Chemical
,	NN	O	O
2	NN	O	O
mg	NN	O	O
.	NN	O	O

Cerebrospinal	NN	O	O
fluid	NN	O	O
was	NN	O	O
obtained	NN	O	O
for	NN	O	O
pharmacokinetic	NN	O	O
analysis	NN	O	O
,	NN	O	O
and	NN	O	O
pain	NN	O	B-Disease
ratings	NN	O	O
in	NN	O	O
response	NN	O	O
to	NN	O	O
acute	NN	O	O
heat	NN	O	O
stimuli	NN	O	O
and	NN	O	O
areas	NN	O	O
of	NN	O	O
mechanical	NN	O	B-Disease
hyperalgesia	NN	O	I-Disease
and	NN	O	O
allodynia	NN	O	B-Disease
after	NN	O	O
intradermal	NN	O	O
capsaicin	NN	O	B-Chemical
injection	NN	O	O
were	NN	O	O
determined	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Adenosine	NN	O	B-Chemical
produced	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
pain	NN	O	B-Disease
report	NN	O	O
to	NN	O	O
acute	NN	O	O
noxious	NN	O	O
thermal	NN	O	O
or	NN	O	O
chemical	NN	O	O
stimulation	NN	O	O
but	NN	O	O
reduced	NN	O	O
mechanical	NN	O	B-Disease
hyperalgesia	NN	O	I-Disease
and	NN	O	O
allodynia	NN	O	B-Disease
from	NN	O	O
intradermal	NN	O	O
capsaicin	NN	O	B-Chemical
injection	NN	O	O
for	NN	O	O
at	NN	O	O
least	NN	O	O
24	NN	O	O
h	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
residence	NN	O	O
time	NN	O	O
of	NN	O	O
adenosine	NN	O	B-Chemical
in	NN	O	O
cerebrospinal	NN	O	O
fluid	NN	O	O
was	NN	O	O
short	NN	O	O
(	NN	O	O
<	NN	O	O
4	NN	O	O
h	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
These	NN	O	O
results	NN	O	O
show	NN	O	O
selective	NN	O	O
inhibition	NN	O	O
by	NN	O	O
intrathecal	NN	O	O
adenosine	NN	O	B-Chemical
of	NN	O	O
hypersensitivity	NN	O	B-Disease
,	NN	O	O
presumed	NN	O	O
to	NN	O	O
reflect	NN	O	O
central	NN	O	O
sensitization	NN	O	O
in	NN	O	O
humans	NN	O	O
after	NN	O	O
peripheral	NN	O	O
capsaicin	NN	O	B-Chemical
injection	NN	O	O
.	NN	O	O

The	NN	O	O
long	NN	O	O
-	NN	O	O
lasting	NN	O	O
effect	NN	O	O
is	NN	O	O
consistent	NN	O	O
with	NN	O	O
that	NN	O	O
observed	NN	O	O
in	NN	O	O
preliminary	NN	O	O
reports	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
chronic	NN	O	O
neuropathic	NN	O	B-Disease
pain	NN	O	I-Disease
and	NN	O	O
is	NN	O	O
not	NN	O	O
due	NN	O	O
to	NN	O	O
prolonged	NN	O	O
residence	NN	O	O
of	NN	O	O
adenosine	NN	O	B-Chemical
in	NN	O	O
cerebrospinal	NN	O	O
fluid	NN	O	O
.	NN	O	O


-DOCSTART- (10354657)

Effect	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
maintenance	NN	O	O
therapy	NN	O	O
on	NN	O	O
thyroid	NN	O	O
and	NN	O	O
parathyroid	NN	O	O
function	NN	O	O
.	NN	O	O

OBJECTIVES	NN	O	O
:	NN	O	O
To	NN	O	O
assess	NN	O	O
changes	NN	O	O
induced	NN	O	O
by	NN	O	O
lithium	NN	O	B-Chemical
maintenance	NN	O	O
therapy	NN	O	O
on	NN	O	O
the	NN	O	O
incidence	NN	O	O
of	NN	O	O
thyroid	NN	O	O
,	NN	O	O
parathyroid	NN	O	O
and	NN	O	O
ion	NN	O	O
alterations	NN	O	O
.	NN	O	O

These	NN	O	O
were	NN	O	O
evaluated	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
the	NN	O	O
duration	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
therapy	NN	O	O
,	NN	O	O
age	NN	O	O
,	NN	O	O
sex	NN	O	O
,	NN	O	O
and	NN	O	O
family	NN	O	O
history	NN	O	O
(	NN	O	O
whether	NN	O	O
or	NN	O	O
not	NN	O	O
the	NN	O	O
patient	NN	O	O
had	NN	O	O
a	NN	O	O
first	NN	O	O
-	NN	O	O
degree	NN	O	O
relative	NN	O	O
with	NN	O	O
thyroid	NN	O	B-Disease
disease	NN	O	I-Disease
)	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Prospective	NN	O	O
study	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
Affective	NN	O	O
Disorders	NN	O	O
Clinic	NN	O	O
at	NN	O	O
St	NN	O	O
.	NN	O	O

Mary	NN	O	O
'	NN	O	O
s	NN	O	O
Hospital	NN	O	O
,	NN	O	O
Montreal	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
:	NN	O	O
One	NN	O	O
hundred	NN	O	O
and	NN	O	O
one	NN	O	O
patients	NN	O	O
(	NN	O	O
28	NN	O	O
men	NN	O	O
and	NN	O	O
73	NN	O	O
women	NN	O	O
)	NN	O	O
with	NN	O	O
bipolar	NN	O	B-Disease
disorder	NN	O	I-Disease
receiving	NN	O	O
lithium	NN	O	B-Chemical
maintenance	NN	O	O
therapy	NN	O	O
ranging	NN	O	O
from	NN	O	O
1	NN	O	O
year	NN	O	O
'	NN	O	O
s	NN	O	O
to	NN	O	O
32	NN	O	O
years	NN	O	O
'	NN	O	O
duration	NN	O	O
.	NN	O	O

The	NN	O	O
control	NN	O	O
group	NN	O	O
consisted	NN	O	O
of	NN	O	O
82	NN	O	O
patients	NN	O	O
with	NN	O	O
no	NN	O	O
psychiatric	NN	O	B-Disease
or	NN	O	O
endocrinological	NN	O	O
diagnoses	NN	O	O
from	NN	O	O
the	NN	O	O
hospital	NN	O	O
'	NN	O	O
s	NN	O	O
out	NN	O	O
-	NN	O	O
patient	NN	O	O
clinics	NN	O	O
.	NN	O	O

OUTCOME	NN	O	O
MEASURES	NN	O	O
:	NN	O	O
Laboratory	NN	O	O
analyses	NN	O	O
of	NN	O	O
calcium	NN	O	B-Chemical
,	NN	O	O
magnesium	NN	O	B-Chemical
and	NN	O	O
thyroid	NN	O	O
-	NN	O	O
stimulating	NN	O	O
hormone	NN	O	O
levels	NN	O	O
performed	NN	O	O
before	NN	O	O
beginning	NN	O	O
lithium	NN	O	B-Chemical
therapy	NN	O	O
and	NN	O	O
at	NN	O	O
biannual	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Hypothyroidism	NN	O	B-Disease
developed	NN	O	O
in	NN	O	O
40	NN	O	O
patients	NN	O	O
,	NN	O	O
excluding	NN	O	O
8	NN	O	O
patients	NN	O	O
who	NN	O	O
were	NN	O	O
hypothyroid	NN	O	B-Disease
at	NN	O	O
baseline	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
having	NN	O	O
first	NN	O	O
-	NN	O	O
degree	NN	O	O
relatives	NN	O	O
affected	NN	O	O
by	NN	O	O
thyroid	NN	O	B-Disease
illness	NN	O	I-Disease
had	NN	O	O
accelerated	NN	O	O
onset	NN	O	O
of	NN	O	O
hypothyroidism	NN	O	B-Disease
(	NN	O	O
3.7	NN	O	O
years	NN	O	O
after	NN	O	O
onset	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
therapy	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
patients	NN	O	O
without	NN	O	O
a	NN	O	O
family	NN	O	O
history	NN	O	O
(	NN	O	O
8.6	NN	O	O
years	NN	O	O
after	NN	O	O
onset	NN	O	O
of	NN	O	O
lithium	NN	O	B-Chemical
therapy	NN	O	O
)	NN	O	O
.	NN	O	O

Women	NN	O	O
over	NN	O	O
60	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
were	NN	O	O
more	NN	O	O
often	NN	O	O
affected	NN	O	O
by	NN	O	O
hypothyroidism	NN	O	B-Disease
than	NN	O	O
women	NN	O	O
under	NN	O	O
60	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
(	NN	O	O
34.6%	NN	O	O
versus	NN	O	O
31.9%	NN	O	O
)	NN	O	O
.	NN	O	O

Magnesium	NN	O	B-Chemical
levels	NN	O	O
in	NN	O	O
patients	NN	O	O
on	NN	O	O
lithium	NN	O	B-Chemical
treatment	NN	O	O
were	NN	O	O
unchanged	NN	O	O
from	NN	O	O
baseline	NN	O	O
levels	NN	O	O
.	NN	O	O

After	NN	O	O
lithium	NN	O	B-Chemical
treatment	NN	O	O
,	NN	O	O
calcium	NN	O	B-Chemical
levels	NN	O	O
were	NN	O	O
higher	NN	O	O
than	NN	O	O
either	NN	O	O
baseline	NN	O	O
levels	NN	O	O
or	NN	O	O
control	NN	O	O
levels	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
lithium	NN	O	B-Chemical
treatment	NN	O	O
counteracted	NN	O	O
the	NN	O	O
decrease	NN	O	O
in	NN	O	O
plasma	NN	O	O
calcium	NN	O	B-Chemical
levels	NN	O	O
associated	NN	O	O
with	NN	O	O
aging	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Familial	NN	O	O
thyroid	NN	O	B-Disease
illness	NN	O	I-Disease
is	NN	O	O
a	NN	O	O
risk	NN	O	O
factor	NN	O	O
for	NN	O	O
hypothyroidism	NN	O	B-Disease
and	NN	O	O
hypercalcemia	NN	O	B-Disease
during	NN	O	O
lithium	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O


-DOCSTART- (10328196)

Systemic	NN	O	O
toxicity	NN	O	B-Disease
following	NN	O	O
administration	NN	O	O
of	NN	O	O
sirolimus	NN	O	B-Chemical
(	NN	O	O
formerly	NN	O	O
rapamycin	NN	O	B-Chemical
)	NN	O	O
for	NN	O	O
psoriasis	NN	O	B-Disease
:	NN	O	O
association	NN	O	O
of	NN	O	O
capillary	NN	O	B-Disease
leak	NN	O	I-Disease
syndrome	NN	O	I-Disease
with	NN	O	O
apoptosis	NN	O	O
of	NN	O	O
lesional	NN	O	O
lymphocytes	NN	O	O
.	NN	O	O

BACKGROUND	NN	O	O
:	NN	O	O
Sirolimus	NN	O	B-Chemical
(	NN	O	O
formerly	NN	O	O
rapamycin	NN	O	B-Chemical
)	NN	O	O
is	NN	O	O
an	NN	O	O
immunosuppressive	NN	O	O
agent	NN	O	O
that	NN	O	O
interferes	NN	O	O
with	NN	O	O
T	NN	O	O
-	NN	O	O
cell	NN	O	O
activation	NN	O	O
.	NN	O	O

After	NN	O	O
2	NN	O	O
individuals	NN	O	O
with	NN	O	O
psoriasis	NN	O	B-Disease
developed	NN	O	O
a	NN	O	O
capillary	NN	O	B-Disease
leak	NN	O	I-Disease
syndrome	NN	O	I-Disease
following	NN	O	O
treatment	NN	O	O
with	NN	O	O
oral	NN	O	O
sirolimus	NN	O	B-Chemical
lesional	NN	O	O
skin	NN	O	O
cells	NN	O	O
and	NN	O	O
activated	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
cells	NN	O	O
were	NN	O	O
analyzed	NN	O	O
for	NN	O	O
induction	NN	O	O
of	NN	O	O
apoptosis	NN	O	O
.	NN	O	O

OBSERVATIONS	NN	O	O
:	NN	O	O
A	NN	O	O
keratome	NN	O	O
skin	NN	O	O
specimen	NN	O	O
from	NN	O	O
1	NN	O	O
patient	NN	O	O
with	NN	O	O
sirolimus	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
capillary	NN	O	B-Disease
leak	NN	O	I-Disease
syndrome	NN	O	I-Disease
had	NN	O	O
a	NN	O	O
2.3	NN	O	O
-	NN	O	O
fold	NN	O	O
increase	NN	O	O
in	NN	O	O
percentage	NN	O	O
of	NN	O	O
apoptotic	NN	O	O
cells	NN	O	O
(	NN	O	O
to	NN	O	O
48%	NN	O	O
)	NN	O	O
compared	NN	O	O
with	NN	O	O
an	NN	O	O
unaffected	NN	O	O
sirolimus	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
patient	NN	O	O
with	NN	O	O
psoriasis	NN	O	B-Disease
(	NN	O	O
21%	NN	O	O
)	NN	O	O
.	NN	O	O

Activated	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
T	NN	O	O
cells	NN	O	O
from	NN	O	O
patients	NN	O	O
with	NN	O	O
psoriasis	NN	O	B-Disease
tended	NN	O	O
to	NN	O	O
exhibit	NN	O	O
greater	NN	O	O
spontaneous	NN	O	O
or	NN	O	O
dexamethasone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
apoptosis	NN	O	O
than	NN	O	O
did	NN	O	O
normal	NN	O	O
T	NN	O	O
cells	NN	O	O
,	NN	O	O
particularly	NN	O	O
in	NN	O	O
the	NN	O	O
presence	NN	O	O
of	NN	O	O
sirolimus	NN	O	B-Chemical
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Severe	NN	O	O
adverse	NN	O	O
effects	NN	O	O
of	NN	O	O
sirolimus	NN	O	B-Chemical
include	NN	O	O
fever	NN	O	B-Disease
,	NN	O	O
anemia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
capillary	NN	O	B-Disease
leak	NN	O	I-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

These	NN	O	O
symptoms	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
result	NN	O	O
of	NN	O	O
drug	NN	O	O
-	NN	O	O
induced	NN	O	O
apoptosis	NN	O	O
of	NN	O	O
lesional	NN	O	O
leukocytes	NN	O	O
,	NN	O	O
especially	NN	O	O
activated	NN	O	O
T	NN	O	O
lymphocytes	NN	O	O
,	NN	O	O
and	NN	O	O
possibly	NN	O	O
release	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
mediators	NN	O	O
.	NN	O	O

Because	NN	O	O
patients	NN	O	O
with	NN	O	O
severe	NN	O	O
psoriasis	NN	O	B-Disease
may	NN	O	O
develop	NN	O	O
capillary	NN	O	B-Disease
leak	NN	O	I-Disease
from	NN	O	O
various	NN	O	O
systemic	NN	O	O
therapies	NN	O	O
,	NN	O	O
clinical	NN	O	O
monitoring	NN	O	O
is	NN	O	O
advisable	NN	O	O
for	NN	O	O
patients	NN	O	O
with	NN	O	O
inflammatory	NN	O	B-Disease
diseases	NN	O	I-Disease
who	NN	O	O
are	NN	O	O
treated	NN	O	O
with	NN	O	O
immune	NN	O	O
modulators	NN	O	O
.	NN	O	O


-DOCSTART- (9630698)

Contribution	NN	O	O
of	NN	O	O
the	NN	O	O
glycine	NN	O	B-Chemical
site	NN	O	O
of	NN	O	O
NMDA	NN	O	B-Chemical
receptors	NN	O	O
in	NN	O	O
rostral	NN	O	O
and	NN	O	O
intermediate	NN	O	O
-	NN	O	O
caudal	NN	O	O
parts	NN	O	O
of	NN	O	O
the	NN	O	O
striatum	NN	O	O
to	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
muscle	NN	O	O
tone	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
contribution	NN	O	O
of	NN	O	O
the	NN	O	O
glycine	NN	O	B-Chemical
site	NN	O	O
of	NN	O	O
NMDA	NN	O	B-Chemical
receptors	NN	O	O
in	NN	O	O
the	NN	O	O
striatum	NN	O	O
to	NN	O	O
the	NN	O	O
regulation	NN	O	O
of	NN	O	O
muscle	NN	O	O
tone	NN	O	O
.	NN	O	O

Muscle	NN	O	O
tone	NN	O	O
was	NN	O	O
examined	NN	O	O
using	NN	O	O
a	NN	O	O
combined	NN	O	O
mechanoand	NN	O	O
electromyographic	NN	O	O
method	NN	O	O
,	NN	O	O
which	NN	O	O
measured	NN	O	O
simultaneously	NN	O	O
the	NN	O	O
muscle	NN	O	O
resistance	NN	O	O
(	NN	O	O
MMG	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
rat	NN	O	O
'	NN	O	O
s	NN	O	O
hind	NN	O	O
foot	NN	O	O
to	NN	O	O
passive	NN	O	O
extension	NN	O	O
and	NN	O	O
flexion	NN	O	O
in	NN	O	O
the	NN	O	O
ankle	NN	O	O
joint	NN	O	O
and	NN	O	O
the	NN	O	O
electromyographic	NN	O	O
activity	NN	O	O
(	NN	O	O
EMG	NN	O	O
)	NN	O	O
of	NN	O	O
the	NN	O	O
antagonistic	NN	O	O
muscles	NN	O	O
of	NN	O	O
that	NN	O	O
joint	NN	O	O
:	NN	O	O
gastrocnemius	NN	O	O
and	NN	O	O
tibialis	NN	O	O
anterior	NN	O	O
.	NN	O	O

Muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
was	NN	O	O
induced	NN	O	O
by	NN	O	O
haloperidol	NN	O	B-Chemical
(	NN	O	O
2.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.p.	NN	O	O
)	NN	O	O
.	NN	O	O

5	NN	O	B-Chemical
,	NN	O	I-Chemical
7	NN	O	I-Chemical
-	NN	O	I-Chemical
dichlorokynurenic	NN	O	I-Chemical
acid	NN	O	I-Chemical
(	NN	O	O
5	NN	O	B-Chemical
,	NN	O	I-Chemical
7	NN	O	I-Chemical
-	NN	O	I-Chemical
DCKA	NN	O	I-Chemical
)	NN	O	O
,	NN	O	O
a	NN	O	O
selective	NN	O	O
glycine	NN	O	B-Chemical
site	NN	O	O
antagonist	NN	O	O
,	NN	O	O
injected	NN	O	O
in	NN	O	O
doses	NN	O	O
of	NN	O	O
2.5	NN	O	O
and	NN	O	O
4.5	NN	O	O
microg	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
bilaterally	NN	O	O
,	NN	O	O
into	NN	O	O
the	NN	O	O
rostral	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
striatum	NN	O	O
,	NN	O	O
decreased	NN	O	O
both	NN	O	O
the	NN	O	O
haloperidol	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
(	NN	O	O
MMG	NN	O	O
)	NN	O	O
and	NN	O	O
the	NN	O	O
enhanced	NN	O	O
electromyographic	NN	O	O
activity	NN	O	O
(	NN	O	O
EMG	NN	O	O
)	NN	O	O
.	NN	O	O

5	NN	O	B-Chemical
,	NN	O	I-Chemical
7	NN	O	I-Chemical
-	NN	O	I-Chemical
DCKA	NN	O	I-Chemical
injected	NN	O	O
bilaterally	NN	O	O
in	NN	O	O
a	NN	O	O
dose	NN	O	O
of	NN	O	O
4.5	NN	O	O
microg	NN	O	O
/	NN	O	O
0.5	NN	O	O
microl	NN	O	O
into	NN	O	O
the	NN	O	O
intermediate	NN	O	O
-	NN	O	O
caudal	NN	O	O
region	NN	O	O
of	NN	O	O
the	NN	O	O
striatum	NN	O	O
of	NN	O	O
rats	NN	O	O
not	NN	O	O
pretreated	NN	O	O
with	NN	O	O
haloperidol	NN	O	B-Chemical
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
the	NN	O	O
muscle	NN	O	O
tone	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
results	NN	O	O
suggest	NN	O	O
that	NN	O	O
blockade	NN	O	O
of	NN	O	O
the	NN	O	O
glycine	NN	O	B-Chemical
site	NN	O	O
of	NN	O	O
NMDA	NN	O	B-Chemical
receptors	NN	O	O
in	NN	O	O
the	NN	O	O
rostral	NN	O	O
part	NN	O	O
of	NN	O	O
the	NN	O	O
striatum	NN	O	O
may	NN	O	O
be	NN	O	O
mainly	NN	O	O
responsible	NN	O	O
for	NN	O	O
the	NN	O	O
antiparkinsonian	NN	O	O
action	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
.	NN	O	O


-DOCSTART- (8480959)

Efficacy	NN	O	O
and	NN	O	O
tolerability	NN	O	O
of	NN	O	O
lovastatin	NN	O	B-Chemical
in	NN	O	O
3390	NN	O	O
women	NN	O	O
with	NN	O	O
moderate	NN	O	O
hypercholesterolemia	NN	O	B-Disease
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
evaluate	NN	O	O
the	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
of	NN	O	O
lovastatin	NN	O	B-Chemical
in	NN	O	O
women	NN	O	O
with	NN	O	O
moderate	NN	O	O
hypercholesterolemia	NN	O	B-Disease
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
The	NN	O	O
Expanded	NN	O	O
Clinical	NN	O	O
Evaluation	NN	O	O
of	NN	O	O
Lovastatin	NN	O	B-Chemical
(	NN	O	O
EXCEL	NN	O	O
)	NN	O	O
Study	NN	O	O
,	NN	O	O
a	NN	O	O
multicenter	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
diet	NN	O	O
-	NN	O	O
and	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
trial	NN	O	O
,	NN	O	O
in	NN	O	O
which	NN	O	O
participants	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
receive	NN	O	O
placebo	NN	O	O
or	NN	O	O
lovastatin	NN	O	B-Chemical
at	NN	O	O
doses	NN	O	O
of	NN	O	O
20	NN	O	O
or	NN	O	O
40	NN	O	O
mg	NN	O	O
once	NN	O	O
daily	NN	O	O
,	NN	O	O
or	NN	O	O
20	NN	O	O
or	NN	O	O
40	NN	O	O
mg	NN	O	O
twice	NN	O	O
daily	NN	O	O
for	NN	O	O
48	NN	O	O
weeks	NN	O	O
.	NN	O	O

SETTING	NN	O	O
:	NN	O	O
Ambulatory	NN	O	O
patients	NN	O	O
recruited	NN	O	O
by	NN	O	O
362	NN	O	O
participating	NN	O	O
centers	NN	O	O
throughout	NN	O	O
the	NN	O	O
United	NN	O	O
States	NN	O	O
.	NN	O	O

PATIENTS	NN	O	O
:	NN	O	O
Women	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
3390	NN	O	O
)	NN	O	O
from	NN	O	O
the	NN	O	O
total	NN	O	O
cohort	NN	O	O
of	NN	O	O
8245	NN	O	O
volunteers	NN	O	O
.	NN	O	O

MEASUREMENTS	NN	O	O
:	NN	O	O
Plasma	NN	O	O
total	NN	O	O
,	NN	O	O
low	NN	O	O
-	NN	O	O
density	NN	O	O
lipoprotein	NN	O	O
(	NN	O	O
LDL	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
high	NN	O	O
-	NN	O	O
density	NN	O	O
lipoprotein	NN	O	O
(	NN	O	O
HDL	NN	O	O
)	NN	O	O
cholesterol	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
triglycerides	NN	O	B-Chemical
;	NN	O	O
and	NN	O	O
laboratory	NN	O	O
and	NN	O	O
clinical	NN	O	O
evidence	NN	O	O
of	NN	O	O
adverse	NN	O	O
events	NN	O	O
monitored	NN	O	O
periodically	NN	O	O
throughout	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Among	NN	O	O
women	NN	O	O
,	NN	O	O
lovastatin	NN	O	B-Chemical
(	NN	O	O
20	NN	O	O
to	NN	O	O
80	NN	O	O
mg	NN	O	O
/	NN	O	O
d	NN	O	O
)	NN	O	O
produced	NN	O	O
sustained	NN	O	O
(	NN	O	O
12	NN	O	O
-	NN	O	O
to	NN	O	O
48	NN	O	O
-	NN	O	O
week	NN	O	O
)	NN	O	O
,	NN	O	O
dose	NN	O	O
-	NN	O	O
related	NN	O	O
changes	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.001	NN	O	O
)	NN	O	O
:	NN	O	O
decreases	NN	O	O
in	NN	O	O
LDL	NN	O	O
cholesterol	NN	O	B-Chemical
(	NN	O	O
24%	NN	O	O
to	NN	O	O
40%	NN	O	O
)	NN	O	O
and	NN	O	O
triglycerides	NN	O	B-Chemical
(	NN	O	O
9%	NN	O	O
to	NN	O	O
18%	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
increases	NN	O	O
in	NN	O	O
HDL	NN	O	O
cholesterol	NN	O	B-Chemical
(	NN	O	O
6.7%	NN	O	O
to	NN	O	O
8.6%	NN	O	O
)	NN	O	O
.	NN	O	O

Depending	NN	O	O
on	NN	O	O
the	NN	O	O
dose	NN	O	O
,	NN	O	O
from	NN	O	O
82%	NN	O	O
to	NN	O	O
95%	NN	O	O
of	NN	O	O
lovastatin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
women	NN	O	O
achieved	NN	O	O
the	NN	O	O
National	NN	O	O
Cholesterol	NN	O	B-Chemical
Education	NN	O	O
Program	NN	O	O
goal	NN	O	O
of	NN	O	O
LDL	NN	O	O
cholesterol	NN	O	B-Chemical
levels	NN	O	O
less	NN	O	O
than	NN	O	O
4.14	NN	O	O
mmol	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
160	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
)	NN	O	O
,	NN	O	O
and	NN	O	O
40%	NN	O	O
to	NN	O	O
87%	NN	O	O
achieved	NN	O	O
the	NN	O	O
goal	NN	O	O
of	NN	O	O
3.36	NN	O	O
mmol	NN	O	O
/	NN	O	O
L	NN	O	O
(	NN	O	O
130	NN	O	O
mg	NN	O	O
/	NN	O	O
dL	NN	O	O
)	NN	O	O
.	NN	O	O

Successive	NN	O	O
transaminase	NN	O	O
elevations	NN	O	O
greater	NN	O	O
than	NN	O	O
three	NN	O	O
times	NN	O	O
the	NN	O	O
upper	NN	O	O
limit	NN	O	O
of	NN	O	O
normal	NN	O	O
occurred	NN	O	O
in	NN	O	O
0.1%	NN	O	O
of	NN	O	O
women	NN	O	O
and	NN	O	O
were	NN	O	O
dose	NN	O	O
dependent	NN	O	O
above	NN	O	O
the	NN	O	O
20	NN	O	O
-	NN	O	O
mg	NN	O	O
dose	NN	O	O
.	NN	O	O

Myopathy	NN	O	B-Disease
,	NN	O	O
defined	NN	O	O
as	NN	O	O
muscle	NN	O	O
symptoms	NN	O	O
with	NN	O	O
creatine	NN	O	B-Chemical
kinase	NN	O	O
elevations	NN	O	O
greater	NN	O	O
than	NN	O	O
10	NN	O	O
times	NN	O	O
the	NN	O	O
upper	NN	O	O
limit	NN	O	O
of	NN	O	O
normal	NN	O	O
,	NN	O	O
was	NN	O	O
rare	NN	O	O
and	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
highest	NN	O	O
recommended	NN	O	O
daily	NN	O	O
dose	NN	O	O
of	NN	O	O
lovastatin	NN	O	B-Chemical
(	NN	O	O
80	NN	O	O
mg	NN	O	O
)	NN	O	O
.	NN	O	O

Estrogen	NN	O	O
-	NN	O	O
replacement	NN	O	O
therapy	NN	O	O
appeared	NN	O	O
to	NN	O	O
have	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
either	NN	O	O
the	NN	O	O
efficacy	NN	O	O
or	NN	O	O
safety	NN	O	O
profile	NN	O	O
of	NN	O	O
lovastatin	NN	O	B-Chemical
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Lovastatin	NN	O	B-Chemical
is	NN	O	O
highly	NN	O	O
effective	NN	O	O
and	NN	O	O
generally	NN	O	O
well	NN	O	O
tolerated	NN	O	O
as	NN	O	O
therapy	NN	O	O
for	NN	O	O
primary	NN	O	O
hypercholesterolemia	NN	O	B-Disease
in	NN	O	O
women	NN	O	O
.	NN	O	O


-DOCSTART- (7197363)

REM	NN	O	B-Disease
sleep	NN	O	I-Disease
deprivation	NN	O	I-Disease
changes	NN	O	O
behavioral	NN	O	O
response	NN	O	O
to	NN	O	O
catecholaminergic	NN	O	O
and	NN	O	O
serotonergic	NN	O	O
receptor	NN	O	O
activation	NN	O	O
in	NN	O	O
rats	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
REM	NN	O	B-Disease
sleep	NN	O	I-Disease
deprivation	NN	O	I-Disease
(	NN	O	O
REMD	NN	O	B-Disease
)	NN	O	O
on	NN	O	O
apomorphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
aggressiveness	NN	O	B-Disease
and	NN	O	O
quipazine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
head	NN	O	B-Disease
twitches	NN	O	I-Disease
in	NN	O	O
rats	NN	O	O
were	NN	O	O
determined	NN	O	O
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
eight	NN	O	O
hr	NN	O	O
of	NN	O	O
REMD	NN	O	B-Disease
increased	NN	O	O
apomorphine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
aggressiveness	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
reduced	NN	O	O
(	NN	O	O
immediately	NN	O	O
after	NN	O	O
completing	NN	O	O
of	NN	O	O
REMD	NN	O	B-Disease
)	NN	O	O
or	NN	O	O
increased	NN	O	O
(	NN	O	O
96	NN	O	O
hr	NN	O	O
after	NN	O	O
completing	NN	O	O
of	NN	O	O
REMD	NN	O	B-Disease
)	NN	O	O
quipazine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
head	NN	O	B-Disease
twitches	NN	O	I-Disease
.	NN	O	O

Results	NN	O	O
are	NN	O	O
discussed	NN	O	O
in	NN	O	O
terms	NN	O	O
of	NN	O	O
similarity	NN	O	O
to	NN	O	O
pharmacological	NN	O	O
effects	NN	O	O
of	NN	O	O
other	NN	O	O
antidepressive	NN	O	O
treatments	NN	O	O
.	NN	O	O


-DOCSTART- (7161250)

Extrapyramidal	NN	O	O
side	NN	O	O
effects	NN	O	O
and	NN	O	O
oral	NN	O	O
haloperidol	NN	O	B-Chemical
:	NN	O	O
an	NN	O	O
analysis	NN	O	O
of	NN	O	O
explanatory	NN	O	O
patient	NN	O	O
and	NN	O	O
treatment	NN	O	O
characteristics	NN	O	O
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
extrapyramidal	NN	O	O
side	NN	O	O
effects	NN	O	O
(	NN	O	O
EPS	NN	O	O
)	NN	O	O
was	NN	O	O
evaluated	NN	O	O
in	NN	O	O
98	NN	O	O
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
haloperidol	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
incidence	NN	O	O
of	NN	O	O
parkinsonism	NN	O	B-Disease
was	NN	O	O
higher	NN	O	O
at	NN	O	O
higher	NN	O	O
doses	NN	O	O
of	NN	O	O
haloperidol	NN	O	B-Chemical
and	NN	O	O
in	NN	O	O
younger	NN	O	O
patients	NN	O	O
.	NN	O	O

Prophylactic	NN	O	O
antiparkinsonian	NN	O	O
medication	NN	O	O
was	NN	O	O
effective	NN	O	O
in	NN	O	O
younger	NN	O	O
but	NN	O	O
not	NN	O	O
in	NN	O	O
older	NN	O	O
patients	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
these	NN	O	O
medications	NN	O	O
were	NN	O	O
more	NN	O	O
effective	NN	O	O
in	NN	O	O
both	NN	O	O
young	NN	O	O
and	NN	O	O
old	NN	O	O
patients	NN	O	O
when	NN	O	O
given	NN	O	O
after	NN	O	O
parkinsonism	NN	O	B-Disease
developed	NN	O	O
.	NN	O	O

Akathisia	NN	O	B-Disease
was	NN	O	O
controlled	NN	O	O
by	NN	O	O
the	NN	O	O
benzodiazepine	NN	O	B-Chemical
lorazepam	NN	O	B-Chemical
in	NN	O	O
14	NN	O	O
out	NN	O	O
of	NN	O	O
16	NN	O	O
patients	NN	O	O
,	NN	O	O
while	NN	O	O
prophylactic	NN	O	O
antiparkinsonians	NN	O	O
were	NN	O	O
ineffective	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
points	NN	O	O
to	NN	O	O
patient	NN	O	O
characteristics	NN	O	O
that	NN	O	O
may	NN	O	O
be	NN	O	O
of	NN	O	O
significance	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
EPS	NN	O	O
due	NN	O	O
to	NN	O	O
haloperidol	NN	O	B-Chemical
.	NN	O	O


-DOCSTART- (7053705)

Hepatic	NN	O	B-Disease
veno	NN	O	I-Disease
-	NN	O	I-Disease
occlusive	NN	O	I-Disease
disease	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
6	NN	O	B-Chemical
-	NN	O	I-Chemical
thioguanine	NN	O	I-Chemical
.	NN	O	O

Clinically	NN	O	O
reversible	NN	O	O
veno	NN	O	B-Disease
-	NN	O	I-Disease
occlusive	NN	O	I-Disease
disease	NN	O	I-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
liver	NN	O	I-Disease
developed	NN	O	O
in	NN	O	O
a	NN	O	O
23	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
man	NN	O	O
with	NN	O	O
acute	NN	O	B-Disease
lymphocytic	NN	O	I-Disease
leukemia	NN	O	I-Disease
after	NN	O	O
10	NN	O	O
months	NN	O	O
of	NN	O	O
maintenance	NN	O	O
therapy	NN	O	O
with	NN	O	O
6	NN	O	B-Chemical
-	NN	O	I-Chemical
thioguanine	NN	O	I-Chemical
.	NN	O	O

Serial	NN	O	O
liver	NN	O	O
biopsies	NN	O	O
showed	NN	O	O
the	NN	O	O
development	NN	O	O
and	NN	O	O
resolution	NN	O	O
of	NN	O	O
intense	NN	O	O
sinusoidal	NN	O	O
engorgement	NN	O	O
.	NN	O	O

Although	NN	O	O
this	NN	O	O
disease	NN	O	O
was	NN	O	O
clinically	NN	O	O
reversible	NN	O	O
,	NN	O	O
some	NN	O	O
subintimal	NN	O	O
fibrosis	NN	O	B-Disease
about	NN	O	O
the	NN	O	O
terminal	NN	O	O
hepatic	NN	O	O
veins	NN	O	O
persisted	NN	O	O
.	NN	O	O

This	NN	O	O
case	NN	O	O
presented	NN	O	O
a	NN	O	O
unique	NN	O	O
opportunity	NN	O	O
to	NN	O	O
observe	NN	O	O
the	NN	O	O
histologic	NN	O	O
features	NN	O	O
of	NN	O	O
clinically	NN	O	O
reversible	NN	O	O
hepatic	NN	O	B-Disease
veno	NN	O	I-Disease
-	NN	O	I-Disease
occlusive	NN	O	I-Disease
disease	NN	O	I-Disease
over	NN	O	O
time	NN	O	O
,	NN	O	O
and	NN	O	O
may	NN	O	O
be	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
of	NN	O	O
veno	NN	O	O
-	NN	O	O
occlusive	NN	O	O
related	NN	O	O
solely	NN	O	O
to	NN	O	O
6	NN	O	B-Chemical
-	NN	O	I-Chemical
thioguanine	NN	O	I-Chemical
.	NN	O	O


-DOCSTART- (6402369)

Treatment	NN	O	O
of	NN	O	O
ifosfamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
urothelial	NN	O	B-Disease
toxicity	NN	O	I-Disease
by	NN	O	O
oral	NN	O	O
administration	NN	O	O
of	NN	O	O
sodium	NN	O	B-Chemical
2	NN	O	I-Chemical
-	NN	O	I-Chemical
mercaptoethane	NN	O	I-Chemical
sulphonate	NN	O	I-Chemical
(	NN	O	O
MESNA	NN	O	B-Chemical
)	NN	O	O
to	NN	O	O
patients	NN	O	O
with	NN	O	O
inoperable	NN	O	O
lung	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
protective	NN	O	O
effect	NN	O	O
of	NN	O	O
oral	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
thiol	NN	O	B-Chemical
compound	NN	O	O
sodium	NN	O	B-Chemical
2	NN	O	I-Chemical
-	NN	O	I-Chemical
mercaptoethane	NN	O	I-Chemical
sulphonate	NN	O	I-Chemical
(	NN	O	O
MESNA	NN	O	B-Chemical
)	NN	O	O
against	NN	O	O
urothelial	NN	O	B-Disease
toxicity	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
ifosfamide	NN	O	B-Chemical
(	NN	O	O
IF	NN	O	B-Chemical
)	NN	O	O
was	NN	O	O
tested	NN	O	O
in	NN	O	O
a	NN	O	O
group	NN	O	O
of	NN	O	O
45	NN	O	O
patients	NN	O	O
with	NN	O	O
inoperable	NN	O	O
lung	NN	O	B-Disease
cancer	NN	O	I-Disease
under	NN	O	O
treatment	NN	O	O
with	NN	O	O
IF	NN	O	B-Chemical
(	NN	O	O
2250	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
on	NN	O	O
days	NN	O	O
2	NN	O	O
-	NN	O	O
5	NN	O	O
)	NN	O	O
as	NN	O	O
part	NN	O	O
of	NN	O	O
a	NN	O	O
polychemotherapy	NN	O	O
regimen	NN	O	O
repeated	NN	O	O
in	NN	O	O
a	NN	O	O
4	NN	O	O
-	NN	O	O
week	NN	O	O
cycle	NN	O	O
.	NN	O	O

MESNA	NN	O	B-Chemical
was	NN	O	O
given	NN	O	O
orally	NN	O	O
on	NN	O	O
the	NN	O	O
days	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
IF	NN	O	B-Chemical
in	NN	O	O
3	NN	O	O
doses	NN	O	O
of	NN	O	O
840	NN	O	O
mg	NN	O	O
/	NN	O	O
m2	NN	O	O
,	NN	O	O
each	NN	O	O
administered	NN	O	O
at	NN	O	O
0	NN	O	O
hr	NN	O	O
(	NN	O	O
=	NN	O	O
injection	NN	O	O
of	NN	O	O
IF	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
4	NN	O	O
hr	NN	O	O
and	NN	O	O
8	NN	O	O
hr	NN	O	O
p.i.	NN	O	O
Out	NN	O	O
of	NN	O	O
a	NN	O	O
total	NN	O	O
of	NN	O	O
88	NN	O	O
courses	NN	O	O
of	NN	O	O
this	NN	O	O
treatment	NN	O	O
we	NN	O	O
observed	NN	O	O
10	NN	O	O
episodes	NN	O	O
of	NN	O	O
asymptomatic	NN	O	O
microscopic	NN	O	O
haematuria	NN	O	B-Disease
and	NN	O	O
no	NN	O	O
episodes	NN	O	O
of	NN	O	O
gross	NN	O	O
haematuria	NN	O	B-Disease
.	NN	O	O

In	NN	O	O
this	NN	O	O
group	NN	O	O
of	NN	O	O
45	NN	O	O
patients	NN	O	O
under	NN	O	O
protection	NN	O	O
with	NN	O	O
MESNA	NN	O	B-Chemical
there	NN	O	O
were	NN	O	O
5	NN	O	O
complete	NN	O	O
remissions	NN	O	O
and	NN	O	O
9	NN	O	O
partial	NN	O	O
remissions	NN	O	O
(	NN	O	O
total	NN	O	O
31%	NN	O	O
)	NN	O	O
.	NN	O	O

A	NN	O	O
further	NN	O	O
group	NN	O	O
of	NN	O	O
25	NN	O	O
patients	NN	O	O
under	NN	O	O
polychemotherapy	NN	O	O
with	NN	O	O
IF	NN	O	B-Chemical
were	NN	O	O
treated	NN	O	O
by	NN	O	O
conventional	NN	O	O
prophylactic	NN	O	O
measures	NN	O	O
(	NN	O	O
raised	NN	O	O
fluid	NN	O	O
intake	NN	O	O
and	NN	O	O
forced	NN	O	O
diuresis	NN	O	O
)	NN	O	O
.	NN	O	O

In	NN	O	O
this	NN	O	O
group	NN	O	O
there	NN	O	O
were	NN	O	O
1	NN	O	O
complete	NN	O	O
and	NN	O	O
5	NN	O	O
partial	NN	O	O
remissions	NN	O	O
(	NN	O	O
total	NN	O	O
24%	NN	O	O
)	NN	O	O
,	NN	O	O
but	NN	O	O
nearly	NN	O	O
all	NN	O	O
patients	NN	O	O
developed	NN	O	O
either	NN	O	O
gross	NN	O	O
haematuria	NN	O	B-Disease
and	NN	O	O
/	NN	O	O
or	NN	O	O
symptoms	NN	O	O
of	NN	O	O
bladder	NN	O	B-Disease
irritation	NN	O	I-Disease
(	NN	O	O
cystitis	NN	O	B-Disease
and	NN	O	O
pollakisuria	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

There	NN	O	O
were	NN	O	O
no	NN	O	O
appreciable	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
MESNA	NN	O	B-Chemical
series	NN	O	O
and	NN	O	O
the	NN	O	O
conventional	NN	O	O
prophylaxis	NN	O	O
series	NN	O	O
with	NN	O	O
respect	NN	O	O
to	NN	O	O
either	NN	O	O
haematological	NN	O	O
or	NN	O	O
systemic	NN	O	O
toxicity	NN	O	B-Disease
of	NN	O	O
the	NN	O	O
cytostatic	NN	O	O
treatment	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
support	NN	O	O
the	NN	O	O
view	NN	O	O
that	NN	O	O
MESNA	NN	O	B-Chemical
,	NN	O	O
given	NN	O	O
orally	NN	O	O
in	NN	O	O
conjunction	NN	O	O
with	NN	O	O
combined	NN	O	O
cytostatic	NN	O	O
regimens	NN	O	O
which	NN	O	O
include	NN	O	O
IF	NN	O	B-Chemical
,	NN	O	O
simplifies	NN	O	O
the	NN	O	O
treatment	NN	O	O
and	NN	O	O
provides	NN	O	O
optimum	NN	O	O
protection	NN	O	O
for	NN	O	O
the	NN	O	O
urinary	NN	O	O
epithelium	NN	O	O
.	NN	O	O

Protection	NN	O	O
with	NN	O	O
oral	NN	O	O
MESNA	NN	O	B-Chemical
is	NN	O	O
particularly	NN	O	O
suitable	NN	O	O
for	NN	O	O
outpatients	NN	O	O
.	NN	O	O


-DOCSTART- (3973521)

Time	NN	O	O
course	NN	O	O
alterations	NN	O	O
of	NN	O	O
QTC	NN	O	O
interval	NN	O	O
due	NN	O	O
to	NN	O	O
hypaque	NN	O	B-Chemical
76	NN	O	I-Chemical
.	NN	O	O

Sequential	NN	O	O
measurement	NN	O	O
of	NN	O	O
QT	NN	O	O
interval	NN	O	O
during	NN	O	O
left	NN	O	O
ventricular	NN	O	O
angiography	NN	O	O
was	NN	O	O
made	NN	O	O
30	NN	O	O
seconds	NN	O	O
and	NN	O	O
one	NN	O	O
,	NN	O	O
three	NN	O	O
,	NN	O	O
five	NN	O	O
and	NN	O	O
ten	NN	O	O
minutes	NN	O	O
after	NN	O	O
injection	NN	O	O
of	NN	O	O
hypaque	NN	O	B-Chemical
76	NN	O	I-Chemical
.	NN	O	O

The	NN	O	O
subjects	NN	O	O
were	NN	O	O
ten	NN	O	O
patients	NN	O	O
found	NN	O	O
to	NN	O	O
have	NN	O	O
normal	NN	O	O
left	NN	O	O
ventricles	NN	O	O
and	NN	O	O
coronary	NN	O	O
arteries	NN	O	O
.	NN	O	O

Significant	NN	O	O
QTC	NN	O	B-Disease
prolongation	NN	O	I-Disease
occurred	NN	O	O
in	NN	O	O
30	NN	O	O
seconds	NN	O	O
to	NN	O	O
one	NN	O	O
minute	NN	O	O
in	NN	O	O
association	NN	O	O
with	NN	O	O
marked	NN	O	O
hypotension	NN	O	B-Disease
and	NN	O	O
elevation	NN	O	O
of	NN	O	O
cardiac	NN	O	O
output	NN	O	O
.	NN	O	O


-DOCSTART- (3461217)

Production	NN	O	O
of	NN	O	O
autochthonous	NN	O	O
prostate	NN	O	B-Disease
cancer	NN	O	I-Disease
in	NN	O	O
Lobund	NN	O	O
-	NN	O	O
Wistar	NN	O	O
rats	NN	O	O
by	NN	O	O
treatments	NN	O	O
with	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
nitroso	NN	O	I-Chemical
-	NN	O	I-Chemical
N	NN	O	I-Chemical
-	NN	O	I-Chemical
methylurea	NN	O	I-Chemical
and	NN	O	O
testosterone	NN	O	B-Chemical
.	NN	O	O

More	NN	O	O
than	NN	O	O
50%	NN	O	O
of	NN	O	O
Lobund	NN	O	O
-	NN	O	O
Wistar	NN	O	O
(	NN	O	O
L	NN	O	O
-	NN	O	O
W	NN	O	O
)	NN	O	O
strain	NN	O	O
rats	NN	O	O
developed	NN	O	O
large	NN	O	O
,	NN	O	O
palpable	NN	O	O
prostate	NN	O	B-Disease
adenocarcinomas	NN	O	I-Disease
(	NN	O	O
PAs	NN	O	B-Disease
)	NN	O	O
following	NN	O	O
treatments	NN	O	O
with	NN	O	O
N	NN	O	B-Chemical
-	NN	O	I-Chemical
nitroso	NN	O	I-Chemical
-	NN	O	I-Chemical
N	NN	O	I-Chemical
-	NN	O	I-Chemical
methylurea	NN	O	I-Chemical
(	NN	O	O
CAS	NN	O	O
:	NN	O	O
684	NN	O	O
-	NN	O	O
93	NN	O	O
-	NN	O	O
5	NN	O	O
)	NN	O	O
and	NN	O	O
testosterone	NN	O	B-Chemical
propionate	NN	O	I-Chemical
[	NN	O	O
(	NN	O	O
TP	NN	O	B-Chemical
)	NN	O	O
CAS	NN	O	O
:	NN	O	O
57	NN	O	O
-	NN	O	O
85	NN	O	O
-	NN	O	O
2	NN	O	O
]	NN	O	O
,	NN	O	O
and	NN	O	O
most	NN	O	O
of	NN	O	O
the	NN	O	O
tumor	NN	O	B-Disease
-	NN	O	O
bearing	NN	O	O
rats	NN	O	O
manifested	NN	O	O
metastatic	NN	O	O
lesions	NN	O	O
.	NN	O	O

The	NN	O	O
incubation	NN	O	O
periods	NN	O	O
averaged	NN	O	O
10.6	NN	O	O
months	NN	O	O
.	NN	O	O

Within	NN	O	O
the	NN	O	O
same	NN	O	O
timeframe	NN	O	O
,	NN	O	O
no	NN	O	O
L	NN	O	O
-	NN	O	O
W	NN	O	O
rat	NN	O	O
developed	NN	O	O
a	NN	O	O
similar	NN	O	O
palpable	NN	O	O
PA	NN	O	B-Disease
when	NN	O	O
treated	NN	O	O
only	NN	O	O
with	NN	O	O
TP	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
L	NN	O	O
-	NN	O	O
W	NN	O	O
rats	NN	O	O
,	NN	O	O
TP	NN	O	B-Chemical
acted	NN	O	O
as	NN	O	O
a	NN	O	O
tumor	NN	O	B-Disease
enhancement	NN	O	O
agent	NN	O	O
,	NN	O	O
with	NN	O	O
primary	NN	O	O
emphasis	NN	O	O
on	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
prostate	NN	O	B-Disease
cancer	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (2840807)

A	NN	O	O
dystonia	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
syndrome	NN	O	O
after	NN	O	O
neuropeptide	NN	O	O
(	NN	O	O
MSH	NN	O	B-Chemical
/	NN	O	O
ACTH	NN	O	B-Chemical
)	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
rat	NN	O	O
locus	NN	O	O
ceruleus	NN	O	O
.	NN	O	O

The	NN	O	O
movement	NN	O	B-Disease
disorder	NN	O	I-Disease
investigated	NN	O	O
in	NN	O	O
these	NN	O	O
studies	NN	O	O
has	NN	O	O
some	NN	O	O
features	NN	O	O
in	NN	O	O
common	NN	O	O
with	NN	O	O
human	NN	O	O
idiopathic	NN	O	O
dystonia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
information	NN	O	O
obtained	NN	O	O
in	NN	O	O
these	NN	O	O
studies	NN	O	O
may	NN	O	O
be	NN	O	O
of	NN	O	O
potential	NN	O	O
clinical	NN	O	O
benefit	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
experimental	NN	O	O
results	NN	O	O
indicated	NN	O	O
that	NN	O	O
peptidergic	NN	O	O
stimulation	NN	O	O
of	NN	O	O
the	NN	O	O
LC	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
NE	NN	O	O
-	NN	O	O
mediated	NN	O	O
inhibition	NN	O	O
of	NN	O	O
cerebellar	NN	O	O
Purkinje	NN	O	O
cells	NN	O	O
located	NN	O	O
at	NN	O	O
terminals	NN	O	O
of	NN	O	O
the	NN	O	O
ceruleo	NN	O	O
-	NN	O	O
cerebellar	NN	O	O
pathway	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
it	NN	O	O
is	NN	O	O
not	NN	O	O
certain	NN	O	O
as	NN	O	O
to	NN	O	O
the	NN	O	O
following	NN	O	O
:	NN	O	O
(	NN	O	O
a	NN	O	O
)	NN	O	O
what	NN	O	O
receptors	NN	O	O
were	NN	O	O
stimulated	NN	O	O
by	NN	O	O
the	NN	O	O
ACTH	NN	O	B-Chemical
N	NN	O	O
-	NN	O	O
terminal	NN	O	O
fragments	NN	O	O
at	NN	O	O
the	NN	O	O
LC	NN	O	O
that	NN	O	O
resulted	NN	O	O
in	NN	O	O
this	NN	O	O
disorder	NN	O	O
;	NN	O	O
(	NN	O	O
b	NN	O	O
)	NN	O	O
whether	NN	O	O
NE	NN	O	O
,	NN	O	O
released	NN	O	O
onto	NN	O	O
Purkinje	NN	O	O
cell	NN	O	O
synapses	NN	O	O
located	NN	O	O
at	NN	O	O
terminals	NN	O	O
of	NN	O	O
the	NN	O	O
ceruleo	NN	O	O
-	NN	O	O
cerebellar	NN	O	O
pathway	NN	O	O
,	NN	O	O
did	NN	O	O
indeed	NN	O	O
cause	NN	O	O
the	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
depression	NN	O	B-Disease
at	NN	O	O
Purkinje	NN	O	O
cell	NN	O	O
synapses	NN	O	O
(	NN	O	O
previously	NN	O	O
described	NN	O	O
by	NN	O	O
others	NN	O	O
)	NN	O	O
that	NN	O	O
resulted	NN	O	O
in	NN	O	O
the	NN	O	O
long	NN	O	O
duration	NN	O	O
of	NN	O	O
the	NN	O	O
movement	NN	O	B-Disease
disorder	NN	O	I-Disease
;	NN	O	O
(	NN	O	O
c	NN	O	O
)	NN	O	O
whether	NN	O	O
the	NN	O	O
inhibition	NN	O	O
of	NN	O	O
inhibitory	NN	O	O
Purkinje	NN	O	O
cells	NN	O	O
resulted	NN	O	O
in	NN	O	O
disinhibition	NN	O	O
or	NN	O	O
increased	NN	O	O
excitability	NN	O	O
of	NN	O	O
the	NN	O	O
unilateral	NN	O	O
cerebellar	NN	O	O
fastigial	NN	O	O
or	NN	O	O
interpositus	NN	O	O
nuclei	NN	O	O
,	NN	O	O
the	NN	O	O
output	NN	O	O
targets	NN	O	O
of	NN	O	O
the	NN	O	O
Purkinje	NN	O	O
cell	NN	O	O
axons	NN	O	O
,	NN	O	O
that	NN	O	O
may	NN	O	O
have	NN	O	O
been	NN	O	O
an	NN	O	O
important	NN	O	O
contributing	NN	O	O
factor	NN	O	O
to	NN	O	O
this	NN	O	O
disorder	NN	O	O
.	NN	O	O

These	NN	O	O
questions	NN	O	O
are	NN	O	O
currently	NN	O	O
being	NN	O	O
investigated	NN	O	O
.	NN	O	O


-DOCSTART- (2569282)

Dexmedetomidine	NN	O	B-Chemical
,	NN	O	O
acting	NN	O	O
through	NN	O	O
central	NN	O	O
alpha	NN	O	O
-	NN	O	O
2	NN	O	O
adrenoceptors	NN	O	O
,	NN	O	O
prevents	NN	O	O
opiate	NN	O	O
-	NN	O	O
induced	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

The	NN	O	O
highly	NN	O	O
-	NN	O	O
selective	NN	O	O
alpha	NN	O	O
-	NN	O	O
2	NN	O	O
adrenergic	NN	O	O
agonist	NN	O	O
dexmedetomidine	NN	O	B-Chemical
(	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
MED	NN	O	I-Chemical
)	NN	O	O
is	NN	O	O
capable	NN	O	O
of	NN	O	O
inducing	NN	O	O
muscle	NN	O	B-Disease
flaccidity	NN	O	I-Disease
and	NN	O	O
anesthesia	NN	O	O
in	NN	O	O
rats	NN	O	O
and	NN	O	O
dogs	NN	O	O
.	NN	O	O

Intense	NN	O	O
generalized	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
is	NN	O	O
an	NN	O	O
undesirable	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
potent	NN	O	O
opiate	NN	O	O
agonists	NN	O	O
.	NN	O	O

Although	NN	O	O
the	NN	O	O
neurochemistry	NN	O	O
of	NN	O	O
opiate	NN	O	O
-	NN	O	O
induced	NN	O	O
rigidity	NN	O	B-Disease
has	NN	O	O
yet	NN	O	O
to	NN	O	O
be	NN	O	O
fully	NN	O	O
elucidated	NN	O	O
,	NN	O	O
recent	NN	O	O
work	NN	O	O
suggests	NN	O	O
a	NN	O	O
role	NN	O	O
for	NN	O	O
a	NN	O	O
central	NN	O	O
adrenergic	NN	O	O
mechanism	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
the	NN	O	O
authors	NN	O	O
determined	NN	O	O
if	NN	O	O
treatment	NN	O	O
with	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
MED	NN	O	I-Chemical
prevents	NN	O	O
the	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
caused	NN	O	O
by	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
alfentanil	NN	O	B-Chemical
anesthesia	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Animals	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
42	NN	O	O
)	NN	O	O
were	NN	O	O
treated	NN	O	O
intraperitoneally	NN	O	O
with	NN	O	O
one	NN	O	O
of	NN	O	O
the	NN	O	O
following	NN	O	O
six	NN	O	O
regimens	NN	O	O
:	NN	O	O
1	NN	O	O
)	NN	O	O
L	NN	O	O
-	NN	O	O
MED	NN	O	O
(	NN	O	O
the	NN	O	O
inactive	NN	O	O
L	NN	O	O
-	NN	O	O
isomer	NN	O	O
of	NN	O	O
medetomidine	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
30	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
;	NN	O	O
2	NN	O	O
)	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
MED	NN	O	I-Chemical
,	NN	O	O
10	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
;	NN	O	O
3	NN	O	O
)	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
MED	NN	O	I-Chemical
,	NN	O	O
30	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
;	NN	O	O
4	NN	O	O
)	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
MED	NN	O	I-Chemical
[	NN	O	O
30	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
]	NN	O	O
and	NN	O	O
the	NN	O	O
central	NN	O	O
-	NN	O	O
acting	NN	O	O
alpha	NN	O	O
-	NN	O	O
2	NN	O	O
antagonist	NN	O	O
,	NN	O	O
idazoxan	NN	O	B-Chemical
[	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
]	NN	O	O
;	NN	O	O
5	NN	O	O
)	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
MED	NN	O	I-Chemical
[	NN	O	O
30	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
]	NN	O	O
and	NN	O	O
the	NN	O	O
peripheral	NN	O	O
-	NN	O	O
acting	NN	O	O
alpha	NN	O	O
-	NN	O	O
2	NN	O	O
antagonist	NN	O	O
DG	NN	O	B-Chemical
-	NN	O	I-Chemical
5128	NN	O	I-Chemical
[	NN	O	O
10	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
]	NN	O	O
,	NN	O	O
or	NN	O	O
;	NN	O	O
6	NN	O	O
)	NN	O	O
saline	NN	O	O
.	NN	O	O

Baseline	NN	O	O
electromyographic	NN	O	O
activity	NN	O	O
was	NN	O	O
recorded	NN	O	O
from	NN	O	O
the	NN	O	O
gastrocnemius	NN	O	O
muscle	NN	O	O
before	NN	O	O
and	NN	O	O
after	NN	O	O
drug	NN	O	O
treatment	NN	O	O
.	NN	O	O

Each	NN	O	O
rat	NN	O	O
was	NN	O	O
then	NN	O	O
injected	NN	O	O
with	NN	O	O
alfentanil	NN	O	B-Chemical
(	NN	O	O
ALF	NN	O	B-Chemical
,	NN	O	O
0.5	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
sc	NN	O	O
)	NN	O	O
.	NN	O	O

ALF	NN	O	B-Chemical
injection	NN	O	O
resulted	NN	O	O
in	NN	O	O
a	NN	O	O
marked	NN	O	O
increase	NN	O	O
in	NN	O	O
hindlimb	NN	O	O
EMG	NN	O	O
activity	NN	O	O
in	NN	O	O
the	NN	O	O
L	NN	O	O
-	NN	O	O
MED	NN	O	O
treatment	NN	O	O
group	NN	O	O
which	NN	O	O
was	NN	O	O
indistinguishable	NN	O	O
from	NN	O	O
that	NN	O	O
seen	NN	O	O
in	NN	O	O
animals	NN	O	O
treated	NN	O	O
with	NN	O	O
saline	NN	O	O
.	NN	O	O

In	NN	O	O
contrast	NN	O	O
,	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
MED	NN	O	I-Chemical
prevented	NN	O	O
alfentanil	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
muscle	NN	O	B-Disease
rigidity	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
dose	NN	O	O
-	NN	O	O
dependent	NN	O	O
fashion	NN	O	O
.	NN	O	O

The	NN	O	O
small	NN	O	O
EMG	NN	O	O
values	NN	O	O
obtained	NN	O	O
in	NN	O	O
the	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
MED	NN	O	I-Chemical
group	NN	O	O
were	NN	O	O
comparable	NN	O	O
with	NN	O	O
those	NN	O	O
recorded	NN	O	O
in	NN	O	O
earlier	NN	O	O
studies	NN	O	O
from	NN	O	O
control	NN	O	O
animals	NN	O	O
not	NN	O	O
given	NN	O	O
any	NN	O	O
opiate	NN	O	O
.	NN	O	O

The	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
D	NN	O	B-Chemical
-	NN	O	I-Chemical
MED	NN	O	I-Chemical
animals	NN	O	O
were	NN	O	O
flaccid	NN	O	O
,	NN	O	O
akinetic	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
lacked	NN	O	O
a	NN	O	O
startle	NN	O	B-Disease
response	NN	O	O
during	NN	O	O
the	NN	O	O
entire	NN	O	O
experimental	NN	O	O
period.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

-DOCSTART- (2343592)

Seizure	NN	O	B-Disease
activity	NN	O	O
with	NN	O	O
imipenem	NN	O	B-Chemical
therapy	NN	O	O
:	NN	O	O
incidence	NN	O	O
and	NN	O	O
risk	NN	O	O
factors	NN	O	O
.	NN	O	O

Two	NN	O	O
elderly	NN	O	O
patients	NN	O	O
with	NN	O	O
a	NN	O	O
history	NN	O	O
of	NN	O	O
either	NN	O	O
cerebral	NN	O	B-Disease
vascular	NN	O	I-Disease
accident	NN	O	I-Disease
(	NN	O	O
CVA	NN	O	B-Disease
)	NN	O	O
or	NN	O	O
head	NN	O	B-Disease
trauma	NN	O	I-Disease
and	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
renal	NN	O	B-Disease
disease	NN	O	I-Disease
developed	NN	O	O
seizures	NN	O	B-Disease
while	NN	O	O
receiving	NN	O	O
maximum	NN	O	O
doses	NN	O	O
of	NN	O	O
imipenem	NN	O	B-Chemical
/	NN	O	I-Chemical
cilastatin	NN	O	I-Chemical
.	NN	O	O

Neither	NN	O	O
patient	NN	O	O
had	NN	O	O
reported	NN	O	O
previous	NN	O	O
seizures	NN	O	B-Disease
or	NN	O	O
seizure	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
activity	NN	O	O
nor	NN	O	O
was	NN	O	O
receiving	NN	O	O
anticonvulsant	NN	O	O
agents	NN	O	O
.	NN	O	O

All	NN	O	O
seizures	NN	O	B-Disease
were	NN	O	O
controlled	NN	O	O
with	NN	O	O
therapeutic	NN	O	O
doses	NN	O	O
of	NN	O	O
phenytoin	NN	O	B-Chemical
.	NN	O	O

Both	NN	O	O
patients	NN	O	O
had	NN	O	O
received	NN	O	O
maximum	NN	O	O
doses	NN	O	O
of	NN	O	O
other	NN	O	O
beta	NN	O	B-Chemical
-	NN	O	I-Chemical
lactam	NN	O	I-Chemical
antibiotics	NN	O	O
without	NN	O	O
evidence	NN	O	O
of	NN	O	O
seizure	NN	O	B-Disease
activity	NN	O	O
.	NN	O	O


-DOCSTART- (2055425)

The	NN	O	O
ability	NN	O	O
of	NN	O	O
insulin	NN	O	O
treatment	NN	O	O
to	NN	O	O
reverse	NN	O	O
or	NN	O	O
prevent	NN	O	O
the	NN	O	O
changes	NN	O	O
in	NN	O	O
urinary	NN	O	O
bladder	NN	O	O
function	NN	O	O
caused	NN	O	O
by	NN	O	O
streptozotocin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
diabetes	NN	O	B-Disease
mellitus	NN	O	I-Disease
.	NN	O	O

1	NN	O	O
.	NN	O	O

The	NN	O	O
effects	NN	O	O
of	NN	O	O
insulin	NN	O	O
treatment	NN	O	O
on	NN	O	O
in	NN	O	O
vivo	NN	O	O
and	NN	O	O
in	NN	O	O
vitro	NN	O	O
urinary	NN	O	O
bladder	NN	O	O
function	NN	O	O
in	NN	O	O
streptozotocin	NN	O	B-Chemical
-	NN	O	O
diabetic	NN	O	B-Disease
rats	NN	O	O
were	NN	O	O
investigated	NN	O	O
.	NN	O	O

2	NN	O	O
.	NN	O	O

Diabetes	NN	O	B-Disease
of	NN	O	O
2	NN	O	O
months	NN	O	O
duration	NN	O	O
resulted	NN	O	O
in	NN	O	O
decreases	NN	O	O
in	NN	O	O
body	NN	O	O
weight	NN	O	O
and	NN	O	O
increases	NN	O	O
in	NN	O	O
fluid	NN	O	O
consumption	NN	O	O
,	NN	O	O
urine	NN	O	O
volume	NN	O	O
,	NN	O	O
frequency	NN	O	O
of	NN	O	O
micturition	NN	O	O
,	NN	O	O
and	NN	O	O
average	NN	O	O
volume	NN	O	O
per	NN	O	O
micturition	NN	O	O
;	NN	O	O
effects	NN	O	O
which	NN	O	O
were	NN	O	O
prevented	NN	O	O
by	NN	O	O
insulin	NN	O	O
treatment	NN	O	O
.	NN	O	O

3	NN	O	O
.	NN	O	O

Insulin	NN	O	O
treatment	NN	O	O
also	NN	O	O
prevented	NN	O	O
the	NN	O	O
increases	NN	O	O
in	NN	O	O
contractile	NN	O	O
responses	NN	O	O
of	NN	O	O
bladder	NN	O	O
body	NN	O	O
strips	NN	O	O
from	NN	O	O
diabetic	NN	O	B-Disease
rats	NN	O	O
to	NN	O	O
nerve	NN	O	O
stimulation	NN	O	O
,	NN	O	O
ATP	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
bethanechol	NN	O	B-Chemical
.	NN	O	O

4	NN	O	O
.	NN	O	O

Diabetes	NN	O	B-Disease
of	NN	O	O
4	NN	O	O
months	NN	O	O
duration	NN	O	O
also	NN	O	O
resulted	NN	O	O
in	NN	O	O
decreases	NN	O	O
in	NN	O	O
body	NN	O	O
weight	NN	O	O
,	NN	O	O
and	NN	O	O
increases	NN	O	O
in	NN	O	O
fluid	NN	O	O
consumption	NN	O	O
,	NN	O	O
urine	NN	O	O
volume	NN	O	O
,	NN	O	O
frequency	NN	O	O
of	NN	O	O
micturition	NN	O	O
,	NN	O	O
and	NN	O	O
average	NN	O	O
volume	NN	O	O
per	NN	O	O
micturition	NN	O	O
,	NN	O	O
effects	NN	O	O
which	NN	O	O
were	NN	O	O
reversed	NN	O	O
by	NN	O	O
insulin	NN	O	O
treatment	NN	O	O
for	NN	O	O
the	NN	O	O
final	NN	O	O
2	NN	O	O
months	NN	O	O
of	NN	O	O
the	NN	O	O
study	NN	O	O
.	NN	O	O

5	NN	O	O
.	NN	O	O

Insulin	NN	O	O
treatment	NN	O	O
reversed	NN	O	O
the	NN	O	O
increases	NN	O	O
in	NN	O	O
contractile	NN	O	O
responses	NN	O	O
of	NN	O	O
bladder	NN	O	O
body	NN	O	O
strips	NN	O	O
from	NN	O	O
diabetic	NN	O	B-Disease
rats	NN	O	O
to	NN	O	O
nerve	NN	O	O
stimulation	NN	O	O
,	NN	O	O
ATP	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
bethanechol	NN	O	B-Chemical
.	NN	O	O

6	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
streptozotocin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
diabetes	NN	O	B-Disease
on	NN	O	O
urinary	NN	O	O
bladder	NN	O	O
function	NN	O	O
are	NN	O	O
both	NN	O	O
prevented	NN	O	O
and	NN	O	O
reversed	NN	O	O
by	NN	O	O
insulin	NN	O	O
treatment	NN	O	O
.	NN	O	O


-DOCSTART- (1711760)

Delayed	NN	O	O
institution	NN	O	O
of	NN	O	O
hypertension	NN	O	B-Disease
during	NN	O	O
focal	NN	O	O
cerebral	NN	O	B-Disease
ischemia	NN	O	I-Disease
:	NN	O	O
effect	NN	O	O
on	NN	O	O
brain	NN	O	B-Disease
edema	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
effect	NN	O	O
of	NN	O	O
induced	NN	O	O
hypertension	NN	O	B-Disease
instituted	NN	O	O
after	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
h	NN	O	O
delay	NN	O	O
following	NN	O	O
middle	NN	O	B-Disease
cerebral	NN	O	I-Disease
artery	NN	O	I-Disease
occlusion	NN	O	I-Disease
(	NN	O	O
MCAO	NN	O	B-Disease
)	NN	O	O
on	NN	O	O
brain	NN	O	B-Disease
edema	NN	O	I-Disease
formation	NN	O	O
and	NN	O	O
histochemical	NN	O	O
injury	NN	O	O
was	NN	O	O
studied	NN	O	O
.	NN	O	O

Under	NN	O	O
isoflurane	NN	O	B-Chemical
anesthesia	NN	O	O
,	NN	O	O
the	NN	O	O
MCA	NN	O	O
of	NN	O	O
14	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B-Disease
rats	NN	O	O
was	NN	O	O
occluded	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
control	NN	O	O
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
mean	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
(	NN	O	O
MAP	NN	O	O
)	NN	O	O
was	NN	O	O
not	NN	O	O
manipulated	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
hypertensive	NN	O	B-Disease
group	NN	O	O
(	NN	O	O
n	NN	O	O
=	NN	O	O
7	NN	O	O
)	NN	O	O
,	NN	O	O
the	NN	O	O
MAP	NN	O	O
was	NN	O	O
elevated	NN	O	O
by	NN	O	O
25	NN	O	O
-	NN	O	O
30	NN	O	O
mm	NN	O	O
Hg	NN	O	O
beginning	NN	O	O
2	NN	O	O
h	NN	O	O
after	NN	O	O
MCAO	NN	O	B-Disease
.	NN	O	O

Four	NN	O	O
hours	NN	O	O
after	NN	O	O
MCAO	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
rats	NN	O	O
were	NN	O	O
killed	NN	O	O
and	NN	O	O
the	NN	O	O
brains	NN	O	O
harvested	NN	O	O
.	NN	O	O

The	NN	O	O
brains	NN	O	O
were	NN	O	O
sectioned	NN	O	O
along	NN	O	O
coronal	NN	O	O
planes	NN	O	O
spanning	NN	O	O
the	NN	O	O
distribution	NN	O	O
of	NN	O	O
ischemia	NN	O	B-Disease
produced	NN	O	O
by	NN	O	O
MCAO	NN	O	B-Disease
.	NN	O	O

Specific	NN	O	O
gravity	NN	O	O
(	NN	O	O
SG	NN	O	O
)	NN	O	O
was	NN	O	O
determined	NN	O	O
in	NN	O	O
the	NN	O	O
subcortex	NN	O	O
and	NN	O	O
in	NN	O	O
two	NN	O	O
sites	NN	O	O
in	NN	O	O
the	NN	O	O
cortex	NN	O	O
(	NN	O	O
core	NN	O	O
and	NN	O	O
periphery	NN	O	O
of	NN	O	O
the	NN	O	O
ischemic	NN	O	B-Disease
territory	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
extent	NN	O	O
of	NN	O	O
neuronal	NN	O	B-Disease
injury	NN	O	I-Disease
was	NN	O	O
determined	NN	O	O
by	NN	O	O
2	NN	O	B-Chemical
,	NN	O	I-Chemical
3	NN	O	I-Chemical
,	NN	O	I-Chemical
5	NN	O	I-Chemical
-	NN	O	I-Chemical
triphenyltetrazolium	NN	O	I-Chemical
staining	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
ischemic	NN	O	B-Disease
core	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
difference	NN	O	O
in	NN	O	O
SG	NN	O	O
in	NN	O	O
the	NN	O	O
subcortex	NN	O	O
and	NN	O	O
cortex	NN	O	O
in	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
periphery	NN	O	O
of	NN	O	O
the	NN	O	O
ischemic	NN	O	B-Disease
territory	NN	O	O
,	NN	O	O
SG	NN	O	O
in	NN	O	O
the	NN	O	O
cortex	NN	O	O
was	NN	O	O
greater	NN	O	O
(	NN	O	O
less	NN	O	O
edema	NN	O	B-Disease
accumulation	NN	O	O
)	NN	O	O
in	NN	O	O
the	NN	O	O
hypertensive	NN	O	B-Disease
group	NN	O	O
(	NN	O	O
1.041	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.001	NN	O	O
vs	NN	O	O
1.039	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.001	NN	O	O
,	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
area	NN	O	O
of	NN	O	O
histochemical	NN	O	O
injury	NN	O	O
(	NN	O	O
as	NN	O	O
a	NN	O	O
percent	NN	O	O
of	NN	O	O
the	NN	O	O
cross	NN	O	O
-	NN	O	O
sectional	NN	O	O
area	NN	O	O
of	NN	O	O
the	NN	O	O
hemisphere	NN	O	O
)	NN	O	O
was	NN	O	O
less	NN	O	O
in	NN	O	O
the	NN	O	O
hypertensive	NN	O	B-Disease
group	NN	O	O
(	NN	O	O
33	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
3%	NN	O	O
vs	NN	O	O
21	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
2%	NN	O	O
,	NN	O	O
P	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
phenylephrine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypertension	NN	O	B-Disease
instituted	NN	O	O
2	NN	O	O
h	NN	O	O
after	NN	O	O
MCAO	NN	O	B-Disease
does	NN	O	O
not	NN	O	O
aggravate	NN	O	O
edema	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
ischemic	NN	O	B-Disease
core	NN	O	O
,	NN	O	O
that	NN	O	O
it	NN	O	O
improves	NN	O	O
edema	NN	O	B-Disease
in	NN	O	O
the	NN	O	O
periphery	NN	O	O
of	NN	O	O
the	NN	O	O
ischemic	NN	O	B-Disease
territory	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
it	NN	O	O
reduces	NN	O	O
the	NN	O	O
area	NN	O	O
of	NN	O	O
histochemical	NN	O	O
neuronal	NN	O	B-Disease
dysfunction	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (1595783)

Amiodarone	NN	O	B-Chemical
pulmonary	NN	O	B-Disease
toxicity	NN	O	I-Disease
.	NN	O	O

Amiodarone	NN	O	B-Chemical
is	NN	O	O
an	NN	O	O
effective	NN	O	O
antiarrhythmic	NN	O	O
agent	NN	O	O
whose	NN	O	O
utility	NN	O	O
is	NN	O	O
limited	NN	O	O
by	NN	O	O
many	NN	O	O
side	NN	O	O
-	NN	O	O
effects	NN	O	O
,	NN	O	O
the	NN	O	O
most	NN	O	O
problematic	NN	O	O
being	NN	O	O
pneumonitis	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
pulmonary	NN	O	B-Disease
toxicity	NN	O	I-Disease
of	NN	O	O
amiodarone	NN	O	B-Chemical
is	NN	O	O
thought	NN	O	O
to	NN	O	O
result	NN	O	O
from	NN	O	O
direct	NN	O	O
injury	NN	O	O
related	NN	O	O
to	NN	O	O
the	NN	O	O
intracellular	NN	O	O
accumulation	NN	O	O
of	NN	O	O
phospholipid	NN	O	O
and	NN	O	O
T	NN	O	O
cell	NN	O	O
-	NN	O	O
mediated	NN	O	O
hypersensitivity	NN	O	B-Disease
pneumonitis	NN	O	I-Disease
.	NN	O	O

The	NN	O	O
clinical	NN	O	O
and	NN	O	O
radiographic	NN	O	O
features	NN	O	O
of	NN	O	O
amiodarone	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
pulmonary	NN	O	B-Disease
toxicity	NN	O	I-Disease
are	NN	O	O
characteristic	NN	O	O
but	NN	O	O
nonspecific	NN	O	O
.	NN	O	O

The	NN	O	O
diagnosis	NN	O	O
depends	NN	O	O
on	NN	O	O
exclusion	NN	O	O
of	NN	O	O
other	NN	O	O
entities	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
,	NN	O	O
infection	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
malignancy	NN	O	B-Disease
.	NN	O	O

While	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
amiodarone	NN	O	B-Chemical
leads	NN	O	O
to	NN	O	O
clinical	NN	O	O
improvement	NN	O	O
in	NN	O	O
majority	NN	O	O
of	NN	O	O
cases	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
not	NN	O	O
always	NN	O	O
possible	NN	O	O
or	NN	O	O
advisable	NN	O	O
.	NN	O	O

Dose	NN	O	O
reduction	NN	O	O
or	NN	O	O
concomitant	NN	O	O
steroid	NN	O	B-Chemical
therapy	NN	O	O
may	NN	O	O
have	NN	O	O
a	NN	O	O
role	NN	O	O
in	NN	O	O
selected	NN	O	O
patients	NN	O	O
.	NN	O	O


-DOCSTART- (804391)

Light	NN	O	O
chain	NN	O	O
proteinuria	NN	O	B-Disease
and	NN	O	O
cellular	NN	O	O
mediated	NN	O	O
immunity	NN	O	O
in	NN	O	O
rifampin	NN	O	B-Chemical
treated	NN	O	O
patients	NN	O	O
with	NN	O	O
tuberculosis	NN	O	B-Disease
.	NN	O	O

Light	NN	O	O
chain	NN	O	O
proteinuria	NN	O	B-Disease
was	NN	O	O
found	NN	O	O
in	NN	O	O
9	NN	O	O
of	NN	O	O
17	NN	O	O
tuberculosis	NN	O	B-Disease
patients	NN	O	O
treated	NN	O	O
with	NN	O	O
rifampin	NN	O	B-Chemical
.	NN	O	O

Concomitant	NN	O	O
assay	NN	O	O
of	NN	O	O
cellular	NN	O	O
mediated	NN	O	O
immunity	NN	O	O
in	NN	O	O
these	NN	O	O
patients	NN	O	O
using	NN	O	O
skin	NN	O	O
test	NN	O	O
antigen	NN	O	O
and	NN	O	O
a	NN	O	O
lymphokine	NN	O	O
in	NN	O	O
vitro	NN	O	O
test	NN	O	O
provided	NN	O	O
results	NN	O	O
that	NN	O	O
were	NN	O	O
different	NN	O	O
.	NN	O	O

Response	NN	O	O
to	NN	O	O
Varidase	NN	O	O
skin	NN	O	O
test	NN	O	O
antigen	NN	O	O
was	NN	O	O
negative	NN	O	O
for	NN	O	O
all	NN	O	O
eight	NN	O	O
tuberculosis	NN	O	B-Disease
patients	NN	O	O
tested	NN	O	O
,	NN	O	O
but	NN	O	O
there	NN	O	O
occurred	NN	O	O
a	NN	O	O
hyper	NN	O	O
-	NN	O	O
responsiveness	NN	O	O
of	NN	O	O
the	NN	O	O
lymphocytes	NN	O	O
of	NN	O	O
these	NN	O	O
eight	NN	O	O
patients	NN	O	O
to	NN	O	O
phytomitogen	NN	O	O
(	NN	O	O
PHA	NN	O	O
-	NN	O	O
P	NN	O	O
)	NN	O	O
.	NN	O	O

as	NN	O	O
well	NN	O	O
as	NN	O	O
of	NN	O	O
those	NN	O	O
of	NN	O	O
seven	NN	O	O
other	NN	O	O
tuberculous	NN	O	B-Disease
patients	NN	O	O
.	NN	O	O

This	NN	O	O
last	NN	O	O
finding	NN	O	O
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
time	NN	O	O
of	NN	O	O
testing	NN	O	O
and	NN	O	O
/	NN	O	O
or	NN	O	O
endogenous	NN	O	O
serum	NN	O	O
binding	NN	O	O
of	NN	O	O
rifampin	NN	O	B-Chemical
which	NN	O	O
could	NN	O	O
have	NN	O	O
inhibited	NN	O	O
mitogen	NN	O	O
activity	NN	O	O
for	NN	O	O
the	NN	O	O
lymphocyte	NN	O	O
.	NN	O	O


-DOCSTART- (28952)

Initial	NN	O	O
potassium	NN	O	B-Chemical
loss	NN	O	O
and	NN	O	O
hypokalaemia	NN	O	B-Disease
during	NN	O	O
chlorthalidone	NN	O	B-Chemical
administration	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
essential	NN	O	O
hypertension	NN	O	B-Disease
:	NN	O	O
the	NN	O	O
influence	NN	O	O
of	NN	O	O
dietary	NN	O	O
sodium	NN	O	B-Chemical
restriction	NN	O	O
.	NN	O	O

To	NN	O	O
investigate	NN	O	O
the	NN	O	O
initial	NN	O	O
potassium	NN	O	B-Chemical
loss	NN	O	O
and	NN	O	O
development	NN	O	O
of	NN	O	O
hypokalaemia	NN	O	B-Disease
during	NN	O	O
the	NN	O	O
administration	NN	O	O
of	NN	O	O
an	NN	O	O
oral	NN	O	O
diuretic	NN	O	O
,	NN	O	O
metabolic	NN	O	O
balance	NN	O	O
studies	NN	O	O
were	NN	O	O
performed	NN	O	O
in	NN	O	O
ten	NN	O	O
patients	NN	O	O
with	NN	O	O
essential	NN	O	O
hypertension	NN	O	B-Disease
who	NN	O	O
had	NN	O	O
shown	NN	O	O
hypokalaemia	NN	O	B-Disease
under	NN	O	O
prior	NN	O	O
oral	NN	O	O
diuretic	NN	O	O
treatment	NN	O	O
.	NN	O	O

Chlorthalidone	NN	O	B-Chemical
(	NN	O	O
50	NN	O	O
mg	NN	O	O
daily	NN	O	O
)	NN	O	O
was	NN	O	O
given	NN	O	O
for	NN	O	O
14	NN	O	O
days	NN	O	O
.	NN	O	O

Six	NN	O	O
patients	NN	O	O
received	NN	O	O
a	NN	O	O
normal	NN	O	O
-	NN	O	O
sodium	NN	O	B-Chemical
diet	NN	O	O
and	NN	O	O
four	NN	O	O
a	NN	O	O
low	NN	O	O
-	NN	O	O
sodium	NN	O	B-Chemical
(	NN	O	O
17	NN	O	O
mmol	NN	O	O
/	NN	O	O
day	NN	O	O
)	NN	O	O
diet	NN	O	O
.	NN	O	O

All	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
normal	NN	O	O
initial	NN	O	O
total	NN	O	O
body	NN	O	O
potassium	NN	O	B-Chemical
(	NN	O	O
40K	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
electrolyte	NN	O	O
balances	NN	O	O
,	NN	O	O
weight	NN	O	O
,	NN	O	O
bromide	NN	O	O
space	NN	O	O
,	NN	O	O
plasma	NN	O	O
renin	NN	O	O
activity	NN	O	O
,	NN	O	O
and	NN	O	O
aldosterone	NN	O	B-Chemical
secretion	NN	O	O
rate	NN	O	O
were	NN	O	O
measured	NN	O	O
.	NN	O	O

In	NN	O	O
both	NN	O	O
groups	NN	O	O
a	NN	O	O
potassium	NN	O	B-Chemical
deficit	NN	O	O
developed	NN	O	O
,	NN	O	O
with	NN	O	O
proportionally	NN	O	O
larger	NN	O	O
losses	NN	O	O
from	NN	O	O
the	NN	O	O
extracellular	NN	O	O
than	NN	O	O
from	NN	O	O
the	NN	O	O
intracellular	NN	O	O
compartment	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
normal	NN	O	O
-	NN	O	O
sodium	NN	O	B-Chemical
group	NN	O	O
the	NN	O	O
highest	NN	O	O
mean	NN	O	O
potassium	NN	O	B-Chemical
deficit	NN	O	O
was	NN	O	O
176	NN	O	O
mmol	NN	O	O
on	NN	O	O
day	NN	O	O
9	NN	O	O
,	NN	O	O
after	NN	O	O
which	NN	O	O
some	NN	O	O
potassium	NN	O	B-Chemical
was	NN	O	O
regained	NN	O	O
;	NN	O	O
in	NN	O	O
the	NN	O	O
low	NN	O	O
-	NN	O	O
sodium	NN	O	B-Chemical
group	NN	O	O
the	NN	O	O
highest	NN	O	O
deficit	NN	O	O
was	NN	O	O
276	NN	O	O
mmol	NN	O	O
on	NN	O	O
day	NN	O	O
13	NN	O	O
.	NN	O	O

The	NN	O	O
normal	NN	O	O
-	NN	O	O
sodium	NN	O	B-Chemical
group	NN	O	O
showed	NN	O	O
an	NN	O	O
immediate	NN	O	O
but	NN	O	O
temporary	NN	O	O
rise	NN	O	O
of	NN	O	O
the	NN	O	O
renin	NN	O	O
and	NN	O	O
aldosterone	NN	O	B-Chemical
levels	NN	O	O
;	NN	O	O
in	NN	O	O
the	NN	O	O
low	NN	O	O
-	NN	O	O
sodium	NN	O	B-Chemical
group	NN	O	O
renin	NN	O	O
and	NN	O	O
aldosterone	NN	O	B-Chemical
increased	NN	O	O
more	NN	O	O
slowly	NN	O	O
but	NN	O	O
remained	NN	O	O
elevated	NN	O	O
.	NN	O	O

It	NN	O	O
is	NN	O	O
concluded	NN	O	O
that	NN	O	O
dietary	NN	O	O
sodium	NN	O	B-Chemical
restriction	NN	O	O
increases	NN	O	O
diuretic	NN	O	O
-	NN	O	O
induced	NN	O	O
potassium	NN	O	B-Chemical
loss	NN	O	O
,	NN	O	O
presumably	NN	O	O
by	NN	O	O
an	NN	O	O
increased	NN	O	O
activity	NN	O	O
of	NN	O	O
the	NN	O	O
renin	NN	O	O
-	NN	O	O
angiotensin	NN	O	B-Chemical
-	NN	O	O
aldosterone	NN	O	B-Chemical
system	NN	O	O
,	NN	O	O
while	NN	O	O
sodium	NN	O	B-Chemical
delivery	NN	O	O
to	NN	O	O
the	NN	O	O
distal	NN	O	O
renal	NN	O	O
tubules	NN	O	O
remains	NN	O	O
sufficiently	NN	O	O
high	NN	O	O
to	NN	O	O
allow	NN	O	O
increased	NN	O	O
potassium	NN	O	B-Chemical
secretion	NN	O	O
.	NN	O	O


-DOCSTART- (19893084)

Dynamic	NN	O	O
response	NN	O	O
of	NN	O	O
blood	NN	O	O
vessel	NN	O	O
in	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
this	NN	O	O
study	NN	O	O
we	NN	O	O
postulated	NN	O	O
that	NN	O	O
during	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
gentamicin	NN	O	B-Chemical
the	NN	O	O
transient	NN	O	O
or	NN	O	O
dynamic	NN	O	O
response	NN	O	O
of	NN	O	O
blood	NN	O	O
vessels	NN	O	O
could	NN	O	O
be	NN	O	O
affected	NN	O	O
,	NN	O	O
and	NN	O	O
that	NN	O	O
antioxidants	NN	O	O
can	NN	O	O
prevent	NN	O	O
the	NN	O	O
changes	NN	O	O
in	NN	O	O
dynamic	NN	O	O
responses	NN	O	O
of	NN	O	O
blood	NN	O	O
vessels	NN	O	O
.	NN	O	O

The	NN	O	O
new	NN	O	O
approach	NN	O	O
to	NN	O	O
ex	NN	O	O
vivo	NN	O	O
blood	NN	O	O
vessel	NN	O	O
experiments	NN	O	O
in	NN	O	O
which	NN	O	O
not	NN	O	O
only	NN	O	O
the	NN	O	O
end	NN	O	O
points	NN	O	O
of	NN	O	O
vessels	NN	O	O
response	NN	O	O
within	NN	O	O
the	NN	O	O
time	NN	O	O
interval	NN	O	O
is	NN	O	O
considered	NN	O	O
,	NN	O	O
but	NN	O	O
also	NN	O	O
dynamics	NN	O	O
of	NN	O	O
this	NN	O	O
response	NN	O	O
,	NN	O	O
was	NN	O	O
used	NN	O	O
in	NN	O	O
this	NN	O	O
paper	NN	O	O
.	NN	O	O

Our	NN	O	O
results	NN	O	O
confirm	NN	O	O
the	NN	O	O
alteration	NN	O	O
in	NN	O	O
dynamic	NN	O	O
response	NN	O	O
of	NN	O	O
blood	NN	O	O
vessels	NN	O	O
during	NN	O	O
the	NN	O	O
change	NN	O	O
of	NN	O	O
pressure	NN	O	O
in	NN	O	O
gentamicin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
.	NN	O	O

The	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
of	NN	O	O
vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
administration	NN	O	O
to	NN	O	O
gentamicin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
are	NN	O	O
also	NN	O	O
confirmed	NN	O	O
through	NN	O	O
:	NN	O	O
lower	NN	O	O
level	NN	O	O
of	NN	O	O
blood	NN	O	O
urea	NN	O	B-Chemical
and	NN	O	O
creatinine	NN	O	B-Chemical
and	NN	O	O
higher	NN	O	O
level	NN	O	O
of	NN	O	O
potassium	NN	O	B-Chemical
.	NN	O	O

The	NN	O	O
pressure	NN	O	O
dynamic	NN	O	O
responses	NN	O	O
of	NN	O	O
isolated	NN	O	O
blood	NN	O	O
vessels	NN	O	O
show	NN	O	O
a	NN	O	O
faster	NN	O	O
pressure	NN	O	O
change	NN	O	O
in	NN	O	O
gentamicin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
(	NN	O	O
8.07	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
1.7	NN	O	O
s	NN	O	O
vs	NN	O	O
.	NN	O	O

5.64	NN	O	O
+	NN	O	O
/	NN	O	O
-	NN	O	O
0.18	NN	O	O
s	NN	O	O
)	NN	O	O
.	NN	O	O

Vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
administration	NN	O	O
induced	NN	O	O
slowdown	NN	O	O
of	NN	O	O
pressure	NN	O	O
change	NN	O	O
back	NN	O	O
to	NN	O	O
the	NN	O	O
control	NN	O	O
values	NN	O	O
.	NN	O	O

The	NN	O	O
pressure	NN	O	O
dynamic	NN	O	O
properties	NN	O	O
,	NN	O	O
quantitatively	NN	O	O
defined	NN	O	O
by	NN	O	O
comparative	NN	O	O
pressure	NN	O	O
dynamic	NN	O	O
and	NN	O	O
total	NN	O	O
pressure	NN	O	O
dynamic	NN	O	O
,	NN	O	O
confirm	NN	O	O
the	NN	O	O
alteration	NN	O	O
in	NN	O	O
dynamic	NN	O	O
response	NN	O	O
of	NN	O	O
blood	NN	O	O
vessels	NN	O	O
during	NN	O	O
the	NN	O	O
change	NN	O	O
of	NN	O	O
pressure	NN	O	O
in	NN	O	O
gentamicin	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
animals	NN	O	O
and	NN	O	O
beneficial	NN	O	O
effects	NN	O	O
of	NN	O	O
vitamin	NN	O	B-Chemical
C	NN	O	I-Chemical
administration	NN	O	O
.	NN	O	O


-DOCSTART- (18513945)

The	NN	O	O
hemodynamics	NN	O	O
of	NN	O	O
oxytocin	NN	O	B-Chemical
and	NN	O	O
other	NN	O	O
vasoactive	NN	O	O
agents	NN	O	O
during	NN	O	O
neuraxial	NN	O	O
anesthesia	NN	O	O
for	NN	O	O
cesarean	NN	O	O
delivery	NN	O	O
:	NN	O	O
findings	NN	O	O
in	NN	O	O
six	NN	O	O
cases	NN	O	O
.	NN	O	O

Oxytocin	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
commonly	NN	O	O
used	NN	O	O
uterotonic	NN	O	O
that	NN	O	O
can	NN	O	O
cause	NN	O	O
significant	NN	O	O
and	NN	O	O
even	NN	O	O
fatal	NN	O	O
hypotension	NN	O	B-Disease
,	NN	O	O
particularly	NN	O	O
when	NN	O	O
given	NN	O	O
as	NN	O	O
a	NN	O	O
bolus	NN	O	O
.	NN	O	O

The	NN	O	O
resulting	NN	O	O
hypotension	NN	O	B-Disease
can	NN	O	O
be	NN	O	O
produced	NN	O	O
by	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
or	NN	O	O
cardiac	NN	O	O
output	NN	O	O
through	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
venous	NN	O	O
return	NN	O	O
.	NN	O	O

Parturients	NN	O	O
with	NN	O	O
normal	NN	O	O
volume	NN	O	O
status	NN	O	O
,	NN	O	O
heart	NN	O	O
valves	NN	O	O
and	NN	O	O
pulmonary	NN	O	O
vasculature	NN	O	O
most	NN	O	O
often	NN	O	O
respond	NN	O	O
to	NN	O	O
this	NN	O	O
hypotension	NN	O	B-Disease
with	NN	O	O
a	NN	O	O
compensatory	NN	O	O
increase	NN	O	O
in	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
stroke	NN	O	B-Disease
volume	NN	O	O
.	NN	O	O

Oxytocin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypotension	NN	O	B-Disease
at	NN	O	O
cesarean	NN	O	O
delivery	NN	O	O
may	NN	O	O
be	NN	O	O
incorrectly	NN	O	O
attributed	NN	O	O
to	NN	O	O
blood	NN	O	B-Disease
loss	NN	O	I-Disease
.	NN	O	O

Pulse	NN	O	O
power	NN	O	O
analysis	NN	O	O
(	NN	O	O
also	NN	O	O
called	NN	O	O
"	NN	O	O
pulse	NN	O	O
contour	NN	O	O
analysis	NN	O	O
"	NN	O	O
)	NN	O	O
of	NN	O	O
an	NN	O	O
arterial	NN	O	O
pressure	NN	O	O
wave	NN	O	O
form	NN	O	O
allows	NN	O	O
continuous	NN	O	O
evaluation	NN	O	O
of	NN	O	O
systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
and	NN	O	O
cardiac	NN	O	O
output	NN	O	O
in	NN	O	O
real	NN	O	O
time	NN	O	O
,	NN	O	O
thereby	NN	O	O
elucidating	NN	O	O
the	NN	O	O
causative	NN	O	O
factors	NN	O	O
behind	NN	O	O
changes	NN	O	O
in	NN	O	O
blood	NN	O	O
pressure	NN	O	O
.	NN	O	O

Pulse	NN	O	O
power	NN	O	O
analysis	NN	O	O
was	NN	O	O
conducted	NN	O	O
in	NN	O	O
six	NN	O	O
cases	NN	O	O
of	NN	O	O
cesarean	NN	O	O
delivery	NN	O	O
performed	NN	O	O
under	NN	O	O
neuraxial	NN	O	O
anesthesia	NN	O	O
.	NN	O	O

Hypotension	NN	O	B-Disease
in	NN	O	O
response	NN	O	O
to	NN	O	O
oxytocin	NN	O	B-Chemical
was	NN	O	O
associated	NN	O	O
with	NN	O	O
a	NN	O	O
decrease	NN	O	O
in	NN	O	O
systemic	NN	O	O
vascular	NN	O	O
resistance	NN	O	O
and	NN	O	O
a	NN	O	O
compensatory	NN	O	O
increase	NN	O	O
in	NN	O	O
stroke	NN	O	B-Disease
volume	NN	O	O
,	NN	O	O
heart	NN	O	O
rate	NN	O	O
and	NN	O	O
cardiac	NN	O	O
output	NN	O	O
.	NN	O	O

Pulse	NN	O	O
power	NN	O	O
analysis	NN	O	O
may	NN	O	O
be	NN	O	O
helpful	NN	O	O
in	NN	O	O
determining	NN	O	O
the	NN	O	O
etiology	NN	O	O
of	NN	O	O
and	NN	O	O
treating	NN	O	O
hypotension	NN	O	B-Disease
during	NN	O	O
cesarean	NN	O	O
delivery	NN	O	O
under	NN	O	O
neuraxial	NN	O	O
anesthesia	NN	O	O
.	NN	O	O


-DOCSTART- (18483878)

Exaggerated	NN	O	O
expression	NN	O	O
of	NN	O	O
inflammatory	NN	O	O
mediators	NN	O	O
in	NN	O	O
vasoactive	NN	O	O
intestinal	NN	O	O
polypeptide	NN	O	O
knockout	NN	O	O
(	NN	O	O
VIP	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
with	NN	O	O
cyclophosphamide	NN	O	B-Chemical
(	NN	O	O
CYP	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B-Disease
.	NN	O	O

Vasoactive	NN	O	O
intestinal	NN	O	O
polypeptide	NN	O	O
(	NN	O	O
VIP	NN	O	O
)	NN	O	O
is	NN	O	O
an	NN	O	O
immunomodulatory	NN	O	O
neuropeptide	NN	O	O
distributed	NN	O	O
in	NN	O	O
micturition	NN	O	O
pathways	NN	O	O
.	NN	O	O

VIP	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
exhibit	NN	O	O
altered	NN	O	O
bladder	NN	O	O
function	NN	O	O
and	NN	O	O
neurochemical	NN	O	O
properties	NN	O	O
in	NN	O	O
micturition	NN	O	O
pathways	NN	O	O
after	NN	O	O
cyclophosphamide	NN	O	B-Chemical
(	NN	O	O
CYP	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B-Disease
.	NN	O	O

Given	NN	O	O
VIP	NN	O	O
'	NN	O	O
s	NN	O	O
role	NN	O	O
as	NN	O	O
an	NN	O	O
anti	NN	O	O
-	NN	O	O
inflammatory	NN	O	O
mediator	NN	O	O
,	NN	O	O
we	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
VIP	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
would	NN	O	O
exhibit	NN	O	O
enhanced	NN	O	O
inflammatory	NN	O	O
mediator	NN	O	O
expression	NN	O	O
after	NN	O	O
cystitis	NN	O	B-Disease
.	NN	O	O

A	NN	O	O
mouse	NN	O	O
inflammatory	NN	O	O
cytokine	NN	O	O
and	NN	O	O
receptor	NN	O	O
RT2	NN	O	O
profiler	NN	O	O
array	NN	O	O
was	NN	O	O
used	NN	O	O
to	NN	O	O
determine	NN	O	O
regulated	NN	O	O
transcripts	NN	O	O
in	NN	O	O
the	NN	O	O
urinary	NN	O	O
bladder	NN	O	O
of	NN	O	O
wild	NN	O	O
type	NN	O	O
(	NN	O	O
WT	NN	O	O
)	NN	O	O
and	NN	O	O
VIP	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
CYP	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cystitis	NN	O	B-Disease
(	NN	O	O
150	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
;	NN	O	O
i.p.	NN	O	O
;	NN	O	O
48	NN	O	O
h	NN	O	O
)	NN	O	O
.	NN	O	O

Four	NN	O	O
binary	NN	O	O
comparisons	NN	O	O
were	NN	O	O
made	NN	O	O
:	NN	O	O
WT	NN	O	O
control	NN	O	O
versus	NN	O	O
CYP	NN	O	B-Chemical
treatment	NN	O	O
(	NN	O	O
48	NN	O	O
h	NN	O	O
)	NN	O	O
,	NN	O	O
VIP	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
control	NN	O	O
versus	NN	O	O
CYP	NN	O	B-Chemical
treatment	NN	O	O
(	NN	O	O
48	NN	O	O
h	NN	O	O
)	NN	O	O
,	NN	O	O
WT	NN	O	O
control	NN	O	O
versus	NN	O	O
VIP	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
control	NN	O	O
,	NN	O	O
and	NN	O	O
WT	NN	O	O
with	NN	O	O
CYP	NN	O	B-Chemical
treatment	NN	O	O
(	NN	O	O
48	NN	O	O
h	NN	O	O
)	NN	O	O
versus	NN	O	O
VIP	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
with	NN	O	O
CYP	NN	O	B-Chemical
treatment	NN	O	O
(	NN	O	O
48	NN	O	O
h	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
genes	NN	O	O
presented	NN	O	O
represent	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
greater	NN	O	O
than	NN	O	O
1.5	NN	O	O
-	NN	O	O
fold	NN	O	O
change	NN	O	O
in	NN	O	O
either	NN	O	O
direction	NN	O	O
and	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
the	NN	O	O
p	NN	O	O
value	NN	O	O
is	NN	O	O
less	NN	O	O
than	NN	O	O
0.05	NN	O	O
for	NN	O	O
the	NN	O	O
comparison	NN	O	O
being	NN	O	O
made	NN	O	O
.	NN	O	O

Several	NN	O	O
regulated	NN	O	O
genes	NN	O	O
were	NN	O	O
validated	NN	O	O
using	NN	O	O
enzyme	NN	O	O
-	NN	O	O
linked	NN	O	O
immunoassays	NN	O	O
including	NN	O	O
IL	NN	O	O
-	NN	O	O
1beta	NN	O	O
and	NN	O	O
CXCL1	NN	O	O
.	NN	O	O

CYP	NN	O	B-Chemical
treatment	NN	O	O
significantly	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0.001	NN	O	O
)	NN	O	O
increased	NN	O	O
expression	NN	O	O
of	NN	O	O
CXCL1	NN	O	O
and	NN	O	O
IL	NN	O	O
-	NN	O	O
1beta	NN	O	O
in	NN	O	O
the	NN	O	O
urinary	NN	O	O
bladder	NN	O	O
of	NN	O	O
WT	NN	O	O
and	NN	O	O
VIP	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
,	NN	O	O
but	NN	O	O
expression	NN	O	O
in	NN	O	O
VIP	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
with	NN	O	O
CYP	NN	O	B-Chemical
treatment	NN	O	O
was	NN	O	O
significantly	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
or	NN	O	O
=	NN	O	O
0.001	NN	O	O
)	NN	O	O
greater	NN	O	O
(	NN	O	O
4.2	NN	O	O
-	NN	O	O
to	NN	O	O
13	NN	O	O
-	NN	O	O
fold	NN	O	O
increase	NN	O	O
)	NN	O	O
than	NN	O	O
that	NN	O	O
observed	NN	O	O
in	NN	O	O
WT	NN	O	O
urinary	NN	O	O
bladder	NN	O	O
(	NN	O	O
3.6	NN	O	O
-	NN	O	O
to	NN	O	O
5	NN	O	O
-	NN	O	O
fold	NN	O	O
increase	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
data	NN	O	O
suggest	NN	O	O
that	NN	O	O
in	NN	O	O
VIP	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
with	NN	O	O
bladder	NN	O	B-Disease
inflammation	NN	O	I-Disease
,	NN	O	O
inflammatory	NN	O	O
mediators	NN	O	O
are	NN	O	O
increased	NN	O	O
above	NN	O	O
that	NN	O	O
observed	NN	O	O
in	NN	O	O
WT	NN	O	O
with	NN	O	O
CYP	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
shift	NN	O	O
in	NN	O	O
balance	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
increased	NN	O	O
bladder	NN	O	B-Disease
dysfunction	NN	O	I-Disease
in	NN	O	O
VIP	NN	O	O
(	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
)	NN	O	O
mice	NN	O	O
with	NN	O	O
bladder	NN	O	B-Disease
inflammation	NN	O	I-Disease
and	NN	O	O
altered	NN	O	O
neurochemical	NN	O	O
expression	NN	O	O
in	NN	O	O
micturition	NN	O	O
pathways	NN	O	O
.	NN	O	O


-DOCSTART- (17923537)

Intraocular	NN	O	O
pressure	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
uveitis	NN	O	B-Disease
treated	NN	O	O
with	NN	O	O
fluocinolone	NN	O	B-Chemical
acetonide	NN	O	I-Chemical
implants	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
report	NN	O	O
the	NN	O	O
incidence	NN	O	O
and	NN	O	O
management	NN	O	O
of	NN	O	O
elevated	NN	O	B-Disease
intraocular	NN	O	I-Disease
pressure	NN	O	I-Disease
(	NN	O	O
IOP	NN	O	O
)	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
uveitis	NN	O	B-Disease
treated	NN	O	O
with	NN	O	O
the	NN	O	O
fluocinolone	NN	O	B-Chemical
acetonide	NN	O	I-Chemical
(	NN	O	O
FA	NN	O	B-Chemical
)	NN	O	O
intravitreal	NN	O	O
implant	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Pooled	NN	O	O
data	NN	O	O
from	NN	O	O
3	NN	O	O
multicenter	NN	O	O
,	NN	O	O
double	NN	O	O
-	NN	O	O
masked	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
controlled	NN	O	O
,	NN	O	O
phase	NN	O	O
2b	NN	O	O
/	NN	O	O
3	NN	O	O
clinical	NN	O	O
trials	NN	O	O
evaluating	NN	O	O
the	NN	O	O
safety	NN	O	O
and	NN	O	O
efficacy	NN	O	O
of	NN	O	O
the	NN	O	O
0.59	NN	O	O
-	NN	O	O
mg	NN	O	O
or	NN	O	O
2.1	NN	O	O
-	NN	O	O
mg	NN	O	O
FA	NN	O	B-Chemical
intravitreal	NN	O	O
implant	NN	O	O
or	NN	O	O
standard	NN	O	O
therapy	NN	O	O
were	NN	O	O
analyzed	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
During	NN	O	O
the	NN	O	O
3	NN	O	O
-	NN	O	O
year	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
,	NN	O	O
71.0%	NN	O	O
of	NN	O	O
implanted	NN	O	O
eyes	NN	O	O
had	NN	O	O
an	NN	O	O
IOP	NN	O	O
increase	NN	O	O
of	NN	O	O
10	NN	O	O
mm	NN	O	O
Hg	NN	O	O
or	NN	O	O
more	NN	O	O
than	NN	O	O
baseline	NN	O	O
and	NN	O	O
55.1%	NN	O	O
,	NN	O	O
24.7%	NN	O	O
,	NN	O	O
and	NN	O	O
6.2%	NN	O	O
of	NN	O	O
eyes	NN	O	O
reached	NN	O	O
an	NN	O	O
IOP	NN	O	O
of	NN	O	O
30	NN	O	O
mm	NN	O	O
Hg	NN	O	O
or	NN	O	O
more	NN	O	O
,	NN	O	O
40	NN	O	O
mm	NN	O	O
Hg	NN	O	O
or	NN	O	O
more	NN	O	O
,	NN	O	O
and	NN	O	O
50	NN	O	O
mm	NN	O	O
Hg	NN	O	O
or	NN	O	O
more	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

Topical	NN	O	O
IOP	NN	O	O
-	NN	O	O
lowering	NN	O	O
medication	NN	O	O
was	NN	O	O
administered	NN	O	O
in	NN	O	O
74.8%	NN	O	O
of	NN	O	O
implanted	NN	O	O
eyes	NN	O	O
,	NN	O	O
and	NN	O	O
IOP	NN	O	O
-	NN	O	O
lowering	NN	O	O
surgeries	NN	O	O
,	NN	O	O
most	NN	O	O
of	NN	O	O
which	NN	O	O
were	NN	O	O
trabeculectomies	NN	O	O
(	NN	O	O
76.2%	NN	O	O
)	NN	O	O
,	NN	O	O
were	NN	O	O
performed	NN	O	O
on	NN	O	O
36.6%	NN	O	O
of	NN	O	O
implanted	NN	O	O
eyes	NN	O	O
.	NN	O	O

Intraocular	NN	O	O
pressure	NN	O	O
-	NN	O	O
lowering	NN	O	O
surgeries	NN	O	O
were	NN	O	O
considered	NN	O	O
a	NN	O	O
success	NN	O	O
(	NN	O	O
postoperative	NN	O	O
IOP	NN	O	O
of	NN	O	O
6	NN	O	O
-	NN	O	O
21	NN	O	O
mm	NN	O	O
Hg	NN	O	O
with	NN	O	O
or	NN	O	O
without	NN	O	O
additional	NN	O	O
IOP	NN	O	O
-	NN	O	O
lowering	NN	O	O
medication	NN	O	O
)	NN	O	O
in	NN	O	O
85.1%	NN	O	O
of	NN	O	O
eyes	NN	O	O
at	NN	O	O
1	NN	O	O
year	NN	O	O
.	NN	O	O

The	NN	O	O
rate	NN	O	O
of	NN	O	O
hypotony	NN	O	B-Disease
(	NN	O	O
IOP	NN	O	O
<	NN	O	O
/	NN	O	O
=	NN	O	O
5	NN	O	O
mm	NN	O	O
Hg	NN	O	O
)	NN	O	O
following	NN	O	O
IOP	NN	O	O
-	NN	O	O
lowering	NN	O	O
surgery	NN	O	O
(	NN	O	O
42.5%	NN	O	O
)	NN	O	O
was	NN	O	O
not	NN	O	O
different	NN	O	O
from	NN	O	O
that	NN	O	O
of	NN	O	O
implanted	NN	O	O
eyes	NN	O	O
not	NN	O	O
subjected	NN	O	O
to	NN	O	O
surgery	NN	O	O
(	NN	O	O
35.4%	NN	O	O
)	NN	O	O
(	NN	O	O
P	NN	O	O
=	NN	O	O
.09	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Elevated	NN	O	O
IOP	NN	O	O
is	NN	O	O
a	NN	O	O
significant	NN	O	O
complication	NN	O	O
with	NN	O	O
the	NN	O	O
FA	NN	O	O
intravitreal	NN	O	O
implant	NN	O	O
but	NN	O	O
may	NN	O	O
be	NN	O	O
controlled	NN	O	O
with	NN	O	O
medication	NN	O	O
and	NN	O	O
surgery	NN	O	O
.	NN	O	O


-DOCSTART- (15096016)

Pallidal	NN	O	O
stimulation	NN	O	O
:	NN	O	O
an	NN	O	O
alternative	NN	O	O
to	NN	O	O
pallidotomy?	NN	O	O
A	NN	O	O
resurgence	NN	O	O
of	NN	O	O
interest	NN	O	O
in	NN	O	O
the	NN	O	O
surgical	NN	O	O
treatment	NN	O	O
of	NN	O	O
Parkinson	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
(	NN	O	O
PD	NN	O	B-Disease
)	NN	O	O
came	NN	O	O
with	NN	O	O
the	NN	O	O
rediscovery	NN	O	O
of	NN	O	O
posteroventral	NN	O	O
pallidotomy	NN	O	O
by	NN	O	O
Laitinen	NN	O	O
in	NN	O	O
1985	NN	O	O
.	NN	O	O

Laitinen	NN	O	O
'	NN	O	O
s	NN	O	O
procedure	NN	O	O
improved	NN	O	O
most	NN	O	O
symptoms	NN	O	O
in	NN	O	O
drug	NN	O	O
-	NN	O	O
resistant	NN	O	O
PD	NN	O	B-Disease
,	NN	O	O
which	NN	O	O
engendered	NN	O	O
wide	NN	O	O
interest	NN	O	O
in	NN	O	O
the	NN	O	O
neurosurgical	NN	O	O
community	NN	O	O
.	NN	O	O

Another	NN	O	O
lesioning	NN	O	O
procedure	NN	O	O
,	NN	O	O
ventrolateral	NN	O	O
thalamotomy	NN	O	O
,	NN	O	O
has	NN	O	O
become	NN	O	O
a	NN	O	O
powerful	NN	O	O
alternative	NN	O	O
to	NN	O	O
stimulate	NN	O	O
the	NN	O	O
nucleus	NN	O	O
ventralis	NN	O	O
intermedius	NN	O	O
,	NN	O	O
producing	NN	O	O
high	NN	O	O
long	NN	O	O
-	NN	O	O
term	NN	O	O
success	NN	O	O
rates	NN	O	O
and	NN	O	O
low	NN	O	O
morbidity	NN	O	O
rates	NN	O	O
.	NN	O	O

Pallidal	NN	O	O
stimulation	NN	O	O
has	NN	O	O
not	NN	O	O
met	NN	O	O
with	NN	O	O
the	NN	O	O
same	NN	O	O
success	NN	O	O
.	NN	O	O

According	NN	O	O
to	NN	O	O
the	NN	O	O
literature	NN	O	O
pallidotomy	NN	O	O
improves	NN	O	O
the	NN	O	O
"	NN	O	O
on	NN	O	O
"	NN	O	O
symptoms	NN	O	O
of	NN	O	O
PD	NN	O	B-Disease
,	NN	O	O
such	NN	O	O
as	NN	O	O
dyskinesias	NN	O	B-Disease
,	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
the	NN	O	O
"	NN	O	O
off	NN	O	O
"	NN	O	O
symptoms	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
rigidity	NN	O	B-Disease
,	NN	O	O
bradykinesia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
on	NN	O	O
-	NN	O	O
off	NN	O	O
fluctuations	NN	O	O
.	NN	O	O

Pallidal	NN	O	O
stimulation	NN	O	O
improves	NN	O	O
bradykinesia	NN	O	B-Disease
and	NN	O	O
rigidity	NN	O	B-Disease
to	NN	O	O
a	NN	O	O
minor	NN	O	O
extent	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
its	NN	O	O
strength	NN	O	O
seems	NN	O	O
to	NN	O	O
be	NN	O	O
in	NN	O	O
improving	NN	O	O
levodopa	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
dyskinesias	NN	O	B-Disease
.	NN	O	O

Stimulation	NN	O	O
often	NN	O	O
produces	NN	O	O
an	NN	O	O
improvement	NN	O	O
in	NN	O	O
the	NN	O	O
hyper	NN	O	B-Disease
-	NN	O	I-Disease
or	NN	O	I-Disease
dyskinetic	NN	O	I-Disease
upper	NN	O	O
limbs	NN	O	O
,	NN	O	O
but	NN	O	O
increases	NN	O	O
the	NN	O	O
"	NN	O	O
freezing	NN	O	O
"	NN	O	O
phenomenon	NN	O	O
in	NN	O	O
the	NN	O	O
lower	NN	O	O
limbs	NN	O	O
at	NN	O	O
the	NN	O	O
same	NN	O	O
time	NN	O	O
.	NN	O	O

Considering	NN	O	O
the	NN	O	O
small	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
independence	NN	O	O
,	NN	O	O
the	NN	O	O
high	NN	O	O
costs	NN	O	O
of	NN	O	O
bilateral	NN	O	O
implants	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
difficulty	NN	O	O
most	NN	O	O
patients	NN	O	O
experience	NN	O	O
in	NN	O	O
handling	NN	O	O
the	NN	O	O
devices	NN	O	O
,	NN	O	O
the	NN	O	O
question	NN	O	O
arises	NN	O	O
as	NN	O	O
to	NN	O	O
whether	NN	O	O
bilateral	NN	O	O
pallidal	NN	O	O
stimulation	NN	O	O
is	NN	O	O
a	NN	O	O
real	NN	O	O
alternative	NN	O	O
to	NN	O	O
pallidotomy	NN	O	O
.	NN	O	O


-DOCSTART- (12734532)

Case	NN	O	O
report	NN	O	O
:	NN	O	O
Dexatrim	NN	O	B-Chemical
(	NN	O	O
Phenylpropanolamine	NN	O	B-Chemical
)	NN	O	O
as	NN	O	O
a	NN	O	O
cause	NN	O	O
of	NN	O	O
myocardial	NN	O	B-Disease
infarction	NN	O	I-Disease
.	NN	O	O

Phenylpropanolamine	NN	O	B-Chemical
(	NN	O	O
PPA	NN	O	B-Chemical
)	NN	O	O
is	NN	O	O
a	NN	O	O
sympathetic	NN	O	O
amine	NN	O	B-Chemical
used	NN	O	O
in	NN	O	O
over	NN	O	O
-	NN	O	O
the	NN	O	O
-	NN	O	O
counter	NN	O	O
cold	NN	O	O
remedies	NN	O	O
and	NN	O	O
weight	NN	O	O
-	NN	O	O
control	NN	O	O
preparations	NN	O	O
worldwide	NN	O	O
.	NN	O	O

Its	NN	O	O
use	NN	O	O
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
hypertensive	NN	O	B-Disease
episodes	NN	O	O
and	NN	O	O
hemorrhagic	NN	O	B-Disease
strokes	NN	O	I-Disease
in	NN	O	O
younger	NN	O	O
women	NN	O	O
.	NN	O	O

Several	NN	O	O
reports	NN	O	O
have	NN	O	O
linked	NN	O	O
the	NN	O	O
abuse	NN	O	O
of	NN	O	O
PPA	NN	O	B-Chemical
with	NN	O	O
myocardial	NN	O	B-Disease
injury	NN	O	I-Disease
,	NN	O	O
especially	NN	O	O
when	NN	O	O
overdose	NN	O	B-Disease
is	NN	O	O
involved	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
here	NN	O	O
the	NN	O	O
first	NN	O	O
case	NN	O	O
of	NN	O	O
Dexatrim	NN	O	B-Chemical
(	NN	O	O
PPA	NN	O	B-Chemical
)	NN	O	O
-	NN	O	O
induced	NN	O	O
myocardial	NN	O	B-Disease
injury	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
young	NN	O	O
woman	NN	O	O
who	NN	O	O
was	NN	O	O
using	NN	O	O
it	NN	O	O
at	NN	O	O
recommended	NN	O	O
doses	NN	O	O
for	NN	O	O
weight	NN	O	O
control	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
,	NN	O	O
we	NN	O	O
review	NN	O	O
the	NN	O	O
7	NN	O	O
other	NN	O	O
cases	NN	O	O
of	NN	O	O
PPA	NN	O	B-Chemical
related	NN	O	O
myocardial	NN	O	B-Disease
injury	NN	O	I-Disease
that	NN	O	O
have	NN	O	O
been	NN	O	O
reported	NN	O	O
so	NN	O	O
far	NN	O	O
.	NN	O	O

Physicians	NN	O	O
and	NN	O	O
patients	NN	O	O
should	NN	O	O
be	NN	O	O
alert	NN	O	O
to	NN	O	O
the	NN	O	O
potential	NN	O	O
cardiac	NN	O	O
risk	NN	O	O
associated	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
PPA	NN	O	B-Chemical
,	NN	O	O
even	NN	O	O
at	NN	O	O
doses	NN	O	O
generally	NN	O	O
considered	NN	O	O
to	NN	O	O
be	NN	O	O
safe	NN	O	O
.	NN	O	O


-DOCSTART- (12013711)

Risperidone	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
,	NN	O	O
benign	NN	O	O
transient	NN	O	O
visual	NN	O	B-Disease
disturbances	NN	O	I-Disease
in	NN	O	O
schizophrenic	NN	O	B-Disease
patients	NN	O	O
with	NN	O	O
a	NN	O	O
past	NN	O	O
history	NN	O	O
of	NN	O	O
LSD	NN	O	B-Chemical
abuse	NN	O	O
.	NN	O	O

Two	NN	O	O
schizophrenic	NN	O	B-Disease
patients	NN	O	O
,	NN	O	O
who	NN	O	O
had	NN	O	O
a	NN	O	O
prior	NN	O	O
history	NN	O	O
of	NN	O	O
LSD	NN	O	B-Chemical
abuse	NN	O	O
and	NN	O	O
who	NN	O	O
had	NN	O	O
previously	NN	O	O
developed	NN	O	O
EPS	NN	O	B-Disease
with	NN	O	O
classic	NN	O	O
antipsychotics	NN	O	O
,	NN	O	O
were	NN	O	O
successfully	NN	O	O
treated	NN	O	O
with	NN	O	O
risperidone	NN	O	B-Chemical
.	NN	O	O

They	NN	O	O
both	NN	O	O
reported	NN	O	O
short	NN	O	O
episodes	NN	O	O
of	NN	O	O
transient	NN	O	O
visual	NN	O	B-Disease
disturbances	NN	O	I-Disease
,	NN	O	O
which	NN	O	O
appeared	NN	O	O
immediately	NN	O	O
after	NN	O	O
starting	NN	O	O
treatment	NN	O	O
with	NN	O	O
risperidone	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
imagery	NN	O	O
resembled	NN	O	O
visual	NN	O	B-Disease
disturbances	NN	O	I-Disease
previously	NN	O	O
experienced	NN	O	O
as	NN	O	O
"	NN	O	O
flashbacks	NN	O	O
"	NN	O	O
related	NN	O	O
to	NN	O	O
prior	NN	O	O
LSD	NN	O	B-Chemical
consumption	NN	O	O
.	NN	O	O

Risperidone	NN	O	B-Chemical
administration	NN	O	O
was	NN	O	O
continued	NN	O	O
and	NN	O	O
the	NN	O	O
visual	NN	O	B-Disease
disturbances	NN	O	I-Disease
gradually	NN	O	O
wore	NN	O	O
off	NN	O	O
.	NN	O	O

During	NN	O	O
a	NN	O	O
six	NN	O	O
-	NN	O	O
month	NN	O	O
follow	NN	O	O
-	NN	O	O
up	NN	O	O
period	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
recurrence	NN	O	O
of	NN	O	O
visual	NN	O	B-Disease
disturbances	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
phenomenon	NN	O	O
may	NN	O	O
be	NN	O	O
interpreted	NN	O	O
as	NN	O	O
a	NN	O	O
benign	NN	O	O
,	NN	O	O
short	NN	O	O
-	NN	O	O
term	NN	O	O
and	NN	O	O
self	NN	O	O
-	NN	O	O
limiting	NN	O	O
side	NN	O	O
effect	NN	O	O
which	NN	O	O
does	NN	O	O
not	NN	O	O
contraindicate	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
risperidone	NN	O	B-Chemical
or	NN	O	O
interfere	NN	O	O
with	NN	O	O
treatment	NN	O	O
.	NN	O	O

Conclusions	NN	O	O
based	NN	O	O
on	NN	O	O
two	NN	O	O
case	NN	O	O
reports	NN	O	O
should	NN	O	O
be	NN	O	O
taken	NN	O	O
with	NN	O	O
appropriate	NN	O	O
caution	NN	O	O
.	NN	O	O


-DOCSTART- (11861791)

Activation	NN	O	O
of	NN	O	O
poly	NN	O	B-Chemical
(	NN	O	I-Chemical
ADP	NN	O	I-Chemical
-	NN	O	I-Chemical
ribose	NN	O	I-Chemical
)	NN	O	I-Chemical
polymerase	NN	O	O
contributes	NN	O	O
to	NN	O	O
development	NN	O	O
of	NN	O	O
doxorubicin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
heart	NN	O	B-Disease
failure	NN	O	I-Disease
.	NN	O	O

Activation	NN	O	O
of	NN	O	O
the	NN	O	O
nuclear	NN	O	O
enzyme	NN	O	O
poly	NN	O	B-Chemical
(	NN	O	I-Chemical
ADP	NN	O	I-Chemical
-	NN	O	I-Chemical
ribose	NN	O	I-Chemical
)	NN	O	I-Chemical
polymerase	NN	O	O
(	NN	O	O
PARP	NN	O	O
)	NN	O	O
by	NN	O	O
oxidant	NN	O	O
-	NN	O	O
mediated	NN	O	O
DNA	NN	O	O
damage	NN	O	O
is	NN	O	O
an	NN	O	O
important	NN	O	O
pathway	NN	O	O
of	NN	O	O
cell	NN	O	O
dysfunction	NN	O	O
and	NN	O	O
tissue	NN	O	O
injury	NN	O	O
in	NN	O	O
conditions	NN	O	O
associated	NN	O	O
with	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
.	NN	O	O

Increased	NN	O	O
oxidative	NN	O	O
stress	NN	O	O
is	NN	O	O
a	NN	O	O
major	NN	O	O
factor	NN	O	O
implicated	NN	O	O
in	NN	O	O
the	NN	O	O
cardiotoxicity	NN	O	B-Disease
of	NN	O	O
doxorubicin	NN	O	B-Chemical
(	NN	O	O
DOX	NN	O	B-Chemical
)	NN	O	O
,	NN	O	O
a	NN	O	O
widely	NN	O	O
used	NN	O	O
antitumor	NN	O	O
anthracycline	NN	O	B-Chemical
antibiotic	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
we	NN	O	O
hypothesized	NN	O	O
that	NN	O	O
the	NN	O	O
activation	NN	O	O
of	NN	O	O
PARP	NN	O	O
may	NN	O	O
contribute	NN	O	O
to	NN	O	O
the	NN	O	O
DOX	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
cardiotoxicity	NN	O	B-Disease
.	NN	O	O

Using	NN	O	O
a	NN	O	O
dual	NN	O	O
approach	NN	O	O
of	NN	O	O
PARP	NN	O	O
-	NN	O	O
1	NN	O	O
suppression	NN	O	O
,	NN	O	O
by	NN	O	O
genetic	NN	O	O
deletion	NN	O	O
or	NN	O	O
pharmacological	NN	O	O
inhibition	NN	O	O
with	NN	O	O
the	NN	O	O
phenanthridinone	NN	O	O
PARP	NN	O	O
inhibitor	NN	O	O
PJ34	NN	O	B-Chemical
,	NN	O	O
we	NN	O	O
now	NN	O	O
demonstrate	NN	O	O
the	NN	O	O
role	NN	O	O
of	NN	O	O
PARP	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
cardiac	NN	O	B-Disease
dysfunction	NN	O	I-Disease
induced	NN	O	O
by	NN	O	O
DOX	NN	O	B-Chemical
.	NN	O	O

PARP	NN	O	O
-	NN	O	O
1+	NN	O	O
/	NN	O	O
+	NN	O	O
and	NN	O	O
PARP	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
mice	NN	O	O
received	NN	O	O
a	NN	O	O
single	NN	O	O
injection	NN	O	O
of	NN	O	O
DOX	NN	O	B-Chemical
(	NN	O	O
25	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
i.p	NN	O	O
)	NN	O	O
.	NN	O	O

Five	NN	O	O
days	NN	O	O
after	NN	O	O
DOX	NN	O	B-Chemical
administration	NN	O	O
,	NN	O	O
left	NN	O	O
ventricular	NN	O	O
performance	NN	O	O
was	NN	O	O
significantly	NN	O	O
depressed	NN	O	O
in	NN	O	O
PARP	NN	O	O
-	NN	O	O
1+	NN	O	O
/	NN	O	O
+	NN	O	O
mice	NN	O	O
,	NN	O	O
but	NN	O	O
only	NN	O	O
to	NN	O	O
a	NN	O	O
smaller	NN	O	O
extent	NN	O	O
in	NN	O	O
PARP	NN	O	O
-	NN	O	O
1	NN	O	O
-	NN	O	O
/	NN	O	O
-	NN	O	O
ones	NN	O	O
.	NN	O	O

Similar	NN	O	O
experiments	NN	O	O
were	NN	O	O
conducted	NN	O	O
in	NN	O	O
BALB	NN	O	O
/	NN	O	O
c	NN	O	O
mice	NN	O	O
treated	NN	O	O
with	NN	O	O
PJ34	NN	O	B-Chemical
or	NN	O	O
vehicle	NN	O	O
.	NN	O	O

Treatment	NN	O	O
with	NN	O	O
a	NN	O	O
PJ34	NN	O	B-Chemical
significantly	NN	O	O
improved	NN	O	O
cardiac	NN	O	B-Disease
dysfunction	NN	O	I-Disease
and	NN	O	O
increased	NN	O	O
the	NN	O	O
survival	NN	O	O
of	NN	O	O
the	NN	O	O
animals	NN	O	O
.	NN	O	O

In	NN	O	O
addition	NN	O	O
PJ34	NN	O	B-Chemical
significantly	NN	O	O
reduced	NN	O	O
the	NN	O	O
DOX	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
increase	NN	O	O
in	NN	O	O
the	NN	O	O
serum	NN	O	O
lactate	NN	O	B-Chemical
dehydrogenase	NN	O	O
and	NN	O	O
creatine	NN	O	B-Chemical
kinase	NN	O	O
activities	NN	O	O
but	NN	O	O
not	NN	O	O
metalloproteinase	NN	O	O
activation	NN	O	O
in	NN	O	O
the	NN	O	O
heart	NN	O	O
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
PARP	NN	O	O
activation	NN	O	O
contributes	NN	O	O
to	NN	O	O
the	NN	O	O
cardiotoxicity	NN	O	B-Disease
of	NN	O	O
DOX	NN	O	B-Chemical
.	NN	O	O

PARP	NN	O	O
inhibitors	NN	O	O
may	NN	O	O
exert	NN	O	O
protective	NN	O	O
effects	NN	O	O
against	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
severe	NN	O	O
cardiac	NN	O	B-Disease
complications	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
the	NN	O	O
DOX	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O


-DOCSTART- (11302406)

Fluconazole	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
To	NN	O	O
present	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
fluconazole	NN	O	B-Chemical
-	NN	O	O
associated	NN	O	O
torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
(	NN	O	O
TDP	NN	O	B-Disease
)	NN	O	O
and	NN	O	O
discuss	NN	O	O
fluconazole	NN	O	B-Chemical
'	NN	O	O
s	NN	O	O
role	NN	O	O
in	NN	O	O
causing	NN	O	O
TDP	NN	O	B-Disease
.	NN	O	O

CASE	NN	O	O
SUMMARY	NN	O	O
:	NN	O	O
A	NN	O	O
68	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
white	NN	O	O
woman	NN	O	O
with	NN	O	O
Candida	NN	O	O
glabrata	NN	O	O
isolated	NN	O	O
from	NN	O	O
a	NN	O	O
presacral	NN	O	O
abscess	NN	O	O
developed	NN	O	O
TDP	NN	O	B-Disease
eight	NN	O	O
days	NN	O	O
after	NN	O	O
commencing	NN	O	O
oral	NN	O	O
fluconazole	NN	O	B-Chemical
The	NN	O	O
patient	NN	O	O
had	NN	O	O
no	NN	O	O
other	NN	O	O
risk	NN	O	O
factors	NN	O	O
for	NN	O	O
TDP	NN	O	B-Disease
,	NN	O	O
including	NN	O	O
coronary	NN	O	B-Disease
artery	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
cardiomyopathy	NN	O	B-Disease
,	NN	O	O
congestive	NN	O	B-Disease
heart	NN	O	I-Disease
failure	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
electrolyte	NN	O	O
abnormalities	NN	O	O
There	NN	O	O
was	NN	O	O
a	NN	O	O
temporal	NN	O	O
association	NN	O	O
between	NN	O	O
the	NN	O	O
initiation	NN	O	O
of	NN	O	O
fluconazole	NN	O	B-Chemical
and	NN	O	O
TDP	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
TDP	NN	O	B-Disease
resolved	NN	O	O
when	NN	O	O
fluconazole	NN	O	B-Chemical
was	NN	O	O
discontinued	NN	O	O
;	NN	O	O
however	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
continued	NN	O	O
to	NN	O	O
have	NN	O	O
premature	NN	O	B-Disease
ventricular	NN	O	I-Disease
contractions	NN	O	I-Disease
and	NN	O	O
nonsustained	NN	O	O
ventricular	NN	O	B-Disease
tachycardia	NN	O	I-Disease
(	NN	O	O
NSVT	NN	O	B-Disease
)	NN	O	O
until	NN	O	O
six	NN	O	O
days	NN	O	O
after	NN	O	O
drug	NN	O	O
cessation	NN	O	O
DISCUSSION	NN	O	O
:	NN	O	O
Use	NN	O	O
of	NN	O	O
the	NN	O	O
Naranjo	NN	O	O
probability	NN	O	O
scale	NN	O	O
indicates	NN	O	O
a	NN	O	O
probable	NN	O	O
relationship	NN	O	O
between	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
fluconazole	NN	O	B-Chemical
and	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
TDP	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
possible	NN	O	O
mechanism	NN	O	O
is	NN	O	O
depression	NN	O	B-Disease
of	NN	O	O
rapidly	NN	O	O
activating	NN	O	O
delayed	NN	O	O
rectifier	NN	O	O
potassium	NN	O	B-Chemical
currents	NN	O	O
.	NN	O	O

In	NN	O	O
our	NN	O	O
patient	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
other	NN	O	O
etiology	NN	O	O
identified	NN	O	O
that	NN	O	O
could	NN	O	O
explain	NN	O	O
QT	NN	O	B-Disease
prolongation	NN	O	I-Disease
or	NN	O	O
TDP	NN	O	B-Disease
The	NN	O	O
complete	NN	O	O
disappearance	NN	O	O
of	NN	O	O
NSVT	NN	O	B-Disease
and	NN	O	O
premature	NN	O	B-Disease
ventricular	NN	O	I-Disease
contractions	NN	O	I-Disease
followed	NN	O	O
by	NN	O	O
normalization	NN	O	O
of	NN	O	O
QT	NN	O	O
interval	NN	O	O
after	NN	O	O
the	NN	O	O
drug	NN	O	O
was	NN	O	O
stopped	NN	O	O
strongly	NN	O	O
suggests	NN	O	O
fluconazole	NN	O	B-Chemical
as	NN	O	O
the	NN	O	O
etiology	NN	O	O
.	NN	O	O

CONCLUSIONS	NN	O	O
:	NN	O	O
Clinicians	NN	O	O
should	NN	O	O
be	NN	O	O
aware	NN	O	O
that	NN	O	O
fluconazole	NN	O	B-Chemical
,	NN	O	O
even	NN	O	O
at	NN	O	O
low	NN	O	O
doses	NN	O	O
,	NN	O	O
may	NN	O	O
cause	NN	O	O
prolongation	NN	O	B-Disease
of	NN	O	I-Disease
the	NN	O	I-Disease
QT	NN	O	I-Disease
interval	NN	O	I-Disease
,	NN	O	O
leading	NN	O	O
to	NN	O	O
TDP	NN	O	B-Disease
.	NN	O	O

Serial	NN	O	O
electrocardiographic	NN	O	O
monitoring	NN	O	O
may	NN	O	O
be	NN	O	O
considered	NN	O	O
when	NN	O	O
fluconazole	NN	O	B-Chemical
is	NN	O	O
administered	NN	O	O
in	NN	O	O
patients	NN	O	O
who	NN	O	O
are	NN	O	O
at	NN	O	O
risk	NN	O	O
for	NN	O	O
ventricular	NN	O	B-Disease
arrhythmias	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (11058428)

High	NN	O	O
-	NN	O	O
dose	NN	O	O
methylprednisolone	NN	O	B-Chemical
may	NN	O	O
do	NN	O	O
more	NN	O	O
harm	NN	O	O
for	NN	O	O
spinal	NN	O	B-Disease
cord	NN	O	I-Disease
injury	NN	O	I-Disease
.	NN	O	O

Because	NN	O	O
of	NN	O	O
the	NN	O	O
National	NN	O	O
Acute	NN	O	O
Spinal	NN	O	B-Disease
Cord	NN	O	I-Disease
Injury	NN	O	I-Disease
Studies	NN	O	O
(	NN	O	O
NASCIS	NN	O	O
)	NN	O	O
,	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
methylprednisolone	NN	O	B-Chemical
became	NN	O	O
the	NN	O	O
standard	NN	O	O
of	NN	O	O
care	NN	O	O
for	NN	O	O
the	NN	O	O
acute	NN	O	O
spinal	NN	O	B-Disease
cord	NN	O	I-Disease
injury	NN	O	I-Disease
.	NN	O	O

In	NN	O	O
the	NN	O	O
NASCIS	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
no	NN	O	O
mention	NN	O	O
regarding	NN	O	O
the	NN	O	O
possibility	NN	O	O
of	NN	O	O
acute	NN	O	O
corticosteroid	NN	O	B-Chemical
myopathy	NN	O	B-Disease
that	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
methylprednisolone	NN	O	B-Chemical
may	NN	O	O
cause	NN	O	O
.	NN	O	O

The	NN	O	O
dosage	NN	O	O
of	NN	O	O
methylprednisolone	NN	O	B-Chemical
recommended	NN	O	O
by	NN	O	O
the	NN	O	O
NASCIS	NN	O	O
3	NN	O	O
is	NN	O	O
the	NN	O	O
highest	NN	O	O
dose	NN	O	O
of	NN	O	O
steroids	NN	O	B-Chemical
ever	NN	O	O
being	NN	O	O
used	NN	O	O
during	NN	O	O
a	NN	O	O
2	NN	O	O
-	NN	O	O
day	NN	O	O
period	NN	O	O
for	NN	O	O
any	NN	O	O
clinical	NN	O	O
condition	NN	O	O
.	NN	O	O

We	NN	O	O
hypothesize	NN	O	O
that	NN	O	O
it	NN	O	O
may	NN	O	O
cause	NN	O	O
some	NN	O	O
damage	NN	O	B-Disease
to	NN	O	I-Disease
the	NN	O	I-Disease
muscle	NN	O	I-Disease
of	NN	O	O
spinal	NN	O	B-Disease
cord	NN	O	I-Disease
injury	NN	O	I-Disease
patients	NN	O	O
.	NN	O	O

Further	NN	O	O
,	NN	O	O
steroid	NN	O	B-Chemical
myopathy	NN	O	B-Disease
recovers	NN	O	O
naturally	NN	O	O
and	NN	O	O
the	NN	O	O
neurological	NN	O	O
improvement	NN	O	O
shown	NN	O	O
in	NN	O	O
the	NN	O	O
NASCIS	NN	O	O
may	NN	O	O
be	NN	O	O
just	NN	O	O
a	NN	O	O
recording	NN	O	O
of	NN	O	O
this	NN	O	O
natural	NN	O	O
motor	NN	O	O
recovery	NN	O	O
from	NN	O	O
the	NN	O	O
steroid	NN	O	B-Chemical
myopathy	NN	O	B-Disease
,	NN	O	O
instead	NN	O	O
of	NN	O	O
any	NN	O	O
protection	NN	O	O
that	NN	O	O
methylprednisolone	NN	O	B-Chemical
offers	NN	O	O
to	NN	O	O
the	NN	O	O
spinal	NN	O	B-Disease
cord	NN	O	I-Disease
injury	NN	O	I-Disease
.	NN	O	O

To	NN	O	O
our	NN	O	O
knowledge	NN	O	O
,	NN	O	O
this	NN	O	O
is	NN	O	O
the	NN	O	O
first	NN	O	O
discussion	NN	O	O
considering	NN	O	O
the	NN	O	O
possibility	NN	O	O
that	NN	O	O
the	NN	O	O
methylprednisolone	NN	O	B-Chemical
recommended	NN	O	O
by	NN	O	O
NASCIS	NN	O	O
may	NN	O	O
cause	NN	O	O
acute	NN	O	O
corticosteroid	NN	O	B-Chemical
myopathy	NN	O	B-Disease
.	NN	O	O


-DOCSTART- (11022397)

Probing	NN	O	O
peripheral	NN	O	O
and	NN	O	O
central	NN	O	O
cholinergic	NN	O	O
system	NN	O	O
responses	NN	O	O
.	NN	O	O

OBJECTIVE	NN	O	O
:	NN	O	O
The	NN	O	O
pharmacological	NN	O	O
response	NN	O	O
to	NN	O	O
drugs	NN	O	O
that	NN	O	O
act	NN	O	O
on	NN	O	O
the	NN	O	O
cholinergic	NN	O	O
system	NN	O	O
of	NN	O	O
the	NN	O	O
iris	NN	O	O
has	NN	O	O
been	NN	O	O
used	NN	O	O
to	NN	O	O
predict	NN	O	O
deficits	NN	O	O
in	NN	O	O
central	NN	O	O
cholinergic	NN	O	O
functioning	NN	O	O
due	NN	O	O
to	NN	O	O
diseases	NN	O	O
such	NN	O	O
as	NN	O	O
Alzheimer	NN	O	B-Disease
'	NN	O	I-Disease
s	NN	O	I-Disease
disease	NN	O	I-Disease
,	NN	O	O
yet	NN	O	O
correlations	NN	O	O
between	NN	O	O
central	NN	O	O
and	NN	O	O
peripheral	NN	O	O
responses	NN	O	O
have	NN	O	O
not	NN	O	O
been	NN	O	O
properly	NN	O	O
studied	NN	O	O
.	NN	O	O

This	NN	O	O
study	NN	O	O
assessed	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
normal	NN	O	O
aging	NN	O	O
on	NN	O	O
(	NN	O	O
1	NN	O	O
)	NN	O	O
the	NN	O	O
tropicamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
increase	NN	O	O
in	NN	O	O
pupil	NN	O	O
diameter	NN	O	O
,	NN	O	O
and	NN	O	O
(	NN	O	O
2	NN	O	O
)	NN	O	O
the	NN	O	O
reversal	NN	O	O
of	NN	O	O
this	NN	O	O
effect	NN	O	O
with	NN	O	O
pilocarpine	NN	O	B-Chemical
.	NN	O	O

Scopolamine	NN	O	B-Chemical
was	NN	O	O
used	NN	O	O
as	NN	O	O
a	NN	O	O
positive	NN	O	O
control	NN	O	O
to	NN	O	O
detect	NN	O	O
age	NN	O	O
-	NN	O	O
dependent	NN	O	O
changes	NN	O	O
in	NN	O	O
central	NN	O	O
cholinergic	NN	O	O
functioning	NN	O	O
in	NN	O	O
the	NN	O	O
elderly	NN	O	O
.	NN	O	O

DESIGN	NN	O	O
:	NN	O	O
Randomized	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

PARTICIPANTS	NN	O	O
:	NN	O	O
Ten	NN	O	O
healthy	NN	O	O
elderly	NN	O	O
(	NN	O	O
mean	NN	O	O
age	NN	O	O
70	NN	O	O
)	NN	O	O
and	NN	O	O
9	NN	O	O
young	NN	O	O
(	NN	O	O
mean	NN	O	O
age	NN	O	O
33	NN	O	O
)	NN	O	O
volunteers	NN	O	O
.	NN	O	O

INTERVENTIONS	NN	O	O
:	NN	O	O
Pupil	NN	O	O
diameter	NN	O	O
was	NN	O	O
monitored	NN	O	O
using	NN	O	O
a	NN	O	O
computerized	NN	O	O
infrared	NN	O	O
pupillometer	NN	O	O
over	NN	O	O
4	NN	O	O
hours	NN	O	O
.	NN	O	O

The	NN	O	O
study	NN	O	O
involved	NN	O	O
4	NN	O	O
sessions	NN	O	O
.	NN	O	O

In	NN	O	O
1	NN	O	O
session	NN	O	O
,	NN	O	O
tropicamide	NN	O	B-Chemical
(	NN	O	O
20	NN	O	O
microL	NN	O	O
,	NN	O	O
0.01%	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
one	NN	O	O
eye	NN	O	O
and	NN	O	O
placebo	NN	O	O
to	NN	O	O
the	NN	O	O
other	NN	O	O
.	NN	O	O

In	NN	O	O
another	NN	O	O
session	NN	O	O
,	NN	O	O
tropicamide	NN	O	B-Chemical
(	NN	O	O
20	NN	O	O
microL	NN	O	O
,	NN	O	O
0.01%	NN	O	O
)	NN	O	O
was	NN	O	O
administered	NN	O	O
to	NN	O	O
both	NN	O	O
eyes	NN	O	O
,	NN	O	O
followed	NN	O	O
23	NN	O	O
minutes	NN	O	O
later	NN	O	O
by	NN	O	O
the	NN	O	O
application	NN	O	O
of	NN	O	O
pilocarpine	NN	O	B-Chemical
(	NN	O	O
20	NN	O	O
microL	NN	O	O
,	NN	O	O
0.1%	NN	O	O
)	NN	O	O
to	NN	O	O
one	NN	O	O
eye	NN	O	O
and	NN	O	O
placebo	NN	O	O
to	NN	O	O
the	NN	O	O
other	NN	O	O
.	NN	O	O

All	NN	O	O
eye	NN	O	O
drops	NN	O	O
were	NN	O	O
given	NN	O	O
in	NN	O	O
a	NN	O	O
randomized	NN	O	O
order	NN	O	O
.	NN	O	O

In	NN	O	O
2	NN	O	O
separate	NN	O	O
sessions	NN	O	O
,	NN	O	O
a	NN	O	O
single	NN	O	O
dose	NN	O	O
of	NN	O	O
scopolamine	NN	O	B-Chemical
(	NN	O	O
0.5	NN	O	O
mg	NN	O	O
,	NN	O	O
intravenously	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	O
was	NN	O	O
administered	NN	O	O
,	NN	O	O
and	NN	O	O
the	NN	O	O
effects	NN	O	O
on	NN	O	O
word	NN	O	O
recall	NN	O	O
were	NN	O	O
measured	NN	O	O
using	NN	O	O
the	NN	O	O
Buschke	NN	O	O
Selective	NN	O	O
Reminding	NN	O	O
Test	NN	O	O
over	NN	O	O
2	NN	O	O
hours	NN	O	O
.	NN	O	O

OUTCOME	NN	O	O
MEASURES	NN	O	O
:	NN	O	O
Pupil	NN	O	O
size	NN	O	O
at	NN	O	O
time	NN	O	O
points	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
tropicamide	NN	O	B-Chemical
and	NN	O	O
pilocarpine	NN	O	B-Chemical
;	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
impairment	NN	O	B-Disease
in	NN	O	I-Disease
word	NN	O	I-Disease
recall	NN	O	I-Disease
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
There	NN	O	O
was	NN	O	O
no	NN	O	O
significant	NN	O	O
difference	NN	O	O
between	NN	O	O
elderly	NN	O	O
and	NN	O	O
young	NN	O	O
volunteers	NN	O	O
in	NN	O	O
pupillary	NN	O	O
response	NN	O	O
to	NN	O	O
tropicamide	NN	O	B-Chemical
at	NN	O	O
any	NN	O	O
time	NN	O	O
point	NN	O	O
(	NN	O	O
p	NN	O	O
>	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

The	NN	O	O
elderly	NN	O	O
group	NN	O	O
had	NN	O	O
a	NN	O	O
significantly	NN	O	O
greater	NN	O	O
pilocarpine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
net	NN	O	O
decrease	NN	O	O
in	NN	O	O
pupil	NN	O	O
size	NN	O	O
85	NN	O	O
,	NN	O	O
125	NN	O	O
,	NN	O	O
165	NN	O	O
and	NN	O	O
215	NN	O	O
minutes	NN	O	O
after	NN	O	O
administration	NN	O	O
,	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
young	NN	O	O
group	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Compared	NN	O	O
with	NN	O	O
the	NN	O	O
young	NN	O	O
group	NN	O	O
,	NN	O	O
the	NN	O	O
elderly	NN	O	O
group	NN	O	O
had	NN	O	O
greater	NN	O	O
scopolamine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
impairment	NN	O	B-Disease
in	NN	O	I-Disease
word	NN	O	I-Disease
recall	NN	O	I-Disease
60	NN	O	O
,	NN	O	O
90	NN	O	O
and	NN	O	O
120	NN	O	O
minutes	NN	O	O
after	NN	O	O
administration	NN	O	O
(	NN	O	O
p	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
There	NN	O	O
is	NN	O	O
an	NN	O	O
age	NN	O	O
-	NN	O	O
related	NN	O	O
pupillary	NN	O	O
response	NN	O	O
to	NN	O	O
pilocarpine	NN	O	B-Chemical
that	NN	O	O
is	NN	O	O
not	NN	O	O
found	NN	O	O
with	NN	O	O
tropicamide	NN	O	B-Chemical
.	NN	O	O

Thus	NN	O	O
,	NN	O	O
pilocarpine	NN	O	B-Chemical
may	NN	O	O
be	NN	O	O
useful	NN	O	O
to	NN	O	O
assess	NN	O	O
variations	NN	O	O
in	NN	O	O
central	NN	O	O
cholinergic	NN	O	O
function	NN	O	O
in	NN	O	O
elderly	NN	O	O
patients	NN	O	O
.	NN	O	O


-DOCSTART- (10692744)

Acetazolamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
Gerstmann	NN	O	B-Disease
syndrome	NN	O	I-Disease
.	NN	O	O

Acute	NN	O	O
confusion	NN	O	B-Disease
induced	NN	O	O
by	NN	O	O
acetazolamide	NN	O	B-Chemical
is	NN	O	O
a	NN	O	O
well	NN	O	O
known	NN	O	O
adverse	NN	O	O
drug	NN	O	O
reaction	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
renal	NN	O	B-Disease
impairment	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
case	NN	O	O
of	NN	O	O
acetazolamide	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
Gerstmann	NN	O	B-Disease
syndrome	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
patient	NN	O	O
with	NN	O	O
normal	NN	O	O
renal	NN	O	O
function	NN	O	O
,	NN	O	O
to	NN	O	O
highlight	NN	O	O
predisposing	NN	O	O
factors	NN	O	O
that	NN	O	O
are	NN	O	O
frequently	NN	O	O
overlooked	NN	O	O
.	NN	O	O


-DOCSTART- (10565806)

Hypomania	NN	O	B-Disease
-	NN	O	O
like	NN	O	O
syndrome	NN	O	O
induced	NN	O	O
by	NN	O	O
olanzapine	NN	O	B-Chemical
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
female	NN	O	O
patient	NN	O	O
with	NN	O	O
a	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
a	NN	O	O
not	NN	O	O
otherwise	NN	O	O
specified	NN	O	O
psychotic	NN	O	B-Disease
disorder	NN	O	I-Disease
(	NN	O	O
DSM	NN	O	O
-	NN	O	O
IV	NN	O	O
)	NN	O	O
who	NN	O	O
developed	NN	O	O
hypomania	NN	O	B-Disease
shortly	NN	O	O
after	NN	O	O
the	NN	O	O
introduction	NN	O	O
of	NN	O	O
olanzapine	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O


-DOCSTART- (9061311)

Neutrophil	NN	O	O
superoxide	NN	O	B-Chemical
and	NN	O	O
hydrogen	NN	O	B-Chemical
peroxide	NN	O	I-Chemical
production	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
.	NN	O	O

Defects	NN	O	O
in	NN	O	O
superoxide	NN	O	B-Chemical
and	NN	O	O
hydrogen	NN	O	B-Chemical
peroxide	NN	O	I-Chemical
production	NN	O	O
may	NN	O	O
be	NN	O	O
implicated	NN	O	O
in	NN	O	O
the	NN	O	O
high	NN	O	O
incidence	NN	O	O
of	NN	O	O
bacterial	NN	O	B-Disease
infections	NN	O	I-Disease
in	NN	O	O
patients	NN	O	O
with	NN	O	O
acute	NN	O	B-Disease
liver	NN	O	I-Disease
failure	NN	O	I-Disease
(	NN	O	O
ALF	NN	O	B-Disease
)	NN	O	O
.	NN	O	O

In	NN	O	O
the	NN	O	O
present	NN	O	O
study	NN	O	O
,	NN	O	O
oxygen	NN	O	B-Chemical
radical	NN	O	O
production	NN	O	O
in	NN	O	O
patients	NN	O	O
with	NN	O	O
ALF	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
paracetamol	NN	O	B-Chemical
overdose	NN	O	B-Disease
was	NN	O	O
compared	NN	O	O
with	NN	O	O
that	NN	O	O
of	NN	O	O
healthy	NN	O	O
volunteers	NN	O	O
.	NN	O	O

Neutrophils	NN	O	O
from	NN	O	O
14	NN	O	O
ALF	NN	O	B-Disease
patients	NN	O	O
were	NN	O	O
stimulated	NN	O	O
via	NN	O	O
the	NN	O	O
complement	NN	O	O
receptors	NN	O	O
using	NN	O	O
zymosan	NN	O	O
opsonized	NN	O	O
with	NN	O	O
ALF	NN	O	B-Disease
or	NN	O	O
control	NN	O	O
serum	NN	O	O
.	NN	O	O

Superoxide	NN	O	B-Chemical
and	NN	O	O
hydrogen	NN	O	B-Chemical
peroxide	NN	O	I-Chemical
production	NN	O	O
by	NN	O	O
ALF	NN	O	B-Disease
neutrophils	NN	O	O
stimulated	NN	O	O
with	NN	O	O
zymosan	NN	O	O
opsonized	NN	O	O
with	NN	O	O
ALF	NN	O	B-Disease
serum	NN	O	O
was	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
compared	NN	O	O
with	NN	O	O
the	NN	O	O
control	NN	O	O
subjects	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.01	NN	O	O
)	NN	O	O
.	NN	O	O

This	NN	O	O
defect	NN	O	O
persisted	NN	O	O
when	NN	O	O
zymosan	NN	O	O
opsonized	NN	O	O
by	NN	O	O
control	NN	O	O
serum	NN	O	O
was	NN	O	O
used	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.05	NN	O	O
)	NN	O	O
.	NN	O	O

Superoxide	NN	O	B-Chemical
and	NN	O	O
hydrogen	NN	O	B-Chemical
peroxide	NN	O	I-Chemical
production	NN	O	O
in	NN	O	O
neutrophils	NN	O	O
stimulated	NN	O	O
with	NN	O	O
formyl	NN	O	B-Chemical
-	NN	O	I-Chemical
methionyl	NN	O	I-Chemical
-	NN	O	I-Chemical
leucyl	NN	O	I-Chemical
-	NN	O	I-Chemical
phenylalanine	NN	O	I-Chemical
(	NN	O	O
fMLP	NN	O	B-Chemical
)	NN	O	O
from	NN	O	O
a	NN	O	O
further	NN	O	O
18	NN	O	O
ALF	NN	O	B-Disease
patients	NN	O	O
was	NN	O	O
unaffected	NN	O	O
compared	NN	O	O
with	NN	O	O
control	NN	O	O
neutrophils	NN	O	O
.	NN	O	O

Serum	NN	O	O
C3	NN	O	O
complement	NN	O	O
levels	NN	O	O
were	NN	O	O
significantly	NN	O	O
reduced	NN	O	O
in	NN	O	O
ALF	NN	O	B-Disease
patients	NN	O	O
compared	NN	O	O
with	NN	O	O
control	NN	O	O
subjects	NN	O	O
(	NN	O	O
P	NN	O	O
<	NN	O	O
0.0005	NN	O	O
)	NN	O	O
.	NN	O	O

These	NN	O	O
results	NN	O	O
demonstrate	NN	O	O
a	NN	O	O
neutrophil	NN	O	O
defect	NN	O	O
in	NN	O	O
ALF	NN	O	B-Disease
due	NN	O	O
to	NN	O	O
paracetamol	NN	O	B-Chemical
overdose	NN	O	B-Disease
,	NN	O	O
that	NN	O	O
is	NN	O	O
complement	NN	O	O
dependent	NN	O	O
but	NN	O	O
independent	NN	O	O
of	NN	O	O
serum	NN	O	O
complement	NN	O	O
,	NN	O	O
possibly	NN	O	O
connected	NN	O	O
to	NN	O	O
the	NN	O	O
complement	NN	O	O
receptor	NN	O	O
.	NN	O	O


-DOCSTART- (8617710)

Absence	NN	O	O
of	NN	O	O
effect	NN	O	O
of	NN	O	O
sertraline	NN	O	B-Chemical
on	NN	O	O
time	NN	O	O
-	NN	O	O
based	NN	O	O
sensitization	NN	O	O
of	NN	O	O
cognitive	NN	O	B-Disease
impairment	NN	O	I-Disease
with	NN	O	O
haloperidol	NN	O	B-Chemical
.	NN	O	O

This	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
,	NN	O	O
randomized	NN	O	O
,	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
study	NN	O	O
evaluated	NN	O	O
the	NN	O	O
effects	NN	O	O
of	NN	O	O
haloperidol	NN	O	B-Chemical
alone	NN	O	O
and	NN	O	O
haloperidol	NN	O	B-Chemical
plus	NN	O	O
sertraline	NN	O	B-Chemical
on	NN	O	O
cognitive	NN	O	O
and	NN	O	O
psychomotor	NN	O	O
function	NN	O	O
in	NN	O	O
24	NN	O	O
healthy	NN	O	O
male	NN	O	O
subjects	NN	O	O
.	NN	O	O

METHOD	NN	O	O
:	NN	O	O
All	NN	O	O
subjects	NN	O	O
received	NN	O	O
placebo	NN	O	O
on	NN	O	O
Day	NN	O	O
1	NN	O	O
and	NN	O	O
haloperidol	NN	O	B-Chemical
2	NN	O	O
mg	NN	O	O
on	NN	O	O
Days	NN	O	O
2	NN	O	O
and	NN	O	O
25	NN	O	O
.	NN	O	O

From	NN	O	O
Days	NN	O	O
9	NN	O	O
to	NN	O	O
25	NN	O	O
,	NN	O	O
subjects	NN	O	O
were	NN	O	O
randomly	NN	O	O
assigned	NN	O	O
to	NN	O	O
either	NN	O	O
sertraline	NN	O	B-Chemical
(	NN	O	O
12	NN	O	O
subjects	NN	O	O
)	NN	O	O
or	NN	O	O
placebo	NN	O	O
(	NN	O	O
12	NN	O	O
subjects	NN	O	O
)	NN	O	O
;	NN	O	O
the	NN	O	O
sertraline	NN	O	B-Chemical
dose	NN	O	O
was	NN	O	O
titrated	NN	O	O
from	NN	O	O
50	NN	O	O
to	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
from	NN	O	O
Days	NN	O	O
9	NN	O	O
to	NN	O	O
16	NN	O	O
,	NN	O	O
and	NN	O	O
remained	NN	O	O
at	NN	O	O
200	NN	O	O
mg	NN	O	O
/	NN	O	O
day	NN	O	O
for	NN	O	O
the	NN	O	O
final	NN	O	O
10	NN	O	O
days	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
administration	NN	O	O
period	NN	O	O
.	NN	O	O

Cognitive	NN	O	O
function	NN	O	O
testing	NN	O	O
was	NN	O	O
performed	NN	O	O
before	NN	O	O
dosing	NN	O	O
and	NN	O	O
over	NN	O	O
a	NN	O	O
24	NN	O	O
-	NN	O	O
hour	NN	O	O
period	NN	O	O
after	NN	O	O
dosing	NN	O	O
on	NN	O	O
Days	NN	O	O
1	NN	O	O
,	NN	O	O
2	NN	O	O
,	NN	O	O
and	NN	O	O
25	NN	O	O
.	NN	O	O

RESULTS	NN	O	O
:	NN	O	O
Impairment	NN	O	B-Disease
of	NN	O	I-Disease
cognitive	NN	O	I-Disease
function	NN	O	I-Disease
was	NN	O	O
observed	NN	O	O
6	NN	O	O
to	NN	O	O
8	NN	O	O
hours	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
haloperidol	NN	O	B-Chemical
on	NN	O	O
Day	NN	O	O
2	NN	O	O
but	NN	O	O
was	NN	O	O
not	NN	O	O
evident	NN	O	O
23	NN	O	O
hours	NN	O	O
after	NN	O	O
dosing	NN	O	O
.	NN	O	O

When	NN	O	O
single	NN	O	O
-	NN	O	O
dose	NN	O	O
haloperidol	NN	O	B-Chemical
was	NN	O	O
given	NN	O	O
again	NN	O	O
25	NN	O	O
days	NN	O	O
later	NN	O	O
,	NN	O	O
greater	NN	O	O
impairment	NN	O	O
with	NN	O	O
earlier	NN	O	O
onset	NN	O	O
was	NN	O	O
noted	NN	O	O
in	NN	O	O
several	NN	O	O
tests	NN	O	O
in	NN	O	O
both	NN	O	O
treatment	NN	O	O
groups	NN	O	O
,	NN	O	O
suggesting	NN	O	O
enhancement	NN	O	O
of	NN	O	O
this	NN	O	O
effect	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
indication	NN	O	O
that	NN	O	O
sertraline	NN	O	B-Chemical
exacerbated	NN	O	O
the	NN	O	O
impairment	NN	O	O
produced	NN	O	O
by	NN	O	O
haloperidol	NN	O	B-Chemical
since	NN	O	O
an	NN	O	O
equivalent	NN	O	O
effect	NN	O	O
also	NN	O	O
occurred	NN	O	O
in	NN	O	O
the	NN	O	O
placebo	NN	O	O
group	NN	O	O
.	NN	O	O

Three	NN	O	O
subjects	NN	O	O
(	NN	O	O
2	NN	O	O
on	NN	O	O
sertraline	NN	O	B-Chemical
and	NN	O	O
1	NN	O	O
on	NN	O	O
placebo	NN	O	O
)	NN	O	O
withdrew	NN	O	O
from	NN	O	O
the	NN	O	O
study	NN	O	O
because	NN	O	O
of	NN	O	O
side	NN	O	O
effects	NN	O	O
.	NN	O	O

Ten	NN	O	O
subjects	NN	O	O
in	NN	O	O
each	NN	O	O
group	NN	O	O
reported	NN	O	O
side	NN	O	O
effects	NN	O	O
related	NN	O	O
to	NN	O	O
treatment	NN	O	O
.	NN	O	O

The	NN	O	O
side	NN	O	O
effect	NN	O	O
profiles	NN	O	O
of	NN	O	O
sertraline	NN	O	B-Chemical
and	NN	O	O
of	NN	O	O
placebo	NN	O	O
were	NN	O	O
similar	NN	O	O
.	NN	O	O

CONCLUSION	NN	O	O
:	NN	O	O
Haloperidol	NN	O	B-Chemical
produced	NN	O	O
a	NN	O	O
clear	NN	O	O
profile	NN	O	O
of	NN	O	O
cognitive	NN	O	B-Disease
impairment	NN	O	I-Disease
that	NN	O	O
was	NN	O	O
not	NN	O	O
worsened	NN	O	O
by	NN	O	O
concomitant	NN	O	O
sertraline	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O


-DOCSTART- (8494478)

Ciprofloxacin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
nephrotoxicity	NN	O	B-Disease
in	NN	O	O
patients	NN	O	O
with	NN	O	O
cancer	NN	O	B-Disease
.	NN	O	O

Nephrotoxicity	NN	O	B-Disease
associated	NN	O	O
with	NN	O	O
ciprofloxacin	NN	O	B-Chemical
is	NN	O	O
uncommon	NN	O	O
.	NN	O	O

Five	NN	O	O
patients	NN	O	O
with	NN	O	O
cancer	NN	O	B-Disease
who	NN	O	O
developed	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
that	NN	O	O
followed	NN	O	O
treatment	NN	O	O
with	NN	O	O
ciprofloxacin	NN	O	B-Chemical
are	NN	O	O
described	NN	O	O
and	NN	O	O
an	NN	O	O
additional	NN	O	O
15	NN	O	O
cases	NN	O	O
reported	NN	O	O
in	NN	O	O
the	NN	O	O
literature	NN	O	O
are	NN	O	O
reviewed	NN	O	O
.	NN	O	O

Other	NN	O	O
than	NN	O	O
elevation	NN	O	O
of	NN	O	O
serum	NN	O	O
creatinine	NN	O	B-Chemical
levels	NN	O	O
,	NN	O	O
characteristic	NN	O	O
clinical	NN	O	O
manifestations	NN	O	O
and	NN	O	O
abnormal	NN	O	O
laboratory	NN	O	O
findings	NN	O	O
are	NN	O	O
not	NN	O	O
frequently	NN	O	O
present	NN	O	O
.	NN	O	O

Allergic	NN	O	O
interstitial	NN	O	B-Disease
nephritis	NN	O	I-Disease
is	NN	O	O
believed	NN	O	O
to	NN	O	O
be	NN	O	O
the	NN	O	O
underlying	NN	O	O
pathological	NN	O	O
-	NN	O	O
process	NN	O	O
.	NN	O	O

Definitive	NN	O	O
diagnosis	NN	O	O
requires	NN	O	O
performance	NN	O	O
of	NN	O	O
renal	NN	O	O
biopsy	NN	O	O
,	NN	O	O
although	NN	O	O
this	NN	O	O
is	NN	O	O
not	NN	O	O
always	NN	O	O
feasible	NN	O	O
.	NN	O	O

An	NN	O	O
improvement	NN	O	O
in	NN	O	O
renal	NN	O	O
function	NN	O	O
that	NN	O	O
followed	NN	O	O
the	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
offending	NN	O	O
antibiotic	NN	O	O
supports	NN	O	O
the	NN	O	O
presumptive	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
ciprofloxacin	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
.	NN	O	O


-DOCSTART- (8475949)

Case	NN	O	O
report	NN	O	O
:	NN	O	O
pentamidine	NN	O	B-Chemical
and	NN	O	O
polymorphic	NN	O	O
ventricular	NN	O	B-Disease
tachycardia	NN	O	I-Disease
revisited	NN	O	O
.	NN	O	O

Pentamidine	NN	O	B-Chemical
isethionate	NN	O	I-Chemical
has	NN	O	O
been	NN	O	O
associated	NN	O	O
with	NN	O	O
ventricular	NN	O	B-Disease
tachyarrhythmias	NN	O	I-Disease
,	NN	O	O
including	NN	O	O
torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
.	NN	O	O

This	NN	O	O
article	NN	O	O
reports	NN	O	O
two	NN	O	O
cases	NN	O	O
of	NN	O	O
this	NN	O	O
complication	NN	O	O
and	NN	O	O
reviews	NN	O	O
all	NN	O	O
reported	NN	O	O
cases	NN	O	O
to	NN	O	O
date	NN	O	O
.	NN	O	O

Pentamidine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
may	NN	O	O
be	NN	O	O
related	NN	O	O
to	NN	O	O
serum	NN	O	O
magnesium	NN	O	B-Chemical
levels	NN	O	O
and	NN	O	O
hypomagnesemia	NN	O	B-Disease
may	NN	O	O
synergistically	NN	O	O
induce	NN	O	O
torsade	NN	O	O
.	NN	O	O

Torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
occurred	NN	O	O
after	NN	O	O
an	NN	O	O
average	NN	O	O
of	NN	O	O
10	NN	O	O
days	NN	O	O
of	NN	O	O
treatment	NN	O	O
with	NN	O	O
pentamidine	NN	O	B-Chemical
.	NN	O	O

In	NN	O	O
these	NN	O	O
patients	NN	O	O
,	NN	O	O
no	NN	O	O
other	NN	O	O
acute	NN	O	O
side	NN	O	O
effects	NN	O	O
of	NN	O	O
pentamidine	NN	O	B-Chemical
were	NN	O	O
observed	NN	O	O
.	NN	O	O

Torsade	NN	O	B-Disease
de	NN	O	I-Disease
pointes	NN	O	I-Disease
can	NN	O	O
be	NN	O	O
treated	NN	O	O
when	NN	O	O
recognized	NN	O	O
early	NN	O	O
,	NN	O	O
possibly	NN	O	O
without	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
pentamidine	NN	O	B-Chemical
.	NN	O	O

When	NN	O	O
QTc	NN	O	B-Disease
interval	NN	O	I-Disease
prolongation	NN	O	I-Disease
is	NN	O	O
observed	NN	O	O
,	NN	O	O
early	NN	O	O
magnesium	NN	O	B-Chemical
supplementation	NN	O	O
is	NN	O	O
advocated	NN	O	O
.	NN	O	O


-DOCSTART- (7710775)

Time	NN	O	O
dependence	NN	O	O
of	NN	O	O
plasma	NN	O	O
malondialdehyde	NN	O	B-Chemical
,	NN	O	O
oxypurines	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
nucleosides	NN	O	B-Chemical
during	NN	O	O
incomplete	NN	O	O
cerebral	NN	O	B-Disease
ischemia	NN	O	I-Disease
in	NN	O	O
the	NN	O	O
rat	NN	O	O
.	NN	O	O

Incomplete	NN	O	O
cerebral	NN	O	B-Disease
ischemia	NN	O	I-Disease
(	NN	O	O
30	NN	O	O
min	NN	O	O
)	NN	O	O
was	NN	O	O
induced	NN	O	O
in	NN	O	O
the	NN	O	O
rat	NN	O	O
by	NN	O	O
bilaterally	NN	O	O
clamping	NN	O	O
the	NN	O	O
common	NN	O	O
carotid	NN	O	O
arteries	NN	O	O
.	NN	O	O

Peripheral	NN	O	O
venous	NN	O	O
blood	NN	O	O
samples	NN	O	O
were	NN	O	O
withdrawn	NN	O	O
from	NN	O	O
the	NN	O	O
femoral	NN	O	O
vein	NN	O	O
four	NN	O	O
times	NN	O	O
(	NN	O	O
once	NN	O	O
every	NN	O	O
5	NN	O	O
min	NN	O	O
)	NN	O	O
before	NN	O	O
ischemia	NN	O	B-Disease
(	NN	O	O
0	NN	O	O
time	NN	O	O
)	NN	O	O
and	NN	O	O
5	NN	O	O
,	NN	O	O
15	NN	O	O
,	NN	O	O
and	NN	O	O
30	NN	O	O
min	NN	O	O
after	NN	O	O
ischemia	NN	O	B-Disease
.	NN	O	O

Plasma	NN	O	O
extracts	NN	O	O
were	NN	O	O
analyzed	NN	O	O
by	NN	O	O
a	NN	O	O
highly	NN	O	O
sensitive	NN	O	O
high	NN	O	O
-	NN	O	O
performance	NN	O	O
liquid	NN	O	O
chromatographic	NN	O	O
method	NN	O	O
for	NN	O	O
the	NN	O	O
direct	NN	O	O
determination	NN	O	O
of	NN	O	O
malondialdehyde	NN	O	B-Chemical
,	NN	O	O
oxypurines	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
nucleosides	NN	O	B-Chemical
.	NN	O	O

During	NN	O	O
ischemia	NN	O	B-Disease
,	NN	O	O
a	NN	O	O
time	NN	O	O
-	NN	O	O
dependent	NN	O	O
increase	NN	O	O
of	NN	O	O
plasma	NN	O	O
oxypurines	NN	O	B-Chemical
and	NN	O	O
nucleosides	NN	O	B-Chemical
was	NN	O	O
observed	NN	O	O
.	NN	O	O

Plasma	NN	O	O
malondialdehyde	NN	O	B-Chemical
,	NN	O	O
which	NN	O	O
was	NN	O	O
present	NN	O	O
in	NN	O	O
minimal	NN	O	O
amount	NN	O	O
at	NN	O	O
zero	NN	O	O
time	NN	O	O
(	NN	O	O
0.058	NN	O	O
mumol	NN	O	O
/	NN	O	O
liter	NN	O	O
plasma	NN	O	O
;	NN	O	O
SD	NN	O	O
0.015	NN	O	O
)	NN	O	O
,	NN	O	O
increased	NN	O	O
after	NN	O	O
5	NN	O	O
min	NN	O	O
of	NN	O	O
ischemia	NN	O	B-Disease
,	NN	O	O
resulting	NN	O	O
in	NN	O	O
a	NN	O	O
fivefold	NN	O	O
increase	NN	O	O
after	NN	O	O
30	NN	O	O
min	NN	O	O
of	NN	O	O
carotid	NN	O	O
occlusion	NN	O	O
(	NN	O	O
0.298	NN	O	O
mumol	NN	O	O
/	NN	O	O
liter	NN	O	O
plasma	NN	O	O
;	NN	O	O
SD	NN	O	O
0.078	NN	O	O
)	NN	O	O
.	NN	O	O

Increased	NN	O	O
plasma	NN	O	O
malondialdehyde	NN	O	B-Chemical
was	NN	O	O
also	NN	O	O
recorded	NN	O	O
in	NN	O	O
two	NN	O	O
other	NN	O	O
groups	NN	O	O
of	NN	O	O
animals	NN	O	O
subjected	NN	O	O
to	NN	O	O
the	NN	O	O
same	NN	O	O
experimental	NN	O	O
model	NN	O	O
,	NN	O	O
one	NN	O	O
receiving	NN	O	O
20	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
b.w.	NN	O	O
of	NN	O	O
the	NN	O	O
cyclooxygenase	NN	O	O
inhibitor	NN	O	O
acetylsalicylate	NN	O	B-Chemical
intravenously	NN	O	O
immediately	NN	O	O
before	NN	O	O
ischemia	NN	O	B-Disease
,	NN	O	O
the	NN	O	O
other	NN	O	O
receiving	NN	O	O
650	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
b.w.	NN	O	O
of	NN	O	O
the	NN	O	O
hypotensive	NN	O	B-Disease
drug	NN	O	O
nitroprusside	NN	O	B-Chemical
at	NN	O	O
a	NN	O	O
flow	NN	O	O
rate	NN	O	O
of	NN	O	O
103	NN	O	O
microliters	NN	O	O
/	NN	O	O
min	NN	O	O
intravenously	NN	O	O
during	NN	O	O
ischemia	NN	O	B-Disease
,	NN	O	O
although	NN	O	O
in	NN	O	O
this	NN	O	O
latter	NN	O	O
group	NN	O	O
malondialdehyde	NN	O	B-Chemical
was	NN	O	O
significantly	NN	O	O
higher	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
data	NN	O	O
indicate	NN	O	O
that	NN	O	O
the	NN	O	O
determination	NN	O	O
of	NN	O	O
malondialdehyde	NN	O	B-Chemical
,	NN	O	O
oxypurines	NN	O	B-Chemical
,	NN	O	O
and	NN	O	O
nucleosides	NN	O	B-Chemical
in	NN	O	O
peripheral	NN	O	O
blood	NN	O	O
,	NN	O	O
may	NN	O	O
be	NN	O	O
used	NN	O	O
to	NN	O	O
monitor	NN	O	O
the	NN	O	O
metabolic	NN	O	O
alterations	NN	O	O
of	NN	O	O
tissues	NN	O	O
occurring	NN	O	O
during	NN	O	O
ischemic	NN	O	B-Disease
phenomena.	NN	O	O
(	NN	O	O
ABSTRACT	NN	O	O
TRUNCATED	NN	O	O
AT	NN	O	O
250	NN	O	O
WORDS	NN	O	O
)	NN	O	O

-DOCSTART- (7650771)

Cholinergic	NN	O	O
toxicity	NN	O	B-Disease
resulting	NN	O	O
from	NN	O	O
ocular	NN	O	O
instillation	NN	O	O
of	NN	O	O
echothiophate	NN	O	B-Chemical
iodide	NN	O	I-Chemical
eye	NN	O	O
drops	NN	O	O
.	NN	O	O

A	NN	O	O
patient	NN	O	O
developed	NN	O	O
a	NN	O	O
severe	NN	O	O
cholinergic	NN	O	O
syndrome	NN	O	O
from	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
echothiophate	NN	O	B-Chemical
iodide	NN	O	I-Chemical
ophthalmic	NN	O	O
drops	NN	O	O
,	NN	O	O
presented	NN	O	O
with	NN	O	O
profound	NN	O	O
muscle	NN	O	B-Disease
weakness	NN	O	I-Disease
and	NN	O	O
was	NN	O	O
initially	NN	O	O
given	NN	O	O
the	NN	O	O
diagnosis	NN	O	O
of	NN	O	O
myasthenia	NN	O	B-Disease
gravis	NN	O	I-Disease
.	NN	O	O

Red	NN	O	O
blood	NN	O	O
cell	NN	O	O
and	NN	O	O
serum	NN	O	O
cholinesterase	NN	O	O
levels	NN	O	O
were	NN	O	O
severely	NN	O	O
depressed	NN	O	O
and	NN	O	O
symptoms	NN	O	O
resolved	NN	O	O
spontaneously	NN	O	O
following	NN	O	O
discontinuation	NN	O	O
of	NN	O	O
the	NN	O	O
eye	NN	O	O
drops	NN	O	O
.	NN	O	O


-DOCSTART- (7565311)

Acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
in	NN	O	O
high	NN	O	O
dose	NN	O	O
carboplatin	NN	O	B-Chemical
chemotherapy	NN	O	O
.	NN	O	O

Carboplatin	NN	O	B-Chemical
has	NN	O	O
been	NN	O	O
reported	NN	O	O
to	NN	O	O
cause	NN	O	O
acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
when	NN	O	O
administered	NN	O	O
in	NN	O	O
high	NN	O	O
doses	NN	O	O
to	NN	O	O
adult	NN	O	O
patients	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
a	NN	O	O
4	NN	O	O
1	NN	O	O
/	NN	O	O
2	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
girl	NN	O	O
who	NN	O	O
was	NN	O	O
treated	NN	O	O
with	NN	O	O
high	NN	O	O
-	NN	O	O
dose	NN	O	O
carboplatin	NN	O	B-Chemical
for	NN	O	O
metastatic	NN	O	O
parameningeal	NN	O	O
embryonal	NN	O	B-Disease
rhabdomyosarcoma	NN	O	I-Disease
.	NN	O	O

Acute	NN	O	B-Disease
renal	NN	O	I-Disease
failure	NN	O	I-Disease
developed	NN	O	O
followed	NN	O	O
by	NN	O	O
a	NN	O	O
slow	NN	O	O
partial	NN	O	O
recovery	NN	O	O
of	NN	O	O
renal	NN	O	O
function	NN	O	O
.	NN	O	O

Possible	NN	O	O
contributing	NN	O	O
factors	NN	O	O
are	NN	O	O
discussed	NN	O	O
.	NN	O	O


-DOCSTART- (7421734)

Endometrial	NN	O	B-Disease
carcinoma	NN	O	I-Disease
after	NN	O	O
Hodgkin	NN	O	B-Disease
disease	NN	O	I-Disease
in	NN	O	O
childhood	NN	O	O
.	NN	O	O

A	NN	O	O
34	NN	O	O
-	NN	O	O
year	NN	O	O
-	NN	O	O
old	NN	O	O
patient	NN	O	O
developed	NN	O	O
metastic	NN	O	O
endometrial	NN	O	B-Disease
carcinoma	NN	O	I-Disease
after	NN	O	O
Hodgkin	NN	O	B-Disease
disease	NN	O	I-Disease
in	NN	O	O
childhood	NN	O	O
.	NN	O	O

She	NN	O	O
had	NN	O	O
ovarian	NN	O	B-Disease
failure	NN	O	I-Disease
after	NN	O	O
abdominal	NN	O	O
irradiation	NN	O	O
and	NN	O	O
chemotherapy	NN	O	O
for	NN	O	O
Hodgkin	NN	O	B-Disease
disease	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
received	NN	O	O
exogenous	NN	O	O
estrogens	NN	O	B-Chemical
,	NN	O	O
a	NN	O	O
treatment	NN	O	O
implicated	NN	O	O
in	NN	O	O
the	NN	O	O
development	NN	O	O
of	NN	O	O
endometrial	NN	O	B-Disease
cancer	NN	O	I-Disease
in	NN	O	O
menopausal	NN	O	O
women	NN	O	O
.	NN	O	O

Young	NN	O	O
women	NN	O	O
on	NN	O	O
replacement	NN	O	O
estrogens	NN	O	B-Chemical
for	NN	O	O
ovarian	NN	O	B-Disease
failure	NN	O	I-Disease
after	NN	O	O
cancer	NN	O	B-Disease
therapy	NN	O	O
may	NN	O	O
also	NN	O	O
have	NN	O	O
increased	NN	O	O
risk	NN	O	O
of	NN	O	O
endometrial	NN	O	B-Disease
carcinoma	NN	O	I-Disease
and	NN	O	O
should	NN	O	O
be	NN	O	O
examined	NN	O	O
periodically	NN	O	O
.	NN	O	O


-DOCSTART- (6732043)

Induction	NN	O	O
of	NN	O	O
the	NN	O	O
obstructive	NN	O	B-Disease
sleep	NN	O	I-Disease
apnea	NN	O	I-Disease
syndrome	NN	O	I-Disease
in	NN	O	O
a	NN	O	O
woman	NN	O	O
by	NN	O	O
exogenous	NN	O	O
androgen	NN	O	B-Chemical
administration	NN	O	O
.	NN	O	O

We	NN	O	O
documented	NN	O	O
airway	NN	O	O
occlusion	NN	O	O
during	NN	O	O
sleep	NN	O	O
and	NN	O	O
an	NN	O	O
abnormally	NN	O	O
high	NN	O	O
supraglottic	NN	O	O
resistance	NN	O	O
while	NN	O	O
awake	NN	O	O
in	NN	O	O
a	NN	O	O
54	NN	O	O
-	NN	O	O
yr	NN	O	O
-	NN	O	O
old	NN	O	O
woman	NN	O	O
who	NN	O	O
had	NN	O	O
developed	NN	O	O
physical	NN	O	O
changes	NN	O	O
and	NN	O	O
the	NN	O	O
syndrome	NN	O	B-Disease
of	NN	O	I-Disease
obstructive	NN	O	I-Disease
sleep	NN	O	I-Disease
apnea	NN	O	I-Disease
while	NN	O	O
being	NN	O	O
administered	NN	O	O
exogenous	NN	O	O
androgens	NN	O	B-Chemical
.	NN	O	O

When	NN	O	O
the	NN	O	O
androgens	NN	O	B-Chemical
were	NN	O	O
withdrawn	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
physical	NN	O	O
changes	NN	O	O
,	NN	O	O
symptoms	NN	O	O
,	NN	O	O
sleep	NN	O	O
study	NN	O	O
,	NN	O	O
and	NN	O	O
supraglottic	NN	O	O
resistance	NN	O	O
all	NN	O	O
returned	NN	O	O
to	NN	O	O
normal	NN	O	O
.	NN	O	O

A	NN	O	O
rechallenge	NN	O	O
with	NN	O	O
androgen	NN	O	B-Chemical
produced	NN	O	O
symptoms	NN	O	O
of	NN	O	O
obstructive	NN	O	B-Disease
sleep	NN	O	I-Disease
apnea	NN	O	I-Disease
that	NN	O	O
abated	NN	O	O
upon	NN	O	O
withdrawal	NN	O	O
of	NN	O	O
the	NN	O	O
hormone	NN	O	O
.	NN	O	O

Previous	NN	O	O
reports	NN	O	O
have	NN	O	O
favored	NN	O	O
a	NN	O	O
role	NN	O	O
of	NN	O	O
androgens	NN	O	B-Chemical
in	NN	O	O
the	NN	O	O
pathogenesis	NN	O	O
of	NN	O	O
sleep	NN	O	B-Disease
apnea	NN	O	I-Disease
.	NN	O	O

Our	NN	O	O
report	NN	O	O
provides	NN	O	O
direct	NN	O	O
evidence	NN	O	O
for	NN	O	O
this	NN	O	O
role	NN	O	O
.	NN	O	O

Structural	NN	O	O
and	NN	O	O
functional	NN	O	O
measurements	NN	O	O
indicate	NN	O	O
that	NN	O	O
androgens	NN	O	B-Chemical
exert	NN	O	O
a	NN	O	O
permissive	NN	O	O
or	NN	O	O
necessary	NN	O	O
action	NN	O	O
on	NN	O	O
the	NN	O	O
structural	NN	O	O
configuration	NN	O	O
of	NN	O	O
the	NN	O	O
oropharynx	NN	O	O
that	NN	O	O
predisposes	NN	O	O
to	NN	O	O
obstruction	NN	O	O
during	NN	O	O
sleep	NN	O	O
.	NN	O	O

Development	NN	O	O
of	NN	O	O
the	NN	O	O
obstructive	NN	O	B-Disease
sleep	NN	O	I-Disease
apnea	NN	O	I-Disease
syndrome	NN	O	I-Disease
must	NN	O	O
be	NN	O	O
considered	NN	O	O
a	NN	O	O
possible	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
androgen	NN	O	B-Chemical
therapy	NN	O	O
.	NN	O	O


-DOCSTART- (6454943)

Effect	NN	O	O
of	NN	O	O
captopril	NN	O	B-Chemical
on	NN	O	O
pre	NN	O	O
-	NN	O	O
existing	NN	O	O
and	NN	O	O
aminonucleoside	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
proteinuria	NN	O	B-Disease
in	NN	O	O
spontaneously	NN	O	O
hypertensive	NN	O	B-Disease
rats	NN	O	O
.	NN	O	O

Proteinuria	NN	O	B-Disease
is	NN	O	O
a	NN	O	O
side	NN	O	O
effect	NN	O	O
of	NN	O	O
captopril	NN	O	B-Chemical
treatment	NN	O	O
in	NN	O	O
hypertensive	NN	O	B-Disease
patients	NN	O	O
.	NN	O	O

The	NN	O	O
possibility	NN	O	O
of	NN	O	O
reproducing	NN	O	O
the	NN	O	O
same	NN	O	O
renal	NN	O	B-Disease
abnormality	NN	O	I-Disease
with	NN	O	O
captopril	NN	O	B-Chemical
was	NN	O	O
examined	NN	O	O
in	NN	O	O
SHR	NN	O	O
.	NN	O	O

Oral	NN	O	O
administration	NN	O	O
of	NN	O	O
captopril	NN	O	B-Chemical
at	NN	O	O
100	NN	O	O
mg	NN	O	O
/	NN	O	O
kg	NN	O	O
for	NN	O	O
14	NN	O	O
days	NN	O	O
failed	NN	O	O
to	NN	O	O
aggravate	NN	O	O
proteinuria	NN	O	B-Disease
pre	NN	O	O
-	NN	O	O
existing	NN	O	O
in	NN	O	O
SHR	NN	O	O
.	NN	O	O

Also	NN	O	O
,	NN	O	O
captopril	NN	O	B-Chemical
treatment	NN	O	O
failed	NN	O	O
to	NN	O	O
potentiate	NN	O	O
or	NN	O	O
facilitate	NN	O	O
development	NN	O	O
of	NN	O	O
massive	NN	O	O
proteinuria	NN	O	B-Disease
invoked	NN	O	O
by	NN	O	O
puromycin	NN	O	B-Chemical
aminonucleoside	NN	O	I-Chemical
in	NN	O	O
SHR	NN	O	O
.	NN	O	O

Captopril	NN	O	B-Chemical
had	NN	O	O
little	NN	O	O
or	NN	O	O
no	NN	O	O
demonstrable	NN	O	O
effects	NN	O	O
on	NN	O	O
serum	NN	O	O
electrolyte	NN	O	O
concentrations	NN	O	O
,	NN	O	O
excretion	NN	O	O
of	NN	O	O
urine	NN	O	O
,	NN	O	O
sodium	NN	O	B-Chemical
and	NN	O	O
potassium	NN	O	B-Chemical
,	NN	O	O
endogenous	NN	O	O
creatinine	NN	O	B-Chemical
clearance	NN	O	O
,	NN	O	O
body	NN	O	O
weight	NN	O	O
,	NN	O	O
and	NN	O	O
food	NN	O	O
and	NN	O	O
water	NN	O	O
consumption	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
ketone	NN	O	B-Chemical
bodies	NN	O	O
were	NN	O	O
consistently	NN	O	O
present	NN	O	O
in	NN	O	O
urine	NN	O	O
and	NN	O	O
several	NN	O	O
lethalities	NN	O	O
occurred	NN	O	O
during	NN	O	O
multiple	NN	O	O
dosing	NN	O	O
of	NN	O	O
captopril	NN	O	B-Chemical
in	NN	O	O
SHR	NN	O	O
.	NN	O	O


-DOCSTART- (6153967)

Epileptogenic	NN	O	O
properties	NN	O	O
of	NN	O	O
enflurane	NN	O	B-Chemical
and	NN	O	O
their	NN	O	O
clinical	NN	O	O
interpretation	NN	O	O
.	NN	O	O

Three	NN	O	O
cases	NN	O	O
of	NN	O	O
EEG	NN	O	O
changes	NN	O	O
induced	NN	O	O
by	NN	O	O
single	NN	O	O
exposure	NN	O	O
to	NN	O	O
enflurane	NN	O	B-Chemical
anesthesia	NN	O	O
are	NN	O	O
reported	NN	O	O
.	NN	O	O

In	NN	O	O
one	NN	O	O
patient	NN	O	O
,	NN	O	O
enflurane	NN	O	B-Chemical
administered	NN	O	O
during	NN	O	O
a	NN	O	O
donor	NN	O	O
nephrectomy	NN	O	O
resulted	NN	O	O
in	NN	O	O
unexpected	NN	O	O
partial	NN	O	O
motor	NN	O	O
seizures	NN	O	B-Disease
.	NN	O	O

Until	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
the	NN	O	O
seizures	NN	O	B-Disease
was	NN	O	O
correctly	NN	O	O
identified	NN	O	O
,	NN	O	O
the	NN	O	O
patient	NN	O	O
was	NN	O	O
inappropriately	NN	O	O
treated	NN	O	O
with	NN	O	O
anticonvulsants	NN	O	O
.	NN	O	O

Two	NN	O	O
other	NN	O	O
patients	NN	O	O
suffered	NN	O	O
from	NN	O	O
partial	NN	O	O
,	NN	O	O
complex	NN	O	O
and	NN	O	O
generalized	NN	O	O
seizures	NN	O	B-Disease
uncontrolled	NN	O	O
by	NN	O	O
medication	NN	O	O
.	NN	O	O

Epileptic	NN	O	B-Disease
foci	NN	O	O
delineated	NN	O	O
and	NN	O	O
activated	NN	O	O
by	NN	O	O
enflurane	NN	O	B-Chemical
were	NN	O	O
surgically	NN	O	O
ablated	NN	O	O
and	NN	O	O
the	NN	O	O
patients	NN	O	O
are	NN	O	O
now	NN	O	O
seizure	NN	O	B-Disease
-	NN	O	O
free	NN	O	O
.	NN	O	O

Previous	NN	O	O
exposures	NN	O	O
to	NN	O	O
enflurane	NN	O	B-Chemical
have	NN	O	O
to	NN	O	O
be	NN	O	O
disclosed	NN	O	O
to	NN	O	O
avoid	NN	O	O
mistakes	NN	O	O
in	NN	O	O
clinical	NN	O	O
interpretation	NN	O	O
of	NN	O	O
the	NN	O	O
EEG	NN	O	O
.	NN	O	O

On	NN	O	O
the	NN	O	O
other	NN	O	O
hand	NN	O	O
,	NN	O	O
enflurane	NN	O	B-Chemical
may	NN	O	O
prove	NN	O	O
to	NN	O	O
be	NN	O	O
a	NN	O	O
safe	NN	O	O
fast	NN	O	O
acting	NN	O	O
activator	NN	O	O
of	NN	O	O
epileptic	NN	O	B-Disease
foci	NN	O	O
during	NN	O	O
corticography	NN	O	O
or	NN	O	O
depth	NN	O	O
electrode	NN	O	O
intraoperative	NN	O	O
recordings	NN	O	O
.	NN	O	O


-DOCSTART- (3183120)

Reversible	NN	O	O
cerebral	NN	O	B-Disease
lesions	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
tiazofurin	NN	O	B-Chemical
usage	NN	O	O
:	NN	O	O
MR	NN	O	O
demonstration	NN	O	O
.	NN	O	O

Tiazofurin	NN	O	B-Chemical
is	NN	O	O
an	NN	O	O
experimental	NN	O	O
chemotherapeutic	NN	O	O
agent	NN	O	O
currently	NN	O	O
undergoing	NN	O	O
clinical	NN	O	O
evaluation	NN	O	O
.	NN	O	O

We	NN	O	O
report	NN	O	O
our	NN	O	O
results	NN	O	O
with	NN	O	O
magnetic	NN	O	O
resonance	NN	O	O
(	NN	O	O
MR	NN	O	O
)	NN	O	O
in	NN	O	O
demonstrating	NN	O	O
reversible	NN	O	O
cerebral	NN	O	B-Disease
abnormalities	NN	O	I-Disease
concurrent	NN	O	O
with	NN	O	O
the	NN	O	O
use	NN	O	O
of	NN	O	O
this	NN	O	O
drug	NN	O	O
.	NN	O	O

The	NN	O	O
abnormalities	NN	O	O
on	NN	O	O
MR	NN	O	O
were	NN	O	O
correlated	NN	O	O
with	NN	O	O
findings	NN	O	O
on	NN	O	O
CT	NN	O	O
as	NN	O	O
well	NN	O	O
as	NN	O	O
with	NN	O	O
cerebral	NN	O	O
angiography	NN	O	O
.	NN	O	O

The	NN	O	O
utility	NN	O	O
of	NN	O	O
MR	NN	O	O
in	NN	O	O
the	NN	O	O
evaluation	NN	O	O
of	NN	O	O
patients	NN	O	O
receiving	NN	O	O
this	NN	O	O
new	NN	O	O
agent	NN	O	O
is	NN	O	O
illustrated	NN	O	O
.	NN	O	O


-DOCSTART- (3120485)

Antagonism	NN	O	O
of	NN	O	O
diazepam	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
sedative	NN	O	O
effects	NN	O	O
by	NN	O	O
Ro15	NN	O	B-Chemical
-	NN	O	I-Chemical
1788	NN	O	I-Chemical
in	NN	O	O
patients	NN	O	O
after	NN	O	O
surgery	NN	O	O
under	NN	O	O
lumbar	NN	O	O
epidural	NN	O	O
block	NN	O	O
.	NN	O	O

A	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
investigation	NN	O	O
of	NN	O	O
efficacy	NN	O	O
and	NN	O	O
safety	NN	O	O
.	NN	O	O

The	NN	O	O
aim	NN	O	O
of	NN	O	O
this	NN	O	O
study	NN	O	O
was	NN	O	O
to	NN	O	O
assess	NN	O	O
the	NN	O	O
efficacy	NN	O	O
of	NN	O	O
Ro15	NN	O	B-Chemical
-	NN	O	I-Chemical
1788	NN	O	I-Chemical
and	NN	O	O
a	NN	O	O
placebo	NN	O	O
in	NN	O	O
reversing	NN	O	O
diazepam	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
effects	NN	O	O
after	NN	O	O
surgery	NN	O	O
under	NN	O	O
epidural	NN	O	O
block	NN	O	O
,	NN	O	O
and	NN	O	O
to	NN	O	O
evaluate	NN	O	O
the	NN	O	O
local	NN	O	O
tolerance	NN	O	O
and	NN	O	O
general	NN	O	O
safety	NN	O	O
of	NN	O	O
Ro15	NN	O	B-Chemical
-	NN	O	I-Chemical
1788	NN	O	I-Chemical
.	NN	O	O

Fifty	NN	O	O
-	NN	O	O
seven	NN	O	O
patients	NN	O	O
were	NN	O	O
sedated	NN	O	O
with	NN	O	O
diazepam	NN	O	B-Chemical
for	NN	O	O
surgery	NN	O	O
under	NN	O	O
epidural	NN	O	O
anaesthesia	NN	O	O
.	NN	O	O

Antagonism	NN	O	O
of	NN	O	O
diazepam	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
effects	NN	O	O
by	NN	O	O
Ro15	NN	O	B-Chemical
-	NN	O	I-Chemical
1788	NN	O	I-Chemical
was	NN	O	O
investigated	NN	O	O
postoperatively	NN	O	O
in	NN	O	O
a	NN	O	O
double	NN	O	O
-	NN	O	O
blind	NN	O	O
placebo	NN	O	O
-	NN	O	O
controlled	NN	O	O
trial	NN	O	O
.	NN	O	O

The	NN	O	O
patient	NN	O	O
'	NN	O	O
s	NN	O	O
subjective	NN	O	O
assessment	NN	O	O
of	NN	O	O
mood	NN	O	O
rating	NN	O	O
,	NN	O	O
an	NN	O	O
objective	NN	O	O
test	NN	O	O
of	NN	O	O
performance	NN	O	O
,	NN	O	O
a	NN	O	O
test	NN	O	O
for	NN	O	O
amnesia	NN	O	B-Disease
,	NN	O	O
and	NN	O	O
vital	NN	O	O
signs	NN	O	O
were	NN	O	O
recorded	NN	O	O
for	NN	O	O
up	NN	O	O
to	NN	O	O
300	NN	O	O
min	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
trial	NN	O	O
drug	NN	O	O
.	NN	O	O

No	NN	O	O
significant	NN	O	O
differences	NN	O	O
between	NN	O	O
the	NN	O	O
two	NN	O	O
groups	NN	O	O
were	NN	O	O
observed	NN	O	O
for	NN	O	O
mood	NN	O	O
rating	NN	O	O
,	NN	O	O
amnesia	NN	O	B-Disease
,	NN	O	O
or	NN	O	O
vital	NN	O	O
signs	NN	O	O
.	NN	O	O

The	NN	O	O
Ro15	NN	O	B-Chemical
-	NN	O	I-Chemical
1788	NN	O	I-Chemical
group	NN	O	O
showed	NN	O	O
a	NN	O	O
significant	NN	O	O
improvement	NN	O	O
in	NN	O	O
the	NN	O	O
performance	NN	O	O
test	NN	O	O
up	NN	O	O
to	NN	O	O
120	NN	O	O
min	NN	O	O
after	NN	O	O
administration	NN	O	O
of	NN	O	O
the	NN	O	O
drug	NN	O	O
.	NN	O	O

There	NN	O	O
was	NN	O	O
no	NN	O	O
evidence	NN	O	O
of	NN	O	O
reaction	NN	O	O
at	NN	O	O
the	NN	O	O
injection	NN	O	O
site	NN	O	O
.	NN	O	O


-DOCSTART- (2886572)

Enhanced	NN	O	O
stimulus	NN	O	O
-	NN	O	O
induced	NN	O	O
neurotransmitter	NN	O	O
overflow	NN	O	O
in	NN	O	O
epinephrine	NN	O	B-Chemical
-	NN	O	O
induced	NN	O	O
hypertensive	NN	O	B-Disease
rats	NN	O	O
is	NN	O	O
not	NN	O	O
mediated	NN	O	O
by	NN	O	O
prejunctional	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
activation	NN	O	O
.	NN	O	O

The	NN	O	O
present	NN	O	O
study	NN	O	O
examines	NN	O	O
the	NN	O	O
effect	NN	O	O
of	NN	O	O
6	NN	O	O
-	NN	O	O
day	NN	O	O
epinephrine	NN	O	B-Chemical
treatment	NN	O	O
(	NN	O	O
100	NN	O	O
micrograms	NN	O	O
/	NN	O	O
kg	NN	O	O
per	NN	O	O
h	NN	O	O
,	NN	O	O
s.c.	NN	O	O
)	NN	O	O
on	NN	O	O
stimulus	NN	O	O
-	NN	O	O
induced	NN	O	O
(	NN	O	O
1	NN	O	O
Hz	NN	O	O
)	NN	O	O
endogenous	NN	O	O
neurotransmitter	NN	O	O
overflow	NN	O	O
from	NN	O	O
the	NN	O	O
isolated	NN	O	O
perfused	NN	O	O
kidney	NN	O	O
of	NN	O	O
vehicle	NN	O	O
-	NN	O	O
and	NN	O	O
epinephrine	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
rats	NN	O	O
.	NN	O	O

Renal	NN	O	O
catecholamine	NN	O	B-Chemical
stores	NN	O	O
and	NN	O	O
stimulus	NN	O	O
-	NN	O	O
induced	NN	O	O
overflow	NN	O	O
in	NN	O	O
the	NN	O	O
vehicle	NN	O	O
-	NN	O	O
treated	NN	O	O
group	NN	O	O
consisted	NN	O	O
of	NN	O	O
norepinephrine	NN	O	B-Chemical
only	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
epinephrine	NN	O	B-Chemical
treatment	NN	O	O
resulted	NN	O	O
in	NN	O	O
the	NN	O	O
incorporation	NN	O	O
of	NN	O	O
epinephrine	NN	O	B-Chemical
into	NN	O	O
renal	NN	O	O
catecholamine	NN	O	B-Chemical
stores	NN	O	O
such	NN	O	O
that	NN	O	O
approximately	NN	O	O
40%	NN	O	O
of	NN	O	O
the	NN	O	O
catecholamine	NN	O	B-Chemical
present	NN	O	O
was	NN	O	O
epinephrine	NN	O	B-Chemical
while	NN	O	O
the	NN	O	O
norepinephrine	NN	O	B-Chemical
content	NN	O	O
was	NN	O	O
reduced	NN	O	O
by	NN	O	O
a	NN	O	O
similar	NN	O	O
degree	NN	O	O
.	NN	O	O

Total	NN	O	O
tissue	NN	O	O
catecholamine	NN	O	B-Chemical
content	NN	O	O
of	NN	O	O
the	NN	O	O
kidney	NN	O	O
on	NN	O	O
a	NN	O	O
molar	NN	O	O
basis	NN	O	O
was	NN	O	O
unchanged	NN	O	O
.	NN	O	O

Stimulus	NN	O	O
-	NN	O	O
induced	NN	O	O
fractional	NN	O	O
overflow	NN	O	O
of	NN	O	O
neurotransmitter	NN	O	O
from	NN	O	O
the	NN	O	O
epinephrine	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
kidneys	NN	O	O
was	NN	O	O
approximately	NN	O	O
twice	NN	O	O
normal	NN	O	O
and	NN	O	O
consisted	NN	O	O
of	NN	O	O
both	NN	O	O
norepinephrine	NN	O	B-Chemical
and	NN	O	O
epinephrine	NN	O	B-Chemical
in	NN	O	O
proportions	NN	O	O
similar	NN	O	O
to	NN	O	O
those	NN	O	O
found	NN	O	O
in	NN	O	O
the	NN	O	O
kidney	NN	O	O
.	NN	O	O

This	NN	O	O
difference	NN	O	O
in	NN	O	O
fractional	NN	O	O
overflow	NN	O	O
between	NN	O	O
groups	NN	O	O
was	NN	O	O
not	NN	O	O
affected	NN	O	O
by	NN	O	O
neuronal	NN	O	O
and	NN	O	O
extraneuronal	NN	O	O
uptake	NN	O	O
blockade	NN	O	O
.	NN	O	O

Propranolol	NN	O	B-Chemical
had	NN	O	O
no	NN	O	O
effect	NN	O	O
on	NN	O	O
stimulus	NN	O	O
-	NN	O	O
induced	NN	O	O
overflow	NN	O	O
in	NN	O	O
either	NN	O	O
group	NN	O	O
.	NN	O	O

Phentolamine	NN	O	B-Chemical
increased	NN	O	O
stimulus	NN	O	O
-	NN	O	O
induced	NN	O	O
overflow	NN	O	O
in	NN	O	O
both	NN	O	O
groups	NN	O	O
although	NN	O	O
the	NN	O	O
increment	NN	O	O
in	NN	O	O
overflow	NN	O	O
was	NN	O	O
greater	NN	O	O
in	NN	O	O
the	NN	O	O
epinephrine	NN	O	B-Chemical
-	NN	O	O
treated	NN	O	O
group	NN	O	O
.	NN	O	O

In	NN	O	O
conclusion	NN	O	O
,	NN	O	O
chronic	NN	O	O
epinephrine	NN	O	B-Chemical
treatment	NN	O	O
results	NN	O	O
in	NN	O	O
enhanced	NN	O	O
fractional	NN	O	O
neurotransmitter	NN	O	O
overflow	NN	O	O
.	NN	O	O

However	NN	O	O
,	NN	O	O
neither	NN	O	O
alterations	NN	O	O
in	NN	O	O
prejunctional	NN	O	O
beta	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
influences	NN	O	O
nor	NN	O	O
alterations	NN	O	O
in	NN	O	O
neuronal	NN	O	O
and	NN	O	O
extraneuronal	NN	O	O
uptake	NN	O	O
mechanisms	NN	O	O
appear	NN	O	O
to	NN	O	O
be	NN	O	O
responsible	NN	O	O
for	NN	O	O
this	NN	O	O
alteration	NN	O	O
.	NN	O	O

Furthermore	NN	O	O
,	NN	O	O
data	NN	O	O
obtained	NN	O	O
with	NN	O	O
phentolamine	NN	O	B-Chemical
alone	NN	O	O
do	NN	O	O
not	NN	O	O
suggest	NN	O	O
alpha	NN	O	O
-	NN	O	O
adrenoceptor	NN	O	O
desensitization	NN	O	O
as	NN	O	O
the	NN	O	O
cause	NN	O	O
of	NN	O	O
the	NN	O	O
enhanced	NN	O	O
neurotransmitter	NN	O	O
overflow	NN	O	O
after	NN	O	O
epinephrine	NN	O	B-Chemical
treatment	NN	O	O
.	NN	O	O


-DOCSTART- (1079693)

Ocular	NN	O	O
manifestations	NN	O	O
of	NN	O	O
juvenile	NN	O	B-Disease
rheumatoid	NN	O	I-Disease
arthritis	NN	O	I-Disease
.	NN	O	O

We	NN	O	O
followed	NN	O	O
210	NN	O	O
cases	NN	O	O
of	NN	O	O
juvenile	NN	O	B-Disease
rheumatoid	NN	O	I-Disease
arthritis	NN	O	I-Disease
closely	NN	O	O
for	NN	O	O
eleven	NN	O	O
years	NN	O	O
.	NN	O	O

Thirty	NN	O	O
-	NN	O	O
six	NN	O	O
of	NN	O	O
the	NN	O	O
210	NN	O	O
patients	NN	O	O
(	NN	O	O
17.2%	NN	O	O
)	NN	O	O
developed	NN	O	O
iridocyclitis	NN	O	B-Disease
.	NN	O	O

Iridocyclitis	NN	O	B-Disease
was	NN	O	O
seen	NN	O	O
most	NN	O	O
frequently	NN	O	O
in	NN	O	O
young	NN	O	O
female	NN	O	O
patients	NN	O	O
(	NN	O	O
0	NN	O	O
to	NN	O	O
4	NN	O	O
years	NN	O	O
)	NN	O	O
with	NN	O	O
the	NN	O	O
monoarticular	NN	O	O
or	NN	O	O
pauciatricular	NN	O	O
form	NN	O	O
of	NN	O	O
the	NN	O	O
arthritis	NN	O	B-Disease
.	NN	O	O

However	NN	O	O
,	NN	O	O
30%	NN	O	O
of	NN	O	O
the	NN	O	O
patients	NN	O	O
developed	NN	O	O
uveitis	NN	O	B-Disease
after	NN	O	O
16	NN	O	O
years	NN	O	O
of	NN	O	O
age	NN	O	O
.	NN	O	O

Although	NN	O	O
61%	NN	O	O
of	NN	O	O
patients	NN	O	O
had	NN	O	O
a	NN	O	O
noncontributory	NN	O	O
ocular	NN	O	O
history	NN	O	O
on	NN	O	O
entry	NN	O	O
,	NN	O	O
42%	NN	O	O
had	NN	O	O
active	NN	O	O
uveitis	NN	O	B-Disease
on	NN	O	O
entry	NN	O	O
.	NN	O	O

Our	NN	O	O
approach	NN	O	O
was	NN	O	O
effective	NN	O	O
in	NN	O	O
detecting	NN	O	O
uveitis	NN	O	B-Disease
in	NN	O	O
new	NN	O	O
cases	NN	O	O
and	NN	O	O
exacerbations	NN	O	O
of	NN	O	O
uveitis	NN	O	B-Disease
in	NN	O	O
established	NN	O	O
cases	NN	O	O
.	NN	O	O

Forty	NN	O	O
-	NN	O	O
four	NN	O	O
percent	NN	O	O
of	NN	O	O
patients	NN	O	O
with	NN	O	O
uveitis	NN	O	B-Disease
had	NN	O	O
one	NN	O	O
or	NN	O	O
more	NN	O	O
identifiable	NN	O	O
signs	NN	O	O
or	NN	O	O
symptoms	NN	O	O
,	NN	O	O
such	NN	O	O
as	NN	O	O
red	NN	O	O
eye	NN	O	O
,	NN	O	O
ocular	NN	O	B-Disease
pain	NN	O	I-Disease
,	NN	O	O
decreased	NN	O	B-Disease
visual	NN	O	I-Disease
acuity	NN	O	I-Disease
,	NN	O	O
or	NN	O	O
photophobia	NN	O	B-Disease
,	NN	O	O
in	NN	O	O
order	NN	O	O
of	NN	O	O
decreasing	NN	O	O
frequency	NN	O	O
.	NN	O	O

Even	NN	O	O
after	NN	O	O
early	NN	O	O
detection	NN	O	O
and	NN	O	O
prompt	NN	O	O
treatment	NN	O	O
,	NN	O	O
41%	NN	O	O
of	NN	O	O
cases	NN	O	O
of	NN	O	O
uveitis	NN	O	B-Disease
did	NN	O	O
not	NN	O	O
respond	NN	O	O
to	NN	O	O
more	NN	O	O
than	NN	O	O
six	NN	O	O
months	NN	O	O
of	NN	O	O
intensive	NN	O	O
topical	NN	O	O
treatment	NN	O	O
with	NN	O	O
corticosteroids	NN	O	B-Chemical
and	NN	O	O
mydriatics	NN	O	O
.	NN	O	O

Despite	NN	O	O
this	NN	O	O
,	NN	O	O
there	NN	O	O
was	NN	O	O
a	NN	O	O
dramatic	NN	O	O
decrease	NN	O	O
in	NN	O	O
the	NN	O	O
50%	NN	O	O
incidence	NN	O	O
of	NN	O	O
blinding	NN	O	O
complications	NN	O	O
of	NN	O	O
uveitis	NN	O	B-Disease
cited	NN	O	O
in	NN	O	O
earlier	NN	O	O
studies	NN	O	O
.	NN	O	O

Cataract	NN	O	B-Disease
and	NN	O	O
band	NN	O	B-Disease
keratopathy	NN	O	I-Disease
occurred	NN	O	O
in	NN	O	O
only	NN	O	O
22	NN	O	O
and	NN	O	O
13%	NN	O	O
of	NN	O	O
our	NN	O	O
group	NN	O	O
,	NN	O	O
respectively	NN	O	O
.	NN	O	O

We	NN	O	O
used	NN	O	O
chloroquine	NN	O	B-Chemical
or	NN	O	O
hydroxychloroquine	NN	O	B-Chemical
in	NN	O	O
173	NN	O	O
of	NN	O	O
210	NN	O	O
cases	NN	O	O
and	NN	O	O
found	NN	O	O
only	NN	O	O
one	NN	O	O
case	NN	O	O
of	NN	O	O
chorioretinopathy	NN	O	B-Disease
attributable	NN	O	O
to	NN	O	O
these	NN	O	O
drugs	NN	O	O
.	NN	O	O

Systemically	NN	O	O
administered	NN	O	O
corticosteroids	NN	O	B-Chemical
were	NN	O	O
used	NN	O	O
in	NN	O	O
75	NN	O	O
of	NN	O	O
210	NN	O	O
cases	NN	O	O
;	NN	O	O
a	NN	O	O
significant	NN	O	O
number	NN	O	O
of	NN	O	O
posterior	NN	O	O
subcapsular	NN	O	O
cataracts	NN	O	B-Disease
was	NN	O	O
found	NN	O	O
.	NN	O	O

Typical	NN	O	O
keratoconjunctivitis	NN	O	B-Disease
sicca	NN	O	O
developed	NN	O	O
in	NN	O	O
three	NN	O	O
of	NN	O	O
the	NN	O	O
uveitis	NN	O	B-Disease
cases	NN	O	O
.	NN	O	O

This	NN	O	O
association	NN	O	O
with	NN	O	O
uveitis	NN	O	B-Disease
and	NN	O	O
JRA	NN	O	O
was	NN	O	O
not	NN	O	O
noted	NN	O	O
previously	NN	O	O
.	NN	O	O

Surgical	NN	O	O
treatment	NN	O	O
of	NN	O	O
cataracts	NN	O	B-Disease
,	NN	O	O
band	NN	O	B-Disease
keratopathy	NN	O	I-Disease
,	NN	O	O
and	NN	O	O
glaucoma	NN	O	B-Disease
achieved	NN	O	O
uniformly	NN	O	O
discouraging	NN	O	O
results	NN	O	O
.	NN	O	O


-DOCSTART- (803783)

Water	NN	O	B-Disease
intoxication	NN	O	I-Disease
associated	NN	O	O
with	NN	O	O
oxytocin	NN	O	B-Chemical
administration	NN	O	O
during	NN	O	O
saline	NN	O	O
-	NN	O	O
induced	NN	O	O
abortion	NN	O	B-Disease
.	NN	O	O

Four	NN	O	O
cases	NN	O	O
of	NN	O	O
water	NN	O	B-Disease
intoxication	NN	O	I-Disease
in	NN	O	O
connection	NN	O	O
with	NN	O	O
oxytocin	NN	O	B-Chemical
administration	NN	O	O
during	NN	O	O
saline	NN	O	O
-	NN	O	O
induced	NN	O	O
abortions	NN	O	B-Disease
are	NN	O	O
described	NN	O	O
.	NN	O	O

The	NN	O	O
mechanism	NN	O	O
of	NN	O	O
water	NN	O	B-Disease
intoxication	NN	O	I-Disease
is	NN	O	O
discussed	NN	O	O
in	NN	O	O
regard	NN	O	O
to	NN	O	O
these	NN	O	O
cases	NN	O	O
.	NN	O	O

Oxytocin	NN	O	B-Chemical
administration	NN	O	O
during	NN	O	O
midtrimester	NN	O	O
-	NN	O	O
induced	NN	O	O
abortions	NN	O	B-Disease
is	NN	O	O
advocated	NN	O	O
only	NN	O	O
if	NN	O	O
it	NN	O	O
can	NN	O	O
be	NN	O	O
carried	NN	O	O
out	NN	O	O
under	NN	O	O
careful	NN	O	O
observations	NN	O	O
of	NN	O	O
an	NN	O	O
alert	NN	O	O
nursing	NN	O	O
staff	NN	O	O
,	NN	O	O
aware	NN	O	O
of	NN	O	O
the	NN	O	O
symptoms	NN	O	O
of	NN	O	O
water	NN	O	B-Disease
intoxication	NN	O	I-Disease
and	NN	O	O
instructed	NN	O	O
to	NN	O	O
watch	NN	O	O
the	NN	O	O
diuresis	NN	O	O
and	NN	O	O
report	NN	O	O
such	NN	O	O
early	NN	O	O
signs	NN	O	O
of	NN	O	O
the	NN	O	O
syndrome	NN	O	O
as	NN	O	O
asthenia	NN	O	B-Disease
,	NN	O	O
muscular	NN	O	O
irritability	NN	O	B-Disease
,	NN	O	O
or	NN	O	O
headaches	NN	O	B-Disease
.	NN	O	O

The	NN	O	O
oxytocin	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
given	NN	O	O
only	NN	O	O
in	NN	O	O
Ringers	NN	O	O
lactate	NN	O	B-Chemical
or	NN	O	O
,	NN	O	O
alternately	NN	O	O
,	NN	O	O
in	NN	O	O
Ringers	NN	O	O
lactate	NN	O	B-Chemical
and	NN	O	O
a	NN	O	O
5	NN	O	O
per	NN	O	O
cent	NN	O	O
dextrose	NN	O	B-Chemical
and	NN	O	O
water	NN	O	O
solutions	NN	O	O
.	NN	O	O

The	NN	O	O
urinary	NN	O	O
output	NN	O	O
should	NN	O	O
be	NN	O	O
monitored	NN	O	O
and	NN	O	O
the	NN	O	O
oxytocin	NN	O	B-Chemical
administration	NN	O	O
discontinued	NN	O	O
and	NN	O	O
the	NN	O	O
serum	NN	O	O
electrolytes	NN	O	O
checked	NN	O	O
if	NN	O	O
the	NN	O	O
urinary	NN	O	O
output	NN	O	O
decreases	NN	O	O
.	NN	O	O

The	NN	O	O
oxytocin	NN	O	B-Chemical
should	NN	O	O
not	NN	O	O
be	NN	O	O
administered	NN	O	O
in	NN	O	O
excess	NN	O	O
of	NN	O	O
36	NN	O	O
hours	NN	O	O
.	NN	O	O

If	NN	O	O
the	NN	O	O
patient	NN	O	O
has	NN	O	O
not	NN	O	O
aborted	NN	O	O
by	NN	O	O
then	NN	O	O
the	NN	O	O
oxytocin	NN	O	B-Chemical
should	NN	O	O
be	NN	O	O
discontinued	NN	O	O
for	NN	O	O
10	NN	O	O
to	NN	O	O
12	NN	O	O
hours	NN	O	O
in	NN	O	O
order	NN	O	O
to	NN	O	O
perform	NN	O	O
electrolyte	NN	O	O
determinations	NN	O	O
and	NN	O	O
correct	NN	O	O
any	NN	O	O
electrolyte	NN	O	O
imbalance	NN	O	O
.	NN	O	O

